<SEC-DOCUMENT>0001129928-18-000028.txt : 20180319
<SEC-HEADER>0001129928-18-000028.hdr.sgml : 20180319
<ACCEPTANCE-DATETIME>20180319163754
ACCESSION NUMBER:		0001129928-18-000028
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		101
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180319
DATE AS OF CHANGE:		20180319

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		18699263

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>oncyf2017-20f.htm
<DESCRIPTION>20-F
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s078C7D66044850E799D8FAEF6B318AD3"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;text-indent:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 20-F</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:15%;"></td><td style="width:4%;"></td><td style="width:81%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For fiscal year ended</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from ____ to ____</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of event requiring this shell company report:</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission file number: 000-31062</font></div><div style="line-height:120%;"><img src="oncolyticslogotaglineblue.jpg" alt="oncolyticslogotaglineblue.jpg" style="height:298px;width:682px;"></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of Registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Province of Alberta, Canada</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Jurisdiction of incorporation or organization)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suite 210, 1167 Kensington Crescent, N.W. Calgary, Alberta, T2N 1X7</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Kirk Look</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suite 210, 1167 Kensington Crescent, N.W. Calgary, Alberta, T2N 1X7</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tel: (403) 670-7377</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E-mail: info@oncolytics.ca</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act: None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(g) of the Act:  Common Shares, no par value</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: &#160;None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate the number of outstanding shares of each of the Registrant&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">141,805,722</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares as at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If this report is an annual or transition report, indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes </font><font style="font-family:Wingdings;font-size:10pt;">&#253; </font><font style="font-family:inherit;font-size:10pt;">No </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every&#160;&#160;Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company.&#160;&#160;See definition of &#8220;large accelerated filer,&#8221;  &#8220;accelerated filer,&#8221; and &#8220;emerging growth company in Rule 12b-2 of the Exchange Act.&#160;&#160;(Check one)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:33%;"></td><td style="width:34%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large accelerated filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Non-accelerated filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange Act.  </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;US GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International Financial Reporting Standards as issued&#160;&#160;by the International Accounting Standards Board</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Other&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 17 </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Item 18&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If this is an annual report, indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s6401CF6D7EFC5347BBCB69C110AA97E6"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 20-F</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:75%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sE8011871014A53D8A61E0BA4E6568154"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 1. &#160;&#160;&#160;&#160; Identity of Directors, Senior Management and Advisers</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sE8011871014A53D8A61E0BA4E6568154">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sFB55EC1FE44458D09C39581AF3649D25"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 2.&#160; &#160;&#160;&#160; Offer Statistics and Expected Timetable</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sFB55EC1FE44458D09C39581AF3649D25">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s9B88EEEB54FE5B48A53A754AE5B05F7E"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 3. &#160;&#160;&#160; &#160;Key Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s9B88EEEB54FE5B48A53A754AE5B05F7E">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sDC66AD1355FF5AD5A8A33A85D3B32EDD"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 4.&#160;&#160;&#160;&#160;&#160; Information on the Company</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sDC66AD1355FF5AD5A8A33A85D3B32EDD">17</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s72C1F8C007D354889D9141FF844BA102"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;Item 4A.    Unresolved Staff Comments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s72C1F8C007D354889D9141FF844BA102">24</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sC79AB28872E35250A2B9231DF1E9AD0A"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 5.&#160; &#160;&#160;&#160; Operating and Financial Review and Prospects</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sC79AB28872E35250A2B9231DF1E9AD0A">24</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s95848A0CB4A250D6BEA12F9A66337A32"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 6.&#160; &#160;&#160; &#160;Directors, Senior Management and Employees</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s95848A0CB4A250D6BEA12F9A66337A32">25</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s1F91BA000BB35769A7852FCD2746F68F"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 7.&#160; &#160;&#160;&#160; Major Shareholders and Related Party Transactions</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s1F91BA000BB35769A7852FCD2746F68F">42</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;color:#000000;" href="#sCFEF8E8CCA1555C18449B6DD2E16DF21"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;color:#000000;">&#160;Item 8.&#160;&#160; &#160;&#160;&#160; Financial Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sCFEF8E8CCA1555C18449B6DD2E16DF21">43</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sC78A92DDC0DE5D76B2320A2A6347E577"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 9.&#160;&#160;&#160;&#160;&#160; The Offer and Listing</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sC78A92DDC0DE5D76B2320A2A6347E577">43</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s561C15BFB5D85A70BDD606EEDC83477C"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 10.&#160;&#160;&#160; Additional Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s561C15BFB5D85A70BDD606EEDC83477C">45</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sE7383B05B67A5306B05A949F8F89F294"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 11.&#160;&#160;&#160; Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sE7383B05B67A5306B05A949F8F89F294">56</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s5B3057773B525624ADFCA2586CCE3810"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 12.&#160;&#160;&#160; Description of Securities Other Than Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s5B3057773B525624ADFCA2586CCE3810">56</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sC9B7617319295ADD98E032548AD9C5ED"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 13.&#160;&#160;&#160; Defaults, Dividend Arrearages and Delinquencies</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sC9B7617319295ADD98E032548AD9C5ED">57</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sBEC7904B849157FF840EB67001E5C6FB"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 14.&#160;&#160;&#160; Material Modifications to the Rights of Security Holders and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sBEC7904B849157FF840EB67001E5C6FB">57</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s9CE8DCF3B1815C64B05B44D0354F8B2E"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 15.&#160;&#160;&#160;&#160; Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s9CE8DCF3B1815C64B05B44D0354F8B2E">57</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s9E20B3277A595B149690EF4C730F3105"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;Item 16.     [Reserved]</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s9E20B3277A595B149690EF4C730F3105">58</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s6BBE53F6CDC65C7997E134B7D6ABA86E"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 16A. &#160;Audit Committee Financial Expert</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s6BBE53F6CDC65C7997E134B7D6ABA86E">58</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s8D1DC7E320D65F59894312960D7C1534"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 16B.&#160;&#160; Code of Ethics</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s8D1DC7E320D65F59894312960D7C1534">58</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sAD8FD3C4B08756F1A597066CC91DB27E"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 16C.&#160;&#160;&#160;Principal Accountant Fees and Services</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sAD8FD3C4B08756F1A597066CC91DB27E">58</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sE2E2EA4A4DC253C2A10E599D52006FB3"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 16D.&#160; &#160;Exemptions from the Listing Standards for Audit Committees</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sE2E2EA4A4DC253C2A10E599D52006FB3">59</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s8C3D371348EC5E308A648987C0A4029A"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 16E.&#160;&#160; Purchase of Equity Securities by the Issuer and Affiliated Purchases</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s8C3D371348EC5E308A648987C0A4029A">59</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sCA306F7FD51B5F1F9ADFA75A6A517DBA"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 16F.&#160;&#160; Change in Registrant's Certifying Accountants</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sCA306F7FD51B5F1F9ADFA75A6A517DBA">59</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sF95976133DDD58C398C79EF544E8B47F"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 16G.&#160; Corporate Governance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sF95976133DDD58C398C79EF544E8B47F">59</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sBE014DF0F6175DB8926DCC9728801AA6"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;Item 16H.   Mine Safety Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sBE014DF0F6175DB8926DCC9728801AA6">59</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s26C42CB3BF315166B6FA85D6893CB7CE"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 17.&#160;&#160;&#160;&#160;&#160; Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s26C42CB3BF315166B6FA85D6893CB7CE">59</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#sE798855B4E245EE89ED46B4C206B6956"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 18&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#sE798855B4E245EE89ED46B4C206B6956">60</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;" href="#s4CBD29E37F9F5816B2C5B14716A3ED78"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">&#160;Item 19.&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s4CBD29E37F9F5816B2C5B14716A3ED78">61</a></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s757CFD266FFD5182A637DF397F9909EE"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s757CFD266FFD5182A637DF397F9909EE">62</a></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;" href="#s91F43AA78B7852DC8BF9FBB111B4FCE6"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">F1 - F26</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s5F8723B048E15C3D86755C7299B3BC94"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All references in this annual report on Form 20-F to the terms &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, &#8220;the Company&#8221; and &#8220;Oncolytics&#8221; refer to Oncolytics Biotech Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain statements in this annual report on Form 20-F and the documents attached as exhibits to this annual report, constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Oncolytics Biotech Inc., or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts, and include, but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to the efficacy of our technologies; the timing and results of clinical studies related to our technologies; future operations, products and services; the impact of regulatory initiatives on our operations; the size of and opportunities related to the markets for our technologies; general industry and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future performance. Forward-looking statements generally, but not always, are identified by the words &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;projects&#8221;, &#8220;potential&#8221;, &#8220;possible&#8221; and similar expressions, or that events or conditions &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could&#8221; or &#8220;should&#8221; occur.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The forward-looking statements in this annual report are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control, including without limitation:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to all of our products, including REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, being in the research and development stage and requiring further development and testing before they can be marketed commercially;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks inherent in pharmaceutical research and development;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to timing and possible delays in our clinical trials;  </font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to some of our clinical trials being conducted in, and subject to the laws of foreign countries;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our pharmaceutical products being subject to intense regulatory approval processes in the United States and other foreign jurisdictions;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to being subject to government manufacturing and testing regulations;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to the extremely competitive biotechnology industry and our competition with larger companies with greater resources;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our reliance on patents and proprietary rights to protect our technology;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to potential products liability claims;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our limited manufacturing experience and reliance on third parties to commercially manufacture our products, if and when developed;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our new products not being accepted by the medical community or consumers;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our technologies becoming obsolete;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our dependence on third party relationships for research and clinical trials;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our license, development, supply and distribution agreement (the &#8220;Licensing Agreement&#8221;) with Adlai Nortye Biopharma Co. Ltd. (&#8220;Adlai&#8221;);</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our lack of operating revenues and history of losses;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">uncertainty regarding our ability to obtain third-party reimbursement for the costs of our product;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to other third-party arrangements; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our ability to obtain additional financing to fund future research and development of our products and to meet ongoing capital requirements;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to potential increases in the cost of director and officer liability insurance;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our dependence on key employees and collaborators;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to Barbados law;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to the effect of changes in the law on our corporate structure;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to expenses in foreign currencies and our exposure to foreign currency exchange rate fluctuations;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our compliance with the Sarbanes-Oxley Act of 2002, as amended;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our status as a foreign private issuer;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;risk related to&#160;&#160;possible &#8220;passive foreign investment company&#8221; status;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to fluctuations in interest rates;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to information technology systems; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our common shares.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This list is not exhaustive of the factors that may affect any of the Company&#8217;s forward-looking statements.&#160;&#160;Some of the important risks and uncertainties that could affect forward-looking statements are described further under the section heading &#8220;Item 3. Key Information &#8211; D. Risk Factors&#8221; below.&#160;&#160;If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, our actual results may vary materially from those expected, estimated or projected.&#160;&#160;Forward-looking statements in this document are not a prediction of future events or circumstances, and those future events or circumstances may not occur.&#160;&#160;Given these uncertainties, users of the information included herein, including investors and prospective investors are cautioned not to place undue reliance on such forward-looking statements.&#160;&#160;Investors should consult our quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements.&#160;&#160;We do not assume responsibility for the accuracy and completeness of these statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward-looking statements are based on our beliefs, opinions and expectations at the time they are made, and we do not assume any obligation to update our forward-looking statements if those beliefs, opinions, or expectations, or other circumstances, should change, except as required by applicable law.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="sE8221D817D435281B5FAD85434A6F1F5"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENCY AND EXCHANGE RATES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Canadian Dollars Per US Dollar</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the exchange rates for United States dollars (&#8220;US$&#8221;) expressed in terms of Canadian dollars (&#8220;Cdn$&#8221;) including the average exchange rates (based on the average of the exchange rates on the last day of each month in such periods) and the range of high and low exchange rates for such periods.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:622px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:137px;"></td><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:97px;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Canadian Dollars Per One US Dollar</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average for the period</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2986</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3248</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2787</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1045</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0299</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:645px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:110px;"></td><td style="width:89px;"></td><td style="width:82px;"></td><td style="width:92px;"></td><td style="width:93px;"></td><td style="width:81px;"></td><td style="width:96px;"></td></tr><tr><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Month of</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">February<br>2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">January<br>2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December<br>2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">November<br>2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">October<br>2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September<br>2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">High for the period</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2809</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2535</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2886</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2888</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2893</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2480</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Low for the period</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2288</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2293</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2545</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2683</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2472</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2128</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exchange rates are based on the Bank of Canada average daily exchange rates (prior to April 2017, rates were based on the Bank of Canada nominal noon exchange rates).&#160;The average daily exchange rate on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;15, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;as reported by the Bank of Canada for the conversion of United States dollars into Canadian dollars was US$1.00 = Cdn</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.3032</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Unless otherwise indicated, in this annual report on Form 20-F, all references herein are to Canadian Dollars.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s02CE66DFE8B9571981A911746128025C"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sE8011871014A53D8A61E0BA4E6568154"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sFB55EC1FE44458D09C39581AF3649D25"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s9B88EEEB54FE5B48A53A754AE5B05F7E"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3. KEY INFORMATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selected Financial Data</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The selected financial data presented below for the five years ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;is presented in Canadian dollars and is derived from our consolidated financial statements in Canadian dollars and in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the International Accounting Standards Board (&#8220;IASB&#8221;).  The information set forth below should be read in conjunction with our consolidated financial statements (including notes thereto) included under Item 18 and "Operating and Financial Review and Prospects" included under Item 5.  For exchange rate data please see the section heading &#8220;Currency and Exchange Rates&#8221; above.</font></div><div style="line-height:120%;text-align:justify;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:270px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,616,851</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,139,979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,722,995</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,619,335</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,532,647</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net comprehensive loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,797,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,346,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,242,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,418,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,395,834</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,150,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,758,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,383,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,193,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,222,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,283,846</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,689,620</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,674,306</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,819,193</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,213,366</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash dividends declared per share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132,395,752</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,880,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,613,845</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,869,149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,530,981</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in net loss and net loss per share for the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are share based payment expenses of </font><font style="font-family:inherit;font-size:10pt;">$578,703</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$406,078</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;-  </font><font style="font-family:inherit;font-size:10pt;">$429,537</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$980,325</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$424,384</font><font style="font-family:inherit;font-size:10pt;">). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We issued </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20,547,500</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12,812,704</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3,106,600</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$956,133</font><font style="font-family:inherit;font-size:10pt;">;  </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">24,639,128</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">$23,667,654</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;-  </font><font style="font-family:inherit;font-size:10pt;">8,708,676</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">$9,044,492</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">8,093,533</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">30,398,036</font><font style="font-family:inherit;font-size:10pt;">).  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not declared or paid any dividends since incorporation.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Capitalization and Indebtedness</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reasons for the Offer and Use of Proceeds</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk Factors</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment in our common shares ("Common Shares") involves a high degree of risk. You should carefully consider, among other matters, the following risk factors in addition to the other information in this Annual Report on Form 20-F when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the material risks described below or in subsequent reports we file with the SEC actually occur, they may materially harm our business, financial condition, operating results or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results or cash flow.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Risks</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">All of our potential products, including REOLYSIN, are in the research and development stage and will require further development and testing before they can be marketed commercially.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly, investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, REOLYSIN, for human application, the riskiest stage for a company in the biotechnology industry. It is not possible to predict, based upon studies in animals and early stage human clinical trials, whether REOLYSIN will prove to be safe and effective in humans. REOLYSIN will require additional research and development, including extensive additional clinical testing, before we will be able to obtain the approvals of the relevant regulatory authorities in applicable countries to market REOLYSIN commercially. There can be no assurance that the research and development programs we conduct will result in REOLYSIN or any other products becoming commercially viable products, and in the event that any product or products result from the research and development program, it is unlikely they will be commercially available for a number of years.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To achieve profitable operations we, alone or with others, must successfully develop, introduce and market our products. To obtain regulatory approvals for products being developed for human use, and to achieve commercial success, human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy. Unsatisfactory results obtained from a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">particular study relating to a program may cause us to abandon our commitment to that program or the product being tested. No assurances can be provided that any current or future animal or human test, if undertaken, will yield favourable results. If we are unable to establish that REOLYSIN is a safe, effective treatment for cancer, we may be required to abandon further development of the product and develop a new business strategy.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">There are inherent risks in pharmaceutical research and development.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical research and development is highly speculative and involves a high and significant degree of risk. The marketability of any product we develop will be affected by numerous factors beyond our control, including but not limited to:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the discovery of unexpected toxicities or lack of sufficient efficacy of products which make them unattractive or unsuitable for human use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">preliminary results as seen in animal and/or limited human testing may not be substantiated in larger, controlled clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manufacturing costs or other production factors may make manufacturing of products ineffective, impractical and non-competitive;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">proprietary rights of third parties or competing products or technologies may preclude commercialization;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requisite regulatory approvals for the commercial distribution of products may not be obtained; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other factors may become apparent during the course of research, up-scaling or manufacturing which may result in the discontinuation of research and other critical projects.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our products under development have never been manufactured on a commercial scale, and there can be no assurance that such products can be manufactured at a cost or in a quantity to render such products commercially viable. Production and utilization of our products may require the development of new manufacturing technologies and expertise. The impact on our business in the event that new manufacturing technologies and expertise are required to be developed is uncertain. There can be no assurance that we will successfully meet any of these technological challenges or others that may arise in the course of development.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Any failure or delay in clinical trials for our products, including REOLYSIN, may cause us to incur additional costs or delay or prevent the commercialization of our products and could severely harm our business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We must conduct extensive clinical trials to demonstrate the safety and efficacy of our products in humans. Clinical testing, in particular, is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome.&#160;&#160;A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process, which could delay or prevent us from receiving marketing approval or commercializing our product candidates, including the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical trials may produce negative or inconclusive results, and we may decide, or regulatory authorities may require us, to conduct additional clinical trials or we may abandon projects that we expect to be promising;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of subjects required for our clinical trials may be larger than we anticipate, enrollment in our clinical trials may be slower than we anticipate, or participants may drop out of our clinical trials at a higher rate than we anticipate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We might have to suspend or terminate our clinical trials if the participants are being exposed to unacceptable health risks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulators or institutional review boards may require that we hold, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulators may refuse to accept or consider data from clinical trials for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cost of our clinical trials may be greater than we anticipate; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The supply or quality of our products or other materials necessary to conduct our clinical trials may be insufficient or inadequate.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, subject enrollment, which is a significant factor in the timing of clinical trials, is affected by a variety of factors, including the following:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The size and nature of the subject population;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The proximity of subjects to clinical sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The eligibility criteria for the trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The design of the clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Competing clinical trials; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinicians&#8217; and subjects&#8217; perceptions as to the potential advantages of the medication being studied in relation to other available therapies, including any new medications that may be approved for the indications we are investigating.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, we plan to rely on clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance. Any delays or unanticipated problems during clinical testing, such as enrollment in our clinical trials being slower than we anticipate or participants dropping out of our clinical trials at a higher rate than we anticipate, could increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenues.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Condition Risks</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have no operating revenues and a history of losses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have not generated sufficient revenues to offset our research and development costs and accordingly have not generated positive cash flow or made an operating profit.  As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$294.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and we incurred net losses of </font><font style="font-family:inherit;font-size:10pt;">$15.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$15.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$13.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.  We anticipate that we will continue to incur significant losses during </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and in the foreseeable future.  We do not expect to reach profitability at least until after successful and profitable commercialization of one or more of our products.  Even if one or more of our products are profitably commercialized, the initial losses incurred by us may never be recovered.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to obtain third-party reimbursement for the cost of our product.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government authorities and third party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the US healthcare industry and elsewhere is cost containment. Government authorities and these third party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Uncertainty exists regarding the reimbursement status of newly-approved pharmaceutical products and reimbursement may not be available for REOLYSIN.&#160;&#160;Any reimbursements granted may not be maintained or limits on reimbursements available from third-party payors may reduce the demand for, or negatively affect the price of, these products. If REOLYSIN does not qualify for reimbursement, if reimbursement levels diminish, or if reimbursement is denied, our sales and profitability would be adversely affected.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third-Party Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the normal course of our business, we have entered into contractual arrangements with third parties which subject us to the risk that such parties may default on their obligations. Oncolytics may be exposed to third party credit risk through our contractual arrangements with our current contract manufacturer, the institutions which operate our clinical trials, or our contract research organizations and other parties.&#160;&#160;In the event such entities fail to meet their contractual obligations to Oncolytics, such failures could have a material adverse effect on Oncolytics and our operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents (including short-term investments) of </font><font style="font-family:inherit;font-size:10pt;">$11.8 million</font><font style="font-family:inherit;font-size:10pt;">. Working capital was approximately </font><font style="font-family:inherit;font-size:10pt;">$12.6 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We anticipate that we will need additional financing in the future to fund research and development and to meet our ongoing capital requirements.&#160;&#160;The amount of future capital requirements will depend on many factors, including continued scientific progress in our drug discovery and development programs, progress in our pre-clinical and clinical evaluation of drug candidates, time and expense associated with filing, prosecuting and enforcing our patent claims and costs associated with obtaining regulatory approvals.&#160;&#160;In order to meet such capital requirements, we will consider contract fees, collaborative research and development arrangements, and additional public or private financings (including the incurrence of debt and the issuance of additional equity securities) to fund all or a part of particular programs as well as potential partnering or licensing opportunities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics, from time to time, along with all other pharmaceutical research and development entities, may have restricted access to capital, bank debt and equity, and, from time to time, may face increased borrowing costs. Although our business and asset base have not changed, the lending capacity of all financial institutions fluctuates causing a corresponding change in risk premiums.   As future operations will be financed out of funds generated from financing activities, our ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the pharmaceutical industry and our securities in particular.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Should we elect to satisfy our cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that our efforts to raise such funding will be successful, or achieved on terms favourable to us or our existing shareholders.&#160;&#160;If adequate funds are not available on terms favorable to us, we may have to reduce substantially or eliminate expenditures for research and development, testing, production and marketing of our proposed product, or obtain funds through arrangements with corporate partners that require us to relinquish rights to certain of our technologies or product.&#160;&#160;There can be no assurance that we will be able to raise additional capital if our current capital resources are exhausted.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Regulatory Risks</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pharmaceutical products are subject to intense regulatory approval processes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The regulatory process for pharmaceuticals, which includes preclinical studies and clinical trials of each compound to establish its safety and efficacy, takes many years and requires the expenditure of substantial resources. Moreover, if regulatory approval of a drug is granted, such approval may entail limitations on the indicated uses for which it may be marketed. Failure to comply with applicable regulatory requirements can, among other things, result in suspension of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Further, government policy may change, and additional government regulations may be established that could prevent or delay regulatory approvals for our products. In addition, a marketed drug and its manufacturer are subject to continual review. Later discovery of previously unknown problems with the product or manufacturer may result in restrictions on such product or manufacturer, including withdrawal of the product from the market.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The United States Food and Drug Administration (&#8220;FDA&#8221;) and similar regulatory authorities in other countries may deny approval of a new drug application if required regulatory criteria are not satisfied, or may require additional testing. Product approvals may be withdrawn if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. The FDA and similar regulatory authorities in other countries may require further testing and surveillance programs to monitor the pharmaceutical product that has been commercialized. Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product withdrawals, product seizures, injunction actions and criminal prosecutions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our own pharmaceuticals, we may supply active pharmaceutical ingredients and advanced pharmaceutical intermediates for use in our customers&#8217; drug products. The final drug products in which the pharmaceutical ingredients and advanced pharmaceutical intermediates are used, however, are subject to regulation for safety and efficacy by the FDA and possibly other regulatory authorities in other jurisdictions.&#160;&#160;Such products must be approved by such agencies before they can be commercially marketed. The process of obtaining regulatory clearance for marketing is uncertain, costly and time consuming. We cannot predict how long the necessary regulatory approvals will take or whether our customers will ever obtain such approval for their products. To the extent that our customers do not obtain the necessary regulatory approvals for marketing new products, our product sales could be adversely affected.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and other governmental regulators have increased requirements for drug purity and have increased environmental burdens upon the pharmaceutical industry. Because pharmaceutical drug manufacturing is a highly regulated industry, requiring significant documentation and validation of manufacturing processes and quality control assurance prior to approval of the facility to manufacture a specific drug, there can be considerable transition time between the initiation of a contract to manufacture a product and the actual initiation of manufacture of that product. Any lag time in the initiation of a contract to manufacture product and the actual initiation of manufacture could cause us to lose profits or incur liabilities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical regulatory regime in Europe and other countries is generally similar to that of the United States. We could face similar risks in these other jurisdictions as the risks described above.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our operations and products may be subject to other government manufacturing and testing regulations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States and similar regulatory agencies in other countries is a long and expensive process, which can delay or prevent product development and marketing. Approval to market products may be for limited applications or may not be received at all.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The products we anticipate manufacturing will have to comply with the FDA&#8217;s current Good Manufacturing Practices (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:10pt;">cGMP</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:10pt;">) and other FDA and local government guidelines and regulations, including other international regulatory requirements and guidelines. Additionally, certain of our customers may require the manufacturing facilities contracted by us to adhere to additional manufacturing standards, even if not required by the FDA. Compliance with cGMP regulations requires manufacturers to expend time, money and effort in production and to maintain precise records and quality control to ensure that the product meets applicable specifications and other requirements. The FDA and other regulatory bodies periodically inspect drug-manufacturing facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities contracted by us fail to comply with the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cGMP requirements, the facilities may become subject to possible FDA or other regulatory action and manufacturing at the facility could consequently be suspended. We may not be able to contract suitable alternative or back-up manufacturing facilities on terms acceptable to us or at all.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA or other regulatory agencies may also require the submission of any lot of a particular product for inspection. If the lot product fails to meet the FDA requirements, then the FDA could take any of the following actions: (i) restrict the release of the product; (ii) suspend manufacturing of the specific lot of the product; (iii) order a recall of the lot of the product; or (iv) order a seizure of the lot of the product.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to regulation by governments in many jurisdictions.&#160;&#160;If we do not comply with healthcare, drug, manufacturing and environmental regulations, among others, in such jurisdiction, our existing and future operations may be curtailed, and we could be subject to liability.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the regulatory approval process, we may be subject to regulations under local, provincial, state, federal and foreign law, including, but not limited to, requirements regarding occupational health, safety, laboratory practices, environmental protection and hazardous substance control, and may be subject to other present and future local, provincial, state, federal and foreign regulations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Risks</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on patents and proprietary rights to protect our technology.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success will depend, in part, on our ability to obtain patents, maintain trade secret protection and operate without infringing the rights of third parties. We have received Granted Patents in countries throughout the world, including the United States, Canada, Europe, and Japan.&#160;&#160;We file our Applications for Patent in the United States and under the PCT, allowing us to subsequently file in other jurisdictions.&#160;&#160;Our success will depend, in part, on our ability to obtain, enforce and maintain patent protection for our technology in Canada, the United States and other countries. We cannot be assured that patents will issue from any pending applications or that claims now or in the future, if any, allowed under issued patents will be sufficiently broad to protect our technology. In addition, no assurance can be given that any patents issued to, or licensed by us, will not be challenged, invalidated, infringed or circumvented, or that the rights granted thereunder will provide continuing competitive advantages to us.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent positions of pharmaceutical and biotechnology firms, including us, are generally uncertain and involve complex legal and factual questions. In addition, it is not known whether any of our current research endeavours will result in the issuance of patents in Canada, the United States, or elsewhere, or if any patents already issued will provide significant proprietary protection or will be circumvented or invalidated. Since patent applications in the United States and Canada may be maintained in secrecy until at least 18 months after filing of the original priority application, and since publication of discoveries in the scientific or patent literature tends to lag behind actual discoveries by several months, we cannot be certain that we or any licensor were the first to create inventions claimed by pending patent applications or that we or the licensor were the first to file patent applications for such inventions. Loss of patent protection could lead to generic competition for these products, and others in the future, which would materially and adversely affect our financial prospects for these products.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Similarly, since patent applications filed before November 29, 2000 in the United States may be maintained in secrecy until the patents issue or foreign counterparts, if any, publish, we cannot be certain that we or any licensor were the first creator of inventions covered by pending patent applications or that we or such licensor were the first to file patent applications for such inventions. There is no assurance that our patents, if issued, would be held valid or enforceable by a court or that a competitor&#8217;s technology or product would be found to infringe such patents.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accordingly, we may not be able to obtain and enforce effective patents to protect our proprietary rights from use by competitors.&#160;&#160;If other such parties obtain patents for certain information relied on by us in conducting our business, then we may be required to stop using, or pay to use, certain intellectual property, and as such, our competitive position and profitability could suffer as a result.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third parties may choose to file patent infringement claims against us; defending ourselves from such allegations would be costly, time-consuming, distracting to management and could materially affect our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be claimed to infringe patents and other intellectual property rights of third parties under which we do not hold sufficient licenses or other rights. Additionally, third parties may be successful in obtaining patent protection for technologies that cover development activities in which we are already engaged. Third parties may own or control these patents and intellectual </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">property rights in the United States and abroad. These third parties may have substantially greater financial resources than us and could bring claims against us that could cause us to incur substantial expenses to defend against these claims and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement or other similar suit were brought against us, we could be forced to stop or delay development, manufacturing or sales of the product or product candidate that is the subject of the suit. Intellectual property litigation in the biopharmaceutical industry is common, and we expect this trend to continue.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of patent infringement or other similar claims, or to avoid potential claims, we may choose or be required to seek a license from the third party and be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, if at all, or if an injunction is granted against us, which could harm our business significantly.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our proprietary information and</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">know-how, the value of our technology and products could be adversely affected.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to patented technology, we rely upon unpatented proprietary technology, processes and know-how. However, these types of trade secrets can be difficult to protect. We seek to protect this confidential information, in part, through agreements with our employees, consultants and third parties as well as confidentiality policies and audits, although these may not be successful in protecting our trade secrets and confidential information.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known, including through a potential cyber security breach, or may be independently developed by competitors. If we are unable to protect the confidentiality of our proprietary information and know-how, competitors may be able to use this information to develop products that compete with our products, which could adversely impact our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Business Risks</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The biotechnology industry is extremely competitive and we must successfully compete with larger companies with substantially greater resources.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technological competition in the pharmaceutical industry is intense and we expect competition to increase. Other companies are conducting research on therapeutics involving innate and adaptive immune responses as well as other novel treatments or therapeutics for the treatment of cancer which may compete with our product. Many of these competitors are more established, benefit from greater name recognition and have substantially greater financial, technical and marketing resources than us. In addition, many of these competitors have significantly greater experience in undertaking research, preclinical studies and human clinical trials of new pharmaceutical products, obtaining regulatory approvals and manufacturing and marketing such products. In addition, there are several other companies and products with which we may compete from time to time, and which may have significantly better and larger resources than we do. Accordingly, our competitors may succeed in manufacturing and/or commercializing products more rapidly or effectively, which could have a material adverse effect on our business, financial condition or results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that we will face increased competition in the future as new products enter the market and advanced technologies become available. There can be no assurance that existing products or new products developed by our competitors will not be more effective, or be more effectively manufactured, marketed and sold, than any that may be developed or sold by us. Competitive products may render our products obsolete and uncompetitive prior to recovering research, development or commercialization expenses incurred with respect to any such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our products may fail or cause harm, subjecting us to product liability claims.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Use of our product during current clinical trials may entail risk of product liability.&#160;&#160;We maintain clinical trial liability insurance; however, it is possible this coverage may not provide full protection against all risks.&#160;&#160;Given the scope and complexity of the clinical development process, the uncertainty of product liability litigation, and the shrinking capacity of insurance underwriters, it is not possible at this time to assess the adequacy of current clinical trial coverage, nor the ability to secure continuing coverage at the same level and at reasonable cost in the foreseeable future.&#160;&#160;While we carry, and intend to continue carrying amounts believed to be appropriate under the circumstances, it is not possible at this time to determine the adequacy of such coverage.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the sale and commercial use of our product entails risk of product liability. We currently do not carry any product liability insurance for this purpose. There can be no assurance that we will be able to obtain appropriate levels of product liability insurance prior to any sale of our pharmaceutical products. An inability to obtain insurance on economically feasible terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization of products developed by us. The obligation to pay any product liability claim or a recall of a product could have a material adverse effect on our business, financial condition and future prospects.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Future legal proceedings and the impact of any finding of liability or damages could adversely impact the company and its financial condition and results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may be named as a defendant in various legal actions or other proceedings, inlcuding class action lawsuits. Certain of these actions include and future actual or threatened legal actions may include, claims for substantial and indeterminate amounts of damages, or may result in other results adverse to us. Management does not currently know of any pending, material legal proceedings against the Company, but such legal action could be brought in the future.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of possible future legal proceedings cannot be predicted with certainty. Accordingly, we cannot determine whether our insurance coverage would be sufficient to cover the costs or potential losses, if any. Regardless of merit, litigation may be both time-consuming and disruptive to our operations and cause significant expense and diversion of management attention. If we do not prevail in future legal proceedings, we may be faced with significant monetary damages or injunctive relief against us that may adversely affect our business, financial condition and results of operations, possibly materially.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have limited manufacturing experience and intend to rely on third parties to commercially manufacture our products, if and when developed.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have relied upon a contract manufacturer to manufacture small quantities of REOLYSIN. The manufacturer may encounter difficulties in scaling up production, including production yields, quality control and quality assurance. Only a limited number of manufacturers can supply therapeutic viruses and failure by the manufacturer to deliver the required quantities of REOLYSIN on a timely basis at a commercially reasonable price may have a material adverse effect on us. We have completed a program for the development of a commercial process for manufacturing REOLYSIN and have filed a number of patent applications related to the process. There can be no assurance that we will successfully obtain sufficient patent protection related to our manufacturing process.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New products may not be accepted by the medical community or consumers.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our primary activity to date has been research and development and we have no experience in marketing or commercializing products. We will likely rely on third parties to market our products, assuming that they receive regulatory approvals. If we rely on third parties to market our products, the commercial success of such product will be subject to a number of risks that may be outside of our control, including:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competition in relation to alternative treatments, including efficacy advantages and cost advantages;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">perceived ease of use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability of coverage or reimbursement by third-party payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">uncertainties regarding marketing and distribution support; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">distribution or use restrictions imposed by regulatory authorities.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, there can be no assurance that physicians, patients or the medical community will accept our product, even if it proves to be safe and effective and is approved for marketing by Health Canada, the FDA and other regulatory authorities. A failure to successfully market our product would have a material adverse effect on our revenue.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our technologies may become obsolete.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical industry is characterized by rapidly changing markets, technology, emerging industry standards and frequent introduction of new products. The introduction of new products embodying new technologies, including new manufacturing processes and the emergence of new industry standards may render our products obsolete, less competitive or less marketable. The process of developing our products is extremely complex and requires significant continuing development efforts and third party commitments. Our failure to develop new technologies and products and the obsolescence of existing technologies could adversely affect our business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unable to anticipate changes in our potential customer requirements that could make our existing technology obsolete. Our success will depend, in part, on our ability to continue to enhance our existing technologies, develop new technology that addresses the increasing sophistication and varied needs of the market, and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks. We may not be successful in using our new technologies or exploiting our niche markets effectively or adapting our businesses to evolving customer or medical requirements or preferences or emerging industry standards.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are highly dependent on third-party relationships for research and clinical trials.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely upon third party relationships for assistance in the conduct of research efforts, pre-clinical development and clinical trials, and manufacturing. In addition, we expect to rely on third parties to seek regulatory approvals for and to market our product. Although we believe that our collaborative partners will have an economic motivation to commercialize our product included in any collaborative agreement, the amount and timing of resources diverted to these activities generally is expected to be controlled by the third party. Furthermore, if we cannot maintain these relationships, our business may suffer.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our license, development, supply and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 16, 2017, we announced that we had entered into the Licensing Agreement with Adlai. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan (the &#8220;Territories&#8221;). Pursuant to the Licensing Agreement, along with payments to be received by us upon meeting certain requirements and milestones, we are also eligible to receive royalty payments in excess of 10% associated with the commercialization of REOLYSIN for all indications, subject to regulatory approval. Under the terms of the Licensing Agreement, Adlai will be responsible for all clinical, regulatory and commercialization activities respecting REOLYSIN in the Territories and therefore the Company will be dependent upon Adlai in successfully undertaking those actions in a timely and economic manner and in compliance with all applicable legal and regulatory requirements within the Territories.  If Adlai is unable to fulfill its obligations under the terms of the Licensing Agreement and in compliance with all applicable legal and regualtory requirements, including clinical, regulatory and commercialization of REOLYSIN, our prospective revenue from royalty payments related to the commercialization of REOLYSIN in the Territories may be materially diminished, delayed or never realized, which could negatively effect our operating results and financial condition.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, conducting business with Adlai within the Territories, and specifically China, subjects us to certain economic, political, currency and legal risks and uncertainties regarding, among other things, the development and commercialization of REOLYSIN and the release and receipt of payments under the terms of the Licensing Agreement, including the payment of royalties upon commercialization of REOLYSIN.  These risks include:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">different regulatory requirements for drug approvals in foreign countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">different standards of care in various countries that could complicate the evaluation of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">different U.S. and foreign drug import and export rules;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduced protection for intellectual property rights in certain countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unexpected changes in tariffs, trade barriers and regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">different reimbursement systems and different competitive drugs indicated to treat the indications for which our product candidates are being developed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">compliance with the FCPA, and other anti-corruption and anti-bribery laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. and foreign taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">foreign currency fluctuations, which could result in reduced revenues, and other obligations incident to doing business in another country;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a reliance on CROs, clinical trial sites, principal investigators and other third parties that may be less experienced with clinical trials or have different methods of performing such clinical trials than we are used to in the U.S.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential liability resulting from development work conducted by foreign distributors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The government&#8217;s of the Territories, and specifically the Chinese government, exercise significant control over all aspects of their respective economies.&#160; Accordingly, any adverse change in the economy, the legal system or governmental, economic or other policies could have a material adverse effect on the business prospects of the the Licensing Agreement with Adlai, including our ability to receive and transfer money out of China under the terms of the Licensing Agreement. Any disruption in relations, inability to work efficiently or disadvantageous treatment of Adlai by the governments of the Territories or other authorities could have a material adverse effect on our business prospects under the Licensing Agreement. Additionally, the regulatory environment in the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Territories is evolving, and officials in the governments in the Territories exercise broad discretion in deciding how to interpret and apply regulations. There can be no assurance that Adlai will be successful in the development and commercialization of REOLYSIN in the Territories.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The cost of director and officer liability insurance may increase substantially and may affect our ability to retain quality directors and officers.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We carry liability insurance on behalf of our directors and officers. Given a number of large director and officer liability insurance claims in the US equity markets, director and officer liability insurance has become increasingly more expensive with increased restrictions. Consequently, there is no assurance that we will continue to be offered this insurance or be able to obtain adequate coverage. The inability to acquire the appropriate insurance coverage may limit our ability to attract and maintain directors and officers as required to conduct our business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent on our key employees and collaborators.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to develop the product will depend, to a great extent, on our ability to attract and retain highly qualified scientific personnel and to develop and maintain relationships with leading research institutions. Competition for such personnel and relationships is intense. We are highly dependent on the principal members of our management staff as well as our advisors and collaborators, the loss of whose services might impede the achievement of development objectives. The persons working with us are affected by a number of influences outside of our control. The loss of key employees and/or key collaborators may affect the speed and success of product development.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Barbados law differs from the laws in effect in Canada and the United States and may afford less protection to holders of our securities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our assets and intellectual property are held by our wholly-owned subsidiary, Oncolytics Barbados, which is organized under the laws of Barbados. It may not be possible to enforce court judgments obtained in Canada or the United States against Oncolytics Barbados in Barbados based on the civil liabilities provisions of applicable securities laws. In addition, there is some doubt as to whether the courts of Barbados would recognize or enforce judgments of courts in Canada or the United States obtained against us or our directors or officers based on the civil liabilities provisions of Canadian and United States securities laws or hear actions against us or those persons based on such laws.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in law could adversely affect our business and corporate structure.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There can be no assurances that changes will not occur in corporate, tax, property and other laws in Canada and/or Barbados (or the interpretation thereof by regulatory or tax authorities) which may materially and adversely affect our businesses and corporate structure.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We incur some of our expenses in foreign currencies and therefore we are exposed to foreign currency exchange rate fluctuations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incur some of our manufacturing, clinical, collaborative and consulting expenses in foreign currencies, primarily the US dollar, the Euro and the British pound (&#8220;GBP&#8221;).&#160;&#160;We are therefore exposed to foreign currency rate fluctuations.&#160;&#160;Also, as we expand to other foreign jurisdictions there may be an increase in our foreign exchange exposure.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We earn interest income on our excess cash reserves and are exposed to changes in interest rates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We invest our excess cash reserves in investment vehicles that provide a rate of return with little risk to principal. As interest rates change the amount of interest income we earn will be directly impacted.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our operations may be adversely affected by disruptions to our information technology ("IT") systems, including disruptions from cybersecurity breaches of our IT infrastructure.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on information technology networks and systems, including those of third-party service providers, to process, transmit and store electronic information. In particular, we depend on our information technology infrastructure for a variety of functions, including financial reporting, data management, and email communications. Any of these systems may be susceptible to outages due to fire, floods, power loss, telecommunications failures, terrorist attacks, sabotage and similar events. Global cybersecurity threats and incidents can range from uncoordinated individual attempts to gain unauthorized access to our information technology systems to sophisticated and targeted measures known as advanced persistent threats. The ever-increasing use and evolution of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our systems or in non-encrypted portable media or storage devices. We could also experience a business interruption, information theft of confidential information, or reputational damage from industrial espionage attacks, malware or other cyber attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. Despite the implementation of network security measures and disaster recovery plans, our systems and those of third parties on which we rely may also be vulnerable to computer viruses, break-ins and similar disruptions. If we or our vendors are unable (or are perceived as unable) to prevent such outages and breaches, our operations may be disrupted and our business reputation could be adversely affected. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that risks and exposures related to cybersecurity attacks will remain high for the foreseeable future due to the rapidly evolving nature and sophistication of these threats. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Company may fail to achieve and maintain adequate internal control over financial reporting pursuant to the requirements of the Sarbanes-Oxley Act and equivalent Canadian legislation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company documented and tested during its most recent fiscal year its internal control procedures in order to satisfy the requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;) and equivalent Canadian legislation. SOX requires an annual assessment by management of the effectiveness of the Company&#8217;s internal controls over financial reporting and an attestation report by the Company&#8217;s independent auditors addressing this assessment, if applicable. The Company may fail to achieve and maintain the adequacy of its internal controls over financial reporting as such standards are modified, supplemented, or amended from time to time, and the Company may not be able to ensure that it can conclude, on an ongoing basis, that it has effective internal controls over financial reporting in accordance with Section&#160;404 of SOX. The Company&#8217;s failure to satisfy the requirements of Section&#160;404 of SOX on an ongoing, timely basis could result in the loss of investor confidence in the reliability of its financial statements, which in turn could harm the Company&#8217;s business and negatively impact the trading price of the common shares or the market value of its other securities. In addition, any failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Company&#8217;s operating results or cause it to fail to meet its reporting obligations. Future acquisitions of companies, if any, may provide the Company with challenges in implementing the required processes, procedures and controls in its acquired operations. No evaluation can provide complete assurance that the Company&#8217;s internal controls over financial reporting will detect or uncover all failures of persons within the Company to disclose material information otherwise required to be reported. The effectiveness of the Company&#8217;s processes, procedures and controls could also be limited by simple errors or faulty judgments. In addition, if the Company expands, the challenges involved in implementing appropriate internal controls over financial reporting will increase and will require that the Company continue to improve its internal controls over financial reporting.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because the Company is a Canadian Company and some of its directors and officers are resident outside the United States, it may be difficult for investors in the United States to enforce civil liabilities against the Company based solely upon the federal securities laws of the United States.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is a Canadian company, with its principal place of business in Canada.  Some of the Company&#8217;s directors and officers, including the Company's Chief Executive Officer and Chief Financial Officer, are residents outside the United States and a significant portion of the Company&#8217;s assets are located outside the United States. Consequently, it may be difficult for US investors to effect service of process within the United States upon the Company or these directors or officers who are not residents of the United States, or to realize in the United States upon judgments of courts of the United States predicated upon civil liabilities under the US Securities Act of 1933, as amended. Investors should not assume that Canadian courts (1)&#160;would enforce judgments of US courts obtained in actions against the Company or such directors or officers predicated upon the civil liability provisions of the US federal securities laws or the securities or &#8220;blue sky&#8221; laws of any state within the United States or (2)&#160;would enforce, in original actions, liabilities against the Company or such directors or officers predicated upon the US federal securities laws or any such state securities or &#8220;blue sky&#8221; laws. In addition, the protections afforded by Canadian securities laws may not be available to investors in the United States.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">As a foreign private issuer, our shareholders may have less complete and timely data.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is a &#8220;foreign private issuer&#8221; as defined in Rule&#160;3b-4 under the United States Securities Exchange Act of 1934, as amended (the &#8220;US Exchange Act&#8221;). Equity securities of the Company are accordingly exempt from Sections&#160;14(a), 14(b), 14(c), 14(f) and 16 of the US Exchange Act pursuant to Rule&#160;3a12-3 of the US Exchange Act. Therefore, the Company is not required to file a Schedule&#160;14A proxy statement in relation to its annual meeting of shareholders. The submission of proxy and annual meeting of&#160;&#160;shareholder information on Form 6-K may result in shareholders having less complete and timely information in connection with shareholder actions. The exemption from Section&#160;16 rules regarding reports of beneficial ownership and purchases </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and sales of common shares by insiders and restrictions on insider trading in our securities may result in shareholders having less data and there being fewer restrictions on insiders&#8217; activities in our securities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Company is likely a "passive foreign investment company" which may have adverse US federal income tax consequences for US shareholders.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US shareholders of the Common Shares should be aware that the Company believes it was classified as a passive foreign investment company (&#8220;PFIC&#8221;) for the tax year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, and based on current business plans and financial expectations, the Company anticipates that it may qualify as a PFIC for its current and subsequent taxable years.&#160;&#160;If the Company is a PFIC for any year during a US shareholder&#8217;s holding period, then such US shareholder generally will be required to treat any gain realized upon a disposition of Common Shares, or any so-called &#8220;excess distribution&#8221; received on its common shares, as ordinary income, and to pay an interest charge on a portion of such gain or distributions, unless the shareholder makes a timely and effective "qualified electing fund" election (&#8220;QEF Election&#8221;) or a "mark-to-market" election with respect to the Common Shares.&#160;&#160;A US shareholder who makes a QEF Election generally must report on a current basis its share of the Company's net capital gain and ordinary earnings for any year in which the Company is a PFIC, whether or not the Company distributes any amounts to its shareholders.&#160;     However, US shareholders should be aware that there can be no assurance that the Company will satisfy the record keeping requirements that apply to a qualified electing fund, or that the Company will supply US shareholders with information that such U.S. shareholders require to report under the QEF Election rules, in the event that the Company is a PFIC and a U.S. shareholder wishes to make a QEF Election. </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">Thus, US shareholders may not be able to make a QEF Election with respect to their Common Shares.  A US shareholder who makes the mark-to-market election generally must include as ordinary income each year the excess of the fair market value of the common shares over the taxpayer&#8217;s basis therein.&#160;&#160;This paragraph is qualified in its entirety by the discussion below under the heading &#8220;Certain United States Federal Income Tax Considerations.&#8221;&#160;&#160;Each US shareholder should consult its own tax advisor regarding the PFIC rules and the US federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to our Common Shares</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our share price may be highly volatile.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market prices for securities of biotechnology companies generally are volatile and the share price for our common shares has been historically volatile. This increases the risk of securities litigation. Factors such as announcements (publicly made or at scientific conferences) of technological innovations, new commercial products, patents, the development of proprietary rights, results of clinical trials, regulatory actions, publications, quarterly financial results, our financial position, public concern over the safety of biotechnology, future sales of shares by us or our current shareholders and other factors could have a significant effect on the market price and volatility of the Common Shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Potential dilution of present and prospective shareholdings.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to finance future operations and development efforts, the Company may raise funds through the issue of common shares or the issue of securities convertible into common shares. The Company cannot predict the size of future issues of common shares or the issue of securities convertible into common shares or the effect, if any, that future issues and sales of the Company&#8217;s common shares will have on the market price of its common shares. Any transaction involving the issue of previously authorized but unissued shares, or securities convertible into shares, would result in dilution, possibly substantial, to present and prospective holders of shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Company does not intend to pay cash dividends in the foreseeable future.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not declared or paid any dividends since its incorporation. The Company intends to retain earnings, if any, to finance the growth and development of its business and does not intend to pay cash dividends on the Common Shares in the foreseeable future. Any return on an investment in the common shares will come from the appreciation, if any, in the value of the Common Shares. The payment of future cash dividends, if any, will be reviewed periodically by the board of directors and will depend upon, among other things, conditions then existing including earnings, financial condition and capital requirements, restrictions in financing agreements, business opportunities and conditions and other factors.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Penny stock&#8221; rules may make buying or selling our securities difficult, which may make our stock less liquid and make it harder for investors to buy and sell our securities. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 5, 2015, we were delisted from the NASDAQ Capital Markets and are now only quoted on an over-the-counter market, the OTCQX International, maintained by OTC Markets, Inc. Trading in our securities is now subject to the SEC&#8217;s &#8220;penny </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">stock&#8221; rules and it is anticipated that trading in our securities will continue to be subject to the penny stock rules for the foreseeable future. The Securities and Exchange Commission has adopted regulations that generally define a penny stock to be any equity security that has a market price of less than $5.00 per share, subject to certain exceptions. These rules require that any broker-dealer who recommends our securities to persons other than prior customers and accredited investors must, prior to the sale, make a special written suitability determination for the purchaser and receive the purchaser&#8217;s written agreement to execute the transaction. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the risks associated with trading in the penny stock market. In addition, broker-dealers must disclose commissions payable to both the broker-dealer and the registered representative and current quotations for the securities they offer. The additional burdens imposed upon broker-dealers by these requirements may discourage broker-dealers from recommending transactions in our securities, which could severely limit the liquidity of our securities and consequently adversely affect the market price for our securities. </font></div><div><a name="sDC66AD1355FF5AD5A8A33A85D3B32EDD"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.&#160;&#160;INFORMATION ON THE COMPANY</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">History and Development of the Company</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech Inc. was formed under the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Corporations Act</font><font style="font-family:inherit;font-size:10pt;">&#32;(Alberta) on April 2, 1998 as 779738 Alberta Ltd.&#160;&#160;On April 8, 1998, we changed our name to Oncolytics Biotech Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our principal executive office is located at 210, 1167 Kensington Cres. NW, Calgary, Alberta, Canada, T2N 1X7, telephone (403) 670-7377. Our agent for service in the US is CT Corporation, 111 Eighth Avenue, 13</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;Floor, New York, New York 10011.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A description of the important events in our development including licensing transactions, our principal capital expenditures and divestitures and a description of acquisitions of material assets can be found in our MD&amp;A and in the notes to our financial statements included elsewhere in this annual report.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Overview </font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company and we have focused our research and development efforts on the development of REOLYSIN (pelareorep), a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts.&#160;We do not expect to generate significant revenues until, if and when, pelareorep becomes commercially viable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our potential product for human use, pelareorep, an unmodified reovirus, is a first in class systemically administered I-O viral agent for the treatment of solid tumors and hematological malignancies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Scientific Background</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pelareorep&#8217;s anti-tumor activity is based on three modes of action which are complementary but not interdependent (Figure 1): </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selective viral replication in permissive cancer cells which leads to tumor cell lysis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activation of innate immunity in response to the infection which results in a cascade of chemokines/cytokines causing natural killer (NK) cells to be activated and attack cancer cells.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A specific adaptive immune response triggered by tumor- and viral-associated antigens displayed by antigen-presenting cells (APCs, infected tumor cells and/or dendritic cells) to T cells.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Summary of Research and Development highlights</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preclinical and Translational Research data to date indicate the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pelareorep has anticancer effects in models of metastatic cancers that can prolong survival in these models when using immuno-competent rodents. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The survival benefit in animal models can be enhanced when pelareorep is given in combination with chemotherapy, immunotherapy (e.g., checkpoint inhibitors, IMiDs, rituximab, etc.) or radiotherapy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A toxic dose of reovirus T3D has not been reached/established in animal models and infection presents with minimal side-effects.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical data to date indicate the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">More than 1,400 patients have been enrolled in clinical studies conducted in the US, Canada and EU. Of these, more than 1,000 patients received pelareorep, with over 930 via intravenous (IV) administration and over 90 by intratumoral injections (ITu). The remaining patients were randomized to control arms. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pelareorep has been administered as single or multiple doses (intratumoral or intravenous), either as a mono-therapy or in combination with chemotherapy, immunotherapy (e.g., checkpoint inhibitors), and radiotherapy.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No Maximum Tolerated Dose (MTD) for intravenous pelareorep as mono-therapy was defined in the two Phase 1 trials (REO 004 and 005). Dose-limiting toxicities (DLTs) were seen in some of the combination trials with pelareorep and chemotherapy, which generally enrolled heavily pre-treated patients. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When combined with chemotherapeutic agents, pelareorep does not appear to enhance either the frequency or severity of the adverse effects of the chemotherapeutic agents.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is emerging evidence that pelareorep may impact overall survival (OS) in metastatic breast cancer (MBC) and metastatic adenocarcinoma of the pancreas (MAP): </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In a randomized, controlled Phase 2 study of paclitaxel with pelareorep versus paclitaxel alone in MBC (CCTG IND.213) median survival time was greater for subjects treated with paclitaxel and pelareorep (median 17.4 months) than subjects treated with paclitaxel alone (10.4 months, hazard ratio [HR] 0.65). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In a single arm study with gemcitabine plus pelareorep in first line MAP (REO 017) the median overall survival (mOS) was 10 months with a 1 year and 2-year survival of 46% and 24%, respectively. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In a two-arm Phase 2 randomized study (NCI 8601), patients with MAP were randomized to receive either carboplatin, paclitaxel and pelareorep (test arm) or carboplatin and paclitaxel alone (control arm). The median OS was similar for both arms, but the probability of survival at Year 2 was 20% in the test arm vs 9% in the control arm.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Mechanism of Action</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 1. Proposed mechanism of action for pelareorep.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><img src="figure1a06.jpg" alt="figure1a06.jpg" style="height:310px;width:461px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Direct cell lysis - Reovirus Replication in Permissive Cancer Cells</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selective viral replication and lysis in cancer cells and not normal cells is mediated by the host cellular protein PKR (dsRNA-activated protein kinase). In non-cancer cells that are infected with reovirus, PKR activates in the presence of the virus which in turn inhibits viral gene translation. However, in permissive cancer cells, PKR activation is inhibited, allowing for viral gene translation and eventual cell lysis. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It was originally established that selective lysis with reovirus</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">was mediated by tumor cells with an activated RAS-pathway, since active RAS inhibits PKR activation. However, more recent investigations have revealed that reovirus replication is not just restricted </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to cells with an active RAS pathway, oncogenic mutations and amplifications in upstream (EGFR) and downstream (BRAF) mediators of the RAS-pathway also allow for viral replication and oncolysis. Moreover, active RAS is known to stimulate over 18 downstream effector proteins, many of which have been shown to facilitate viral replication, such as activation of Raf/MEK/ERK, RalGEF/p38, and JNK signalling pathways. Cells bearing dysfunctional or deleted tumor suppressor genes (p53, ATM and Rb) and or chemo- or radiation-induced cell stress also show increased sensitivity to reovirus replication and lysis. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Induction of Innate Immunity</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preclinical and clinical studies provide compelling lines of evidence that pelareorep functions as an immunogenic agent. Indeed, preclinical studies by Steele and colleagues demonstrated that melanoma cells infected with pelareorep can produce an innate immune response triggering the release of inflammatory cytokines. This inflammatory milieu promotes a chemotactic response in NK cells, dendritic cells, and cytotoxic T-cells, altering the tumour microenvironment to support bystander immune-mediated cancer cell death. Intriguingly, preclinical studies have also demonstrated that the beneficial immunogenic functions of pelareorep can occur independent of viral replication. Pelareorep performs this immunogenic function, in part, by activating dendritic cells, key regulators of both adaptive and innate immunity. Dendritic cells activated by reovirus in turn stimulate the innate antitumor activity of NK (natural killer) cells through the release of proinflammatory cytokines, demonstrating that dendritic cells' recognition of reovirus may trigger a beneficial innate immune response. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A clinical trial with pelareorep (REO 013) provided an opportunity to study human NK cell activation, in humans,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">in a controlled manner. Ten colorectal cancer patients with liver metastases received between one and five doses of pelareorep prior to surgical resection of their tumor. NK cell activation peaked 24-48 hours post-infection, coincident with a peak of pro-inflammatory cytokines. NK cells within reovirus-treated blood mononuclear cells were stimulated to kill tumor targets, but not normal hepatocytes. Moreover, NK cells were able to hand-off virus to tumors for direct oncolytic killing. Similarly, NK cells within liver mononuclear cells became selectively cytotoxic towards tumor cells when activated by reovirus. These results showed that reovirus modulates human NK cell activity </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;and suggest that this may contribute to the therapeutic effect of pelareorep.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Induction of Adaptive Immunity</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adaptive anti-tumor immunity allows for elimination of existing cancer cells and performs constant surveillance, preventing relapse, and increasing patient overall survival. An adaptive immune response requires two signals: a signal from an antigen presenting cell (APC), as well as a co-stimulation signal in the form of cytokines. In the absence of both signals, the adaptive immune response fails. Therapy with pelareorep has the potential to activate both signals. Following its therapeutic administration, pelareorep enhances the expression of &#8216;foreign&#8217; antigens/markers on tumor cells. Oncolysis of tumor cells exposes tumor-associated antigens (TAAs) and viral-associated antigens (VAAs) for processing and presentation by APCs, such as dendritic cells. Through the combined actions of these immunological events, pelareorep facilitates the display of novel &#8216;foreign&#8217; antigens on the surface of infected tumor cells and APCs. Simultaneously, pelareorep induces an inflammatory response promoting the expression of co-stimulatory molecules and inflammatory cytokines. Together, pelareorep mediated immunological events over-rule tumor antigen presentation impairments and initiate adaptive anti-tumor immunity.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By promoting the expression of novel antigens and the release of inflammatory cytokines, pelareorep, promotes an inflamed tumor phenotype. An inflamed tumor phenotype is characterized by NK and T-cell infiltration, increased expression of chemokines/cytokines, and increased expression of checkpoint ligands. This phenotype correlates with an increase in overall survival and has a positive prognostic value for early stage cancers. In patients with metastatic cancer, an inflamed tumor phenotype is associated with better clinical outcomes when treated with immunotherapies, including immune checkpoint blockade inhibitors, cancer vaccines, and adoptive T-cell therapies. By promoting an inflamed tumor phenotype, pelareorep primes an anti-cancer immune response (Figure 2).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 2. Pelareorep (REOLYSIN) primes an anti-cancer immune response</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;"><img src="figure2a02.jpg" alt="figure2a02.jpg" style="height:330px;width:490px;"></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Development Plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are directing a three-part clinical development program with the objective of developing pelareorep as a human cancer therapeutic.  Our clinical development program focuses on the three components of pelareorep's mechanism of action and includes the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chemo combinations</font><font style="font-family:inherit;font-size:10pt;">&#32;- Our primary focus has been on the investigation of chemotherapy combination clinical trials investigating the use of different chemotherapy agents in various cancer indications.  In 2017, we reported additional clinical data from our randomized clinical program which includes the clinical trial collaborations with the Canadian Cancer Trials Group (CCTG, formerly known as the National Cancer Institute of Canada). Specifically, subgroup analysis in the IND.213 trial in MBC revealed a significant improvement in overall survival of patients that are hormone receptor positive (HR+) / human epidermal growth factor receptor 2 negative (HER2-). In HR+/HER2- patients, REOLYSIN therapy in combination with paclitaxel doubled the overall survival from 10.8 month with paclitaxel therapy alone to 21.8 months with REOLYSIN plus paclitaxel. This increase in overall survival is consistent with previous survival data reported from our NCI pancreatic trial which suggests a long term survival benefit when comparing test and control arms at 24 months.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Combination with IMiDs/targeted therapy</font><font style="font-family:inherit;font-size:10pt;">&#32;- Our second program focuses on the potential of pelareorep to stimulate a patient's innate immunity and the potential for an infection to cause a cascade of chemokines/cytokines activating natural killer (NK) cells to attack cancer cells.  In 2017, patient enrollment commenced on a clinical collaboration with Myeloma UK and Celgene that combines pelareorep with immune modulator therapies (IMiDs) which enhance NK cell activation.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Immunotherapy combinations</font><font style="font-family:inherit;font-size:10pt;">&#32;- Our third program focuses on the potential for pelareorep to cause a specific adaptive immune response triggered by tumor- and viral-associated antigens displayed by antigen-presenting cells (APCs, infected tumor cells and/or dendritic cells) to T cells. In 2017 we announced our first data set combining a checkpoint inhibitor with pelareorep and pembrolizumab (Keytruda&#174;) in pancreatic cancer, which demonstrated safety and tolerability and in five efficacy evaluable patients, one had a partial response (six-month duration) and two had stable disease (lasting 126 and 221 days). Additional basket study concepts are now being planned.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patents and Trade Secrets</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent positions and proprietary rights of pharmaceutical and biotechnology firms, including us, are generally uncertain and involve complex legal and factual questions. We believe there will continue to be significant litigation in the industry regarding patent and other intellectual property rights.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currently, we have over </font><font style="font-family:inherit;font-size:10pt;">411</font><font style="font-family:inherit;font-size:10pt;">&#32;issued patents including </font><font style="font-family:inherit;font-size:10pt;">47</font><font style="font-family:inherit;font-size:10pt;">&#32;issued in the US and </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;in Canada. We also have 35 patents pending in the US, Canada, and other jurisdictions, but we cannot be certain whether any given patent application filed by us will result in the issuance of a patent or if any given patent issued to us will later be challenged and invalidated. Nor can we be certain whether any given patent that may be issued to us will provide any significant proprietary protection to our product and business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Litigation or other proceedings may also be necessary to enforce or defend our proprietary rights and patents. In Europe, patents can be revoked through opposition or nullity proceedings. In the United States patents may be revoked or invalidated in court actions or challenged in interference, post-grant review, derivation or re-examination proceedings in the USPTO. Such litigation or proceedings could result in substantial cost or distraction to us, or result in an adverse decision as to our or our licensors&#8217; patent applications and patents.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial success depends, in part, on not infringing the patents or proprietary rights of others and not breaching licenses granted that may be granted to us. Competitors may have filed patent applications and obtained patents and may in the future file patent applications and obtain patents relevant to our product and technologies.&#160;&#160;We are not aware of competing intellectual property relating to our pelareorep project.&#160;&#160;While we currently believe that we have the necessary freedom to operate in these areas, there can be no assurance that others will not challenge our position in the future.&#160;&#160;Litigation to defend our position could be costly and time consuming. We also cannot be certain that we will be successful. We may be required to obtain a license from a prevailing party in order to continue the portion of our business that relates to the proceeding. We may also be required to obtain licenses to other third-party technologies necessary in order to market our products. Such licenses may not be available to us on acceptable terms or on any terms and we may have to discontinue that portion of our business. Any failure to license any technologies required to commercialize our technologies or products at reasonable cost may have a material adverse effect on our business, results of operations, financial condition, cash flow and future prospects. We are not currently involved in any litigation concerning our competitors&#8217; patent applications and patents. We may be involved in such litigation in the future.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also rely on unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. No assurance can be given that others will not independently develop substantially equivalent proprietary information and techniques, or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our rights to our unpatented trade secrets.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We require our employees and consultants to execute confidentiality agreements upon the commencement of employment and consulting relationships with us. These agreements provide that all confidential information developed by or made known to an individual during the course of the employment or consulting relationship generally must be kept confidential. In the case of employees, the agreements provide that all inventions conceived by the individual, while employed by us, relating to our business are our exclusive property. While we have implemented reasonable business measurements to protect confidential information, these agreements may not provide meaningful protection for our trade secrets in the event of unauthorized use or disclosure of such information.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Strategy</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business strategy is to develop and market pelareorep in an effective and timely manner, and access additional technologies at a time and in a manner that we believe is best for our development.&#160;&#160;We intend to achieve our business strategy by focusing on these key areas:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Develop pelareorep through our clinical development plan assessing the safety and efficacy in human subjects;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Establish collaborations with experts to assist us with scientific and clinical developments of this new potential pharmaceutical product;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Implement strategic alliances with selected pharmaceutical and biotechnology companies and selected laboratories, at a time and in a manner where such alliances may complement and expand our research and development efforts on the product and provide sales and marketing capabilities;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Utilize our broadening patent base and collaborator network as a mechanism to meet our strategic objectives; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Develop relationships with companies that could be instrumental in assisting us to access other innovative therapeutics.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business strategy is based on attaining a number of commercial objectives, which, in turn, are supported by a number of product development goals.&#160;&#160;Our new product development presently being conducted is primarily of a research and development nature.&#160;&#160;In the context of this Annual Report, statements of our "belief" are based primarily upon our results derived to date from our research and development program with animals, early stage human trials and our most recent data in HR+/HER2- mBC patients, and upon which we believe that we have a reasonable scientific basis to expect the particular results to occur.&#160;&#160;It is not possible to predict, based upon studies in animals, or early stage human trials, whether a new therapeutic will ultimately prove to be safe and effective in humans.&#160;&#160;There are no assurances that the particular result expected by us will occur.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At this time we do not intend to become a fully integrated pharmaceutical company with substantial in-house research and development, marketing and distribution or manufacturing capabilities.&#160;&#160;We are pursuing a strategy of establishing relationships with larger companies as strategic partners.&#160;&#160;We intend to partner or joint venture with larger pharmaceutical companies that have existing and relevant marketing capability for our products.&#160;&#160;It is anticipated that future clinical development into large international or pivotal trials would generally occur in conjunction with a strategic partner or partners, who would contribute expertise and financial assistance.&#160;&#160;In exchange for certain product rights and commitments to market our products, the strategic partners would be expected to share in gross proceeds from the sale of our product or products and potentially share in various market or manufacturing opportunities.&#160;&#160;The proceeds generated from partnering or joint venturing projects are expected to be distributed on the basis of relative risk taken and resources contributed by each party to the partnership or joint venture.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory Requirements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The development of new pharmaceuticals is strongly influenced by a country's regulatory environment.&#160;&#160;The drug approval process in Canada is regulated by Health Canada.&#160;&#160;The primary regulatory body in the United States is the FDA and in Europe is the European Medicines Agency (the &#8220;EMA&#8221;).&#160;&#160;Similar processes are conducted in specific countries by equivalent regulatory bodies.&#160;&#160;Regulations in each jurisdiction require the licensing of manufacturing facilities and mandate strict research and product testing standards.&#160;&#160;Companies must establish the safety and efficacy of their products, comply with current Good Manufacturing Practices and submit marketing materials before being allowed to market pharmaceutical products.&#160;&#160;While we plan to pursue or support the pursuit of the approval of our product, success in acquiring regulatory approval for any product is not assured.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to market our pharmaceutical product in Canada, the United States, Europe and other jurisdictions, we must successfully meet the requirements of those jurisdictions. The requirements of the Appropriate Regulatory Authority will generally include the following stages as part of the regulatory process:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pre-Pharmacological Studies</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;">- Pre-Pharmacological studies involve extensive testing on laboratory animals to determine if a potential therapeutic product has utility in an </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;disease model and has any adverse toxicology in a disease model.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investigational New Drug Application</font><font style="font-family:inherit;font-size:10pt;">&#32;- An Investigational New Drug ("IND") Submission, or the equivalent, must be submitted to the appropriate regulatory authority prior to conducting Pharmacological Studies.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pharmacological Studies&#160;</font><font style="font-family:inherit;font-size:10pt;">(or Phase 1 Clinical Trials)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">- Pharmacological studies are designed to assess the potential harmful or other side effects that an individual receiving the therapeutic compound may experience.&#160;&#160;These studies, usually short in duration, are often conducted with healthy volunteers or actual patients and use up to the maximum expected therapeutic dose.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Therapeutic Studies</font><font style="font-family:inherit;font-size:10pt;">&#160;(or Phase 2 and 3 Clinical Trials) - Therapeutic studies are designed primarily to determine the appropriate manner for administering a drug to produce a preventive action or a significant beneficial effect against a disease.&#160;&#160;These studies are conducted using actual patients with the condition that the therapeutic is designed to remedy.  Prior to initiating these studies, the organization sponsoring the program is required to satisfy a number of requirements via the submission of documentation to support the approval for a clinical trial.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Drug Submission </font><font style="font-family:inherit;font-size:10pt;">- After all three phases of a clinical trial have been completed, the results are submitted with the original IND Submission to the appropriate regulatory authority for marketing approval.&#160;&#160;Once marketing approval is granted, the product is approved for commercial sales.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketing Approvals</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of the preclinical and clinical testing, together with manufacturing and controls information, are submitted to regulatory agencies in order to obtain approval to commence commercial sales. In responding to such an application, regulatory agencies may grant marketing approval, request additional information or further research, or deny the application if they determine that </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the application does not satisfy their regulatory approval criteria. Approval for a pharmaceutical or biologic product may not be granted on a timely basis, if at all, or if granted may not cover all the clinical indications for which approval is sought, or may contain significant limitations in the form of warnings, precautions or contraindications with respect to conditions of use.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Satisfaction of pre-market approval requirements for new drugs and biologics typically takes several years, and the actual time required may vary substantially based upon the type, complexity and novelty of the product or targeted disease. Government regulation may delay or prevent marketing of potential products for a considerable period of time and impose costly procedures upon our activities. Success in early stage clinical trials or with prior versions of products does not assure success in later stage clinical trials. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations that could delay, limit or prevent regulatory approval.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Post-Marketing Regulations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once approved, regulatory agencies may withdraw the product approval if compliance with pre- and/or post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, they may require post-marketing studies, referred to as Phase 4 studies, to monitor the effect of an approved product, and may limit further marketing of the product based on the results of these post-market studies. The FDA and other foreign regulatory agencies have broad post-market regulatory and enforcement powers, including the ability to levy fines and penalties, suspend or delay issuance of approvals, seize or recall products, or withdraw approvals.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Manufacturing Regulations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use contract toll manufacturers to produce pelareorep.&#160;&#160;Our toll manufacturers are subject to periodic inspection by the FDA, the United States Drug Enforcement Administration, or DEA, and other domestic and foreign authorities where applicable, and must comply with cGMP regulations. Manufacturers of biologics also must comply with general biological product standards. Failure to comply with the statutory and regulatory requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product, or mandatory or voluntary recall of a product.&#160;&#160;Adverse experiences with the product must be reported to the FDA and foreign agencies and could result in the imposition of market restrictions through labeling changes or in product removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following approval.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising and Promotion Regulations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to both pre- and post-market product advertising and promotion, the FDA and similar foreign agencies impose a number of complex regulations on entities that advertise and promote pharmaceuticals and biologics, which include, among other things, standards and regulations relating to direct-to-consumer advertising, off-label promotion, industry sponsored scientific and educational activities, and promotional activities involving the Internet. These agencies have very broad enforcement authority and failure to abide by these regulations can result in penalties including the issuance of a warning letter directing the entity to correct deviations from requisite standards, a requirement that future advertising and promotional materials be pre-cleared by the FDA or relevant foreign agencies, and foreign, state and federal civil and criminal investigations and prosecutions.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Government Regulations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances in connection with our research. In each of these areas, as above, the government has broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products, and withdraw approvals, any one or more of which could have a material adverse effect upon us.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Market and Competition </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">According to estimates for 2018 from the American Cancer Society, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;Americans are expected to be diagnosed with cancer in the year, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">609,640</font><font style="font-family:inherit;font-size:10pt;">&#32;Americans are expected to die of cancer.&#160;&#160;Cancer is the second most common cause of death in the United States, exceeded only by heart disease.&#160;In the United States, the relative lifetime risk of a male or female developing cancer is 1 in </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">&#32;(Source: American Cancer Society's Cancer Facts &amp; Figures 2018).  The prevalence of breast cancer in the United States in 2016 was 3.56 million, of which there were 2.6 million patients with HR+/HER2- subtype and 154,885 patients with HR+/HER2- stage IV breast cancer. (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Source: </font><font style="font-family:inherit;font-size:10pt;color:#282828;font-style:italic;">https://seer.cancer.gov/statfacts/html/breast.html. Accessed on March 28, 2017. Howlader, Nadia, et al. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. Journal of the National Cancer Institute. Accessed March 28, 2017).</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The costs of this disease state are also significant.&#160;&#160;In the United States, the American Cancer Society reported in its Cancer Facts &amp; Figures 2018 that the Agency for Healthcare Research and Quality estimated the 2015 direct medical costs for cancer were </font><font style="font-family:inherit;font-size:10pt;">$80.2 billion</font><font style="font-family:inherit;font-size:10pt;">.  (Source: American Cancer Society's Cancer Facts &amp; Figures 2018).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We face substantial competition in the development of products for cancer and other diseases. This competition from other manufacturers of the same types of products and from manufacturers of different types of products designed for the same uses is expected to continue in both US and international markets.&#160;&#160;Oncolytic virus therapies, our primary focus area, are rapidly evolving areas in the biotechnology industry and are expected to undergo many changes in the coming years as a result of technological advances. We are currently aware of a number of groups that are developing oncolytic virus therapies including early-stage and established biotechnology companies, pharmaceutical companies, academic institutions, government agencies and research institutions. We face competition from all of these groups in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. It is possible that our competitors could achieve earlier market commercialization, could have superior patent protection, or could have safer, more effective or more cost-effective products. These factors could render our potential products less competitive, which could adversely affect our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Marketing Strategy</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The markets for the cancer product being developed by us may be large and could require substantial sales and marketing capability.&#160;&#160;Before or upon successful completion of the development of a cancer product, we intend to enter into one or more strategic partnerships or other collaborative arrangements with a pharmaceutical company or other company with marketing and distribution expertise to address this need.&#160;&#160;If necessary, we will establish arrangements with various partners for different geographical areas or specific applications at various times in the development process.&#160;&#160;Our management and consultants have relevant experience with the partnering process.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Seasonality of Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our results of operations have not been materially impacted by seasonality.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organizational Structure</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had one material wholly-owned operating subsidiary; Oncolytics Biotech (Barbados) Inc. (&#8220;OBB&#8221;), a Barbados company.&#160;&#160;In addition, Oncolytics Biotech (US) Inc., a Delaware corporation, is a material wholly owned subsidiary  of OBB.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.&#160;&#160;&#160;&#160;&#160;&#160;Property, Plant and Equipment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently lease our head office in Calgary, Alberta, Canada as well as our office spaces in San Diego, California, US and Barbados. We do not own or lease any other office space, manufacturing facilities or equipment and do not have any current plans to construct or acquire any facilities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s72C1F8C007D354889D9141FF844BA102"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4A.&#160;&#160;UNRESOLVED STAFF COMMENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sC79AB28872E35250A2B9231DF1E9AD0A"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Management Discussion and Analysis (&#8220;MD&amp;A&#8221;) contains forward-looking statements, including our belief as to the potential of REOLYSIN, a therapeutic reovirus, as a cancer therapeutic and our expectations as to the success of our research and development and manufacturing programs in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.&#160;&#160;See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the forward-looking statements made within our MD&amp;A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our development program, our ability to receive regulatory approval to commence enrollment in our clinical trial program, the final results of our co-therapy clinical trials, our ability to maintain our supply of REOLYSIN and future expense levels being within our current expectations.&#160;&#160;Investors are cautioned against placing undue reliance </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">on forward-looking statements.&#160;&#160;We do not undertake to update these forward-looking statements except as required by applicable law.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Results</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please see our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please see our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development, Patents, and Licenses, etc.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please see the disclosure in "Item 4.&#160;&#160;Information on the Company B. Business Overview" for information on the Company&#8217;s research and development policies.&#160;Our research and development expenses were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$9,392,623</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$9,770,007</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8,601,864</font><font style="font-family:inherit;font-size:10pt;">&#32;for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Trend Information</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is important to note that historical patterns of expenditures cannot be taken as an indication of future expenditures.&#160;&#160;The amount and timing of expenditures and availability of capital resources vary substantially from period to period, depending on the level of research and development activity being undertaken at any one time and the availability of funding from investors and prospective commercial partners.  See our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;Management Discussion and Analysis in Exhibit 15.1 for our comparative discussion on our expenditures between </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and our expectations for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except as disclosed elsewhere in our annual report, we know of no trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our liquidity or capital resources or that would cause reported financial information not necessarily to be indicative of future operating results or financial conditions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had not entered into any off-balance sheet arrangements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">F.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tabular Disclosure of Contractual Obligations</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have the following contractual obligations as at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:580px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:172px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:94px;"></td><td style="width:4px;"></td><td style="width:70px;"></td><td style="width:4px;"></td><td style="width:72px;"></td><td style="width:4px;"></td><td style="width:82px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations</font></div></td><td colspan="10" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Less than 1 year</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2 -3 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4 - 5 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">After 5 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital lease obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">740,850</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,987</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">411,733</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,130</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,980,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,980,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long term obligations</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total contractual obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,721,304</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,266,441</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">411,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,130</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Our operating leases are comprised of our office leases and exclude our portion of operating costs.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to fund our capital expenditure requirements and commitments with existing working capital.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">G.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Safe Harbor</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We seek safe harbor for our forward-looking statements contained in Items 5.E and F.&#160;&#160;See &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cautionary Note Regarding Forward-Looking Statements&#8221;.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s95848A0CB4A250D6BEA12F9A66337A32"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Directors and Senior Management</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the names and places of residence of all our directors and officers as at December 31, 2017, as well as the positions and offices held by such persons and their principal occupations.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:120px;"></td><td style="width:96px;"></td><td style="width:380px;"></td><td style="width:86px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Place of Residence&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position with the Company</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Occupation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director of the Company Since</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deborah M. Brown, BSc, MBA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(2)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ontario, Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to being a Management Consultant since 2014, Ms. Brown is currently the Managing Partner at Accelera CANADA, a specialty consultancy firm that assists emerging biopharma ventures in the United States and Europe with the development and implementation of Canadian market strategies. She held progressively senior roles at EMD Serono from 2000 to 2014, including Executive Vice President of Neuroimmunology for the company's U.S. operations, and President and Managing Director of the company's Canadian operations. In 2012, Ms. Brown was Chair of the Canadian National Pharmaceutical Organization (now Innovative Medicines Canada) and served on its Board of Directors from 2007 to 2014. She currently sits on the Boards of Life Sciences Ontario, the Strategic Executive Advisory Council for Canadian Cancer Trials Group, and her local SPCA. Ms. Brown holds an MBA from University of Western Ontario's Ivey School of Business, an Hons B.Sc. from the University of Guelph and completed the Merck executive development programme at the University of Hong Kong, INSEAD and Northwestern University's Kellogg School of Management.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 2, 2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew C. Coffey, PhD</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alberta, Canada</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer and Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A co-founder of the Company, Dr. Coffey has been the President and Chief Executive Officer of the Company since January 2017.  Dr. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey has held the positions of Interim President and Chief Executive Officer from November 2016 to January 2017, Chief Operating Officer of the Company from December 2008 to November 2016, Chief Scientific Officer from December 2004 to December 2008, Vice-President of Product Development from July 1999 to December 2004 and Chief Financial Officer from September 1999 to May 2000.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 11, 2011</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andrew de Guttadauro</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">California, USA</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andrew de Guttadauro has more than 25 years of biopharmaceutical commercialization and business development experience in. He has held executive and senior-level positions at leading pharmaceutical and biotechnology companies, working on initiatives across both developed and emerging markets globally.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. de Guttadauro began his career at TAP Pharmaceuticals, supporting the launch of blockbuster drugs, Lupron&#174; and Prevacid&#174;. He held a variety of marketing positions at Amgen, contributing to the success of Enbrel&#174;, Aranesp&#174;, and Epogen&#174; before joining MedImmune to lead marketing efforts for the FluMist&#174; inhaled influenza vaccine. Following a two-year assignment overseeing the commercial development of Zevalin&#174;, the first radioimmunotherapy product approved for use in the United States, Mr. de Guttadauro took on the role of Senior Director of Strategy at Biogen Idec. He then served as Vice President of Corporate Development at Vical, supporting the execution of distribution agreements for Allovectin&#174;. Prior to joining Oncolytics, Mr. de Guttadauro was a Principal at 1798 Consultants Inc., a healthcare consulting firm providing commercialization, market access, and compliance strategic advice to leading and emerging biopharmaceutical companies.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. de Guttadauro has a Bachelor of Science degree in engineering from the United States Military Academy at West Point.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:120px;"></td><td style="width:96px;"></td><td style="width:380px;"></td><td style="width:86px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Place of Residence&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position with the Company</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Occupation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director of the Company Since</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andres A. Gutierrez, MD, PhD</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey, USA</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Medical Officer</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Gutierrez is board certified in internal medicine and completed a fellowship in medical oncology. Most recently he has held progressively senior clinical development positions designing and implementing both early and later-stage oncology clinical studies at a range of U.S. and European companies including Sellas Life Sciences Group, Bristol-Myers Squibb, Sunesis Pharmaceuticals Inc., Biomarin Pharmaceutical Inc., Proteolix, and Oculus Innovative Sciences. Prior to that, he held a series of academic and consulting positions. Over his 32 year career, he has authored and co-authored more than 90 peer-reviewed publications and abstracts and presented at numerous conferences. He received his MD and a PhD in Biomedical Sciences from the National Autonomous University of Mexico.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham, MBA, FCPA, FCMA, ICD.D</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(2)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ontario, Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ms. Holtham held a number of financial positions over a 19-year career with the Canadian subsidiary of Nabisco Inc., rising to become Senior Vice President and Chief Financial Officer. Then in 2002, she joined Toronto, Ontario-based Hospital for Sick Children as Vice President, Finance and Chief Financial Officer, a position she held for eight years. Through her career she has participated in many initiatives ranging from traditional finance functions and operations oversight to intellectual property portfolio management and mergers and acquisitions. Ms. Holtham is an FCPA, FCMA, holds an MBA from the University of Toronto and has completed the Institute of Corporate Directors Designation (ICD.D). Ms. Holtham holds a number of board and audit committee positions in both private and public sectors, including audit committee chair and director of Jamieson Wellness.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 18, 2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">J. Mark Lievonen, CM, FCPA, FCA, LLD</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(3)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ontario, Canada</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Lievonen held the position of President of Sanofi Pasteur Limited, a vaccine development, manufacturing and marketing company, from 1999 to 2016. He is a Director of Acerus Pharmeceuticals Corporation, Quest PharmaTech Inc., and the Gairdner Foundation. Mr. Lievonen has served on a number of industry and not-for-profit boards including as the chair of Rx&amp;D (now Innovative Medicines Canada), BIOTECanada, and the Markham Stouffville Hospital Foundation, as Vice-Chair of the Ontario Institute for Cancer Research, as a Director of the Public Policy Forum, and as a Governor of York University Mr. Lievonen was appointed to the Order of Canada in 2015,  named a Chevalier de l'Ordre National de M&#233;rite by the government of France in 2007, and inducted into the Canadian Healthcare Marketing Hall of Fame in 2013.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 5, 2004</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk J. Look, CA</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alberta, Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Look is a Chartered Accountant with more than fifteen years of experience in accounting, finance, tax and treasury. Mr. Look joined Oncolytics as the Company's Controller in April 2003, and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, from 2000 to April 2003, Mr. Look was Manager of Audit and Assurance Services with Ernst &amp; Young LLP in Canada. From 1998 to the end of 1999, Mr. Look held the positions of Audit Manager and Senior Accountant at Ernst &amp; Young LLP in Chile.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano, MBA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(2)(5)</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;New Jersey, USA</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chair of the Board</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Pisano has more than 30 years of experience as a pharmaceutical industry executive and was recognized in 2010 as Pharma Executive of the Year by the World Vaccine Congress. Mr. Pisano is the former president and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. He is credited with driving Sanofi Pasteur's leadership within the worldwide influenza market and capturing 50 percent of global sales. He also laid the foundation for the company's global pediatric vaccines strategy. During his tenure as CEO, Mr. Pisano bolstered the Sanofi Pasteur pipeline with the acquisitions of Acambis PLC, a bio-tech based in Boston in 2008 and Shantha Biotechnics, a highly regarded Indian vaccine company in 2010. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor's degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio. Mr. Pisano is a Board director and Chairman of the compensation and Governance Committee for Immunovaccine; a biotech based in Halifax.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 9, 2013</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:120px;"></td><td style="width:96px;"></td><td style="width:380px;"></td><td style="width:86px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Place of Residence&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position with the Company</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Occupation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director of the Company Since</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William G. Rice, PhD</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)(4)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">California, USA</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Rice holds the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. Also, from 2003 to present, he has served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. He served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center, and as a faculty member in the Division of Pediatric Hematology and Oncology at Emory School of Medicine. Dr. Rice holds a PhD in biochemistry from Emory University and was a post-doctoral trainee in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Michigan Medical Center.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 8, 2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd R. Seizinger, MD, PhD</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)(4)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey, USA and Munich, Germany</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Seizinger is currently Chairman and/or Board member of a number of biotech companies in the U.S. and Europe, including: Oxford BioTherapeutics Ltd., CryptoMedicx Inc., Opsona Ltd., Aprea AB, and Vaccibody AS. From 1998 to 2009, he served as President and Chief Executive Officer of GPC Biotech. He also served as Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances at Bristol-Myers Squibb in Princeton, NJ. Prior to his appointments in the biotechnology and pharmaceuticals sectors, Dr. Seizinger held professorships and senior staff appointments at Harvard Medical School, Princeton University and Massachusetts General Hospital.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 8, 2015</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">Member of the Audit Committee.&#160;Ms. Holtham is Chair of this Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">Member of the Compensation Committee.&#160;Mr. Pisano is Chair of this Committee. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">Member of the Governance Committee.&#160;Mr. Lievonen is Chair of this Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">Member of the Science and Technology Committee. Dr.'s Rice and Seizinger serve as Co-Chairs of this Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">Mr. Pisano, as Chair of the Board, serves as an ex-officio member of the Governance and Science and Technology Committees.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;19, 2018</font><font style="font-family:inherit;font-size:10pt;">, the directors and senior officers as a group beneficially owned, directly or indirectly, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">400,250</font><font style="font-family:inherit;font-size:10pt;">&#32;of our common shares, representing </font><font style="font-family:inherit;font-size:10pt;">0.28%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the issued and outstanding common shares.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our directors are associated with other companies, which may give rise to conflicts of interest.&#160;&#160;In accordance with the</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;">ABCA, directors who have a material interest in any person who is a party to a material contract or a proposed material contract with us are required, subject to certain exceptions, to disclose that interest and abstain from voting on any resolution to approve that contract.&#160;&#160;In addition, the directors are required to act honestly and in good faith with a view to the best interests of Oncolytics Biotech Inc.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None of our directors have been a director or officer of a company that went bankrupt in the last 10 years.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None of our directors or officers are related by blood, marriage or adoption to any other director or officer.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not aware of any arrangement or understanding with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as a director or officer.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Compensation</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Directors</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth information concerning the total compensation paid in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to each director.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:679px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:129px;"></td><td style="width:81px;"></td><td style="width:77px;"></td><td style="width:78px;"></td><td style="width:92px;"></td><td style="width:66px;"></td><td style="width:90px;"></td><td style="width:62px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fees Earned</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Based Awards</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Option-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Based Awards</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Equity Incentive Plan Compensation</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pension Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other Compensation</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deborah Brown</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,249</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,278</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,666</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,193</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,003</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,278</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Lievonen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,270</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,278</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,548</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,270</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,770</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,040</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William Rice</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,270</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,278</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,548</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd Seizinger</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,108</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,164</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,272</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Directors are paid fees in US Dollars.&#160;These amounts are presented in Canadian dollars and have been converted at a US/CDN exchange rate of $1.2545.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><font style="font-family:inherit;font-size:10pt;">The value of share based and option based awards are based on the grant date assumptions as disclosed in note 8 "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share Based Payments" </font><font style="font-family:inherit;font-size:10pt;">in our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;audited consolidated financial statements.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><font style="font-family:inherit;font-size:10pt;">Ms. Brown was appointed as a director on November 2, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Officers</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Summary Compensation Table</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth information concerning the total compensation paid to our officers in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:697px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:146px;"></td><td style="width:36px;"></td><td style="width:53px;"></td><td style="width:54px;"></td><td style="width:57px;"></td><td style="width:52px;"></td><td style="width:81px;"></td><td style="width:52px;"></td><td style="width:81px;"></td><td style="width:82px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Name and principal position</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Salary<br>$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Share-<br>based awards<br>$</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Option-<br>based </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">awards </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;$</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Bonus</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-equity incentive<br>plan compensation<br>$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Pension value<br>$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">All other compensation<br>  $</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total<br>compensation </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dr. Matthew C. Coffey</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">430,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,964</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">172,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">62,235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">726,199</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Kirk J. Look</font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Chief Financial Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">345,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">46,473</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">55,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">567,446</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dr. Andres A. Gutierrez</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Chief Medical Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">376,350</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,723</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">35,482</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">543,555</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Andrew de Guttadauro</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)(5)</sup></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">President, Oncolytics Biotech (US) Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">144,267</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38,487</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72,134</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">299,903</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The value of share and option based awards are based on the grant date assumptions as disclosed in note 8 "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share Based Payments" </font><font style="font-family:inherit;font-size:10pt;">in our </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;audited consolidated financial statements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The dollar amounts set forth under this column are related to contributions to the officers' respective retirement savings plan and amounts provided for health care benefits by the Company. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None of the compensation paid to Dr. Coffey related to his role as a director of the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US Employees are paid salaries, bonuses and other compensation in US Dollars.&#160;&#160;These amounts are presented in Canadian dollars and have been converted at a US/CDN exchange rate of $1.2545, $1.3427 and $1.3840 for the years 2017, 2016 and 2015, respectively.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. de Guttadauro was appointed as President, Oncolytics Biotech (US) Inc., a wholly-owned subsidiary of the Corporation, on June 29, 2017.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Narrative Discussion</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into employment agreements with each of the following Executive Officers (each an "Employment Agreement").&#160;&#160;Pursuant to the terms of the Employment Agreements,</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:398px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:261px;"></td><td style="width:64px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and principal position</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;Salary</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Matthew C. Coffey</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">475,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk J. Look, C.A.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">365,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Andres A. Gutierrez</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Medical Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andrew de Guttadauro</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Oncolytics Biotech (US) Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 1:</font><font style="font-family:inherit;font-size:10pt;">&#160;US Employees are paid in US Dollars and salaries above for those US employees are presented in US dollars.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, each Executive Officer is entitled to additional benefits and performance-based bonuses.&#160;&#160;As well, the Employment Agreements provide that each Executive Officer is subject to certain confidentiality and non-competition restrictions during and following the course of their respective employment with the Company.&#160;&#160;Each Employment Agreement shall continue until terminated by either party in accordance with the notice provisions thereof.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not provide pension plan benefits to its Executive Officers and employees. The Company does not currently have a stock appreciation rights plan.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Termination of Employment or Change of Control</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reflects amounts payable to the Executive Officers based on each Executive Officer's employment agreement assuming that their employment was terminated on December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;without cause or due to a change of control of the Company.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:509px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:242px;"></td><td style="width:128px;"></td><td style="width:4px;"></td><td style="width:128px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Termination without Cause Severance</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Change of Control Severance</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr.&#160;Matthew C. Coffey<br>Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">541,168</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,082,335</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk J. Look, C.A.<br>Chief Financial Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">844,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr.&#160;Andres A. Gutierrez</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)<br></sup></font><font style="font-family:inherit;font-size:10pt;">Chief Medical Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349,619</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">699,238</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andrew de Guttadauro</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Oncolytics Biotech (US) Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">526,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, all options granted to Officers had fully vested except for the options granted on December 1, 2015, November 10, 2016 and July 3, 2017.  As a result, all Officers shall be entitled to exercise all or any part of their vested Options, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such Officer is terminated unless otherwise approved by the Board of Directors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a change of control of the Company, the Officers shall be entitled to exercise all or a part of their Options, whether vested or not, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such Officer is terminated.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US Employees are paid in US Dollars and are presented in US dollars.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Board Practices</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our directors are elected by the shareholders at each Annual General Meeting (or Annual Special Meeting) and typically hold office until the next meeting, at which time they may be re-elected or replaced.&#160;&#160;Casual vacancies on the board are filled by the remaining directors and the persons filling those vacancies hold office until the next Annual General Meeting (or Annual Special Meeting), at which time they may be re-elected or replaced.&#160;&#160;The officers are appointed by the Board of Directors and hold office indefinitely at the pleasure of the Board of Directors.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:37%;"></td><td style="width:20%;"></td><td style="width:18%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Place of Residence</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position with the Corporation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director of the Corporation Since</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Expiration of Current Term of Office</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew C. Coffey Ph.D</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alberta, Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer and Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 11, 2011</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2018 Annual General Meeting of the Shareholders</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deborah Brown, B.Sc., MBA</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ontario, Canada</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 2, 2017</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2018 Annual General Meeting of the Shareholders</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;</sup></font><font style="font-family:inherit;font-size:10pt;">FCPA, FCMA, ICD.D</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ontario, Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 18, 2014</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2018 Annual General Meeting of the Shareholders</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">J. Mark Lievonen, CM, FCPA, FCA, LLD</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ontario, Canada</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 5, 2004</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2018 Annual General Meeting of the Shareholders</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano, MBA</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey, USA</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chair and Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 9, 2013</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2018 Annual General Meeting of the Shareholders</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William G. Rice, Ph.D.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">California, USA</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 8, 2015</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2018 Annual General Meeting of the Shareholders</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd R. Seizinger, M.D., Ph.D.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey, USA and Munich Germany</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 8, 2015</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2018 Annual General Meeting of the Shareholders</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Directors&#8217; Contracts</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We receive a director&#8217;s consent from each of the independent directors upon their acceptance of their director&#8217;s position.&#160;&#160;We also enter into an Indemnity Agreement and Directors Confidentiality and Intellectual Property Assignment Agreement with each director.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not have any contracts with any of its directors which provide for benefits upon the termination of employment.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation of Directors</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each director who is not a salaried employee of the Company is entitled to the following fees:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Annual Retainer </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each director receives a base retainer of US$40,000.  In addition to the base retainer directors are eligible to receive the following additional fees depending on committee involvement:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Retainers (USD):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Board chair&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$40,000</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit Committee chair&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$20,000</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Governance &amp; Compensation Committee chair&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$10,000</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Science &amp; Technology co-chair&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$15,000</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-chair member of the Audit Committee&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$10,000</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-chair member of the Governance or Compensation Committee&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$  5,000</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Directors, annually, may opt to take up to 100% of their respective annual retainer in restricted share awards. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Share Units </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the combined retainer, the Corporation will grant annually $20,000 of restricted share awards that will vest over a three year period. The annual restricted share unit award will be granted on or about October 1 of each year.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also grant to directors, from time to time, stock options in accordance with the Option Plan and the reimbursement of any reasonable expenses incurred by them while acting in their directors' capacity.&#160;&#160;During the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, total compensation of </font><font style="font-family:inherit;font-size:10pt;">$746,879</font><font style="font-family:inherit;font-size:10pt;">&#32;was paid to the independent directors which consisted of fee payments of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$326,170</font><font style="font-family:inherit;font-size:10pt;">, share based awards of </font><font style="font-family:inherit;font-size:10pt;">$406,043</font><font style="font-family:inherit;font-size:10pt;">&#32;and option based awards of </font><font style="font-family:inherit;font-size:10pt;">$14,666</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation Committee</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Corporation has formed a compensation committee (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Compensation Committee</font><font style="font-family:inherit;font-size:10pt;">&#8221;) which consists of four outside, independent directors, Dr. Seizinger, Ms. Holtham and Ms. Brown, and Mr. Pisano, the Chair of the Board. Mr. Pisano is the Chair of the Compensation Committee. No member of the Compensation Committee has been an employee or officer of the Company or any of its affiliates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The objectives of the Corporation&#8217;s compensation arrangements are: (i)&#160;to attract and retain key personnel; (ii)&#160;to encourage commitment to the Corporation and its goals; (iii)&#160;to align executive interests with those of its shareholders; and (iv)&#160;to reward executives for performance in relation to overall corporate progress goals.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The key elements of the compensation program are the base salary, health benefits, and payments allocated to employees to be directed by them to their personal retirement accounts. Bonuses and the granting of Options (as defined herein) and Share Awards (as defined herein) are also part of the Corporation&#8217;s compensation program and are based on corporate performance. Part of corporate performance includes goals and objectives that are determined based on the strategic planning and budgeting process, which is conducted at least annually. The elements of the compensation plan are intended to reward performance, and the various elements are intended to provide a blend of short-term and long-term incentives to align the interests of management and the shareholders.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In arriving at its recommendations for compensation, the Compensation Committee considers the long-term interests of the Corporation as well as its current stage of development and the economic environment within which it operates. The market for biotechnology companies in the development phase is challenging. Based on these factors, the Compensation Committee recognized the need to strike a balance between compensation to retain employees and resources expended to maintain operations. In the past, the Compensation Committee has engaged specialist consultants to assist in benchmarking its compensation practices and provide recommendations to the committee with respect to compensation for directors and officers.  In 2017, the Committee engaged Radford, An Aon Hewitt Company as a specialist consultant to assist with the benchmarking of officer compensation for 2018.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following a review of the risks in the Corporation&#8217;s compensation policies and practices, the Compensation Committee found no risks that are reasonably likely to have a material adverse effect on the Corporation. The Compensation Committee&#8217;s role of approving the compensation policies and practices includes considering whether the compensation policies and practices could encourage an officer of the Company to take inappropriate or excessive risks.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Corporation&#8217;s corporate trading policy, insiders (including officers and directors) are not permitted to hedge their position in Common Shares, Options, Share Awards, deferred share units, performance share units, debentures or other debt instruments by use of any financial instrument, which would include but is not limited to options, puts, calls, warrants or short sells, designed to benefit the holder from a change in the market value of the Common Shares of the Corporation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the following guidelines were employed by the Board in granting bonuses, Options and Share Awards to the Corporation&#8217;s executive and senior officers. For </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, similar guidelines are expected to be applied.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Annual Bonus, Option Grants and Share Award Grants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the Chief Executive Officer of the Corporation is eligible for a cash bonus of up to 40% of his base salary, the Chief Financial Officer and the Chief Medical Officer is eligible for a cash bonus of up to 35% of his base salary and the other senior officers are eligible for a cash bonus of up to 15 to 25% of their respective base salaries. In addition, when available, the officers are eligible for a combination of Option and Share Award grants. The amount of each grant is determined and approved by the Board with the actual bonus provided and the number of Options and Share Awards granted based upon the overall performance of the Corporation as assessed by the Compensation Committee and approved by the Board. The overall performance of the Corporation is determined by the annual goals and objectives approved by the Board and includes specific objectives with respect to the clinical, manufacturing, and intellectual property plans in combination with financial goals. Previous grants are taken into account when considering new grants of Options and Share Awards.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For 2018, similar guidelines are expected to be applied except the cash bonus target for the Chief Executive Officer will increase to up to 50% of base salary and for the Chief Financial Officer and Chief Medical Officer the cash bonus target will increase to up to  40% of base salary.   For the other senior officers the cash bonus target will increase to up to 30% of base salary.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation Committee Mandate </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Policy Statement</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is the policy of Oncolytics Biotech Inc. (the "Corporation") to establish and maintain a Compensation Committee (the "Committee"), composed entirely of independent directors, to assist the Board of Directors of the Corporation (the "Board") in carrying out its responsibility for the Corporation&#8217;s human resources and compensation policies and processes.  The Committee will be provided with resources commensurate with the duties and responsibilities assigned to it by the Board, including administrative support.  If determined necessary by the Committee, it will have the discretion to investigate and conduct reviews of any human resource or compensation matter including the standing authority to retain experts and special counsel.  In the event of a conflict of interest or potential conflict of interest involving one or more of the directors or members of management, the Committee may modify the procedures and requirements set out in this Mandate restrict communication and sharing of information to independent directors or otherwise take reasonable measures to manage the conflict of interest or potential conflict of interest.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Composition of Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall consist of a minimum of three (3) directors.  The Board shall appoint the members (&#8220;Members&#8221;) of the Committee and may seek the advice and assistance of the Governance Committee in identifying qualified candidates.  The Board shall appoint one Member of the Committee to be the Chair of the Committee, or delegate such authority to appoint the Chair of the Committee to the Committee.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chair of the Committee shall be responsible for the leadership of the Committee, including preparing or approving the agenda, presiding over the meetings, and making committee assignments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each director appointed to the Committee by the Board shall be an outside director who is unrelated.  An outside, unrelated director is a director who meets the requirements of NASDAQ Rule 5605 and National Instrument 58-101 who is independent of management and is free from any interest, any business or other relationship which could, or could reasonably be perceived, to materially interfere with the director&#8217;s ability to be independent of management and to act with a view to the best interests of the Corporation, including, but not limited to the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by the Corporation to such director and whether such director is affiliated with the Corporation, a subsidiary of the Corporation or an affiliate of a subsidiary of the Corporation other than interests and relationships arising from shareholding.  In determining whether a director is independent of management, the Board shall make reference to the then current legislation, rules, policies and instruments of applicable regulatory authorities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Member shall be appointed by the Board annually at the next scheduled meeting of the Board following the AGM.  The Members will be appointed to hold office until the next annual general meeting of shareholders or until their successors are appointed. The Board may remove a Member at any time and may fill any vacancy occurring on the Committee.  A Member may resign at any time and a Member will automatically cease to be a Member upon ceasing to be a director. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chair of the Board shall be an ex officio Member of the committee. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Meetings of the Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall meet a minimum of twice per year at such time and place as may be designated by the Chair of the Committee and whenever a meeting is requested by the Board, a Member of the Committee, or the Chief Executive Officer of the Corporation (the "CEO"). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of each meeting of the Committee shall be given to each Member of the Committee.  The CEO shall attend each meeting of the Committee whenever requested to do so by a Member of the Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of a meeting of the Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be in writing, including by electronic communication facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state the nature of the business to be transacted at the meeting in reasonable detail;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to the extent practicable, be accompanied by copies of documentation to be considered at the meeting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be given at least two business days prior to the time stipulated for the meeting or such shorter period as the Members of the Committee may permit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A quorum for the transaction of business at a meeting of the Committee shall consist of a majority of the Members of the Committee.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Member or Members of the Committee may participate in a meeting of the Committee by means of such telephonic, electronic or other communication facilities, as permits all persons participating in the meeting to communicate adequately with each other.  A Member participating in such a meeting by any such means is deemed to be present at the meeting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the absence of the Chair of the Committee, the Members of the Committee shall choose one of the Members present to be Chair of the meeting.  If the Board has appointed a Corporate Secretary, the Corporate Secretary </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">shall be the secretary of the meeting.  If the Board has not appointed a Corporate Secretary, the Members of the Committee shall choose one of the persons present to be the secretary of the meeting or may have another person who is not a Member of the Committee present to record the minutes of the meeting.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Minutes shall be kept of all meetings of the Committee and shall be signed by the Chair and the secretary of the meeting.  Minutes of the meetings of the Committee shall be distributed to members of the Committee, to other members of the Board and, with the exception of &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in camera</font><font style="font-family:inherit;font-size:10pt;">&#8221; items, to the Chief Executive Officer and Chief Financial Officer.  Notwithstanding the foregoing, distribution of minutes of meetings or parts thereof may be restricted to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Duties and Responsibilities of the Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee&#8217;s primary duties and responsibilities are to review and make recommendations to the Board in respect of:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">human resource policies, practices and structures (to monitor consistency with the Corporation&#8217;s goals and near and long-term strategies, support of operational effectiveness and efficiency, and maximization of human resources potential);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">compensation policies and guidelines;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">management incentive and perquisite plans and any non-standard remuneration plans;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">senior management, executive and officer appointments and their compensation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">management succession plans, management training and development plans, termination policies and termination arrangements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Board compensation matters.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In carrying out its duties and responsibilities, the Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually assess and make a recommendation to the Board with regard to the competitiveness and appropriateness of the compensation package of the CEO, all other officers of the Corporation and such other key employees of the Corporation or any subsidiary of the Corporation as may be identified by the CEO and approved by the Committee (collectively, the "Designated Employees");</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually review the performance goals and criteria for the CEO and evaluate the performance of the CEO against such goals and criteria and recommend to the Board the amount of regular and incentive compensation to be paid to the CEO;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually, review and make a recommendation to the Board regarding the CEO&#8217;s performance evaluation of Designated Employees and the CEO&#8217;s recommendations with respect to the amount of regular and incentive compensation to be paid to such Designated Employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review and make a recommendation to the Board regarding any employment contracts or arrangements with each of the Designated Employees, including any retiring allowance arrangements or any similar arrangements to take effect in the event of a termination of employment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">periodically, review the compensation philosophy statement of the Corporation and make recommendations for change to the Board as considered necessary;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">from time to time, review and make recommendations to the Board in respect of the design, benefit provisions, investment options and text of applicable pension, retirement and savings plans or related matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually, in conjunction with the Corporation&#8217;s general and administrative budget, review and make recommendations to the Board regarding compensation guidelines for the forthcoming budget period;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">when requested by the CEO, review and make recommendations to the Board regarding short term incentive or reward plans and, to the extent delegated by the Board, approve awards to eligible participants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review and make recommendations to the Board regarding incentive stock option plans or any other long term incentive plans and to the extent delegated by the Board, approve grants to participants and the magnitude and terms of their participation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">as required, fulfill the obligations assigned to the Committee pursuant to any other employee benefit plans approved by the Board;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually, prepare or review the report on executive compensation required to be disclosed in the Corporation&#8217;s information circular or any other human resource or compensation matter required to be publicly disclosed by the Corporation;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually, review and make a recommendation to the Board regarding the compensation of the Board of Directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xiii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">as determined in the sole discretion of the Committee, retain independent advice in respect of human resources and compensation matters from a compensation consultant, legal counsel or other advisor (the &#8220;Advisor&#8221;) and, if deemed necessary by the Committee, meet separately with the Advisor; the Committee shall be directly responsible for the appointment, compensation and oversight of the work of the Advisor retained by the Committee; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xiv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">select, or receive advice from, an Advisor to the Committee, other than in-house legal counsel, after taking into consideration the following factors:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the provision of other services to the Corporation by the entity that employs the Advisor ;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the amount of fees received from the Corporation by the entity that employs the Advisor, as a percentage of the total revenue of the entity that employs the Advisor;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the policies and procedures of the entity that employs the Advisor that are designed to prevent conflicts of interest;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any business or personal relationship of the Advisor with a member of the Board;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any stock of the Corporation owned by the Advisor; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any business or personal relationship of the Advisor or the entity employing the Advisor with an executive officer of the Corporation;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provided however, none of the above factors shall prevent the Committee from retaining any Advisor as the Committee deems appropriate, in its sole discretion, after consideration of the above factors. </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review and consider the implications of the risks associated with the Corporation&#8217;s compensation policies and practices, specifically, situations that could potentially encourage an insider to expose the Corporation to inappropriate or excessive risks; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xvi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">assess, on an annual basis, the adequacy of this Mandate and the performance of the Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the foregoing, the Committee shall undertake on behalf of the Board such other initiatives as may be necessary or desirable to assist the Board in discharging its responsibility for the Corporation&#8217;s human resources development, performance evaluation, compensation and succession planning programs are in place and operating effectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall assess, on an annual basis, the adequacy of this Mandate and the performance of the Committee.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reporting</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.  The Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">External Advisors</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If, in order to properly discharge its function, duties and responsibilities, it is necessary, in the opinion of the Committee that the Committee obtains the advice and counsel of external advisors, the Chair shall, at the request of the Committee, engage the necessary experts. The Committee shall keep the Board apprised of both the selection of experts and the expert&#8217;s findings through the Committee&#8217;s regular reports to the Board.  The Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Mandate</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Mandate was last reviewed, amended and approved by the Board on March 9, 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Audit Committee</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Corporation has formed an Audit Committee in accordance with Section 3(a)(58)(A) of the United States Securities Exchange Act of 1934, as amended ("Exchange Act"), consisting of four independent directors pursuant to the Rule 5605(a)(2) of the NASDAQ Capital Market and Rule 10A-3 of the Exchange Act: Ms. Deborah Brown, Ms. Angela Holtham, Mr. Lievonen and Mr. Pisano, none of whom are nor have been employees or officers of the Company or any of its affiliates.&#160;&#160;Ms. Holtham is presently the Chair of the Audit Committee.&#160;&#160;Each Audit Committee member is financially literate.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Audit Committee Mandate </font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Policy Statement</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is the policy of Oncolytics Biotech Inc. (the "Corporation") to establish and maintain an Audit Committee, composed entirely of independent directors, to assist the Board of Directors (the "Board") in carrying out their oversight responsibility for the Corporation&#8217;s internal controls, financial reporting and financial risk management processes.  The Audit Committee will be provided with resources commensurate with the duties and responsibilities assigned to it by the Board including administrative support.  If determined necessary by the Audit Committee, it will have the discretion to institute investigations of improprieties, or suspected improprieties within the scope of its responsibilities, including the standing authority to retain special counsel or experts.  In the event of a conflict of interest or potential conflict of interest involving one or more of the directors or members of management, the Audit Committee may modify the procedures and requirements set out in this Mandate restrict communication and sharing of information to independent directors or otherwise take reasonable measures to manage the conflict of interest or potential conflict of interest.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Composition of the Committee</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall consist of a minimum of three (3) directors.   The Board shall appoint the members (&#8220;Members&#8221;) of the Audit Committee and may seek the advice and assistance of the Governance Committee in identifying qualified candidates.  The Board shall appoint one Member of the Audit Committee to be the Chair of the Audit Committee, or delegate such authority to appoint the Chair of the Audit Committee to the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chair of the Committee shall be responsible for leadership of the Committee, including preparing or approving the agenda, presiding over the meetings, and making committee assignments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each director appointed to the Audit Committee by the Board shall be an outside director who is unrelated and independent.  An outside, unrelated and independent director is a director who meets the requirements of NASDAQ Rule 5605(a)(2) and National Instrument 52-110. A director appointed to the audit committee shall also meet the requirements of NASDAQ Rule 5605(c)(2) and Rule 10A-3(b)(1) of the United States Securities Exchange Act of 1934, as amended. Such director shall be independent of management and free from any interest, any business or other relationship which could, or could reasonably be perceived, to materially interfere with the director&#8217;s ability to act with a view to the best interests of the Corporation, other than interests and relationships arising from shareholding.  In determining whether a director is independent of management, the Board shall make reference to the abovementioned rules and any applicable revisions thereto, and any additional relevant and then current legislation, rules, policies and instruments of applicable regulatory authorities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Member of the Audit Committee shall be financially literate.  In order to be financially literate, a director must be, at a minimum, able to read and understand financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Corporation's financial statements. At least one Member shall have accounting or related financial management expertise, meaning the ability to analyze and interpret a full set of financial statements, including the notes attached thereto, in accordance with generally accepted accounting principles and shall be a &#8220;financial expert&#8221; as defined in Item 407 of Regulation S-K promulgated by the U.S. Securities and Exchange Commission and &#8220;financially sophisticated&#8221; as defined in NASDAQ Rule 5605(c)(2).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining whether a Member of the Audit Committee is financially literate or has accounting or related financial expertise, reference shall be made to the then current legislation, rules, policies and instruments of applicable regulatory authorities. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Member of the Audit Committee shall be appointed by the Board annually at the next scheduled meeting of the Board following the AGM.  The Members will be appointed to hold office until the next annual general meeting of shareholders or until their successors are appointed. The Board may remove a Member at any time and may fill any vacancy occurring on the Audit Committee.  A Member may resign at any time and a Member will automatically cease to be a Member upon ceasing to be a director.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chair of the Board shall be an ex officio Member of the committee.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Meetings of the Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall convene a minimum of four times each year at such times and places as may be designated by the Chair of the Audit Committee and whenever a meeting is requested by the Board, a Member of the Audit Committee, the auditors, or senior management of the Corporation.  Scheduled meetings of the </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">Audit Committee shall correspond with the review of the year-end and quarterly financial statements and management discussion and analysis.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of each meeting of the Audit Committee shall be given to each Member of the Audit Committee and to the auditors, who shall be entitled to attend each meeting of the Audit Committee and shall attend whenever requested to do so by a Member of the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of a meeting of the Audit Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be in writing, including by electronic communication facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state the nature of the business to be transacted at the meeting in reasonable detail;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to the extent practicable, be accompanied by copies of documentation to be considered at the meeting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be given at least two business days prior to the time stipulated for the meeting or such shorter period as the Members of the Audit Committee may permit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A quorum for the transaction of business at a meeting of the Audit Committee shall consist of a majority of the Members of the Audit Committee.  However, it shall be the practice of the Audit Committee to require review, and, if necessary, approval of certain important matters by all Members of the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Member or Members of the Audit Committee may participate in a meeting of the Audit Committee by means of such telephonic, electronic or other communication facilities, as permits all persons participating in the meeting to communicate adequately with each other.  A Member participating in such a meeting by any such means is deemed to be present at the meeting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the absence of the Chair of the Audit Committee, the Members of the Audit Committee shall choose one of the Members present to be Chair of the meeting.  If the Board has appointed a Corporate Secretary, the Corporate Secretary shall act as the secretary of the meeting.  If the Board has not appointed a Corporate Secretary, the Members of the Committee shall choose one of the persons present to be the secretary of the meeting or may have another person who is not a Member of the Committee present to record the minutes of the meeting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A member of the Board, senior management of the Corporation and other parties may attend meetings of the Audit Committee; however the Audit Committee (i) shall, at each meeting, meet with the external auditors independent of other individuals other than the Audit Committee; (ii) may exclude: (A) management, (B) directors who are not independent directors, or (C) any party that has a conflict of interest or potential conflict of interest, from part or all of a meeting of the Audit Committee if reasonably necessary for the Audit Committee to properly discharge its responsibilities; and (iii) may meet separately with management.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chief Executive Officer and the Chief Financial Officer shall each attend meetings of the Audit Committee when requested to do so by a Member of the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Minutes shall be kept of all meetings of the Audit Committee and shall be signed by the Chair and the secretary of the meeting.  Minutes of the meetings of the Audit Committee shall be distributed to Members of the Audit Committee, to other members of the Board and, with the exception of &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in camera</font><font style="font-family:inherit;font-size:10pt;">&#8221; items, to the Chief Executive Officer and Chief Financial Officer.  Notwithstanding the foregoing, distribution of minutes of meetings or parts thereof may be restricted to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Audit Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Duties and Responsibilities of the Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee&#8217;s primary duties and responsibilities are to:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">identify and monitor the management of the principal risks that could impact the financial reporting of the Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">monitor the integrity of the Corporation&#8217;s financial reporting process and system of internal controls regarding financial reporting and accounting compliance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">monitor the independence and performance of the Corporation&#8217;s external auditors. This will include receipt, review and evaluation, at least annually, of a formal written statement from the independent auditors confirming their independence, and qualifications, including their compliance with the requirements of the relevant oversight boards and actively engage in a dialogue with the auditors with respect to any disclosed relationships or services that may impact objectivity and independence of the auditors and take, or recommend that the full board take, appropriate action to oversee the independence of the external auditors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">deal directly with the external auditors to pre-approve external audit plans, other services (if any) and fees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">directly oversee the external audit process and results (in addition to items described in Section 4(d) below);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide an avenue of communication among the external auditors, management and the Board; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">carry out a review designed to ensure that an effective "whistle blowing" procedure exists to permit stakeholders to express any concerns to an appropriately independent individual;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pre-approve any related party transactions to be entered into by the Company, and ensure appropriate disclosure thereof;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ensure financial disclosure incorporates inclusion of any material correcting adjustments required by the external auditors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require and ensure that the external auditors are directly responsible to the Audit Committee, to whom they report.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall have the authority to:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inspect any and all of the books and records of the Corporation and its affiliates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discuss with the management of the Corporation and its affiliates, any affected party and the external auditors, such accounts, records and other matters as any Member of the Audit Committee considers necessary and appropriate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">engage independent counsel and other advisors as it determines necessary to carry out its duties.  The Audit Committee shall keep the Board apprised of both the selection of experts and the expert&#8217;s findings through the Audit Committee&#8217;s regular reports to the Board.  The Audit Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Audit Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">communicate directly with the external auditors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">set and pay the compensation for (A) any external auditor engaged for the purpose of preparing or issuing an audit report or performing other audit, review, or attest services for the Corporation, (b) any advisors employed by the Audit Committee, and (C) ordinary administrative expenses of the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.  The Audit Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Audit Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review the audit plan with the Corporation&#8217;s external auditors and with management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review with the independent auditors the matters required to be discussed relating to the conduct of the audit, including (a) the proposed scope of their examination, with emphasis on accounting and financial areas where the Committee, the independent auditors or management believes special attention should be directed; (b) the results of their audit, including their audit findings report and resulting letter, if any, of recommendations for management; (c) their evaluation of the adequacy and effectiveness of the Company&#8217;s internal controls over financial reporting; (d) significant areas of disagreement, if any, with management; (e) co-operation received from management in the conduct of the audit; (f) significant accounting, reporting, regulatory or industry developments affecting the Company; and (g) any proposed changes in major accounting policies or principles proposed or contemplated by the independent auditors or management, the presentation and impact of material risks and uncertainties and key estimates and judgements of management that may be material to financial reporting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review with management and with the external auditors material financial reporting issues arising during the most recent fiscal period and the resolution or proposed resolution of such issues;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review any problems experienced or concerns expressed by the external auditors in performing an audit, including any restrictions imposed by management or material accounting issues on which there was a disagreement with management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review with senior management the process of identifying, monitoring and reporting the principal risks affecting financial reporting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review audited annual financial statements (including management discussion and analysis) and related documents in conjunction with the report of the external auditors and obtain an explanation from management of all material variances between comparative reporting periods. Without restricting the generality of the foregoing, the committee will discuss with management and the independent auditors to the extent required, any issues and disclosure requirements regarding (a) the use of &#8220;pro forma&#8221; or &#8220;adjusted&#8221; non-GAAP information, as well as financial information and earnings guidance provided to analysts and rating agencies, (b) any off balance sheet arrangements, and (c) any going concern qualification.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">consider and review with management, the internal control memorandum or management letter containing the recommendations of the external auditors and management&#8217;s response, if any, including </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">an evaluation of the adequacy and effectiveness of the internal financial controls of the Corporation and subsequent follow-up to any identified weaknesses;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review with financial management and the external auditors the quarterly unaudited financial statements, management discussion and analysis, letter to shareholders and press release (all to be considered the &#8220;Quarterly Financial Reports&#8221;) and recommend the Quarterly Financial Reports to the Board for approval by the Board before release to the public;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">before release, review and if appropriate, recommend for approval by the Board, all public disclosure documents containing audited or unaudited financial information, including any prospectuses, financial statements, including the notes thereto, annual reports, annual information forms, management discussion and analysis and press releases; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">oversee, any of the financial affairs of the Corporation or its affiliates, and, if deemed appropriate, make recommendations to the Board, external auditors or management.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evaluate the independence and performance of the external auditors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">recommend the nomination of the external auditors to the Board for appointment by the shareholders at the Corporation&#8217;s annual general meeting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;recommend the discharge of the external auditor when circumstances warrant;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">monitor the rotation of the audit partner of the external auditors as required by applicable law or regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">consider the recommendations of management in respect of the appointment of the external auditors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pre-approve all non-audit services to be provided to the Corporation or its subsidiary entities by its external auditors, or the external auditors of affiliates of the Corporation subject to the over-riding principle that the external auditors are not permitted to be retained by the Corporation to perform specifically listed categories of non-audit services as set forth by the Securities and Exchange Commission as well as internal audit outsourcing services, financial information systems work and expert services.  Notwithstanding, the foregoing the pre-approval of non-audit services may be delegated to a Member of the Audit Committee, with any decisions of the Member with the delegated authority reporting to the Audit Committee at the next scheduled meeting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">approve the engagement letter for non-audit services to be provided by the external auditors or affiliates, together with estimated fees, and considering the potential impact of such services on the independence of the external auditors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">when there is to be a change of external auditors, review all issues and provide documentation related to the change, including the information to be included in the Notice of Change of Auditors and documentation required pursuant to the then current legislation, rules, policies and instruments of applicable regulatory authorities and the planned steps for an orderly transition period; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review all reportable events, including disagreements, unresolved issues and consultations, as defined by applicable securities policies, on a routine basis, whether or not there is to be a change of external auditors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall enquire into and determine the appropriate resolution of any conflict of interest in respect of audit or financial matters, which are directed to the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review the Corporation&#8217;s accounting and reporting of revenues, costs, liabilities and contingencies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall establish and maintain procedures for:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal controls, or auditing matters; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the confidential, anonymous submission by employees of the Corporation or concerns regarding questionable accounting or auditing matters.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review and approve the Corporation's hiring policies regarding partners and employees and former partners and employees of the present and former external auditors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(j)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review with the Corporation's legal counsel, on no less than an annual basis, any legal matter that could have a material impact on the Corporation's financial statements, and any enquiries received from regulators, or government agencies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(k)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review with management and the Corporation&#8217;s external auditors, on no less than an annual basis, any taxation matters that could have a material impact on the Corporation&#8217;s financial statements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(l)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee, through the Chair, shall receive notice from management of any instance of non-trivial fraud or other failure or weakness of the control system promptly upon management becoming aware of such.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(m)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review and approve the signing authority for the Corporation at least annually or when a change is required. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(n)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall assess, on an annual basis, the adequacy of this Mandate and the performance of the Audit Committee.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reporting</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.  The Audit Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Audit Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Mandate</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Mandate was last reviewed and approved by the Board on March 9, 2018.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the number of our employees at the end of each of the last three fiscal years by activity and geographic location.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:512px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:349px;"></td><td style="width:58px;"></td><td style="width:52px;"></td><td style="width:52px;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Activity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:462px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:310px;"></td><td style="width:52px;"></td><td style="width:46px;"></td><td style="width:52px;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Geographic location</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Ownership</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the share ownership and options held of our directors and officers as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;19, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:635px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="width:101px;"></td><td style="width:71px;"></td><td style="width:4px;"></td><td style="width:85px;"></td><td style="width:71px;"></td><td style="width:4px;"></td><td style="width:62px;"></td><td style="width:4px;"></td><td style="width:132px;"></td><td style="width:87px;"></td><td style="width:11px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of&#160;&#160;<br>Ownership</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">&#160;<br>Options</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise<br>Price</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry Date</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of Outstanding</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Officers</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Matthew C. Coffey</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;8, 2019</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">July&#160;27, 2021</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.89</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2021</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;17, 2022</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.74</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2023</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">734,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;1, 2025</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January&#160;16, 2027</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,267,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;8, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,054,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.96</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk J. Look</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;8, 2019</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:635px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="width:101px;"></td><td style="width:71px;"></td><td style="width:4px;"></td><td style="width:85px;"></td><td style="width:71px;"></td><td style="width:4px;"></td><td style="width:62px;"></td><td style="width:4px;"></td><td style="width:132px;"></td><td style="width:87px;"></td><td style="width:11px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2020</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.89</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2021</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;13, 2022</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;17, 2022</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2023</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">464,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;1, 2025</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January&#160;16, 2027</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">567,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;8, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,801,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.08</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Andres A. Gutierrez</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;10, 2026</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;8, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andrew de Guttadauro</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">July&#160;3, 2027</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;8, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Directors</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deborah Brown</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;7, 2027</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;18, 2024</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Lievonen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;8, 2019</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2021</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;17, 2022</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2023</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.89</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;9, 2023</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2023</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William Rice</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;8, 2025</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd Seizinger</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;8, 2025</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TOTAL:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,002,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">** Less than 1% ownership</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on </font><font style="font-family:inherit;font-size:10pt;">142,325,222</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares issued and outstanding on </font><font style="font-family:inherit;font-size:10pt;">March&#160;15, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable to acquire common shares.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ownership percentage assumes aggregate beneficial ownership of common shares, common shares acquirable upon exercise of options and fully diluted shares outstanding of </font><font style="font-family:inherit;font-size:10pt;">170,544,856</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Share Units</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the restricted share units held by our directors as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;19, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:383px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:133px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:81px;"></td><td style="width:71px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Granted</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Vested</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Unvested</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deborah Brown</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,729</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,729</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Lievonen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267,315</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267,315</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">438,311</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">438,311</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William Rice</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267,315</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267,315</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd Seizinger</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,899</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,899</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,709,067</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,709,067</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the restricted share units held by our officers as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;19, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:339px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:132px;"></td><td style="width:71px;"></td><td style="width:4px;"></td><td style="width:58px;"></td><td style="width:4px;"></td><td style="width:64px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Granted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Vested</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Unvested</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andrew de Guttadauro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Performance Share Units</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the performance share units held by our officers as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;19, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:408px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:133px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:96px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PSUs Granted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PSUs Vested</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PSUs Unvested</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Coffey</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andres Gutierrez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">840,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">840,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1F91BA000BB35769A7852FCD2746F68F"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Major Shareholders</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not directly or indirectly owned or controlled by another corporation(s) or by any foreign government. To the knowledge of our directors and senior officers, as at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;19, 2018</font><font style="font-family:inherit;font-size:10pt;">, we are not aware of any shareholder who beneficially owns, directly or indirectly, or exercises control or direction over, our common shares carrying more than 5% of the voting rights.   </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shares Held in the United States</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table indicates, as of </font><font style="font-family:inherit;font-size:10pt;">February&#160;19, 2018</font><font style="font-family:inherit;font-size:10pt;">, the total number of common shares issued and outstanding, the approximate total number of holders of record of common shares, the number of holders of record of common shares with US&#160;addresses, the portion of the outstanding common shares held by US&#160;holders of record, and the percentage of common shares held by US&#160;holders of record. This table does not indicate beneficial ownership of common&#160;shares.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:44%;"></td><td style="width:14%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Number of Holders of Record</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Number of Common Shares Issued and Outstanding</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of US&#160;Holders of Record</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Common Shares Held by US&#160;Holders of Record&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage of Common Shares Held by US&#160;Holders of Record&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,325,222</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,230,108</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48.64</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Change of Control</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;19, 2018</font><font style="font-family:inherit;font-size:10pt;">, there were no arrangements known to the Company which may, at a subsequent date, result in a change of control of the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Control by Others</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the best of the Company&#8217;s knowledge, the Company is not directly or indirectly owned or controlled by another corporation, any foreign government, or any other natural or legal person, severally or jointly.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into employment contracts with each of our officers (see Item 6).&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2017, with the signing of a regional licensing agreement with upfront license fees, the Company triggered a liability of US$178,125 to an officer as detailed in the Assumption Agreement. As at December 31, 2017, US$178,125 was included in accounts payable and accrued liabilities. US$35,625 was paid in January 2018 and the balance will be paid after receipt of the contract receivable from Adlai (see Notes 10 and 12 in our audited consolidated financial statements included under Item 18). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since the beginning of the fiscal year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;19, 2018</font><font style="font-family:inherit;font-size:10pt;">, we did not enter into any other related party transactions and we do not have any loans outstanding with any officer, director or major shareholder.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interests of Experts and Council</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sCFEF8E8CCA1555C18449B6DD2E16DF21"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 8. FINANCIAL INFORMATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements and Other Financial Statements</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Statements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements filed as part of this annual report are filed under Item 18.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The directors and the management of the Company do not know of any material, active or pending, legal proceedings against them; nor is the Company involved as a plaintiff in any material proceeding or pending litigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The directors and the management of the Company know of no active or pending proceedings against anyone that might materially adversely affect an interest of the Company.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dividend Policy</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not paid any dividends on its common shares.&#160;&#160;The Company may pay dividends on its common shares in the future if it generates profits.&#160;&#160;Any decision to pay dividends on common shares in the future will be made by the board of directors on the basis of the earnings, financial requirements and other conditions existing at such time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Changes</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no significant changes to our annual financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sC78A92DDC0DE5D76B2320A2A6347E577"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9. THE OFFER AND LISTING</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Offering and Listing Details</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Common Shares are traded on the TSX under the symbol ONC.  As well, effective November 5, 2015, our Common Shares commenced quotations on the OTCQX International ("OTCQX") under the symbol ONCYF.  Prior to November 5, 2015 our Common Shares traded on the NASDAQ Capital Market under the symbol ONCY.  On November 5, 2015, our Common Shares were delisted from the NASDAQ.  The last reported sales price of our common shares on </font><font style="font-family:inherit;font-size:10pt;">March&#160;15, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;on the TSX was Cdn</font><font style="font-family:inherit;font-size:10pt;">$0.79</font><font style="font-family:inherit;font-size:10pt;">&#32;and on the OTCQX was US</font><font style="font-family:inherit;font-size:10pt;">$0.62</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The following table sets forth the high and low per share sales prices for our common shares on the NASDAQ and TSX for the periods indicated.  In relation to the OTCQX, the following quotations reflect inter-dealer prices without retail mark-up, mark-down or commission and may not represent actual transactions.&#160;&#160;The following table sets forth the range of high and low bid prices during the periods indicated on the OTCQX.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:98px;"></td></tr><tr><td colspan="7" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTCQX</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NASDAQ</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TSX</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">High</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Low</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">High</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Low</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">High</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Low</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.93</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.45</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.94</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.54</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.99</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.40</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.20</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.45</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.37</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.24</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.16</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.35</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.75</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.21</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.82</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.10</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.25</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.56</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.36</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.34</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.75</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.44</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.25</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.49</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.34</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.33</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.21</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.64</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.82</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.33</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.10</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.44</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.38</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.69</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.48</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.43</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.77</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.54</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.41</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.69</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.51</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.54</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.43</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.64</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.54</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.44</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.77</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.56</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.52</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.77</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.67</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.56</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.06</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.70</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.61</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.48</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.80</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.60</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March (1 &#8211; 15)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.64</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.59</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.83</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.75</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Market Price Volatility of Common Shares</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market prices for the securities of biotechnology companies, including our securities, have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Factors, such as fluctuations in our operating results, the aftermath of our public announcements, and general market conditions, can have an adverse effect on the market price of our common shares and other securities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Plan of Distribution</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Markets</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Common Shares, no par value, are traded/quoted on the OTCQX and the TSX under the symbol &#8220;ONCYF" and &#8220;ONC&#8221;, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selling Shareholders</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dilution</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">F.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses of the Issue</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s561C15BFB5D85A70BDD606EEDC83477C"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 10.&#160; ADDITIONAL INFORMATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Capital</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Memorandum and Articles of Association</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Articles of Continuance</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are governed by our amended articles of incorporation (the "Articles") under the Business Corporations Act of Alberta (the &#8220;Act&#8221;) and by our by-laws (the&#160;"By-laws"). Our Alberta corporate access number is 207797382. Our Articles provide that there are no restrictions on the business we may carry on or on the powers we may exercise. Companies incorporated under the Act are not required to include specific objects or purposes in their articles or by-laws.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Directors</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to certain exceptions, including in respect of voting on any resolution to approve a contract that relates primarily to the director's remuneration, directors may not vote on resolutions to approve a material contract or material transaction if the director is a party to such contract or transaction. The directors are entitled to remuneration as shall from time to time be determined by the Board of Directors with no requirement for a quorum of independent directors. The directors have the ability under the Act to exercise our borrowing power, without authorization of the shareholders. The Act permits shareholders to restrict this authority through a company's articles or by-laws (or through a unanimous shareholder agreement), but no such restrictions are in place for us. Our Articles and By-laws do not require directors to hold shares for qualification.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rights, Preferences and Dividends Attaching to Shares</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of common shares have the right to receive dividends if and when declared. Each holder of common shares, as of the record date prior to a meeting, is entitled to attend and to cast one vote for each common share held as of such record date at such annual and/or special meeting, including with respect to the election or re-election of directors. Subject to the provisions of our By-laws, all directors may, if still qualified to serve as directors, stand for re-election. The numbers of our Board of Directors are not replaced at staggered intervals but are elected annually.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a distribution of assets on a winding-up, dissolution or other return of capital (subject to certain exceptions) the holders of common shares shall have a right to receive their </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">pro&#160;rata</font><font style="font-family:inherit;font-size:10pt;">&#32;share of such distribution. There are no sinking fund or redemption provisions in respect of the common shares. Our shareholders have no liability to further capital calls as all shares issued and outstanding are fully paid and non-assessable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No other classes of shares are currently permitted to be issued.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Action Necessary to Change the Rights of Shareholders</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rights attaching to the different classes of shares may be varied by special resolution passed at a meeting of that class's shareholders.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Annual and Special Meetings of Shareholders</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Act and our By-laws, we are required to mail a Notice of Meeting and Management Information Circular to registered shareholders not less than 21&#160;days and not more than 50 days prior to the date of the meeting. Such materials must be filed concurrently with the applicable securities regulatory authorities in Canada and the US.&#160;Subject to certain provisions of the By-laws, a quorum of two or more shareholders in person or represented by proxy holding or representing by proxy not less than five (5%) percent of the total number of issued and outstanding shares enjoying voting rights at such meeting is required to properly constitute a meeting of shareholders.&#160;&#160;Shareholders and their duly appointed proxies and corporate representatives are entitled to be admitted to our annual and/or special meetings.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Limitations on the Rights to Own Shares</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Articles do not contain any limitations on the rights to own shares. Except as described below, there are currently no limitations imposed by Canadian federal or provincial laws on the rights of non-resident or foreign owners of Canadian securities to hold or vote the securities held. There are also no such limitations imposed by the Articles and By-laws with respect to our common&#160;shares.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure of Share Ownership</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In general, under applicable securities regulation in Canada, a person or company who beneficially owns, directly or indirectly, voting securities of an issuer or who exercises control or direction over voting securities of an issuer or a combination of both, carrying more than 10% of the voting rights attached to all the issuer's outstanding voting securities is an insider and must, within 10&#160;days of becoming an insider, file&#160;a report in the required form effective the date on which the person became an insider. The report must disclose any direct or indirect beneficial ownership of, or control or direction over, securities of the reporting issuer. Additionally, securities regulation in Canada provides for the filing of a report by an insider of a reporting issuer whose holdings change, which report must be filed within 10&#160;days from the day on which the change takes place.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rules in the US governing the ownership threshold above which shareholder ownership must be disclosed are more stringent than those discussed above. Section 13 of the Exchange Act imposes reporting requirements on persons who acquire beneficial ownership (as such term is defined in Rule 13d-3 under the Exchange Act) of more than 5% of a class of an equity security registered under Section 12 of the Exchange Act.&#160;&#160;In general, such persons must file, within 10&#160;days after such acquisition, a report of beneficial ownership with the SEC containing the information prescribed by the regulations under Section&#160;13 of the Exchange Act. This information is also required to be sent to the issuer of the securities and to each exchange where the securities are&#160;traded.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Provisions of Articles and By-laws</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no provisions in the Articles or By-laws:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delaying or prohibiting a change in control of our company that operate only with respect to a merger, acquisition or corporate restructuring;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discriminating against any existing or prospective holder of shares as a result of such shareholder owning a substantial number of&#160;shares;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requiring disclosure of share ownership; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">governing changes in capital, where such provisions are more stringent than those required by&#160;law.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Material Contracts</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have employment contracts with each of our officers as summarized in Item 6B. Other than these employment contracts and the Licensing Agreement described below, we have not entered into any other contract other than in the ordinary course of business over the last two years.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 16, 2017, the Company announced that it had, through its subsidiary, Oncolytics Biotech (Barbados) Inc., entered into a license, development, supply and distribution agreement (the &#8220;Licensing Agreement&#8221;) with Adlai Nortye Biopharma Co., Ltd. (&#8220;Adlai&#8221;), a biopharmaceutical company focused on discovering and developing new treatments for cancer and metabolic diseases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan (the &#8220;Territories&#8221;). Pursuant to the Licensing Agreement, Oncolytics is entitled to receive an upfront payment of approximately US$5.3 million; payment of US$7.9 million upon certain regulatory milestones being achieved; and payment of up to US$65.4 million upon certain clinical, regulatory and commercialization milestones being achieved.Oncolytics is also eligible to receive royalty payments in excess of 10% associated with the commercialization of REOLYSIN for all indications, subject to regulatory approval.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Licensing Agreement, Adlai will be responsible for all clinical, regulatory and commercialization activities respecting REOLYSIN in the Territories. Oncolytics will maintain exclusive rights to REOLYSIN outside of the Territories and will be responsible for all development activities respecting REOLYSIN outside of the Territories.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the entering into of the Licensing Agreement, the Company and Adlai also entered into a warrant agreement pursuant to which the Company issued to Adlai:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a common share purchase warrant (the &#8220;First Warrant&#8221;) entitling Adlai to purchase, for a period of 12 months from the date of the Warrant Agreement, up to US$2 million of common shares (&#8220;Common Shares&#8221;) of the Company, at a price equal to 120% of the five-day weighted average price of the Common Shares on the Toronto Stock Exchange (the &#8220;Principal Market&#8221;, unless the Common Shares begin trading on the NASDAQ Capital Market, in which case the Principal Market shall mean the NASDAQ Capital Market as of the date such trading commences) immediately preceding the exercise date; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a Common Share purchase warrant (the &#8220;Second Warrant&#8221;) entitling Adlai to purchase, for a period of 36 months from the date of the Warrant Agreement, up to US$6 million of Common Shares, at a price equal to 120% of the five-day weighted average price of the Common Shares on the Principal immediately preceding the exercise date.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Warrant Agreement, the Company has the right to require the exercise by Adlai, within five business days of receipt of notice thereof, of:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the First Warrant, upon the later of: (i) six months after the effective date of the Licensing Agreement; and (ii) the date of the enrollment of the first patient in the Global mBC Study (as such term is defined in the Licensing Agreement); and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)  the Second Warrant, upon the date of the enrollment of the fiftieth (50th) patient in the Global mBC Study.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exchange Controls</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canada has no system of exchange controls. There are no Canadian restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors. There are no laws in Canada or exchange restrictions affecting the remittance of dividends, profits, interest, royalties and other payments to non-resident holders of our securities, except as discussed below in Section&#160;E,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Taxation</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restrictions on Share Ownership by Non-Canadians</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no limitations under the laws of Canada or in our organizational documents on the right of foreigners to hold or vote securities of our company, except that the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investment Canada Act</font><font style="font-family:inherit;font-size:10pt;">&#32;(the "Investment Canada Act") may require review and approval by the Minister of Industry (Canada) of certain acquisitions of "control" of our Company by a "non-Canadian."</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investment Canada Act</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Investment Canada Act, transactions exceeding certain financial thresholds, and which involve the acquisition of control of a Canadian business by a non-Canadian, are subject to review and cannot be implemented unless the Minister of Industry and/or, in the case of a Canadian business engaged in cultural activities, the Minister of Canadian Heritage, are satisfied that the transaction is likely to be of "net benefit to Canada". If a transaction is subject to review (a&#160;"Reviewable Transaction"), an application for review must be filed with the Investment Review Division of Industry Canada and/or the Department of Canadian Heritage prior to the implementation of the Reviewable Transaction. The responsible Minister is then required to determine whether the Reviewable Transaction is likely to be of net benefit to Canada taking into account, among other things, certain factors specified in the Investment Canada Act and any written undertakings that may have been given by the applicant. The Investment Canada Act contemplates an initial review period of up to 45&#160;days after filing; however, if the responsible Minister has not completed the review by that date, the Minister may unilaterally extend the review period by up to 30&#160;days (or&#160;such longer period as may be agreed to by the applicant and the Minister) to permit completion of the review. Direct acquisitions of control of most Canadian businesses by or from World Trade Organization ("WTO") investors are reviewable under the Investment Canada Act only if, in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the case of an acquisition of voting securities, the value of the worldwide assets of the Canadian business or, in the case of an acquisition of substantially all the assets of a Canadian business, the value of those assets exceed C$295 million for the year 2008 (this figure is adjusted annually to reflect inflation). Indirect acquisitions (e.g., an acquisition of a US corporation with a Canadian subsidiary) of control of such businesses by or from WTO investors are not subject to review, regardless of the value of the Canadian businesses' assets. Significantly lower review thresholds apply where neither the investor nor the Canadian business is WTO investor controlled or where the Canadian business is engaged in uranium mining, certain cultural businesses, financial services or transportation services.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if the transaction is not reviewable because it does not meet or exceed the applicable financial threshold, the non-Canadian investor must still give notice to Industry Canada and, in the case of a Canadian business engaged in cultural activities, Canadian Heritage, of its acquisition of control of a Canadian business within 30&#160;days of its implementation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Competition Act</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Competition Act</font><font style="font-family:inherit;font-size:10pt;">&#32;(Canada) (the&#160;"Competition Act") requires that a pre-merger notification filing be submitted to the Commissioner of Competition (the&#160;"Commissioner") in respect of proposed transactions that exceed certain financial and other thresholds. If a proposed transaction is subject to pre-merger notification, a pre-merger notification filing must be submitted to the Commissioner and a waiting period must expire or be waived by the Commissioner before the transaction may be completed. The parties to a proposed transaction may choose to submit either a short-form filing (in&#160;respect of which there is a 14-day statutory waiting period) or a long-form filing (in&#160;respect of which there is a 42-day statutory waiting period). However, where the parties choose to submit a short-form filing, the Commissioner may, within 14&#160;days, require that the parties submit a long-form filing, in which case the proposed transaction generally may not be completed until 42&#160;days after the long-form filing is submitted by the&#160;parties.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Commissioner may, upon request, issue an advance ruling certificate ("ARC") in respect of a proposed transaction where she is satisfied that she would not have sufficient grounds on which to apply to the Competition Tribunal for an order under the merger provisions of the Competition Act. If the Commissioner issues an ARC in respect of a proposed transaction, the transaction is exempt from the pre-merger notification provisions. In addition, if the transaction to which the ARC relates is substantially completed within one year after the ARC is issued, the Commissioner cannot seek an order of the Competition Tribunal under the merger provisions of the Competition Act in respect of the transaction solely on the basis of information that is the same or substantially the same as the information on the basis of which the ARC was&#160;issued.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Commissioner is unwilling to issue an ARC, she may nevertheless issue a "no action" letter waiving notification and confirming that she is of the view that grounds do not then exist to initiate proceedings before the Competition Tribunal under the merger provisions of the Competition Act with respect to the proposed transaction, while preserving, during the three years following completion of the proposed transaction, her authority to initiate proceedings should circumstances change.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regardless of whether pre-merger notification is required, the Commissioner may apply to the Competition Tribunal (a special purpose tribunal) for an order under the merger provisions of the Competition Act. If the Competition Tribunal finds that the transaction is or is likely to prevent or lessen competition substantially, it may order that the parties not proceed with the transaction or part of it or, in the event that the transaction has already been completed, order its dissolution or the disposition of some of the assets or shares involved. In addition, the Competition Tribunal may, with the consent of the person against whom the order is directed and the Commissioner, order that person to take any other action as is deemed necessary to remedy any substantial lessening or prevention of competition that the Competition Tribunal determines would or would likely result from the transaction.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Taxation</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a general summary of certain material U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating to the acquisition, ownership and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder arising from and relating to the acquisition, ownership, and disposition of Common Shares.  In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder,</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">including, without limitation, specific tax consequences to a U.S. Holder under an applicable income tax treaty.  Accordingly, this summary is not </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder.  This summary does not address the U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the acquisition, ownership, and disposition of Common Shares.  In addition, except as specifically set forth below, this summary does not discuss applicable tax reporting requirements.  Each prospective U.S. Holder should consult its own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No legal opinion from U.S. legal counsel or ruling from the Internal Revenue Service (the &#8220;IRS&#8221;) has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.  This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary.  In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the conclusions described in this summary.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Scope of this Summary</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Authorities</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This summary is based on the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Treasury Regulations (whether final, temporary, or proposed), published rulings of the IRS, published administrative positions of the IRS, the Convention Between Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended (the &#8220;Canada-U.S. Tax Convention&#8221;), and U.S. court decisions that are applicable, and, in each case, as in effect and available, as of the date of this document.  Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied retroactively.  This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">U.S. Holders</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of this summary, the term "U.S. Holder" means a beneficial owner of Common Shares that is for U.S. federal income tax purposes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an individual who is a citizen or resident of the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state thereof or the District of Columbia;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a trust that (1) is subject to the primary supervision of a court within the U.S. and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:81px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This summary does not address the U.S. federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders that:  (a) are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; (b) are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies; (c) are broker-dealers, dealers, or traders in securities or currencies that elect to apply a mark-to-market accounting method; (d) have a &#8220;functional currency&#8221; other than the U.S. dollar; (e) own Common Shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other arrangement involving more than one position; (f) acquire Common Shares in connection with the exercise of employee stock options or otherwise as compensation for services; (g) hold Common Shares other than as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment purposes); (h) own, have owned or will own  (directly, indirectly, or by attribution) 10% or more of the total combined voting power or value of the outstanding shares of the Company or (i) a person required to accelerate the recognition of an item of income with respect to the Common Shares as a result of such income being recognized on an applicable financial statement. This summary also does not address the U.S. federal income tax considerations applicable to U.S. Holders who are:  (a) U.S. expatriates or former long-term residents of the U.S.; (b) persons that have been, are, or will be a resident or deemed to be a resident in Canada for purposes of the Income Tax Act (Canada) (the &#8220;Tax Act&#8221;); (c) persons that use or hold, will use or hold, or that are or will be deemed to use or hold Common Shares in connection with carrying on a business in Canada; (d) persons whose Common Shares constitute &#8220;taxable Canadian property&#8221; under the Tax Act; or (e) persons that have a permanent establishment in Canada for the purposes of the Canada-U.S. Tax Convention.  U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders described immediately above, should </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">consult their own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an entity or arrangement that is classified as a partnership (or other &#8220;pass-through&#8221; entity) for U.S. federal income tax purposes holds Common Shares, the U.S. federal income tax consequences to such entity or arrangement and the partners (or other owners or participants) of such entity or arrangement generally will depend on the activities of the entity or arrangement and the status of such partners (or owners or participants).  This summary does not address the tax consequences to any such partner (or owner or participants).  Partners (or other owners or participants) of entities or arrangements that are classified as partnerships or as &#8220;pass-through&#8221; entities for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences arising from and relating to the acquisition, ownership and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Passive Foreign Investment Company Rules</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">PFIC Status of the Company</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company were to constitute a &#8220;passive foreign investment company&#8221; under the meaning of Section 1297 of the Code (a &#8220;PFIC&#8221;, as defined below) for any year during a U.S. Holder&#8217;s holding period, then certain potentially adverse rules may affect the U.S. federal income tax consequences to a U.S. Holder as a result of the acquisition, ownership and disposition of Common Shares.  The Company believes that it was classified as a PFIC for the tax year ended December 31, 2017, and based on current business plans and financial expectations, the Company anticipates that it may be a PFIC for its current tax year and subsequent tax years.  The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations.  In addition, whether any corporation will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and, as a result, cannot be predicted with certainty as of the date of this document.  Accordingly, there can be no assurance that the IRS will not challenge any determination made by the Company (or any subsidiary of the Company) concerning its PFIC status.  Each U.S. Holder should consult its own tax advisors regarding the PFIC status of the Company and each subsidiary of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In any year in which the Company is classified as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require.  In addition to penalties, a failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax.  U.S. Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generally will be a PFIC if, for a tax year, (a) 75% or more of the gross income of the Company is passive income (the &#8220;PFIC income test&#8221;) or (b) 50% or more of the value of the Company&#8217;s assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets (the &#8220;PFIC asset test&#8221;).  &#8220;Gross income&#8221; generally includes all sales revenues less the cost of goods sold, plus income from investments and from incidental or outside operations or sources, and &#8220;passive income&#8221; generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of the PFIC income test and PFIC asset test described above, if the Company owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, the Company will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation.  In addition, for purposes of the PFIC income test and PFIC asset test described above, and assuming certain other requirements are met, &#8220;passive income&#8221; does not include certain interest, dividends, rents, or royalties that are received or accrued by the Company from certain &#8220;related persons&#8221; (as defined in Section 954(d)(3) of the Code) also organized in Canada, to the extent such items are properly allocable to the income of such related person that is not passive income.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under certain attribution rules, if the Company is a PFIC, U.S. Holders will generally be deemed to own their proportionate share of the Company&#8217;s direct or indirect equity interest in any company that is also a PFIC (a &#8216;&#8216;Subsidiary PFIC&#8217;&#8217;), and will generally be subject to U.S. federal income tax on their proportionate share of (a) any &#8220;excess distributions,&#8221; as described below, on the stock of a Subsidiary PFIC and (b) a disposition or deemed disposition of the stock of a Subsidiary PFIC by the Company or another Subsidiary PFIC, both as if such U.S. Holders directly held the shares of such Subsidiary PFIC.  In addition, U.S. Holders may be subject to U.S. federal income tax on any indirect gain realized on the stock of a Subsidiary PFIC on the sale or disposition of Common Shares.  Accordingly, U.S. Holders should be aware that they could be subject to tax under the PFIC rules even if no distributions are received and no redemptions or other dispositions of Common Shares are made.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Default PFIC Rules Under Section 1291 of the Code</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company is a PFIC for any tax year during which a U.S. Holder owns Common Shares, the U.S. federal income tax consequences to such U.S. Holder of the acquisition, ownership, and disposition of Common Shares will depend on whether and when such U.S. Holder makes an election to treat the Company and each Subsidiary PFIC, if any, as a &#8220;qualified electing fund&#8221; or &#8220;QEF&#8221; under Section 1295 of the Code (a &#8220;QEF Election&#8221;) or makes a mark-to-market election under Section 1296 of the Code (a &#8220;Mark-to-Market Election&#8221;).  A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election will be referred to in this summary as a &#8220;Non-Electing U.S. Holder.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Non-Electing U.S. Holder will be subject to the rules of Section 1291 of the Code (described below) with respect to (a) any gain recognized on the sale or other taxable disposition of Common Shares and (b) any &#8220;excess distribution&#8221; received on the Common Shares.  A distribution generally will be an &#8220;excess distribution&#8221; to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S. Holder&#8217;s holding period for the Common Shares, if shorter).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of Common Shares (including an indirect disposition of the stock of any Subsidiary PFIC), and any &#8220;excess distribution&#8221; received on Common Shares or with respect to the stock of a Subsidiary PFIC, must be ratably allocated to each day in a Non-Electing U.S. Holder&#8217;s holding period for the respective Common Shares.  The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income (and not eligible for certain preferred rates).  The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year.  A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as &#8220;personal interest,&#8221; which is not deductible.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company is a PFIC for any tax year during which a Non-Electing U.S. Holder holds Common Shares, the Company will continue to be treated as a PFIC with respect to such Non-Electing U.S. Holder, regardless of whether the Company ceases to be a PFIC in one or more subsequent tax years.  A Non-Electing U.S. Holder may terminate this deemed PFIC status by electing to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above), but not loss, as if such Common Shares were sold on the last day of the last tax year for which the Company was a PFIC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">QEF Election</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a timely and effective QEF Election for the first tax year in which the holding period of its Common Shares begins generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its Common Shares.  A U.S. Holder that makes a timely and effective QEF Election will be subject to U.S. federal income tax on such U.S. Holder&#8217;s pro rata share of (a) the net capital gain of the Company, which will be taxed as long-term capital gain to such U.S. Holder, and (b) the ordinary earnings of the Company, which will be taxed as ordinary income to such U.S. Holder.  Generally, &#8220;net capital gain&#8221; is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and &#8220;ordinary earnings&#8221; are the excess of (a) &#8220;earnings and profits&#8221; over (b) net capital gain.  A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which the Company is a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by the Company.  However, for any tax year in which the Company is a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election would not have any income inclusions as a result of the QEF Election.  If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge.  If such U.S. Holder is not a corporation, any such interest paid will be treated as &#8220;personal interest,&#8221; which is not deductible.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a timely and effective QEF Election with respect to the Company generally (a) may receive a tax-free distribution from the Company to the extent that such distribution represents &#8220;earnings and profits&#8221; of the Company that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election.  In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely.  A QEF Election will be treated as &#8220;timely&#8221; if such QEF Election is made for the first year in the U.S. Holder&#8217;s holding period for the Common Shares in which the Company was a PFIC.  A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year.  If a U.S. Holder does not make a timely and effective QEF Election for the first year in the U.S. Holder&#8217;s holding period for the Common Shares, the U.S. Holder may still be able to make a timely and effective QEF Election in a subsequent year if such U.S. Holder meets certain requirements and makes a &#8220;purging&#8221; election to recognize gain (which will be </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">taxed under the rules of Section 1291 of the Code discussed above) as if such Common Shares were sold for their fair market value on the day the QEF Election is effective.  If a U.S. Holder makes a QEF Election but does not make a &#8220;purging&#8221; election to recognize gain as discussed in the preceding sentence, then such U.S. Holder shall be subject to the QEF Election rules and shall continue to be subject to tax under the rules of Section 1291 discussed above with respect to its Common Shares.   If a U.S. Holder owns PFIC stock indirectly through another PFIC, separate QEF Elections must be made for the PFIC in which the U.S. Holder is a direct shareholder and the Subsidiary PFIC for the QEF rules to apply to both PFICs. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A QEF Election will apply to the tax year for which such QEF Election is timely made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election.  If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the Company ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which the Company is not a PFIC.  Accordingly, if the Company becomes a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which the Company qualifies as a PFIC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Holders should be aware that there can be no assurances that the Company will satisfy the record keeping requirements that apply to a QEF, or that the Company will supply U.S. Holders with information that such U.S. Holders are required to report under the QEF rules, in the event that the Company is a PFIC.  Thus, U.S. Holders may not be able to make a QEF Election with respect to their Common Shares.  Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a QEF Election.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder makes a QEF Election by attaching a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed United States federal income tax return.  However, if the Company does not provide the required information with regard to the Company or any of its Subsidiary PFICs, U.S. Holders will not be able to make a QEF Election for such entity and will continue to be subject to the rules of Section 1291 of the Code discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Mark-to-Market Election</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder may make a Mark-to-Market Election only if the Common Shares are marketable stock.  The Common Shares generally will be &#8220;marketable stock&#8221; if the Common Shares are regularly traded on (a) a national securities exchange that is registered with the Securities and Exchange Commission, (b) the national market system established pursuant to section 11A of the Securities and Exchange Act of 1934, or (c) a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such foreign exchange has trading volume, listing, financial disclosure, and surveillance requirements, and meets other requirements and the laws of the country in which such foreign exchange is located, together with the rules of such foreign exchange, ensure that such requirements are actually enforced and (ii) the rules of such foreign exchange effectively promote active trading of listed stocks.  If such stock is traded on such a qualified exchange or other market, such stock generally will be &#8220;regularly traded&#8221; for any calendar year during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter.  Provided that the Common Shares are &#8220;regularly traded&#8221; as described in the preceding sentence, the Common Shares are expected to be marketable stock.  However, each U.S. Holder should consult its own tax advisor in this regard.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a Mark-to-Market Election with respect to its Common Shares generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to such Common Shares.  However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax year of such U.S. Holder&#8217;s holding period for the Common Shares for which the Company is a PFIC and such U.S. Holder has not made a timely QEF Election, the rules of Section&#160;1291 of the Code discussed above will apply to certain dispositions of, and distributions on, the Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which the Company is a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the Common Shares, as of the close of such tax year over (b) such U.S. Holder&#8217;s adjusted tax basis in such Common Shares.  A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the excess, if any, of (a) such U.S. Holder&#8217;s adjusted tax basis in the Common Shares, over (b) the fair market value of such Common Shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a Mark-to-Market Election generally also will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election.  In addition, upon a sale or other taxable disposition of Common Shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for prior tax years).  Losses that exceed this limitation are subject to the rules generally applicable to losses provided in the Code and Treasury Regulations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder makes a Mark-to-Market  Election by attaching a completed IRS Form 8621 to a timely filed United States federal income tax return.  A Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the Common Shares cease to be &#8220;marketable stock&#8221; or the IRS consents to revocation of such election.  Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a Mark-to-Market Election.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to the Common Shares, no such election may be made with respect to the stock of any Subsidiary PFIC that a U.S. Holder is treated as owning, because such stock is not marketable.  Hence, the Mark-to-Market Election will not be effective to avoid the application of the default rules of Section 1291 of the Code described above with respect to deemed dispositions of Subsidiary PFIC stock or excess distributions from a Subsidiary PFIC to its shareholder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other PFIC Rules</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under Section 1291(f) of the Code, the IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause a U.S. Holder that had not made a timely QEF Election to recognize gain (but not loss) upon certain transfers of Common Shares that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate reorganizations).  However, the specific U.S. federal income tax consequences to a U.S. Holder may vary based on the manner in which Common Shares are transferred.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain additional adverse rules may apply with respect to a U.S. Holder if the Company is a PFIC, regardless of whether such U.S. Holder makes a QEF Election.  For example, under Section 1298(b)(6) of the Code, a U.S. Holder that uses Common Shares as security for a loan will, except as may be provided in Treasury Regulations, be treated as having made a taxable disposition of such Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Special rules also apply to the amount of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC.  Subject to such special rules, foreign taxes paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit.  The rules relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Holder should consult with its own tax advisors regarding the availability of the foreign tax credit with respect to distributions by a PFIC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The PFIC rules are complex, and each U.S. Holder should consult its own tax advisors regarding the PFIC rules and how the PFIC rules may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General Rules Applicable to the Ownership and Disposition of Common Shares</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion describes the general rules applicable to the ownership and disposition of the Common Shares but is subject in its entirety to the special rules described above under the heading &#8220;Passive Foreign Investment Company Rules.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Distributions on Common Shares</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that receives a distribution, including a constructive distribution, with respect to a Common Share will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of the current and accumulated &#8220;earnings and profits&#8221; of the Company, as computed for U.S. federal income tax purposes.  A dividend generally will be taxed to a U.S. Holder at ordinary income tax rates if the Company is a PFIC for the tax year of such distribution or the preceding tax year.  To the extent that a distribution exceeds the current and accumulated &#8220;earnings and profits&#8221; of the Company, such distribution will be treated first as a tax-free return of capital to the extent of a U.S. Holder's tax basis in the Common Shares and thereafter as gain from the sale or exchange of such Common Shares.  (See &#8220;Sale or Other Taxable Disposition of Common Shares&#8221; below).  However, the Company may not maintain the calculations of its earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder may have to assume that any distribution by the Company with respect to the Common Shares will constitute ordinary dividend income.  Dividends received on Common Shares by corporate U.S. Holders generally will not be eligible for the &#8220;dividends received deduction.&#8221;  Subject to applicable limitations and provided the Company is eligible for the benefits of the Canada-U.S. Tax Convention, dividends paid by the Company to non-corporate U.S. Holders, including individuals, generally will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions are satisfied, including </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">that the Company not be classified as a PFIC in the tax year of distribution or in the preceding tax year.  The dividend rules are complex, and each U.S. Holder should consult its own tax advisors regarding the application of such rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sale or Other Taxable Disposition of Common Shares</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the sale or other taxable disposition of Common Shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the U.S. dollar value of cash received plus the fair market value of any property received and such U.S. Holder's tax basis in such Common Shares sold or otherwise disposed of.  A U.S. Holder&#8217;s tax basis in Common Shares generally will be such holder&#8217;s U.S. dollar cost for such Common Shares.  Gain or loss recognized on such sale or other disposition generally will be long-term capital gain or loss if, at the time of the sale or other disposition, the Common Shares have been held for more than one year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferential tax rates currently apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust.  There are currently no preferential tax rates for long-term capital gain of a U.S. Holder that is a corporation.  Deductions for capital losses are subject to significant limitations under the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Considerations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Additional Tax on Passive Income</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain U.S. Holders that are individuals, estates or trusts (other than trusts that are exempt from tax) will be subject to a 3.8% tax on all or a portion of their &#8220;net investment income,&#8221; which includes dividends on the Common Shares and net gains from the disposition of the Common Shares.  Further, excess distributions treated as dividends, gains treated as excess distributions under the PFIC rules discussed above, and mark-to-market inclusions and deductions are all included in the calculation of net investment income.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Treasury Regulations provide, subject to the election described in the following paragraph, that solely for purposes of this additional tax, that distributions of previously taxed income will be treated as dividends and included in net investment income subject to the additional 3.8% tax.  Additionally, to determine the amount of any capital gain from the sale or other taxable disposition of Common Shares that will be subject to the additional tax on net investment income, a U.S. Holder who has made a QEF Election will be required to recalculate its basis in the Common Shares excluding QEF basis adjustments. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alternatively, a U.S. Holder may make an election which will be effective with respect to all interests in controlled foreign corporations and QEFs held in that year or acquired in future years.  Under this election, a U.S. Holder pays the additional 3.8% tax on QEF income inclusions and on gains calculated after giving effect to related tax basis adjustments.  U.S. Holders that are individuals, estates or trusts should consult their own tax advisors regarding the applicability of this tax to any of their income or gains in respect of the Common Shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Receipt of Foreign Currency</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amount of any distribution paid to a U.S. Holder in foreign currency, or on the sale, exchange or other taxable disposition of Common Shares, generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless of whether such foreign currency is converted into U.S. dollars at that time).  A U.S. Holder will have a basis in the foreign currency equal to its U.S. dollar value on the date of receipt.  Any U.S. Holder who converts or otherwise disposes of the foreign currency after the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes.  Different rules apply to U.S. Holders who use the accrual method.  Each U.S. Holder should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Foreign Tax Credit</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to the PFIC rules discussed above, a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the Common Shares generally will be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian income tax.  Generally, a credit will reduce a U.S. Holder&#8217;s U.S. federal income tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Holder&#8217;s income that is subject to U.S. federal income tax.  This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through withholding) by a U.S. Holder during a year.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Complex limitations apply to the foreign tax credit, including the general limitation that the credit cannot exceed the proportionate share of a U.S. Holder&#8217;s U.S. federal income tax liability that such U.S. Holder&#8217;s &#8220;foreign source&#8221; taxable income bears to such U.S. Holder&#8217;s worldwide taxable income.  In applying this limitation, a U.S. Holder&#8217;s various items of income and deduction must be classified, under complex rules, as either &#8220;foreign source&#8221; or &#8220;U.S. source.&#8221;  Generally, dividends paid by a foreign corporation should be treated as foreign source for this purpose, and gains recognized on the sale of stock of a foreign corporation by a U.S. Holder should be treated as U.S. source for this purpose, except as otherwise provided in an applicable income tax treaty, and if an election is properly made under the Code.  However, the amount of a distribution with respect to the Common Shares that is treated as a &#8220;dividend&#8221; may be lower for U.S. federal income tax purposes than it is for Canadian federal income tax purposes, resulting in a reduced foreign tax credit allowance to a U.S. Holder.  In addition, this limitation is calculated separately with respect to specific categories of income.  The foreign tax credit rules are complex, and each U.S. Holder should consult its own U.S. tax advisors regarding the foreign tax credit rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Backup Withholding and Information Reporting</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under U.S. federal income tax law, certain categories of U.S. Holders must file information returns with respect to their investment in, or involvement in, a foreign corporation.  For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. Holders that hold certain specified foreign financial assets in excess of certain thresholds.  The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest in a foreign entity.  U.S. Holders may be subject to these reporting requirements unless their Common Shares are held in an account at certain financial institutions.  Penalties for failure to file certain of these information returns are substantial.  U.S. Holders should consult with their own tax advisors regarding the requirements of filing information returns, including the requirement to file an IRS Form 8938.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments made within the U.S., or by a U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable disposition of, Common Shares will generally be subject to information reporting and backup withholding tax, at the rate of 24%, if a U.S. Holder (a) fails to furnish such U.S. Holder&#8217;s correct U.S. taxpayer identification number (generally on Form W-9), (b) furnishes an incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously failed to properly report items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that such U.S. Holder has furnished its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup withholding tax.  However, certain exempt persons generally are excluded from these information reporting and backup withholding rules.  Backup withholding is not an additional tax.  Any amounts withheld under the U.S. backup withholding tax rules will be allowed as a credit against a U.S. Holder&#8217;s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes required information to the IRS in a timely manner.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The discussion of reporting requirements set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Holder.  A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess a tax and, under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting requirement.  Each U.S. Holder should consult its own tax advisors regarding the information reporting and backup withholding rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE ABOVE SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO U.S. HOLDERS WITH RESPECT TO THE ACQUISITION, OWNERSHIP, AND DISPOSITION OF COMMON SHARES.  U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE TAX CONSIDERATIONS APPLICABLE TO THEM IN THEIR OWN PARTICULAR CIRCUMSTANCES.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">F.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dividends and Paying Agents</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">G.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Statements by Experts</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">H.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Documents on Display</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to the informational requirements of the Exchange Act and file reports and other information with the SEC. You may read and copy any of our reports and other information at, and obtain copies upon payment of prescribed fees from, the Public </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reference Room maintained by the SEC at 100&#160;F&#160;Street, N.E., Washington,&#160;D.C. 20549. In addition, the SEC maintains a Website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC at http://www.sec.gov. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are required to file reports and other information with the securities commissions in Canada. You are invited to read and copy any reports, statements or other information, other than confidential filings, that we file with the provincial securities commissions. These filings are also electronically available from the Canadian System for Electronic Document Analysis and Retrieval ("SEDAR") (http://www.sedar.com), the Canadian equivalent of the SEC's electronic document gathering and retrieval system.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We "incorporate by reference" information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this Form&#160;20-F and&#160;more recent information automatically updates and supersedes more dated information contained or incorporated by reference in this Form&#160;20-F.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements to shareholders.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will provide without charge to each person, including any beneficial owner, to whom a copy of this annual report has been delivered, on the written or oral request of such person, a copy of any or all documents referred to above which have been or may be incorporated by reference in this annual report (not&#160;including exhibits to such incorporated information that are not specifically incorporated by reference into such information). Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 210 &#8211; 1167 Kensington Crescent, NW, Calgary, Alberta, Canada, T2N 1X7, Attention:&#160;&#160;Kirk Look.&#160;&#160;Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolytics.ca.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">I.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsidiary Information</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE7383B05B67A5306B05A949F8F89F294"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 11.&#160;&#160; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate primarily in Canada, the US, the U.K. and Europe.&#160;Therefore, we are exposed to foreign currency risk associated with our expenses outside of Canada.&#160;&#160;We do not use financial derivative instruments to manage this market risk.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Rate Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The primary objective of our policy for the investment of temporary cash surpluses is the protection of principal, and, accordingly, we generally invest in investment-grade debt securities with varying maturities.&#160;&#160;As it is our intent and policy to hold these investments until maturity, we do not have a material exposure to interest rate risk.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not currently have any long-term debt, nor do we currently utilize interest rate swap contracts to hedge against interest rate&#160;risk.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not use financial instruments for trading purposes and are not parties to any leverage derivatives.&#160;&#160;We do not currently engage in hedging transactions.&#160;&#160;See &#8220;Currency and Exchange Rates&#8221; and Item 4 &#8211; &#8220;Information on the Company&#8221;.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5B3057773B525624ADFCA2586CCE3810"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 12.&#160;&#160; DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt Securities</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants and Rights</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Securities</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">American Depository Shares</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Common Shares are not represented by American Depository Receipts.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sECDF3A0BE3875984A91CD2C8085365CB"></a></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sC9B7617319295ADD98E032548AD9C5ED"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 13.&#160; &#160;DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sBEC7904B849157FF840EB67001E5C6FB"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 14.&#160;&#160; MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Modification of Instruments Defining Rights of Security Holders</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Modification or Issuance of Other Class of Securities</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Withdrawal or Substitution of Security</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Change of Trustee or Paying Agent</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Proceeds</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There has been no change to the information provided in our first annual report on Form 20-F.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9CE8DCF3B1815C64B05B44D0354F8B2E"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 15.&#160;&#160;CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosures and Procedures</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is the conclusion of our Chief Executive Officer and Chief Financial Officer that our Company's disclosure controls and procedures (as defined in Exchange Act rules 13a-15(e) and 15d-15(e)), based on their evaluation of these controls and procedures as of the end of the period covered by this annual report, are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management's Annual Report on Internal Control Over Financial Reporting</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer and effected by the board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with International Reporting Standards as issued by the International Accounting Standards Board ("IFRS"), and includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with  IFRS, and that receipts and expenditures of the Company are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, 2013 Framework,  (COSO) in Internal Control-Integrated Framework.&#160;&#160;Based on this assessment, management believes that, as of December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Attestation Report of the Registered Public Accounting Firms</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with Securities and Exchange Commission&#8217;s rules regarding non-accelerated filers, this Annual Report does not include an attestation report of the Company's independent registered public accounting firm regarding the Company's internal control over financial reporting. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Controls over Financial Reporting</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal controls over financial reporting that occurred during the period that is covered by this annual report that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9E20B3277A595B149690EF4C730F3105"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16 .&#160; [RESERVED]</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s6BBE53F6CDC65C7997E134B7D6ABA86E"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16A.&#160; AUDIT COMMITTEE FINANCIAL EXPERT</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Board has determined that each of the Audit Committee members, Angela Holtham, Wayne Pisano, Mark Lievonen and Deborah Brown, is a financial expert and each is independent pursuant to the Rule 5605(d)(2) of the NASDAQ Capital Market and Rule 10A-3 of the Exchange Act.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8D1DC7E320D65F59894312960D7C1534"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16B.&#160; CODE OF ETHICS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Board of Directors has adopted a Code of Ethics for our Chief Executive Officer, Chief Financial Officer and Accounting Officer that applies to our Chief Executive Officer, Chief Financial Officer and Controller.&#160;&#160;A copy of this Code of Ethics may be found on the Company&#8217;s website at http://www.oncolyticsbiotech.com.&#160;&#160;Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 210 &#8211; 1167 Kensington Crescent, NW, Calgary, Alberta, Canada, T2N 1X7, Attention:&#160;&#160;Kirk Look &#160;Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolyticsbiotech.com.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no amendments to our Code of Ethics during the fiscal year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">.  We did not grant any waivers to the provisions of our Code of Ethics during the fiscal year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sAD8FD3C4B08756F1A597066CC91DB27E"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16C.&#160; PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Audit Fees and Services</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the financial years ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, Ernst &amp; Young LLP received the following fees:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:301px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:133px;"></td><td style="width:51px;"></td><td style="width:4px;"></td><td style="width:51px;"></td><td style="width:4px;"></td><td style="width:51px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291,509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit-related fees </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1),(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,327</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,145</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,017</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax fees </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,843</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other fees</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes review of interim financial statements, accounting consultations and subscription to on-line accounting services.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprised of tax return preparation, scientific research and development return and other tax consultation fees.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes fees associated with matters relating to the provision of a consent letter for various filings.  </font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Audit Fees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit fees were for professional services rendered by Ernst &amp; Young, LLP for the audit of our annual financial statements and services provided in connection with statutory and regulatory filings or engagements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Audit-Related Fees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit-related fees were for assurance and related services reasonably related to the performance of the audit or review of the annual statements and are not reported under the heading Audit Fees above.&#160;&#160;These services consisted of accounting consultations, assistance with prospectus filings and assistance with preparations for compliance with section 404 of the Sarbanes-Oxley Act of 2002.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Tax Fees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax fees were for tax compliance and professional tax consultations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">All Other Fees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other fees are for products and services other than those described under the headings Audit Fees, Audit-Related Fees and Tax Fees above.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee pre-approves all audit services to be provided to us by our independent auditors. The Audit Committee&#8217;s policy regarding the pre-approval of non-audit services to be provided to us by our independent auditors is that all such services shall be pre-approved by the Audit Committee or by the Chair of the Audit Committee, who must report all such pre-approvals to the Audit Committee at their next meeting following the granting thereof. Non-audit services that are prohibited to be provided to us by our independent auditors may not be pre-approved. In addition, prior to the granting of any pre-approval, the Audit Committee or the Chair, as the case may be, must be satisfied that the performance of the services in question will not compromise the independence of the independent auditors.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE2E2EA4A4DC253C2A10E599D52006FB3"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8C3D371348EC5E308A648987C0A4029A"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16E. PURCHASE OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sCA306F7FD51B5F1F9ADFA75A6A517DBA"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16F.&#160; CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF95976133DDD58C398C79EF544E8B47F"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16G. CORPORATE GOVERNANCE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sBE014DF0F6175DB8926DCC9728801AA6"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16H.&#160; MINE SAFETY DISCLOSURE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0A4C1B097F2E5AB9BDBEA69C3A3530E3"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s26C42CB3BF315166B6FA85D6893CB7CE"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 17. FINANCIAL STATEMENTS.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><a name="sE798855B4E245EE89ED46B4C206B6956"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 18 FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements appear on pages F-1 through F-26.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><a name="s4CBD29E37F9F5816B2C5B14716A3ED78"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 19. EXHIBITS.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following exhibits are filed as part of this annual report:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">EXHIBIT</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;text-decoration:underline;">NUMBER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">DESCRIPTION</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Constating Documents</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Articles of Incorporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By-laws</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Material Contracts</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228203000300/ex4_15.htm"><font style="font-family:inherit;font-size:10pt;">Services Agreement, dated October 16, 2002, between the Company and its Senior Vice President, Clinical and Regulatory Affairs, George Gill</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228208000801/ex4_2.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement No. 1, dated January 6, 2005, to the Services Agreement between the Company and its Senior Vice President, Clinical and Regulatory Affairs, George Gill, dated October 16, 2001</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228208000801/ex4_3.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated January 12, 2007, between the Company and its Vice President, Intellectual Property, Mary Ann Dillahunty</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228208000801/ex4_4.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated May 29, 2007, between the Company and its Chief Scientific Officer, Matthew Coffey</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228208000801/ex4_5.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated May 29, 2007, between the Company and its Chief Medical Officer, Dr. Karl Mettinger</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228208000801/ex4_6.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated May 30, 2007, between the Company and its Chief Financial Officer, Douglas Ball</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.7</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228208000801/ex4_7.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated June 6, 2007, between the Company and its Chief Executive Officer, Bradley Thompson</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.8</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228208000801/ex4_8.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement No. 1, dated December 3, 2007, to the Employment Agreement between the Company and its Vice President, Intellectual Property, Mary Ann Dillahunty, dated January 12, 2007</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.9</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228208000801/ex4_9.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No. 1, dated March 7, 2008, to the Executive Employment Agreement between the Company and its Chief Financial Officer, Douglas Ball, dated May 30, 2007</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.10</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228208000801/ex4_10.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No.1, dated March 7, 2008, between the Company and its Chief Scientific Officer, Matthew Coffey, dated May 29, 2007</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.11</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228208000801/ex4_11.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No. 1, dated March 7, 2008, to the Executive Employment Agreement between the Company and its Chief Executive Officer, Bradley Thompson, dated June 6, 2007</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.12</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228208000801/ex4_12.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No. 1, dated March 20, 2008, to the Employment Agreement between the Company and its Vice President, Intellectual Property, Mary Ann Dillahunty, dated January 12, 2007</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.13</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228208000801/ex4_13.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No. 1, dated March 28, 2008, to the Executive Employment Agreement between the Company and its Chief Medical Officer, Dr. Karl Mettinger, dated May 29, 2007</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.14</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228208000801/ex4_14.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No. 2, dated March 31, 2008, to the Services Agreement between the Company and its Senior Vice President, Clinical and Regulatory Affairs, George Gill, dated October 16, 2001</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.15</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228209000336/ex4_15.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated January 26, 2009, between Oncolytics Biotech (U.S.) Inc. and its Chief Medical Officer, Dr. Karl Mettinger</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.16</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228209000336/ex4_16.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated January 22, 2009 between the Company and its Vice President, Intellectual Property, Mary Ann Dillahunty.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.17</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(e)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000091228211000145/ex4_17.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No. 2, dated January 1, 2011, to the Executive Employment Agreement between the Company and its Chief Executive Officer, Bradley Thompson, dated June 6, 2007</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.18</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(f)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992812000013/georgegillemploymentagreem.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated January 1, 2011 between the Company and its Senior Vice President, Clinical and Regulatory Affairs, George Gill.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.19</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(f)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992812000013/ex419gkinnealemploymentagr.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated November 10, 2011 between the Company and its Senior Vice President of Clinical Development and Chief Medical Officer, Gerard T. Kennealey.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.20</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(g)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992813000016/ex420coffeyexecutiveemploym.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated March 22, 2013, between the Company and its Chief Operating Officer, Matthew Coffey</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(g)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992813000016/ex421tuchmanemploymentagree.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated September 27, 2012, between Oncolytics Biotech (U.S.) Inc. and its Senior Vice President, Medical and Clinical Affairs Chief Medical Officer, Dr. Alan Tuchman</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.22</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(g)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992813000016/ex422lookexecutiveemploymen.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated March 22, 2013, between the Company and its Chief Financial Officer, Kirk Look</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.23</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(g)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992813000016/ex423thompsonexecutiveemplo.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated March 22, 2013, between the Company and its Chief Executive Officer, Bradley Thompson</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.24</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(h)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992814000008/ex424amendingagreement-bt.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2014, between the Company and its Chief Executive Officer, Bradley Thompson</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.25</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(h)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992814000008/ex425amendingagreement-kl.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2014, between the Company and its Chief Financial Officer, Kirk Look</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.26</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(h)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992814000008/ex426amendingagreement-mc.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2014, between the Company and its Chief Operating Officer, Matthew Coffey</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.27</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(i)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992815000002/ex427amendment-tuchman.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2015, between Oncolytics Biotech (U.S.) Inc. and its Senior Vice President, Medical and Clinical Affairs Chief Medical Officer, Dr. Alan Tuchman</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.28</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(i)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992815000002/ex428amendment-dillahunty.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2015, between Oncolytics Biotech (U.S.) Inc. and its Vice President, Intellectual Property, Mary Ann Dillahunty.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.29</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(i)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992815000002/ex429amendment-thompson.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2015, between the Company and its Chief Executive Officer, Bradley Thompson</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.30</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(i)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992815000002/ex430amendment-gill.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2015, between Oncolytics Biotech (U.S.) Inc. and its Senior Vice President, Clinical and Regulatory Affairs, George Gill.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.31</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(i)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992815000002/ex431amendment-look.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2015, between the Company and its Chief Financial Officer, Kirk Look</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.32</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(i)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992815000002/ex432amendment-coffey.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 12, 2015, between the Company and its Chief Operating Officer, Matthew Coffey</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.33</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(j)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992816000013/ex433thompson.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 8, 2016, between the Company and its Chief Executive Officer, Bradley Thompson</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.34</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(j)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992816000013/ex434look.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 8, 2016, between the Company and its Chief Financial Officer, Kirk Look</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.35</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(j)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992816000013/ex435coffey.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 8, 2016, between the Company and its Chief Operating Officer, Matthew Coffey</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.36</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(j)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992816000013/ex436tuchman.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated November 10, 2015, between Oncolytics Biotech (U.S.) Inc. and its Senior Vice President, Medical and Clinical Affairs Chief Medical Officer, Dr. Alan Tuchman</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.37</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(j)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992816000013/ex437tuchman.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 8, 2016, between Oncolytics Biotech (U.S.) Inc. and its Senior Vice President, Medical and Clinical Affairs Chief Medical Officer, Dr. Alan Tuchman</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.38</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(j)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992816000013/ex438gill.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 8, 2016, between Oncolytics Biotech (U.S.) Inc. and its Senior Vice President, Clinical and Regulatory Affairs, George Gill.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.39</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(k)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992817000003/ex439guttierrez.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated October 27, 2016, between Oncolytics Biotech (U.S.) Inc. and its Chief Medical Officer, Dr. Andres Gutierrez.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.40</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(k)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992817000003/ex440coffey.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated February 23, 2017, between the Company and its Chief Executive Officer, Matthew Coffey.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.41</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(k)*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992817000003/ex441look.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated February 23, 2017, between the Company and its Chief Financial Officer, Kirk Look.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.42</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(k)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992817000003/ex442thompson.htm"><font style="font-family:inherit;font-size:10pt;">Settlement Agreement and Release, dated December 5, 2016 between the Company and its former Chief Executive Officer, Brad Thompson.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.43</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex443deguttadauro.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated June 29, 2017 between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.44</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">#</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex444regionallicensingagre.htm"><font style="font-family:inherit;font-size:10pt;">License, development, supply and distribution agreement with Adlai Nortye Biopharma Co., Ltd dated November 14, 2017</font></a><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.45</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex445coffey.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 8, 2018, between the Company and its Chief Executive Officer, Matthew Coffey.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.46</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex446look.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 8, 2018, between the Company and its Chief Financial Officer, Kirk Look.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.47</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex447deguttadauro.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 8, 2018 between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.48</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">*</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex448gutierrez.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March 8, 2018, between Oncolytics Biotech (U.S.) Inc. and its Chief Medical Officer, Dr. Andres Gutierrez.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsidiaries</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.0</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex80subsidiaries2017.htm"><font style="font-family:inherit;font-size:10pt;">List of subsidiaries</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certifications</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.1</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex121ceocertfication2017.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.2</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex122cfocertification2017.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.1</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex131ceocertification2017.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.2</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex132cfocertification2017.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Exhibits</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.1</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex151-2017mda.htm"><font style="font-family:inherit;font-size:10pt;">The Registrant's Management's Discussion and Analysis for the Year Ended December 31, 2017</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.2</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex152eyconsentletter2017.htm"><font style="font-family:inherit;font-size:10pt;">Consent of Ernst &amp; Young LLP</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.1</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interactive Data Files (XBRL-Related Documents)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">* - Denotes management contract or agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"># - Certain portions of this exhibit have been redacted pursuant to a confidential treatment request filed with the SEC on March 19, 2018</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;Previously filed with the SEC on Form 20-F dated June 14, 2002.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;Previously filed with the SEC on Form 20-F dated June 27, 2003.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;Previously filed with the SEC on Form 20-F dated May 23, 2008.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Previously filed with the SEC on Form 20-F dated March 6, 2009.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(e) Previously filed with the SEC on Form 20-F dated March 24, 2011.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(f) Previously filed with the SEC on Form 20-F dated March 23, 2012.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(g) Previously filed with the SEC on Form 20-F dated March 22, 2013.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(h) Previously filed with the SEC on Form 20-F dated March 19, 2014.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i) Previously filed with the SEC on Form 20-F dated March 20, 2015.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(j) Previously filed with the SEC on Form 20-F dated March 24, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(k) Previously filed with the SEC on Form 20-F dated March 28, 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><a name="s757CFD266FFD5182A637DF397F9909EE"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;19, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">/s/ Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">/s/ Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Coffey, Ph.D&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look, CA</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><a name="s91F43AA78B7852DC8BF9FBB111B4FCE6"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Consolidated Financial Statements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;color:#000000;text-decoration:none;">2016</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s7C4A88126A0655AA817C4918EE7BDA2E"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STATEMENT OF MANAGEMENT&#8217;S RESPONSIBILITY</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management is responsible for the preparation and presentation of the consolidated financial statements, Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;) and all other information in the Annual Report.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In management&#8217;s opinion, the accompanying consolidated financial statements have been properly prepared within reasonable limits of materiality and in accordance with the appropriately selected International Financial Reporting Standards as issued by the International Accounting Standards Board consistently applied and summarized in the consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The MD&amp;A has been prepared in accordance with the requirements of securities regulators as applicable to Oncolytics Biotech Inc.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements and information in the MD&amp;A generally include estimates that are necessary when transactions affecting the current accounting period cannot be finalized with certainty until future periods.&#160;&#160;Based on careful judgments by management, such estimates have been properly reflected in the accompanying consolidated financial statements and MD&amp;A.&#160;&#160;The MD&amp;A also includes information regarding the impact of current transactions and events, sources of liquidity and capital resources and risks and uncertainty.&#160;&#160;Actual results in the future may differ materially from our present assessment of this information because future events and circumstances may not occur as expected.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Systems of internal controls, including organizational and procedural controls and internal controls over financial reporting, assessed as reasonable and appropriate in the circumstances, are designed and maintained by management to provide reasonable assurance that assets are safeguarded from loss or unauthorized use and to produce reliable records for financial purposes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We, as the Chief Executive Officer and Chief Financial Officer, will certify to our annual filings with the CSA and the SEC as required in Canada by National Instrument 52-109 (Certification of Disclosure in Issuers&#8217; Annual Interim Filings) and in the United States by the Sarbanes-Oxley Act.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The external auditors conducted an independent examination of corporate and accounting records in accordance with generally accepted auditing standards to express their opinion on the consolidated financial statements.&#160;&#160;Their examination included such tests and procedures as they considered necessary to provide reasonable assurance that the consolidated financial statements are presented fairly.&#160;&#160;The external auditors have full and free access to our Board of Directors and its Committees to discuss audit, financial reporting and related matters.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors is responsible for ensuring that management fulfills its responsibilities for financial reporting and internal control.&#160;&#160;The Board exercises this responsibility through the Audit Committee of the Board.&#160;&#160;This Committee meets with management and the external auditors to satisfy itself that management&#8217;s responsibilities are properly discharged and to review the consolidated financial statements and MD&amp;A before they are presented to the Board of Directors for approval.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Matt Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;/s/ Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matt Coffey, Ph.D&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look, CA</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-1</font></div></div><hr style="page-break-after:always"><div><a name="s3C8FEB9FCF355972BAA3EA78679D6734"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Shareholders and Directors of </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on the consolidated financial statements</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated financial statements of </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;[the &#8220;Company&#8221;], which comprise the consolidated statements of financial position as at December 31, 2017 and December&#160;31, 2016, the consolidated statements of loss and comprehensive loss, changes in equity and cash flows for each of the years in the three-year period ended December 31, 2017, and the related notes, comprising a summary of significant accounting policies and other explanatory information [collectively referred to as the &#8220;consolidated financial statements&#8221;]. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as at December 31, 2017 and December 31, 2016, and its consolidated financial performance and its consolidated cash flows for each of the years in the three-year period ended December 31, 2017, in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis for opinion </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Management&#8217;s responsibility for the consolidated financial statements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Auditors&#8217; responsibility</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted auditing standards and the standards of the Public Company Accounting Oversight Board (United States) [&#8220;PCAOB&#8221;]. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement, whether due to error or fraud. Those standards also require that we comply with ethical requirements, including independence. We are required to be independent with respect to the Company in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in Canada, the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We are a public accounting firm registered with the PCAOB.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An audit includes performing procedures to assess the risks of material misstatements of the consolidated financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included obtaining and examining, on a test basis, audit evidence regarding the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.  In making those risk assessments, we consider internal control relevant to the Company&#8217;s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Accordingly, we express no such opinion.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An audit also includes evaluating the appropriateness of accounting policies and principles used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. </font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that the audit evidence we have obtained in our audits is sufficient and appropriate to provide a reasonable basis for our audit opinion.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have served as the Company&#8217;s auditor since 1999.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:48%;"></td><td style="width:52%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Calgary, Canada</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;"><img src="eysignaturecpalpa.jpg" alt="eysignaturecpalpa.jpg" style="height:93px;width:247px;"></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;8, 2018</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-2</font></div></div><hr style="page-break-after:always"><div><a name="sEDFB1268C46752D4881F769DBF2ED896"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:536px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:304px;"></td><td style="width:40px;"></td><td style="width:91px;"></td><td style="width:4px;"></td><td style="width:91px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,836,119</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,034,282</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,767,100</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">37,726</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,176,063</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260,841</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">17,817,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,438,329</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">333,441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319,955</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total non-current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">333,441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319,955</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18,150,449</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,758,284</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities And Shareholders&#8217; Equity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,684,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,068,664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,545,645</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,229,668</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,068,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,636,935</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total non-current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,636,935</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;font-style:italic;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9,866,603</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,068,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and contingencies</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">11, 12 and 17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share capital<br>&#160;&#160;Authorized: unlimited<br>&#160;&#160;Issued:<br>  December 31, 2017 &#8211; 141,805,722  <br>  December 31, 2016 &#8211; 121,258,222<br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">271,710,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,321,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,900</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contributed surplus</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27,028,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,643,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">373,730</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554,060</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(294,446,160</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(278,829,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,283,846</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,689,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18,150,449</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,758,284</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:65.234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:47%;"></td><td style="width:53%;"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;On behalf of the Board:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Angela Holtham</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Wayne Pisano</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Director&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Director&#160;&#160;&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-3</font></div></div><hr style="page-break-after:always"><div><a name="s9E3E591F690C53CE8B0C90AC050A59C1"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:657px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:314px;"></td><td style="width:65px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ending December 31,</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8, 19, 20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9,392,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,770,007</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,601,864</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Operating</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8, 19, 20</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,212,831</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,524,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,315,837</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before the following</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,605,454</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,294,507</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,917,701</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Interest</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">130,101</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,902</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,859</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,475,353</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,130,605</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,719,842</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(141,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,374</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,153</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,616,851</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,139,979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,722,995</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other comprehensive (loss) income items that may be<br>  reclassified to net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Translation adjustment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(180,330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(206,918</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480,935</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,797,181</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,346,897</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,242,060</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(0.12</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.12</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Weighted average number of shares (basic and diluted)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">132,395,752</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,880,200</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,613,845</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:60px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-4</font></div></div><hr style="page-break-after:always"><div><a name="sC97311B9CFA2538C8AAEF9205536E9F1"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:920px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:252px;"></td><td style="width:89px;"></td><td style="width:86px;"></td><td style="width:4px;"></td><td style="width:95px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:106px;"></td><td style="width:4px;"></td><td style="width:106px;"></td><td style="width:4px;"></td><td style="width:83px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Capital</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contributed Surplus</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Deficit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">As at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,657,056</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,848,429</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">280,043</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(249,966,335</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,819,193</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480,935</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,722,995</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,242,060</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Share Purchase Agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,371,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,371,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,049,693</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,049,693</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429,537</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429,537</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(753,744</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(753,744</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">As at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,324,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,277,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">760,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(263,689,330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,674,306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(206,918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,139,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,346,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issue pursuant to "At the Market" Agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">406,078</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">406,078</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,321,825</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,643,044</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554,060</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(278,829,309</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,689,620</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(180,330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,616,851</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,797,181</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">536,949</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(193,509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,348,821</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,348,821</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,893,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,511,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">578,703</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">578,703</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,391,057</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,391,057</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">271,710,138</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,900</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27,028,238</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">373,730</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(294,446,160</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,283,846</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-5</font></div></div><hr style="page-break-after:always"><div><a name="sA1B73E169A945AD393C4292F7D98D71E"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:647px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:313px;"></td><td style="width:66px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ending December 31,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,616,851</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,139,979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,722,995</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization - property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90,768</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8, 19, 20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">578,703</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">406,078</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429,537</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized foreign exchange gain</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(124,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(139,810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(816,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change in non-cash working capital</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">180,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,233,865</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,105,464</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash used in operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(14,891,318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,477,613</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,034,830</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing Activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition of property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(105,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,527</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(108,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redemption (purchase) of short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,088,800</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,823</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,292</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash  provided by (used in) investing activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,983,035</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,560</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing Activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from Share Purchase Agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,305,396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from "At the Market" equity distribution  agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,103,166</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">956,133</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,362,240</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from public offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,366,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">343,440</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash provided by financing activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,812,704</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">956,133</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,667,636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Decrease) increase in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(95,579</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,572,830</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,495,246</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, beginning of year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,034,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,016,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,152,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of foreign exchange on cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(102,584</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(409,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,368,204</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and cash equivalents, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,836,119</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,034,282</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,016,275</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-6</font></div></div><hr style="page-break-after:always"><div><a name="s93179528747D53E0B918603A92909DCF"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8B62BAFD49F0556787BBCB036301AAE6"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 1: Incorporation and Nature of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;8, 2018</font><font style="font-family:inherit;font-size:10pt;">.  We are a limited company incorporated and domiciled in Canada.  Our shares are publicly traded and our registered office is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics.  Our lead product, REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to existing cytotoxic or cytostatic therapies. Our clinical development program for REOLYSIN emphasizes three programs: chemotherapy combinations to trigger selective tumor lysis;  immune modulator (IMiD) combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB138C4ED2CA7516BA094459311EB9A09"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 2: Basis of Financial Statement Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries Oncolytics Biotech (Barbados) Inc., Oncolytics Biotech (US) Inc., and Oncolytics Biotech (UK) Inc. and are presented in Canadian dollars, our functional currency.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our accounts include the accounts of Oncolytics Biotech Inc. and our subsidiaries.  Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and has the ability to affect those returns through our power to govern.  Accounting policies of subsidiaries are consistent with our accounting policies and all intra-group transactions, balances, income and expenses are eliminated on consolidation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A change in ownership interest of a subsidiary, without a change in control, is accounted for as an equity transaction.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5A6DAB7FB63A5777AA631430CBF51932"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 3: Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Deferred income taxes</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We follow the liability method of accounting for income taxes.  Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Financial instruments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial assets</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets are comprised of cash and cash equivalents, contract receivable, other receivables and short-term investments.  Financial assets are initially recorded at fair market value and are classified as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents consist of cash on hand and interest bearing deposits with our bank and have been designated as held for trading.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contract receivable and other receivables</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable and other receivables have been classified as loans and receivables.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term investments </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determine the appropriate classification of our short-term investments at the time of purchase and re-evaluate such classification as of each reporting date.  We classify our short-term investments as held-to-maturity as we have the positive intent and ability to hold the securities to maturity.  Held-to-maturity securities are stated at original cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest rate method.  Such amortization and interest on securities classified as held-to-maturity are included in interest income. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of financial assets</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We assess at each reporting date whether there is any objective evidence that a financial asset or a group of financial assets is impaired. A financial asset or a group of financial assets is deemed to be impaired if, and only if, there is objective evidence of impairment as a result of one or more events that has occurred after the initial recognition of the asset (an incurred loss event) and that loss event has an impact on the estimated future cash flows of the financial asset or the group of financial assets that can be reliably estimated.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial liabilities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Trade accounts payable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable are non interest-bearing and recorded at fair market value.  They are classified as other financial liabilities and are subsequently measured at amortized cost using the effective interest rate method.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Transaction Costs</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction costs are expensed as incurred for financial instruments designated as held for trading.  Transaction costs for other financial instruments are recognized as part of the financial instrument's carrying value.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Foreign currency translation</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements for each of our subsidiaries are prepared using their functional currency.  Our presentation currency is the Canadian dollar which is also Oncolytics Biotech Inc.'s functional currency.  Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions.  Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency.  These exchange differences are initially recognized in equity.  The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period.  Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used.  Exchange differences on translation into Canadian dollars are recognized as a separate component of equity.  On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Investment tax credits</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment tax credits ("ITCs") relating to qualifying scientific research and experimental development expenditures that are refundable are accounted for as a reduction in research and development expenditures.  ITCs that are non-refundable, but are recoverable against future taxes payable, are accrued only when there is reasonable assurance that the credits will be realized.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ITCs are subject to technical and financial review by the Canadian tax authorities on a project-by-project basis.  Therefore,  amounts ultimately received may vary significantly from the amounts recorded. Any such differences are recorded as an adjustment to the recognized amount in the year the review by the Canadian tax authority is completed and the results are made known to us.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loss per common share</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the treasury stock method to calculate diluted loss per common share.  Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive.  The number of additional common shares is calculated by assuming that any outstanding &#8220;in the money&#8221; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Property and equipment </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives.  Depreciation is recorded using the declining balance method at the following annual rates:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:49%;"></td><td style="width:51%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line over the term of the lease</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Research and development costs</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research costs are expensed as incurred, net of recoveries.  We record accruals for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the treatment phase of clinical trials based on the total estimated cost of the treatment phase on a per patient basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized.  To date, all development costs have been expensed. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract receivable</font><font style="font-family:inherit;font-size:10pt;">&#32;- Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&#8217;s credit risk and payment histories, including payments made subsequent to year-end.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract liability</font><font style="font-family:inherit;font-size:10pt;">&#32;- Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Share based payments</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock option plan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;stock option plan (the &#8220;Option Plan&#8221;) available to officers, directors, employees, consultants and suppliers with grants under the Option Plan approved from time to time by our Board of Directors (the &#8220;Board&#8221;).  Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines.  Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;">&#32;from the date of grant.  Exercised stock options are settled with common shares issued from treasury. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the fair value based method of accounting for stock option awards granted under the Option Plan.  We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black Scholes Option Pricing Model. The fair value of stock options with a graded vesting schedule is determined based on different expected lives for the options that vest each year, as it would be if the award were viewed as several separate awards, each with a different vesting date, and it is accounted for over the respective vesting period taking into consideration forfeiture estimates.      Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments to non-employees are measured at the date we obtain the goods or the date the counterparty renders the service. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Incentive share award plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board.  Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria.  Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 15 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue from Contracts with Customers</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the IASB issued IFRS 15 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">. The new standard will replace IAS 18 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue</font><font style="font-family:inherit;font-size:10pt;">&#32;and IAS 11 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Construction Contracts</font><font style="font-family:inherit;font-size:10pt;">. IFRS 15 establishes a comprehensive framework for determining whether, how much and when revenue is recognised, and also contains new requirements related to presentation. The core principle in that framework is that revenue should be recognised dependent on the transfer of promised goods or services to the customer for an amount that reflects the consideration which should be received in exchange for those goods or services. The objective of the standard is to provide a five-step approach to revenue recognition that includes identifying contracts with customers, identifying performance obligations, determining transaction prices, allocating transaction prices to performance obligations, and recognising revenue when or as performance obligations are satisfied. Judgment will need to be applied, including making estimates and assumptions, for multiple-element contracts in identifying performance obligations, in constraining estimates of variable consideration and in allocating the transaction price to each performance obligation. This new standard is effective for annual periods beginning on or after January 1, 2018, with early adoption permitted. We early adopted this standard effective for our year ended December 31, 2017 using the full retrospective method. There were no adjustments to our consolidated financial statements resulting from this early adoption. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Accounting Standards and Interpretations Issued but Not Yet Effective</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 9 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014, on completion of the impairment phase of the project to reform accounting for financial instruments and replace IAS 39 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments: Recognition and Measurement</font><font style="font-family:inherit;font-size:10pt;">, the IASB issued the final version of IFRS 9 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments. </font><font style="font-family:inherit;font-size:10pt;">IFRS 9 includes guidance on the classification and measurement of financial assets and financial liabilities and impairment of financial assets (i.e. recognition of credit losses).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the classification and measurement requirements for financial assets, financial assets must be classified and measured at either amortized cost or at fair value through profit or loss or through other comprehensive income, depending on the basis of the entity&#8217;s business model for managing the financial asset and the contractual cash flow characteristics of the financial asset. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The classification requirements for financial liabilities are unchanged from IAS 39. IFRS 9 requirements address the problem of volatility in net earnings arising from an issuer choosing to measure certain liabilities at fair value and require that the portion of the change in fair value due to changes in the entity&#8217;s own credit risk be presented in other comprehensive income, rather than within net earnings. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new requirements for impairment of financial assets introduce an expected loss impairment model that requires more timely recognition of expected credit losses. IAS 39 impairment requirements are based on an incurred loss model where credit losses are not recognized until there is evidence of a trigger event. IFRS 9 is effective for annual periods beginning on or after January 1, 2018 with early adoption permitted. We are assessing the impact of adopting this standard on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 16 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the IASB issued IFRS 16 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;IFRS 16&#8221;), which replaces IAS 17 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;IAS 17&#8221;) and related interpretations. IFRS 16 provides a single lessee accounting model, requiring the recognition of assets and liabilities for all leases, unless the lease term is 12-months or less or the underlying asset has a low value. IFRS 16 substantially carries forward the lessor accounting in IAS 17 with the distinction between operating leases and finance leases being retained. IFRS 16 will be applied retrospectively for annual periods beginning on or after January 1, 2019. Early adoption is permitted under certain circumstances.  We are assessing the potential impact of adopting this standard on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s304722548E405D9EBE2765654D45EA7C"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 4:  Significant Judgments, Estimates and Assumptions</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Judgments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amount of expenses, assets, liabilities, and the disclosure of contingent liabilities, at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Estimates and assumptions</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods.  Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting our consolidated financial statements include:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue recognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into an Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share based payments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Part of our share based payment expense is measured by reference to the fair value of our stock options at the date at which they are granted.  Estimating fair value for granted stock options requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant.  This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the option, volatility, dividend yield, and rate of forfeitures and making assumptions about them.  The value of the share based payment expense for the year along with the assumptions and model used for estimating fair value for share based compensation transactions are disclosed in Note 8.    </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income.  Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset.  Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date we have determined that none of our deferred tax assets should be recognized.  Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits.  These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries.  As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFA3600EC7B91537E92817785767881E3"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 5: Cash Equivalents and Short Term Investments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of interest bearing deposits with our bank totaling $</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">9,204,919</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10,679,992</font><font style="font-family:inherit;font-size:10pt;">).&#160;&#160;The current annual interest rate earned on these deposits is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.38%</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.96%</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term Investments </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments consisted of guaranteed investment certificates which are liquid investments that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.&#160;&#160;The objectives for holding short-term investments were to invest our excess cash resources in investment vehicles that provided a better rate of return compared to our interest bearing bank account with limited risk to the principal invested.&#160;&#160;We intended to match the maturities of these short-term investments with the cash requirements of the Company&#8217;s activities and treat these as held-to-maturity short-term investments.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:20%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Face</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Original Cost</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Accrued Interest</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Carrying</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Fair</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Effective</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Interest Rate</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.41%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is determined by using published market prices provided by our investment advisor.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sBC9218C837CF51C687326074359A1BDD"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 6: Property and Equipment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:164px;"></td><td style="width:80px;"></td><td style="width:4px;"></td><td style="width:87px;"></td><td style="width:4px;"></td><td style="width:79px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Computer Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Furniture</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leasehold Improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">685,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,651,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,098</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,502</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">770</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,370</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,673,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,778</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,811</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,665</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,254</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">197,870</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">681,985</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">225,896</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">89,466</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">534,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,729,517</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">505,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,191,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization for the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,929</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,241</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,233</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">452,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,353,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization for the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,365</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,558</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,710</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,620</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,515</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,768</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">154,334</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">549,564</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">147,334</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">68,787</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">476,057</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,396,076</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net book value</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">43,536</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">132,421</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">78,562</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20,679</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">58,243</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">333,441</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,901</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,201</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,461</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,299</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,093</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319,955</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s36F202266CD856C1A9FADA282B85588D"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 7: Share Capital</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Authorized:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unlimited number of no par value common shares</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:595px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:222px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued:</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,512,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,657,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Share Purchase<br>   Agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,778,674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,371,687</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" sales agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,860,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,049,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(753,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,151,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,324,692</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,006,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500,163</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,258,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,321,825</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">801,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">536,949</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,301,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,348,821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,893,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,391,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">141,805,722</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">271,710,138</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,900</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2014, we entered into a share purchase agreement (the "Share Purchase Agreement") with Lincoln Park Capital Fund, LLC ("LPC") to sell up to </font><font style="font-family:inherit;font-size:10pt;">US$26,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of common stock.  Subject to the terms and conditions of the Share Purchase Agreement and at our sole discretion, we may sell up to </font><font style="font-family:inherit;font-size:10pt;">US$26.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;worth of common shares to LPC over the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-month term. The purchase price of the common shares was based on prevailing market prices of our  common shares immediately preceding the notice of a sale without any fixed discount. Subject to the Share Purchase Agreement, we controlled the timing and amount of each investment and LPC was obligated to make such purchases, if and when elected.  The Share Purchase Agreement did not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities, but required that we maintained our NASDAQ listing. Under the Share Purchase Agreement, we issued an initial  commitment fee of </font><font style="font-family:inherit;font-size:10pt;">292,793</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares to LPC valued at fair value of </font><font style="font-family:inherit;font-size:10pt;">US$455,000</font><font style="font-family:inherit;font-size:10pt;">.  An additional </font><font style="font-family:inherit;font-size:10pt;">292,793</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares was to be issued on a pro rata basis under the terms of the Share Purchase Agreement as an additional commitment fee.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 20, 2014, we reached an agreement to amend the Share Purchase Agreement.  The specific amendments included allowing the Company to sell shares to LPC at the Company's sole option independent of the closing price of the Common Stock, increasing the number of shares that may have been sold to LPC at certain price levels and changed the way the number of Commitment Shares issuable was to be calculated. In consideration of the amendments to the Agreement, the Company issued </font><font style="font-family:inherit;font-size:10pt;">146,397</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Common Stock to LPC. </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2015, under the terms of the amended Share Purchase Agreement, we issued </font><font style="font-family:inherit;font-size:10pt;">5,778,674</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">US$3.5 million</font><font style="font-family:inherit;font-size:10pt;">. As part of the shares issued, we issued </font><font style="font-family:inherit;font-size:10pt;">78,674</font><font style="font-family:inherit;font-size:10pt;">&#32;commitment shares. The commitment shares have been valued at fair value of </font><font style="font-family:inherit;font-size:10pt;">US$50,024</font><font style="font-family:inherit;font-size:10pt;">&#32;and have been recorded as additional share issue costs.  On November 5, 2015, we were delisted from the NASDAQ Capital Market and as a result we were unable to sell common shares under the Share Purchase Agreement.</font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 24, 2014, we entered into an "at-the-market" ("ATM") equity distribution agreement with Canaccord Genuity Inc. acting as sole agent. Under the terms of the distribution agreement, we were able to, from time to time, sell shares of our common stock having an aggregate offering value of up to </font><font style="font-family:inherit;font-size:10pt;">US$20 million</font><font style="font-family:inherit;font-size:10pt;">&#32;through Canaccord Genuity Inc. directly to investors in the US through our NASDAQ listing.  We were able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility.  During 2015, we issued </font><font style="font-family:inherit;font-size:10pt;">18,860,454</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">US$15.5 million</font><font style="font-family:inherit;font-size:10pt;">. On November 5, 2015, we were delisted from the NASDAQ Capital Market and as a result we were unable to sell common shares under our existing ATM.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During 2017, we sold </font><font style="font-family:inherit;font-size:10pt;">3,301,500</font><font style="font-family:inherit;font-size:10pt;">&#32;(2016 - </font><font style="font-family:inherit;font-size:10pt;">3,006,600</font><font style="font-family:inherit;font-size:10pt;">) common shares for gross proceeds of $</font><font style="font-family:inherit;font-size:10pt;">2,348,821</font><font style="font-family:inherit;font-size:10pt;">&#32;(2016 - $</font><font style="font-family:inherit;font-size:10pt;">1,456,296</font><font style="font-family:inherit;font-size:10pt;">). We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">245,655</font><font style="font-family:inherit;font-size:10pt;">&#32;(2016 - </font><font style="font-family:inherit;font-size:10pt;">$500,163</font><font style="font-family:inherit;font-size:10pt;">).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2017, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">16,445,000</font><font style="font-family:inherit;font-size:10pt;">&#32;units were sold at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.70</font><font style="font-family:inherit;font-size:10pt;">&#32;per unit for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$11,511,500</font><font style="font-family:inherit;font-size:10pt;">. Each unit included </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share (ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$0.48</font><font style="font-family:inherit;font-size:10pt;">) and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share purchase warrant (ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$0.22</font><font style="font-family:inherit;font-size:10pt;">). The ascribed value was determined using the relative fair value method. The ascribed value of the common share purchase warrants was determined using the Black Scholes option pricing model. Each common share purchase warrant entitles the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share in the capital of the Company until June 1, 2022, at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.95</font><font style="font-family:inherit;font-size:10pt;">. The common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds </font><font style="font-family:inherit;font-size:10pt;">$2.50</font><font style="font-family:inherit;font-size:10pt;">&#32;for </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;">&#32;consecutive trading dates. We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$1,145,402</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the assumptions used in the Black Scholes Option Pricing Model with respect to the valuation of warrants issued:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:394px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:261px;"></td><td style="width:133px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.70%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility in the price of the Company's shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">89.30%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the warrants. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the warrants represents the estimated length of time the warrants are expected to remain outstanding.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our outstanding warrants at December 31, 2017:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:531px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:6px;"></td><td style="width:77px;"></td><td style="width:4px;"></td><td style="width:100px;"></td><td style="width:4px;"></td><td style="width:102px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td><td style="width:134px;"></td><td style="width:4px;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, Beginning of the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Granted During the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, End of the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.95</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.42</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s3C9677D67196524D9D74E4204626CECC"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 8: Share Based Payments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Stock Option Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:650px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:158px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:74px;"></td><td style="width:4px;"></td><td style="width:82px;"></td><td style="width:80px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,674,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,561,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,446,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">405,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.48</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,572,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,280,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,012,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(737,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(116,900</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(721,667</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.61</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.49</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(801,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.43</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,148,667</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,674,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.83</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,561,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,453,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.51</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,729,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,476,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the stock options outstanding and exercisable at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:182px;"></td><td style="width:96px;"></td><td style="width:4px;"></td><td style="width:100px;"></td><td style="width:100px;"></td><td style="width:96px;"></td><td style="width:4px;"></td><td style="width:100px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.26 - $0.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,437,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.46</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,921,834</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.51 - $0.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">538,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">358,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.70</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.45 - $2.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,002,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.62</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.77</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,002,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.77</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$2.13 - $3.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">545,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">545,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$4.01 - $6.72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.94</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.34</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.34</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,148,667</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,453,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.51</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-exercisable options vest either annually over periods ranging from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">&#32;or upon satisfaction of certain performance criteria.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of stock options issued during the year was determined using the Black Scholes Option Pricing Model using the following weighted average assumptions and fair value of options: </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:464px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:245px;"></td><td style="width:74px;"></td><td style="width:72px;"></td><td style="width:72px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.18%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.82%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.63%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility in the price of the Company's shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90.73%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94.84%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rate of forfeiture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$0.28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.24</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incentive Share Award Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Share Units</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued restricted share units ("RSUs") to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;year period. The following RSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:515px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:269px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,322,829</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,831</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">486,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,053,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Vested during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,809,067</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,322,829</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:36px;"><font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:24px;">(1)</font><font style="font-family:inherit;font-size:8pt;">The weighted average fair value of the RSUs granted was </font><font style="font-family:inherit;font-size:8pt;">$0.63</font><font style="font-family:inherit;font-size:8pt;">&#32;in 2017 (2016 - </font><font style="font-family:inherit;font-size:8pt;">$0.31</font><font style="font-family:inherit;font-size:8pt;">).</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Performance Share Units</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also issued performance share units ("PSUs") to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after </font><font style="font-family:inherit;font-size:10pt;">3 years</font><font style="font-family:inherit;font-size:10pt;">&#32;or vest over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;year period, depending on the grant. PSU grants to certain officers will vest immediately upon a change of control of the Company. If certain officers cease employment with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. The following PSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:521px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:274px;"></td><td style="width:79px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">840,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">60,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(660,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Outstanding, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">900,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">840,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:36px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) &#160;&#160;&#160;&#160;The weighted average fair value of the PSUs granted was $</font><font style="font-family:inherit;font-size:8pt;">0.35</font><font style="font-family:inherit;font-size:8pt;">&#32;in 2017 (2016 - </font><font style="font-family:inherit;font-size:8pt;">$0.36</font><font style="font-family:inherit;font-size:8pt;">).</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have reserved </font><font style="font-family:inherit;font-size:10pt;">14,180,572</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for issuance relating to our outstanding equity compensation plans.  Compensation expense related to stock options, RSUs and PSUs for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$578,703</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;(</font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$406,078</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$429,537</font><font style="font-family:inherit;font-size:10pt;">).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-18</font></div></div><hr style="page-break-after:always"><div><a name="s30B437B2B2705B39B3100ABB1D87DA87"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 9: Loss Per Common Share</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">132,395,752</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">119,880,200</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">112,613,845</font><font style="font-family:inherit;font-size:10pt;">).  The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="saf62aec5ac69411e91fba02694332726"></a></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 10: Contract liability and receivable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Regional licensing agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into a regional licensing agreement (the "Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrant purchase agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also entered into a warrant purchase agreement with Adlai. Under the terms of the warrant purchase agreement, we are entitled to receive two milestone payments totaling US</font><font style="font-family:inherit;font-size:10pt;">$8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;made of of two common share purchase warrants:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One common share purchase warrant of US</font><font style="font-family:inherit;font-size:10pt;">$2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;whereby, upon exercise, Adlai may purchase our common shares priced at a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;">&#32;premium to the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant when the first patient is enrolled in the phase 3 metastatic breast cancer study or </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;months after execution of the Agreement, whichever is later.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One common share purchase warrant of US</font><font style="font-family:inherit;font-size:10pt;">$6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;whereby, upon exercise, Adlai may purchase our common shares priced at a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;">&#32;premium to the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant upon the enrollment of the </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;">th patient in the phase 3 metastatic breast cancer study.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contract liability</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Our contract liability balance at December 31, which w</font><font style="font-family:inherit;font-size:10pt;">e expect to record in revenue over the next </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:443px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:236px;"></td><td style="width:102px;"></td><td style="width:4px;"></td><td style="width:96px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regional licensing agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,182,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized in the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,182,580</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,545,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - non-current</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,636,935</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,182,580</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contract receivable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our contract receivable due from Adlai at December 31, 2017 is </font><font style="font-family:inherit;font-size:10pt;">$4,767,100</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFEE8E1FA079D51A1B3103BCAF55BA3F5"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 11: Commitments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to payments totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5,980,454</font><font style="font-family:inherit;font-size:10pt;">&#32;during </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;for activities related to our clinical trial, manufacturing and collaboration programs. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to rental payments (excluding our portion of operating costs and rental taxes) under the terms of our office leases.  Annual payments under the terms of these leases are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:33.984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:59%;"></td><td style="width:40%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,987</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,990</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">740,850</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;">&#32;plus an overhead repayment of </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">, upon sales of a specified product.&#160;&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of gross sales of a specified product; or (b) </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum once sales of a specified product commence.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC519E2098DA75184B2DD113CADCB0041"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 12: Contingencies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assumption Agreement</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 1999, we entered into an agreement that assumed certain obligations (the &#8220;Assumption Agreement&#8221;) in connection with a Share Purchase Agreement (the &#8220;Agreement&#8221;) between SYNSORB and our former shareholders to make milestone payments and royalty payments.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, a milestone payment was still outstanding for </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">, due within </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;">&#32;of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;to the public or the approval of a new drug application for REOLYSIN.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the milestone payment, payments may become due and payable in accordance with the Agreement upon realization of sales of REOLYSIN.&#160;&#160;If we receive royalty payments or other payments as a result of entering into partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders </font><font style="font-family:inherit;font-size:10pt;">10.75%</font><font style="font-family:inherit;font-size:10pt;">&#32;(2016 - </font><font style="font-family:inherit;font-size:10pt;">11.75%</font><font style="font-family:inherit;font-size:10pt;">) of the royalty payments and other payments received.&#160;&#160;Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of </font><font style="font-family:inherit;font-size:10pt;">2.15%</font><font style="font-family:inherit;font-size:10pt;">&#32;(2016 -  </font><font style="font-family:inherit;font-size:10pt;">2.35%</font><font style="font-family:inherit;font-size:10pt;">) of Net Sales received for such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">BRI &#8220;Work in Kind&#8221; Contribution</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into an engineering and process development agreement with the Biotechnology Research Institute of the National Research Council of Canada (&#8220;BRI&#8221;).&#160;&#160;The terms of this Agreement include a &#8220;work in kind&#8221; contribution from BRI.&#160;&#160;In exchange for this &#8220;work in kind&#8221; contribution, we agreed to provide a royalty, contingent upon receiving Sales Revenue, at the lesser of </font><font style="font-family:inherit;font-size:10pt;">0.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of Sales Revenue or </font><font style="font-family:inherit;font-size:10pt;">$20,000</font><font style="font-family:inherit;font-size:10pt;">&#32;per year.&#160;&#160;The total royalty under this Agreement is equal to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;times the &#8220;work in kind&#8221; contribution.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we estimate that the accumulated work in kind totals approximately </font><font style="font-family:inherit;font-size:10pt;">$301,000</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s89253E3390615E67B470E20D82140EE8"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 13: Income Taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:583px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:316px;"></td><td style="width:76px;"></td><td style="width:13px;"></td><td style="width:78px;"></td><td style="width:11px;"></td><td style="width:78px;"></td><td style="width:11px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,475,353</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,130,605</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,719,842</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statutory Canadian corporate tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anticipated tax recovery</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,178,345</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,085,263</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,567,159</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign jurisdiction tax rate difference</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,899,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,184,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,659,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee stock based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">156,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,641</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,336,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to opening tax pools</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">162,162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,569</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,339,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other permanent differences</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">53,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in deferred tax benefits deemed not probable to <br>  be recovered</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,051,725</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,739,557</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,455,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">144,021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment in respect to prior periods</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,523</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(313</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,347</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">141,498</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,374</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,153</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we have the following non-capital losses for income tax purposes in Canada:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:37%;"></td><td style="width:62%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,809,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,170,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,009,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,774,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,343,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,873,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,457,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,472,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,125,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,430,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2037</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,846,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">57,308,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:190px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:97px;"></td><td style="width:88px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">471,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">596,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2028</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">622,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2030</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2032</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">487,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2037</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">600</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,463,600</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As well, we have unclaimed scientific research and experimental development expenditures available to reduce future years&#8217; taxable income of approximately </font><font style="font-family:inherit;font-size:10pt;">$27,400,000</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We have not recorded the potential benefits of these tax pools in these consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized.  The components of our unrecognized deferred tax asset are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:612px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:345px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses carried forward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19,160,218</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,821,631</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,950,044</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific research and experimental development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,406,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,394,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,278,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,988,325</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,990,664</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,987,214</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,927,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,908,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,839,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">493,343</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">432,659</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">619,066</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net capital losses carried forward</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized deferred tax asset</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">32,983,223</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,555,913</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,681,313</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s27A12511753556B59B5510125B9ABCB9"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 14: Capital Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our objective when managing capital is to maintain a strong statement of financial position.  We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs and intellectual property expansion and protection.&#160;&#160;We include shareholders&#8217; equity, cash and cash equivalents and short-term investments in the definition of capital.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:72%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,836,119</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,034,282</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,283,846</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,689,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of REOLYSIN.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 16, 2016, we renewed our short form base shelf prospectus (the &#8220;Base Shelf&#8221;) that qualifies for distribution of up to </font><font style="font-family:inherit;font-size:10pt;">$150,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of common shares, subscription receipts, warrants, or units (the &#8220;Securities&#8221;) in Canada. Under our Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received from a Prospectus Supplement will be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf expires on March 16, 2018 and allowed us to enter into our Canadian ATM equity distribution agreement (see Note 7). We use this equity arrangement to assist us in achieving our capital objective.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4E8160AA4C08569A90E23F1A44FE6AC9"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 15: Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents, short-term investments,&#160;contract receivable, other receivables and accounts payable.&#160;&#160;As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there are no significant differences between the carrying values of these amounts and their estimated market values.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;&#160;We are exposed to credit risk on our cash and cash equivalents, short-term investments and contract receivable in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents, short-term investments and contract receivable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also mitigate our exposure to credit risk by restricting our portfolio to investment grade securities with short-term maturities and by monitoring the credit risk and credit standing of counterparties.&#160;As at December 31, 2016, </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;of our short-term investments were in guaranteed investment certificates.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk connected to our contract receivable by performing a review of our customer's credit risk and payment histories, including payments made subsequent to year-end. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments.&#160;&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Currency risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.&#160;In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from operating and financing activities.  As well, we are exposed to currency risk related to our regional licensing agreement. The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the U.S. dollar against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5,056</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.10</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the British pound against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$21,492</font><font style="font-family:inherit;font-size:10pt;">.  The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.10</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the Euro against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$11,736</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:596px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:197px;"></td><td style="width:128px;"></td><td style="width:4px;"></td><td style="width:128px;"></td><td style="width:4px;"></td><td style="width:128px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">US dollars </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">British pounds</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">&#163;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro<br>&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,948,573</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,755</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,372</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,800,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(777,271</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,949</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,971,302</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,806</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 14. Accounts payable are all due within the current operating period.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD633279CDB9D5475A1FD014C060FA3E2"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 16: Additional Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change In Non-Cash Working Capital</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:629px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:392px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,767,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,653</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148,308</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(915,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(215,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(384,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,359,172</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(664,505</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,182,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash impact of foreign exchange</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">48,558</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,212</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77,535</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in non-cash working capital related to operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">180,855</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,233,865</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,105,464</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:342px;"></td><td style="width:58px;"></td><td style="width:4px;"></td><td style="width:51px;"></td><td style="width:4px;"></td><td style="width:51px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash interest received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">130,101</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,902</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,859</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash taxes paid</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">136,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,468</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,421</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s376048B96D985411AEB542B2BABDB80B"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 17: Indemnification of Officers and Directors</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal or administrative action or proceeding as it relates to their services to the Company.&#160;&#160;The by-laws provide no limit to the amount of the indemnification.&#160;&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD7CC4BD8942F52E3BF545C77687CBCFA"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 18: Economic Dependence</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are economically dependent on our toll manufacturers. We primarily use </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;toll manufacturer in the US to produce the clinical grade REOLYSIN required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturer has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade REOLYSIN at a smaller scale.&#160;We have attempted to mitigate this risk by producing sufficient REOLYSIN in advance of patient enrollment in a particular clinical trial.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB50D6B15088E5B4E8B012E30FB053C7F"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 19:  Other Expenses and Adjustments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We present our expenses based on the function of each expense and therefore include realized foreign exchange gains and losses, unrealized non-cash foreign exchange gains and losses and non-cash stock based compensation associated with research and development activity as a component of research and development expenses and amortization of property and equipment and stock based compensation associated with operating activities as a component of operating expenses.  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:420px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in research and development expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Realized foreign exchange (gain) loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(120,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized non-cash foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">55,538</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,109</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(816,319</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">230,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90,768</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,233</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,411</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">348,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">231,509</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,600</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196,601</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sBDA35FB149D05C0190CE80A2D13D3EEE"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 20:  Related Party Transactions</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation of Key Management Personnel</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole.  We have determined that key management personnel consists of the members of the Board of Directors along with certain officers of the Company.   </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:520px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:301px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term employee compensation and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,596,082</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,753,553</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,941,342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">779,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,330,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">459,298</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">372,008</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353,419</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,835,046</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,456,389</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,294,761</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assumption Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2017, with the signing of a regional licensing agreement with upfront license fees (see Note 10), the Company triggered a liability of US</font><font style="font-family:inherit;font-size:10pt;">$178,125</font><font style="font-family:inherit;font-size:10pt;">&#32;to an officer as detailed in the Assumption Agreement (see Note 12). As at December 31, 2017, US$</font><font style="font-family:inherit;font-size:10pt;">178,125</font><font style="font-family:inherit;font-size:10pt;">&#32;was included in accounts payable and accrued liabilities. US</font><font style="font-family:inherit;font-size:10pt;">$35,625</font><font style="font-family:inherit;font-size:10pt;">&#32;was paid in January 2018 and the balance will be paid after receipt of the contract receivable from Adlai.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-26</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.43
<SEQUENCE>2
<FILENAME>ex443deguttadauro.htm
<DESCRIPTION>EXHIBIT 4.43
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sFBD29B84BC93BE04300B21565F11683F"></a></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 1 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">THIS AGREEMENT </font><font style="font-family:inherit;font-size:11pt;">made the 29st day of June, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ONCOLYTICS BIOTECH (U.S.), INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">("OBUS")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">-and-</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ANDREW DE GUTTADAURO</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">OBUS and its Affiliates are engaged in the business of developing pharmaceutical products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">OBUS has made an offer of employment to the Employee, subject to the terms and conditions contained herein, and subject to the termination of the Services Agreement concurrent with the commencement of employment under this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee is prepared to accept the offer of employment;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NOW THEREFORE the parties agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:0px;"><font style="padding-bottom:16px;padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;padding-right:96px;">Section 1 - </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Definitions and Interpretation</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">In this Agreement the following defined terms shall have the meanings indicated:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">&#8221;Affiliate&#8221; means any entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with a party.  For the purposes of this definition, control shall mean: (i) the direct or indirect ownership of fifty percent (50%) or more of the voting stock of a corporation; or (ii) the direct or indirect ownership of fifty (50%) or more of the ownership interest of any other entity; or (iii) the ability to elect a majority of the directors of the entity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">"Business" means the business currently carried on by OBUS and its Affiliates, which is the development, testing, marketing and sale of pharmaceutical products together with such additional business as OBUS or its Affiliates may decide to undertake from time to time;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">"Commencement Date" means July 3, 2017;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Good Reason&#8221; means any one of the following events occurring on or after the Commencement Date:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Any reduction in the Employee&#8217;s then existing annual base compensation and benefits, unless comparable reductions are made for all other executive employees of Oncolytics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Any material diminution of the Employee&#8217;s duties, responsibilities, authority or reporting structure, excluding for this purpose an isolated or inadvertent action </font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 2 -</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:left;"><font style="font-family:inherit;font-size:11pt;">not taken in bad faith which is remedied by Oncolytics immediately after notice thereof is given by the Employee;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Any request that the Employee relocate to a work site that would increase the Employee&#8217;s one-way commute distance by more than eighty (80) kilometers from the Employee&#8217;s then principal residence, unless the Employee accepts such relocation opportunity; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Any material breach by Oncolytics of its obligations under this agreement that is not remedied within thirty (30) days of written notice of such breach from the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">"Confidential Information" means all confidential information of OBUS and its Affiliates, and includes:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">any data or information directly or indirectly related to the Business or arising directly or indirectly in the course of, or derived from the Employee's employment with OBUS whether related to products, equipment, inventions, ideas, designs, methods, systems, improvements, processes, research or otherwise;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">any technical or scientific know-how;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">financial and sales information, customer lists, pricing policies, lists of suppliers, proprietary computer programs in any format whatsoever, programming techniques, the manner of plans or methods of operation and the like relating to the Business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">patent applications, drawings, blueprints, manuals, letters, notebooks, reports and all other materials (written or otherwise) related to the Business or to the agents, joint venturers or contractors of OBUS or its Affiliates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">any information provided to or received by OBUS or its Affiliates on a confidential basis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">"Intellectual Property" means all information, data, designs, processes, software, algorithms and inventions, including those that may be the subject of patent, copyright, industrial design, trademarks, trade secret or other forms of legal protection, made, conceived or developed by the Employee during the term of employment with OBUS, whether alone or jointly with others and whether during or after regular working hours, that relates to or in any way pertains to or connects with any matter developed, or under investigation or development by OBUS or its Affiliates, or related to the Business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">"Cause" means:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">breach by the Employee of any material provision of this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">material violation by the Employee of any statutory or common law duty of loyalty to OBUS and its Affiliates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Employee&#8217;s failure to perform Employee&#8217;s duties for the Company in a competent and effective manner as judged in good faith by either the Chief </font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 3 -</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:8px;text-align:left;"><font style="font-family:inherit;font-size:11pt;">Executive Officer of the Company or the Company&#8217;s Board of Directors in their sole discretion.  </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">the commission of a criminal offence by the Employee against OBUS or its Affiliates; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">personal or professional conduct of the Employee which in the reasonable and good faith judgment of OBUS may significantly injure OBUS' Business or interfere with the Employee's job performance.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">This Agreement shall be governed by and construed in accordance with the laws of California.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The following schedules are attached to and form part of this Agreement:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Schedule "A" &#8211; Job Description</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Schedule "B" &#8211; Benefits</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 2 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Employment</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OBUS agrees to employ the Employee in the position of Vice President, Business Development and the Employee accepts the employment, starting on the Commencement Date.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee shall perform the duties and responsibilities associated with the position of Vice President, Business Development including those set out on the Job Description attached as Schedule "A".  The Employee may, from time to time, be assigned or undertake additional duties and responsibilities consistent with those generally appropriate for a Vice President, Business Development and the Employee's duties and responsibilities may be modified or expanded from time to time.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee shall perform the duties and responsibilities set out in Section 2(2):</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">diligently, faithfully and to the best of the Employee's ability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">in the best interests of OBUS.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee shall comply with the terms, conditions and requirements of OBUS' Policy Manual and benefit plans, as the same may be amended, revised or added to from time to time.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 4 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 3 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Remuneration</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OBUS shall pay to the Employee a salary of Two Hundred and Thirty Thousand ($230,000.00) United States dollars per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of Nine Thousand Five Hundred and Eighty-Three United States Dollars and Thirty-Three Cents ($9,583.33) on the fifteenth (15) and last day of each month.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OBUS shall, on or before the anniversary date of this Agreement in each year, evaluate and set the Employee's salary for the next ensuing year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OBUS shall reimburse the Employee for all reasonable out-of-pocket expenses incurred by the Employee in the performance of the Employee's obligations under this Agreement, subject to OBUS' policies then in force.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OBUS shall be entitled to withhold from any payments made to the Employee any amounts that OBUS is required to withhold pursuant to any Act in force that relates to income tax, social security, medicare or pension in any jurisdiction under which such payments are required to be made by or on behalf of the Employee.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 4 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Benefits and Equity Compensation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall be entitled to participate in benefit plans described in Schedule "B" and in other benefit plans instituted or as amended by OBUS from time to time.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Performance Share Units</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall be granted 60,000 restricted share units (&#8220;RSU&#8217;s&#8221;) on the Commencement Date under Oncolytic Biotech Inc.&#8217;s Incentive Award Plan.  One third of the RSU&#8217;s will vest after the second employment anniversary with the remaining two thirds of the RSUs vesting after three years of service.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall be granted 125,000 stock options on the Commencement Date under Oncolytics Biotech Inc.&#8217;s Stock Option Plan.  These options will be priced on the Commencement Date and 25% of the stock options will vest immediately, followed by 25% vesting after twelve (12) months from the Commencement Date and the final 50%vesting after twenty-four (24) months from the Commencement Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 5 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Vacations</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall, in addition to all statutory holidays, be entitled to twenty (20) Business Days paid vacation during each twelve (12) month period of employment under this Agreement.  The Employee's vacation time shall be governed by applicable policies of OBUS.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 5 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 6 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Place of Employment</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall perform the majority of the Employee&#8217;s employment obligations from and out of the Company&#8217;s offices located in La Jolla, California.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall be available to travel within the United States and outside the United States as required to fulfill his duties and responsibilities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 7 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Confidential Information</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee confirms that the Confidential Information is the sole and exclusive property of OBUS or its Affiliates and is held by the Employee in trust for the benefit of OBUS and its Affiliates.  The Employee shall use the Employee's best efforts and exercise utmost diligence to protect and safeguard the Confidential Information. Neither during the period of employment by OBUS nor thereafter for a period of three years shall the Employee, directly or indirectly, use or disclose to any other person any Confidential Information, whether or not acquired, learned or obtained or developed by the Employee alone or in conjunction with others, except as such disclosure or use may be required in connection with the employment with OBUS or as may be agreed to in writing by OBUS.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Subsection 7(1) shall not apply to Confidential Information that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">is in the public domain at the time of its disclosure, or which, after disclosure, becomes part of the public domain other than by disclosure by the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">the Employee can show was in the Employee's possession at the time of disclosure and was not acquired from OBUS or its Affiliates; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">was received by the Employee from a third party without a covenant of confidentiality, provided such third party is under no obligation of confidentiality with respect to the Confidential Information.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee shall keep informed of OBUS' policies and procedures for safeguarding OBUS' property including, without limitation, the Confidential Information and the confidentiality thereof, and will strictly comply therewith at all times.  The Employee shall not, except as required in the course of the employment with OBUS, remove from OBUS' premises any OBUS property including, without limitation, Confidential Information.  The Employee shall, immediately upon termination of employment with OBUS, return to OBUS all of OBUS' property in the Employee's possession, including, without limitation, all tangible parts of or relating to the Confidential Information as is in the Employee's possession or under the Employee's control without retaining any copies or record thereof or any other mechanical means that, alone or in combination with other means, would permit the Employee to reproduce or make available the Confidential Information.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee shall advise any future employer, associate or affiliate that the Employee has signed this Agreement and is bound by its terms and conditions.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 8 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Intellectual Property</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee confirms that any and all Intellectual Property shall be the sole and exclusive property of OBUS or its Affiliates and shall be assigned by the Employee to OBUS, or its nominee.  The Employee agrees to disclose promptly to OBUS or its nominee any and all Intellectual Property and to </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 6 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">execute written assignments of the Employee's right, title and interest in and to the Intellectual Property to OBUS or its nominee.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">With respect to any Intellectual Property, the Employee also agrees:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">to assist OBUS or its nominee in preparing any necessary copyright and patent applications, including Canadian and foreign applications, covering the Intellectual Property;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">to sign and deliver all such applications and their assignment to OBUS or its nominee; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">generally to give all information and testimony, to co-operate with OBUS and its solicitors, to sign all lawful papers, and to do all lawful things that may be needed or requested by OBUS to obtain, extend, reissue, maintain or enforce copyrights or patents covering the Intellectual Property.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OBUS shall bear all expenses that are incurred in obtaining, extending, reissuing, maintaining and enforcing any and all copyrights or patents in respect of the Intellectual Property assigned to OBUS or its nominee by the Employee, and in the vesting and perfecting of title thereto in OBUS or its nominee and shall pay the Employee reasonable compensation for any time that OBUS may require the Employee to expend in order to accomplish the above subsequent to the termination of employment with OBUS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee hereby waives in favour of OBUS and its Affiliates, all moral rights in any and all copyright works authored or co-authored by the Employee during the term of this Agreement that directly relate to the Business of OBUS or its Affiliates.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(5)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">In accordance with California Labor Code Section 2870, Employee is notified that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Relate at the time of conception or reduction to practice of the invention to the employer&#8217;s business, or actual or demonstrably anticipated research or development of the employer; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Result from any work performed by the employee for the employer.&#8221;</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 7 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 9 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Term and Termination</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee's employment under this Agreement shall commence on the Commencement Date and shall continue until terminated in accordance with this Section 9.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">If OBUS has Cause to terminate Employee&#8217;s employment as &#8220;Cause&#8221; is defined above, OBUS shall not be required to compensate the Employee in respect of such termination or provide any period of notice in lieu of compensation with respect to such termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Subject to Section 9(4), if this Agreement is terminated by OBUS for any reason other than for Cause, or if this Agreement is terminated by the Employee for Good Reason, the Employee shall be entitled to severance in the form of continued salary for six (6) months after the termination of Employee&#8217;s employment (the &#8220;Severance Period&#8221;) at the rate in effect on the date of Employee&#8217;s termination. Within 14 days of the end of the Severance Period, Employee shall also be entitled to a payment in an amount equal to the value of all benefits to which the Employee would otherwise have been entitled during the Severance Period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Notwithstanding Section 9(3), if there is a change of control of OBUS, as defined herein, and if this Agreement is terminated by OBUS at any time within one (1) year following the change of control other than for Cause, the Employee shall be entitled to twenty-four (24) months of continued salary at the rate in effect on the date of Employee&#8217;s termination. Within 14 days of the end of the twenty-four (24) months of continued salary, Employee shall also be entitled to a payment in an amount equal to the value of all benefits to which the Employee would otherwise have been entitled during the twelve (12) month continued salary period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">For the purposes of this section 9(4), &#8220;change of control&#8221; means any amalgamation, merger or other corporation reorganization which results in any change in the present effective voting control of OBUS, or will result in a change of the person or persons who own or control sufficient voting shares in OBUS to elect a majority of the directors of OBUS, or will result in a person acquiring sufficient voting shares in OBUS to elect a majority of the directors of OBUS, or any sale, lease, exchange, partnership, or other transfer (in one transaction or a series of transactions) of all or substantially all of the assets of OBUS or a plan of liquidation of OBUS and/or an agreement for the sale or liquidation of OBUS is approved and completed, or the Board of Directors determines in its sole discretion the a change of control has occurred, whether or not any event described has occurred or is contemplated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(5)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee confirms that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">any breach of this Agreement or unauthorized disclosure of Confidential Information may result in irreparable harm to the Business of OBUS or its Affiliates and considerable monetary damages to OBUS and its Affiliates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">the damages suffered by OBUS may be difficult to establish; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">interim and permanent injunctions may be the only suitable remedy for OBUS;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">but nothing herein shall in any way limit or restrict any other remedies available to OBUS at law or in equity including an action for damages.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 8 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(6)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Termination of the Employee's employment with OBUS for any reason whatsoever shall not terminate the Employee's obligations under Sections 7, 8 and 10 of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 10 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Non-Competition</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee shall not, during the term of this Agreement, engage, hold an interest in or have any involvement, either directly or indirectly, in any business entity, venture or undertaking if such would materially interfere with or conflict with the Employee's duties and obligations to OBUS as provided for under this Agreement, provided that the acquisition of a non-control position in publicly traded companies will not contravene this Section.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee shall not, during the term of this Agreement, either individually or in partnership or jointly or in conjunction with any person, firm or corporation as principal, employee, partner, director or as a shareholder or investor (if actually involved in the management of a business which is competitive with the Business of OBUS or its Affiliates) carry on or be engaged in any business which is directly competitive with the Business of OBUS or its Affiliates. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 11 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Notices</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All notices, reports, invoices, payments and formal communications (collectively referred to as "Notices") required or permitted to be given hereunder shall be in writing and shall be delivered personally or sent by prepaid registered mail or facsimile transmission to the following address or such other address as the relevant party may notify from time to time:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">TO:&#160;&#160;&#160;&#160;OBUS</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ONCOLYTICS BIOTECH (U.S.), INC.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attention: President</font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WITH COPY TO:</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Suite 210, 1167 Kensington Crescent N.W.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Calgary, Alberta</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">T2N 1X7</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attention: President</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">TO:&#160;&#160;&#160;&#160;Employee</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Andrew de Guttadauro</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Notices sent by prepaid registered mail shall be deemed to be received by the addressee on the seventh day (excluding Saturdays, Sundays, Statutory Holidays and any period of postal disruption) following the mailing thereof.  Notices personally served shall be deemed to be received when actually delivered, provided such delivery shall be during normal business hours.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 12 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Enurement</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 9 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement shall enure to the benefit of and be binding upon the parties hereto and:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">in the case of OBUS, its successors and permitted assigns; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">in the case of the Employee, his heirs, executors, administrators or other personal representatives.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF the parties have executed this Agreement as of the day and year first above written.</font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:52.991452991452995%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:14%;"></td><td style="width:86%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ONCOLYTICS BIOTECH (U.S.), INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Per:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">/S/ Andres Gutierrez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Andres Gutierrez</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Director</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Per:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">/S/ Gilles Gosselin</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Gilles Gosselin </font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Director</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;text-decoration:underline;">/s/ Roshawn Blunt</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;text-decoration:underline;">/S/ Andrew de Guttadauro&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Andrew de Guttadauro</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><a name="s78493B5A1428B38CC59C21565F436E6A"></a></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SCHEDULE "A"</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">JOB DESCRIPTION</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">INSERT JOB DESCRIPTION</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><a name="sDCD2629D2090DCF13E4621565F6B0285"></a></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SCHEDULE "B"</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BENEFITS</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Physical Fitness Benefit:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee is entitled to the Physical Fitness Benefit in the amount of Seven Hundred and Fifty ($750.00) United States Dollars per annum to use towards an item or service that promotes physical activity; the details of which are outlined in the Company Policy Manual.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Deferred Compensation:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Employee shall, if qualified to do so, be entitled to allocate a portion of his salary to a 401(K) Plan established for the Employee, up to the prescribed maximum, and in accordance with the requirements thereof.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Benefit Plan Alternatives:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Alternative 1:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Employee can elect to receive an additional amount of 9.25% of base salary. Such amount shall be the employee&#8217;s full Health Benefit Allocation, and shall be taxable in accordance with the relevant regulations.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Alternative 2:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Employee can elect to direct (the lesser of the maximum available or allowable by the employee under the Flexible Spending Plan), a portion of the Health Benefit Allocation (9.25% of base salary) to a Flexible Spending Account, and receive the remainder (9.25% of base salary less the amount directed to the Flexible Spending Account) of the Health Benefit Allocation as a taxable amount in accordance with the relevant regulations.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Alternative 3:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Whether or not the Employee elects to participate in Alternative 2, the Employee can also elect to participate in an individual Health Insurance Program utilizing any amount still remaining from the Health Benefit Allocation. Any additional amounts required to be paid for this Program would be drawn from Employee&#8217;s net pay.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.44
<SEQUENCE>3
<FILENAME>ex444regionallicensingagre.htm
<DESCRIPTION>EXHIBIT 4.44
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE06A1CABE008137B91333F80FC099484"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 4.44</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONFIDENTIAL TREATMENT MATERIAL</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></div><div style="line-height:180%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-bottom:128px;padding-top:16px;text-align:center;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DATED &#160;&#160;&#160;&#160;NOVEMBER 16, 2017</font></div><div style="line-height:180%;padding-bottom:32px;padding-top:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH (BARBADOS) INC.</font></div><div style="line-height:180%;padding-bottom:32px;padding-top:32px;text-align:left;text-indent:276px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">- and -&#160;&#160;&#160;&#160;</font></div><div style="line-height:180%;padding-bottom:112px;padding-top:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ADLAI NORTYE BIOPHARMA CO., LTD.</font></div><div style="line-height:120%;padding-left:130px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:61.44578313253012%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:32px;padding-bottom:32px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:32px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENT</font></div></td></tr></table></div></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s4FC0B6C5B1259FA8A2E03F80FC3B7FA4"></a></div><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Page</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s3EE4AFB4E0DD4ABF7C673F80FC8BCD7E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">1.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">DEFINITIONS</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;2</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#sE7929B826DF762DB196A3F80FCB3D4AD"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">2.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">MANAGEMENT OF THE RELATIONSHIP</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;16</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sF40D49F207F9D2DAA75B3F80FCDBDFE9"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">2.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">The Joint Steering Committee</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;16</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s434BC7E006733B4084013F80FD0339E5"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">2.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Membership and Governance of the JSC</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;18</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s4586E27A91E4F1575CE83F80FD35D213"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">2.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">JSC Meetings</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;19</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sDCE581696FFAABA354783F80FD534136"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">2.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">JSC Decision Making</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;20</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sFB128EF11574ABE87CC33F80FD856C82"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">2.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Dispute Resolution</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;21</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sB74B6859268AB4108CF13F80FDA302BF"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">2.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Approval of Sub-Committee Actions</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;21</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s55E710B4CECA258AD2663F80FDDF61CD"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">2.7</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Alliance Managers</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;21</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s2C79A56FA3DC1347FE8A3F80FDFDD2DE"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">3.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">GRANT OF RIGHTS AND EXCLUSIVITY</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;22</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s01084C62E1B7814246803F80FE2F015A"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">3.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">License to Licensee</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;22</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s2354C1B009A974FEF1393F80FE4D6006"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">3.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Manufacturing Rights</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;22</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sA253A97457E6B8141C8A3F80FE7F6B3B"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">3.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Sublicense Rights</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;22</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s157B08D40180EB1976293F80FE9D3052"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">3.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Diversion</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;22</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sBB855875BC9F2FBB8BBF3F80FED9FA94"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">3.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">[**]</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;22</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#sD7BDD0005C36E74784033F80FEF762CA"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">4.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">DEVELOPMENT OF LICENSED PRODUCTS</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;23</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sDA7C3940D19C62A91BA63F80FF294752"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">4.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Development of Licensed Products</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;23</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sC9228D23410CCD78034B3F80FF47A8DF"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">4.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Development Plan</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;23</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s4789F98940066189EF4B3F80FF7925FE"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">4.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Development in respect of the PRC</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;23</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s40FE16C7324E498C603A3F80FF97B896"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">4.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Ongoing Clinical Studies</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;23</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sB153808596ADB119748F3F80FFD35F57"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">4.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Clinical Studies</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;23</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s4DDC41C5FC670D0F0CE43F80FFF1C689"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">4.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Development Plan</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;25</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s9DE7099F51DC405DFEE03F8100232686"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">4.7</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Conduct of Development Plans</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;25</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s6390D3B3324DBF9F77563F8100411D40"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">4.8</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Development Costs</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;26</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s7539169F69EFEF9D297F3F810073777E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">4.9</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Obligations</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;26</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s78F22F0EF2141152882F3F81009119CD"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">4.10</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Supply Agreement</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;26</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s9318E03E544219B808EB3F8100CD81BC"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">4.11</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Contract Manufacturer</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;27</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#sCCA75F934D57ECD888003F8100EBE605"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">5.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">AUTHORIZED USE OF MATERIALS</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;28</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sCA6E66E14CB095EC38F63F81011D4CDD"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">5.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Research Materials</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;28</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sAE025204AF8511C517083F81013B1426"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">5.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Limited Warranties</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;28</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s102BA02FE9C080A67F0D3F81016D141E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">5.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Exclusion of Warranties</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;29</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sBCC1389FD26AD6505D8A3F81018B5C77"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">5.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Return of Materials</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;29</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s6CF9F1231083035FFE423F8101C7CC36"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">5.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Unauthorized Use of Materials</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;30</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s908103547F48946FFA4B3F8101E5E648"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">5.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Restriction on Use of Materials</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;30</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sB9E957A79378CD53C5793F8102175FE7"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">5.7</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Compliance with Regulations</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;30</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s9739EF70F737C836FB303F810235F155"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">5.8</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Exceptions</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;31</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s990B9F58FB0EF960825D3F8102675702"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">6.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">REGULATORY AND CLINICAL DEVELOPMENT</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;31</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sE2B8EAF2968EEA538A933F8102855379"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">6.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Master File</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;31</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s0D1DBB229B1EB47313E03F8102C1957B"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">6.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Responsibility for Regulatory Applications in the Territory</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;31</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s7B089C7440CF9CA4DAC53F8102DFAF72"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">6.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Dealings with Regulatory Authorities</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;32</font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- i &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sD6DD595AD314882623683F8103119523"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">6.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Oncolytics Regulatory Support</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;32</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s7D5C299565199848909E3F81032F1B77"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">6.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Performance Obligation</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;32</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s7A90886D84DD77AFE4983F81036153CD"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">7.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">MARKETING OF LICENSED PRODUCTS</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;33</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s1C29FA6DBAEE65E2F4813F81037FDA82"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">7.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Use of Trademarks</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;33</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s091E0BFC5F4F579516B93F8103BB702F"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">7.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Sales and Marketing Plan</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;33</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s72ECE300C2CA3D4EEF733F8103D9B37F"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">7.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Post-marketing and observational Studies</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;34</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sF9DD79B311187AB080B33F81040BBE0D"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">7.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Promotional Materials</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;34</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s7A504527BE72011903A53F8104296AB2"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">7.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Promotional Activities</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;34</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s8E0D32DF80296738E3BB3F81045B7192"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">8.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">DILIGENCE</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;35</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s66EBF0BBE9449EB345103F810483AAB6"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">8.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;35</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sD9559176DF75386F05B03F8104B5BA51"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">8.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Development and Regulatory Diligence</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;35</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s3A6373135FDB02612C353F8104D3A260"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">8.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Compliance with Sales and Marketing Plans</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;35</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sE5564A7B560DC5B09CB73F810505FDE5"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">8.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Satisfying Diligence</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;35</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sFDF7540BEF1CA4A4FD493F810523F13C"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">8.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Sales Data</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;36</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s04BF2BD5114B61C60F313F8105551C88"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">8.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Recordkeeping and Inspection</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;36</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s58A5EBCA6251FDFA85EA3F81057D33EC"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">8.7</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Material Terms</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;37</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s0AAE066FDA72E61B5EAD3F8105AFD78E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">9.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">ADVERSE EVENTS AND PHARMACOVIGILANCE</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;37</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s7A5FCE46376FEB69AC313F8105CD7D39"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">9.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Pharmacovigilance</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;37</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s7E08428B351EC1103A5A3F8105FFA1A1"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">9.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Responsibilities of the Qualified Person</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;37</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s7F8D5052CAF3B818DFF33F81061D090E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">10.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">FINANCIAL TERMS</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;38</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s2EC1C0113D2422B943353F81064F1EB0"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">10.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Upfront Payment Obligations</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;38</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s26D83ABE68687BAAA9A73F8106779006"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">10.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Purchase of Warrants</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;38</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s98EF661D3A1D48EA28683F8106A96DF0"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">10.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Development and Regulatory Milestone Payments</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;38</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s9FD34DC27F61E02E414C3F8106C74414"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">10.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Sales Milestone Payments</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;39</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sD3D09935F633585140483F81070D3B64"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">10.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Running Royalties Payable by Licensee</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;39</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s5A4204901BBD8036CCDD3F810721F28C"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">10.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Duration of Royalty Obligations</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;40</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s836523094C1A14951F0B3F810749FFCE"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">10.7</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Failure to Pay</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;40</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s49409D88116D79172B643F810767CBFB"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">10.8</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Third Party Licenses</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;40</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s8263200F394CD81B17F93F8107A35050"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">11.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">PAYMENT</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;41</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sB511CEAF695D551FF7963F8107C126D6"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">11.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Currency and Timing of Payments</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;41</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s68854E3F4CC06E98EA783F8107F30D69"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">11.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Manner of Payment</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;42</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s73BFAFDE2425D4C9F4CF3F8108110476"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">11.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Taxes</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;42</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s454078F10421BA4EA0C53F810843050D"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">11.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Interest</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;42</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s26EF0D01607E66FEE85A3F81086B4B41"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">11.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Record Keeping and Audit</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;43</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s7C7E41D34D72BE784C5D3F81089D6BFE"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">12.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">OWNERSHIP OF INTELLECTUAL PROPERTY</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;43</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sA60B2437CEF08B588D8F3F8108BBBC7E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">12.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Excluded IP</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;43</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sAB0CBB55AD01E614FD7A3F8108ED0F8F"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">12.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Inventions</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;44</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sC42C0CF99E02AD45C40F3F81090BD480"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">12.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">[**].</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;44</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sD4A29F82673842988D703F81093DAA4E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">12.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Licensee and Cooperation with Respect to Inventions</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;44</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s0E69E1DB947181F92C333F81095B393B"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">12.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Patent Term Extension</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;45</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sF8E9B5A5192CB679F5D43F810997ED07"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">12.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Ownership of Clinical Data</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;45</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s6EB526314A3697C7D5293F8109ACCDF4"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">13.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">MANAGEMENT OF PATENT RIGHTS</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;45</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s79501C268742690A90B13F8109E833E4"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">13.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Prosecution, Maintenance and Defense of Patent Rights</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;45</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s842E52A67D1E8CC00B2F3F810A06A5C9"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">13.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Abandonment of Patent Rights by Oncolytics</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;45</font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- ii &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s0AF98666D1220570A9A83F810A38683F"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">13.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Inventions:  Licensee Patent Filing</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;45</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s0A46A7B9D9B5E64A13253F810A5646E6"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">13.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Inventions:  Oncolytics Patent Filing</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;46</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sFBB7AE4F49241F3E48793F810A92171F"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">13.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Notification of Infringement</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;47</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sA53DBD08C2EB2402316F3F810AB0F457"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">13.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Infringement in Territory</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;47</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s059C8451243B5BAB97883F810AE2789C"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">13.7</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Settlement</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;48</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s311A5EB046F0D29CF22C3F810B005C2D"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">13.8</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Recovery</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;49</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sBC61F12931CE0EF737933F810B322C0A"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">13.9</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Interferences and Other Proceedings</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;49</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:120px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sBCD0EA003FEDA9FFBD083F810B50BE6B"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">13.10</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Notice or Infringement Claims</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;49</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:120px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sE554EE6C7372E6DBDAD43F810B8933C5"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">13.11</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Product Marking</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;50</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s9CC32C96076D804EC2FE3F810BA774D7"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">14.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">TRADEMARKS</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;50</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s0B3689F220BB3BD45F1A3F810BD98E91"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">14.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Ownership of Marks</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;50</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sB8393FC05202119864E33F810BF77AA9"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">14.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Ownership of Licensed Product Marks</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;50</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s2663948B7B8214A495C53F810C29A341"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">14.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Use of Licensed Product Marks</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;50</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s2241F7ED868F849012B63F810C51C09B"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">14.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Registration of Licensed Product Marks</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;51</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s542A9CE108638C41DDEF3F810C83AA91"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">14.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Infringement of Licensed Product Marks</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;51</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s47A1D81A73D230E73B563F810CA14401"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">14.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Recovery in respect of Infringement of Licensed Product Marks</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;52</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s20C0A2F9304D55D402103F810CD3BBA8"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">14.7</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Settlements</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;52</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#sD388993DFA5B004234F43F810CF119A8"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">15.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">TERMINATION</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;52</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s7C81FA9FDA02472882613F810D23D3C0"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">15.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Term of Agreement</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;52</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sF31989C0B142D6B3076C3F810D4BAAA7"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">15.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Termination by Oncolytics for Patent Challenge</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;53</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s62A9D279A49536BA45AA3F810D7D4882"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">15.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Termination for Breach</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;53</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s17352169C794AF6B97393F810D9BA759"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">15.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Insolvency</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;53</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s4ADE6DB22CEB0D5CC3303F810DCD0B71"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">15.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Competing Product Divestment</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;54</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#sFA1ECC12491979F1B7793F810DEB7CF2"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">16.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">CONSEQUENCES OF TERMINATION</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;55</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s364B9E693BFE539297833F810E1DB911"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">16.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Accrued Rights</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;58</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s37CBE719568C886B21CA3F810E45E02F"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">16.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Surviving Clauses</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;58</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s6417B3694283EA58333C3F810E7727B0"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">16.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Related Agreements</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;58</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s03BC725D798B87133F1F3F810E95A687"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">17.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">CONFIDENTIALITY</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;59</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sDB4E41DE53DC5D48D0283F810EC7927A"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">17.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;59</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s13C5E8E02C4C4643FC1A3F810EE5BE85"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">17.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Confidentiality Obligations</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;59</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s9C5DD93981CDB2D063E93F810F17F4C6"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">17.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Internal Disclosure of Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;60</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s197C47A9140026B11DA63F810F3FEAAD"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">17.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Exceptions</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;60</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sE47FA660C4FFFFD5F0C83F810F71B474"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">17.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Disclosure Required by Law</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;60</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sB65EF41F8114E79956133F810F8F6035"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">17.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Permitted Use and Disclosures</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;61</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#sBEF8B0337FF2AA1ACA123F810FC180BF"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">18.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">WARRANTIES</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;61</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s15CCC676D60E7B26EE803F810FDFB44B"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">18.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Warranties</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;61</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s8F4E4EB5E561499C520A3F811011EE2B"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">18.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Warranties by Oncolytics. Oncolytics represents and warrants to Licensee:</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;62</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sB5E057D196F5ED376ED93F811039CEAC"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">18.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Undertaking by Licensee</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;62</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s8AC991643C9BA3AC216D3F81106BE242"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">18.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">No Implied Warranties</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;62</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s9EB409A6F2149288C67D3F811089BC5E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">18.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">No Warranties of Patent Rights</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;62</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s2D2FEBD952242BB3465A3F8110BB0C9E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">18.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">No Further Representations or Warranties</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;63</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s2D0E33B3520F377330E93F8110D9198B"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">19.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">LIABILITY AND INDEMNITIES</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;63</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s3E73B0067B350313F8CE3F81110B6C41"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">19.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">No Consequential Damages</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;63</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s2912E0C7123F6F15A4C43F811133B2FC"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">19.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Indemnification by Licensee</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;63</font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- iii &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sA04DA687A9F75AA75C0E3F8111657E33"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">19.3</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Indemnification by Oncolytics</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;64</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sFF849B165EAABA042E4D3F811183EAA1"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">19.4</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Notification of Liabilities/Losses</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;64</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s27D74E571C0F07A0320E3F8111B5A0DB"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">19.5</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Supply</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;65</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#sC56492E5404388E1A0153F8111D335AA"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">19.6</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Mitigation</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;65</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s29FB64516AFDC851F9053F811205109A"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">19.7</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Restriction on Limitation of Liability</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;65</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s3EF32B81A9C12F86778A3F81122D1A64"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">19.8</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Insurance</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;66</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s8D0F8B1115A32EB033663F81125FA6D4"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">20.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">WAIVER</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;66</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s99F18AE1681441F97E463F81127D1ED4"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">21.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">ENTIRE AGREEMENT/VARIATIONS</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;66</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s43E0AC3812380E0207803F8112AFF68E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">22.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">NOTICES</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;67</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s89D75E6B3725AB4DC3853F8112CD85C6"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">23.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">AFFILIATES, ETC.</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;68</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s8DDC6E6526BD458100083F8112FF8A07"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">24.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">ASSIGNMENT</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;68</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s3657C67822374D51C1323F8113273653"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">25.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">FORCE MAJEURE</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;69</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#sE510230BD4D44793A6693F811359AA59"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">26.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">SEVERANCE OF TERMS</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;70</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s9460D48ACD8AB3C914713F811377262E"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">27.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">NATURE OF THIS AGREEMENT</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;70</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s0D2A64B5F0694601CE2A3F8113A9BB1D"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">28.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">PUBLIC STATEMENTS</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;70</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s12A98A5972BB5E1FF8B83F8113C7F75F"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">29.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">NO THIRD PARTY RIGHTS</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;71</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#sA452681DF78AC0DEF83C3F8113F96C31"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">30.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">COSTS</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;71</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#sCEB1F5925D48A7D3D9E33F8114215CBE"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">31.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">EXECUTION AND COUNTERPARTS</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;71</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s820E343B994DAFBF9FED3F81145396BD"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">32.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">CONSTRUCTION</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;72</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#sDF62F4FBCE6A2CD74ED43F8114712A27"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">33.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">DISPUTE RESOLUTION</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;72</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s789E574764668E07FFD43F8114A372DC"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">33.1</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Governing Law; Arbitration</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;72</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:96px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s43B75BDB22A0B7B58CCA3F8114C1DD0F"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">33.2</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Informal Resolution</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;72</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s59B9DBCE14A55636044D3F8114F34A6B"><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">34.</font></a><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;color:#0000ff;font-weight:bold;text-decoration:underline;">IMPORT &amp; EXPORT CONTROL</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;73</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s6A0BAD45A7112D2670D73F81154D4868"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">SCHEDULE&#160;1  LICENSED PRODUCT</font></a><font style="font-family:inherit;font-size:12pt;">75</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s09593B2EDC2D8356C8093F81159DA774"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">SCHEDULE&#160;2  PATENT RIGHTS</font></a><font style="font-family:inherit;font-size:12pt;">76</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s776E47C56082996AA6193F81161592E9"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">SCHEDULE&#160;4  ONGOING CLINICAL STUDIES</font></a><font style="font-family:inherit;font-size:12pt;">89</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s89C2E09F4302B6280D1B3F811665A800"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">SCHEDULE&#160;5  THE TERRITORY</font></a><font style="font-family:inherit;font-size:12pt;">90</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:594px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;" href="#s1FE5D1335C0E1F06A6BA3F8116B5E6EA"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">SCHEDULE&#160;6  FORM OF WARRANT PURCHASE AGREEMENT</font></a><font style="font-family:inherit;font-size:12pt;">91</font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- iv &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s90133A6052B3C6C1158D3F80FC595E4B"></a></div><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">THIS LICENSE, DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENT, DATED THE 16</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;DAY OF NOVEMBER 2017 (the &#8220;Effective Date&#8221;)</font></div><div style="line-height:180%;padding-bottom:32px;padding-top:32px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">IS MADE BETWEEN:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH (BARBADOS) INC.</font><font style="font-family:inherit;font-size:12pt;">, a corporation organized under the laws of Barbados, having its principal offices at 1</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Floor, Hastings House, Balmoral Gap, Hastings, Christ Church, Barbados WI BB14034 (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics</font><font style="font-family:inherit;font-size:12pt;">&#8221;); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ADLAI NORTYE BIOPHARMA CO. LTD.</font><font style="font-family:inherit;font-size:12pt;">, a limited company organized under the laws of the Peoples Republic of China, which has principal offices at 21 Floor, Building 2, No. 452, 6</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Street, Hangzhou Eco. &amp; Tech. Development Area, 31008, PRC (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensee</font><font style="font-family:inherit;font-size:12pt;">&#8221;);</font></div></td></tr></table><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Oncolytics and Licensee are referred to from time to time herein individually as a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; or collectively as the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Parties</font><font style="font-family:inherit;font-size:12pt;">&#8221;.</font></div><div style="line-height:180%;padding-bottom:32px;padding-top:32px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RECITALS</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(A)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Oncolytics is a wholly-owned subsidiary of Oncolytics Biotech Inc., which is a biotechnology company headquartered in Calgary, Alberta, Canada (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Biotech</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  The Oncolytics Group has considerable expertise in developing and producing novel viral products for the treatment and prevention of various forms of cancer.  The Oncolytics Group </font><font style="font-family:inherit;font-size:12pt;">has developed and own the exclusive rights to a certain strain of reovir</font><font style="font-family:inherit;font-size:12pt;">us (Serotype-3 Dearing Strain) iden</font><font style="font-family:inherit;font-size:12pt;">tified by Oncolytics as Pelareorep. </font><font style="font-family:inherit;font-size:12pt;">&#32;In particular, the Oncolytics Group is undertaking the Ongoing Clinical Studies (as defined below) and has developed certain intellectual property relating to the use of Pelareorep for oncological treatments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(B)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Licensee is a biopharmaceutical business dedicated to developing and commercializing new drugs, with a focus on new treatments for cancer and metabolic diseases, but does not currently market or sell any metastatic breast cancer treatments.  </font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(C)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">The Parties desire to collaborate in conducting development and related activities, marketing in certain territories, and selling of product(s) containing Pelareorep for certain indications in those territories all on the terms and subject to the conditions set forth herein, but it is not the intention of the Parties to undertake an employment, joint venture, partnership or other fiduciary relationship.</font></div></td></tr></table><div style="line-height:180%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NOW THEREFORE</font><font style="font-family:inherit;font-size:11pt;">, in consideration of the following mutual promises and obligations, and for other good and valuable consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:</font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 2 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><a name="s3EE4AFB4E0DD4ABF7C673F80FC8BCD7E"></a></div><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DEFINITIONS</font></div></td></tr></table><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In this Agreement and in the Schedules to this Agreement the following capitalized terms, whether used in the singular or plural, shall have the meanings set forth below:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Adverse Event</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AE</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any untoward medical occurrence in a patient to whom a medicinal product has been administered and which does not necessarily have to have a causal relationship with the administration of such medicinal product and includes without limitation any unfavorable and unintended sign (for example, an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product together, in relation to pharmacovigilance standards, policies, and procedures, with all medical device events, (including incidents, near-incidents, serious injuries, malfunctions and failures) or untoward medical events and events such as suicide or aggressive behavior threats, overdose, abuse, misuse, medication errors and other events that may reasonably be related to biomedical research.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Party, any Person (other than an individual) that Controls, is Controlled by, or is under common Control with such Person.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means this agreement and all schedules, appendices and other addenda attached thereto as any of the foregoing may be amended in accordance with the provisions of this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Alliance Manager</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall have the meaning set forth in Clause&#160;2.7.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BLA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a biologics license application, as described in 21&#160;C.F.R. Section&#160;601.2, submitted to the FDA to obtain permission to deliver or introduce a biologic product into interstate commerce in the United States, or the analogous application filed with any other Regulatory Authority outside the United States (including without limitation the EMA and CFDA), and all amendments and supplements thereto.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Business Day</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a day other than a Saturday, Sunday or a day on which banks are not open for business in Canada, the PRC, Taiwan, Macau, the Republic of Singapore, South Korea, or Hong Kong.</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 3 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.7</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CFDA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the China Food and Drug Administration in the PRC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.8</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any claim, action, demand, inquiry or investigation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.9</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Clinical Data</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any clinical Know How that is, or is intended to be, included in, or supports, a regulatory submission for approval of the testing of drugs in humans or the approval for the placing of medicinal products on the market (including without limitation submissions to the FDA, the CFDA, the EMA and other Regulatory Authorities).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.10</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Clinical Study</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall have the meaning set out in Clause&#160;4.5.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.11</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercially Reasonable Efforts</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the degree of effort and resources used by international pharmaceutical businesses with respect to pharmaceutical products of similar commercial potential, maturity, market size and profitability, taking into account product safety and efficacy, development and commercialization costs and risks, market competition, the proprietary position of the product and other technical, legal, scientific, medical or commercial factors that have direct relevance to the relevant Licensed Product.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.12</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall have the meaning set out in Clause&#160;17.1.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.13</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Control</font><font style="font-family:inherit;font-size:12pt;">,&#8221; &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Controls</font><font style="font-family:inherit;font-size:12pt;">,&#8221; &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Controlled</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Controlling</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">in respect of any Person, the direct or indirect ownership or control (whether through contract or otherwise) of more than fifty percent (50%) of the outstanding shares, equity interests or other voting rights of the subject Person having the power to vote for the election of directors (in the case of corporate entities) or to direct the management policies and affairs of the entity (in the case of non-corporate entities) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction).  Any other relationship which in fact results in actual control over the management, business and affairs of a Person shall also be deemed to constitute Control; and</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 4 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">in respect of any Patent Rights, Know How or other Intellectual Property Rights whether owned by or licensed to a Person, the possession of the legal right and ability to grant the respective licenses or sublicenses as provided herein without violating the terms of any agreement or other arrangement with any Third Party.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.14</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cost of Goods</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, for Licensed Products, the cost paid by Oncolytics to a Third -Party manufacturer together, where not included in that payment to such manufacturer, with the fully allocated cost of manufacture, transportation, insurance and other costs incurred by Oncolytics.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.15</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Budget</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the budget of prospective costs (including FTE Costs and Out-of-Pocket Expenses related to the Development Plan (including the cost of supply of Licensed Products for Clinical Studies conducted by the Licensee)) to be incurred by Licensee in connection with the Development Plan.  The Development Budget shall include, without limitation:  (i)&#160;a detailed itemized budget for the relevant calendar year; and (ii)&#160;an estimated budget of projected costs and expenses for the next three (3)&#160;calendar years.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.16</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the annual development plan for the development and Regulatory Approval of a Licensed Product for use in the Field in the Territory by Licensee, including without limitation, development activities to support any Marketing Authorizations for any Licensed Product.  The Development Plan shall initially cover three (3)&#160;years from the Effective Date and shall be updated in accordance with Clause&#160;4.6.  The Development Plan shall include the Development Budget.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.17</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dollars</font><font style="font-family:inherit;font-size:12pt;">&#8221;, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">$</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">US$</font><font style="font-family:inherit;font-size:12pt;">&#8221; means United States dollars, the lawful currency of the United States of America.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.18</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall have the meaning set forth above.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.19</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the European Medicines Agency in Europe.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.20</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FDA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Food and Drug Administration in the United States of America.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.21</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Field</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the treatment and prevention of human diseases.</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 5 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.22</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Finished Product</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall have the meaning set forth in Clause&#160;4.11.4.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.23</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Commercial Sale</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean, with respect to any Licensed Product, the first sale for end use or consumption of such Licensed Product in a country or regulatory jurisdiction in the Territory for value, excluding, however, any sale or other distribution for use in a clinical trial or prior to grant of a Marketing Authorization in that country.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.24</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Indication</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the indication identified in the first filing of an NDA in the Territory or the first approval of an NDA in the Territory, as the case may be, related to Pelareorep. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.25</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Force Majeure</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall have the meaning set forth in Clause&#160;25.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.26</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FTE</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the equivalent of one person working full time for one twelve (12) month period in a research, development, commercialization, regulatory or other relevant capacity, approximating 1,650 hours per year.  For clarity, a single individual who works more than 1,650 hours in a single year shall be treated as one FTE regardless of the number of hours worked.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.27</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FTE Cost</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the fully burdened annual internal cost of employing an FTE, including all employee-related compensation and benefits, such as salary, bonuses, profit sharing, taxes, insurances, training, travel, subsistence, professional dues, catering and employee-related overheads (including human relations, payroll, purchasing, supervisory costs, space allocation and computer and information systems).  The FTE Cost shall be set and revised from time to time by the JSC.  Thereafter, it shall be increased on January&#160;1 of each year by the increase in the annual percentage change of the US Consumer Price Index published by the US Bureau of Labor Statistics.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.28</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Generic Product</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Licensed Product in the Field in a particular country in the Territory, another pharmaceutical product that: (x) contains as an active ingredient Pelareorep; and (y) is approved for use in such country (pursuant to 21 U.S.C. 355(b)(2), an ANDA, a separate NDA, compendia listing, other drug approval application or otherwise, including foreign equivalents of the foregoing, as applicable) in the same Field.</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 6 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.29</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Global Study</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a Phase III Study or other global study to support registration of an NDA with the FDA or a Marketing Authorization with the EMA related to Pelareorep.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.30</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Good Clinical Practice</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">GCP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the FDA regulations and applicable ICH guidelines for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials, as applicable to the development of the Licensed Product from time to time, including 21&#160;C.F.R. Part&#160;11, 50, 54, 56, 312, and 314 and Commission Directive 2005/28/EC as amended from time to time.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.31</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">HKIAC</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Hong Kong International Arbitration Centre.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.32</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Hong Kong</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Hong Kong Special Administrative Region of the PRC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.33</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">IND</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an Investigational New Drug application, as described in 21&#160;C.F.R.&#160;Section&#160;312.23, filed for purposes of conducting Clinical Studies on a Licensed Product in the Field in accordance with the requirements of the Law and the regulations promulgated thereunder, including all supplements and amendments thereto, and any analogous application and process required by a Regulatory Authority in a country or regulatory jurisdiction elsewhere in the Territory in order to conduct clinical studies on a Licensed Product in the Field in such country or regulatory jurisdiction.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.34</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Intellectual Property Rights</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all intellectual property and industrial design rights, whether protected, created or arising under the Laws of the United States or any other foreign jurisdiction, including the following:  (i) patents, patent applications (along with all patents issuing thereon), statutory invention registrations, divisions, continuations, continuations-in-part, substitute applications of the foregoing and any extensions, reissues, restorations and reexaminations thereof, and all rights therein provided by international treaties or conventions; (ii) copyrights, mask work rights, database rights and design rights, whether or not registered, published or unpublished, and registrations and applications for registration thereof, and all rights therein whether provided by international treaties or conventions or otherwise; (iii) trade secrets; and (iv) all other applications and registrations related to any of the rights set forth in the foregoing clauses (i) &#8211; (iii) above </font><font style="font-family:inherit;font-size:12pt;">and </font><font style="font-family:inherit;font-size:12pt;">the right to apply for registrations, certificates, or </font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 7 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-left:48px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">renewals with respect thereto and the right to prosecute, enforce, obtain damages relating to, settle, or release any past, present, or future infringement thereof.  As used in this Agreement, the term &#8220;Intellectual Property Rights&#8221; expressly excludes Trademarks.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.35</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indications</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Oncolytics Indication, First Indication, Second Indication and any additional indications.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.36</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Inventions</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all inventions or discoveries (whether patentable or not) which are generated by either or both Parties or their Affiliates in performance of its or their obligations under this Agreement.  Inventions are more particularly identified as:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">1.36.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Inventions</font><font style="font-family:inherit;font-size:12pt;">&#8221;, meaning those Inventions that are conceived of, or reduced to practice by, Oncolytics, its Affiliates, or subcontractors in performance of its or their obligations under this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">1.36.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensee Inventions</font><font style="font-family:inherit;font-size:12pt;">&#8221;, meaning those Inventions that are conceived of, or reduced to practice by, Licensee or its Affiliates, subcontractors or Sublicensees in performance of its or their obligations under this Agreement; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">1.36.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Joint Inventions</font><font style="font-family:inherit;font-size:12pt;">&#8221;, meaning those Inventions that are conceived of or reduced to practice by one or more employees, agents or consultants of Oncolytics or its Affiliates or subcontractors, together with one or more employees, agents or consultants of Licensee or its Affiliates, Sublicensees or subcontractors in performance of its or their obligations under this Agreement.</font></div></td></tr></table><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">It is acknowledged that any work undertaken by Licensee or its Affiliates, subcontractors or Sublicensees in relation to any Licensed Product shall be considered to be undertaken in performance of Licensee&#8217;s obligations under this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.37</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Joint Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Patent Rights filed by either Party in respect of any Joint Inventions.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.38</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Joint Steering Committee</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">JSC</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the committee to be established by the Parties pursuant to Clause&#160;2.1 to oversee and manage the relationship between the Parties.</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 8 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.39</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Know How</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, individually and collectively, unpatented technical and other information of a Party that is not in the public domain, disclosed hereunder and concerns any Licensed Product, including, ideas, concepts, inventions, discoveries, data, formulae, specifications, information relating to materials, manufacturing and production processes and SOPs, models, assays, analytical processes and SOPs, materials relating to assays, analytical systems or processes, procedures for experiments and tests and results of experimentation and testing, results of research and development including laboratory records, data relating to the pharmacology of products (including data relating to toxicology, bioavailability, metabolism, metabolites and pharmacokinetics), clinical trial data, case report forms, data analyses, reports or summaries and information contained in submissions to and information from ethical committees and Regulatory Authorities.  The fact that a part of a compilation of data is in the public domain shall not prevent the compilation of data as such, or any one or more of the other elements of the compilation from being Know How.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.40</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Law</font><font style="font-family:inherit;font-size:12pt;">&#8221;&#160;&#160;&#160;&#160;means all applicable domestic or foreign federal, regional, national and supra national laws, regulations, rules, directives and regulatory guidance.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.41</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Clinical Data</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Clinical Data Controlled by Oncolytics during the term of this Agreement which directly relates to the use of any Licensed Product in humans.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.42</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Patent Rights</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Patent Rights licensed to Licensee pursuant to Clause&#160;3.1.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.43</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Know How</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Know How Controlled by Oncolytics during the term of this Agreement which directly relates to the development and commercialization of the Licensed Product.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.44</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Product</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any product containing or including Oncolytics&#8217; proprietary variant of Pelareorep as further described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule&#160;1</font><font style="font-family:inherit;font-size:12pt;">&#32;for use in the Field.</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 9 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.45</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Product Mark</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a product specific Trademark and its foreign language counterparts selected by the Parties in accordance with the terms of this Agreement and used by the Parties in connection with the Licensed Product marketed in the Territory.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.46</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensee House Mark</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a Trademark and its foreign language counterparts that is used by Licensee in relation to the Licensed Product and which is not a Licensed Product Mark.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.47</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Macau</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Macau Special Administrative Region of the PRC. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.48</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Marketing Authorization</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any approval required from the relevant Regulatory Authority or Authorities to distribute, promote, market and sell a Licensed Product in a country or region.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.49</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Net Sales</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a given period of time, the gross amounts invoiced by or on behalf of Licensee, its Affiliates or permitted Sublicensees to Third Parties on account of sales of Licensed Products in the Territory, less reasonable and customary discounts and deductions from such gross amounts which are actually incurred, allowed, paid, accrued or specifically allocated, [**].</font></div></td></tr></table><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The inter-company transfer of any Licensed Product by Licensee or one of its Affiliates to Licensee or another Affiliate of Licensee shall not be considered a sale.  In such cases, Net Sales shall be determined based on the gross invoiced price of the Licensed Product sold by Licensee or its Affiliate to the first Third Party purchaser less the discounts and deductions allowed under this definition.</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall not be permitted to sell or otherwise dispose for value of Licensed Product other than in a bona fide arms-length transaction exclusively for money, [**]</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Distribution of Licensed Products for, or use of Licensed Products in, clinical or pre-clinical trials, samples or compassionate use shall not give rise to any deemed sale under this definition.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.50</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NDA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a New Drug Application, as described in 21&#160;C.F.R.&#160;Section&#160;314, including all supplements and amendments thereto, and any analogous application and process </font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 10 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-left:48px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">required by a Regulatory Authority in a country or regulatory jurisdiction elsewhere in the Territory in order to market a Licensed Product in the Field in such country or regulatory jurisdiction. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.51</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Biotech</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Recital (A).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.52</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Group</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Oncolytics, its Affiliates and their respective employees, agents and Third Party independent contractors. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.53</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Indication</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the indication identified in the first filing of an NDA outside the Territory or the first approval of an NDA outside the Territory, as the case may be, related to Pelareorep.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.54</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Patent Rights</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Patent Rights Controlled by Oncolytics during the term of this Agreement which relate to, or are necessary or useful for the development, testing, use, manufacturing, distribution or sale of a Licensed Product.  Oncolytics Patent Rights are listed in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule&#160;2 &#8211; Part&#160;B</font><font style="font-family:inherit;font-size:12pt;">, which shall be updated from time to time.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.55</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ongoing Clinical Studies</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the clinical studies relating to Licensed Products further described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule&#160;4</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.56</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Out-of-Pocket Costs</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to any Party or any of its Affiliates, direct costs and expenses paid or accrued as owing by such Party or any such Affiliate to Third Parties, other than employees or a contract sales force and specifically identifiable and incurred to develop or commercialize Licensed Products pursuant to a Development Plan or Sales and Marketing Plan approved hereunder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.57</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Patent Rights</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any patent applications, patents and any foreign counterparts thereof, including, without limitation, all provisional applications, divisions, renewals, continuations, continuations-in-part, extensions, reissues, re-examinations, substitutions, confirmations, registrations, revalidations and additions of or to them, as well as any supplementary protection certificates, patent term adjustment or patent term extension, or like form of protection, on file with the appropriate governmental agencies.</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 11 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.58</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pelareorep</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Oncolytics&#8217; proprietary variant of a respiratory enteric orphan virus, as more fully described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1</font><font style="font-family:inherit;font-size:12pt;">&#32;to this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.59</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Person</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an individual, partnership, corporation, joint stock company, estate, trust (including a business trust), limited liability company, unincorporated association, joint venture or other entity or a Regulatory Authority.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.60</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pharmacovigilance Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an Adverse Event collecting, exchanging and reporting agreement that addresses the issues and reflects the principles set out in Clause&#160;9, and that the parties will enter into promptly after the Effective Date, substantially in the form attached at </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule&#160;3</font><font style="font-family:inherit;font-size:12pt;">&#32;hereto.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.61</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Phase&#160;III Study</font><font style="font-family:inherit;font-size:12pt;">&#8221; means one or more clinical trials on sufficient numbers of subjects, which trial(s) are designed to: (a)&#160;establish that a drug is safe and efficacious for its intended use; (b)&#160;define warnings, precautions and adverse reactions that are associated with the drug in the dosage range to be prescribed; and (c)&#160;support Regulatory Approvals for such drug.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.62</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Phase&#160;IV Study</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Licensed Product study or data collection effort for such Licensed Product that is initiated in a country/countries after receipt of Marketing Authorization and is principally intended to support the commercialization of such Licensed Product in such country/countries and not to support or maintain a Marketing Authorization or otherwise obtain any labelling change approval from an applicable Regulatory Authority.  Phase&#160;IV Studies shall include, without limitation, clinical experience trials, but shall exclude studies that are required by a Regulatory Authority as a condition to receiving Marketing Authorization for the Licensed Product.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.63</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PRC</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the People&#8217;s Republic of China, but for the purpose of this Agreement only, excludes Hong Kong, Macau and Taiwan. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.64</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Quarter</font><font style="font-family:inherit;font-size:12pt;">&#8221; means each period of three consecutive calendar months commencing on 1&#160;January, 1&#160;April, 1&#160;July and 1&#160;October of the relevant calendar year.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.65</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Approval</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all registrations, approvals (including, without limitation, labeling, pricing or reimbursement approvals), licenses (including, without </font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 12 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-left:48px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">limitation, product and establishment licenses) and authorizations (including, without limitation, a Marketing Authorization) granted by a Regulatory Authority that are required for the marketing, importation, exportation, transport, storage, manufacture, commercial use and sale of a product in a country or jurisdiction.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.66</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Authority</font><font style="font-family:inherit;font-size:12pt;">&#8221; means CFDA, EMA, FDA or any national, supranational, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity in a given country or jurisdiction in the Territory responsible for granting and administering any Regulatory Approvals.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.67</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Confidential Information or Know How: (i)&#160;which is, or is intended, to be included in, or support an IND, NDA or Marketing Authorization for approval of the testing of drugs in humans or for obtaining or supporting Marketing Authorization for a pharmaceutical product, or any supplements thereto; or (ii)&#160;constitutes Clinical Data relating to a Licensed Product.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.68</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Exclusivity</font><font style="font-family:inherit;font-size:12pt;">&#8221; means market exclusivity granted by a Regulatory Authority designed to prevent the entry of Generic Product(s) onto the market in the Field, including new chemical entity exclusivity, new use or indication exclusivity, new formulation exclusivity, orphan drug exclusivity, pediatric exclusivity and 180-day generic product exclusivity.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.69</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Related Agreements</font><font style="font-family:inherit;font-size:12pt;">&#8221; means:</font></div></td></tr></table><div style="line-height:180%;padding-left:96px;padding-bottom:16px;text-align:justify;text-indent:0px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:24px;">(i)</font><font style="font-family:inherit;font-size:12pt;">the Pharmacovigilance Agreement; </font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Supply Agreement; and</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Warrant Purchase Agreement.</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any other agreements entered into between the Parties or their respective Affiliates contemporaneously with, or during the term of, this Agreement in order to facilitate the development or commercialization of any Licensed Product in the Territory under this Agreement.</font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 13 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.70</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Research Material</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Clause&#160;5.1.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.71</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sales and Marketing Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221; means each plan setting forth guidelines for the sales and marketing of Licensed Products in the Territory by or on behalf of Licensee all as described in Clause&#160;7.2.  The Sales and Marketing Plan shall cover a period of at least three (3)&#160;years and shall be broken down on a country-by-country basis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.72</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Second Indication</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the indication identified in the second filing of an NDA in the Territory or the second approval of an NDA in the Territory, as the case may be, related to Pelareorep. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.73</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">South Korea</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Republic of Korea. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.74</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Study Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall have the meaning designated in Clause 4.5.2.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.75</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sublicensee</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a Third Party to whom Licensee or its Affiliates will have granted a license or sublicense under its rights under this Agreement to sell or offer for sale Licensed Product in one or more countries in the Territory; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, &#8220;Sublicensee&#8221; will not include any Third Party who receives a license to use a unit of Licensed Product arising by operation of law or otherwise, or as a consequence of the purchase of said unit of Licensed Product.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.76</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Supply Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an agreement governing the supply of Licensed Product by Oncolytics to Licensee for sale in the Territory as agreed in accordance with Clause&#160;4.10.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.77</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Tax Withholding Amount</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall have the meaning set forth in Clause&#160;11.3. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.78</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Termination Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the effective date of expiration or earlier termination (as applicable) of this Agreement pursuant to Clause 15.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.79</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Territory</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the countries listed in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule&#160;5</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.80</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Person other than the Parties or their respective Affiliates.</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 14 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.81</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Trademarks</font><font style="font-family:inherit;font-size:12pt;">&#8221; means rights in trademarks, trade names, service marks, service names, design marks, logos, slogans, trade dress, or similar rights with respect to indicators of origin, whether registered or unregistered, as well as rights in internet domain names, uniform resource locators, e-mail addresses and similar rights.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.82</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;US GAAP&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means the Generally Accepted Accounting Principles determined by the Financial Accounting Standards Board.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.83</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Valid Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221; means either:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a claim of an issued and unexpired patent (which include any patent term extension, patent term adjustment or supplementary protection certificate) in the relevant country in the Territory which covers a Licensed Product and that:  (i)&#160;has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal; or (ii)&#160;has not been abandoned, disclaimed, or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a claim of a pending patent application, which claim has been filed in good faith and has not been abandoned or finally disallowed without the possibility of appeal or re-filing of the application provided always that any claim that has been pending for greater than [**] from the filing date of the patent application shall cease being a Valid Claim until the patent issues.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.84</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Warrant Purchase Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a warrant purchase agreement to be entered between Oncolytics Biotech and Licensee or its designated Affiliate simultaneously with this Agreement pursuant to which Licensee or its designated Affiliate shall purchase warrants to purchase shares of capital stock of Oncolytics Biotech on the terms and subject to the conditions set out therein, substantially in the form attached at </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule&#160;6</font><font style="font-family:inherit;font-size:12pt;">&#32;hereto.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.85</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Wholly-Owned Subsidiary</font><font style="font-family:inherit;font-size:12pt;">&#8221; of a Person a Person (other than an individual) 100% of the outstanding voting securities of which are owned, directly or indirectly, by such Person.</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 15 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In this Agreement:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">1.85.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">all references to a particular clause or schedule shall be a reference to that clause or schedule in or to this Agreement as it may be amended from time to time pursuant to this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">1.85.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the headings are inserted for convenience only and shall be ignored in construing this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">1.85.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">words importing the masculine gender shall include the feminine and vice versa and words in the singular include the plural and vice versa;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">1.85.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">words denoting persons shall include any individual, partnership, company, corporation, joint venture, trust association, organization or other entity, in each case whether or not having separate legal personality;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">1.85.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the words &#8220;include&#8221;, &#8220;included&#8221; and &#8220;including&#8221; are to be construed without limitation to the generality of the preceding words; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">1.85.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">reference to any statute or regulation includes any modification or re-enactment of that statute or regulation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.86</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the event of any inconsistency or conflict between this Agreement and any of the Schedules, this Agreement shall prevail.  In the event or any discrepancy or contradiction between this Agreement and any Related Agreement, save where expressly provided, this Agreement shall take precedence.</font></div></td></tr></table><div><a name="sE7929B826DF762DB196A3F80FCB3D4AD"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MANAGEMENT OF THE RELATIONSHIP</font></div></td></tr></table><div><a name="sF40D49F207F9D2DAA75B3F80FCDBDFE9"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">2.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">The Joint Steering Committee</font><font style="font-family:inherit;font-size:11pt;">.  Within thirty (30)&#160;days after the Effective Date, the Parties shall establish the Joint Steering Committee (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">JSC</font><font style="font-family:inherit;font-size:11pt;">&#8221;) to oversee and manage the relationship between the Parties.  In particular, the JSC shall be responsible for:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">providing a forum for addressing strategic issues and holding discussions between the Parties related to the development and commercialization of Licensed Products in the Field and in the Territory;</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 16 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">review and approval of the Development Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">review, consideration and approval of any Clinical Study to be undertaken by Licensee in relation to any Licensed Product, together with the associated Study Plan, pursuant to Clause&#160;4.5.2;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">review and coordination of branding strategies and guidelines for each Licensed Product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">review and approval of any Licensed Product Mark to be used by Licensee in relation to a Licensed Product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">review of regulatory strategies for obtaining and maintaining Marketing Authorizations for each Licensed Product in the Territory, including review and approval of any deadline extension requests submitted by Licensee pursuant to Clauses 4.3 and 6.5.1 of this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.7</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">review and approval of the Sales and Marketing Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.8</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.9</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">review of annual reports provided by Licensee of its sales and marketing activities and otherwise monitoring if Licensee&#8217;s performance and compliance against the current Sales and Marketing Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.10</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">proposing any amendments to the Sales and Marketing Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.11</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">development of the core scientific and promotional messages and advertising strategies for Licensed Product in the Field and in the Territory, and planning and implementing educational and professional symposia and meetings in the Territory;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.12</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">review issues concerning the manufacture, procurement, packaging, distribution and supply of Licensed Products in the Field and in the Territory;</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 17 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.13</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">review the supply chain for Licensed Products to identify risks and appropriate actions to avoid or address those risks, including without limitation, identifying sources of supply and second sources of supply, reviewing quality assurance/quality control procedures, records and compliance with current good manufacturing practices (CGMP) and recommending changes or improvements to address issues or problems in those areas, and recommending inventory levels and methods of allocating of supplies in the event of shortfalls;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.14</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">working with and advising the Parties in connection with the negotiation of agreements with Third Party contractors related to the manufacture and supply of Licensed Products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.15</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">developing contingency plans (including without limitation, consideration of whether to establish any second sources of supply) to be implemented in the event of projected or actual supply shortages or inability to supply;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.16</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">facilitating the negotiation and implementation of the Supply Agreement and any other agreements needed to support the supply chain;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.17</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">determining which documents, materials and information are to be translated to another language, who will be responsible and how costs will be shared and allocated between the Parties; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.1.18</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">addressing safety issues relating to Licensed Products.</font></div></td></tr></table><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For the avoidance of doubt, Oncolytics shall not be required to disclose or discuss at the JSC or with Licensee any information which does not relate to development and commercialization of Licensed Products for use in the Field and in the Territory.</font></div><div><a name="s434BC7E006733B4084013F80FD0339E5"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">2.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Membership and Governance of the JSC</font><font style="font-family:inherit;font-size:11pt;">.  The JSC shall comprise six (6)&#160;members (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Members</font><font style="font-family:inherit;font-size:11pt;">&#8221;), with Oncolytics appointing three (3)&#160;Members and Licensee appointing three (3)&#160;Members as their respective representatives on the JSC.  The initial Members of the JSC shall be Matt Coffey (CEO, Oncolytics Biotech), Kirk Look (CFO, Oncolytics Biotech) and Andrew de Guttadauro (President, Oncolytics Biotech (U.S.), Inc.) appointed by Oncolytics and Victor Yang (SVP), Dexter Fong (CFO) and Alex Ye (VP Business Development) appointed by </font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 18 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-left:48px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">Licensee.  Each Party shall have the right to invite additional representatives to provide information and additional expertise to the JSC and to otherwise participate in JSC Meetings as non-voting representatives.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.2.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Party shall be entitled to remove any Member appointed by it and to appoint any person to fill the vacancy arising from the removal or retirement of such Member.  Each Party shall give the other Party prior written notice of any changes in the identity of its Members.  The Parties shall ensure that all of their appointed Members are of a suitable level of expertise, seniority and decision-making authority to deal with the issues that may arise in connection with matters to be considered by the JSC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.2.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The JSC shall exercise this authority in good faith and in accordance with the terms of this Agreement.  The JSC shall have no authority to bind the Parties unless the Parties expressly delegate matters to the JSC in writing or ratify the decision of the JSC in writing.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.2.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">From time to time, the JSC may establish one or more subcommittees to oversee particular projects or activities related to this Agreement, and such subcommittees will be constituted as the JSC agrees.  The Parties may replace their respective subcommittee representatives at any time, with prior written&#160;notice to the other Party.  Any such sub-committee shall be run on the same basis as the JSC save that any issue within the purview of such a subcommittee that is not settled or determined by the applicable subcommittee shall be submitted to the JSC for resolution.  The chair of each subcommittee shall report on subcommittee efforts at each JSC meeting, and either Party may invite its own representatives on such subcommittee to also report on such efforts.</font></div></td></tr></table><div><a name="s4586E27A91E4F1575CE83F80FD35D213"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">2.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">JSC Meetings</font><font style="font-family:inherit;font-size:11pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.3.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">At least twenty-one (21)&#160;days prior to each regularly scheduled meeting of the JSC, written notice shall be given to each Member by the Party convening the meeting and at least fourteen (14)&#160;days prior each such meeting, each Party shall provide to the other all written information to be disclosed including any update </font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 19 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">to the Development Plan or the Sales and Marketing Plan.  In addition, special meetings of the JSC may be called on not less than ten (10)&#160;days&#8217; notice by any Member upon written request to the then current chairperson of the JSC.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.3.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Oncolytics shall designate a Oncolytics Member as the chairperson of the JSC.  The chairperson of the JSC shall set meeting agendas for the JSC provided that the agenda shall include any matter that either Party requests to be included.  Such agendas shall be circulated to all Members at least seven (7)&#160;Business Days prior to the date of the relevant meeting.  The JSC chairperson shall be responsible for recording, preparing and within ten (10)&#160;Business Days issuing draft minutes of the JSC meetings, which draft minutes shall be reviewed, modified and approved in writing by the Members.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.3.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The JSC shall have its first meeting within forty-five (45)&#160;days after the Effective Date, and thereafter shall hold Quarterly meetings.  The venue for the first meeting of the JSC shall be at Oncolytics&#8217; facilities in Calgary, Alberta, Canada, unless otherwise agreed by the Members.  Thereafter, the venue for each meeting of the JSC shall alternate between Licensee&#8217;s facilities in Hangzhou Economic and Technology Development Area, PRC and Oncolytics&#8217; facilities in Calgary, Alberta, Canada, or such other locations as may be agreed upon by the Members.  Except for the first meeting of the JSC which shall be a face-to-face meeting, meetings of the JSC may be held as a teleconference or video conference, provided that the JSC shall hold at least one face-to-face meeting during each calendar year.  Each Party shall bear its own costs for its Members to attend JSC meetings and, as applicable, for its obligations to host such meetings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.3.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The JSC shall review the Development Plan prior to the start of the relevant calendar year.  The JSC shall also review the progress of each Licensed Product against the Development Plan.</font></div></td></tr></table><div><a name="sDCE581696FFAABA354783F80FD534136"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">2.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">JSC Decision Making</font><font style="font-family:inherit;font-size:11pt;">.  All decisions by the JSC shall be made by unanimous vote of a quorum of the Members, with each of Oncolytics and Licensee having one (1)&#160;vote.  The presence of at least two (2)&#160;Members of the JSC representing each of Oncolytics and Licensee (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">i.e.</font><font style="font-family:inherit;font-size:11pt;">, a total of four (4)&#160;Members) shall constitute a quorum.  The Members shall use their reasonable efforts to reach agreement on any and all matters to be determined or resolved by the JSC.</font></div></td></tr></table><div><a name="sFB128EF11574ABE87CC33F80FD856C82"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">2.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Dispute Resolution</font><font style="font-family:inherit;font-size:11pt;">.  In the event that agreement on a matter cannot be reached within thirty (30)&#160;days (or sooner, if required) after the submission of a written notice to the JSC by a Member of the existence of such a disagreement, the matter shall be referred to Licensee&#8217;s CEO and the CEO of Oncolytics for resolution.  In the event that Licensee&#8217;s CEO and the CEO of Oncolytics cannot reach agreement within twenty (20)&#160;Business Days (or sooner, if required) after such referral, the matter shall be resolved as follows:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">[**];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">in accordance with Oncolytics&#8217; position, where the matter concerns the development, promotion, sale and distribution of Licensed Products outside the Territory;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">in accordance with Oncolytics&#8217; position where the matter concerns the Global Study or any of the Ongoing Clinical Studies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">in accordance with Oncolytics&#8217; position where the matter concerns the any Clinical Study proposed by a Party pursuant to Clause&#160;4.5; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(e)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">in the event that Oncolytics remains responsible for commercial manufacture of Licensed Products, Oncolytics shall have the final say in relation to manufacturing issues.</font></div></td></tr></table><div><a name="sB74B6859268AB4108CF13F80FDA302BF"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">2.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Approval of Sub-Committee Actions</font><font style="font-family:inherit;font-size:11pt;">.  Any recommendations prepared by any of the Sub-Committees which are identified herein as requiring JSC approval shall be submitted to the JSC for review and approval.  The terms of any additional contractual agreements or relationships (including, without limitation, agreements with Third Parties) related to development or commercialization of Licensed Products discussed or negotiated by the JSC or a Sub-Committee shall not be binding on the Parties unless and until such terms have been formally reviewed by each Party and signed in accordance with each Party&#8217;s normal procedures.</font></div></td></tr></table><div><a name="s55E710B4CECA258AD2663F80FDDF61CD"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">2.7</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Alliance Managers</font><font style="font-family:inherit;font-size:11pt;">.  Each Party shall appoint one (1)&#160;alliance manager (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Alliance Manager</font><font style="font-family:inherit;font-size:11pt;">&#8221;) to serve as the point person for communications between the Parties on matters arising under this Agreement.  The Alliance Manager may also be a Member of the JSC.  Each Alliance Manager shall be primarily responsible for facilitating the flow of information and otherwise promoting communications and collaboration between the Parties and internally within the Parties.  Each Alliance Manager shall also be responsible for:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.7.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">facilitating coordination among the various functional representatives of Oncolytics or Licensee, as appropriate; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">2.7.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">providing single-point communication for seeking consensus, including facilitating review of external corporate communications pursuant to Clause&#160;28.1.</font></div></td></tr></table><div><a name="s2C79A56FA3DC1347FE8A3F80FDFDD2DE"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">GRANT OF RIGHTS AND EXCLUSIVITY</font></div></td></tr></table><div><a name="s01084C62E1B7814246803F80FE2F015A"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">3.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">License to Licensee</font><font style="font-family:inherit;font-size:11pt;">.  Subject to the terms of this Agreement, Oncolytics grants the following licenses to Licensee effective as of the earlier of the next date following the Effective Date or the date on which Licensee makes its first payment to Oncolytics under this Agreement:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">3.1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">an exclusive license under the Oncolytics Patent Rights and the Oncolytics Inventions (in each case, to the extent that Oncolytics has exclusive rights and does not infringe Licensee&#8217;s Intellectual Property Rights or any Third Party&#8217;s Intellectual Property Rights) and Oncolytics&#8217; interest in the Joint Patents to [**] Licensed Products in the Field in the Territory; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">3.1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a license under the Licensed Know How and Licensed Clinical Data [**] Licensed Products in the Field in the Territory, such license being exclusive to the extent that Oncolytics or its Affiliates have exclusivity and in other cases non-exclusive. </font></div></td></tr></table><div><a name="s2354C1B009A974FEF1393F80FE4D6006"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">3.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Manufacturing Rights</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall have no rights to make or to have made Licensed Products anywhere in the world except as permitted pursuant to Clause 4.11. </font></div></td></tr></table><div><a name="sA253A97457E6B8141C8A3F80FE7F6B3B"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">3.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Sublicense Rights</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall have no right to sublicense any of the licenses and other rights granted under Clause&#160;3.1 to any Third Party, except that [**]</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 20 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><a name="s157B08D40180EB1976293F80FE9D3052"></a></div><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">3.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Diversion</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall not sell, distribute or otherwise dispose of Licensed Product, including via the Internet or mail order, to any Third Party, address or IP address in the any country or jurisdiction outside of the Territory. [**]  </font></div></td></tr></table><div><a name="sBB855875BC9F2FBB8BBF3F80FED9FA94"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">3.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">[**]</font></div></td></tr></table><div><a name="sD7BDD0005C36E74784033F80FEF762CA"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DEVELOPMENT OF LICENSED PRODUCTS</font></div></td></tr></table><div><a name="sDA7C3940D19C62A91BA63F80FF294752"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Development of Licensed Products</font><font style="font-family:inherit;font-size:11pt;">.  The Licensee shall be responsible for developing the Licensed Product for use in the Field in the Territory in accordance with the terms of this Agreement.</font></div></td></tr></table><div><a name="sC9228D23410CCD78034B3F80FF47A8DF"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Development Plan</font><font style="font-family:inherit;font-size:11pt;">.  As soon as reasonably practicable after the Effective Date, the Parties shall, acting through the JSC in accordance with the provisions of Clause&#160;2, agree on and finalize the Development Plan, which shall focus on the development of Licensed Products, and Licensee&#8217;s filing for Regulatory Approval of the Licensed Product in the Territory for at least the First Indication.  The Development Plan shall set out the steps necessary to obtain Regulatory Approval in at least the PRC in respect of the Licensed Product.</font></div></td></tr></table><div><a name="s4789F98940066189EF4B3F80FF7925FE"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Development in respect of the PRC</font><font style="font-family:inherit;font-size:11pt;">.  Obtaining Marketing Authorization for the Licensed Product for use in the Field in the PRC is of the essence of this Agreement.  On or before [**], Licensee shall produce strategy for the development and Regulatory Approval [**] in the PRC for at least the First Indication and this strategy shall be provided to the JSC for approval and incorporation into the Development Plan in respect of the Licensed Product.  [**]. Within the same period, Licensee shall also commence work to generate or obtain any other data that may be necessary for Regulatory Approval in the PRC. </font></div></td></tr></table><div><a name="s40FE16C7324E498C603A3F80FF97B896"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Ongoing Clinical Studies</font><font style="font-family:inherit;font-size:11pt;">.  Subject to Clause&#160;4.8, Oncolytics shall be responsible for and shall use its Commercially Reasonable Efforts to undertake the Ongoing Clinical Studies in accordance with the relevant protocols.</font></div></td></tr></table><div><a name="sB153808596ADB119748F3F80FFD35F57"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Clinical Studies</font><font style="font-family:inherit;font-size:11pt;">.  Subject to the provision of this Clause&#160;4.5, Licensee shall have the right to undertake Clinical Studies (whether alone or together with Oncolytics) in respect of Licensed Products in the Territory and Oncolytics shall have the right to undertake Clinical Studies (whether alone or together with the Licensee or another Person) in respect of Licensed Products anywhere in the world outside the Territory.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If Licensee intends to undertake a clinical study on humans or using material derived from humans (a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Clinical Study</font><font style="font-family:inherit;font-size:12pt;">&#8221;), then prior to submitting any IND (or any other application) for approval to conduct the Clinical Study, Licensee shall notify Oncolytics and provide it with a near final draft protocol and details of the proposed clinical study together with any further information that Oncolytics may reasonably request.  Oncolytics shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">4.5.1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">4.5.1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">notify Licensee within [**] of receipt of the draft protocol (provided that all such other information reasonably requested has been provided) that it agrees to the Clinical Study being undertaken in which case the provisions of Clauses&#160;4.5.2 through Clause&#160;4.5.5 shall apply.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If it is agreed [**] that a Clinical Study should be conducted, then the JSC shall meet to discuss the plan for such Clinical Study (including the protocol) and to develop a study plan for the Clinical Study (a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Study Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  Prior to the submission of any IND or other application for approval, the Parties shall discuss and decide whether the Clinical Study should be conducted jointly or separately.  Such clinical study shall be conducted in accordance with the Study Plan.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.5.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Clinical Studies Required by a Regulatory Authority</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall be responsible for and bear the cost of all Clinical Studies required by a Regulatory Authority in the Territory in respect of a Licensed Product and the rights set out in Clause&#160;4.5.4 shall apply without payment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.5.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Rights to use Clinical Data from Clinical Studies</font><font style="font-family:inherit;font-size:11pt;">.  The Clinical Data generated shall be subject to Clause&#160;12.6.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.5.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Sublicensing Rights</font><font style="font-family:inherit;font-size:11pt;">. Oncolytics may exercise the rights provided for in this Clause&#160;4.5 on behalf and for the benefit of any Third Party to which it has granted a license to develop or commercialize Licensed Products outside the Territory if such Third Party has agreed to be bound by the obligations provided for in this Clause&#160;4.5.</font></div></td></tr></table><div><a name="s4DDC41C5FC670D0F0CE43F80FFF1C689"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Development Plan</font><font style="font-family:inherit;font-size:11pt;">.  Subject to Clauses&#160;4.1 and 4.3, the Development Plan shall set forth for at least a three (3)&#160;year period:  (i)&#160;all of the remaining Clinical Studies (including the Ongoing Clinical Studies and any future Clinical Studies), any development of a production process and all other development activities to be performed by Licensee for each Licensed Product; (ii)&#160;the activities necessary to a long-term strategy for the development of each Licensed Product in the Territory; and (iii)&#160;the corresponding Development Budget.  Development activities to be provided for in the Development Plan may include, without limitation, any studies (clinical or otherwise), formulation development, development/applications of relevant diagnostics analytical method development, and quality control and stability testing necessary or useful in connection with obtaining and maintaining Marketing Authorizations for each Licensed Product in the Territory and any new indications, labelling changes or product improvements (including changes in formulation or dosage, combinations with other active pharmaceutical ingredients and other life cycle management activities) for each Licensed Product.</font></div></td></tr></table><div><a name="s9DE7099F51DC405DFEE03F8100232686"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.7</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Conduct of Development Plans</font><font style="font-family:inherit;font-size:11pt;">.  Each Party shall undertake the tasks allotted to it in the Development Plan with reasonable skill and care and in a timely manner.  All such development activities shall be performed in compliance with all applicable Laws, including, without limitation, current good laboratory practices and Good Clinical Practice.  The Development Plan shall be reviewed by the JSC at each meeting and at least once in each twelve (12)&#160;month period, Licensee shall provide an amended or up-dated Development Plan to the JSC to reflect progress in the development of Licensed Product.  Licensee shall submit to the JSC for review any protocols (and any substantive changes thereto) for any Clinical Studies which it proposes to undertake pursuant to the Development Plan in relation to Licensed Product within the Territory (including without limitation, any Phase&#160;IV Study), and shall not commence any such study until the JSC has approved the final protocol.  Either Party may, as far as is expressly set out in the Development Plan, fulfill its obligations under the Development Plan through sub-contractors, provided always that the subcontracting Party shall remain responsible for such obligations and further provided that the sub-contractor agrees in writing to adopt and implement suitable quality assurance policies and procedures to ensure such compliance.</font></div></td></tr></table><div><a name="s6390D3B3324DBF9F77563F8100411D40"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.8</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Development Costs</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall be responsible for all of the costs (including Oncolytics&#8217; costs incurred before or after the Effective Date as approved by the JSC or reasonably and necessarily incurred in the Development Plan) of carrying out the Development Plan, except for the costs of any development activities required solely by the Oncolytics Group. Oncolytics shall submit to Licensee an invoice in respect of the costs incurred by it pursuant to the Development Plan with no mark-up within thirty (30)&#160;days of the end of each Quarter and Licensee shall pay the amount invoiced by Oncolytics within thirty (30)&#160;days of receipt of such invoice.</font></div></td></tr></table><div><a name="s7539169F69EFEF9D297F3F810073777E"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.9</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Obligations</font><font style="font-family:inherit;font-size:11pt;">.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.9.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Oncolytics agrees to have manufactured and supplied to Licensee all of Licensee&#8217;s requirements for the Licensed Product (i) for clinical development, and (ii) for commercial use, pursuant to the Supply Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.9.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall be responsible for providing Oncolytics with all information relating to labeling requirements for the Finished Product, including English translations of all draft and final labels, product inserts and similar documents, to ensure compliance with all applicable Law at all times.</font></div></td></tr></table><div><a name="s78F22F0EF2141152882F3F81009119CD"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.10</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Supply Agreement</font><font style="font-family:inherit;font-size:11pt;">.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.10.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Unless the Parties agree otherwise in writing, Oncolytics shall or shall procure the manufacture of Licensed Product for Licensee on the terms and conditions of a separate written supply agreement to be entered into between the Parties.  Clinical batches and commercial supply will be covered by the supply agreement.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.10.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Subject to Clause 4.11, under the terms of the supply agreement to be negotiated in good faith by the Parties, Licensee shall be responsible for Oncolytics&#8217; costs in manufacture and supply of Licensed Product, including any Cost of Goods necessary for the manufacture; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that Licensee shall be afforded the opportunity to provide input on the costs of manufacture to be agreed between Oncolytics and the Contract Manufacturer chosen by Oncolytics from time to time pursuant to Clause 4.11.  In particular, the supply agreement shall include the following terms:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:150px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">4.10.2.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**].</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:150px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">4.10.2.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**].</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:150px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">4.10.2.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**].</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:150px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">4.10.2.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**].</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.10.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Parties acknowledge that timely negotiation of a mutually-agreeable supply agreement will be critical to the ability to launch the Licensed Product.  If at any time more than [**] after the commencement of negotiation of such agreement, either Party believes such negotiations have reached an impasse, such Party may refer the impasse to an expert (acting as an expert and not an arbitrator) of at least fifteen (15)&#160;years&#8217; experience in the pharmaceutical industry, selected jointly by the Parties, or in the absence of agreement between the Parties within [**] of the proposing Party requesting that the matter is referred to expert determination, then the matter shall be referred to mediation administered the HKIAC, with one mediator appointed by the HKIAC, in accordance with the HKIAC Mediation Rules in force at the relevant time (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Expert</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  The Expert shall receive one written submission from each Party setting out that Party&#8217;s proposal for the terms of the supply agreement and shall provide his decision as to the terms of supply agreement that are to be implemented within [**] of his appointment.  The Expert&#8217;s decision shall be final and binding on the Parties.  The costs of the Expert shall be borne by the Parties in equal shares. </font></div></td></tr></table><div><a name="s9318E03E544219B808EB3F8100CD81BC"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.11</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Contract Manufacturer</font><font style="font-family:inherit;font-size:11pt;">.  Oncolytics may meet its obligations to supply the Licensed Product to Licensee hereunder or under the Supply Agreement through subcontracting with Third Parties jointly selected, qualified and validated by Licensee and Oncolytics (each, a &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Contract Manufacturer</font><font style="font-family:inherit;font-size:11pt;">&#8221;), subject to the following requirements and Clause 4.10:  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.11.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.11.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.11.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.11.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.11.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.11.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.11.7</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.11.8</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">4.11.9</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table><div><a name="sCCA75F934D57ECD888003F8100EBE605"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AUTHORIZED USE OF MATERIALS</font></div></td></tr></table><div><a name="sCA6E66E14CB095EC38F63F81011D4CDD"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Research Materials</font><font style="font-family:inherit;font-size:11pt;">.  Oncolytics may from time to time during the term of this Agreement supply Licensee with proprietary research materials for use in connection with the development of Licensed Products hereunder (collectively &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Research Materials</font><font style="font-family:inherit;font-size:11pt;">&#8221;).  All such Research Materials are and shall remain the property and Confidential Information of Oncolytics.  Licensee covenants and agrees that it shall only use Oncolytics&#8217; Research Materials for the specific research purposes contemplated by this Agreement, and shall not use the Research Materials for any other purpose or for administration to humans without the prior written consent of Oncolytics.  In addition, Licensee shall not supply or transfer the Research Materials to any Third Party without Oncolytics&#8217; prior written consent; </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:11pt;">, </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:11pt;">, that Research Materials may be supplied to a Wholly-Owned Subsidiary solely for use in connection with the performance of activities under the Development Plan pursuant to a materials transfer agreement in a form no less protective of Oncolytics&#8217; rights in the Research Materials as this Clause&#160;5.1 signed by the Wholly-Owned Subsidiary and Oncolytics.</font></div></td></tr></table><div><a name="sAE025204AF8511C517083F81013B1426"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Limited Warranties</font><font style="font-family:inherit;font-size:11pt;">.  Oncolytics represents and warrants as follows:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.2.1.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:11pt;">Research Materials supplied by Oncolytics for Clinical Studies shall be manufactured and shipped in compliance with cGMP and all applicable Laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.2.2.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:11pt;">&#32;Research Materials supplied by Oncolytics for Clinical Studies shall conform to the quality agreement and specifications agreed to between Oncolytics and the manufacturer;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.2.3.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:11pt;">the facility at which Research Materials for Clinical Studies are manufactured has been validated to meet all applicable regulatory requirements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.2.4.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:11pt;">the manufacturer of Research Materials for Clinical Studies has all such approvals and permits as are required under applicable Law to operate the facility for the purposes of manufacturing Research Materials for Clinical Studies.</font></div></td></tr></table><div><a name="s102BA02FE9C080A67F0D3F81016D141E"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exclusion of Warranties</font><font style="font-family:inherit;font-size:11pt;">.  EXCEPT AS EXPRESSLY SET FORTH IN CLAUSE 5.2 OR FOR ANY LICENSED PRODUCT SUPPLIED AND PAID FOR UNDER A SEPARATE SUPPLY AGREEMENT, LICENSEE ACKNOWLEDGES AND ACCEPTS THAT ALL MATERIALS ARE PROVIDED &#8220;AS IS&#8221; FOR THE SPECIFIC PURPOSES AUTHORIZED HEREUNDER, ARE EXPERIMENTAL IN NATURE, AND ARE PROVIDED WITHOUT WARRANTY OF NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PURPOSE OR ANY OTHER WARRANTY (EXPRESS OR IMPLIED). WITHOUT LIMITATION OF THE FOREGOING AND TO THE FULLEST EXTENT PERMITTED BY LAW, ONCOLYTICS SHALL HAVE NO LIABILITY WHATSOEVER TO LICENSEE OR ANY OTHER PERSON FOR OR ON ACCOUNT OF ANY LOSS OR DAMAGE, OF ANY KIND OR NATURE, SUSTAINED BY, OR ANY DAMAGE ASSESSED OR ASSERTED AGAINST, OR ANY OTHER LIABILITY INCURRED BY OR IMPOSED ON LICENSEE OR ANY OTHER PERSON, ARISING OUT OF OR IN CONNECTION WITH OR RESULTING FROM (A) THE MANUFACTURE, USE, OFFER FOR SALE, SALE OR IMPORT OF A LICENSED PRODUCT, OR (B) ANY ADVERTISING OR OTHER PROMOTIONAL ACTIVITIES CONCERNING ANY OF THE FOREGOING. </font></div></td></tr></table><div><a name="sBCC1389FD26AD6505D8A3F81018B5C77"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Return of Materials</font><font style="font-family:inherit;font-size:11pt;">.  Upon the first to occur of either termination of this Agreement or the ceasing of development by Licensee of the relevant Licensed Product under this Agreement, Licensee shall promptly return, or, at Oncolytics&#8217; request, Licensee shall destroy, and provide written confirmation certified by an authorized officer of Licensee, any of Oncolytics&#8217; Research Materials in its possession or control received by it and all copies thereof, progeny, derivatives, variants, cellular material (such as proteins antibodies, nucleic acids, genes and the like, purified or unpurified) and fragments of the Research Materials (all of which are acknowledged to be the property of Oncolytics), for use in connection with the development of the relevant Licensed Product.</font></div></td></tr></table><div><a name="s6CF9F1231083035FFE423F8101C7CC36"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Unauthorized Use of Materials</font><font style="font-family:inherit;font-size:11pt;">.  Notwithstanding anything in this Agreement to the contrary, any patentable inventions or discoveries made, derivative works, progeny, derivatives, variants, cellular material (such as proteins antibodies, nucleic acids, genes and the like, purified or unpurified) and fragments of the Research Materials created through unauthorized use of Research Materials by Licensee or any Third Party receiving Research Materials from Licensee shall be the exclusive property of Oncolytics, and Licensee shall, and shall procure that its Affiliates and such Third Party shall, upon Oncolytics&#8217; request, take all reasonable steps requested by Oncolytics to perfect Oncolytics&#8217; rights, title and interest in and to such patentable inventions, discoveries, derivative works, progeny, derivatives, variants, cellular material (such as proteins antibodies, nucleic acids, genes and the like, purified or unpurified) and fragments of the Research Materials.</font></div></td></tr></table><div><a name="s908103547F48946FFA4B3F8101E5E648"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Restriction on Use of Materials</font><font style="font-family:inherit;font-size:11pt;">.  Licensee agrees that it will not incorporate Oncolytics&#8217; Research Materials in any of its products or services and shall not utilize Oncolytics&#8217; Research Materials in connection with the commercialization of any products in or outside the Territory other than the development and commercialization of the relevant Licensed Product in the Territory pursuant to this Agreement.</font></div></td></tr></table><div><a name="sB9E957A79378CD53C5793F8102175FE7"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.7</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compliance with Regulations</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall comply, and shall ensure and guarantee that any permitted assignees and all of its Affiliates comply, with all applicable Laws in connection with the use, storage and handling of any Research Materials provided pursuant to this Clause&#160;5.6.  </font></div></td></tr></table><div><a name="s9739EF70F737C836FB303F810235F155"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.8</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exceptions</font><font style="font-family:inherit;font-size:11pt;">.  Notwithstanding any provision of this Clause 5, Licensee&#8217;s non-use obligations with respect to Research Materials under this Clause 5 are subject to the exceptions set forth in Clause 17.4.</font></div></td></tr></table><div><a name="s990B9F58FB0EF960825D3F8102675702"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">REGULATORY AND CLINICAL DEVELOPMENT</font></div></td></tr></table><div><a name="sE2B8EAF2968EEA538A933F8102855379"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Master File</font><font style="font-family:inherit;font-size:11pt;">.  [**]  </font></div></td></tr></table><div><a name="s0D1DBB229B1EB47313E03F8102C1957B"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Responsibility for Regulatory Applications in the Territory</font><font style="font-family:inherit;font-size:11pt;">.  Save in respect of the Ongoing Clinical Studies [**], Licensee shall be responsible, at its own cost, for filing and maintaining, in Licensee&#8217;s name, the INDs, BLAs and other regulatory applications necessary to obtain and maintain Marketing Authorization for each Licensed Product in all countries and jurisdictions in the Territory.  Licensee shall allow Oncolytics to review and comment on all INDs, BLAs and other similar regulatory applications for each Licensed Product prior to submission to any Regulatory Authority in the Territory, as well as confer with Oncolytics regarding the preparation of such filings and communications and the registration process and any revisions to any filings or communications with the Regulatory Authorities.  Licensee shall keep Oncolytics informed as to the status of its draft regulatory applications for each Licensed Product and shall provide copies of all communications with Regulatory Authorities on reasonable request by Oncolytics. If recording of this Agreement or any part of it by a Regulatory Authority is necessary for Licensee or Oncolytics to fully enjoy the rights, privileges and benefits of this Agreement, Licensee shall at its own expense record this Agreement or all such parts of this Agreement and information concerning the license granted hereunder with each such appropriate Regulatory Authority.  Licensee shall (a)&#160;provide to Oncolytics for Oncolytics&#8217; review and approval all documents or information it proposes to record complete at least ten (10)&#160;Business Days prior to the submission thereof, except submission required immediately, and (b)&#160;promptly notify Oncolytics with verification of Licensee&#8217;s recordation or any related agency decision.  In making any such disclosures, Licensee shall maintain, to the fullest extent permitted by Law, the confidentiality of this Agreement, the terms and conditions of this Agreement and any other Confidential Information.  Any specific disclosure made in accordance with this Clause</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">6.2</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">and not objected to by Oncolytics shall not constitute a breach of the Licensee&#8217;s obligations under Clause 17.</font></div></td></tr></table><div><a name="s7B089C7440CF9CA4DAC53F8102DFAF72"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Dealings with Regulatory Authorities</font><font style="font-family:inherit;font-size:11pt;">.  Except as may be prohibited by Law, Licensee shall provide prior written notice to Oncolytics of any meetings between Licensee and a Regulatory Authority in the Territory relating to the development, commercialization or marketing of each Licensed Product, and allow a sufficient opportunity for representatives of Oncolytics to attend any such meetings as an observer.  Licensee shall promptly provide Oncolytics with copies of material correspondence received by Licensee from Regulatory Authorities in the Territory that relates to each Licensed Product, and Licensee shall provide Oncolytics an opportunity to review and comment on material correspondence with Regulatory Authorities in the Territory at least fifteen (15) Business days prior to submission, and shall consider in good faith the comments of Oncolytics to such correspondence.</font></div></td></tr></table><div><a name="sD6DD595AD314882623683F8103119523"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Oncolytics Regulatory Support</font><font style="font-family:inherit;font-size:11pt;">.  Subject to any obligation of confidentiality owed by Oncolytics to a Third Party, Oncolytics shall provide such technical data and support as is necessary to assist Licensee to prepare regulatory applications for Licensed Products in the Territory.  Details of the obligations of the Parties including for associated costs shall be as determined by the JSC or set out in the Development Plan.</font></div></td></tr></table><div><a name="s7D5C299565199848909E3F81032F1B77"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Performance Obligation</font><font style="font-family:inherit;font-size:11pt;">.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">6.5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall file for Regulatory Approval for the Licensed Product for the First Indication in the Field in the PRC [**], </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that the applicable Clinical Data is timely delivered to Licensee by Oncolytics; and, provided, further, that in the event that Licensee experiences delays in completing the Clinical Study in the PRC necessary for obtaining Regulatory Approval from the CFDA (or other relevant Regulatory Authority) for the Licensed Product for the First Indication in the Field despite having used its Commercially Reasonable Efforts to meet the [**] set out in this Clause 6.5.1, Licensee may seek the approval of the JSC to extend such deadline.  If Licensee fails to meet the timing requirements of this Clause 6.5.1 (including any extension that may be approved by the JSC), then, upon Oncolytics&#8217; written request, the Parties shall meet to discuss future activities relating to the Licensed Product for the First Indication in the Field in the PRC.  If, following such discussions, Oncolytics determines in its opinion that Licensee is not pursuing development activities with diligence, Oncolytics may, at its option, terminate Licensee&#8217;s license as granted under this Agreement to Licensed Product in respect of the PRC (and reduce the Territory accordingly) or the entire Territory, and the Parties shall proceed as if there had been a termination by Oncolytics pursuant to Clause 15.3. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:94px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:46px;"><font style="font-family:inherit;font-size:12pt;">6.5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall use Commercially Reasonable Efforts to:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:70px;"><font style="font-family:inherit;font-size:12pt;">6.5.2.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:70px;"><font style="font-family:inherit;font-size:12pt;">6.5.2.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:70px;"><font style="font-family:inherit;font-size:12pt;">6.5.2.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**].</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If Licensee fails to meet the obligations set out in Clause 6.5.2, Oncolytics may terminate Licensee&#8217;s license to Licensed Product in the affected country or jurisdiction with written notice to Licensee within ninety (90) days of the applicable failure, and, in such cases, Licensee shall cooperate with Oncolytics in the transfer to Oncolytics or its designee of the Licensed Product rights in such territory(ies).  Such transfer of product rights shall be effected by means of removing the relevant country or jurisdiction from the Territory.</font></div></td></tr></table><div><a name="s7A90886D84DD77AFE4983F81036153CD"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MARKETING OF LICENSED PRODUCTS</font></div></td></tr></table><div><a name="s1C29FA6DBAEE65E2F4813F81037FDA82"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">7.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Use of Trademarks</font><font style="font-family:inherit;font-size:11pt;">.  Licensee will market and label each Licensed Product in the Territory under a Licensed Product Mark approved by the JSC.  Each packet shall bear on the outer packaging, the secondary packaging and any patient information leaflet or summary of product characteristics an Oncolytics Trademark designated by Oncolytics and an acknowledgement that the relevant Licensed Product is licensed to Licensee by Oncolytics, all subject to applicable Law and limitations imposed by CFDA.</font></div></td></tr></table><div><a name="s091E0BFC5F4F579516B93F8103BB702F"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">7.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Sales and Marketing Plan</font><font style="font-family:inherit;font-size:11pt;">.  Prior to filing an application for a BLA or an application for any Marketing Authorization for the relevant Licensed Product in the Territory, Licensee shall provide Oncolytics with a proposed Sales and Marketing Plan for the relevant Licensed Product for review and approval by the JSC.  The Sales and Marketing Plan shall include, among other topics, the proposed Licensed Product Mark, positioning, the marketing and promotional investment, Phase&#160;IV Studies (if any) and publication plans, sales and marketing headcount, promotional tools/activities and the timing and budget for the foregoing.  Any Trademark to be used in connection with a Licensed Product, shall require Oncolytics&#8217; prior written consent and Licensee shall consider as part of its evaluation market research concerning any marks suggested by Oncolytics.  Such evaluation and market activities shall consider any Third Party intellectual property rights position affecting the Trademarks in question.  Licensee shall be solely responsible for, and bear the costs of, the generation (including any English translation) of all promotional materials to be used by Licensee or its Affiliates in connection with the marketing, promotion and sale of the Licensed Product in the Territory.  Licensee shall provide an updated Sales and Marketing Plan for the Licensed Product on or before 30&#160;September in each year.</font></div></td></tr></table><div><a name="s72ECE300C2CA3D4EEF733F8103D9B37F"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">7.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Post-marketing and observational Studies</font><font style="font-family:inherit;font-size:11pt;">.  Subject to Clause&#160;4.6, Licensee shall undertake any pharmacovigilance and observational studies set out in the Pharmacovigilance Agreement and any Phase&#160;IV Studies that may be required or it deems desirable for any Licensed Product.  Licensee shall design and control such studies and bear their expenses and provide Oncolytics with a copy of such study protocols within thirty (30)&#160;days of internal protocol approval.</font></div></td></tr></table><div><a name="sF9DD79B311187AB080B33F81040BBE0D"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">7.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Promotional Materials</font><font style="font-family:inherit;font-size:11pt;">.  All promotional materials used by Licensee for Licensed Products shall comply with applicable Laws in the Territory, and shall be consistent with the positioning statements in the Sales and Marketing Plan.  A physical as well as an electronic sample of each item of promotional material for use by the Licensee shall be provided to Oncolytics within thirty (30)&#160;days of approval by Licensee along with the applicable promotional regulations for the country where the promotional material is to be used.</font></div></td></tr></table><div><a name="s7A504527BE72011903A53F8104296AB2"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">7.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Promotional Activities</font><font style="font-family:inherit;font-size:11pt;">. All promotional activities enacted by Licensee for Licensed Products shall comply with applicable Laws in the Territory, and shall be consistent with the positioning statements in the Sales and Marketing Plan.  A description of each planned promotional activity shall be provided to Oncolytics within thirty (30)&#160;days of approval by Licensee along with the applicable promotional regulations for the country where the activity is to take place.</font></div></td></tr></table><div><a name="s8E0D32DF80296738E3BB3F81045B7192"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DILIGENCE</font></div></td></tr></table><div><a name="s66EBF0BBE9449EB345103F810483AAB6"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">8.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall use its Commercially Reasonable Efforts to perform its responsibilities and obligations under this Agreement with regard to the development and commercialization of the Licensed Product in each country and jurisdiction in the Territory.</font></div></td></tr></table><div><a name="sD9559176DF75386F05B03F8104B5BA51"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">8.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Development and Regulatory Diligence</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall use Commercially Reasonable Efforts to develop, and to achieve Marketing Authorization for, the Licensed Product in each country and jurisdiction in the Territory.  In performing such efforts, Licensee shall also observe GCP, safety standards and any other applicable Law relevant to the development of the Licensed Product in the Territory.</font></div></td></tr></table><div><a name="s3A6373135FDB02612C353F8104D3A260"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">8.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compliance with Sales and Marketing Plans</font><font style="font-family:inherit;font-size:11pt;">.  Once Licensee receives Marketing Authorization for a Licensed Product, Licensee shall use Commercially Reasonable Efforts to market and sell the Licensed Product in each country in the Territory where it is approved consistent with the relevant Sales and Marketing Plan.  By January 31 of each year after the First Commercial Sale of a Licensed Product in the Territory, Licensee shall inform Oncolytics of the results of its sales and marketing performance relating to the Licensed Product in the Territory for the prior year.</font></div></td></tr></table><div><a name="sE5564A7B560DC5B09CB73F810505FDE5"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">8.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Satisfying Diligence</font><font style="font-family:inherit;font-size:11pt;">.  Licensee will be deemed to have failed to have met its diligence obligations under Clauses&#160;8.2 and 8.3 in respect of Licensed Products in a particular calendar year if it fails to meet the targets for development activity and for promotional activity established in accordance with this Clause&#160;8.4.  [**].  The development activity target for the Licensed Product in the first full calendar year following Effective Date shall be based on the Development Plan.  Licensee&#8217;s promotional activity target for Licensed Products during the first year after launch shall be based on the Sales and Marketing Budget approved by the JSC from time to time.</font></div></td></tr></table><div><a name="sFDF7540BEF1CA4A4FD493F810523F13C"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">8.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Sales Data</font><font style="font-family:inherit;font-size:11pt;">.  Within fifteen (15)&#160;Business Days after the end of each Quarter, Licensee shall provide to Oncolytics a report of all sales of each Licensed Product occurring in the Territory.  In addition, within two (2)&#160;weeks after the end of each calendar month, Licensee shall provide to Oncolytics on a country-by-country basis IMS recorded sales of each Licensed Product by volume and value and market share percentage by volume and value.</font></div></td></tr></table><div><a name="s04BF2BD5114B61C60F313F8105551C88"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">8.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Recordkeeping and Inspection</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall, and shall ensure that its respective Affiliates and permitted Sublicensees (if any) shall, maintain complete and accurate books and records in English to document the work done by it and its Affiliates and Sublicensees in connection with the development and commercialization of each Licensed Product under this Agreement.  Such books and records shall be maintained and retained in accordance with all applicable Law.  Such books and records shall be kept for at least six (6)&#160;years following the end of the calendar year to which such records relate.  For the sole purpose of verifying compliance with the diligence </font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 21 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-left:48px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">obligations set out in this Clause&#160;8, Oncolytics shall be entitled, not more than once per calendar year, to have such books and records inspected by an internationally recognized independent accounting firm identified by Oncolytics and reasonably acceptable to Licensee.  Oncolytics shall provide Licensee with thirty (30)&#160;days notice of such inspection, which shall be conducted during normal business hours at a single location, being Licensee&#8217;s principal place of business or such other place as may be agreed, where Licensee shall make available such records.  Licensee shall make available to the independent accountant those books and records required for the purpose of that inspection.  The results of such inspection shall be made available to Oncolytics, and the records and results of such audits shall be deemed Licensee&#8217;s Confidential Information except that Oncolytics shall be entitled to use the results of the inspection in any proceedings initiated pursuant to Clause&#160;33 in the event that Oncolytics concludes that Licensee has failed to comply with the diligence obligations set out in this Clause&#160;8.  Oncolytics shall be responsible for the cost of the independent accountants&#8217; services in connection with such audit; </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:11pt;">&#32;that Licensee shall reimburse Oncolytics for such costs if the results of the audit conclude (i)&#160;that it has understated the monies payable to Oncolytics by more than [**] or (ii)&#160;that there are material deviations from the diligence obligations.  Any outstanding under-payments or over-payments which are identified as a result of carrying out the audit and certification shall be paid to or by Licensee within thirty (30)&#160;days after Oncolytics receives the audit results.  No inspection shall take place more than [**] after the expiration of the term or termination of this Agreement.</font></div><div><a name="s58A5EBCA6251FDFA85EA3F81057D33EC"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">8.7</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Material Terms</font><font style="font-family:inherit;font-size:11pt;">.  Licensee&#8217;s obligations in this Clause&#160;8 regarding Licensed Products in the Territory are material terms of this Agreement.</font></div></td></tr></table><div><a name="s0AAE066FDA72E61B5EAD3F8105AFD78E"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ADVERSE EVENTS AND PHARMACOVIGILANCE</font></div></td></tr></table><div><a name="s7A5FCE46376FEB69AC313F8105CD7D39"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">9.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Pharmacovigilance</font><font style="font-family:inherit;font-size:11pt;">.  Licensee and Oncolytics shall ensure that an appropriate system for pharmacovigilance activities is in place to assume responsibility and liability for Licensed Product in accordance with all relevant Law.  It is the intention of the Parties that Licensee shall be responsible for and manage the collection, investigation and reporting of Adverse Events from the Territory to Oncolytics and the relevant Regulatory Authority and Oncolytics shall be responsible for the creation, maintenance and updating of a global safety database for each Licensed Product.  Oncolytics may subcontract this responsibility in its discretion.  The Parties shall comply with the provisions of the Pharmacovigilance Agreement in relation to the collection, investigation, reporting and exchange of safety data.</font></div></td></tr></table><div><a name="s7E08428B351EC1103A5A3F8105FFA1A1"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">9.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Responsibilities of the Qualified Person</font><font style="font-family:inherit;font-size:11pt;">.  Each Party shall designate a suitably-qualified person responsible for compliance with its pharmacovigilance obligations.  The qualified person shall be responsible for:  (i)&#160;the collection of Adverse Event reports for the Product reported to Licensee or Oncolytics (as the case may be) and their Affiliates; (ii)&#160;notification to Licensee and Oncolytics of such reports in accordance with the terms of the Pharmacovigilance Agreement; (iii)&#160;the timely submission of individual written reports to the relevant Regulatory Authority in compliance with applicable Law; (iv)&#160;the timely submission of Periodic Safety Update Reports; (v)&#160;answering pharmacovigilance related questions; and (vi)&#160;all notifications and communications with any Regulatory Authority related to pharmacovigilance, as appropriate or required by Licensee or Oncolytics.</font></div></td></tr></table><div><a name="s7F8D5052CAF3B818DFF33F81061D090E"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FINANCIAL TERMS</font></div></td></tr></table><div><a name="s2EC1C0113D2422B943353F81064F1EB0"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">10.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Upfront Payment Obligations</font><font style="font-family:inherit;font-size:11pt;">.  In consideration of the research and clinical work conducted by Oncolytics regarding Licensed Products and the benefit Licensee will gain from using this as supporting material when filing for Marketing Authorizations in the Territory and in partial consideration of the grant of the rights to Licensee by Oncolytics, Licensee shall, in accordance with the provisions of Clause&#160;11, pay to Oncolytics the sum of US$5,277,778 as follows:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">10.1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">within ten (10)&#160;business days after execution and delivery of this Agreement, US$1,055,556; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">10.1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">within ninety (90)&#160;days after the Effective Date, US$4,222,222.  </font></div></td></tr></table><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Under no circumstances shall this amount be refundable, creditable or returnable against any future monies payable under this Agreement. </font></div><div><a name="s26D83ABE68687BAAA9A73F8106779006"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">10.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Purchase of Warrants</font><font style="font-family:inherit;font-size:11pt;">.  By no later than the Effective Date, Oncolytics Biotech and Licensee shall enter into the Warrant Purchase Agreement.  </font></div></td></tr></table><div><a name="s98EF661D3A1D48EA28683F8106A96DF0"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">10.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Development and Regulatory Milestone Payments</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall, in accordance with the provisions of Clause&#160;11, pay to Oncolytics the milestone payments set forth in this Clause&#160;10.3 in respect of each Licensed Product within forty-five (45) days after the completion of certain development milestones, as set forth below:  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">i.</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">[**];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">ii.</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">[**];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">iii.</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">[**];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">iv.</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">[**];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">v.</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">[**];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">vi.</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">&#32;[**]:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:141px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**], or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:141px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">vii.</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">&#32;[**]:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:141px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**], or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:141px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**].</font></div></td></tr></table><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Under no circumstances shall any of the payments referred to in this Clause&#160;10.3 be refundable, creditable or returnable against any future monies payable under this Agreement.</font></div><div><a name="s9FD34DC27F61E02E414C3F8106C74414"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">10.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Sales Milestone Payments</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall, in accordance with the provisions of Clause&#160;11, pay to Oncolytics the milestone payments set forth in this Clause&#160;10.4 within thirty (30)&#160;days after the following milestones have been met:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">a one-time payment of [**] for the first time in which total Net Sales of Licensed Product across all jurisdictions in the Territory in any calendar year [**]; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">one-time payment of [**] for the first time in which total Net Sales of Licensed Product across all jurisdictions in the Territory in any calendar year reaches [**].</font></div></td></tr></table><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Under no circumstances shall any of the payments referred to in this Clause&#160;10.4 be refundable, creditable or returnable against any future monies payable under this Agreement.</font></div><div><a name="sD3D09935F633585140483F81070D3B64"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">10.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Running Royalties Payable by Licensee</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall, in accordance with the provisions of Clause&#160;11, pay to Oncolytics as earned royalties on sales of all Licensed Product in each calendar year in the Territory, the following royalty payments:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">10.5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">for the first [**] of total Net Sales earned for Licensed Product sold in all jurisdictions in the Territory in a calendar year, Licensee shall pay Oncolytics a royalty at the rate of [**] of all such Net Sales; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">10.5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">for any additional Net Sales earned for Licensed Product in the Territory in the same calendar year, Licensee shall pay Oncolytics a royalty at the rate of [**] of all such Net Sales. </font></div></td></tr></table><div><a name="s5A4204901BBD8036CCDD3F810721F28C"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">10.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Duration of Royalty Obligations</font><font style="font-family:inherit;font-size:11pt;">.  The royalties payable by Licensee to Oncolytics under Clause&#160;10.5 in respect of a given Licensed Product shall be allocated [**] to the Oncolytics Patent Rights and [**] to the combined Licensed Clinical Data and Licensed Know How.  For the convenience of the Licensee, the royalties payable by Licensee to Oncolytics under Clause 10.5 in respect of Licensed Product shall be reduced by [**] of the amounts payable under Clause&#160;10.5 on a country-by-country basis on the later of:  (i)&#160;the last to expire of any Oncolytics Patent Rights having at least one Valid Claim covering the manufacture, use, importation, or sale of Licensed Product in such country; or (ii)&#160;[**] after the date of the First Commercial Sale of Licensed Product in such country.  The reduced royalty shall be payable in respect of the continued use of the Licensed Know How and the Licensed Clinical Data and as a reasonable manufacturing margin.  The obligation to pay any royalty whatsoever in respect of a particular Licensed Product shall cease on a country-by-country basis on the later of: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">10.6.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**] years after the relevant Licensed Product was placed on the market in that country; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">10.6.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the expiration of all Regulatory Exclusivity covering such Licensed Product in the Field in such country.</font></div></td></tr></table><div><a name="s836523094C1A14951F0B3F810749FFCE"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">10.7</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Failure to Pay</font><font style="font-family:inherit;font-size:11pt;">.  Any breach by Licensee of its obligations to make payments under the terms of this Clause&#160;10.7 when properly due and which is not cured within the time permitted in Clause&#160;15.3 shall be a material breach of this Agreement. </font></div></td></tr></table><div><a name="s49409D88116D79172B643F810767CBFB"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">10.8</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party Licenses</font><font style="font-family:inherit;font-size:11pt;">.  If the use, sale, offer for sale or import by Licensee of the Licensed Product in South Korea is determined by a court of competent jurisdiction to infringe Intellectual Property Rights owned by a Third Party, or if Licensee and Oncolytics agree that the use, sale, offer for sale or import by Licensee of the Licensed Product in South Korea would infringe Intellectual Property Rights owned by a Third Party, Licensee and Oncolytics shall attempt to obtain a license under such Third Party Intellectual Property Rights. If Licensee obtains a license under such Third Party Intellectual Property Rights, [**] of any payments made by Licensee to such Third Party shall be deductible from royalty payments due from Licensee to Oncolytics pursuant to Clause 10.5; provided, however, that in no event shall royalties payable to Oncolytics for Net Sales in South Korea be reduced by more than [**] as a result of all such deductions. </font></div></td></tr></table><div><a name="s8263200F394CD81B17F93F8107A35050"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PAYMENT</font></div></td></tr></table><div><a name="sB511CEAF695D551FF7963F8107C126D6"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">11.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Currency and Timing of Payments</font><font style="font-family:inherit;font-size:11pt;">.  All payments due to Oncolytics under this Agreement shall be made in US Dollars within the relevant period, or if no period is stipulated, within thirty (30)&#160;days of receipt of the relevant invoice.  Each payment shall be accompanied by a written report that shall provide such information as is reasonably required by Oncolytics to permit an accurate determination of the amount payable.  In the event that Licensee receives payment in respect of Net Sales in a currency other than US Dollars, the relevant royalties payable shall be calculated in US Dollars at the rate of exchange based on the average daily exchange rate calculated by averaging the closing daily rate between the country in which the Licensed Product was sold and the United States, as obtained from the Federal Reserve Bank of New York as set forth in the H.10 weekly statistical release of the Federal Reserve Board or equivalent successor, on the last day of the Quarter in which the royalties accrue.  Payments shall be made by electronic wire transfer of immediately available funds directly to the account of Oncolytics designated below or to any other account which Oncolytics may specify by written notice.</font></div></td></tr></table><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Written confirmation of such transfer shall be sent by Licensee at the time of the transfer to the Chief Financial Officer of Oncolytics at the address provided below, or to such other individual/address as may be designated by written notice. </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:245px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:74px;"><font style="font-family:inherit;font-size:12pt;">Address of Oncolytics:</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">210, 1167 Kensington Crescent NW</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:245px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Calgary, AB, Canada T2N 1X7</font></div><div style="line-height:180%;text-align:justify;padding-left:245px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s68854E3F4CC06E98EA783F8107F30D69"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">11.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Manner of Payment</font><font style="font-family:inherit;font-size:11pt;">.  For the first two (2) years following First Commercial Sale, the royalties provided for in Clauses&#160;10.5 shall be paid semi-annually in respect of all Licensed Products sold within the relevant period and thereafter the royalties provided for in Clauses&#160;10.5 shall be paid quarterly in respect of all Licensed Products sold within the relevant Quarter.  The royalties shall be paid to Oncolytics within thirty (30)&#160;days of the end of the relevant period in which the relevant sale is made.  Each such payment shall be accompanied by a self-invoicing statement setting out the Net Sales of Licensed Products during the relevant period and a written report that shall provide such information as is reasonably required by Oncolytics to permit an accurate determination of the amount payable.</font></div></td></tr></table><div><a name="s73BFAFDE2425D4C9F4CF3F8108110476"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">11.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Taxes</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall use its best efforts to obtain a waiver from the relevant taxing governmental authority in the PRC of any obligation to withhold or pay any withholding or other taxes (including without limitation any value-added taxes) on behalf of Oncolytics in relation to amounts payable to Oncolytics under this Agreement.  Each Party shall furnish the other Party with appropriate documents to secure application of the most favorable rate of withholding or other tax under applicable Law.  In the event that Licensee is required by Law to withhold or pay any taxes (including without limitation any value-added taxes) on behalf of Oncolytics (such amount, the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Tax Withholding Amount</font><font style="font-family:inherit;font-size:11pt;">&#8221;) with respect to any payments to Oncolytics hereunder and is unable to obtain any waiver therefrom (in whole or in part), [**]</font></div></td></tr></table><div><a name="s454078F10421BA4EA0C53F810843050D"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">11.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Interest</font><font style="font-family:inherit;font-size:11pt;">.  Where Oncolytics does not receive payment of any sums properly due and payable to it hereunder within the relevant period, interest shall accrue on the sum due and owing at the rate equivalent to an annual rate of eight percent (8%) over the then current base rate of LIBOR, calculated on a daily basis, without prejudice to Oncolytics&#8217; right to receive payment within the relevant period.</font></div></td></tr></table><div><a name="s26EF0D01607E66FEE85A3F81086B4B41"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">11.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Record Keeping and Audit</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall, and shall ensure that its respective Affiliates and permitted licensees (if any) shall, keep true and accurate records and books of account in accordance with US GAAP and containing all data necessary for the calculation of the amounts payable to Oncolytics pursuant to this Agreement.  Such records and books of account shall be kept for at least three (3)&#160;years following the end of the term of this Agreement.  For the sole purpose of verifying amounts due under this Agreement, during the term of this Agreement and for three (3) years thereafter, Oncolytics shall have access to and the right to examine such relevant records and accounts that Licensee is required to maintain pursuant to this Clause 11.5 at Licensee&#8217;s premises and the right to have any statement that it receives from Licensee audited by an internationally-recognized independent accounting firm identified by Oncolytics and reasonably acceptable to Licensee.  Oncolytics shall provide Licensee with at least fifteen (15) business days notice of such audit, which shall be conducted during normal business hours at the location(s) where Licensee maintains such records.  All audits shall be conducted in accordance with U.S. Generally Accepted Auditing Standards.  Licensee shall make available to the independent accountant those books and records required for the purpose of that audit and certification, and the statements so certified shall be final and binding between the Parties.  Full details, including the results, of such audit shall be made available to Licensee, and the records and results of such audits shall be deemed Licensee&#8217;s Confidential Information.  Oncolytics shall be responsible for the cost of the independent accountants&#8217; services in connection with such audit; </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:11pt;">&#32;that Licensee shall reimburse Oncolytics for such costs if the results of the audit conclude that it has understated the monies payable to Oncolytics by more than five percent (5%).  Any outstanding under-payments or over-payments which are identified as a result of carrying out the audit and certification shall be paid to or by Oncolytics within thirty (30)&#160;days after Licensee receives the audit results.  No inspection shall take place more than six (6)&#160;years after the submission of the annual statement to which it relates.</font></div></td></tr></table><div><a name="s7C7E41D34D72BE784C5D3F81089D6BFE"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OWNERSHIP OF INTELLECTUAL PROPERTY</font></div></td></tr></table><div><a name="sA60B2437CEF08B588D8F3F8108BBBC7E"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">12.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Excluded IP</font><font style="font-family:inherit;font-size:11pt;">.  Except for those rights expressly granted under this Agreement, nothing herein shall be construed as creating, granting or conveying to one Party any license, rights, title or other interest in or to any intellectual property rights and Know How owned or controlled by the other Party or its Affiliates:  (i)&#160;existing prior to the Effective Date; or (ii)&#160;independently discovered and developed during the term of this Agreement by such other Party or its Affiliates other than in performance of its obligations under this Agreement and without use of such other Party&#8217;s intellectual property rights, Research Materials, Know How or other Confidential Information.</font></div></td></tr></table><div><a name="sAB0CBB55AD01E614FD7A3F8108ED0F8F"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">12.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Inventions</font><font style="font-family:inherit;font-size:11pt;">.  Ownership of all rights, title and interest in and to any Inventions shall be as follows:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">12.2.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Oncolytics or its Affiliates shall have exclusive ownership of all Oncolytics Inventions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">12.2.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall have exclusive ownership of all Licensee Inventions; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">12.2.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**].</font></div></td></tr></table><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Inventorship of Inventions shall be determined for the purposes of this Clause&#160;12.2 in accordance with the applicable patent Laws of the United States of America.  [**].</font></div><div><a name="sC42C0CF99E02AD45C40F3F81090BD480"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">12.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">[**].</font></div></td></tr></table><div><a name="sD4A29F82673842988D703F81093DAA4E"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">12.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Licensee and Cooperation with Respect to Inventions</font><font style="font-family:inherit;font-size:11pt;">.  Each Party shall promptly inform the other of all Inventions arising during the term of this Agreement.  Each Party shall have the right to file for patent protection on any Invention that it owns pursuant to Clause&#160;12.2 and each of the Parties agrees to undertake such acts as may be reasonably necessary to perfect the Parties respective rights, title and interests in and to Inventions as provided for in Clause&#160;12.2 (including, without limitation, any patent applications or patents filed during or after the term of this Agreement to protect such Inventions in or outside the Territory), which shall include ensuring that the filing Party has reasonable and timely access to any employees or consultants of the other Party who were involved in the research leading to such Inventions to, amongst other things, establish inventorship and determine the scope and patentability of the relevant inventions and causing the execution of any assignments or other documents necessary to perfect each Party&#8217;s interests in such Inventions.  The Party filing patent applications for Joint Inventions shall do so in the name of and on behalf of both Licensee and Oncolytics or their respective designees.  Each of Licensee and Oncolytics shall hold all information it presently knows or acquires under this Clause&#160;12.4 that is related to all such patents and patent applications as confidential, subject to the provisions of this Agreement.</font></div></td></tr></table><div><a name="s0E69E1DB947181F92C333F81095B393B"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">12.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Patent Term Extension</font><font style="font-family:inherit;font-size:11pt;">.  Oncolytics shall have the right to obtain patent term extensions in or outside the Territory including supplementary protection certificates relating to Licensed Products that are solely invented by Oncolytics in the Territory and to select which patent or basic patents and in which jurisdiction are used for such extensions.  Licensee agrees to cooperate with Oncolytics in the filing for such applications and to do all such acts, provide and sign all documents or copies thereof which may be reasonably necessary or desirable for the filing of any application for patent term extension relating to Licensed Products in the Territory.</font></div></td></tr></table><div><a name="sF8E9B5A5192CB679F5D43F810997ED07"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">12.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Ownership of Clinical Data.  [**]</font></div></td></tr></table><div><a name="s6EB526314A3697C7D5293F8109ACCDF4"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MANAGEMENT OF PATENT RIGHTS</font></div></td></tr></table><div><a name="s79501C268742690A90B13F8109E833E4"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">13.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Prosecution, Maintenance and Defense of Patent Rights</font><font style="font-family:inherit;font-size:11pt;">.  Oncolytics shall be responsible for, and undertake (whether itself, through Affiliates or Third Parties), the filing, prosecution, defense and maintenance of any patent applications relating to the Oncolytics Patent Rights.</font></div></td></tr></table><div><a name="s842E52A67D1E8CC00B2F3F810A06A5C9"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">13.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Abandonment of Patent Rights by Oncolytics</font><font style="font-family:inherit;font-size:11pt;">.  If Oncolytics, during the term of this Agreement, determines in its sole discretion to abandon or not maintain any Oncolytics Patent Rights applicable to a Licensed Product in the Territory, then Oncolytics shall, subject to any Third Party rights existing at the relevant time, provide Licensee with prior written notice in advance of any abandonment to enable Licensee, at Licensee&#8217;s expense, to prosecute and maintain such Patent Rights in the Territory on behalf of Oncolytics and in Oncolytics&#8217; name and assume the prosecution or maintenance on behalf of Oncolytics.</font></div></td></tr></table><div><a name="s0AF98666D1220570A9A83F810A38683F"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">13.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Inventions:  Licensee Patent Filing</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall have the first right, at its cost, to prepare, file, prosecute, maintain and extend patent applications and patents concerning all Licensee Inventions throughout the world.  Licensee shall solicit Oncolytics&#8217; advice and review of the nature and text of any such patent applications to the extent such are related to Licensed Products and important prosecution matters related thereto in reasonably sufficient time prior to filing thereof, and Licensee shall take into account Oncolytics&#8217; reasonable comments related thereto.  If Licensee, prior or subsequent to filing patent applications on any Licensee Inventions anywhere in the world elects not to file, prosecute or maintain any patent application relating to a Licensed Product or any subject-matter of an Oncolytics Invention or ensuing patents or subject matters encompassed by such patent applications or ensuing patents in any country of the world or Territory, as the case may be, Licensee shall give Oncolytics notice thereof within a reasonable period prior to allowing such patent applications or patents or such subject matters encompassed by such patent applications or patents to lapse or become abandoned or unenforceable, and Oncolytics shall thereafter have the right, at its sole expense, to prepare, file, prosecute and maintain patent applications and patents or divisional, provisional, continuation, continuation-in-part, re-examination, reissue applications or similar applications related to such subject matters encompassed by such patent applications or patents concerning all such Inventions in such country in Licensee&#8217;s name. </font></div></td></tr></table><div><a name="s0A46A7B9D9B5E64A13253F810A5646E6"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">13.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Inventions:  Oncolytics Patent Filing</font><font style="font-family:inherit;font-size:11pt;">.  Oncolytics shall have the first right, at its cost, to prepare, file, prosecute, maintain and extend patent applications and patents concerning all Oncolytics Inventions and Joint Inventions throughout the world.  Oncolytics may solicit Licensee&#8217;s advice and review of the nature and text of any such patent applications to the extent such are related to a Licensed Product and important prosecution matters related thereto in reasonably sufficient time prior to filing thereof, and Oncolytics shall take into account Licensee&#8217;s reasonable comments related thereto.  If Oncolytics, prior or subsequent to filing patent applications on any Oncolytics Inventions relating to a Licensed Product anywhere in the Territory or a Joint Invention relating to Licensed Product anywhere in the Territory elects not to file, prosecute or maintain such patent applications or ensuing patents or subject matters encompassed by such patent applications or ensuing patents in any country of the world or outside the Territory, as the case may be, Oncolytics shall, subject to any Third Party rights existing at the Effective Date, give Licensee notice thereof within a reasonable period prior to allowing such patent applications or patents or such subject matters encompassed by such patent applications or patents to lapse or become abandoned or unenforceable, and Licensee shall thereafter have the right, at its sole expense, to prepare, file, prosecute and maintain patent applications and patents or divisional applications related to such subject matters encompassed by such patent applications or patents concerning all such Inventions in such country in Oncolytics&#8217; name for Oncolytics Inventions and in Oncolytics and Licensee&#8217;s joint names for Joint Inventions.</font></div></td></tr></table><div><a name="sFBB7AE4F49241F3E48793F810A92171F"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">13.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notification of Infringement</font><font style="font-family:inherit;font-size:11pt;">.  Each Party shall promptly notify the other Party of any actual or potential infringement of any Licensed Patent Rights by a Third Party in the Territory which comes to that Party&#8217;s attention during the term of this Agreement.  Each Party shall promptly notify the other Party upon receiving notification that any Licensed Patent Right in the Territory is subject to a declaratory judgment action alleging non-infringement, invalidity or unenforceability.</font></div></td></tr></table><div><a name="sA53DBD08C2EB2402316F3F810AB0F457"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">13.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Infringement in Territory</font><font style="font-family:inherit;font-size:11pt;">.  In the Territory, Oncolytics shall have the initial right, but not the obligation, using counsel of its choice at its own cost to enforce the Licensed Patent Rights in the Field or defend any declaratory action with respect thereto.  Oncolytics shall have sole control of any decisions or other aspects of the action, subject to Clause&#160;13.7, and Licensee shall, upon request, give Oncolytics such reasonable assistance as Oncolytics may reasonably request, including by signing or executing any necessary documents and consenting to its name being used in the proceedings; provided that Oncolytics shall reimburse Licensee for any reasonable out-of-pocket expenses incurred while providing such assistance and provide an indemnity in respect of any costs order made against Licensee by reason of lending its name to the proceedings. In this circumstance, Oncolytics shall reimburse Licensee for any reasonable out-of-pocket expenses incurred while providing such assistance, provided that Licensee provides written evidence to support such expenses.  Oncolytics shall keep Licensee reasonably informed of the progress of the action and shall consider the comments and observations of Licensee in prosecuting the action.  If Oncolytics does not institute any such action within ninety (90)&#160;days of a notice from Licensee requiring such action, then Licensee shall have the right, but not the obligation, at its own cost, to commence proceedings in the Territory regarding the infringement or declaratory judgment action, Licensee shall, subject to Clause&#160;13.7, have sole control of any decisions or other aspects of the action and Oncolytics shall, upon request, give to Licensee such reasonable assistance as Licensee may reasonably request provided that Licensee shall reimburse Oncolytics for any reasonable out-of-pocket expenses incurred while providing such assistance and that nothing in this Clause&#160;13.6 shall oblige Oncolytics to lend its name to, or be joined in, any proceedings commenced by Licensee pursuant to the foregoing, save for cases involving Joint Patents. In the event that Oncolytics determines not to exercise its rights under this Clause 13.6, Licensee shall have the right, but not the obligation, at its own cost, to commence proceedings in the Territory to enforce the Licensed Patent Rights in the Field or defend any declaratory judgment action with respect thereto, provided that Licensee shall notify Oncolytics in writing of its exercise of such rights as soon as commercially practicable and shall keep Oncolytics promptly informed of any material updates regarding such action. Licensee also have the right, but not the obligation, at its own cost, to commence proceedings in the Territory regarding the infringement or declaratory judgment action without informing Oncolytics in advance where the infringement may cause Licensee irreparable damage or there is an emergency.  If it is reasonably necessary for Licensee to add Oncolytics as a party plaintiff in any action or proceeding commenced by Licensee, Licensee shall indemnify Oncolytics against any and all costs and expenses incurred as a result.</font></div></td></tr></table><div><a name="s059C8451243B5BAB97883F810AE2789C"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">13.7</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Settlement</font><font style="font-family:inherit;font-size:11pt;">.  In no case shall Licensee, without the prior written consent of Oncolytics, make any admission or enter into a settlement, consent to judgment or other voluntary final disposition in connection with any such proceedings under this Clause&#160;13 that:  (i)&#160;extends, or purports to exercise, Licensee&#8217;s rights under any Licensed Patent Rights or Know How beyond the rights granted pursuant to this Agreement; (ii)&#160;makes any admission regarding wrongdoing by Oncolytics, an Affiliate or any licensee, or the invalidity, unenforceability or absence of infringement of any Licensed Patent Rights; (iii)&#160;subjects Oncolytics to an injunction or other equitable relief; or (iv)&#160;obligates Oncolytics to make a monetary payment; in all cases without the prior written consent of Oncolytics, which consent shall not be unreasonably withheld or delayed.  Similarly, in no case may Oncolytics enter into any settlement or consent judgment or other voluntary final disposition that:  (a)&#160;limits Licensee&#8217;s rights under this Agreement other than as expressly stated herein; (b)&#160;makes any admission regarding wrongdoing on the part of Licensee, an Affiliate or Sublicensee; (c)&#160;subjects Licensee to an injunction or other equitable relief; or (d)&#160;obligates Licensee to make a monetary payment; in all cases without the prior written consent of Licensee, which consent shall not be unreasonably withheld or delayed.</font></div></td></tr></table><div><a name="s311A5EB046F0D29CF22C3F810B005C2D"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">13.8</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Recovery</font><font style="font-family:inherit;font-size:11pt;">.  Any damages or award (including any award of costs) made in any proceedings referred to in this Clause&#160;13 shall be used first to reimburse each Party for any costs or expenses that it may have incurred in connection with the infringement proceedings (including without limitation, any amounts paid by the Party bringing the action to the other Party as reimbursement for expenses related to assisting in the proceedings) and any remaining amounts shall be retained by the Party to which they were awarded, save that any award paid to Licensee with respect to the Territory shall, following reimbursement of costs and expenses in accordance with the foregoing, be treated as Net Sales and royalties shall be paid on it to Oncolytics accordingly.</font></div></td></tr></table><div><a name="sBC61F12931CE0EF737933F810B322C0A"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">13.9</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Interferences and Other Proceedings</font><font style="font-family:inherit;font-size:11pt;">.  In the event that any Third Party interference, invalidation, infringement or opposition proceedings are commenced in the Territory against one of the Parties with respect to Licensed Patent Rights, or that a Party considers it desirable to contest interference proceedings with a Third Party in respect to such Patent Rights or to seek a declaration of non-infringement with regard to Licensed Product under any Third Party patent rights, the Parties shall consult with each other with a view to agreeing the strategy to be adopted.  To the extent that the validity, existence, inventorship or ownership of any of the Licensed Patent Rights is in issue in such proceedings, Oncolytics shall have the sole control of decisions and proceedings directly relating to those issues and Licensee, at its own cost, shall give Oncolytics such reasonable assistance as Oncolytics may reasonably request in the defense of such claims.  The cost of any such proceedings shall be borne by Oncolytics.</font></div></td></tr></table><div><a name="sBCD0EA003FEDA9FFBD083F810B50BE6B"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">13.10</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notice or Infringement Claims</font><font style="font-family:inherit;font-size:11pt;">.  If during the term of this Agreement any Party receives any notice of a Claim from any Third Party alleging infringement of that Third Party&#8217;s intellectual property by reason of manufacture, promotion, use or sale of Licensed Product, the Party receiving that notice shall, subject to any obligation of confidentiality that it may owe to a Third Party, forthwith notify the other Party of the Claim.</font></div></td></tr></table><div><a name="sE554EE6C7372E6DBDAD43F810B8933C5"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">13.11</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Product Marking</font><font style="font-family:inherit;font-size:11pt;">.  The Parties agree that, except where expressly prohibited by applicable Law or to the extent not commercially reasonable, Licensed Product, its packaging or both where appropriate shall bear the words &#8220;Patent Pending&#8221; together with the numbers of relevant patents granted in the country where Licensed Product is to be sold having one or more Valid Claims of any Licensed Patent Rights.</font></div></td></tr></table><div><a name="s9CC32C96076D804EC2FE3F810BA774D7"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TRADEMARKS</font></div></td></tr></table><div><a name="s0B3689F220BB3BD45F1A3F810BD98E91"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Ownership of Marks</font><font style="font-family:inherit;font-size:11pt;">.  Nothing in this Agreement shall operate to grant to Oncolytics any rights, title or interest in and to any Licensee House Mark nor authorize Oncolytics to affix any Licensee House Mark to any product except as expressly authorized by Licensee in writing.  Nothing in this Agreement shall operate to grant to Licensee any rights, title or interest in any Trademark belonging to Oncolytics nor to affix any Trademark belonging to Oncolytics to any product except as expressly authorized by Oncolytics in writing or as provided in Clauses&#160;14.3 and 14.4.</font></div></td></tr></table><div><a name="sB8393FC05202119864E33F810BF77AA9"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Ownership of Licensed Product Marks</font><font style="font-family:inherit;font-size:11pt;">.  The Parties acknowledge and agree that each Licensed Product Mark shall be applied for, and registered in the name of, Oncolytics and shall be owned by Oncolytics.  Upon request by Oncolytics and at Oncolytics&#8217; expense, Licensee shall undertake such acts as may be reasonably necessary to assign to Oncolytics or to otherwise perfect Oncolytics&#8217; rights, title and interests in and to any Licensed Product Marks.  Licensee agrees that any goodwill arising through the use of any Licensed Product Mark by Licensee in the Territory shall inure solely to the benefit of, and vest exclusively in, Oncolytics.</font></div></td></tr></table><div><a name="s2663948B7B8214A495C53F810C29A341"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Use of Licensed Product Marks</font><font style="font-family:inherit;font-size:11pt;">.  Licensee may use such Licensed Product Marks as are agreed by the Parties in writing in connection with the sale, use, marketing and promotion of Licensed Products in the Territory; provided that:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">14.3.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any Licensed Product Mark may be used only on the relevant Licensed Product and on no other products whatsoever; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">14.3.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">whenever a Licensed Product Mark is affixed to a Licensed Product it shall be accompanied by wording or clear marking by the use of the &#174; symbol to show where appropriate that the Licensed Product Mark in question has been registered as a trademark and in other cases by the suffix TM, however, the foregoing does not apply to regulatory filings or correspondence with Regulatory Authorities.</font></div></td></tr></table><div><a name="s2241F7ED868F849012B63F810C51C09B"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Registration of Licensed Product Marks</font><font style="font-family:inherit;font-size:11pt;">.  Oncolytics shall take all reasonable steps to register in Oncolytics&#8217; name the Licensed Product Marks at the relevant national trade mark offices and to maintain any such registration, including but not limited to paying all renewal fees, to keep its registration particulars up-to-update, to file for any necessary application for recording any trademark license for use of the Licensed Product Mark granted under this Agreement,  in the Territory at its own expense to maintain the validity of the Licensed Product Marks.  The Parties agree to consider any difficulties or issues that arise in the registration of any Licensed Product Mark in the Territory and to give the other all reasonable assistance in filing, prosecuting and maintaining a Licensed Product Mark, including in the provision of evidence for the validity and registrability of the Licensed Product Mark.  Oncolytics hereby grants to Licensee the right to place the relevant Licensed Product on the market under the relevant Licensed Product Mark in the Territory.</font></div></td></tr></table><div><a name="s542A9CE108638C41DDEF3F810C83AA91"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Infringement of Licensed Product Marks</font><font style="font-family:inherit;font-size:11pt;">.  In the event that either Party becomes aware of any actual or threatened infringement or misappropriation of any Licensed Product Mark by a Third Party in the Territory, that Party shall promptly inform the other of such infringement, and the Parties shall consult with each other in good faith to determine jointly the best way to prevent the infringement, including, without limitation, by instituting a legal proceeding against such Third Party.  Licensee shall have the sole right, at its own cost, to defend and enforce the Licensed Product Mark in the Territory and shall take such steps as it considers appropriate in the enforcement of the Licensed Product Mark, or in respect of any actual or threatened infringement of any Licensed Product Mark in the country in question.  If Licensee elects not to take any action which Oncolytics considers appropriate within thirty (30)&#160;days of being requested to do so by Oncolytics, Oncolytics shall have the right, at its own cost, to bring proceedings in its own and Licensee&#8217;s name in respect of such infringement.  The Party bringing proceedings in accordance with the foregoing shall have sole control of any decisions or other aspects of the action, subject to Clause&#160;14.7, and the other Party shall, upon request, give to the prosecuting Party such reasonable assurances as the prosecuting Party may reasonably request, including by signing or executing any necessary documents and consenting to its name being used in the proceedings; provided that the prosecuting Party shall reimburse the other Party for any reasonable out-of-pocket expenses incurred while providing such assistance.  The prosecuting Party shall keep the other Party reasonably informed of the progress of the action and shall consider the comments and observations of the other Party in prosecuting the action.</font></div></td></tr></table><div><a name="s47A1D81A73D230E73B563F810CA14401"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Recovery in respect of Infringement of Licensed Product Marks</font><font style="font-family:inherit;font-size:11pt;">.  Any and all amounts recovered with respect to infringement, unfair competition, passing off or misappropriation action brought by Oncolytics or Licensee under Clause&#160;14.5 shall be applied first to reimburse the Parties for their out-of-pocket expenses (including attorneys&#8217; fees) in prosecuting such action, or pro rata portions thereof if such expenses exceed the amount recovered.  The remainder shall be divided between the Parties as follows:  if the action concerns an Licensed Product Mark, with [**] going to the Party that funded the action and [**] going to the other Party.</font></div></td></tr></table><div><a name="s20C0A2F9304D55D402103F810CD3BBA8"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.7</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Settlements</font><font style="font-family:inherit;font-size:11pt;">.  In the event that any action or suit shall be brought against Oncolytics or Licensee in connection with the Licensed Product Marks for alleged infringement, unfair competition, passing off or misappropriation of a Third Party&#8217;s Trademark, neither Oncolytics nor Licensee shall, without the prior written consent of the other Party, enter into a settlement agreement that will restrict or limit the rights to the Licensed Product Mark granted to Licensee hereunder.</font></div></td></tr></table><div><a name="sD388993DFA5B004234F43F810CF119A8"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TERMINATION</font></div></td></tr></table><div><a name="s7C81FA9FDA02472882613F810D23D3C0"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">15.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Term of Agreement</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement shall come into effect on the Effective Date and terminate and be terminable only in accordance with this Clause&#160;15.  </font></div></td></tr></table><div><a name="sF31989C0B142D6B3076C3F810D4BAAA7"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">15.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination by Oncolytics for Patent Challenge</font><font style="font-family:inherit;font-size:11pt;">.  To the extent permitted by applicable Law, Oncolytics may terminate this Agreement on thirty (30)&#160;days notice if Licensee, directly or indirectly, challenges or contests or assists a Third Party to challenge or contest the validity of any of the Licensed Patent Rights, except for a challenge or contest by Licensee if Oncolytics has infringed the Patent Rights and Know-How of Licensee. </font></div></td></tr></table><div><a name="s62A9D279A49536BA45AA3F810D7D4882"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">15.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination for Breach</font><font style="font-family:inherit;font-size:11pt;">.  Either Oncolytics on the one hand or Licensee on the other hand (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Terminating Party</font><font style="font-family:inherit;font-size:11pt;">&#8221;) shall have the right to terminate this Agreement in accordance with the following provisions of this Clause&#160;15.3 in the event that Licensee or Oncolytics, respectively, commits a material breach of this Agreement, including material breach of a Development Plan, or any Related Agreement.  The non-breaching Party shall provide written notice to the Party that committed the breach (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Defaulting Party</font><font style="font-family:inherit;font-size:11pt;">&#8221;), which notice shall clearly describe the nature of the breach.  The Defaulting Party shall have ninety (90)&#160;days to cure the breach.  If the Defaulting Party fails to cure the breach within such ninety (90)&#160;day period, then the Agreement shall terminate effective on the expiry of the relevant cure period.  The foregoing notwithstanding, the cure period for breach by the Defaulting Party of an obligation to make a payment when properly due pursuant to Clause&#160;11.1 shall be thirty (30)&#160;days; provided, however, [**].</font></div></td></tr></table><div><a name="s17352169C794AF6B97393F810D9BA759"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">15.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insolvency</font><font style="font-family:inherit;font-size:11pt;">.  Either Party shall have the right to terminate this Agreement forthwith upon giving written notice of termination to the other Party (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Insolvent Party</font><font style="font-family:inherit;font-size:11pt;">&#8221;) upon the occurrence of any of the following events:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">15.4.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Insolvent Party suspends or threatens to suspend payment of its debts as they fall due in circumstances where the Insolvent Party is unable to pay its debts within the meaning of the relevant bankruptcy or insolvency laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">15.4.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the failure to discharge or dismiss a petition for the winding-up of the Insolvent Party within sixty (60)&#160;days after the filing thereof;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">15.4.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a proposal is made or a nominee or supervisor is appointed for a composition in satisfaction of the debts of the Insolvent Party or a scheme or voluntary arrangement of its affairs within the meaning of the relevant bankruptcy or insolvency laws, or the Insolvent Party enters into any composition or voluntary arrangement for the benefit of its creditors, or proceedings are commenced in relation to the Insolvent Party under any Law relating to the re-construction, deferment or re-adjustment of all or substantially all of the Insolvent Party&#8217;s debts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">15.4.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Insolvent Party takes any action, or any legal proceedings are started whether by a Third Party or not, for the purpose of the winding up or dissolution of the Insolvent Party, other than for a solvent reconstruction or amalgamation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">15.4.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the appointment of a liquidator, trustee, receiver, administrative receiver, receiver and manager, interim receiver custodian, sequestrator or similar officer, in respect of all or a substantial part of the assets of the Insolvent Party;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">15.4.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">an effective resolution being passed for the winding-up of the Insolvent Party;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">15.4.7</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a distress, execution or other legal process being levied against all or substantially all of the assets of the Insolvent Party, and not being discharged or paid out in full within ten (10)&#160;Business Days;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">15.4.8</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the occurrence in respect of the Insolvent Party of any event in any jurisdiction to which it is subject having an effect similar to that of any of the events referred to in Clauses&#160;15.4.1-15.4.7 above; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">15.4.9</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Insolvent Party ceases or threatens to cease to carry on all or a substantial part of its business or operations necessary for the completion of its obligations under this Agreement.</font></div></td></tr></table><div><a name="s4ADE6DB22CEB0D5CC3303F810DCD0B71"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">15.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Competing Product Divestment</font><font style="font-family:inherit;font-size:11pt;">.  In the event Licensee or an Affiliate of Licensee consummates a corporate transaction (whether by way of asset acquisition or share acquisition) that results in Licensee or an Affiliate of Licensee acquiring rights (whether by way of corporate transaction, ownership or license) from a Third Party to develop, import, market, manufacture, promote, distribute, offer for sale or sell any therapy based on oncolytic viruses selectively replicating in cancer cells in the Field in any country in the Territory (an &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Acquired Competing Product</font><font style="font-family:inherit;font-size:11pt;">&#8221;), [**].</font></div></td></tr></table><div><a name="sFA1ECC12491979F1B7793F810DEB7CF2"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSEQUENCES OF TERMINATION</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">16.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Upon a termination of this Agreement:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">16.1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination of Rights</font><font style="font-family:inherit;font-size:11pt;">.  All of the rights of Licensee under this Agreement shall terminate upon the Termination Date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">16.1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Intellectual Property After Termination</font><font style="font-family:inherit;font-size:11pt;">.  If this Agreement has been terminated by Oncolytics pursuant to Clause 15.3 (breach of this Agreement by Licensee), Clause 15.4 (insolvency of Licensee) or Clause 15.2 (patent challenge by Licensee), Licensee shall grant Oncolytics a non-exclusive, fully-paid-up license with the right to grant sublicenses in and to any Patent Rights or Know-How controlled by it which are necessary for the development, manufacturing or commercialization of Licensed Products for the purpose of the further development and exploitation of Licensed Products. The Parties shall continue to be obliged to continue providing the support and assistance in relation to any litigation concerning infringement of Patent Rights or infringement of Licensed Product Marks in the relevant country in the Territory that had been initiated pursuant to Clauses&#160;13 and 14 prior to the Termination Date and not settled as of the Termination Date.  Licensee shall have no further obligation to pay for, or support, filing, prosecutions, maintenance or defense of Patent Rights or Licensed Product Marks in the relevant country in the Territory as set out in Clauses&#160;13 and 14.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">16.1.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Licensed Product Marks After Termination</font><font style="font-family:inherit;font-size:11pt;">.  To the extent not already done under the terms of Clause&#160;14.2, Licensee shall assign to Oncolytics, free of all encumbrances all of its, and its Affiliates, distributors and sub-licensees (if any) interest in and to any Licensed Product Marks in the relevant country in the Territory within thirty (30)&#160;days of termination of this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">16.1.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Supplies of Products After Termination</font><font style="font-family:inherit;font-size:11pt;">. Licensee and its Affiliates and permitted Sublicensees shall have the right, for a period of up to [**] following such termination, to sell (in the Field and in the relevant country in the Territory) stocks of Licensed Product in its possession at the time of such termination (for which a Marketing Authorization in the Field in the relevant country in the Territory has been approved prior to such termination), subject to all applicable payment and other related obligations in this Agreement.  Upon expiration of such [**] period, Licensee shall deliver up to Oncolytics or its designee in the Territory, at the breaching Party&#8217;s cost, any and all remaining quantities of any Licensed Product in its possession or control.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">16.1.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Clinical Studies After Termination</font><font style="font-family:inherit;font-size:11pt;">.  Licensee has the right, but not the obligation, to decide whether to complete (in accordance with the established protocols) any Clinical Studies on Licensed Product that were commenced prior to the termination of this Agreement.  Commencement shall mean the point at which the first study subject has been dosed with Licensed Product.  Should Licensee decide to terminate or cease to proceed with a Clinical Study that has already commenced, Licensee shall comply with all applicable Laws, including, without limitation, current good laboratory practices, Good Clinical Practice and safety standards in connection with such termination or cessation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">16.1.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Transfer of Regulatory Approvals After Termination</font><font style="font-family:inherit;font-size:11pt;">.  If this Agreement has been terminated by Oncolytics pursuant to Clause 15.3 (breach of this Agreement by Licensee), Clause 15.4 (insolvency of Licensee) or Clause 15.2 (patent challenge by Licensee), Licensee shall, to the extent permitted by applicable Law, promptly transfer, to Oncolytics or to its designee, all Regulatory Approvals relating to each Licensed Product in the relevant country in the Territory, together with any applications for Regulatory Approvals (including BLAs or other such applications, as well as all existing and planned INDs, approvals to develop, market and sell Licensed Products, pricing approvals and other similar regulatory filings in the relevant country in the Territory with respect to any Licensed Product) together with all documents relating thereto and all Regulatory Confidential Information.  All such transfers shall be completed in accordance with applicable Laws.  In the event that such a transfer is not possible, Licensee shall use reasonable endeavors to ensure that Oncolytics or its designee has the benefit of the existing Regulatory Approvals and applications for the same for Licensed Products in the Territory, including, without limitation, granting Oncolytics or its designees rights to cross-reference the data and information on file with Regulatory Authorities in the relevant country in the Territory as may be necessary to facilitate the granting of separate Regulatory Approvals to Oncolytics.  </font><font style="font-family:inherit;font-size:11pt;">If this Agreement has been terminated by Licensee pursuant to Clause 15.3 (breach of this Agreement by Oncolytics) or Clause 15.4 (insolvency of Oncolytics), Licensee has the right to maintain all the aforesaid approvals and Oncolytics shall compensate all the cost of applying for the aforesaid approvals and damages.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">16.1.7</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Return of Confidential Information After Termination</font><font style="font-family:inherit;font-size:11pt;">.  Upon termination for any reason, Licensee shall, at Oncolytics&#8217; option, either return to Oncolytics all tangible Confidential Information disclosed to Licensee by or on behalf of Oncolytics (including all copies thereof) or destroy under oath such Confidential Information; provided that Licensee shall have the right to retain one (1)&#160;copy of the Confidential Information in a secure location solely for purposes of identifying its confidentiality obligations under Clause&#160;17.  Upon termination by Licensee pursuant to Clause&#160;15.3 or 15.4, Licensee shall use reasonable endeavors to delete all electronic copies of such Confidential Information from its systems.  Upon termination, Oncolytics shall, at Licensee&#8217;s option, either return to Licensee all tangible Confidential Information disclosed to Oncolytics by or on behalf of Licensee (including all copies thereof) or destroy such Confidential Information; provided that Oncolytics shall have the right to retain one (1)&#160;copy of the Confidential Information in a secure location solely for purposes of identifying its confidentiality obligations under Clause&#160;17.  Oncolytics shall use reasonable endeavors to delete all electronic copies of such Confidential Information from its systems.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">16.1.8</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Return of Virus Seed Banks</font><font style="font-family:inherit;font-size:11pt;">.  Upon termination for any reason, Licensee shall, at Oncolytics&#8217; option, either destroy or return to Oncolytics all master and working virus seed banks provided to Licensee by or on behalf of Oncolytics.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">16.1.9</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Provision of Promotional and Marketing Materials, Information and Records After Termination</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall provide to Oncolytics a copy of all promotional and marketing materials used in the promotion of Licensed Products (including the Licensed Product) together and hereby grants a license to Oncolytics in the Territory, effective as of the date of termination, to use and create any such materials, copies or derivative works thereof in Oncolytics&#8217; promotion of Licensed Products; provided that such license does not extend to use of any tradename, Trademark or service mark of Licensee.  Oncolytics shall be entitled to sublicense such rights to any Third Party it grants the right to market Licensed Products in the Territory.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">16.1.10</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Distribution Services After Termination</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall, at Oncolytics&#8217; request provide distribution services to Oncolytics in relation to Licensed Products for such period as Oncolytics determines (but in any event to be no more than six (6)&#160;months).  Licensee shall provide the distribution services through the same channels as it distributed Licensed Products prior to the termination of this Agreement and to the same standard as it applied prior to the termination of this Agreement.  Oncolytics shall pay Licensee an amount equal to [**] of its net sales of such Licensed Product in the relevant country in the Territory (calculated on the same basis as set out in the Net Sales definition set out above) in consideration of the provision of these services.</font></div></td></tr></table><div><a name="s364B9E693BFE539297833F810E1DB911"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">16.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Accrued Rights</font><font style="font-family:inherit;font-size:11pt;">.  The expiration or earlier termination of this Agreement for whatever reason shall not affect any rights or obligations of the Parties arising in any way out of this Agreement which are accrued prior to the Termination Date, including, without limitation, the right to recover damages against the other Party for any breach of this Agreement occurring prior to such termination.</font></div></td></tr></table><div><a name="s37CBE719568C886B21CA3F810E45E02F"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">16.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Surviving Clauses</font><font style="font-family:inherit;font-size:11pt;">.  In the event of expiry or termination of this Agreement for any reason the provisions of Clauses 1, 8.6, 9, 11.3, 11.4, 11.5, 12.1-12.4, 12.6, 15, 17, and 19-33 shall remain in full force and effect.</font></div></td></tr></table><div><a name="s6417B3694283EA58333C3F810E7727B0"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">16.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Related Agreements</font><font style="font-family:inherit;font-size:11pt;">.  The Supply Agreement shall terminate on the same date as termination of this Agreement subject to the provisions of the Supply Agreement dealing with the consequences of termination.  The Pharmacovigilence Agreement shall survive pursuant to its own terms after termination of this Agreement.</font></div></td></tr></table><div><a name="s03BC725D798B87133F1F3F810E95A687"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONFIDENTIALITY</font></div></td></tr></table><div><a name="sDB4E41DE53DC5D48D0283F810EC7927A"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">17.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Confidential Information</font><font style="font-family:inherit;font-size:11pt;">.  Prior to the Effective Date and during the term of this Agreement, each Party (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Disclosing Party</font><font style="font-family:inherit;font-size:11pt;">&#8221;) may disclose or make available to the other Party (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Receiving Party</font><font style="font-family:inherit;font-size:11pt;">&#8221;) confidential materials and information, either orally or in writing, related to its products, technology, research plans, testing protocols, formulations, business methods and practices, information about the expertise of employees and consultants, other technical, business, financial, customer and product development plans, training materials and methods of training, identity and location of existing and prospective customers, supplier information, forecasts, strategies and similar information, financial information, inventions, processes, Know How, methods, products, patent applications, specifications, drawings, sketches, models, samples, designs, ideas, technical information, and all other confidential business information and trade secrets, including without limitation the Research Materials defined in Clause 5.1 of this Agreement (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Confidential Information</font><font style="font-family:inherit;font-size:11pt;">&#8221;).  This Agreement shall supersede the confidentiality agreement entered into by the Parties on July 4, 2017, and any and all confidential information that was disclosed by a Party to the other Party thereunder shall be deemed to be Confidential Information of the Disclosing Party under this Agreement.  All Clinical Data shall be treated as the Confidential Information of and disclosed by Oncolytics notwithstanding that it may have been generated and disclosed by Licensee.  Any and all Confidential Information is and shall remain the property of the Disclosing Party.</font></div></td></tr></table><div><a name="s13C5E8E02C4C4643FC1A3F810EE5BE85"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">17.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Confidentiality Obligations</font><font style="font-family:inherit;font-size:11pt;">.  Each Party undertakes and agrees that except as otherwise expressly permitted pursuant to this Agreement it shall not, and shall ensure that its Affiliates do not, disclose or permit to be disclosed to any Third Party (other than Agents of the Receiving Party or its Affiliates), or use or permit the use for any purpose other than in performance of its obligations under this Agreement, any of the other Party&#8217;s Confidential Information.  The obligations of confidentiality and non-use set forth in this Clause&#160;17.2 are subject to the exceptions set forth in Clause&#160;17.4 and shall otherwise remain in effect during the term of this Agreement and for a period of fifteen (15)&#160;years after the expiration or earlier termination of this Agreement.</font></div></td></tr></table><div><a name="s9C5DD93981CDB2D063E93F810F17F4C6"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">17.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Internal Disclosure of Confidential Information</font><font style="font-family:inherit;font-size:11pt;">.  The Receiving Party shall ensure that the Disclosing Party&#8217;s Confidential Information is only disclosed or made available to those of its and its Affiliates&#8217; officers, directors, employees, agents and consultants (collectively &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Agents</font><font style="font-family:inherit;font-size:11pt;">&#8221;) who are directly concerned with the performance or exercise of one or more of such Party&#8217;s rights or obligations under this Agreement and who have a genuine operational need to know.  The Receiving Party shall inform its Agents, prior to any such disclosure, of the confidential nature of the Disclosing Party&#8217;s Confidential Information, and shall be responsible for any breach of these confidentiality provisions by its Agents.</font></div></td></tr></table><div><a name="s197C47A9140026B11DA63F810F3FEAAD"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">17.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exceptions</font><font style="font-family:inherit;font-size:11pt;">.  The Receiving Party&#8217;s confidentiality and non-use obligations under this Clause&#160;17.4 shall not extend to any of the Disclosing Party&#8217;s Confidential Information which:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">17.4.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">is at the time of disclosure, or thereafter becomes, generally available to the public other than by reason of a breach by the Receiving Party of the provisions of this Clause&#160;17.4.1; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">17.4.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">is known to the Receiving Party prior to its receipt from the Disclosing Party, as can be shown by written record; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">17.4.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">is lawfully disclosed to the Receiving Party by an independent Third Party without obligations of confidence to the Disclosing Party; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">17.4.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">is independently developed by the Receiving Party or its Affiliates without the application, aid or use of the Disclosing Party&#8217;s Confidential Information, as demonstrated by the Receiving Party&#8217;s written records.</font></div></td></tr></table><div><a name="sE47FA660C4FFFFD5F0C83F810F71B474"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">17.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Disclosure Required by Law</font><font style="font-family:inherit;font-size:11pt;">.  If the Receiving Party is compelled by a court, government regulatory agency or requirement of a stock exchange to disclose any Confidential Information, the Receiving Party will provide the Disclosing Party with prompt written notice in order to permit the Disclosing Party to seek a protective order, or other appropriate remedy, or to waive compliance with the provisions of this Agreement.  If such a protective order or other remedy is not obtained or compliance is not waived, the Receiving Party will furnish only that portion of the Confidential Information required by the court, government regulatory agency or stock exchange requirement.</font></div></td></tr></table><div><a name="sB65EF41F8114E79956133F810F8F6035"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">17.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Permitted Use and Disclosures</font><font style="font-family:inherit;font-size:11pt;">.  The Receiving Party may disclose the Disclosing Party&#8217;s Confidential Information to Regulatory Authorities to the extent that such disclosure is reasonably necessary to exercise any rights under this Agreement to develop, manufacture or commercialize Licensed Products in the Field in the Territory.  Further, a Party may disclose (a)&#160;the existence and terms of this Agreement to existing or potential investors or acquirers or merger partners, or to professional advisors (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:11pt;">, attorneys, accountants and prospective investment bankers) involved in such activities, for the limited purpose of evaluating such investment or transaction and under appropriate conditions of confidentiality, only to the extent reasonably necessary and (b)&#160;the existence and terms (other than financial terms) of this Agreement to actual or bone fide potential Sub-licensees (in the case of disclosure by Licensee) or actual or bone fide potential licensees in the case of Oncolytics, in each of cases (a)&#160;and (b)&#160;above with the agreement by these permitted persons to maintain such Confidential Information in strict confidence.</font></div></td></tr></table><div><a name="sBEF8B0337FF2AA1ACA123F810FC180BF"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WARRANTIES</font></div></td></tr></table><div><a name="s15CCC676D60E7B26EE803F810FDFB44B"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">18.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Warranties</font><font style="font-family:inherit;font-size:11pt;">.  Each Party hereby represents and warrants to the other Party that, as of the Effective Date:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">it is duly organized and validly existing under the Laws of its place of incorporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">it has legal power, authority and right to enter into this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(iii)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">the execution and performance by it of its obligations hereunder will not constitute a breach of, or conflict with, its organizational documents nor any other material agreement or arrangement, whether written or oral, by which it is bound;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(iv)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">it has full corporate power and authority and has taken all corporate action necessary to enter into and perform this Agreement, and that this Agreement has been duly authorized, executed, and delivered by that Party; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(v)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">that this Agreement is a valid, binding, and legally enforceable obligation of that Party (subject to applicable laws of bankruptcy and moratorium).</font></div></td></tr></table><div><a name="s8F4E4EB5E561499C520A3F811011EE2B"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">18.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Warranties by Oncolytics.</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;Oncolytics represents and warrants to Licensee:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">Oncolytics is the owner of the Licensed Patents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">the Licensed Patents are in good standing and all maintenance fees in respect of the Licensed Patents have been paid;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(iii)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">Oncolytics has not received any written claim alleging that the development, manufacture, use or sale of Licensed Products would infringe any Third Party Intellectual Property Rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(iv)</font></div></td><td style="vertical-align:top;padding-left:2.6666666666666665px;"><div style="line-height:180%;text-align:justify;font-size:12pt;text-indent:-2.6666666666666665px;"><font style="font-family:inherit;font-size:12pt;">Oncolytics has the authority to grant the licenses set out in Clause 3.1.</font></div></td></tr></table><div><a name="sB5E057D196F5ED376ED93F811039CEAC"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">18.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Undertaking by Licensee</font><font style="font-family:inherit;font-size:11pt;">.  Additionally, Licensee hereby undertakes to Oncolytics that (i) it will not use in any capacity, in connection with any activities to be performed under this Agreement, any individual who has been debarred pursuant to the U.S. Federal Food, Drug and Cosmetic Act, or excluded from a federal healthcare program in the U.S., and (ii) it will at all times comply with all applicable Laws relating or pertaining to its obligations under this Agreement. </font></div></td></tr></table><div><a name="s8AC991643C9BA3AC216D3F81106BE242"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">18.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Implied Warranties</font><font style="font-family:inherit;font-size:11pt;">.  The representations and warranties provided in this Clause&#160;18.4 are in lieu of any other representations or warranties, express or implied, and to the fullest extent permitted by the applicable Law, nothing herein shall be construed as a representation or warranty by either Party of any kind, including without limitation, any implied warranty of fitness for a specific purpose or merchantable quality, all of which are expressly and specifically excluded.</font></div></td></tr></table><div><a name="s9EB409A6F2149288C67D3F811089BC5E"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">18.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Warranties of Patent Rights</font><font style="font-family:inherit;font-size:11pt;">.  To the fullest extent permitted by the applicable Law, nothing in this Agreement shall be construed as a representation made or warranty given by any Party (i)&#160;that any patent will issue after the Effective Date based upon any pending patent application included in the Licensed Patent Rights, or (ii)&#160;that any granted patent which issues from such pending patent applications will be valid and enforceable, or (iii)&#160;that after the Effective Date the manufacture, use or sale of Licensed Product or the use of any Oncolytics&#8217; intellectual property will not infringe the patent or proprietary rights of any Third Party. </font></div></td></tr></table><div><a name="s2D2FEBD952242BB3465A3F8110BB0C9E"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">18.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Further Representations or Warranties</font></div></td></tr></table><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No director, officer, employee or agent of any Party or its Affiliates is authorized to make any further representation or warranty to the other Party which is not contained in this Agreement, and each Party acknowledges that it has not relied on any such oral or written representations or warranties.</font></div><div><a name="s2D0E33B3520F377330E93F8110D9198B"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LIABILITY AND INDEMNITIES</font></div></td></tr></table><div><a name="s3E73B0067B350313F8CE3F81110B6C41"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">19.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Consequential Damages</font><font style="font-family:inherit;font-size:11pt;">.  Subject to Clause&#160;19.7, but otherwise notwithstanding any other provision of this Agreement, neither Party shall be liable to the other Party or to any Affiliate of the other Party for any lost profits, business opportunities, special, indirect, consequential, exemplary, or punitive damages of any nature arising under or in relation to this Agreement even if that Party was advised in advance of the possibility of such loss or damage.</font></div></td></tr></table><div><a name="s2912E0C7123F6F15A4C43F811133B2FC"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">19.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnification by Licensee</font><font style="font-family:inherit;font-size:11pt;">.  Licensee shall, subject to Clause&#160;19.1, indemnify, defend and hold harmless Oncolytics, its Affiliates, and its and their respective directors, officers, employees and agents (collectively the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Oncolytics Indemnified Parties</font><font style="font-family:inherit;font-size:11pt;">&#8221;) against any and all Claims, causes of action, demands, liabilities, losses, damages, costs or expenses, including reasonable attorneys&#8217; fees asserted by a Third Party (each a &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Loss</font><font style="font-family:inherit;font-size:11pt;">&#8221;) to the extent such Loss arose out of or was caused by:  (a)&#160;the development, distribution, marketing, promotion or sale of Licensed Products by or on behalf of Licensee or its Affiliates or Sublicensees; (b)&#160;any breach or alleged breach of a warranty made by Licensee in this Agreement or any Related Agreement; (c) any breach or alleged breach of any covenant or obligation required to be performed by Licensee contained in this Agreement or any Related Agreement; (d) a negligent act or omission or willful misconduct by Licensee, its Affiliates or Sublicensees in the performance of its obligations under this Agreement or any Related Agreement; or (e) the violation by Licensee of any Regulatory Approval involving the Licensed Product; except, in all cases, to the extent that such Loss arises out of the negligence or willful misconduct of Oncolytics.</font></div></td></tr></table><div><a name="sA04DA687A9F75AA75C0E3F8111657E33"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">19.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnification by Oncolytics</font><font style="font-family:inherit;font-size:11pt;">.  Oncolytics shall, subject to Clause&#160;19.1, indemnify, defend and hold harmless Licensee, its Affiliates, and its and their respective, directors, officers, employees and agents (collectively the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Licensee Indemnified Parties</font><font style="font-family:inherit;font-size:11pt;">&#8221;) against any and all Losses incurred or suffered by the Licensee Indemnified Parties to the extent such Loss was caused by (a)&#160;any breach or alleged breach of a warranty made by Oncolytics in this Agreement or any Related Agreement; (b) any breach or alleged breach of any covenant or obligation required to be performed by Oncolytics contained in this Agreement or any Related Agreement; or (c) a negligent act or omission or willful misconduct by Oncolytics or its Affiliates in the performance of its obligations under this Agreement or any Related Agreement; except, in all cases, to the extent that such Loss arises out of the negligence or willful misconduct of Licensee.</font></div></td></tr></table><div><a name="sFF849B165EAABA042E4D3F811183EAA1"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">19.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notification of Liabilities/Losses</font><font style="font-family:inherit;font-size:11pt;">.  A person or entity entitled to indemnification under this Clause&#160;19.4 (an &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Indemnified Party</font><font style="font-family:inherit;font-size:11pt;">&#8221;) shall give prompt written notification (within twenty (20)&#160;days) to the Party from whom indemnification is sought (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Indemnifying Party</font><font style="font-family:inherit;font-size:11pt;">&#8221;) of the commencement or notice of Loss for which indemnification may be sought or, if earlier, upon the assertion of any such Loss (it being understood and agreed, however, that the failure by an Indemnified Party to give notice of a Loss as provided in this Clause&#160;19.4 shall not relieve the Indemnifying Party of its indemnification obligation under this Agreement except, and only, to the extent that such Indemnifying Party is materially prejudiced as a result of such failure to give notice).  The Indemnifying Party shall be liable for any reasonable legal fees and expenses subsequently incurred in connection with the defence of such Loss after receiving such notice.  The Parties shall thereafter keep the other Party informed of any Losses or threatened Losses (as described in Clauses&#160;19.2 and 19.3).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">19.4.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the case of a Loss for which Oncolytics seeks indemnification under Clause&#160;19.2, Oncolytics shall permit Licensee to direct and control the defense of the Loss and shall provide such reasonable assistance as is reasonably requested by Licensee (at Licensee&#8217;s cost) in the defense of the Loss; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;that nothing in this Clause&#160;19.4.1 shall permit Licensee to make any admission on behalf of Oncolytics, or to settle any Claim or litigation which would impose any financial obligations on Oncolytics or would result in any loss or diminution of the scope, validity or enforceability of the Licensed Patent Rights or a Joint Invention without the prior written consent of Oncolytics, such consent not to be unreasonably withheld or delayed.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">19.4.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the case of a Loss for which Licensee seeks indemnification under Clause&#160;19.3, Licensee shall permit Oncolytics to direct and control the defense of the Loss and shall provide such reasonable assistance as is reasonably requested by Oncolytics (at Oncolytics&#8217; cost) in the defense of the Loss, provided always that nothing in this Clause&#160;19.4.2 shall permit Oncolytics to make any admission on behalf of Licensee, to settle any Claim or litigation which would impose any financial obligations on Licensee or would result in any loss or diminution of the scope, validity or enforceability of a Joint Patent without the prior written consent of Licensee, such consent not to be unreasonably withheld or delayed.</font></div></td></tr></table><div><a name="s27D74E571C0F07A0320E3F8111B5A0DB"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">19.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Supply</font><font style="font-family:inherit;font-size:11pt;">.  The indemnities in this Agreement shall not apply to the supply of Licensed Products which shall be governed by the Supply Agreement which will provide for the manufacturer of Licensed Products to bear certain liabilities on terms to be agreed for Losses for product liability Claims arising out of the negligent manufacture or supply of those Licensed Products.</font></div></td></tr></table><div><a name="sC56492E5404388E1A0153F8111D335AA"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">19.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Mitigation</font><font style="font-family:inherit;font-size:11pt;">.  Any Party making a Claim under this Clause&#160;19.6 shall take all reasonable steps to mitigate and minimize the Losses suffered and shall not do anything nor fail to do some thing which would have the effect of increasing the Losses.</font></div></td></tr></table><div><a name="s29FB64516AFDC851F9053F811205109A"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">19.7</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Restriction on Limitation of Liability</font><font style="font-family:inherit;font-size:11pt;">.  Neither Party limits or excludes its liability for fraud, fraudulent concealment or fraudulent misrepresentation, nor for death or personal injury arising from its negligence, nor for losses to the property of the other Party arising from its willful misconduct or gross negligence.</font></div></td></tr></table><div><a name="s3EF32B81A9C12F86778A3F81122D1A64"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">19.8</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insurance</font><font style="font-family:inherit;font-size:11pt;">.  During the term of this Agreement and thereafter for a period of five (5) years, each Party shall maintain comprehensive general liability insurance, and product liability coverage, in such amount as is required by applicable Law or as may be consistent with market practice in the relevant jurisdiction for biopharmaceutical businesses of similar size and capabilities.  Oncolytics may, upon the approval of the JSC, require that the Licensee maintain a higher amount of insurance coverage.  Upon request, the insured Party shall provide the other Party with a certificate of insurance as evidence of the requested coverage and shall notify the other Party within thirty (30)&#160;days of any cancellation or termination of such insurance. </font></div></td></tr></table><div><a name="s8D0F8B1115A32EB033663F81125FA6D4"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WAIVER</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">20.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Neither Party shall be deemed to have waived any of its rights or remedies under this Agreement unless the waiver is expressly made in writing and signed by a duly authorized representative of that Party.  In particular, no delay or failure of any Party in exercising or enforcing any of its rights or remedies under this Agreement shall operate as a waiver of those rights or remedies or so as to preclude or impair the exercise or enforcement of those rights or remedies nor shall any partial exercise or enforcement of any right or remedy by any Party preclude or impair any other exercise or enforcement of that right or remedy by that Party.</font></div></td></tr></table><div><a name="s99F18AE1681441F97E463F81127D1ED4"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ENTIRE AGREEMENT/VARIATIONS</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">21.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement, together with the Related Agreements, and any Schedules or other attachments hereto or thereto, constitutes the entire agreement and understanding between the Parties relating to the subject matter hereof, and together they supersede and replace all prior drafts, previous understandings, arrangements, representations or agreements, whether in writing or oral, between the Parties relating to the subject matter of this Agreement.  For the avoidance of doubt, the confidentiality agreement entered into between the Parties made on July 4, 2017 as amended by the Parties has been superseded by the provisions of Clause&#160;17.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">21.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">No variation, amendments, modification or supplement to this Agreement shall be valid unless and until it is made in writing in the English language and signed by a duly authorized representative of each Party.</font></div></td></tr></table><div><a name="s43E0AC3812380E0207803F8112AFF68E"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">22.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTICES</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">22.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Any notice to be given pursuant to this Agreement shall be in writing in the English language and shall be delivered by overnight courier, by registered, recorded delivery or certified mail (postage prepaid) or by facsimile confirmed by registered, recorded delivery or certified mail (postage prepaid) to the address or facsimile number of the recipient Party set out below or such other address or facsimile number as a Party may from time to time designate by written notice to the other Party.</font></div></td></tr></table><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:114px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Address of Oncolytics</font></div><div style="line-height:120%;text-align:justify;padding-left:114px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Oncolytics Biotech (Barbados) Inc.</font></div><div style="line-height:120%;text-align:justify;padding-left:114px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Floor, Hastings House, </font></div><div style="line-height:120%;text-align:justify;padding-left:114px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Balmoral Gap, Hastings,</font></div><div style="line-height:120%;text-align:justify;padding-left:114px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Christ Church, Barbados WI, BB14034</font></div><div style="line-height:120%;text-align:justify;padding-left:114px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:114px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention: </font><font style="font-family:inherit;font-size:12pt;">Managing Director</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:114px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">and a copy to </font></div><div style="line-height:120%;text-align:justify;padding-left:114px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Oncolytics Biotech Inc.</font></div><div style="line-height:120%;text-align:justify;padding-left:113px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">210, 1167 Kensington Crescent NW</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:114px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Calgary, AB, Canada T2N 1X7</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:114px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention: President and Chief Executive Officer</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:113px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Address of Licensee</font></div><div style="line-height:176%;text-align:left;padding-left:113px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ADLAI NORTYE BIOPHARMA CO., LTD.&#160;</font></div><div style="line-height:176%;text-align:left;padding-left:113px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">21 Floor, Building 2, No.452, 6th St.</font></div><div style="line-height:176%;text-align:left;padding-left:113px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Hangzhou Eco. &amp; Tech. Development Area</font></div><div style="line-height:176%;padding-bottom:8px;text-align:left;padding-left:113px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">310018, PRC</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:113px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attention: Vice President, Business Development</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">22.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Any notice given pursuant to this Clause&#160;22 shall be deemed to have been received:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">22.2.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">in the case of delivery by courier or sending by mail on the day of receipt provided receipt occurs on a Business Day of the recipient Party or otherwise on the next following Business Day of the recipient; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">22.2.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">in the case of facsimile, on acknowledgement by the recipient facsimile receiving equipment on a Business Day if the acknowledgement occurs before 5.00&#160;pm local time of the recipient and in any other case on the next following Business Day.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">22.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Any notice that is required in this Agreement to be given in writing may be given by personal delivery, fax or post but shall not be effective if given by e-mail.</font></div></td></tr></table><div><a name="s89D75E6B3725AB4DC3853F8112CD85C6"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">23.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AFFILIATES, ETC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">23.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Party may have one or more Affiliates perform or otherwise act on its behalf under this Agreement.  Each Party shall be responsible for the compliance by its Affiliates performing or otherwise acting under this Agreement on its behalf with the terms and conditions of this Agreement.</font></div></td></tr></table><div><a name="s8DDC6E6526BD458100083F8112FF8A07"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">24.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ASSIGNMENT</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">24.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Neither Party shall, without the prior written consent of the other Party, assign, novate, transfer or convey this Agreement (in whole or in part) or any of its rights and obligations hereunder to any Third Party; provided always that either Party may assign or novate this Agreement (in whole or in part) to any Affiliate or to a successor to substantially all of the business of the assigning Party relating to Licensed Products whether in a merger, sale of stock, sale of assets or otherwise, without such consent; subject only to the assigning or novating Party giving written notice to the non-assigning Party and the party to which this Agreement is assigned or novated entering into a direct undertaking with the non-assigning or novating Party to be bound by the terms of this Agreement.  Any assignment, novation, transfer or conveyance of this Agreement or any part of it in breach of this Clause&#160;24.1 shall be ineffective and void from the beginning.</font></div></td></tr></table><div><a name="s3657C67822374D51C1323F8113273653"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">25.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORCE MAJEURE</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">25.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If a Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Non-Performing Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is unable to carry out one or more of its obligations under this Agreement due to an event constituting Force Majeure, then this Agreement shall remain in effect, but the Non-Performing Party&#8217;s relevant obligations under this Agreement and the relevant obligations of the other Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Other Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) under this Agreement shall be suspended for the duration of the circumstance of Force Majeure; provided that:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">25.1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Non-Performing Party gives the Other Party prompt notice describing the circumstance of Force Majeure, including the nature of the occurrence and its expected duration, and continues to furnish regular reports during the period of Force Majeure;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">25.1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Non-Performing Party uses diligent efforts to remedy its inability to perform and to mitigate the effects of the circumstance of Force Majeure; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">25.1.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">in the event of a delay of more than thirty (30)&#160;days, the Parties shall promptly meet to discuss how best to continue their operations as far as possible in accordance with this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">25.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For purposes of this Agreement, the term &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Force Majeure</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean any cause or causes beyond the reasonable control of the Non-Performing Party, including without limitation, acts of God, fire, explosion, flood, drought, war, riot, sabotage, terrorism, embargo, strikes or other labor trouble, failure in whole or in part of suppliers to deliver on schedule materials, equipment or machinery, interruption of or delay in transportation, a national health emergency or compliance with any order or regulation of any government that cannot be complied with using Commercially Reasonable Efforts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">25.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nothing herein shall be deemed to require the Non-Performing Party to settle on terms unsatisfactory to such Party any strike, lock-out or other labor difficulty, any investigation or proceeding by any public authority, or any litigation by any Third Party.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">25.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the event that a Force Majeure event continues for more than ninety (90)&#160;days the other Party shall be entitled to terminate this Agreement on ninety (90) days notice.</font></div></td></tr></table><div><a name="sE510230BD4D44793A6693F811359AA59"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">26.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SEVERANCE OF TERMS</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">26.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If the whole or any part of this Agreement is or becomes or is declared illegal, invalid or unenforceable in any jurisdiction for any reason (including both by reason of the provisions of any Law and also by reason of any court or competent authority which either has jurisdiction over this Agreement or has jurisdiction over any of the Parties):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">26.1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">in the case of the illegality, invalidity or un-enforceability of the whole of this Agreement it shall terminate only in relation to the jurisdiction in question; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">26.1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">in the case of the illegality, invalidity or un-enforceability of part of this Agreement that part shall be severed from this Agreement only in the jurisdiction in question and that illegality, invalidity or un-enforceability shall not in any way whatsoever prejudice or affect the remaining parts of this Agreement which shall continue in full force and effect.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">26.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If, in the reasonable opinion of any Party, any severance under this Clause&#160;26.2 materially affects the commercial basis of this Agreement, then the Parties shall discuss, in good faith, ways to eliminate the material effect.</font></div></td></tr></table><div><a name="s9460D48ACD8AB3C914713F811377262E"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">27.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NATURE OF THIS AGREEMENT</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">27.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Parties are independent contractors and none of the provisions of this Agreement shall be deemed to constitute a partnership or joint venture between the Parties.  Neither Party shall have any authority to bind the other in any way.</font></div></td></tr></table><div><a name="s0D2A64B5F0694601CE2A3F8113A9BB1D"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">28.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PUBLIC STATEMENTS</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">28.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Other than as expressly permitted in this Agreement, a Party may not use the name of the other Party or its Affiliates in any publicity, advertising or in any other public way.  Further, neither Party may issue any press releases or otherwise publicize or disclose any information related to the existence of this Agreement, the terms or conditions of this Agreement, or any information relating to the subject matter hereof, without the prior written consent of the other Party, other than in confidential communications to a Party&#8217;s lawyers, commercial and investment bankers, investors, potential investors and the advisers of any of the foregoing.  The Parties shall agree in writing upon an initial press release to be made by both Parties or upon the initial press releases to be made by each Party to announce the execution of this Agreement, together with a corresponding Q&amp;A outline for use in responding to inquiries about the Agreement.  Each Party shall provide the other Party with a copy of the proposed press release for review and comment not less than 48 hours prior to the press release being made public. Following such initial press release, either Party may use the specific information contained therein, or in any subsequent public announcements or publications made by the Parties, in such Party&#8217;s investor relations and public relations activities.  Nothing in the foregoing, however, shall prohibit a Party from making disclosures as it determines, based on the advice of counsel, required to comply with Law of any nationally recognized securities exchange (such exchange to include the Canadian Stock Exchange and the New York Stock Exchange), provided the same is accurate.  In such event, however, the disclosing Party shall consult with the other Party prior to such disclosure and, where applicable, shall request confidential treatment to the fullest extent available.</font></div></td></tr></table><div><a name="s12A98A5972BB5E1FF8B83F8113C7F75F"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">29.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NO THIRD PARTY RIGHTS</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">29.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Except where expressly stated in this Agreement to the contrary, no person who is not a party to this Agreement (or his/her successors or permitted assignees under this Agreement) has any rights under any relevant Law to enforce or enjoy the benefit of any term of this Agreement.</font></div></td></tr></table><div><a name="sA452681DF78AC0DEF83C3F8113F96C31"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">30.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">COSTS</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">30.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Party shall bear its own legal costs, legal fees and other expenses incurred in the preparation and execution of this Agreement.</font></div></td></tr></table><div><a name="sCEB1F5925D48A7D3D9E33F8114215CBE"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">31.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXECUTION AND COUNTERPARTS</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">31.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement shall become binding when any one or more counterparts hereof, individually or taken together, have been executed on behalf of each of the Parties hereto.  This Agreement may be executed in any number of counterparts, each of which shall be an original as against any Party whose signature appears thereon, but all of which taken together shall constitute but one and the same instrument.  Execution of this Agreement shall require signatures of authorized officers of the respective Parties and affixing of the corporate seal of each Party.</font></div></td></tr></table><div><a name="s820E343B994DAFBF9FED3F81145396BD"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">32.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSTRUCTION</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">32.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement has been prepared jointly and shall not be strictly construed against either Party.  The captions used herein are inserted for convenience of reference only and shall not be construed to create obligations, benefits, or limitations.</font></div></td></tr></table><div><a name="sDF62F4FBCE6A2CD74ED43F8114712A27"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">33.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DISPUTE RESOLUTION</font></div></td></tr></table><div><a name="s789E574764668E07FFD43F8114A372DC"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">33.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law; Arbitration</font><font style="font-family:inherit;font-size:11pt;">.  The validity, construction and performance of this Agreement shall be governed by the laws of Hong Kong, without regard to conflicts of law principles and without regard to the United Nations Convention on Contracts for the International Sale of Goods.  Any Claim, dispute or controversy between the Parties arising out of or related to this Agreement, including the existence, validity, interpretation, performance, breach or termination thereof or any dispute regarding non-contractual obligations arising out of or relating to it shall be referred to and finally resolved by international arbitration administered by the HKIAC under the HKIAC Administered Arbitration Rules in force when the Notice of Arbitration is submitted. The law of this arbitration clause shall be Hong Kong law.  The seat of arbitration shall be Hong Kong.  The number of arbitrators shall be one. The Parties shall jointly select the arbitrator within thirty (30) days of commencement of arbitration proceedings in accordance with the HKIAC Administered Arbitration Rules.  In the absence of an agreement between the Parties within such 30-day period, the HKIAC shall appoint the arbitrator. The arbitration proceedings shall be conducted in English.</font></div></td></tr></table><div><a name="s43B75BDB22A0B7B58CCA3F8114C1DD0F"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">33.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Informal Resolution</font><font style="font-family:inherit;font-size:11pt;">.  In the event of any controversy or Claim arising out of or relating to this Agreement, or the rights or obligations of the Parties hereunder, the Parties shall prior to commencing any form of proceedings try to settle their differences amicably between themselves.  Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other Party, and within thirty (30)&#160;days after such notice, appropriate representatives of the Parties shall meet for attempted resolution by good faith negotiations.  If such representatives are unable to promptly resolve such disputed matter within the said thirty (30)&#160;days, either Party may refer the matter by written notice to the other to the Chief Executive Officer of Licensee, or his/her designee, and the Chief Executive Officer of Oncolytics, or his/her designee, for discussion and resolution.  If such individuals or their designees are unable to resolve such dispute within thirty (30)&#160;days of such written notice, either Party may initiate proceedings in accordance with the provisions of Clause&#160;33.1.</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 22 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><a name="s59B9DBCE14A55636044D3F8114F34A6B"></a></div><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">34.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">IMPORT &amp; EXPORT CONTROL</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">34.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement is made subject to any restrictions or prohibitions concerning the export / import of products or technical information from the United States of America into the Territory which may be imposed upon or related to Oncolytics or Licensee from time to time by the governments of the United States of America and the Territory.  Furthermore, Licensee agrees that it will not export, directly or indirectly, nor re-export any technical information acquired from Oncolytics under this Agreement or any products using such technical information acquired from Oncolytics under this Agreement or any products using such technical information to any country for which the governments of the United States and the Territory or any agency thereof at the time of export / import requires an export / import license or other governmental approval, without first obtaining the written consent to do so from the Department of Commerce or other agency of the United States government or the Territory when required by an applicable Law.</font></div></td></tr></table><div style="line-height:180%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">This Agreement has been entered into on the date stated at the beginning of this Agreement.</font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;<br>Signed by Matt Coffey</font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">State position: Director</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By and on behalf of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ONCOLYTICS BIOTECH (BARBADOS) INC.</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date:&#160;&#160;&#160;&#160;</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Signed by Andres Gutierrez</font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">State position: Director</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By and on behalf of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ONCOLYTICS BIOTECH (BARBADOS) INC.</font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date:&#160;&#160;&#160;&#160;</font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 23 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;<br>Signed by Carsten Lu</font></div><div style="line-height:180%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">State position: Chairman and Chief Executive Officer&#160;&#160;&#160;&#160;</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By and on behalf of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ADLAI NORTYE BIOPHARMA CO. LTD.</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date:&#160;&#160;&#160;&#160;</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="sB7ED6C6A04310B6C50653F81151B79E3"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 24 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><a name="s6A0BAD45A7112D2670D73F81154D4868"></a></div><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SCHEDULE&#160;1</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;<br>LICENSED PRODUCT</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Products containing </font><font style="font-family:inherit;font-size:12pt;">Pelareorep, a proprietary form of the Dearing type III strain of the human wild-type Reovirus (Respiratory Enteric Orphan virus) as an active ingredient.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s5F78B743043A73EE9E863F81156B9048"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 25 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><a name="s09593B2EDC2D8356C8093F81159DA774"></a></div><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SCHEDULE&#160;2</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;<br>PATENT RIGHTS</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Oncolytics</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Issued</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Patents October 2017</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**]</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Pending Patent Applications October 2017</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[**]</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s44CD53BBEB35A5F793963F8115BB89D1"></a></div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SCHEDULE 3 </font></div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORM OF</font></div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PHARMACOVIGILANCE AGREEMENT</font></div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">THIS PHARMACOVIGILANCE AGREEMENT, DATED THE __________ (the &#8220;Effective Date&#8221;)</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">IS MADE BETWEEN:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH (BARBADOS) INC.</font><font style="font-family:inherit;font-size:12pt;">, a corporation organized under the laws of Barbados, having its principal offices at 1</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Floor, Hastings House, Balmoral Gap, Hastings, Christ Church, Barbados WI BB14034 (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics</font><font style="font-family:inherit;font-size:12pt;">&#8221;); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ADLAI NORTYE BIOPHARMA CO. LTD.</font><font style="font-family:inherit;font-size:12pt;">, a limited company organized under the laws of the Peoples Republic of China, which has principal offices at 21 Floor, Building 2, No. 452, 6</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Street, Hangzhou Eco. &amp; Tech. Development Area, 31008, PRC (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensee</font><font style="font-family:inherit;font-size:12pt;">&#8221;);</font></div></td></tr></table><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Oncolytics and Licensee are referred to from time to time herein individually as a &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Party</font><font style="font-family:inherit;font-size:11pt;">&#8221; or collectively as the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Parties</font><font style="font-family:inherit;font-size:11pt;">&#8221;.</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RECITALS</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 26 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Oncolytics is a wholly-owned subsidiary of Oncolytics Biotech Inc., which is a biotechnology company headquartered in Calgary, Alberta, Canada (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Biotech</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  The Oncolytics Group has considerable expertise in developing and producing novel viral products for the treatment and prevention of various forms of cancer. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Oncolytics Group </font><font style="font-family:inherit;font-size:12pt;">has developed and owns the exclusive rights to a certain strain of reovir</font><font style="font-family:inherit;font-size:12pt;">us (Serotype-3 Dearing Strain) iden</font><font style="font-family:inherit;font-size:12pt;">tified by Oncolytics as Pelareorep.</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(C)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee is a biopharmaceutical business dedicated to developing and commercializing new drugs, with a focus on new treatments for cancer and metabolic diseases, but does not currently market or sell any metastatic breast cancer treatments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(D)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Oncolytics and Licensee entered into a License, Development, Supply and Distribution Agreement with an effective date of November __, 2017 and agreed to enter into this Pharmacovigilance Agreement</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOW THEREFORE,</font><font style="font-family:inherit;font-size:12pt;">&#32;in consideration of the following mutual promises and obligations, and for other good and valuable consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows: </font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DEFINITIONS</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In this Pharmacovigilance Agreement and in the Appendices to this Pharmacovigilance Agreement the following capitalized terms, whether used in the singular or plural, shall have the meanings set forth below:</font></div><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Adverse Event</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AE</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, </font><font style="font-family:inherit;font-size:12pt;">subject to any amendment pursuant to the ICH from time to time,</font><font style="font-family:inherit;font-size:12pt;">&#32;any untoward medical occurrence in a patient to whom a medicinal product has been administered and which does not necessarily have to have a causal relationship with the administration of such medicinal product and includes without limitation any unfavorable and unintended sign (for example, an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product together, in relation to pharmacovigilance </font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 27 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-left:37px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">standards, policies, and procedures, with all medical device events, (including incidents, near-incidents, serious injuries, malfunctions and failures) or untoward medical events and events such as suicide or aggressive behavior threats, overdose, abuse, misuse, medication errors and other events that may reasonably be related to biomedical research.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Adverse Drug Reaction&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;ADR&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means any noxious and unintended response to a medicinal product occurring at any dose where there is at least a possibility of causal link between the administration of the medicinal product and the noxious and unintended response. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Business Day</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a day other than a Saturday, Sunday or a day on which banks are not open for business in Canada, the PRC, Taiwan, Macau, the Republic of Singapore, the Republic of Korea, or Hong Kong.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CFDA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the China Food and Drug Administration in the PRC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.5</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Clinical Study&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means studies required by a Regulatory Authority in respect of Licensed Product, including those studies required to obtain Marketing Authorization, and includes all studies described in the Development Plan. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.6</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Effective Date&#8221; </font><font style="font-family:inherit;font-size:12pt;">shall have the meaning set forth above.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.7</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;EMA&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means the European Medicines Agency in Europe.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.8</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FDA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Food and Drug Administration in the United States of America.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.9</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Field&#8221; </font><font style="font-family:inherit;font-size:12pt;">means the treatment and prevention of human diseases.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.10</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;ICH&#8221;&#160;</font><font style="font-family:inherit;font-size:12pt;">means International Conference on Harmonisation guidelines including (but not limited to) E2A, E2B, E2C, and E2D as amended and any replacement thereof from time to time.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.11</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Individual Case Safety Report&#8221; </font><font style="font-family:inherit;font-size:12pt;">or</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#8220;ICSR&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means a report that contains information describing a suspected AE, ADR, SAE or SUSAR related to the administration of one or more medicinal products to an individual patient and,</font><font style="font-family:inherit;font-size:12pt;">&#32;subject to any amendment pursuant to the ICH from time to time, contains the minimum information required for expedited reporting, including: an identifiable patient, a suspected medicinal product, an identifiable reporter, and an </font><font style="font-family:inherit;font-size:12pt;">AE, ADR, SAE or SUSAR.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.12</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;License Agreement&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means the License, Development, Supply and Distribution Agreement entered into by the Parties with an effective date of November __, 2017. </font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 28 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.13</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Licensed Product&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means any product intended for use in the Field containing or including Pelareorep.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.14</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Marketing Authorization&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;or </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;MA&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means any approval required from the relevant Regulatory Authority or authorities to distribute, promote, market and sell Licensed Product in the Field, in a country or region within the Territory.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.15</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Group</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Oncolytics, its Affiliates and their respective employees, agents and Third Party independent contractors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.16</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pelareorep</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Oncolytics&#8217; proprietary variant of a respiratory enteric orphan virus, as more fully described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule 1</font><font style="font-family:inherit;font-size:12pt;">&#32;to the License Agreement. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.17</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Periodic Safety Update Report&#8221; </font><font style="font-family:inherit;font-size:12pt;">or </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;PSUR&#8221; </font><font style="font-family:inherit;font-size:12pt;">means a pharmacovigilance document intended to provide an evaluation of the risk-benefit balance of a medicinal product at defined time points post-market authorization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.18</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Person</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an individual, partnership, corporation, joint stock company, estate, trust (including a business trust), limited liability company, unincorporated association, joint venture or other entity or a Regulatory Authority.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.19</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PRC</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the People&#8217;s Republic of China, but for the purpose of this Agreement only, excludes Hong Kong, Macau and Taiwan.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.20</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Regulatory Authority&#8221; </font><font style="font-family:inherit;font-size:12pt;">means the CFDA, EMA, FDA or any national, supranational, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity in a given country or jurisdiction in the Territory responsible for granting and administering any Regulatory Approvals.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.21</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Report&#8221;&#160;</font><font style="font-family:inherit;font-size:12pt;">means a report of an AE, ADR, SAE or SUSAR.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.22</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Safety Issue&#8221;&#160;</font><font style="font-family:inherit;font-size:12pt;">means any significant issues related to the Licensed Product, including those originating from: requests from regulatory authorities, potential changes in the risk/benefit of a Licensed Product, Licensed Product quality issues which may have a clinical impact (e.g. Licensed Product contamination, deterioration or defects); external influences (media, literature), and ongoing safety surveillance.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.23</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Serious Adverse Event&#8221; </font><font style="font-family:inherit;font-size:12pt;">or</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#8220;SAE&#8221; </font><font style="font-family:inherit;font-size:12pt;">means, subject to any amendment pursuant to the ICH from time to time, any Adverse Event that at any dose</font><font style="font-family:inherit;font-size:12pt;">:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:56px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">results in death;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:56px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">is life-threatening;</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 29 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:56px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">requires hospitalization or prolongation of existing hospitalization</font><font style="font-family:inherit;font-size:12pt;">; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:56px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">results in persistent or significant disability or incapacity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:56px;"><font style="font-family:inherit;font-size:12pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">is a congenital anomaly or birth defect; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:56px;"><font style="font-family:inherit;font-size:12pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;color:#222222;">requires intervention to prevent permanent impairment or damage</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.24</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Signal&#8221;&#160;</font><font style="font-family:inherit;font-size:12pt;">means, an observation of possible unexpected hazards or changes in the severity, characteristics or frequency of expected Adverse Events that emerge, the relevant information for which needs to be brought together for effective evaluation over a timescale appropriate to the importance and likely impact of the signal.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.25</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;SOP&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means a standard operating procedure of Licensee or Oncolytics, as the case may be.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.26</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Spontaneous Sources</font><font style="font-family:inherit;font-size:12pt;">&#8221; means sources other than </font><font style="font-family:inherit;font-size:12pt;">a Clinical Study or any organized data collection scheme, including health care professionals, caretakers, pharmacists and consumers</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.27</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Spontaneous Report&#8221; </font><font style="font-family:inherit;font-size:12pt;">means</font><font style="font-family:inherit;font-size:12pt;">, subject to any amendment pursuant to the ICH from time to time, any unsolicited communication to a Party, Regulatory Authority or other Person that describes an Adverse Event or an Adverse Drug Reaction in a patient administered the Product, whether alone or together with one or more other medicinal products, and which does not derive from a Clinical Study or any organized data collection scheme. Spontaneous reports include reports from health care professionals (medically confirmed reports) and non-health care professionals or consumers (medically unconfirmed reports). All spontaneous reports received from consumers or health care professionals are considered as suspected Adverse Drug Reactions</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.28</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;SUSAR&#8221; </font><font style="font-family:inherit;font-size:12pt;">means a suspected unexpected serious adverse reaction.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.29</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Territory&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;means those countries listed in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Schedule&#160;5</font><font style="font-family:inherit;font-size:12pt;">&#32;of the Licensee Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.30</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Third Party&#8221; </font><font style="font-family:inherit;font-size:12pt;">means any entity or person other than the Parties or their respective Affiliates.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.31</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In this Pharmacovigilance Agreement capitalized terms that are not defined in this Section 1 shall have the meaning set out in the License Agreement.</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PURPOSE</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 30 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">2.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The purpose of this Pharmacovigilance Agreement is to describe the procedures relating to the exchange of safety and pharmacovigilance information and to define the responsibilities to ensure compliance with good pharmacovigilance practice and maintain compliance with the world-wide reporting requirements for the relevant Regulatory Authorities for the Licensed Product. </font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;text-indent:-38px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SCOPE </font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement covers:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:130px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:56px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">all Spontaneous Reports and Solicited Reports of </font><font style="font-family:inherit;font-size:12pt;">AEs, ADRs, SAEs and SUSARs </font><font style="font-family:inherit;font-size:12pt;">in relation to the Licensed Product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:130px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:56px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">all SAEs and SUSARs arising from Clinical Studies and post-marketing surveillance (PMS) with the Licensed Product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:130px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:56px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">suspected ADRs in association with off label use of the Licensed Product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:130px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:56px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">all information required for periodic reporting in relation to the Licensed Product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:130px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:56px;"><font style="font-family:inherit;font-size:12pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Safety Issues and Signals; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:130px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:56px;"><font style="font-family:inherit;font-size:12pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the reporting of all other information as required by Regulatory Authorities for the Licensed Product.</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LANGUAGE OF ALL INFORMATION EXCHANGE</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The language of all information exchanged pursuant to this Agreement, including reports to Regulatory Authorities, shall be in English, or if any other language, accompanied by a translation into English. In the event of any conflict between the English text and the text in any other language, the English text shall prevail</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ROLES OF ONCOLYTICS AND LICENSEE</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee or any Third Party that holds Marketing Authorization for Licensed Product shall be involved in the pharmacovigilance of Licensed Product in the Territory, and be responsible in fulfilling the obligations defined in Appendix 2 of this Pharmacovigilance Agreement. </font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 31 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall be responsible for the safety database of Licensed Product in the Territory according to Section 7.1.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">5.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Oncolytics or its designate shall be responsible for the complete global safety database according to Section 7.2. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">5.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall make all Reports, including all ICSRs and Spontaneous Reports, and other relevant information available to Oncolytics according to Section 8, in order to allow Oncolytics to fulfill its obligations and responsibilities. </font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">QUALIFIED PERSON</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Party shall designate a suitably qualified person responsible for Adverse Event monitoring (the &#8220;Qualified Person&#8221;) for the Licensed Product. The Qualified Person for each Party is identified in Appendix 1 of this Pharmacovigilance Agreement. Each Party may change its Qualified Person and shall notify the other Party thereof in writing.</font></div><div style="line-height:180%;text-align:justify;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SAFETY DATABASES</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">7.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Territory safety database</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall be responsible for the creation, maintenance and update of a safety database related to the use of Licensed Product in the Territory. This database shall be comprised of information from all Reports from Territory. Licensee shall share with Oncolytics an updated version of the safety database not less than quarterly or more frequently as required by Regulatory Authorities. </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">7.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Complete global safety database</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Oncolytics or its designate shall be responsible for the creation, maintenance and update of a complete global safety database of the Licensed Product. Oncolytics shall share with Licensee an updated version of the complete global safety database not less than quarterly or more frequently as required by Regulatory Authorities. </font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INDIVIDUAL CASE SAFETY REPORTS AND SPONTANEOUS REPORTS</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">8.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Individual Case Safety Reports</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:38px;"><font style="font-family:inherit;font-size:12pt;">8.1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall be responsible for its own medical assessment of the reported ADRs when entering the report into Licensee&#8217;s safety database according to local </font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 32 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-left:85px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">requirements and its internal SOPs. In general, the principle of the implied positive causality (meaning that the report is considered to be related with regard to further Licensee and regulatory submission) shall be applied to all Spontaneous Reports of ADRs. Licensee shall assess the expectedness, seriousness and causality according to local requirements and their internal SOPs. Licensee will provide information about reported ADRs to Oncolytics and solicit comment from Oncolytics for reports to be entered into Licensee&#8217;s safety database. Oncolytics will respond promptly to any request for comment received from Licensee.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:38px;"><font style="font-family:inherit;font-size:12pt;">8.1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ICSRs shall be sent to the Qualified Person of Oncolytics. The reports shall be distributed in Oncolytics safety networks according to Oncolytics&#8217; SOP. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:38px;"><font style="font-family:inherit;font-size:12pt;">8.1.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ICSRs in Licensee&#8217;s safety database shall be crosschecked at regular intervals to ensure that all the applicable ICSRs are appropriate according to this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">8.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Spontaneous Report</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:42px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall provide to Oncolytics information of Spontaneous Reports in the Territory in writing, using any mutually agreed format within the timeframes defined in Section 8.3. The reporting form shall include all the information provided by the Spontaneous Source. </font><font style="font-family:inherit;font-size:12pt;">All Spontaneous Reports received from consumers or health care professionals are considered as suspected Adverse Drug Reactions. Cases originating from the internet where the website is under management or responsibility of Licensee or </font><font style="font-family:inherit;font-size:12pt;">any Third Party which holds Marketing Authorization for Licensed Product,</font><font style="font-family:inherit;font-size:12pt;">&#32;should be screened for potential Adverse Events by the appropriate Party. </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">8.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Reporting Timing and Content</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:38px;"><font style="font-family:inherit;font-size:12pt;">8.3.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All ICSRs and Spontaneous Reports related to SAEs arising from within the Territory shall be sent to Oncolytics no later than two (2) calendar days after the receipt of the Reports by Licensee. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:38px;"><font style="font-family:inherit;font-size:12pt;">8.3.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All ICSRs and Spontaneous Reports related to non-serious AE Reports arising from within the Territory shall be sent to Oncolytics no later than five (5) calendar Days after the receipt of the Reports by Licensee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:38px;"><font style="font-family:inherit;font-size:12pt;">8.3.3</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Party shall use every effort to ensure that all Reports of AEs and SAEs meet the minimum criteria for an ICSR. If the minimum information cannot be obtained within the required timeframes, each Party shall still send the Report to the other </font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 33 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-left:85px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">Party within such timeframes. Every effort should then be made to obtain and send the missing minimum information required for an ICSR as soon as reasonably possible</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">8.4</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Follow up information</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:42px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee is responsible for obtaining follow up information in order to allow proper assessment of all ADRs. This information shall be reported to Oncolytics as described in Section 8.</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SAFETY ISSUES OR SIGNALS AND REGULATORY INQUIRIES INVOLVING SAFETY ISSUES</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Reporting Safety Issues and Signals</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee </font><font style="font-family:inherit;font-size:12pt;">shall as soon as reasonably possible notify Oncolytics of any Safety Issues or Signals in relation to the Licensed Product by telephone and in writing. Oncolytics and </font><font style="font-family:inherit;font-size:12pt;">Licensee </font><font style="font-family:inherit;font-size:12pt;">shall co-operate with the reasonable requests of the other Party in relation to such issues. Safety Issues or Signals relating to the Licensed Product may occur as a result of: a request from a Regulatory Authority; potential changes to the risk/benefit of the Licensed Product; Licensed Product quality issues that may have a clinical impact such as a Licensed Product contamination or deterioration; external influences such as media or literature; and ongoing safety surveillance</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Regulatory Inquiries </font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall as soon as reasonably possible and in any event within two (2)&#160;calendar days inform Oncolytics of any inquiries from any Regulatory Authority involving Safety Issues or Signals in relation to the Licensed Product</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PERIODIC SAFETY UPDATE REPORT</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee and Oncolytics shall prepare PSURs and submit them at intervals required by Regulatory Authorities. All relevant ADR information shall be included in the PSURs. Licensee shall share the PSURs with Oncolytics and vice versa upon written request. </font></div><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SUBMISSION TO REGULATORY AUTHORITY</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 34 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall submit AE Reports, ICSRs and PSURs to Regulatory Authorities in the Territory according to format, timing and guidelines of the Regulatory Authority. </font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">REQUESTS FOR ADDITIONAL SAFETY INFORMATION</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">11.1</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall respond to all requests from Regulatory Authorities regarding additional safety information related to pharmacovigilance of the Licensed Product. Licensee shall provide Oncolytics with copies of such requests and documentations pertaining to the requests, within ten (10) Business Days upon receipt. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">11.2</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall also provide Oncolytics with copies of its responses to the requests within ten (10) Business Days upon provision of such response to the Regulatory Authority.</font></div></td></tr></table><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">REPORTING RELATED TO CLINICAL STUDY</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall be responsible for submission of Reports related to Clinical Studies to the Regulatory Authority according to the applicable study protocol. Licensee shall promptly inform Oncolytics of any ADR arising from a Clinical Study.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SAFETY INFORMATION OF LABEL</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Based on the ADR identified in a Clinical Study and Spontaneous Report, Licensee shall promptly notify Oncolytics in writing if the need to modify the safety information on the label arises. Oncolytics </font><font style="font-family:inherit;font-size:12pt;">will be responsible for maintaining the safety labeling text for the Licensed Product in accordance with the laws, rules, regulations and guidances applicable to the Marketing Authorization(s) for the Licensed Product</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PHARMACOVIGILANCE TRAINING</font></div></td></tr></table><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee shall be responsible for providing adequate training to Licensee&#8217;s Qualified Person in order to carry out the pharmacovigilance responsibility as described in this Pharmacovigilance Agreement.</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MEETING</font></div></td></tr></table><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 35 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;text-align:justify;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Parties shall meet either face-to-face or through web/ telephone conference to discuss pharmacovigilance issues or changes to this Pharmacovigilance Agreement upon the reasonable request of either Party. </font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">This Pharmacovigilance</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement has been agreed upon by the Parties and will be in force immediately upon the commencement of the License Agreement. </font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Signed by [Director </font><font style="font-family:inherit;font-size:12pt;">or Officer]&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></div><div style="line-height:180%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">State position:&#160;&#160;&#160;&#160;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></div><div style="line-height:180%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By and on behalf of </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH BARBADOS INC.</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:180%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date:&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.</font></div><div style="line-height:180%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Signed by [Director </font><font style="font-family:inherit;font-size:12pt;">or Officer]&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></div><div style="line-height:180%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">State position:&#160;&#160;&#160;&#160;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></div><div style="line-height:180%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By and on behalf of </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH BARBADOS INC.</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:180%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date:&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.</font></div><div style="line-height:180%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Signed by [Director </font><font style="font-family:inherit;font-size:12pt;">or Officer]&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></div><div style="line-height:180%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">State position:&#160;&#160;&#160;&#160;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></div><div style="line-height:180%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By and on behalf of</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;NIPPON ZENYAKU KOGYO CO., LTD.</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:180%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date:&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 36 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Appendix 1</font></div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">List of the Qualified Person</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS:</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: </font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Division: </font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Phone: </font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Fax: </font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Email:</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Address: </font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LICENSEE:</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Division: </font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Phone: </font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Fax: </font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Email: </font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Address:</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;</font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 37 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Appendix 2</font></div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Obligations of the Marketing Authorization Holder in Pharmacovigilance Operations </font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Management of adverse events:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Reception</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Registration</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Review and data management</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quality control and duplicate detection</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Investigation and monitoring</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Coding, evaluation et classification</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Expedited reporting to Competent Authorities</font></div></td></tr></table><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ongoing evaluation of the benefit-risk ratio of the veterinary drug:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Preparation, development, verification and transmission of&#160;PSURs</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Signal detection and evaluation</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Management of information from literature</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Reporting and communication on the change of the benefit-risk ratio of the veterinary drug</font></div></td></tr></table><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Management of exchanges with Competent Authorities:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Request by authorities </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Management of restrictions and variations</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Compliance with commitments in connection with the granting of the marketing authorization</font></div></td></tr></table><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quality Management related to pharmacovigilance activities:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Training</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Documentation and contracts of subcontracting </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quality management and control of corrective and preventive actions (CAPA)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Maintenance of the pharmacovigilance system</font></div></td></tr></table><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 38 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><a name="s110ADD88F59EB7E8E9353F8115EDB661"></a></div><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 39 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><a name="s776E47C56082996AA6193F81161592E9"></a></div><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SCHEDULE&#160;4</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;<br>ONGOING CLINICAL STUDIES</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">USC / Norris Comprehensive Cancer Center (REO-019) </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Oncolytics&#8217; sponsored study (REO-022)</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Study of REOLYSIN&#174; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Oncolytics&#8217; sponsored study (REO-024) </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A Phase Ib study of pembrolizumab (KEYTRUDA&#174;) in combination with REOLYSIN&#174; (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Ohio State University NCI </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pilot Trial Evaluating Viral Protein Production from the Combination of Reolysin and Carfilzomib in Multiple Myeloma</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">MUK, OBI &amp; Celgene&#8217;s Sponsorship</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VIRel: Viral immunotherapy in Relapsed/Refractory Multiple Myeloma - A Phase I Study to Assess the Safety and Tolerability of REOLYSIN&#174; (pelareorep) in Combination with Lenalidomide or Pomalidomide</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ReoGlio University of Leeds </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A dose-finding study of the safety and tolerability of intravenous reovirus (REOLYSIN&#174;) (pelareorep) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with standard of care chemoradiotherapy /adjuvant chemotherapy (temozolomide) for Glioblastoma Multiforme (GBM)</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">MC1472 Mayo Clinic Rochester, MN </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Phase 1 Study of Replication Competent Reovirus (REOLYSIN</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;">) in Combination with GM-CSF in Pediatric Patients with Relapsed or Refractory Brain Tumors</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s19898C6E8DB44053C9B53F8116470F0E"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 40 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><a name="s89C2E09F4302B6280D1B3F811665A800"></a></div><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SCHEDULE&#160;5</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;<br>THE TERRITORY</font></div><div style="line-height:180%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Territory shall include the following countries and jurisdictions:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">PRC</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Hong Kong </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Macau</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Republic of Singapore</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">South Korea</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:180%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Taiwan</font></div></td></tr></table><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s1927E54845EAB442CF5A3F8116972DBD"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 41 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div><hr style="page-break-after:always"><div><a name="s1FE5D1335C0E1F06A6BA3F8116B5E6EA"></a></div><div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:180%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SCHEDULE&#160;6</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;<br>FORM OF WARRANT PURCHASE AGREEMENT</font></div><div style="line-height:180%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 42 &#8211;</font></div><div style="line-height:180%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.&#160;&#160;CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [**].&#160;&#160;A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.45
<SEQUENCE>4
<FILENAME>ex445coffey.htm
<DESCRIPTION>EXHIBIT 4.45
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7C8F7E02A03968D43D052162E84ABF90"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AMENDING AGREEMENT #5</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AMENDING AGREEMENT</font><font style="font-family:Arial;font-size:12pt;">&#32;made effective as of the 8</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;day of March, 2018.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOYLYTICS BIOTECH INC.,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("ONCOLYTICS")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">- and -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">MATTHEW C. COFFEY,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS the Employee is an officer of Oncolytics whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective January 1, 2013 as amended by an Amending Agreement #1 dated March 12, 2014, Amending Agreement #2 dated March 12, 2015, Amending Agreement #3 dated March 8, 2016, and Amending Agreement #4 dated February 23, 2017 (together the "Employment Agreement");</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Interpretation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Amendment to the Employment Agreement</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows:</font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:0px;"><font style="padding-bottom:16px;text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(1)</font><font style="font-family:Arial;font-size:12pt;">Commencing January 1, 2018, Oncolytics shall pay to the Employee a salary of four hundred seventy-five thousand ($475,000) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of nineteen thousand seven hundred ninety-one CANADIAN DOLLARS and sixty-seven cents ($19,791.67) on the 15</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;and last day of each month.  </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Confirmation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Miscellaneous</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:49%;"></td><td style="width:3%;"></td><td style="width:7%;"></td><td style="width:41%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">/s/ Wayne Pisano</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">/s/ Kirk Look</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/S/ Floriane Riouall&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/S/ Matthew Coffey</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">___________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________________________</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">MATTHEW COFFEY</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.46
<SEQUENCE>5
<FILENAME>ex446look.htm
<DESCRIPTION>EXHIBIT 4.46
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF41A442A4E1539D08A032164726070B6"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AMENDING AGREEMENT #5</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AMENDING AGREEMENT</font><font style="font-family:Arial;font-size:12pt;">&#32;made effective as of the 8 day of March, 2018.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOYLYTICS BIOTECH INC.,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("ONCOLYTICS")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">- and -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">KIRK LOOK,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS the Employee is an officer of Oncolytics whose terms of employment are set forth in the Executive Employment Agreement dated effective January 1, 2013, as amended by an Amending Agreement #1 dated March 12, 2014, Amending Agreement #2 dated March 12, 2015, Amending Agreement #3 dated March 8, 2016, and Amending Agreement #4 dated February 23, 2017 (together the "Employment Agreement");</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Interpretation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.  In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Amendment to the Employment Agreement</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:0px;"><font style="padding-bottom:16px;text-align:justify;font-family:Arial;font-size:12pt;padding-right:0px;">(1)</font><font style="font-family:Arial;font-size:12pt;">Commencing January 1, 2018, Oncolytics shall pay to the Employee a salary of three hundred sixty-five thousand ($365,000) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of fifteen thousand two hundred eight CANADIAN DOLLARS and thirty-three cents ($15,208.34) on the 15</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;and last day of each month.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Confirmation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Miscellaneous</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:49%;"></td><td style="width:3%;"></td><td style="width:7%;"></td><td style="width:41%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Wayne Pisano</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Matt Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/S/ Floriane Riouall&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/S/ Kirk Look</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">___________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________________________</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">KIRK LOOK</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.47
<SEQUENCE>6
<FILENAME>ex447deguttadauro.htm
<DESCRIPTION>EXHIBIT 4.47
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s82425CED0F46EFF7E396219140BD46FC"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AMENDING AGREEMENT #1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AMENDING AGREEMENT</font><font style="font-family:Arial;font-size:12pt;">&#32;made effective as of the 8</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;day of March, 2018.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOYLYTICS BIOTECH (U.S.), INC.,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("OBUS")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">- and -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ANDREW DE GUTTADAURO</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement ("Employment Agreement") dated effective June 29, 2017;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS OBUS and the Employee wish to amend the Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Interpretation</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.  In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Amendment to the Employment Agreement</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)&#160;&#160;&#160;&#160;Commencing January 1, 2018, OBUS shall pay to the Employee a salary of two hundred fifty-three thousand ($253,000) UNITED STATES DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of ten thousand five hundred forty-one UNITED STATES DOLLARS and sixty-seven cents ($10,541.67) on the 15th and last day of each month</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Confirmation</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)&#160;&#160;&#160;&#160;The parties confirm that the increase in Base Salary is a result of an assessment of increases in cost-of-living indices and salary benchmarking.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)&#160;&#160;&#160;&#160;The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Miscellaneous</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws of California.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:7%;"></td><td style="width:41%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH (U.S.), INC.</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/S/ Matt Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Matt Coffey</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Director</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/S/ Gilles Gosselin</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Gilles Gosselin</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Director</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/S/ Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/S/ Andrew de Guttadauro</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">___________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________________________</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ANDREW DE GUTTADAURO</font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.48
<SEQUENCE>7
<FILENAME>ex448gutierrez.htm
<DESCRIPTION>EXHIBIT 4.48
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s376B7A14C010B424B7E321933D23CFE7"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AMENDING AGREEMENT #1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AMENDING AGREEMENT</font><font style="font-family:Arial;font-size:12pt;">&#32;made effective as of the 8</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;day of March, 2018.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOYLYTICS BIOTECH (U.S.), INC.,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("OBUS")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">- and -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ANDRES GUTIERREZ</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement ("Employment Agreement") dated effective October 27, 2016;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS OBUS and the Employee wish to amend the Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Interpretation</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.  In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Amendment to the Employment Agreement</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)&#160;&#160;&#160;&#160;Commencing January 1, 2018, OBUS shall pay to the Employee a salary of three hundred thirty thousand ($330,000) UNITED STATES DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of thirteen thousand seven hundred fifty ($13,750) UNITED STATES DOLLARS on the 15th and last day of each month.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Confirmation</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)&#160;&#160;&#160;&#160;The parties confirm that the increase in Base Salary is a result of an assessment of increases in cost-of-living indices and salary benchmarking.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)&#160;&#160;&#160;&#160;The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Miscellaneous</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws of California.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:7%;"></td><td style="width:41%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH (U.S.), INC.</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/S/ Matt Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Matt Coffey</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Director</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/S/ Gilles Gosselin</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Gilles Gosselin</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Director</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/S/ Kirk Look &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/S/ Andres Gutierrez</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">___________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________________________</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ANDRES GUTIERREZ</font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.0
<SEQUENCE>8
<FILENAME>ex80subsidiaries2017.htm
<DESCRIPTION>EXHIBIT 8.0
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF5BD86AFF0E851D49280AA15B0FABD26"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LIST OF SUBSIDIARIES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.4609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:73%;"></td><td style="width:27%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Jurisdiction</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech (Barbados) Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Barbados</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech (US) Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware</font></div></td></tr></table></div></div><div style="line-height:144%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>9
<FILENAME>ex121ceocertfication2017.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4E00A8F76B8E57C584511C2154731275"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 12.1</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Matthew Coffey, certify that:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.;</font></div></td></tr></table><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></div></td></tr></table><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:7%;"></td><td style="width:41%;"></td><td style="width:7%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;19, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">/s/ Matthew Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Coffey, PhD</font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div><div style="padding-bottom:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>10
<FILENAME>ex122cfocertification2017.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA17475A0E9B85558B119488C9B213418"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 12.2</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Kirk Look, certify that:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.;</font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:144%;text-align:left;padding-left:96px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:9px;text-align:left;padding-left:96px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:6%;"></td><td style="width:41%;"></td><td style="width:6%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;19, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Kirk Look</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look, CA</font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div><div style="padding-bottom:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Accounting and Financial Officer</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>11
<FILENAME>ex131ceocertification2017.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s88DBB16B47B252CCB7ABD20DC5965D98"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 13.1</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. &#167;1350,</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Matthew Coffey, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Matthew Coffey</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_________________________________</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Coffey, PhD</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Executive Officer</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;19, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>12
<FILENAME>ex132cfocertification2017.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sFF0C0D39C1485FA1AD5DE824BC9949F8"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 13.2</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. &#167;1350,</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Kirk Look, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Kirk Look</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look, CA</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Accounting and Financial Officer</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;19, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>13
<FILENAME>ex151-2017mda.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEE13C550825F5DEB8AB2687F4F40751B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;"><img src="oncolyticslogoblue.jpg" alt="oncolyticslogoblue.jpg" style="height:290px;width:665px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">MANAGEMENT DISCUSSION &amp; ANALYSIS</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;color:#000000;font-weight:bold;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:16pt;font-weight:bold;">&#32;</font></div><div><br></div><hr style="page-break-after:always"><div><a name="sD872EAEB02BB5809AF496D59831D5959"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">MANAGEMENT DISCUSSION &amp; ANALYSIS</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;color:#000000;font-weight:bold;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:14pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.3046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:81%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s41BE6C1F008451008D711E13E6382506"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Basis of Presentation</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s41BE6C1F008451008D711E13E6382506">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward-Looking Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s3987C0755D5F5646BA770D598EFFAE7C">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">REOLYSIN</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s547E39D9EC82552096039C23FF993346"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">&#160;Development For 201</font></a><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#sD4B575A2302553F7BEB5416A98D7371F">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s3CAFE06F3FB35586AC6F5EF7FFAC9E85"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Clinical Trial Program</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s3CAFE06F3FB35586AC6F5EF7FFAC9E85">2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s307F83829F86515AAB787818778FFDB2"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Manufacturing </font></a><font style="font-family:inherit;font-size:11pt;font-style:italic;">and Process Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s307F83829F86515AAB787818778FFDB2">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s1682603F299A5D37AF0DB72250A68292"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Intellectual Property</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s1682603F299A5D37AF0DB72250A68292">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Business Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s1682603F299A5D37AF0DB72250A68292">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s1A07193A44985B1FAA0A9BD8F591E259"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Financing Activity</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s1A07193A44985B1FAA0A9BD8F591E259">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#sFECE9F709665539D8B42EF747E6A5069"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Financial Impact</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#sFECE9F709665539D8B42EF747E6A5069">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s95B6E04106AB547F8007F1CC10C224C5"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Cash Resources</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s95B6E04106AB547F8007F1CC10C224C5">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">REOLYSIN</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;Development For 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s9DB2A31933935AFD803E23B40E7952CC"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Accounting Policies</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s9DB2A31933935AFD803E23B40E7952CC">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s0EC5A8C97A455851B756D34DDB7F6B11"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Critical Accounting Policies</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s0EC5A8C97A455851B756D34DDB7F6B11">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Adoption of New Accounting Standards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Accounting Standards and Interpretations Issued but not yet Effective</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s012A225785D053ECBBD2BD19385F65B6">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s3ED6EF4FEB43532581109799CBC40A12"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Significant Estimates</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s3ED6EF4FEB43532581109799CBC40A12">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s6A876B49EBA157C8927C9BEE406AAB51"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Selected Annual Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s6A876B49EBA157C8927C9BEE406AAB51">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s1C7B577B558A511AA8EE8AE12E19E68B"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s2E2DD2E29B8E5557BFCC5A64E3396903"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Summary of Quarterly Results</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">13</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s5E587377BBD65E77A922FAC894ED0E98"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Fourth Quarter</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">13</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;" href="#s4AD4C17F8B5B5BC98DB3BB0EAEB6F476"><font style="font-family:inherit;font-size:11pt;font-style:italic;color:#000000;text-decoration:none;">Fourth Quarter - Review of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">14</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s0145045A4EE75D5990FE012F9C6B4128"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Liquidity and Capital Resources</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s0145045A4EE75D5990FE012F9C6B4128">16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sFBB099C413E85319BB056A359D459631"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Off-Balance Sheet Arrangements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#sFBB099C413E85319BB056A359D459631">17</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sCB0FD16F23CC5E0E9EFA6086A5F690CE"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Transactions with Related Parties</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#sCB0FD16F23CC5E0E9EFA6086A5F690CE">17</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s3D7980531A2E556DA77180549B701034"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Financial Instruments and Other Instruments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s3D7980531A2E556DA77180549B701034">18</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s6EC5B4B1E6C250D4AA5B733D15F273F5"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Risk Factors Affecting Future Performance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s6EC5B4B1E6C250D4AA5B733D15F273F5">19</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s5116C5AB95C1555E9779CBD1FAFCBB9E"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;">Other MD&amp;A Requirements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;" href="#s5116C5AB95C1555E9779CBD1FAFCBB9E">22</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">i</font></div></div><hr style="page-break-after:always"><div><a name="s41BE6C1F008451008D711E13E6382506"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;color:#000000;font-weight:bold;text-decoration:none;">March&#160;8, 2018</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BASIS OF PRESENTATION </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Management Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) should be read in conjunction with our </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;audited consolidated financial statements and notes thereto, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). This MD&amp;A along with our consolidated financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;8, 2018</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s3987C0755D5F5646BA770D598EFFAE7C"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and under applicable Canadian provincial securities legislation.  Forward-looking statements, including our belief as to the potential of REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(pelareorep)</font><font style="font-family:inherit;font-size:10pt;">, an intravenously delivered immuno-oncolytic virus, as a cancer therapeutic and our expectations as to the success of our research and development and manufacturing programs in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the forward-looking statements made within this MD&amp;A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investors should consult our quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and/or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements.  We do not undertake to update these forward-looking statements except as required by applicable law.</font></div><div><a name="sD4B575A2302553F7BEB5416A98D7371F"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">REOLYSIN Development Update For </font><font style="font-family:inherit;font-size:16pt;color:#000000;font-weight:bold;text-decoration:none;">2017</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc. is a Development Stage Company</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception in April of 1998, Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;Inc. has been a development stage company and we have focused our research and development efforts on the development of REOLYSIN, also known as pelareorep, an intravenously delivered immuno-oncolytic virus with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until, and unless, pelareorep becomes commercially viable.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our goal each year is to advance pelareorep through the various steps and stages of development required for potential pharmaceutical products.  In order to achieve this goal, we believe that we have to actively manage the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and pelareorep</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">supply, and our intellectual property.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s3CAFE06F3FB35586AC6F5EF7FFAC9E85"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Clinical Trial Program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are directing a three-part clinical development program with the objective of developing pelareorep as a human cancer therapeutic. Our clinical development plan has two main objectives. The primary objective is to obtain regulatory approval for pelareorep as quickly as possible and is based on the compelling metastatic breast cancer survival data presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, in Washington, D.C. The second objective is to expand pelareorep into commercially valuable new treatment areas that include immuno-therapy along with immuno-modulatory (IMiD) and other targeted agents in collaboration with pharmaceutical partners. Our clinical development program focuses on the three components of pelareorep's mechanism of action (MOA) and includes the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Program 1 - Chemo combinations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, our primary focus has been on the investigation of chemotherapy combination clinical trials investigating the use of different chemotherapy agents in various cancer indications. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Program 2 - Combination with IMiDs/targeted therapy</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our second program focuses on the potential of pelareorep to stimulate a patient's innate immunity and the potential for an infection to cause a cascade of chemokines/cytokines activating natural killer (NK) cells to attack cancer cells.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Program 3 - Immunotherapy combinations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our third program focuses on the potential for pelareorep to cause a specific adaptive immune response triggered by tumor- and viral-associated antigens displayed by antigen-presenting cells (APCs), infected tumor cells and/or dendritic cells to T cells.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">2017 Developments:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">Program 1 - Chemo combinations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Metastatic Breast Cancer</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statistically significant phase 2 overall survival (OS) data</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the AACR annual meeting in April 2017, clinical data from an open-label, randomized, phase 2 study assessing the therapeutic combination of intravenously-administered REOLYSIN given in combination with the chemotherapy agent paclitaxel versus paclitaxel alone, in patients with advanced or metastatic breast cancer (IND 213) was presented.  This clinical study was conducted by the Canadian Cancer Trials Group and the combined treatment demonstrated a statistically significant increase in median overall survival in the intention-to-treat patient population from 10.4 months on the control arm to 17.4 months on the test arm (n=74, hazard ratio 0.65, 80% CI 0.47 - 0.91, p-0.1). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fast track designation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, we announced that the United States Food and Drug Administration (FDA) granted Fast Track Designation (FTD) for REOLYSIN for the treatment of metastatic breast cancer. Receiving the FTD represented an important step for our clinical development plan as the FDA's Fast Track process is designed to facilitate the development, and expedite the review of drugs that treat serious conditions and fill an unmet medical need. The FTD supports more frequent dialogue with the FDA on our drug development plan, data requirements and clinical trial design. It also, in certain situations, enables the FDA to take action on a new drug or biologics license application more rapidly than under the standard review process.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Productive End-of-Phase 2 meeting</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2017, we announced a productive End-of-Phase 2 meeting with the FDA for REOLYSIN in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer (mBC) patients. The purpose of the meeting was to discuss the preclinical and clinical programs, including the design of the phase 3 registration study to support a future Biologics License Application (BLA) submission in the U.S. The FDA's feedback and the End-of-Phase 2 meeting outcome support our proposed target patient population of HR positive/HER2 negative metastatic breast cancer patients for our registration study. Importantly, the FDA provided guidance that if the study achieves its primary endpoint, then it will be the only study required for BLA approval which would allow us to commercialize and sell REOLYSIN.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Updated overall survival data</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, at the European Society for Medical Oncology (ESMO) 2017 Congress, we announced updated overall survival data from IND 213.  The updated survival data demonstrated that median overall survival more than doubled from 10.8 months on the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">control arm (paclitaxel alone) to 21.8 months in Hormone Receptor Positive (ER+PR+) / HER2 receptor negative patients  (n="47").  The hazard ratio was 0.36 and p-value was 0.003.&#160; </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Favorable Final Advice Letter</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, we received a favorable Final Advice Letter from the European Medicines Agency (EMA). The Letter refers to the proposed use of pelareorep in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer patients in a pivotal phase 3 registration study and suggests that a single 400-450 patient study may be acceptable to form the basis of a Marketing Authorization Application (MAA) in Europe. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">Program 2 - Combination with IMiDs/targeted therapy </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial activity supporting the innate immunity component of REOLYSIN's MOA, is in collaboration with Celgene Corporation (Celgene) and Myeloma UK, a cancer charity. MUK </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">eleven</font><font style="font-family:inherit;font-size:10pt;">&#32;was launched in March of 2017: a first of its kind immuno-therapy trial that aims to modulate the immune system to target myeloma. The Phase 1b trial will study REOLYSIN in combination with Celgene's Imnovid</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(pomalidomide) or Revlimid</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(lenalidomide) as a rescue treatment in relapsing myeloma patients. The dose escalation trial will look at the safety and tolerability of these combinations, and will investigate whether the addition of REOLYSIN extends disease control in this patient group. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trial, which commenced enrollment in September 2017, will recruit approximately 44 patients across up to six Myeloma UK Clinical Trial Network centres in the UK. MUK </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">eleven</font><font style="font-family:inherit;font-size:10pt;">&#32;is part of the Myeloma UK Clinical Trial Network, a portfolio of early-stage trials coordinated by the Clinical Trials Research Unit at the University of Leeds, which aims to test and speed up access to promising new treatments for patients.  Oncolytics and Celgene UK &amp; Ireland are providing their respective products for MUK </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">eleven</font><font style="font-family:inherit;font-size:10pt;">: Oncolytics is providing REOLYSIN and Celgene UK &amp; Ireland is providing Imnovid</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;and Revlimid</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">Program 3 - Immunotherapy combinations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In support of the adaptive immunity component of the MOA, we continued with our first checkpoint inhibitor study an open label design to assess the safety and dose-limiting toxicity of REOLYSIN in combination with pembrolizumab (KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) and chemotherapy in patients with histologically confirmed, advanced or metastatic adenocarcinoma of the pancreas (MAP) who have failed, or did not tolerate, first-line treatment (REO 024). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017, at the American Society of Clinical Oncology (ASCO) Annual Meeting, we presented safety data from REO 024 expanding our library of clinical data and established REOLYSIN as safe in combination with KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">.  The study enrolled 11 patients who were given REOLYSIN plus pembrolizumab, along with one of gemcitabine, 5-fluouracil or irinotecan. Grade 1 and 2 treatment emergent adverse events (TEAE) occurred in all patients and Grade 3 and 4 TEAE occurred in eight patients. Of the five efficacy evaluable patients, one had a partial response (six-month duration) and two had stable disease (lasting 126 and 221 days). Investigators noted that on-treatment biopsies revealed reovirus infection in cancer cells and immune infiltrates and concluded that the combination therapy showed manageable safety profiles and anti-tumour activity in previously treated MAP patients.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">Immuno-Oncolytic Virus Safety Database</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the ESMO 2017 Congress, we announced pooled data analysis of the safety and tolerability of intravenous pelareorep in combination with chemotherapy in 500+ cancer patients. The analysis demonstrates a strong safety profile in support of our clinical development plan. Highlights of the pooled safety data study include:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adverse events reported most frequently by REOLYSIN-treated patients were reversible Grade 1 and 2 events, including fever, chills, fatigue and the gastrointestinal-related AEs of nausea, vomiting, diarrhea.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">REOLYSIN did not modify or increase chemotherapy-induced Grade 3 or 4 treatment-emergent adverse events (TEAEs).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain serious TEAEs were more common in the REOLYSIN-treated arms, however the incidence of serious AEs due to febrile neutropenia and/or infection was similar in each group.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s307F83829F86515AAB787818778FFDB2"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Manufacturing and Process Development </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Throughout 2017, we supplied our clinical development program with previously filled product from our existing supply of REOLYSIN, labeled for the applicable usage. As well, we continued our activities to source and develop commercial production capabilities to fill REOLYSIN into vials, the next step in the process validation master plan. Process validation is required to ensure </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">that the resulting product meets required specifications and quality standards and will form part of the Company&#8217;s submission to regulators, including the FDA, for product approval. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1682603F299A5D37AF0DB72250A68292"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Intellectual Property</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the end of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">411</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">47</font><font style="font-family:inherit;font-size:10pt;">&#32;US and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents as well as issuances in other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028.  Our patent portfolio also includes methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sca3a2a50ed7a4f529474a69e532371c5"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Business Development</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2017, we entered into a regional licensing agreement (the "Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). Under the terms of the Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan.  We are entitled to receive upfront license fees and milestone payments to support our phase 3 registration study of US$21.2 million and we are eligible to receive up to an additional US$65.4 million upon achievement of clinical, regulatory and commercialization milestones. We are also eligible to receive double digit royalty payments associated with the commercialization of REOLYSIN for all indications, subject to regulatory approval.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1A07193A44985B1FAA0A9BD8F591E259"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financing Activity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">"At-the-Market" equity distribution agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, we entered into an "at-the-market" equity distribution agreement with Canaccord Genuity Inc. acting as sole agent in Canada (our "Canadian ATM"). Under the terms of our Canadian ATM, we may, from time to time, sell shares of our common stock having an aggregate offering value of up to $4.6 million through Canaccord Genuity Inc. Sales of  common shares, if any, pursuant to the Canadian ATM, will be made in transactions that are deemed to be "at-the-market distributions", through the facilities of the Toronto Stock Exchange or other "marketplace" (as defined in National Instrument 21-101 Marketplace Operation) in Canada. We will determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility.   During the year ending December 31, 2017, we sold </font><font style="font-family:inherit;font-size:10pt;">3,301,500</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$2,348,821</font><font style="font-family:inherit;font-size:10pt;">. We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">245,655</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public offering</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2017, pursuant to an underwritten public offering, we sold 16,445,000 units at a purchase price of $0.70 per unit for gross proceeds of $11,511,500. Each unit included one common share and one common share purchase warrant. Each common share purchase warrant entitles the holder to purchase one common share at an exercise price of $0.95 expiring on June 1, 2022. The common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds $2.50 for 15 consecutive trading dates. We incurred share issue costs of $1,145,402.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Options</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ending December 31, 2017, we received cash proceeds of $343,440 with respect to the exercise of 801,000 options by former employees.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFECE9F709665539D8B42EF747E6A5069"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Impact</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimated that our cash requirements for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to fund our operations for the year would be between $14 and $16 million. Our cash usage for the year was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$14,891,318</font><font style="font-family:inherit;font-size:10pt;">&#32;for operating activities and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$105,765</font><font style="font-family:inherit;font-size:10pt;">&#32;for the acquisition of property and equipment. Our net loss for the year was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15,616,851</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s95B6E04106AB547F8007F1CC10C224C5"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Cash Resources </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We exited </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;with cash and cash equivalents totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$11,836,119</font><font style="font-family:inherit;font-size:10pt;">&#32;(see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Liquidity and Capital Resources&#8221;)</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s547E39D9EC82552096039C23FF993346"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Expected REOLYSIN Development For 2018</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our planned 2018 development activity for REOLYSIN focuses on our three-part clinical development program, manufacturing program and intellectual property program. Our primary objective in 2018 is to finalize the development of our registration strategy in an effort to commence a phase 3 clinical study in mBC. Our focus will be on the adaptive study design that will include approximately four hundred patients with a pre-determined interim analysis. Our proposed target population for the phase 3 study of pelareorep is patients with HR+/HER2- mBC, which represents approximately 73 percent of metastatic breast cancer cases that have limited treatment options that offer survival benefit. Our planned activity also includes expanding our research collaborations with large pharma in an effort support further development around the innate and adaptive immunity components of REOLYSIN's MOA. We expect these potential collaborations to include combinations with immunotherapies and IMiDs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our 2018 manufacturing program includes continued production of 100-litre cGMP production runs along with the related fill, labeling, packaging and shipping of REOLYSIN to our various clinical sites.  We also plan to continue progressing through our process validation master plan and related conformity testing in 2018. Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently estimate the cash requirements to fund our operations for </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;will be approximately $16 million, but will depend on our ultimate clinical program.  (see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Liquidity and Capital Resources&#8221;</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9DB2A31933935AFD803E23B40E7952CC"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Our Accounting Policies </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing our financial statements we use IFRS as issued by the International Accounting Standards Board.  IFRS requires that we make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available in selecting our accounting policies. Our selection of accounting policies, along with our estimates and assumptions affect the reported amounts of our assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s0EC5A8C97A455851B756D34DDB7F6B11"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Critical Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing our financial statements, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets at the date of the financial statements and the reported amounts of expenses during the periods presented.  Significant estimates are used for, but not limited to, the treatment of our research and development expenditures, revenue recognition and the calculation of stock based compensation (see Note 4 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">" Significant Judgments, Estimates and Assumptions</font><font style="font-family:inherit;font-size:10pt;">") of our audited consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The significant accounting policies which we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research costs are expensed as incurred, net of recoveries.  We record accruals for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the treatment phase of clinical trials based on the total estimated cost of the treatment phase on a per patient basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized.  To date, all development costs have been expensed. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract receivable</font><font style="font-family:inherit;font-size:10pt;">&#32;- Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&#8217;s credit risk and payment histories, including payments made subsequent to year-end.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract liability</font><font style="font-family:inherit;font-size:10pt;">&#32;- Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.</font></div><div><a name="s603b3a334bc940debb59d7d4481b50ec"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 15 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue from Contracts with Customers</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the IASB issued IFRS 15 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">. The new standard will replace IAS 18 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue</font><font style="font-family:inherit;font-size:10pt;">&#32;and IAS 11 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Construction Contracts</font><font style="font-family:inherit;font-size:10pt;">. IFRS 15 establishes a comprehensive framework for determining whether, how much and when revenue is recognised, and also contains new requirements related to presentation. The core principle in that framework is that revenue should be recognised dependent on the transfer of promised goods or services to the customer for an amount that reflects the consideration which should be received in exchange for those goods or services. The objective of the standard is to provide a five-step approach to revenue recognition that includes identifying contracts with customers, identifying performance obligations, determining transaction prices, allocating transaction prices to performance obligations, and recognising revenue when or as performance obligations are satisfied. Judgment will need to be applied, including making estimates and assumptions, for multiple-element contracts in identifying performance obligations, in constraining estimates of variable consideration and in allocating the transaction price to each performance obligation. This new standard is effective for annual periods beginning on or </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">after January 1, 2018, with early adoption permitted. We early adopted this standard effective for our year ended December 31, 2017 using the full retrospective method. There were no adjustments to our consolidated financial statements resulting from this early adoption.</font></div><div><a name="s012A225785D053ECBBD2BD19385F65B6"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Accounting Standards and Interpretations Issued but Not Yet Effective</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 9 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014, on completion of the impairment phase of the project to reform accounting for financial instruments and replace IAS 39 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments: Recognition and Measurement</font><font style="font-family:inherit;font-size:10pt;">, the IASB issued the final version of IFRS 9 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments. </font><font style="font-family:inherit;font-size:10pt;">IFRS 9 includes guidance on the classification and measurement of financial assets and financial liabilities and impairment of financial assets (i.e. recognition of credit losses).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the classification and measurement requirements for financial assets, financial assets must be classified and measured at either amortized cost or at fair value through profit or loss or through other comprehensive income, depending on the basis of the entity&#8217;s business model for managing the financial asset and the contractual cash flow characteristics of the financial asset. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The classification requirements for financial liabilities are unchanged from IAS 39. IFRS 9 requirements address the problem of volatility in net earnings arising from an issuer choosing to measure certain liabilities at fair value and require that the portion of the change in fair value due to changes in the entity&#8217;s own credit risk be presented in other comprehensive income, rather than within net earnings. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new requirements for impairment of financial assets introduce an expected loss impairment model that requires more timely recognition of expected credit losses. IAS 39 impairment requirements are based on an incurred loss model where credit losses are not recognized until there is evidence of a trigger event. IFRS 9 is effective for annual periods beginning on or after January 1, 2018 with early adoption permitted. We are assessing the impact of adopting this standard on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 16 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the IASB issued IFRS 16 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;IFRS 16&#8221;), which replaces IAS 17 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;IAS 17&#8221;) and related interpretations. IFRS 16 provides a single lessee accounting model, requiring the recognition of assets and liabilities for all leases, unless the lease term is 12-months or less or the underlying asset has a low value. IFRS 16 substantially carries forward the lessor accounting in IAS 17 with the distinction between operating leases and finance leases being retained. IFRS 16 will be applied retrospectively for annual periods beginning on or after January 1, 2019. Early adoption is permitted under certain circumstances.  We are assessing the potential impact of adopting this standard on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s3ED6EF4FEB43532581109799CBC40A12"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Significant Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue recognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into an Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share Based Payments </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As required by IFRS, share based payments are to be recorded at their fair value at the date of grant.  We have chosen to use the Black Scholes Option Pricing Model (&#8220;Black Scholes&#8221; or the &#8220;Model&#8221;) to calculate the fair value of our stock options and warrants.  Though there are other models available to calculate the option values (for example, the binomial model), Black Scholes is currently widely used and accepted by other publicly traded companies.  Therefore, we have concluded that Black Scholes is the appropriate option pricing model to use for our stock options at this time.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Black Scholes uses inputs in its calculation of fair value that require us to make certain estimates and assumptions.  For </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, we used the following weighted average assumptions for the calculation of the fair value of the stock options granted during the year:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:378px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:245px;"></td><td style="width:133px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.18%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility in the price of the Company's shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90.73%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rate of forfeiture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.67%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$0.28</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A change in these estimates and assumptions will impact the value calculated by the model.  For instance, the volatility in the price of our shares is based on the quoted trading price. We assume that weekly trading prices best reflect our trading price volatility. However, an entity can choose between daily, weekly, or monthly trading prices in the volatility calculation.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Model also uses an expected hold period to exercise in its calculation of fair value.  When we are estimating the expected hold period to exercise we take into consideration past history, the current trading price, the volatility of our common shares and the progress in our clinical program. Our conclusions resulted in an expected hold period for the stock options issued in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to be 3.0 years and we believe this is an appropriate estimate. However, our options have a 10-year life and given the fluctuations in our stock price the expected hold period could be different.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consequently, in complying with IFRS and selecting what we believe are the most appropriate assumptions under the circumstances, we have recorded non-cash share based payment expense for the year of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$578,703</font><font style="font-family:inherit;font-size:10pt;">.  However, given the above discussion, this expense could have been different and still be in accordance with IFRS.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s6A876B49EBA157C8927C9BEE406AAB51"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Selected Annual Information</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:586px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:318px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,616,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,139,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,722,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1), (2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(0.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18,150,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,758,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,383,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash dividends declared per share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="7" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Notes:</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1)  Included in consolidated net loss and loss per common share for 2017, 2016, and 2015 are share based payment expenses of $578,703, $406,078 and $429,537, respectively.</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2)  We issued 20,547,500 common shares for net cash proceeds of $12.8 million in 2017 (2016 - 3,106,600 common shares for net cash proceeds of $1.0 million; 2015 - 24,639,128 common shares for net cash proceeds of  $23.7 million).  </font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3)  We have not declared or paid any dividends since incorporation.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1C7B577B558A511AA8EE8AE12E19E68B"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the year was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15,616,851</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15,139,979</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$13,722,995</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:624px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:384px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,475,918</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,806,335</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,553,037</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,726,432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,725,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,306,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenditures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">847,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,096,097</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,032,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">252,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">369,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">698,909</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,926,197</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,367,595</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,868,753</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific research and development refund</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange loss (gain) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(65,256</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,960</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,051,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">230,141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,919</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9,392,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,770,007</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,601,864</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trial Program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses include those costs associated with our clinical trial program which primarily included our randomized phase 2 studies investigating chemotherapy combinations (Program 1) and immunotherapy combinations (Program 3). Included in clinical trial expenses are direct patient enrollment costs, contract research organization (&#8220;CRO&#8221;) expenses, clinical trial site selection and initiation costs, data management expenses and other costs associated with our clinical trial program.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:602px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:376px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,475,918</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,806,335</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,553,037</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, our clinical trial expenses were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,475,918</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,806,335</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,553,037</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.  In 2017, our clinical trial program focused mainly on the preparation and development of our breast cancer registration study. These activities included costs to complete our supporting regulatory documents, regulatory filing fees, planning for and attending scientific advisory meetings with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and key opinion leader activities. In addition, with the signing of our Regional Licensing Agreement that included upfront licensing fees in November 2017, we triggered payments of $640,579 as detailed in our Assumption Agreement (see Notes 10 and 12 of our audited consolidated financial statements). Costs associated with these activities were partially offset as we continued to close out legacy clinical trial sites truing up our cost estimates with the actual costs incurred. In 2017 and 2016, our clinical activities included patient enrollment in our checkpoint inhibitor pancreatic cancer study investigating pembrolizumab (KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) in combination with REOLYSIN. In 2016, our clinical trial expenses also included costs associated with the completion of enrollment in our randomized Phase 2 studies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in clinical trial expenses in 2016 compared to 2015 was due to completion of enrollment in our Randomized Studies and close out of fully enrolled clinical trials in 2015.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our clinical trial expenses to increase in 2018 compared to 2017. During 2018, we expect to finalize the development of our registration strategy and possibly commence enrollment in a registration study as part of Program 1 of our clinical development plan. As well, we expect to expand Program 2 and Program 3 of our clinical development plan to include both checkpoint inhibitors and immune modulators (IMiDs).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing &amp; Related Process Development (&#8220;M&amp;P&#8221;)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">M&amp;P expenses include product manufacturing and process development activities. Product manufacturing expenses include third party direct manufacturing costs, quality control testing, fill, label, packaging and storage costs and are net of any recoveries that </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">are received from any R&amp;D collaborators. Process development expenses include costs associated with studies that examine components of our manufacturing process looking for improvements and costs associated with the creation of our process validation master plan and related conformity testing. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.6484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product manufacturing expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,054,903</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,162,446</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,618,165</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">671,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563,389</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">687,859</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,726,432</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,725,835</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,306,024</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our M&amp;P expenses for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,726,432</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,725,835</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,306,024</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. During 2017 and 2016, our product manufacturing activities mainly related to shipping and storage costs of our bulk and vialed product. In 2016, these costs were partly offset by recoveries from a development collaboration. During 2015, our production manufacturing activities mainly related to supplying our clinical programs with sufficient REOLYSIN, including the fill, labeling and lot release testing of product and the shipping and storage of our bulk and vialed product. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our process development expenses for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$671,529</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$563,389</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$687,859</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. During 2017, our process development activities focused on stability, process optimization studies, assay development and biodistribution studies. In 2016 and 2015, our process development activities focused on our validation master plan, which included included stability, scale up and process optimization studies. In 2015 these  activities also included assay development and validation studies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our M&amp;P expenses for 2018 to increase compared to 2017.  In 2018, we expect to fill, label and store sufficient product as we attempt to commence a registration study. We also expect to continue to perform stability testing and analytical development related to our process validation master plan and stability program.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses include legal and filing fees associated with our patent portfolio.  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.1796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:64%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">847,650</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,096,097</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,032,227</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intellectual property expenses for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$847,650</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,096,097</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,032,227</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.  The change in intellectual property expenditures reflects the timing of filing costs and expiration and lapsing of patents in certain jurisdictions in 2017. The decline in 2017 is also a result of the maturation of our patent portfolio, which incurs less fees. At the end of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">411</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">47</font><font style="font-family:inherit;font-size:10pt;">&#32;US and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents, as well as issuances in other jurisdictions.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that our intellectual property expenses will remain consistent in 2018 compared to 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaborations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaborations are intended to expand our intellectual property related to REOLYSIN and identify potential licensing opportunities arising from our technology base.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.5234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaborations</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">252,482</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">369,469</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">698,909</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, our research collaboration expenses were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$252,482</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$369,469</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$698,909</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. In 2017 and 2016, our research collaborations included studies investigating the interaction of the immune system and REOLYSIN along with biomarker studies. In 2015, our research collaborations also included the use of the reovirus as a co-therapy with existing chemotherapeutics and radiation.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that our research collaborations in 2018 will increase compared to 2017. We expect to complete our ongoing collaborative program carried over from 2017 and will continue to be selective in the types of new collaborations we enter into in 2018.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Research and Development Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other research and development expenses include compensation expenses for employees (excluding share based payments), travel and other miscellaneous R&amp;D expenses.  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D salaries and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,662,638</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,138,235</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,388,272</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">263,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,926,197</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,367,595</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,868,753</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, our Other Research and Development expenses were </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">$3,926,197</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">$4,367,595</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">$3,868,753</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. Our Other Research and Development activities focused on supporting our clinical development program along with other third party trials and clinical trials sponsored by Oncolytics. R&amp;D salaries and benefits in 2017 included severance payments of $779,666 to certain officers of the Company and in 2016 included a retirement allowance of $1,330,828 paid to the previous Chief Executive Officer. Normalizing for these payments, our R&amp;D salaries and benefits increased compared to 2016 primarily due to an increase in bonuses paid to officers and employees in 2017. R&amp;D salaries and benefits was also impacted by the change in officers in 2017 and 2016. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in Other R&amp;D expenses in 2017 compared to 2016 was due to an increase in conference attendance and related travel expenses. The change in Other R&amp;D expenses in 2016 compared to 2015 was due to the completion of enrollment in our CCTG trials and the close out of completed Company sponsored studies in 2015.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our Other R&amp;D expenses to increase in 2018 compared to 2017 due to an increase in headcount to support our registration study.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Scientific Research and Development Refund</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.15625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:66%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific research and development refund</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(941</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,203</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,144</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">,  </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we received Alberta and Quebec scientific research and development refunds totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$941</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1,203</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$62,144</font><font style="font-family:inherit;font-size:10pt;">, respectively. During the three year period 2015-2017, our qualified expenditures for scientific research and development refunds in Canada have declined.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Exchange (Gain) Loss</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange (gain) loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(65,256</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,960</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,051,958</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, our foreign exchange (gain) loss was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$(65,256)</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$171,960</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ending December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$(1,051,958)</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. The foreign exchange (gain) losses incurred in 2017 and 2016 were primarily a result of the fluctuations in the US dollar, Euro and Pound Sterling exchange rates. In 2015, our foreign exchange gain was primarily a result of the strengthening of the US dollar and that the proceeds from our financing activities were in US dollars.     </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Based Payments</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">230,141</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,919</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based payments for the year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$230,141</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$233,919</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$257,016</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. We incurred share based payment expenses associated with the granting of options and restricted share units to employees associated with our research and development activities and the vesting of previously granted share awards.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2016<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><br>2015<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,970,707</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,172,676</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,932,436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,802,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,017,432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,030,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90,768</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,233</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,411</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">348,562</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,159</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,521</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,212,831</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,524,500</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,315,837</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses include costs associated with investor relations and business development activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our U.S. and Canadian stock listings.   In </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, we incurred public company related expenses of </font><font style="font-family:inherit;font-size:10pt;">$2,970,707</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$3,172,676</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2,932,436</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The change in these costs in 2017 compared to 2016 was a result of our change in philosophy regarding investor relations (IR) activities, where we eliminated certain IR services and brought elements in-house and rationalized IR related travel activity which was partly offset by an increase in business development activities in 2017. The increase in public company related expenses in 2016 compared to 2015 was due to an increase in investor relations activities.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses include compensation costs (excluding share based payments), office rent and other office related costs.  In </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, we incurred office expenses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$2,802,794</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$2,017,432</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,030,469</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The change in office expenses in 2017 compared to 2016 was due to an increase in headcount and a change in salary levels during the first half of 2017. In 2016 and 2015, our office expenses remained relatively consistent. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, our non-cash share based payment expenses were </font><font style="font-family:inherit;font-size:10pt;">$348,562</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$172,159</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$172,521</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. In </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, 2016 and 2015, we incurred share based payment expenses associated with the granting of options, restricted share units and performance share units to officers, employees and independent board members along with the vesting of previously granted share awards. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our operating expenses in 2018 to increase compared to 2017.    </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2E2DD2E29B8E5557BFCC5A64E3396903"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Summary of Quarterly Results</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:663px;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:225px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:39px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:40px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:43px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:43px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:46px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:43px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:42px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="12" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="12" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dec.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sept.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dec.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sept.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,746</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,004</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,349</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,518</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,210</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,332</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,017</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,848</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,579</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,758</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,368</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,023</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1), (3)</sup></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash dividends declared</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:8pt;text-indent:-36px;"><font style="font-family:inherit;font-size:8pt;">Included in total cash are cash and cash equivalents plus short-term investments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Included in net loss and loss per common share between December 2017 and January 2016 are quarterly share based payment expenses of </font><font style="font-family:inherit;font-size:8pt;">$140,659</font><font style="font-family:inherit;font-size:8pt;">, $148,447, $155,708, $133,889, $106,443, $98,369, $119,626 and $81,640, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We issued </font><font style="font-family:inherit;font-size:8pt;">20,547,500</font><font style="font-family:inherit;font-size:8pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:8pt;">$12.8 million</font><font style="font-family:inherit;font-size:8pt;">&#32;in </font><font style="font-family:inherit;font-size:8pt;">2017</font><font style="font-family:inherit;font-size:8pt;">&#32;(</font><font style="font-family:inherit;font-size:8pt;">2016</font><font style="font-family:inherit;font-size:8pt;">&#32;- </font><font style="font-family:inherit;font-size:8pt;">3,106,600</font><font style="font-family:inherit;font-size:8pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:8pt;">$1.0 million</font><font style="font-family:inherit;font-size:8pt;">).  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We have not declared or paid any dividends since incorporation.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><a name="s5E587377BBD65E77A922FAC894ED0E98"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Fourth Quarter</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statement of loss for the three month period ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:486px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:316px;"></td><td style="width:83px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three month periods ending December 31,</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,479,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,411,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Operating</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,158,381</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,816,183</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before the following</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,637,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,227,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Interest</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">33,464</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,053</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,604,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,200,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(141,514</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,707</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,745,584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,210,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Other comprehensive gain - translation adjustment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,733,580</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,148,599</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Weighted average number of shares (basic and diluted)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">141,162,287</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,145,249</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4AD4C17F8B5B5BC98DB3BB0EAEB6F476"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Fourth Quarter Review of Operations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three month period ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;our net loss was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4,745,584</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$5,210,022</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three month period ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:544px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:384px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">459,884</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,945</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">483,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450,149</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">105,192</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">269,025</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">73,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,198,164</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,300,862</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">110,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">47,281</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,507</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,479,153</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,411,185</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trial Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.8828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">459,884</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,945</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, our clinical trial expenses were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$459,884</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$229,945</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">.  In the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, our clinical trial program activities related primarily to the preparation and development of our breast cancer registration study, which included costs to complete our supporting regulatory documents, regulatory filing fees and attending an End of Phase 2 meeting with the EMA. Our clinical trial program activities also included patient enrollment in our checkpoint inhibitor pancreatic cancer study investigating pembrolizumab (KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) in combination with REOLYSIN. In addition, with the signing of a regional licensing agreement with upfront licensing fees in November 2017, we triggered payments to former shareholders of $640,579 as detailed in the Assumption Agreement (see Notes 10 and 12 of our audited consolidated financial statements). Costs associated with these activities were offset as we continued to close out legacy clinical trial sites truing up our cost estimates with the actual costs incurred.  I</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">n the fourth quarter of 2016, our clinical trial program activities related primarily to the patient enrollment in our checkpoint inhibitor pancreatic cancer study investigating pembrolizumab (KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) in combination with REOLYSIN.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing &amp; Related Process Development Expenses (&#8220;M&amp;P&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.90625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product manufacturing expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">226,553</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353,605</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">257,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,544</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">483,887</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450,149</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, our M&amp;P expenses were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$483,887</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$450,149</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">.  During the fourth quarters of 2017 and 2016, our product manufacturing costs mainly related to shipping and storage costs of our bulk and vialed product. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our process development activity for the fourth quarter of 2017 related to stability studies and a biodistribution study compared to stability studies for the fourth quarter of 2016. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">105,192</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">269,025</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intellectual property expenses for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$105,192</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$269,025</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">. The change in intellectual property expenditures reflects the timing of filing costs and expiration and lapsing of patents in certain jurisdictions in 2017. The decline in 2017 is also a result of the maturation of our patent portfolio, which incurs less fees.  At the end of the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:inherit;font-size:10pt;">411</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;">47</font><font style="font-family:inherit;font-size:10pt;">&#32;US and </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents, as well as issuances in other jurisdictions. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaboration Expenses </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:70%;"></td><td style="width:15%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">73,966</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177,794</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research collaboration expenses were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$73,966</font><font style="font-family:inherit;font-size:10pt;">&#32;in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$177,794</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">.  During the fourth quarter of 2017, our research collaborations were primarily focused on studies investigating the interaction of the immune system and REOLYSIN. During the fourth quarter of 2016, our research collaborations were primarily focused on biomarker studies.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Research and Development Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D salaries and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,120,534</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,225,080</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">77,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,198,164</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,300,862</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our other research and development expenses were </font><font style="font-family:inherit;font-size:10pt;">$1,198,164</font><font style="font-family:inherit;font-size:10pt;">&#32;in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$2,300,862</font><font style="font-family:inherit;font-size:10pt;">&#32;in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.  In the fourth quarter of 2016, our salaries and benefits costs included a retirement allowance of $1,330,828 paid to the previous chief executive officer. Normalizing for the retirement allowance, our R&amp;D salaries and benefits increased in the fourth quarter of 2017 compared to 2016 primarily due to an increase in bonuses paid to officers and employees. Our Other R&amp;D expenses in the fourth quarter of 2017 were consistent with 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Based Payments</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">47,281</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,507</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarters of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, we incurred share based payment expenses associated with the granting of options and restricted share units to employees associated with our research and development activities and the vesting of previously granted share awards.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:531px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:377px;"></td><td style="width:72px;"></td><td style="width:4px;"></td><td style="width:72px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">969,018</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">911,811</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,075,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">813,834</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20,453</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,602</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">93,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,158,381</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,816,183</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operating expenses in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$2,158,381</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1,816,183</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our Canadian and U.S. stock listings. During the fourth quarter of 2017, our public company related expenses were $</font><font style="font-family:inherit;font-size:10pt;">969,018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">911,811</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of 2016. The increase was due to an increase in business development activities in the fourth quarter </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of 2017 partly offset by a decrease in IR activities as a result of our change in philosophy, where we eliminated certain IR services and brought elements in-house.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses include compensation costs (excluding share based payments), office rent and other office related costs. During the fourth quarter of 2017, our office expenses were $</font><font style="font-family:inherit;font-size:10pt;">1,075,532</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">813,834</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of 2016. The change was due to an increase in headcount and an increase in bonuses paid to officers and employees in 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our non-cash share based payment expenses in the fourth quarter of 2017 were $</font><font style="font-family:inherit;font-size:10pt;">93,378</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">62,936</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of 2016. We incurred share based payment expenses associated with the granting of options and restricted share units to officers, employees and independent board members along with the vesting of previously granted share awards.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0145045A4EE75D5990FE012F9C6B4128"></a></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><a name="s847AC4C9EA5E57178A146F8881BADE54"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">&#32;Financing Activities </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Canadian "At the Market" Equity Distribution Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, we issued </font><font style="font-family:inherit;font-size:10pt;">3,301,500</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net proceeds of $</font><font style="font-family:inherit;font-size:10pt;">2,103,166</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public offering </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2017 we closed a public offering whereby we sold 16,445,000 units at a purchase price of $0.70 per unit for gross proceeds of $11,511,500. Each unit included one common share and one common share purchase warrant. Each common share purchase warrant entitles the holder to purchase one common share at an exercise price of $0.95 expiring on June 1, 2022. The common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds $2.50 for 15 consecutive trading dates. We incurred share issue costs of $1,145,402.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Options</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2017, we received cash proceeds of $343,440 with respect to the exercise of 801,000 options by former employees.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB07A48A9C902522C8BA9A5534BEB7609"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">2016 Financing Activities </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Canadian "At the Market" Equity Distribution Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2016, we issued 3,006,600 common shares for net proceeds of $956,133.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s12A6DA0DBC0754BB97837956490F19AD"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents, short-term investments and working capital positions as follows: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:67%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br>$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,836,119</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,034,282</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital position</font></div></td><td style="vertical-align:middle;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,587,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,369,665</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The decrease in our cash and cash equivalent and short term investment positions reflects the cash usage from our operating activities of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$14.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;along with the cash provided by our financing activities of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$12.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We desire to maintain adequate cash and short-term investment reserves to support our planned activities which include our clinical trial program, product manufacturing, administrative costs, and our intellectual property expansion and protection.  To date, we have funded our operations mainly through the issue of additional capital via public and private offerings and through the exercise of warrants and stock options. In February 2016, we were able to raise funds through our Canadian ATM (our "Financing Arrangement"). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no assurances that we will be able to raise additional funds through the sale of our common shares, consequently, we will continue to evaluate all types of financing arrangements.  In an effort to be able to evaluate all types of financing arrangements, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we maintain a current short form base shelf prospectus (the &#8220;Base Shelf&#8221;) that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the &#8220;Securities&#8221;). We renewed our Base Shelf on February 16, 2016 which allows us to sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also allows us to sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement. Our Base Shelf expires on March 16, 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maintaining our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. </font><font style="font-family:inherit;font-size:10pt;color:#ee2724;">&#32;</font><font style="font-family:inherit;font-size:10pt;">By utilizing our Base Shelf, we were able to enter into our Financing Arrangement. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Financing Arrangement provides us with access to, subject to the respective terms and conditions, $4.6 million of which we have raised gross proceeds of approximately $3.8 million at December 31, 2017. We expect to continue to access our Financing Arrangement to help support our current clinical trial, manufacturing, intellectual property and collaboration programs. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that the expected cash usage from our operations in 2018 will be approximately $16 million. We continue to manage our research and development plan with the objective of ensuring optimal use of our existing resources. Additional activities continue to be subject to adequate resources and we believe we will have sufficient cash resources and access to additional cash resources through our Financing Arrangements to fund our presently planned operations into 2018. Factors that will affect our anticipated cash usage in 2018, and for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&amp;D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8EB99E227DDB501682F25525E6609626"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have the following contractual obligations as at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.14634146341464%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:30%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations</font></div></td><td colspan="10" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Less than 1 year</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2 -3 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4 - 5 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">More than </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital lease obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">740,850</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,987</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">411,733</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,130</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,980,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,980,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long term obligations</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total contractual obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,721,304</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,266,441</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">411,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,130</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Note:</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1. Our operating leases are comprised of our office leases and exclude our portion of operating costs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to fund our capital expenditure requirements and commitments with existing working capital.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFBB099C413E85319BB056A359D459631"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had not entered into any off-balance sheet arrangements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sCB0FD16F23CC5E0E9EFA6086A5F690CE"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Transactions with Related Parties</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, with the signing of our Regional Licensing Agreement with upfront license fees (see Note 10 of our audited consolidated financial statements), we triggered a liability of US$178,125 to an officer as detailed in the Assumption Agreement (see Note 12 of our audited consolidated financial statements).  As at December 31, 2017, US$178,125 was included in accounts payable and </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">accrued liabilities. US$35,625 was paid in January 2018 and the balance will be paid after receipt of the contract receivable from Adlai Nortye Biopharma Co., Ltd.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, we did not enter into any other related party transactions other than compensation paid to Key Management Personnel disclosed in Note 20 of our audited consolidated financial statements.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s3D7980531A2E556DA77180549B701034"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Instruments and Other Instruments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents, contract receivable, other receivables and accounts payable.  As at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there are no significant differences between the carrying values of these amounts and their estimated market values.  These financial instruments expose us to the following risks:</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counter-party to a financial instrument fails to meet its contractual obligations.  We are exposed to credit risk on our cash and cash equivalents and contract receivable in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and contract receivable.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada. For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk connected to our contract receivable by performing a review of our customer's credit risk and payment histories, including payments made subsequent to year-end. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.  We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments.  We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Currency risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from operating and financing activities.  As well, we are exposed to currency risk related to our regional licensing agreement. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5,056</font><font style="font-family:inherit;font-size:10pt;">. The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$21,492</font><font style="font-family:inherit;font-size:10pt;">. The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$11,736</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk  by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:63%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">US</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">dollars <br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">British pounds</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#163;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,948,573</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,755</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,372</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,800,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(777,271</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,949</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,971,302</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,806</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in the notes to our audited financial statements.  Accounts payable are all due within the current operating period.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s6EC5B4B1E6C250D4AA5B733D15F273F5"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Risk Factors Affecting Future Performance</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General Risk Factors</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prospects for biotechnology companies in the research and development stage should generally be regarded as speculative.  It is not possible to predict, based upon studies in animals, or early studies in humans, whether a new therapeutic will ultimately prove to be safe and effective in humans, or whether necessary and sufficient data can be developed through the clinical trial process to support a successful product application and approval. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users at a commercially reasonable price may not be successful.  There can be no assurance that we will generate adequate funds to continue development, or will ever achieve significant revenues or profitable operations.  Many factors (e.g. competition, patent protection, appropriate regulatory approvals) can influence the revenue and product profitability potential.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In developing a pharmaceutical product, we rely upon our employees, contractors, consultants and collaborators and other third party relationships, including the ability to obtain appropriate product liability insurance.  There can be no assurance that this reliance and these relationships will continue as required.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to developmental and operational considerations, market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress we have made or are making.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our product REOLYSIN is in the research and development stage and will require further development and testing before it can be marketed commercially.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly, investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, REOLYSIN, for human application, the riskiest stage for a company in the biotechnology industry.  It is not possible to predict, based upon studies in animals, or early studies in humans, whether REOLYSIN will prove to be safe and effective in humans.  REOLYSIN will require additional research and development, including extensive clinical testing, before we will be able to obtain the approval of the United States Food and Drug Administration (the &#8220;FDA&#8221;) or from similar regulatory authorities in other countries to market REOLYSIN commercially.  There can be no assurance that the research and development programs conducted by us will result in REOLYSIN or any other products becoming commercially viable products, and in the event that any product or products result from the research and development program, it is unlikely they will be commercially available for a number of years.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To achieve profitable operations, we, alone or with others, must successfully develop, introduce and market our products.  To obtain regulatory approvals for products being developed for human use, and to achieve commercial success, human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy.  Unsatisfactory results obtained from a particular study relating to a program may cause us to abandon our commitment to that program or the product being tested.  No assurances can be provided that any current or future animal or human test, if undertaken, will yield favorable results.  If we are unable to establish that REOLYSIN is a safe, effective treatment for cancer, we may be required to abandon further development of the product and develop a new business strategy.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">There are inherent risks in pharmaceutical research and development.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical research and development is highly speculative and involves a high and significant degree of risk.  The marketability of any product developed by us will be affected by numerous factors beyond our control, including:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the discovery of unexpected toxicities or lack of sufficient efficacy of products which make them unattractive or unsuitable for human use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">preliminary results as seen in animal and/or limited human testing may not be substantiated in larger controlled clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manufacturing costs or other factors may make manufacturing of products impractical and non-competitive;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">proprietary rights of third parties or competing products or technologies may preclude commercialization;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requisite regulatory approvals for the commercial distribution of products may not be obtained; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other factors may become apparent during the course of research, up-scaling or manufacturing which may result in the discontinuation of research and other critical projects.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our product under development has never been manufactured on a commercial scale, and there can be no assurance that such products can be manufactured at a cost or in a quantity to render such products commercially viable.  Production and utilization of our products may require the development of new manufacturing technologies and expertise. The impact on our business in the event that new manufacturing technologies and expertise are required to be developed is uncertain. There can be no assurance that we will successfully meet any of these technological challenges, or others that may arise in the course of development.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical products are subject to intense regulatory approval processes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The regulatory process for pharmaceuticals, which includes preclinical studies and clinical trials of each compound to establish its safety and efficacy, takes many years and requires the expenditure of substantial resources.  Moreover, if regulatory approval of a drug is granted, such approval may entail limitations on the indicated uses for which it may be marketed.  Failure to comply with applicable regulatory requirements can, among other things, result in suspension of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.  Further, government policy may change, and additional government regulations may be established that could prevent or delay regulatory approvals for our products.  In addition, a marketed drug and its manufacturer are subject to continual review.  Later discovery of previously unknown problems with the product or manufacturer may result in restrictions on such product or manufacturer, including withdrawal of the product from the market.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA in the United States and other relevant regulatory authorities may deny approval of a new drug application (&#8220;NDA&#8221;) or its equivalent in the relevant jurisdiction if required regulatory criteria are not satisfied, or may require additional testing.  Product approvals may be withdrawn if compliance with regulatory standards are not maintained or if problems occur after the product reaches the market.  The FDA may require further testing and surveillance programs to monitor the pharmaceutical product that has been commercialized.  Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product withdrawals, product seizures, injunction actions and criminal prosecutions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our own pharmaceuticals, we may supply active pharmaceutical ingredients and advanced pharmaceutical intermediates for use in or with  our customers' other drug products. The final drug products in which the pharmaceutical ingredients and advanced pharmaceutical intermediates are used, however, are subject to regulation for safety and efficacy by the FDA and other jurisdictions, as the case may be. Such products must be approved by such agencies before they can be commercially marketed. The process of obtaining regulatory clearance for marketing is uncertain, costly and time consuming.  We cannot predict how long the necessary regulatory approvals will take or whether our customers will ever obtain such approval for their products. To the extent that our customers do not obtain the necessary regulatory approvals for marketing new products, our product sales could be adversely affected.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and other governmental regulators have increased requirements for drug purity and have increased environmental burdens upon the pharmaceutical industry. Because pharmaceutical drug manufacturing is a highly regulated industry, requiring significant documentation and validation of manufacturing processes and quality control assurance prior to approval of the facility to manufacture a specific drug, there can be considerable transition time between the initiation of a contract to manufacture a product and the actual initiation of manufacture of that product. Any lag time in the initiation of a contract to manufacture product and the actual initiation of manufacture could cause us to lose profits or incur liabilities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical regulatory regime in Europe and other countries is, by and large, generally similar to that of Canada and the United States.  We could face similar risks in these other jurisdictions, as the risks described above.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our operations and products may be subject to other government manufacturing and testing regulations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States and similar regulatory agencies in other countries is a long and expensive process, which can delay or prevent product development and marketing.  Approval to market products may be for limited applications or may not be received at all.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The products anticipated to be manufactured by us will have to comply with the FDA's cGMP  and other FDA and local government guidelines and regulations, including other international regulatory requirements and guidelines.  Additionally, certain of our customers may require the manufacturing facilities contracted by us to adhere to additional manufacturing standards, even if not required by the FDA. Compliance with cGMP regulations requires manufacturers to expend time, money and effort in production, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and to maintain precise records and quality control to ensure that the product meets applicable specifications and other requirements. The FDA and other regulatory bodies periodically inspect drug-manufacturing facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities contracted by us fail to comply with the cGMP requirements, the facilities may become subject to possible FDA or other regulatory action and manufacturing at the facility could consequently be suspended.  We may not be able to contract suitable alternative or back-up manufacturing facilities on terms acceptable to us or at all.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA or other regulatory agencies may also require the submission of any lot of a particular product for inspection. If the lot product fails to meet the FDA requirements, then the FDA could take any of the following actions: (i) restrict the release of the product; (ii) suspend manufacturing of the specific lot of the product; (iii) order a recall of the lot of the product; or (iv) order a seizure of the lot of the product.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to regulation by governments in many jurisdictions and, if we do not comply with healthcare, drug, manufacturing and environmental regulations, among others, our existing and future operations may be curtailed, and we could be subject to liability.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the regulatory approval process, we may be subject to regulations under local, provincial, state, federal and foreign law, including requirements regarding occupational health, safety, laboratory practices, environmental protection and hazardous substance control, and may be subject to other present and future local, provincial, state, federal and foreign regulations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our products may fail or cause harm, subjecting us to product liability claims, which are uninsured.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The sale and use of our products entail risk of product liability.  We currently do not have any product liability insurance.  There can be no assurance that we will be able to obtain appropriate levels of product liability insurance prior to any sale of our pharmaceutical products.  An inability to obtain insurance on economically feasible terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization of products developed by us.  The obligation to pay any product liability claim or a recall of a product could have a material adverse effect on our business, financial condition and future prospects.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our technologies may become obsolete.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical industry is characterized by rapidly changing markets, technology, emerging industry standards and frequent introduction of new products.  The introduction of new products embodying new technologies, including new manufacturing processes, and the emergence of new industry standards may render our products obsolete, less competitive or less marketable.  The process of developing our products is extremely complex and requires significant continuing development efforts and third party commitments.  Our failure to develop new technologies and products and the obsolescence of existing technologies could adversely affect our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unable to anticipate changes in our potential customer requirements that could make our existing technology obsolete.  Our success will depend, in part, on our ability to continue to enhance our existing technologies, develop new technology that addresses the increasing sophistication and varied needs of the market, and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks.  We may not be successful in using our new technologies or exploiting the respective niche markets effectively or adapting our businesses to evolving customer or medical requirements or preferences or emerging industry standards.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We have no operating revenues and a history of losses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have not generated sufficient revenues to offset our research and development costs and accordingly have not generated positive cash flow or made an operating profit.  As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$294.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;and we incurred net losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$15.6 million</font><font style="font-family:inherit;font-size:10pt;">,  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$15.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$13.7 million</font><font style="font-family:inherit;font-size:10pt;">, for the years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.  We anticipate that we will continue to incur significant losses during </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and in the foreseeable future.  We do not expect to reach profitability at least until after successful and profitable commercialization of one or more of our products.  Even if one or more of our products are profitably commercialized, the initial losses incurred by us may never be recovered.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that we may need additional financing in the future to fund research and development and to meet our ongoing capital requirements.  The amount of future capital requirements will depend on many factors, including continued scientific </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">progress in our drug discovery and development programs, progress in our pre-clinical and clinical evaluation of drug candidates, time and expense associated with filing, prosecuting and enforcing our patent claims and costs associated with obtaining regulatory approvals.  In order to meet such capital requirements, we will consider contract fees, collaborative research and development arrangements, and additional public or private financings (including the incurrence of debt and the issuance of additional equity securities) to fund all or a part of particular programs as well as potential partnering or licensing opportunities.  There can be no assurance that additional funding will be available or, if available, that it will be available on acceptable terms.  If adequate funds are not available on terms favorable to us, we may have to reduce substantially or eliminate expenditures for research and development, testing, production and marketing of our proposed product, or obtain funds through arrangements with corporate partners that require us to relinquish rights to certain of our technologies or product.  There can be no assurance that we will be able to raise additional capital if our current capital resources are exhausted.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The cost of director and officer liability insurance may continue to increase substantially or may not be available to us and may affect our ability to retain quality directors and officers.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We carry liability insurance on behalf of our directors and officers. Given a number of large director and officer liability insurance claims in the US equity markets, director and officer liability insurance had until recently become increasingly more expensive with increased restrictions. Consequently, there is no assurance that we will continue to be offered this insurance or be able to obtain adequate coverage. The inability to acquire the appropriate insurance coverage will limit our ability to attract and maintain directors and officers as required to conduct our business. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We incur some of our expenses in foreign currencies and therefore are exposed to foreign currency exchange rate fluctuations.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incur some of our manufacturing, clinical, collaborative and consulting expenses in foreign currencies, primarily the US dollar, the Pound Sterling and the Euro.  We are therefore exposed to foreign currency rate fluctuations.  Also, as we expand to other foreign jurisdictions there may be an increase in our foreign exchange exposure.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We earn interest income on our excess cash reserves and are exposed to changes in interest rates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We invest our excess cash reserves in investment vehicles that provide a rate of return with little risk to principle.  As interest rates change the amount of interest income we earn will be directly impacted.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5116C5AB95C1555E9779CBD1FAFCBB9E"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Other MD&amp;A Requirements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">142,325,222</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;8, 2018</font><font style="font-family:inherit;font-size:10pt;">.  If all of our options, restricted share units and performance share units (</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">8,857,734</font><font style="font-family:inherit;font-size:10pt;">) and common share purchase warrants (</font><font style="font-family:inherit;font-size:10pt;">16,445,000</font><font style="font-family:inherit;font-size:10pt;">) were exercised or were to vest, we would have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">167,627,956</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;annual report on Form 20-F will be available on www.sedar.com.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD54978AB857A5DABB92FEEA759ECC2CA"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Disclosure Controls and Procedures</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Evaluation of Disclosure Controls and Procedures</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our chief executive and financial officers reviewed and evaluated our disclosure controls and procedures.  Based on that evaluation, they have concluded that our disclosure controls and procedures are effective in providing them with timely material information relating to the Company.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Management's Annual Report on Internal Control Over Financial Reporting</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, and has designed such internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation and fair presentation of financial statements for external purposes in accordance with International Financial Reporting Standards.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls and procedures over financial reporting will prevent all error and all fraud.  A control system can provide only reasonable, not absolute, assurance that the objectives of the control system are met.  Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.  These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">can occur because of simple error or mistake.  Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control.  The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions.  Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management has evaluated the design and operation of our internal control over financial reporting as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, and has concluded that such internal control over financial reporting is effective as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. There are no material weaknesses that have been identified by management in this regard.  This assessment was based on criteria for effective internal control over financial reporting described in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Changes in Internal Controls over Financial Reporting</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal control over financial reporting that occurred during the last fiscal year that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>14
<FILENAME>ex152eyconsentletter2017.htm
<DESCRIPTION>EXHIBIT 15.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s53A3066091F25CC693E4A71F9E83BA87"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">We consent the use of our report dated March 8, 2018 with respect to the consolidated financial statements of Oncolytics Biotech Inc. (Oncolytics) as at December 31, 2017 and 2016 and for each of the years in the three year period ended December 31, 2017, included in the Annual Report on Form 20-F of Oncolytics for the year ended December 31, 2017, as filed with the United States Securities Exchange Commission (SEC). </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">We also consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333- 171625 and 333-205708) of our report dated March 8, 2018 with respect to the consolidated financial statements of Oncolytics as at December 31, 2017 and 2016 and for each of the years in the three year period ended December 31, 2017, included in the Annual Report on Form 20-F of Oncolytics for the year ended December 31, 2017, as filed with the SEC. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:28%;"></td><td style="width:34%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Calgary, Canada</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;"><img src="eysignaturecpalpa.jpg" alt="eysignaturecpalpa.jpg" style="height:78px;width:208px;"></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 19, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>15
<FILENAME>oncyf-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:3403AEA93F8E50558CEF98995D29BB7B,x:918aaba9809441ca975a51e59ed2f545-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2016-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2016-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2016-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2014-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2014-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2014-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2014-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:full_ifrs_doc_entry_point="http://xbrl.ifrs.org/taxonomy/2017-03-09/ifrs/full_ifrs_doc_entry_point" xmlns:full_ifrs_entry_point="http://xbrl.ifrs.org/taxonomy/2017-03-09/ifrs/full_ifrs_entry_point" xmlns:gen="http://xbrl.org/2008/generic" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2017-03-09/ifrs-full" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:label="http://xbrl.org/2008/label" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:oncyf="http://www.oncolyticsbiotech.com/20171231" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:reference1="http://xbrl.org/2008/reference" xmlns:rol_dim="http://xbrl.ifrs.org/role/ifrs/dimensions" xmlns:rol_ias_10_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_10_2017-03-09" xmlns:rol_ias_11_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_11_2017-03-09" xmlns:rol_ias_12_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_12_2017-03-09" xmlns:rol_ias_16_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_16_2017-03-09" xmlns:rol_ias_17_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_17_2017-03-09" xmlns:rol_ias_18_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_18_2017-03-09" xmlns:rol_ias_19_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_19_2017-03-09" xmlns:rol_ias_1_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_1_2017-03-09" xmlns:rol_ias_20_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_20_2017-03-09" xmlns:rol_ias_21_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_21_2017-03-09" xmlns:rol_ias_23_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_23_2017-03-09" xmlns:rol_ias_24_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_24_2017-03-09" xmlns:rol_ias_26_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_26_2017-03-09" xmlns:rol_ias_27_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_27_2017-03-09" xmlns:rol_ias_29_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_29_2017-03-09" xmlns:rol_ias_2_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_2_2017-03-09" xmlns:rol_ias_33_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_33_2017-03-09" xmlns:rol_ias_34_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_34_2017-03-09" xmlns:rol_ias_36_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_36_2017-03-09" xmlns:rol_ias_37_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_37_2017-03-09" xmlns:rol_ias_38_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_38_2017-03-09" xmlns:rol_ias_40_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_40_2017-03-09" xmlns:rol_ias_41_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_41_2017-03-09" xmlns:rol_ias_7_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_7_2017-03-09" xmlns:rol_ias_8_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ias_8_2017-03-09" xmlns:rol_ifric_2_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifric_2_2017-03-09" xmlns:rol_ifric_5_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifric_5_2017-03-09" xmlns:rol_ifrs_12_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_12_2017-03-09" xmlns:rol_ifrs_13_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_13_2017-03-09" xmlns:rol_ifrs_14_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_14_2017-03-09" xmlns:rol_ifrs_15_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_15_2017-03-09" xmlns:rol_ifrs_16_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_16_2017-03-09" xmlns:rol_ifrs_1_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_1_2017-03-09" xmlns:rol_ifrs_2_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_2_2017-03-09" xmlns:rol_ifrs_3_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_3_2017-03-09" xmlns:rol_ifrs_4_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_4_2017-03-09" xmlns:rol_ifrs_5_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_5_2017-03-09" xmlns:rol_ifrs_6_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_6_2017-03-09" xmlns:rol_ifrs_7_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_7_2017-03-09" xmlns:rol_ifrs_8_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_8_2017-03-09" xmlns:rol_sic_27_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_sic_27_2017-03-09" xmlns:rol_sic_29_2017-03-09="http://xbrl.ifrs.org/role/ifrs/rol_sic_29_2017-03-09" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all/2011-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all/2011-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="oncyf-20171231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:HeldtomaturityInvestmentsCategoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_MeasurementAxis_ifrs-full_AtCostMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:HeldtomaturityInvestmentsCategoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_MeasurementAxis_ifrs-full_AtCostMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:HeldtomaturityInvestmentsCategoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:HeldtomaturityInvestmentsCategoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_oncyf_FinancialAssetsAtFaceValueMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:HeldtomaturityInvestmentsCategoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">oncyf:FinancialAssetsAtFaceValueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:HeldtomaturityInvestmentsCategoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:HeldtomaturityInvestmentsCategoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:HeldtomaturityInvestmentsCategoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:HeldtomaturityInvestmentsCategoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_oncyf_FinancialAssetsAtFaceValueMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:HeldtomaturityInvestmentsCategoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">oncyf:FinancialAssetsAtFaceValueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun1_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-01</xbrli:startDate>
			<xbrli:endDate>2017-06-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAmendedSharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAmendedSharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q3Oct20_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-10-20</xbrli:startDate>
			<xbrli:endDate>2014-10-20</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Oct24_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-10-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_AmendedInitialCommitmentFeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:AmendedInitialCommitmentFeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_InitialCommitmentFeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:InitialCommitmentFeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2106Q1Feb26_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-25</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun1_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_InitialCommitmentFeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:InitialCommitmentFeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ifrs-full_ReserveOfSharebasedPaymentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Nov1-30_oncyf_MilestoneAxis_oncyf_MilestoneOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:MilestoneAxis">oncyf:MilestoneOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-01</xbrli:startDate>
			<xbrli:endDate>2017-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Nov1-30_oncyf_MilestoneAxis_oncyf_MilestoneTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:MilestoneAxis">oncyf:MilestoneTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-01</xbrli:startDate>
			<xbrli:endDate>2017-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Nov1-30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-01</xbrli:startDate>
			<xbrli:endDate>2017-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">oncyf:SYNSORBMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">oncyf:SYNSORBMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_InvestmentTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedCapitalLossCarryForwardNetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedCapitalLossCarryForwardNetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_ShareIssueCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_InvestmentTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedNetOperatingLossCarryForwardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedNetOperatingLossCarryForwardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_ShareIssueCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedCapitalLossCarryForwardNetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_ShareIssueCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedNetOperatingLossCarryForwardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_InvestmentTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyThreeMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySevenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyOneMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyTwoMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyOneMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFiveMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFiveMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyEightMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyEightMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySevenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyNineMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyNineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyTwoMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyFourMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyFiveMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFiveMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyThreeMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFourMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFourMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySevenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyTwoMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyThreeMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyOneMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyNineMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyNineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFiveMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFiveMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySevenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb16">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_oncyf_Currency1Axis_currency_USD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:Currency1Axis">currency:USD</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_oncyf_Currency1Axis_currency_EUR">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:Currency1Axis">currency:EUR</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_oncyf_Currency1Axis_currency_GBP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:Currency1Axis">currency:GBP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_GBP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:Currency1Axis">currency:GBP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_EUR">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:Currency1Axis">currency:EUR</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_USD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:Currency1Axis">currency:USD</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_oncyf_ConcentrationRiskType1Axis_oncyf_SupplierConcentrationRisk1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:ConcentrationRiskType1Axis">oncyf:SupplierConcentrationRisk1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan1-31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Nov30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="eur">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="gbp">
		<xbrli:measure>iso4217:GBP</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="CAD_PER_shares">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:CAD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="plan">
		<xbrli:measure>oncyf:plan</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="year">
		<xbrli:measure>oncyf:year</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="manufacturer">
		<xbrli:measure>oncyf:manufacturer</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="cad">
		<xbrli:measure>iso4217:CAD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="patient">
		<xbrli:measure>oncyf:patient</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2017Q4YTD" id="Fact-F02ED0310C780DD70675C803E64BAB19">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q4YTD" id="Fact-609AA997CA2D0701D01AC803E64B60DB">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q4YTD" id="Fact-5AC593F34148F48DDC47C803E64B3A4B">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q4YTD" id="Fact-73FF9AAFF4FCFC143672C803E64B006F">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q4YTD" id="Fact-172B07288EE94F12AF91C803E64AB5EA">2017-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q4YTD" id="Fact-A099DD20DCEDAC623CA6C803E64BAA57">20-F</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q4YTD" id="Fact-9283EFCF53BEB691C96520DCE509146B">0001129928</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="FI2017Q4" decimals="0" id="Fact-356752F912AD8C0E4598C803E64B4BE8" unitRef="shares">141805722</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2017Q4YTD" id="Fact-B1847B1E1755F2155845C803E64BFBFE">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2017Q4YTD" id="Fact-6E726B35D4BAEA3394ADC803E64B928E">Non-accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2017Q4YTD" id="Fact-EBE78AFB74FD599E2886C803E64B19C4">ONCOLYTICS BIOTECH INC</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2017Q4YTD" id="Fact-EBE5D41FDCC68BE158C9C803E64BC8EA">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2017Q4YTD" id="Fact-3F474F7BC811027930BBC803E64A515F">Yes</dei:EntityWellKnownSeasonedIssuer>
	<ifrs-full:AccountingProfit contextRef="FD2015Q4YTD" decimals="0" id="Fact-CF5F4094AA2240146083C803E649037E" unitRef="cad">-13719842</ifrs-full:AccountingProfit>
	<ifrs-full:AccountingProfit contextRef="FD2016Q4YTD" decimals="0" id="Fact-4BF60B96FE8E44D3D371C803E64DB085" unitRef="cad">-15130605</ifrs-full:AccountingProfit>
	<ifrs-full:AccountingProfit contextRef="FD2017Q4YTD" decimals="0" id="Fact-13380CA872820EAA3EF6E14B71F16E70" unitRef="cad">-15475353</ifrs-full:AccountingProfit>
	<ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="FI2016Q4" decimals="0" id="Fact-9DD16AC213F6F067BB8AC803E64B9000" unitRef="cad">554060</ifrs-full:AccumulatedOtherComprehensiveIncome>
	<ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="FI2017Q4" decimals="0" id="Fact-DB6E99B59806C1102969C803E64B4516" unitRef="cad">373730</ifrs-full:AccumulatedOtherComprehensiveIncome>
	<ifrs-full:AdditionalPaidinCapital contextRef="FI2016Q4" decimals="0" id="Fact-2373EF1FA06A59451856C803E64BD238" unitRef="cad">26643044</ifrs-full:AdditionalPaidinCapital>
	<ifrs-full:AdditionalPaidinCapital contextRef="FI2017Q4" decimals="0" id="Fact-A2020CFE31904E683045C803E64A2767" unitRef="cad">27028238</ifrs-full:AdditionalPaidinCapital>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" decimals="0" id="Fact-D25352AADF552B9DD6B8C803E64B8F56" unitRef="cad">162233</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-E8CF7FBEA44EB84CADD5C803E6471827" unitRef="cad">48929</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-39A1643BDB6AAE6BA83DC803E64D6074" unitRef="cad">10241</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-862EC147AFEF880D1D5AC803E6484F54" unitRef="cad">86163</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-E8B60A161BB7B2430F18C803E648A89D" unitRef="cad">5408</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-8D19E29056E4A85FFDB9C803E6487227" unitRef="cad">11492</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember" decimals="0" id="Fact-8336C7BE46E281091906C803E64597E4" unitRef="cad">22370</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-D642557B207C3140FD62C803E64AC9E8" unitRef="cad">20098</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-31784787F240398CF0BCC803E649FE1A" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-922D7210701268327034C803E648AA63" unitRef="cad">770</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-3A1C92F03412D4BFCD93C803E64B12E7" unitRef="cad">1502</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2016Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-85677C57EB9EB5C85396C803E645E180" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" decimals="0" id="Fact-617683274EB7F582089DC803E64886B1" unitRef="cad">90768</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-08BC25DE52D2F3114974C803E64C2903" unitRef="cad">43558</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-F9EF5535C32717195CD0C803E647B134" unitRef="cad">9710</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-F2692B11425D1D08EF9CC803E649FBCB" unitRef="cad">23515</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-E1B4455FE9F9611DC667C803E64BE3D2" unitRef="cad">4620</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-8E3FCE01282FB50A5531C803E64402DB" unitRef="cad">9365</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember" decimals="0" id="Fact-31944A16D446C3D80857C803E64AB330" unitRef="cad">104254</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-F416D09CAE62B356928DC803E64A634F" unitRef="cad">24778</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-D7F85A22FD4F0F52B38DC803E646A2AA" unitRef="cad">11811</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-F20DFC35D0E1FB231473C803E647E67B" unitRef="cad">67665</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-FBC80AE7BB19CD6B82A1C803E64BA94A" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-19E40632BAE00D603622C803E64CCE76" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdjustedWeightedAverageShares contextRef="FD2015Q4YTD" decimals="0" id="Fact-F9C943A8A572F554CB7CE1450C93803A" unitRef="shares">112613845</ifrs-full:AdjustedWeightedAverageShares>
	<ifrs-full:AdjustedWeightedAverageShares contextRef="FD2016Q4YTD" decimals="0" id="Fact-2EC1BE481E3CC45F8EAEE1450CB707F0" unitRef="shares">119880200</ifrs-full:AdjustedWeightedAverageShares>
	<ifrs-full:AdjustedWeightedAverageShares contextRef="FD2017Q4YTD" decimals="0" id="Fact-689D49E3310A6ABA7D9EE1450CD643E0" unitRef="shares">132395752</ifrs-full:AdjustedWeightedAverageShares>
	<ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="FD2015Q4YTD" decimals="0" id="Fact-BBD5B4596B56657F1406C803E645AE71" unitRef="cad">-3347</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
	<ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="FD2016Q4YTD" decimals="0" id="Fact-F582CD2D7917DCD2CD00C803E645CA9C" unitRef="cad">-313</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
	<ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="FD2017Q4YTD" decimals="0" id="Fact-14D84D5EEC3C4E67E9E9C803E649E4B7" unitRef="cad">-2523</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
	<ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="FD2015Q4YTD" decimals="0" id="Fact-0BA749088A9883F701C6F2DEB2B5A87D" unitRef="cad">-148308</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
	<ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="FD2016Q4YTD" decimals="0" id="Fact-27498A7B42038D8F4299F2DEB2B71C57" unitRef="cad">285653</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
	<ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="FD2017Q4YTD" decimals="0" id="Fact-FC97894765BB93055727F2DEB2BB2073" unitRef="cad">16680</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
	<ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="FD2015Q4YTD" decimals="0" id="Fact-5EE91D2C49383171FEF4C803E649C11D" unitRef="cad">0</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
	<ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="FD2016Q4YTD" decimals="0" id="Fact-06EB99722ECBA7A63F3DC803E64ADA76" unitRef="cad">0</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
	<ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="FD2017Q4YTD" decimals="0" id="Fact-8AF919C8445157FCCB51F2DE4FA28B2B" unitRef="cad">-4767100</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
	<ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="FD2015Q4YTD" decimals="0" id="Fact-A62AD699AB8FC17FDDF2C803E64B5832" unitRef="cad">180411</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
	<ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="FD2016Q4YTD" decimals="0" id="Fact-BD4654BA0EEAE27B4214C803E6466FA8" unitRef="cad">162233</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
	<ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="FD2017Q4YTD" decimals="0" id="Fact-56A6FA5AD253A0E5B441C803E6469DBD" unitRef="cad">90768</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
	<ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="FD2015Q4YTD" decimals="0" id="Fact-619302892D0AE978500BF2DEE2B50078" unitRef="cad">0</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
	<ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="FD2016Q4YTD" decimals="0" id="Fact-0F1A450E4BE24847C872F2DEE2BB8B46" unitRef="cad">0</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
	<ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="FD2017Q4YTD" decimals="0" id="Fact-0CBBD892111C42C62570F2DEE2B7D21E" unitRef="cad">6182580</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
	<ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="FD2015Q4YTD" decimals="0" id="Fact-263BB6875CF0D18C567BC803E64CF0A7" unitRef="cad">-664505</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
	<ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="FD2016Q4YTD" decimals="0" id="Fact-A2FD38D295E24CC92E9BC803E64CD886" unitRef="cad">1359172</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
	<ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="FD2017Q4YTD" decimals="0" id="Fact-E8396B4D078AC319D06EF2DE4F9FCE04" unitRef="cad">-384641</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
	<ifrs-full:AdjustmentsForSharebasedPayments contextRef="FD2015Q4YTD" decimals="0" id="Fact-B9DFB14DD4B81AB9C56DC803E64D0AEC" unitRef="cad">429537</ifrs-full:AdjustmentsForSharebasedPayments>
	<ifrs-full:AdjustmentsForSharebasedPayments contextRef="FD2016Q4YTD" decimals="0" id="Fact-9268D396A078EB049A1FC803E649D66A" unitRef="cad">406078</ifrs-full:AdjustmentsForSharebasedPayments>
	<ifrs-full:AdjustmentsForSharebasedPayments contextRef="FD2017Q4YTD" decimals="0" id="Fact-500F0CFDCA57EA55D08AC803E6455DE5" unitRef="cad">578703</ifrs-full:AdjustmentsForSharebasedPayments>
	<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="FD2015Q4YTD" decimals="0" id="Fact-B36EA097FC3E4D4CF9F9C803E64C4318" unitRef="cad">-816319</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
	<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="FD2015Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-CC149D10AB7CD9114AA7C803E64DE58C" unitRef="cad">-816319</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
	<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="FD2016Q4YTD" decimals="0" id="Fact-2E8DD75B27DD744234E9C803E64A3113" unitRef="cad">-139810</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
	<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="FD2016Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-7D7089DEF218EBB79F19C803E64B5DCE" unitRef="cad">67109</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
	<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="FD2017Q4YTD" decimals="0" id="Fact-5A3465C6847B5D6DA1EEC803E64571A9" unitRef="cad">-124793</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
	<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-BC3C9751B13372286592C803E64D5F4F" unitRef="cad">55538</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
	<ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="FD2015Q4YTD" decimals="0" id="Fact-B1C7FD2BCD1C85329933C803E64B6427" unitRef="cad">-1105464</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
	<ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="FD2016Q4YTD" decimals="0" id="Fact-6224E062157B0076D12AC803E6490C0C" unitRef="cad">2233865</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
	<ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="FD2017Q4YTD" decimals="0" id="Fact-AB955F81824B558D48F8C803E64976BC" unitRef="cad">180855</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
	<ifrs-full:AmortisationExpense contextRef="FD2015Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-2CEB5618B13A3245306AC803E64AEC48" unitRef="cad">180411</ifrs-full:AmortisationExpense>
	<ifrs-full:AmortisationExpense contextRef="FD2016Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-90AE892A6E4012984CFBC803E646467E" unitRef="cad">162233</ifrs-full:AmortisationExpense>
	<ifrs-full:AmortisationExpense contextRef="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-EE286DE34A73FB15F3C6C803E649A240" unitRef="cad">90768</ifrs-full:AmortisationExpense>
	<ifrs-full:ApplicableTaxRate contextRef="FD2015Q4YTD" decimals="INF" id="Fact-F0B78DF568D87C48E9D8C803E64995C7" unitRef="number">0.26</ifrs-full:ApplicableTaxRate>
	<ifrs-full:ApplicableTaxRate contextRef="FD2016Q4YTD" decimals="INF" id="Fact-F8BD17E6A63466D9C2C5C803E649DE17" unitRef="number">0.27</ifrs-full:ApplicableTaxRate>
	<ifrs-full:ApplicableTaxRate contextRef="FD2017Q4YTD" decimals="INF" id="Fact-E23CDC44B5EF369DF7CBC803E64800D7" unitRef="number">0.27</ifrs-full:ApplicableTaxRate>
	<ifrs-full:Assets contextRef="FI2016Q4" decimals="0" id="Fact-5A12D4490C653C3BC32EC803E64B842C" unitRef="cad">14758284</ifrs-full:Assets>
	<ifrs-full:Assets contextRef="FI2017Q4" decimals="0" id="Fact-E1FF799C14464984C91CC803E64A798C" unitRef="cad">18150449</ifrs-full:Assets>
	<ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="FD2015Q4YTD" decimals="2" id="Fact-2B4F6B1240E4AE160CB3C803E64C46AC" unitRef="CAD_PER_shares">-0.12</ifrs-full:BasicAndDilutedEarningsLossPerShare>
	<ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="FD2016Q4YTD" decimals="2" id="Fact-78F6CAFE54D5B6A93A5DC803E64CD111" unitRef="CAD_PER_shares">-0.13</ifrs-full:BasicAndDilutedEarningsLossPerShare>
	<ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="FD2017Q4YTD" decimals="2" id="Fact-B7E53CDB2D0F7B5042A4C803E64CC9B9" unitRef="CAD_PER_shares">-0.12</ifrs-full:BasicAndDilutedEarningsLossPerShare>
	<ifrs-full:CashAndCashEquivalents contextRef="FI2014Q4" decimals="0" id="Fact-DFB9CE5EF6DDB3607299C803E645A621" unitRef="cad">14152825</ifrs-full:CashAndCashEquivalents>
	<ifrs-full:CashAndCashEquivalents contextRef="FI2015Q4" decimals="0" id="Fact-1D0F9B3076130D302BBFC803E64C2015" unitRef="cad">24016275</ifrs-full:CashAndCashEquivalents>
	<ifrs-full:CashAndCashEquivalents contextRef="FI2016Q4" decimals="0" id="Fact-C952AEDC1D1709F9BDD3C803E64ACFDC" unitRef="cad">12034282</ifrs-full:CashAndCashEquivalents>
	<ifrs-full:CashAndCashEquivalents contextRef="FI2017Q4" decimals="0" id="Fact-D6537C812FFF844723AEC803E64AA173" unitRef="cad">11836119</ifrs-full:CashAndCashEquivalents>
	<ifrs-full:CashAndCashEquivalents contextRef="FI2017Q4_oncyf_Currency1Axis_currency_EUR" decimals="0" id="Fact-0BE18DEDD93F8402227AC803E6493751" unitRef="eur">19372</ifrs-full:CashAndCashEquivalents>
	<ifrs-full:CashAndCashEquivalents contextRef="FI2017Q4_oncyf_Currency1Axis_currency_GBP" decimals="0" id="Fact-D1BC2EC8F46B1430AD7DC803E64B40F8" unitRef="gbp">21755</ifrs-full:CashAndCashEquivalents>
	<ifrs-full:CashAndCashEquivalents contextRef="FI2017Q4_oncyf_Currency1Axis_currency_USD" decimals="0" id="Fact-99E9B9030B56956D78C6C803E64C7EB8" unitRef="usd">1948573</ifrs-full:CashAndCashEquivalents>
	<ifrs-full:CashEquivalents contextRef="FI2016Q4" decimals="0" id="Fact-14759BFAC7568A296A83C803E64DD1B1" unitRef="cad">10679992</ifrs-full:CashEquivalents>
	<ifrs-full:CashEquivalents contextRef="FI2017Q4" decimals="0" id="Fact-D65E2311E907DE101178C803E64CEE4C" unitRef="cad">9204919</ifrs-full:CashEquivalents>
	<ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="FD2015Q4YTD" decimals="0" id="Fact-BC88ECA4CA88B47A5C09C803E64C98A5" unitRef="cad">-29292</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
	<ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="FD2016Q4YTD" decimals="0" id="Fact-08DD6799B7F6EF95F404C803E64A6D3C" unitRef="cad">-27823</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
	<ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="FD2017Q4YTD" decimals="0" id="Fact-25D6D3939720EE46DD0DC803E64BC661" unitRef="cad">2088800</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
	<ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="FD2015Q4YTD" decimals="0" id="Fact-E686DECE785BCE4FC7C3C803E6460C4D" unitRef="cad">23667636</ifrs-full:CashFlowsFromUsedInFinancingActivities>
	<ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="FD2016Q4YTD" decimals="0" id="Fact-A9EC5A3817E634EF85D4C803E64B6E6A" unitRef="cad">956133</ifrs-full:CashFlowsFromUsedInFinancingActivities>
	<ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="FD2017Q4YTD" decimals="0" id="Fact-9484C107B46C0DF4F95DC803E64A6645" unitRef="cad">12812704</ifrs-full:CashFlowsFromUsedInFinancingActivities>
	<ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="FD2015Q4YTD" decimals="0" id="Fact-A5C475584B3824075AE2C803E64DB603" unitRef="cad">-137560</ifrs-full:CashFlowsFromUsedInInvestingActivities>
	<ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="FD2016Q4YTD" decimals="0" id="Fact-8A9942929F43332C081AC803E64CBBD4" unitRef="cad">-51350</ifrs-full:CashFlowsFromUsedInInvestingActivities>
	<ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="FD2017Q4YTD" decimals="0" id="Fact-C2459C4B1D46B203B5C9C803E64DDC0F" unitRef="cad">1983035</ifrs-full:CashFlowsFromUsedInInvestingActivities>
	<ifrs-full:CashFlowsFromUsedInOperations contextRef="FD2015Q4YTD" decimals="0" id="Fact-9398532610ECD23E4468C803E646E7B2" unitRef="cad">-15034830</ifrs-full:CashFlowsFromUsedInOperations>
	<ifrs-full:CashFlowsFromUsedInOperations contextRef="FD2016Q4YTD" decimals="0" id="Fact-20BCD8BE0D99558F89E7C803E64C11D5" unitRef="cad">-12477613</ifrs-full:CashFlowsFromUsedInOperations>
	<ifrs-full:CashFlowsFromUsedInOperations contextRef="FD2017Q4YTD" decimals="0" id="Fact-2DAFF0BB130875FA787AC803E64BA126" unitRef="cad">-14891318</ifrs-full:CashFlowsFromUsedInOperations>
	<ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions contextRef="FD2017Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember" decimals="-5" id="Fact-25DB2BA74257086BA085C803E648844D" unitRef="cad">1000000</ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions>
	<ifrs-full:ComprehensiveIncome contextRef="FD2015Q4YTD" decimals="0" id="Fact-CE6FF46B87F24D6D9EE6C803E64D9398" unitRef="cad">-13242060</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2015Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-3DB048C4D602D1BBFC71C803E646A3B5" unitRef="cad">480935</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2015Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" decimals="0" id="Fact-6F0AD2B2029F1619D9BCC803E6466918" unitRef="cad">-13722995</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2016Q4YTD" decimals="0" id="Fact-9982388B47E9C966300FC803E64B57AE" unitRef="cad">-15346897</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2016Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-4B73742CC4760CCFC3C5C803E645D188" unitRef="cad">-206918</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2016Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" decimals="0" id="Fact-66AF9F894611C9F9A884C803E6459629" unitRef="cad">-15139979</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2017Q4YTD" decimals="0" id="Fact-0D1F63610569562D8CFEC803E64BF6CE" unitRef="cad">-15797181</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-4DADAB68EF68C99F03FEC803E647CE94" unitRef="cad">-180330</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" decimals="0" id="Fact-C8B969EDB65748560727C803E6486660" unitRef="cad">-15616851</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ContractLiabilities contextRef="FI2015Q4" decimals="0" id="Fact-35D3B44681B70C08DF24E39BA2E801C0" unitRef="usd">0</ifrs-full:ContractLiabilities>
	<ifrs-full:ContractLiabilities contextRef="FI2016Q4" decimals="0" id="Fact-AF96CC578AF134808C60E39A22543ABF" unitRef="usd">0</ifrs-full:ContractLiabilities>
	<ifrs-full:ContractLiabilities contextRef="FI2017Q4" decimals="0" id="Fact-CC7286DD92CE0F56E751E39A224D0B00" unitRef="usd">6182580</ifrs-full:ContractLiabilities>
	<ifrs-full:CurrentAssets contextRef="FI2016Q4" decimals="0" id="Fact-1F6B6EC188AB20354450C803E6493A25" unitRef="cad">14438329</ifrs-full:CurrentAssets>
	<ifrs-full:CurrentAssets contextRef="FI2017Q4" decimals="0" id="Fact-8EB14B76B2554EA85B58C803E64B57BB" unitRef="cad">17817008</ifrs-full:CurrentAssets>
	<ifrs-full:CurrentContractLiabilities contextRef="FI2016Q4" decimals="0" id="Fact-1AEB346FE87DE67E6134E399FBBAA298" unitRef="usd">0</ifrs-full:CurrentContractLiabilities>
	<ifrs-full:CurrentContractLiabilities contextRef="FI2016Q4" decimals="0" id="Fact-35965E7AF526BFC6DA2EE3BD2C24A4D7" unitRef="cad">0</ifrs-full:CurrentContractLiabilities>
	<ifrs-full:CurrentContractLiabilities contextRef="FI2017Q4" decimals="0" id="Fact-4D4016966D5EC5BA4606E399FBC1381E" unitRef="usd">1545645</ifrs-full:CurrentContractLiabilities>
	<ifrs-full:CurrentContractLiabilities contextRef="FI2017Q4" decimals="0" id="Fact-9508E4F2970385FC7B0EE3BD2C11BC1B" unitRef="cad">1545645</ifrs-full:CurrentContractLiabilities>
	<ifrs-full:CurrentInvestments contextRef="FI2016Q4" decimals="0" id="Fact-F1BE892CA816BE9EAAFCC803E64BD7EE" unitRef="cad">2088800</ifrs-full:CurrentInvestments>
	<ifrs-full:CurrentInvestments contextRef="FI2017Q4" decimals="0" id="Fact-B665C63FB49B1A1A3895C803E64AA9CB" unitRef="cad">0</ifrs-full:CurrentInvestments>
	<ifrs-full:CurrentLiabilities contextRef="FI2016Q4" decimals="0" id="Fact-6CB6AE3359EEA974BD71C803E64A0CDC" unitRef="cad">4068664</ifrs-full:CurrentLiabilities>
	<ifrs-full:CurrentLiabilities contextRef="FI2017Q4" decimals="0" id="Fact-C61F696DAA0FA3FA4D4CC803E64B6161" unitRef="cad">5229668</ifrs-full:CurrentLiabilities>
	<ifrs-full:CurrentPrepaidExpenses contextRef="FI2016Q4" decimals="0" id="Fact-5ADABFED929B98EE082EC803E64BC76F" unitRef="cad">260841</ifrs-full:CurrentPrepaidExpenses>
	<ifrs-full:CurrentPrepaidExpenses contextRef="FI2017Q4" decimals="0" id="Fact-3A1BF5CDEECDDC5D517FC803E64A88CC" unitRef="cad">1176063</ifrs-full:CurrentPrepaidExpenses>
	<ifrs-full:CurrentReceivablesFromContractsWithCustomers contextRef="FI2016Q4" decimals="0" id="Fact-C81600896209EDEB99F7C803E64AF029" unitRef="cad">0</ifrs-full:CurrentReceivablesFromContractsWithCustomers>
	<ifrs-full:CurrentReceivablesFromContractsWithCustomers contextRef="FI2017Q4" decimals="0" id="Fact-2FE1B8B9CFBB0D4981E2C803E64BB302" unitRef="cad">4767100</ifrs-full:CurrentReceivablesFromContractsWithCustomers>
	<ifrs-full:CurrentReceivablesFromContractsWithCustomers contextRef="FI2017Q4_oncyf_Currency1Axis_currency_EUR" decimals="0" id="Fact-EF86AC23268CE10CDE2EF2DB763BCC59" unitRef="eur">0</ifrs-full:CurrentReceivablesFromContractsWithCustomers>
	<ifrs-full:CurrentReceivablesFromContractsWithCustomers contextRef="FI2017Q4_oncyf_Currency1Axis_currency_GBP" decimals="0" id="Fact-983454950F3D89D2B01AF2DB7620C533" unitRef="gbp">0</ifrs-full:CurrentReceivablesFromContractsWithCustomers>
	<ifrs-full:CurrentReceivablesFromContractsWithCustomers contextRef="FI2017Q4_oncyf_Currency1Axis_currency_USD" decimals="0" id="Fact-E1B89A81ACF73E44F290F2DB764DA505" unitRef="usd">3800000</ifrs-full:CurrentReceivablesFromContractsWithCustomers>
	<ifrs-full:CurrentTaxExpenseIncome contextRef="FD2015Q4YTD" decimals="0" id="Fact-D5DC77EF1936A31181D6C803E64D9B02" unitRef="cad">6500</ifrs-full:CurrentTaxExpenseIncome>
	<ifrs-full:CurrentTaxExpenseIncome contextRef="FD2016Q4YTD" decimals="0" id="Fact-E073778683F912777292C803E64DFC3D" unitRef="cad">9687</ifrs-full:CurrentTaxExpenseIncome>
	<ifrs-full:CurrentTaxExpenseIncome contextRef="FD2017Q4YTD" decimals="0" id="Fact-CDD80373CF58257CDB59C803E6495D1E" unitRef="cad">144021</ifrs-full:CurrentTaxExpenseIncome>
	<ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods contextRef="FD2015Q4YTD" decimals="0" id="Fact-E625727EFC7F2F5A3C8EC803E6496BC6" unitRef="cad">3153</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
	<ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods contextRef="FD2016Q4YTD" decimals="0" id="Fact-2E3B3BA2BA6A1FC44DCDC803E64DCADB" unitRef="cad">9374</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
	<ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods contextRef="FD2017Q4YTD" decimals="0" id="Fact-C3F3DB109A0CA9608749C803E64921EA" unitRef="cad">141498</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
	<ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="FD2016Q4YTD" decimals="0" id="Fact-7973A7508321123DE12FE39D0B65EF2B" unitRef="usd">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
	<ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="FD2017Q4YTD" decimals="0" id="Fact-BEC561B3E8B9A1E76C8AE39D0B6215F6" unitRef="usd">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2015Q4" decimals="0" id="Fact-EF6D7867D29A90C20DEDC803E64D4505" unitRef="cad">29681313</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2015Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_InvestmentTaxCreditsMember" decimals="0" id="Fact-06E4E55BF40595CD0190C803E64D399B" unitRef="cad">3987214</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2015Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" decimals="0" id="Fact-0DE4E7E2C03A21C07DFDC803E64D09D0" unitRef="cad">1839107</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2015Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_ShareIssueCostsMember" decimals="0" id="Fact-D09C49BEF2392FBE3C7DC803E64C5CB7" unitRef="cad">619066</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2015Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" decimals="0" id="Fact-AC07D708800B2F1D0B7CC803E64B4ED9" unitRef="cad">7278284</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2015Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedCapitalLossCarryForwardNetMember" decimals="0" id="Fact-6CCEA2D768BFB7DE84CFC803E64D2A02" unitRef="cad">7598</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2015Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedNetOperatingLossCarryForwardsMember" decimals="0" id="Fact-0AD354FD10A45F909113C803E6447C70" unitRef="cad">15950044</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2016Q4" decimals="0" id="Fact-1128C25D35762558F88FC803E64CECB1" unitRef="cad">31555913</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2016Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_InvestmentTaxCreditsMember" decimals="0" id="Fact-8117CA1D3A7FAC11A6D5C803E64D6A35" unitRef="cad">3990664</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2016Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" decimals="0" id="Fact-606617E6C2A1BD3D70EBC803E64DB1AF" unitRef="cad">1908654</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2016Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_ShareIssueCostsMember" decimals="0" id="Fact-682D16D8586111BFA8E6C803E64CC3D5" unitRef="cad">432659</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2016Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" decimals="0" id="Fact-515C9049CCBC60B9F05FC803E64D20E8" unitRef="cad">7394707</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2016Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedCapitalLossCarryForwardNetMember" decimals="0" id="Fact-2F993708C6C450278CA4C803E64D9083" unitRef="cad">7598</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2016Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedNetOperatingLossCarryForwardsMember" decimals="0" id="Fact-F366E1BB1436C562B65EC803E64DD234" unitRef="cad">17821631</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2017Q4" decimals="0" id="Fact-3BEB07677BEB00D110B4C803E64D86F1" unitRef="cad">32983223</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_InvestmentTaxCreditsMember" decimals="0" id="Fact-EE4807D418AA8C9567D1C803E64D0466" unitRef="cad">3988325</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" decimals="0" id="Fact-BC765A5B3A77E1909C03C803E64D2CC9" unitRef="cad">1927640</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_ShareIssueCostsMember" decimals="0" id="Fact-EAE112AFDBBF8B09513AC803E64D549F" unitRef="cad">493343</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" decimals="0" id="Fact-CE569369A82C4A10561DC803E64DA4DB" unitRef="cad">7406099</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedCapitalLossCarryForwardNetMember" decimals="0" id="Fact-FCAD83922D254E37F8D6C803E64C8AA1" unitRef="cad">7598</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedNetOperatingLossCarryForwardsMember" decimals="0" id="Fact-3E880F798164F7F0FB88C803E64C9FD7" unitRef="cad">19160218</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="FD2015Q4YTD" decimals="4" id="Fact-50D0EC67677E1B87641CC803E649ED70" unitRef="number">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
	<ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="FD2016Q4YTD" decimals="4" id="Fact-9F18332942B6AD84B2BDC803E6453EA0" unitRef="number">0.9484</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
	<ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="FD2017Q4YTD" decimals="4" id="Fact-84DCDA43B829F9AB2F61C803E64756C9" unitRef="number">0.9073</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
	<ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="4" id="Fact-197956B4684D758F3574F2FCC5ACB6BF" unitRef="number">0.8930</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
	<ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="FD2015Q4YTD" decimals="1" id="Fact-2C4D54A99121FFC3C582C803E6464BD8" unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
	<ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="FD2016Q4YTD" decimals="1" id="Fact-6337B381176FCE8C1D85C803E6458E79" unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
	<ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="FD2017Q4YTD" decimals="1" id="Fact-EDD36E4737E4248ED0C2C803E646325E" unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
	<ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-011C01A948554A13AE03F2FE74091C0F" unitRef="number">2</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
	<ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="FD2015Q4YTD" decimals="4" id="Fact-ACD38C212D294A336EF6C803E645033B" unitRef="number">0.0063</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
	<ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="FD2016Q4YTD" decimals="4" id="Fact-3C6D69D33DF251414BFAC803E6483C2B" unitRef="number">0.0082</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
	<ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="FD2017Q4YTD" decimals="4" id="Fact-03F66033E9F82A4656C6C803E648097B" unitRef="number">0.0118</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
	<ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="4" id="Fact-94FBA4BC65354FBEF251F2FC89C88115" unitRef="number">0.0070</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember" decimals="0" id="Fact-220E459448487D130BABE7BA8CC0FC43" unitRef="cad">-48168</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-F54D90781C0E51227DF2E7BA700CDECA" unitRef="cad">-48168</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-C72EBD482904EFA4523BE7BA8D414586" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-1B17FFF61DBD60AFA8D9E7BA8D1CD7DE" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-FD14BBEC1B953CE9848EE7BA70344E8B" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2017Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-AEA668A6ED4941459557E7BA8CD7FE55" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="FD2015Q4YTD" decimals="0" id="Fact-B0100ECB2BC149D1F56FC803E64DDDDC" unitRef="cad">1368204</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
	<ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="FD2016Q4YTD" decimals="0" id="Fact-1804DC98F60CE0567127C803E6468A9E" unitRef="cad">-409163</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
	<ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="FD2017Q4YTD" decimals="0" id="Fact-EC0F3E4F29DE0EA7B5FDC803E64DA727" unitRef="cad">-102584</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
	<ifrs-full:Equity contextRef="FI2014Q4" decimals="0" id="Fact-C938A3735137C0D84EDAC803E648FF73" unitRef="cad">13819193</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2014Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-C626A90B317B9216F83AC803E64524C5" unitRef="cad">237657056</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2014Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="0" id="Fact-F6C17BD61061BD87949BC803E648EB3A" unitRef="cad">0</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2014Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-4B934E185A75C6B770B7C803E6467A12" unitRef="cad">280043</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2014Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-CDE75C2C616C2D8EF748C803E648845A" unitRef="cad">237657056</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2014Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" decimals="0" id="Fact-2D8A398C342E9415D33FC803E6466DAC" unitRef="cad">-249966335</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2014Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-C0FF75EDA45265BE3D92C803E6473DA5" unitRef="cad">25848429</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2014Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember" decimals="0" id="Fact-12CE0DD34CC8C2AE9A8CC803E6457728" unitRef="cad">0</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2015Q4" decimals="0" id="Fact-D75307C08EE0EDE3238BC803E6484947" unitRef="cad">24674306</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2015Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-124535AAB9410A3CEC19C803E64740E1" unitRef="cad">261324692</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2015Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="0" id="Fact-60CBAFD13248BF083767C803E647C0D9" unitRef="cad">0</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2015Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-2FD5A8F314C651C5F621C803E6483EC5" unitRef="cad">760978</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2015Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-E293569E194BD8AA5F57C803E648D4EF" unitRef="cad">261324692</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2015Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" decimals="0" id="Fact-F0BB4EA6DB0C4BA45EC7C803E6487093" unitRef="cad">-263689330</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2015Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-C81B15A0165F617EC625C803E646C661" unitRef="cad">26277966</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2015Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember" decimals="0" id="Fact-93DD349BE73F03A1EEF5C803E6480265" unitRef="cad">0</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4" decimals="0" id="Fact-B4EE761FC2C52FC711CEC803E64BF31C" unitRef="cad">10689620</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-C42430306ECD9F410C7CC803E64825AD" unitRef="cad">262321825</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="0" id="Fact-AB2804631CE44DF193EAC803E6472177" unitRef="cad">0</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-A964865FF41A23247AEAC803E64877E2" unitRef="cad">554060</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-AD7C28397278A91ED330C803E6461BBF" unitRef="cad">262321825</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" decimals="0" id="Fact-988FE55E3C0E22A19ACEC803E6470933" unitRef="cad">-278829309</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-F801EB13D7A8D709F61BC803E646B12E" unitRef="cad">26643044</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember" decimals="0" id="Fact-5E59B0C80CD42C7AE909C803E6481534" unitRef="cad">0</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4" decimals="0" id="Fact-9F7C89F20D9F0508A63CC803E64BE6FA" unitRef="cad">8283846</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-625D69AFC24943B46DF3C803E6477CF7" unitRef="cad">271710138</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="0" id="Fact-5BAA3C3E69A13D180702C803E645D68F" unitRef="cad">3617900</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-82DF74BBE3B9DC508C68C803E649A7B9" unitRef="cad">373730</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-8F5BD23C722BA130B1BEC803E648D315" unitRef="cad">271710138</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" decimals="0" id="Fact-8DEB35D02E8FCC203CC6C803E648D5E7" unitRef="cad">-294446160</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-745A6B98F85D1997EEE3C803E6468C6E" unitRef="cad">27028238</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember" decimals="0" id="Fact-83D9035B0141277D8CC4C803E6469249" unitRef="cad">3617900</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="I2106Q1Feb26_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="-5" id="Fact-115443B6011EB195DD1BC803E647CD99" unitRef="cad">4600000</ifrs-full:Equity>
	<ifrs-full:EquityAndLiabilities contextRef="FI2016Q4" decimals="0" id="Fact-77A9542075633A87BEA4C803E64B95AF" unitRef="cad">14758284</ifrs-full:EquityAndLiabilities>
	<ifrs-full:EquityAndLiabilities contextRef="FI2017Q4" decimals="0" id="Fact-625D4C1DEA199A03D7CFC803E64B6CCF" unitRef="cad">18150449</ifrs-full:EquityAndLiabilities>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-4142F48B3DBB07A90B75F317B2071A77" unitRef="cad">0.95</ifrs-full:ExercisePriceOfOutstandingShareOptions>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember" decimals="INF" id="Fact-BD5D69656ABC6137F6C9C803E6489C8A" unitRef="cad">4.01</ifrs-full:ExercisePriceOfOutstandingShareOptions>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember" decimals="INF" id="Fact-81D68ABF8D49F48A038BC803E648D53C" unitRef="cad">2.13</ifrs-full:ExercisePriceOfOutstandingShareOptions>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember" decimals="INF" id="Fact-D97995EDF2E2CC6C69D5C803E649E7CA" unitRef="cad">0.26</ifrs-full:ExercisePriceOfOutstandingShareOptions>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember" decimals="INF" id="Fact-CEA74C9F8D22E832DC3AC803E6486B2A" unitRef="cad">1.45</ifrs-full:ExercisePriceOfOutstandingShareOptions>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember" decimals="INF" id="Fact-9B306F3CBEC0A5F9A544C803E6471AC3" unitRef="cad">0.51</ifrs-full:ExercisePriceOfOutstandingShareOptions>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember" decimals="INF" id="Fact-0C99D40C0073F13A74EFC803E6487B4D" unitRef="cad">6.72</ifrs-full:ExercisePriceOfOutstandingShareOptions>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember" decimals="INF" id="Fact-AE8A9E2958840F74C610C803E647CAFE" unitRef="cad">3.89</ifrs-full:ExercisePriceOfOutstandingShareOptions>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember" decimals="INF" id="Fact-ECEE8227A12F202FE76DC803E647E390" unitRef="cad">0.42</ifrs-full:ExercisePriceOfOutstandingShareOptions>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember" decimals="INF" id="Fact-8057FDD31CF84D96D490C803E6482DC8" unitRef="cad">2.00</ifrs-full:ExercisePriceOfOutstandingShareOptions>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember" decimals="INF" id="Fact-997EF737CB4BFA03AA30C803E647CB12" unitRef="cad">0.8</ifrs-full:ExercisePriceOfOutstandingShareOptions>
	<ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6A312B518A169420935948FDFFCC6473" unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
	<ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="FD2016Q4YTD" decimals="0" id="Fact-D8A99498E06D2481B66B48FDFFC3581E" unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
	<ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="FD2017Q4YTD" decimals="-3" id="Fact-617523913E140521432248FDFFC939B2" unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2015Q4YTD" decimals="0" id="Fact-5A63FFD3A364B15A7C0E1B3B5A28D2E7" unitRef="cad">429537</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2015Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-038FB94AA8FB1147E757C803E6476D7D" unitRef="cad">172521</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2015Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-307E5B30D1D963FD1D70C803E646B5CD" unitRef="cad">257016</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2016Q4YTD" decimals="0" id="Fact-3E0AD5672B5246F55693C803E64C9C19" unitRef="cad">406078</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2016Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-777B25BC8BE767AB4D6EC803E649435E" unitRef="cad">172159</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2016Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-6AAC2EBAB3D24199D7EAC803E64CEC8D" unitRef="cad">233919</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2017Q4YTD" decimals="0" id="Fact-A3A44F3A97CF0579B3D8C803E64D04F9" unitRef="cad">578703</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-B3077146BDB232440092C803E64D419A" unitRef="cad">348562</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-61395046003D0E03676CC803E64B8EC9" unitRef="cad">230141</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:FinancialAssets contextRef="FI2016Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostMember" decimals="0" id="Fact-3412068593363C1303B6C803E64ADA74" unitRef="cad">2088800</ifrs-full:FinancialAssets>
	<ifrs-full:FinancialAssets contextRef="FI2016Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember" decimals="0" id="Fact-351737F00F8CF3B818F9C803E64950B6" unitRef="cad">2088800</ifrs-full:FinancialAssets>
	<ifrs-full:FinancialAssets contextRef="FI2016Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_oncyf_FinancialAssetsAtFaceValueMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember" decimals="0" id="Fact-F9BC2F544EB3560CED73C803E64BC982" unitRef="cad">2088800</ifrs-full:FinancialAssets>
	<ifrs-full:FinancialAssets contextRef="FI2016Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_MeasurementAxis_ifrs-full_AtCostMember" decimals="0" id="Fact-5D61F8832263FDB47139C803E64A2E79" unitRef="cad">2088800</ifrs-full:FinancialAssets>
	<ifrs-full:FinancialAssets contextRef="FI2017Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostMember" decimals="0" id="Fact-6413A21E10C813786560C803E64C4611" unitRef="cad">0</ifrs-full:FinancialAssets>
	<ifrs-full:FinancialAssets contextRef="FI2017Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember" decimals="0" id="Fact-5FB04ECC19AFB4157FA0C803E64B0F31" unitRef="cad">0</ifrs-full:FinancialAssets>
	<ifrs-full:FinancialAssets contextRef="FI2017Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_oncyf_FinancialAssetsAtFaceValueMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember" decimals="0" id="Fact-4406D20CC74DD4A464DFC803E64C8826" unitRef="cad">0</ifrs-full:FinancialAssets>
	<ifrs-full:FinancialAssets contextRef="FI2017Q4_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember_ifrs-full_MeasurementAxis_ifrs-full_AtCostMember" decimals="0" id="Fact-CCE2B1C93542DF04D868C803E64BC13F" unitRef="cad">0</ifrs-full:FinancialAssets>
	<ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="FD2015Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-BD6654FC07D9B02BCFAAC803E64C9986" unitRef="cad">-238709</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
	<ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="FD2016Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-0940B0F6C41D8B956035C803E6456B04" unitRef="cad">-104851</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
	<ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-9BC8CC290CD04A89F439C803E64C519C" unitRef="cad">120794</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
	<ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="FD2015Q4YTD" decimals="0" id="Fact-939A0C492C16D4EAB424C803E64DF127" unitRef="cad">3153</ifrs-full:IncomeTaxExpenseContinuingOperations>
	<ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="FD2016Q4YTD" decimals="0" id="Fact-67CD00BD6B4A3A073ADCC803E64C5647" unitRef="cad">9374</ifrs-full:IncomeTaxExpenseContinuingOperations>
	<ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="FD2017Q4YTD" decimals="0" id="Fact-05257ABC21DBE84D5348C803E64BEFB1" unitRef="cad">141498</ifrs-full:IncomeTaxExpenseContinuingOperations>
	<ifrs-full:IncomeTaxesPaidRefund contextRef="FD2015Q4YTD" decimals="0" id="Fact-FF895B4D9EC907682746C803E64B5A8A" unitRef="cad">3421</ifrs-full:IncomeTaxesPaidRefund>
	<ifrs-full:IncomeTaxesPaidRefund contextRef="FD2016Q4YTD" decimals="0" id="Fact-44CF53B035E317F41ED6C803E64C508C" unitRef="cad">4468</ifrs-full:IncomeTaxesPaidRefund>
	<ifrs-full:IncomeTaxesPaidRefund contextRef="FD2017Q4YTD" decimals="0" id="Fact-9B1952AA08E2FD2B76EDC803E64CF22E" unitRef="cad">136163</ifrs-full:IncomeTaxesPaidRefund>
	<ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="FD2015Q4YTD" decimals="0" id="Fact-40092C063BF7DCF54E50C803E64ACA78" unitRef="cad">8495246</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
	<ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="FD2016Q4YTD" decimals="0" id="Fact-6737218C843BDDDC42BCC803E64D3EEA" unitRef="cad">-11572830</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
	<ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="FD2017Q4YTD" decimals="0" id="Fact-C3C41784416EAF836652C803E64D4270" unitRef="cad">-95579</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
	<ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="FD2015Q4YTD" decimals="0" id="Fact-E81308BA1AD3518AAEF2C803E64A766D" unitRef="cad">1105464</ifrs-full:IncreaseDecreaseInWorkingCapital>
	<ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="FD2016Q4YTD" decimals="0" id="Fact-2D8EE17D13951F172F06C803E64A4DBC" unitRef="cad">-2233865</ifrs-full:IncreaseDecreaseInWorkingCapital>
	<ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="FD2017Q4YTD" decimals="0" id="Fact-270AF548DCAA8F747D5CC803E645DFBF" unitRef="cad">-180855</ifrs-full:IncreaseDecreaseInWorkingCapital>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="FD2016Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" decimals="0" id="Fact-785AA9C97B5DEE4CB3D6F3E2F44C7439" unitRef="cad">41000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="FD2016Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-8915075E9B7D129D8194F3E3483E0C85" unitRef="cad">-41000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="FD2016Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" decimals="0" id="Fact-C10CA7F7290383E79F2AF3E2F4316920" unitRef="cad">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" decimals="0" id="Fact-A1307258EC5264333DEBC803E647F220" unitRef="cad">536949</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-95B5473353F1A0E41B68F3E389211173" unitRef="cad">-193509</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" decimals="0" id="Fact-080A71F28C6449E9FA9648CECB41E65B" unitRef="cad">343440</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
	<ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets contextRef="FD2015Q4YTD" decimals="0" id="Fact-9F57169367CA902848C7C803E64A96A8" unitRef="cad">-77535</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
	<ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets contextRef="FD2016Q4YTD" decimals="0" id="Fact-81F3C1ED49C4F98AA2DCC803E64B56A9" unitRef="cad">343212</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
	<ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets contextRef="FD2017Q4YTD" decimals="0" id="Fact-D61774878E239FFF2DCFC803E64BC16F" unitRef="cad">48558</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
	<ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="FD2015Q4YTD" decimals="0" id="Fact-8322E067DAA55B2D37DBC803E646FC3C" unitRef="cad">429537</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
	<ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="FD2015Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-857DA59429F7AA1B5509C803E645E0C6" unitRef="cad">429537</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
	<ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="FD2016Q4YTD" decimals="0" id="Fact-7FAA127B3B609DCEA5B1C803E648A6CE" unitRef="cad">406078</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
	<ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="FD2016Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-77546ACAF0E3CC08D771C803E64837D1" unitRef="cad">406078</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
	<ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="FD2017Q4YTD" decimals="0" id="Fact-54B45E1F18CB9BA2456EC803E6479500" unitRef="cad">578703</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
	<ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-AD431544DEE786EA0326C803E6474E5E" unitRef="cad">578703</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
	<ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="FD2015Q4YTD" decimals="0" id="Fact-1CEDF204740F05382AA3C803E64D87BA" unitRef="cad">197859</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
	<ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="FD2016Q4YTD" decimals="0" id="Fact-D7796A69E145A7DAAA66C803E64B6FC9" unitRef="cad">163902</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
	<ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="FD2017Q4YTD" decimals="0" id="Fact-7478AE68ED686E7D57D9C803E64C8F4E" unitRef="cad">130101</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
	<ifrs-full:IssueOfEquity contextRef="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-3F3A20D9A74A726D4114C803E6471CF5" unitRef="cad">20049693</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" decimals="0" id="Fact-B994A9FE1F1E7C4D1DDDC803E6485630" unitRef="cad">4371687</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2015Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-40F58F733B9BA9EB0FC0C803E646BF13" unitRef="cad">20049693</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2015Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" decimals="0" id="Fact-60E895C44CA4D70B56DEC803E64738A2" unitRef="cad">4371687</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2015Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-DD933E835D8630CB3E2FC803E6477BC3" unitRef="cad">20049693</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2015Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" decimals="0" id="Fact-F29F5CCF67DC331157F9C803E646678C" unitRef="cad">4371687</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2016Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-745C2DA615669B8FDD42C803E64597F9" unitRef="cad">41000</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2016Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-A6B0E179722858A0D5F0C803E648DF68" unitRef="cad">1456296</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2016Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-47895A4CBEAE421FB3FDC803E6474410" unitRef="cad">1456296</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-074C7B2B72445425C2A6C803E646E703" unitRef="cad">536949</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-9CE201FE2CA62F38F83DE7D6B67ACB17" unitRef="cad">7893600</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-452EF10324367966E1B0C803E645965A" unitRef="cad">2348821</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-ACA99A449763E5199EF9E7D87CA43B9E" unitRef="cad">3617900</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-341939C7BB4433C3CB5AF3E6C5354194" unitRef="cad">7893600</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-230B784DB3B7DEBD506EC803E6452EE7" unitRef="cad">2348821</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-879E53898766BC111176F3E74A04B9DF" unitRef="cad">3617900</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-6185FABB35448366E06BF3E7BD2C00CB" unitRef="cad">11511500</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-03F48001301DF3807601C803E647343E" unitRef="cad">2348821</ifrs-full:IssueOfEquity>
	<ifrs-full:IssuedCapital contextRef="FI2016Q4" decimals="0" id="Fact-C65E702BC87EC5DF3297C803E64923CC" unitRef="cad">262321825</ifrs-full:IssuedCapital>
	<ifrs-full:IssuedCapital contextRef="FI2017Q4" decimals="0" id="Fact-742CB8D547937EB4F111C803E64AA3BE" unitRef="cad">271710138</ifrs-full:IssuedCapital>
	<ifrs-full:KeyManagementPersonnelCompensation contextRef="FD2015Q4YTD" decimals="0" id="Fact-B87456CC171ADA763750C803E6460C1C" unitRef="cad">3294761</ifrs-full:KeyManagementPersonnelCompensation>
	<ifrs-full:KeyManagementPersonnelCompensation contextRef="FD2016Q4YTD" decimals="0" id="Fact-4FFB3470CE581F11C9D7C803E6467484" unitRef="cad">4456389</ifrs-full:KeyManagementPersonnelCompensation>
	<ifrs-full:KeyManagementPersonnelCompensation contextRef="FD2017Q4YTD" decimals="0" id="Fact-5FB70487EEBE632FA75BC803E645E593" unitRef="cad">3835046</ifrs-full:KeyManagementPersonnelCompensation>
	<ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="FD2015Q4YTD" decimals="0" id="Fact-F655CBB3A10007B61014C803E645E7CF" unitRef="cad">353419</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
	<ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="FD2016Q4YTD" decimals="0" id="Fact-DD0DACFB5BC2F461CD8DC803E64604E1" unitRef="cad">372008</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
	<ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="FD2017Q4YTD" decimals="0" id="Fact-40E8393A9730805F7363C803E646C379" unitRef="cad">459298</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
	<ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="FD2015Q4YTD" decimals="0" id="Fact-48C3EB875A86E7564022C803E6456932" unitRef="cad">2941342</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
	<ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="FD2016Q4YTD" decimals="0" id="Fact-0C58582A5C0E320FBAEBC803E6466E27" unitRef="cad">2753553</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
	<ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="FD2017Q4YTD" decimals="0" id="Fact-789C15BDD4934BA4989AC803E646E8C2" unitRef="cad">2596082</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
	<ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="FD2015Q4YTD" decimals="0" id="Fact-16B817320A36002A9AD7C803E6466749" unitRef="cad">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
	<ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="FD2016Q4YTD" decimals="0" id="Fact-416D5DCFFD3E612829BAC803E646F0AC" unitRef="cad">1330828</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
	<ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="FD2017Q4YTD" decimals="0" id="Fact-C75D18BF0183EDCFEBDDC803E646E526" unitRef="cad">779666</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
	<ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense contextRef="FD2015Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-C063D6CACA0555BE974FC803E64CAA06" unitRef="cad">196601</ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense>
	<ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense contextRef="FD2016Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-B96D5FDB2E2940AED61AC803E6460A04" unitRef="cad">148600</ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense>
	<ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense contextRef="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-58BFD502A8CDABBB27C6F2E2ACC92087" unitRef="cad">231509</ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense>
	<ifrs-full:Liabilities contextRef="FI2016Q4" decimals="0" id="Fact-36CB5AABBC74CB4F27E8E3C523A6D95B" unitRef="cad">4068664</ifrs-full:Liabilities>
	<ifrs-full:Liabilities contextRef="FI2017Q4" decimals="0" id="Fact-857B0CE7612439B1CDCDE3C5240D6BE7" unitRef="cad">9866603</ifrs-full:Liabilities>
	<ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="FI2017Q4" decimals="0" id="Fact-DEF13D64B159D1B2613EC803E648FAF4" unitRef="cad">740850</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
	<ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="FI2017Q4_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" decimals="0" id="Fact-0472821A08676A0D1090C803E648554D" unitRef="cad">251743</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
	<ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="FI2017Q4_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" decimals="0" id="Fact-B025047B13DC899C2ECFC803E6488476" unitRef="cad">43130</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
	<ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="FI2017Q4_ifrs-full_MaturityAxis_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" decimals="0" id="Fact-0C0656DE7E6F0BB5B30FC803E649B517" unitRef="cad">159990</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
	<ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="FI2017Q4_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember" decimals="0" id="Fact-76ACDA7D3DFE9730793CC803E6446742" unitRef="cad">285987</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
	<ifrs-full:NoncurrentAssets contextRef="FI2016Q4" decimals="0" id="Fact-F03337670786631300BBC803E64BA99E" unitRef="cad">319955</ifrs-full:NoncurrentAssets>
	<ifrs-full:NoncurrentAssets contextRef="FI2017Q4" decimals="0" id="Fact-298C0A8E63F11C04B8ADC803E64A1B6F" unitRef="cad">333441</ifrs-full:NoncurrentAssets>
	<ifrs-full:NoncurrentContractLiabilities contextRef="FI2016Q4" decimals="0" id="Fact-BCD130A78C75F9043DA2E399D794D7A4" unitRef="usd">0</ifrs-full:NoncurrentContractLiabilities>
	<ifrs-full:NoncurrentContractLiabilities contextRef="FI2016Q4" decimals="0" id="Fact-C6E9F4A5E4B3DAE887FDE3C45CB2C09E" unitRef="cad">0</ifrs-full:NoncurrentContractLiabilities>
	<ifrs-full:NoncurrentContractLiabilities contextRef="FI2017Q4" decimals="0" id="Fact-284F90E00443F995EDD9E3C45CAEDD2B" unitRef="cad">4636935</ifrs-full:NoncurrentContractLiabilities>
	<ifrs-full:NoncurrentContractLiabilities contextRef="FI2017Q4" decimals="0" id="Fact-75AC455ACF6F8A3281AFE399D790FDDC" unitRef="usd">4636935</ifrs-full:NoncurrentContractLiabilities>
	<ifrs-full:NoncurrentLiabilities contextRef="FI2016Q4" decimals="0" id="Fact-6829699A78AA6BBE56CAE3C4EE8C35C6" unitRef="cad">0</ifrs-full:NoncurrentLiabilities>
	<ifrs-full:NoncurrentLiabilities contextRef="FI2017Q4" decimals="0" id="Fact-45BD6E11CA5DC885F0A9E3C4EE93BE36" unitRef="cad">4636935</ifrs-full:NoncurrentLiabilities>
	<ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="FD2015Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-C77626025A90B4936023C803E6499E27" unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
	<ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="FD2015Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-1B1A3D3F2B4285916FD4C803E6487AF0" unitRef="shares">368831</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
	<ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="FD2016Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-9034FA4AC92E0077B633C803E647E462" unitRef="shares">1500000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
	<ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="FD2016Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-A26BDAC4A72AAFD03A5EC803E6489413" unitRef="shares">1053998</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
	<ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-2358134F1AE9E25DD80FC803E64871C6" unitRef="shares">60000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
	<ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-98C91E909DA7758FD8EDC803E64AC9B1" unitRef="shares">486238</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
	<ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="FD2015Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-6958F469CC3C96364747C803E647C655" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="FD2016Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-039A66FDF9E327CC37AEC803E648EBC5" unitRef="shares">100000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-60DF696276D6083C326AC803E648B5D9" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="FD2015Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-7EB7F975E3E96072DD45C803E6469093" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="FD2015Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-14E939BEF1521C949325C803E649651E" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="FD2016Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-706792ACE47A5E5252F8C803E645EA90" unitRef="shares">660000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="FD2016Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-BBD8741F3FB38086330FC803E64992BC" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-66A42852B5DDBBA34424C803E647829B" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-A7E22F9F549E66B990EBC803E649617F" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2014Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-00367D94ED3F0EBB4D08C803E649FFA7" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2014Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-151F6BBCA45DB0D87E80C803E6499E47" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2015Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-826D0E1619F2E8E9E62EC803E649B38B" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2015Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-13240EA2824E1C9732CBC803E6471D47" unitRef="shares">368831</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2016Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-0F8AF9189ED3BA105FD9C803E647CC96" unitRef="shares">840000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2016Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-AB7336DD20BF59048291C803E6490B9A" unitRef="shares">1322829</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-9911C779B1744B6C56BDC803E64676EF" unitRef="shares">900000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-D476AE9D34470FDFCA1FC803E647ADB8" unitRef="shares">1809067</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2014Q4" decimals="INF" id="Fact-DC5522575B099CCD286FC803E648162A" unitRef="shares">5446394</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2015Q4" decimals="INF" id="Fact-1201B1F6668D7D153AA3C803E64CAB13" unitRef="shares">8561394</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2016Q4" decimals="INF" id="Fact-AC7E5C5DADBCAE1918DEC803E6488922" unitRef="shares">8674227</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2017Q4" decimals="INF" id="Fact-85815C78233139D5E36DC803E646F06E" unitRef="shares">6148667</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember" decimals="INF" id="Fact-D3198331CA5EF0FFCAB2C803E6470455" unitRef="shares">625500</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember" decimals="INF" id="Fact-DA8EBE74C1C1C3A7C8E4C803E646C4C6" unitRef="shares">545500</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember" decimals="INF" id="Fact-A7448F38518D2B3B1308C803E646D65C" unitRef="shares">3437000</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember" decimals="INF" id="Fact-F9004FC9BCA0CAFFD239C803E6457AA2" unitRef="shares">1002667</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember" decimals="INF" id="Fact-9E8C357BB7967006A64AC803E64531F8" unitRef="shares">538000</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2015Q4" decimals="INF" id="Fact-282E24F7AAB477C6AE8CC803E6496BE5" unitRef="shares">6476394</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2016Q4" decimals="INF" id="Fact-F2548FE6240CC83A1A5AC803E649D237" unitRef="shares">6729643</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2017Q4" decimals="INF" id="Fact-685F1DA896AB8158FD1BC803E6471590" unitRef="number">5453501</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2017Q4" decimals="INF" id="Fact-A574640F8F8AA42C8676C803E64DA088" unitRef="shares">5453501</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember" decimals="INF" id="Fact-12EAED44E3D97760E59FC803E648827B" unitRef="number">625500</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember" decimals="INF" id="Fact-B6A9B8868BD6DEA5CE10C803E6469F33" unitRef="number">545500</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember" decimals="INF" id="Fact-4C32C156D606317C724FC803E64650DE" unitRef="number">2921834</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember" decimals="INF" id="Fact-F8AF82244EA103DB9789C803E647879F" unitRef="number">1002667</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember" decimals="INF" id="Fact-78225D5AA0292FE9C3DAC803E6473D8C" unitRef="number">358000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="FD2015Q4YTD" decimals="INF" id="Fact-25BF991C787A6ABBA9B2C803E64D5A6D" unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="FD2016Q4YTD" decimals="INF" id="Fact-1083E5C14DDCE53F4E3DC803E64B91E7" unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD" decimals="INF" id="Fact-12BD1F423039092BEEC9C803E6473EF6" unitRef="shares">801000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="FD2015Q4YTD" decimals="INF" id="Fact-EDA05797F1BA0010F036C803E648A619" unitRef="shares">65000</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="FD2016Q4YTD" decimals="INF" id="Fact-8FB9B2E5024037577CBAC803E64A9F64" unitRef="shares">721667</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="FD2017Q4YTD" decimals="INF" id="Fact-785F8770FCF19B2D714CC803E6489C5E" unitRef="shares">116900</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="FD2015Q4YTD" decimals="INF" id="Fact-83BCA865F4ADE451A1E8C803E64C47F8" unitRef="shares">100000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="FD2016Q4YTD" decimals="INF" id="Fact-72DE5D24919C437BB865C803E648D763" unitRef="shares">737500</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD" decimals="INF" id="Fact-7517D05D031BE84CA045C803E647144D" unitRef="shares">2012660</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="FD2015Q4YTD" decimals="INF" id="Fact-008E3660AAF88DC40188C803E64CC935" unitRef="shares">3280000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="FD2016Q4YTD" decimals="INF" id="Fact-A351217462F7F38B6AFFC803E64924D6" unitRef="shares">1572000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD" decimals="INF" id="Fact-BA945D78098C41E38029C803E64C04B7" unitRef="shares">405000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2014Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="INF" id="Fact-5A5B2579C7F225F634D7C803E6477C5B" unitRef="shares">93512494</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2014Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-BDD6050D0E251B514EDEC803E6473A70" unitRef="shares">0</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2015Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="INF" id="Fact-B9A77A0BE3FE9461D8D4C803E64818CC" unitRef="shares">118151622</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2015Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-F49E841F050C31C60BA2C803E6489A15" unitRef="shares">0</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-70E767A200C82642AC76C803E6486174" unitRef="shares">121258222</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2016Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="INF" id="Fact-83FEF840F061EDC940CEC803E648ABA4" unitRef="shares">121258222</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2016Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-1F95A4A640ED704E4CDFC803E645BC1E" unitRef="shares">0</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-0386087B478E69FE115DC803E648AE57" unitRef="shares">141805722</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="INF" id="Fact-D2F830875C24E526AD65C803E6485A8E" unitRef="shares">141805722</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-B84C8B259983C6EB0373C803E64662B4" unitRef="shares">16445000</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:OperatingExpense contextRef="FD2015Q4YTD" decimals="0" id="Fact-F807E96D8754AC581920C803E64C7787" unitRef="cad">5315837</ifrs-full:OperatingExpense>
	<ifrs-full:OperatingExpense contextRef="FD2016Q4YTD" decimals="0" id="Fact-1420748E04A2D50F62D2C803E64C8D44" unitRef="cad">5524500</ifrs-full:OperatingExpense>
	<ifrs-full:OperatingExpense contextRef="FD2017Q4YTD" decimals="0" id="Fact-1515D1D39FA7EAED259AC803E64DF159" unitRef="cad">6212831</ifrs-full:OperatingExpense>
	<ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="FD2015Q4YTD" decimals="0" id="Fact-A30F791801BEF0A36479C803E64CB8D2" unitRef="cad">480935</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
	<ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="FD2016Q4YTD" decimals="0" id="Fact-BB7167759515AC3D39F0C803E64CACED" unitRef="cad">-206918</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
	<ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="FD2017Q4YTD" decimals="0" id="Fact-99154039159F14AD9D75C803E64B6D8B" unitRef="cad">-180330</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
	<ifrs-full:OtherCurrentReceivables contextRef="FI2016Q4" decimals="0" id="Fact-48ADA580474559AA1DD7E39016B1F5A6" unitRef="cad">54406</ifrs-full:OtherCurrentReceivables>
	<ifrs-full:OtherCurrentReceivables contextRef="FI2017Q4" decimals="0" id="Fact-8661BF0E92437D053970E39016B8D393" unitRef="cad">37726</ifrs-full:OtherCurrentReceivables>
	<ifrs-full:ProceedsFromExerciseOfOptions contextRef="FD2015Q4YTD" decimals="0" id="Fact-639B411921E14BE449071B078905B165" unitRef="cad">0</ifrs-full:ProceedsFromExerciseOfOptions>
	<ifrs-full:ProceedsFromExerciseOfOptions contextRef="FD2016Q4YTD" decimals="0" id="Fact-7DDA85B95FE716241BE91B07892412E1" unitRef="cad">0</ifrs-full:ProceedsFromExerciseOfOptions>
	<ifrs-full:ProceedsFromExerciseOfOptions contextRef="FD2017Q4YTD" decimals="0" id="Fact-95663B5581D42B485F091B078912C412" unitRef="cad">343440</ifrs-full:ProceedsFromExerciseOfOptions>
	<ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="FD2015Q4YTD" decimals="0" id="Fact-55C6692B86B4BB60A5A1C803E64BE715" unitRef="cad">4305396</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
	<ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="FD2016Q4YTD" decimals="0" id="Fact-B8C67134C982F3E3A331C803E64A72A8" unitRef="cad">0</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
	<ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="FD2017Q4YTD" decimals="0" id="Fact-1E94A8D9331F6403C204C803E64D9931" unitRef="cad">0</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2015Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-E38C5CD4BCF14A7ED68E1B04A019BD9C" unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2015Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-27A1EE056F28C41AD7C6C803E64BFB53" unitRef="cad">19362240</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2016Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-7CBADC409CEF0620DDB91B049F209FDB" unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2016Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-3DAC97E827E48CA96066C803E6465064" unitRef="cad">956133</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-D9ED41D89737C50D2F4A1B049E22C26B" unitRef="cad">10366098</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-8DB18EA5D6134011F58AC803E64D29B4" unitRef="cad">2103166</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProfitLoss contextRef="FD2015Q4YTD" decimals="0" id="Fact-DBA132685CABB69AA4B8C803E64DDAAF" unitRef="cad">-13722995</ifrs-full:ProfitLoss>
	<ifrs-full:ProfitLoss contextRef="FD2016Q4YTD" decimals="0" id="Fact-DF7BF2F5B44D310DDB7FC803E64CDFFE" unitRef="cad">-15139979</ifrs-full:ProfitLoss>
	<ifrs-full:ProfitLoss contextRef="FD2017Q4YTD" decimals="0" id="Fact-24CFB5BEB70482376736C803E64BC68A" unitRef="cad">-15616851</ifrs-full:ProfitLoss>
	<ifrs-full:ProfitLossBeforeTax contextRef="FD2015Q4YTD" decimals="0" id="Fact-E92D0B72B63A642940A5C803E64DE47A" unitRef="cad">-13719842</ifrs-full:ProfitLossBeforeTax>
	<ifrs-full:ProfitLossBeforeTax contextRef="FD2016Q4YTD" decimals="0" id="Fact-6C6A6ADF9A8B76D40D3AC803E64A2033" unitRef="cad">-15130605</ifrs-full:ProfitLossBeforeTax>
	<ifrs-full:ProfitLossBeforeTax contextRef="FD2017Q4YTD" decimals="0" id="Fact-E946981FF971D6D4CFAEC803E64B9EB7" unitRef="cad">-15475353</ifrs-full:ProfitLossBeforeTax>
	<ifrs-full:ProfitLossFromOperatingActivities contextRef="FD2015Q4YTD" decimals="0" id="Fact-E8017E92B80E2FE5B5C4C803E64C9EAE" unitRef="cad">-13917701</ifrs-full:ProfitLossFromOperatingActivities>
	<ifrs-full:ProfitLossFromOperatingActivities contextRef="FD2016Q4YTD" decimals="0" id="Fact-C8C2A55983C4B8D665A8C803E64DDA47" unitRef="cad">-15294507</ifrs-full:ProfitLossFromOperatingActivities>
	<ifrs-full:ProfitLossFromOperatingActivities contextRef="FD2017Q4YTD" decimals="0" id="Fact-8695B155C5A110E81EF9C803E64CAEEE" unitRef="cad">-15605454</ifrs-full:ProfitLossFromOperatingActivities>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" decimals="0" id="Fact-52D03B618355E8C196CCC803E649A9B2" unitRef="cad">1191243</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-4C857C83D2961BD7FACFC803E647C372" unitRef="cad">505245</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-DBE5DD927FE20F47B518C803E648683F" unitRef="cad">127383</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-D3AF8F9114E65B77C5B0C803E647E641" unitRef="cad">366379</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-FE4FF680252AEBF99D4EC803E6491537" unitRef="cad">58759</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-53ABA809EEF702CE42F6C803E647AB25" unitRef="cad">133477</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember" decimals="0" id="Fact-43EB07019DCAF1F1A88EC803E64564CD" unitRef="cad">1651061</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-B2DD475ED9650EAE4809C803E64A7D2B" unitRef="cad">685277</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-4F7CCDD7D75C9829E716C803E64B88FF" unitRef="cad">214085</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-27E819C65269B2A7BFFDC803E6488700" unitRef="cad">465865</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-7EA71D5A980C732C328EC803E64CCC8A" unitRef="cad">87964</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2015Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-6A8503088BA724333CCFC803E646CF72" unitRef="cad">197870</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4" decimals="0" id="Fact-DEFCA298131191C56A04C803E64ADE94" unitRef="cad">319955</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" decimals="0" id="Fact-C580B38CC99FBE2F7AADC803E6462D98" unitRef="cad">1353476</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-0CAAFFB3CF0D08EDF2CEC803E64DAE8D" unitRef="cad">554174</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-C7C1F8579AB483995C22C803E64921D6" unitRef="cad">137624</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-A6B8D601EF5A3FD99E55C803E6456BFB" unitRef="cad">452542</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-888ABEB36988D0EA68BAC803E64518DC" unitRef="cad">64167</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-64FB024CF1EFD7F91FD6C803E6487BC3" unitRef="cad">144969</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember" decimals="0" id="Fact-E345CED036845E40719EC803E646FD2B" unitRef="cad">1673431</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-002265D6EB07D21BBD68C803E64412BF" unitRef="cad">705375</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-A6E19E5469342AB6029EC803E64A3339" unitRef="cad">214085</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-9BD9ADCAB5080ED66ECFC803E64AF614" unitRef="cad">466635</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-D6B9A68C5C7FF9974725C803E646F49B" unitRef="cad">89466</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-9C6367A254B830879DEDC803E6461535" unitRef="cad">197870</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-4A88032BBA09B48E1AD0C803E64D1F8B" unitRef="cad">151201</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-C7189B29452BED2E67FBC803E64DC748" unitRef="cad">76461</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-F663922C13C8D90A8306C803E64A3EEF" unitRef="cad">14093</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-CFE6A5A722C5515A0250C803E647613A" unitRef="cad">25299</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2016Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-93352F59E5B6589712A8C803E6481A20" unitRef="cad">52901</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4" decimals="0" id="Fact-0442E931E637E6BC18D4C803E64B059D" unitRef="cad">333441</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" decimals="0" id="Fact-6E310B85DDF7EC759E12C803E646ACA8" unitRef="cad">1396076</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-5897A27EC5B437061644C803E6453F30" unitRef="cad">549564</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-80208428DE2ED2DDAB4DC803E64CF458" unitRef="cad">147334</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-851E90C34BE9FAC13AE5C803E6499025" unitRef="cad">476057</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-3460E3AA33A45870F4DEC803E64D4E7D" unitRef="cad">68787</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-D18A0C6D79ED8D040E9AC803E647A58F" unitRef="cad">154334</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember" decimals="0" id="Fact-6EC6AC810F8B7D818991C803E645E5E6" unitRef="cad">1729517</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-1A621BA0EBF984D02D30C803E64DC92B" unitRef="cad">681985</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-11024EE1358619E3F7F3C803E64A6D99" unitRef="cad">225896</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-DB223B6C2E7DF7D308DBC803E648A91E" unitRef="cad">534300</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-C8821251688E1B9B2278C803E64A21CA" unitRef="cad">89466</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-9B036754B31DCFCE92B8C803E64BF6F9" unitRef="cad">197870</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-E4B9DC5D55659B24FDC7C803E64C1ECA" unitRef="cad">132421</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-5DE671DF1285687E60ABC803E645C773" unitRef="cad">78562</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-159E246DDBBD5E98B5FFC803E645B02A" unitRef="cad">58243</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-577E9D73FBEAE0651354C803E64D1137" unitRef="cad">20679</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-1C057500C2C16AB6EF27C803E64D333B" unitRef="cad">43536</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="FD2015Q4YTD" decimals="0" id="Fact-D86FFB3905433703A643C803E64CB1FD" unitRef="cad">108268</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
	<ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="FD2016Q4YTD" decimals="0" id="Fact-C4198EB91B0D4CDB6183C803E6494F0B" unitRef="cad">23527</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
	<ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="FD2017Q4YTD" decimals="0" id="Fact-AFF19A27AB1F6359BCC2C803E645070F" unitRef="cad">105765</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
	<ifrs-full:ResearchAndDevelopmentExpense contextRef="FD2015Q4YTD" decimals="0" id="Fact-FF2723D92793BE75A0C2C803E64B2ECC" unitRef="cad">8601864</ifrs-full:ResearchAndDevelopmentExpense>
	<ifrs-full:ResearchAndDevelopmentExpense contextRef="FD2016Q4YTD" decimals="0" id="Fact-24119D7632F369D85982C803E64A1B04" unitRef="cad">9770007</ifrs-full:ResearchAndDevelopmentExpense>
	<ifrs-full:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="0" id="Fact-BF597D0754DCA33ABD48C803E64A8253" unitRef="cad">9392623</ifrs-full:ResearchAndDevelopmentExpense>
	<ifrs-full:RetainedEarnings contextRef="FI2016Q4" decimals="0" id="Fact-57A8FC915F9FBF86FEE1C803E64AE3DF" unitRef="cad">-278829309</ifrs-full:RetainedEarnings>
	<ifrs-full:RetainedEarnings contextRef="FI2017Q4" decimals="0" id="Fact-F9F02EB08E127FC05EA4C803E64AF4F6" unitRef="cad">-294446160</ifrs-full:RetainedEarnings>
	<ifrs-full:RevenueFromContractsWithCustomers contextRef="FD2016Q4YTD" decimals="0" id="Fact-A1D40FB38717B8FD5302E39FCA3FD3B5" unitRef="usd">0</ifrs-full:RevenueFromContractsWithCustomers>
	<ifrs-full:RevenueFromContractsWithCustomers contextRef="FD2017Q4YTD" decimals="0" id="Fact-69C3DDED1624FC8402A8E39FCA563E65" unitRef="usd">6182580</ifrs-full:RevenueFromContractsWithCustomers>
	<ifrs-full:ShareIssueRelatedCost contextRef="D2017Q2Jun1_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-4ADDA753B978B72C7F28F317FE934191" unitRef="cad">1145402</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2015Q4YTD" decimals="0" id="Fact-CF5D14E15D55B720A9CCC803E647D296" unitRef="cad">753744</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-3F1EA56420146F03FF58C803E6475762" unitRef="cad">753744</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2015Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-982D3038D1F9FC55BA04C803E645C118" unitRef="cad">753744</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2016Q4YTD" decimals="0" id="Fact-E6FFB50BB5AFE60582DAC803E64707E5" unitRef="cad">500163</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2016Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-4EB1CC8E74B9A976633EC803E647C251" unitRef="cad">500163</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2016Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-D75FF445A3D9AE0AA523C803E6483AA5" unitRef="cad">500163</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2016Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-C46618EF667C72644423E7E57D345EC2" unitRef="cad">500163</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2017Q4YTD" decimals="0" id="Fact-031FB108CD2226DBEB43C803E64756AC" unitRef="cad">1391057</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-D22D4BBED13E126F1846C803E646C7B5" unitRef="cad">1391057</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-2A9C425E426D96C0E6D8C803E6488753" unitRef="cad">1391057</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-7CC5102335C92BFEABDFC803E649B81D" unitRef="cad">245655</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares contextRef="FI2017Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ifrs-full_ReserveOfSharebasedPaymentsMember" decimals="INF" id="Fact-A8E56061243C85A417D8C803E64CA1B4" unitRef="shares">14180572</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
	<ifrs-full:TaxEffectFromChangeInTaxRate contextRef="FD2015Q4YTD" decimals="0" id="Fact-977842B8AABEBA0C463BC803E64DF43A" unitRef="cad">-1336941</ifrs-full:TaxEffectFromChangeInTaxRate>
	<ifrs-full:TaxEffectFromChangeInTaxRate contextRef="FD2016Q4YTD" decimals="0" id="Fact-A6788D0F62C82188C314C803E6490EFE" unitRef="cad">0</ifrs-full:TaxEffectFromChangeInTaxRate>
	<ifrs-full:TaxEffectFromChangeInTaxRate contextRef="FD2017Q4YTD" decimals="0" id="Fact-07098357677EF845E397C803E649C21B" unitRef="cad">0</ifrs-full:TaxEffectFromChangeInTaxRate>
	<ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="FD2015Q4YTD" decimals="0" id="Fact-480187556C175B6EDC9FC803E64D073A" unitRef="cad">23620</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
	<ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="FD2016Q4YTD" decimals="0" id="Fact-B1B9D38EAD76AD01A158C803E64A0288" unitRef="cad">100525</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
	<ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="FD2017Q4YTD" decimals="0" id="Fact-F671D451D12A300E6478C803E64D62D1" unitRef="cad">53039</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
	<ifrs-full:TaxEffectOfForeignTaxRates contextRef="FD2015Q4YTD" decimals="0" id="Fact-9ED46ACCBBE77955ED79C803E64A64CC" unitRef="cad">2659145</ifrs-full:TaxEffectOfForeignTaxRates>
	<ifrs-full:TaxEffectOfForeignTaxRates contextRef="FD2016Q4YTD" decimals="0" id="Fact-B49767296A1E89AD1582C803E649E787" unitRef="cad">2184796</ifrs-full:TaxEffectOfForeignTaxRates>
	<ifrs-full:TaxEffectOfForeignTaxRates contextRef="FD2017Q4YTD" decimals="0" id="Fact-1C6D6A4A9CB11AE1EC45C803E6495237" unitRef="cad">2899190</ifrs-full:TaxEffectOfForeignTaxRates>
	<ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="FD2015Q4YTD" decimals="0" id="Fact-9CEAF3544B9182873195C803E6479FD0" unitRef="cad">-3567159</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
	<ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="FD2016Q4YTD" decimals="0" id="Fact-AD6AF78361D95D71162AC803E6450E1D" unitRef="cad">-4085263</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
	<ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="FD2017Q4YTD" decimals="0" id="Fact-870A4EAAB65C7D9647B3C803E649ADB0" unitRef="cad">-4178345</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
	<ifrs-full:TradeAndOtherCurrentPayables contextRef="FI2016Q4" decimals="0" id="Fact-BF20BF34A7DD5649DA6BC803E64B7EA6" unitRef="cad">4068664</ifrs-full:TradeAndOtherCurrentPayables>
	<ifrs-full:TradeAndOtherCurrentPayables contextRef="FI2017Q4" decimals="0" id="Fact-864C8EBE46A8DB97CC30C803E64BA978" unitRef="cad">3684023</ifrs-full:TradeAndOtherCurrentPayables>
	<ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties contextRef="FI2017Q4" decimals="0" id="Fact-8BF41F5339AD716AC09D1AFA170FA246" unitRef="usd">178125</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
	<ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties contextRef="I2017Q4Nov30" decimals="0" id="Fact-FDA450FF9D54439F7AE11AF98EB279E7" unitRef="usd">178125</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
	<ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="FI2017Q4_oncyf_Currency1Axis_currency_EUR" decimals="0" id="Fact-2B52B2EBBDFB25FB9287C803E64A2320" unitRef="eur">-1100</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
	<ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="FI2017Q4_oncyf_Currency1Axis_currency_GBP" decimals="0" id="Fact-675E9342C462AE78B849C803E64B75B7" unitRef="gbp">-13949</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
	<ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="FI2017Q4_oncyf_Currency1Axis_currency_USD" decimals="0" id="Fact-A2AECFB0502F6C3F502DC803E64A1688" unitRef="usd">-777271</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFiveMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-5AE247B97AFA75533B43C803E6445ED0" unitRef="cad">183000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFourMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-70CEFA7C2F2BFCD191A4C803E64D4E6A" unitRef="cad">270000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-C43E87EA5F4B7E353B2BC803E644EE53" unitRef="cad">91000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyOneMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-9D53E44A6674BDAFBF06C803E6494CDA" unitRef="cad">114000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-DEC189FD12709862B797F2D4E21905C0" unitRef="cad">600</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-7D8023AA9A29EF57DBC3C803E64DF729" unitRef="cad">41000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyThreeMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-E24C177027B13E433F1EC803E6443D6F" unitRef="cad">487000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyTwoMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-7DC11F4CE32323900A2BC803E64DE4EC" unitRef="cad">381000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyEightMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-074B3E21A6A4AAE12510C803E6456073" unitRef="cad">622000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyFiveMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-99D52A87B3F2EB2A0D42C803E644CF4F" unitRef="cad">271000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyFourMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-0FAE363C856B7ED078AAC803E64DA846" unitRef="cad">228000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-4794FB62372797A3A663C803E645AA10" unitRef="cad">189000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyNineMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-B29795340A182E18F442C803E645B69F" unitRef="cad">173000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyOneMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-8EB981DBAE7154996CFDC803E6448F56" unitRef="cad">471000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-05E48B2B33C75A966F18C803E64A2F21" unitRef="cad">596000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-AF62E5649F67E1CBA68CC803E64A8D3C" unitRef="cad">520000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyThreeMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-1657B6865551E740B6E4C803E64D4C53" unitRef="cad">361000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyTwoMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-1A138699A024D884196AC803E649AF38" unitRef="cad">465000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-2E2F65E9FB7F82EEAE1BC803E64DDFB2" unitRef="cad">5463600</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" decimals="-5" id="Fact-0798C75AAD4957DA9E1CC803E64A7286" unitRef="cad">27400000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFiveMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-5E8A110E10F4943C5732C803E64635A8" unitRef="cad">3125000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFourMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-CB91D0BC2E4DF668BA98C803E645237F" unitRef="cad">2472000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-60ABC1F016E6B856F469C803E645C417" unitRef="cad">4774000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyOneMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-E2BB8F4DDFF0D5190CDDC803E64537F4" unitRef="cad">4343000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-39F5C00E136121785063F2D47D3D5395" unitRef="cad">4846000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-A3E3E598F145398B9A54C803E645A60B" unitRef="cad">6430000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyThreeMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-B5DB8EC6174853E0BDDFC803E6440A93" unitRef="cad">2457000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyTwoMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-197A8F8FF4FC87D1735DC803E645CD1B" unitRef="cad">2873000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyNineMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-473C0D591580A539DB8AC803E64B9ABA" unitRef="cad">4009000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-3FB967A220FBE0041248C803E6445754" unitRef="cad">12170000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-42ED0115B4557B85578FC803E645ED06" unitRef="cad">9809000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-056895293F1B8C94B35BC803E645D63D" unitRef="cad">57308000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2015Q4" decimals="2" id="Fact-74886EA6E31D20361BEDC803E6489BCF" unitRef="cad">2.73</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2016Q4" decimals="2" id="Fact-D5B4C1795A383FE9D094C803E649F151" unitRef="cad">2.27</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2017Q4" decimals="2" id="Fact-71D68CD8B3E77966AF2BC803E645612B" unitRef="cad">1.51</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember" decimals="2" id="Fact-5D07E633D09FB4C121C9C803E6469645" unitRef="cad">5.34</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember" decimals="2" id="Fact-974A156F965422FC2B38C803E6492AC6" unitRef="cad">3.42</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember" decimals="2" id="Fact-5CA84D08FCCA10E79461C803E646C9C2" unitRef="cad">0.35</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember" decimals="2" id="Fact-08D5E0DB4565BA3BB05DC803E647E9DF" unitRef="cad">1.77</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember" decimals="2" id="Fact-109A6DCCE633E9E569F4C803E64611F9" unitRef="cad">0.70</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="FD2015Q4YTD" decimals="0" id="Fact-37FA7C70982B27AB74A5C803E64C2E7D" unitRef="cad">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="FD2016Q4YTD" decimals="2" id="Fact-D264B3070D0CCEDA1BCEC803E647A5EE" unitRef="cad">0.00</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD" decimals="2" id="Fact-62801ABFD2A03BCFC330C803E64D354C" unitRef="cad">0.43</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="FD2015Q4YTD" decimals="2" id="Fact-BCD4D615FAE625C4A998C803E6484E54" unitRef="cad">1.49</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="FD2016Q4YTD" decimals="2" id="Fact-671FDEC0AD9E2DB5B594C803E6471EC7" unitRef="cad">3.61</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="FD2017Q4YTD" decimals="2" id="Fact-AC7F6DAE9D6B2118436AC803E64A0B32" unitRef="cad">2.22</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="FD2015Q4YTD" decimals="2" id="Fact-B6966339160436AE6F00C803E647C737" unitRef="cad">1.69</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="FD2016Q4YTD" decimals="2" id="Fact-D608E0DBFF93404ABB2CC803E64BFD3E" unitRef="cad">0.65</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD" decimals="2" id="Fact-CCA671566A53A4620CFEC803E64A8C24" unitRef="cad">3.45</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="FD2015Q4YTD" decimals="2" id="Fact-8F8F56724E6461471AD1C803E64C321E" unitRef="cad">0.43</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="FD2016Q4YTD" decimals="2" id="Fact-69E5CF92A93B1BBF030FC803E647D749" unitRef="cad">0.28</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD" decimals="2" id="Fact-39D808FB4E7B2C98345EC803E649B1E8" unitRef="cad">0.48</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="FI2014Q4" decimals="2" id="Fact-3BA055FC35470E987F2CC803E64AF6C4" unitRef="cad">3.19</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="FI2015Q4" decimals="2" id="Fact-DC178984AA0F302E91BAC803E64AFDCC" unitRef="cad">2.17</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="FI2016Q4" decimals="2" id="Fact-DA68322EB85772832F2BC803E64948D4" unitRef="cad">1.83</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="FI2017Q4" decimals="2" id="Fact-CD82731D0F72E06FBD55C803E64504C3" unitRef="cad">1.39</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember" decimals="2" id="Fact-21516FC881CF6A06AD64C803E64603E4" unitRef="cad">5.34</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember" decimals="2" id="Fact-C6B18963EFEAB3A06B67C803E64677C3" unitRef="cad">3.42</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember" decimals="2" id="Fact-472054FD2FCE166D6373C803E6462A26" unitRef="cad">0.35</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember" decimals="2" id="Fact-199B9E323C6A513B0D9BC803E64542DA" unitRef="cad">1.77</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember" decimals="2" id="Fact-953BFDEC99B9B63A0376C803E6460639" unitRef="cad">0.64</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="FI2016Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="2" id="Fact-C802E4BF4EAD3617E4921B0049344548" unitRef="cad">0.36</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
	<ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="FI2016Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="2" id="Fact-25B064E24F63414A59D0C803E64C4506" unitRef="cad">0.31</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
	<ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="FI2017Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="2" id="Fact-34C6BB22694534A13BF8C803E64DC3EA" unitRef="cad">0.35</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
	<ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="FI2017Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="2" id="Fact-4E590F8F34FB6EEED4C9C803E64CF494" unitRef="cad">0.63</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
	<ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="FI2015Q4" decimals="2" id="Fact-35E52A049FE44E2201DFC803E6489A53" unitRef="cad">0.24</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
	<ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="FI2016Q4" decimals="2" id="Fact-1315C4357E9B1B846576C803E6463D10" unitRef="cad">0.17</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
	<ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="FI2017Q4" decimals="2" id="Fact-A74DCA7AAC29079E8D12C803E645ED21" unitRef="cad">0.28</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
	<ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="FI2017Q4" decimals="2" id="Fact-D8CDB16726B9D0623F92C803E64768ED" unitRef="year">7.09</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
	<ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-A3038CBF672D6FCC60E3F3138396CC33" unitRef="shares">4.42</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
	<ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember" decimals="2" id="Fact-CBAC1370C1F3CC14F394C803E64744FE" unitRef="year">3.94</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
	<ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember" decimals="2" id="Fact-B371FE6DB2EB4877272BC803E646DEE5" unitRef="year">3.74</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
	<ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember" decimals="2" id="Fact-5DFCAF28AACC22DCFD80C803E646F3CB" unitRef="year">8.46</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
	<ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember" decimals="2" id="Fact-B06CDAB7FA7CB4457674C803E6452CD3" unitRef="year">5.62</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
	<ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="FI2017Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember" decimals="2" id="Fact-9C3DAE8025F5B9027A4EC803E6471428" unitRef="year">8.22</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
	<ifrs-full:WeightedAverageShares contextRef="FD2015Q4YTD" decimals="0" id="Fact-60FD5A130D889D7A153DC803E64CB032" unitRef="shares">112613845</ifrs-full:WeightedAverageShares>
	<ifrs-full:WeightedAverageShares contextRef="FD2016Q4YTD" decimals="0" id="Fact-D1AB065DE74DBC1ECF24C803E64BE934" unitRef="shares">119880200</ifrs-full:WeightedAverageShares>
	<ifrs-full:WeightedAverageShares contextRef="FD2017Q4YTD" decimals="0" id="Fact-4F6EAF8CC9957BDE3B68C803E64D80B6" unitRef="shares">132395752</ifrs-full:WeightedAverageShares>
	<oncyf:AccruedRoyalties1 contextRef="FI2017Q4" decimals="-3" id="Fact-6C6D03396E1929F2C79CC803E64AAAEB" unitRef="cad">301000</oncyf:AccruedRoyalties1>
	<oncyf:AnnualContingentPayment contextRef="FI2017Q4" decimals="INF" id="Fact-6C81750AF11348BE97B3C803E647CA55" unitRef="cad">100000</oncyf:AnnualContingentPayment>
	<oncyf:AnnualContingentPaymentGrossSalesPercent contextRef="FI2017Q4" decimals="INF" id="Fact-5EF5B8F54ACF086500BBC803E648612D" unitRef="number">0.05</oncyf:AnnualContingentPaymentGrossSalesPercent>
	<oncyf:BalanceHeldInForeignCurrencyNet contextRef="FI2017Q4_oncyf_Currency1Axis_currency_EUR" decimals="0" id="Fact-54A04DE086F2A3FC53F6C803E6495DE5" unitRef="eur">18272</oncyf:BalanceHeldInForeignCurrencyNet>
	<oncyf:BalanceHeldInForeignCurrencyNet contextRef="FI2017Q4_oncyf_Currency1Axis_currency_GBP" decimals="0" id="Fact-320AC93963CACBA07496C803E64A2932" unitRef="gbp">7806</oncyf:BalanceHeldInForeignCurrencyNet>
	<oncyf:BalanceHeldInForeignCurrencyNet contextRef="FI2017Q4_oncyf_Currency1Axis_currency_USD" decimals="0" id="Fact-3767FE38AA6278F70259C803E64BE586" unitRef="usd">4971302</oncyf:BalanceHeldInForeignCurrencyNet>
	<oncyf:CashEquivalentsInterestRate contextRef="FD2016Q4YTD" decimals="4" id="Fact-9B6FCFD80AD8624D678BC803E64CBD72" unitRef="number">0.0096</oncyf:CashEquivalentsInterestRate>
	<oncyf:CashEquivalentsInterestRate contextRef="FD2017Q4YTD" decimals="4" id="Fact-DCA970D04559B8157A14C803E64C3D26" unitRef="number">0.0138</oncyf:CashEquivalentsInterestRate>
	<oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1 contextRef="I2017Q2Jun1" decimals="0" id="Fact-FD8BF8CCBCFFBC17178E1B2E8A20D196" unitRef="shares">1</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1>
	<oncyf:CommitmentsAndContingencies1 contextRef="FI2016Q4" id="Fact-33D30B36E653A577C017C803E64551B7" unitRef="cad" xsi:nil="true" />
	<oncyf:CommitmentsAndContingencies1 contextRef="FI2017Q4" id="Fact-B290D413DCCF7D30F410C803E6454077" unitRef="cad" xsi:nil="true" />
	<oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue contextRef="FD2017Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember" id="Fact-75FC5C5AF27ABA145AD9C803E64908A5">P90D</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue>
	<oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage contextRef="FD2016Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember" decimals="INF" id="Fact-418A8DD99A21FB1FA8BEC803E649B1B8" unitRef="number">0.0235</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage>
	<oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage contextRef="FD2017Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember" decimals="INF" id="Fact-CF511630AB5D978873E61B33AF68B957" unitRef="number">0.0215</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage>
	<oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage contextRef="FD2016Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember" decimals="INF" id="Fact-D34E1BE4F39D4D78C391C803E6494266" unitRef="number">0.1175</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage>
	<oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage contextRef="FD2017Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember" decimals="INF" id="Fact-DECC66664EBA476A1A2F1B33491CF598" unitRef="number">0.1075</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage>
	<oncyf:CommonSharePurchaseWarrantPerUnit contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-1DC016CA8A8FAAABA638F31C35D5BC4C" unitRef="usdPerShare">1</oncyf:CommonSharePurchaseWarrantPerUnit>
	<oncyf:CommonSharesPerUnit contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-CB9943B7C1BB3506B5E7F31AD828F7A3" unitRef="usdPerShare">1</oncyf:CommonSharesPerUnit>
	<oncyf:ConcentrationRiskNumber contextRef="FD2017Q4YTD_oncyf_ConcentrationRiskType1Axis_oncyf_SupplierConcentrationRisk1Member" decimals="INF" id="Fact-069722F0C115B3F8F46DC803E645E5A0" unitRef="manufacturer">1</oncyf:ConcentrationRiskNumber>
	<oncyf:ContingentRoyaltyPaymentAnnualMaximum contextRef="FD2017Q4YTD" decimals="INF" id="Fact-868B7342F258504FB0D3C803E6481C04" unitRef="cad">20000</oncyf:ContingentRoyaltyPaymentAnnualMaximum>
	<oncyf:ContingentRoyaltyPaymentContributionRate contextRef="FD2017Q4YTD" decimals="INF" id="Fact-D828550733458F8BF92BC803E649A612" unitRef="number">2</oncyf:ContingentRoyaltyPaymentContributionRate>
	<oncyf:ContingentRoyaltyPaymentPercentOfSalesRevenue contextRef="FI2017Q4" decimals="INF" id="Fact-EE8A7ADB9C15632BCBACC803E6487403" unitRef="number">0.005</oncyf:ContingentRoyaltyPaymentPercentOfSalesRevenue>
	<oncyf:ContractLiabilityRecognitionPeriod contextRef="D2017Q4Nov1-30" decimals="INF" id="Fact-49276958A4C6641C85D0F3B298B7F632" unitRef="number">5</oncyf:ContractLiabilityRecognitionPeriod>
	<oncyf:DividendYieldPercent contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-F767ADFEA0937C5D2D17F2FCE2F74F47" unitRef="number">0</oncyf:DividendYieldPercent>
	<oncyf:EquityAuthorized contextRef="I2016Q1Feb16" decimals="INF" id="Fact-B2355EC5FDC5074A5217C803E648E800" unitRef="cad">150000000</oncyf:EquityAuthorized>
	<oncyf:ExercisePriceofOutstandingWarrants contextRef="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="2" id="Fact-337CB2ECA7A7E7E0DBF1F31093E07954" unitRef="cad">0.95</oncyf:ExercisePriceofOutstandingWarrants>
	<oncyf:ExpectedForfeitureShareOptionsGranted contextRef="FD2015Q4YTD" decimals="4" id="Fact-6566EC4C1457459EB488C803E647BF60" unitRef="number">0.0367</oncyf:ExpectedForfeitureShareOptionsGranted>
	<oncyf:ExpectedForfeitureShareOptionsGranted contextRef="FD2016Q4YTD" decimals="4" id="Fact-054A69BF2F4F827C47B6C803E6484A28" unitRef="number">0.0367</oncyf:ExpectedForfeitureShareOptionsGranted>
	<oncyf:ExpectedForfeitureShareOptionsGranted contextRef="FD2017Q4YTD" decimals="4" id="Fact-7EE15D48989DD3412CD9C803E645B9E3" unitRef="number">0.0367</oncyf:ExpectedForfeitureShareOptionsGranted>
	<oncyf:FundedandRoyaltyRepayment contextRef="FI2017Q4" decimals="INF" id="Fact-BA69F2CCC60B4ECED35EC803E648D0EF" unitRef="cad">400000</oncyf:FundedandRoyaltyRepayment>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="D2017Q2Jun1_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-05C980552B534D229ED9F31741485BFB" unitRef="cad">11511500</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="FD2016Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="INF" id="Fact-47D3CF03132C2DB4A01FC803E647D023" unitRef="cad">1456296</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="INF" id="Fact-FF7FFE418F41865C8B88C803E645D5AA" unitRef="cad">2348821</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:IncreaseDecreaseinPrepaidExpense1 contextRef="FD2015Q4YTD" decimals="0" id="Fact-1BF73054475FCFC73934C803E64BDC5E" unitRef="cad">-215116</oncyf:IncreaseDecreaseinPrepaidExpense1>
	<oncyf:IncreaseDecreaseinPrepaidExpense1 contextRef="FD2016Q4YTD" decimals="0" id="Fact-8FDBA0621CB058EF1B7FC803E64A2FC7" unitRef="cad">245828</oncyf:IncreaseDecreaseinPrepaidExpense1>
	<oncyf:IncreaseDecreaseinPrepaidExpense1 contextRef="FD2017Q4YTD" decimals="0" id="Fact-C943C6C3641876818180F2DE4FA1E8D6" unitRef="cad">-915222</oncyf:IncreaseDecreaseinPrepaidExpense1>
	<oncyf:InitialCommitmentFeeSharesIssuedFairValue contextRef="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_AmendedInitialCommitmentFeeMember" decimals="0" id="Fact-A98EC6EEEED77158A225C803E649E2CC" unitRef="usd">50024</oncyf:InitialCommitmentFeeSharesIssuedFairValue>
	<oncyf:InitialCommitmentFeeSharesIssuedFairValue contextRef="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_InitialCommitmentFeeMember" decimals="-3" id="Fact-3F35AE0FDA8949E1051FC803E6484A6C" unitRef="usd">455000</oncyf:InitialCommitmentFeeSharesIssuedFairValue>
	<oncyf:InitialCommitmentFeeSharesIssuedFairValue contextRef="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAmendedSharePurchaseAgreementMember" decimals="-5" id="Fact-1F86CAF9E9DC5532911FC803E64843EE" unitRef="usd">3500000</oncyf:InitialCommitmentFeeSharesIssuedFairValue>
	<oncyf:InitialCommitmentFeeSharesIssuedFairValue contextRef="FD2015Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="-5" id="Fact-6982E7B1016C14B07F46C803E648A390" unitRef="usd">15500000</oncyf:InitialCommitmentFeeSharesIssuedFairValue>
	<oncyf:IssueOfEquitySharePurchaseAgreementFutureIssuesShares contextRef="FD2014Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="INF" id="Fact-E319F899907BAA78690EC803E649887D" unitRef="shares">292793</oncyf:IssueOfEquitySharePurchaseAgreementFutureIssuesShares>
	<oncyf:IssueOfEquityShares contextRef="D2014Q3Oct20_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="INF" id="Fact-1F4525DF2AFEB145C629C803E64643A5" unitRef="shares">146397</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="D2017Q2Jun1_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-721975D6AB7D73760B1BE7EF079941DB" unitRef="shares">16445000</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2014Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_InitialCommitmentFeeMember" decimals="INF" id="Fact-4271034DE5352B47D305C803E6483386" unitRef="shares">292793</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_AmendedInitialCommitmentFeeMember" decimals="INF" id="Fact-97C150322DDB8AC6DA54C803E648F26B" unitRef="shares">78674</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAmendedSharePurchaseAgreementMember" decimals="INF" id="Fact-D5644B37167A0A6FDEA4C803E648DEEF" unitRef="shares">5778674</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="INF" id="Fact-F7EA361E1312B08BED43C803E647D42C" unitRef="shares">18860454</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2015Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" decimals="INF" id="Fact-0E8B88370450878166FDC803E646F65B" unitRef="shares">5778674</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2015Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="INF" id="Fact-60A60D1C7D1BE7326611C803E647C692" unitRef="shares">18860454</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2016Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="INF" id="Fact-3DBDF9BBC5206FFF593EC803E648D594" unitRef="shares">100000</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2016Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="INF" id="Fact-2B312A14041410457FF5C803E6481926" unitRef="shares">3006600</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="INF" id="Fact-F926105BA67A72AFFABAC803E647D4AD" unitRef="shares">801000</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-7BAEDB0A84589F521B04E7D6B4237775" unitRef="shares">16445000</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="INF" id="Fact-E4E260A3571B7CE7EE17C803E648982D" unitRef="shares">3301500</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-908D28D2B8EB0D69CDFBF312ABF80DE1" unitRef="shares">16445000</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-9A329BAF24C461C77B2DE7D878DB963D" unitRef="shares">16445000</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="INF" id="Fact-408487F572119740837FC803E6467D67" unitRef="shares">3301500</oncyf:IssueOfEquityShares>
	<oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement contextRef="FD2017Q4YTD" id="Fact-12011AD0CB3FC6BC00B5C803E64CC6EF">P10Y</oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement>
	<oncyf:NumberOfStockOptionPlans contextRef="FI2017Q4" decimals="INF" id="Fact-75C6D3D2E5E6143EA16EC803E647FEA7" unitRef="plan">1</oncyf:NumberOfStockOptionPlans>
	<oncyf:NumberofPatients contextRef="D2017Q4Nov1-30_oncyf_MilestoneAxis_oncyf_MilestoneOneMember" decimals="INF" id="Fact-DCA214D6C98C42CBF66B20CBFE1D0811" unitRef="patient">1</oncyf:NumberofPatients>
	<oncyf:NumberofPatients contextRef="D2017Q4Nov1-30_oncyf_MilestoneAxis_oncyf_MilestoneTwoMember" decimals="INF" id="Fact-283EA9399CD29CDC3380F3B82DB6A179" unitRef="patient">50</oncyf:NumberofPatients>
	<oncyf:OverheadRepayment contextRef="FI2017Q4" decimals="INF" id="Fact-8B71E23D8F46C69E8F50C803E6480F92" unitRef="cad">100000</oncyf:OverheadRepayment>
	<oncyf:ProceedsfromInterestReceived contextRef="FD2015Q4YTD" decimals="0" id="Fact-D1624A1949B69093BE0EC803E64DB190" unitRef="cad">197859</oncyf:ProceedsfromInterestReceived>
	<oncyf:ProceedsfromInterestReceived contextRef="FD2016Q4YTD" decimals="0" id="Fact-B3CC41A97EF157C1C02AC803E64CFA21" unitRef="cad">163902</oncyf:ProceedsfromInterestReceived>
	<oncyf:ProceedsfromInterestReceived contextRef="FD2017Q4YTD" decimals="0" id="Fact-CAA93CCD46F4CD87BDA5C803E64BF13F" unitRef="cad">130101</oncyf:ProceedsfromInterestReceived>
	<oncyf:PropertyPlantandEquipmentAnnualDepreciationRate contextRef="FD2017Q4YTD_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="INF" id="Fact-0D9FA70B28D2CA770E1DE7B142BF3073" unitRef="number">0.3</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
	<oncyf:PropertyPlantandEquipmentAnnualDepreciationRate contextRef="FD2017Q4YTD_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="INF" id="Fact-1CF80A1FFEA83745797DE7B12E027364" unitRef="number">0.2</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
	<oncyf:PropertyPlantandEquipmentAnnualDepreciationRate contextRef="FD2017Q4YTD_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="INF" id="Fact-1360FD44A779444C75A7E7B142C75838" unitRef="number">0.2</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
	<oncyf:PurchaseObligation1 contextRef="FI2017Q4" decimals="0" id="Fact-ED51699E6DC4B87D21FFC803E649DBF5" unitRef="cad">5980454</oncyf:PurchaseObligation1>
	<oncyf:RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1 contextRef="D2018Q1Jan1-31" decimals="0" id="Fact-C6F74277C6968FBD94111AFA6408E02C" unitRef="usd">35625</oncyf:RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1>
	<oncyf:RighttoCallWarrantMilestoneOneTerm contextRef="D2017Q4Nov1-30_oncyf_MilestoneAxis_oncyf_MilestoneOneMember" decimals="INF" id="Fact-83CAB2E6CFD6FF295340F3B508E36BD8" unitRef="number">6</oncyf:RighttoCallWarrantMilestoneOneTerm>
	<oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount contextRef="FD2017Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_EUR" decimals="INF" id="Fact-1ED29FAF8CEBA1ED21AFC803E6458A5B" unitRef="cad">0.10</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
	<oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount contextRef="FD2017Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_GBP" decimals="INF" id="Fact-20F63AEFAE2C1A6D8F0FC803E64D0109" unitRef="cad">0.10</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
	<oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount contextRef="FD2017Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_USD" decimals="INF" id="Fact-0648320F4104F02F6AEDC803E6460FB3" unitRef="cad">0.01</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
	<oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings contextRef="FD2017Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_EUR" decimals="0" id="Fact-85D06F2B8D9E6FFA0906C803E645E828" unitRef="cad">-11736</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
	<oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings contextRef="FD2017Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_GBP" decimals="0" id="Fact-D84B910CAB41DEF843C0C803E64592EE" unitRef="cad">-21492</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
	<oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings contextRef="FD2017Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_USD" decimals="0" id="Fact-B3108C598606F9B74F36C803E646F70C" unitRef="cad">5056</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
	<oncyf:SharePricePremiumPercent contextRef="D2017Q4Nov1-30_oncyf_MilestoneAxis_oncyf_MilestoneOneMember" decimals="INF" id="Fact-B2A83B0754EC6C97000EF3AFCBC15878" unitRef="number">0.2</oncyf:SharePricePremiumPercent>
	<oncyf:SharePricePremiumPercent contextRef="D2017Q4Nov1-30_oncyf_MilestoneAxis_oncyf_MilestoneTwoMember" decimals="INF" id="Fact-5DE70EEBF4A94722CB72F3B04C88A067" unitRef="number">0.2</oncyf:SharePricePremiumPercent>
	<oncyf:SharePurchaseAgreementAmount contextRef="FI2014Q4_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" decimals="-5" id="Fact-A63BC855B70B0468524EC803E6474A3C" unitRef="usd">26000000</oncyf:SharePurchaseAgreementAmount>
	<oncyf:SharePurchaseAgreementAmount contextRef="FI2014Q4_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" decimals="INF" id="Fact-CFE0BE11A00E59AD5D29C803E646B92F" unitRef="usd">26000000</oncyf:SharePurchaseAgreementAmount>
	<oncyf:SharePurchaseAgreementAmount contextRef="I2014Q4Oct24_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="-6" id="Fact-CCB686AF3B40ED831837C803E64647DB" unitRef="usd">20000000</oncyf:SharePurchaseAgreementAmount>
	<oncyf:SharePurchaseAgreementTerm contextRef="FD2014Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" id="Fact-1313EE765B106D9E2E2FC803E649EB02">P30M</oncyf:SharePurchaseAgreementTerm>
	<oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="FD2017Q4YTD_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember" decimals="INF" id="Fact-7B670679C2640D5D4892C803E64C3A02" unitRef="number">1.0</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
	<oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="FD2017Q4YTD_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember" decimals="INF" id="Fact-BDAB7F3554022C822DBCC803E64D6C2E" unitRef="number">3.0</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
	<oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-915B586009718133BB94C803E64C378A" unitRef="number">3</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
	<oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-76D14A9C26FB446684EE1B3111F5074A" unitRef="number">3</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
	<oncyf:SharesIssuedPricePerShare1 contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="2" id="Fact-AA73052150DCBA4EE9D7F31F1181A45F" unitRef="CAD_PER_shares">0.48</oncyf:SharesIssuedPricePerShare1>
	<oncyf:SharesIssuedPricePerShare1 contextRef="I2017Q2Jun1_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="2" id="Fact-94115B2566D229B6B588E7F6F66EAAC7" unitRef="CAD_PER_shares">0.70</oncyf:SharesIssuedPricePerShare1>
	<oncyf:SharesIssuedWarrantPricePerShare contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="2" id="Fact-0B47842394B338D2DDBFF32486A5596B" unitRef="CAD_PER_shares">0.22</oncyf:SharesIssuedWarrantPricePerShare>
	<oncyf:ShortTermInvestmentEffectiveInterestRate contextRef="FD2016Q4YTD_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember" decimals="4" id="Fact-FD95BFA21DA23258C70BC803E64AADE1" unitRef="number">0.0141</oncyf:ShortTermInvestmentEffectiveInterestRate>
	<oncyf:ShortTermInvestmentEffectiveInterestRate contextRef="FD2017Q4YTD_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_HeldtomaturityInvestmentsCategoryMember" decimals="4" id="Fact-9479B496D6DCF239CEC1C803E64A3417" unitRef="number">0.0000</oncyf:ShortTermInvestmentEffectiveInterestRate>
	<oncyf:ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent contextRef="FD2017Q4YTD" decimals="INF" id="Fact-6DED91CE893EC52CBB36C803E6457116" unitRef="number">1</oncyf:ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent>
	<oncyf:TaxEffectOfStockBasedCompensation contextRef="FD2015Q4YTD" decimals="0" id="Fact-66FCA2C6372D99C85599C803E64A9F45" unitRef="cad">-111680</oncyf:TaxEffectOfStockBasedCompensation>
	<oncyf:TaxEffectOfStockBasedCompensation contextRef="FD2016Q4YTD" decimals="0" id="Fact-12C1BE94AE02115A2134C803E648DC81" unitRef="cad">-109641</oncyf:TaxEffectOfStockBasedCompensation>
	<oncyf:TaxEffectOfStockBasedCompensation contextRef="FD2017Q4YTD" decimals="0" id="Fact-B9D63B2AC4E5EA6FE009C803E6495469" unitRef="cad">-156250</oncyf:TaxEffectOfStockBasedCompensation>
	<oncyf:TaxEffectOfTaxPools contextRef="FD2015Q4YTD" decimals="0" id="Fact-15133F0AED0C9CA63FF1C803E64936FA" unitRef="cad">-1339467</oncyf:TaxEffectOfTaxPools>
	<oncyf:TaxEffectOfTaxPools contextRef="FD2016Q4YTD" decimals="0" id="Fact-596BEABE5C527C59886BC803E64A874A" unitRef="cad">-39569</oncyf:TaxEffectOfTaxPools>
	<oncyf:TaxEffectOfTaxPools contextRef="FD2017Q4YTD" decimals="0" id="Fact-AC579098E175B8BDEF35C803E64D032A" unitRef="cad">162162</oncyf:TaxEffectOfTaxPools>
	<oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1 contextRef="FD2015Q4YTD" decimals="0" id="Fact-127F8701AF0D93FF0358C803E6495A3B" unitRef="cad">-3455622</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
	<oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1 contextRef="FD2016Q4YTD" decimals="0" id="Fact-66322B9F0C1265C23A34C803E64D7E30" unitRef="cad">-1739557</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
	<oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1 contextRef="FD2017Q4YTD" decimals="0" id="Fact-23759E8D7FB5CCC0A5E9C803E649DDBE" unitRef="cad">-1051725</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
	<oncyf:WarrantPricePerShareAccelerationThreshold contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="2" id="Fact-DB4DB5D779405102991DF325F46C52E0" unitRef="CAD_PER_shares">2.50</oncyf:WarrantPricePerShareAccelerationThreshold>
	<oncyf:WarrantPricePerShareAccelerationThresholdTradingDays contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-6B1E3BDD86B304366C6AF32707E16CC3" unitRef="number">15</oncyf:WarrantPricePerShareAccelerationThresholdTradingDays>
	<oncyf:WarrantPurchaseAgreement contextRef="D2017Q4Nov1-30" decimals="-6" id="Fact-F66B836FEFF2820CD8A3F3AB8AFC1B7A" unitRef="usd">8000000</oncyf:WarrantPurchaseAgreement>
	<oncyf:WarrantPurchaseAgreement contextRef="D2017Q4Nov1-30_oncyf_MilestoneAxis_oncyf_MilestoneOneMember" decimals="-6" id="Fact-EA8F8CB4FD9CD7833211F3AC78E80011" unitRef="usd">2000000</oncyf:WarrantPurchaseAgreement>
	<oncyf:WarrantPurchaseAgreement contextRef="D2017Q4Nov1-30_oncyf_MilestoneAxis_oncyf_MilestoneTwoMember" decimals="-6" id="Fact-062862C889646B11FD0EF3AEC9EFEE7D" unitRef="usd">6000000</oncyf:WarrantPurchaseAgreement>
	<oncyf:WarrantsandRightsOutstanding contextRef="FI2016Q4" decimals="0" id="Fact-F44721EE77832B6565DAD5CC9A0E865D" unitRef="cad">0</oncyf:WarrantsandRightsOutstanding>
	<oncyf:WarrantsandRightsOutstanding contextRef="FI2017Q4" decimals="0" id="Fact-E9D6BA5C99C355F58C27D5CC99FCEFF3" unitRef="cad">3617900</oncyf:WarrantsandRightsOutstanding>
	<oncyf:WeightedAverageClosingPriceDuration contextRef="D2017Q4Nov1-30_oncyf_MilestoneAxis_oncyf_MilestoneOneMember" decimals="INF" id="Fact-3D5CCF4BE8F753723751F3ADAC2A240B" unitRef="number">5</oncyf:WeightedAverageClosingPriceDuration>
	<oncyf:WeightedAverageClosingPriceDuration contextRef="D2017Q4Nov1-30_oncyf_MilestoneAxis_oncyf_MilestoneTwoMember" decimals="INF" id="Fact-EA4122F7287A631F9BB1F3AEAD8756B3" unitRef="number">5</oncyf:WeightedAverageClosingPriceDuration>
	<ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory contextRef="FD2017Q4YTD" id="Fact-8C39484D06C72730E389C803E6476542">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We follow the liability method of accounting for income taxes.  Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="FD2017Q4YTD" id="Fact-C820CDE8B78E9E857FC1C803E645FC2A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We use the treasury stock method to calculate diluted loss per common share.  Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive.  The number of additional common shares is calculated by assuming that any outstanding &amp;#8220;in the money&amp;#8221; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="FD2017Q4YTD" id="Fact-4E3186D1908731ACCA0DC803E647EA58">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForFinanceCostsExplanatory contextRef="FD2017Q4YTD" id="Fact-3B0240B9AA235A417FE3C803E6466650">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Transaction costs are expensed as incurred for financial instruments designated as held for trading.  Transaction costs for other financial instruments are recognized as part of the financial instrument's carrying value.  &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinanceCostsExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory contextRef="FD2017Q4YTD" id="Fact-6E360CA6E06FBF35E9ACC803E646439B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial assets are comprised of cash and cash equivalents, contract receivable, other receivables and short-term investments.  Financial assets are initially recorded at fair market value and are classified as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents consist of cash on hand and interest bearing deposits with our bank and have been designated as held for trading.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Contract receivable and other receivables&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract receivable and other receivables have been classified as loans and receivables.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Short-term investments &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We determine the appropriate classification of our short-term investments at the time of purchase and re-evaluate such classification as of each reporting date.  We classify our short-term investments as held-to-maturity as we have the positive intent and ability to hold the securities to maturity.  Held-to-maturity securities are stated at original cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest rate method.  Such amortization and interest on securities classified as held-to-maturity are included in interest income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Impairment of financial assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We assess at each reporting date whether there is any objective evidence that a financial asset or a group of financial assets is impaired. A financial asset or a group of financial assets is deemed to be impaired if, and only if, there is objective evidence of impairment as a result of one or more events that has occurred after the initial recognition of the asset (an incurred loss event) and that loss event has an impact on the estimated future cash flows of the financial asset or the group of financial assets that can be reliably estimated.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory contextRef="FD2017Q4YTD" id="Fact-EE295E8F2111AC52960EC803E6462FC6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Trade accounts payable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Trade accounts payable are non interest-bearing and recorded at fair market value.  They are classified as other financial liabilities and are subsequently measured at amortized cost using the effective interest rate method.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="FD2017Q4YTD" id="Fact-BD52AB8C594E13E7C011C803E64747F5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The financial statements for each of our subsidiaries are prepared using their functional currency.  Our presentation currency is the Canadian dollar which is also Oncolytics Biotech Inc.'s functional currency.  Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions.  Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency.  These exchange differences are initially recognized in equity.  The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period.  Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used.  Exchange differences on translation into Canadian dollars are recognized as a separate component of equity.  On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="FD2017Q4YTD" id="Fact-C1C878373788C7A5F03BC803E64D79ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives.  Depreciation is recorded using the declining balance method at the following annual rates:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office equipment and furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Medical equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Straight-line over the term of the lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="FD2017Q4YTD" id="Fact-CB40193E34C76B2EA7D5F28D81545B13">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue relates to a long-term contract associated with a regional licensing agreement (the "Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contract receivable&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&amp;#8217;s credit risk and payment histories, including payments made subsequent to year-end.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contract liability&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
	<ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="FD2017Q4YTD" id="Fact-F8266481D2DCC55D6EEAC803E64CEB2C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research costs are expensed as incurred, net of recoveries.  We record accruals for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the treatment phase of clinical trials based on the total estimated cost of the treatment phase on a per patient basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized.  To date, all development costs have been expensed. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="FD2017Q4YTD" id="Fact-881F6A975F1134691004C803E64C092B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock option plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; stock option plan (the &amp;#8220;Option Plan&amp;#8221;) available to officers, directors, employees, consultants and suppliers with grants under the Option Plan approved from time to time by our Board of Directors (the &amp;#8220;Board&amp;#8221;).  Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines.  Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the date of grant.  Exercised stock options are settled with common shares issued from treasury. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We use the fair value based method of accounting for stock option awards granted under the Option Plan.  We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black Scholes Option Pricing Model. The fair value of stock options with a graded vesting schedule is determined based on different expected lives for the options that vest each year, as it would be if the award were viewed as several separate awards, each with a different vesting date, and it is accounted for over the respective vesting period taking into consideration forfeiture estimates.      Compensation expense is adjusted for subsequent changes in management&amp;#8217;s estimate of the number of options that are expected to vest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share based payments to non-employees are measured at the date we obtain the goods or the date the counterparty renders the service. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Incentive share award plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board.  Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria.  Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&amp;#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory contextRef="FD2017Q4YTD" id="Fact-91C138F2552D651F69D8C803E64D9FBA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Investment tax credits ("ITCs") relating to qualifying scientific research and experimental development expenditures that are refundable are accounted for as a reduction in research and development expenditures.  ITCs that are non-refundable, but are recoverable against future taxes payable, are accrued only when there is reasonable assurance that the credits will be realized.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ITCs are subject to technical and financial review by the Canadian tax authorities on a project-by-project basis.  Therefore,  amounts ultimately received may vary significantly from the amounts recorded. Any such differences are recorded as an adjustment to the recognized amount in the year the review by the Canadian tax authority is completed and the results are made known to us.  &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory>
	<ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="FD2017Q4YTD" id="Fact-BE242E0AA59A02A4B497C803E64C7147">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;IFRS 9 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2014, on completion of the impairment phase of the project to reform accounting for financial instruments and replace IAS 39 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments: Recognition and Measurement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the IASB issued the final version of IFRS 9 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IFRS 9 includes guidance on the classification and measurement of financial assets and financial liabilities and impairment of financial assets (i.e. recognition of credit losses).  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the classification and measurement requirements for financial assets, financial assets must be classified and measured at either amortized cost or at fair value through profit or loss or through other comprehensive income, depending on the basis of the entity&amp;#8217;s business model for managing the financial asset and the contractual cash flow characteristics of the financial asset. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The classification requirements for financial liabilities are unchanged from IAS 39. IFRS 9 requirements address the problem of volatility in net earnings arising from an issuer choosing to measure certain liabilities at fair value and require that the portion of the change in fair value due to changes in the entity&amp;#8217;s own credit risk be presented in other comprehensive income, rather than within net earnings. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The new requirements for impairment of financial assets introduce an expected loss impairment model that requires more timely recognition of expected credit losses. IAS 39 impairment requirements are based on an incurred loss model where credit losses are not recognized until there is evidence of a trigger event. IFRS 9 is effective for annual periods beginning on or after January 1, 2018 with early adoption permitted. We are assessing the impact of adopting this standard on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;IFRS 16 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the IASB issued IFRS 16 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;IFRS 16&amp;#8221;), which replaces IAS 17 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;IAS 17&amp;#8221;) and related interpretations. IFRS 16 provides a single lessee accounting model, requiring the recognition of assets and liabilities for all leases, unless the lease term is 12-months or less or the underlying asset has a low value. IFRS 16 substantially carries forward the lessor accounting in IAS 17 with the distinction between operating leases and finance leases being retained. IFRS 16 will be applied retrospectively for annual periods beginning on or after January 1, 2019. Early adoption is permitted under certain circumstances.  We are assessing the potential impact of adopting this standard on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
	<ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations contextRef="FD2017Q4YTD" id="Fact-6B3BFC4C08C4729400E7209F8D7D2127">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;IFRS 15 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the IASB issued IFRS 15 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The new standard will replace IAS 18 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and IAS 11 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Construction Contracts&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. IFRS 15 establishes a comprehensive framework for determining whether, how much and when revenue is recognised, and also contains new requirements related to presentation. The core principle in that framework is that revenue should be recognised dependent on the transfer of promised goods or services to the customer for an amount that reflects the consideration which should be received in exchange for those goods or services. The objective of the standard is to provide a five-step approach to revenue recognition that includes identifying contracts with customers, identifying performance obligations, determining transaction prices, allocating transaction prices to performance obligations, and recognising revenue when or as performance obligations are satisfied. Judgment will need to be applied, including making estimates and assumptions, for multiple-element contracts in identifying performance obligations, in constraining estimates of variable consideration and in allocating the transaction price to each performance obligation. This new standard is effective for annual periods beginning on or after January 1, 2018, with early adoption permitted. We early adopted this standard effective for our year ended December 31, 2017 using the full retrospective method. There were no adjustments to our consolidated financial statements resulting from this early adoption. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations>
	<ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="FD2017Q4YTD" id="Fact-CD77509C9EEF49F0ABFAC803E646E7AB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Significant Judgments, Estimates and Assumptions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Judgments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amount of expenses, assets, liabilities, and the disclosure of contingent liabilities, at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Estimates and assumptions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods.  Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting our consolidated financial statements include:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We entered into an Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Share based payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Part of our share based payment expense is measured by reference to the fair value of our stock options at the date at which they are granted.  Estimating fair value for granted stock options requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant.  This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the option, volatility, dividend yield, and rate of forfeitures and making assumptions about them.  The value of the share based payment expense for the year along with the assumptions and model used for estimating fair value for share based compensation transactions are disclosed in Note 8.    &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income.  Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset.  Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To date we have determined that none of our deferred tax assets should be recognized.  Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits.  These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries.  As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
	<ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="FD2017Q4YTD" id="Fact-5081A75274A0E85ED2ADC803E6482DD3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Basis of Financial Statement Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries Oncolytics Biotech (Barbados) Inc., Oncolytics Biotech (US) Inc., and Oncolytics Biotech (UK) Inc. and are presented in Canadian dollars, our functional currency.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Basis of consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our accounts include the accounts of Oncolytics Biotech Inc. and our subsidiaries.  Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and has the ability to affect those returns through our power to govern.  Accounting policies of subsidiaries are consistent with our accounting policies and all intra-group transactions, balances, income and expenses are eliminated on consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A change in ownership interest of a subsidiary, without a change in control, is accounted for as an equity transaction.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
	<ifrs-full:DisclosureOfCashFlowStatementExplanatory contextRef="FD2017Q4YTD" id="Fact-F1894E8F7AE74B0B8F21C803E64B0E59">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Additional Cash Flow Disclosures&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Change In Non-Cash Working Capital&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:629px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:392px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Change in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(4,767,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other receivables&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;16,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;285,653&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(148,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(915,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;245,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(215,116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(384,641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,359,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(664,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,182,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash impact of foreign exchange&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;48,558&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;343,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(77,535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in non-cash working capital related to operating activities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;180,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,233,865&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,105,464&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Other Cash Flow Disclosures&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:342px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:58px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:51px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:51px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash interest received&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;130,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;163,902&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;197,859&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash taxes paid&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;136,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,468&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashFlowStatementExplanatory>
	<ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="FD2017Q4YTD" id="Fact-21C652078EF0BE840104C803E6474A66">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Authorized:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unlimited number of no par value common shares&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:595px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:222px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amount&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amount&lt;br clear="none"/&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93,512,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;237,657,056&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to Share Purchase&lt;br clear="none"/&gt;   Agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,778,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,371,687&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to "At the Market" sales agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(b)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,860,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,049,693&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(753,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,151,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;261,324,692&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to incentive share award plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to "At the Market" equity distribution agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(c)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,006,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,456,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(500,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;121,258,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;262,321,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to stock option plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;801,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;536,949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to "At the Market" equity distribution agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt"&gt;(c)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,301,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,348,821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to public offering&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt"&gt;(d)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,893,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,617,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,391,057&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;141,805,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;271,710,138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,617,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2014, we entered into a share purchase agreement (the "Share Purchase Agreement") with Lincoln Park Capital Fund, LLC ("LPC") to sell up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$26,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of common stock.  Subject to the terms and conditions of the Share Purchase Agreement and at our sole discretion, we may sell up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$26.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; worth of common shares to LPC over the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month term. The purchase price of the common shares was based on prevailing market prices of our  common shares immediately preceding the notice of a sale without any fixed discount. Subject to the Share Purchase Agreement, we controlled the timing and amount of each investment and LPC was obligated to make such purchases, if and when elected.  The Share Purchase Agreement did not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities, but required that we maintained our NASDAQ listing. Under the Share Purchase Agreement, we issued an initial  commitment fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;292,793&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares to LPC valued at fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$455,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  An additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;292,793&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares was to be issued on a pro rata basis under the terms of the Share Purchase Agreement as an additional commitment fee.  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 20, 2014, we reached an agreement to amend the Share Purchase Agreement.  The specific amendments included allowing the Company to sell shares to LPC at the Company's sole option independent of the closing price of the Common Stock, increasing the number of shares that may have been sold to LPC at certain price levels and changed the way the number of Commitment Shares issuable was to be calculated. In consideration of the amendments to the Agreement, the Company issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;146,397&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Common Stock to LPC. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2015, under the terms of the amended Share Purchase Agreement, we issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,778,674&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares for net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$3.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As part of the shares issued, we issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,674&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; commitment shares. The commitment shares have been valued at fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$50,024&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and have been recorded as additional share issue costs.  On November 5, 2015, we were delisted from the NASDAQ Capital Market and as a result we were unable to sell common shares under the Share Purchase Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 24, 2014, we entered into an "at-the-market" ("ATM") equity distribution agreement with Canaccord Genuity Inc. acting as sole agent. Under the terms of the distribution agreement, we were able to, from time to time, sell shares of our common stock having an aggregate offering value of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$20 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through Canaccord Genuity Inc. directly to investors in the US through our NASDAQ listing.  We were able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility.  During 2015, we issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,860,454&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares for net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$15.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. On November 5, 2015, we were delisted from the NASDAQ Capital Market and as a result we were unable to sell common shares under our existing ATM.  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&amp;#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During 2017, we sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,301,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2016 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,006,600&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) common shares for gross proceeds of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,348,821&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2016 - $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,456,296&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). We incurred share issue costs of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;245,655&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2016 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$500,163&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 1, 2017, pursuant to an underwritten public offering, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; units were sold at a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.70&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11,511,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Each unit included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share (ascribed value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.48&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share purchase warrant (ascribed value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.22&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). The ascribed value was determined using the relative fair value method. The ascribed value of the common share purchase warrants was determined using the Black Scholes option pricing model. Each common share purchase warrant entitles the holder to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share in the capital of the Company until June 1, 2022, at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.95&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive trading dates. We incurred share issue costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,145,402&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
	<ifrs-full:DisclosureOfCommitmentsExplanatory contextRef="FD2017Q4YTD" id="Fact-944FDD823E627099621DC803E64C0781">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are committed to payments totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$5,980,454&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for activities related to our clinical trial, manufacturing and collaboration programs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are committed to rental payments (excluding our portion of operating costs and rental taxes) under the terms of our office leases.  Annual payments under the terms of these leases are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:33.984375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;285,987&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;251,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;159,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,130&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;740,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under a clinical trial agreement entered into with the Alberta Cancer Board (&amp;#8220;ACB&amp;#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$400,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; plus an overhead repayment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, upon sales of a specified product.&amp;#160;&amp;#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of gross sales of a specified product; or (b) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum once sales of a specified product commence.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsExplanatory>
	<ifrs-full:DisclosureOfContingentLiabilitiesExplanatory contextRef="FD2017Q4YTD" id="Fact-6F222C3A367F0E07082CC803E64816CF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Assumption Agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 1999, we entered into an agreement that assumed certain obligations (the &amp;#8220;Assumption Agreement&amp;#8221;) in connection with a Share Purchase Agreement (the &amp;#8220;Agreement&amp;#8221;) between SYNSORB and our former shareholders to make milestone payments and royalty payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, a milestone payment was still outstanding for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, due within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90 days&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell REOLYSIN&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the public or the approval of a new drug application for REOLYSIN.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition to the milestone payment, payments may become due and payable in accordance with the Agreement upon realization of sales of REOLYSIN.&amp;#160;&amp;#160;If we receive royalty payments or other payments as a result of entering into partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2016 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) of the royalty payments and other payments received.&amp;#160;&amp;#160;Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.15%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2016 -  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.35%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) of Net Sales received for such products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;BRI &amp;#8220;Work in Kind&amp;#8221; Contribution&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We entered into an engineering and process development agreement with the Biotechnology Research Institute of the National Research Council of Canada (&amp;#8220;BRI&amp;#8221;).&amp;#160;&amp;#160;The terms of this Agreement include a &amp;#8220;work in kind&amp;#8221; contribution from BRI.&amp;#160;&amp;#160;In exchange for this &amp;#8220;work in kind&amp;#8221; contribution, we agreed to provide a royalty, contingent upon receiving Sales Revenue, at the lesser of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of Sales Revenue or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year.&amp;#160;&amp;#160;The total royalty under this Agreement is equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; times the &amp;#8220;work in kind&amp;#8221; contribution.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we estimate that the accumulated work in kind totals approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$301,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfContingentLiabilitiesExplanatory>
	<ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="FD2017Q4YTD" id="Fact-FF7F4BF13F928EE6A470C803E6451D03">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation is recorded using the declining balance method at the following annual rates:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office equipment and furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Medical equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Straight-line over the term of the lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:164px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:80px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:87px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:90px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Medical Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Computer Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Office Furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Office Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;197,870&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;685,277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;214,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;465,865&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,651,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions, net of foreign exchange impact&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;197,870&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;705,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;214,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89,466&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;466,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,673,431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions, net of foreign exchange impact&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;104,254&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Disposals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(48,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(48,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;197,870&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;681,985&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;225,896&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;89,466&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;534,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,729,517&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;505,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;58,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;366,379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,191,243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization for the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,241&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,408&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;144,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;554,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137,624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;452,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,353,476&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization for the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,558&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,515&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Disposals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(48,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(48,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;154,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;549,564&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;147,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;68,787&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;476,057&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,396,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net book value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;43,536&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;132,421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;78,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;20,679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;58,243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;333,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52,901&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;151,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;76,461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;319,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
	<ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="FD2017Q4YTD" id="Fact-29CD6EA21F9B8F846365C803E64AA106">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Loss Per Common Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;132,395,752&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;119,880,200&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;112,613,845&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).  The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
	<ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="FD2017Q4YTD" id="Fact-CF634123CEE4C42E581EC803E6459207">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our financial instruments consist of cash and cash equivalents, short-term investments,&amp;#160;contract receivable, other receivables and accounts payable.&amp;#160;&amp;#160;As at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there are no significant differences between the carrying values of these amounts and their estimated market values.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Credit risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&amp;#160;&amp;#160;We are exposed to credit risk on our cash and cash equivalents, short-term investments and contract receivable in the event of non-performance by counterparties, but we do not anticipate such non-performance.&amp;#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents, short-term investments and contract receivable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&amp;#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We also mitigate our exposure to credit risk by restricting our portfolio to investment grade securities with short-term maturities and by monitoring the credit risk and credit standing of counterparties.&amp;#160;As at December 31, 2016, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of our short-term investments were in guaranteed investment certificates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We mitigate our exposure to credit risk connected to our contract receivable by performing a review of our customer's credit risk and payment histories, including payments made subsequent to year-end. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Interest rate risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&amp;#160;We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments.&amp;#160;&amp;#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Currency risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.&amp;#160;In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from operating and financing activities.  As well, we are exposed to currency risk related to our regional licensing agreement. The impact of a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.01&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; increase in the value of the U.S. dollar against the Canadian dollar would have increased our net loss in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; by approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$5,056&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160;The impact of a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; increase in the value of the British pound against the Canadian dollar would have increased our net loss in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; by approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$21,492&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The impact of a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; increase in the value of the Euro against the Canadian dollar would have increased our net loss in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; by approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$11,736&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balances in foreign currencies at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:596px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:197px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:128px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:128px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:128px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;US dollars &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;"&gt;British pounds&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-align:center;"&gt;&amp;#163;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Euro&lt;br clear="none"/&gt;&amp;#8364;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,948,573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,755&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,372&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,800,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(777,271&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,971,302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liquidity risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&amp;#160;We manage liquidity risk through the management of our capital structure as outlined in Note 14. Accounts payable are all due within the current operating period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
	<ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="FD2017Q4YTD" id="Fact-82A92DA5947942ED1A0BC803E64BECDD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Incorporation and Nature of Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our consolidated financial statements for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;March&amp;#160;8, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  We are a limited company incorporated and domiciled in Canada.  Our shares are publicly traded and our registered office is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics.  Our lead product, REOLYSIN&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to existing cytotoxic or cytostatic therapies. Our clinical development program for REOLYSIN emphasizes three programs: chemotherapy combinations to trigger selective tumor lysis;  immune modulator (IMiD) combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
	<ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="FD2017Q4YTD" id="Fact-E0B6B8CF451298E34E3FC803E64A3282">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:583px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:316px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(15,475,353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,130,605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,719,842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Statutory Canadian corporate tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;27.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Anticipated tax recovery&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(4,178,345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,085,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,567,159&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign jurisdiction tax rate difference&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2,899,190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,184,796&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,659,145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employee stock based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;156,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;109,641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;111,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,336,941&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Adjustment to opening tax pools&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;162,162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(39,569&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,339,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other permanent differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;53,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in deferred tax benefits deemed not probable to &lt;br clear="none"/&gt;  be recovered&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,051,725&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,739,557&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,455,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;144,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,687&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Adjustment in respect to prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(2,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net current tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;141,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,374&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,153&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we have the following non-capital losses for income tax purposes in Canada:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Expiry&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,809,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,009,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2030&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,774,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,343,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,873,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,457,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,472,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,125,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2036&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,430,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2037&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,846,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;57,308,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:190px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:97px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Expiry&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;189,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;471,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;465,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;361,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;228,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;271,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;520,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;596,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;622,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;173,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2030&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;114,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;487,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;270,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2036&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2037&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;5,463,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As well, we have unclaimed scientific research and experimental development expenditures available to reduce future years&amp;#8217; taxable income of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$27,400,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160;We have not recorded the potential benefits of these tax pools in these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized.  The components of our unrecognized deferred tax asset are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:612px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:345px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net operating losses carried forward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;19,160,218&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,821,631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,950,044&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Scientific research and experimental development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;7,406,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,394,707&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,278,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Investment tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,988,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,990,664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,987,214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Undepreciated capital costs in excess of book value of property and equipment and intellectual property&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,927,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,908,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,839,107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;493,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;432,659&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;619,066&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net capital losses carried forward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;7,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrecognized deferred tax asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;32,983,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,555,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,681,313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
	<ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory contextRef="FD2017Q4YTD" id="Fact-324AA51C1CD8D6E15E65E7EB90F483DB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the assumptions used in the Black Scholes Option Pricing Model with respect to the valuation of warrants issued:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:394px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:261px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:133px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;0.70%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected hold period to exercise &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volatility in the price of the Company's shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;89.30%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory>
	<ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="FD2017Q4YTD" id="Fact-36E54AA0C21C858449C9C803E64CAF44">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The estimated fair value of stock options issued during the year was determined using the Black Scholes Option Pricing Model using the following weighted average assumptions and fair value of options: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:464px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:245px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:74px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1.18%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.82%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.63%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected hold period to exercise&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volatility in the price of the Company's shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;90.73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94.84%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Rate of forfeiture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3.67%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.67%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.67%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average fair value of options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
	<ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory contextRef="FD2017Q4YTD" id="Fact-D74EDBD17641F65CD697C803E6469386">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are committed to rental payments (excluding our portion of operating costs and rental taxes) under the terms of our office leases.  Annual payments under the terms of these leases are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:33.984375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;285,987&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;251,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;159,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,130&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;740,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory>
	<ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory contextRef="FD2017Q4YTD" id="Fact-803ECFB9443113A7C372C803E64C1260">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following RSUs are outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:515px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:269px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,322,829&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368,831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Granted during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;486,238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,053,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368,831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Vested during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(100,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,809,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,322,829&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368,831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:36px;"&gt;&lt;font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:24px;"&gt;(1)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;The weighted average fair value of the RSUs granted was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$0.63&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; in 2017 (2016 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$0.31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The following PSUs are outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:521px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:274px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:75px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;840,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Granted during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;60,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(660,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Outstanding, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;900,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;840,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:36px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1) &amp;#160;&amp;#160;&amp;#160;&amp;#160;The weighted average fair value of the PSUs granted was $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;0.35&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; in 2017 (2016 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$0.36&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
	<ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="FD2017Q4YTD" id="Fact-4A672A1A07338E4CD11FC803E64CDB3A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:650px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:158px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:75px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:74px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:82px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:80px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;8,674,227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,561,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,446,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;405,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;0.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,572,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,280,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(2,012,660&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(737,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(100,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(116,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(721,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(65,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(801,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;0.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, end of the&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,148,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,674,227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,561,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercisable, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;5,453,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,729,643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,476,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
	<ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory contextRef="FD2017Q4YTD" id="Fact-6C6E76B35120CE3D9849E7EC8928C486">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes our outstanding warrants at December 31, 2017:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:531px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:6px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:77px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:102px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:90px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:134px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Outstanding, Beginning of the Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Granted During the Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Outstanding, End of the Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Remaining Contractual Life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes information about the stock options outstanding and exercisable at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:182px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Range of Exercise Prices&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Remaining Contractual Life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$0.26 - $0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3,437,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;8.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,921,834&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$0.51 - $0.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;538,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;8.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;358,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.45 - $2.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,002,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,002,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$2.13 - $3.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;545,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;545,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$4.01 - $6.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;625,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;625,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;6,148,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;7.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5,453,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
	<ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory contextRef="FD2017Q4YTD" id="Fact-061EE05F125F58FBC457C803E64AE684">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Capital Disclosures&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our objective when managing capital is to maintain a strong statement of financial position.  We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection.&amp;#160;&amp;#160;We include shareholders&amp;#8217; equity, cash and cash equivalents and short-term investments in the definition of capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;11,836,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,034,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,088,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shareholders&amp;#8217; equity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;8,283,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,689,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of REOLYSIN.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&amp;#8217;s activity.&amp;#160;&amp;#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&amp;#160;&amp;#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&amp;#160;&amp;#160;There are no assurances that funds will be made available to us when required.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 16, 2016, we renewed our short form base shelf prospectus (the &amp;#8220;Base Shelf&amp;#8221;) that qualifies for distribution of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$150,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of common shares, subscription receipts, warrants, or units (the &amp;#8220;Securities&amp;#8221;) in Canada. Under our Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received from a Prospectus Supplement will be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf expires on March 16, 2018 and allowed us to enter into our Canadian ATM equity distribution agreement (see Note 7). We use this equity arrangement to assist us in achieving our capital objective.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory>
	<ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory contextRef="FD2017Q4YTD" id="Fact-00F0DE11026923E5206BC803E64D4368">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Other Expenses and Adjustments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We present our expenses based on the function of each expense and therefore include realized foreign exchange gains and losses, unrealized non-cash foreign exchange gains and losses and non-cash stock based compensation associated with research and development activity as a component of research and development expenses and amortization of property and equipment and stock based compensation associated with operating activities as a component of operating expenses.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:420px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;br clear="none"/&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Included in research and development expenses:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Realized foreign exchange (gain) loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(120,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;104,851&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;238,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrealized non-cash foreign exchange loss (gain)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;55,538&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(816,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash share based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;230,141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;233,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;257,016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Included in operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization of property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;90,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;180,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash share based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;348,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;172,159&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;172,521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;231,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;148,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;196,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory>
	<ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="FD2017Q4YTD" id="Fact-EB495343504E256FBB28C803E64C266C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:164px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:80px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:87px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:90px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Medical Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Computer Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Office Furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Office Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;197,870&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;685,277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;214,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;465,865&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,651,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions, net of foreign exchange impact&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;197,870&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;705,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;214,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89,466&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;466,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,673,431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions, net of foreign exchange impact&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;104,254&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Disposals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(48,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(48,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;197,870&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;681,985&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;225,896&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;89,466&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;534,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,729,517&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;505,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;58,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;366,379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,191,243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization for the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,241&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,408&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;144,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;554,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137,624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;452,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,353,476&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization for the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,558&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,515&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Disposals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(48,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(48,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;154,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;549,564&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;147,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;68,787&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;476,057&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,396,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net book value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;43,536&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;132,421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;78,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;20,679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;58,243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;333,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52,901&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;151,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;76,461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;319,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
	<ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="FD2017Q4YTD" id="Fact-6DB2971CF408E861203EC803E64C1A41">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes information about the stock options outstanding and exercisable at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:182px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Range of Exercise Prices&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Remaining Contractual Life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$0.26 - $0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3,437,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;8.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,921,834&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$0.51 - $0.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;538,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;8.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;358,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.45 - $2.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,002,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,002,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$2.13 - $3.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;545,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;545,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$4.01 - $6.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;625,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;625,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;6,148,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;7.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5,453,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
	<ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="FD2017Q4YTD" id="Fact-108D0983583DDC69D93AC803E64DE143">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Related Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Compensation of Key Management Personnel&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole.  We have determined that key management personnel consists of the members of the Board of Directors along with certain officers of the Company.   &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:520px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:301px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2,596,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,753,553&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,941,342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Termination benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;779,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,330,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share-based payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;459,298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;372,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;353,419&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,835,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,456,389&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,294,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Assumption Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2017, with the signing of a regional licensing agreement with upfront license fees (see Note 10), the Company triggered a liability of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$178,125&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to an officer as detailed in the Assumption Agreement (see Note 12). As at December 31, 2017, US$&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;178,125&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was included in accounts payable and accrued liabilities. US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$35,625&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was paid in January 2018 and the balance will be paid after receipt of the contract receivable from Adlai.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
	<ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory contextRef="FD2017Q4YTD" id="Fact-BF3B5CC6CD3DA17C659EE392CBAB134F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Contract liability and receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Regional licensing agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We entered into a regional licensing agreement (the "Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Warrant purchase agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We also entered into a warrant purchase agreement with Adlai. Under the terms of the warrant purchase agreement, we are entitled to receive two milestone payments totaling US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; made of of two common share purchase warrants:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;One common share purchase warrant of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; whereby, upon exercise, Adlai may purchase our common shares priced at a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; premium to the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant when the first patient is enrolled in the phase 3 metastatic breast cancer study or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months after execution of the Agreement, whichever is later.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;One common share purchase warrant of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; whereby, upon exercise, Adlai may purchase our common shares priced at a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; premium to the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant upon the enrollment of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;th patient in the phase 3 metastatic breast cancer study.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Contract liability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#333333;"&gt;Our contract liability balance at December 31, which w&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;e expect to record in revenue over the next &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:443px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:236px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:102px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Regional licensing agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,182,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue recognized in the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,182,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract liability - current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,545,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract liability - non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;4,636,935&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,182,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Contract receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our contract receivable due from Adlai at December 31, 2017 is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4,767,100&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
	<ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="FD2017Q4YTD" id="Fact-8726E12F0D58FDCA2753C803E64960B6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Share Capital&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Authorized:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unlimited number of no par value common shares&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:595px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:222px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amount&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amount&lt;br clear="none"/&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93,512,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;237,657,056&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to Share Purchase&lt;br clear="none"/&gt;   Agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,778,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,371,687&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to "At the Market" sales agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(b)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,860,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,049,693&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(753,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,151,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;261,324,692&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to incentive share award plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to "At the Market" equity distribution agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(c)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,006,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,456,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(500,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;121,258,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;262,321,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to stock option plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;801,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;536,949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to "At the Market" equity distribution agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt"&gt;(c)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,301,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,348,821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to public offering&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt"&gt;(d)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,893,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,617,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,391,057&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;141,805,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;271,710,138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,617,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2014, we entered into a share purchase agreement (the "Share Purchase Agreement") with Lincoln Park Capital Fund, LLC ("LPC") to sell up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$26,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of common stock.  Subject to the terms and conditions of the Share Purchase Agreement and at our sole discretion, we may sell up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$26.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; worth of common shares to LPC over the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month term. The purchase price of the common shares was based on prevailing market prices of our  common shares immediately preceding the notice of a sale without any fixed discount. Subject to the Share Purchase Agreement, we controlled the timing and amount of each investment and LPC was obligated to make such purchases, if and when elected.  The Share Purchase Agreement did not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities, but required that we maintained our NASDAQ listing. Under the Share Purchase Agreement, we issued an initial  commitment fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;292,793&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares to LPC valued at fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$455,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  An additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;292,793&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares was to be issued on a pro rata basis under the terms of the Share Purchase Agreement as an additional commitment fee.  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 20, 2014, we reached an agreement to amend the Share Purchase Agreement.  The specific amendments included allowing the Company to sell shares to LPC at the Company's sole option independent of the closing price of the Common Stock, increasing the number of shares that may have been sold to LPC at certain price levels and changed the way the number of Commitment Shares issuable was to be calculated. In consideration of the amendments to the Agreement, the Company issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;146,397&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Common Stock to LPC. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2015, under the terms of the amended Share Purchase Agreement, we issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,778,674&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares for net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$3.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As part of the shares issued, we issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,674&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; commitment shares. The commitment shares have been valued at fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$50,024&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and have been recorded as additional share issue costs.  On November 5, 2015, we were delisted from the NASDAQ Capital Market and as a result we were unable to sell common shares under the Share Purchase Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 24, 2014, we entered into an "at-the-market" ("ATM") equity distribution agreement with Canaccord Genuity Inc. acting as sole agent. Under the terms of the distribution agreement, we were able to, from time to time, sell shares of our common stock having an aggregate offering value of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$20 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through Canaccord Genuity Inc. directly to investors in the US through our NASDAQ listing.  We were able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility.  During 2015, we issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,860,454&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares for net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$15.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. On November 5, 2015, we were delisted from the NASDAQ Capital Market and as a result we were unable to sell common shares under our existing ATM.  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&amp;#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During 2017, we sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,301,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2016 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,006,600&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) common shares for gross proceeds of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,348,821&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2016 - $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,456,296&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). We incurred share issue costs of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;245,655&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2016 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$500,163&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 1, 2017, pursuant to an underwritten public offering, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; units were sold at a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.70&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11,511,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Each unit included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share (ascribed value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.48&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share purchase warrant (ascribed value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.22&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). The ascribed value was determined using the relative fair value method. The ascribed value of the common share purchase warrants was determined using the Black Scholes option pricing model. Each common share purchase warrant entitles the holder to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share in the capital of the Company until June 1, 2022, at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.95&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive trading dates. We incurred share issue costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,145,402&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the assumptions used in the Black Scholes Option Pricing Model with respect to the valuation of warrants issued:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:394px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:261px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:133px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;0.70%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected hold period to exercise &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volatility in the price of the Company's shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;89.30%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the warrants. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the warrants represents the estimated length of time the warrants are expected to remain outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes our outstanding warrants at December 31, 2017:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:531px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:6px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:77px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:102px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:90px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:134px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Outstanding, Beginning of the Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Granted During the Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Outstanding, End of the Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Remaining Contractual Life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
	<ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="FD2017Q4YTD" id="Fact-0679D5021EFAA4D82292C803E64CE50F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:1px;text-align:justify;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Share Based Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Stock Option Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:650px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:158px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:75px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:74px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:82px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:80px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;8,674,227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,561,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,446,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;405,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;0.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,572,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,280,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(2,012,660&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(737,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(100,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(116,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(721,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(65,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(801,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;0.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, end of the&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,148,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,674,227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,561,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercisable, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;5,453,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,729,643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,476,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes information about the stock options outstanding and exercisable at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:182px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Range of Exercise Prices&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Remaining Contractual Life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$0.26 - $0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3,437,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;8.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,921,834&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$0.51 - $0.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;538,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;8.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;358,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.45 - $2.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,002,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,002,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$2.13 - $3.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;545,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;545,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$4.01 - $6.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;625,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;625,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;6,148,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;7.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5,453,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-exercisable options vest either annually over periods ranging from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or upon satisfaction of certain performance criteria.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The estimated fair value of stock options issued during the year was determined using the Black Scholes Option Pricing Model using the following weighted average assumptions and fair value of options: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:464px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:245px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:74px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1.18%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.82%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.63%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected hold period to exercise&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volatility in the price of the Company's shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;90.73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94.84%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Rate of forfeiture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3.67%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.67%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.67%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average fair value of options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Incentive Share Award Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Share Units&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have issued restricted share units ("RSUs") to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; year period. The following RSUs are outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:515px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:269px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,322,829&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368,831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Granted during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;486,238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,053,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368,831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Vested during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(100,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,809,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,322,829&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368,831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:36px;"&gt;&lt;font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:24px;"&gt;(1)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;The weighted average fair value of the RSUs granted was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$0.63&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; in 2017 (2016 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$0.31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Performance Share Units&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have also issued performance share units ("PSUs") to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or vest over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; year period, depending on the grant. PSU grants to certain officers will vest immediately upon a change of control of the Company. If certain officers cease employment with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. The following PSUs are outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:521px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:274px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:75px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;840,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Granted during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;60,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(660,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Outstanding, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;900,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;840,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:36px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1) &amp;#160;&amp;#160;&amp;#160;&amp;#160;The weighted average fair value of the PSUs granted was $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;0.35&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; in 2017 (2016 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$0.36&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have reserved &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,180,572&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares for issuance relating to our outstanding equity compensation plans.  Compensation expense related to stock options, RSUs and PSUs for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$578,703&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;  (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$406,078&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$429,537&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
	<ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="FD2017Q4YTD" id="Fact-533F55CF47626C322E13C803E64D914F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Deferred income taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We follow the liability method of accounting for income taxes.  Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Financial instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Financial assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial assets are comprised of cash and cash equivalents, contract receivable, other receivables and short-term investments.  Financial assets are initially recorded at fair market value and are classified as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents consist of cash on hand and interest bearing deposits with our bank and have been designated as held for trading.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Contract receivable and other receivables&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract receivable and other receivables have been classified as loans and receivables.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Short-term investments &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We determine the appropriate classification of our short-term investments at the time of purchase and re-evaluate such classification as of each reporting date.  We classify our short-term investments as held-to-maturity as we have the positive intent and ability to hold the securities to maturity.  Held-to-maturity securities are stated at original cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest rate method.  Such amortization and interest on securities classified as held-to-maturity are included in interest income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Impairment of financial assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We assess at each reporting date whether there is any objective evidence that a financial asset or a group of financial assets is impaired. A financial asset or a group of financial assets is deemed to be impaired if, and only if, there is objective evidence of impairment as a result of one or more events that has occurred after the initial recognition of the asset (an incurred loss event) and that loss event has an impact on the estimated future cash flows of the financial asset or the group of financial assets that can be reliably estimated.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Financial liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Trade accounts payable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Trade accounts payable are non interest-bearing and recorded at fair market value.  They are classified as other financial liabilities and are subsequently measured at amortized cost using the effective interest rate method.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Transaction Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Transaction costs are expensed as incurred for financial instruments designated as held for trading.  Transaction costs for other financial instruments are recognized as part of the financial instrument's carrying value.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Foreign currency translation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The financial statements for each of our subsidiaries are prepared using their functional currency.  Our presentation currency is the Canadian dollar which is also Oncolytics Biotech Inc.'s functional currency.  Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions.  Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency.  These exchange differences are initially recognized in equity.  The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period.  Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used.  Exchange differences on translation into Canadian dollars are recognized as a separate component of equity.  On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Investment tax credits&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Investment tax credits ("ITCs") relating to qualifying scientific research and experimental development expenditures that are refundable are accounted for as a reduction in research and development expenditures.  ITCs that are non-refundable, but are recoverable against future taxes payable, are accrued only when there is reasonable assurance that the credits will be realized.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ITCs are subject to technical and financial review by the Canadian tax authorities on a project-by-project basis.  Therefore,  amounts ultimately received may vary significantly from the amounts recorded. Any such differences are recorded as an adjustment to the recognized amount in the year the review by the Canadian tax authority is completed and the results are made known to us.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Loss per common share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We use the treasury stock method to calculate diluted loss per common share.  Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive.  The number of additional common shares is calculated by assuming that any outstanding &amp;#8220;in the money&amp;#8221; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Property and equipment &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives.  Depreciation is recorded using the declining balance method at the following annual rates:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office equipment and furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Medical equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Straight-line over the term of the lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Research and development costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research costs are expensed as incurred, net of recoveries.  We record accruals for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the treatment phase of clinical trials based on the total estimated cost of the treatment phase on a per patient basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized.  To date, all development costs have been expensed. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue relates to a long-term contract associated with a regional licensing agreement (the "Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contract receivable&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&amp;#8217;s credit risk and payment histories, including payments made subsequent to year-end.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contract liability&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Share based payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock option plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; stock option plan (the &amp;#8220;Option Plan&amp;#8221;) available to officers, directors, employees, consultants and suppliers with grants under the Option Plan approved from time to time by our Board of Directors (the &amp;#8220;Board&amp;#8221;).  Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines.  Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the date of grant.  Exercised stock options are settled with common shares issued from treasury. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We use the fair value based method of accounting for stock option awards granted under the Option Plan.  We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black Scholes Option Pricing Model. The fair value of stock options with a graded vesting schedule is determined based on different expected lives for the options that vest each year, as it would be if the award were viewed as several separate awards, each with a different vesting date, and it is accounted for over the respective vesting period taking into consideration forfeiture estimates.      Compensation expense is adjusted for subsequent changes in management&amp;#8217;s estimate of the number of options that are expected to vest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share based payments to non-employees are measured at the date we obtain the goods or the date the counterparty renders the service. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Incentive share award plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board.  Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria.  Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&amp;#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Adoption of New Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;IFRS 15 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the IASB issued IFRS 15 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The new standard will replace IAS 18 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and IAS 11 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Construction Contracts&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. IFRS 15 establishes a comprehensive framework for determining whether, how much and when revenue is recognised, and also contains new requirements related to presentation. The core principle in that framework is that revenue should be recognised dependent on the transfer of promised goods or services to the customer for an amount that reflects the consideration which should be received in exchange for those goods or services. The objective of the standard is to provide a five-step approach to revenue recognition that includes identifying contracts with customers, identifying performance obligations, determining transaction prices, allocating transaction prices to performance obligations, and recognising revenue when or as performance obligations are satisfied. Judgment will need to be applied, including making estimates and assumptions, for multiple-element contracts in identifying performance obligations, in constraining estimates of variable consideration and in allocating the transaction price to each performance obligation. This new standard is effective for annual periods beginning on or after January 1, 2018, with early adoption permitted. We early adopted this standard effective for our year ended December 31, 2017 using the full retrospective method. There were no adjustments to our consolidated financial statements resulting from this early adoption. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Accounting Standards and Interpretations Issued but Not Yet Effective&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;IFRS 9 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2014, on completion of the impairment phase of the project to reform accounting for financial instruments and replace IAS 39 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments: Recognition and Measurement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the IASB issued the final version of IFRS 9 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IFRS 9 includes guidance on the classification and measurement of financial assets and financial liabilities and impairment of financial assets (i.e. recognition of credit losses).  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the classification and measurement requirements for financial assets, financial assets must be classified and measured at either amortized cost or at fair value through profit or loss or through other comprehensive income, depending on the basis of the entity&amp;#8217;s business model for managing the financial asset and the contractual cash flow characteristics of the financial asset. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The classification requirements for financial liabilities are unchanged from IAS 39. IFRS 9 requirements address the problem of volatility in net earnings arising from an issuer choosing to measure certain liabilities at fair value and require that the portion of the change in fair value due to changes in the entity&amp;#8217;s own credit risk be presented in other comprehensive income, rather than within net earnings. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The new requirements for impairment of financial assets introduce an expected loss impairment model that requires more timely recognition of expected credit losses. IAS 39 impairment requirements are based on an incurred loss model where credit losses are not recognized until there is evidence of a trigger event. IFRS 9 is effective for annual periods beginning on or after January 1, 2018 with early adoption permitted. We are assessing the impact of adopting this standard on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;IFRS 16 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the IASB issued IFRS 16 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;IFRS 16&amp;#8221;), which replaces IAS 17 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;IAS 17&amp;#8221;) and related interpretations. IFRS 16 provides a single lessee accounting model, requiring the recognition of assets and liabilities for all leases, unless the lease term is 12-months or less or the underlying asset has a low value. IFRS 16 substantially carries forward the lessor accounting in IAS 17 with the distinction between operating leases and finance leases being retained. IFRS 16 will be applied retrospectively for annual periods beginning on or after January 1, 2019. Early adoption is permitted under certain circumstances.  We are assessing the potential impact of adopting this standard on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
	<ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory contextRef="FD2017Q4YTD" id="Fact-F3499C2CDE5F7E722EA6C803E6493657">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we have the following non-capital losses for income tax purposes in Canada:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Expiry&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,809,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,009,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2030&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,774,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,343,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,873,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,457,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,472,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,125,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2036&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,430,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2037&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,846,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;57,308,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:190px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:97px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Expiry&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;189,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;471,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;465,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;361,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;228,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;271,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;520,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;596,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;622,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;173,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2030&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;114,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;487,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;270,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2036&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2037&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;5,463,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized.  The components of our unrecognized deferred tax asset are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:612px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:345px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net operating losses carried forward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;19,160,218&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,821,631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,950,044&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Scientific research and experimental development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;7,406,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,394,707&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,278,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Investment tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,988,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,990,664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,987,214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Undepreciated capital costs in excess of book value of property and equipment and intellectual property&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,927,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,908,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,839,107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;493,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;432,659&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;619,066&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net capital losses carried forward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;7,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrecognized deferred tax asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;32,983,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,555,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,681,313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
	<ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="FD2017Q4YTD" id="Fact-ED6CE150849AE4DD45F5C803E64D779C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:520px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:301px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2,596,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,753,553&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,941,342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Termination benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;779,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,330,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share-based payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;459,298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;372,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;353,419&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,835,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,456,389&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,294,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
	<ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory contextRef="FD2017Q4YTD" id="Fact-A08A164C0771675183A2E3962C57707D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#333333;"&gt;Our contract liability balance at December 31, which w&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;e expect to record in revenue over the next &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:443px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:236px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:102px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Regional licensing agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,182,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue recognized in the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,182,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract liability - current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,545,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract liability - non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;4,636,935&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,182,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
	<oncyf:CashEquivalentsAndShortTermInvestmentsTextBlock contextRef="FD2017Q4YTD" id="Fact-FC95D947869A61D4393AC803E64C3813">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Cash Equivalents and Short Term Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents consist of interest bearing deposits with our bank totaling $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;9,204,919&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$10,679,992&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&amp;#160;&amp;#160;The current annual interest rate earned on these deposits is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1.38%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;  (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;0.96%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Short-Term Investments &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments consisted of guaranteed investment certificates which are liquid investments that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.&amp;#160;&amp;#160;The objectives for holding short-term investments were to invest our excess cash resources in investment vehicles that provided a better rate of return compared to our interest bearing bank account with limited risk to the principal invested.&amp;#160;&amp;#160;We intended to match the maturities of these short-term investments with the cash requirements of the Company&amp;#8217;s activities and treat these as held-to-maturity short-term investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Face&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Original Cost&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Accrued Interest&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Effective&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Interest Rate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,088,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,088,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,088,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,088,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.41%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value is determined by using published market prices provided by our investment advisor.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:CashEquivalentsAndShortTermInvestmentsTextBlock>
	<oncyf:CashFlowOperatingCapital1TableTextBlock contextRef="FD2017Q4YTD" id="Fact-AB6E1DFEE6C0978FCE13C803E64B6693">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Change In Non-Cash Working Capital&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:629px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:392px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Change in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(4,767,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other receivables&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;16,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;285,653&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(148,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(915,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;245,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(215,116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(384,641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,359,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(664,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,182,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash impact of foreign exchange&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;48,558&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;343,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(77,535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in non-cash working capital related to operating activities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;180,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,233,865&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,105,464&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:CashFlowOperatingCapital1TableTextBlock>
	<oncyf:DisclosureOfCapitalComponentsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-259C0B24C99138DF316BC803E64BBEC8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;11,836,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,034,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,088,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shareholders&amp;#8217; equity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;8,283,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,689,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:DisclosureOfCapitalComponentsTableTextBlock>
	<oncyf:DisclosureOfEconomicDependenceTextBlock contextRef="FD2017Q4YTD" id="Fact-40A0213AF90D2C1E03C1C803E6476131">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Economic Dependence&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are economically dependent on our toll manufacturers. We primarily use &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; toll manufacturer in the US to produce the clinical grade REOLYSIN required for our clinical trial program.&amp;#160;Any significant disruption of the services provided by our primary toll manufacturer has the potential to delay the progress of our clinical trial program.&amp;#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade REOLYSIN at a smaller scale.&amp;#160;We have attempted to mitigate this risk by producing sufficient REOLYSIN in advance of patient enrollment in a particular clinical trial.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:DisclosureOfEconomicDependenceTextBlock>
	<oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock contextRef="FD2017Q4YTD" id="Fact-827386BB546C8601E7E3C803E646E0A6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Indemnification of Officers and Directors&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal or administrative action or proceeding as it relates to their services to the Company.&amp;#160;&amp;#160;The by-laws provide no limit to the amount of the indemnification.&amp;#160;&amp;#160;We have purchased directors&amp;#8217; and officers&amp;#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&amp;#160;&amp;#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&amp;#160;&amp;#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock>
	<oncyf:OtherExpensesAndAdjustmentsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-12CD302B2289D76A1B47C803E64C53AD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:420px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;br clear="none"/&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Included in research and development expenses:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Realized foreign exchange (gain) loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(120,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;104,851&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;238,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrealized non-cash foreign exchange loss (gain)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;55,538&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(816,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash share based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;230,141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;233,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;257,016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Included in operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization of property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;90,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;180,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash share based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;348,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;172,159&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;172,521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;231,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;148,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;196,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:OtherExpensesAndAdjustmentsTableTextBlock>
	<oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock contextRef="FD2017Q4YTD" id="Fact-7476A3F7CEB1A2E5D398C803E647A8B7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balances in foreign currencies at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:596px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:197px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:128px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:128px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:128px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;US dollars &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;"&gt;British pounds&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-align:center;"&gt;&amp;#163;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Euro&lt;br clear="none"/&gt;&amp;#8364;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,948,573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,755&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,372&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,800,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(777,271&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,971,302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock>
	<oncyf:ScheduleOfShortTermInvestmentsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-1B8358D64F103FC3BDD9C803E64C72FE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Face&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Original Cost&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Accrued Interest&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Effective&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;"&gt;Interest Rate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:middle;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;vertical-align:middle;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,088,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,088,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,088,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,088,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.41%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:ScheduleOfShortTermInvestmentsTableTextBlock>
	<oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock contextRef="FD2017Q4YTD" id="Fact-68CE353E65A79933FAEDC803E64A92FA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Other Cash Flow Disclosures&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:342px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:58px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:51px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:51px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash interest received&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;130,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;163,902&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;197,859&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash taxes paid&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;136,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,468&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock>
	<oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock contextRef="FD2017Q4YTD" id="Fact-BBE1CD82E28860068410C803E64AFF07">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:583px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:316px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(15,475,353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,130,605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,719,842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Statutory Canadian corporate tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;27.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Anticipated tax recovery&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(4,178,345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,085,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,567,159&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign jurisdiction tax rate difference&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2,899,190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,184,796&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,659,145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employee stock based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;156,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;109,641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;111,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,336,941&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Adjustment to opening tax pools&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;162,162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(39,569&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,339,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other permanent differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;53,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in deferred tax benefits deemed not probable to &lt;br clear="none"/&gt;  be recovered&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,051,725&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,739,557&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,455,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;144,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,687&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Adjustment in respect to prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(2,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net current tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;141,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,374&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,153&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>oncyf-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.oncolyticsbiotech.com/20171231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:oncyf="http://www.oncolyticsbiotech.com/20171231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.ifrs.org/taxonomy/2017-03-09/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AdditionalCashFlowDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures">
        <link:definition>2146100 - Disclosure - Additional Cash Flow Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails">
        <link:definition>2446402 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails">
        <link:definition>2446403 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables">
        <link:definition>2346301 - Disclosure - Additional Cash Flow Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfFinancialStatementPresentation" roleURI="http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation">
        <link:definition>2104100 - Disclosure - Basis of Financial Statement Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures">
        <link:definition>2140100 - Disclosure - Capital Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails">
        <link:definition>2440402 - Disclosure - Capital Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables">
        <link:definition>2340301 - Disclosure - Capital Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsAndShortTermInvestments" roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestments">
        <link:definition>2113100 - Disclosure - Cash Equivalents and Short Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsAndShortTermInvestmentsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsNarrativeDetails">
        <link:definition>2413402 - Disclosure - Cash Equivalents and Short Term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails">
        <link:definition>2413403 - Disclosure - Cash Equivalents and Short Term Investments - Schedule Of Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsAndShortTermInvestmentsTables" roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsTables">
        <link:definition>2313301 - Disclosure - Cash Equivalents and Short Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitments" roleURI="http://www.oncolyticsbiotech.com/role/Commitments">
        <link:definition>2131100 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails">
        <link:definition>2431402 - Disclosure - Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsTables" roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsTables">
        <link:definition>2331301 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfChangesInEquity" roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInEquity">
        <link:definition>1003000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfFinancialPosition" roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition">
        <link:definition>1001000 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfFinancialPositionParenthetical" roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical">
        <link:definition>1001001 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfLossAndComprehensiveLoss" roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss">
        <link:definition>1002000 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.oncolyticsbiotech.com/role/Contingencies">
        <link:definition>2134100 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails">
        <link:definition>2434401 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityAndReceivable" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable">
        <link:definition>2128100 - Disclosure - Contract Liability and Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityAndReceivableNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails">
        <link:definition>2428402 - Disclosure - Contract Liability and Receivable - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails">
        <link:definition>2428403 - Disclosure - Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityAndReceivableTables" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables">
        <link:definition>2328301 - Disclosure - Contract Liability and Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformationDocument" roleURI="http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformationDocument">
        <link:definition>0001000 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EconomicDependence" roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence">
        <link:definition>2152100 - Disclosure - Economic Dependence</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EconomicDependenceDetails" roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails">
        <link:definition>2452401 - Disclosure - Economic Dependence (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments">
        <link:definition>2143100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2443402 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails">
        <link:definition>2443403 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables">
        <link:definition>2343301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes">
        <link:definition>2137100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionForIncomeTaxesDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails">
        <link:definition>2437402 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails">
        <link:definition>2437405 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryOfNonCapitalLossesDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails">
        <link:definition>2437403 - Disclosure - Income Taxes - Summary of Non-capital Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails">
        <link:definition>2437404 - Disclosure - Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables">
        <link:definition>2337301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncorporationAndNatureOfOperations" roleURI="http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations">
        <link:definition>2101100 - Disclosure - Incorporation and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndemnificationOfOfficersAndDirectors" roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors">
        <link:definition>2149100 - Disclosure - Indemnification of Officers and Directors</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare">
        <link:definition>2125100 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareDetails" roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails">
        <link:definition>2425401 - Disclosure - Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpensesAndAdjustments" roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments">
        <link:definition>2155100 - Disclosure - Other Expenses and Adjustments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpensesAndAdjustmentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails">
        <link:definition>2455402 - Disclosure - Other Expenses and Adjustments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpensesAndAdjustmentsTables" roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables">
        <link:definition>2355301 - Disclosure - Other Expenses and Adjustments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipment">
        <link:definition>2116100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetails" roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails">
        <link:definition>2416402 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables">
        <link:definition>2316301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions">
        <link:definition>2156100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2456402 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables">
        <link:definition>2356301 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPayments">
        <link:definition>2122100 - Disclosure - Share Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails">
        <link:definition>2422405 - Disclosure - Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails">
        <link:definition>2422403 - Disclosure - Share Based Payments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails">
        <link:definition>2422406 - Disclosure - Share Based Payments - Schedule of Number of Other Equity Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails">
        <link:definition>2422402 - Disclosure - Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails">
        <link:definition>2422404 - Disclosure - Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables">
        <link:definition>2322301 - Disclosure - Share Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapital" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital">
        <link:definition>2119100 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleOfShareCapitalDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails">
        <link:definition>2419402 - Disclosure - Share Capital - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleOfShareCapitalFootnotesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails">
        <link:definition>2419403 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails">
        <link:definition>2419404 - Disclosure - Share Capital - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalSummaryOfOutstandingWarrantsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails">
        <link:definition>2419405 - Disclosure - Share Capital - Summary of Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalTables" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables">
        <link:definition>2319301 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantJudgmentsEstimatesAndAssumptions" roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions">
        <link:definition>2110100 - Disclosure - Significant Judgments, Estimates and Assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2107100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2407404 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2207201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2307302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="oncyf_AccruedRoyalties1" name="AccruedRoyalties1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_AmendedInitialCommitmentFeeMember" name="AmendedInitialCommitmentFeeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_AnnualContingentPayment" name="AnnualContingentPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_AnnualContingentPaymentGrossSalesPercent" name="AnnualContingentPaymentGrossSalesPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_BalanceHeldInForeignCurrencyNet" name="BalanceHeldInForeignCurrencyNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" name="CashEquivalentsAndShortTermInvestmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock" name="CashEquivalentsAndShortTermInvestmentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_CashEquivalentsInterestRate" name="CashEquivalentsInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_CashFlowOperatingCapital1TableTextBlock" name="CashFlowOperatingCapital1TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ClassofWarrantorRight1LineItems" name="ClassofWarrantorRight1LineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ClassofWarrantorRight1Table" name="ClassofWarrantorRight1Table" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" name="ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_CommitmentsAbstract" name="CommitmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_CommitmentsAndContingencies1" name="CommitmentsAndContingencies1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" name="CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" name="CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" name="CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_CommonSharePurchaseWarrantPerUnit" name="CommonSharePurchaseWarrantPerUnit" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_CommonSharesPerUnit" name="CommonSharesPerUnit" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_ConcentrationRisk1Table" name="ConcentrationRisk1Table" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ConcentrationRiskNumber" name="ConcentrationRiskNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ConcentrationRiskType1Axis" name="ConcentrationRiskType1Axis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ConcentrationRiskType1Domain" name="ConcentrationRiskType1Domain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ConcentrationRiskType1LineItems" name="ConcentrationRiskType1LineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ContingenciesAbstract" name="ContingenciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ContingentRoyaltyPaymentAnnualMaximum" name="ContingentRoyaltyPaymentAnnualMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ContingentRoyaltyPaymentContributionRate" name="ContingentRoyaltyPaymentContributionRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" name="ContingentRoyaltyPaymentPercentOfSalesRevenue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_ContractLiabilityRecognitionPeriod" name="ContractLiabilityRecognitionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" name="CorporateInformationAndStatementOfIFRSComplianceAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_Currency1Axis" name="Currency1Axis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_Currency1LineItems" name="Currency1LineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_Currency1Table" name="Currency1Table" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_DisclosureOfCapitalComponentsTableTextBlock" name="DisclosureOfCapitalComponentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureOfEconomicDependenceAbstract" name="DisclosureOfEconomicDependenceAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_DisclosureOfEconomicDependenceTextBlock" name="DisclosureOfEconomicDependenceTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" name="DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" name="DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" name="DisclosureOfNotesAndOtherExplanatoryInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" name="DisclosureOfSharebasedPaymentArrangementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" name="DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureofincometaxAbstract" name="DisclosureofincometaxAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureofrelatedpartyAbstract" name="DisclosureofrelatedpartyAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" name="DisclosureofrevenuefromcontractswithcustomersAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureofsharebasedpaymentarrangementAbstract" name="DisclosureofsharebasedpaymentarrangementAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_DividendYieldPercent" name="DividendYieldPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_EquityAuthorized" name="EquityAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_ExercisePriceRangeFiveMember" name="ExercisePriceRangeFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ExercisePriceRangeFourMember" name="ExercisePriceRangeFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ExercisePriceRangeOneMember" name="ExercisePriceRangeOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ExercisePriceRangeThreeMember" name="ExercisePriceRangeThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ExercisePriceRangeTwoMember" name="ExercisePriceRangeTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ExercisePriceofOutstandingWarrants" name="ExercisePriceofOutstandingWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_ExpectedForfeitureShareOptionsGranted" name="ExpectedForfeitureShareOptionsGranted" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_FinancialAssetsAtFaceValueMember" name="FinancialAssetsAtFaceValueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_FundedandRoyaltyRepayment" name="FundedandRoyaltyRepayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_GrossProceedsFromIssueOfOrdinaryShares" name="GrossProceedsFromIssueOfOrdinaryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_IncomeStatementLocation1Axis" name="IncomeStatementLocation1Axis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_IncomeStatementLocation1Domain" name="IncomeStatementLocation1Domain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_IncreaseDecreaseinPrepaidExpense1" name="IncreaseDecreaseinPrepaidExpense1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_InitialCommitmentFeeMember" name="InitialCommitmentFeeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_InitialCommitmentFeeSharesIssuedFairValue" name="InitialCommitmentFeeSharesIssuedFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_InvestmentTaxCreditsMember" name="InvestmentTaxCreditsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_IssueOfEquityShareAgreement" name="IssueOfEquityShareAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares" name="IssueOfEquitySharePurchaseAgreementFutureIssuesShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_IssueOfEquityShares" name="IssueOfEquityShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" name="MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_MedicalEquipmentMember" name="MedicalEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_MilestoneAxis" name="MilestoneAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_MilestoneDomain" name="MilestoneDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_MilestoneOneMember" name="MilestoneOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_MilestoneTwoMember" name="MilestoneTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_NumberOfStockOptionPlans" name="NumberOfStockOptionPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_NumberofPatients" name="NumberofPatients" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_OperatingExpensesMember" name="OperatingExpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_OtherExpensesAndAdjustmentsLineItems" name="OtherExpensesAndAdjustmentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_OtherExpensesAndAdjustmentsTable" name="OtherExpensesAndAdjustmentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_OtherExpensesAndAdjustmentsTableTextBlock" name="OtherExpensesAndAdjustmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_OverheadRepayment" name="OverheadRepayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_PerformanceShareUnitsMember" name="PerformanceShareUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ProceedsfromInterestReceived" name="ProceedsfromInterestReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" name="PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" name="PropertyPlantandEquipmentAnnualDepreciationRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_PurchaseObligation1" name="PurchaseObligation1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1" name="RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ResearchAndDevelopmentMember" name="ResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_RestrictedShareUnitsMember" name="RestrictedShareUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_RighttoCallWarrantMilestoneOneTerm" name="RighttoCallWarrantMilestoneOneTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SYNSORBMember" name="SYNSORBMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SaleOfStockAxis" name="SaleOfStockAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SaleOfStockDomain" name="SaleOfStockDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" name="ScheduleOfForeignCurrencyHeldTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ScheduleOfShortTermInvestmentsTableTextBlock" name="ScheduleOfShortTermInvestmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" name="ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" name="ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ShareIssueCostsMember" name="ShareIssueCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_SharePricePremiumPercent" name="SharePricePremiumPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_SharePurchaseAgreementAmount" name="SharePurchaseAgreementAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_SharePurchaseAgreementTerm" name="SharePurchaseAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_SharesIssuedPricePerShare1" name="SharesIssuedPricePerShare1" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_SharesIssuedWarrantPricePerShare" name="SharesIssuedWarrantPricePerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_SharesPublicOfferingMember" name="SharesPublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SharesUnderAmendedSharePurchaseAgreementMember" name="SharesUnderAmendedSharePurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SharesUnderAtthemarketAgreementMember" name="SharesUnderAtthemarketAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SharesUnderSharePurchaseAgreementMember" name="SharesUnderSharePurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ShortTermInvestmentEffectiveInterestRate" name="ShortTermInvestmentEffectiveInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent" name="ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" name="SignificantJudgmentsEstimatesAndAssumptionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_Statement1LineItems" name="Statement1LineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_Statement1Table" name="Statement1Table" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SummaryOfSignificantAccountingPolicieAbstract" name="SummaryOfSignificantAccountingPolicieAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SummaryOfSignificantAccountingPoliciesAbstract" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SupplierConcentrationRisk1Member" name="SupplierConcentrationRisk1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_TaxEffectOfStockBasedCompensation" name="TaxEffectOfStockBasedCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_TaxEffectOfTaxPools" name="TaxEffectOfTaxPools" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtyFiveMember" name="TwentyThirtyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtyFourMember" name="TwentyThirtyFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtyMember" name="TwentyThirtyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtyOneMember" name="TwentyThirtyOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtySevenMember" name="TwentyThirtySevenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtySixMember" name="TwentyThirtySixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtyThreeMember" name="TwentyThirtyThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtyTwoMember" name="TwentyThirtyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyEightMember" name="TwentyTwentyEightMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyFiveMember" name="TwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyFourMember" name="TwentyTwentyFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyMember" name="TwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyNineMember" name="TwentyTwentyNineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyOneMember" name="TwentyTwentyOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentySevenMember" name="TwentyTwentySevenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentySixMember" name="TwentyTwentySixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyThreeMember" name="TwentyTwentyThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyTwoMember" name="TwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" name="UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_UnusedCapitalLossCarryForwardNetMember" name="UnusedCapitalLossCarryForwardNetMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_UnusedNetOperatingLossCarryForwardsMember" name="UnusedNetOperatingLossCarryForwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" name="ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_WarrantPricePerShareAccelerationThreshold" name="WarrantPricePerShareAccelerationThreshold" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_WarrantPricePerShareAccelerationThresholdTradingDays" name="WarrantPricePerShareAccelerationThresholdTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_WarrantPurchaseAgreement" name="WarrantPurchaseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_WarrantsMember" name="WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_WarrantsandRightsOutstanding" name="WarrantsandRightsOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_WeightedAverageClosingPriceDuration" name="WeightedAverageClosingPriceDuration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>oncyf-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:href="oncyf-20171231.xsd#AdditionalCashFlowDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:href="oncyf-20171231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:href="oncyf-20171231.xsd#AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:href="oncyf-20171231.xsd#AdditionalCashFlowDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation" xlink:href="oncyf-20171231.xsd#BasisOfFinancialStatementPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:href="oncyf-20171231.xsd#CapitalDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:href="oncyf-20171231.xsd#CapitalDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:href="oncyf-20171231.xsd#CapitalDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestments" xlink:href="oncyf-20171231.xsd#CashEquivalentsAndShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsNarrativeDetails" xlink:href="oncyf-20171231.xsd#CashEquivalentsAndShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:href="oncyf-20171231.xsd#CashEquivalentsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:href="oncyf-20171231.xsd#CashEquivalentsAndShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Commitments" xlink:href="oncyf-20171231.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:href="oncyf-20171231.xsd#CommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsTables" xlink:href="oncyf-20171231.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInEquity" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfChangesInEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfFinancialPosition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:href="oncyf-20171231.xsd#Contingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:href="oncyf-20171231.xsd#ContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable" xlink:href="oncyf-20171231.xsd#ContractLiabilityAndReceivable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails" xlink:href="oncyf-20171231.xsd#ContractLiabilityAndReceivableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:href="oncyf-20171231.xsd#ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables" xlink:href="oncyf-20171231.xsd#ContractLiabilityAndReceivableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformationDocument" xlink:href="oncyf-20171231.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:href="oncyf-20171231.xsd#EconomicDependence" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:href="oncyf-20171231.xsd#EconomicDependenceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:href="oncyf-20171231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:href="oncyf-20171231.xsd#FinancialInstrumentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:href="oncyf-20171231.xsd#FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:href="oncyf-20171231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:href="oncyf-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" xlink:href="oncyf-20171231.xsd#IncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:href="oncyf-20171231.xsd#IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:href="oncyf-20171231.xsd#IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:href="oncyf-20171231.xsd#IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:href="oncyf-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations" xlink:href="oncyf-20171231.xsd#IncorporationAndNatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors" xlink:href="oncyf-20171231.xsd#IndemnificationOfOfficersAndDirectors" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:href="oncyf-20171231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:href="oncyf-20171231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments" xlink:href="oncyf-20171231.xsd#OtherExpensesAndAdjustments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails" xlink:href="oncyf-20171231.xsd#OtherExpensesAndAdjustmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables" xlink:href="oncyf-20171231.xsd#OtherExpensesAndAdjustmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipment" xlink:href="oncyf-20171231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails" xlink:href="oncyf-20171231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables" xlink:href="oncyf-20171231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:href="oncyf-20171231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:href="oncyf-20171231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:href="oncyf-20171231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:href="oncyf-20171231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:href="oncyf-20171231.xsd#ShareCapital" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails" xlink:href="oncyf-20171231.xsd#ShareCapitalScheduleOfShareCapitalDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:href="oncyf-20171231.xsd#ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:href="oncyf-20171231.xsd#ShareCapitalSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:href="oncyf-20171231.xsd#ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:href="oncyf-20171231.xsd#ShareCapitalTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions" xlink:href="oncyf-20171231.xsd#SignificantJudgmentsEstimatesAndAssumptions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:label="loc_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_03a28181-1bac-24fe-f3fe-d096731763b5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_77895883-b314-9f60-f8bb-16dd220ca3a3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_03a28181-1bac-24fe-f3fe-d096731763b5" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_77895883-b314-9f60-f8bb-16dd220ca3a3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_38958cca-0871-5505-a80a-f44ac9768600" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_03a28181-1bac-24fe-f3fe-d096731763b5" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_38958cca-0871-5505-a80a-f44ac9768600" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IncreaseDecreaseinPrepaidExpense1" xlink:label="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_4f90e60a-f542-9832-eddf-c803f14c7562" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_03a28181-1bac-24fe-f3fe-d096731763b5" xlink:to="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_4f90e60a-f542-9832-eddf-c803f14c7562" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_39066725-1012-876d-8dd6-a1c7b29a2d5c" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_03a28181-1bac-24fe-f3fe-d096731763b5" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_39066725-1012-876d-8dd6-a1c7b29a2d5c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_5df1741f-7f61-1136-ab01-e586d087499f" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_03a28181-1bac-24fe-f3fe-d096731763b5" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_5df1741f-7f61-1136-ab01-e586d087499f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_9be548b2-a768-9d39-cb98-4f5435e870d1" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_03a28181-1bac-24fe-f3fe-d096731763b5" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_9be548b2-a768-9d39-cb98-4f5435e870d1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/Commitments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1e105b62-b2a8-13e9-d78d-cf50170ee6a6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_17742188-7397-f20f-bc25-ee8d7db7fb48" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1e105b62-b2a8-13e9-d78d-cf50170ee6a6" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_17742188-7397-f20f-bc25-ee8d7db7fb48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_941742c3-4409-7e85-2a82-d2e7eda0b6e5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_17742188-7397-f20f-bc25-ee8d7db7fb48" xlink:to="loc_ifrs-full_ProfitLoss_941742c3-4409-7e85-2a82-d2e7eda0b6e5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_38e1c60a-e07c-47af-ae3d-3e9a66c09fb4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_17742188-7397-f20f-bc25-ee8d7db7fb48" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_38e1c60a-e07c-47af-ae3d-3e9a66c09fb4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_c66e49c1-419e-1658-c5aa-3755665a5485" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_17742188-7397-f20f-bc25-ee8d7db7fb48" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_c66e49c1-419e-1658-c5aa-3755665a5485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7a73fe1f-b922-d567-3d75-ecf3d68fca55" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_17742188-7397-f20f-bc25-ee8d7db7fb48" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7a73fe1f-b922-d567-3d75-ecf3d68fca55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_daac473c-53e6-a017-355b-c5117d6c5a34" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_17742188-7397-f20f-bc25-ee8d7db7fb48" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_daac473c-53e6-a017-355b-c5117d6c5a34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_f10eb10d-b3df-9fd6-f406-2557dadd5e32" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1e105b62-b2a8-13e9-d78d-cf50170ee6a6" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_f10eb10d-b3df-9fd6-f406-2557dadd5e32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_6fb7bce3-14d3-3e88-bda7-94679522d55b" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_f10eb10d-b3df-9fd6-f406-2557dadd5e32" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_6fb7bce3-14d3-3e88-bda7-94679522d55b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_c8b620ad-e04b-9fcd-5f01-0eb846ef438c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_f10eb10d-b3df-9fd6-f406-2557dadd5e32" xlink:to="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_c8b620ad-e04b-9fcd-5f01-0eb846ef438c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a8bef3a1-290c-100e-b16d-0dac4e42d07f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1e105b62-b2a8-13e9-d78d-cf50170ee6a6" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a8bef3a1-290c-100e-b16d-0dac4e42d07f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_27cdecfe-2750-3799-3f55-d01c06b2881e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a8bef3a1-290c-100e-b16d-0dac4e42d07f" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_27cdecfe-2750-3799-3f55-d01c06b2881e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_11f83f77-11b2-8d24-6693-d58c3af1357b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a8bef3a1-290c-100e-b16d-0dac4e42d07f" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_11f83f77-11b2-8d24-6693-d58c3af1357b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_c73d3b25-76fd-c8bd-7811-e5067c232f3d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a8bef3a1-290c-100e-b16d-0dac4e42d07f" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_c73d3b25-76fd-c8bd-7811-e5067c232f3d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_2bdd0886-f81c-d20d-0611-12351e02bb2a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_5d36c60b-0fe2-4b40-1a74-d544048f9f11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_2bdd0886-f81c-d20d-0611-12351e02bb2a" xlink:to="loc_ifrs-full_CurrentAssets_5d36c60b-0fe2-4b40-1a74-d544048f9f11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_3876baec-7a47-27d3-b64e-8fc1b160f559" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_5d36c60b-0fe2-4b40-1a74-d544048f9f11" xlink:to="loc_ifrs-full_CashAndCashEquivalents_3876baec-7a47-27d3-b64e-8fc1b160f559" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentInvestments" xlink:label="loc_ifrs-full_CurrentInvestments_3a63b8d3-dc72-67aa-c256-dc5632d9eba0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_5d36c60b-0fe2-4b40-1a74-d544048f9f11" xlink:to="loc_ifrs-full_CurrentInvestments_3a63b8d3-dc72-67aa-c256-dc5632d9eba0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentReceivablesFromContractsWithCustomers" xlink:label="loc_ifrs-full_CurrentReceivablesFromContractsWithCustomers_187c8e80-09ea-fe63-9cf6-fc86cac10504" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_5d36c60b-0fe2-4b40-1a74-d544048f9f11" xlink:to="loc_ifrs-full_CurrentReceivablesFromContractsWithCustomers_187c8e80-09ea-fe63-9cf6-fc86cac10504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_83e8544a-7cb4-4758-df8c-1873074571b2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_5d36c60b-0fe2-4b40-1a74-d544048f9f11" xlink:to="loc_ifrs-full_OtherCurrentReceivables_83e8544a-7cb4-4758-df8c-1873074571b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_d61e7935-a33f-f513-971e-1bce15c3a260" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_5d36c60b-0fe2-4b40-1a74-d544048f9f11" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_d61e7935-a33f-f513-971e-1bce15c3a260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_de3acfa1-2db3-3f2c-34c2-8fb573a68fa6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_2bdd0886-f81c-d20d-0611-12351e02bb2a" xlink:to="loc_ifrs-full_NoncurrentAssets_de3acfa1-2db3-3f2c-34c2-8fb573a68fa6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_e91d3344-0538-cca8-b817-ccf4cc89a53a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_de3acfa1-2db3-3f2c-34c2-8fb573a68fa6" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_e91d3344-0538-cca8-b817-ccf4cc89a53a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_e1dfd4c7-2963-ab0b-ea9d-c0605ce6dd55" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_99e8abe2-bb0f-0b24-e945-fb68a19fe103" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_e1dfd4c7-2963-ab0b-ea9d-c0605ce6dd55" xlink:to="loc_ifrs-full_Equity_99e8abe2-bb0f-0b24-e945-fb68a19fe103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_f120169a-28d8-2a97-57f1-a188cf2be306" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_99e8abe2-bb0f-0b24-e945-fb68a19fe103" xlink:to="loc_ifrs-full_IssuedCapital_f120169a-28d8-2a97-57f1-a188cf2be306" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsandRightsOutstanding" xlink:label="loc_oncyf_WarrantsandRightsOutstanding_EFCE5F58E34A43D340DC481CB6572C52" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_99e8abe2-bb0f-0b24-e945-fb68a19fe103" xlink:to="loc_oncyf_WarrantsandRightsOutstanding_EFCE5F58E34A43D340DC481CB6572C52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionalPaidinCapital" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_6fb253c4-5c35-8cc1-9cf8-c5d9eea38247" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_99e8abe2-bb0f-0b24-e945-fb68a19fe103" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_6fb253c4-5c35-8cc1-9cf8-c5d9eea38247" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_7b6256c0-7072-4403-b0d5-f852f0da2bd3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_99e8abe2-bb0f-0b24-e945-fb68a19fe103" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_7b6256c0-7072-4403-b0d5-f852f0da2bd3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_cc3c53b0-23cf-fe6f-b3a8-fa87621dd81f" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_99e8abe2-bb0f-0b24-e945-fb68a19fe103" xlink:to="loc_ifrs-full_RetainedEarnings_cc3c53b0-23cf-fe6f-b3a8-fa87621dd81f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_85f09b22-4350-3eec-ef55-a57e2ccc69bb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_e1dfd4c7-2963-ab0b-ea9d-c0605ce6dd55" xlink:to="loc_ifrs-full_Liabilities_85f09b22-4350-3eec-ef55-a57e2ccc69bb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_ef30eb94-2bbc-8a03-e757-8ec92142bae5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_85f09b22-4350-3eec-ef55-a57e2ccc69bb" xlink:to="loc_ifrs-full_CurrentLiabilities_ef30eb94-2bbc-8a03-e757-8ec92142bae5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_3fa58832-4633-0d32-0f83-b86e6917ac9a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_ef30eb94-2bbc-8a03-e757-8ec92142bae5" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_3fa58832-4633-0d32-0f83-b86e6917ac9a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_eadfa2d5-711d-bd35-2d03-e019f25a0a66" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_ef30eb94-2bbc-8a03-e757-8ec92142bae5" xlink:to="loc_ifrs-full_CurrentContractLiabilities_eadfa2d5-711d-bd35-2d03-e019f25a0a66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_abab4a8e-514c-0094-69ee-8bff6be6d5a5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_85f09b22-4350-3eec-ef55-a57e2ccc69bb" xlink:to="loc_ifrs-full_NoncurrentLiabilities_abab4a8e-514c-0094-69ee-8bff6be6d5a5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_c683c286-865e-5f5d-b4d1-5cab9360d3a1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_abab4a8e-514c-0094-69ee-8bff6be6d5a5" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_c683c286-865e-5f5d-b4d1-5cab9360d3a1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsAndContingencies1" xlink:label="loc_oncyf_CommitmentsAndContingencies1_56e34e5e-d57a-f343-7c9c-c803f18aae66" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_e1dfd4c7-2963-ab0b-ea9d-c0605ce6dd55" xlink:to="loc_oncyf_CommitmentsAndContingencies1_56e34e5e-d57a-f343-7c9c-c803f18aae66" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_f1f655b3-16d3-6ec0-d3be-bb34022c965a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_941742c3-4409-7e85-2a82-d2e7eda0b6e5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_f1f655b3-16d3-6ec0-d3be-bb34022c965a" xlink:to="loc_ifrs-full_ProfitLoss_941742c3-4409-7e85-2a82-d2e7eda0b6e5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_d974c768-3d62-095e-e933-9ffe8a9e03d6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_941742c3-4409-7e85-2a82-d2e7eda0b6e5" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_d974c768-3d62-095e-e933-9ffe8a9e03d6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_0588e943-8dd5-38b2-5c03-3e79642ad1a6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_d974c768-3d62-095e-e933-9ffe8a9e03d6" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_0588e943-8dd5-38b2-5c03-3e79642ad1a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_748d3752-7178-5f47-ab73-05eb6df9c013" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_0588e943-8dd5-38b2-5c03-3e79642ad1a6" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_748d3752-7178-5f47-ab73-05eb6df9c013" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OperatingExpense" xlink:label="loc_ifrs-full_OperatingExpense_074ff643-cd76-d176-cfb4-e953d6042322" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_0588e943-8dd5-38b2-5c03-3e79642ad1a6" xlink:to="loc_ifrs-full_OperatingExpense_074ff643-cd76-d176-cfb4-e953d6042322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_40723116-e5bf-0f1d-475c-a7813e10dc69" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_d974c768-3d62-095e-e933-9ffe8a9e03d6" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_40723116-e5bf-0f1d-475c-a7813e10dc69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_a587217f-5cc4-ca59-bde5-1ce40d4075ff" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_941742c3-4409-7e85-2a82-d2e7eda0b6e5" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_a587217f-5cc4-ca59-bde5-1ce40d4075ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_49d99c29-3afb-d91b-d62a-2d8bbd4712ee" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_f1f655b3-16d3-6ec0-d3be-bb34022c965a" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_49d99c29-3afb-d91b-d62a-2d8bbd4712ee" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_829c3dc5-053b-a0a6-bac3-dbabf1d97936" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_eadfa2d5-711d-bd35-2d03-e019f25a0a66" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ContractLiabilities_829c3dc5-053b-a0a6-bac3-dbabf1d97936" xlink:to="loc_ifrs-full_CurrentContractLiabilities_eadfa2d5-711d-bd35-2d03-e019f25a0a66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_c683c286-865e-5f5d-b4d1-5cab9360d3a1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ContractLiabilities_829c3dc5-053b-a0a6-bac3-dbabf1d97936" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_c683c286-865e-5f5d-b4d1-5cab9360d3a1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformationDocument" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_d608a91b-40c5-5f0e-92f1-8462f81e8e0f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_9f38c273-7bba-cdeb-c65b-a6c39d87eefa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_d608a91b-40c5-5f0e-92f1-8462f81e8e0f" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_9f38c273-7bba-cdeb-c65b-a6c39d87eefa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_9448a76e-72cc-3098-72e9-4d9fa5b66534" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_9f38c273-7bba-cdeb-c65b-a6c39d87eefa" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_9448a76e-72cc-3098-72e9-4d9fa5b66534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_12b7ca06-91a0-2938-41a8-12084d0d7592" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_9f38c273-7bba-cdeb-c65b-a6c39d87eefa" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_12b7ca06-91a0-2938-41a8-12084d0d7592" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TaxEffectOfStockBasedCompensation" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_5fcd3768-ee16-28b8-b205-c803f1768c9a" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_9f38c273-7bba-cdeb-c65b-a6c39d87eefa" xlink:to="loc_oncyf_TaxEffectOfStockBasedCompensation_5fcd3768-ee16-28b8-b205-c803f1768c9a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_feb2e32d-ee87-94ea-de51-79a3722c8d04" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_9f38c273-7bba-cdeb-c65b-a6c39d87eefa" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_feb2e32d-ee87-94ea-de51-79a3722c8d04" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TaxEffectOfTaxPools" xlink:label="loc_oncyf_TaxEffectOfTaxPools_fb35a276-fe58-0565-4080-c803f1666abd" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_9f38c273-7bba-cdeb-c65b-a6c39d87eefa" xlink:to="loc_oncyf_TaxEffectOfTaxPools_fb35a276-fe58-0565-4080-c803f1666abd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_823cf4db-7fd4-7e82-5728-3c38650c57db" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_9f38c273-7bba-cdeb-c65b-a6c39d87eefa" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_823cf4db-7fd4-7e82-5728-3c38650c57db" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_743f0278-0f57-15b0-e925-c803f1b76361" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_9f38c273-7bba-cdeb-c65b-a6c39d87eefa" xlink:to="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_743f0278-0f57-15b0-e925-c803f1b76361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_113ee648-48c2-aebf-010d-daa96643f935" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_d608a91b-40c5-5f0e-92f1-8462f81e8e0f" xlink:to="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_113ee648-48c2-aebf-010d-daa96643f935" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_a59a5560-ac66-66bb-b10d-4c0b50780afe" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_56c1bbd7-53f3-3ff4-84d1-87b5962afa43" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_a59a5560-ac66-66bb-b10d-4c0b50780afe" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_56c1bbd7-53f3-3ff4-84d1-87b5962afa43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_6215bd10-a982-f509-a684-a8c6868d9c43" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_a59a5560-ac66-66bb-b10d-4c0b50780afe" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_6215bd10-a982-f509-a684-a8c6868d9c43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_57c07b6f-5901-e694-821d-302023974395" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_a59a5560-ac66-66bb-b10d-4c0b50780afe" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_57c07b6f-5901-e694-821d-302023974395" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>oncyf-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:href="oncyf-20171231.xsd#AdditionalCashFlowDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:href="oncyf-20171231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:href="oncyf-20171231.xsd#AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:href="oncyf-20171231.xsd#AdditionalCashFlowDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation" xlink:href="oncyf-20171231.xsd#BasisOfFinancialStatementPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:href="oncyf-20171231.xsd#CapitalDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:href="oncyf-20171231.xsd#CapitalDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:href="oncyf-20171231.xsd#CapitalDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestments" xlink:href="oncyf-20171231.xsd#CashEquivalentsAndShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsNarrativeDetails" xlink:href="oncyf-20171231.xsd#CashEquivalentsAndShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:href="oncyf-20171231.xsd#CashEquivalentsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:href="oncyf-20171231.xsd#CashEquivalentsAndShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Commitments" xlink:href="oncyf-20171231.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:href="oncyf-20171231.xsd#CommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsTables" xlink:href="oncyf-20171231.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInEquity" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfChangesInEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfFinancialPosition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:href="oncyf-20171231.xsd#Contingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:href="oncyf-20171231.xsd#ContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable" xlink:href="oncyf-20171231.xsd#ContractLiabilityAndReceivable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails" xlink:href="oncyf-20171231.xsd#ContractLiabilityAndReceivableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:href="oncyf-20171231.xsd#ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables" xlink:href="oncyf-20171231.xsd#ContractLiabilityAndReceivableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformationDocument" xlink:href="oncyf-20171231.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:href="oncyf-20171231.xsd#EconomicDependence" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:href="oncyf-20171231.xsd#EconomicDependenceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:href="oncyf-20171231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:href="oncyf-20171231.xsd#FinancialInstrumentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:href="oncyf-20171231.xsd#FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:href="oncyf-20171231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:href="oncyf-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" xlink:href="oncyf-20171231.xsd#IncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:href="oncyf-20171231.xsd#IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:href="oncyf-20171231.xsd#IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:href="oncyf-20171231.xsd#IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:href="oncyf-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations" xlink:href="oncyf-20171231.xsd#IncorporationAndNatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors" xlink:href="oncyf-20171231.xsd#IndemnificationOfOfficersAndDirectors" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:href="oncyf-20171231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:href="oncyf-20171231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments" xlink:href="oncyf-20171231.xsd#OtherExpensesAndAdjustments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails" xlink:href="oncyf-20171231.xsd#OtherExpensesAndAdjustmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables" xlink:href="oncyf-20171231.xsd#OtherExpensesAndAdjustmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipment" xlink:href="oncyf-20171231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails" xlink:href="oncyf-20171231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables" xlink:href="oncyf-20171231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:href="oncyf-20171231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:href="oncyf-20171231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:href="oncyf-20171231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:href="oncyf-20171231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:href="oncyf-20171231.xsd#ShareCapital" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails" xlink:href="oncyf-20171231.xsd#ShareCapitalScheduleOfShareCapitalDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:href="oncyf-20171231.xsd#ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:href="oncyf-20171231.xsd#ShareCapitalSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:href="oncyf-20171231.xsd#ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:href="oncyf-20171231.xsd#ShareCapitalTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions" xlink:href="oncyf-20171231.xsd#SignificantJudgmentsEstimatesAndAssumptions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_37B0C0BCE458B06E35061AEC02FE7FC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:to="loc_ifrs-full_MeasurementAxis_37B0C0BCE458B06E35061AEC02FE7FC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_37B0C0BCE458B06E35061AEC02FE7FC7" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_37B0C0BCE458B06E35061AEC02FE7FC7" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AtCostMember" xlink:label="loc_ifrs-full_AtCostMember_EB255EBFF518ED35416B1AEC02FE5ED9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3" xlink:to="loc_ifrs-full_AtCostMember_EB255EBFF518ED35416B1AEC02FE5ED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_A05E0F5199E8AB7D233D1AEC02FE6E0F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3" xlink:to="loc_ifrs-full_AtFairValueMember_A05E0F5199E8AB7D233D1AEC02FE6E0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_72911D79B93BDAE747451AEC02FE8EF1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_72911D79B93BDAE747451AEC02FE8EF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_72911D79B93BDAE747451AEC02FE8EF1" xlink:to="loc_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_72911D79B93BDAE747451AEC02FE8EF1" xlink:to="loc_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_FinancialAssetsAtFaceValueMember" xlink:label="loc_oncyf_FinancialAssetsAtFaceValueMember_966EF8D7C6669825EB301AEC02FE8108" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:to="loc_oncyf_FinancialAssetsAtFaceValueMember_966EF8D7C6669825EB301AEC02FE8108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember_267A21191001F82B2F481AEC02FE2D0A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember_267A21191001F82B2F481AEC02FE2D0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueMember_A04EEFED1480A41499181AEC02FE79B8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueMember_A04EEFED1480A41499181AEC02FE79B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_EBA6C6745F4C728EC77F1AEC02FE564F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_EBA6C6745F4C728EC77F1AEC02FE564F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_EBA6C6745F4C728EC77F1AEC02FE564F" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_EBA6C6745F4C728EC77F1AEC02FE564F" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_HeldtomaturityInvestmentsCategoryMember" xlink:label="loc_ifrs-full_HeldtomaturityInvestmentsCategoryMember_13101ABE816E23212B631AEC02FE5D4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0" xlink:to="loc_ifrs-full_HeldtomaturityInvestmentsCategoryMember_13101ABE816E23212B631AEC02FE5D4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_720B236F2751DA6E21FC1AEC02FF58E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B" xlink:to="loc_ifrs-full_FinancialAssets_720B236F2751DA6E21FC1AEC02FF58E7" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ShortTermInvestmentEffectiveInterestRate" xlink:label="loc_oncyf_ShortTermInvestmentEffectiveInterestRate_59A4717C67EE0F4D86B71AEC02FF3813" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B" xlink:to="loc_oncyf_ShortTermInvestmentEffectiveInterestRate_59A4717C67EE0F4D86B71AEC02FF3813" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/Commitments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_8149EA20DE88DD602705F2828B0A382D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_FDEDE0353411E07E7F4EF2828B09E1F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_8149EA20DE88DD602705F2828B0A382D" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_FDEDE0353411E07E7F4EF2828B09E1F3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_2F077569D2F40DCFE8B7F2828B097D36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_FDEDE0353411E07E7F4EF2828B09E1F3" xlink:to="loc_ifrs-full_MaturityAxis_2F077569D2F40DCFE8B7F2828B097D36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_2F077569D2F40DCFE8B7F2828B097D36" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_2F077569D2F40DCFE8B7F2828B097D36" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_3FC6B46C00951C403485F2828B0AD4B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_3FC6B46C00951C403485F2828B0AD4B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_0866F12E219FB302D0CBF2828B0A7772" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_0866F12E219FB302D0CBF2828B0A7772" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_4838EF5D9934C7DCD28AF2828B0AAD46" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_4838EF5D9934C7DCD28AF2828B0AAD46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_49AD26E04553910EA50FF2828B0ADD8B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_49AD26E04553910EA50FF2828B0ADD8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_989F86529337D2E9FB21F2828B0AE8D8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_989F86529337D2E9FB21F2828B0AE8D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" xlink:label="loc_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease_01F578EF883B5BE184F1F2828B0A98EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_8149EA20DE88DD602705F2828B0A382D" xlink:to="loc_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease_01F578EF883B5BE184F1F2828B0A98EA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Statement1LineItems" xlink:label="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Statement1Table" xlink:label="loc_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="loc_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_67E8D578FBCD4A71C8993F4B2FF08477" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192" xlink:to="loc_oncyf_SaleOfStockAxis_67E8D578FBCD4A71C8993F4B2FF08477" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_604769D8094B5BBB5A5B3F4B2FF045C0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_67E8D578FBCD4A71C8993F4B2FF08477" xlink:to="loc_oncyf_SaleOfStockDomain_604769D8094B5BBB5A5B3F4B2FF045C0_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_604769D8094B5BBB5A5B3F4B2FF045C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_67E8D578FBCD4A71C8993F4B2FF08477" xlink:to="loc_oncyf_SaleOfStockDomain_604769D8094B5BBB5A5B3F4B2FF045C0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_BF7A9F15D6E95C44EB903F4B2FF05809" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_604769D8094B5BBB5A5B3F4B2FF045C0" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_BF7A9F15D6E95C44EB903F4B2FF05809" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_5FFDB8DB350C6C44EC913F4B2FF04EFB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_604769D8094B5BBB5A5B3F4B2FF045C0" xlink:to="loc_oncyf_SharesPublicOfferingMember_5FFDB8DB350C6C44EC913F4B2FF04EFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_3A7AB543C8CE64FB297A3F4B2FF01534" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:to="loc_ifrs-full_ProfitLoss_3A7AB543C8CE64FB297A3F4B2FF01534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_E80D3A04EECEA7F2A5603F4B2FF04C81" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_E80D3A04EECEA7F2A5603F4B2FF04C81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_49ED0C51F2F8605E90FF3F4B2FF0114D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_49ED0C51F2F8605E90FF3F4B2FF0114D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_483746CDE6FF8CE15DE33F4B2FF04864" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_483746CDE6FF8CE15DE33F4B2FF04864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_2A34A11C040E4BB95A9D3F4B2FF068E1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_2A34A11C040E4BB95A9D3F4B2FF068E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_DB785FA1777C42B2FA9D3F4B2FF1B25A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_DB785FA1777C42B2FA9D3F4B2FF1B25A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4330616D3763897795663F4B2FF16368" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4330616D3763897795663F4B2FF16368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_4440D1FF9AADBA9EBECA3F4B2FF145F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:to="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_4440D1FF9AADBA9EBECA3F4B2FF145F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_CC7A5F118EAEE5CFC8543F4B2FF1188E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_CC7A5F118EAEE5CFC8543F4B2FF1188E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_26CB2CE5B91C0D46D1043F4B2FF14ACF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_26CB2CE5B91C0D46D1043F4B2FF14ACF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_F88D1CC494D18BBEF9C93F4B2FF1731E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_F88D1CC494D18BBEF9C93F4B2FF1731E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_C9EFCA6A7415DCBCD2F03F4B2FF1B584" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_C9EFCA6A7415DCBCD2F03F4B2FF1B584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_EF3AA6FD808E257D9FB63F4B2FF1CFAA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_EF3AA6FD808E257D9FB63F4B2FF1CFAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1D3E2E681AE7C37284B63F4B2FF19F11" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1D3E2E681AE7C37284B63F4B2FF19F11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_B3364E2776BD965828003F4B2FF1A366" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="loc_ifrs-full_CashAndCashEquivalents_B3364E2776BD965828003F4B2FF1A366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_FF03400CCFDB3D7576B73F4B2FF2663A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_FF03400CCFDB3D7576B73F4B2FF2663A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_03C8D6DE211237C52048F724F71324D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_03C8D6DE211237C52048F724F71324D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_03C8D6DE211237C52048F724F71324D3" xlink:to="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_03C8D6DE211237C52048F724F71324D3" xlink:to="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_B7D571B80B6FCB3E2E35F724F7149405" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:to="loc_ifrs-full_IssuedCapitalMember_B7D571B80B6FCB3E2E35F724F7149405" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_B09E3D30E2B14C21636DF724F7140395" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:to="loc_oncyf_WarrantsMember_B09E3D30E2B14C21636DF724F7140395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_C9B89C0480327A560702F724F714C1E5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:to="loc_ifrs-full_SharePremiumMember_C9B89C0480327A560702F724F714C1E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_045F82EF94C642E87833F724F714B11D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_045F82EF94C642E87833F724F714B11D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_376A3C10CC6B6C67DBE6F724F714C9FA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:to="loc_ifrs-full_RetainedEarningsMember_376A3C10CC6B6C67DBE6F724F714C9FA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_D74EACAD1F0FFA778956F724F714AE9D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635" xlink:to="loc_oncyf_SaleOfStockAxis_D74EACAD1F0FFA778956F724F714AE9D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_A1FF55ACAE765DBF6D11F724F714C18B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_D74EACAD1F0FFA778956F724F714AE9D" xlink:to="loc_oncyf_SaleOfStockDomain_A1FF55ACAE765DBF6D11F724F714C18B_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_A1FF55ACAE765DBF6D11F724F714C18B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_D74EACAD1F0FFA778956F724F714AE9D" xlink:to="loc_oncyf_SaleOfStockDomain_A1FF55ACAE765DBF6D11F724F714C18B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember_919EAB58EBF8632C029BF724F7145E44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_A1FF55ACAE765DBF6D11F724F714C18B" xlink:to="loc_oncyf_SharesUnderSharePurchaseAgreementMember_919EAB58EBF8632C029BF724F7145E44" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_78ACCF9F9D8D9393D194F724F714597C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_A1FF55ACAE765DBF6D11F724F714C18B" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_78ACCF9F9D8D9393D194F724F714597C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_35715F1A8332BEB4B818F724F714B3FD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_A1FF55ACAE765DBF6D11F724F714C18B" xlink:to="loc_oncyf_SharesPublicOfferingMember_35715F1A8332BEB4B818F724F714B3FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_7C08E7DE83135CE43464F724F7148AC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_ifrs-full_Equity_7C08E7DE83135CE43464F724F7148AC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_93DD86EB680123E3FEB3F724F714F592" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_ifrs-full_ComprehensiveIncome_93DD86EB680123E3FEB3F724F714F592" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IssueOfEquityShareAgreement" xlink:label="loc_oncyf_IssueOfEquityShareAgreement_C288D310914ED9FDB907F724F714D194" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_oncyf_IssueOfEquityShareAgreement_C288D310914ED9FDB907F724F714D194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_10D1F8AF96632C93CAEFF724F714C4AA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_ifrs-full_IssueOfEquity_10D1F8AF96632C93CAEFF724F714C4AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_0A28DE08B5E2E95399DAF724F71528D7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_0A28DE08B5E2E95399DAF724F71528D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_CC9EF5837F561F27B916F724F715C4E0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_CC9EF5837F561F27B916F724F715C4E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_84EF5032F15E6BF1A1F6F724F715CD87" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_84EF5032F15E6BF1A1F6F724F715CD87" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_C071EF18F2EECD74F16B1AEC02A24BF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_C071EF18F2EECD74F16B1AEC02A24BF6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-full_CounterpartiesAxis_A15292E8A1314608B5E51AEC02A26300" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_C071EF18F2EECD74F16B1AEC02A24BF6" xlink:to="loc_ifrs-full_CounterpartiesAxis_A15292E8A1314608B5E51AEC02A26300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_A15292E8A1314608B5E51AEC02A26300" xlink:to="loc_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_A15292E8A1314608B5E51AEC02A26300" xlink:to="loc_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SYNSORBMember" xlink:label="loc_oncyf_SYNSORBMember_ECCA39B4512AB8A0F5B91AEC02A21154" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE" xlink:to="loc_oncyf_SYNSORBMember_ECCA39B4512AB8A0F5B91AEC02A21154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_F53DDAF258928FC96DAC1AEC02A2C755" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:to="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_F53DDAF258928FC96DAC1AEC02A2C755" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_FC774DD9975E6D0DF2811AEC02A2B433" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_FC774DD9975E6D0DF2811AEC02A2B433" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_B14AE2A84E42BF4092F51AEC02A2EEFF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_B14AE2A84E42BF4092F51AEC02A2EEFF" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_B789B3922626C2DE13E11AEC02A210AA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_B789B3922626C2DE13E11AEC02A210AA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ClassofWarrantorRight1LineItems" xlink:label="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ClassofWarrantorRight1Table" xlink:label="loc_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:to="loc_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MilestoneAxis" xlink:label="loc_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8" xlink:to="loc_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MilestoneDomain" xlink:label="loc_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E" xlink:to="loc_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MilestoneDomain" xlink:label="loc_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E" xlink:to="loc_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MilestoneOneMember" xlink:label="loc_oncyf_MilestoneOneMember_8809401FEA66750CF0A020C2C66CA95C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E" xlink:to="loc_oncyf_MilestoneOneMember_8809401FEA66750CF0A020C2C66CA95C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MilestoneTwoMember" xlink:label="loc_oncyf_MilestoneTwoMember_B82B6EF5DBDEB0A01FF220C2C66CD5D3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E" xlink:to="loc_oncyf_MilestoneTwoMember_B82B6EF5DBDEB0A01FF220C2C66CD5D3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantPurchaseAgreement" xlink:label="loc_oncyf_WarrantPurchaseAgreement_9F41C45A650C64D179E120C2C66C31F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:to="loc_oncyf_WarrantPurchaseAgreement_9F41C45A650C64D179E120C2C66C31F0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharePricePremiumPercent" xlink:label="loc_oncyf_SharePricePremiumPercent_81A423743992B05FD0F720C2C66CBF6F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:to="loc_oncyf_SharePricePremiumPercent_81A423743992B05FD0F720C2C66CBF6F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WeightedAverageClosingPriceDuration" xlink:label="loc_oncyf_WeightedAverageClosingPriceDuration_61570DEB8B25AB43FB3B20C2C66C2233" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:to="loc_oncyf_WeightedAverageClosingPriceDuration_61570DEB8B25AB43FB3B20C2C66C2233" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_NumberofPatients" xlink:label="loc_oncyf_NumberofPatients_797BF9D2ED73EF104BCF20C2C66C3E3F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:to="loc_oncyf_NumberofPatients_797BF9D2ED73EF104BCF20C2C66C3E3F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_RighttoCallWarrantMilestoneOneTerm" xlink:label="loc_oncyf_RighttoCallWarrantMilestoneOneTerm_31CBF5FBCDC0913D825F20C2C66C1B0A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:to="loc_oncyf_RighttoCallWarrantMilestoneOneTerm_31CBF5FBCDC0913D825F20C2C66C1B0A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformationDocument" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRiskType1LineItems" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRisk1Table" xlink:label="loc_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A" xlink:to="loc_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRiskType1Axis" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59" xlink:to="loc_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRiskType1Domain" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRiskType1Domain" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SupplierConcentrationRisk1Member" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_882CACBFC4FFEAD20CE1C8041F83C494" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3" xlink:to="loc_oncyf_SupplierConcentrationRisk1Member_882CACBFC4FFEAD20CE1C8041F83C494" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRiskNumber" xlink:label="loc_oncyf_ConcentrationRiskNumber_7C1D09E01BA5EBC50CBEC8041F83F577" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A" xlink:to="loc_oncyf_ConcentrationRiskNumber_7C1D09E01BA5EBC50CBEC8041F83F577" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_4976FFF7234A3347E2BDE10D70DD7158" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF" xlink:to="loc_ifrs-full_TypesOfRisksAxis_4976FFF7234A3347E2BDE10D70DD7158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_4976FFF7234A3347E2BDE10D70DD7158" xlink:to="loc_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_4976FFF7234A3347E2BDE10D70DD7158" xlink:to="loc_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_E944AB366FC39ECF7795E10D70DD11C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE" xlink:to="loc_ifrs-full_CurrencyRiskMember_E944AB366FC39ECF7795E10D70DD11C6" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Currency1Axis" xlink:label="loc_oncyf_Currency1Axis_EE14F3C7F93838ABCF4FE10D70DD0AF8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF" xlink:to="loc_oncyf_Currency1Axis_EE14F3C7F93838ABCF4FE10D70DD0AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_F17CF689B2C2BC1AB349E10D70DD1C6B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_Currency1Axis_EE14F3C7F93838ABCF4FE10D70DD0AF8" xlink:to="loc_currency_AllCurrenciesDomain_F17CF689B2C2BC1AB349E10D70DD1C6B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_F17CF689B2C2BC1AB349E10D70DD1C6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_Currency1Axis_EE14F3C7F93838ABCF4FE10D70DD0AF8" xlink:to="loc_currency_AllCurrenciesDomain_F17CF689B2C2BC1AB349E10D70DD1C6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_B92863666E4728EC96E0E10D70DD2B99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_F17CF689B2C2BC1AB349E10D70DD1C6B" xlink:to="loc_currency_USD_B92863666E4728EC96E0E10D70DD2B99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_0ED5E843BB8F8638A8D0E10D70DD4DD8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_F17CF689B2C2BC1AB349E10D70DD1C6B" xlink:to="loc_currency_GBP_0ED5E843BB8F8638A8D0E10D70DD4DD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_DC23A0F0E504E295A2D5E10D70DDBA8E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_F17CF689B2C2BC1AB349E10D70DD1C6B" xlink:to="loc_currency_EUR_DC23A0F0E504E295A2D5E10D70DDBA8E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_B58767F2FFFA79FE1DE8E10D70DEAD3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_B58767F2FFFA79FE1DE8E10D70DEAD3B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_1DE952282B60B653D7D7E10D70DE5D95" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_1DE952282B60B653D7D7E10D70DE5D95" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Currency1LineItems" xlink:label="loc_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Currency1Table" xlink:label="loc_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:to="loc_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Currency1Axis" xlink:label="loc_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205" xlink:to="loc_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22" xlink:to="loc_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22" xlink:to="loc_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_04DFBF375FC64C3E7A872571A5A08467" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:to="loc_currency_USD_04DFBF375FC64C3E7A872571A5A08467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_2C8316D63E3560BCD3BA2571A5A0E054" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:to="loc_currency_GBP_2C8316D63E3560BCD3BA2571A5A0E054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_30804A3CF9AE50B93B3E2571A5A00586" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:to="loc_currency_EUR_30804A3CF9AE50B93B3E2571A5A00586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_54261128838DECF017F02571A5A00C86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:to="loc_ifrs-full_CashAndCashEquivalents_54261128838DECF017F02571A5A00C86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentReceivablesFromContractsWithCustomers" xlink:label="loc_ifrs-full_CurrentReceivablesFromContractsWithCustomers_A7C16D9BAE89CA761A7C2571A5A07ED1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:to="loc_ifrs-full_CurrentReceivablesFromContractsWithCustomers_A7C16D9BAE89CA761A7C2571A5A07ED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_AD82FE3B91729A7EAF142571A5A0E593" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_AD82FE3B91729A7EAF142571A5A0E593" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_BalanceHeldInForeignCurrencyNet" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_0F861A88888584983EC22571A5A088D3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:to="loc_oncyf_BalanceHeldInForeignCurrencyNet_0F861A88888584983EC22571A5A088D3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_472F35AF4B9575852FB0E10D70ED9F02" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_22C95833D71CB0D6AED1E10D70ECCAD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_472F35AF4B9575852FB0E10D70ED9F02" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_22C95833D71CB0D6AED1E10D70ECCAD0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_2E563E3ECF78D7659184E10D70EC1AF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_22C95833D71CB0D6AED1E10D70ECCAD0" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_2E563E3ECF78D7659184E10D70EC1AF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_2E563E3ECF78D7659184E10D70EC1AF7" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_2E563E3ECF78D7659184E10D70EC1AF7" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_6FF1943E41984583B2E4E10D70ED72E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:to="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_6FF1943E41984583B2E4E10D70ED72E4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_EC9445383F455C09F1ADE10D70EDF155" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_EC9445383F455C09F1ADE10D70EDF155" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_InvestmentTaxCreditsMember" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_E5A47591CAE8F0A5CC24E10D70EDD546" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:to="loc_oncyf_InvestmentTaxCreditsMember_E5A47591CAE8F0A5CC24E10D70EDD546" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:label="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_C55B7398F4215EA18C0AE10D70ED4188" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:to="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_C55B7398F4215EA18C0AE10D70ED4188" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ShareIssueCostsMember" xlink:label="loc_oncyf_ShareIssueCostsMember_175AB8B1B42314C91831E10D70EDF8E5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:to="loc_oncyf_ShareIssueCostsMember_175AB8B1B42314C91831E10D70EDF8E5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_D30C192EFDECD7CE0874E10D70EDC7B8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:to="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_D30C192EFDECD7CE0874E10D70EDC7B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_4E52ABBF375345F9FD78E10D70ED77AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_472F35AF4B9575852FB0E10D70ED9F02" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_4E52ABBF375345F9FD78E10D70ED77AB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_F26CB551F19CC812C9FCF2828AF460E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_F26CB551F19CC812C9FCF2828AF460E8" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_5DB9EE2BA3AFD6D60013F2828AF37C93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE" xlink:to="loc_ifrs-full_MaturityAxis_5DB9EE2BA3AFD6D60013F2828AF37C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_5DB9EE2BA3AFD6D60013F2828AF37C93" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_5DB9EE2BA3AFD6D60013F2828AF37C93" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentySixMember" xlink:label="loc_oncyf_TwentyTwentySixMember_12ED0A6AC1AF61A8B44FF2828AF3D1F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyTwentySixMember_12ED0A6AC1AF61A8B44FF2828AF3D1F5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentySevenMember" xlink:label="loc_oncyf_TwentyTwentySevenMember_A1EEAFBC16D1617DFF40F2828AF38428" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyTwentySevenMember_A1EEAFBC16D1617DFF40F2828AF38428" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyNineMember" xlink:label="loc_oncyf_TwentyTwentyNineMember_A35705262A2E3718584AF2828AF3B821" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyTwentyNineMember_A35705262A2E3718584AF2828AF3B821" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyMember" xlink:label="loc_oncyf_TwentyThirtyMember_B0D9FF8A79E281167036F2828AF35AFD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtyMember_B0D9FF8A79E281167036F2828AF35AFD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyOneMember" xlink:label="loc_oncyf_TwentyThirtyOneMember_59F6E6F17590EB2D08C0F2828AF35465" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtyOneMember_59F6E6F17590EB2D08C0F2828AF35465" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyTwoMember" xlink:label="loc_oncyf_TwentyThirtyTwoMember_F31E20799D9C5711E8FEF2828AF4FBFA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtyTwoMember_F31E20799D9C5711E8FEF2828AF4FBFA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyThreeMember" xlink:label="loc_oncyf_TwentyThirtyThreeMember_922C0D1D5334453A79DDF2828AF4BEDB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtyThreeMember_922C0D1D5334453A79DDF2828AF4BEDB" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyFourMember" xlink:label="loc_oncyf_TwentyThirtyFourMember_D4A65F09A07CFAFA6118F2828AF44370" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtyFourMember_D4A65F09A07CFAFA6118F2828AF44370" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyFiveMember" xlink:label="loc_oncyf_TwentyThirtyFiveMember_F7DDCCB0928F90C1392DF2828AF46B04" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtyFiveMember_F7DDCCB0928F90C1392DF2828AF46B04" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtySixMember" xlink:label="loc_oncyf_TwentyThirtySixMember_D0BDC12167D58057B7FAF2828AF4184B" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtySixMember_D0BDC12167D58057B7FAF2828AF4184B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtySevenMember" xlink:label="loc_oncyf_TwentyThirtySevenMember_5EC92037CE7883FBDFD1F2D64EBDFFE1" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtySevenMember_5EC92037CE7883FBDFD1F2D64EBDFFE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_A0D1440383EA16A39829F2828AF4B8A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_A0D1440383EA16A39829F2828AF4B8A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_A0D1440383EA16A39829F2828AF4B8A9" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_A0D1440383EA16A39829F2828AF4B8A9" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_E40FA1CBF8E6DBC046CEF2828AF40B32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_E40FA1CBF8E6DBC046CEF2828AF40B32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_001564CDD4F94D5DB818F2828AF4D3FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_F26CB551F19CC812C9FCF2828AF460E8" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_001564CDD4F94D5DB818F2828AF4D3FC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_204000747528CC9A913CF2828AEDCF73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1304CC760014AC1F0C18F2828AEB5A86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_204000747528CC9A913CF2828AEDCF73" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1304CC760014AC1F0C18F2828AEB5A86" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_76960C4F6777ACDFFF2BF2828AEB9A17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1304CC760014AC1F0C18F2828AEB5A86" xlink:to="loc_ifrs-full_MaturityAxis_76960C4F6777ACDFFF2BF2828AEB9A17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_76960C4F6777ACDFFF2BF2828AEB9A17" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_76960C4F6777ACDFFF2BF2828AEB9A17" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyMember" xlink:label="loc_oncyf_TwentyTwentyMember_A6871FB6FE6D1174AA69F2828AECE44A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyMember_A6871FB6FE6D1174AA69F2828AECE44A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyOneMember" xlink:label="loc_oncyf_TwentyTwentyOneMember_A566C4E1528EE21EEA25F2828AEC93E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyOneMember_A566C4E1528EE21EEA25F2828AEC93E9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyTwoMember" xlink:label="loc_oncyf_TwentyTwentyTwoMember_FBCFCD9040ED00D07251F2828AEC68F5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyTwoMember_FBCFCD9040ED00D07251F2828AEC68F5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyThreeMember" xlink:label="loc_oncyf_TwentyTwentyThreeMember_B0483F97ED97EA19567FF2828AEC107E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyThreeMember_B0483F97ED97EA19567FF2828AEC107E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyFourMember" xlink:label="loc_oncyf_TwentyTwentyFourMember_FDD0FCC8FC7023367863F2828AECC62D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyFourMember_FDD0FCC8FC7023367863F2828AECC62D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyFiveMember" xlink:label="loc_oncyf_TwentyTwentyFiveMember_3979DA2281FCD9F0E11BF2828AEC51AE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyFiveMember_3979DA2281FCD9F0E11BF2828AEC51AE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentySixMember" xlink:label="loc_oncyf_TwentyTwentySixMember_2DF474F1E3898D3284E4F2828AEC9F86" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentySixMember_2DF474F1E3898D3284E4F2828AEC9F86" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentySevenMember" xlink:label="loc_oncyf_TwentyTwentySevenMember_C75BBC65BE2C9556D65AF2828AECAE28" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentySevenMember_C75BBC65BE2C9556D65AF2828AECAE28" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyEightMember" xlink:label="loc_oncyf_TwentyTwentyEightMember_7282DCA9F5ED5512676FF2828AEC8722" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyEightMember_7282DCA9F5ED5512676FF2828AEC8722" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyNineMember" xlink:label="loc_oncyf_TwentyTwentyNineMember_E359EFE3F0E37B752AA9F2828AEC7D1F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyNineMember_E359EFE3F0E37B752AA9F2828AEC7D1F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyMember" xlink:label="loc_oncyf_TwentyThirtyMember_99D563E9AACFA2423EFEF2828AEC4765" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtyMember_99D563E9AACFA2423EFEF2828AEC4765" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyOneMember" xlink:label="loc_oncyf_TwentyThirtyOneMember_C417BBA549E34C4A1204F2828AEC8EB3" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtyOneMember_C417BBA549E34C4A1204F2828AEC8EB3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyTwoMember" xlink:label="loc_oncyf_TwentyThirtyTwoMember_CA92C6DA1D55DA50D21DF2828AEDD20C" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtyTwoMember_CA92C6DA1D55DA50D21DF2828AEDD20C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyThreeMember" xlink:label="loc_oncyf_TwentyThirtyThreeMember_5BC9C836E10F22F05518F2828AED8499" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtyThreeMember_5BC9C836E10F22F05518F2828AED8499" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyFourMember" xlink:label="loc_oncyf_TwentyThirtyFourMember_67E2E05204466CF341A2F2828AEDC4B4" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtyFourMember_67E2E05204466CF341A2F2828AEDC4B4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyFiveMember" xlink:label="loc_oncyf_TwentyThirtyFiveMember_E5286152BABFB2CBEA49F2828AED5809" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtyFiveMember_E5286152BABFB2CBEA49F2828AED5809" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtySixMember" xlink:label="loc_oncyf_TwentyThirtySixMember_65865EB5BFFF84802C54F2828AED8339" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtySixMember_65865EB5BFFF84802C54F2828AED8339" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtySevenMember" xlink:label="loc_oncyf_TwentyThirtySevenMember_E9F9D5265D3BF5D24BEDF2D6D41E5402" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtySevenMember_E9F9D5265D3BF5D24BEDF2D6D41E5402" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_3C775D1787DA59D20894F2828AED327E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1304CC760014AC1F0C18F2828AEB5A86" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_3C775D1787DA59D20894F2828AED327E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_6920923EEACD0D1B9D39F2828AEDFD17_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_3C775D1787DA59D20894F2828AED327E" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_6920923EEACD0D1B9D39F2828AEDFD17_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_6920923EEACD0D1B9D39F2828AEDFD17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_3C775D1787DA59D20894F2828AED327E" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_6920923EEACD0D1B9D39F2828AEDFD17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxCreditsMember" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_308D3002B3863DCB282FF2828AED0DE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_6920923EEACD0D1B9D39F2828AEDFD17" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_308D3002B3863DCB282FF2828AED0DE4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_58C8482A59E4B418C465F2828AEDC721" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_6920923EEACD0D1B9D39F2828AEDFD17" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_58C8482A59E4B418C465F2828AEDC721" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_D37E4DE42DE767533ECFF2828AEDD7A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_204000747528CC9A913CF2828AEDCF73" xlink:to="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_D37E4DE42DE767533ECFF2828AEDD7A3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_OtherExpensesAndAdjustmentsTable" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IncomeStatementLocation1Axis" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IncomeStatementLocation1Domain" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IncomeStatementLocation1Domain" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ResearchAndDevelopmentMember" xlink:label="loc_oncyf_ResearchAndDevelopmentMember_D9C42B4CE655BCC54544E33E939F54B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9" xlink:to="loc_oncyf_ResearchAndDevelopmentMember_D9C42B4CE655BCC54544E33E939F54B5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_OperatingExpensesMember" xlink:label="loc_oncyf_OperatingExpensesMember_9339A330464CDF91D914E33E939FBD7E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9" xlink:to="loc_oncyf_OperatingExpensesMember_9339A330464CDF91D914E33E939FBD7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_82109F2ACF7818EF9AA6E33E93A0CFB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_82109F2ACF7818EF9AA6E33E93A0CFB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_1BF2F47F72CF6766DCD3E33E93A04BA9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_1BF2F47F72CF6766DCD3E33E93A04BA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ACB44C7EBBB76CA21745E33E93A0F416" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ACB44C7EBBB76CA21745E33E93A0F416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense_C942044F91480CA91A70E33E93A0718B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:to="loc_ifrs-full_AmortisationExpense_C942044F91480CA91A70E33E93A0718B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense" xlink:label="loc_ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense_75622CDCD9E2CD467704E33E93A0E68E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:to="loc_ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense_75622CDCD9E2CD467704E33E93A0E68E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7EBAA235773A6D6198972047BAFAD085" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7EBAA235773A6D6198972047BAFAD085" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_DD778459E0C2B1D0C8182047BAF9CB08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_DD778459E0C2B1D0C8182047BAF9CB08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_DD778459E0C2B1D0C8182047BAF9CB08" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_DD778459E0C2B1D0C8182047BAF9CB08" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MedicalEquipmentMember" xlink:label="loc_oncyf_MedicalEquipmentMember_A27ABF1FA7BDC8ACC8572047BAFA900A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:to="loc_oncyf_MedicalEquipmentMember_A27ABF1FA7BDC8ACC8572047BAFA900A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_87C76C8ABF4E14FC52912047BAFA9D22" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:to="loc_ifrs-full_ComputerEquipmentMember_87C76C8ABF4E14FC52912047BAFA9D22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FixturesAndFittingsMember" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_DBAF2A6B05BCB4DB6FA32047BAFACEAB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_DBAF2A6B05BCB4DB6FA32047BAFACEAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_79877C206BB6799BA49D2047BAFA450C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:to="loc_ifrs-full_OfficeEquipmentMember_79877C206BB6799BA49D2047BAFA450C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_DCD2E1C066C6B50C69E22047BAFA82FD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_DCD2E1C066C6B50C69E22047BAFA82FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506C87E19EF1BA40BC192047BAFA7752" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506C87E19EF1BA40BC192047BAFA7752" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506C87E19EF1BA40BC192047BAFA7752" xlink:to="loc_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506C87E19EF1BA40BC192047BAFA7752" xlink:to="loc_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_10993A50FFE97AF7981C2047BAFA3B1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_10993A50FFE97AF7981C2047BAFA3B1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_D7F454BD229AD37201E420AFEDC85B26" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_D7F454BD229AD37201E420AFEDC85B26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7EBAA235773A6D6198972047BAFAD085" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_A0E0C1AC278BDDCAD39A2047BAFAACB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_A0E0C1AC278BDDCAD39A2047BAFAACB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_CF1FD2CC56E070EBD5A72047BAFA6CD1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_CF1FD2CC56E070EBD5A72047BAFA6CD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_AB32D376AFDCFDF48B1D2047BAFA1C93" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_AB32D376AFDCFDF48B1D2047BAFA1C93" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_48D0622AD92D352D51FB2046781AD419" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5C32566CD34C0F4FB29820467819F98C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_48D0622AD92D352D51FB2046781AD419" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5C32566CD34C0F4FB29820467819F98C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_082F668E1ED0B26F88262046781A4371" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5C32566CD34C0F4FB29820467819F98C" xlink:to="loc_ifrs-full_RangeAxis_082F668E1ED0B26F88262046781A4371" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_082F668E1ED0B26F88262046781A4371" xlink:to="loc_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_082F668E1ED0B26F88262046781A4371" xlink:to="loc_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_C52447AEBB7F76B73C932046781A4368" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED" xlink:to="loc_ifrs-full_BottomOfRangeMember_C52447AEBB7F76B73C932046781A4368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_71F83A92D45ABD0374A62046781A91A1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED" xlink:to="loc_ifrs-full_TopOfRangeMember_71F83A92D45ABD0374A62046781A91A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D547FE7F39AC39C8EA312046781A1622" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5C32566CD34C0F4FB29820467819F98C" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D547FE7F39AC39C8EA312046781A1622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_04ABC0E5384FEDF00A802046781A9652_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D547FE7F39AC39C8EA312046781A1622" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_04ABC0E5384FEDF00A802046781A9652_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_04ABC0E5384FEDF00A802046781A9652" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D547FE7F39AC39C8EA312046781A1622" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_04ABC0E5384FEDF00A802046781A9652" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_RestrictedShareUnitsMember" xlink:label="loc_oncyf_RestrictedShareUnitsMember_ECA435AF33BA6E3781C82046781A2E25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_04ABC0E5384FEDF00A802046781A9652" xlink:to="loc_oncyf_RestrictedShareUnitsMember_ECA435AF33BA6E3781C82046781A2E25" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_PerformanceShareUnitsMember" xlink:label="loc_oncyf_PerformanceShareUnitsMember_A43EA4C5C77A8399B1942046781A63BA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_04ABC0E5384FEDF00A802046781A9652" xlink:to="loc_oncyf_PerformanceShareUnitsMember_A43EA4C5C77A8399B1942046781A63BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_551390C13971680DDD1D2046781A6736" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_04ABC0E5384FEDF00A802046781A9652" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_551390C13971680DDD1D2046781A6736" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_8EEEECAB5981F1502F162046781AC7D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_48D0622AD92D352D51FB2046781AD419" xlink:to="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_8EEEECAB5981F1502F162046781AC7D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_BEF69B21E2A1C7FDFA462046781AD1DE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_48D0622AD92D352D51FB2046781AD419" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_BEF69B21E2A1C7FDFA462046781AD1DE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_29F16755F9574BC7317F1AEC02BD6C39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_29F16755F9574BC7317F1AEC02BD6C39" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D862FFD738E94710EB8A1AEC02BDFF7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_29F16755F9574BC7317F1AEC02BD6C39" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D862FFD738E94710EB8A1AEC02BDFF7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D862FFD738E94710EB8A1AEC02BDFF7D" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D862FFD738E94710EB8A1AEC02BDFF7D" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_RestrictedShareUnitsMember" xlink:label="loc_oncyf_RestrictedShareUnitsMember_14970D45A3088A3A7D521AEC02BD90C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182" xlink:to="loc_oncyf_RestrictedShareUnitsMember_14970D45A3088A3A7D521AEC02BD90C9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_PerformanceShareUnitsMember" xlink:label="loc_oncyf_PerformanceShareUnitsMember_F2F19594E66289A945101AEC02BD4EA5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182" xlink:to="loc_oncyf_PerformanceShareUnitsMember_F2F19594E66289A945101AEC02BD4EA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_31EDB7151FFBB02702991AEC02BD7780" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_31EDB7151FFBB02702991AEC02BD7780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_90AFE20F770A60DE69111AEC02BD6C91" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_90AFE20F770A60DE69111AEC02BD6C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_5DB1C742558477EE5B261AEC02BD56F8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_5DB1C742558477EE5B261AEC02BD56F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_B6E5E032930E5161EE701AEC02BE6FB2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_B6E5E032930E5161EE701AEC02BE6FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_245082FC8D924B5108F21AFF94565908" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_245082FC8D924B5108F21AFF94565908" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_7D1BA527A2094093C0C0F2828B28F517" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_7D1BA527A2094093C0C0F2828B28F517" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_7D1BA527A2094093C0C0F2828B28F517" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeOneMember" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_CA8FD4E9B7AE35E9E582F2828B286A89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:to="loc_oncyf_ExercisePriceRangeOneMember_CA8FD4E9B7AE35E9E582F2828B286A89" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeTwoMember" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_35A657991535A6766568F2828B288CD1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:to="loc_oncyf_ExercisePriceRangeTwoMember_35A657991535A6766568F2828B288CD1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeThreeMember" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_CC6A86863A308352989DF2828B28A0B1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:to="loc_oncyf_ExercisePriceRangeThreeMember_CC6A86863A308352989DF2828B28A0B1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeFourMember" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_D85FD74D89FB6900AA2CF2828B2865CE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:to="loc_oncyf_ExercisePriceRangeFourMember_D85FD74D89FB6900AA2CF2828B2865CE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeFiveMember" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_E304FDF1C3FF4BB8B366F2828B28DA93" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:to="loc_oncyf_ExercisePriceRangeFiveMember_E304FDF1C3FF4BB8B366F2828B28DA93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_A60D04C13D1790DAE651F2828B29B79A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_A60D04C13D1790DAE651F2828B29B79A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_05349B8248F66A5BFC4AF2828B29AECA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_05349B8248F66A5BFC4AF2828B29AECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_4E543325854729012840F2828B296027" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_4E543325854729012840F2828B296027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_899DA1861668D3D8942FF2828B290263" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_899DA1861668D3D8942FF2828B290263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_1422826ACD0CE25DB530F2828B295D79" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_1422826ACD0CE25DB530F2828B295D79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_8658DA0E1656EB55385AF2828B2ABC01" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_8658DA0E1656EB55385AF2828B2ABC01" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_0DC9A68DBB761C83A3CFF2828B290C02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_0DC9A68DBB761C83A3CFF2828B290C02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_BB72133B41441779ED77F2828B2AE6A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D" xlink:to="loc_ifrs-full_RangeAxis_BB72133B41441779ED77F2828B2AE6A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2AC7F71AAC6C1D1C864BF2828B2A331E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_BB72133B41441779ED77F2828B2AE6A9" xlink:to="loc_ifrs-full_RangesMember_2AC7F71AAC6C1D1C864BF2828B2A331E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2AC7F71AAC6C1D1C864BF2828B2A331E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_BB72133B41441779ED77F2828B2AE6A9" xlink:to="loc_ifrs-full_RangesMember_2AC7F71AAC6C1D1C864BF2828B2A331E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_486342F4DEBB1F915345F2828B2A940F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2AC7F71AAC6C1D1C864BF2828B2A331E" xlink:to="loc_ifrs-full_BottomOfRangeMember_486342F4DEBB1F915345F2828B2A940F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_A0B5392BB3070E82F72BF2828B2A63C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2AC7F71AAC6C1D1C864BF2828B2A331E" xlink:to="loc_ifrs-full_TopOfRangeMember_A0B5392BB3070E82F72BF2828B2A63C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions_EF3C8FCDC56637C90FE1F2828B2A973B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_8658DA0E1656EB55385AF2828B2ABC01" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions_EF3C8FCDC56637C90FE1F2828B2A973B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_E9F43D5F01E15999AED5F2828B430955" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_E9F43D5F01E15999AED5F2828B430955" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_BAFB72D406F4BCF20640F2828B430510" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_E9F43D5F01E15999AED5F2828B430955" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_BAFB72D406F4BCF20640F2828B430510" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_842BC0026BDE5EA399A5F2828B43687E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_BAFB72D406F4BCF20640F2828B430510" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_842BC0026BDE5EA399A5F2828B43687E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_842BC0026BDE5EA399A5F2828B43687E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_BAFB72D406F4BCF20640F2828B430510" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_842BC0026BDE5EA399A5F2828B43687E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_DCBB376752E4B4E3163DF2828B43654D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_842BC0026BDE5EA399A5F2828B43687E" xlink:to="loc_ifrs-full_IssuedCapitalMember_DCBB376752E4B4E3163DF2828B43654D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_6DF30158075EBAB2BB53F2828B43BDA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_842BC0026BDE5EA399A5F2828B43687E" xlink:to="loc_oncyf_WarrantsMember_6DF30158075EBAB2BB53F2828B43BDA0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_9149420C8FE277B1F52DF2828B43A1FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_E9F43D5F01E15999AED5F2828B430955" xlink:to="loc_oncyf_SaleOfStockAxis_9149420C8FE277B1F52DF2828B43A1FC" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_D906DA826F415FD60CFFF2828B437DA1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_9149420C8FE277B1F52DF2828B43A1FC" xlink:to="loc_oncyf_SaleOfStockDomain_D906DA826F415FD60CFFF2828B437DA1_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_D906DA826F415FD60CFFF2828B437DA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_9149420C8FE277B1F52DF2828B43A1FC" xlink:to="loc_oncyf_SaleOfStockDomain_D906DA826F415FD60CFFF2828B437DA1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember_9ED32AF51DE6B0802342F2828B43A864" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_D906DA826F415FD60CFFF2828B437DA1" xlink:to="loc_oncyf_SharesUnderSharePurchaseAgreementMember_9ED32AF51DE6B0802342F2828B43A864" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_4F9EF3B8E07F0195C539F2828B432B4C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_D906DA826F415FD60CFFF2828B437DA1" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_4F9EF3B8E07F0195C539F2828B432B4C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_DB22957AD1EA1CE0D46BF2828B437DF7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_D906DA826F415FD60CFFF2828B437DA1" xlink:to="loc_oncyf_SharesPublicOfferingMember_DB22957AD1EA1CE0D46BF2828B437DF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_1ABE01A54EE39DFECA35F2828B445875" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_ifrs-full_Equity_1ABE01A54EE39DFECA35F2828B445875" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_19860B82186ABF5E0C3FF2828B449720" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_ifrs-full_NumberOfSharesIssued_19860B82186ABF5E0C3FF2828B449720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_527AD7FA96751CFE63E2F2828B44F0AA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_ifrs-full_IssueOfEquity_527AD7FA96751CFE63E2F2828B44F0AA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_BFCA43952A30A0BCF8C5F2828B44DAA9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_oncyf_IssueOfEquityShares_BFCA43952A30A0BCF8C5F2828B44DAA9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_1E5D43ED64A8E634D8E5F2828B447AFA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_1E5D43ED64A8E634D8E5F2828B447AFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_0C86FDC88DF46B893D89F2828B4482D9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_0C86FDC88DF46B893D89F2828B4482D9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_24A4249285DF114639C61AEC02E4B84F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_24A4249285DF114639C61AEC02E4B84F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_57CA6F3E663D25FD622D1AEC02E4C88F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_24A4249285DF114639C61AEC02E4B84F" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_57CA6F3E663D25FD622D1AEC02E4C88F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_07630ABCE5595CC436D51AEC02E490ED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_57CA6F3E663D25FD622D1AEC02E4C88F" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_07630ABCE5595CC436D51AEC02E490ED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_07630ABCE5595CC436D51AEC02E490ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_57CA6F3E663D25FD622D1AEC02E4C88F" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_07630ABCE5595CC436D51AEC02E490ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_D1695E471AFF4350CACF1AEC02E43ACA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_07630ABCE5595CC436D51AEC02E490ED" xlink:to="loc_ifrs-full_IssuedCapitalMember_D1695E471AFF4350CACF1AEC02E43ACA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_E0903843998A9AE2CB8E1AEC02E5D592" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_07630ABCE5595CC436D51AEC02E490ED" xlink:to="loc_oncyf_WarrantsMember_E0903843998A9AE2CB8E1AEC02E5D592" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_24A4249285DF114639C61AEC02E4B84F" xlink:to="loc_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A" xlink:to="loc_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A" xlink:to="loc_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:to="loc_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_InitialCommitmentFeeMember" xlink:label="loc_oncyf_InitialCommitmentFeeMember_75B5FA50029B5793EE871AEC02E5F335" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F" xlink:to="loc_oncyf_InitialCommitmentFeeMember_75B5FA50029B5793EE871AEC02E5F335" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderAmendedSharePurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F" xlink:to="loc_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_AmendedInitialCommitmentFeeMember" xlink:label="loc_oncyf_AmendedInitialCommitmentFeeMember_7E2F393782837A1DEA6A1AEC02E5CB12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062" xlink:to="loc_oncyf_AmendedInitialCommitmentFeeMember_7E2F393782837A1DEA6A1AEC02E5CB12" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_B7AFA10ED55F86598A681AEC02E5969D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_B7AFA10ED55F86598A681AEC02E5969D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_76513E681A918A3A84821AEC02E5323E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:to="loc_oncyf_SharesPublicOfferingMember_76513E681A918A3A84821AEC02E5323E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharePurchaseAgreementAmount" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_29E74CB7BE4464B386321AEC02E6D58B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_SharePurchaseAgreementAmount_29E74CB7BE4464B386321AEC02E6D58B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharePurchaseAgreementTerm" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_15FD2647627EE43F8E691AEC02E6D8B3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_SharePurchaseAgreementTerm_15FD2647627EE43F8E691AEC02E6D8B3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_127AB15630ECC07FBA7A1AEC02E64A6F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_IssueOfEquityShares_127AB15630ECC07FBA7A1AEC02E64A6F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_InitialCommitmentFeeSharesIssuedFairValue" xlink:label="loc_oncyf_InitialCommitmentFeeSharesIssuedFairValue_78F527A7C7F404957C9F1AEC02E62B26" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_InitialCommitmentFeeSharesIssuedFairValue_78F527A7C7F404957C9F1AEC02E62B26" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares" xlink:label="loc_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares_C6F99CF91AB3AC6A085F1AEC02E6823F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares_C6F99CF91AB3AC6A085F1AEC02E6823F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_BBBE3A5623F346C3E32D1AEC02E693F9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_ifrs-full_Equity_BBBE3A5623F346C3E32D1AEC02E693F9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E39E4D2FB42F01EB6B251AEC02E6C61B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E39E4D2FB42F01EB6B251AEC02E6C61B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_B047E72B7169C27114B71AEC02E6550F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_B047E72B7169C27114B71AEC02E6550F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesIssuedPricePerShare1" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_7D7576C3A733734036C51AEC02E68549" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_7D7576C3A733734036C51AEC02E68549" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommonSharesPerUnit" xlink:label="loc_oncyf_CommonSharesPerUnit_D971B397FA5474F6D6931AEC02E67B13" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_CommonSharesPerUnit_D971B397FA5474F6D6931AEC02E67B13" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit_EA62F3E26A7DCA9DCCA31AEC02E6C07E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_CommonSharePurchaseWarrantPerUnit_EA62F3E26A7DCA9DCCA31AEC02E6C07E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesIssuedWarrantPricePerShare" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare_1FD62CA8A736D58C74981AEC02E6083E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_SharesIssuedWarrantPricePerShare_1FD62CA8A736D58C74981AEC02E6083E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8696FE7CEFD98F66ACF51B2E88DA5CCC" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8696FE7CEFD98F66ACF51B2E88DA5CCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions_441C9C519C3656BEF1011AEC02E6F6FA" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions_441C9C519C3656BEF1011AEC02E6F6FA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantPricePerShareAccelerationThreshold" xlink:label="loc_oncyf_WarrantPricePerShareAccelerationThreshold_BC488F6FC5BD5FD969B81AEC02E6E6CB" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_WarrantPricePerShareAccelerationThreshold_BC488F6FC5BD5FD969B81AEC02E6E6CB" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantPricePerShareAccelerationThresholdTradingDays" xlink:label="loc_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_FD0CE4621DB137EA1C3B1AEC02E67000" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_FD0CE4621DB137EA1C3B1AEC02E67000" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_411D9B6096F9101C11D0F30DF8DB9EB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_411D9B6096F9101C11D0F30DF8DB9EB2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_71533538A37C3846CAC8F30DF8DC2761" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_411D9B6096F9101C11D0F30DF8DB9EB2" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_71533538A37C3846CAC8F30DF8DC2761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_71533538A37C3846CAC8F30DF8DC2761" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_71533538A37C3846CAC8F30DF8DC2761" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_2FE9354B3489B8BE3F1FF30E4A05A2DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C" xlink:to="loc_oncyf_WarrantsMember_2FE9354B3489B8BE3F1FF30E4A05A2DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_529BAED6F43F69C3CEC4F2FC89B917C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_529BAED6F43F69C3CEC4F2FC89B917C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_61CBAEC925685A32B64CF2FF452C783D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_61CBAEC925685A32B64CF2FF452C783D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_ED1D712D3BFCF8D3185CF2FCC59A3D9E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_ED1D712D3BFCF8D3185CF2FCC59A3D9E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DividendYieldPercent" xlink:label="loc_oncyf_DividendYieldPercent_87CCF1811E734D82D3FAF2FCE2E568DC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:to="loc_oncyf_DividendYieldPercent_87CCF1811E734D82D3FAF2FCE2E568DC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9262DF78934ED9444B572047BA99685F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_C0A6E4F8A3D253414BD32047BA99FB41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9262DF78934ED9444B572047BA99685F" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_C0A6E4F8A3D253414BD32047BA99FB41" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_DB4EAAD38A54B54FCE2E2047BA99586B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_C0A6E4F8A3D253414BD32047BA99FB41" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_DB4EAAD38A54B54FCE2E2047BA99586B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_53199C932ACD0CA7AF852047BA99F494_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_DB4EAAD38A54B54FCE2E2047BA99586B" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_53199C932ACD0CA7AF852047BA99F494_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_53199C932ACD0CA7AF852047BA99F494" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_DB4EAAD38A54B54FCE2E2047BA99586B" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_53199C932ACD0CA7AF852047BA99F494" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_B817244B68848DE8E51E2047BA994C19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_53199C932ACD0CA7AF852047BA99F494" xlink:to="loc_oncyf_WarrantsMember_B817244B68848DE8E51E2047BA994C19" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceofOutstandingWarrants" xlink:label="loc_oncyf_ExercisePriceofOutstandingWarrants_E4E19EA3DF241EFCE4E620C1ED049727" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9262DF78934ED9444B572047BA99685F" xlink:to="loc_oncyf_ExercisePriceofOutstandingWarrants_E4E19EA3DF241EFCE4E620C1ED049727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_F0D940E465D6BFE94D552047BA996651" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9262DF78934ED9444B572047BA99685F" xlink:to="loc_ifrs-full_NumberOfSharesIssued_F0D940E465D6BFE94D552047BA996651" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_B4FC7A468E4C447E66192047BA9A0029" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9262DF78934ED9444B572047BA99685F" xlink:to="loc_oncyf_IssueOfEquityShares_B4FC7A468E4C447E66192047BA9A0029" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_460E6D8A11D4DEEA52192047BA9ADEE3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9262DF78934ED9444B572047BA99685F" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_460E6D8A11D4DEEA52192047BA9ADEE3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_D2FBD0CB44CB522BF8C5E7B00A409F8F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3570C1E5494D82692A98E7B00A3F7085" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_D2FBD0CB44CB522BF8C5E7B00A409F8F" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3570C1E5494D82692A98E7B00A3F7085" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1DCF4C137A9CF452D829E7B00A3FE96E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3570C1E5494D82692A98E7B00A3F7085" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1DCF4C137A9CF452D829E7B00A3FE96E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_6980EDF49E733F05F738E7B00A40CAF3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1DCF4C137A9CF452D829E7B00A3FE96E" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_6980EDF49E733F05F738E7B00A40CAF3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_6980EDF49E733F05F738E7B00A40CAF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1DCF4C137A9CF452D829E7B00A3FE96E" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_6980EDF49E733F05F738E7B00A40CAF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_2F1161D1E0377DACE7AFE7B00A40A2ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6980EDF49E733F05F738E7B00A40CAF3" xlink:to="loc_ifrs-full_OfficeEquipmentMember_2F1161D1E0377DACE7AFE7B00A40A2ED" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MedicalEquipmentMember" xlink:label="loc_oncyf_MedicalEquipmentMember_A3B9E61176C9062A09F7E7B00A40259A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6980EDF49E733F05F738E7B00A40CAF3" xlink:to="loc_oncyf_MedicalEquipmentMember_A3B9E61176C9062A09F7E7B00A40259A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_0E966E948DCAE67035ABE7B00A40C114" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6980EDF49E733F05F738E7B00A40CAF3" xlink:to="loc_ifrs-full_ComputerEquipmentMember_0E966E948DCAE67035ABE7B00A40C114" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_6F70152F59A8C778CA65E7B00A407671" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_D2FBD0CB44CB522BF8C5E7B00A409F8F" xlink:to="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_6F70152F59A8C778CA65E7B00A407671" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>oncyf-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1943EF1910A504BD7B1A2571A59FBD4B_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1943EF1910A504BD7B1A2571A59FBD4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1943EF1910A504BD7B1A2571A59FBD4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1943EF1910A504BD7B1A2571A59FBD4B" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1943EF1910A504BD7B1A2571A59FBD4B" xlink:type="arc" />
    <link:label id="lab_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205_terseLabel_en-US" xlink:label="lab_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:label id="lab_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205_label_en-US" xlink:label="lab_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:label id="lab_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205_documentation_en-US" xlink:label="lab_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Currency1Table" xlink:label="loc_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205" xlink:to="lab_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205" xlink:type="arc" />
    <link:label id="lab_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22_terseLabel_en-US" xlink:label="lab_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency1 [Axis]</link:label>
    <link:label id="lab_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22_label_en-US" xlink:label="lab_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency1 [Axis]</link:label>
    <link:label id="lab_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22_documentation_en-US" xlink:label="lab_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Currency1 [Axis]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Currency1Axis" xlink:label="loc_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22" xlink:to="lab_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:to="lab_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:type="arc" />
    <link:label id="lab_currency_USD_04DFBF375FC64C3E7A872571A5A08467_terseLabel_en-US" xlink:label="lab_currency_USD_04DFBF375FC64C3E7A872571A5A08467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US dollars $</link:label>
    <link:label id="lab_currency_USD_04DFBF375FC64C3E7A872571A5A08467_label_en-US" xlink:label="lab_currency_USD_04DFBF375FC64C3E7A872571A5A08467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_04DFBF375FC64C3E7A872571A5A08467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD_04DFBF375FC64C3E7A872571A5A08467" xlink:to="lab_currency_USD_04DFBF375FC64C3E7A872571A5A08467" xlink:type="arc" />
    <link:label id="lab_currency_GBP_2C8316D63E3560BCD3BA2571A5A0E054_terseLabel_en-US" xlink:label="lab_currency_GBP_2C8316D63E3560BCD3BA2571A5A0E054" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pounds &#163;</link:label>
    <link:label id="lab_currency_GBP_2C8316D63E3560BCD3BA2571A5A0E054_label_en-US" xlink:label="lab_currency_GBP_2C8316D63E3560BCD3BA2571A5A0E054" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_2C8316D63E3560BCD3BA2571A5A0E054" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_2C8316D63E3560BCD3BA2571A5A0E054" xlink:to="lab_currency_GBP_2C8316D63E3560BCD3BA2571A5A0E054" xlink:type="arc" />
    <link:label id="lab_currency_EUR_30804A3CF9AE50B93B3E2571A5A00586_terseLabel_en-US" xlink:label="lab_currency_EUR_30804A3CF9AE50B93B3E2571A5A00586" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Euro &#8364;</link:label>
    <link:label id="lab_currency_EUR_30804A3CF9AE50B93B3E2571A5A00586_label_en-US" xlink:label="lab_currency_EUR_30804A3CF9AE50B93B3E2571A5A00586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_30804A3CF9AE50B93B3E2571A5A00586" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_30804A3CF9AE50B93B3E2571A5A00586" xlink:to="lab_currency_EUR_30804A3CF9AE50B93B3E2571A5A00586" xlink:type="arc" />
    <link:label id="lab_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638_terseLabel_en-US" xlink:label="lab_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638_label_en-US" xlink:label="lab_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638_documentation_en-US" xlink:label="lab_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Currency1 [Table]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Currency1LineItems" xlink:label="loc_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:to="lab_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_54261128838DECF017F02571A5A00C86_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents_54261128838DECF017F02571A5A00C86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_54261128838DECF017F02571A5A00C86_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents_54261128838DECF017F02571A5A00C86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_54261128838DECF017F02571A5A00C86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents_54261128838DECF017F02571A5A00C86" xlink:to="lab_ifrs-full_CashAndCashEquivalents_54261128838DECF017F02571A5A00C86" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentReceivablesFromContractsWithCustomers_A7C16D9BAE89CA761A7C2571A5A07ED1_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromContractsWithCustomers_A7C16D9BAE89CA761A7C2571A5A07ED1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract receivable</link:label>
    <link:label id="lab_ifrs-full_CurrentReceivablesFromContractsWithCustomers_A7C16D9BAE89CA761A7C2571A5A07ED1_label_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromContractsWithCustomers_A7C16D9BAE89CA761A7C2571A5A07ED1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current receivables from contracts with customers</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentReceivablesFromContractsWithCustomers" xlink:label="loc_ifrs-full_CurrentReceivablesFromContractsWithCustomers_A7C16D9BAE89CA761A7C2571A5A07ED1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentReceivablesFromContractsWithCustomers_A7C16D9BAE89CA761A7C2571A5A07ED1" xlink:to="lab_ifrs-full_CurrentReceivablesFromContractsWithCustomers_A7C16D9BAE89CA761A7C2571A5A07ED1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_AD82FE3B91729A7EAF142571A5A0E593_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_AD82FE3B91729A7EAF142571A5A0E593" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_AD82FE3B91729A7EAF142571A5A0E593_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_AD82FE3B91729A7EAF142571A5A0E593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_AD82FE3B91729A7EAF142571A5A0E593" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_AD82FE3B91729A7EAF142571A5A0E593" xlink:to="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_AD82FE3B91729A7EAF142571A5A0E593" xlink:type="arc" />
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_0F861A88888584983EC22571A5A088D3_terseLabel_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet_0F861A88888584983EC22571A5A088D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balances in foreign currencies</link:label>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_0F861A88888584983EC22571A5A088D3_label_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet_0F861A88888584983EC22571A5A088D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Held In Foreign Currency, Net</link:label>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_0F861A88888584983EC22571A5A088D3_documentation_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet_0F861A88888584983EC22571A5A088D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Balance Held In Foreign Currency, Net</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_BalanceHeldInForeignCurrencyNet" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_0F861A88888584983EC22571A5A088D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_BalanceHeldInForeignCurrencyNet_0F861A88888584983EC22571A5A088D3" xlink:to="lab_oncyf_BalanceHeldInForeignCurrencyNet_0F861A88888584983EC22571A5A088D3" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E_label_en-US" xlink:label="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_3AF6E4658C831A4F04E8E19BEF41DAC2_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_3AF6E4658C831A4F04E8E19BEF41DAC2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_3AF6E4658C831A4F04E8E19BEF41DAC2_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_3AF6E4658C831A4F04E8E19BEF41DAC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_3AF6E4658C831A4F04E8E19BEF41DAC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions_3AF6E4658C831A4F04E8E19BEF41DAC2" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions_3AF6E4658C831A4F04E8E19BEF41DAC2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_8439BE90EECD3B08BD65E19BEF41791B_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_8439BE90EECD3B08BD65E19BEF41791B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_8439BE90EECD3B08BD65E19BEF41791B_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_8439BE90EECD3B08BD65E19BEF41791B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_8439BE90EECD3B08BD65E19BEF41791B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_8439BE90EECD3B08BD65E19BEF41791B" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_8439BE90EECD3B08BD65E19BEF41791B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_30A56D49F2ABB8F85785E19BEF416DB0_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_30A56D49F2ABB8F85785E19BEF416DB0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_30A56D49F2ABB8F85785E19BEF416DB0_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_30A56D49F2ABB8F85785E19BEF416DB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_30A56D49F2ABB8F85785E19BEF416DB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_30A56D49F2ABB8F85785E19BEF416DB0" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_30A56D49F2ABB8F85785E19BEF416DB0" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_50F0E33878B3899B1226E19BEF417055_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_50F0E33878B3899B1226E19BEF417055" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_50F0E33878B3899B1226E19BEF417055_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_50F0E33878B3899B1226E19BEF417055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_50F0E33878B3899B1226E19BEF417055" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_50F0E33878B3899B1226E19BEF417055" xlink:to="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_50F0E33878B3899B1226E19BEF417055" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_A9EA63A4CA0D09E7E4E7E19BEF41D338_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_A9EA63A4CA0D09E7E4E7E19BEF41D338" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_A9EA63A4CA0D09E7E4E7E19BEF41D338_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_A9EA63A4CA0D09E7E4E7E19BEF41D338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_A9EA63A4CA0D09E7E4E7E19BEF41D338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_A9EA63A4CA0D09E7E4E7E19BEF41D338" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_A9EA63A4CA0D09E7E4E7E19BEF41D338" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_48CF693201A00C8B91B5E19BEF419052_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_48CF693201A00C8B91B5E19BEF419052" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of the year (shares)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_48CF693201A00C8B91B5E19BEF419052" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions_48CF693201A00C8B91B5E19BEF419052" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions_48CF693201A00C8B91B5E19BEF419052" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3082C2ABA2AAA116CB23E19BEF41EC32_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3082C2ABA2AAA116CB23E19BEF41EC32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, end of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3082C2ABA2AAA116CB23E19BEF41EC32_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3082C2ABA2AAA116CB23E19BEF41EC32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3082C2ABA2AAA116CB23E19BEF41EC32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3082C2ABA2AAA116CB23E19BEF41EC32" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3082C2ABA2AAA116CB23E19BEF41EC32" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_C8A9E6B422313D2F1AFFE19BEF411213_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_C8A9E6B422313D2F1AFFE19BEF411213" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_C8A9E6B422313D2F1AFFE19BEF411213_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_C8A9E6B422313D2F1AFFE19BEF411213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_C8A9E6B422313D2F1AFFE19BEF411213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_C8A9E6B422313D2F1AFFE19BEF411213" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_C8A9E6B422313D2F1AFFE19BEF411213" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_7B1BF6068C15BAD4DF68E19BEF41CF7C_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_7B1BF6068C15BAD4DF68E19BEF41CF7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_7B1BF6068C15BAD4DF68E19BEF41CF7C_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_7B1BF6068C15BAD4DF68E19BEF41CF7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_7B1BF6068C15BAD4DF68E19BEF41CF7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_7B1BF6068C15BAD4DF68E19BEF41CF7C" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_7B1BF6068C15BAD4DF68E19BEF41CF7C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement_1C8D8116D335A357DADBE19BEF4126AF_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement_1C8D8116D335A357DADBE19BEF4126AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement_1C8D8116D335A357DADBE19BEF4126AF_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement_1C8D8116D335A357DADBE19BEF4126AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement_1C8D8116D335A357DADBE19BEF4126AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement_1C8D8116D335A357DADBE19BEF4126AF" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement_1C8D8116D335A357DADBE19BEF4126AF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement_889A1585572A029CE644E19BEF41A343_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement_889A1585572A029CE644E19BEF41A343" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement_889A1585572A029CE644E19BEF41A343_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement_889A1585572A029CE644E19BEF41A343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement_889A1585572A029CE644E19BEF41A343" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement_889A1585572A029CE644E19BEF41A343" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement_889A1585572A029CE644E19BEF41A343" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_8C8B7427BF6099CC172EE19BEF413875_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_8C8B7427BF6099CC172EE19BEF413875" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_8C8B7427BF6099CC172EE19BEF413875_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_8C8B7427BF6099CC172EE19BEF413875" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_8C8B7427BF6099CC172EE19BEF413875" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_8C8B7427BF6099CC172EE19BEF413875" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_8C8B7427BF6099CC172EE19BEF413875" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_19DE7A9B848F522495E1E19BEF418939_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_19DE7A9B848F522495E1E19BEF418939" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of the year (cad per share)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_19DE7A9B848F522495E1E19BEF418939" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_19DE7A9B848F522495E1E19BEF418939" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_19DE7A9B848F522495E1E19BEF418939" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_3BC1640465973DC4B41DE19BEF41C4A2_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_3BC1640465973DC4B41DE19BEF41C4A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, end of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_3BC1640465973DC4B41DE19BEF41C4A2_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_3BC1640465973DC4B41DE19BEF41C4A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_3BC1640465973DC4B41DE19BEF41C4A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_3BC1640465973DC4B41DE19BEF41C4A2" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_3BC1640465973DC4B41DE19BEF41C4A2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_D227A4417E61E2BEFFC9F2828ACA2ECF_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract_D227A4417E61E2BEFFC9F2828ACA2ECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_D227A4417E61E2BEFFC9F2828ACA2ECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_D227A4417E61E2BEFFC9F2828ACA2ECF" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract_D227A4417E61E2BEFFC9F2828ACA2ECF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_408F5781AC21B158D1B9F2828ACAA636_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_408F5781AC21B158D1B9F2828ACAA636" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Cash Flow Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_408F5781AC21B158D1B9F2828ACAA636_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_408F5781AC21B158D1B9F2828ACAA636" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of cash flow statement [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_408F5781AC21B158D1B9F2828ACAA636" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_408F5781AC21B158D1B9F2828ACAA636" xlink:to="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_408F5781AC21B158D1B9F2828ACAA636" xlink:type="arc" />
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_0E00F63F8F408ABCDD53E10D70E6D19B_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract_0E00F63F8F408ABCDD53E10D70E6D19B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_0E00F63F8F408ABCDD53E10D70E6D19B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_0E00F63F8F408ABCDD53E10D70E6D19B" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract_0E00F63F8F408ABCDD53E10D70E6D19B" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2D177B8BF3DE0A07A981E1932BFA4F88_verboseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2D177B8BF3DE0A07A981E1932BFA4F88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of capital components</link:label>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2D177B8BF3DE0A07A981E1932BFA4F88_label_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2D177B8BF3DE0A07A981E1932BFA4F88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Capital Components [Table Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2D177B8BF3DE0A07A981E1932BFA4F88_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2D177B8BF3DE0A07A981E1932BFA4F88" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Capital Components [Table Text Block]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:label="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2D177B8BF3DE0A07A981E1932BFA4F88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2D177B8BF3DE0A07A981E1932BFA4F88" xlink:to="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2D177B8BF3DE0A07A981E1932BFA4F88" xlink:type="arc" />
    <link:label id="lab_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093_label_en-US" xlink:label="lab_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093_documentation_en-US" xlink:label="lab_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DocumentAndEntityInformationAbstract" xlink:label="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="lab_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_0C4D7F85300CEEF67836C8041E7D9564_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_0C4D7F85300CEEF67836C8041E7D9564" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_0C4D7F85300CEEF67836C8041E7D9564_label_en-US" xlink:label="lab_dei_EntityRegistrantName_0C4D7F85300CEEF67836C8041E7D9564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_0C4D7F85300CEEF67836C8041E7D9564" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_0C4D7F85300CEEF67836C8041E7D9564" xlink:to="lab_dei_EntityRegistrantName_0C4D7F85300CEEF67836C8041E7D9564" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_BF126F8ED706E2531F7DC8041E7E4A04_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_BF126F8ED706E2531F7DC8041E7E4A04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_BF126F8ED706E2531F7DC8041E7E4A04_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_BF126F8ED706E2531F7DC8041E7E4A04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_BF126F8ED706E2531F7DC8041E7E4A04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_BF126F8ED706E2531F7DC8041E7E4A04" xlink:to="lab_dei_EntityCentralIndexKey_BF126F8ED706E2531F7DC8041E7E4A04" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_E0C90D63C8A20247119FC8041E7E95DB_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_E0C90D63C8A20247119FC8041E7E95DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_E0C90D63C8A20247119FC8041E7E95DB_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_E0C90D63C8A20247119FC8041E7E95DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_E0C90D63C8A20247119FC8041E7E95DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_E0C90D63C8A20247119FC8041E7E95DB" xlink:to="lab_dei_CurrentFiscalYearEndDate_E0C90D63C8A20247119FC8041E7E95DB" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_BC3AB24B94DC327CD676C8041E7EE9C7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_BC3AB24B94DC327CD676C8041E7EE9C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_BC3AB24B94DC327CD676C8041E7EE9C7_label_en-US" xlink:label="lab_dei_EntityFilerCategory_BC3AB24B94DC327CD676C8041E7EE9C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_BC3AB24B94DC327CD676C8041E7EE9C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_BC3AB24B94DC327CD676C8041E7EE9C7" xlink:to="lab_dei_EntityFilerCategory_BC3AB24B94DC327CD676C8041E7EE9C7" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_D97BD137D60E7FD46160C8041E7E712C_terseLabel_en-US" xlink:label="lab_dei_DocumentType_D97BD137D60E7FD46160C8041E7E712C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_D97BD137D60E7FD46160C8041E7E712C_label_en-US" xlink:label="lab_dei_DocumentType_D97BD137D60E7FD46160C8041E7E712C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_D97BD137D60E7FD46160C8041E7E712C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_D97BD137D60E7FD46160C8041E7E712C" xlink:to="lab_dei_DocumentType_D97BD137D60E7FD46160C8041E7E712C" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_64D0A4424A44FC84EB89C8041E7ECD65_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_64D0A4424A44FC84EB89C8041E7ECD65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_64D0A4424A44FC84EB89C8041E7ECD65_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_64D0A4424A44FC84EB89C8041E7ECD65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_64D0A4424A44FC84EB89C8041E7ECD65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_64D0A4424A44FC84EB89C8041E7ECD65" xlink:to="lab_dei_DocumentPeriodEndDate_64D0A4424A44FC84EB89C8041E7ECD65" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_11A6035C732A95A79512C8041E7ED819_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_11A6035C732A95A79512C8041E7ED819" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_11A6035C732A95A79512C8041E7ED819_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_11A6035C732A95A79512C8041E7ED819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_11A6035C732A95A79512C8041E7ED819" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_11A6035C732A95A79512C8041E7ED819" xlink:to="lab_dei_DocumentFiscalYearFocus_11A6035C732A95A79512C8041E7ED819" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ECF80B968B471C971985C8041E7E0319_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_ECF80B968B471C971985C8041E7E0319" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ECF80B968B471C971985C8041E7E0319_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_ECF80B968B471C971985C8041E7E0319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ECF80B968B471C971985C8041E7E0319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_ECF80B968B471C971985C8041E7E0319" xlink:to="lab_dei_DocumentFiscalPeriodFocus_ECF80B968B471C971985C8041E7E0319" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_BECE54237232C528E27BC8041E7E643F_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_BECE54237232C528E27BC8041E7E643F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_BECE54237232C528E27BC8041E7E643F_label_en-US" xlink:label="lab_dei_AmendmentFlag_BECE54237232C528E27BC8041E7E643F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_BECE54237232C528E27BC8041E7E643F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_BECE54237232C528E27BC8041E7E643F" xlink:to="lab_dei_AmendmentFlag_BECE54237232C528E27BC8041E7E643F" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_BE62AA4C428729A586B2C8041E7E6C07_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_BE62AA4C428729A586B2C8041E7E6C07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_BE62AA4C428729A586B2C8041E7E6C07_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_BE62AA4C428729A586B2C8041E7E6C07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_BE62AA4C428729A586B2C8041E7E6C07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_BE62AA4C428729A586B2C8041E7E6C07" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_BE62AA4C428729A586B2C8041E7E6C07" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_4D61927AAB2ABCFB0AD7C8041E7ED946_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_4D61927AAB2ABCFB0AD7C8041E7ED946" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_4D61927AAB2ABCFB0AD7C8041E7ED946_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_4D61927AAB2ABCFB0AD7C8041E7ED946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_4D61927AAB2ABCFB0AD7C8041E7ED946" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_4D61927AAB2ABCFB0AD7C8041E7ED946" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_4D61927AAB2ABCFB0AD7C8041E7ED946" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_D594AD78A74140A875C6C8041E7EEE1A_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_D594AD78A74140A875C6C8041E7EEE1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_D594AD78A74140A875C6C8041E7EEE1A_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_D594AD78A74140A875C6C8041E7EEE1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_D594AD78A74140A875C6C8041E7EEE1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_D594AD78A74140A875C6C8041E7EEE1A" xlink:to="lab_dei_EntityVoluntaryFilers_D594AD78A74140A875C6C8041E7EEE1A" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_C91A9E2ACCA271E290AAC8041E7F0B87_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_C91A9E2ACCA271E290AAC8041E7F0B87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_C91A9E2ACCA271E290AAC8041E7F0B87_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_C91A9E2ACCA271E290AAC8041E7F0B87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_C91A9E2ACCA271E290AAC8041E7F0B87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_C91A9E2ACCA271E290AAC8041E7F0B87" xlink:to="lab_dei_EntityCurrentReportingStatus_C91A9E2ACCA271E290AAC8041E7F0B87" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_E949B4084FCF30C6A6F4C8041E7F6DC2_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_E949B4084FCF30C6A6F4C8041E7F6DC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_E949B4084FCF30C6A6F4C8041E7F6DC2_label_en-US" xlink:label="lab_dei_EntityPublicFloat_E949B4084FCF30C6A6F4C8041E7F6DC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_E949B4084FCF30C6A6F4C8041E7F6DC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_E949B4084FCF30C6A6F4C8041E7F6DC2" xlink:to="lab_dei_EntityPublicFloat_E949B4084FCF30C6A6F4C8041E7F6DC2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9D0E968DEE19E35F60E1C8041EC14E47_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9D0E968DEE19E35F60E1C8041EC14E47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9D0E968DEE19E35F60E1C8041EC14E47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9D0E968DEE19E35F60E1C8041EC14E47" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9D0E968DEE19E35F60E1C8041EC14E47" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_0ED095200291EEAB6B30C8041EC10AC6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_0ED095200291EEAB6B30C8041EC10AC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Expenses and Adjustments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_0ED095200291EEAB6B30C8041EC10AC6_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_0ED095200291EEAB6B30C8041EC10AC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other operating expense [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_0ED095200291EEAB6B30C8041EC10AC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_0ED095200291EEAB6B30C8041EC10AC6" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_0ED095200291EEAB6B30C8041EC10AC6" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_800B00192484D446DDBAE7C722CA026E_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_800B00192484D446DDBAE7C722CA026E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_800B00192484D446DDBAE7C722CA026E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_800B00192484D446DDBAE7C722CA026E" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_800B00192484D446DDBAE7C722CA026E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_0D5E17F631CFD53366D4E7C722CA5D8F_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_0D5E17F631CFD53366D4E7C722CA5D8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_0D5E17F631CFD53366D4E7C722CA5D8F_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_0D5E17F631CFD53366D4E7C722CA5D8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_0D5E17F631CFD53366D4E7C722CA5D8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_0D5E17F631CFD53366D4E7C722CA5D8F" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_0D5E17F631CFD53366D4E7C722CA5D8F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_16086248548EF915A447E19BEF466CBB_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_16086248548EF915A447E19BEF466CBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Payments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_16086248548EF915A447E19BEF466CBB_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_16086248548EF915A447E19BEF466CBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_16086248548EF915A447E19BEF466CBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_16086248548EF915A447E19BEF466CBB" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_16086248548EF915A447E19BEF466CBB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_0D5DD6A6555962A034091AE318F47823_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract_0D5DD6A6555962A034091AE318F47823" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_0D5DD6A6555962A034091AE318F47823" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_0D5DD6A6555962A034091AE318F47823" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract_0D5DD6A6555962A034091AE318F47823" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AssetsAbstract_4C01827713A596AFE52D1AE318F7F8C2_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract_4C01827713A596AFE52D1AE318F7F8C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_4C01827713A596AFE52D1AE318F7F8C2_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract_4C01827713A596AFE52D1AE318F7F8C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_4C01827713A596AFE52D1AE318F7F8C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract_4C01827713A596AFE52D1AE318F7F8C2" xlink:to="lab_ifrs-full_AssetsAbstract_4C01827713A596AFE52D1AE318F7F8C2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97" xlink:to="lab_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentInvestments_0EAC836599B7C519B8FE1AE318FBD3E5_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentInvestments_0EAC836599B7C519B8FE1AE318FBD3E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_ifrs-full_CurrentInvestments_0EAC836599B7C519B8FE1AE318FBD3E5_label_en-US" xlink:label="lab_ifrs-full_CurrentInvestments_0EAC836599B7C519B8FE1AE318FBD3E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current investments</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentInvestments" xlink:label="loc_ifrs-full_CurrentInvestments_0EAC836599B7C519B8FE1AE318FBD3E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentInvestments_0EAC836599B7C519B8FE1AE318FBD3E5" xlink:to="lab_ifrs-full_CurrentInvestments_0EAC836599B7C519B8FE1AE318FBD3E5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentReceivablesFromContractsWithCustomers_B0DD7DAC3394D20DB0A31AE31C09E185_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromContractsWithCustomers_B0DD7DAC3394D20DB0A31AE31C09E185" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract receivable</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentReceivablesFromContractsWithCustomers" xlink:label="loc_ifrs-full_CurrentReceivablesFromContractsWithCustomers_B0DD7DAC3394D20DB0A31AE31C09E185" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentReceivablesFromContractsWithCustomers_B0DD7DAC3394D20DB0A31AE31C09E185" xlink:to="lab_ifrs-full_CurrentReceivablesFromContractsWithCustomers_B0DD7DAC3394D20DB0A31AE31C09E185" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_7BBE818A7A937D1E556E1AE318FBD6D1_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables_7BBE818A7A937D1E556E1AE318FBD6D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_7BBE818A7A937D1E556E1AE318FBD6D1_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables_7BBE818A7A937D1E556E1AE318FBD6D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current receivables</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_7BBE818A7A937D1E556E1AE318FBD6D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables_7BBE818A7A937D1E556E1AE318FBD6D1" xlink:to="lab_ifrs-full_OtherCurrentReceivables_7BBE818A7A937D1E556E1AE318FBD6D1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_57CAD074A42F8EB136DA1AE319005984_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses_57CAD074A42F8EB136DA1AE319005984" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_57CAD074A42F8EB136DA1AE319005984_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses_57CAD074A42F8EB136DA1AE319005984" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_57CAD074A42F8EB136DA1AE319005984" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses_57CAD074A42F8EB136DA1AE319005984" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses_57CAD074A42F8EB136DA1AE319005984" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentAssets_350C1DCFF548EEF0D8511AE319009902_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets_350C1DCFF548EEF0D8511AE319009902" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_350C1DCFF548EEF0D8511AE319009902_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets_350C1DCFF548EEF0D8511AE319009902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_350C1DCFF548EEF0D8511AE319009902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets_350C1DCFF548EEF0D8511AE319009902" xlink:to="lab_ifrs-full_CurrentAssets_350C1DCFF548EEF0D8511AE319009902" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_B86B435C4916CF6F506C1AE319000637_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract_B86B435C4916CF6F506C1AE319000637" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_B86B435C4916CF6F506C1AE319000637_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract_B86B435C4916CF6F506C1AE319000637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_B86B435C4916CF6F506C1AE319000637" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_B86B435C4916CF6F506C1AE319000637" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract_B86B435C4916CF6F506C1AE319000637" xlink:type="arc" />
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_0564A9EABD9F5037B2401AE319003B0F_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment_0564A9EABD9F5037B2401AE319003B0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_0564A9EABD9F5037B2401AE319003B0F_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment_0564A9EABD9F5037B2401AE319003B0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_0564A9EABD9F5037B2401AE319003B0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment_0564A9EABD9F5037B2401AE319003B0F" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment_0564A9EABD9F5037B2401AE319003B0F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NoncurrentAssets_59643613E229D54D6A681AE31901071B_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets_59643613E229D54D6A681AE31901071B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_59643613E229D54D6A681AE31901071B_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets_59643613E229D54D6A681AE31901071B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_59643613E229D54D6A681AE31901071B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets_59643613E229D54D6A681AE31901071B" xlink:to="lab_ifrs-full_NoncurrentAssets_59643613E229D54D6A681AE31901071B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Assets_70682DA5788FDF08C6261AE319013299_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets_70682DA5788FDF08C6261AE319013299" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_70682DA5788FDF08C6261AE319013299_label_en-US" xlink:label="lab_ifrs-full_Assets_70682DA5788FDF08C6261AE319013299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_70682DA5788FDF08C6261AE319013299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets_70682DA5788FDF08C6261AE319013299" xlink:to="lab_ifrs-full_Assets_70682DA5788FDF08C6261AE319013299" xlink:type="arc" />
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities And Shareholders&#8217; Equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_F60B7868A236185BC1551AE319018047_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract_F60B7868A236185BC1551AE319018047" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_F60B7868A236185BC1551AE319018047_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract_F60B7868A236185BC1551AE319018047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_F60B7868A236185BC1551AE319018047" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_F60B7868A236185BC1551AE319018047" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract_F60B7868A236185BC1551AE319018047" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_90A89915CA2D100B58EB1AE319010CE9_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables_90A89915CA2D100B58EB1AE319010CE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_90A89915CA2D100B58EB1AE319010CE9_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables_90A89915CA2D100B58EB1AE319010CE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_90A89915CA2D100B58EB1AE319010CE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_90A89915CA2D100B58EB1AE319010CE9" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables_90A89915CA2D100B58EB1AE319010CE9" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_69B1E4F39DDB921BF99F1AE319014D08_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities_69B1E4F39DDB921BF99F1AE319014D08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_69B1E4F39DDB921BF99F1AE319014D08_label_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities_69B1E4F39DDB921BF99F1AE319014D08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_69B1E4F39DDB921BF99F1AE319014D08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities_69B1E4F39DDB921BF99F1AE319014D08" xlink:to="lab_ifrs-full_CurrentContractLiabilities_69B1E4F39DDB921BF99F1AE319014D08" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentLiabilities_D357BF893298B9958F711AE31901BB7B_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities_D357BF893298B9958F711AE31901BB7B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_D357BF893298B9958F711AE31901BB7B_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities_D357BF893298B9958F711AE31901BB7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_D357BF893298B9958F711AE31901BB7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities_D357BF893298B9958F711AE31901BB7B" xlink:to="lab_ifrs-full_CurrentLiabilities_D357BF893298B9958F711AE31901BB7B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_46FF1C87E7D279F636361AE31901C90A_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract_46FF1C87E7D279F636361AE31901C90A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_46FF1C87E7D279F636361AE31901C90A_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract_46FF1C87E7D279F636361AE31901C90A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_46FF1C87E7D279F636361AE31901C90A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_46FF1C87E7D279F636361AE31901C90A" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract_46FF1C87E7D279F636361AE31901C90A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_A24AEBEEFD6D8331B87B1AE31901A0FD_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities_A24AEBEEFD6D8331B87B1AE31901A0FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_A24AEBEEFD6D8331B87B1AE31901A0FD_label_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities_A24AEBEEFD6D8331B87B1AE31901A0FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current contract liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_A24AEBEEFD6D8331B87B1AE31901A0FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities_A24AEBEEFD6D8331B87B1AE31901A0FD" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities_A24AEBEEFD6D8331B87B1AE31901A0FD" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_7DC7C4A37D29B1B3B2101AE3190192CB_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities_7DC7C4A37D29B1B3B2101AE3190192CB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_7DC7C4A37D29B1B3B2101AE3190192CB_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities_7DC7C4A37D29B1B3B2101AE3190192CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_7DC7C4A37D29B1B3B2101AE3190192CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities_7DC7C4A37D29B1B3B2101AE3190192CB" xlink:to="lab_ifrs-full_NoncurrentLiabilities_7DC7C4A37D29B1B3B2101AE3190192CB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Liabilities_8C88D7E7936B610737911AE31901A30C_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities_8C88D7E7936B610737911AE31901A30C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_8C88D7E7936B610737911AE31901A30C_label_en-US" xlink:label="lab_ifrs-full_Liabilities_8C88D7E7936B610737911AE31901A30C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_8C88D7E7936B610737911AE31901A30C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities_8C88D7E7936B610737911AE31901A30C" xlink:to="lab_ifrs-full_Liabilities_8C88D7E7936B610737911AE31901A30C" xlink:type="arc" />
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_E1FAA8A3275187BAE9211AE31901BF2E_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1_E1FAA8A3275187BAE9211AE31901BF2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_E1FAA8A3275187BAE9211AE31901BF2E_label_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1_E1FAA8A3275187BAE9211AE31901BF2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies1</link:label>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_E1FAA8A3275187BAE9211AE31901BF2E_documentation_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1_E1FAA8A3275187BAE9211AE31901BF2E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies1</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsAndContingencies1" xlink:label="loc_oncyf_CommitmentsAndContingencies1_E1FAA8A3275187BAE9211AE31901BF2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsAndContingencies1_E1FAA8A3275187BAE9211AE31901BF2E" xlink:to="lab_oncyf_CommitmentsAndContingencies1_E1FAA8A3275187BAE9211AE31901BF2E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D" xlink:to="lab_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IssuedCapital_B1D958BF4EC1A734F9641AE319014414_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital_B1D958BF4EC1A734F9641AE319014414" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital Authorized: unlimited Issued: December 31, 2017 &#8211; 141,805,722 December 31, 2016 &#8211; 121,258,222</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_B1D958BF4EC1A734F9641AE319014414_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital_B1D958BF4EC1A734F9641AE319014414" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_B1D958BF4EC1A734F9641AE319014414" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital_B1D958BF4EC1A734F9641AE319014414" xlink:to="lab_ifrs-full_IssuedCapital_B1D958BF4EC1A734F9641AE319014414" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_585DD9B6A37434D6D1B91AE319021246_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding_585DD9B6A37434D6D1B91AE319021246" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_585DD9B6A37434D6D1B91AE319021246_label_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding_585DD9B6A37434D6D1B91AE319021246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_585DD9B6A37434D6D1B91AE319021246_documentation_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding_585DD9B6A37434D6D1B91AE319021246" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsandRightsOutstanding" xlink:label="loc_oncyf_WarrantsandRightsOutstanding_585DD9B6A37434D6D1B91AE319021246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsandRightsOutstanding_585DD9B6A37434D6D1B91AE319021246" xlink:to="lab_oncyf_WarrantsandRightsOutstanding_585DD9B6A37434D6D1B91AE319021246" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_C7D426257E95A4ED0F431AE31902A78E_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital_C7D426257E95A4ED0F431AE31902A78E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributed surplus</link:label>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_C7D426257E95A4ED0F431AE31902A78E_label_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital_C7D426257E95A4ED0F431AE31902A78E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionalPaidinCapital" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_C7D426257E95A4ED0F431AE31902A78E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapital_C7D426257E95A4ED0F431AE31902A78E" xlink:to="lab_ifrs-full_AdditionalPaidinCapital_C7D426257E95A4ED0F431AE31902A78E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_6CAB0A9EB3FAD4A9B55C1AE31902F724_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_6CAB0A9EB3FAD4A9B55C1AE31902F724" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_6CAB0A9EB3FAD4A9B55C1AE31902F724_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_6CAB0A9EB3FAD4A9B55C1AE31902F724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_6CAB0A9EB3FAD4A9B55C1AE31902F724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_6CAB0A9EB3FAD4A9B55C1AE31902F724" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_6CAB0A9EB3FAD4A9B55C1AE31902F724" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RetainedEarnings_1F5F64E90B0E67C53C801AE319021148_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarnings_1F5F64E90B0E67C53C801AE319021148" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarnings_1F5F64E90B0E67C53C801AE319021148_label_en-US" xlink:label="lab_ifrs-full_RetainedEarnings_1F5F64E90B0E67C53C801AE319021148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_1F5F64E90B0E67C53C801AE319021148" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings_1F5F64E90B0E67C53C801AE319021148" xlink:to="lab_ifrs-full_RetainedEarnings_1F5F64E90B0E67C53C801AE319021148" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Equity_6273925024F100C7659F1AE3190234E4_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity_6273925024F100C7659F1AE3190234E4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_Equity_6273925024F100C7659F1AE3190234E4_label_en-US" xlink:label="lab_ifrs-full_Equity_6273925024F100C7659F1AE3190234E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_6273925024F100C7659F1AE3190234E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_6273925024F100C7659F1AE3190234E4" xlink:to="lab_ifrs-full_Equity_6273925024F100C7659F1AE3190234E4" xlink:type="arc" />
    <link:label id="lab_ifrs-full_EquityAndLiabilities_28222493A2BEC72335551AE3190297C7_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities_28222493A2BEC72335551AE3190297C7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_28222493A2BEC72335551AE3190297C7_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities_28222493A2BEC72335551AE3190297C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_28222493A2BEC72335551AE3190297C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities_28222493A2BEC72335551AE3190297C7" xlink:to="lab_ifrs-full_EquityAndLiabilities_28222493A2BEC72335551AE3190297C7" xlink:type="arc" />
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_D5721FAD5386FF378521E10FCFD2F942_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract_D5721FAD5386FF378521E10FCFD2F942" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_D5721FAD5386FF378521E10FCFD2F942" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_D5721FAD5386FF378521E10FCFD2F942" xlink:to="lab_ifrs-full_EarningsPerShareAbstract_D5721FAD5386FF378521E10FCFD2F942" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_34C58C3B50D9CF297415E10FCFD35952_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_34C58C3B50D9CF297415E10FCFD35952" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_34C58C3B50D9CF297415E10FCFD35952_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_34C58C3B50D9CF297415E10FCFD35952" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_34C58C3B50D9CF297415E10FCFD35952" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_34C58C3B50D9CF297415E10FCFD35952" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_34C58C3B50D9CF297415E10FCFD35952" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_29F16755F9574BC7317F1AEC02BD6C39_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_29F16755F9574BC7317F1AEC02BD6C39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_29F16755F9574BC7317F1AEC02BD6C39_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_29F16755F9574BC7317F1AEC02BD6C39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_29F16755F9574BC7317F1AEC02BD6C39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_29F16755F9574BC7317F1AEC02BD6C39" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_29F16755F9574BC7317F1AEC02BD6C39" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D862FFD738E94710EB8A1AEC02BDFF7D_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D862FFD738E94710EB8A1AEC02BDFF7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D862FFD738E94710EB8A1AEC02BDFF7D_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D862FFD738E94710EB8A1AEC02BDFF7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D862FFD738E94710EB8A1AEC02BDFF7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D862FFD738E94710EB8A1AEC02BDFF7D" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D862FFD738E94710EB8A1AEC02BDFF7D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182_terseLabel_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182_label_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182" xlink:type="arc" />
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_14970D45A3088A3A7D521AEC02BD90C9_terseLabel_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember_14970D45A3088A3A7D521AEC02BD90C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share units</link:label>
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_14970D45A3088A3A7D521AEC02BD90C9_label_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember_14970D45A3088A3A7D521AEC02BD90C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Units [Member]</link:label>
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_14970D45A3088A3A7D521AEC02BD90C9_documentation_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember_14970D45A3088A3A7D521AEC02BD90C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Units [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_RestrictedShareUnitsMember" xlink:label="loc_oncyf_RestrictedShareUnitsMember_14970D45A3088A3A7D521AEC02BD90C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_RestrictedShareUnitsMember_14970D45A3088A3A7D521AEC02BD90C9" xlink:to="lab_oncyf_RestrictedShareUnitsMember_14970D45A3088A3A7D521AEC02BD90C9" xlink:type="arc" />
    <link:label id="lab_oncyf_PerformanceShareUnitsMember_F2F19594E66289A945101AEC02BD4EA5_terseLabel_en-US" xlink:label="lab_oncyf_PerformanceShareUnitsMember_F2F19594E66289A945101AEC02BD4EA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance share units</link:label>
    <link:label id="lab_oncyf_PerformanceShareUnitsMember_F2F19594E66289A945101AEC02BD4EA5_label_en-US" xlink:label="lab_oncyf_PerformanceShareUnitsMember_F2F19594E66289A945101AEC02BD4EA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Share Units [Member]</link:label>
    <link:label id="lab_oncyf_PerformanceShareUnitsMember_F2F19594E66289A945101AEC02BD4EA5_documentation_en-US" xlink:label="lab_oncyf_PerformanceShareUnitsMember_F2F19594E66289A945101AEC02BD4EA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Share Units [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_PerformanceShareUnitsMember" xlink:label="loc_oncyf_PerformanceShareUnitsMember_F2F19594E66289A945101AEC02BD4EA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PerformanceShareUnitsMember_F2F19594E66289A945101AEC02BD4EA5" xlink:to="lab_oncyf_PerformanceShareUnitsMember_F2F19594E66289A945101AEC02BD4EA5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_31EDB7151FFBB02702991AEC02BD7780_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_31EDB7151FFBB02702991AEC02BD7780" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_31EDB7151FFBB02702991AEC02BD7780_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_31EDB7151FFBB02702991AEC02BD7780" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_31EDB7151FFBB02702991AEC02BD7780" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_31EDB7151FFBB02702991AEC02BD7780" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_31EDB7151FFBB02702991AEC02BD7780" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_90AFE20F770A60DE69111AEC02BD6C91_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_90AFE20F770A60DE69111AEC02BD6C91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_90AFE20F770A60DE69111AEC02BD6C91_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_90AFE20F770A60DE69111AEC02BD6C91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_90AFE20F770A60DE69111AEC02BD6C91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_90AFE20F770A60DE69111AEC02BD6C91" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_90AFE20F770A60DE69111AEC02BD6C91" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_5DB1C742558477EE5B261AEC02BD56F8_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_5DB1C742558477EE5B261AEC02BD56F8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_5DB1C742558477EE5B261AEC02BD56F8_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_5DB1C742558477EE5B261AEC02BD56F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_5DB1C742558477EE5B261AEC02BD56F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_5DB1C742558477EE5B261AEC02BD56F8" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_5DB1C742558477EE5B261AEC02BD56F8" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_B6E5E032930E5161EE701AEC02BE6FB2_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_B6E5E032930E5161EE701AEC02BE6FB2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_B6E5E032930E5161EE701AEC02BE6FB2_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_B6E5E032930E5161EE701AEC02BE6FB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_B6E5E032930E5161EE701AEC02BE6FB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_B6E5E032930E5161EE701AEC02BE6FB2" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_B6E5E032930E5161EE701AEC02BE6FB2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_F0D5E1AEA5033F0D204B1AEC02BEC562_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_F0D5E1AEA5033F0D204B1AEC02BEC562" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of the year (shares)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_F0D5E1AEA5033F0D204B1AEC02BEC562" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_F0D5E1AEA5033F0D204B1AEC02BEC562" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_F0D5E1AEA5033F0D204B1AEC02BEC562" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_245082FC8D924B5108F21AFF94565908_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_245082FC8D924B5108F21AFF94565908" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_245082FC8D924B5108F21AFF94565908_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_245082FC8D924B5108F21AFF94565908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_245082FC8D924B5108F21AFF94565908" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_245082FC8D924B5108F21AFF94565908" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_245082FC8D924B5108F21AFF94565908" xlink:type="arc" />
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_778B2863D71064AF0BFBF2828AC9ADE5_terseLabel_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_778B2863D71064AF0BFBF2828AC9ADE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in non-cash working capital</link:label>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_778B2863D71064AF0BFBF2828AC9ADE5_label_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_778B2863D71064AF0BFBF2828AC9ADE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Capital1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_778B2863D71064AF0BFBF2828AC9ADE5_documentation_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_778B2863D71064AF0BFBF2828AC9ADE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Capital1 [Table Text Block]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:label="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_778B2863D71064AF0BFBF2828AC9ADE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_778B2863D71064AF0BFBF2828AC9ADE5" xlink:to="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_778B2863D71064AF0BFBF2828AC9ADE5" xlink:type="arc" />
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_953127EF78ECFA383744F2828AC9DD32_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_953127EF78ECFA383744F2828AC9DD32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other cash flow disclosures</link:label>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_953127EF78ECFA383744F2828AC9DD32_label_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_953127EF78ECFA383744F2828AC9DD32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_953127EF78ECFA383744F2828AC9DD32_documentation_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_953127EF78ECFA383744F2828AC9DD32" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:label="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_953127EF78ECFA383744F2828AC9DD32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_953127EF78ECFA383744F2828AC9DD32" xlink:to="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_953127EF78ECFA383744F2828AC9DD32" xlink:type="arc" />
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_D2EEC3D4DD9FD2CA4672F2828AC3CCC4_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived_D2EEC3D4DD9FD2CA4672F2828AC3CCC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash interest received</link:label>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_D2EEC3D4DD9FD2CA4672F2828AC3CCC4_label_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived_D2EEC3D4DD9FD2CA4672F2828AC3CCC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_D2EEC3D4DD9FD2CA4672F2828AC3CCC4_documentation_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived_D2EEC3D4DD9FD2CA4672F2828AC3CCC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ProceedsfromInterestReceived" xlink:label="loc_oncyf_ProceedsfromInterestReceived_D2EEC3D4DD9FD2CA4672F2828AC3CCC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsfromInterestReceived_D2EEC3D4DD9FD2CA4672F2828AC3CCC4" xlink:to="lab_oncyf_ProceedsfromInterestReceived_D2EEC3D4DD9FD2CA4672F2828AC3CCC4" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefund_2646409F0C705673CB0CF2828AC38AFF_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund_2646409F0C705673CB0CF2828AC38AFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash taxes paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefund_2646409F0C705673CB0CF2828AC38AFF_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund_2646409F0C705673CB0CF2828AC38AFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund_2646409F0C705673CB0CF2828AC38AFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefund_2646409F0C705673CB0CF2828AC38AFF" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefund_2646409F0C705673CB0CF2828AC38AFF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RangeAxis_082F668E1ED0B26F88262046781A4371_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis_082F668E1ED0B26F88262046781A4371" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_082F668E1ED0B26F88262046781A4371_label_en-US" xlink:label="lab_ifrs-full_RangeAxis_082F668E1ED0B26F88262046781A4371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_082F668E1ED0B26F88262046781A4371" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis_082F668E1ED0B26F88262046781A4371" xlink:to="lab_ifrs-full_RangeAxis_082F668E1ED0B26F88262046781A4371" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
    <link:label id="lab_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED_label_en-US" xlink:label="lab_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED" xlink:to="lab_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED" xlink:type="arc" />
    <link:label id="lab_ifrs-full_BottomOfRangeMember_C52447AEBB7F76B73C932046781A4368_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember_C52447AEBB7F76B73C932046781A4368" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_C52447AEBB7F76B73C932046781A4368_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember_C52447AEBB7F76B73C932046781A4368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_C52447AEBB7F76B73C932046781A4368" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember_C52447AEBB7F76B73C932046781A4368" xlink:to="lab_ifrs-full_BottomOfRangeMember_C52447AEBB7F76B73C932046781A4368" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TopOfRangeMember_71F83A92D45ABD0374A62046781A91A1_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember_71F83A92D45ABD0374A62046781A91A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_71F83A92D45ABD0374A62046781A91A1_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember_71F83A92D45ABD0374A62046781A91A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_71F83A92D45ABD0374A62046781A91A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember_71F83A92D45ABD0374A62046781A91A1" xlink:to="lab_ifrs-full_TopOfRangeMember_71F83A92D45ABD0374A62046781A91A1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_551390C13971680DDD1D2046781A6736_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_551390C13971680DDD1D2046781A6736" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_551390C13971680DDD1D2046781A6736_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_551390C13971680DDD1D2046781A6736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_551390C13971680DDD1D2046781A6736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_551390C13971680DDD1D2046781A6736" xlink:to="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_551390C13971680DDD1D2046781A6736" xlink:type="arc" />
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_8EEEECAB5981F1502F162046781AC7D1_verboseLabel_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_8EEEECAB5981F1502F162046781AC7D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_8EEEECAB5981F1502F162046781AC7D1_label_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_8EEEECAB5981F1502F162046781AC7D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</link:label>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_8EEEECAB5981F1502F162046781AC7D1_documentation_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_8EEEECAB5981F1502F162046781AC7D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_8EEEECAB5981F1502F162046781AC7D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_8EEEECAB5981F1502F162046781AC7D1" xlink:to="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_8EEEECAB5981F1502F162046781AC7D1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_BEF69B21E2A1C7FDFA462046781AD1DE_terseLabel_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_BEF69B21E2A1C7FDFA462046781AD1DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares reserved for issuance</link:label>
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_BEF69B21E2A1C7FDFA462046781AD1DE_label_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_BEF69B21E2A1C7FDFA462046781AD1DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares reserved for issue under options and contracts for sale of shares</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_BEF69B21E2A1C7FDFA462046781AD1DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_BEF69B21E2A1C7FDFA462046781AD1DE" xlink:to="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_BEF69B21E2A1C7FDFA462046781AD1DE" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_B37499C9D107EEEAFC2C2046781AF937_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_B37499C9D107EEEAFC2C2046781AF937" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash share based compensation</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_B37499C9D107EEEAFC2C2046781AF937_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_B37499C9D107EEEAFC2C2046781AF937" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_B37499C9D107EEEAFC2C2046781AF937" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_B37499C9D107EEEAFC2C2046781AF937" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_B37499C9D107EEEAFC2C2046781AF937" xlink:type="arc" />
    <link:label id="lab_oncyf_ContingenciesAbstract_2BA75BF0EFF5A253E7F61AEC02A40762_label_en-US" xlink:label="lab_oncyf_ContingenciesAbstract_2BA75BF0EFF5A253E7F61AEC02A40762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:label id="lab_oncyf_ContingenciesAbstract_2BA75BF0EFF5A253E7F61AEC02A40762_documentation_en-US" xlink:label="lab_oncyf_ContingenciesAbstract_2BA75BF0EFF5A253E7F61AEC02A40762" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ContingenciesAbstract" xlink:label="loc_oncyf_ContingenciesAbstract_2BA75BF0EFF5A253E7F61AEC02A40762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingenciesAbstract_2BA75BF0EFF5A253E7F61AEC02A40762" xlink:to="lab_oncyf_ContingenciesAbstract_2BA75BF0EFF5A253E7F61AEC02A40762" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_BEA86258899B178DE2D71AEC02A4A168_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_BEA86258899B178DE2D71AEC02A4A168" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_BEA86258899B178DE2D71AEC02A4A168_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_BEA86258899B178DE2D71AEC02A4A168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_BEA86258899B178DE2D71AEC02A4A168" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_BEA86258899B178DE2D71AEC02A4A168" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_BEA86258899B178DE2D71AEC02A4A168" xlink:type="arc" />
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_D9B0E0681BED7B88E670E19BEF6E2829_label_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_D9B0E0681BED7B88E670E19BEF6E2829" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_D9B0E0681BED7B88E670E19BEF6E2829_documentation_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_D9B0E0681BED7B88E670E19BEF6E2829" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:label="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_D9B0E0681BED7B88E670E19BEF6E2829" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_D9B0E0681BED7B88E670E19BEF6E2829" xlink:to="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_D9B0E0681BED7B88E670E19BEF6E2829" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_B41029DAEC468C21542DE19BEF6EAC3D_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_B41029DAEC468C21542DE19BEF6EAC3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Judgments, Estimates and Assumptions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_B41029DAEC468C21542DE19BEF6EAC3D_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_B41029DAEC468C21542DE19BEF6EAC3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_B41029DAEC468C21542DE19BEF6EAC3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_B41029DAEC468C21542DE19BEF6EAC3D" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_B41029DAEC468C21542DE19BEF6EAC3D" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_F888CD992E8CC28572E8E10D71076722_label_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract_F888CD992E8CC28572E8E10D71076722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_F888CD992E8CC28572E8E10D71076722_documentation_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract_F888CD992E8CC28572E8E10D71076722" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofincometaxAbstract" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_F888CD992E8CC28572E8E10D71076722" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_F888CD992E8CC28572E8E10D71076722" xlink:to="lab_oncyf_DisclosureofincometaxAbstract_F888CD992E8CC28572E8E10D71076722" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_68C867761D5700583F69E10D71070B3D_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_68C867761D5700583F69E10D71070B3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_68C867761D5700583F69E10D71070B3D_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_68C867761D5700583F69E10D71070B3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_68C867761D5700583F69E10D71070B3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_68C867761D5700583F69E10D71070B3D" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_68C867761D5700583F69E10D71070B3D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AccountingProfit_A8EE06A527A3BEF8ECEE1AEC029AD20B_terseLabel_en-US" xlink:label="lab_ifrs-full_AccountingProfit_A8EE06A527A3BEF8ECEE1AEC029AD20B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_ifrs-full_AccountingProfit_A8EE06A527A3BEF8ECEE1AEC029AD20B_label_en-US" xlink:label="lab_ifrs-full_AccountingProfit_A8EE06A527A3BEF8ECEE1AEC029AD20B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting profit</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccountingProfit" xlink:label="loc_ifrs-full_AccountingProfit_A8EE06A527A3BEF8ECEE1AEC029AD20B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccountingProfit_A8EE06A527A3BEF8ECEE1AEC029AD20B" xlink:to="lab_ifrs-full_AccountingProfit_A8EE06A527A3BEF8ECEE1AEC029AD20B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ApplicableTaxRate_991F85482E56322119E01AEC029A7995_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate_991F85482E56322119E01AEC029A7995" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory Canadian corporate tax rate</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_991F85482E56322119E01AEC029A7995_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate_991F85482E56322119E01AEC029A7995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_991F85482E56322119E01AEC029A7995" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate_991F85482E56322119E01AEC029A7995" xlink:to="lab_ifrs-full_ApplicableTaxRate_991F85482E56322119E01AEC029A7995" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_41B35362066B6F55ED451AEC029A3D65_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_41B35362066B6F55ED451AEC029A3D65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anticipated tax recovery</link:label>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_41B35362066B6F55ED451AEC029A3D65_label_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_41B35362066B6F55ED451AEC029A3D65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income) at applicable tax rate</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_41B35362066B6F55ED451AEC029A3D65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_41B35362066B6F55ED451AEC029A3D65" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_41B35362066B6F55ED451AEC029A3D65" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_83078D441F16DAA6F1811AEC029A6C8B_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates_83078D441F16DAA6F1811AEC029A6C8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign jurisdiction tax rate difference</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_83078D441F16DAA6F1811AEC029A6C8B_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates_83078D441F16DAA6F1811AEC029A6C8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect of foreign tax rates</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_83078D441F16DAA6F1811AEC029A6C8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfForeignTaxRates_83078D441F16DAA6F1811AEC029A6C8B" xlink:to="lab_ifrs-full_TaxEffectOfForeignTaxRates_83078D441F16DAA6F1811AEC029A6C8B" xlink:type="arc" />
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_B0E01D7730E6AE57A0AC1AEC029AACB0_negatedTerseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation_B0E01D7730E6AE57A0AC1AEC029AACB0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Employee stock based compensation</link:label>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_B0E01D7730E6AE57A0AC1AEC029AACB0_label_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation_B0E01D7730E6AE57A0AC1AEC029AACB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Stock Based Compensation</link:label>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_B0E01D7730E6AE57A0AC1AEC029AACB0_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation_B0E01D7730E6AE57A0AC1AEC029AACB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Stock Based Compensation</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TaxEffectOfStockBasedCompensation" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_B0E01D7730E6AE57A0AC1AEC029AACB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfStockBasedCompensation_B0E01D7730E6AE57A0AC1AEC029AACB0" xlink:to="lab_oncyf_TaxEffectOfStockBasedCompensation_B0E01D7730E6AE57A0AC1AEC029AACB0" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TaxEffectFromChangeInTaxRate_E09CB1BD910FEB90821F1AEC029A4A7A_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate_E09CB1BD910FEB90821F1AEC029A4A7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in tax rate</link:label>
    <link:label id="lab_ifrs-full_TaxEffectFromChangeInTaxRate_E09CB1BD910FEB90821F1AEC029A4A7A_label_en-US" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate_E09CB1BD910FEB90821F1AEC029A4A7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect from change in tax rate</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_E09CB1BD910FEB90821F1AEC029A4A7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectFromChangeInTaxRate_E09CB1BD910FEB90821F1AEC029A4A7A" xlink:to="lab_ifrs-full_TaxEffectFromChangeInTaxRate_E09CB1BD910FEB90821F1AEC029A4A7A" xlink:type="arc" />
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_5A6DB7D01D1673EA56DF1AEC029A870D_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools_5A6DB7D01D1673EA56DF1AEC029A870D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to opening tax pools</link:label>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_5A6DB7D01D1673EA56DF1AEC029A870D_label_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools_5A6DB7D01D1673EA56DF1AEC029A870D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Tax Pools</link:label>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_5A6DB7D01D1673EA56DF1AEC029A870D_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools_5A6DB7D01D1673EA56DF1AEC029A870D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Tax Pools</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TaxEffectOfTaxPools" xlink:label="loc_oncyf_TaxEffectOfTaxPools_5A6DB7D01D1673EA56DF1AEC029A870D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfTaxPools_5A6DB7D01D1673EA56DF1AEC029A870D" xlink:to="lab_oncyf_TaxEffectOfTaxPools_5A6DB7D01D1673EA56DF1AEC029A870D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_A3815BBB4D0FEA699FA51AEC029AEB3A_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_A3815BBB4D0FEA699FA51AEC029AEB3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_A3815BBB4D0FEA699FA51AEC029AEB3A_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_A3815BBB4D0FEA699FA51AEC029AEB3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect of expense not deductible in determining taxable profit (tax loss)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_A3815BBB4D0FEA699FA51AEC029AEB3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_A3815BBB4D0FEA699FA51AEC029AEB3A" xlink:to="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_A3815BBB4D0FEA699FA51AEC029AEB3A" xlink:type="arc" />
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_6F1247DB81C325BED9001AEC029A9ECF_negatedTerseLabel_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_6F1247DB81C325BED9001AEC029A9ECF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in deferred tax benefits deemed not probable to be recovered</link:label>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_6F1247DB81C325BED9001AEC029A9ECF_label_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_6F1247DB81C325BED9001AEC029A9ECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</link:label>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_6F1247DB81C325BED9001AEC029A9ECF_documentation_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_6F1247DB81C325BED9001AEC029A9ECF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_6F1247DB81C325BED9001AEC029A9ECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_6F1247DB81C325BED9001AEC029A9ECF" xlink:to="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_6F1247DB81C325BED9001AEC029A9ECF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_11920AFAA3197514AD6D1AEC029A8423_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome_11920AFAA3197514AD6D1AEC029A8423" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current income taxes</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_11920AFAA3197514AD6D1AEC029A8423_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome_11920AFAA3197514AD6D1AEC029A8423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_11920AFAA3197514AD6D1AEC029A8423" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_11920AFAA3197514AD6D1AEC029A8423" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome_11920AFAA3197514AD6D1AEC029A8423" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_402436FAE0EC37462B131AEC029AD864_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_402436FAE0EC37462B131AEC029AD864" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment in respect to prior periods</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_402436FAE0EC37462B131AEC029AD864_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_402436FAE0EC37462B131AEC029AD864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for current tax of prior periods</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_402436FAE0EC37462B131AEC029AD864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_402436FAE0EC37462B131AEC029AD864" xlink:to="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_402436FAE0EC37462B131AEC029AD864" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_6A945C583C8F350442BA1AEC029A63D1_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_6A945C583C8F350442BA1AEC029A63D1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net current tax expense</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_6A945C583C8F350442BA1AEC029A63D1_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_6A945C583C8F350442BA1AEC029A63D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income) and adjustments for current tax of prior periods</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_6A945C583C8F350442BA1AEC029A63D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_6A945C583C8F350442BA1AEC029A63D1" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_6A945C583C8F350442BA1AEC029A63D1" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7E320FFB4B801D48D70320C2C66B6610_label_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7E320FFB4B801D48D70320C2C66B6610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7E320FFB4B801D48D70320C2C66B6610_documentation_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7E320FFB4B801D48D70320C2C66B6610" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7E320FFB4B801D48D70320C2C66B6610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7E320FFB4B801D48D70320C2C66B6610" xlink:to="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7E320FFB4B801D48D70320C2C66B6610" xlink:type="arc" />
    <link:label id="lab_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right1 [Table]</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right1 [Table]</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right1 [Table]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ClassofWarrantorRight1Table" xlink:label="loc_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8" xlink:to="lab_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8" xlink:type="arc" />
    <link:label id="lab_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E_terseLabel_en-US" xlink:label="lab_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E_label_en-US" xlink:label="lab_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E_documentation_en-US" xlink:label="lab_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MilestoneAxis" xlink:label="loc_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E" xlink:to="lab_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E" xlink:type="arc" />
    <link:label id="lab_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E_terseLabel_en-US" xlink:label="lab_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E_label_en-US" xlink:label="lab_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E_documentation_en-US" xlink:label="lab_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Milestone [Axis]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MilestoneDomain" xlink:label="loc_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E" xlink:to="lab_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E" xlink:type="arc" />
    <link:label id="lab_oncyf_MilestoneOneMember_8809401FEA66750CF0A020C2C66CA95C_terseLabel_en-US" xlink:label="lab_oncyf_MilestoneOneMember_8809401FEA66750CF0A020C2C66CA95C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone 1</link:label>
    <link:label id="lab_oncyf_MilestoneOneMember_8809401FEA66750CF0A020C2C66CA95C_label_en-US" xlink:label="lab_oncyf_MilestoneOneMember_8809401FEA66750CF0A020C2C66CA95C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_oncyf_MilestoneOneMember_8809401FEA66750CF0A020C2C66CA95C_documentation_en-US" xlink:label="lab_oncyf_MilestoneOneMember_8809401FEA66750CF0A020C2C66CA95C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MilestoneOneMember" xlink:label="loc_oncyf_MilestoneOneMember_8809401FEA66750CF0A020C2C66CA95C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MilestoneOneMember_8809401FEA66750CF0A020C2C66CA95C" xlink:to="lab_oncyf_MilestoneOneMember_8809401FEA66750CF0A020C2C66CA95C" xlink:type="arc" />
    <link:label id="lab_oncyf_MilestoneTwoMember_B82B6EF5DBDEB0A01FF220C2C66CD5D3_terseLabel_en-US" xlink:label="lab_oncyf_MilestoneTwoMember_B82B6EF5DBDEB0A01FF220C2C66CD5D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone 2</link:label>
    <link:label id="lab_oncyf_MilestoneTwoMember_B82B6EF5DBDEB0A01FF220C2C66CD5D3_label_en-US" xlink:label="lab_oncyf_MilestoneTwoMember_B82B6EF5DBDEB0A01FF220C2C66CD5D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_oncyf_MilestoneTwoMember_B82B6EF5DBDEB0A01FF220C2C66CD5D3_documentation_en-US" xlink:label="lab_oncyf_MilestoneTwoMember_B82B6EF5DBDEB0A01FF220C2C66CD5D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MilestoneTwoMember" xlink:label="loc_oncyf_MilestoneTwoMember_B82B6EF5DBDEB0A01FF220C2C66CD5D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MilestoneTwoMember_B82B6EF5DBDEB0A01FF220C2C66CD5D3" xlink:to="lab_oncyf_MilestoneTwoMember_B82B6EF5DBDEB0A01FF220C2C66CD5D3" xlink:type="arc" />
    <link:label id="lab_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Class of Warrant or Right1 [Table]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ClassofWarrantorRight1LineItems" xlink:label="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:to="lab_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantPurchaseAgreement_9F41C45A650C64D179E120C2C66C31F0_terseLabel_en-US" xlink:label="lab_oncyf_WarrantPurchaseAgreement_9F41C45A650C64D179E120C2C66C31F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant purchase agreement</link:label>
    <link:label id="lab_oncyf_WarrantPurchaseAgreement_9F41C45A650C64D179E120C2C66C31F0_label_en-US" xlink:label="lab_oncyf_WarrantPurchaseAgreement_9F41C45A650C64D179E120C2C66C31F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Purchase Agreement</link:label>
    <link:label id="lab_oncyf_WarrantPurchaseAgreement_9F41C45A650C64D179E120C2C66C31F0_documentation_en-US" xlink:label="lab_oncyf_WarrantPurchaseAgreement_9F41C45A650C64D179E120C2C66C31F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Purchase Agreement</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantPurchaseAgreement" xlink:label="loc_oncyf_WarrantPurchaseAgreement_9F41C45A650C64D179E120C2C66C31F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantPurchaseAgreement_9F41C45A650C64D179E120C2C66C31F0" xlink:to="lab_oncyf_WarrantPurchaseAgreement_9F41C45A650C64D179E120C2C66C31F0" xlink:type="arc" />
    <link:label id="lab_oncyf_SharePricePremiumPercent_81A423743992B05FD0F720C2C66CBF6F_terseLabel_en-US" xlink:label="lab_oncyf_SharePricePremiumPercent_81A423743992B05FD0F720C2C66CBF6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common share premium</link:label>
    <link:label id="lab_oncyf_SharePricePremiumPercent_81A423743992B05FD0F720C2C66CBF6F_label_en-US" xlink:label="lab_oncyf_SharePricePremiumPercent_81A423743992B05FD0F720C2C66CBF6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price Premium, Percent</link:label>
    <link:label id="lab_oncyf_SharePricePremiumPercent_81A423743992B05FD0F720C2C66CBF6F_documentation_en-US" xlink:label="lab_oncyf_SharePricePremiumPercent_81A423743992B05FD0F720C2C66CBF6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Price Premium, Percent</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharePricePremiumPercent" xlink:label="loc_oncyf_SharePricePremiumPercent_81A423743992B05FD0F720C2C66CBF6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePricePremiumPercent_81A423743992B05FD0F720C2C66CBF6F" xlink:to="lab_oncyf_SharePricePremiumPercent_81A423743992B05FD0F720C2C66CBF6F" xlink:type="arc" />
    <link:label id="lab_oncyf_WeightedAverageClosingPriceDuration_61570DEB8B25AB43FB3B20C2C66C2233_terseLabel_en-US" xlink:label="lab_oncyf_WeightedAverageClosingPriceDuration_61570DEB8B25AB43FB3B20C2C66C2233" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average closing price term</link:label>
    <link:label id="lab_oncyf_WeightedAverageClosingPriceDuration_61570DEB8B25AB43FB3B20C2C66C2233_label_en-US" xlink:label="lab_oncyf_WeightedAverageClosingPriceDuration_61570DEB8B25AB43FB3B20C2C66C2233" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Closing Price Duration</link:label>
    <link:label id="lab_oncyf_WeightedAverageClosingPriceDuration_61570DEB8B25AB43FB3B20C2C66C2233_documentation_en-US" xlink:label="lab_oncyf_WeightedAverageClosingPriceDuration_61570DEB8B25AB43FB3B20C2C66C2233" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Closing Price Duration</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WeightedAverageClosingPriceDuration" xlink:label="loc_oncyf_WeightedAverageClosingPriceDuration_61570DEB8B25AB43FB3B20C2C66C2233" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WeightedAverageClosingPriceDuration_61570DEB8B25AB43FB3B20C2C66C2233" xlink:to="lab_oncyf_WeightedAverageClosingPriceDuration_61570DEB8B25AB43FB3B20C2C66C2233" xlink:type="arc" />
    <link:label id="lab_oncyf_NumberofPatients_797BF9D2ED73EF104BCF20C2C66C3E3F_terseLabel_en-US" xlink:label="lab_oncyf_NumberofPatients_797BF9D2ED73EF104BCF20C2C66C3E3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patients</link:label>
    <link:label id="lab_oncyf_NumberofPatients_797BF9D2ED73EF104BCF20C2C66C3E3F_label_en-US" xlink:label="lab_oncyf_NumberofPatients_797BF9D2ED73EF104BCF20C2C66C3E3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Patients</link:label>
    <link:label id="lab_oncyf_NumberofPatients_797BF9D2ED73EF104BCF20C2C66C3E3F_documentation_en-US" xlink:label="lab_oncyf_NumberofPatients_797BF9D2ED73EF104BCF20C2C66C3E3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Patients</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_NumberofPatients" xlink:label="loc_oncyf_NumberofPatients_797BF9D2ED73EF104BCF20C2C66C3E3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberofPatients_797BF9D2ED73EF104BCF20C2C66C3E3F" xlink:to="lab_oncyf_NumberofPatients_797BF9D2ED73EF104BCF20C2C66C3E3F" xlink:type="arc" />
    <link:label id="lab_oncyf_RighttoCallWarrantMilestoneOneTerm_31CBF5FBCDC0913D825F20C2C66C1B0A_terseLabel_en-US" xlink:label="lab_oncyf_RighttoCallWarrantMilestoneOneTerm_31CBF5FBCDC0913D825F20C2C66C1B0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right to call warrant from time of agreement, term</link:label>
    <link:label id="lab_oncyf_RighttoCallWarrantMilestoneOneTerm_31CBF5FBCDC0913D825F20C2C66C1B0A_label_en-US" xlink:label="lab_oncyf_RighttoCallWarrantMilestoneOneTerm_31CBF5FBCDC0913D825F20C2C66C1B0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right to Call Warrant, Milestone One, Term</link:label>
    <link:label id="lab_oncyf_RighttoCallWarrantMilestoneOneTerm_31CBF5FBCDC0913D825F20C2C66C1B0A_documentation_en-US" xlink:label="lab_oncyf_RighttoCallWarrantMilestoneOneTerm_31CBF5FBCDC0913D825F20C2C66C1B0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right to Call Warrant, Milestone One, Term</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_RighttoCallWarrantMilestoneOneTerm" xlink:label="loc_oncyf_RighttoCallWarrantMilestoneOneTerm_31CBF5FBCDC0913D825F20C2C66C1B0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_RighttoCallWarrantMilestoneOneTerm_31CBF5FBCDC0913D825F20C2C66C1B0A" xlink:to="lab_oncyf_RighttoCallWarrantMilestoneOneTerm_31CBF5FBCDC0913D825F20C2C66C1B0A" xlink:type="arc" />
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_62B3FAFA2EFBB66717C820C2C66C76CF_terseLabel_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod_62B3FAFA2EFBB66717C820C2C66C76CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected recognition period</link:label>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_62B3FAFA2EFBB66717C820C2C66C76CF_label_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod_62B3FAFA2EFBB66717C820C2C66C76CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Liability, Recognition Period</link:label>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_62B3FAFA2EFBB66717C820C2C66C76CF_documentation_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod_62B3FAFA2EFBB66717C820C2C66C76CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Liability, Recognition Period</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ContractLiabilityRecognitionPeriod" xlink:label="loc_oncyf_ContractLiabilityRecognitionPeriod_62B3FAFA2EFBB66717C820C2C66C76CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContractLiabilityRecognitionPeriod_62B3FAFA2EFBB66717C820C2C66C76CF" xlink:to="lab_oncyf_ContractLiabilityRecognitionPeriod_62B3FAFA2EFBB66717C820C2C66C76CF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_FBB43CD385103E590BE1C8041F7B3965_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_FBB43CD385103E590BE1C8041F7B3965" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_FBB43CD385103E590BE1C8041F7B3965_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_FBB43CD385103E590BE1C8041F7B3965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of objectives, policies and processes for managing capital [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_FBB43CD385103E590BE1C8041F7B3965" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_FBB43CD385103E590BE1C8041F7B3965" xlink:to="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_FBB43CD385103E590BE1C8041F7B3965" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ContractLiabilities_10A928C2157F6584146B253CCB35791B_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities_10A928C2157F6584146B253CCB35791B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of the year</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_10A928C2157F6584146B253CCB35791B_label_en-US" xlink:label="lab_ifrs-full_ContractLiabilities_10A928C2157F6584146B253CCB35791B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_10A928C2157F6584146B253CCB35791B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities_10A928C2157F6584146B253CCB35791B" xlink:to="lab_ifrs-full_ContractLiabilities_10A928C2157F6584146B253CCB35791B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_7E18F9C0BC04E4597282253B15D1A392_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers_7E18F9C0BC04E4597282253B15D1A392" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regional licensing agreement</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_7E18F9C0BC04E4597282253B15D1A392_label_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers_7E18F9C0BC04E4597282253B15D1A392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_7E18F9C0BC04E4597282253B15D1A392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers_7E18F9C0BC04E4597282253B15D1A392" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers_7E18F9C0BC04E4597282253B15D1A392" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_4E97F3E4560C92D28807253B15D16258_terseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_4E97F3E4560C92D28807253B15D16258" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized in the year</link:label>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_4E97F3E4560C92D28807253B15D16258_label_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_4E97F3E4560C92D28807253B15D16258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through performance obligation being satisfied, contract liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_4E97F3E4560C92D28807253B15D16258" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_4E97F3E4560C92D28807253B15D16258" xlink:to="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_4E97F3E4560C92D28807253B15D16258" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ContractLiabilities_916627DB9971A1B5BA25253E73C542B4_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities_916627DB9971A1B5BA25253E73C542B4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, end of the year</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_916627DB9971A1B5BA25253E73C542B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities_916627DB9971A1B5BA25253E73C542B4" xlink:to="lab_ifrs-full_ContractLiabilities_916627DB9971A1B5BA25253E73C542B4" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_C9B04EC3FA2E8BC7546F253B15D1577D_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities_C9B04EC3FA2E8BC7546F253B15D1577D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract liability - current</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_C9B04EC3FA2E8BC7546F253B15D1577D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities_C9B04EC3FA2E8BC7546F253B15D1577D" xlink:to="lab_ifrs-full_CurrentContractLiabilities_C9B04EC3FA2E8BC7546F253B15D1577D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_C2332600593C074D8783253B15D15B31_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities_C2332600593C074D8783253B15D15B31" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract liability - non-current</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_C2332600593C074D8783253B15D15B31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities_C2332600593C074D8783253B15D15B31" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities_C2332600593C074D8783253B15D15B31" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ContractLiabilities_59673666BBA426B9F8E7253B15D24F40_totalLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities_59673666BBA426B9F8E7253B15D24F40" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_59673666BBA426B9F8E7253B15D24F40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities_59673666BBA426B9F8E7253B15D24F40" xlink:to="lab_ifrs-full_ContractLiabilities_59673666BBA426B9F8E7253B15D24F40" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE" xlink:type="arc" />
    <link:label id="lab_ifrs-full_MaturityAxis_5DB9EE2BA3AFD6D60013F2828AF37C93_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis_5DB9EE2BA3AFD6D60013F2828AF37C93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_5DB9EE2BA3AFD6D60013F2828AF37C93_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis_5DB9EE2BA3AFD6D60013F2828AF37C93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_5DB9EE2BA3AFD6D60013F2828AF37C93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis_5DB9EE2BA3AFD6D60013F2828AF37C93" xlink:to="lab_ifrs-full_MaturityAxis_5DB9EE2BA3AFD6D60013F2828AF37C93" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509_label_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentySixMember_12ED0A6AC1AF61A8B44FF2828AF3D1F5_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentySixMember_12ED0A6AC1AF61A8B44FF2828AF3D1F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_oncyf_TwentyTwentySixMember_12ED0A6AC1AF61A8B44FF2828AF3D1F5_label_en-US" xlink:label="lab_oncyf_TwentyTwentySixMember_12ED0A6AC1AF61A8B44FF2828AF3D1F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Six [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentySixMember_12ED0A6AC1AF61A8B44FF2828AF3D1F5_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentySixMember_12ED0A6AC1AF61A8B44FF2828AF3D1F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Six [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentySixMember" xlink:label="loc_oncyf_TwentyTwentySixMember_12ED0A6AC1AF61A8B44FF2828AF3D1F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentySixMember_12ED0A6AC1AF61A8B44FF2828AF3D1F5" xlink:to="lab_oncyf_TwentyTwentySixMember_12ED0A6AC1AF61A8B44FF2828AF3D1F5" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentySevenMember_A1EEAFBC16D1617DFF40F2828AF38428_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentySevenMember_A1EEAFBC16D1617DFF40F2828AF38428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_oncyf_TwentyTwentySevenMember_A1EEAFBC16D1617DFF40F2828AF38428_label_en-US" xlink:label="lab_oncyf_TwentyTwentySevenMember_A1EEAFBC16D1617DFF40F2828AF38428" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Seven [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentySevenMember_A1EEAFBC16D1617DFF40F2828AF38428_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentySevenMember_A1EEAFBC16D1617DFF40F2828AF38428" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Seven [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentySevenMember" xlink:label="loc_oncyf_TwentyTwentySevenMember_A1EEAFBC16D1617DFF40F2828AF38428" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentySevenMember_A1EEAFBC16D1617DFF40F2828AF38428" xlink:to="lab_oncyf_TwentyTwentySevenMember_A1EEAFBC16D1617DFF40F2828AF38428" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyNineMember_A35705262A2E3718584AF2828AF3B821_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyNineMember_A35705262A2E3718584AF2828AF3B821" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_oncyf_TwentyTwentyNineMember_A35705262A2E3718584AF2828AF3B821_label_en-US" xlink:label="lab_oncyf_TwentyTwentyNineMember_A35705262A2E3718584AF2828AF3B821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Nine [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyNineMember_A35705262A2E3718584AF2828AF3B821_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyNineMember_A35705262A2E3718584AF2828AF3B821" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Nine [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyNineMember" xlink:label="loc_oncyf_TwentyTwentyNineMember_A35705262A2E3718584AF2828AF3B821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyNineMember_A35705262A2E3718584AF2828AF3B821" xlink:to="lab_oncyf_TwentyTwentyNineMember_A35705262A2E3718584AF2828AF3B821" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtyMember_B0D9FF8A79E281167036F2828AF35AFD_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyMember_B0D9FF8A79E281167036F2828AF35AFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_oncyf_TwentyThirtyMember_B0D9FF8A79E281167036F2828AF35AFD_label_en-US" xlink:label="lab_oncyf_TwentyThirtyMember_B0D9FF8A79E281167036F2828AF35AFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyMember_B0D9FF8A79E281167036F2828AF35AFD_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyMember_B0D9FF8A79E281167036F2828AF35AFD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyMember" xlink:label="loc_oncyf_TwentyThirtyMember_B0D9FF8A79E281167036F2828AF35AFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyMember_B0D9FF8A79E281167036F2828AF35AFD" xlink:to="lab_oncyf_TwentyThirtyMember_B0D9FF8A79E281167036F2828AF35AFD" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtyOneMember_59F6E6F17590EB2D08C0F2828AF35465_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyOneMember_59F6E6F17590EB2D08C0F2828AF35465" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2031</link:label>
    <link:label id="lab_oncyf_TwentyThirtyOneMember_59F6E6F17590EB2D08C0F2828AF35465_label_en-US" xlink:label="lab_oncyf_TwentyThirtyOneMember_59F6E6F17590EB2D08C0F2828AF35465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty One [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyOneMember_59F6E6F17590EB2D08C0F2828AF35465_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyOneMember_59F6E6F17590EB2D08C0F2828AF35465" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty One [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyOneMember" xlink:label="loc_oncyf_TwentyThirtyOneMember_59F6E6F17590EB2D08C0F2828AF35465" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyOneMember_59F6E6F17590EB2D08C0F2828AF35465" xlink:to="lab_oncyf_TwentyThirtyOneMember_59F6E6F17590EB2D08C0F2828AF35465" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtyTwoMember_F31E20799D9C5711E8FEF2828AF4FBFA_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyTwoMember_F31E20799D9C5711E8FEF2828AF4FBFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2032</link:label>
    <link:label id="lab_oncyf_TwentyThirtyTwoMember_F31E20799D9C5711E8FEF2828AF4FBFA_label_en-US" xlink:label="lab_oncyf_TwentyThirtyTwoMember_F31E20799D9C5711E8FEF2828AF4FBFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty Two [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyTwoMember_F31E20799D9C5711E8FEF2828AF4FBFA_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyTwoMember_F31E20799D9C5711E8FEF2828AF4FBFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty Two [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyTwoMember" xlink:label="loc_oncyf_TwentyThirtyTwoMember_F31E20799D9C5711E8FEF2828AF4FBFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyTwoMember_F31E20799D9C5711E8FEF2828AF4FBFA" xlink:to="lab_oncyf_TwentyThirtyTwoMember_F31E20799D9C5711E8FEF2828AF4FBFA" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtyThreeMember_922C0D1D5334453A79DDF2828AF4BEDB_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyThreeMember_922C0D1D5334453A79DDF2828AF4BEDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2033</link:label>
    <link:label id="lab_oncyf_TwentyThirtyThreeMember_922C0D1D5334453A79DDF2828AF4BEDB_label_en-US" xlink:label="lab_oncyf_TwentyThirtyThreeMember_922C0D1D5334453A79DDF2828AF4BEDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty Three [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyThreeMember_922C0D1D5334453A79DDF2828AF4BEDB_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyThreeMember_922C0D1D5334453A79DDF2828AF4BEDB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty Three [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyThreeMember" xlink:label="loc_oncyf_TwentyThirtyThreeMember_922C0D1D5334453A79DDF2828AF4BEDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyThreeMember_922C0D1D5334453A79DDF2828AF4BEDB" xlink:to="lab_oncyf_TwentyThirtyThreeMember_922C0D1D5334453A79DDF2828AF4BEDB" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtyFourMember_D4A65F09A07CFAFA6118F2828AF44370_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyFourMember_D4A65F09A07CFAFA6118F2828AF44370" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2034</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFourMember_D4A65F09A07CFAFA6118F2828AF44370_label_en-US" xlink:label="lab_oncyf_TwentyThirtyFourMember_D4A65F09A07CFAFA6118F2828AF44370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty Four [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFourMember_D4A65F09A07CFAFA6118F2828AF44370_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyFourMember_D4A65F09A07CFAFA6118F2828AF44370" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty Four [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyFourMember" xlink:label="loc_oncyf_TwentyThirtyFourMember_D4A65F09A07CFAFA6118F2828AF44370" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyFourMember_D4A65F09A07CFAFA6118F2828AF44370" xlink:to="lab_oncyf_TwentyThirtyFourMember_D4A65F09A07CFAFA6118F2828AF44370" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtyFiveMember_F7DDCCB0928F90C1392DF2828AF46B04_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyFiveMember_F7DDCCB0928F90C1392DF2828AF46B04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2035</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFiveMember_F7DDCCB0928F90C1392DF2828AF46B04_label_en-US" xlink:label="lab_oncyf_TwentyThirtyFiveMember_F7DDCCB0928F90C1392DF2828AF46B04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty Five [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFiveMember_F7DDCCB0928F90C1392DF2828AF46B04_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyFiveMember_F7DDCCB0928F90C1392DF2828AF46B04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty Five [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyFiveMember" xlink:label="loc_oncyf_TwentyThirtyFiveMember_F7DDCCB0928F90C1392DF2828AF46B04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyFiveMember_F7DDCCB0928F90C1392DF2828AF46B04" xlink:to="lab_oncyf_TwentyThirtyFiveMember_F7DDCCB0928F90C1392DF2828AF46B04" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtySixMember_D0BDC12167D58057B7FAF2828AF4184B_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtySixMember_D0BDC12167D58057B7FAF2828AF4184B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2036</link:label>
    <link:label id="lab_oncyf_TwentyThirtySixMember_D0BDC12167D58057B7FAF2828AF4184B_label_en-US" xlink:label="lab_oncyf_TwentyThirtySixMember_D0BDC12167D58057B7FAF2828AF4184B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty Six [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtySixMember_D0BDC12167D58057B7FAF2828AF4184B_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtySixMember_D0BDC12167D58057B7FAF2828AF4184B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty Six [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtySixMember" xlink:label="loc_oncyf_TwentyThirtySixMember_D0BDC12167D58057B7FAF2828AF4184B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtySixMember_D0BDC12167D58057B7FAF2828AF4184B" xlink:to="lab_oncyf_TwentyThirtySixMember_D0BDC12167D58057B7FAF2828AF4184B" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtySevenMember_5EC92037CE7883FBDFD1F2D64EBDFFE1_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtySevenMember_5EC92037CE7883FBDFD1F2D64EBDFFE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2037</link:label>
    <link:label id="lab_oncyf_TwentyThirtySevenMember_5EC92037CE7883FBDFD1F2D64EBDFFE1_label_en-US" xlink:label="lab_oncyf_TwentyThirtySevenMember_5EC92037CE7883FBDFD1F2D64EBDFFE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty Seven [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtySevenMember_5EC92037CE7883FBDFD1F2D64EBDFFE1_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtySevenMember_5EC92037CE7883FBDFD1F2D64EBDFFE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty Seven [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtySevenMember" xlink:label="loc_oncyf_TwentyThirtySevenMember_5EC92037CE7883FBDFD1F2D64EBDFFE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtySevenMember_5EC92037CE7883FBDFD1F2D64EBDFFE1" xlink:to="lab_oncyf_TwentyThirtySevenMember_5EC92037CE7883FBDFD1F2D64EBDFFE1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_A0D1440383EA16A39829F2828AF4B8A9_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_A0D1440383EA16A39829F2828AF4B8A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_A0D1440383EA16A39829F2828AF4B8A9_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_A0D1440383EA16A39829F2828AF4B8A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_A0D1440383EA16A39829F2828AF4B8A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_A0D1440383EA16A39829F2828AF4B8A9" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_A0D1440383EA16A39829F2828AF4B8A9" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6" xlink:type="arc" />
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_E40FA1CBF8E6DBC046CEF2828AF40B32_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember_E40FA1CBF8E6DBC046CEF2828AF40B32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-capital losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_E40FA1CBF8E6DBC046CEF2828AF40B32_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember_E40FA1CBF8E6DBC046CEF2828AF40B32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_E40FA1CBF8E6DBC046CEF2828AF40B32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember_E40FA1CBF8E6DBC046CEF2828AF40B32" xlink:to="lab_ifrs-full_UnusedTaxLossesMember_E40FA1CBF8E6DBC046CEF2828AF40B32" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_F26CB551F19CC812C9FCF2828AF460E8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_F26CB551F19CC812C9FCF2828AF460E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_F26CB551F19CC812C9FCF2828AF460E8_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_F26CB551F19CC812C9FCF2828AF460E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_F26CB551F19CC812C9FCF2828AF460E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_F26CB551F19CC812C9FCF2828AF460E8" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_F26CB551F19CC812C9FCF2828AF460E8" xlink:type="arc" />
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_001564CDD4F94D5DB818F2828AF4D3FC_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_001564CDD4F94D5DB818F2828AF4D3FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused tax losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_001564CDD4F94D5DB818F2828AF4D3FC_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_001564CDD4F94D5DB818F2828AF4D3FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_001564CDD4F94D5DB818F2828AF4D3FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_001564CDD4F94D5DB818F2828AF4D3FC" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_001564CDD4F94D5DB818F2828AF4D3FC" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_DD778459E0C2B1D0C8182047BAF9CB08_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_DD778459E0C2B1D0C8182047BAF9CB08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_DD778459E0C2B1D0C8182047BAF9CB08_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_DD778459E0C2B1D0C8182047BAF9CB08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_DD778459E0C2B1D0C8182047BAF9CB08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_DD778459E0C2B1D0C8182047BAF9CB08" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_DD778459E0C2B1D0C8182047BAF9CB08" xlink:type="arc" />
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:type="arc" />
    <link:label id="lab_oncyf_MedicalEquipmentMember_A27ABF1FA7BDC8ACC8572047BAFA900A_terseLabel_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember_A27ABF1FA7BDC8ACC8572047BAFA900A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical equipment</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_A27ABF1FA7BDC8ACC8572047BAFA900A_label_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember_A27ABF1FA7BDC8ACC8572047BAFA900A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_A27ABF1FA7BDC8ACC8572047BAFA900A_documentation_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember_A27ABF1FA7BDC8ACC8572047BAFA900A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MedicalEquipmentMember" xlink:label="loc_oncyf_MedicalEquipmentMember_A27ABF1FA7BDC8ACC8572047BAFA900A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MedicalEquipmentMember_A27ABF1FA7BDC8ACC8572047BAFA900A" xlink:to="lab_oncyf_MedicalEquipmentMember_A27ABF1FA7BDC8ACC8572047BAFA900A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_87C76C8ABF4E14FC52912047BAFA9D22_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember_87C76C8ABF4E14FC52912047BAFA9D22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_87C76C8ABF4E14FC52912047BAFA9D22_label_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember_87C76C8ABF4E14FC52912047BAFA9D22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer equipment [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_87C76C8ABF4E14FC52912047BAFA9D22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerEquipmentMember_87C76C8ABF4E14FC52912047BAFA9D22" xlink:to="lab_ifrs-full_ComputerEquipmentMember_87C76C8ABF4E14FC52912047BAFA9D22" xlink:type="arc" />
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_DBAF2A6B05BCB4DB6FA32047BAFACEAB_terseLabel_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember_DBAF2A6B05BCB4DB6FA32047BAFACEAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office Furniture</link:label>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_DBAF2A6B05BCB4DB6FA32047BAFACEAB_label_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember_DBAF2A6B05BCB4DB6FA32047BAFACEAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixtures and fittings [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FixturesAndFittingsMember" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_DBAF2A6B05BCB4DB6FA32047BAFACEAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FixturesAndFittingsMember_DBAF2A6B05BCB4DB6FA32047BAFACEAB" xlink:to="lab_ifrs-full_FixturesAndFittingsMember_DBAF2A6B05BCB4DB6FA32047BAFACEAB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_79877C206BB6799BA49D2047BAFA450C_verboseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember_79877C206BB6799BA49D2047BAFA450C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Office Equipment</link:label>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_79877C206BB6799BA49D2047BAFA450C_label_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember_79877C206BB6799BA49D2047BAFA450C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office equipment [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_79877C206BB6799BA49D2047BAFA450C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember_79877C206BB6799BA49D2047BAFA450C" xlink:to="lab_ifrs-full_OfficeEquipmentMember_79877C206BB6799BA49D2047BAFA450C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_DCD2E1C066C6B50C69E22047BAFA82FD_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember_DCD2E1C066C6B50C69E22047BAFA82FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_DCD2E1C066C6B50C69E22047BAFA82FD_label_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember_DCD2E1C066C6B50C69E22047BAFA82FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold improvements [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_DCD2E1C066C6B50C69E22047BAFA82FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseholdImprovementsMember_DCD2E1C066C6B50C69E22047BAFA82FD" xlink:to="lab_ifrs-full_LeaseholdImprovementsMember_DCD2E1C066C6B50C69E22047BAFA82FD" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506C87E19EF1BA40BC192047BAFA7752_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506C87E19EF1BA40BC192047BAFA7752" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506C87E19EF1BA40BC192047BAFA7752_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506C87E19EF1BA40BC192047BAFA7752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506C87E19EF1BA40BC192047BAFA7752" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506C87E19EF1BA40BC192047BAFA7752" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506C87E19EF1BA40BC192047BAFA7752" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F" xlink:to="lab_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_10993A50FFE97AF7981C2047BAFA3B1E_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember_10993A50FFE97AF7981C2047BAFA3B1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_10993A50FFE97AF7981C2047BAFA3B1E_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember_10993A50FFE97AF7981C2047BAFA3B1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_10993A50FFE97AF7981C2047BAFA3B1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember_10993A50FFE97AF7981C2047BAFA3B1E" xlink:to="lab_ifrs-full_GrossCarryingAmountMember_10993A50FFE97AF7981C2047BAFA3B1E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_D7F454BD229AD37201E420AFEDC85B26_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_D7F454BD229AD37201E420AFEDC85B26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_D7F454BD229AD37201E420AFEDC85B26_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_D7F454BD229AD37201E420AFEDC85B26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_D7F454BD229AD37201E420AFEDC85B26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_D7F454BD229AD37201E420AFEDC85B26" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_D7F454BD229AD37201E420AFEDC85B26" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7EBAA235773A6D6198972047BAFAD085_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7EBAA235773A6D6198972047BAFAD085" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7EBAA235773A6D6198972047BAFAD085_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7EBAA235773A6D6198972047BAFAD085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7EBAA235773A6D6198972047BAFAD085" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7EBAA235773A6D6198972047BAFAD085" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7EBAA235773A6D6198972047BAFAD085" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:to="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_A0E0C1AC278BDDCAD39A2047BAFAACB2_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment_A0E0C1AC278BDDCAD39A2047BAFAACB2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_A0E0C1AC278BDDCAD39A2047BAFAACB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment_A0E0C1AC278BDDCAD39A2047BAFAACB2" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment_A0E0C1AC278BDDCAD39A2047BAFAACB2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_CF1FD2CC56E070EBD5A72047BAFA6CD1_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_CF1FD2CC56E070EBD5A72047BAFA6CD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_CF1FD2CC56E070EBD5A72047BAFA6CD1_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_CF1FD2CC56E070EBD5A72047BAFA6CD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_CF1FD2CC56E070EBD5A72047BAFA6CD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_CF1FD2CC56E070EBD5A72047BAFA6CD1" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_CF1FD2CC56E070EBD5A72047BAFA6CD1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_AB32D376AFDCFDF48B1D2047BAFA1C93_terseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_AB32D376AFDCFDF48B1D2047BAFA1C93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals</link:label>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_AB32D376AFDCFDF48B1D2047BAFA1C93_label_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_AB32D376AFDCFDF48B1D2047BAFA1C93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals, property, plant and equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_AB32D376AFDCFDF48B1D2047BAFA1C93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_AB32D376AFDCFDF48B1D2047BAFA1C93" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_AB32D376AFDCFDF48B1D2047BAFA1C93" xlink:type="arc" />
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_D02C1C4C43E04FC2B7AE2047BAFB94FC_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment_D02C1C4C43E04FC2B7AE2047BAFB94FC" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_D02C1C4C43E04FC2B7AE2047BAFB94FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment_D02C1C4C43E04FC2B7AE2047BAFB94FC" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment_D02C1C4C43E04FC2B7AE2047BAFB94FC" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_079D878AF851DA6F8F3BC8041F83A020_label_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract_079D878AF851DA6F8F3BC8041F83A020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_079D878AF851DA6F8F3BC8041F83A020_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract_079D878AF851DA6F8F3BC8041F83A020" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_079D878AF851DA6F8F3BC8041F83A020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_079D878AF851DA6F8F3BC8041F83A020" xlink:to="lab_oncyf_DisclosureOfEconomicDependenceAbstract_079D878AF851DA6F8F3BC8041F83A020" xlink:type="arc" />
    <link:label id="lab_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59_label_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRisk1Table" xlink:label="loc_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59" xlink:to="lab_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59" xlink:type="arc" />
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRiskType1Axis" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D" xlink:to="lab_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D" xlink:type="arc" />
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Domain]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Domain]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Concentration Risk Type1 [Axis]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRiskType1Domain" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3" xlink:to="lab_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3" xlink:type="arc" />
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_882CACBFC4FFEAD20CE1C8041F83C494_terseLabel_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member_882CACBFC4FFEAD20CE1C8041F83C494" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Toll manufacturer</link:label>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_882CACBFC4FFEAD20CE1C8041F83C494_label_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member_882CACBFC4FFEAD20CE1C8041F83C494" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk1 [Member]</link:label>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_882CACBFC4FFEAD20CE1C8041F83C494_documentation_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member_882CACBFC4FFEAD20CE1C8041F83C494" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk1 [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SupplierConcentrationRisk1Member" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_882CACBFC4FFEAD20CE1C8041F83C494" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SupplierConcentrationRisk1Member_882CACBFC4FFEAD20CE1C8041F83C494" xlink:to="lab_oncyf_SupplierConcentrationRisk1Member_882CACBFC4FFEAD20CE1C8041F83C494" xlink:type="arc" />
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Concentration Risk Type1 [Table]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRiskType1LineItems" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A" xlink:to="lab_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A" xlink:type="arc" />
    <link:label id="lab_oncyf_ConcentrationRiskNumber_7C1D09E01BA5EBC50CBEC8041F83F577_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber_7C1D09E01BA5EBC50CBEC8041F83F577" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration, number</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_7C1D09E01BA5EBC50CBEC8041F83F577_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber_7C1D09E01BA5EBC50CBEC8041F83F577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_7C1D09E01BA5EBC50CBEC8041F83F577_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber_7C1D09E01BA5EBC50CBEC8041F83F577" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRiskNumber" xlink:label="loc_oncyf_ConcentrationRiskNumber_7C1D09E01BA5EBC50CBEC8041F83F577" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskNumber_7C1D09E01BA5EBC50CBEC8041F83F577" xlink:to="lab_oncyf_ConcentrationRiskNumber_7C1D09E01BA5EBC50CBEC8041F83F577" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_17ACD098F545445E6943F2FC673E5263_label_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_17ACD098F545445E6943F2FC673E5263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_17ACD098F545445E6943F2FC673E5263_documentation_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_17ACD098F545445E6943F2FC673E5263" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_17ACD098F545445E6943F2FC673E5263" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_17ACD098F545445E6943F2FC673E5263" xlink:to="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_17ACD098F545445E6943F2FC673E5263" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_411D9B6096F9101C11D0F30DF8DB9EB2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_411D9B6096F9101C11D0F30DF8DB9EB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_411D9B6096F9101C11D0F30DF8DB9EB2_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_411D9B6096F9101C11D0F30DF8DB9EB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_411D9B6096F9101C11D0F30DF8DB9EB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_411D9B6096F9101C11D0F30DF8DB9EB2" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_411D9B6096F9101C11D0F30DF8DB9EB2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_71533538A37C3846CAC8F30DF8DC2761_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis_71533538A37C3846CAC8F30DF8DC2761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_71533538A37C3846CAC8F30DF8DC2761_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis_71533538A37C3846CAC8F30DF8DC2761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_71533538A37C3846CAC8F30DF8DC2761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_71533538A37C3846CAC8F30DF8DC2761" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis_71533538A37C3846CAC8F30DF8DC2761" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share capital [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantsMember_2FE9354B3489B8BE3F1FF30E4A05A2DB_verboseLabel_en-US" xlink:label="lab_oncyf_WarrantsMember_2FE9354B3489B8BE3F1FF30E4A05A2DB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_oncyf_WarrantsMember_2FE9354B3489B8BE3F1FF30E4A05A2DB_label_en-US" xlink:label="lab_oncyf_WarrantsMember_2FE9354B3489B8BE3F1FF30E4A05A2DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [Member]</link:label>
    <link:label id="lab_oncyf_WarrantsMember_2FE9354B3489B8BE3F1FF30E4A05A2DB_documentation_en-US" xlink:label="lab_oncyf_WarrantsMember_2FE9354B3489B8BE3F1FF30E4A05A2DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_2FE9354B3489B8BE3F1FF30E4A05A2DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsMember_2FE9354B3489B8BE3F1FF30E4A05A2DB" xlink:to="lab_oncyf_WarrantsMember_2FE9354B3489B8BE3F1FF30E4A05A2DB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_529BAED6F43F69C3CEC4F2FC89B917C2_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_529BAED6F43F69C3CEC4F2FC89B917C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_529BAED6F43F69C3CEC4F2FC89B917C2_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_529BAED6F43F69C3CEC4F2FC89B917C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk free interest rate, share options granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_529BAED6F43F69C3CEC4F2FC89B917C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_529BAED6F43F69C3CEC4F2FC89B917C2" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_529BAED6F43F69C3CEC4F2FC89B917C2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_61CBAEC925685A32B64CF2FF452C783D_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_61CBAEC925685A32B64CF2FF452C783D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected hold period to exercise</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_61CBAEC925685A32B64CF2FF452C783D_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_61CBAEC925685A32B64CF2FF452C783D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option life, share options granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_61CBAEC925685A32B64CF2FF452C783D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_61CBAEC925685A32B64CF2FF452C783D" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_61CBAEC925685A32B64CF2FF452C783D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_ED1D712D3BFCF8D3185CF2FCC59A3D9E_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_ED1D712D3BFCF8D3185CF2FCC59A3D9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Volatility in the price of the Company's shares</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_ED1D712D3BFCF8D3185CF2FCC59A3D9E_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_ED1D712D3BFCF8D3185CF2FCC59A3D9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility, share options granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_ED1D712D3BFCF8D3185CF2FCC59A3D9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_ED1D712D3BFCF8D3185CF2FCC59A3D9E" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_ED1D712D3BFCF8D3185CF2FCC59A3D9E" xlink:type="arc" />
    <link:label id="lab_oncyf_DividendYieldPercent_87CCF1811E734D82D3FAF2FCE2E568DC_verboseLabel_en-US" xlink:label="lab_oncyf_DividendYieldPercent_87CCF1811E734D82D3FAF2FCE2E568DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_oncyf_DividendYieldPercent_87CCF1811E734D82D3FAF2FCE2E568DC_label_en-US" xlink:label="lab_oncyf_DividendYieldPercent_87CCF1811E734D82D3FAF2FCE2E568DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend Yield, Percent</link:label>
    <link:label id="lab_oncyf_DividendYieldPercent_87CCF1811E734D82D3FAF2FCE2E568DC_documentation_en-US" xlink:label="lab_oncyf_DividendYieldPercent_87CCF1811E734D82D3FAF2FCE2E568DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividend Yield, Percent</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DividendYieldPercent" xlink:label="loc_oncyf_DividendYieldPercent_87CCF1811E734D82D3FAF2FCE2E568DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DividendYieldPercent_87CCF1811E734D82D3FAF2FCE2E568DC" xlink:to="lab_oncyf_DividendYieldPercent_87CCF1811E734D82D3FAF2FCE2E568DC" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_B727C3E7D4CDC145F45D1AEC01F51C70_label_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract_B727C3E7D4CDC145F45D1AEC01F51C70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_B727C3E7D4CDC145F45D1AEC01F51C70_documentation_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract_B727C3E7D4CDC145F45D1AEC01F51C70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofrelatedpartyAbstract" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_B727C3E7D4CDC145F45D1AEC01F51C70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_B727C3E7D4CDC145F45D1AEC01F51C70" xlink:to="lab_oncyf_DisclosureofrelatedpartyAbstract_B727C3E7D4CDC145F45D1AEC01F51C70" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_354D8EA6FC96D4EB9C6E1AEC01F58B98_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_354D8EA6FC96D4EB9C6E1AEC01F58B98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of related party transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_354D8EA6FC96D4EB9C6E1AEC01F58B98_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_354D8EA6FC96D4EB9C6E1AEC01F58B98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_354D8EA6FC96D4EB9C6E1AEC01F58B98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_354D8EA6FC96D4EB9C6E1AEC01F58B98" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_354D8EA6FC96D4EB9C6E1AEC01F58B98" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IssuedCapitalMember_D1695E471AFF4350CACF1AEC02E43ACA_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember_D1695E471AFF4350CACF1AEC02E43ACA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_D1695E471AFF4350CACF1AEC02E43ACA_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember_D1695E471AFF4350CACF1AEC02E43ACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_D1695E471AFF4350CACF1AEC02E43ACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember_D1695E471AFF4350CACF1AEC02E43ACA" xlink:to="lab_ifrs-full_IssuedCapitalMember_D1695E471AFF4350CACF1AEC02E43ACA" xlink:type="arc" />
    <link:label id="lab_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A_terseLabel_en-US" xlink:label="lab_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A_label_en-US" xlink:label="lab_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A_documentation_en-US" xlink:label="lab_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A" xlink:to="lab_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A" xlink:type="arc" />
    <link:label id="lab_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0_terseLabel_en-US" xlink:label="lab_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0_label_en-US" xlink:label="lab_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0_documentation_en-US" xlink:label="lab_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:to="lab_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F_label_en-US" xlink:label="lab_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F_documentation_en-US" xlink:label="lab_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under Share Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F" xlink:to="lab_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F" xlink:type="arc" />
    <link:label id="lab_oncyf_InitialCommitmentFeeMember_75B5FA50029B5793EE871AEC02E5F335_terseLabel_en-US" xlink:label="lab_oncyf_InitialCommitmentFeeMember_75B5FA50029B5793EE871AEC02E5F335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial commitment fee</link:label>
    <link:label id="lab_oncyf_InitialCommitmentFeeMember_75B5FA50029B5793EE871AEC02E5F335_label_en-US" xlink:label="lab_oncyf_InitialCommitmentFeeMember_75B5FA50029B5793EE871AEC02E5F335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Commitment Fee [Member]</link:label>
    <link:label id="lab_oncyf_InitialCommitmentFeeMember_75B5FA50029B5793EE871AEC02E5F335_documentation_en-US" xlink:label="lab_oncyf_InitialCommitmentFeeMember_75B5FA50029B5793EE871AEC02E5F335" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Commitment Fee [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_InitialCommitmentFeeMember" xlink:label="loc_oncyf_InitialCommitmentFeeMember_75B5FA50029B5793EE871AEC02E5F335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_InitialCommitmentFeeMember_75B5FA50029B5793EE871AEC02E5F335" xlink:to="lab_oncyf_InitialCommitmentFeeMember_75B5FA50029B5793EE871AEC02E5F335" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended Share Purchase Agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062_label_en-US" xlink:label="lab_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under Amended Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062_documentation_en-US" xlink:label="lab_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under Amended Share Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderAmendedSharePurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062" xlink:to="lab_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062" xlink:type="arc" />
    <link:label id="lab_oncyf_AmendedInitialCommitmentFeeMember_7E2F393782837A1DEA6A1AEC02E5CB12_terseLabel_en-US" xlink:label="lab_oncyf_AmendedInitialCommitmentFeeMember_7E2F393782837A1DEA6A1AEC02E5CB12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended initial commitment fee</link:label>
    <link:label id="lab_oncyf_AmendedInitialCommitmentFeeMember_7E2F393782837A1DEA6A1AEC02E5CB12_label_en-US" xlink:label="lab_oncyf_AmendedInitialCommitmentFeeMember_7E2F393782837A1DEA6A1AEC02E5CB12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended Initial Commitment Fee [Member]</link:label>
    <link:label id="lab_oncyf_AmendedInitialCommitmentFeeMember_7E2F393782837A1DEA6A1AEC02E5CB12_documentation_en-US" xlink:label="lab_oncyf_AmendedInitialCommitmentFeeMember_7E2F393782837A1DEA6A1AEC02E5CB12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended Initial Commitment Fee [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_AmendedInitialCommitmentFeeMember" xlink:label="loc_oncyf_AmendedInitialCommitmentFeeMember_7E2F393782837A1DEA6A1AEC02E5CB12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AmendedInitialCommitmentFeeMember_7E2F393782837A1DEA6A1AEC02E5CB12" xlink:to="lab_oncyf_AmendedInitialCommitmentFeeMember_7E2F393782837A1DEA6A1AEC02E5CB12" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_B7AFA10ED55F86598A681AEC02E5969D_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember_B7AFA10ED55F86598A681AEC02E5969D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-market agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_B7AFA10ED55F86598A681AEC02E5969D_label_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember_B7AFA10ED55F86598A681AEC02E5969D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under At-the-market Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_B7AFA10ED55F86598A681AEC02E5969D_documentation_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember_B7AFA10ED55F86598A681AEC02E5969D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under At-the-market Agreement [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_B7AFA10ED55F86598A681AEC02E5969D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderAtthemarketAgreementMember_B7AFA10ED55F86598A681AEC02E5969D" xlink:to="lab_oncyf_SharesUnderAtthemarketAgreementMember_B7AFA10ED55F86598A681AEC02E5969D" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesPublicOfferingMember_76513E681A918A3A84821AEC02E5323E_terseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember_76513E681A918A3A84821AEC02E5323E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_76513E681A918A3A84821AEC02E5323E_label_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember_76513E681A918A3A84821AEC02E5323E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Public Offering [Member]</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_76513E681A918A3A84821AEC02E5323E_documentation_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember_76513E681A918A3A84821AEC02E5323E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Public Offering [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_76513E681A918A3A84821AEC02E5323E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingMember_76513E681A918A3A84821AEC02E5323E" xlink:to="lab_oncyf_SharesPublicOfferingMember_76513E681A918A3A84821AEC02E5323E" xlink:type="arc" />
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_29E74CB7BE4464B386321AEC02E6D58B_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount_29E74CB7BE4464B386321AEC02E6D58B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_29E74CB7BE4464B386321AEC02E6D58B_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount_29E74CB7BE4464B386321AEC02E6D58B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Amount</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_29E74CB7BE4464B386321AEC02E6D58B_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount_29E74CB7BE4464B386321AEC02E6D58B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Amount</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharePurchaseAgreementAmount" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_29E74CB7BE4464B386321AEC02E6D58B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementAmount_29E74CB7BE4464B386321AEC02E6D58B" xlink:to="lab_oncyf_SharePurchaseAgreementAmount_29E74CB7BE4464B386321AEC02E6D58B" xlink:type="arc" />
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_15FD2647627EE43F8E691AEC02E6D8B3_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm_15FD2647627EE43F8E691AEC02E6D8B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement term</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_15FD2647627EE43F8E691AEC02E6D8B3_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm_15FD2647627EE43F8E691AEC02E6D8B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Term</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_15FD2647627EE43F8E691AEC02E6D8B3_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm_15FD2647627EE43F8E691AEC02E6D8B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Term</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharePurchaseAgreementTerm" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_15FD2647627EE43F8E691AEC02E6D8B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementTerm_15FD2647627EE43F8E691AEC02E6D8B3" xlink:to="lab_oncyf_SharePurchaseAgreementTerm_15FD2647627EE43F8E691AEC02E6D8B3" xlink:type="arc" />
    <link:label id="lab_oncyf_IssueOfEquityShares_127AB15630ECC07FBA7A1AEC02E64A6F_terseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquityShares_127AB15630ECC07FBA7A1AEC02E64A6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued (shares)</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_127AB15630ECC07FBA7A1AEC02E64A6F_label_en-US" xlink:label="lab_oncyf_IssueOfEquityShares_127AB15630ECC07FBA7A1AEC02E64A6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_127AB15630ECC07FBA7A1AEC02E64A6F_documentation_en-US" xlink:label="lab_oncyf_IssueOfEquityShares_127AB15630ECC07FBA7A1AEC02E64A6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_127AB15630ECC07FBA7A1AEC02E64A6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssueOfEquityShares_127AB15630ECC07FBA7A1AEC02E64A6F" xlink:to="lab_oncyf_IssueOfEquityShares_127AB15630ECC07FBA7A1AEC02E64A6F" xlink:type="arc" />
    <link:label id="lab_oncyf_InitialCommitmentFeeSharesIssuedFairValue_78F527A7C7F404957C9F1AEC02E62B26_terseLabel_en-US" xlink:label="lab_oncyf_InitialCommitmentFeeSharesIssuedFairValue_78F527A7C7F404957C9F1AEC02E62B26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from shares issued under Share Purchase Agreement</link:label>
    <link:label id="lab_oncyf_InitialCommitmentFeeSharesIssuedFairValue_78F527A7C7F404957C9F1AEC02E62B26_label_en-US" xlink:label="lab_oncyf_InitialCommitmentFeeSharesIssuedFairValue_78F527A7C7F404957C9F1AEC02E62B26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Commitment Fee, Shares Issued, Fair Value</link:label>
    <link:label id="lab_oncyf_InitialCommitmentFeeSharesIssuedFairValue_78F527A7C7F404957C9F1AEC02E62B26_documentation_en-US" xlink:label="lab_oncyf_InitialCommitmentFeeSharesIssuedFairValue_78F527A7C7F404957C9F1AEC02E62B26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Commitment Fee, Shares Issued, Fair Value</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_InitialCommitmentFeeSharesIssuedFairValue" xlink:label="loc_oncyf_InitialCommitmentFeeSharesIssuedFairValue_78F527A7C7F404957C9F1AEC02E62B26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_InitialCommitmentFeeSharesIssuedFairValue_78F527A7C7F404957C9F1AEC02E62B26" xlink:to="lab_oncyf_InitialCommitmentFeeSharesIssuedFairValue_78F527A7C7F404957C9F1AEC02E62B26" xlink:type="arc" />
    <link:label id="lab_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares_C6F99CF91AB3AC6A085F1AEC02E6823F_terseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares_C6F99CF91AB3AC6A085F1AEC02E6823F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future issuance pursuant to Share Purchase Agreement (shares)</link:label>
    <link:label id="lab_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares_C6F99CF91AB3AC6A085F1AEC02E6823F_label_en-US" xlink:label="lab_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares_C6F99CF91AB3AC6A085F1AEC02E6823F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Share Purchase Agreement, Future Issues, Shares</link:label>
    <link:label id="lab_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares_C6F99CF91AB3AC6A085F1AEC02E6823F_documentation_en-US" xlink:label="lab_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares_C6F99CF91AB3AC6A085F1AEC02E6823F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Share Purchase Agreement, Future Issues, Shares</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares" xlink:label="loc_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares_C6F99CF91AB3AC6A085F1AEC02E6823F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares_C6F99CF91AB3AC6A085F1AEC02E6823F" xlink:to="lab_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares_C6F99CF91AB3AC6A085F1AEC02E6823F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Equity_BBBE3A5623F346C3E32D1AEC02E693F9_verboseLabel_en-US" xlink:label="lab_ifrs-full_Equity_BBBE3A5623F346C3E32D1AEC02E693F9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_BBBE3A5623F346C3E32D1AEC02E693F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_BBBE3A5623F346C3E32D1AEC02E693F9" xlink:to="lab_ifrs-full_Equity_BBBE3A5623F346C3E32D1AEC02E693F9" xlink:type="arc" />
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E39E4D2FB42F01EB6B251AEC02E6C61B_terseLabel_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E39E4D2FB42F01EB6B251AEC02E6C61B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from common shares</link:label>
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E39E4D2FB42F01EB6B251AEC02E6C61B_label_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E39E4D2FB42F01EB6B251AEC02E6C61B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issue Of Ordinary Shares</link:label>
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E39E4D2FB42F01EB6B251AEC02E6C61B_documentation_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E39E4D2FB42F01EB6B251AEC02E6C61B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issue Of Ordinary Shares</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E39E4D2FB42F01EB6B251AEC02E6C61B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E39E4D2FB42F01EB6B251AEC02E6C61B" xlink:to="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E39E4D2FB42F01EB6B251AEC02E6C61B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_B047E72B7169C27114B71AEC02E6550F_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost_B047E72B7169C27114B71AEC02E6550F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue related cost</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_B047E72B7169C27114B71AEC02E6550F_label_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost_B047E72B7169C27114B71AEC02E6550F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share issue related cost</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_B047E72B7169C27114B71AEC02E6550F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost_B047E72B7169C27114B71AEC02E6550F" xlink:to="lab_ifrs-full_ShareIssueRelatedCost_B047E72B7169C27114B71AEC02E6550F" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_7D7576C3A733734036C51AEC02E68549_terseLabel_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1_7D7576C3A733734036C51AEC02E68549" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price (cad per share)</link:label>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_7D7576C3A733734036C51AEC02E68549_label_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1_7D7576C3A733734036C51AEC02E68549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share1</link:label>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_7D7576C3A733734036C51AEC02E68549_documentation_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1_7D7576C3A733734036C51AEC02E68549" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share1</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesIssuedPricePerShare1" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_7D7576C3A733734036C51AEC02E68549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesIssuedPricePerShare1_7D7576C3A733734036C51AEC02E68549" xlink:to="lab_oncyf_SharesIssuedPricePerShare1_7D7576C3A733734036C51AEC02E68549" xlink:type="arc" />
    <link:label id="lab_oncyf_CommonSharesPerUnit_D971B397FA5474F6D6931AEC02E67B13_terseLabel_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit_D971B397FA5474F6D6931AEC02E67B13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares per unit</link:label>
    <link:label id="lab_oncyf_CommonSharesPerUnit_D971B397FA5474F6D6931AEC02E67B13_label_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit_D971B397FA5474F6D6931AEC02E67B13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Shares Per Unit</link:label>
    <link:label id="lab_oncyf_CommonSharesPerUnit_D971B397FA5474F6D6931AEC02E67B13_documentation_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit_D971B397FA5474F6D6931AEC02E67B13" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Shares Per Unit</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommonSharesPerUnit" xlink:label="loc_oncyf_CommonSharesPerUnit_D971B397FA5474F6D6931AEC02E67B13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommonSharesPerUnit_D971B397FA5474F6D6931AEC02E67B13" xlink:to="lab_oncyf_CommonSharesPerUnit_D971B397FA5474F6D6931AEC02E67B13" xlink:type="arc" />
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_EA62F3E26A7DCA9DCCA31AEC02E6C07E_terseLabel_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit_EA62F3E26A7DCA9DCCA31AEC02E6C07E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common share purchase warrant per unit</link:label>
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_EA62F3E26A7DCA9DCCA31AEC02E6C07E_label_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit_EA62F3E26A7DCA9DCCA31AEC02E6C07E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Share Purchase Warrant Per Unit</link:label>
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_EA62F3E26A7DCA9DCCA31AEC02E6C07E_documentation_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit_EA62F3E26A7DCA9DCCA31AEC02E6C07E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Share Purchase Warrant Per Unit</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit_EA62F3E26A7DCA9DCCA31AEC02E6C07E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommonSharePurchaseWarrantPerUnit_EA62F3E26A7DCA9DCCA31AEC02E6C07E" xlink:to="lab_oncyf_CommonSharePurchaseWarrantPerUnit_EA62F3E26A7DCA9DCCA31AEC02E6C07E" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_1FD62CA8A736D58C74981AEC02E6083E_terseLabel_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare_1FD62CA8A736D58C74981AEC02E6083E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price (cad per share)</link:label>
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_1FD62CA8A736D58C74981AEC02E6083E_label_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare_1FD62CA8A736D58C74981AEC02E6083E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Warrant Price Per Share</link:label>
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_1FD62CA8A736D58C74981AEC02E6083E_documentation_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare_1FD62CA8A736D58C74981AEC02E6083E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Issued, Warrant Price Per Share</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesIssuedWarrantPricePerShare" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare_1FD62CA8A736D58C74981AEC02E6083E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesIssuedWarrantPricePerShare_1FD62CA8A736D58C74981AEC02E6083E" xlink:to="lab_oncyf_SharesIssuedWarrantPricePerShare_1FD62CA8A736D58C74981AEC02E6083E" xlink:type="arc" />
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8696FE7CEFD98F66ACF51B2E88DA5CCC_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8696FE7CEFD98F66ACF51B2E88DA5CCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common shares issuable per warrant</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8696FE7CEFD98F66ACF51B2E88DA5CCC_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8696FE7CEFD98F66ACF51B2E88DA5CCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8696FE7CEFD98F66ACF51B2E88DA5CCC_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8696FE7CEFD98F66ACF51B2E88DA5CCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8696FE7CEFD98F66ACF51B2E88DA5CCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8696FE7CEFD98F66ACF51B2E88DA5CCC" xlink:to="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8696FE7CEFD98F66ACF51B2E88DA5CCC" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions_441C9C519C3656BEF1011AEC02E6F6FA_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions_441C9C519C3656BEF1011AEC02E6F6FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions_441C9C519C3656BEF1011AEC02E6F6FA_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions_441C9C519C3656BEF1011AEC02E6F6FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding share options</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions_441C9C519C3656BEF1011AEC02E6F6FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions_441C9C519C3656BEF1011AEC02E6F6FA" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions_441C9C519C3656BEF1011AEC02E6F6FA" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantPricePerShareAccelerationThreshold_BC488F6FC5BD5FD969B81AEC02E6E6CB_terseLabel_en-US" xlink:label="lab_oncyf_WarrantPricePerShareAccelerationThreshold_BC488F6FC5BD5FD969B81AEC02E6E6CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acceleration threshold weighted average price (cad per share)</link:label>
    <link:label id="lab_oncyf_WarrantPricePerShareAccelerationThreshold_BC488F6FC5BD5FD969B81AEC02E6E6CB_label_en-US" xlink:label="lab_oncyf_WarrantPricePerShareAccelerationThreshold_BC488F6FC5BD5FD969B81AEC02E6E6CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Price Per Share, Acceleration Threshold</link:label>
    <link:label id="lab_oncyf_WarrantPricePerShareAccelerationThreshold_BC488F6FC5BD5FD969B81AEC02E6E6CB_documentation_en-US" xlink:label="lab_oncyf_WarrantPricePerShareAccelerationThreshold_BC488F6FC5BD5FD969B81AEC02E6E6CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Price Per Share, Acceleration Threshold</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantPricePerShareAccelerationThreshold" xlink:label="loc_oncyf_WarrantPricePerShareAccelerationThreshold_BC488F6FC5BD5FD969B81AEC02E6E6CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantPricePerShareAccelerationThreshold_BC488F6FC5BD5FD969B81AEC02E6E6CB" xlink:to="lab_oncyf_WarrantPricePerShareAccelerationThreshold_BC488F6FC5BD5FD969B81AEC02E6E6CB" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_FD0CE4621DB137EA1C3B1AEC02E67000_terseLabel_en-US" xlink:label="lab_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_FD0CE4621DB137EA1C3B1AEC02E67000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acceleration threshold weighted average price, trading days</link:label>
    <link:label id="lab_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_FD0CE4621DB137EA1C3B1AEC02E67000_label_en-US" xlink:label="lab_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_FD0CE4621DB137EA1C3B1AEC02E67000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Price Per Share, Acceleration Threshold Trading Days</link:label>
    <link:label id="lab_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_FD0CE4621DB137EA1C3B1AEC02E67000_documentation_en-US" xlink:label="lab_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_FD0CE4621DB137EA1C3B1AEC02E67000" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Price Per Share, Acceleration Threshold Trading Days</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantPricePerShareAccelerationThresholdTradingDays" xlink:label="loc_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_FD0CE4621DB137EA1C3B1AEC02E67000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_FD0CE4621DB137EA1C3B1AEC02E67000" xlink:to="lab_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_FD0CE4621DB137EA1C3B1AEC02E67000" xlink:type="arc" />
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_DB36668DE6B51A9A7B7E1AEC02FEDA23_label_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_DB36668DE6B51A9A7B7E1AEC02FEDA23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Short Term Investments [Abstract]</link:label>
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_DB36668DE6B51A9A7B7E1AEC02FEDA23_documentation_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_DB36668DE6B51A9A7B7E1AEC02FEDA23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Short Term Investments [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_DB36668DE6B51A9A7B7E1AEC02FEDA23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_DB36668DE6B51A9A7B7E1AEC02FEDA23" xlink:to="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_DB36668DE6B51A9A7B7E1AEC02FEDA23" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:type="arc" />
    <link:label id="lab_ifrs-full_MeasurementAxis_37B0C0BCE458B06E35061AEC02FE7FC7_terseLabel_en-US" xlink:label="lab_ifrs-full_MeasurementAxis_37B0C0BCE458B06E35061AEC02FE7FC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
    <link:label id="lab_ifrs-full_MeasurementAxis_37B0C0BCE458B06E35061AEC02FE7FC7_label_en-US" xlink:label="lab_ifrs-full_MeasurementAxis_37B0C0BCE458B06E35061AEC02FE7FC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_37B0C0BCE458B06E35061AEC02FE7FC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementAxis_37B0C0BCE458B06E35061AEC02FE7FC7" xlink:to="lab_ifrs-full_MeasurementAxis_37B0C0BCE458B06E35061AEC02FE7FC7" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated measurement [member]</link:label>
    <link:label id="lab_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3_label_en-US" xlink:label="lab_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated measurement [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3" xlink:to="lab_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AtCostMember_EB255EBFF518ED35416B1AEC02FE5ED9_terseLabel_en-US" xlink:label="lab_ifrs-full_AtCostMember_EB255EBFF518ED35416B1AEC02FE5ED9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original Cost</link:label>
    <link:label id="lab_ifrs-full_AtCostMember_EB255EBFF518ED35416B1AEC02FE5ED9_label_en-US" xlink:label="lab_ifrs-full_AtCostMember_EB255EBFF518ED35416B1AEC02FE5ED9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At cost [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AtCostMember" xlink:label="loc_ifrs-full_AtCostMember_EB255EBFF518ED35416B1AEC02FE5ED9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AtCostMember_EB255EBFF518ED35416B1AEC02FE5ED9" xlink:to="lab_ifrs-full_AtCostMember_EB255EBFF518ED35416B1AEC02FE5ED9" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AtFairValueMember_A05E0F5199E8AB7D233D1AEC02FE6E0F_terseLabel_en-US" xlink:label="lab_ifrs-full_AtFairValueMember_A05E0F5199E8AB7D233D1AEC02FE6E0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_ifrs-full_AtFairValueMember_A05E0F5199E8AB7D233D1AEC02FE6E0F_label_en-US" xlink:label="lab_ifrs-full_AtFairValueMember_A05E0F5199E8AB7D233D1AEC02FE6E0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At fair value [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_A05E0F5199E8AB7D233D1AEC02FE6E0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AtFairValueMember_A05E0F5199E8AB7D233D1AEC02FE6E0F" xlink:to="lab_ifrs-full_AtFairValueMember_A05E0F5199E8AB7D233D1AEC02FE6E0F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_72911D79B93BDAE747451AEC02FE8EF1_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis_72911D79B93BDAE747451AEC02FE8EF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_72911D79B93BDAE747451AEC02FE8EF1_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis_72911D79B93BDAE747451AEC02FE8EF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_72911D79B93BDAE747451AEC02FE8EF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_72911D79B93BDAE747451AEC02FE8EF1" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis_72911D79B93BDAE747451AEC02FE8EF1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets, class [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, class [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:to="lab_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:type="arc" />
    <link:label id="lab_oncyf_FinancialAssetsAtFaceValueMember_966EF8D7C6669825EB301AEC02FE8108_terseLabel_en-US" xlink:label="lab_oncyf_FinancialAssetsAtFaceValueMember_966EF8D7C6669825EB301AEC02FE8108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Face Value</link:label>
    <link:label id="lab_oncyf_FinancialAssetsAtFaceValueMember_966EF8D7C6669825EB301AEC02FE8108_label_en-US" xlink:label="lab_oncyf_FinancialAssetsAtFaceValueMember_966EF8D7C6669825EB301AEC02FE8108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Assets At Face Value [Member]</link:label>
    <link:label id="lab_oncyf_FinancialAssetsAtFaceValueMember_966EF8D7C6669825EB301AEC02FE8108_documentation_en-US" xlink:label="lab_oncyf_FinancialAssetsAtFaceValueMember_966EF8D7C6669825EB301AEC02FE8108" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Assets At Face Value [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_FinancialAssetsAtFaceValueMember" xlink:label="loc_oncyf_FinancialAssetsAtFaceValueMember_966EF8D7C6669825EB301AEC02FE8108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_FinancialAssetsAtFaceValueMember_966EF8D7C6669825EB301AEC02FE8108" xlink:to="lab_oncyf_FinancialAssetsAtFaceValueMember_966EF8D7C6669825EB301AEC02FE8108" xlink:type="arc" />
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember_267A21191001F82B2F481AEC02FE2D0A_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember_267A21191001F82B2F481AEC02FE2D0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember_267A21191001F82B2F481AEC02FE2D0A_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember_267A21191001F82B2F481AEC02FE2D0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, class [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember_267A21191001F82B2F481AEC02FE2D0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember_267A21191001F82B2F481AEC02FE2D0A" xlink:to="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember_267A21191001F82B2F481AEC02FE2D0A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueMember_A04EEFED1480A41499181AEC02FE79B8_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueMember_A04EEFED1480A41499181AEC02FE79B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueMember_A04EEFED1480A41499181AEC02FE79B8_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueMember_A04EEFED1480A41499181AEC02FE79B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value, class [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueMember_A04EEFED1480A41499181AEC02FE79B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueMember_A04EEFED1480A41499181AEC02FE79B8" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueMember_A04EEFED1480A41499181AEC02FE79B8" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_EBA6C6745F4C728EC77F1AEC02FE564F_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_EBA6C6745F4C728EC77F1AEC02FE564F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_EBA6C6745F4C728EC77F1AEC02FE564F_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_EBA6C6745F4C728EC77F1AEC02FE564F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_EBA6C6745F4C728EC77F1AEC02FE564F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_EBA6C6745F4C728EC77F1AEC02FE564F" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_EBA6C6745F4C728EC77F1AEC02FE564F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets, category [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, category [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0" xlink:to="lab_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0" xlink:type="arc" />
    <link:label id="lab_ifrs-full_HeldtomaturityInvestmentsCategoryMember_13101ABE816E23212B631AEC02FE5D4F_terseLabel_en-US" xlink:label="lab_ifrs-full_HeldtomaturityInvestmentsCategoryMember_13101ABE816E23212B631AEC02FE5D4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity short-term investments</link:label>
    <link:label id="lab_ifrs-full_HeldtomaturityInvestmentsCategoryMember_13101ABE816E23212B631AEC02FE5D4F_label_en-US" xlink:label="lab_ifrs-full_HeldtomaturityInvestmentsCategoryMember_13101ABE816E23212B631AEC02FE5D4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held-to-maturity investments, category [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_HeldtomaturityInvestmentsCategoryMember" xlink:label="loc_ifrs-full_HeldtomaturityInvestmentsCategoryMember_13101ABE816E23212B631AEC02FE5D4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HeldtomaturityInvestmentsCategoryMember_13101ABE816E23212B631AEC02FE5D4F" xlink:to="lab_ifrs-full_HeldtomaturityInvestmentsCategoryMember_13101ABE816E23212B631AEC02FE5D4F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_FinancialAssets_720B236F2751DA6E21FC1AEC02FF58E7_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssets_720B236F2751DA6E21FC1AEC02FF58E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_ifrs-full_FinancialAssets_720B236F2751DA6E21FC1AEC02FF58E7_label_en-US" xlink:label="lab_ifrs-full_FinancialAssets_720B236F2751DA6E21FC1AEC02FF58E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_720B236F2751DA6E21FC1AEC02FF58E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssets_720B236F2751DA6E21FC1AEC02FF58E7" xlink:to="lab_ifrs-full_FinancialAssets_720B236F2751DA6E21FC1AEC02FF58E7" xlink:type="arc" />
    <link:label id="lab_oncyf_ShortTermInvestmentEffectiveInterestRate_59A4717C67EE0F4D86B71AEC02FF3813_terseLabel_en-US" xlink:label="lab_oncyf_ShortTermInvestmentEffectiveInterestRate_59A4717C67EE0F4D86B71AEC02FF3813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Interest Rate %</link:label>
    <link:label id="lab_oncyf_ShortTermInvestmentEffectiveInterestRate_59A4717C67EE0F4D86B71AEC02FF3813_label_en-US" xlink:label="lab_oncyf_ShortTermInvestmentEffectiveInterestRate_59A4717C67EE0F4D86B71AEC02FF3813" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investment, Effective Interest Rate</link:label>
    <link:label id="lab_oncyf_ShortTermInvestmentEffectiveInterestRate_59A4717C67EE0F4D86B71AEC02FF3813_documentation_en-US" xlink:label="lab_oncyf_ShortTermInvestmentEffectiveInterestRate_59A4717C67EE0F4D86B71AEC02FF3813" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-Term Investment, Effective Interest Rate</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ShortTermInvestmentEffectiveInterestRate" xlink:label="loc_oncyf_ShortTermInvestmentEffectiveInterestRate_59A4717C67EE0F4D86B71AEC02FF3813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShortTermInvestmentEffectiveInterestRate_59A4717C67EE0F4D86B71AEC02FF3813" xlink:to="lab_oncyf_ShortTermInvestmentEffectiveInterestRate_59A4717C67EE0F4D86B71AEC02FF3813" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_7D1BA527A2094093C0C0F2828B28F517_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_7D1BA527A2094093C0C0F2828B28F517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_7D1BA527A2094093C0C0F2828B28F517_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_7D1BA527A2094093C0C0F2828B28F517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_7D1BA527A2094093C0C0F2828B28F517" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_7D1BA527A2094093C0C0F2828B28F517" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_7D1BA527A2094093C0C0F2828B28F517" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:type="arc" />
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_CA8FD4E9B7AE35E9E582F2828B286A89_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember_CA8FD4E9B7AE35E9E582F2828B286A89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$0.26 - $0.42</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_CA8FD4E9B7AE35E9E582F2828B286A89_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember_CA8FD4E9B7AE35E9E582F2828B286A89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_CA8FD4E9B7AE35E9E582F2828B286A89_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember_CA8FD4E9B7AE35E9E582F2828B286A89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeOneMember" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_CA8FD4E9B7AE35E9E582F2828B286A89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeOneMember_CA8FD4E9B7AE35E9E582F2828B286A89" xlink:to="lab_oncyf_ExercisePriceRangeOneMember_CA8FD4E9B7AE35E9E582F2828B286A89" xlink:type="arc" />
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_35A657991535A6766568F2828B288CD1_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember_35A657991535A6766568F2828B288CD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$0.51 - $0.80</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_35A657991535A6766568F2828B288CD1_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember_35A657991535A6766568F2828B288CD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_35A657991535A6766568F2828B288CD1_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember_35A657991535A6766568F2828B288CD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeTwoMember" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_35A657991535A6766568F2828B288CD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeTwoMember_35A657991535A6766568F2828B288CD1" xlink:to="lab_oncyf_ExercisePriceRangeTwoMember_35A657991535A6766568F2828B288CD1" xlink:type="arc" />
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_CC6A86863A308352989DF2828B28A0B1_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember_CC6A86863A308352989DF2828B28A0B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$1.45 - $2.00</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_CC6A86863A308352989DF2828B28A0B1_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember_CC6A86863A308352989DF2828B28A0B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_CC6A86863A308352989DF2828B28A0B1_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember_CC6A86863A308352989DF2828B28A0B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeThreeMember" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_CC6A86863A308352989DF2828B28A0B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeThreeMember_CC6A86863A308352989DF2828B28A0B1" xlink:to="lab_oncyf_ExercisePriceRangeThreeMember_CC6A86863A308352989DF2828B28A0B1" xlink:type="arc" />
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_D85FD74D89FB6900AA2CF2828B2865CE_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember_D85FD74D89FB6900AA2CF2828B2865CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$2.13 - $3.89</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_D85FD74D89FB6900AA2CF2828B2865CE_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember_D85FD74D89FB6900AA2CF2828B2865CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_D85FD74D89FB6900AA2CF2828B2865CE_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember_D85FD74D89FB6900AA2CF2828B2865CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeFourMember" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_D85FD74D89FB6900AA2CF2828B2865CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeFourMember_D85FD74D89FB6900AA2CF2828B2865CE" xlink:to="lab_oncyf_ExercisePriceRangeFourMember_D85FD74D89FB6900AA2CF2828B2865CE" xlink:type="arc" />
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_E304FDF1C3FF4BB8B366F2828B28DA93_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember_E304FDF1C3FF4BB8B366F2828B28DA93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$4.01 - $6.72</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_E304FDF1C3FF4BB8B366F2828B28DA93_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember_E304FDF1C3FF4BB8B366F2828B28DA93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_E304FDF1C3FF4BB8B366F2828B28DA93_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember_E304FDF1C3FF4BB8B366F2828B28DA93" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeFiveMember" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_E304FDF1C3FF4BB8B366F2828B28DA93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeFiveMember_E304FDF1C3FF4BB8B366F2828B28DA93" xlink:to="lab_oncyf_ExercisePriceRangeFiveMember_E304FDF1C3FF4BB8B366F2828B28DA93" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_A60D04C13D1790DAE651F2828B29B79A_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_A60D04C13D1790DAE651F2828B29B79A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Outstanding (options)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_A60D04C13D1790DAE651F2828B29B79A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions_A60D04C13D1790DAE651F2828B29B79A" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions_A60D04C13D1790DAE651F2828B29B79A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_05349B8248F66A5BFC4AF2828B29AECA_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_05349B8248F66A5BFC4AF2828B29AECA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life (years)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_05349B8248F66A5BFC4AF2828B29AECA_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_05349B8248F66A5BFC4AF2828B29AECA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_05349B8248F66A5BFC4AF2828B29AECA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_05349B8248F66A5BFC4AF2828B29AECA" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_05349B8248F66A5BFC4AF2828B29AECA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_4E543325854729012840F2828B296027_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_4E543325854729012840F2828B296027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (cad per share)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_4E543325854729012840F2828B296027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_4E543325854729012840F2828B296027" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_4E543325854729012840F2828B296027" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_899DA1861668D3D8942FF2828B290263_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_899DA1861668D3D8942FF2828B290263" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number Exercisable (options)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_899DA1861668D3D8942FF2828B290263" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_899DA1861668D3D8942FF2828B290263" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_899DA1861668D3D8942FF2828B290263" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_1422826ACD0CE25DB530F2828B295D79_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_1422826ACD0CE25DB530F2828B295D79" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (cad per share)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_1422826ACD0CE25DB530F2828B295D79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_1422826ACD0CE25DB530F2828B295D79" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_1422826ACD0CE25DB530F2828B295D79" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D" xlink:to="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_8658DA0E1656EB55385AF2828B2ABC01_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_8658DA0E1656EB55385AF2828B2ABC01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_8658DA0E1656EB55385AF2828B2ABC01_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_8658DA0E1656EB55385AF2828B2ABC01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_8658DA0E1656EB55385AF2828B2ABC01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_8658DA0E1656EB55385AF2828B2ABC01" xlink:to="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_8658DA0E1656EB55385AF2828B2ABC01" xlink:type="arc" />
    <link:label id="lab_oncyf_CommitmentsAbstract_7E8D210E411CD69BC779C8041FBA1BBA_label_en-US" xlink:label="lab_oncyf_CommitmentsAbstract_7E8D210E411CD69BC779C8041FBA1BBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments [Abstract]</link:label>
    <link:label id="lab_oncyf_CommitmentsAbstract_7E8D210E411CD69BC779C8041FBA1BBA_documentation_en-US" xlink:label="lab_oncyf_CommitmentsAbstract_7E8D210E411CD69BC779C8041FBA1BBA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsAbstract" xlink:label="loc_oncyf_CommitmentsAbstract_7E8D210E411CD69BC779C8041FBA1BBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsAbstract_7E8D210E411CD69BC779C8041FBA1BBA" xlink:to="lab_oncyf_CommitmentsAbstract_7E8D210E411CD69BC779C8041FBA1BBA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_90B4EFF855ECBB9B3C63C8041FBA6A33_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_90B4EFF855ECBB9B3C63C8041FBA6A33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of rental payments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_90B4EFF855ECBB9B3C63C8041FBA6A33_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_90B4EFF855ECBB9B3C63C8041FBA6A33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_90B4EFF855ECBB9B3C63C8041FBA6A33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_90B4EFF855ECBB9B3C63C8041FBA6A33" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_90B4EFF855ECBB9B3C63C8041FBA6A33" xlink:type="arc" />
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0780194BED4105516FCC259B37CD146F_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0780194BED4105516FCC259B37CD146F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term employee compensation and benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0780194BED4105516FCC259B37CD146F_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0780194BED4105516FCC259B37CD146F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0780194BED4105516FCC259B37CD146F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0780194BED4105516FCC259B37CD146F" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0780194BED4105516FCC259B37CD146F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_32EEC68FF5BCE644E080259B37D0E287_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_32EEC68FF5BCE644E080259B37D0E287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_32EEC68FF5BCE644E080259B37D0E287_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_32EEC68FF5BCE644E080259B37D0E287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, termination benefits</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_32EEC68FF5BCE644E080259B37D0E287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_32EEC68FF5BCE644E080259B37D0E287" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_32EEC68FF5BCE644E080259B37D0E287" xlink:type="arc" />
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_27F898C65B105BC3AEF1259B37D05B4A_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_27F898C65B105BC3AEF1259B37D05B4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_27F898C65B105BC3AEF1259B37D05B4A_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_27F898C65B105BC3AEF1259B37D05B4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_27F898C65B105BC3AEF1259B37D05B4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_27F898C65B105BC3AEF1259B37D05B4A" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_27F898C65B105BC3AEF1259B37D05B4A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_FE72EA1541F0B4A54532259B37D050D6_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation_FE72EA1541F0B4A54532259B37D050D6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Compensation of key management personnel</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_FE72EA1541F0B4A54532259B37D050D6_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation_FE72EA1541F0B4A54532259B37D050D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_FE72EA1541F0B4A54532259B37D050D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_FE72EA1541F0B4A54532259B37D050D6" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation_FE72EA1541F0B4A54532259B37D050D6" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_83C5D5518A1396990932259B37D58FA5_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_83C5D5518A1396990932259B37D58FA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability to officer</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_83C5D5518A1396990932259B37D58FA5_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_83C5D5518A1396990932259B37D58FA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current payables to related parties</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_83C5D5518A1396990932259B37D58FA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_83C5D5518A1396990932259B37D58FA5" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_83C5D5518A1396990932259B37D58FA5" xlink:type="arc" />
    <link:label id="lab_oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1_64CC156E82BE5F047007259E03205815_terseLabel_en-US" xlink:label="lab_oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1_64CC156E82BE5F047007259E03205815" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Officer liability paid</link:label>
    <link:label id="lab_oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1_64CC156E82BE5F047007259E03205815_label_en-US" xlink:label="lab_oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1_64CC156E82BE5F047007259E03205815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party1</link:label>
    <link:label id="lab_oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1_64CC156E82BE5F047007259E03205815_documentation_en-US" xlink:label="lab_oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1_64CC156E82BE5F047007259E03205815" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party1</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1" xlink:label="loc_oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1_64CC156E82BE5F047007259E03205815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1_64CC156E82BE5F047007259E03205815" xlink:to="lab_oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1_64CC156E82BE5F047007259E03205815" xlink:type="arc" />
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_E352701571CD6DD0F8D2C8041F0D871E_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_E352701571CD6DD0F8D2C8041F0D871E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expenses and adjustments</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_E352701571CD6DD0F8D2C8041F0D871E_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_E352701571CD6DD0F8D2C8041F0D871E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table Text Block]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_E352701571CD6DD0F8D2C8041F0D871E_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_E352701571CD6DD0F8D2C8041F0D871E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table Text Block]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_E352701571CD6DD0F8D2C8041F0D871E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_E352701571CD6DD0F8D2C8041F0D871E" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_E352701571CD6DD0F8D2C8041F0D871E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_AE3CE717C90F091547F4C8041F0E058F_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_AE3CE717C90F091547F4C8041F0E058F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_AE3CE717C90F091547F4C8041F0E058F_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_AE3CE717C90F091547F4C8041F0E058F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_AE3CE717C90F091547F4C8041F0E058F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_AE3CE717C90F091547F4C8041F0E058F" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_AE3CE717C90F091547F4C8041F0E058F" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_9AFE4B8E97889724592F2047BB31BD85_label_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_9AFE4B8E97889724592F2047BB31BD85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_9AFE4B8E97889724592F2047BB31BD85_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_9AFE4B8E97889724592F2047BB31BD85" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_9AFE4B8E97889724592F2047BB31BD85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_9AFE4B8E97889724592F2047BB31BD85" xlink:to="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_9AFE4B8E97889724592F2047BB31BD85" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_F4B4F169909F7E27118520769ABB37FD_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_F4B4F169909F7E27118520769ABB37FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incorporation and Nature of Operations</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_F4B4F169909F7E27118520769ABB37FD_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_F4B4F169909F7E27118520769ABB37FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_F4B4F169909F7E27118520769ABB37FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_F4B4F169909F7E27118520769ABB37FD" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_F4B4F169909F7E27118520769ABB37FD" xlink:type="arc" />
    <link:label id="lab_oncyf_ExercisePriceofOutstandingWarrants_E4E19EA3DF241EFCE4E620C1ED049727_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceofOutstandingWarrants_E4E19EA3DF241EFCE4E620C1ED049727" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_oncyf_ExercisePriceofOutstandingWarrants_E4E19EA3DF241EFCE4E620C1ED049727_label_en-US" xlink:label="lab_oncyf_ExercisePriceofOutstandingWarrants_E4E19EA3DF241EFCE4E620C1ED049727" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price of Outstanding Warrants</link:label>
    <link:label id="lab_oncyf_ExercisePriceofOutstandingWarrants_E4E19EA3DF241EFCE4E620C1ED049727_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceofOutstandingWarrants_E4E19EA3DF241EFCE4E620C1ED049727" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price of Outstanding Warrants</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceofOutstandingWarrants" xlink:label="loc_oncyf_ExercisePriceofOutstandingWarrants_E4E19EA3DF241EFCE4E620C1ED049727" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceofOutstandingWarrants_E4E19EA3DF241EFCE4E620C1ED049727" xlink:to="lab_oncyf_ExercisePriceofOutstandingWarrants_E4E19EA3DF241EFCE4E620C1ED049727" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_F0D940E465D6BFE94D552047BA996651_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued_F0D940E465D6BFE94D552047BA996651" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Share capital issued, beginning (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_F0D940E465D6BFE94D552047BA996651_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued_F0D940E465D6BFE94D552047BA996651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_F0D940E465D6BFE94D552047BA996651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued_F0D940E465D6BFE94D552047BA996651" xlink:to="lab_ifrs-full_NumberOfSharesIssued_F0D940E465D6BFE94D552047BA996651" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_873F02DD6A2790C1C6F82047BA9A6B89_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued_873F02DD6A2790C1C6F82047BA9A6B89" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Share capital issued ending (shares)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_873F02DD6A2790C1C6F82047BA9A6B89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued_873F02DD6A2790C1C6F82047BA9A6B89" xlink:to="lab_ifrs-full_NumberOfSharesIssued_873F02DD6A2790C1C6F82047BA9A6B89" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_460E6D8A11D4DEEA52192047BA9ADEE3_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_460E6D8A11D4DEEA52192047BA9ADEE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_460E6D8A11D4DEEA52192047BA9ADEE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_460E6D8A11D4DEEA52192047BA9ADEE3" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_460E6D8A11D4DEEA52192047BA9ADEE3" xlink:type="arc" />
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9DF307384362FE2DBAF8E7B00A3F25A5_label_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9DF307384362FE2DBAF8E7B00A3F25A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9DF307384362FE2DBAF8E7B00A3F25A5_documentation_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9DF307384362FE2DBAF8E7B00A3F25A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9DF307384362FE2DBAF8E7B00A3F25A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9DF307384362FE2DBAF8E7B00A3F25A5" xlink:to="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9DF307384362FE2DBAF8E7B00A3F25A5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_2F1161D1E0377DACE7AFE7B00A40A2ED_terseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember_2F1161D1E0377DACE7AFE7B00A40A2ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_2F1161D1E0377DACE7AFE7B00A40A2ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember_2F1161D1E0377DACE7AFE7B00A40A2ED" xlink:to="lab_ifrs-full_OfficeEquipmentMember_2F1161D1E0377DACE7AFE7B00A40A2ED" xlink:type="arc" />
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_6F70152F59A8C778CA65E7B00A407671_terseLabel_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_6F70152F59A8C778CA65E7B00A407671" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual depreciation rate</link:label>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_6F70152F59A8C778CA65E7B00A407671_label_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_6F70152F59A8C778CA65E7B00A407671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Annual Depreciation Rate</link:label>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_6F70152F59A8C778CA65E7B00A407671_documentation_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_6F70152F59A8C778CA65E7B00A407671" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Annual Depreciation Rate</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_6F70152F59A8C778CA65E7B00A407671" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_6F70152F59A8C778CA65E7B00A407671" xlink:to="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_6F70152F59A8C778CA65E7B00A407671" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashEquivalents_8195CB23AC15F9ABBE89E19BEF68722D_terseLabel_en-US" xlink:label="lab_ifrs-full_CashEquivalents_8195CB23AC15F9ABBE89E19BEF68722D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashEquivalents_8195CB23AC15F9ABBE89E19BEF68722D_label_en-US" xlink:label="lab_ifrs-full_CashEquivalents_8195CB23AC15F9ABBE89E19BEF68722D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashEquivalents" xlink:label="loc_ifrs-full_CashEquivalents_8195CB23AC15F9ABBE89E19BEF68722D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashEquivalents_8195CB23AC15F9ABBE89E19BEF68722D" xlink:to="lab_ifrs-full_CashEquivalents_8195CB23AC15F9ABBE89E19BEF68722D" xlink:type="arc" />
    <link:label id="lab_oncyf_CashEquivalentsInterestRate_247CAEC10D04F64FB47EE19BEF6849DA_terseLabel_en-US" xlink:label="lab_oncyf_CashEquivalentsInterestRate_247CAEC10D04F64FB47EE19BEF6849DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current annual interest rate</link:label>
    <link:label id="lab_oncyf_CashEquivalentsInterestRate_247CAEC10D04F64FB47EE19BEF6849DA_label_en-US" xlink:label="lab_oncyf_CashEquivalentsInterestRate_247CAEC10D04F64FB47EE19BEF6849DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, Interest Rate</link:label>
    <link:label id="lab_oncyf_CashEquivalentsInterestRate_247CAEC10D04F64FB47EE19BEF6849DA_documentation_en-US" xlink:label="lab_oncyf_CashEquivalentsInterestRate_247CAEC10D04F64FB47EE19BEF6849DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Equivalents, Interest Rate</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CashEquivalentsInterestRate" xlink:label="loc_oncyf_CashEquivalentsInterestRate_247CAEC10D04F64FB47EE19BEF6849DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashEquivalentsInterestRate_247CAEC10D04F64FB47EE19BEF6849DA" xlink:to="lab_oncyf_CashEquivalentsInterestRate_247CAEC10D04F64FB47EE19BEF6849DA" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_104D2BECE2CDBB25920EC8041F2805D4_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_104D2BECE2CDBB25920EC8041F2805D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Economic Dependence</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_104D2BECE2CDBB25920EC8041F2805D4_label_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_104D2BECE2CDBB25920EC8041F2805D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_104D2BECE2CDBB25920EC8041F2805D4_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_104D2BECE2CDBB25920EC8041F2805D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Text Block]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_104D2BECE2CDBB25920EC8041F2805D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_104D2BECE2CDBB25920EC8041F2805D4" xlink:to="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_104D2BECE2CDBB25920EC8041F2805D4" xlink:type="arc" />
    <link:label id="lab_oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent_B6F30AD1CAC551AD0F21E10D70DD01EC_terseLabel_en-US" xlink:label="lab_oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent_B6F30AD1CAC551AD0F21E10D70DD01EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Investment Held In Guaranteed Investment Certificates, Percent</link:label>
    <link:label id="lab_oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent_B6F30AD1CAC551AD0F21E10D70DD01EC_label_en-US" xlink:label="lab_oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent_B6F30AD1CAC551AD0F21E10D70DD01EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investment Held In Guaranteed Investment Certificates, Percent</link:label>
    <link:label id="lab_oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent_B6F30AD1CAC551AD0F21E10D70DD01EC_documentation_en-US" xlink:label="lab_oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent_B6F30AD1CAC551AD0F21E10D70DD01EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-Term Investment Held In Guaranteed Investment Certificates, Percent</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent" xlink:label="loc_oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent_B6F30AD1CAC551AD0F21E10D70DD01EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent_B6F30AD1CAC551AD0F21E10D70DD01EC" xlink:to="lab_oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent_B6F30AD1CAC551AD0F21E10D70DD01EC" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_4976FFF7234A3347E2BDE10D70DD7158_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis_4976FFF7234A3347E2BDE10D70DD7158" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_4976FFF7234A3347E2BDE10D70DD7158_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis_4976FFF7234A3347E2BDE10D70DD7158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_4976FFF7234A3347E2BDE10D70DD7158" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis_4976FFF7234A3347E2BDE10D70DD7158" xlink:to="lab_ifrs-full_TypesOfRisksAxis_4976FFF7234A3347E2BDE10D70DD7158" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks [member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE" xlink:to="lab_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrencyRiskMember_E944AB366FC39ECF7795E10D70DD11C6_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember_E944AB366FC39ECF7795E10D70DD11C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency risk</link:label>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_E944AB366FC39ECF7795E10D70DD11C6_label_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember_E944AB366FC39ECF7795E10D70DD11C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency risk [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_E944AB366FC39ECF7795E10D70DD11C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember_E944AB366FC39ECF7795E10D70DD11C6" xlink:to="lab_ifrs-full_CurrencyRiskMember_E944AB366FC39ECF7795E10D70DD11C6" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01" xlink:type="arc" />
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_B58767F2FFFA79FE1DE8E10D70DEAD3B_terseLabel_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_B58767F2FFFA79FE1DE8E10D70DEAD3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of increase in value of currency, amount</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_B58767F2FFFA79FE1DE8E10D70DEAD3B_label_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_B58767F2FFFA79FE1DE8E10D70DEAD3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Amount</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_B58767F2FFFA79FE1DE8E10D70DEAD3B_documentation_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_B58767F2FFFA79FE1DE8E10D70DEAD3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_B58767F2FFFA79FE1DE8E10D70DEAD3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_B58767F2FFFA79FE1DE8E10D70DEAD3B" xlink:to="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_B58767F2FFFA79FE1DE8E10D70DEAD3B" xlink:type="arc" />
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_1DE952282B60B653D7D7E10D70DE5D95_negatedTerseLabel_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_1DE952282B60B653D7D7E10D70DE5D95" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Increase) decrease in net loss due to change in currency value</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_1DE952282B60B653D7D7E10D70DE5D95_label_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_1DE952282B60B653D7D7E10D70DE5D95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_1DE952282B60B653D7D7E10D70DE5D95_documentation_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_1DE952282B60B653D7D7E10D70DE5D95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_1DE952282B60B653D7D7E10D70DE5D95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_1DE952282B60B653D7D7E10D70DE5D95" xlink:to="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_1DE952282B60B653D7D7E10D70DE5D95" xlink:type="arc" />
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_1545A6FBC606DCEDFB9CE10D71051932_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_1545A6FBC606DCEDFB9CE10D71051932" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_1545A6FBC606DCEDFB9CE10D71051932_label_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_1545A6FBC606DCEDFB9CE10D71051932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_1545A6FBC606DCEDFB9CE10D71051932_documentation_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_1545A6FBC606DCEDFB9CE10D71051932" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:label="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_1545A6FBC606DCEDFB9CE10D71051932" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_1545A6FBC606DCEDFB9CE10D71051932" xlink:to="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_1545A6FBC606DCEDFB9CE10D71051932" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_EDF0593B5C7F6C46A9D0E10D7105CD96_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_EDF0593B5C7F6C46A9D0E10D7105CD96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_EDF0593B5C7F6C46A9D0E10D7105CD96_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_EDF0593B5C7F6C46A9D0E10D7105CD96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_EDF0593B5C7F6C46A9D0E10D7105CD96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_EDF0593B5C7F6C46A9D0E10D7105CD96" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_EDF0593B5C7F6C46A9D0E10D7105CD96" xlink:type="arc" />
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_3E63C2F81E5F14DA43EFE19BEF6CE632_terseLabel_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_3E63C2F81E5F14DA43EFE19BEF6CE632" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents and Short Term Investments</link:label>
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_3E63C2F81E5F14DA43EFE19BEF6CE632_label_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_3E63C2F81E5F14DA43EFE19BEF6CE632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Short Term Investments [Text Block]</link:label>
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_3E63C2F81E5F14DA43EFE19BEF6CE632_documentation_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_3E63C2F81E5F14DA43EFE19BEF6CE632" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Short Term Investments [Text Block]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_3E63C2F81E5F14DA43EFE19BEF6CE632" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_3E63C2F81E5F14DA43EFE19BEF6CE632" xlink:to="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_3E63C2F81E5F14DA43EFE19BEF6CE632" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_C071EF18F2EECD74F16B1AEC02A24BF6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_C071EF18F2EECD74F16B1AEC02A24BF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_C071EF18F2EECD74F16B1AEC02A24BF6_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_C071EF18F2EECD74F16B1AEC02A24BF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_C071EF18F2EECD74F16B1AEC02A24BF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_C071EF18F2EECD74F16B1AEC02A24BF6" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_C071EF18F2EECD74F16B1AEC02A24BF6" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CounterpartiesAxis_A15292E8A1314608B5E51AEC02A26300_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis_A15292E8A1314608B5E51AEC02A26300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_A15292E8A1314608B5E51AEC02A26300_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis_A15292E8A1314608B5E51AEC02A26300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-full_CounterpartiesAxis_A15292E8A1314608B5E51AEC02A26300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis_A15292E8A1314608B5E51AEC02A26300" xlink:to="lab_ifrs-full_CounterpartiesAxis_A15292E8A1314608B5E51AEC02A26300" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [member]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE" xlink:to="lab_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE" xlink:type="arc" />
    <link:label id="lab_oncyf_SYNSORBMember_ECCA39B4512AB8A0F5B91AEC02A21154_terseLabel_en-US" xlink:label="lab_oncyf_SYNSORBMember_ECCA39B4512AB8A0F5B91AEC02A21154" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SYNSORB</link:label>
    <link:label id="lab_oncyf_SYNSORBMember_ECCA39B4512AB8A0F5B91AEC02A21154_label_en-US" xlink:label="lab_oncyf_SYNSORBMember_ECCA39B4512AB8A0F5B91AEC02A21154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SYNSORB [Member]</link:label>
    <link:label id="lab_oncyf_SYNSORBMember_ECCA39B4512AB8A0F5B91AEC02A21154_documentation_en-US" xlink:label="lab_oncyf_SYNSORBMember_ECCA39B4512AB8A0F5B91AEC02A21154" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SYNSORB [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SYNSORBMember" xlink:label="loc_oncyf_SYNSORBMember_ECCA39B4512AB8A0F5B91AEC02A21154" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SYNSORBMember_ECCA39B4512AB8A0F5B91AEC02A21154" xlink:to="lab_oncyf_SYNSORBMember_ECCA39B4512AB8A0F5B91AEC02A21154" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_F53DDAF258928FC96DAC1AEC02A2C755_terseLabel_en-US" xlink:label="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_F53DDAF258928FC96DAC1AEC02A2C755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment in connection with Share Purchase Agreement</link:label>
    <link:label id="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_F53DDAF258928FC96DAC1AEC02A2C755_label_en-US" xlink:label="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_F53DDAF258928FC96DAC1AEC02A2C755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments made by entity, related party transactions</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_F53DDAF258928FC96DAC1AEC02A2C755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_F53DDAF258928FC96DAC1AEC02A2C755" xlink:to="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_F53DDAF258928FC96DAC1AEC02A2C755" xlink:type="arc" />
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_FC774DD9975E6D0DF2811AEC02A2B433_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_FC774DD9975E6D0DF2811AEC02A2B433" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment due period</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_FC774DD9975E6D0DF2811AEC02A2B433_label_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_FC774DD9975E6D0DF2811AEC02A2B433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Period Due</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_FC774DD9975E6D0DF2811AEC02A2B433_documentation_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_FC774DD9975E6D0DF2811AEC02A2B433" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Period Due</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_FC774DD9975E6D0DF2811AEC02A2B433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_FC774DD9975E6D0DF2811AEC02A2B433" xlink:to="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_FC774DD9975E6D0DF2811AEC02A2B433" xlink:type="arc" />
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_B14AE2A84E42BF4092F51AEC02A2EEFF_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_B14AE2A84E42BF4092F51AEC02A2EEFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment due to founding shareholders, percent</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_B14AE2A84E42BF4092F51AEC02A2EEFF_label_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_B14AE2A84E42BF4092F51AEC02A2EEFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Received,Percentage</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_B14AE2A84E42BF4092F51AEC02A2EEFF_documentation_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_B14AE2A84E42BF4092F51AEC02A2EEFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Received, Percentage</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_B14AE2A84E42BF4092F51AEC02A2EEFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_B14AE2A84E42BF4092F51AEC02A2EEFF" xlink:to="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_B14AE2A84E42BF4092F51AEC02A2EEFF" xlink:type="arc" />
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_B789B3922626C2DE13E11AEC02A210AA_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_B789B3922626C2DE13E11AEC02A210AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment on net sales due to founding shareholders, percent</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_B789B3922626C2DE13E11AEC02A210AA_label_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_B789B3922626C2DE13E11AEC02A210AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_B789B3922626C2DE13E11AEC02A210AA_documentation_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_B789B3922626C2DE13E11AEC02A210AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_B789B3922626C2DE13E11AEC02A210AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_B789B3922626C2DE13E11AEC02A210AA" xlink:to="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_B789B3922626C2DE13E11AEC02A210AA" xlink:type="arc" />
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_41EB090034C1314E1FEB1AEC02A2CB35_terseLabel_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_41EB090034C1314E1FEB1AEC02A2CB35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment on sales revenue, percent</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_41EB090034C1314E1FEB1AEC02A2CB35_label_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_41EB090034C1314E1FEB1AEC02A2CB35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Payment, Percent Of Sales Revenue</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_41EB090034C1314E1FEB1AEC02A2CB35_documentation_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_41EB090034C1314E1FEB1AEC02A2CB35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Payment, Percent Of Sales Revenue</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:label="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_41EB090034C1314E1FEB1AEC02A2CB35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_41EB090034C1314E1FEB1AEC02A2CB35" xlink:to="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_41EB090034C1314E1FEB1AEC02A2CB35" xlink:type="arc" />
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_EFB0962D94F019A4383D1AEC02A2F1EA_terseLabel_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_EFB0962D94F019A4383D1AEC02A2F1EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment maximum</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_EFB0962D94F019A4383D1AEC02A2F1EA_label_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_EFB0962D94F019A4383D1AEC02A2F1EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Payment, Annual Maximum</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_EFB0962D94F019A4383D1AEC02A2F1EA_documentation_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_EFB0962D94F019A4383D1AEC02A2F1EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Payment, Annual Maximum</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:label="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_EFB0962D94F019A4383D1AEC02A2F1EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_EFB0962D94F019A4383D1AEC02A2F1EA" xlink:to="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_EFB0962D94F019A4383D1AEC02A2F1EA" xlink:type="arc" />
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentContributionRate_18A714F0D07D450E9CE71AEC02A3AFF3_terseLabel_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentContributionRate_18A714F0D07D450E9CE71AEC02A3AFF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Royalty Payment, Contribution Rate</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentContributionRate_18A714F0D07D450E9CE71AEC02A3AFF3_label_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentContributionRate_18A714F0D07D450E9CE71AEC02A3AFF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Payment, Contribution Rate</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentContributionRate_18A714F0D07D450E9CE71AEC02A3AFF3_documentation_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentContributionRate_18A714F0D07D450E9CE71AEC02A3AFF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Payment, Contribution Rate</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ContingentRoyaltyPaymentContributionRate" xlink:label="loc_oncyf_ContingentRoyaltyPaymentContributionRate_18A714F0D07D450E9CE71AEC02A3AFF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingentRoyaltyPaymentContributionRate_18A714F0D07D450E9CE71AEC02A3AFF3" xlink:to="lab_oncyf_ContingentRoyaltyPaymentContributionRate_18A714F0D07D450E9CE71AEC02A3AFF3" xlink:type="arc" />
    <link:label id="lab_oncyf_AccruedRoyalties1_A0063782B8DA355538C21AEC02A38AC3_terseLabel_en-US" xlink:label="lab_oncyf_AccruedRoyalties1_A0063782B8DA355538C21AEC02A38AC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated accumulated work in kind total</link:label>
    <link:label id="lab_oncyf_AccruedRoyalties1_A0063782B8DA355538C21AEC02A38AC3_label_en-US" xlink:label="lab_oncyf_AccruedRoyalties1_A0063782B8DA355538C21AEC02A38AC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties1</link:label>
    <link:label id="lab_oncyf_AccruedRoyalties1_A0063782B8DA355538C21AEC02A38AC3_documentation_en-US" xlink:label="lab_oncyf_AccruedRoyalties1_A0063782B8DA355538C21AEC02A38AC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Royalties1</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_AccruedRoyalties1" xlink:label="loc_oncyf_AccruedRoyalties1_A0063782B8DA355538C21AEC02A38AC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AccruedRoyalties1_A0063782B8DA355538C21AEC02A38AC3" xlink:to="lab_oncyf_AccruedRoyalties1_A0063782B8DA355538C21AEC02A38AC3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_A8A6681D1A88BE0A0806E3906E2E9FE9_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued_A8A6681D1A88BE0A0806E3906E2E9FE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital issued (shares)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_A8A6681D1A88BE0A0806E3906E2E9FE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued_A8A6681D1A88BE0A0806E3906E2E9FE9" xlink:to="lab_ifrs-full_NumberOfSharesIssued_A8A6681D1A88BE0A0806E3906E2E9FE9" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_51465EFF5A8705EA3DFCE19BEF5756F9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_51465EFF5A8705EA3DFCE19BEF5756F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_51465EFF5A8705EA3DFCE19BEF5756F9_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_51465EFF5A8705EA3DFCE19BEF5756F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_51465EFF5A8705EA3DFCE19BEF5756F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_51465EFF5A8705EA3DFCE19BEF5756F9" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_51465EFF5A8705EA3DFCE19BEF5756F9" xlink:type="arc" />
    <link:label id="lab_oncyf_ScheduleOfShortTermInvestmentsTableTextBlock_F8FB760B8F50090A0E63E19BEF6AFCE5_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleOfShortTermInvestmentsTableTextBlock_F8FB760B8F50090A0E63E19BEF6AFCE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of short-term investments</link:label>
    <link:label id="lab_oncyf_ScheduleOfShortTermInvestmentsTableTextBlock_F8FB760B8F50090A0E63E19BEF6AFCE5_label_en-US" xlink:label="lab_oncyf_ScheduleOfShortTermInvestmentsTableTextBlock_F8FB760B8F50090A0E63E19BEF6AFCE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Short-Term Investments [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleOfShortTermInvestmentsTableTextBlock_F8FB760B8F50090A0E63E19BEF6AFCE5_documentation_en-US" xlink:label="lab_oncyf_ScheduleOfShortTermInvestmentsTableTextBlock_F8FB760B8F50090A0E63E19BEF6AFCE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Short-Term Investments [Table Text Block]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ScheduleOfShortTermInvestmentsTableTextBlock" xlink:label="loc_oncyf_ScheduleOfShortTermInvestmentsTableTextBlock_F8FB760B8F50090A0E63E19BEF6AFCE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleOfShortTermInvestmentsTableTextBlock_F8FB760B8F50090A0E63E19BEF6AFCE5" xlink:to="lab_oncyf_ScheduleOfShortTermInvestmentsTableTextBlock_F8FB760B8F50090A0E63E19BEF6AFCE5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_90B116A1B9A5916C0B59E396304C7DF9_terseLabel_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_90B116A1B9A5916C0B59E396304C7DF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Explanation of significant changes in contract assets and contract liabilities [text block]</link:label>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_90B116A1B9A5916C0B59E396304C7DF9_label_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_90B116A1B9A5916C0B59E396304C7DF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Explanation of significant changes in contract assets and contract liabilities [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_90B116A1B9A5916C0B59E396304C7DF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_90B116A1B9A5916C0B59E396304C7DF9" xlink:to="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_90B116A1B9A5916C0B59E396304C7DF9" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_A09FEBE06D0954ADB26F3FC3B08E86C0_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_A09FEBE06D0954ADB26F3FC3B08E86C0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_A09FEBE06D0954ADB26F3FC3B08E86C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_A09FEBE06D0954ADB26F3FC3B08E86C0" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_A09FEBE06D0954ADB26F3FC3B08E86C0" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_F102E0D65D0B6775BDE03FC3B08EDFC1_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_F102E0D65D0B6775BDE03FC3B08EDFC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option life, share options granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_F102E0D65D0B6775BDE03FC3B08EDFC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_F102E0D65D0B6775BDE03FC3B08EDFC1" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_F102E0D65D0B6775BDE03FC3B08EDFC1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_7418EBB8A8F5CDC2FA0B3FC3B08E2643_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_7418EBB8A8F5CDC2FA0B3FC3B08E2643" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility in the price of the Company's shares</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_7418EBB8A8F5CDC2FA0B3FC3B08E2643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_7418EBB8A8F5CDC2FA0B3FC3B08E2643" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_7418EBB8A8F5CDC2FA0B3FC3B08E2643" xlink:type="arc" />
    <link:label id="lab_oncyf_ExpectedForfeitureShareOptionsGranted_0E9C2062328E85DD7D933FC3B08E7231_terseLabel_en-US" xlink:label="lab_oncyf_ExpectedForfeitureShareOptionsGranted_0E9C2062328E85DD7D933FC3B08E7231" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate of forfeiture</link:label>
    <link:label id="lab_oncyf_ExpectedForfeitureShareOptionsGranted_0E9C2062328E85DD7D933FC3B08E7231_label_en-US" xlink:label="lab_oncyf_ExpectedForfeitureShareOptionsGranted_0E9C2062328E85DD7D933FC3B08E7231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Forfeiture, Share Options Granted</link:label>
    <link:label id="lab_oncyf_ExpectedForfeitureShareOptionsGranted_0E9C2062328E85DD7D933FC3B08E7231_documentation_en-US" xlink:label="lab_oncyf_ExpectedForfeitureShareOptionsGranted_0E9C2062328E85DD7D933FC3B08E7231" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Forfeiture, Share Options Granted</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExpectedForfeitureShareOptionsGranted" xlink:label="loc_oncyf_ExpectedForfeitureShareOptionsGranted_0E9C2062328E85DD7D933FC3B08E7231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExpectedForfeitureShareOptionsGranted_0E9C2062328E85DD7D933FC3B08E7231" xlink:to="lab_oncyf_ExpectedForfeitureShareOptionsGranted_0E9C2062328E85DD7D933FC3B08E7231" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_AB99AA5FD4982C4BD6FB3FC3B08EBB5B_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_AB99AA5FD4982C4BD6FB3FC3B08EBB5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_AB99AA5FD4982C4BD6FB3FC3B08EBB5B_label_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_AB99AA5FD4982C4BD6FB3FC3B08EBB5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected dividend as percentage, share options granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_AB99AA5FD4982C4BD6FB3FC3B08EBB5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_AB99AA5FD4982C4BD6FB3FC3B08EBB5B" xlink:to="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_AB99AA5FD4982C4BD6FB3FC3B08EBB5B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_B4B78555AC5EE193ED3F3FC3B08E6AB2_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_B4B78555AC5EE193ED3F3FC3B08E6AB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value of options (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_B4B78555AC5EE193ED3F3FC3B08E6AB2_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_B4B78555AC5EE193ED3F3FC3B08E6AB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_B4B78555AC5EE193ED3F3FC3B08E6AB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_B4B78555AC5EE193ED3F3FC3B08E6AB2" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_B4B78555AC5EE193ED3F3FC3B08E6AB2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_03C8D6DE211237C52048F724F71324D3_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis_03C8D6DE211237C52048F724F71324D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_03C8D6DE211237C52048F724F71324D3_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis_03C8D6DE211237C52048F724F71324D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_03C8D6DE211237C52048F724F71324D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_03C8D6DE211237C52048F724F71324D3" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis_03C8D6DE211237C52048F724F71324D3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
    <link:label id="lab_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780_label_en-US" xlink:label="lab_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:to="lab_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IssuedCapitalMember_B7D571B80B6FCB3E2E35F724F7149405_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember_B7D571B80B6FCB3E2E35F724F7149405" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital $</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_B7D571B80B6FCB3E2E35F724F7149405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember_B7D571B80B6FCB3E2E35F724F7149405" xlink:to="lab_ifrs-full_IssuedCapitalMember_B7D571B80B6FCB3E2E35F724F7149405" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantsMember_B09E3D30E2B14C21636DF724F7140395_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsMember_B09E3D30E2B14C21636DF724F7140395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants $</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_B09E3D30E2B14C21636DF724F7140395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsMember_B09E3D30E2B14C21636DF724F7140395" xlink:to="lab_oncyf_WarrantsMember_B09E3D30E2B14C21636DF724F7140395" xlink:type="arc" />
    <link:label id="lab_ifrs-full_SharePremiumMember_C9B89C0480327A560702F724F714C1E5_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember_C9B89C0480327A560702F724F714C1E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributed Surplus $</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_C9B89C0480327A560702F724F714C1E5_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember_C9B89C0480327A560702F724F714C1E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_C9B89C0480327A560702F724F714C1E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember_C9B89C0480327A560702F724F714C1E5" xlink:to="lab_ifrs-full_SharePremiumMember_C9B89C0480327A560702F724F714C1E5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_045F82EF94C642E87833F724F714B11D_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_045F82EF94C642E87833F724F714B11D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income $</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_045F82EF94C642E87833F724F714B11D_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_045F82EF94C642E87833F724F714B11D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_045F82EF94C642E87833F724F714B11D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_045F82EF94C642E87833F724F714B11D" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_045F82EF94C642E87833F724F714B11D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RetainedEarningsMember_376A3C10CC6B6C67DBE6F724F714C9FA_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember_376A3C10CC6B6C67DBE6F724F714C9FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit $</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_376A3C10CC6B6C67DBE6F724F714C9FA_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember_376A3C10CC6B6C67DBE6F724F714C9FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_376A3C10CC6B6C67DBE6F724F714C9FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember_376A3C10CC6B6C67DBE6F724F714C9FA" xlink:to="lab_ifrs-full_RetainedEarningsMember_376A3C10CC6B6C67DBE6F724F714C9FA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Equity_7C08E7DE83135CE43464F724F7148AC2_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity_7C08E7DE83135CE43464F724F7148AC2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_7C08E7DE83135CE43464F724F7148AC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_7C08E7DE83135CE43464F724F7148AC2" xlink:to="lab_ifrs-full_Equity_7C08E7DE83135CE43464F724F7148AC2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ComprehensiveIncome_93DD86EB680123E3FEB3F724F714F592_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome_93DD86EB680123E3FEB3F724F714F592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss and other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_93DD86EB680123E3FEB3F724F714F592_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome_93DD86EB680123E3FEB3F724F714F592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_93DD86EB680123E3FEB3F724F714F592" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome_93DD86EB680123E3FEB3F724F714F592" xlink:to="lab_ifrs-full_ComprehensiveIncome_93DD86EB680123E3FEB3F724F714F592" xlink:type="arc" />
    <link:label id="lab_oncyf_IssueOfEquityShareAgreement_C288D310914ED9FDB907F724F714D194_terseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquityShareAgreement_C288D310914ED9FDB907F724F714D194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to Share Purchase Agreement</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShareAgreement_C288D310914ED9FDB907F724F714D194_label_en-US" xlink:label="lab_oncyf_IssueOfEquityShareAgreement_C288D310914ED9FDB907F724F714D194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Share Agreement</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShareAgreement_C288D310914ED9FDB907F724F714D194_documentation_en-US" xlink:label="lab_oncyf_IssueOfEquityShareAgreement_C288D310914ED9FDB907F724F714D194" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Share Agreement</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IssueOfEquityShareAgreement" xlink:label="loc_oncyf_IssueOfEquityShareAgreement_C288D310914ED9FDB907F724F714D194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssueOfEquityShareAgreement_C288D310914ED9FDB907F724F714D194" xlink:to="lab_oncyf_IssueOfEquityShareAgreement_C288D310914ED9FDB907F724F714D194" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IssueOfEquity_10D1F8AF96632C93CAEFF724F714C4AA_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity_10D1F8AF96632C93CAEFF724F714C4AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue pursuant to At the Market Agreement</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_10D1F8AF96632C93CAEFF724F714C4AA_label_en-US" xlink:label="lab_ifrs-full_IssueOfEquity_10D1F8AF96632C93CAEFF724F714C4AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_10D1F8AF96632C93CAEFF724F714C4AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity_10D1F8AF96632C93CAEFF724F714C4AA" xlink:to="lab_ifrs-full_IssueOfEquity_10D1F8AF96632C93CAEFF724F714C4AA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_0A28DE08B5E2E95399DAF724F71528D7_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_0A28DE08B5E2E95399DAF724F71528D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to stock option plan</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_0A28DE08B5E2E95399DAF724F71528D7_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_0A28DE08B5E2E95399DAF724F71528D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_0A28DE08B5E2E95399DAF724F71528D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_0A28DE08B5E2E95399DAF724F71528D7" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_0A28DE08B5E2E95399DAF724F71528D7" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_CC9EF5837F561F27B916F724F715C4E0_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_CC9EF5837F561F27B916F724F715C4E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_CC9EF5837F561F27B916F724F715C4E0_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_CC9EF5837F561F27B916F724F715C4E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_CC9EF5837F561F27B916F724F715C4E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_CC9EF5837F561F27B916F724F715C4E0" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_CC9EF5837F561F27B916F724F715C4E0" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_84EF5032F15E6BF1A1F6F724F715CD87_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost_84EF5032F15E6BF1A1F6F724F715CD87" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share issue costs</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_84EF5032F15E6BF1A1F6F724F715CD87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost_84EF5032F15E6BF1A1F6F724F715CD87" xlink:to="lab_ifrs-full_ShareIssueRelatedCost_84EF5032F15E6BF1A1F6F724F715CD87" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Equity_9CD8B258C83ECAFC1D17F724F715AEE1_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity_9CD8B258C83ECAFC1D17F724F715AEE1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_9CD8B258C83ECAFC1D17F724F715AEE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_9CD8B258C83ECAFC1D17F724F715AEE1" xlink:to="lab_ifrs-full_Equity_9CD8B258C83ECAFC1D17F724F715AEE1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_A08599DBCBC99870C7A1C8041F8EEC3B_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_A08599DBCBC99870C7A1C8041F8EEC3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_A08599DBCBC99870C7A1C8041F8EEC3B_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_A08599DBCBC99870C7A1C8041F8EEC3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_A08599DBCBC99870C7A1C8041F8EEC3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_A08599DBCBC99870C7A1C8041F8EEC3B" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_A08599DBCBC99870C7A1C8041F8EEC3B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_9313DD142E90A42736B8E7B03DF30F76_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_9313DD142E90A42736B8E7B03DF30F76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of depreciation rates</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_9313DD142E90A42736B8E7B03DF30F76_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_9313DD142E90A42736B8E7B03DF30F76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_9313DD142E90A42736B8E7B03DF30F76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_9313DD142E90A42736B8E7B03DF30F76" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_9313DD142E90A42736B8E7B03DF30F76" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IssueOfEquity_527AD7FA96751CFE63E2F2828B44F0AA_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity_527AD7FA96751CFE63E2F2828B44F0AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued shares</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_527AD7FA96751CFE63E2F2828B44F0AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity_527AD7FA96751CFE63E2F2828B44F0AA" xlink:to="lab_ifrs-full_IssueOfEquity_527AD7FA96751CFE63E2F2828B44F0AA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_138E7665361DF3A01D56F2828B47BAF9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_138E7665361DF3A01D56F2828B47BAF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_138E7665361DF3A01D56F2828B47BAF9_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_138E7665361DF3A01D56F2828B47BAF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_138E7665361DF3A01D56F2828B47BAF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_138E7665361DF3A01D56F2828B47BAF9" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_138E7665361DF3A01D56F2828B47BAF9" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_AB09A61A459505A46A58F2828B47E0C8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_AB09A61A459505A46A58F2828B47E0C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of assumptions used in the Black Scholes Option Pricing Model for Warrants</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_AB09A61A459505A46A58F2828B47E0C8_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_AB09A61A459505A46A58F2828B47E0C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_AB09A61A459505A46A58F2828B47E0C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_AB09A61A459505A46A58F2828B47E0C8" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_AB09A61A459505A46A58F2828B47E0C8" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_24DE23591F6B0A497F82F2828B47F22A_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_24DE23591F6B0A497F82F2828B47F22A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Outstanding Warrants</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_24DE23591F6B0A497F82F2828B47F22A_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_24DE23591F6B0A497F82F2828B47F22A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_24DE23591F6B0A497F82F2828B47F22A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_24DE23591F6B0A497F82F2828B47F22A" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_24DE23591F6B0A497F82F2828B47F22A" xlink:type="arc" />
    <link:label id="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_99764D041376E2126BD7E19BEF7E05A9_label_en-US" xlink:label="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_99764D041376E2126BD7E19BEF7E05A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_99764D041376E2126BD7E19BEF7E05A9_documentation_en-US" xlink:label="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_99764D041376E2126BD7E19BEF7E05A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:label="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_99764D041376E2126BD7E19BEF7E05A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_99764D041376E2126BD7E19BEF7E05A9" xlink:to="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_99764D041376E2126BD7E19BEF7E05A9" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_EC2B4DF9B41E7723DF2DE19BEF7E960D_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_EC2B4DF9B41E7723DF2DE19BEF7E960D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of Financial Statement Presentation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_EC2B4DF9B41E7723DF2DE19BEF7E960D_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_EC2B4DF9B41E7723DF2DE19BEF7E960D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_EC2B4DF9B41E7723DF2DE19BEF7E960D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_EC2B4DF9B41E7723DF2DE19BEF7E960D" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_EC2B4DF9B41E7723DF2DE19BEF7E960D" xlink:type="arc" />
    <link:label id="lab_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192_terseLabel_en-US" xlink:label="lab_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192_label_en-US" xlink:label="lab_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement1 [Table]</link:label>
    <link:label id="lab_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192_documentation_en-US" xlink:label="lab_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Statement1 [Table]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Statement1Table" xlink:label="loc_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192" xlink:to="lab_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192" xlink:type="arc" />
    <link:label id="lab_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F_terseLabel_en-US" xlink:label="lab_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F_label_en-US" xlink:label="lab_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F_documentation_en-US" xlink:label="lab_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Statement1 [Table]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Statement1LineItems" xlink:label="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="lab_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ProfitLoss_3A7AB543C8CE64FB297A3F4B2FF01534_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss_3A7AB543C8CE64FB297A3F4B2FF01534" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss for the year</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_3A7AB543C8CE64FB297A3F4B2FF01534_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss_3A7AB543C8CE64FB297A3F4B2FF01534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_3A7AB543C8CE64FB297A3F4B2FF01534" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss_3A7AB543C8CE64FB297A3F4B2FF01534" xlink:to="lab_ifrs-full_ProfitLoss_3A7AB543C8CE64FB297A3F4B2FF01534" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_E80D3A04EECEA7F2A5603F4B2FF04C81_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_E80D3A04EECEA7F2A5603F4B2FF04C81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization - property and equipment</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_E80D3A04EECEA7F2A5603F4B2FF04C81_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_E80D3A04EECEA7F2A5603F4B2FF04C81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_E80D3A04EECEA7F2A5603F4B2FF04C81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_E80D3A04EECEA7F2A5603F4B2FF04C81" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_E80D3A04EECEA7F2A5603F4B2FF04C81" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_49ED0C51F2F8605E90FF3F4B2FF0114D_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments_49ED0C51F2F8605E90FF3F4B2FF0114D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_49ED0C51F2F8605E90FF3F4B2FF0114D_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments_49ED0C51F2F8605E90FF3F4B2FF0114D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_49ED0C51F2F8605E90FF3F4B2FF0114D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments_49ED0C51F2F8605E90FF3F4B2FF0114D" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments_49ED0C51F2F8605E90FF3F4B2FF0114D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_483746CDE6FF8CE15DE33F4B2FF04864_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_483746CDE6FF8CE15DE33F4B2FF04864" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign exchange gain</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_483746CDE6FF8CE15DE33F4B2FF04864_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_483746CDE6FF8CE15DE33F4B2FF04864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_483746CDE6FF8CE15DE33F4B2FF04864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_483746CDE6FF8CE15DE33F4B2FF04864" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_483746CDE6FF8CE15DE33F4B2FF04864" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_2A34A11C040E4BB95A9D3F4B2FF068E1_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_2A34A11C040E4BB95A9D3F4B2FF068E1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net change in non-cash working capital</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_2A34A11C040E4BB95A9D3F4B2FF068E1_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_2A34A11C040E4BB95A9D3F4B2FF068E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in working capital</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_2A34A11C040E4BB95A9D3F4B2FF068E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_2A34A11C040E4BB95A9D3F4B2FF068E1" xlink:to="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_2A34A11C040E4BB95A9D3F4B2FF068E1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_DB785FA1777C42B2FA9D3F4B2FF1B25A_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations_DB785FA1777C42B2FA9D3F4B2FF1B25A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_DB785FA1777C42B2FA9D3F4B2FF1B25A_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations_DB785FA1777C42B2FA9D3F4B2FF1B25A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_DB785FA1777C42B2FA9D3F4B2FF1B25A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_DB785FA1777C42B2FA9D3F4B2FF1B25A" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperations_DB785FA1777C42B2FA9D3F4B2FF1B25A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:type="arc" />
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4330616D3763897795663F4B2FF16368_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4330616D3763897795663F4B2FF16368" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4330616D3763897795663F4B2FF16368_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4330616D3763897795663F4B2FF16368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4330616D3763897795663F4B2FF16368" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4330616D3763897795663F4B2FF16368" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4330616D3763897795663F4B2FF16368" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_4440D1FF9AADBA9EBECA3F4B2FF145F3_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_4440D1FF9AADBA9EBECA3F4B2FF145F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption (purchase) of short-term investments</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_4440D1FF9AADBA9EBECA3F4B2FF145F3_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_4440D1FF9AADBA9EBECA3F4B2FF145F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) decrease (increase) in short-term deposits and investments</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_4440D1FF9AADBA9EBECA3F4B2FF145F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_4440D1FF9AADBA9EBECA3F4B2FF145F3" xlink:to="lab_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_4440D1FF9AADBA9EBECA3F4B2FF145F3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_CC7A5F118EAEE5CFC8543F4B2FF1188E_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_CC7A5F118EAEE5CFC8543F4B2FF1188E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash provided by (used in) investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_CC7A5F118EAEE5CFC8543F4B2FF1188E_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_CC7A5F118EAEE5CFC8543F4B2FF1188E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_CC7A5F118EAEE5CFC8543F4B2FF1188E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_CC7A5F118EAEE5CFC8543F4B2FF1188E" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_CC7A5F118EAEE5CFC8543F4B2FF1188E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_26CB2CE5B91C0D46D1043F4B2FF14ACF_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_26CB2CE5B91C0D46D1043F4B2FF14ACF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Share Purchase Agreement</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_26CB2CE5B91C0D46D1043F4B2FF14ACF_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_26CB2CE5B91C0D46D1043F4B2FF14ACF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issue of ordinary shares</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_26CB2CE5B91C0D46D1043F4B2FF14ACF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_26CB2CE5B91C0D46D1043F4B2FF14ACF" xlink:to="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_26CB2CE5B91C0D46D1043F4B2FF14ACF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_F88D1CC494D18BBEF9C93F4B2FF1731E_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares_F88D1CC494D18BBEF9C93F4B2FF1731E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from share issuance</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_F88D1CC494D18BBEF9C93F4B2FF1731E_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares_F88D1CC494D18BBEF9C93F4B2FF1731E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_F88D1CC494D18BBEF9C93F4B2FF1731E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares_F88D1CC494D18BBEF9C93F4B2FF1731E" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares_F88D1CC494D18BBEF9C93F4B2FF1731E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_C9EFCA6A7415DCBCD2F03F4B2FF1B584_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions_C9EFCA6A7415DCBCD2F03F4B2FF1B584" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_C9EFCA6A7415DCBCD2F03F4B2FF1B584_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions_C9EFCA6A7415DCBCD2F03F4B2FF1B584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_C9EFCA6A7415DCBCD2F03F4B2FF1B584" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfOptions_C9EFCA6A7415DCBCD2F03F4B2FF1B584" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfOptions_C9EFCA6A7415DCBCD2F03F4B2FF1B584" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_EF3AA6FD808E257D9FB63F4B2FF1CFAA_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_EF3AA6FD808E257D9FB63F4B2FF1CFAA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_EF3AA6FD808E257D9FB63F4B2FF1CFAA_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_EF3AA6FD808E257D9FB63F4B2FF1CFAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_EF3AA6FD808E257D9FB63F4B2FF1CFAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_EF3AA6FD808E257D9FB63F4B2FF1CFAA" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_EF3AA6FD808E257D9FB63F4B2FF1CFAA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1D3E2E681AE7C37284B63F4B2FF19F11_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1D3E2E681AE7C37284B63F4B2FF19F11" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Decrease) increase in cash</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1D3E2E681AE7C37284B63F4B2FF19F11_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1D3E2E681AE7C37284B63F4B2FF19F11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1D3E2E681AE7C37284B63F4B2FF19F11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1D3E2E681AE7C37284B63F4B2FF19F11" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1D3E2E681AE7C37284B63F4B2FF19F11" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_B3364E2776BD965828003F4B2FF1A366_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents_B3364E2776BD965828003F4B2FF1A366" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_B3364E2776BD965828003F4B2FF1A366" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents_B3364E2776BD965828003F4B2FF1A366" xlink:to="lab_ifrs-full_CashAndCashEquivalents_B3364E2776BD965828003F4B2FF1A366" xlink:type="arc" />
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_FF03400CCFDB3D7576B73F4B2FF2663A_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_FF03400CCFDB3D7576B73F4B2FF2663A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of foreign exchange on cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_FF03400CCFDB3D7576B73F4B2FF2663A_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_FF03400CCFDB3D7576B73F4B2FF2663A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_FF03400CCFDB3D7576B73F4B2FF2663A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_FF03400CCFDB3D7576B73F4B2FF2663A" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_FF03400CCFDB3D7576B73F4B2FF2663A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_28607FA0DB4AF2142E183F4B2FF22574_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents_28607FA0DB4AF2142E183F4B2FF22574" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_28607FA0DB4AF2142E183F4B2FF22574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents_28607FA0DB4AF2142E183F4B2FF22574" xlink:to="lab_ifrs-full_CashAndCashEquivalents_28607FA0DB4AF2142E183F4B2FF22574" xlink:type="arc" />
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_6FF1943E41984583B2E4E10D70ED72E4_terseLabel_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_6FF1943E41984583B2E4E10D70ED72E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses carried forward</link:label>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_6FF1943E41984583B2E4E10D70ED72E4_label_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_6FF1943E41984583B2E4E10D70ED72E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused Net Operating Loss Carry Forwards [Member]</link:label>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_6FF1943E41984583B2E4E10D70ED72E4_documentation_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_6FF1943E41984583B2E4E10D70ED72E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unused Net Operating Loss Carry Forwards [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_6FF1943E41984583B2E4E10D70ED72E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_6FF1943E41984583B2E4E10D70ED72E4" xlink:to="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_6FF1943E41984583B2E4E10D70ED72E4" xlink:type="arc" />
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_EC9445383F455C09F1ADE10D70EDF155_verboseLabel_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_EC9445383F455C09F1ADE10D70EDF155" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Scientific research and experimental development</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_EC9445383F455C09F1ADE10D70EDF155_label_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_EC9445383F455C09F1ADE10D70EDF155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unclaimed Scientific Research And Experimental Development Expenditures [Member]</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_EC9445383F455C09F1ADE10D70EDF155_documentation_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_EC9445383F455C09F1ADE10D70EDF155" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unclaimed Scientific Research And Experimental Development Expenditures [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_EC9445383F455C09F1ADE10D70EDF155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_EC9445383F455C09F1ADE10D70EDF155" xlink:to="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_EC9445383F455C09F1ADE10D70EDF155" xlink:type="arc" />
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_E5A47591CAE8F0A5CC24E10D70EDD546_terseLabel_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember_E5A47591CAE8F0A5CC24E10D70EDD546" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment tax credits</link:label>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_E5A47591CAE8F0A5CC24E10D70EDD546_label_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember_E5A47591CAE8F0A5CC24E10D70EDD546" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Tax Credits [Member]</link:label>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_E5A47591CAE8F0A5CC24E10D70EDD546_documentation_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember_E5A47591CAE8F0A5CC24E10D70EDD546" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment Tax Credits [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_InvestmentTaxCreditsMember" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_E5A47591CAE8F0A5CC24E10D70EDD546" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_InvestmentTaxCreditsMember_E5A47591CAE8F0A5CC24E10D70EDD546" xlink:to="lab_oncyf_InvestmentTaxCreditsMember_E5A47591CAE8F0A5CC24E10D70EDD546" xlink:type="arc" />
    <link:label id="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_C55B7398F4215EA18C0AE10D70ED4188_terseLabel_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_C55B7398F4215EA18C0AE10D70ED4188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</link:label>
    <link:label id="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_C55B7398F4215EA18C0AE10D70ED4188_label_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_C55B7398F4215EA18C0AE10D70ED4188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]</link:label>
    <link:label id="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_C55B7398F4215EA18C0AE10D70ED4188_documentation_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_C55B7398F4215EA18C0AE10D70ED4188" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:label="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_C55B7398F4215EA18C0AE10D70ED4188" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_C55B7398F4215EA18C0AE10D70ED4188" xlink:to="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_C55B7398F4215EA18C0AE10D70ED4188" xlink:type="arc" />
    <link:label id="lab_oncyf_ShareIssueCostsMember_175AB8B1B42314C91831E10D70EDF8E5_terseLabel_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember_175AB8B1B42314C91831E10D70EDF8E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue costs</link:label>
    <link:label id="lab_oncyf_ShareIssueCostsMember_175AB8B1B42314C91831E10D70EDF8E5_label_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember_175AB8B1B42314C91831E10D70EDF8E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Issue Costs [Member]</link:label>
    <link:label id="lab_oncyf_ShareIssueCostsMember_175AB8B1B42314C91831E10D70EDF8E5_documentation_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember_175AB8B1B42314C91831E10D70EDF8E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Issue Costs [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ShareIssueCostsMember" xlink:label="loc_oncyf_ShareIssueCostsMember_175AB8B1B42314C91831E10D70EDF8E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareIssueCostsMember_175AB8B1B42314C91831E10D70EDF8E5" xlink:to="lab_oncyf_ShareIssueCostsMember_175AB8B1B42314C91831E10D70EDF8E5" xlink:type="arc" />
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_D30C192EFDECD7CE0874E10D70EDC7B8_terseLabel_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_D30C192EFDECD7CE0874E10D70EDC7B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net capital losses carried forward</link:label>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_D30C192EFDECD7CE0874E10D70EDC7B8_label_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_D30C192EFDECD7CE0874E10D70EDC7B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused Capital Loss Carry Forward, Net [Member]</link:label>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_D30C192EFDECD7CE0874E10D70EDC7B8_documentation_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_D30C192EFDECD7CE0874E10D70EDC7B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unused Capital Loss Carry Forward, Net [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_D30C192EFDECD7CE0874E10D70EDC7B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_D30C192EFDECD7CE0874E10D70EDC7B8" xlink:to="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_D30C192EFDECD7CE0874E10D70EDC7B8" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_4E52ABBF375345F9FD78E10D70ED77AB_terseLabel_en-US" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_4E52ABBF375345F9FD78E10D70ED77AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized deferred tax asset</link:label>
    <link:label id="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_4E52ABBF375345F9FD78E10D70ED77AB_label_en-US" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_4E52ABBF375345F9FD78E10D70ED77AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deductible temporary differences for which no deferred tax asset is recognised</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_4E52ABBF375345F9FD78E10D70ED77AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_4E52ABBF375345F9FD78E10D70ED77AB" xlink:to="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_4E52ABBF375345F9FD78E10D70ED77AB" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_296077F6BFC84D699AAFC8041E6C24B6_label_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_296077F6BFC84D699AAFC8041E6C24B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_296077F6BFC84D699AAFC8041E6C24B6_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_296077F6BFC84D699AAFC8041E6C24B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_296077F6BFC84D699AAFC8041E6C24B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_296077F6BFC84D699AAFC8041E6C24B6" xlink:to="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_296077F6BFC84D699AAFC8041E6C24B6" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_C1E07A50AFF864BD4A01C8041E6CD677_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_C1E07A50AFF864BD4A01C8041E6CD677" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnification of Officers and Directors</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_C1E07A50AFF864BD4A01C8041E6CD677_label_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_C1E07A50AFF864BD4A01C8041E6CD677" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_C1E07A50AFF864BD4A01C8041E6CD677_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_C1E07A50AFF864BD4A01C8041E6CD677" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Text Block]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_C1E07A50AFF864BD4A01C8041E6CD677" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_C1E07A50AFF864BD4A01C8041E6CD677" xlink:to="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_C1E07A50AFF864BD4A01C8041E6CD677" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_11496F68BD9DC7BA2DC3E10D7137FC0F_label_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_11496F68BD9DC7BA2DC3E10D7137FC0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_11496F68BD9DC7BA2DC3E10D7137FC0F_documentation_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_11496F68BD9DC7BA2DC3E10D7137FC0F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:label="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_11496F68BD9DC7BA2DC3E10D7137FC0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_11496F68BD9DC7BA2DC3E10D7137FC0F" xlink:to="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_11496F68BD9DC7BA2DC3E10D7137FC0F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_A881080D97D06A37B81FE10D713723B5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_A881080D97D06A37B81FE10D713723B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock options and weighted average exercise prices of share options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_A881080D97D06A37B81FE10D713723B5_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_A881080D97D06A37B81FE10D713723B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_A881080D97D06A37B81FE10D713723B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_A881080D97D06A37B81FE10D713723B5" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_A881080D97D06A37B81FE10D713723B5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_4F8DB2B2431E16883782E10D7137F938_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_4F8DB2B2431E16883782E10D7137F938" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock options outstanding and exercisable by range of exercise price</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_4F8DB2B2431E16883782E10D7137F938_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_4F8DB2B2431E16883782E10D7137F938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_4F8DB2B2431E16883782E10D7137F938" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_4F8DB2B2431E16883782E10D7137F938" xlink:to="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_4F8DB2B2431E16883782E10D7137F938" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_8C02828B8EB372692139E10D71387BFF_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_8C02828B8EB372692139E10D71387BFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of weighted average remaining contractual life and outstanding stock options by exercise price</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_8C02828B8EB372692139E10D71387BFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_8C02828B8EB372692139E10D71387BFF" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_8C02828B8EB372692139E10D71387BFF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_7945B444451E53DEFE9FE10D71383C36_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_7945B444451E53DEFE9FE10D71383C36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure weighted average assumptions and fair value of options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_7945B444451E53DEFE9FE10D71383C36_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_7945B444451E53DEFE9FE10D71383C36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_7945B444451E53DEFE9FE10D71383C36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_7945B444451E53DEFE9FE10D71383C36" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_7945B444451E53DEFE9FE10D71383C36" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1E00F8717589C723D714E10D7138C4C1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1E00F8717589C723D714E10D7138C4C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of number of other equity instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1E00F8717589C723D714E10D7138C4C1_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1E00F8717589C723D714E10D7138C4C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1E00F8717589C723D714E10D7138C4C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1E00F8717589C723D714E10D7138C4C1" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1E00F8717589C723D714E10D7138C4C1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_D98D4474DC6254187C8D1AEC01F706D6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_D98D4474DC6254187C8D1AEC01F706D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_D98D4474DC6254187C8D1AEC01F706D6_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_D98D4474DC6254187C8D1AEC01F706D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_D98D4474DC6254187C8D1AEC01F706D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_D98D4474DC6254187C8D1AEC01F706D6" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_D98D4474DC6254187C8D1AEC01F706D6" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageShares_05847BDF6BD34EBCB13DE1487D35A443_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares_05847BDF6BD34EBCB13DE1487D35A443" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_05847BDF6BD34EBCB13DE1487D35A443_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares_05847BDF6BD34EBCB13DE1487D35A443" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_05847BDF6BD34EBCB13DE1487D35A443" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares_05847BDF6BD34EBCB13DE1487D35A443" xlink:to="lab_ifrs-full_WeightedAverageShares_05847BDF6BD34EBCB13DE1487D35A443" xlink:type="arc" />
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPolicieAbstract_996334BC5530EBB9084DE7B03A79DE4D_label_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPolicieAbstract_996334BC5530EBB9084DE7B03A79DE4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policie [Abstract]</link:label>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPolicieAbstract_996334BC5530EBB9084DE7B03A79DE4D_documentation_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPolicieAbstract_996334BC5530EBB9084DE7B03A79DE4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policie [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SummaryOfSignificantAccountingPolicieAbstract" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_996334BC5530EBB9084DE7B03A79DE4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_996334BC5530EBB9084DE7B03A79DE4D" xlink:to="lab_oncyf_SummaryOfSignificantAccountingPolicieAbstract_996334BC5530EBB9084DE7B03A79DE4D" xlink:type="arc" />
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_3082B508CC8EA0261A9EE7B03A797D50_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans_3082B508CC8EA0261A9EE7B03A797D50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of plans</link:label>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_3082B508CC8EA0261A9EE7B03A797D50_label_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans_3082B508CC8EA0261A9EE7B03A797D50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_3082B508CC8EA0261A9EE7B03A797D50_documentation_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans_3082B508CC8EA0261A9EE7B03A797D50" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_NumberOfStockOptionPlans" xlink:label="loc_oncyf_NumberOfStockOptionPlans_3082B508CC8EA0261A9EE7B03A797D50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfStockOptionPlans_3082B508CC8EA0261A9EE7B03A797D50" xlink:to="lab_oncyf_NumberOfStockOptionPlans_3082B508CC8EA0261A9EE7B03A797D50" xlink:type="arc" />
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_07C67D036D00589D8C42E7B03A79DEDB_terseLabel_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_07C67D036D00589D8C42E7B03A79DEDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum option expiration term</link:label>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_07C67D036D00589D8C42E7B03A79DEDB_label_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_07C67D036D00589D8C42E7B03A79DEDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Term Of Options Granted For Share-based Payment Arrangement</link:label>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_07C67D036D00589D8C42E7B03A79DEDB_documentation_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_07C67D036D00589D8C42E7B03A79DEDB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Term Of Options Granted For Share-based Payment Arrangement</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:label="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_07C67D036D00589D8C42E7B03A79DEDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_07C67D036D00589D8C42E7B03A79DEDB" xlink:to="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_07C67D036D00589D8C42E7B03A79DEDB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_D12E34E049305F54C61FE7B041F6062F_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_D12E34E049305F54C61FE7B041F6062F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_D12E34E049305F54C61FE7B041F6062F_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_D12E34E049305F54C61FE7B041F6062F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant accounting policies [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_D12E34E049305F54C61FE7B041F6062F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_D12E34E049305F54C61FE7B041F6062F" xlink:to="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_D12E34E049305F54C61FE7B041F6062F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_865E3E842CBBDF7840772B9E1BDD78C7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_865E3E842CBBDF7840772B9E1BDD78C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liability and receivable</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_865E3E842CBBDF7840772B9E1BDD78C7_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_865E3E842CBBDF7840772B9E1BDD78C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_865E3E842CBBDF7840772B9E1BDD78C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_865E3E842CBBDF7840772B9E1BDD78C7" xlink:to="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_865E3E842CBBDF7840772B9E1BDD78C7" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyMember_A6871FB6FE6D1174AA69F2828AECE44A_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyMember_A6871FB6FE6D1174AA69F2828AECE44A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_oncyf_TwentyTwentyMember_A6871FB6FE6D1174AA69F2828AECE44A_label_en-US" xlink:label="lab_oncyf_TwentyTwentyMember_A6871FB6FE6D1174AA69F2828AECE44A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyMember_A6871FB6FE6D1174AA69F2828AECE44A_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyMember_A6871FB6FE6D1174AA69F2828AECE44A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyMember" xlink:label="loc_oncyf_TwentyTwentyMember_A6871FB6FE6D1174AA69F2828AECE44A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyMember_A6871FB6FE6D1174AA69F2828AECE44A" xlink:to="lab_oncyf_TwentyTwentyMember_A6871FB6FE6D1174AA69F2828AECE44A" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyOneMember_A566C4E1528EE21EEA25F2828AEC93E9_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyOneMember_A566C4E1528EE21EEA25F2828AEC93E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_oncyf_TwentyTwentyOneMember_A566C4E1528EE21EEA25F2828AEC93E9_label_en-US" xlink:label="lab_oncyf_TwentyTwentyOneMember_A566C4E1528EE21EEA25F2828AEC93E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty One [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyOneMember_A566C4E1528EE21EEA25F2828AEC93E9_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyOneMember_A566C4E1528EE21EEA25F2828AEC93E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty One [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyOneMember" xlink:label="loc_oncyf_TwentyTwentyOneMember_A566C4E1528EE21EEA25F2828AEC93E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyOneMember_A566C4E1528EE21EEA25F2828AEC93E9" xlink:to="lab_oncyf_TwentyTwentyOneMember_A566C4E1528EE21EEA25F2828AEC93E9" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyTwoMember_FBCFCD9040ED00D07251F2828AEC68F5_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyTwoMember_FBCFCD9040ED00D07251F2828AEC68F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_oncyf_TwentyTwentyTwoMember_FBCFCD9040ED00D07251F2828AEC68F5_label_en-US" xlink:label="lab_oncyf_TwentyTwentyTwoMember_FBCFCD9040ED00D07251F2828AEC68F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyTwoMember_FBCFCD9040ED00D07251F2828AEC68F5_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyTwoMember_FBCFCD9040ED00D07251F2828AEC68F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyTwoMember" xlink:label="loc_oncyf_TwentyTwentyTwoMember_FBCFCD9040ED00D07251F2828AEC68F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyTwoMember_FBCFCD9040ED00D07251F2828AEC68F5" xlink:to="lab_oncyf_TwentyTwentyTwoMember_FBCFCD9040ED00D07251F2828AEC68F5" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyThreeMember_B0483F97ED97EA19567FF2828AEC107E_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyThreeMember_B0483F97ED97EA19567FF2828AEC107E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_oncyf_TwentyTwentyThreeMember_B0483F97ED97EA19567FF2828AEC107E_label_en-US" xlink:label="lab_oncyf_TwentyTwentyThreeMember_B0483F97ED97EA19567FF2828AEC107E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Three [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyThreeMember_B0483F97ED97EA19567FF2828AEC107E_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyThreeMember_B0483F97ED97EA19567FF2828AEC107E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Three [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyThreeMember" xlink:label="loc_oncyf_TwentyTwentyThreeMember_B0483F97ED97EA19567FF2828AEC107E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyThreeMember_B0483F97ED97EA19567FF2828AEC107E" xlink:to="lab_oncyf_TwentyTwentyThreeMember_B0483F97ED97EA19567FF2828AEC107E" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyFourMember_FDD0FCC8FC7023367863F2828AECC62D_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyFourMember_FDD0FCC8FC7023367863F2828AECC62D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFourMember_FDD0FCC8FC7023367863F2828AECC62D_label_en-US" xlink:label="lab_oncyf_TwentyTwentyFourMember_FDD0FCC8FC7023367863F2828AECC62D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Four [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFourMember_FDD0FCC8FC7023367863F2828AECC62D_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyFourMember_FDD0FCC8FC7023367863F2828AECC62D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Four [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyFourMember" xlink:label="loc_oncyf_TwentyTwentyFourMember_FDD0FCC8FC7023367863F2828AECC62D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyFourMember_FDD0FCC8FC7023367863F2828AECC62D" xlink:to="lab_oncyf_TwentyTwentyFourMember_FDD0FCC8FC7023367863F2828AECC62D" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyFiveMember_3979DA2281FCD9F0E11BF2828AEC51AE_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyFiveMember_3979DA2281FCD9F0E11BF2828AEC51AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFiveMember_3979DA2281FCD9F0E11BF2828AEC51AE_label_en-US" xlink:label="lab_oncyf_TwentyTwentyFiveMember_3979DA2281FCD9F0E11BF2828AEC51AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFiveMember_3979DA2281FCD9F0E11BF2828AEC51AE_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyFiveMember_3979DA2281FCD9F0E11BF2828AEC51AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyFiveMember" xlink:label="loc_oncyf_TwentyTwentyFiveMember_3979DA2281FCD9F0E11BF2828AEC51AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyFiveMember_3979DA2281FCD9F0E11BF2828AEC51AE" xlink:to="lab_oncyf_TwentyTwentyFiveMember_3979DA2281FCD9F0E11BF2828AEC51AE" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyEightMember_7282DCA9F5ED5512676FF2828AEC8722_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyEightMember_7282DCA9F5ED5512676FF2828AEC8722" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_oncyf_TwentyTwentyEightMember_7282DCA9F5ED5512676FF2828AEC8722_label_en-US" xlink:label="lab_oncyf_TwentyTwentyEightMember_7282DCA9F5ED5512676FF2828AEC8722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Eight [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyEightMember_7282DCA9F5ED5512676FF2828AEC8722_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyEightMember_7282DCA9F5ED5512676FF2828AEC8722" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Eight [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyEightMember" xlink:label="loc_oncyf_TwentyTwentyEightMember_7282DCA9F5ED5512676FF2828AEC8722" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyEightMember_7282DCA9F5ED5512676FF2828AEC8722" xlink:to="lab_oncyf_TwentyTwentyEightMember_7282DCA9F5ED5512676FF2828AEC8722" xlink:type="arc" />
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_308D3002B3863DCB282FF2828AED0DE4_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember_308D3002B3863DCB282FF2828AED0DE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable federal investment tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_308D3002B3863DCB282FF2828AED0DE4_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember_308D3002B3863DCB282FF2828AED0DE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax credits [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxCreditsMember" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_308D3002B3863DCB282FF2828AED0DE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsMember_308D3002B3863DCB282FF2828AED0DE4" xlink:to="lab_ifrs-full_UnusedTaxCreditsMember_308D3002B3863DCB282FF2828AED0DE4" xlink:type="arc" />
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_58C8482A59E4B418C465F2828AEDC721_terseLabel_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_58C8482A59E4B418C465F2828AEDC721" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unclaimed scientific research and experimental development expenditures</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_58C8482A59E4B418C465F2828AEDC721" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_58C8482A59E4B418C465F2828AEDC721" xlink:to="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_58C8482A59E4B418C465F2828AEDC721" xlink:type="arc" />
    <link:label id="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_D37E4DE42DE767533ECFF2828AEDD7A3_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_D37E4DE42DE767533ECFF2828AEDD7A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_D37E4DE42DE767533ECFF2828AEDD7A3_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_D37E4DE42DE767533ECFF2828AEDD7A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax credits for which no deferred tax asset recognised</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_D37E4DE42DE767533ECFF2828AEDD7A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_D37E4DE42DE767533ECFF2828AEDD7A3" xlink:to="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_D37E4DE42DE767533ECFF2828AEDD7A3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:to="lab_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_44719553D8CEC3870F262047BB426F7F_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract_44719553D8CEC3870F262047BB426F7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_44719553D8CEC3870F262047BB426F7F_label_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract_44719553D8CEC3870F262047BB426F7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses by nature [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpenseByNatureAbstract" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_44719553D8CEC3870F262047BB426F7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_44719553D8CEC3870F262047BB426F7F" xlink:to="lab_ifrs-full_ExpenseByNatureAbstract_44719553D8CEC3870F262047BB426F7F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_BBCC4E474F701887C2682047BB42913E_terseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense_BBCC4E474F701887C2682047BB42913E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_BBCC4E474F701887C2682047BB42913E_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense_BBCC4E474F701887C2682047BB42913E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_BBCC4E474F701887C2682047BB42913E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_BBCC4E474F701887C2682047BB42913E" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense_BBCC4E474F701887C2682047BB42913E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OperatingExpense_8C31CBA0E3078400A81B2047BB422662_terseLabel_en-US" xlink:label="lab_ifrs-full_OperatingExpense_8C31CBA0E3078400A81B2047BB422662" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_ifrs-full_OperatingExpense_8C31CBA0E3078400A81B2047BB422662_label_en-US" xlink:label="lab_ifrs-full_OperatingExpense_8C31CBA0E3078400A81B2047BB422662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OperatingExpense" xlink:label="loc_ifrs-full_OperatingExpense_8C31CBA0E3078400A81B2047BB422662" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingExpense_8C31CBA0E3078400A81B2047BB422662" xlink:to="lab_ifrs-full_OperatingExpense_8C31CBA0E3078400A81B2047BB422662" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_835DE23EBAD2186712DC2047BB423292_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities_835DE23EBAD2186712DC2047BB423292" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before the following</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_835DE23EBAD2186712DC2047BB423292_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities_835DE23EBAD2186712DC2047BB423292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_835DE23EBAD2186712DC2047BB423292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_835DE23EBAD2186712DC2047BB423292" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities_835DE23EBAD2186712DC2047BB423292" xlink:type="arc" />
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_A188492895360CA913DE2089D70E8209_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_A188492895360CA913DE2089D70E8209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_A188492895360CA913DE2089D70E8209_label_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_A188492895360CA913DE2089D70E8209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income on cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_A188492895360CA913DE2089D70E8209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_A188492895360CA913DE2089D70E8209" xlink:to="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_A188492895360CA913DE2089D70E8209" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_8FDFE4F0421B3ABB29472047BB42C8F2_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax_8FDFE4F0421B3ABB29472047BB42C8F2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_8FDFE4F0421B3ABB29472047BB42C8F2_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax_8FDFE4F0421B3ABB29472047BB42C8F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_8FDFE4F0421B3ABB29472047BB42C8F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_8FDFE4F0421B3ABB29472047BB42C8F2" xlink:to="lab_ifrs-full_ProfitLossBeforeTax_8FDFE4F0421B3ABB29472047BB42C8F2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_58D6EB0EDC838235012E2047BB4254D4_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_58D6EB0EDC838235012E2047BB4254D4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_58D6EB0EDC838235012E2047BB4254D4_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_58D6EB0EDC838235012E2047BB4254D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income), continuing operations</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_58D6EB0EDC838235012E2047BB4254D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_58D6EB0EDC838235012E2047BB4254D4" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_58D6EB0EDC838235012E2047BB4254D4" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ProfitLoss_5839D59F7AA3A4A8C7002047BB435E55_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss_5839D59F7AA3A4A8C7002047BB435E55" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_5839D59F7AA3A4A8C7002047BB435E55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss_5839D59F7AA3A4A8C7002047BB435E55" xlink:to="lab_ifrs-full_ProfitLoss_5839D59F7AA3A4A8C7002047BB435E55" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_35B37F68EEF6FE82D3612047BB432523_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract_35B37F68EEF6FE82D3612047BB432523" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income items that may be reclassified to net loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_35B37F68EEF6FE82D3612047BB432523_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract_35B37F68EEF6FE82D3612047BB432523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_35B37F68EEF6FE82D3612047BB432523" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_35B37F68EEF6FE82D3612047BB432523" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract_35B37F68EEF6FE82D3612047BB432523" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0618FD3F56E9020664582047BB43ACDF_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0618FD3F56E9020664582047BB43ACDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation adjustment</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0618FD3F56E9020664582047BB43ACDF_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0618FD3F56E9020664582047BB43ACDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0618FD3F56E9020664582047BB43ACDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0618FD3F56E9020664582047BB43ACDF" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0618FD3F56E9020664582047BB43ACDF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ComprehensiveIncome_405928908C29968654272047BB43EB20_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome_405928908C29968654272047BB43EB20" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_405928908C29968654272047BB43EB20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome_405928908C29968654272047BB43EB20" xlink:to="lab_ifrs-full_ComprehensiveIncome_405928908C29968654272047BB43EB20" xlink:type="arc" />
    <link:label id="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_4554F563B7091183DB542047BB4315DD_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_4554F563B7091183DB542047BB4315DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted loss per common share (cad per share)</link:label>
    <link:label id="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_4554F563B7091183DB542047BB4315DD_label_en-US" xlink:label="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_4554F563B7091183DB542047BB4315DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings (loss) per share</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_4554F563B7091183DB542047BB4315DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_4554F563B7091183DB542047BB4315DD" xlink:to="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_4554F563B7091183DB542047BB4315DD" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageShares_F9DC1AEF981B702B48F72047BB43162D_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares_F9DC1AEF981B702B48F72047BB43162D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares (basic)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_F9DC1AEF981B702B48F72047BB43162D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares_F9DC1AEF981B702B48F72047BB43162D" xlink:to="lab_ifrs-full_WeightedAverageShares_F9DC1AEF981B702B48F72047BB43162D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_259A577C420E7D1974012047BB433616_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares_259A577C420E7D1974012047BB433616" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares (diluted)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_259A577C420E7D1974012047BB433616_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares_259A577C420E7D1974012047BB433616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjusted weighted average number of ordinary shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_259A577C420E7D1974012047BB433616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_259A577C420E7D1974012047BB433616" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares_259A577C420E7D1974012047BB433616" xlink:type="arc" />
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_AA348CA70FD6FD08537BC8041FD191E1_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_AA348CA70FD6FD08537BC8041FD191E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of balances in foreign currencies</link:label>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_AA348CA70FD6FD08537BC8041FD191E1_label_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_AA348CA70FD6FD08537BC8041FD191E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Foreign Currency Held [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_AA348CA70FD6FD08537BC8041FD191E1_documentation_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_AA348CA70FD6FD08537BC8041FD191E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Foreign Currency Held [Table Text Block]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:label="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_AA348CA70FD6FD08537BC8041FD191E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_AA348CA70FD6FD08537BC8041FD191E1" xlink:to="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_AA348CA70FD6FD08537BC8041FD191E1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_9129140E85FE3998566C2047BB2A76DD_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_9129140E85FE3998566C2047BB2A76DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_9129140E85FE3998566C2047BB2A76DD_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_9129140E85FE3998566C2047BB2A76DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for deferred income tax [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_9129140E85FE3998566C2047BB2A76DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_9129140E85FE3998566C2047BB2A76DD" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_9129140E85FE3998566C2047BB2A76DD" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_BABE20BC79FEF1C847C02047BB2AB775_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_BABE20BC79FEF1C847C02047BB2AB775" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_BABE20BC79FEF1C847C02047BB2AB775_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_BABE20BC79FEF1C847C02047BB2AB775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_BABE20BC79FEF1C847C02047BB2AB775" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_BABE20BC79FEF1C847C02047BB2AB775" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_BABE20BC79FEF1C847C02047BB2AB775" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_9BAF9F564EA9DBCAF6C12047BB2AD96B_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_9BAF9F564EA9DBCAF6C12047BB2AD96B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_9BAF9F564EA9DBCAF6C12047BB2AD96B_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_9BAF9F564EA9DBCAF6C12047BB2AD96B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial liabilities [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_9BAF9F564EA9DBCAF6C12047BB2AD96B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_9BAF9F564EA9DBCAF6C12047BB2AD96B" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_9BAF9F564EA9DBCAF6C12047BB2AD96B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_4B9DD74C1C673C0FEA472047BB2AD1C0_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_4B9DD74C1C673C0FEA472047BB2AD1C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurement</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_4B9DD74C1C673C0FEA472047BB2AD1C0_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_4B9DD74C1C673C0FEA472047BB2AD1C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_4B9DD74C1C673C0FEA472047BB2AD1C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_4B9DD74C1C673C0FEA472047BB2AD1C0" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_4B9DD74C1C673C0FEA472047BB2AD1C0" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory_52B95F11EE826E0758322047BB2A2EC5_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory_52B95F11EE826E0758322047BB2A2EC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory_52B95F11EE826E0758322047BB2A2EC5_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory_52B95F11EE826E0758322047BB2A2EC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for finance costs [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory_52B95F11EE826E0758322047BB2A2EC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory_52B95F11EE826E0758322047BB2A2EC5" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory_52B95F11EE826E0758322047BB2A2EC5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_7EB3D0BA77ACACF01B412047BB2A3A3F_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_7EB3D0BA77ACACF01B412047BB2A3A3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_7EB3D0BA77ACACF01B412047BB2A3A3F_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_7EB3D0BA77ACACF01B412047BB2A3A3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_7EB3D0BA77ACACF01B412047BB2A3A3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_7EB3D0BA77ACACF01B412047BB2A3A3F" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_7EB3D0BA77ACACF01B412047BB2A3A3F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_CC950BFB23342F1F00392047BB2A1ED1_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_CC950BFB23342F1F00392047BB2A1ED1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment tax credits</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_CC950BFB23342F1F00392047BB2A1ED1_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_CC950BFB23342F1F00392047BB2A1ED1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for taxes other than income tax [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_CC950BFB23342F1F00392047BB2A1ED1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_CC950BFB23342F1F00392047BB2A1ED1" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_CC950BFB23342F1F00392047BB2A1ED1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_57BE55BACEF4E476F8082047BB2A2AFE_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_57BE55BACEF4E476F8082047BB2A2AFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_57BE55BACEF4E476F8082047BB2A2AFE_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_57BE55BACEF4E476F8082047BB2A2AFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_57BE55BACEF4E476F8082047BB2A2AFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_57BE55BACEF4E476F8082047BB2A2AFE" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_57BE55BACEF4E476F8082047BB2A2AFE" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_6ED284826394F42D63D72047BB2AC682_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_6ED284826394F42D63D72047BB2AC682" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_6ED284826394F42D63D72047BB2AC682_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_6ED284826394F42D63D72047BB2AC682" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_6ED284826394F42D63D72047BB2AC682" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_6ED284826394F42D63D72047BB2AC682" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_6ED284826394F42D63D72047BB2AC682" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_5FC0C791FD46D5B903322047BB2A0ACA_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_5FC0C791FD46D5B903322047BB2A0ACA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_5FC0C791FD46D5B903322047BB2A0ACA_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_5FC0C791FD46D5B903322047BB2A0ACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_5FC0C791FD46D5B903322047BB2A0ACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_5FC0C791FD46D5B903322047BB2A0ACA" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_5FC0C791FD46D5B903322047BB2A0ACA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_9BC183A141CC8D4FBE392047BB2AB26A_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_9BC183A141CC8D4FBE392047BB2AB26A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_9BC183A141CC8D4FBE392047BB2AB26A_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_9BC183A141CC8D4FBE392047BB2AB26A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_9BC183A141CC8D4FBE392047BB2AB26A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_9BC183A141CC8D4FBE392047BB2AB26A" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_9BC183A141CC8D4FBE392047BB2AB26A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_74655DB649DF44276F3C2047BB2BCED1_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_74655DB649DF44276F3C2047BB2BCED1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based payments</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_74655DB649DF44276F3C2047BB2BCED1_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_74655DB649DF44276F3C2047BB2BCED1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_74655DB649DF44276F3C2047BB2BCED1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_74655DB649DF44276F3C2047BB2BCED1" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_74655DB649DF44276F3C2047BB2BCED1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_EEF6429C5BD701405CBC20A00B88B477_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_EEF6429C5BD701405CBC20A00B88B477" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of new accounting standards</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_EEF6429C5BD701405CBC20A00B88B477_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_EEF6429C5BD701405CBC20A00B88B477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_EEF6429C5BD701405CBC20A00B88B477" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_EEF6429C5BD701405CBC20A00B88B477" xlink:to="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_EEF6429C5BD701405CBC20A00B88B477" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_A40127DE69D94FFDAA8F2047BB2B6283_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_A40127DE69D94FFDAA8F2047BB2B6283" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting standards and interpretations issued but not yet effective</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_A40127DE69D94FFDAA8F2047BB2B6283_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_A40127DE69D94FFDAA8F2047BB2B6283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_A40127DE69D94FFDAA8F2047BB2B6283" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_A40127DE69D94FFDAA8F2047BB2B6283" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_A40127DE69D94FFDAA8F2047BB2B6283" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_CAB8BE8BE95BE4B011011AEC026DCB62_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_CAB8BE8BE95BE4B011011AEC026DCB62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract receivable</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_CAB8BE8BE95BE4B011011AEC026DCB62_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_CAB8BE8BE95BE4B011011AEC026DCB62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_CAB8BE8BE95BE4B011011AEC026DCB62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_CAB8BE8BE95BE4B011011AEC026DCB62" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_CAB8BE8BE95BE4B011011AEC026DCB62" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_AC671F43F5BC4527F6941AEC026D248D_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_AC671F43F5BC4527F6941AEC026D248D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_AC671F43F5BC4527F6941AEC026D248D_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_AC671F43F5BC4527F6941AEC026D248D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in other operating receivables</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_AC671F43F5BC4527F6941AEC026D248D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_AC671F43F5BC4527F6941AEC026D248D" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_AC671F43F5BC4527F6941AEC026D248D" xlink:type="arc" />
    <link:label id="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_D7DE483AB78DB8E3EC181AEC026D6C63_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_D7DE483AB78DB8E3EC181AEC026D6C63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_D7DE483AB78DB8E3EC181AEC026D6C63_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_D7DE483AB78DB8E3EC181AEC026D6C63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense1</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_D7DE483AB78DB8E3EC181AEC026D6C63_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_D7DE483AB78DB8E3EC181AEC026D6C63" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense1</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IncreaseDecreaseinPrepaidExpense1" xlink:label="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_D7DE483AB78DB8E3EC181AEC026D6C63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_D7DE483AB78DB8E3EC181AEC026D6C63" xlink:to="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_D7DE483AB78DB8E3EC181AEC026D6C63" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_072450E7B37DB9445B211AEC026DD0DB_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_072450E7B37DB9445B211AEC026DD0DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_072450E7B37DB9445B211AEC026DD0DB_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_072450E7B37DB9445B211AEC026DD0DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_072450E7B37DB9445B211AEC026DD0DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_072450E7B37DB9445B211AEC026DD0DB" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_072450E7B37DB9445B211AEC026DD0DB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9D0E5B2A255833F38C1F1AEC026DCB5C_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9D0E5B2A255833F38C1F1AEC026DCB5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9D0E5B2A255833F38C1F1AEC026DCB5C_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9D0E5B2A255833F38C1F1AEC026DCB5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in other operating payables</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9D0E5B2A255833F38C1F1AEC026DCB5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9D0E5B2A255833F38C1F1AEC026DCB5C" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9D0E5B2A255833F38C1F1AEC026DCB5C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_BEFDFE0BDF22A8ACAE4C1AEC026D66D0_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_BEFDFE0BDF22A8ACAE4C1AEC026D66D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash impact of foreign exchange</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_BEFDFE0BDF22A8ACAE4C1AEC026D66D0_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_BEFDFE0BDF22A8ACAE4C1AEC026D66D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through foreign exchange, financial assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_BEFDFE0BDF22A8ACAE4C1AEC026D66D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_BEFDFE0BDF22A8ACAE4C1AEC026D66D0" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_BEFDFE0BDF22A8ACAE4C1AEC026D66D0" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_1DA4AB6F311BDA640ABB1AEC026DDC02_totalLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_1DA4AB6F311BDA640ABB1AEC026DDC02" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Change in non-cash working capital related to operating activities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_1DA4AB6F311BDA640ABB1AEC026DDC02_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_1DA4AB6F311BDA640ABB1AEC026DDC02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss) other than changes in working capital</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:label="loc_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_1DA4AB6F311BDA640ABB1AEC026DDC02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_1DA4AB6F311BDA640ABB1AEC026DDC02" xlink:to="lab_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_1DA4AB6F311BDA640ABB1AEC026DDC02" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_322F56F67ED5EAF9EAEAE7C7207A5DFB_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_322F56F67ED5EAF9EAEAE7C7207A5DFB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_322F56F67ED5EAF9EAEAE7C7207A5DFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_322F56F67ED5EAF9EAEAE7C7207A5DFB" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_322F56F67ED5EAF9EAEAE7C7207A5DFB" xlink:type="arc" />
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_OtherExpensesAndAdjustmentsTable" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E" xlink:type="arc" />
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5_terseLabel_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5_label_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5_documentation_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IncomeStatementLocation1Axis" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5" xlink:to="lab_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5" xlink:type="arc" />
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9_terseLabel_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9_label_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Domain]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9_documentation_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Income Statement Location1 [Axis]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IncomeStatementLocation1Domain" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9" xlink:to="lab_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9" xlink:type="arc" />
    <link:label id="lab_oncyf_ResearchAndDevelopmentMember_D9C42B4CE655BCC54544E33E939F54B5_terseLabel_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentMember_D9C42B4CE655BCC54544E33E939F54B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Included in research and development expenses:</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentMember_D9C42B4CE655BCC54544E33E939F54B5_label_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentMember_D9C42B4CE655BCC54544E33E939F54B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentMember_D9C42B4CE655BCC54544E33E939F54B5_documentation_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentMember_D9C42B4CE655BCC54544E33E939F54B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ResearchAndDevelopmentMember" xlink:label="loc_oncyf_ResearchAndDevelopmentMember_D9C42B4CE655BCC54544E33E939F54B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ResearchAndDevelopmentMember_D9C42B4CE655BCC54544E33E939F54B5" xlink:to="lab_oncyf_ResearchAndDevelopmentMember_D9C42B4CE655BCC54544E33E939F54B5" xlink:type="arc" />
    <link:label id="lab_oncyf_OperatingExpensesMember_9339A330464CDF91D914E33E939FBD7E_terseLabel_en-US" xlink:label="lab_oncyf_OperatingExpensesMember_9339A330464CDF91D914E33E939FBD7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Included in operating expenses</link:label>
    <link:label id="lab_oncyf_OperatingExpensesMember_9339A330464CDF91D914E33E939FBD7E_label_en-US" xlink:label="lab_oncyf_OperatingExpensesMember_9339A330464CDF91D914E33E939FBD7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Member]</link:label>
    <link:label id="lab_oncyf_OperatingExpensesMember_9339A330464CDF91D914E33E939FBD7E_documentation_en-US" xlink:label="lab_oncyf_OperatingExpensesMember_9339A330464CDF91D914E33E939FBD7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Expenses [Member]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_OperatingExpensesMember" xlink:label="loc_oncyf_OperatingExpensesMember_9339A330464CDF91D914E33E939FBD7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OperatingExpensesMember_9339A330464CDF91D914E33E939FBD7E" xlink:to="lab_oncyf_OperatingExpensesMember_9339A330464CDF91D914E33E939FBD7E" xlink:type="arc" />
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Line Items]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Line Items]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Other Expenses And Adjustments [Table]</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_82109F2ACF7818EF9AA6E33E93A0CFB6_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_82109F2ACF7818EF9AA6E33E93A0CFB6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Realized foreign exchange (gain) loss</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_82109F2ACF7818EF9AA6E33E93A0CFB6_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_82109F2ACF7818EF9AA6E33E93A0CFB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_82109F2ACF7818EF9AA6E33E93A0CFB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_82109F2ACF7818EF9AA6E33E93A0CFB6" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_82109F2ACF7818EF9AA6E33E93A0CFB6" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_1BF2F47F72CF6766DCD3E33E93A04BA9_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_1BF2F47F72CF6766DCD3E33E93A04BA9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized non-cash foreign exchange loss (gain)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_1BF2F47F72CF6766DCD3E33E93A04BA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_1BF2F47F72CF6766DCD3E33E93A04BA9" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_1BF2F47F72CF6766DCD3E33E93A04BA9" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AmortisationExpense_C942044F91480CA91A70E33E93A0718B_terseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationExpense_C942044F91480CA91A70E33E93A0718B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of property and equipment</link:label>
    <link:label id="lab_ifrs-full_AmortisationExpense_C942044F91480CA91A70E33E93A0718B_label_en-US" xlink:label="lab_ifrs-full_AmortisationExpense_C942044F91480CA91A70E33E93A0718B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense_C942044F91480CA91A70E33E93A0718B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense_C942044F91480CA91A70E33E93A0718B" xlink:to="lab_ifrs-full_AmortisationExpense_C942044F91480CA91A70E33E93A0718B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense_75622CDCD9E2CD467704E33E93A0E68E_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense_75622CDCD9E2CD467704E33E93A0E68E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office minimum lease payments</link:label>
    <link:label id="lab_ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense_75622CDCD9E2CD467704E33E93A0E68E_label_en-US" xlink:label="lab_ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense_75622CDCD9E2CD467704E33E93A0E68E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease and sublease payments recognised as expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense" xlink:label="loc_ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense_75622CDCD9E2CD467704E33E93A0E68E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense_75622CDCD9E2CD467704E33E93A0E68E" xlink:to="lab_ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense_75622CDCD9E2CD467704E33E93A0E68E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentInvestments_99CD57681D68FFF9B2D9C8041E74577B_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentInvestments_99CD57681D68FFF9B2D9C8041E74577B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentInvestments" xlink:label="loc_ifrs-full_CurrentInvestments_99CD57681D68FFF9B2D9C8041E74577B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentInvestments_99CD57681D68FFF9B2D9C8041E74577B" xlink:to="lab_ifrs-full_CurrentInvestments_99CD57681D68FFF9B2D9C8041E74577B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Equity_ABA7E61ED58D78DB8418C8041E74DABD_terseLabel_en-US" xlink:label="lab_ifrs-full_Equity_ABA7E61ED58D78DB8418C8041E74DABD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_ABA7E61ED58D78DB8418C8041E74DABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_ABA7E61ED58D78DB8418C8041E74DABD" xlink:to="lab_ifrs-full_Equity_ABA7E61ED58D78DB8418C8041E74DABD" xlink:type="arc" />
    <link:label id="lab_oncyf_EquityAuthorized_81BBDC42097744B1983FC8041E74BADF_terseLabel_en-US" xlink:label="lab_oncyf_EquityAuthorized_81BBDC42097744B1983FC8041E74BADF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Shelf securities authorized</link:label>
    <link:label id="lab_oncyf_EquityAuthorized_81BBDC42097744B1983FC8041E74BADF_label_en-US" xlink:label="lab_oncyf_EquityAuthorized_81BBDC42097744B1983FC8041E74BADF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Authorized</link:label>
    <link:label id="lab_oncyf_EquityAuthorized_81BBDC42097744B1983FC8041E74BADF_documentation_en-US" xlink:label="lab_oncyf_EquityAuthorized_81BBDC42097744B1983FC8041E74BADF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Authorized</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_EquityAuthorized" xlink:label="loc_oncyf_EquityAuthorized_81BBDC42097744B1983FC8041E74BADF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_EquityAuthorized_81BBDC42097744B1983FC8041E74BADF" xlink:to="lab_oncyf_EquityAuthorized_81BBDC42097744B1983FC8041E74BADF" xlink:type="arc" />
    <link:label id="lab_oncyf_PurchaseObligation1_82FB2D61C38937B4DE5BF2828B0960F2_terseLabel_en-US" xlink:label="lab_oncyf_PurchaseObligation1_82FB2D61C38937B4DE5BF2828B0960F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment for payment</link:label>
    <link:label id="lab_oncyf_PurchaseObligation1_82FB2D61C38937B4DE5BF2828B0960F2_label_en-US" xlink:label="lab_oncyf_PurchaseObligation1_82FB2D61C38937B4DE5BF2828B0960F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation1</link:label>
    <link:label id="lab_oncyf_PurchaseObligation1_82FB2D61C38937B4DE5BF2828B0960F2_documentation_en-US" xlink:label="lab_oncyf_PurchaseObligation1_82FB2D61C38937B4DE5BF2828B0960F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Obligation1</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_PurchaseObligation1" xlink:label="loc_oncyf_PurchaseObligation1_82FB2D61C38937B4DE5BF2828B0960F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PurchaseObligation1_82FB2D61C38937B4DE5BF2828B0960F2" xlink:to="lab_oncyf_PurchaseObligation1_82FB2D61C38937B4DE5BF2828B0960F2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_FDEDE0353411E07E7F4EF2828B09E1F3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_FDEDE0353411E07E7F4EF2828B09E1F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_FDEDE0353411E07E7F4EF2828B09E1F3_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_FDEDE0353411E07E7F4EF2828B09E1F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_FDEDE0353411E07E7F4EF2828B09E1F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_FDEDE0353411E07E7F4EF2828B09E1F3" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_FDEDE0353411E07E7F4EF2828B09E1F3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_3FC6B46C00951C403485F2828B0AD4B2_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember_3FC6B46C00951C403485F2828B0AD4B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_3FC6B46C00951C403485F2828B0AD4B2_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember_3FC6B46C00951C403485F2828B0AD4B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_3FC6B46C00951C403485F2828B0AD4B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember_3FC6B46C00951C403485F2828B0AD4B2" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember_3FC6B46C00951C403485F2828B0AD4B2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_0866F12E219FB302D0CBF2828B0A7772_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_0866F12E219FB302D0CBF2828B0A7772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_0866F12E219FB302D0CBF2828B0A7772_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_0866F12E219FB302D0CBF2828B0A7772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than two years [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_0866F12E219FB302D0CBF2828B0A7772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_0866F12E219FB302D0CBF2828B0A7772" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_0866F12E219FB302D0CBF2828B0A7772" xlink:type="arc" />
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_4838EF5D9934C7DCD28AF2828B0AAD46_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_4838EF5D9934C7DCD28AF2828B0AAD46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_4838EF5D9934C7DCD28AF2828B0AAD46_label_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_4838EF5D9934C7DCD28AF2828B0AAD46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than two years and not later than three years [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_4838EF5D9934C7DCD28AF2828B0AAD46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_4838EF5D9934C7DCD28AF2828B0AAD46" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_4838EF5D9934C7DCD28AF2828B0AAD46" xlink:type="arc" />
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_49AD26E04553910EA50FF2828B0ADD8B_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_49AD26E04553910EA50FF2828B0ADD8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_49AD26E04553910EA50FF2828B0ADD8B_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_49AD26E04553910EA50FF2828B0ADD8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three years and not later than four years [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_49AD26E04553910EA50FF2828B0ADD8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_49AD26E04553910EA50FF2828B0ADD8B" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_49AD26E04553910EA50FF2828B0ADD8B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_989F86529337D2E9FB21F2828B0AE8D8_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_989F86529337D2E9FB21F2828B0AE8D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_989F86529337D2E9FB21F2828B0AE8D8_label_en-US" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_989F86529337D2E9FB21F2828B0AE8D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than four years and not later than five years [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_989F86529337D2E9FB21F2828B0AE8D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_989F86529337D2E9FB21F2828B0AE8D8" xlink:to="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_989F86529337D2E9FB21F2828B0AE8D8" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_8149EA20DE88DD602705F2828B0A382D_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_8149EA20DE88DD602705F2828B0A382D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_8149EA20DE88DD602705F2828B0A382D_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_8149EA20DE88DD602705F2828B0A382D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_8149EA20DE88DD602705F2828B0A382D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_8149EA20DE88DD602705F2828B0A382D" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_8149EA20DE88DD602705F2828B0A382D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease_01F578EF883B5BE184F1F2828B0A98EA_terseLabel_en-US" xlink:label="lab_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease_01F578EF883B5BE184F1F2828B0A98EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rental payments</link:label>
    <link:label id="lab_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease_01F578EF883B5BE184F1F2828B0A98EA_label_en-US" xlink:label="lab_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease_01F578EF883B5BE184F1F2828B0A98EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum lease payments payable under non-cancellable operating lease</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" xlink:label="loc_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease_01F578EF883B5BE184F1F2828B0A98EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease_01F578EF883B5BE184F1F2828B0A98EA" xlink:to="lab_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease_01F578EF883B5BE184F1F2828B0A98EA" xlink:type="arc" />
    <link:label id="lab_oncyf_FundedandRoyaltyRepayment_C435D7BFFBA7028BE9EEF2828B0A0F88_terseLabel_en-US" xlink:label="lab_oncyf_FundedandRoyaltyRepayment_C435D7BFFBA7028BE9EEF2828B0A0F88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment, maximum</link:label>
    <link:label id="lab_oncyf_FundedandRoyaltyRepayment_C435D7BFFBA7028BE9EEF2828B0A0F88_label_en-US" xlink:label="lab_oncyf_FundedandRoyaltyRepayment_C435D7BFFBA7028BE9EEF2828B0A0F88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Funded and Royalty Repayment</link:label>
    <link:label id="lab_oncyf_FundedandRoyaltyRepayment_C435D7BFFBA7028BE9EEF2828B0A0F88_documentation_en-US" xlink:label="lab_oncyf_FundedandRoyaltyRepayment_C435D7BFFBA7028BE9EEF2828B0A0F88" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Funded and Royalty Repayment</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_FundedandRoyaltyRepayment" xlink:label="loc_oncyf_FundedandRoyaltyRepayment_C435D7BFFBA7028BE9EEF2828B0A0F88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_FundedandRoyaltyRepayment_C435D7BFFBA7028BE9EEF2828B0A0F88" xlink:to="lab_oncyf_FundedandRoyaltyRepayment_C435D7BFFBA7028BE9EEF2828B0A0F88" xlink:type="arc" />
    <link:label id="lab_oncyf_OverheadRepayment_632E499824368DF3E466F2828B0A18D2_terseLabel_en-US" xlink:label="lab_oncyf_OverheadRepayment_632E499824368DF3E466F2828B0A18D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overhead repayment</link:label>
    <link:label id="lab_oncyf_OverheadRepayment_632E499824368DF3E466F2828B0A18D2_label_en-US" xlink:label="lab_oncyf_OverheadRepayment_632E499824368DF3E466F2828B0A18D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Overhead Repayment</link:label>
    <link:label id="lab_oncyf_OverheadRepayment_632E499824368DF3E466F2828B0A18D2_documentation_en-US" xlink:label="lab_oncyf_OverheadRepayment_632E499824368DF3E466F2828B0A18D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Overhead Repayment</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_OverheadRepayment" xlink:label="loc_oncyf_OverheadRepayment_632E499824368DF3E466F2828B0A18D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OverheadRepayment_632E499824368DF3E466F2828B0A18D2" xlink:to="lab_oncyf_OverheadRepayment_632E499824368DF3E466F2828B0A18D2" xlink:type="arc" />
    <link:label id="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_D644097F0B4AFE1F0225F2828B0A5BA8_terseLabel_en-US" xlink:label="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_D644097F0B4AFE1F0225F2828B0A5BA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual installment of gross sales of product, percent</link:label>
    <link:label id="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_D644097F0B4AFE1F0225F2828B0A5BA8_label_en-US" xlink:label="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_D644097F0B4AFE1F0225F2828B0A5BA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Contingent Payment, Gross Sales, Percent</link:label>
    <link:label id="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_D644097F0B4AFE1F0225F2828B0A5BA8_documentation_en-US" xlink:label="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_D644097F0B4AFE1F0225F2828B0A5BA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Contingent Payment, Gross Sales, Percent</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:label="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_D644097F0B4AFE1F0225F2828B0A5BA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_D644097F0B4AFE1F0225F2828B0A5BA8" xlink:to="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_D644097F0B4AFE1F0225F2828B0A5BA8" xlink:type="arc" />
    <link:label id="lab_oncyf_AnnualContingentPayment_DD105AE55FFDCAC60003F2828B0A38B5_terseLabel_en-US" xlink:label="lab_oncyf_AnnualContingentPayment_DD105AE55FFDCAC60003F2828B0A38B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual installment of annual product sales</link:label>
    <link:label id="lab_oncyf_AnnualContingentPayment_DD105AE55FFDCAC60003F2828B0A38B5_label_en-US" xlink:label="lab_oncyf_AnnualContingentPayment_DD105AE55FFDCAC60003F2828B0A38B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Contingent Payment</link:label>
    <link:label id="lab_oncyf_AnnualContingentPayment_DD105AE55FFDCAC60003F2828B0A38B5_documentation_en-US" xlink:label="lab_oncyf_AnnualContingentPayment_DD105AE55FFDCAC60003F2828B0A38B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Contingent Payment</link:label>
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_AnnualContingentPayment" xlink:label="loc_oncyf_AnnualContingentPayment_DD105AE55FFDCAC60003F2828B0A38B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AnnualContingentPayment_DD105AE55FFDCAC60003F2828B0A38B5" xlink:to="lab_oncyf_AnnualContingentPayment_DD105AE55FFDCAC60003F2828B0A38B5" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>oncyf-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:href="oncyf-20171231.xsd#AdditionalCashFlowDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:href="oncyf-20171231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:href="oncyf-20171231.xsd#AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:href="oncyf-20171231.xsd#AdditionalCashFlowDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation" xlink:href="oncyf-20171231.xsd#BasisOfFinancialStatementPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:href="oncyf-20171231.xsd#CapitalDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:href="oncyf-20171231.xsd#CapitalDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:href="oncyf-20171231.xsd#CapitalDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestments" xlink:href="oncyf-20171231.xsd#CashEquivalentsAndShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsNarrativeDetails" xlink:href="oncyf-20171231.xsd#CashEquivalentsAndShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:href="oncyf-20171231.xsd#CashEquivalentsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:href="oncyf-20171231.xsd#CashEquivalentsAndShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Commitments" xlink:href="oncyf-20171231.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:href="oncyf-20171231.xsd#CommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsTables" xlink:href="oncyf-20171231.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInEquity" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfChangesInEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfFinancialPosition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:href="oncyf-20171231.xsd#ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:href="oncyf-20171231.xsd#Contingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:href="oncyf-20171231.xsd#ContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable" xlink:href="oncyf-20171231.xsd#ContractLiabilityAndReceivable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails" xlink:href="oncyf-20171231.xsd#ContractLiabilityAndReceivableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:href="oncyf-20171231.xsd#ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables" xlink:href="oncyf-20171231.xsd#ContractLiabilityAndReceivableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformationDocument" xlink:href="oncyf-20171231.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:href="oncyf-20171231.xsd#EconomicDependence" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:href="oncyf-20171231.xsd#EconomicDependenceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:href="oncyf-20171231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:href="oncyf-20171231.xsd#FinancialInstrumentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:href="oncyf-20171231.xsd#FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:href="oncyf-20171231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:href="oncyf-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" xlink:href="oncyf-20171231.xsd#IncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:href="oncyf-20171231.xsd#IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:href="oncyf-20171231.xsd#IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:href="oncyf-20171231.xsd#IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:href="oncyf-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations" xlink:href="oncyf-20171231.xsd#IncorporationAndNatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors" xlink:href="oncyf-20171231.xsd#IndemnificationOfOfficersAndDirectors" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:href="oncyf-20171231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:href="oncyf-20171231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments" xlink:href="oncyf-20171231.xsd#OtherExpensesAndAdjustments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails" xlink:href="oncyf-20171231.xsd#OtherExpensesAndAdjustmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables" xlink:href="oncyf-20171231.xsd#OtherExpensesAndAdjustmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipment" xlink:href="oncyf-20171231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails" xlink:href="oncyf-20171231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables" xlink:href="oncyf-20171231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:href="oncyf-20171231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:href="oncyf-20171231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:href="oncyf-20171231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:href="oncyf-20171231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:href="oncyf-20171231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:href="oncyf-20171231.xsd#ShareCapital" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails" xlink:href="oncyf-20171231.xsd#ShareCapitalScheduleOfShareCapitalDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:href="oncyf-20171231.xsd#ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:href="oncyf-20171231.xsd#ShareCapitalSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:href="oncyf-20171231.xsd#ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:href="oncyf-20171231.xsd#ShareCapitalTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions" xlink:href="oncyf-20171231.xsd#SignificantJudgmentsEstimatesAndAssumptions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="oncyf-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_D227A4417E61E2BEFFC9F2828ACA2ECF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_408F5781AC21B158D1B9F2828ACAA636" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_D227A4417E61E2BEFFC9F2828ACA2ECF" xlink:to="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_408F5781AC21B158D1B9F2828ACAA636" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_C0DBBBBFFE972238794C1AEC026D1F70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_CAB8BE8BE95BE4B011011AEC026DCB62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_C0DBBBBFFE972238794C1AEC026D1F70" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_CAB8BE8BE95BE4B011011AEC026DCB62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_AC671F43F5BC4527F6941AEC026D248D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_C0DBBBBFFE972238794C1AEC026D1F70" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_AC671F43F5BC4527F6941AEC026D248D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IncreaseDecreaseinPrepaidExpense1" xlink:label="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_D7DE483AB78DB8E3EC181AEC026D6C63" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_C0DBBBBFFE972238794C1AEC026D1F70" xlink:to="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_D7DE483AB78DB8E3EC181AEC026D6C63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_072450E7B37DB9445B211AEC026DD0DB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_C0DBBBBFFE972238794C1AEC026D1F70" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_072450E7B37DB9445B211AEC026DD0DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9D0E5B2A255833F38C1F1AEC026DCB5C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_C0DBBBBFFE972238794C1AEC026D1F70" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9D0E5B2A255833F38C1F1AEC026DCB5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_BEFDFE0BDF22A8ACAE4C1AEC026D66D0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_C0DBBBBFFE972238794C1AEC026D1F70" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_BEFDFE0BDF22A8ACAE4C1AEC026D66D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:label="loc_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_1DA4AB6F311BDA640ABB1AEC026DDC02" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_C0DBBBBFFE972238794C1AEC026D1F70" xlink:to="loc_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_1DA4AB6F311BDA640ABB1AEC026DDC02" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_3B068BF01F6890317201F2828AC3A51A" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ProceedsfromInterestReceived" xlink:label="loc_oncyf_ProceedsfromInterestReceived_D2EEC3D4DD9FD2CA4672F2828AC3CCC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_3B068BF01F6890317201F2828AC3A51A" xlink:to="loc_oncyf_ProceedsfromInterestReceived_D2EEC3D4DD9FD2CA4672F2828AC3CCC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund_2646409F0C705673CB0CF2828AC38AFF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_3B068BF01F6890317201F2828AC3A51A" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefund_2646409F0C705673CB0CF2828AC38AFF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_D695A0C2BBCAED77F4ADF2828AC88686" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:label="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_778B2863D71064AF0BFBF2828AC9ADE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_D695A0C2BBCAED77F4ADF2828AC88686" xlink:to="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_778B2863D71064AF0BFBF2828AC9ADE5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:label="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_953127EF78ECFA383744F2828AC9DD32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_D695A0C2BBCAED77F4ADF2828AC88686" xlink:to="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_953127EF78ECFA383744F2828AC9DD32" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:label="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_99764D041376E2126BD7E19BEF7E05A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_EC2B4DF9B41E7723DF2DE19BEF7E960D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_99764D041376E2126BD7E19BEF7E05A9" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_EC2B4DF9B41E7723DF2DE19BEF7E960D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_78363C67D885046B6D61C8041F7B8433" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_FBB43CD385103E590BE1C8041F7B3965" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_78363C67D885046B6D61C8041F7B8433" xlink:to="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_FBB43CD385103E590BE1C8041F7B3965" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_714A5C8FDAD7CE309DE0C8041E73B9F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_88E564E1FE17B1350A76C8041E736AF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_714A5C8FDAD7CE309DE0C8041E73B9F4" xlink:to="loc_ifrs-full_CashAndCashEquivalents_88E564E1FE17B1350A76C8041E736AF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentInvestments" xlink:label="loc_ifrs-full_CurrentInvestments_99CD57681D68FFF9B2D9C8041E74577B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_714A5C8FDAD7CE309DE0C8041E73B9F4" xlink:to="loc_ifrs-full_CurrentInvestments_99CD57681D68FFF9B2D9C8041E74577B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_ABA7E61ED58D78DB8418C8041E74DABD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_714A5C8FDAD7CE309DE0C8041E73B9F4" xlink:to="loc_ifrs-full_Equity_ABA7E61ED58D78DB8418C8041E74DABD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_EquityAuthorized" xlink:label="loc_oncyf_EquityAuthorized_81BBDC42097744B1983FC8041E74BADF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_714A5C8FDAD7CE309DE0C8041E73B9F4" xlink:to="loc_oncyf_EquityAuthorized_81BBDC42097744B1983FC8041E74BADF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_0E00F63F8F408ABCDD53E10D70E6D19B" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:label="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2D177B8BF3DE0A07A981E1932BFA4F88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_0E00F63F8F408ABCDD53E10D70E6D19B" xlink:to="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2D177B8BF3DE0A07A981E1932BFA4F88" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestments" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_943597304FE92AAA23B9E19BEF6C7566" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_3E63C2F81E5F14DA43EFE19BEF6CE632" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_943597304FE92AAA23B9E19BEF6C7566" xlink:to="loc_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_3E63C2F81E5F14DA43EFE19BEF6CE632" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_0452D4D9D986A67D1A2DE19BEF681948" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashEquivalents" xlink:label="loc_ifrs-full_CashEquivalents_8195CB23AC15F9ABBE89E19BEF68722D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_0452D4D9D986A67D1A2DE19BEF681948" xlink:to="loc_ifrs-full_CashEquivalents_8195CB23AC15F9ABBE89E19BEF68722D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CashEquivalentsInterestRate" xlink:label="loc_oncyf_CashEquivalentsInterestRate_247CAEC10D04F64FB47EE19BEF6849DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_0452D4D9D986A67D1A2DE19BEF681948" xlink:to="loc_oncyf_CashEquivalentsInterestRate_247CAEC10D04F64FB47EE19BEF6849DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_DB36668DE6B51A9A7B7E1AEC02FEDA23" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_DB36668DE6B51A9A7B7E1AEC02FEDA23" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-full_MeasurementAxis_37B0C0BCE458B06E35061AEC02FE7FC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:to="loc_ifrs-full_MeasurementAxis_37B0C0BCE458B06E35061AEC02FE7FC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_37B0C0BCE458B06E35061AEC02FE7FC7" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AtCostMember" xlink:label="loc_ifrs-full_AtCostMember_EB255EBFF518ED35416B1AEC02FE5ED9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3" xlink:to="loc_ifrs-full_AtCostMember_EB255EBFF518ED35416B1AEC02FE5ED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AtFairValueMember" xlink:label="loc_ifrs-full_AtFairValueMember_A05E0F5199E8AB7D233D1AEC02FE6E0F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7C77BA49CD95CF25C02F1AEC02FEAFB3" xlink:to="loc_ifrs-full_AtFairValueMember_A05E0F5199E8AB7D233D1AEC02FE6E0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_72911D79B93BDAE747451AEC02FE8EF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_72911D79B93BDAE747451AEC02FE8EF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsMember" xlink:label="loc_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_72911D79B93BDAE747451AEC02FE8EF1" xlink:to="loc_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_FinancialAssetsAtFaceValueMember" xlink:label="loc_oncyf_FinancialAssetsAtFaceValueMember_966EF8D7C6669825EB301AEC02FE8108" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:to="loc_oncyf_FinancialAssetsAtFaceValueMember_966EF8D7C6669825EB301AEC02FE8108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember_267A21191001F82B2F481AEC02FE2D0A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember_267A21191001F82B2F481AEC02FE2D0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueMember_A04EEFED1480A41499181AEC02FE79B8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_918BEE8E8E041C25EEDD1AEC02FE7D64" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueMember_A04EEFED1480A41499181AEC02FE79B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_EBA6C6745F4C728EC77F1AEC02FE564F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_EBA6C6745F4C728EC77F1AEC02FE564F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_EBA6C6745F4C728EC77F1AEC02FE564F" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_HeldtomaturityInvestmentsCategoryMember" xlink:label="loc_ifrs-full_HeldtomaturityInvestmentsCategoryMember_13101ABE816E23212B631AEC02FE5D4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_013040A8DD20334BFA171AEC02FEBEF0" xlink:to="loc_ifrs-full_HeldtomaturityInvestmentsCategoryMember_13101ABE816E23212B631AEC02FE5D4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_36344E4A3786183F77081AEC02FE4C42" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssets" xlink:label="loc_ifrs-full_FinancialAssets_720B236F2751DA6E21FC1AEC02FF58E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B" xlink:to="loc_ifrs-full_FinancialAssets_720B236F2751DA6E21FC1AEC02FF58E7" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ShortTermInvestmentEffectiveInterestRate" xlink:label="loc_oncyf_ShortTermInvestmentEffectiveInterestRate_59A4717C67EE0F4D86B71AEC02FF3813" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_EE6FAD633C62FD2F4B7A1AEC02FFA40B" xlink:to="loc_oncyf_ShortTermInvestmentEffectiveInterestRate_59A4717C67EE0F4D86B71AEC02FF3813" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_F9C0312904B6BCBC7E7AE19BEF6A42DC" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ScheduleOfShortTermInvestmentsTableTextBlock" xlink:label="loc_oncyf_ScheduleOfShortTermInvestmentsTableTextBlock_F8FB760B8F50090A0E63E19BEF6AFCE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_F9C0312904B6BCBC7E7AE19BEF6A42DC" xlink:to="loc_oncyf_ScheduleOfShortTermInvestmentsTableTextBlock_F8FB760B8F50090A0E63E19BEF6AFCE5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsAbstract" xlink:label="loc_oncyf_CommitmentsAbstract_0E916DE11446FBF60F07C8041F0EC9CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_AE3CE717C90F091547F4C8041F0E058F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_0E916DE11446FBF60F07C8041F0EC9CC" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_AE3CE717C90F091547F4C8041F0E058F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsAbstract" xlink:label="loc_oncyf_CommitmentsAbstract_190CA6AAE38C5F8D2FC6F2828B091A2E" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_PurchaseObligation1" xlink:label="loc_oncyf_PurchaseObligation1_82FB2D61C38937B4DE5BF2828B0960F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_190CA6AAE38C5F8D2FC6F2828B091A2E" xlink:to="loc_oncyf_PurchaseObligation1_82FB2D61C38937B4DE5BF2828B0960F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_FDEDE0353411E07E7F4EF2828B09E1F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_190CA6AAE38C5F8D2FC6F2828B091A2E" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_FDEDE0353411E07E7F4EF2828B09E1F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_2F077569D2F40DCFE8B7F2828B097D36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_FDEDE0353411E07E7F4EF2828B09E1F3" xlink:to="loc_ifrs-full_MaturityAxis_2F077569D2F40DCFE8B7F2828B097D36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_2F077569D2F40DCFE8B7F2828B097D36" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_3FC6B46C00951C403485F2828B0AD4B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_3FC6B46C00951C403485F2828B0AD4B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_0866F12E219FB302D0CBF2828B0A7772" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_0866F12E219FB302D0CBF2828B0A7772" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_4838EF5D9934C7DCD28AF2828B0AAD46" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_4838EF5D9934C7DCD28AF2828B0AAD46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_49AD26E04553910EA50FF2828B0ADD8B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_49AD26E04553910EA50FF2828B0ADD8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_989F86529337D2E9FB21F2828B0AE8D8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_CA1C65935DA451CBBCCDF2828B0A2E6B" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_989F86529337D2E9FB21F2828B0AE8D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_8149EA20DE88DD602705F2828B0A382D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_FDEDE0353411E07E7F4EF2828B09E1F3" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_8149EA20DE88DD602705F2828B0A382D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" xlink:label="loc_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease_01F578EF883B5BE184F1F2828B0A98EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_8149EA20DE88DD602705F2828B0A382D" xlink:to="loc_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease_01F578EF883B5BE184F1F2828B0A98EA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_FundedandRoyaltyRepayment" xlink:label="loc_oncyf_FundedandRoyaltyRepayment_C435D7BFFBA7028BE9EEF2828B0A0F88" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_190CA6AAE38C5F8D2FC6F2828B091A2E" xlink:to="loc_oncyf_FundedandRoyaltyRepayment_C435D7BFFBA7028BE9EEF2828B0A0F88" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_OverheadRepayment" xlink:label="loc_oncyf_OverheadRepayment_632E499824368DF3E466F2828B0A18D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_190CA6AAE38C5F8D2FC6F2828B091A2E" xlink:to="loc_oncyf_OverheadRepayment_632E499824368DF3E466F2828B0A18D2" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:label="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_D644097F0B4AFE1F0225F2828B0A5BA8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_190CA6AAE38C5F8D2FC6F2828B091A2E" xlink:to="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_D644097F0B4AFE1F0225F2828B0A5BA8" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_AnnualContingentPayment" xlink:label="loc_oncyf_AnnualContingentPayment_DD105AE55FFDCAC60003F2828B0A38B5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_190CA6AAE38C5F8D2FC6F2828B091A2E" xlink:to="loc_oncyf_AnnualContingentPayment_DD105AE55FFDCAC60003F2828B0A38B5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsAbstract" xlink:label="loc_oncyf_CommitmentsAbstract_7E8D210E411CD69BC779C8041FBA1BBA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_90B4EFF855ECBB9B3C63C8041FBA6A33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_7E8D210E411CD69BC779C8041FBA1BBA" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_90B4EFF855ECBB9B3C63C8041FBA6A33" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_A51353F0938B2CF919C73F4B2FF05E1B" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Statement1Table" xlink:label="loc_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_A51353F0938B2CF919C73F4B2FF05E1B" xlink:to="loc_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_67E8D578FBCD4A71C8993F4B2FF08477" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192" xlink:to="loc_oncyf_SaleOfStockAxis_67E8D578FBCD4A71C8993F4B2FF08477" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_604769D8094B5BBB5A5B3F4B2FF045C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_67E8D578FBCD4A71C8993F4B2FF08477" xlink:to="loc_oncyf_SaleOfStockDomain_604769D8094B5BBB5A5B3F4B2FF045C0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_BF7A9F15D6E95C44EB903F4B2FF05809" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_604769D8094B5BBB5A5B3F4B2FF045C0" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_BF7A9F15D6E95C44EB903F4B2FF05809" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_5FFDB8DB350C6C44EC913F4B2FF04EFB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_604769D8094B5BBB5A5B3F4B2FF045C0" xlink:to="loc_oncyf_SharesPublicOfferingMember_5FFDB8DB350C6C44EC913F4B2FF04EFB" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Statement1LineItems" xlink:label="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1Table_96CF2204155A21EFFDB63F4B2FF00192" xlink:to="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_3A7AB543C8CE64FB297A3F4B2FF01534" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:to="loc_ifrs-full_ProfitLoss_3A7AB543C8CE64FB297A3F4B2FF01534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_E80D3A04EECEA7F2A5603F4B2FF04C81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_E80D3A04EECEA7F2A5603F4B2FF04C81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_49ED0C51F2F8605E90FF3F4B2FF0114D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_49ED0C51F2F8605E90FF3F4B2FF0114D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_483746CDE6FF8CE15DE33F4B2FF04864" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_483746CDE6FF8CE15DE33F4B2FF04864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_2A34A11C040E4BB95A9D3F4B2FF068E1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_2A34A11C040E4BB95A9D3F4B2FF068E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_DB785FA1777C42B2FA9D3F4B2FF1B25A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_A63EAFD5A1C3AD233A9A3F4B2FF05692" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_DB785FA1777C42B2FA9D3F4B2FF1B25A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4330616D3763897795663F4B2FF16368" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4330616D3763897795663F4B2FF16368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_4440D1FF9AADBA9EBECA3F4B2FF145F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:to="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_4440D1FF9AADBA9EBECA3F4B2FF145F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_CC7A5F118EAEE5CFC8543F4B2FF1188E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_E184CF33821CB2D289273F4B2FF15992" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_CC7A5F118EAEE5CFC8543F4B2FF1188E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_26CB2CE5B91C0D46D1043F4B2FF14ACF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_26CB2CE5B91C0D46D1043F4B2FF14ACF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_F88D1CC494D18BBEF9C93F4B2FF1731E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_F88D1CC494D18BBEF9C93F4B2FF1731E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_C9EFCA6A7415DCBCD2F03F4B2FF1B584" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_C9EFCA6A7415DCBCD2F03F4B2FF1B584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_EF3AA6FD808E257D9FB63F4B2FF1CFAA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1ECCB4D2BADD1F7618593F4B2FF167FB" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_EF3AA6FD808E257D9FB63F4B2FF1CFAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1D3E2E681AE7C37284B63F4B2FF19F11" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_1D3E2E681AE7C37284B63F4B2FF19F11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_B3364E2776BD965828003F4B2FF1A366" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="loc_ifrs-full_CashAndCashEquivalents_B3364E2776BD965828003F4B2FF1A366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_FF03400CCFDB3D7576B73F4B2FF2663A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_FF03400CCFDB3D7576B73F4B2FF2663A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_28607FA0DB4AF2142E183F4B2FF22574" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_25A7E99408BC8AD107C53F4B2FF07A7F" xlink:to="loc_ifrs-full_CashAndCashEquivalents_28607FA0DB4AF2142E183F4B2FF22574" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_BCBC85894E60A596C005F724F713203F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_BCBC85894E60A596C005F724F713203F" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_03C8D6DE211237C52048F724F71324D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_03C8D6DE211237C52048F724F71324D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_03C8D6DE211237C52048F724F71324D3" xlink:to="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_B7D571B80B6FCB3E2E35F724F7149405" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:to="loc_ifrs-full_IssuedCapitalMember_B7D571B80B6FCB3E2E35F724F7149405" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_B09E3D30E2B14C21636DF724F7140395" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:to="loc_oncyf_WarrantsMember_B09E3D30E2B14C21636DF724F7140395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_C9B89C0480327A560702F724F714C1E5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:to="loc_ifrs-full_SharePremiumMember_C9B89C0480327A560702F724F714C1E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_045F82EF94C642E87833F724F714B11D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_045F82EF94C642E87833F724F714B11D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_376A3C10CC6B6C67DBE6F724F714C9FA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_ED2FEC0F923F06C6D2F5F724F7140780" xlink:to="loc_ifrs-full_RetainedEarningsMember_376A3C10CC6B6C67DBE6F724F714C9FA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_D74EACAD1F0FFA778956F724F714AE9D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635" xlink:to="loc_oncyf_SaleOfStockAxis_D74EACAD1F0FFA778956F724F714AE9D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_A1FF55ACAE765DBF6D11F724F714C18B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_D74EACAD1F0FFA778956F724F714AE9D" xlink:to="loc_oncyf_SaleOfStockDomain_A1FF55ACAE765DBF6D11F724F714C18B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember_919EAB58EBF8632C029BF724F7145E44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_A1FF55ACAE765DBF6D11F724F714C18B" xlink:to="loc_oncyf_SharesUnderSharePurchaseAgreementMember_919EAB58EBF8632C029BF724F7145E44" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_78ACCF9F9D8D9393D194F724F714597C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_A1FF55ACAE765DBF6D11F724F714C18B" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_78ACCF9F9D8D9393D194F724F714597C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_35715F1A8332BEB4B818F724F714B3FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_A1FF55ACAE765DBF6D11F724F714C18B" xlink:to="loc_oncyf_SharesPublicOfferingMember_35715F1A8332BEB4B818F724F714B3FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_F65B46D37A2B1227948BF724F7130635" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_7C08E7DE83135CE43464F724F7148AC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_ifrs-full_Equity_7C08E7DE83135CE43464F724F7148AC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_93DD86EB680123E3FEB3F724F714F592" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_ifrs-full_ComprehensiveIncome_93DD86EB680123E3FEB3F724F714F592" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IssueOfEquityShareAgreement" xlink:label="loc_oncyf_IssueOfEquityShareAgreement_C288D310914ED9FDB907F724F714D194" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_oncyf_IssueOfEquityShareAgreement_C288D310914ED9FDB907F724F714D194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_10D1F8AF96632C93CAEFF724F714C4AA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_ifrs-full_IssueOfEquity_10D1F8AF96632C93CAEFF724F714C4AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_0A28DE08B5E2E95399DAF724F71528D7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_0A28DE08B5E2E95399DAF724F71528D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_CC9EF5837F561F27B916F724F715C4E0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_CC9EF5837F561F27B916F724F715C4E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_84EF5032F15E6BF1A1F6F724F715CD87" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_84EF5032F15E6BF1A1F6F724F715CD87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_9CD8B258C83ECAFC1D17F724F715AEE1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_18F766D136394C00CE2DF724F7142A46" xlink:to="loc_ifrs-full_Equity_9CD8B258C83ECAFC1D17F724F715AEE1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_0D5DD6A6555962A034091AE318F47823" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_4C01827713A596AFE52D1AE318F7F8C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_0D5DD6A6555962A034091AE318F47823" xlink:to="loc_ifrs-full_AssetsAbstract_4C01827713A596AFE52D1AE318F7F8C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_4C01827713A596AFE52D1AE318F7F8C2" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_4DDB7F4CB01ABC111D811AE318FBCAB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97" xlink:to="loc_ifrs-full_CashAndCashEquivalents_4DDB7F4CB01ABC111D811AE318FBCAB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentInvestments" xlink:label="loc_ifrs-full_CurrentInvestments_0EAC836599B7C519B8FE1AE318FBD3E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97" xlink:to="loc_ifrs-full_CurrentInvestments_0EAC836599B7C519B8FE1AE318FBD3E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentReceivablesFromContractsWithCustomers" xlink:label="loc_ifrs-full_CurrentReceivablesFromContractsWithCustomers_B0DD7DAC3394D20DB0A31AE31C09E185" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97" xlink:to="loc_ifrs-full_CurrentReceivablesFromContractsWithCustomers_B0DD7DAC3394D20DB0A31AE31C09E185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_7BBE818A7A937D1E556E1AE318FBD6D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97" xlink:to="loc_ifrs-full_OtherCurrentReceivables_7BBE818A7A937D1E556E1AE318FBD6D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_57CAD074A42F8EB136DA1AE319005984" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_57CAD074A42F8EB136DA1AE319005984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_350C1DCFF548EEF0D8511AE319009902" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_B95624EB99DF728D5B571AE318FA8C97" xlink:to="loc_ifrs-full_CurrentAssets_350C1DCFF548EEF0D8511AE319009902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_B86B435C4916CF6F506C1AE319000637" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_4C01827713A596AFE52D1AE318F7F8C2" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_B86B435C4916CF6F506C1AE319000637" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_0564A9EABD9F5037B2401AE319003B0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_B86B435C4916CF6F506C1AE319000637" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_0564A9EABD9F5037B2401AE319003B0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_59643613E229D54D6A681AE31901071B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_B86B435C4916CF6F506C1AE319000637" xlink:to="loc_ifrs-full_NoncurrentAssets_59643613E229D54D6A681AE31901071B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_70682DA5788FDF08C6261AE319013299" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_0D5DD6A6555962A034091AE318F47823" xlink:to="loc_ifrs-full_Assets_70682DA5788FDF08C6261AE319013299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_0D5DD6A6555962A034091AE318F47823" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_F60B7868A236185BC1551AE319018047" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_F60B7868A236185BC1551AE319018047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_90A89915CA2D100B58EB1AE319010CE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_F60B7868A236185BC1551AE319018047" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_90A89915CA2D100B58EB1AE319010CE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_69B1E4F39DDB921BF99F1AE319014D08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_F60B7868A236185BC1551AE319018047" xlink:to="loc_ifrs-full_CurrentContractLiabilities_69B1E4F39DDB921BF99F1AE319014D08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_D357BF893298B9958F711AE31901BB7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_F60B7868A236185BC1551AE319018047" xlink:to="loc_ifrs-full_CurrentLiabilities_D357BF893298B9958F711AE31901BB7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_46FF1C87E7D279F636361AE31901C90A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_46FF1C87E7D279F636361AE31901C90A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_A24AEBEEFD6D8331B87B1AE31901A0FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_46FF1C87E7D279F636361AE31901C90A" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_A24AEBEEFD6D8331B87B1AE31901A0FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_7DC7C4A37D29B1B3B2101AE3190192CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_46FF1C87E7D279F636361AE31901C90A" xlink:to="loc_ifrs-full_NoncurrentLiabilities_7DC7C4A37D29B1B3B2101AE3190192CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_8C88D7E7936B610737911AE31901A30C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8" xlink:to="loc_ifrs-full_Liabilities_8C88D7E7936B610737911AE31901A30C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsAndContingencies1" xlink:label="loc_oncyf_CommitmentsAndContingencies1_E1FAA8A3275187BAE9211AE31901BF2E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8" xlink:to="loc_oncyf_CommitmentsAndContingencies1_E1FAA8A3275187BAE9211AE31901BF2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8" xlink:to="loc_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_B1D958BF4EC1A734F9641AE319014414" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D" xlink:to="loc_ifrs-full_IssuedCapital_B1D958BF4EC1A734F9641AE319014414" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsandRightsOutstanding" xlink:label="loc_oncyf_WarrantsandRightsOutstanding_585DD9B6A37434D6D1B91AE319021246" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D" xlink:to="loc_oncyf_WarrantsandRightsOutstanding_585DD9B6A37434D6D1B91AE319021246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionalPaidinCapital" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_C7D426257E95A4ED0F431AE31902A78E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_C7D426257E95A4ED0F431AE31902A78E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_6CAB0A9EB3FAD4A9B55C1AE31902F724" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_6CAB0A9EB3FAD4A9B55C1AE31902F724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_1F5F64E90B0E67C53C801AE319021148" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D" xlink:to="loc_ifrs-full_RetainedEarnings_1F5F64E90B0E67C53C801AE319021148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_6273925024F100C7659F1AE3190234E4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_D4AA4CBA31984411F0241AE31901991D" xlink:to="loc_ifrs-full_Equity_6273925024F100C7659F1AE3190234E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_28222493A2BEC72335551AE3190297C7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_BD020418A21D4877ECFC1AE319018FB8" xlink:to="loc_ifrs-full_EquityAndLiabilities_28222493A2BEC72335551AE3190297C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_76C852514D4EBEA99627E3906E2CCC0D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_A8A6681D1A88BE0A0806E3906E2E9FE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_76C852514D4EBEA99627E3906E2CCC0D" xlink:to="loc_ifrs-full_NumberOfSharesIssued_A8A6681D1A88BE0A0806E3906E2E9FE9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpenseByNatureAbstract" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_44719553D8CEC3870F262047BB426F7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:to="loc_ifrs-full_ExpenseByNatureAbstract_44719553D8CEC3870F262047BB426F7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_BBCC4E474F701887C2682047BB42913E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_44719553D8CEC3870F262047BB426F7F" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_BBCC4E474F701887C2682047BB42913E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OperatingExpense" xlink:label="loc_ifrs-full_OperatingExpense_8C31CBA0E3078400A81B2047BB422662" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_44719553D8CEC3870F262047BB426F7F" xlink:to="loc_ifrs-full_OperatingExpense_8C31CBA0E3078400A81B2047BB422662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_835DE23EBAD2186712DC2047BB423292" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_835DE23EBAD2186712DC2047BB423292" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_A188492895360CA913DE2089D70E8209" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_A188492895360CA913DE2089D70E8209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_8FDFE4F0421B3ABB29472047BB42C8F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_8FDFE4F0421B3ABB29472047BB42C8F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_58D6EB0EDC838235012E2047BB4254D4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_58D6EB0EDC838235012E2047BB4254D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_5839D59F7AA3A4A8C7002047BB435E55" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:to="loc_ifrs-full_ProfitLoss_5839D59F7AA3A4A8C7002047BB435E55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_35B37F68EEF6FE82D3612047BB432523" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_35B37F68EEF6FE82D3612047BB432523" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0618FD3F56E9020664582047BB43ACDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_35B37F68EEF6FE82D3612047BB432523" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0618FD3F56E9020664582047BB43ACDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_405928908C29968654272047BB43EB20" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:to="loc_ifrs-full_ComprehensiveIncome_405928908C29968654272047BB43EB20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_4554F563B7091183DB542047BB4315DD" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:to="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_4554F563B7091183DB542047BB4315DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_F9DC1AEF981B702B48F72047BB43162D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:to="loc_ifrs-full_WeightedAverageShares_F9DC1AEF981B702B48F72047BB43162D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_259A577C420E7D1974012047BB433616" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0E3C0BE0C6F7630FA81B2047BB429338" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_259A577C420E7D1974012047BB433616" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ContingenciesAbstract" xlink:label="loc_oncyf_ContingenciesAbstract_2BA75BF0EFF5A253E7F61AEC02A40762" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_BEA86258899B178DE2D71AEC02A4A168" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_2BA75BF0EFF5A253E7F61AEC02A40762" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_BEA86258899B178DE2D71AEC02A4A168" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ContingenciesAbstract" xlink:label="loc_oncyf_ContingenciesAbstract_982FDEF2C68FB1EC6B9F1AEC02A2A520" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_C071EF18F2EECD74F16B1AEC02A24BF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_982FDEF2C68FB1EC6B9F1AEC02A2A520" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_C071EF18F2EECD74F16B1AEC02A24BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-full_CounterpartiesAxis_A15292E8A1314608B5E51AEC02A26300" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_C071EF18F2EECD74F16B1AEC02A24BF6" xlink:to="loc_ifrs-full_CounterpartiesAxis_A15292E8A1314608B5E51AEC02A26300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_A15292E8A1314608B5E51AEC02A26300" xlink:to="loc_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SYNSORBMember" xlink:label="loc_oncyf_SYNSORBMember_ECCA39B4512AB8A0F5B91AEC02A21154" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_942F4684E3A056C12A321AEC02A2B4BE" xlink:to="loc_oncyf_SYNSORBMember_ECCA39B4512AB8A0F5B91AEC02A21154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_C071EF18F2EECD74F16B1AEC02A24BF6" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_F53DDAF258928FC96DAC1AEC02A2C755" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:to="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_F53DDAF258928FC96DAC1AEC02A2C755" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_FC774DD9975E6D0DF2811AEC02A2B433" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_FC774DD9975E6D0DF2811AEC02A2B433" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_B14AE2A84E42BF4092F51AEC02A2EEFF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_B14AE2A84E42BF4092F51AEC02A2EEFF" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_B789B3922626C2DE13E11AEC02A210AA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_951A6498A1101ADC0F021AEC02A24C7B" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_B789B3922626C2DE13E11AEC02A210AA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:label="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_41EB090034C1314E1FEB1AEC02A2CB35" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_982FDEF2C68FB1EC6B9F1AEC02A2A520" xlink:to="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_41EB090034C1314E1FEB1AEC02A2CB35" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:label="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_EFB0962D94F019A4383D1AEC02A2F1EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_982FDEF2C68FB1EC6B9F1AEC02A2A520" xlink:to="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_EFB0962D94F019A4383D1AEC02A2F1EA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ContingentRoyaltyPaymentContributionRate" xlink:label="loc_oncyf_ContingentRoyaltyPaymentContributionRate_18A714F0D07D450E9CE71AEC02A3AFF3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_982FDEF2C68FB1EC6B9F1AEC02A2A520" xlink:to="loc_oncyf_ContingentRoyaltyPaymentContributionRate_18A714F0D07D450E9CE71AEC02A3AFF3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_AccruedRoyalties1" xlink:label="loc_oncyf_AccruedRoyalties1_A0063782B8DA355538C21AEC02A38AC3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_982FDEF2C68FB1EC6B9F1AEC02A2A520" xlink:to="loc_oncyf_AccruedRoyalties1_A0063782B8DA355538C21AEC02A38AC3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_F0FFDEE12D3841DA123F2B9E1BDCB1E1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_865E3E842CBBDF7840772B9E1BDD78C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_F0FFDEE12D3841DA123F2B9E1BDCB1E1" xlink:to="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_865E3E842CBBDF7840772B9E1BDD78C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7E320FFB4B801D48D70320C2C66B6610" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ClassofWarrantorRight1Table" xlink:label="loc_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7E320FFB4B801D48D70320C2C66B6610" xlink:to="loc_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MilestoneAxis" xlink:label="loc_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8" xlink:to="loc_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MilestoneDomain" xlink:label="loc_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_MilestoneAxis_726CB13541E95061211B20C2C66C2B5E" xlink:to="loc_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MilestoneOneMember" xlink:label="loc_oncyf_MilestoneOneMember_8809401FEA66750CF0A020C2C66CA95C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E" xlink:to="loc_oncyf_MilestoneOneMember_8809401FEA66750CF0A020C2C66CA95C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MilestoneTwoMember" xlink:label="loc_oncyf_MilestoneTwoMember_B82B6EF5DBDEB0A01FF220C2C66CD5D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_MilestoneDomain_4B3FD53077DDD01A74F720C2C66C131E" xlink:to="loc_oncyf_MilestoneTwoMember_B82B6EF5DBDEB0A01FF220C2C66CD5D3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ClassofWarrantorRight1LineItems" xlink:label="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ClassofWarrantorRight1Table_DA5499128CDF8387D5FF20C2C66C93E8" xlink:to="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantPurchaseAgreement" xlink:label="loc_oncyf_WarrantPurchaseAgreement_9F41C45A650C64D179E120C2C66C31F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:to="loc_oncyf_WarrantPurchaseAgreement_9F41C45A650C64D179E120C2C66C31F0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharePricePremiumPercent" xlink:label="loc_oncyf_SharePricePremiumPercent_81A423743992B05FD0F720C2C66CBF6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:to="loc_oncyf_SharePricePremiumPercent_81A423743992B05FD0F720C2C66CBF6F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WeightedAverageClosingPriceDuration" xlink:label="loc_oncyf_WeightedAverageClosingPriceDuration_61570DEB8B25AB43FB3B20C2C66C2233" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:to="loc_oncyf_WeightedAverageClosingPriceDuration_61570DEB8B25AB43FB3B20C2C66C2233" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_NumberofPatients" xlink:label="loc_oncyf_NumberofPatients_797BF9D2ED73EF104BCF20C2C66C3E3F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:to="loc_oncyf_NumberofPatients_797BF9D2ED73EF104BCF20C2C66C3E3F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_RighttoCallWarrantMilestoneOneTerm" xlink:label="loc_oncyf_RighttoCallWarrantMilestoneOneTerm_31CBF5FBCDC0913D825F20C2C66C1B0A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ClassofWarrantorRight1LineItems_E5F0729DE28059359B5820C2C66C0B4D" xlink:to="loc_oncyf_RighttoCallWarrantMilestoneOneTerm_31CBF5FBCDC0913D825F20C2C66C1B0A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ContractLiabilityRecognitionPeriod" xlink:label="loc_oncyf_ContractLiabilityRecognitionPeriod_62B3FAFA2EFBB66717C820C2C66C76CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7E320FFB4B801D48D70320C2C66B6610" xlink:to="loc_oncyf_ContractLiabilityRecognitionPeriod_62B3FAFA2EFBB66717C820C2C66C76CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentReceivablesFromContractsWithCustomers" xlink:label="loc_ifrs-full_CurrentReceivablesFromContractsWithCustomers_CF149621ACE5FF52F9B220D498DCD3B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7E320FFB4B801D48D70320C2C66B6610" xlink:to="loc_ifrs-full_CurrentReceivablesFromContractsWithCustomers_CF149621ACE5FF52F9B220D498DCD3B4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_B20C59859E5BAA13DB11253B15D1760E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_10A928C2157F6584146B253CCB35791B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_B20C59859E5BAA13DB11253B15D1760E" xlink:to="loc_ifrs-full_ContractLiabilities_10A928C2157F6584146B253CCB35791B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_7E18F9C0BC04E4597282253B15D1A392" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_B20C59859E5BAA13DB11253B15D1760E" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_7E18F9C0BC04E4597282253B15D1A392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_4E97F3E4560C92D28807253B15D16258" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_B20C59859E5BAA13DB11253B15D1760E" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_4E97F3E4560C92D28807253B15D16258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_916627DB9971A1B5BA25253E73C542B4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_B20C59859E5BAA13DB11253B15D1760E" xlink:to="loc_ifrs-full_ContractLiabilities_916627DB9971A1B5BA25253E73C542B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_C9B04EC3FA2E8BC7546F253B15D1577D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_B20C59859E5BAA13DB11253B15D1760E" xlink:to="loc_ifrs-full_CurrentContractLiabilities_C9B04EC3FA2E8BC7546F253B15D1577D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_C2332600593C074D8783253B15D15B31" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_B20C59859E5BAA13DB11253B15D1760E" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_C2332600593C074D8783253B15D15B31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_59673666BBA426B9F8E7253B15D24F40" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_B20C59859E5BAA13DB11253B15D1760E" xlink:to="loc_ifrs-full_ContractLiabilities_59673666BBA426B9F8E7253B15D24F40" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_5EF5E5AF00B7B92BFC58E3962E81E902" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_90B116A1B9A5916C0B59E396304C7DF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_5EF5E5AF00B7B92BFC58E3962E81E902" xlink:to="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_90B116A1B9A5916C0B59E396304C7DF9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DocumentAndEntityInformationAbstract" xlink:label="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_0C4D7F85300CEEF67836C8041E7D9564" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="loc_dei_EntityRegistrantName_0C4D7F85300CEEF67836C8041E7D9564" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_BF126F8ED706E2531F7DC8041E7E4A04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="loc_dei_EntityCentralIndexKey_BF126F8ED706E2531F7DC8041E7E4A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_E0C90D63C8A20247119FC8041E7E95DB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="loc_dei_CurrentFiscalYearEndDate_E0C90D63C8A20247119FC8041E7E95DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_BC3AB24B94DC327CD676C8041E7EE9C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="loc_dei_EntityFilerCategory_BC3AB24B94DC327CD676C8041E7EE9C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_D97BD137D60E7FD46160C8041E7E712C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="loc_dei_DocumentType_D97BD137D60E7FD46160C8041E7E712C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_64D0A4424A44FC84EB89C8041E7ECD65" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="loc_dei_DocumentPeriodEndDate_64D0A4424A44FC84EB89C8041E7ECD65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_11A6035C732A95A79512C8041E7ED819" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="loc_dei_DocumentFiscalYearFocus_11A6035C732A95A79512C8041E7ED819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ECF80B968B471C971985C8041E7E0319" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ECF80B968B471C971985C8041E7E0319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_BECE54237232C528E27BC8041E7E643F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="loc_dei_AmendmentFlag_BECE54237232C528E27BC8041E7E643F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_BE62AA4C428729A586B2C8041E7E6C07" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_BE62AA4C428729A586B2C8041E7E6C07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_4D61927AAB2ABCFB0AD7C8041E7ED946" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_4D61927AAB2ABCFB0AD7C8041E7ED946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_D594AD78A74140A875C6C8041E7EEE1A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="loc_dei_EntityVoluntaryFilers_D594AD78A74140A875C6C8041E7EEE1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_C91A9E2ACCA271E290AAC8041E7F0B87" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="loc_dei_EntityCurrentReportingStatus_C91A9E2ACCA271E290AAC8041E7F0B87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_E949B4084FCF30C6A6F4C8041E7F6DC2" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_FD474E9B36FF2529B376C8041E7D1093" xlink:to="loc_dei_EntityPublicFloat_E949B4084FCF30C6A6F4C8041E7F6DC2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_5E74E54C792CE382EB25C8041F274B69" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_104D2BECE2CDBB25920EC8041F2805D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_5E74E54C792CE382EB25C8041F274B69" xlink:to="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_104D2BECE2CDBB25920EC8041F2805D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_079D878AF851DA6F8F3BC8041F83A020" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRisk1Table" xlink:label="loc_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_079D878AF851DA6F8F3BC8041F83A020" xlink:to="loc_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRiskType1Axis" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59" xlink:to="loc_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRiskType1Domain" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_F617574705F30B36F197C8041F83137D" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SupplierConcentrationRisk1Member" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_882CACBFC4FFEAD20CE1C8041F83C494" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_FB05D88B528A04E41AF6C8041F8395D3" xlink:to="loc_oncyf_SupplierConcentrationRisk1Member_882CACBFC4FFEAD20CE1C8041F83C494" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRiskType1LineItems" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRisk1Table_3A35BEEB2BC7A7BE940CC8041F83EE59" xlink:to="loc_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ConcentrationRiskNumber" xlink:label="loc_oncyf_ConcentrationRiskNumber_7C1D09E01BA5EBC50CBEC8041F83F577" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_C4B4B11FF1FCD97A5DC9C8041F83996A" xlink:to="loc_oncyf_ConcentrationRiskNumber_7C1D09E01BA5EBC50CBEC8041F83F577" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_EF3D3A7A7B2716CAA61FC8041F8EB146" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_A08599DBCBC99870C7A1C8041F8EEC3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_EF3D3A7A7B2716CAA61FC8041F8EB146" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_A08599DBCBC99870C7A1C8041F8EEC3B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_E6293F6293A488B8E220E10D70DD5624" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent" xlink:label="loc_oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent_B6F30AD1CAC551AD0F21E10D70DD01EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_E6293F6293A488B8E220E10D70DD5624" xlink:to="loc_oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent_B6F30AD1CAC551AD0F21E10D70DD01EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_E6293F6293A488B8E220E10D70DD5624" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_4976FFF7234A3347E2BDE10D70DD7158" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF" xlink:to="loc_ifrs-full_TypesOfRisksAxis_4976FFF7234A3347E2BDE10D70DD7158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_4976FFF7234A3347E2BDE10D70DD7158" xlink:to="loc_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_E944AB366FC39ECF7795E10D70DD11C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_333F8F44B44C3BAE9251E10D70DDBCDE" xlink:to="loc_ifrs-full_CurrencyRiskMember_E944AB366FC39ECF7795E10D70DD11C6" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Currency1Axis" xlink:label="loc_oncyf_Currency1Axis_EE14F3C7F93838ABCF4FE10D70DD0AF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF" xlink:to="loc_oncyf_Currency1Axis_EE14F3C7F93838ABCF4FE10D70DD0AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_F17CF689B2C2BC1AB349E10D70DD1C6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Axis_EE14F3C7F93838ABCF4FE10D70DD0AF8" xlink:to="loc_currency_AllCurrenciesDomain_F17CF689B2C2BC1AB349E10D70DD1C6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_B92863666E4728EC96E0E10D70DD2B99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_F17CF689B2C2BC1AB349E10D70DD1C6B" xlink:to="loc_currency_USD_B92863666E4728EC96E0E10D70DD2B99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_0ED5E843BB8F8638A8D0E10D70DD4DD8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_F17CF689B2C2BC1AB349E10D70DD1C6B" xlink:to="loc_currency_GBP_0ED5E843BB8F8638A8D0E10D70DD4DD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_DC23A0F0E504E295A2D5E10D70DDBA8E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_F17CF689B2C2BC1AB349E10D70DD1C6B" xlink:to="loc_currency_EUR_DC23A0F0E504E295A2D5E10D70DDBA8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_0E72E9A0D64974C391B4E10D70DD67FF" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_B58767F2FFFA79FE1DE8E10D70DEAD3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_B58767F2FFFA79FE1DE8E10D70DEAD3B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_1DE952282B60B653D7D7E10D70DE5D95" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5983B13527DB967D769CE10D70DD3C01" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_1DE952282B60B653D7D7E10D70DE5D95" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1943EF1910A504BD7B1A2571A59FBD4B" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Currency1Table" xlink:label="loc_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1943EF1910A504BD7B1A2571A59FBD4B" xlink:to="loc_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Currency1Axis" xlink:label="loc_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205" xlink:to="loc_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Axis_0A66B0F3E92B2D706E4E2571A59FFD22" xlink:to="loc_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_04DFBF375FC64C3E7A872571A5A08467" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:to="loc_currency_USD_04DFBF375FC64C3E7A872571A5A08467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_2C8316D63E3560BCD3BA2571A5A0E054" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:to="loc_currency_GBP_2C8316D63E3560BCD3BA2571A5A0E054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_30804A3CF9AE50B93B3E2571A5A00586" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_CF3BAF0A65A3DF4D8CC32571A5A01610" xlink:to="loc_currency_EUR_30804A3CF9AE50B93B3E2571A5A00586" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_Currency1LineItems" xlink:label="loc_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_EF2D8198C29DBB5945D22571A59F4205" xlink:to="loc_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_54261128838DECF017F02571A5A00C86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:to="loc_ifrs-full_CashAndCashEquivalents_54261128838DECF017F02571A5A00C86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentReceivablesFromContractsWithCustomers" xlink:label="loc_ifrs-full_CurrentReceivablesFromContractsWithCustomers_A7C16D9BAE89CA761A7C2571A5A07ED1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:to="loc_ifrs-full_CurrentReceivablesFromContractsWithCustomers_A7C16D9BAE89CA761A7C2571A5A07ED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_AD82FE3B91729A7EAF142571A5A0E593" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_AD82FE3B91729A7EAF142571A5A0E593" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_BalanceHeldInForeignCurrencyNet" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_0F861A88888584983EC22571A5A088D3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_CFBB3069B33A37587E222571A5A0C638" xlink:to="loc_oncyf_BalanceHeldInForeignCurrencyNet_0F861A88888584983EC22571A5A088D3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_FC619BD04C034CA8C7B9C8041FD1975E" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:label="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_AA348CA70FD6FD08537BC8041FD191E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_FC619BD04C034CA8C7B9C8041FD1975E" xlink:to="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_AA348CA70FD6FD08537BC8041FD191E1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofincometaxAbstract" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_F888CD992E8CC28572E8E10D71076722" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_68C867761D5700583F69E10D71070B3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_F888CD992E8CC28572E8E10D71076722" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_68C867761D5700583F69E10D71070B3D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofincometaxAbstract" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_1B7E5EEFEA3C340D96971AEC0299200C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccountingProfit" xlink:label="loc_ifrs-full_AccountingProfit_A8EE06A527A3BEF8ECEE1AEC029AD20B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_1B7E5EEFEA3C340D96971AEC0299200C" xlink:to="loc_ifrs-full_AccountingProfit_A8EE06A527A3BEF8ECEE1AEC029AD20B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_991F85482E56322119E01AEC029A7995" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_1B7E5EEFEA3C340D96971AEC0299200C" xlink:to="loc_ifrs-full_ApplicableTaxRate_991F85482E56322119E01AEC029A7995" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_41B35362066B6F55ED451AEC029A3D65" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_1B7E5EEFEA3C340D96971AEC0299200C" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_41B35362066B6F55ED451AEC029A3D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_83078D441F16DAA6F1811AEC029A6C8B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_1B7E5EEFEA3C340D96971AEC0299200C" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_83078D441F16DAA6F1811AEC029A6C8B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TaxEffectOfStockBasedCompensation" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_B0E01D7730E6AE57A0AC1AEC029AACB0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_1B7E5EEFEA3C340D96971AEC0299200C" xlink:to="loc_oncyf_TaxEffectOfStockBasedCompensation_B0E01D7730E6AE57A0AC1AEC029AACB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_E09CB1BD910FEB90821F1AEC029A4A7A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_1B7E5EEFEA3C340D96971AEC0299200C" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_E09CB1BD910FEB90821F1AEC029A4A7A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TaxEffectOfTaxPools" xlink:label="loc_oncyf_TaxEffectOfTaxPools_5A6DB7D01D1673EA56DF1AEC029A870D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_1B7E5EEFEA3C340D96971AEC0299200C" xlink:to="loc_oncyf_TaxEffectOfTaxPools_5A6DB7D01D1673EA56DF1AEC029A870D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_A3815BBB4D0FEA699FA51AEC029AEB3A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_1B7E5EEFEA3C340D96971AEC0299200C" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_A3815BBB4D0FEA699FA51AEC029AEB3A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_6F1247DB81C325BED9001AEC029A9ECF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_1B7E5EEFEA3C340D96971AEC0299200C" xlink:to="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_6F1247DB81C325BED9001AEC029A9ECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_11920AFAA3197514AD6D1AEC029A8423" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_1B7E5EEFEA3C340D96971AEC0299200C" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_11920AFAA3197514AD6D1AEC029A8423" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_402436FAE0EC37462B131AEC029AD864" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_1B7E5EEFEA3C340D96971AEC0299200C" xlink:to="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_402436FAE0EC37462B131AEC029AD864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_6A945C583C8F350442BA1AEC029A63D1" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_1B7E5EEFEA3C340D96971AEC0299200C" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_6A945C583C8F350442BA1AEC029A63D1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofincometaxAbstract" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_79C38D0994072DCBFCA2E10D70ECB34A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_22C95833D71CB0D6AED1E10D70ECCAD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_79C38D0994072DCBFCA2E10D70ECB34A" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_22C95833D71CB0D6AED1E10D70ECCAD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_2E563E3ECF78D7659184E10D70EC1AF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_22C95833D71CB0D6AED1E10D70ECCAD0" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_2E563E3ECF78D7659184E10D70EC1AF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_2E563E3ECF78D7659184E10D70EC1AF7" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_6FF1943E41984583B2E4E10D70ED72E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:to="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_6FF1943E41984583B2E4E10D70ED72E4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_EC9445383F455C09F1ADE10D70EDF155" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_EC9445383F455C09F1ADE10D70EDF155" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_InvestmentTaxCreditsMember" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_E5A47591CAE8F0A5CC24E10D70EDD546" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:to="loc_oncyf_InvestmentTaxCreditsMember_E5A47591CAE8F0A5CC24E10D70EDD546" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:label="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_C55B7398F4215EA18C0AE10D70ED4188" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:to="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_C55B7398F4215EA18C0AE10D70ED4188" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ShareIssueCostsMember" xlink:label="loc_oncyf_ShareIssueCostsMember_175AB8B1B42314C91831E10D70EDF8E5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:to="loc_oncyf_ShareIssueCostsMember_175AB8B1B42314C91831E10D70EDF8E5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_D30C192EFDECD7CE0874E10D70EDC7B8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5E2DB079AFFDDF361BE1E10D70ECBCFE" xlink:to="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_D30C192EFDECD7CE0874E10D70EDC7B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_472F35AF4B9575852FB0E10D70ED9F02" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_22C95833D71CB0D6AED1E10D70ECCAD0" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_472F35AF4B9575852FB0E10D70ED9F02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_4E52ABBF375345F9FD78E10D70ED77AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_472F35AF4B9575852FB0E10D70ED9F02" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_4E52ABBF375345F9FD78E10D70ED77AB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofincometaxAbstract" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_FB4605D6AE32857D76CBF2828AF389A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_FB4605D6AE32857D76CBF2828AF389A8" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_5DB9EE2BA3AFD6D60013F2828AF37C93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE" xlink:to="loc_ifrs-full_MaturityAxis_5DB9EE2BA3AFD6D60013F2828AF37C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_5DB9EE2BA3AFD6D60013F2828AF37C93" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentySixMember" xlink:label="loc_oncyf_TwentyTwentySixMember_12ED0A6AC1AF61A8B44FF2828AF3D1F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyTwentySixMember_12ED0A6AC1AF61A8B44FF2828AF3D1F5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentySevenMember" xlink:label="loc_oncyf_TwentyTwentySevenMember_A1EEAFBC16D1617DFF40F2828AF38428" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyTwentySevenMember_A1EEAFBC16D1617DFF40F2828AF38428" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyNineMember" xlink:label="loc_oncyf_TwentyTwentyNineMember_A35705262A2E3718584AF2828AF3B821" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyTwentyNineMember_A35705262A2E3718584AF2828AF3B821" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyMember" xlink:label="loc_oncyf_TwentyThirtyMember_B0D9FF8A79E281167036F2828AF35AFD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtyMember_B0D9FF8A79E281167036F2828AF35AFD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyOneMember" xlink:label="loc_oncyf_TwentyThirtyOneMember_59F6E6F17590EB2D08C0F2828AF35465" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtyOneMember_59F6E6F17590EB2D08C0F2828AF35465" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyTwoMember" xlink:label="loc_oncyf_TwentyThirtyTwoMember_F31E20799D9C5711E8FEF2828AF4FBFA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtyTwoMember_F31E20799D9C5711E8FEF2828AF4FBFA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyThreeMember" xlink:label="loc_oncyf_TwentyThirtyThreeMember_922C0D1D5334453A79DDF2828AF4BEDB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtyThreeMember_922C0D1D5334453A79DDF2828AF4BEDB" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyFourMember" xlink:label="loc_oncyf_TwentyThirtyFourMember_D4A65F09A07CFAFA6118F2828AF44370" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtyFourMember_D4A65F09A07CFAFA6118F2828AF44370" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyFiveMember" xlink:label="loc_oncyf_TwentyThirtyFiveMember_F7DDCCB0928F90C1392DF2828AF46B04" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtyFiveMember_F7DDCCB0928F90C1392DF2828AF46B04" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtySixMember" xlink:label="loc_oncyf_TwentyThirtySixMember_D0BDC12167D58057B7FAF2828AF4184B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtySixMember_D0BDC12167D58057B7FAF2828AF4184B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtySevenMember" xlink:label="loc_oncyf_TwentyThirtySevenMember_5EC92037CE7883FBDFD1F2D64EBDFFE1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_DC0067154E654A44659DF2828AF34509" xlink:to="loc_oncyf_TwentyThirtySevenMember_5EC92037CE7883FBDFD1F2D64EBDFFE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_A0D1440383EA16A39829F2828AF4B8A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_A0D1440383EA16A39829F2828AF4B8A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_A0D1440383EA16A39829F2828AF4B8A9" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_E40FA1CBF8E6DBC046CEF2828AF40B32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_41BB61B7AFDD5028BFD0F2828AF416B6" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_E40FA1CBF8E6DBC046CEF2828AF40B32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_F26CB551F19CC812C9FCF2828AF460E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_002FF6ED2BE3FFF1CFEEF2828AF3BFDE" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_F26CB551F19CC812C9FCF2828AF460E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_001564CDD4F94D5DB818F2828AF4D3FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_F26CB551F19CC812C9FCF2828AF460E8" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_001564CDD4F94D5DB818F2828AF4D3FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofincometaxAbstract" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_E54761A6300113EFD45CF2828AEB08F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1304CC760014AC1F0C18F2828AEB5A86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_E54761A6300113EFD45CF2828AEB08F4" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1304CC760014AC1F0C18F2828AEB5A86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_76960C4F6777ACDFFF2BF2828AEB9A17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1304CC760014AC1F0C18F2828AEB5A86" xlink:to="loc_ifrs-full_MaturityAxis_76960C4F6777ACDFFF2BF2828AEB9A17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_76960C4F6777ACDFFF2BF2828AEB9A17" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyMember" xlink:label="loc_oncyf_TwentyTwentyMember_A6871FB6FE6D1174AA69F2828AECE44A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyMember_A6871FB6FE6D1174AA69F2828AECE44A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyOneMember" xlink:label="loc_oncyf_TwentyTwentyOneMember_A566C4E1528EE21EEA25F2828AEC93E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyOneMember_A566C4E1528EE21EEA25F2828AEC93E9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyTwoMember" xlink:label="loc_oncyf_TwentyTwentyTwoMember_FBCFCD9040ED00D07251F2828AEC68F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyTwoMember_FBCFCD9040ED00D07251F2828AEC68F5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyThreeMember" xlink:label="loc_oncyf_TwentyTwentyThreeMember_B0483F97ED97EA19567FF2828AEC107E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyThreeMember_B0483F97ED97EA19567FF2828AEC107E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyFourMember" xlink:label="loc_oncyf_TwentyTwentyFourMember_FDD0FCC8FC7023367863F2828AECC62D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyFourMember_FDD0FCC8FC7023367863F2828AECC62D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyFiveMember" xlink:label="loc_oncyf_TwentyTwentyFiveMember_3979DA2281FCD9F0E11BF2828AEC51AE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyFiveMember_3979DA2281FCD9F0E11BF2828AEC51AE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentySixMember" xlink:label="loc_oncyf_TwentyTwentySixMember_2DF474F1E3898D3284E4F2828AEC9F86" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentySixMember_2DF474F1E3898D3284E4F2828AEC9F86" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentySevenMember" xlink:label="loc_oncyf_TwentyTwentySevenMember_C75BBC65BE2C9556D65AF2828AECAE28" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentySevenMember_C75BBC65BE2C9556D65AF2828AECAE28" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyEightMember" xlink:label="loc_oncyf_TwentyTwentyEightMember_7282DCA9F5ED5512676FF2828AEC8722" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyEightMember_7282DCA9F5ED5512676FF2828AEC8722" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyTwentyNineMember" xlink:label="loc_oncyf_TwentyTwentyNineMember_E359EFE3F0E37B752AA9F2828AEC7D1F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyTwentyNineMember_E359EFE3F0E37B752AA9F2828AEC7D1F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyMember" xlink:label="loc_oncyf_TwentyThirtyMember_99D563E9AACFA2423EFEF2828AEC4765" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtyMember_99D563E9AACFA2423EFEF2828AEC4765" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyOneMember" xlink:label="loc_oncyf_TwentyThirtyOneMember_C417BBA549E34C4A1204F2828AEC8EB3" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtyOneMember_C417BBA549E34C4A1204F2828AEC8EB3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyTwoMember" xlink:label="loc_oncyf_TwentyThirtyTwoMember_CA92C6DA1D55DA50D21DF2828AEDD20C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtyTwoMember_CA92C6DA1D55DA50D21DF2828AEDD20C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyThreeMember" xlink:label="loc_oncyf_TwentyThirtyThreeMember_5BC9C836E10F22F05518F2828AED8499" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtyThreeMember_5BC9C836E10F22F05518F2828AED8499" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyFourMember" xlink:label="loc_oncyf_TwentyThirtyFourMember_67E2E05204466CF341A2F2828AEDC4B4" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtyFourMember_67E2E05204466CF341A2F2828AEDC4B4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtyFiveMember" xlink:label="loc_oncyf_TwentyThirtyFiveMember_E5286152BABFB2CBEA49F2828AED5809" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtyFiveMember_E5286152BABFB2CBEA49F2828AED5809" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtySixMember" xlink:label="loc_oncyf_TwentyThirtySixMember_65865EB5BFFF84802C54F2828AED8339" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtySixMember_65865EB5BFFF84802C54F2828AED8339" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_TwentyThirtySevenMember" xlink:label="loc_oncyf_TwentyThirtySevenMember_E9F9D5265D3BF5D24BEDF2D6D41E5402" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_F662F636B28ABBDAA8C9F2828AEC7B92" xlink:to="loc_oncyf_TwentyThirtySevenMember_E9F9D5265D3BF5D24BEDF2D6D41E5402" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_3C775D1787DA59D20894F2828AED327E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1304CC760014AC1F0C18F2828AEB5A86" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_3C775D1787DA59D20894F2828AED327E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_6920923EEACD0D1B9D39F2828AEDFD17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_3C775D1787DA59D20894F2828AED327E" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_6920923EEACD0D1B9D39F2828AEDFD17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxCreditsMember" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_308D3002B3863DCB282FF2828AED0DE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_6920923EEACD0D1B9D39F2828AEDFD17" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_308D3002B3863DCB282FF2828AED0DE4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_58C8482A59E4B418C465F2828AEDC721" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_6920923EEACD0D1B9D39F2828AEDFD17" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_58C8482A59E4B418C465F2828AEDC721" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_204000747528CC9A913CF2828AEDCF73" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_1304CC760014AC1F0C18F2828AEB5A86" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_204000747528CC9A913CF2828AEDCF73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_D37E4DE42DE767533ECFF2828AEDD7A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_204000747528CC9A913CF2828AEDCF73" xlink:to="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_D37E4DE42DE767533ECFF2828AEDD7A3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofincometaxAbstract" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_45CBF13F04BB9FE39C00E10D7104E6C2" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:label="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_1545A6FBC606DCEDFB9CE10D71051932" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_45CBF13F04BB9FE39C00E10D7104E6C2" xlink:to="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_1545A6FBC606DCEDFB9CE10D71051932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_EDF0593B5C7F6C46A9D0E10D7105CD96" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_45CBF13F04BB9FE39C00E10D7104E6C2" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_EDF0593B5C7F6C46A9D0E10D7105CD96" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_9AFE4B8E97889724592F2047BB31BD85" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_F4B4F169909F7E27118520769ABB37FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_9AFE4B8E97889724592F2047BB31BD85" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_F4B4F169909F7E27118520769ABB37FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_296077F6BFC84D699AAFC8041E6C24B6" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_C1E07A50AFF864BD4A01C8041E6CD677" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_296077F6BFC84D699AAFC8041E6C24B6" xlink:to="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_C1E07A50AFF864BD4A01C8041E6CD677" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_D5721FAD5386FF378521E10FCFD2F942" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1E1107C0D8779C80E3CEE10D711983A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_D5721FAD5386FF378521E10FCFD2F942" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1E1107C0D8779C80E3CEE10D711983A2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_B51B83BBBB43ABCF5E4DE1487D2B89CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_05847BDF6BD34EBCB13DE1487D35A443" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_B51B83BBBB43ABCF5E4DE1487D2B89CA" xlink:to="loc_ifrs-full_WeightedAverageShares_05847BDF6BD34EBCB13DE1487D35A443" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9D0E968DEE19E35F60E1C8041EC14E47" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_0ED095200291EEAB6B30C8041EC10AC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9D0E968DEE19E35F60E1C8041EC14E47" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_0ED095200291EEAB6B30C8041EC10AC6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_261D11797024CF5BBA13E33E939E75AD" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_OtherExpensesAndAdjustmentsTable" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_261D11797024CF5BBA13E33E939E75AD" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IncomeStatementLocation1Axis" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IncomeStatementLocation1Domain" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_CEBCFB2CFDFED3CA79C6E33E939F22A5" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ResearchAndDevelopmentMember" xlink:label="loc_oncyf_ResearchAndDevelopmentMember_D9C42B4CE655BCC54544E33E939F54B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9" xlink:to="loc_oncyf_ResearchAndDevelopmentMember_D9C42B4CE655BCC54544E33E939F54B5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_OperatingExpensesMember" xlink:label="loc_oncyf_OperatingExpensesMember_9339A330464CDF91D914E33E939FBD7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_B957735605337AB0FD5EE33E939F69C9" xlink:to="loc_oncyf_OperatingExpensesMember_9339A330464CDF91D914E33E939FBD7E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_5B6D8161435860ACDC54E33E939FF98E" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_82109F2ACF7818EF9AA6E33E93A0CFB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_82109F2ACF7818EF9AA6E33E93A0CFB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_1BF2F47F72CF6766DCD3E33E93A04BA9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_1BF2F47F72CF6766DCD3E33E93A04BA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ACB44C7EBBB76CA21745E33E93A0F416" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ACB44C7EBBB76CA21745E33E93A0F416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense_C942044F91480CA91A70E33E93A0718B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:to="loc_ifrs-full_AmortisationExpense_C942044F91480CA91A70E33E93A0718B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense" xlink:label="loc_ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense_75622CDCD9E2CD467704E33E93A0E68E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_2719E0399827817FADE0E33E939FE55C" xlink:to="loc_ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense_75622CDCD9E2CD467704E33E93A0E68E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_CD9A31B293C9D168A41EC8041F0D56B3" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_E352701571CD6DD0F8D2C8041F0D871E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_CD9A31B293C9D168A41EC8041F0D56B3" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_E352701571CD6DD0F8D2C8041F0D871E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_800B00192484D446DDBAE7C722CA026E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_0D5E17F631CFD53366D4E7C722CA5D8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_800B00192484D446DDBAE7C722CA026E" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_0D5E17F631CFD53366D4E7C722CA5D8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_F681462335C30E2B1C002047BAF93925" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_F681462335C30E2B1C002047BAF93925" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_DD778459E0C2B1D0C8182047BAF9CB08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_DD778459E0C2B1D0C8182047BAF9CB08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_DD778459E0C2B1D0C8182047BAF9CB08" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MedicalEquipmentMember" xlink:label="loc_oncyf_MedicalEquipmentMember_A27ABF1FA7BDC8ACC8572047BAFA900A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:to="loc_oncyf_MedicalEquipmentMember_A27ABF1FA7BDC8ACC8572047BAFA900A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_87C76C8ABF4E14FC52912047BAFA9D22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:to="loc_ifrs-full_ComputerEquipmentMember_87C76C8ABF4E14FC52912047BAFA9D22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FixturesAndFittingsMember" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_DBAF2A6B05BCB4DB6FA32047BAFACEAB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_DBAF2A6B05BCB4DB6FA32047BAFACEAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_79877C206BB6799BA49D2047BAFA450C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:to="loc_ifrs-full_OfficeEquipmentMember_79877C206BB6799BA49D2047BAFA450C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_DCD2E1C066C6B50C69E22047BAFA82FD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6C0D064FB3D07B6A41BB2047BAF9123A" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_DCD2E1C066C6B50C69E22047BAFA82FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506C87E19EF1BA40BC192047BAFA7752" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506C87E19EF1BA40BC192047BAFA7752" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506C87E19EF1BA40BC192047BAFA7752" xlink:to="loc_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_10993A50FFE97AF7981C2047BAFA3B1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_10993A50FFE97AF7981C2047BAFA3B1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_D7F454BD229AD37201E420AFEDC85B26" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_015EF9EB2A3F27FF2BCB2047BAFAE22F" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_D7F454BD229AD37201E420AFEDC85B26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7EBAA235773A6D6198972047BAFAD085" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_D01A21BE7FBCCA9EB4C92047BAF91D17" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7EBAA235773A6D6198972047BAFAD085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_7EBAA235773A6D6198972047BAFAD085" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_A0E0C1AC278BDDCAD39A2047BAFAACB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_A0E0C1AC278BDDCAD39A2047BAFAACB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_CF1FD2CC56E070EBD5A72047BAFA6CD1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_CF1FD2CC56E070EBD5A72047BAFA6CD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_AB32D376AFDCFDF48B1D2047BAFA1C93" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_AB32D376AFDCFDF48B1D2047BAFA1C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_D02C1C4C43E04FC2B7AE2047BAFB94FC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_537A994A87951BE0B34B2047BAFA1B3C" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_D02C1C4C43E04FC2B7AE2047BAFB94FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_3CE01DBF5BD84B72B14CE7C7207AB697" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_322F56F67ED5EAF9EAEAE7C7207A5DFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_3CE01DBF5BD84B72B14CE7C7207AB697" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_322F56F67ED5EAF9EAEAE7C7207A5DFB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofrelatedpartyAbstract" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_D2FCA17692FC4AE08EEB1AEC01F7A766" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_D98D4474DC6254187C8D1AEC01F706D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_D2FCA17692FC4AE08EEB1AEC01F7A766" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_D98D4474DC6254187C8D1AEC01F706D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofrelatedpartyAbstract" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_A55D9243A0B457824752259B37C81D82" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0780194BED4105516FCC259B37CD146F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_A55D9243A0B457824752259B37C81D82" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0780194BED4105516FCC259B37CD146F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_32EEC68FF5BCE644E080259B37D0E287" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_A55D9243A0B457824752259B37C81D82" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_32EEC68FF5BCE644E080259B37D0E287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_27F898C65B105BC3AEF1259B37D05B4A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_A55D9243A0B457824752259B37C81D82" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_27F898C65B105BC3AEF1259B37D05B4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_FE72EA1541F0B4A54532259B37D050D6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_A55D9243A0B457824752259B37C81D82" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_FE72EA1541F0B4A54532259B37D050D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_83C5D5518A1396990932259B37D58FA5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_A55D9243A0B457824752259B37C81D82" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_83C5D5518A1396990932259B37D58FA5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1" xlink:label="loc_oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1_64CC156E82BE5F047007259E03205815" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_A55D9243A0B457824752259B37C81D82" xlink:to="loc_oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1_64CC156E82BE5F047007259E03205815" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofrelatedpartyAbstract" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_B727C3E7D4CDC145F45D1AEC01F51C70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_354D8EA6FC96D4EB9C6E1AEC01F58B98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_B727C3E7D4CDC145F45D1AEC01F51C70" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_354D8EA6FC96D4EB9C6E1AEC01F58B98" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_2935372728B42AC4172FE19BEF466670" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_16086248548EF915A447E19BEF466CBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_2935372728B42AC4172FE19BEF466670" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_16086248548EF915A447E19BEF466CBB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_2A8C1608D9E3BCCE31BB3FC3B08EA5DD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_A09FEBE06D0954ADB26F3FC3B08E86C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_2A8C1608D9E3BCCE31BB3FC3B08EA5DD" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_A09FEBE06D0954ADB26F3FC3B08E86C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_F102E0D65D0B6775BDE03FC3B08EDFC1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_2A8C1608D9E3BCCE31BB3FC3B08EA5DD" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_F102E0D65D0B6775BDE03FC3B08EDFC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_7418EBB8A8F5CDC2FA0B3FC3B08E2643" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_2A8C1608D9E3BCCE31BB3FC3B08EA5DD" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_7418EBB8A8F5CDC2FA0B3FC3B08E2643" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExpectedForfeitureShareOptionsGranted" xlink:label="loc_oncyf_ExpectedForfeitureShareOptionsGranted_0E9C2062328E85DD7D933FC3B08E7231" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_2A8C1608D9E3BCCE31BB3FC3B08EA5DD" xlink:to="loc_oncyf_ExpectedForfeitureShareOptionsGranted_0E9C2062328E85DD7D933FC3B08E7231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_AB99AA5FD4982C4BD6FB3FC3B08EBB5B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_2A8C1608D9E3BCCE31BB3FC3B08EA5DD" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_AB99AA5FD4982C4BD6FB3FC3B08EBB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_B4B78555AC5EE193ED3F3FC3B08E6AB2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_2A8C1608D9E3BCCE31BB3FC3B08EA5DD" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_B4B78555AC5EE193ED3F3FC3B08E6AB2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_927F54B52F620E772720204678191448" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5C32566CD34C0F4FB29820467819F98C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_927F54B52F620E772720204678191448" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5C32566CD34C0F4FB29820467819F98C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_082F668E1ED0B26F88262046781A4371" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5C32566CD34C0F4FB29820467819F98C" xlink:to="loc_ifrs-full_RangeAxis_082F668E1ED0B26F88262046781A4371" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_082F668E1ED0B26F88262046781A4371" xlink:to="loc_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_C52447AEBB7F76B73C932046781A4368" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED" xlink:to="loc_ifrs-full_BottomOfRangeMember_C52447AEBB7F76B73C932046781A4368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_71F83A92D45ABD0374A62046781A91A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_671C7816C852C1149B982046781AF5ED" xlink:to="loc_ifrs-full_TopOfRangeMember_71F83A92D45ABD0374A62046781A91A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D547FE7F39AC39C8EA312046781A1622" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5C32566CD34C0F4FB29820467819F98C" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D547FE7F39AC39C8EA312046781A1622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_04ABC0E5384FEDF00A802046781A9652" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D547FE7F39AC39C8EA312046781A1622" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_04ABC0E5384FEDF00A802046781A9652" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_RestrictedShareUnitsMember" xlink:label="loc_oncyf_RestrictedShareUnitsMember_ECA435AF33BA6E3781C82046781A2E25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_04ABC0E5384FEDF00A802046781A9652" xlink:to="loc_oncyf_RestrictedShareUnitsMember_ECA435AF33BA6E3781C82046781A2E25" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_PerformanceShareUnitsMember" xlink:label="loc_oncyf_PerformanceShareUnitsMember_A43EA4C5C77A8399B1942046781A63BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_04ABC0E5384FEDF00A802046781A9652" xlink:to="loc_oncyf_PerformanceShareUnitsMember_A43EA4C5C77A8399B1942046781A63BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_551390C13971680DDD1D2046781A6736" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_04ABC0E5384FEDF00A802046781A9652" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_551390C13971680DDD1D2046781A6736" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_48D0622AD92D352D51FB2046781AD419" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5C32566CD34C0F4FB29820467819F98C" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_48D0622AD92D352D51FB2046781AD419" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_8EEEECAB5981F1502F162046781AC7D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_48D0622AD92D352D51FB2046781AD419" xlink:to="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_8EEEECAB5981F1502F162046781AC7D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_BEF69B21E2A1C7FDFA462046781AD1DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_48D0622AD92D352D51FB2046781AD419" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_BEF69B21E2A1C7FDFA462046781AD1DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_B37499C9D107EEEAFC2C2046781AF937" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_927F54B52F620E772720204678191448" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_B37499C9D107EEEAFC2C2046781AF937" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_B788B2D10596586AE62C1AEC02BD409B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_29F16755F9574BC7317F1AEC02BD6C39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_B788B2D10596586AE62C1AEC02BD409B" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_29F16755F9574BC7317F1AEC02BD6C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D862FFD738E94710EB8A1AEC02BDFF7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_29F16755F9574BC7317F1AEC02BD6C39" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D862FFD738E94710EB8A1AEC02BDFF7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_D862FFD738E94710EB8A1AEC02BDFF7D" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_RestrictedShareUnitsMember" xlink:label="loc_oncyf_RestrictedShareUnitsMember_14970D45A3088A3A7D521AEC02BD90C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182" xlink:to="loc_oncyf_RestrictedShareUnitsMember_14970D45A3088A3A7D521AEC02BD90C9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_PerformanceShareUnitsMember" xlink:label="loc_oncyf_PerformanceShareUnitsMember_F2F19594E66289A945101AEC02BD4EA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_F4EDE3A751F13F2D56371AEC02BD0182" xlink:to="loc_oncyf_PerformanceShareUnitsMember_F2F19594E66289A945101AEC02BD4EA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_29F16755F9574BC7317F1AEC02BD6C39" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_31EDB7151FFBB02702991AEC02BD7780" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_31EDB7151FFBB02702991AEC02BD7780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_90AFE20F770A60DE69111AEC02BD6C91" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_90AFE20F770A60DE69111AEC02BD6C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_5DB1C742558477EE5B261AEC02BD56F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_5DB1C742558477EE5B261AEC02BD56F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_B6E5E032930E5161EE701AEC02BE6FB2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_B6E5E032930E5161EE701AEC02BE6FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_F0D5E1AEA5033F0D204B1AEC02BEC562" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_F0D5E1AEA5033F0D204B1AEC02BEC562" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_245082FC8D924B5108F21AFF94565908" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_999F8910D375F37C9A571AEC02BD40A7" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_245082FC8D924B5108F21AFF94565908" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_3AF6E4658C831A4F04E8E19BEF41DAC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_3AF6E4658C831A4F04E8E19BEF41DAC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_8439BE90EECD3B08BD65E19BEF41791B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_8439BE90EECD3B08BD65E19BEF41791B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_30A56D49F2ABB8F85785E19BEF416DB0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_30A56D49F2ABB8F85785E19BEF416DB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_50F0E33878B3899B1226E19BEF417055" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_50F0E33878B3899B1226E19BEF417055" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_A9EA63A4CA0D09E7E4E7E19BEF41D338" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_A9EA63A4CA0D09E7E4E7E19BEF41D338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_48CF693201A00C8B91B5E19BEF419052" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_48CF693201A00C8B91B5E19BEF419052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3082C2ABA2AAA116CB23E19BEF41EC32" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3082C2ABA2AAA116CB23E19BEF41EC32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_C8A9E6B422313D2F1AFFE19BEF411213" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_C8A9E6B422313D2F1AFFE19BEF411213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_7B1BF6068C15BAD4DF68E19BEF41CF7C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_7B1BF6068C15BAD4DF68E19BEF41CF7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement_1C8D8116D335A357DADBE19BEF4126AF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement_1C8D8116D335A357DADBE19BEF4126AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement_889A1585572A029CE644E19BEF41A343" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement_889A1585572A029CE644E19BEF41A343" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_8C8B7427BF6099CC172EE19BEF413875" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_8C8B7427BF6099CC172EE19BEF413875" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_19DE7A9B848F522495E1E19BEF418939" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_19DE7A9B848F522495E1E19BEF418939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_3BC1640465973DC4B41DE19BEF41C4A2" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_69DFD27EF12C6E4879D9E19BEF40109E" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_3BC1640465973DC4B41DE19BEF41C4A2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_E8843333AC71817F2872F2828B288BC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_7D1BA527A2094093C0C0F2828B28F517" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_E8843333AC71817F2872F2828B288BC9" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_7D1BA527A2094093C0C0F2828B28F517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_7D1BA527A2094093C0C0F2828B28F517" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeOneMember" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_CA8FD4E9B7AE35E9E582F2828B286A89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:to="loc_oncyf_ExercisePriceRangeOneMember_CA8FD4E9B7AE35E9E582F2828B286A89" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeTwoMember" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_35A657991535A6766568F2828B288CD1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:to="loc_oncyf_ExercisePriceRangeTwoMember_35A657991535A6766568F2828B288CD1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeThreeMember" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_CC6A86863A308352989DF2828B28A0B1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:to="loc_oncyf_ExercisePriceRangeThreeMember_CC6A86863A308352989DF2828B28A0B1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeFourMember" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_D85FD74D89FB6900AA2CF2828B2865CE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:to="loc_oncyf_ExercisePriceRangeFourMember_D85FD74D89FB6900AA2CF2828B2865CE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceRangeFiveMember" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_E304FDF1C3FF4BB8B366F2828B28DA93" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_E37A3AE79706F2A0F321F2828B2831D9" xlink:to="loc_oncyf_ExercisePriceRangeFiveMember_E304FDF1C3FF4BB8B366F2828B28DA93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_7D1BA527A2094093C0C0F2828B28F517" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_A60D04C13D1790DAE651F2828B29B79A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_A60D04C13D1790DAE651F2828B29B79A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_05349B8248F66A5BFC4AF2828B29AECA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_05349B8248F66A5BFC4AF2828B29AECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_4E543325854729012840F2828B296027" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_4E543325854729012840F2828B296027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_899DA1861668D3D8942FF2828B290263" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_899DA1861668D3D8942FF2828B290263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_1422826ACD0CE25DB530F2828B295D79" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_193F35B7829451600A68F2828B295761" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_1422826ACD0CE25DB530F2828B295D79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_E8843333AC71817F2872F2828B288BC9" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_63014978C14925C2350FF2828B281D22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_BB72133B41441779ED77F2828B2AE6A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D" xlink:to="loc_ifrs-full_RangeAxis_BB72133B41441779ED77F2828B2AE6A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_2AC7F71AAC6C1D1C864BF2828B2A331E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_BB72133B41441779ED77F2828B2AE6A9" xlink:to="loc_ifrs-full_RangesMember_2AC7F71AAC6C1D1C864BF2828B2A331E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_486342F4DEBB1F915345F2828B2A940F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2AC7F71AAC6C1D1C864BF2828B2A331E" xlink:to="loc_ifrs-full_BottomOfRangeMember_486342F4DEBB1F915345F2828B2A940F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_A0B5392BB3070E82F72BF2828B2A63C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2AC7F71AAC6C1D1C864BF2828B2A331E" xlink:to="loc_ifrs-full_TopOfRangeMember_A0B5392BB3070E82F72BF2828B2A63C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_8658DA0E1656EB55385AF2828B2ABC01" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_DB909B1CF82C9CFAF8AEF2828B299D0D" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_8658DA0E1656EB55385AF2828B2ABC01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions_EF3C8FCDC56637C90FE1F2828B2A973B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_8658DA0E1656EB55385AF2828B2ABC01" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions_EF3C8FCDC56637C90FE1F2828B2A973B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:label="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_11496F68BD9DC7BA2DC3E10D7137FC0F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_A881080D97D06A37B81FE10D713723B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_11496F68BD9DC7BA2DC3E10D7137FC0F" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_A881080D97D06A37B81FE10D713723B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_4F8DB2B2431E16883782E10D7137F938" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_11496F68BD9DC7BA2DC3E10D7137FC0F" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_4F8DB2B2431E16883782E10D7137F938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_8C02828B8EB372692139E10D71387BFF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_11496F68BD9DC7BA2DC3E10D7137FC0F" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_8C02828B8EB372692139E10D71387BFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_7945B444451E53DEFE9FE10D71383C36" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_11496F68BD9DC7BA2DC3E10D7137FC0F" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_7945B444451E53DEFE9FE10D71383C36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1E00F8717589C723D714E10D7138C4C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_11496F68BD9DC7BA2DC3E10D7137FC0F" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1E00F8717589C723D714E10D7138C4C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_3D95F053B9EC6C3033B7E19BEF56EC89" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_51465EFF5A8705EA3DFCE19BEF5756F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_3D95F053B9EC6C3033B7E19BEF56EC89" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_51465EFF5A8705EA3DFCE19BEF5756F9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_1F25F219B4F23F7DA1E2F2828B439706" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_E9F43D5F01E15999AED5F2828B430955" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_1F25F219B4F23F7DA1E2F2828B439706" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_E9F43D5F01E15999AED5F2828B430955" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_BAFB72D406F4BCF20640F2828B430510" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_E9F43D5F01E15999AED5F2828B430955" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_BAFB72D406F4BCF20640F2828B430510" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_842BC0026BDE5EA399A5F2828B43687E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_BAFB72D406F4BCF20640F2828B430510" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_842BC0026BDE5EA399A5F2828B43687E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_DCBB376752E4B4E3163DF2828B43654D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_842BC0026BDE5EA399A5F2828B43687E" xlink:to="loc_ifrs-full_IssuedCapitalMember_DCBB376752E4B4E3163DF2828B43654D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_6DF30158075EBAB2BB53F2828B43BDA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_842BC0026BDE5EA399A5F2828B43687E" xlink:to="loc_oncyf_WarrantsMember_6DF30158075EBAB2BB53F2828B43BDA0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_9149420C8FE277B1F52DF2828B43A1FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_E9F43D5F01E15999AED5F2828B430955" xlink:to="loc_oncyf_SaleOfStockAxis_9149420C8FE277B1F52DF2828B43A1FC" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_D906DA826F415FD60CFFF2828B437DA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_9149420C8FE277B1F52DF2828B43A1FC" xlink:to="loc_oncyf_SaleOfStockDomain_D906DA826F415FD60CFFF2828B437DA1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember_9ED32AF51DE6B0802342F2828B43A864" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_D906DA826F415FD60CFFF2828B437DA1" xlink:to="loc_oncyf_SharesUnderSharePurchaseAgreementMember_9ED32AF51DE6B0802342F2828B43A864" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_4F9EF3B8E07F0195C539F2828B432B4C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_D906DA826F415FD60CFFF2828B437DA1" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_4F9EF3B8E07F0195C539F2828B432B4C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_DB22957AD1EA1CE0D46BF2828B437DF7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_D906DA826F415FD60CFFF2828B437DA1" xlink:to="loc_oncyf_SharesPublicOfferingMember_DB22957AD1EA1CE0D46BF2828B437DF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_E9F43D5F01E15999AED5F2828B430955" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_1ABE01A54EE39DFECA35F2828B445875" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_ifrs-full_Equity_1ABE01A54EE39DFECA35F2828B445875" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_19860B82186ABF5E0C3FF2828B449720" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_ifrs-full_NumberOfSharesIssued_19860B82186ABF5E0C3FF2828B449720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_527AD7FA96751CFE63E2F2828B44F0AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_ifrs-full_IssueOfEquity_527AD7FA96751CFE63E2F2828B44F0AA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_BFCA43952A30A0BCF8C5F2828B44DAA9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_oncyf_IssueOfEquityShares_BFCA43952A30A0BCF8C5F2828B44DAA9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_1E5D43ED64A8E634D8E5F2828B447AFA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_1E5D43ED64A8E634D8E5F2828B447AFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_0C86FDC88DF46B893D89F2828B4482D9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_0C86FDC88DF46B893D89F2828B4482D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_BB0F13045ADA30AF0504F2828B447F35" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_ifrs-full_Equity_BB0F13045ADA30AF0504F2828B447F35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_894CED3E38E19A6EC80AF2828B4445ED" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ACB5682CBFDCD8FBF7D1F2828B446A53" xlink:to="loc_ifrs-full_NumberOfSharesIssued_894CED3E38E19A6EC80AF2828B4445ED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_198D58B2333CFC16E99F1AEC02E4212A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_24A4249285DF114639C61AEC02E4B84F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_198D58B2333CFC16E99F1AEC02E4212A" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_24A4249285DF114639C61AEC02E4B84F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_57CA6F3E663D25FD622D1AEC02E4C88F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_24A4249285DF114639C61AEC02E4B84F" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_57CA6F3E663D25FD622D1AEC02E4C88F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_07630ABCE5595CC436D51AEC02E490ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_57CA6F3E663D25FD622D1AEC02E4C88F" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_07630ABCE5595CC436D51AEC02E490ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_D1695E471AFF4350CACF1AEC02E43ACA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_07630ABCE5595CC436D51AEC02E490ED" xlink:to="loc_ifrs-full_IssuedCapitalMember_D1695E471AFF4350CACF1AEC02E43ACA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_E0903843998A9AE2CB8E1AEC02E5D592" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_07630ABCE5595CC436D51AEC02E490ED" xlink:to="loc_oncyf_WarrantsMember_E0903843998A9AE2CB8E1AEC02E5D592" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_24A4249285DF114639C61AEC02E4B84F" xlink:to="loc_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_C97FA1CEC3A552964DF01AEC02E55C8A" xlink:to="loc_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:to="loc_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_InitialCommitmentFeeMember" xlink:label="loc_oncyf_InitialCommitmentFeeMember_75B5FA50029B5793EE871AEC02E5F335" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F" xlink:to="loc_oncyf_InitialCommitmentFeeMember_75B5FA50029B5793EE871AEC02E5F335" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderAmendedSharePurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SharesUnderSharePurchaseAgreementMember_852171699674C5F688171AEC02E5BD5F" xlink:to="loc_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_AmendedInitialCommitmentFeeMember" xlink:label="loc_oncyf_AmendedInitialCommitmentFeeMember_7E2F393782837A1DEA6A1AEC02E5CB12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SharesUnderAmendedSharePurchaseAgreementMember_A7F94D1DBDBAC54B9D9C1AEC02E5F062" xlink:to="loc_oncyf_AmendedInitialCommitmentFeeMember_7E2F393782837A1DEA6A1AEC02E5CB12" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_B7AFA10ED55F86598A681AEC02E5969D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_B7AFA10ED55F86598A681AEC02E5969D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_76513E681A918A3A84821AEC02E5323E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_F9D725F51F2C289B148D1AEC02E5BFF0" xlink:to="loc_oncyf_SharesPublicOfferingMember_76513E681A918A3A84821AEC02E5323E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_24A4249285DF114639C61AEC02E4B84F" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharePurchaseAgreementAmount" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_29E74CB7BE4464B386321AEC02E6D58B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_SharePurchaseAgreementAmount_29E74CB7BE4464B386321AEC02E6D58B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharePurchaseAgreementTerm" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_15FD2647627EE43F8E691AEC02E6D8B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_SharePurchaseAgreementTerm_15FD2647627EE43F8E691AEC02E6D8B3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_127AB15630ECC07FBA7A1AEC02E64A6F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_IssueOfEquityShares_127AB15630ECC07FBA7A1AEC02E64A6F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_InitialCommitmentFeeSharesIssuedFairValue" xlink:label="loc_oncyf_InitialCommitmentFeeSharesIssuedFairValue_78F527A7C7F404957C9F1AEC02E62B26" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_InitialCommitmentFeeSharesIssuedFairValue_78F527A7C7F404957C9F1AEC02E62B26" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares" xlink:label="loc_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares_C6F99CF91AB3AC6A085F1AEC02E6823F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares_C6F99CF91AB3AC6A085F1AEC02E6823F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_BBBE3A5623F346C3E32D1AEC02E693F9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_ifrs-full_Equity_BBBE3A5623F346C3E32D1AEC02E693F9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E39E4D2FB42F01EB6B251AEC02E6C61B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E39E4D2FB42F01EB6B251AEC02E6C61B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_B047E72B7169C27114B71AEC02E6550F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_B047E72B7169C27114B71AEC02E6550F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesIssuedPricePerShare1" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_7D7576C3A733734036C51AEC02E68549" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_7D7576C3A733734036C51AEC02E68549" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommonSharesPerUnit" xlink:label="loc_oncyf_CommonSharesPerUnit_D971B397FA5474F6D6931AEC02E67B13" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_CommonSharesPerUnit_D971B397FA5474F6D6931AEC02E67B13" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit_EA62F3E26A7DCA9DCCA31AEC02E6C07E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_CommonSharePurchaseWarrantPerUnit_EA62F3E26A7DCA9DCCA31AEC02E6C07E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SharesIssuedWarrantPricePerShare" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare_1FD62CA8A736D58C74981AEC02E6083E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_SharesIssuedWarrantPricePerShare_1FD62CA8A736D58C74981AEC02E6083E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8696FE7CEFD98F66ACF51B2E88DA5CCC" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8696FE7CEFD98F66ACF51B2E88DA5CCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions_441C9C519C3656BEF1011AEC02E6F6FA" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions_441C9C519C3656BEF1011AEC02E6F6FA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantPricePerShareAccelerationThreshold" xlink:label="loc_oncyf_WarrantPricePerShareAccelerationThreshold_BC488F6FC5BD5FD969B81AEC02E6E6CB" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_WarrantPricePerShareAccelerationThreshold_BC488F6FC5BD5FD969B81AEC02E6E6CB" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantPricePerShareAccelerationThresholdTradingDays" xlink:label="loc_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_FD0CE4621DB137EA1C3B1AEC02E67000" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_646A97ADDE589DDA44081AEC02E5180C" xlink:to="loc_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_FD0CE4621DB137EA1C3B1AEC02E67000" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_17ACD098F545445E6943F2FC673E5263" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_411D9B6096F9101C11D0F30DF8DB9EB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_17ACD098F545445E6943F2FC673E5263" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_411D9B6096F9101C11D0F30DF8DB9EB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_71533538A37C3846CAC8F30DF8DC2761" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_411D9B6096F9101C11D0F30DF8DB9EB2" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_71533538A37C3846CAC8F30DF8DC2761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_71533538A37C3846CAC8F30DF8DC2761" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_2FE9354B3489B8BE3F1FF30E4A05A2DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_2BD1CE7013EC3DC30736F30DF8DD130C" xlink:to="loc_oncyf_WarrantsMember_2FE9354B3489B8BE3F1FF30E4A05A2DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_411D9B6096F9101C11D0F30DF8DB9EB2" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_529BAED6F43F69C3CEC4F2FC89B917C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_529BAED6F43F69C3CEC4F2FC89B917C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_61CBAEC925685A32B64CF2FF452C783D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_61CBAEC925685A32B64CF2FF452C783D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_ED1D712D3BFCF8D3185CF2FCC59A3D9E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_ED1D712D3BFCF8D3185CF2FCC59A3D9E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DividendYieldPercent" xlink:label="loc_oncyf_DividendYieldPercent_87CCF1811E734D82D3FAF2FCE2E568DC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_F57D2A2D0904BA477D37F30DF8DD1ABD" xlink:to="loc_oncyf_DividendYieldPercent_87CCF1811E734D82D3FAF2FCE2E568DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_8D55C32A9F1906E0192B2047BA9968DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_C0A6E4F8A3D253414BD32047BA99FB41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_8D55C32A9F1906E0192B2047BA9968DF" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_C0A6E4F8A3D253414BD32047BA99FB41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_DB4EAAD38A54B54FCE2E2047BA99586B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_C0A6E4F8A3D253414BD32047BA99FB41" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_DB4EAAD38A54B54FCE2E2047BA99586B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_53199C932ACD0CA7AF852047BA99F494" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_DB4EAAD38A54B54FCE2E2047BA99586B" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_53199C932ACD0CA7AF852047BA99F494" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_B817244B68848DE8E51E2047BA994C19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_53199C932ACD0CA7AF852047BA99F494" xlink:to="loc_oncyf_WarrantsMember_B817244B68848DE8E51E2047BA994C19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9262DF78934ED9444B572047BA99685F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_C0A6E4F8A3D253414BD32047BA99FB41" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9262DF78934ED9444B572047BA99685F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_ExercisePriceofOutstandingWarrants" xlink:label="loc_oncyf_ExercisePriceofOutstandingWarrants_E4E19EA3DF241EFCE4E620C1ED049727" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9262DF78934ED9444B572047BA99685F" xlink:to="loc_oncyf_ExercisePriceofOutstandingWarrants_E4E19EA3DF241EFCE4E620C1ED049727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_F0D940E465D6BFE94D552047BA996651" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9262DF78934ED9444B572047BA99685F" xlink:to="loc_ifrs-full_NumberOfSharesIssued_F0D940E465D6BFE94D552047BA996651" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_B4FC7A468E4C447E66192047BA9A0029" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9262DF78934ED9444B572047BA99685F" xlink:to="loc_oncyf_IssueOfEquityShares_B4FC7A468E4C447E66192047BA9A0029" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_873F02DD6A2790C1C6F82047BA9A6B89" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9262DF78934ED9444B572047BA99685F" xlink:to="loc_ifrs-full_NumberOfSharesIssued_873F02DD6A2790C1C6F82047BA9A6B89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_460E6D8A11D4DEEA52192047BA9ADEE3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9262DF78934ED9444B572047BA99685F" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_460E6D8A11D4DEEA52192047BA9ADEE3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_9509AAC644552B147DFDF2828B47CB5F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_138E7665361DF3A01D56F2828B47BAF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_9509AAC644552B147DFDF2828B47CB5F" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_138E7665361DF3A01D56F2828B47BAF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_AB09A61A459505A46A58F2828B47E0C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_9509AAC644552B147DFDF2828B47CB5F" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_AB09A61A459505A46A58F2828B47E0C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_24DE23591F6B0A497F82F2828B47F22A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_9509AAC644552B147DFDF2828B47CB5F" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_24DE23591F6B0A497F82F2828B47F22A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:label="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_D9B0E0681BED7B88E670E19BEF6E2829" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_B41029DAEC468C21542DE19BEF6EAC3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_D9B0E0681BED7B88E670E19BEF6E2829" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_B41029DAEC468C21542DE19BEF6EAC3D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_83E6BF29F6D1C135C942E7B041F60380" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_D12E34E049305F54C61FE7B041F6062F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_83E6BF29F6D1C135C942E7B041F60380" xlink:to="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_D12E34E049305F54C61FE7B041F6062F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SummaryOfSignificantAccountingPolicieAbstract" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_996334BC5530EBB9084DE7B03A79DE4D" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_NumberOfStockOptionPlans" xlink:label="loc_oncyf_NumberOfStockOptionPlans_3082B508CC8EA0261A9EE7B03A797D50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_996334BC5530EBB9084DE7B03A79DE4D" xlink:to="loc_oncyf_NumberOfStockOptionPlans_3082B508CC8EA0261A9EE7B03A797D50" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:label="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_07C67D036D00589D8C42E7B03A79DEDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_996334BC5530EBB9084DE7B03A79DE4D" xlink:to="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_07C67D036D00589D8C42E7B03A79DEDB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SummaryOfSignificantAccountingPolicieAbstract" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_9129140E85FE3998566C2047BB2A76DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_9129140E85FE3998566C2047BB2A76DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_BABE20BC79FEF1C847C02047BB2AB775" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_BABE20BC79FEF1C847C02047BB2AB775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_9BAF9F564EA9DBCAF6C12047BB2AD96B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_9BAF9F564EA9DBCAF6C12047BB2AD96B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_4B9DD74C1C673C0FEA472047BB2AD1C0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_4B9DD74C1C673C0FEA472047BB2AD1C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory_52B95F11EE826E0758322047BB2A2EC5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory_52B95F11EE826E0758322047BB2A2EC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_7EB3D0BA77ACACF01B412047BB2A3A3F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_7EB3D0BA77ACACF01B412047BB2A3A3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_CC950BFB23342F1F00392047BB2A1ED1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_CC950BFB23342F1F00392047BB2A1ED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_57BE55BACEF4E476F8082047BB2A2AFE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_57BE55BACEF4E476F8082047BB2A2AFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_6ED284826394F42D63D72047BB2AC682" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_6ED284826394F42D63D72047BB2AC682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_5FC0C791FD46D5B903322047BB2A0ACA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_5FC0C791FD46D5B903322047BB2A0ACA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_9BC183A141CC8D4FBE392047BB2AB26A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_9BC183A141CC8D4FBE392047BB2AB26A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_74655DB649DF44276F3C2047BB2BCED1" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_74655DB649DF44276F3C2047BB2BCED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_EEF6429C5BD701405CBC20A00B88B477" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:to="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_EEF6429C5BD701405CBC20A00B88B477" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_A40127DE69D94FFDAA8F2047BB2B6283" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPolicieAbstract_010DF1671E7AED6C72A92047BB2A5A0F" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_A40127DE69D94FFDAA8F2047BB2B6283" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9DF307384362FE2DBAF8E7B00A3F25A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3570C1E5494D82692A98E7B00A3F7085" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9DF307384362FE2DBAF8E7B00A3F25A5" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3570C1E5494D82692A98E7B00A3F7085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1DCF4C137A9CF452D829E7B00A3FE96E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3570C1E5494D82692A98E7B00A3F7085" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1DCF4C137A9CF452D829E7B00A3FE96E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_6980EDF49E733F05F738E7B00A40CAF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1DCF4C137A9CF452D829E7B00A3FE96E" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_6980EDF49E733F05F738E7B00A40CAF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_2F1161D1E0377DACE7AFE7B00A40A2ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6980EDF49E733F05F738E7B00A40CAF3" xlink:to="loc_ifrs-full_OfficeEquipmentMember_2F1161D1E0377DACE7AFE7B00A40A2ED" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_MedicalEquipmentMember" xlink:label="loc_oncyf_MedicalEquipmentMember_A3B9E61176C9062A09F7E7B00A40259A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6980EDF49E733F05F738E7B00A40CAF3" xlink:to="loc_oncyf_MedicalEquipmentMember_A3B9E61176C9062A09F7E7B00A40259A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_0E966E948DCAE67035ABE7B00A40C114" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_6980EDF49E733F05F738E7B00A40CAF3" xlink:to="loc_ifrs-full_ComputerEquipmentMember_0E966E948DCAE67035ABE7B00A40C114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_D2FBD0CB44CB522BF8C5E7B00A409F8F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3570C1E5494D82692A98E7B00A3F7085" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_D2FBD0CB44CB522BF8C5E7B00A409F8F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_6F70152F59A8C778CA65E7B00A407671" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_D2FBD0CB44CB522BF8C5E7B00A409F8F" xlink:to="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_6F70152F59A8C778CA65E7B00A407671" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20171231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_3E3725FEAB8B6CE9C530E7B03DF39E35" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_9313DD142E90A42736B8E7B03DF30F76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_3E3725FEAB8B6CE9C530E7B03DF39E35" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_9313DD142E90A42736B8E7B03DF30F76" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>eysignaturecpalpa.jpg
<TEXT>
begin 644 eysignaturecpalpa.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "% 6$# 2(  A$! Q$!_\0
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M82C!CA,C!5"G<_+'Y>!]A_\ !3+XWWWPB_9QNM(T*21?%/C.Y70=/6#/FA9
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MH6N+&SUJ*1O.:\MHV>?>.5,9*2*,8(*@G.[C[/H **** "BBB@ HKXR^,/\
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M58,I!!Z$5UM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!X]^U/^T9HO[+_P?U;QGJVRXN4_T;3-/9MK7MVP/EQCVX+,>RJQ]*_,
MKP]XIO?A;H2_M ?$B+_A,_VB_B,^/ 7AV>+S?[.B<[(KWR?X1R!$OIM Y9BM
M+_@IQ^T9I_BO]KO1O#>IV#^(O!7@"2)+K14N#"E]<OMDN%+X.,CRXB<9&QL=
M:^F_V%/V3/$_BCQ[)^T7\:4\WQ=J0\_0-$F3"Z9"RXCD,9XCVQD+%&/N+R?F
MQM />_V*/V7X_P!G'X:M-K)&H?$7Q(_]I>)M7D;?++<N2QB#]U0L?]YBS=Z^
MC:*\<_:E_:3\/_LN?";4O%VM21S7V#!I6EE\27UT1\D:CKM'WF;LH/? (!^:
M?_!9WXRV_BCXL^%OAY87 EB\,6;W=\$.0MU<;2J'W6)$/_;6OT9_8:\:+X]_
M9(^%FJB02R)HD-C(W^W;YMVS[YBKX&^%G['U[XU_9=^.'QU^,EO]H\8^*]$O
M=6TH7B8DLT13<+<X/W&D=$"CM&,='(KZ _X(X^*&UC]E"^TV5O\ D#^(;JW3
MGI&\<4W_ *%(] 'V'\3OB1X>^$/@/6O&'BF^&GZ%I,!N+B;&6(Z!57^)F)"A
M1U) K#^#7[0WP]_:!T/^U/ GB>QUV-5!FMXWV7-OGM+"V'3\1@]B:_*#_@J9
M^V9#\;/&47PS\&W_ -J\&Z!<;KVZMWS'J-\,K\I'WHX\E0>A8L>0%-?/=M\+
M/B?^RA\3/A;KFM177@_5=;E@U"R6&Z\NY6#SE5EE"G*;@>4;L<$=10!_177A
M_P 8OVT/@U\!?$":%XT\;6NFZT0K-800RW4T2MT,BQ(VS(Y^;''-<]^W%^UI
MIO[*GPGN+VWFAN?&^JJUMH.FMAF:4C!G9?\ GG'G)]3M7O7Y^:__ ,$Z+GP_
M^S3X[^-OQK\5:E_PG$NF3:O#ID3+F.ZEQY0NI&!+NSNH*+MVEL9- 'ZY>!O'
M.@?$CPKIWB/POJUKKFAWZ>9;7UH^Z.09(/T((((/(((/-?-GQ[_X*4?!WX,2
M>*]!77YM7\;Z.DUNNE6EA,R_;%4A8VE*B, /@,0QQS]*\S_X(P?VHO[,_B-K
MMI/[,_X26;[$'/ 'V>#S-OMN_7/O7P-_P4BU/X4:O^TAKEU\,YKF\NIYGE\0
M7BSK)82WQ/S_ &88SUSN;<5+$[>!D@#?V%T^-1^,]_\ $#X7> (O'NOP1W$,
MUYJ@*6EM-<#YI&E,D:B0@MP6Z,W%?H_\'O G[:7B7XHZ3X@^)'CWP]X4\)6\
MZRW?A[3+6WN6N(P<F$ 1G;D<;S*2O49KUC]@KX26OP;_ &5/ >E16RP7^H6$
M>L:@P'S27%RHD.[W52B?1!7M.O>,-!\*R6,>M:UI^E2WTRV]I'>W*1-<2L0%
M2,,078D@ #)YH W**** .&^-_P 0Q\)?@]XT\9^4)WT+2+F_CB;H[QQLR*?8
ML /QK\9?V+OV^->^$GQB\7>)OB+XGU;7-&UG3+RYGLIYWF6:_7]Y $4Y$99@
MT8(  #\\"OVQ\>>!](^)?@S6O"GB"W:ZT76+22RO(5D:-GC=<, RD$'W%?@'
M^U'^S/9?"O\ :TO?A%X'O+G6EGN[*VL!>,IE62Y2-EB=E !VF0#=@<=10!]
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M>?G(9F7N-@Z$@@'Z;PS)<1+)$ZR(PRK*<@_0U+7P]\-/%EM_P3>_8+\.7?Q
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MY0)QRW)_A#'BO!_A+^R;XZ_:;^)]I\9OVE85MHK8B3P[\/%),-C'D,AN%]>
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MST#2[33M.M(;#3[2)8+>UMXPD<,:C"JJC@    "K]%% !1110 4444 %%%%
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MBS]E'3O%GAKXI:4WB*]LY?&^N6WB!;R"",OIMS;I;"+8&R' :U1B&'.XCWH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>figure1a06.jpg
<TEXT>
begin 644 figure1a06.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (( P(# 2(  A$! Q$!_\0
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M'H?[..J>(-8U^&W\3^'SH&AI&UYXF-U_H&YT#!4;'S$9P>@![\BO3/!_Q?\
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M.B^!5V?$'3]?DM;WR/+^T%4D501OXP8QE<]BV.:^.8;^YM[O[5'<S1W08O\
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M:?!SP!!\4/B3HWAFZO);&"_,@:XA4,Z[8W<8!XZKC\37%NO&<5V7P:^(%O\
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M T.6EAW9J)8ZMM[5"S;:"["=!4+N%ZTYIASS561LT#)A(#0[>E55;GBI<YH
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M$<BKT.&Q3I$[T 8Q4J:FMU)(J:2/YJ=&NWI0!*GRU>TG3WUB_2W4[4P7D?\
MN(/O'_/<U4. M:MFZV_A^:&9FMHM3N%B>Y')\F,%W4#T)*Y/L*1G6G[.#D=!
MX/TU-<U>2Y^SNOA.SF_=C=A;R3)^7=_$HQR0>2?2NX\1?%2&74E2Y"Q+'Q!N
M!V9]% XS7F-GXMGO/L< 5DLXV$,-M$N,*. !GV_G4?CCQA]CU!-(MXX;5;H%
MV-PV6C4X"Y R<XY_$T+4^==Y.[-/7-0N]4\3/#:/9W)N4QO2)64*?4MT(-3Z
MEX!,@BM[O==SA K,\F1&.V".!2> H&*>26BO+D*RR+##_JP.AW=^*[:UL[B
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MDU.[\/ZSJWV-[*\CB\^.>*6(%6(^1XF$J$X .-PK1\4:S%XBLOB[<)>ZI?\
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M*Q9LMQC..*0G&>W]?UL:DOA/PIJ&M>*]0AN-8L/#F@9-W&T<+7,DSW!BBA@
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M^C3:_42=V>;I</;R++&YCEC8.CCJK Y!_,5[W#IL'Q1\'C5&22\MY"(YXHV
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ME97?]HS:=8"VN+SSA-N;>S+&9!]_8I"[AZ>U<]I/@_6_$EO<3Z7I-YJ$-O\
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M HLJPB-G!0L=IWX"JPR/F!Z5RGBS3%TCQ!=VB6%QI:Q[2+2[N4N)8\J#AI$
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MJSD97>WE>%F7D$JQ!(]N*MZ#KUEIMG?Z7K&DIK>B7S1RRVK.$=)8R?+E1B"
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MQ(R(?^/E]P+< HK8<9X7U+]GW]H+4;&.+P?K^C:CJ?A&Z<"SGM8'EGLV/+,
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M0;"BEY&8$9RXPO&0*G^)'PS/AF^EFL)EOK [66:/^ZRAUR.Q*L#@^M<YX?\
M&>N>&89H-+U.>RCE;<T:8(W8QN (.UL?Q#!KPI8=QH\F&?+?4^TIXQ5<1[;'
M)U.C3=GIIOY%FXU/6?AQXBU?3M.U(H89VMY2BAHIMC$ E&!!]>1Q51X;_P 5
M78OM0U6"34[X2R017<Q\^Z$2Y<J,8 4# R0#@@4_P_HL&NW%_<:IJ::5I=C
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MI&$732T_JQ'>?%+1FOO$.LP^%I(M>U^QN;6\F-_FWB>="))88]F5+-\Q#,<
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M;327O9+VTT^ZM8KM;%F/!B,JG:0 HR,9VC-8UYKVI:AI;:?=733VC7DE^RL
M2T\BA7<MU)(4=\<54M\%<GK4Q0&D:*"6R-R#XE:_%J6H7LEU!=2:@D<=W%=V
MD4T,PC4+'NC92N5 X(&>M8GB#6;[Q-J4E_J-Q]HNG"IN"JBJJ@*JJJ@*J@
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M+=4CFM)EG@DD@GC;<DD3%65AW!'0UZSX-\42?$C08M+OKR33C:*S-.%W*S*
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M)[T 2:>QR*UF9<>]9EG&4YJW(=HS2*1E:U(&!6L:WMS)*!BKVH,6D/O3-/\
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M\3?#GQ-I:KNF2W%];C_II$=QQ]0"/QK8D2VM[.PL+&%H;&Q@$$*N1N(R26;
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M>)/$5AXMA:UMFBT:[G?S;FU\E56X9<[6:0#D\YYXY-;\>O7NN2-96NHK'/,
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MH)?,;-[8+J?J*]?D^+6GZM_;-U;65YIL.G3)"TFH*FV=9"RD;.J]#\K#D&O
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M>LI?4)W\R-0B']XW*J.@]/PK1\*ZQ:17EA=:I]K46]PMRB6LN!,J\%"H^Z2
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M8=J1I#F?Q"_9:*L>8GK13Y30YUR=M0A<MG'-:+1#O4)50PQ3%8(;?=]X4^2
M(N *EA^\*)CN) J;L9@W7^LY'%5?,VL<5<U5C"IXYK#2=_-YXJ]"'H:JCS%.
M>M563Y_>K4)^2FF%FP0IYI#+5C;EDS4-_'L4X'-:&GV[J!FDU%5Z=:1=M#GH
MVW9&,&I/LYDY-3P6Q,QVBMF.P'D\BALFQC[$CCP.M9=S&%8GM6]<6?) %8MV
M@1BK'F@;V&0J&7Y:>\#R+4FGQ FN@AMXO+ /6A@D<K]G>/'%6[>8KBMJZL4V
MY K-6V5),DXH3N.Q;CF9U.:J72B53SS5U81M&#4;P#/%.^I1A7T+>4%'XU!I
MNGF616[9K5O+4Y"@%B3T7G-=#X?\!Z_J#(T6E3JC=&D78/UJ93C'63L$8.3L
MD485$6 !Q5C[0@ZUV]I\&_$MX<)9*/?S :Z'PC\$X['4WE\3W$*+&1Y=NC;@
MWUQ_*N2>+H05W(V5&;=K'F-CX>U+6N;&RGN@3C,<9(_.II?AOXBCN/+;2Y@_
MI@5],74=MHEJJZ?<PJFW 1?D'3L*YN#7/L4TEQ>?NU[-D,7]E[?C7F?VE4;O
M"&AWK!QM>4CQP_"WQ+';I*^F2*K<<D#'U]*[GPO\'M)ALC=:EYE_<;=S(IVQ
MH?3WKJ/$7C][=YK86-W%!'9"[%\8U-L[%PGDA\YW\YQCL?K7%+\1+B539POO
M,QPMNHX=CVP.]8_7*U=-1T-GA(8>253=JZ]'ML=9I]QHOANZO/[/BT^.YLY$
MAO%MY$DEMG()59!R5) /Y$=:Z[0O$:,XF=9E69Q%O)*L%)^9U'?Z]N:\IDUO
M2M)N+JYCTBSM-9OI1-J$D'2:8 X9\D@D$D\<9)-7/#WC=M<O(TGB96M%N9I>
M<D*L1XY_VB!QCO1A(.55.IJ_ZL<>:2IPHS6';4;+>U[Z76G2][>6^IZ1IM[J
M#:EJNL>)M!TVQ>P98M%:$$N^7;.')Q(-@#;L<$]>PN+XD_M.ZFDO)RD;1C;@
M95CV /U[^U<9JGQ \.06ME?V6IQZC#<C8;>RC)=2,%A*C8X'J.XKF_&'BM]+
M$8LXYEBN%'EF,[ASC!/MG^'%?5X/#N%+EDW+S/E\5B(8RJZL*2IJRTCMHK?C
MN>B7EUHUR;'1H[R2PU;52TEO#;QNT3*-ZAI)!P@9HWP>>G-4=-\-P^%[#4)]
M7G.C6UK&INF\DS2,78*BJH^\69ACG'-</X=U*QUKP?<Z!XANY]-GAF5K2XMH
M]YB .74.#OVN22R@_3N*]-\*^*?#NFZ-I>APZK VGV-F+2:75XLQ7"YW9 8M
MQDX"DY&!3IQQ*JU*;BDFKQET7DT>K*GE4<+1K)RY[VG#JUNY*5K+LE9]S@O&
MVBM!?:3J&G*KZ'<PQW$,C0E6=&]4;D/P00?>M+2].O=8M!+:NH91\K!  V/7
MC^52:[KUMXJUYTT^],]LK!+='01QHH  51T4#';'2K'AOQ!!X2OKF)[F.[A4
M;TC0\*Q!R >XSZ<<UZU.$84.5N\GU/)J2I)2C0ND[M7Z=E?JTMQZXT_6H%;*
M7BQC=E<>;D8R,?GSV%>A+=V_B#2-3\-W<]S:7-U";:>>*41O&I(977IGH 1D
M9!-<CI^J_;;AM20EY9(VC2615!&3V';M3]6L[>.Q;S+HS:DP5U;'(4,,9/=C
MFN'$4TX.$M>YE3<\,H3B[2C9I^:=T0^+]'T;P;X/T;2+6\0067FO/J%TI0)O
MD$C;06.T97IDGD^M>):[\4-%OIY6CL]\08E7\HY([9(]JZ[]I;6M,T_X":A-
MXACC^V>>B:3',F9)KACD%>.J@.Q/3 /K7E'PF6T\::"(U\NQNT7@Y";_ &KX
M?-<9#+5#W?=C^!]QD.&>9RJXS$S?-)ZNW7>]OF2:AJVB:Y#)]GOSI5X>0LG,
M9_J*\OU^#4/#L,4\^]IKTR2K<Q\I]G#!-RMWRRN/;'O7I^IW<FA7QM9[6TU5
M-V&M[E=Z-]<BO3_$TWAGXA?LW?\ "-V&@VOAS7-,<7%O!([LI228L[0RDGC)
M8F-C]T'%<L<U6.UJRZ:7ZGUDLLJY?6A6I+GC+2ZTM?JU^JV/D4:D\D; /M1<
M!G8],UK^%-=,>KV]M:W4R3;EE6:#*LI!SP>N1BN\\-_#ZRTT+;6*_;9F;_7R
MH"7;U[[1[#I6_-X8U"/Y(([A+L?>V1\C\>U<_P!;HP:<XW2/;J9<ZT;5:JBW
MTW_R-S1]4U_Q;</=OK$6F:3IS)<75S/9F".>8Y"L1&@:60@-QVP:OZ%IO_"*
M_M%6=O<-&-'\0QI<)-%GRG64;U9<]MXQR.-QJCX>U+4=#\S1H(H]9OKY )M+
M:-IPRCGYL$;2.N0> 35KXH2:SK/ANQUK48#I^LZ1<*IA9-FR%L>7M _A#*N,
M'N:^@R#&PKXJ5!Q485$X_/H_O/S?B[*7A\)',*4W*I0DI7[Q5D]-^]W>UDC)
M_:0UZ31_ >G:=]K62YM=9NU1X#AA$"K1Y(Y R[X^IKYK3Q)(UPTDSN\K'+-(
M26/N2:^O-6TRPU2WD\5W:W%QI=]#%ML+39^]D>-W8.S A5&QATZXKQGXC_!'
M2O[<CM="FDTR>ZMXKF.WNF##;(,[&.<*P/&0<'BO)=50JRHU5:VGW'WU/GQ-
M"GB,-[T6K^M_>=OO.6\)^)M06Z,MJ+B7:HVB*4)@@Y&2>PQV]:O:MK7BCQ>E
MII<FGM:P6K,ZQQ1^5;*S?>D)_ODGDYY]*OKX N? *VEE?Q,VI-"LTL+H5,6\
M952I[[<'G^\*ZS3-'O-7$:(55BP4*[XY)P![$GBO7J8K]Q]5H2;7;\7H>?'*
M\'#$+-L5RPEI9];6LM?-/S_!6YO3?A>/LOGZKJIB Y(M\'\ ,<UZ3X#^(S?"
MR1FLXI+A_)DCAFN%,93>I7=@?> S6!=6-WH=] I<RF++>4RG:<=L_P!:P_&G
MBZ#5%0&-S<;B[.V 0,!0N><]#Z=C7D4:$I1G5J5+2CLK'KSQ$)U:=&%+FI5%
MK*^EOG_G^5C \3>%WDN)+K3]0W02'>J2KT]02OO[>E6/A[HNJWNOQKJ>(=*@
M5II[I?F1(UZG/^/J*L^'YH)+JVCE+,';Y5920^".XZ5Z#K]O)=6R>&["."QN
M;EPKI""2ZB3=^](Z;5.XY'85Z&38&6.K-5?ACJ[]CYKB[-J62T$J,92J5+J-
MMN;M_P ,RE&&\5ZK=^*+F/9H6DJ(K&TEZ.PY1/?^^WN0*\?U;QMJ6O:M<RG<
MUV[MG?SCZ5Z3\0]2#V]KH.@3R1V6G_NU9<$2/U:1O<GFN%T;X9ZQJUY=WAN[
M*"),F:9I@A7TSNQ@GL!Z&O1S7,,+BK1HNRAHEY?\'<\[AO(<1EM'GQ2YJE76
M;\W^BV70FM=6EM]%D6[F99<[]Z\8-0Z+XU^WZE#$\N[#@,>FX9YS[UWWBCX8
M^!M%AM(8_%T%],T8^T1Q7#2@-CT5>.?0^E6+?X>_".\LK6>WU:32]6C0++AY
M)(I6 QN"LF<YYSD=*^:IPIIRE(^SAAZL8*45I)]G]^QZ=X'OKV'2=3ATPQVP
MDD$FTC!.0#U_&L:\^+\>EAK6:&1+U'*N7;@8ZY%8NDZXNAZ\LC^(M)2PV(@^
M>3S)-J*.5V8#$CUQS7N?P=^#^A^.IKKQ?<Z/#%;7$S%;J\)F>?& 6C3[JJ#Q
MGJ2#71A:?M'&+5]#XO-^?#*5::Y8I];J_P#GMH9GPVC\.ZAX?D\4>*I8YDN9
M&ALK.%BH<+PTC%<$\\ >QK5@N[2Z,O\ 9EHNG:>,D-Y?4^Y)Y]>>E=?XK\(^
M&]/N&1;)+QH4SYK28$0YPJH#A23Z#UJOX7TVSU77--TZ[1?)CS));JI\M5 )
M5"?<_GBONJ-&C2CSPA;\?Q>I^*YAC,1C:TE*5H7T7^?_  +G-6M\(8YD#LSS
M?+]KDR% ]!78?">;3])FO[Z9!(R,(HKASD8 ^8CT.2*V_'<TT@CL=(LK9BQP
M!(H$2X[M[<?RKQOQ%X@OM)<VLTMM''#\[^7_ ,M&/1@OIZC!Z5UPC[?W=KGG
MPA[.LEO;R/0OB-XBTCQ(N;BVCN)K5\PR>7O9">.G<>WL*X7P=9PZ:9FU5(KN
MUE/RJJD;3VP3R/\ ]5<'>>,)KA0DUU';%'W"8_+YG0#('!%;4'B!+98W$\DB
M;=Y;C;@#YL@]N?T-=#H.FN4PQ,)*:J26IW?CVWLU\-_;M-/[KI)"Y+RP'LX/
M5D_O ] <CI7E%QH/B*ZBBDF:WM8VP?WDW.#[#_/-8NI>-M8_MQOLCL]E.P$6
M5X)/)0GMQT]JZ;Q)!=Z'X8TZYEBFCEEN3!!"5R6R"P4?3&?QKQL=A4J7/&*<
MOQ_X?[SZ;A_-YK$_5*J?*]O)_P"3_ Z#X9_#V^UCQ+;RWUY#+IMC_I%T@!YQ
M]U,GU./P!KWE->O%F<NO#'*XY ]JX_PKH5SX3\'VEG< _P!IW@%U>\9(8CY4
M_P" C]:O6UY+ IN W"G KPE0E3@N9;GUU6JJM1R6QU=KK5U=;O+1B.FYN!3]
MTTVX//&G^SU%8DFM&2V-PC8C'#8ZK[_2GV>I030RK&%N[[:6AC+E%D('W2>Q
M^M.-)R;Y49.PS4O#,-TADCECBESSM&%/KQZU7M_ OF%2+KS@>ODQD_EFO,M;
M^/VJ6NH-IT6F6.CW:,R,MTC.ZL.,?,0,UAVGQR\0WUX8+O59%CY4I#MC'Y+1
M.K4H>[-/[O\ ,ZXX&<O>E9+U_P CW6Z\%65G#ONKT:>HZM<R*,_A7(:U?:'H
MJ.]I/-XCG'2WLRL7YLY'Z5Y3XE\>?9;Z**YEDD\Y=ZMD_..^#WQ4ND^(M(UI
M%BMWD>Y&/W?E/WZ?-C!_.L_;8KD]I&'N]]_Q.V&749?%+7[O\QOB#XY:_;2/
M;:;HEOX>;H&EC,TY^A;C\@:\9\;W'B7Q-<M<ZO+J6H;?FS<!V1?H/NC\!7OV
MG1W*S>8+=XIK9MT;S0Y'OC(]/2NJM?%UE<0EWC<7*_))$6^7/T]*S_M*5O@*
MCE\4[+0^1_#UD1)\WR^QXKKE@"*,5[M/HVD:K?&ZET^S:X[,T2G^E8FL^#=*
MU!7 L3:2C)$EH3@^Y7IBJCF4).THM&CP-2.B=SR3:,'O63?0B3.*[Q?A;XCU
M&:1=-B@NXE?:&:81G;ZD'I_]:K5K\$M>F9TN+BQMY%. K3%L_B!7H_6*-K\R
M.3V-2[3BSR^WT\2./EYK673=J@]*[#4_A;K^A*TK6T=U"O62V</C\.M8:L>5
M92#[BMHU(U%[KN9N+CHT9C(8AZU0OLL<]*UKIUC4YX%4EM_M/3G-40S%,F)!
M6OI\?VH]*1M#;<*U]-L1;+S3N2B*/3R&S4EQ9_N\#FM1D&.*54#<&IN4<P;<
MK)M J_;Z>'7IS6I)IH;D"B* V^3UI7N24?L>UAGBK4<:CC'%3K'YE.^SLHZ5
M06&A@JX J*2$L":N0V^\=*D>':O2D(Q_*-%:GEKZ455V28=Q'MC)K%N)VC;B
MMV9C-\JJS'V&:RKW3Y5;E&7OR,4]ADUM.)%4'K5Z. ,V:RM/LY?,#$87U/'Z
M5KJI6IOJ-%#5M*-Q&2%S7+MIDD<F&'2O185^7FLV_L%F8D"@;C?4R--M4*C-
M::V,;-G&:@AMF@/%:=O&[+D(S>I )IC1 UJ(HSMK*FM7D8\9K<8%N,5#(55L
M8YI:C90M]-\GG;[UHV\7&#5^RT#5-47=;Z=<S)QRD9(YJ_;^$]6\PQ_V;<[P
M<8\LBLW)+=C2,"YL4920N#7%:W9M'-D<+W]:]KM?A=XCU"94&G21(>LDG  K
MHH?@OH4/SZU]MNB/O>4!&N?3UK&6)IT]V:1HSJ:11\UZ<Q6M^!2Z@U[[;_"?
MP.MQ$\-C*[1CF-YSAOK72GX?>'DM5=]'M;2(<9?()KG_ +0I=$S98.K'XE8^
M:%LYKB,I%$\S]E123^50V/PY\4Z]=JEKI-PJ'GS9EV(![DU]7^%M)TOP_;SB
MPM+:-VY\Q?F./J:PO$FLM;.L2AI)9FPB\Y8^G%82S&3;]E UCA/YV>5Z7\!-
M7>UW3W]NC#JJY/ZU##\,8=-U!TU.[\Z-.BV_4GT)KV#2[.YL[22\O;H)'M_U
M$7S%3[FN*U/4+"0O'B;'F;A*)!GZ5R+&UI-J_P"!TJA16R^\-+T73-'F1[32
MX]^,^;*-Q'_UZZ"'7X[^:*S;!9N!Y1^85R*QW%]%-]@UVXM80O[U94!&W_>'
M>NI\*VEKI]E=+IL2F]:$R+<2?/+)C[V#V^E35A&RE*?,WTUO^/Z'3&7(K+3\
MC4_M";1P8K)I'7#;V8'>_P"/I[5R_BCQI9V&[S3-%<;<F/9\V3T'/>L6?QE<
MV]X8[IY(I/7.*V].\0+J$,\^H*EW88VQQS*&,C_CV'K65-4N=2KQ;CY:,RE4
M47;KYG/VTFH>,3 ]G')#89_>S2?*!CJ ?6K6K:+?W.$6YM8X8UVK&6)V@=.@
MZUJG6H+J&2U6+RO-0B'Y]J(PYQ@?YZ5Q$^H2;79)FF<,0OE@E6QUQZUT4Z-2
MO)K#4VTNF[7K8)R3U6Y#?>#]8NL![ZUN8NI\J8J_'&<,.N/3TK)GTZZ\.PW-
MS:VTD-T%VHS<D=BRGN?\370>#9+C7-2>-AY2H-TA8X"CWKU.QGTG38_,G2,)
M$I(D<;G]\>GTK66+Y*/L'37K;WOO,H.,I*4D?,FE:?XJURX/DZ1>NG+!FB*A
MN>N3BNG\#KXATOQ#=WOB#0KJ"R:V>/+*-BG 48(/)()/U KN=>\1/?W%P^E6
MMY< <D)$SE5]2 .!7,V?B07]Y%92W#1_:#Y+%QC:6&!Q^-;X:K4I^_[-6>E]
M=/3S/.Q-.+A.%V<@OFZ=J!EMT#(F)ML;Y49')SZD9!Q[UZG_ ,(A:ZEX3@GL
M=5DFD9/,\BX.!'*1@+NSSP!S@#@<U%-\.(M$\#:CJ&L;K?5UQ+9)"HE%PA4?
M+L7+=VZXQSUQ57P[#K6E@6\0>:REBS"%4%'!ZD9PV!G')'IUKZ:A4E%.Q\;&
M7*F7/#VEQZK#&)C]G.&$39!61AP<>GTS47B#X?:KJUTZ6DL3VFY0[Y("MP20
MN.?_ -=7=&\)7.I![>+2;]-C)+-]E+.B,#G;GO\ 0C->O^&_%7AQ+-K6"RO1
M,L3 M/']XCA@ >GU[8->C[15HN'4WC)U(MV:/(O#.E?\(_<3I>P;[>0%5E8D
M  'DD]LUHZ/X=BO-08)"UUYD@2+S,X [\=__ *U=AYCS:A-#_923,UP[0*R'
M='NX)'&,8/IQR171:7IWB#5;JSLH%A@G4]< #9QDJ>IP.Y]36=O9Q;?R\C6*
MY+S;]$8MSX9GT=$N)(5A1<JD?5P3T %9FG":7SKF>/"QG#QD9(R3U].U>X:=
M\.19;S?7PG5D( SDA0.%^G^ K@]8\)VM_KWV#29U43,QD/+(K 9/.?;I7F3J
M.3U9RSJ-[LYWQE\,]&_:)^%VO^"+R9;34X8/MNE:DR\V]PN=CX].S+W5C7YS
M:/;^)_AWXFUCPSK1DLM8TJX:UN45LC<.C*>ZD$,#W!%?J=X \-ZQ"M]97E@M
ME<BVD:&Z!!W$@A00#G.>WH*^#_V@K:[U3]H#Q/<BP:[CC^S65S=QX57GAMXX
MY7!_WE(_"O!S.G"5+F:3?G8^\X,Q56EC732;C;U*^EW%YKFF6[,N;@G:D@7+
M,W&!7:^?='2[33[B=?/ACQ/\PPK,<D#UQP,^Q]:YR:Z3PIIXDMH62+RV2"0]
M$9@ \@/=@#@<]2/2N.D\37'F%D; !&!]!@#\A7P<<))KF@MS]UJ4;RW2/3X3
M_P (Y=;7NF5!C '4^U>J^'%M-8TF)I%>Y\Y)6DN/-0) RA2B,A;<2^3@@8^4
MYKYFL_$,FN:A'%<7*RRJJC*,&P" 1DCOV_*OHWX4Z*?+CW&&1_)$PB,BB41D
MX#E,[MI(QNQBNRIAI4ER5])'RN,K4*U#VV'FIKNO^!V_X==#F)&@\'ZW?RMI
MT[V,UNUO<R6A(EC0LK!E(Z<J,@D9!(S2Z?XCM_&$+^&[*SFMM*&G26D$EV?W
MC-N,@<@<#YR,*"<5WVH6=M=:PB2K,D5C>+.AMYVB664IMV2@#YTYZ$C^+UJ&
M'PJ-/U &&W%L+4*R2<?/D;@W';\Z^HRC+9PG&O4NK6:9\OF.94<1A98-RYI2
M3O'K>S7?^6^NG;<XCP;-KFF?#ZXL8Q<6.H6LK!?,AW1S0,=W1@58*X89QP36
M5H_AK4->\207=[<S75U<3+OFD.7SD ?A[#TKU'PO9[?&&G>&-5NKB+4-1A8P
M %3!&)'DE!V8Y+9X(/4 $"MK3;70])UCP[<F6X@AO[R:WAAOXTMIWDAY8*A;
M+ XXQD^HKU.(L'3IXUSA_P O%<^2X&SFO++'2JQ:E2?+Y[72?W?@<KJWAJ-O
M&4MU<QM>M&VQ99 &;Y5VJ<'@XP#@\< 5F+X;O%@%FK73_:(XXKF\VQ12,4;+
M3,HPJ@#C@^G6O4M+99]:M])UB:T?7;I;J^A73[29(/LJ287<S9 <=^><C\?,
M_$OBGP+X<^",\&J_VIJFC7AN;!8K_?%=W,T$K.Y+L1M =,@DX( &#TKY_ U'
MAJGMX1O)7W_4^SS:G',J"P.(;C&7+=Q6MD]XWM?9V6B;WV*^K>$D*;OL[0*B
ML [2%Q(Q8G?D@'G.2,=<XXKS[_A![5M8:YOHVO8@VY8+<%69MI&2P.=HXR/>
MO7/!^E:IJ_PQT_5=0N?,COX8[FSMV@\K[';&-5B@ R2< 9R2<Y/-<I]AT^\\
M2G2;A?.E:,,DDGF&)6#*2K"/#8*AL8/7;FNJ6+E6QT:LX7ONE_6OZ]SS*>$^
MJ95+!X6K9Q5E)^7STOUM>VNC,>.&UT/PS%X@N--A2WA1$M8BVUGN%#+C&,@9
M&2.^,UREQ?/X3\,76M7KR'7=;!*R'EHX"<EO8N>?H!7J/CCP3'X@\16<C72M
MX=MXS<M#YC27$B!F#,X PK' 7<>PSFO#/B=K"^*-8N+IBT4"92-4X55 X ]L
M<5]SF$?8X;D@K2GOW26R]>_W'P/"N'_M3,7B:M3FIT&^6^J<GNU?9=EYW.2M
MM9NENE^R3&6ZD;#1GHWU%/\ &&K/?VOF1RR"2)XPX0;0QSAL#TR?TJOX'NHM
M+UU+[48O,LHE>0-(1GA2!@'Y6()!P<\@5U7C'7=%\47T<=I)YEP8V(N(U*H2
M2-I ..P[=Q7YW/"PC2>(YE=.UNO3\#]R69RJ8^. 5%M2C?FZ+?3UO;0Y+3/M
M5W=6]M%#-/)(ZIM'#$E@!SV))'7UKT*^^&NIZ41F:*[N%C$LUO&V9+=2Q"[L
M<'IG /05Y_X4UFXT>^+VYWW*N$D?)V+@\AO45ZII?Q.TZ\L;B7[);F8QB$HS
M'8FQN'3^($C'!]*[,+2P]6C4572:V_X&OYGG9QC,YPV(H?4H)TG\6OFM]-.N
ML;O>_0L_L_?!JU^*WC_5KCQ"\R:'H"12MIZ,4-Y(Y;;&S?PIA&+8Y/ 'K7UK
M??&*RT**/2K.PDL;>T58H[""-8T"\XV,ORJ!Z$?K7S#\$_C+;Z/\1WTKRHXA
MKJ>2NY]H^T(K&-23_>RR_5EKV37-/LM)UC2;S55D6PN)(S=JOSE%.<#C!/'\
MS7NY30C&BN=>\?B/&N+QWU_EF[1LFE>ZUW_&_P CL_#-I_PG%Y-+<R/9W"GS
MF6*,;R"!@ '/(&22<]*ZRXU72=!M%L]*2*(1-OD)W$[C_$6YW,1W)K/UJ/2M
M/N0MM*FGO( 5))5)4'&&('0CCZ9KB/$?B33DT^\FLY56'?Y:KD.RYZ,>/NGH
M&QS7NQINJU9:'RD?W:M;7N=GJ,NH:A-)=Z?/:O% ,W"W;!8(P1U:3.5..G\J
M\:U.'_A,M0=X;E657*RK;G?&J@D+^\XSZ\#TJGKUS-?262.K21R.IN!N.R49
MRH(]/7Z5TNDMI>@O"US((+60J,PJ0D:YS]Q>HZ#GWKT84702DMWL34ARV:O=
M_@<YXVL;+2;$3167V80*HPQX)/4^XP"?QKDM/D_MJ&1(Q&)$5FCV,0$';(/!
MS_2O4?B[I]Y-H<FH)Y*V*3"$>5("\\;M@-M/.#@$'T%>9^$8?L>KM:1Q*(I
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M.<M[(YJ=">,Q5*G?1M:J_P#6B/C>SUA](N+B-[J6*>%RLC*W1@<<YZ]*U/\
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M>^(4D>I *GFI#A=V>#CKQ_GI7G8>C&M52D^5=SIJ2C%69ZSK(.L_Z6L;+NY
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M6ML3CGB(6@M#/*N'89-6<L1:51^6B7S[_EH>E>,?B'XM\?2VQ\2Z[=:FEO\
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M;R94++CB1E8QC<>1D]J^7O"S>)[B&_;2K.^EMM)A-U?21IB.UCP3ND)X7..
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M(I7<.@XSG&1TK"^!]IIUEX"BNO/L[NYO;^7S(Y)XP8I('>VPN6RQ<PLX([$
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M3\E:ZU]#L-8UR'0=8M$U5&FT/R4A-N$/F6\JJJLT9QTSQP2K #!KG;OX/?\
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M?8&8\,.H(_ Y_&IO"3,+I #N8G(/I6O\0OAC-XN\16/V>9;>X:Q1IU;[N 2
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M=HV\]9&4_)ADP5]-W^(KW#PS\$_$'QV676;&V_X1@6KF:WN+XG_26SE=FWG
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MV2V6^KT_IO;MKU,?P+X;UF^TV?3]1P8]10RFS>$6[6$L8$8:.-> K$/D')(
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M@H!RA^N0>.*\UI\MXK4^HHXCVE*-WJ4?AI\+SK%W;V\/F*N<RL9BJH/?G_\
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M4,=M''"JB1V4Y:94;'S?W@1DGAW@6\\/:E#!-=RQPZ;:VDUA=:@MEYEW=_O
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M17K&E62>'M!FO[U/('0!N"?0"NS,<5#$M>RC9+[SK512M8QH]/;^S[A;P-'
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M&<@LF-H^A-=+XEMKWQ%I(7PQXGL]#GMU++'&4*,O\(S_  _7WK>_:(T/X?\
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M_/\  Q]+LCI^CBP2\FBMI IEMHY&"RD>J@X/XCTKI?"F@>#[LW::UYA=E58
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MU/7+OS(K>#Y6(R9<9(SP,"D>&X> &2]E5VYW'G=G.#@]O:LUKJ.)D@O,POC
ME[X]/?FL3Q!JDTLRF"Y)3Y1T&3C Y/X5[V E@*5*U:.O72Y$:D?M(LWNFR";
M==+^[Z*XZ,?<=O\ ]=4+/1;-;[S88%C8G=P,<^M;_AWPUJ_B1LE9)=HY=CPH
M],]!776/PWU.-PKVRJO:3=Q7EXIT956\,K1,G:3T94\33"?X3ZP]R-[6B+(C
MGJ"#Q7+Z;J4T_AW2K2T?="UN)BW9F/)R:[3QM:Z=IOPWUBWU:Z:"VN"L1$1
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M*(IX8\EF] *[N2P3P_<(K _,1R.]>IC<9]82C"-K&'/%[(YKQII+6'P]O0^
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M1;^%=6\4>#K+7(]8U[4]BFU\-:4R"&Z5C@,[<;2Q&,J<X4].M<;^SRTOAO\
M:0UO2+;2Y/#UC-;3>;HKW N!!M",JEAPQ4D\]1DBO4]5^ ?PXU/3=&M%;4(&
MTE&CM[NWNV68J7+D,V.?F8D' (SQ3])^!O@'1_$VEZYIGVRTOM/8.I2\<B=@
M2=TN<EB2>>1GC-<D<QPE+!RPKE)WC):K2][IVYK?@WYV/4J9+F-7,(8YTX*T
MHRT>K5K-7Y;O[U%K[-V>'_L__"G1?BEX@\8V^O&XEL+&X\V.TAF,:-([R+O.
M.I"K@?4T_P 3V%UXT_:.\0Z9?>'6\7IIX>WL]'DU$62K$BH%*L>O!W;1R=V>
MU?2GP^^'?A+X9W6J7&BFY6;4V5K@SSF0$@L1@'IRQ_2N;^+OPY^'_B_6K74]
M?@N+:]D0)]ML)O)D8+P W4-@=\9QWJUGM&>-G-M\CC:/]UV5W9-;VULTS'_5
M?$0RVE2C&/M(SYI=I*\K)MQ:T3TO%K<\:\'VOB[X<_#7XI/:JMCI:P@VL5OJ
M45V]E(9A'(,QL2K"-B"Q Y4'K61=?#'PI!^R[:^-(SM\4-=#_2Q<G>9//*&+
M;GJ$&[IGC.:^H_AGX$\ >#?#M[I^@V*S6>H+LO&NCYKW*X(VN6ZC!/  ')KE
MF_99^%-OJ@O'M+\6X?S/L$E\QM\^F/O8[8W=*UAG5#VDY-N/O*5TOB25N5^]
MU]6<]3AK%^QA!1C/W)0M*6D'*5^:+Y5MMHEY'B7QFU#4O$7@WX':A?W$J:K=
MVKYN_P#EH&\V)5ES_>P V?6NV_:&\!Z9\$_@Y=6'@\7EG::QJ<,.I3R3M(\R
MI'(1N/8,PY X/->K?$;POX"\>76@_P!K6UTO]C?)8_8Y?)BC&5(7 ZCY%P/:
MKNO:UX9\;:+=Z/K$,=_I]SQ)#)TZY# CD$'D$'(K@>=4X?5U%-1C*3E'IK*Z
M];=/,]-<-UYK%NHTYSC&,)=5:'+)OMS6UM?0^7)OAOK-C'X(U;PEX1@\*ZHO
MERP:F_B6W<ZD=JME59EP>N57LQ!%=-XVT/3?%'[9-SI6MNT>FWT44=S%'*8O
M/Q:JPB+ @X9E48SSC%>G>$OV;?AMI6JV^JVT%UJ,MLXD@M[^[,D4; Y!V8&<
M'G!)' K@?$OP[_X3C]K*]AUG2+RZ\/7=OMDNO*D6/<+4;2LH& P8#!!ZBO9H
M9A2Q=6;A-VC3GK9\VK3TO*3=NFJUV\O!KY-7P=&E&=--SK4_=NG'123ORPBD
MGUT>F^N]#X5Z5;>"_P!J;Q!X;\-R-_8)AE5X%DWJNV-' )[E')7)YY(KHO#L
M?V;]M'5X;?B.;3";D+TR8(R<_B%_.O5/!/P=\-_!VSU6\\+Z;-?ZO-"PW7MR
M&DEQ\PB#D ("0.<>F>E<=\%? .L:'J7B#QWXP58?%.O,V+-2#]DA)!VG'0G"
MC&> H[YKSL5C:$O;5U*_[M0UWDW;6WRU?H>UALJQ-'ZMA>2S]LZKM=QA%7]U
M.RWOHO70V?'FC6.H22PLGEL1E<#!_#UKRQ/A==:AJD9EO\VRMD*PP3]?>O5?
M&6O6.G:)J%WJ.W[.(F6-G&3O/0CWKQGP?\9!))Y-W&TENAX=A\QK\TG[WO6/
MV:--J*MVZGO_ (1\'Z3H:H2(Y)-N/WF,#\*Z+6+?3K.&/;'#$9&W,R@#CUKP
M^Y^,NCVIS!!<8/7:P'^-<[XL^+\.J6;16H:#CE6;.[V)K%TH./8=*E4YU)O\
M5_F:/Q0U&'XB>+8[1E#:5IZX$1/#GM_C7!:Y\)=&O]SV#-8W YV9WI_];\ZF
MTV>XFNI+R('R[I Q/9<<8J_;_:'D,-R_EQLI7<O7GO42;YKWLCL<(TXJ,CRW
M_A&]0@O?LR0K*N<";=A6 [__ *ZL?V+<P8$T3(S?=[@_B/K7HLJS:/;EP%=&
M^\01@CC/7_"K.GWT%S9NL<$;[@05D;<5)&,BOH7A\#[)MU+/O>_X'+*G!K1G
MG=KH4X(8JIY[U[)X!U0R69M+D^8F,#=U%86D^'?MMQLVG.?SKT/PMX!DAG\R
M4-&A/R'')/M7SSDK6-:?NQY9;'.^+-.5)A'-$VQAE'QUJ/PKX1LYK@37 ,B*
M?E5NE7OB%XSA\):@UE/"MY;<;5ZD'N?SKG(?B]IH0);Z?<;@<;>,5I[.R,E#
MFMYGN^EF*WLTA@1(XU_A48JQKNO&WTF1 0C!2S,>-BCJ:\1/QFGA@ CL]A_V
MY,?3@#^M1_\ "8:EXDT.YB"Y\V4&01#^$#A?4^O-2J=D:NG[-\TE>QQ7Q(UZ
M?Q9K42;F%G;G9"I]^K8]359-$66S"A/EQBMN/PV]]>H&'E[NF[IG'&:Z"/0)
MX[4[HLJO7WJU)744<LZCJ2YF>27&FR6,W4[>Q4U/#<ZAG;#<2!>HYZ5ZR_A.
MWUR,2.JQF09&, $^F?6J,W@/[&JK&#N'7G.:]RI@94XN<7=(OWH_"SS6WM;Y
MKR%'NL^=(J'S"0HR0,GVY_G7H?Q(_9P\->!?AG=^,(=>?6M9@OH[:5;)U^PJ
MQ8!D QN)&>N>IZ<4L/@62[F567@GFNH\<FRL_P!F>\T$7MM%J!UE'6U,@\S9
MYBY;;UP ,].U<5*TDVT<52M6IR7+)ZGS6VO7T'S02_9PO0)TKV3P1X?\&?\
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,*]7ZC0[?BQ>S1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>figure2a02.jpg
<TEXT>
begin 644 figure2a02.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )N YD# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7RQ_P %,/%^N^!?V/\ Q;K/AO6M0\/ZO!<V BU#
M2[J2VG0-=Q*P61"&&02#@\@D=Z^IZ^0O^"KG_)D?C/\ Z^]._P#2R*@#XS\
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M6L]KXTL8Y(;B.1V)\N,KM,T !.2"ZB3(V9!( .>^$7[.'QM\!^//"FK?!O\
M:;T[XJ>&)K^-=;BN+XW-M;6Y!9I'M_M$JR @%1L9'W,N"!EEE^/7Q7\;:/\
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MY/(.\;<D 9*X)#*3%\;OVH/#/P/\1>'=#U-9+O4-8?.R)P!!$&"F1L DY).
M!SM;)&.?E+Q)<^);B'4+K4;33K1KG5+J<WJ7:RI<@8:*YMPZA !#MC9-NU@?
MF*D&OI7]F_X=>!KCPO\ V@NAV^J:\MW]JN=8UAUU&^FDZQRFX8$Y"D;0N !R
MO!R?FL;@*.'A'$VO'JO,^NP&95L5*6%3M+HSWJVF2ZMXI5SMD0,-P*GD9Z'I
M]*GHHKY7T/L0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCYAS@ ^HJ*S[?7-.O-/DOX+^UGLH]Q>YBF5HU"\DE@<# Z^E4_#WCCPYXO\
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M-.6GAFK[O1'TN2\U3$K2]NIZG1117PY^B!1110 4444 %%%% !1110 4444
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M'7  QT% 'AO_  5%\2:OKMQ^R_X@%\UGK][H_P!O%]" IBN7-G)YB@< ASD
M>@KC/VV/@'HG[&'[0_P@U3X=ZGK$.IW92^N+V^NS--+=1W"AIBYP<R!SN7H<
MD8P2*^T/''_!,N/XD>!_A3H?B+XJ:QJ5_P" X)X$U.:Q5FO$>5'12K2$QK&L
M:1J S?*!S7>_M:?L+:7^U=XT\'^(=0\5WGAZ3PY&T<<%M:),)LR*^22P(Y7'
M&>M 'U"OW:_)GXY?#_X)^._VM/'<?B+6/B-\?O&$\<R#PMX-T\,-$96"^6;@
M2!2L.53 7:K$[]S$BOUG PN*^#]:_P""6QC^-WB;Q[X1^,WB;P/;^)9KF34K
M/2H MTT=Q+YLT*7*R+A"V" T;$87)8C- 'S9_P $T?%FL3_ G]I[PG<7EQ)H
M>F^'9;JTL;ALBVD>WO%DP.@+!$W <$J#ZYX']D7]E[P[\=/V0/B_XL\4ZIJ\
MS>$DOIM"T^WNC';6EREFLSSE.0S/MB0Y'W8_H1]R_"?_ ()CZ;\&?'7C/4/#
M/Q)UNV\*>)-)N]+E\.20!@/.ADC5I91(!,(O-=E#(#G&6[GO/V?_ -AO2_@#
M\"/B!\,K/Q5>:O:>+A<B74)[18Y+;SK46YVJ&(; &[DCGB@#X1_9;\%6/QN_
MX)G_ !>TWQ9<7M]9^![_ %#7-#C6X*BVGBTTR(OO'O=V*="6)[FNE_X),_LI
M^ OBCX3;XH:[;WTGBOPQXI TZ2"[*0KY44$J;D ^;YG.<GI@5]J_LR_L0^'_
M -G3X0^,OAY-K=SXMT7Q3+,U[]K@%N?+EMQ \8"L>"H/.0>:\M^ _P#P3+O?
MV?\ XE6FM>'_ (V^*(_"5OJ,>HOX7AA\B*\:,_(ERRR[)1C@GR@2.F." #Q#
M_@D#Q\>OCQCL(\#_ +>IJ]+N/V[_ -IZ.XE2/]E#6Y(U<A6\F]Y&>#_J:]N_
M91_8?TS]E?QQXU\26'BJ[U^7Q/M\VWN+185@Q*\G!#'/+D<XZ5].T ?E3_P5
M1^*WB_Q1X9^!/@Z_6Z\&V/BVT34]<L=[H$N&\A3!(" 2(6D<E6QR5) *BO7M
M)_X)F> ?A;\=? 'B#X?_ !(U'P+J>F1"Y;2GF6XO-6,3IYCKN=2(V#!9%",I
M#@87.#]!_M8?LB>$/VN?!ECHOB6:[TV_TR5Y]-U:Q(,MLS !P58%61MJ;E."
M=HP01FO!/AS_ ,$M(=+^)'ASQ9\1_BYXB^*'_"-O&VE:?J$31Q1+&0T<;F2:
M4F,$ E%V@XP>,@@'CG[3?@7X+^,_VQ?$,?B[6?B%\:O%$UJ8X_ /@_3S*=(*
MJNU1.)5 15!)11PSEG.<@\O_ ,$M=<U73#^T-X+:XU"+0;/1IKB+2]0DRUM,
MIFC)* [5D*D!RH )49Z#'TSXZ_X)GSZM^T!X@^)W@OXQ>(OAY<>())I-3MM*
MM\SL)2&F2.X$JE59@&PRM@@$=!BQ\'/^"9>F_ CXM:EXF\*?$G7(O#FHZ7<:
M==^'[J .UR98&CW2S*ZB0*[>8%,8PP'- 'PM^P3^RSX9_:1^"_Q<N?%FI:N(
M/#<?GZ596=T8K>&[DMY";EDP0[@0QJ >,!@<Y!'3?LA_&SQ?\-_^"=7[0%YH
MFIS0W.CWMI%ILNXEK(WC1PS/&<Y4@$L,8 ;YASG/W[^RK^PWI?[+7@?QUX;L
M/%5YKT?BI566>XM%A:WQ%)'\H#'=Q(3SCI57]G'_ ()_^$_@+\,/'G@/4-8G
M\;:!XPVB^AOK98-J"-DPNUCS\V0P(((!'(!H ^)?V:?^"?\ \._V@?V.8?B%
MX@\6S^&O&6J:G,\GB2^N0]O9JEV8BCQLZ*Q< G+,&W2+SC@V_P#@I9<>*/AG
MX1^!WP1F\7ZYXH\.M:-+?ZD%!N]6(G5(E(!Q(8T.%4L<DJ6)(##V";_@C^(+
M6Y\-:;\<_%5E\-[JZ6ZG\+O;!UE<$89B)5B+\##&$D$ X.!CW'XL?\$[?AE\
M4/@;X0^&Z-?Z''X21ET;6;=Q+=1%^93(6&'61L.RC;\P&W:!B@#X&D^#?B3X
M7_'GX<>,/V?O@_\ &+P?#8SQ1:U!XETMML\8E0.=R.^4D0N)%8!1A2 ,\;'[
M1WP[?XO?\%9M1\"'6;S0K'Q'#:V%_=Z>P$YM?[*CDFC4D$#>D93)!&&.01D'
MZI^%?_!-2[\-?$SP]XQ^('QJ\6_$F;PZZOI=G=22VZ1!2"B.S3R,4! )12H;
M !R,@^A:E^P[I>I?ME6O[09\57B:E 4QH@M%,)VV1M?]9NW=#NZ=>* /3OV>
M_P!GOPK^S/\ #_\ X0[P?]L.D?;);TM?RK+,9)-H.6"KD * ,C( Q7YV_P#!
M0Y1_P\P^ _\ URT+G_N+7%?K#VQ7R[\>OV%]+^.W[17@CXLW?BN\TF\\+K9)
M'IL-HDD=Q]FNI+@9<L"-QD*G . ,\T ?#/QI^']O\6/^"O&J>";_ %"^T[2=
M>,%IJ#Z=+Y4TML-)CEDAWCD+((]C8YVL17'>#/V=-#TO_@H]XA^ VEZQKFD_
M#W499+6_M;.^9);NT6S%X+:1P,LA=54DC.W/.<FOT9N?V&=+N?VS(OV@SXKO
M!J4;AAH8M%\GBR-I_K-V[H=W3KQ3=+_85TO3?VR+C]H$>*[R34II))#HAM$\
MD;K3[-CS-V>!\W3KQ0!\6?L8^$XO@3_P5$\8_#GPO>WD7A>.._M3:S3%M\2Q
M+-&K_P!XHQ #$9P#SR<\-^R9^S_H'[27[8GQK\(^+;S5$\,17.HZC<:?IMV;
M<7DJ7YCB$A R53SG8 8^8*3P"#^B'A']AS2_"?[7FL?'F/Q5>7.H:D;@MHK6
MB"%/-B$1Q(&R< 9Y'-1_LY_L+Z5^SO\ '#QM\2;/Q9>:S=>)TN4DL+BT6)(/
M.N5G)#!B3@K@9 X.: /SI_8%_9IT7XZ_%CXG_##Q9KNNR^!=!,ES_9%C?-!%
M=74<YMXIY ,C<JEB,#DD9R!@Z'[#^H7VD_ ?]LCPB+V:?1K'PI=RQ0R'(618
M;N,N!T!90N[ YVKZ"OT*_9A_8=TO]F?XI>-_&MEXJO-=N/% <2VEQ:+$L&Z<
MR\,&)/)QR!Q6;^SS_P $^?#/P)N?B:+GQ#=>+--\>VC6.H6-U:K J0L9=ZAE
M8DY$I&>,8S0!\F_L!2QP_P#!-;]I!I75$\O6068@#G28P!^)./QKSKX1+_QI
MT^-1Q_S-]O\ ^CM+KZ:\(?\ !(/2_"]YK>G2?%[Q1<^!-2^:3PQ;1FVCN& _
M=&Z9)=LVQL'_ %:DXZBO3/"O_!.K1_"W[)GC#X%Q^-+ZXT_Q'JJ:I)K#62++
M"RO;-L$8?!'^B@9)'WCQQ0!\ 0_LH^&-<_X)F3?&G4=3UB\\7Z=)MT])+DFT
MM+4:D+<VZ1$8"L7DD)&#O;/3(.I\=?C;XRM_^"97P"T>/6+Q+?Q!<ZG::E<+
M*V^>VM+F2.&!VSRFTK\N<'RE!X&*_1&S_8?TNT_8SN/V?!XJNVTZ;/\ Q//L
MB^<,WHN_]7NV]1MZ].:SY_\ @GKX(UK]E'0?@?K^J7VIVFASS7>G^((8TAN[
M>:2>67<J_,N,3,A4Y!7G@@$ 'YR>-?@+KG@V3X>^)?V?_A%\9_#?C+1BLM]J
MFLZ0?+O'"J5EC$;N!DAP8\;&5L$8!S^VV@W5S?:'87-Y ;:[FMXY)H6&#&Y4
M%E(/0@DC\*^%/!__  2MN+?Q%X=F\;_'+Q=XU\->'9%;2]")EM5MT4@B-9#/
M(8U(4*?*"' P",#'WRB"-54<*!@#Z4 ?C)XL^$D7QV_X*K>/? %[K-_H>C:Y
M<31ZG+IC!9I[:.SCG:$$@@!VB0$D$8SP>E:G_!0KP3%\"(O@S^SUX4N_$7_"
MNIY)M1N+2W99[R^EN+TC8  BRO&"PC5B!EUSSAJ^Z/#G[#.E^'?VPM1^/J>*
M[R;4;QYG.BM:*(5\RW\@@2;LG YZ>U=#^UO^QKX._:[\-Z99Z_<W6BZWI,CR
M:;K5A@RP;P-\;*W#HQ5"1P05&&'.0#\Y=/\ A)XH^%?[2'PZ\7? +X/?%SP=
MI-M/!!K=MXFTM\3H90)<LKN#&\1.X,0%*AAC@B3]MCX3?$;1?VM/$_CWXC_#
M36_B]\-LLUC%IMY<0VMO:% (T,L"LUN8\'<"H#-ECG=D_7OPB_X)MW7A'XIZ
M#XZ\?_&CQ7\3-0\/LITRWO'E@2,+RB.S3RLR!OFV*54D $$9!UOBQ^P3XE\5
M?%;Q#X_\!?'OQE\.]6\0%3J%O$6NH6"@*B(%EB*HHSM5BVW)P0.* /CSX5Z_
M\'-6_8S_ &EA\-6\3:-?SZ9#=77A77KWSX+"(NB@VY!Q,-X8&1E#@%%(Q@MS
MWP)_95\)?&K_ ()\^-/B)XFUO49/$7A&WU--#Q=D6VFQ6Z&Z\CRONGS99)"Q
M.3^\7'(Y^E/B%^Q'X8_9(_8M^.EW9:S?>*/$^N:0!J&M:@@1F5958(B G:"S
M%CEF+'!)P !X1^QO^PE/^TW^RO#?:=\4?$'@:UOM7GMM9T>U#7.GZBL3*8W:
M#S8QY@! W$L,*OR@@D@'-V?[07CK3_\ @E"+2VUB_A;_ (3@^%%OEF83+IIM
M?M1A$F=P7=^[P"/D^3[O%'[0W[)'@KX%_L3_  D^,'A+5-1L_'>H/IMS<:E'
M?,!,]S;/.1$ 1Y;1LHVE<'"DG)Y'Z0V?["/PTA_9@7X'S07ESX=W&Y;4&D O
M/MA);[4& VAP3@#&W: I!&0?GO3_ /@D+'>MI&B^*OC;XI\2_#_2)S-8>&#
M8D@!))",TSHF<D$I&I()QC.: /GO_@HQ\0M<^(/[,O[*7C'6)BWB'4-.N[RY
MN0BH7G$=F3*%  &XC=@  9X %<M_P4$_9]TG]DWQ#\(/$_@O6=;_ .$JUF*X
MU#4-:O+UI)Y;Z%K=_M(;JK,TS$@'' ]R?T7_ &K/V!O#7[37A7P#X=AUR;P5
MI'@V*:WL+73K-)4\ITA14 9AM"K"H&,YS[4O[7W["&E?M<+X(74?%EYX=_X1
M>&XAC^RVB3>?YODY)W,,8\D=,YW&@#X[_P""BOPE^*GB#]HW1_'&L>!]7^*O
MPHMM.MW@T71Y9D2!1%B>.0P O"QEW2>8%(*E%S\I 9^Q;\5?A!X77XR>)_AC
MIWB?P/X[L?!UWJ$'@W5K][S35:VC9FD23(,[!O*^690R@OM)!.WZ]^.O[#>L
M_$SXF1_$#P;\:/%OPX\3BPBTUVLW:>V\A!PB1B2,JI.6*[BI8EL DDG[,?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW\3K;P-9^,&EU.YNEL8KW[)(+%YV8*$$^-O+$ -]PDCYL<T ?3]%-W5\M?\
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M5> OA1H'F:=J\WAI)H9_MT+2B7Y5(:0F1(T#'<J@;@#SD _8&BORS3XN:_\
M\-Z?L\:!X=^(OBW6/ FI^%]+GV:AJ=PHU16M[@^?<PE@K2/M1FW G('H*^M_
MC5_P4+^"?P&\:3^$_$GB*YGU^UV_:[32[*2Y^READ"1@-H;!!*@EAD9 S0!]
M*T5XS;_M<?##4/@/??&&P\0-?^!+$A+F\M[:0S0OYBQ&-X2 X8-(G!'1@PX(
M)\MU#_@J9^SMIMUI,,GBV[D_M"))S)#ID[K:JW($Q"_*V.2H!(R,@4 ?7%%?
M,3?\%'O@)_PM*+P&GC/S]3ENUL5O[>UDDT\SLP4+]H *D%B!O'R#J6 &:ZS]
MH+]LOX5?LQW=A8^.?$#6VK7T1G@TRQMGN;@Q@XWLJ A%)R 6(W8;&=IP >XT
M5X]\#?VL/AA^T3X;U76O!?B2.ZM](&[48;V-K6:S7:6WR+(!A, _."5^5AG(
M('RC^T]_P4D^%7C_ .!_Q&\.?#CQUJ>G^,DLE;3+^"&XL#,RSQE_(FPK!M@<
M\[21D#/2@#]#Z*^9?^"</BK6_&W['?@36?$.L7^O:O<&^$U_J=T]S/)MO9U7
M=(Y+'"@ 9/  ':O!/VU?^"DU[\%_CIH7@/P=>6D5IIUY%'XMN+K37EG@0O$Y
M6 D[6S"S$D*QSC!!H _16BOF"?\ X*-?!&U\*^%O$<FMZD-+\37=Q8Z=(-+F
MW/+ T:R!EQE0#,F">#DXZ5Z'\0OVH? /PQ^+GA/X:Z]?W4'BSQ1Y1TVWBM'D
MCD\R5HDW2 %5^92#GMS0!ZY17S9XV_X*$?!+X=>+/%WASQ#XEN-.UCPN0M];
MO8RDNY9%"0X!\QLN#A>@#$D $C 7_@J#^STW@1O%'_"7S+&+K['_ &6;&3[?
MYFW?D0X^YC_EIG9GC.>* /K*BO(?!_[5WPM\;_!F^^*NG>*[9/!6GAQ?7UTK
M1-:NI ,4D9&X2$LFU0"6WKM!W+GS'P!_P4V^ /Q&\:6?AC3_ !3=65_?3BWM
M)M2T^6WMYI&.%42,,)DX W[1D@=30!]645X3\6/VT_A/\$/B,O@GQGKTVD:T
M=.;526LY'A$"I*^=Z@@L1"X"#YF;: "2 >T^!_QP\,?M#> H/&/@^6ZFT.>>
M6WCDO+=H'9HVVL0I[9SS['WH ]"HHHH **** "BBB@ HHHH **** "BBOA7X
M-_M)?$;Q5_P4@^)GPNU7Q#]J\":/8W$UEI7V*W7RF7[-M/F+&)&QYC_>8CGV
M% 'W517R5??\%1OV?-/T"?5)/%%XWE7C60LETZ4W+NJ@LPC(^X 0-QP,\#)X
MKD_VM?\ @H%X2TG]DJ3Q=\-/$\CZWXJ$VGZ!=):NKPS1RQ+=;PP'E21Q2,R[
MAR=I&002 ?<-%?B]\)?C*LO[+GQ5UO3?CC\1-<^*H\,_;=1TZ]OKE;73V.HV
MR"6WF+9\T*RH6#9(D8# R*^YOV2_C]IO@/\ 8%\$?$?XI>+;EH%@N?MFL:K-
M+=7,[F]G2-<G=)(Y "@#)P/0< 'UW17S'\'_ /@HQ\#OC9XWL_"6@>)+FUUR
M^D,5E#JEC);)=. 2%1R-NXXP%8@DX !) K5^(7[>7P;^%GC[Q1X-\4>))=)U
MSPW:K=7T<EG(4*LL3(L; 'S'(FCPJY/))X4D 'T/17R;I_\ P5"_9YU#P7J'
MB+_A,)[>.RGCMWTV>PE6]D:0,5,<6#O7"-E@2JX 8J64'U#X7_M9?"[XO?"[
M5OB%H/BB!/#.CEQJ=QJ"FW>Q*J&(E1P",@C!&0V< D\4 >Q45\F>$?\ @J%^
MSWXR\86GAVT\5W5I/=SK;V]YJ&G36]K([$!09&'R DXRX4#N17?_ +0O[:'P
MJ_9CU'3=-\<Z[+;ZK?QF>'3[&V>YG6(';YCJOW%)R 6(W;6P#M. #W2BOS.^
M _[1FH?&#_@J!K"^'/'FK:W\-+[1_M6GZ:NH3FP'^@0$D6[':CB0MD%0RMN!
MP<U]J_M1?'[2?V;?@[K/C'59?*F5&M=-5K=YDDOFC<P(ZJ00A9 "<C SR* /
M7**_/[]A_P#X*5:9\7-/?0/B7JBI\0KV^O+BTL]-TMTM4L8;438##/($4Y^9
MBQ.!GD"OHSP%^VA\,/B5\)/%GQ*T+4KV?PIX7+C4KB6QDCDCV1K(VV,C<V%<
M=* /=:*^>;[]N[X1Z?\  _3_ (M3:O?CP7?:F=(@NAITIE-P Y*F/&X#$;<]
M.!7/6?\ P4O_ &?;[X@6WA*/QH5NKB5;==0DM)$L%E8@!6G("@ G!<_(,'+=
MZ /J>BOFSX8?\%"O@C\8/B;#X$\-^)Y[C7+F1XK-[BQEAM[QU!8K'(P R0I(
MW8W8P,D@5/\ '3]OSX,_L\^+6\+^*O$<S^(8T22?3],M)+E[=6&5\QE&U6(P
M=I.[!!Q@C(!]&45XGH_[8GPI\0_!'6/BQI7B3^T?!VD<7\MO;R&XM6WJNR2
M@.K$NI (Y!!&0<UB_#O]N[X/_%;XA^&?!7A;7;G5?$&OVCWEO!'9R!(46-Y2
M)F( 1MB$[3D\C.,B@#Z&HHHH **** "BBB@ HHHH **** "BDHH 6BBDH 1O
MNM]*_%?]E/\ 9G3]IW]D/XT:/8P*_BW1_$2:IH,N '^T+ <P!CC"RK\AY W!
M&.=HK]J<U2L-'L-)5ULK*WLU<[F6WB5 Q]3@#)H _'7_ ()[^*/%GQO_ &B?
MC/>WLAM_&FJ_#NZTXW#$HWVM!:6RRMGHQ9 S=,,3C XKF/@?\<_AG\$?V._C
M3\(OB+X;NK7XGZA<7UO!I]UH^Z5IGMXXH-TC#]V8)E9\,05ZH"Q(K]KK/0M-
MT^ZDN;6PM;:YESOFAA57?)R<D $Y/-17GA71-0U"._NM'L+F_B_U=U-;(\J_
M1R,C\Z /QK^,W@CQ#X!_X)-?#*R\2VEQI]U=>-C?6]G=J5DBMY8;UH\J>0&&
M7 .#AP>]=M_P48\*Z+X8\(_LD_V1I5GIA%KY.ZUA6,E%6P8 D#) 9W//=F/4
MG/ZSZAI5GJT(AO;6"\B5MPCN(U=0<$ X(/."?SIEWH>G:@L NK"UN1!_JA-"
MK^7T^[D''0=/04 ?+O[1W[(/Q/\ C-\3)O$GA3]HCQ/\-M(DM8H%T+2EN3"K
M("&D!CNHURV<GY<^YKP7]O\ ^%WB'X/?\$\['PSXI\<ZA\1=8M_$\$LGB#5!
M()Y5<SLJG?+(V%!"C+'@=NE?I952_P!-M-6A\F]M8;R'.[RYXPZY'0X((S0!
M^-G[2UC;:MX;_8/LKR".YM+C0]/AF@E4,LB,]D&4@]002#GKFO5/VB-)L=%_
MX*[?!N/3K.WL8Y+33F=;:,1AB&N4!. .=JJ/HH':OTXE\/Z7/]E$FG6D@M0!
M &@4^4!C 3CY>@Z8Z"I)M&T^XOH[V6RMI;R/ 2X>)3(N,XPQ&1U/0]S0!^87
M@/0]-F_X+-^,K"33[5[$63D6K0J8L_V; <[<8SDD_CFLOXC^/-$^!/\ P6"D
M\3>+3-I.@3:?!%;S16SR!Q+IBV\>U$!)4R@ID# (.< &OU071=/CU!KY;*V%
M\W!NO*42GC'+8R> !UIE_P"'=+U2\M[J]TVTN[JV.8)YX%=XCZJ2"1^% 'XT
M>//VA+;XC>*/CUX6TBP\.?":YU%I])MO"^C>#CJ&K^*[O?+$L3R %8)"^"SJ
M%8&3(#,I:N?\*^,M+U3_ ()1^._#$5V\FM:-XPM+B[M6C<>1%/(GE'<1M.XQ
M2\ D@J<@9&?VU7PSHZZN=572K%=488-Z+9/.(]"^-V/QJ./PGHD,-U%'H^GI
M%=2":>-;:,+*XZ,XQ\Q]SDT ?CW^V]X7T?1?^"?_ .S!<:?I=G9W$MK%))-;
MP*CNTMFLDA) R2S_ #$]SR:[O]N[P[I7AG]HC]D>/2-.M=,11I\06TA6+Y4O
M+;8/E X&3CTR:_4^Y\/Z9>6L-M<:=:3V\/$4,D*LD?&/E!'''I3KK0].OI()
M;FPMKB6#'E/)"K-'@@C:2..0.E 'XY_&R;5/@/\ \%$/B#KOB_QG??#*RU^*
M2YTKQ7'X9AUQ98'$6U$CE!V@!&C+H"RE-I 5B:U/AC\);;QI^R+^T_KGPOU[
MQ3XIEUS[(T_V_P -1Z3#=M;W1N)S:I#-(K9B,F8U52H=5VC< /UWUCP_I?B"
MW$&JZ=::E #N$5Y LJY]<,"*LV=C;:?;QV]K!';6\8PD4*!%4>@ &!^% 'X=
M:Y\</AMXI_X)N:5\,](\/W-[\0]"N1?:C-%I9VZ>GVQMUX]P!MVNLT</)SF4
M+C %?JY^P_\ \FA?"/\ [%RT_P#0!7K,7A/1+=;I8M'T^(79#7"I:H/.(.07
MP/F.<=<]*T;:VBLX(X8(D@AC 58XU"JH'8 =!0!^5O\ P4-O=%^%7_!03X*>
M-O$-@+/PA#9VL]]=1V>])3%>SM.2H'[Q@LD988)(8<'(SS'[=WQ-\,:M\;_V
M:?C1H$,[_#%6AG@OH+)H586FJ%YU6,@$-@$A2 3G..M?K?J^@:9X@MQ;ZIIU
MIJ=N#N$5Y LJ9]<,",TV^\-Z3JFFII]YIEG=V"XVVL]NCQ#'3"$8&/I0!^4F
M@_&'0OCO_P %:OAQXQ\+QWI\.7EF\5C>7MJUO]L2.QNXVEC5P&V;U= 2 <H>
M!TJ_^P3X;TK7OVXOVFGU+3K74#"^L+&+J)9 H?46#X!!'(&#Z@D=":_4V/0=
M,ANH+A-.M4GMT\N*585#1K@@*IQP,$\#U-/M=%TZQN)KBVL;:WGFSYLL4*J[
MY.3N(&3SSS0!^/G_  3Y\)Z+JG['_P"U9?7NE65Y>)HMQ&D]Q KLBI8W,B!2
M02,. PQCD ]0,>:ZKX&\3^*O^"7WA75=&BN;W1]"\;7UQJMO;JS^7&\*JD[@
M#A48LI)Z>:.V37[E6N@:98V\\%KI]K;PS@B6.*%560'(PP YX)'/K4MII-E8
M6IM;:T@MK9LYAAC"H<]<@#'- 'XX?M+?%3P5^V#\1OV>/#'P)T>X?Q+I>([I
MX-.-F;-<VY2,D 96$12N6!*J"2"<G'J6M>%=&\9?\%J+FPUW2[36+!;&.?[+
M?0K-"9$T92C%&&"58 C(." 1R 1^FFD^%]&T&6:33-*L=.DF.96M;=(C(3SE
MBH&?QJQ_8UA_:!O_ +%;_;CQ]J\I?-QC'WL9Z<?2@!=)TFRT2QBLM.L[?3[.
M+/EV]K$L4:Y))PJ@ 9))..Y)J[244 +1110 444E "TA-+24 ?BY^PG^RM%^
MTMXP^-!F\?>*?!2Z3JL*E/#=V(!="62[SYH(.[;Y?'IN;UK['\=_ ?X;_L _
ML?\ Q&OO#W@N+X@B>.W?48?% 6Y&H,9DCC,X"!1%$9"X55&""<@G</L^QT>P
MTMI3965O9F4@R&WB5-Y'0G &>IZ^IJQ-#'<1O'+&LL;@JR. 00>,$=Q0!_/K
M^T+\27^+'P3^'US;Z_I>HKHXD6X\,^'/"C6%EX823"Q1/>-EIFD\LD L1E2<
MD\GZM_:;OO"_QN_;[_9?O$6'Q%X4US0]*E5;J!A%=1&]NB-\<@!*DCD,,$<$
M$'G]2+?P9X?M=+FTV#0]-ATZ8YEM([2-89/]Y ,'\15A?#NE)-:RC3;,26JB
M.W<0+F%1T"''R@9X H ^#/\ @KQ\.K#3_P!D_3KCP_X=L[.'3_$MK/=2:=9I
M$(86AN(]S;0,*7DB!SP2R]\5XO\ M"?'+X=_%S_@FU%I7@B0/JGAH>'+/7%^
MP-;;;@QNN"Q4"0AHI/F!(]^:_6>XM8KNW>&>))XG!5HY%#*P/4$'@BLVV\(Z
M%9Z<;"WT;3X+$MO-K':QK$6ZY* 8SGOB@#\HOBU\>K/X7_"C]D_1CX4\+V^H
MW7AC3;M/B#XDT<Z@VC1C$;>1&H!<QY,A4EARN%R0PYW]DOXD:3HG_!2H^(-6
M\42ZWI_BJWEM-+\0MH#:6FLRRB.*.2.UC4A$>6-U#$ $J68@DX_8+4/"VC:M
M8P6=[I-C>6D',5O<6R.D>.!M4@@<>@I\GAW2IKNTNGTRS>YLQMMIF@4O ,=$
M.,J/IB@#\F?^"=_Q"TGP?X\_:%^%VJ&Z@\;>*YKFWTK35M78RRVT5^TR,P!"
M%01]XC/09/%;/_!+'4/!GQ2^ /Q1^ 6MR2G7=<>]OI;1[5RL=HT%O;B;?C:'
M24J0"0P(! XR/U.C\/:5!JTFIQZ99QZE(-KWBP()F'H7 R1^->;_ !R^'OC3
M5/ NHQ_!W5M#\"^.;NXBD;6[O3DE#QJV75OD;); &65N,\9(( /R%^&>B^)/
MBSJ'PQ_9(UF&=#X9\=ZG/KT$;$1K:QA"Y5_5?]/P<<^8F.2*_33]IC]D_P"(
M/QJ\5:-J/@CXZ>(/A-I6GZ:M@VCZ*D_DRLLCL)2([F(9VLJXVDX0<] ,/]D7
M]BG7/@W\2_%GQ5^)OBNV\;?$[Q"#$]Y9PF."WC8J7*Y"Y9MB#A%"JH X)KZ\
MH _/#]J[X,^*O@;_ ,$W_B=H/C#XDZK\4=3GU.QO$UC6!()8HVO+-1 /,FE.
MT%&;[P&7/ Y)^-_VH/\ E'Y^RE]=;_\ 2D5^YM[8VVIV[6]W!%=0-C=%,@=3
M@Y&000>0/RJI-X9T>XMH;:72K*6VASY4+VR%(\]=H(P,]\4 ?EW^WMX?TOPW
M^VG^RY%I.G6NFQK)I402TA6(;4U) @PHQ@ D =LUO_$C1[";_@LWX%M9+*V>
MWFTLO+"8E*.QT^[)+#&"2><GG/-?I5=:+I]]<0SW-C;7$\)'E22Q*S)@Y&TD
M9'/I3FT>PDU!+]K*W-\HPMR8E\T#!& V,]"1^- 'Y9?MD^+-'^!__!3SX6^-
M/$B2:3X2L-(M9&N8+9G18U^TQD(B D[2P!"@D CCI7/?%K]IS2]5_:6^+NAV
MD/AOX.Q?9;C3Y-2A\''5M9\42;MJ0LI&Q6F+[@S*#C;EFP"/UJU3P_I>N&%M
M1TVTU P-OA^U0+)Y;>J[@<'W%,F\,Z/<:JFIRZ58R:E& $O'MD,R@= 'QD?G
M0!^*7P%\3V-A_P $Y/VE/ UW+-;>)K+4;34)],FAD5H8C<6<)8DKM#;XV4J3
MN^7IQ6Q\9/#NE6/_  2+^#>H6^G6D%]<>*'>6ZCA42R,6U $LX&3D(@Y/15'
M0#'[*+X7T;?>O_95B'OB#=-]F3,Y!R"YQ\V#ZYJ23P_I<UC%92:;:/91G<EN
MT"F-3SR%Q@'D]/4T ?CO^W)X?TO1?V4_V/+BPT^ULIY=&A>2:WB5'<M:V<C$
ML "269F)/4DGKFM[]M>/5?A+_P %%HO'.O\ B&^\!>'-8T^#^R_%D>@Q:REO
MLM%AD"P2@J2'#;MH+J) P'S#/ZU77A_3+R"WAN-.M)X;<8ACD@5EC& ,*".!
M@#IZ"I-4T>PUNU-MJ-E;W]LW)ANHEE0_@P(H _)G]GOX;Z;\5M'_ &FO$?PW
M\7^)_&VO:QX5OM+FNKGPG#HUC?W$I60>089F'F.(F7RS&A_>DD#//DG@'XT_
M#MO^"=_C/X1'P_<WOQ0>]FU#R8M+9BD<4L<SW;S 8010QNIR00%QC!)K]P].
MTNST>T2UL+2"RM8QA8+>,1HOT   _"JL?A?1H[F[N4TFQ2XO%VW,JVR!IQZ.
M<?,/KF@#YG_X);_\F/\ P\_WM0_]+KBOF3_@K59VWA'XZ? ?QE?:;LT"WO&>
M_O(;<,',5Q;R,K8'S-L!P#U ('0U^H%C8VVFVZV]I!%;0+G;%"@11DY. .!S
M_.HM4T>PURT:UU&RM]0M6Y:"ZB61#CU# B@#\CO^"E'Q.\)_%SP5\$?B5\/;
M>6\\"6&KZE:37D%@]LB3AK9]A5E7:S"-RN0"P4D=#3_C%^T#X7_:2_X*&?L\
M>*/!:ZC-X=M[S3]/34+ZS:V6XF6]:201AADA!*BDX'S9 R "?UID\.Z3/I(T
MN33+.33<!?L;6Z&''ILQM_2DC\-Z3#]D\O2[-/L@ M]MN@\D Y&S ^7GTQ0!
M^9/[/^A:=KG_  5]^+@U&RM[X6MK?3P"XB#B.3_1DW@$$ [7<9]&-8O_  3Q
M\#>'=5\=?M;"\T/3KM;-9K*V6:V1A#!)+?!XT!'"L(XP0.#M'I7ZJPZ+I]O?
MR7L5C;1WLF0]PD2B1LXSE@,GH._846FB:?8O.UM8VUNUQS,T,*J9.OWB!SU/
M7U- 'X7?#CP#XI\>_P#!,WQY_P (S%<7B:-X_BU34[2V!9Y+-+!5<[1DL$>2
M.0CH A8_=K<_:"^+?@3]H[]G_P#9[^%?PMT*XU+XDZ7';6=U:VVG&-XI!;+%
M)&)" '#R@2%@2 $+,0:_;;3](L=)A>*RL[>SB8[FCMXE12<8R0 .<8JMI_A7
M1=)O);RPTBPLKN;_ %EQ;VR1R/\ 5@ 3^- 'Y<_M">#;37O^"I7P3\/>*+6W
MUR'^Q=,CO8+I!)%<21BY8EE888%T!P00>A'-?J;I&BZ?X?L5L]+L+;3;-69E
MM[2%8HP2220J@ $DDGCG-+)HVGSWT=[)96\E[&,)<-$ID7&>C8R.I_.K] !1
M124 +1110 4444 %%)FB@!:*2B@!:_,G]GG_ )3 _&?_ +!EW_[9U^FU48M&
MT^&_DO8[*WCO)!A[A8E$C XZL!D]!^5 'Y$_\$X?"NBZU\(?VK[S4-+M+ZYC
MTIH$EN85D9(S!>L5!(. 652<8R54GH,<]\+[2";_ ((Z_%J:6".6:#Q='Y,C
MJ"T>9M+!VDCC(X..HK]E+/0=-T^.>.UT^UMHY^)5AA51)U&& '/!/7U--3P]
MI4=A)8KIMFME(VY[98%$;'CDKC!/ _(4 ?F_X9\-Q77_  1AO+BQTV*349-#
MN7EFA@'FM''JC.Q9@,D*J$G/ "Y[5Y5X<_:N\%Z#_P $S="\-0>#-.^(NN^'
MK]=-U.P\0:=))8Z7+=2W\L%R6P-S%$95,;*07P6&<']?;?3[6SLQ:V]O%!;*
M"!#&@5 #U& ,8YJE;^$=#M-/N+"#1M/AL;@DS6T=K&L4A/4LH&#^(H _#OQM
M\9M.UCX^? 'X@:OXWM/$FCZ+>Z;+JE_I/A(Z18:,$GBF>RC*KON#$F23C(&
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MCW\1F_YFV^'_  &/_P"(K@EPRY!IV_;5GT?LX;V.\'Q]^(J\?\)9>GZK'_\
M$5'<?'[XC;<IXMOA_P !C_\ B*X1VW=J0'C%!/LX=CN8?V@/B0V<^+;X_P#
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M7#"/('K2;<4![.'8[O\ X7]\1?\ H;+W_OF/_P")I?\ AH#XA]_%E[^*Q_\
MQ-<%MW4UJ ]G#L=__P - ?$0_P#,UWO_ 'S'_P#$T\?'SXB?]#9>_P#?,?\
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M&D/_ "-M]_WS'_\ $5P%Q%A013+4?O* ]G#L>AM^T)\15;'_  EE[_WQ'_\
M$U,GQ_\ B)(O_(V7W_?,?_Q%>;3K\QI\+D#% >SAV/1V^/GQ%[>++[_OF/\
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MC4$_]]*U3U)A&/-JCLM)_:.^+.K22BV\5:M=>3$T\HA@1RD:C+.V$.% ZDX
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M7O1KDEC$MU/,L2PB-6Y$;J20> 2>YSG P"]Q_9*Y_:&^(P8_\59>_P#?,?\
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M D0DX8#MTP1S@@CM6;Y>VO9ISC5@IP=TS!THQ=FCN5^/WQ%[>*[[CD_+'_\
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M,]+\%_$&WT3P]J^E:C;RW4$UM<FPDCP6MKB6!X6SDCY&5P6 YRBD \UFVOQ
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M<'!!P>"02<=SG^'/$-[;O+93O'!!(%F($N>0"0O!&>O.,\"NO+\).3YI>O\
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MK%1+&">N*L&,1]* '2*K+6?)'M;(]:M-)Z4W:&^M!6I''QUI^T[@>HJ)FVR
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MJRL"000>00000>1BJ^[:W7G->HQ>5\7[-89S';^.84Q',Y"IJR@<*Q/ G &
M3@.!@] :X2T\+WNH2W:(AB>U8QS+(K95@0"I !.02,@\CGTJDG+1*YC/$0HJ
M]5V*<;;DXJI=,8W_ ,*]&L?@_=R6]R4U2VGN820+>%&)?!*D@MM)P0W0'@9Z
M$5S/BOP-J.A?O)#%=VF2/M5JQ= 0<$-P"ISV8#VS3<916J(IXRA5ERQEJ<_"
MIF JVMKA.*6W@6*,'OBGM<KR!R:SW.WH9,S;9"",U>@C#)G&!BFR6NY]^>.M
M3QRI&F">U C*U28PX'Y5N^'-%:>""YU%Y+*PE8;9BH^89&2,D8 !SG!^A'1-
M&T<:QJ#W<D+2V5B!+,J@$'GY003]TD<GG@'J2 ?0?#MUIUU=32ZK&+N_P8(+
M6>%6$8ZDKG('H !@9) S@5I"#J2Y8G!B*[B^2&YZ#\+H;;3/#<Z:_&'\'3KY
M]NL8:XECD+##+LR55@.<<$X.!S5B3X?:?=7$D>D:CJ&C RC_ $?,822-EQG:
M"#E@1TR !DXY(\]AT?7?&49\I+@);JQ6!0Q4@LQ8@@ '&W!YSP![BC##J]OJ
M%S;3O-#(\;1EF W,>.%QR,@8/?G!/7/IK 7V>IYKB]6V>@^)OA=HEG;W?_"0
M(1$"0VLA9 8W<@*Q/)*@D$ECCGIP2?"=<\-2:#.7AG74-,=MMO?QJ0DHP".O
M0X()!Y&:]GE^(\]GX=BT+5M*-S;N5P&!1MO)*L  7&2Y'.0<YJ7_ (5W9:EX
M7D6QN8/[)N&>XM;2>3)@N"/EW,,$*0"#@$?,"20!7GU*,J>K1K1K2IVOJF>!
M[0PYZU4DMLMGWK8U;3O[-U"6 $D*01N&#@@$9'K@C(['-5 -W;O66I[:::NB
MH;7(J)83&W3C-6;C<O'(H7[O/3WJ1D4WW0#6+<*?,.16Q)@L.>*3[&)!D_A5
MBW&:8"L8S4&J7!63 JXH$/&>E4+Z/SFX/(H%TL+I\YDZ]C6S8R%9!^%9-A;%
M3N(].*VK6,#!/%3<E['6Z7<;E&?TK85MJY%<WIK?,,<C-=-"G[O<?RH9A(\E
M_:ITM+O1?!>K@?O%-S8RMCL"KH"?H7KQ32U' 'M7TC\?+(:E\%[R7;\^EZE;
MW0;_ &9,Q$?FPKYETVX^<?A3U-J?PV.RL;<MC _6NAM1Y*@DXK#TVX"P@CTJ
M[+?9  Y]Z2-'W.CL[D,,9[U.\22-GUK$TURTG!^M;*9_PH9);A0*O-4-13=T
M^M:"9*>E5Y4W-ZU0&?;H8\G%6TF)[T^2,)&234=KB1\#F@"Q&I(R3UJQ:PB2
M4[WV0QJ9)']%'7'J22  !DD@=Z:T!4#]*L0)$FG7\LLI@>- R-D <'/.3C (
M4]">!QZSH15DX0<D=GX5U9_"NEW+^5NNI_\ EC%("88_<YP7(Y)SP#@8P<Y7
MVB7Q!J<L\,GD68 (9@_#$<J!DC.1G..H!S7F.J^,'AT+[- )L7;+^\!/"@X)
MQP"3AA@\XSTYKMOA[XLT2%EM]0O8;2T=<^=Y; XR,@! 3DY)P<#L".<[TZ=_
M>EL>#N^:1H6]C>Z1JDI$DEZ\B %?/&\9.1C)!/?IP>G:NQ\.^,=4DU*.#38D
MM'W A9FW,6& <XP1R1W/88-<OHZW'B#4KO58FB2"-B+<!2#(%  )!)QG@GH
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M?5?Y'QF83P^<QISC+DE'2S_S/$_A=!8:'\0S>6EA8R-<(8)(Y8%FCR2,C!!
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M'I%I'>O-YA:W! W[D(())Z@ $#K@8KMH2Y9>IX-5-5FF<3/<1VLR)97*13S
MA]O$)()/*C R2S'J.I->=Z]=7,=T]E=Q(UT9 \,T *+M&01M(R3G R#C@@9[
M>@?8-.U2UN+.YMKB.Z=5D2XM(]WS#!W-\I"C@$D9SN(. *R]:T.SM;-YSJ2F
M]A7S%$A 9F' R"0<9[@XZCWKVZ:A1DDU=LBI34='N><SS7-QJ-EE8WFC5HVW
MC[K@;@!C'H>><\^E0>*];E\+^'=+2X:1'FB6200(5*1@J00<XR"2I'J#T(K8
M@_TB2_=X )\DB>,DH,?*,'@<9(P"23CJ#7$>+Y$\1>+H]&D<W"Q1K 44EL G
M)7 X! P3W))] !GF7*X(SE%17*D)XOG@U#5A<V^"DMO&[,J[0Q*@[L=L@C/O
MGD]:Q(8PS5U7CBUM+?Q!/;6@\N.*-$:,$81MH+*,=,$D8[8Q7+QKMFX.>U?.
ML]VC_#B+/:AN< U3GM2O %:4K[%_2JRMN.>W>A&YAW4+HV>U6K<$P]*NR0B4
M_C2+'M7%5<G8S)E^8U44_O.1S6G=6YYQW-4U@*OS3U)L7(<*O R:?YQ5Q487
MRTIT.)).G/K1J)[6.JT)?,4'%=0JGRZY?2)EB51W[5TEO)YB^E28R13\3Z6N
MO?#[QCI;C)FTN:=!_P!-(L2I^JU\:::^YE_"ON[08XVU:".<9AN-T#@C@AP5
M/\Z^&Y--;1]:O=/DX>TN'MV^J,5/ZB@*>[.KT]CY(J;<5?!]:JZ?*JQ@>W>K
M18&7/>GL;R.@T5:Z)<!1GKZUAZ FY5.,DUT#0GY<?6A@MAZXVFJTHVGBK'ED
M*1WILD1923TQ1T I7+M)&0*BLLK,#SBII%VG%;EY=P:A# D5N(]F#_JHUV@(
MJE054%@2I;+DG+$9X),N3322T9<8IIMO5?B0Q_,H!K#^($(?PM<Q@_/(T:YY
MS@,#GCZ5UMU816^GQ2I)O=D1BPE0C<2X9-@.X%0BDL>#O '3EGA^&RO-8LEU
M(%K5)5D("[@2.@88.5.<$ $XS@9Q2C-25T9XFG*,&NMCR/29K"\T^ /9M'>Q
MCRYF63(8ALDD'/4<8]@>Y%>L>!?A_8^)K.*XEB-LD>XK&K!2Y'7C!)'0Y)XY
MZD&L[1_AO+/XBO=/.F>5?K')*&D)$4JB1@3$A09 !Q@@'*D$#G'4>%)9?"NM
M;9](COV)$06<%MI'+@$#&""2.N 1U/%>UAZD723M>QX2O&7+)?>=#HWA6WT_
M2W'VW;=A@! K+B(,"T1=0<@%1D<<@$FO3= \!_;(=,NH=8DT^2&Y^T7$-JJ$
M7L2 HT$A8$A&;#97DX''0CG?#=G=^)+V&6*-Y/*5$D .((2 ,L>BY.S<44
MD8X -?0NBW6EZ7I*VME?6=U%%%MVP@,S[0 3N!PQ&5!('!(!/(I8F?-3Y9Z7
M/0]HJ$KTO\^GI^AP'A[24U*YD%NDB[;F2VN!+$Z;3%(4? < N-P.& *GJ"1S
M7GO[1FGR6[:9]B=[C2HV9?.QD!BJ[ 2/8. #Z&O>;=KEM:@GEBBE<,"'WX:-
M20H!&<$$=.O)->;_ +2LEAX?\&66B6B^5-?7?VDPK]U40,"1W&6=<#&.#Z5Y
M;>USEI2YJR<4?+\T-Q=2Q00(7ED8(JCJ6)  _$G%:>G^')KR1DTN[MO$#QRB
M"5-)9K@QR%2P4X')PK<KD94C.0178?#SX;WOB80:G++]CT^-RT<B']](RG("
M#&!EAC<>!@\$C!]2\)ZII'P9L=5U.\73/".C*YN[R1 P3<SA%R"3M!9@ J@
MDG %8RC5NI)I1ZGJ+%X=<U%1E*J[<J6U[]?TL>'W6BWFF+!'>VNI:<T:WLDL
M+Z<##,!"@032.-T1#-E /OD,." :X(2237!'/7O7TKXVU:#Q)<074=U#=64R
MI+'.Q9%DB=68-M,;;F#;1M;;PS9((P?/O[!\-7FL"RU MHE]/(1;W2 ""3
MVE3P#N'8@_-R,X%;4\-)<TXN]SCK9LH\E+$PY;773N]^J^=SR^729&D!QD5M
M6<914CR 6(&YC@<^M;FHZ2-/NI[8.LIC8J)%((/OW_+L<BL"XTO49HO,@MI)
M$:01*_"JSG&$!) +'/"C)/8&LY-13YG8].E^\LX:WUT.DT2U2SUJTE"741CU
M.2Q*WMMY!?8RJ94!8YB;=PQQD \4>)9S_9NE1*I$212%E/7SC(WFY[[LA<CV
M%<SH#27R[W)8*  6)/ Z8K=\5/J6HV-I)IDELDEQ.1=1W*?+YP !D4CE3(-I
M8#@LI)ZC'BXA/#U*>(G[UM'\SM=2$E*,8V3^9BPQCS=_W2.A%=WX/US4VN9?
MWDFHRP0"6"WN)"PQ&ZNRJ23MRH)X]!P< 5P]Y;R:>D<UQ+;F%G$1FMY=RAB<
M#((#*"> 2,$\9S6WI-_)HUU%<P,5EC)XSC@@@@GW!(/UKU*%:G4ES+='E8O#
MNK0E3ON6/%CZGXD\53)+:7^EVQD>79J$2IM4J%!W9QQD*<G X/&2!4TF.-;V
MSN&>6TB$9;!W8>0 C((R02 .<<''&!FNPOHSI_CBPU2&W%N=6E2_U"*0R-N<
M*L8P&<C85"'Y  -PXX%:'B&/3_[)C&EW\FL?8+J33+IH99+HK- 5#++(V69A
MD98YY/' P/K,)B'94Y))OS/@HX.#A4E0;ERM)W7??J^NB."NH[O6O$-I%?7,
MEY<QRCRIGD5UQP20<$<XY)&2>3R>%\3>'Y=-FN]5$6QMI2=0RJ&( !(R1P,#
M/.?0=AVFCZ?HRWC27\=PDLTL:[5B,0B !('(.2<,1CDD C !(CU#3X=46]M[
MC[&+:1)(6DO5V,J$X# 8Z D$%<'J#D$FO7ER1]Q+5"EAZ7LY0^TCSK5/B$_C
MAH-,Q);V)B029FP&?>H))  ( !P !@Y.>U=?H-F_@WQ%I]I9)B.10SS&(/@$
MM@AB"0"">,@D8SDCA^B^ ](\%R?:(9X=1>-,KNMR58CYLIN'.,$$XX'(R:Z:
M&,V$,'B779+BW@8A%$AD+2LH!"A<C(QG )"XR2>Q\C$5(I'E^QJ59QB]9GD7
MCO7&\2>*M2U$Q>1YT@ 0G) 50@S[X49]ZP;?&[VZUKZ](=4U:]O1$L"W$TDP
MB4\)N8G ]AG'X5GPV_;OFOG/,_5*<>6*CV1-(WR8'''-9KN?,(Y-:$WR\>U0
M1Q[F!QCFC4MJY=M8,1@X[5-Y9]:C$PVX4<^M,\X^M&HRI<1;@3GMR*P67RY.
M1_%@>U=<UK^[.>:PKFT'G''(S2N)FOI[#R,"HVFVS8)[]*+'*1$5');NTV<<
M9)HN,N9&,U'(^Y3G&>U-5&VX/;I39(R>,G\Z>H#;.-/,R?7-:BX'053L[!MP
M..]:K6XCCYZXS4C1";=9OFJS GEKM ]JAMY,-CM5Q9X^PR:6I13N[(LP(]:L
MPKMCV?G4GF%F&1P*T?L DCDVOF6)8FDC,3@*) Q0ARH5LA#D*21CD Y SE-1
MLI&D:<I7<5MN5Y+"2WM_-.P@A25612P#9*D@'(SM8C(&<&HX=,2^MQ(02<R!
MW%PJ>5B/=&=A!:3<WR_*1MZG@\:<D\\]K%:RW$DD$)/EQ,Q*H3UP.@S[4@C%
MNF-GZ5#4FK7LS2,HQE?ENO/T\K>J,FWMC;KC'-/N]/::'=CMQQ6JJC:24^;W
M%1[WD81A"6)P% R<UI?0R*%C;^7#C&?PJ=>.,?-706?AK4W (TRY(;H1$<<>
MM4;VP>WF*/&T;@\JPP?RJ.=-V3N'*X]#->W)YH\EOI6_I_AV_P!40-!;.8O^
M>C#:OX$\'\,U)J'A>_L[=W:V9E4<LG/_ -?\J3K03Y;ZE\DK7MH<WMC;A^>V
M*H3>&X+J\#I&SMU*J"3@=>!6[:65_);S?V39:=?:IYL:K%JMP8HEB.[S''S*
M&<$)A2PR"V#P*Z6X\':@M]</9V+FT,J2)_I#0GY)!(F&#*Q7<HX/4=1D\93Q
M"BVC>.'3C&<GH^VK7R./D@40@*, #%0I8B8$/^ KH+W3)[-F%U$T4I))W# R
M>>.V*S8H7N9]D8)). JC)_*MXR4E>^AR<K6A#?6J*MW%Y%G"D$L:6$MK*SR7
M,)0M(TP( 5@Y  ';(Y !-%K5PN?YUL76C75G^\EMID3KN:,@?RJDTAF&%Z9[
M4J:48V3N:U7[27-R\ICO:R&3G^56+CY8P!Z5MS()%GS.+C?<R31*MHD'V>%@
MH6#*DF3;@G>V"2Q) K/:W#MWSZ4XSYE=D5(*#LG=&'#EIL'UJU<6[=0.U)<6
M[1W7RC S6BN$C&>3BK,49FS;'DC&*@23S&(QQ5RZRW"C [@5';VH7GJ>N*K0
MHJ74("@XY^E0KB-,GZ"M.6'S,_3%9%]F/A>U,EDMK"LTG'\ZTEM_*<$&L337
M?SNO4UTJQ^8@SUHN3T-336&T#/..E=%:@L%].]<UIZF-@6^E=-9L74 4&$CG
MOC/IL>J_!?Q/$1NELFM[Z+V*R!7/_?+FOD.%?W7KS7V[>V(UC2];T=QD:CIM
MQ;*#_>,9*G\"!7Q/9J&A&>F*K4=/J;F@R8N$[<"O1[.3-NI%>;Z1'MD&/7@U
MWNGLS0 =L4:FR-FSF#'!.3[FK^X+]<5D6<+JV?>M)5) R?K2Z#&W&&0=*L6*
M($]35?[.96P.?K6E8V)7K2]0\R1<=#PM.%H-V?Z5?M9H+-?WC.C":.0E(8I?
M,122\1$@(4," 6 R,<=2*K6\PQEAQGI[5FI-MJVB-W%**DGN2JOF*$ ]L5VN
MBZ=8:3X/O)'5;O[1$MPWF21LIF5ROD"(C<248L22,;1@ $-7.:+K*Z7<22(9
M(G>)HTN("!)"3CYD)[\$'!!() ()!%M-0&J>)%ECB9O/*1#SW+.Y*A"S,!RS
M$;B><DG.<G*4IJJNB1AB:,:V%G!>]*5TEK\G]Y7\!>!#JVE>9%;.;_[2%6%@
M 8_F("@@_P!T Y)(.1TY%=G86D%Y</<W4<-RB6JE+@D?.,$;D89!RI ) SP1
MW.<#P_XKU713ID=H%N]/O5:2&[%O)!,H)8',;@$$,K,,KDCD$UV;3?VO<6X^
MWK).Q$1N)&W"17(&6)R#MZ$9'3H"#CZFC6]I'?W6?!48\B>%KQ:J1=O2W1HJ
M36J:5-=RI')9["@@+72S&XC$0+%XP!Y95B5 ;.<9[Y+)]<EU"[TV5[NZM1%/
M'++]GCB<W,05E-NX<$A"S*Q*D,"B@$ G#=7MW.EVLWV2:TRK!!=PBWD!5BI+
M(7;@@$C!!/.<XKDO$.HWEK9RC3);9[Q(S(HCQMC."5W$8&0!P.F22<9XE>SJ
MTN9RO?J=.,F\-7YFE&4=';;1>=[M]3T/Q=Y%S>:?*\$;&&R=)<84&+S5W* !
M@$ N>@QDX]O+A&%7 !*] 6ZX[9KI?!?A74V\&O=ZG%?7FL7MM)(DRQEK>)5=
M/E9BWWVPP  YW9Z'A/\ A&=1C@=Y--N$1>KM&<?G7SV(K0YN1/8]K)L+5IT7
M7J+X]5Z'/V\$EU*D42;Y'8*JJ.22< ?B:3R;*YAFETS6+#5X[>407#6$I<0R
M$$A22!G(#<J2,J1U!%788I8;J,Q;EE5@5* Y# \8[Y!%;UOX5OFT]H+;2+?2
M[1I?M#PPIY8>0C&XJ2<<9P  O)P.:X:E1Q<;-6/J:<:<J<^9/FZ6V\[F/X7\
M17_@W6H-4L)3'/&<,I^ZZG&5;U!Q^'!'(!KVFR\96WQ"6.]2Z6TGBB,ESI\#
M<J1@%\$C=ZY X!YQW\7UK1+O3P//MWC4]& R/S[?C5_P]I^I-?6C:=;6*6$=
MF\LE['.W]H"\RP550,"% V'<%8$%LX/(T>(5-*:U1Q2P7UEO7EDEU_(]JLM6
M2:1+G3H&2=<A_+C)5SW(' P02"!@C.1[87C>\,U^7OY((IF7"QHQ4;<#DKDY
MQTR>N1P:I>#+JXT75EU/6=#FEGAM'@$MC<E28P3+C[.&V%RR@9 !(('2L37/
MB-I_BK0EU'^Q+C3_ #KN>'R9)T<L(F W!U'W<DC'JIY(P3V4LR7,HMILY98'
M$QI^UC&\59-Z;OYZE6;4)?LHL],LUN[J:&0Q27+E8O,VL44[0>-P0$@< D]1
MQS&M>$Y_"FDZ)).4L]9EA+W=K;RF5$E90&"N<L0N, DGELY. 1?M-9U.X+G2
M(GM/E*;[8$R8.,@L/IU !P2*PK^.ZMYGDO4F,K'EYP23]2?QK.I6=6IS.7R'
M2HR]GRU(K>_GZ>AC36LBYYR3SD]:@MK<K)ENE:X5YH[@).;262&2.*Z$*S>0
M[*0LGEL0K;20<$@'%2WL:2'>OSC:JE_+";R  6VKPI)!.!P,X'2LN=\W+;0[
M_9KDYKZ]C!O2=IP*CLTWCU-:<MF'C/&3UKEI]<%GJR:= Z&[8!CYAPB*2!DG
M(Y.>!D9X]1G>$7-\L4<&(Q%/"P=2J[(U986C?GC)P,G'-:^C>&I]=D=(+BSM
MR%)!NIPF2.P R<GUQCW%>-^,?$%[J#3R6UI+<2VS$K(H/RX'( .<=.@Z_7KM
M^!_ M_\ $#2X-0N?$=II:/G$;*SS*P/H..>G4< 5WQPNEY,^2J9_4DVJ,-/,
M[F[TJ\L9#'=VSP,.[#(/T(R"/<$UESQ[9.!Q7?\ @G1;/PKI\EIJ.OZO)J!R
M(KE)0MNRXX"J<@GCD$\]L=!GKH[WRSV=[;01W,;!5OH %8C/5H@0"3G&<=<8
M)&*SEAFKN+.NAGL&U&O&USCG9%4+^-7;"V#KFJGB33+C0]4FLIBI>,@AD.0P
M(!!'U!''4=.M6-%9VQDUQO31GTT9*:4HNZ9KV:>7(!72V+!@".?6L&.'<P(K
M;TUO+VBC<SD;MDWD312G_EFP8?@0?Z5\E_'311X=^-GBFVC/[J6[^V(>V)E6
M4_D7(_"OK%5+1$X[5\]_M2:>(_'>AZHH^74=*C#-_P!-(F9&_0)3ZDQTDCS[
M3&W+SQZ5L;2LBX].M9.DJ#MY[5T'EJV.S=N*+G0S>\-R=.QSTKH+A]O.<5SN
MBIY;"MR:,S*.YHN"VL:&F26[W5N;GS#;;QYHBQOVY&<9XSC.,\9J;59K8W2B
MV$(&P"3[.'$1;G)3S"6QC'WCG.>@P*S88750/SK6N+Z.318+/[((W5N;C@A@
M&8Y VYW?/@G<00J@ $9.<K\RD;0]Z+BS'DPTV3ZGBM*';Y8"C\:FUC08;&Z1
M+>99UW,N5F24,H.%D!4D*&'(4DE>A.:V/#_A*]UB.1X(6,,) DEP=H). /<G
ML/0$] 2'&2DKHBI'V+M-F2JB3@U8L2^GW4=Q"=LL;!U;&<$$$'\Q73-X#CC)
M+ZS:Q$.$,;*2^?IGW'?N/6M7_A$]%@6XD%S+=1Z?.+34##,FZ&8J&VLNWY"0
MP./FP,C.> G;9]3!5XV<HZI;^14\&ZQI.GZAIJ'3[31A!<O(M[;H6$?F-F1B
MK!CDDD@@C&!@8&*[&6WEUJWTJ[O-+MQ<S2/(PBO%N8<H2%<N!AG(!.%YSM)P
M" ."U'0A*9)=-</$" (7;<X&#SD  C@GD#\:71=2UCP[B2UGN=/=C@8R V0"
M3@C!Z#]/2G!.E).F[6%4E#$QE)6<I:W=[_TSW/2[>-+6S2XL98U\\(D>UFB,
MSM\N0B_>.0N2   <D#D;+:%'ITL^IQZ/I\>J16TUO:W#?((1( YC+!"PC9E0
MD@'&,XSU\+T_X@^)=,N))H]8N 7(+!B&!P01P1@= , =!5JZUS6/'#75QJMQ
MJ&J);@/%I]GMY)8+E$.% &>3@G')XRP=;$.47*;%2PM24U%/5_U8]'\;?%ZZ
M\):3HEM8+IDWB0Q))J7V?=<6\#[<E$8D$_,3@D9P!G!Q7&^"8[KXP_$Y[CQ%
M<W-[;3".YN;6:8?9;>.!&&V%  4#LZE\L<D \8&./OM,DL]2NH44W=O#*T:W
M,:'9(%) 8'D8(&1R>M=Q\*M6C\,3:U?O')/='33/';10NS-"LRK(00-N<@#:
M&W$ D BL4XR<;L<Z;HTISIQUL_N_R/9OB!H<<-C;7I2.62W7;%';G8$&#P!T
M(//7D=J\C\;:7<^-/!>L:4-5MM':^BCBBOKNW2X\O$T<APC@J<A2 V"5+!@"
M5%;>FZY=:E<7NGSW4C1-<SHOGR+^_1 F)4VY 1E. #R=A.220*^N:);V]NLL
M4<]RXS(;)F^?.202F02, ]L#(Y&17M4HTZM)QELSYM5)X&LIQ^*-GT?F<U\1
MH='T/2Y;VZUBVM+"QM(//N98]J*JA(EPBC +.0 H'<]!S7(^*M.NM8T_4)M2
MUO3KS0+BRMIM$LK>S>*ZAG 0M,[,H.[*R?Q<AMI']VQK%[JY6>Z>R'V9\0/9
MR0AX]H8$!T((Z@,/0C(Z"L.XCN;S4M/\_4;&RN+RY2RT^TG;RC<F,+E84 P
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MDT"6T\ VMS:7LJLS,DDJ6L*GS%# LK&4-\KC*DC!P>&&35+49K^&%Y].,=^
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M'O.BI0C4@]);'F<=K&K9QD_2M&''EXSBO8X=/\+:EO@3PU&2HY9 RD9P>6!
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M&TG25(6<9:)SP.0 <GD$X).TYV]1^&-]>7,TUII[:W$68QS:>A=0 1D948)
M(.>>&!."<#S#7M0O=- MA+)]F+;0A )!X ST)( P,YQR!CFLZ6#=-.LVXMK1
M'JUL9*NU"G:23]Y^G3^M3TO3=%TO1?+34-;EDTX!?-M7GB+;FVM)&) !E?E
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M:V>GK$FV2>5BV2&X(R><XP3@8P1Z&KOC?PO::=);3MJ ;4YB%.\_(<C;N.>
M "<'CKTX KS\5-R]R.C#VT*<O>A?_ACYW_:>A\3Z!\,O#VJ:+!!>Z':ZG_Q-
MY&0O/:%EVPD 9 B)+@G&0VS! )SYWH?C/2/$%@+:]G/]KL56W:UCP)"<  ^I
M)(P<=Z^N_P"R9/#O@'Q5)JL<*:>MONNF\X.EQ;_,#M /#%2P X)+#'7CX)N+
M.+5O%H>VMKBT1F!#RQ<-A0"25 4$D9P,=>23DGXS-L!2JI5YS:L];'Z)PAC:
MLZ4\'&'G&7GV9['\.?%0T.;68M3L=-OK34-/:VE=X(S<>2Y4964 DX;82AR
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M'&#(A!.,NPR001U!!!P1@G'T+8_MBCQQX5BT/6(6T;QZTB06UW:V!N8+UB0
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M68$YVA%+,2P('&0> ?S-UC7)=!UX1:%:-J,L<2+<6P87:1S'DH710K@$ Y&
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ME3CD,HV,".1C&"#7T%+&RHPFVDW+J?&_V?*M4@\,W%4]++9^I]%>&_B9\/\
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M@K3W ;<TIRP7@9. &) &< #J<FYI?CC2_A_HL6E'1X[73A+=&X?5&*3/CFW
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M>>A\?B.'8>W3K3E*$=&XN[2/MB/5(-#OIXY=?CM]I/FP1W,9?(XRVTDY(P,
M$]>@-<MXN^)/BK4-4N=,T+0]4^UQ* =1DW,0K -E 1M7(QDDEN3C%9G@)M'U
M)K;Q#>&(S2L+E0[L'F)4%C*C !2'X"J ,9 R "='^VI[2UN+/1ENGT^*26YD
M'G2W)4NQ=B78L0,DX&0 !QWJ)YC5J6:5C"EDN'P[;E)R?3J><ZQX<\6>9)+=
M:9-+(XW-(K LS9Y+ ,<DY//O4,/A&[U?P[?V]W/_ &8B21F-KB(L0V<D 9&2
M5!'7'<UU&J^,)5@+AVD0 @;.,_CFL^#QH-2A%M=Q V[8(#'++VR#U!YZ_ATJ
M9RK2M.JMSM;BK6#P[X)T+3F#R2W=TXY)GN"$SQR%7:!TXZ]3UKI]+\&^'_M7
MVQ#<@1MO8-.64G.<8()/IP:XK5-9_LR\CMYRSVC F.5#@$>_N.X_QK0M-8@O
MHPD<[IWP2<?_ %JZHT:E:*DYF<JL4=L=&TZ]UB]U;42MS]IF!AM=IV1*  H;
M^\< #TX[D\;C:M:>'['4M22TMPFG64UTOEP ?<C) &!Z@"N-TR^*R"-OFBD4
M*RD\X_SC\:R/&6M7>@?#_P 7N[2?(D=BK,">9) #R>A*@G'O2BM^9['-SIM)
M=3YVT:WOFM[01V\DAD42O(Y"AF//4D#CI77VUGK6H7<<=S;L;+ "M'(KJ"0,
MYP3C)'4]:YR+Q!'<P^0=J21G(9FP?7!.??\ #->@?#>\'VAKER4AC4;U')?.
M< 9'?DD]@*E2J4'[3ET9[-HVL:$$>J27$>GZ=833I#\I:-3M![DGH,G/4_TK
M5T_P[XJN+R<W=CY$.[:I6>-L@'@@ GJ /3OD5T-QX\MX;>2RL42*3)++C:.Q
MSP.ISR?YUU6@>%=4U#1?[4NG@MX5C\XP%COP02A*@Y 8 D9P"!D$T89UX/GI
MI*_4Y<17A0BZD[V1@V-I=:-(VGVL-O-JEQ'E)+UV6)YBX"QEE().T2$*""2.
MO%8_B'Q0^C:[97'V/4#:W%O*\0AA(N("6>,,000&4@,I/!P,@'I2OOBI=V>I
M9FL[:XC@89MY84<;UR ^7!(8 M@@@@$C/)K.\0?'_5]4CBC1[72ESB29H@S
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M/S \*<$X)'.,@\D]:X/X'WN@>%+&_P#!^JWEI!<:O=-?6=W&Y,5PC)%&8=Y
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MIHQK+M<%)Q:[F^SR!68B1R H(6-LD$@%2"1QF_K/A?6]0T^+5;/PW?7-VI!
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M6.R5"/D)'4 @D@'D@YQ@@G/TN:/Q=<QPMI-Y/I=I.D]W+""66,$ @D X!&[
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MP&# , "!P #C.,\9P*FL?A1\--0U"[L-,LV^S0HS1RZA>.SL54G:2#DDXP
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M"O0;LYR<"N9U/0-3T.SEMX+U[?2[AC'<VZMM5@3U('7&>AR.W3BM#P5#K/Q
MNH_$MK-%IP,K0PV@5V,T@4$@E5VKD$#) !], D=9'X;US4/*DN/#\GEW%O'<
M;6=<JK*K@. <J2''! ))XY! \RI5C6A-83W815G_ %YG[1E])T:,5FTE.I-\
MT4[=-;+O;U,GP+H^B^$?$6EW=S*WD;E6:(C/F(W#%1@?PD\Y[UO_ !B_LE;V
MYL("R:JK>6%C0'S0 "I!'08(/7D'BL?7O OB#7KJVTVRT6YLM2C<B%6+[!&
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M%'&<\)5(/1;^1^:5,AQN#K1P\FHREMUOIMY'TI'>7=Y;P0)!F\D$D$S#Y$@
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MH'UKA_B=K&H?$2^TO1[JPLX_ Q@NI=<U35H[62WMI%C80OLE)),4BJQ& "&
M)P#CGKB2VU&:"RGVW#,V4W<A,8R?7H<<$$@D>M=1O^P6H2UNYI3C+(Y!4\<\
M$8QUXKLH.%6@E'X_P'&E6CB7+3DM\[GS5^UY\#M&^'_A?PUXY\/Z(_AZ+4+B
M6SU'3S<1LBR#+02JB#:AD1)&94.Q3@ #J?';C5+S3[C2XO$MF=(GU.RBU"QN
M@ &,$A/ENP!/RMM) .#C! P17V_\>/ ]M\>?AKH^A7>KQZ08]4M;YV;!<Q@/
M'*%![A)'8<$93D8)JS^UMJVD^*/V9+JWT+PO<>*$BN+6#2TTNUD(@*,,2 (
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MFP=T:I]T9Z X" D<D1J"2!BN:\+B\E@TW3[?39-0GU+4&BLV4L1-=[45@H)
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MO>FY>-&\PB#9$%'E@D\D'.22>"">!@@  ^<>"CJ2^*4BB>1[AAB+"':[$XV
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M.3Q@9L\(-N_)-L&)()Y!.23S]3[#I[5POB#7I+NZM[*WG9VD?9D<X7 R<_0
M=.I)Y))/53^K5H2A&_,[6_6Y,7C:<Z>L>37F7Y6/H*Z\;1^++66V,2RVF.6D
M)"L>1@8P2.2"<X/(Y!(K#TW6XO"$6N0SR16UG-$)HU9 %B(+M*?,Y9M[2$JI
M.%)PH .*\ZO/&W]GW$,7FM.ZJL9<L2%    &=H ')( )))).:/%OBNVN="B
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M[J3-W<0?-(!NY"MQN;&5P".A(  P,G3;6TT6"#S+.ZG,#-FZDD)+ L& .#C
M(49 #8'49.</QY\1O MQJEMI6L:4VGV\+1W-M-;B2.7SP& (VEPQ*Y&6' /!
M! (]"KCZ?(W3:N>-A<LQ$JBIUHN*?5*[^[0S?B[XPMOAYX&\1ZQ9%4UA9X].
MTT7B@2_:&8EY&5R23&JNP]U4$#.*\-\#:O;>)I[X^)+R&.[U&)D;6+B.66=)
M&! 8$ \ G@ #'&",5)\8O'4OQL\;1Q:?NM]&MS+<0+/&%,D\A!EE(!.&8J
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MG*T^GY%/]KWP[9KXJL;NS=')\/R)=*",J!*3"P]SND_[Y[U\BV7A/4=2C\V
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M2(@0RVY0)-@ (Y'8X<;P  ""1G)'C=U9VWA?Q(\6NW$^E"V+1NRQ"5B3C:0
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M=3'F\-W>CJ;W3S))IK-ME@!+- Q[^I4]B>1T)/4]+X2T"]UV1=L+@$9+2#
M]R?Y=:V?"]O=PV^IN(Y'01#  ZL6  S^?X9KT;1XM0M=-0R:;,AQG=Y?.3SZ
M '\ZE-6O(YIPUNNI5\,>&1IEY)<7A_T>U3?N4X&X=![\]J[/P&D5Q;VSB0R2
M33LS;CG^(]<^P%>;>)+K4;]?*^T2648;<L-Q%L1CZ9!(_/O4^D^+9/#_ (?U
MAW<Q7>GZ;<3JK#'S!3MQZY)&#WI<M[6(E*RY5L?+'B;7I/&7C+Q#J".3)=7T
M\T>2<8,C$#\L?E1X<,ZR&WGW(#@D-Q6AX3\(RW<T;B,11JP+2'I7J>G^%+>V
MFEGBF25,[@)H@P^@R0>>>])U%O>QWJ#Y=!G@#PSJ'BF1K8-OLK<AC,QR%&/Y
M]L5[/>7D>E6]OH\!\J-0!(PZL0,X/\ZX#2_$FL:?&;:WM;>.*5@-\#;6!/&=
MA&#CZFM#4I);;5#YLAE) 8LPYR0/YUSUIN;YN:YU46TGS(ZC7KB&XT5[2#4[
MS27E5=]WIC[)T(=6*ANP8 J<$'!X(-<WK&IQ:A>7!\O=%*Q+1_>R#Z]B>Y(
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MS2&"WNV(E>,%B,CID*I)R0<@^Y'$>%+V_P# LTT$L0O_ #)(V^RI,8'<JP8
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M<;1DA$#.=J\GC!R"!TJ+PWI&FZY>6WF0S:UJ$B;!&LI)<#&U5C4%@ <@$G&
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MF+A&A1CYL: $$,X  ;G !Z$@CM-8OHO#:F"3R[J13F6VN+=)$0J.& 8-R-S
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M25=HDCN-P!!(.<L #V(X.2#VZUY#K2W/]H03SRG2OG(*W0;?CVC')!YY'7!
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M-:7R7'F^:&>-!,?)A!'ENI5@3ABY<_=W&N#E]G:,5<]:553C*;DDM_7RWO\
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M\]I/[0OX;<;CSM3,I_55IIJ1R.,%)<J/#]&<W0CCG)V9X56P2?>N]\,V*37
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M8OXAU^PO /-L;*P@L8KC!'VGRP<R8(!P22!GL!5BRADM?*@L[8&XF; .,D#
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MN=-=:Q*RM% 0B1C!W#)8X!/X?2O%?VEA>ZQI/A+3[!S;S*]Q>R,AYSE44X.
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M?'>QVL]K=R^;C:K-'M5<\$@<\X/7->23>"3#>RQV-RKVJ9&Z0?,#Z=1GG_\
M54C^$;F#9YHPC$[6'(;@'\.HXKKEAZBI^UM[IS_PY7MH>@Z&DMOI2")Q/#([
M2B0'.XDY.<=ZM?:XH#/<+M=R,E6.&#8Z#\O;MZ<U?A[YMEFS=3) PX4C@$]Q
MZ5J:IX9-QJ7SQYC)XEC/&.X/H165&HZ$^>&YI*3B[QV,W3+R[UJX'V>R!GPR
MDA=X*D$%2",$$'!!!!!QBNDTOP[J NQ<7$$B$%5.Z,(H            P  !
M75>%XK+2+/RH(XX>,$]S]3U-9_Q&\9O:Z4J64H\\AE0KU!'!8_0\#/<'TJ:U
M2>(GSU-Q*3?Q;'G&O>(;;1_'^MQ7K&\MIIQ)MMSGR2%"X<D8.<9( X]:["SU
MG0]2MT2.:Y@!CV%H&)!'N #CTYKRS2=%^T6\KN-[NQ+,W))S^=1G2[[2[P+'
MYD>X@*P. #VY'%:J,I:QZ&5XRT:/;O"GAWP_;WR3[Y90@^59<E<^N,8X[<5W
M>I>(-&M;$ S0IR "2!MP?_K5X1'IM[;SM_Q,;YF@N'MF\V,1AW4*6*<G<GS8
M!(!R#D"J7B3PE!H^I?:T!\ZX4-Y;'*HV,D@'C)X_.LN=U%=MLTE1C&=IMJQW
M#>#=.UKQ-8^*(+VZNM0TV*:&V@ANR+9@Y8;VC&06PS#<.2#@YYKC_&*S_:C'
M;6DT!8YDM^H8YSD$#\:SEO-2TN;:GVA(XYFA+7T82.1556,T)5BS18) ) )*
MG )X%S2OB?::UH]CJ=I>R7>GWD9DBF$9(8!BIP) &'*GL,C!%*C5]D_W3LV=
M=:GB)QYY.\8V7I?5+\QGACX8ZK?3->P1OICLDBI<J%:2!V0J)45@064D, 1C
M(_++^.'PO%OX%C%YJLFHWL-LEO+=3 >9<,<J7D/(W$L !DG &2>M>I:7XZ\S
M3S%9P2W):-&5O***^XL"J,2 6782PXP&7KG%>;>+=0E\7>=931XM@Q#*>YZ
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M)=:AN/%TIN);C[);@Y!7@X'3@= .@ Z5V5QX7M]4T>+489'E*W!,L;$DQA@
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MFZ7JNH:UY=M9SV\' /F @9SCV Z_Y[^H:!\*7^UA[FYC((RRJ"3GOR:^@?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y;??&2
M2RU6\M5T22X2WN)( T<S%FV'!. A SQ@9R>V:LV_QJTYF FTV\B4])D:)HB>
M> V_&>#Q_7BO/;J-&\0:V\SR1VXU&8.Z-(N!O.3N4X4@9((P?3-/DCL[B&41
MR74L3!EC;]](O08.X<Y/.3G(&,G&#6'.^Y]1' T)03:U9Z=;_%[0YMA,=_&&
M&5/V1V##U!7((Y'(]16C#\2O#L@!-_Y/_7:)X_\ T(#T->0QL&GB73&OO,7#
M;IG+#=@Y 60\# (.T $$8.1PNW4V9$1YHQMP?)$8+("<@YR>23DC&.V.ZYV2
M\MI=&SVB'QQX>N,"/6K!B>F+E,_SK4@U"VNEW07$<P]8W!_E7S\UC;W6XC3[
MS:L9<BXNB![$ N04&.F,9/ JLVBI'(\D&E31@KM?S"CJ!UW F7(SD$$9(&01
MP 7[0Q>5Q>TCZ1W4NX5\ZQV<5I@1SZL+@N%14>6('H2"%VJ#U'TQC@YK3M]<
MN+6:-3JVJ6(\PAO.GD8(N/ER7RN<X)P3C)S3]IY&3RR?V97/=Q]**\0C\;:P
ML,7V;Q)+=W.\+):A8&8$Y[%00,XY)Z'/<5=@\?>+H_E"6]T0"2KP ' )'!$B
MC.1CG'J*?M$8O+:RV:9[']**\AC^+'B*,@RZ1;3 @X"^9&6.0!@X9<'/4GCN
M!D9T;7XM:A)#))+X>RD9(9H;Q3C&<XW*,]*?/$R>!KQ^R>F\T5Y]%\6XO+W3
MZ#JD ! ;(B;!/3.),\Y';O6A#\4-&8XFCOK8@A3YEI(V"<<$J#ZC\Z?-'N8O
M"UH[Q9V/-''>N67XF>&FDV-JT<3YZ3JT9XZ_> K0M_&6A7F/)UFQD_W;A<_S
MI\R>QDZ51;Q9LT;:ACO8)ERDT<B^JL#_ "J7>OK5&=F.HI,BB@0M%%)0 M%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\W(Y(+$DLP.,@AN0 ,Y!QT?,=.7N+7H/:&3>$M[V%7Z+'#?ERI()& 5(7(R
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M;EW^VM9A61TU:\MUB;9E[V3#$9/R^9$=V1Z9 '(STK1C\2^*H89)(]861(B
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M],ENV#DXQC'.?46Q\_&7NI%".W-K,L]O+.\VX@I);OAA@@9<J3GDG .03R0
M:8TDEQ"4::'RB"&'V1CM!P,$%1DG Y(/4^H-:DD;+'E)-04Y8AFX Z\].">K
M9QCGWPB0B9L">ZG<@_N%>,M&,#EAG !.3UY&,<T6ZLOG[F5'9B.,%FD(C(\O
MS()V&<9P<N0 .W !Z@ <U.EA+)93RB^.R-@1YO)/4@L&Y')) /';& !5A;=E
MDD<"X9R@&Y9%)9<@@$@85?0+D#/<$@RS64%Q,LD8N;N1<(DSK&2&.?ER0"0,
MG[I/<=.*JP<Y0A@#*TT>HABI&YK>&,K(>I)PN<#;GY2,D8Y)Q2QEUD1VDVB(
MY5A:2X )R/EZXY( )&  #V)N7.GPW<@:\%Q)J*O\NZW5MIR#D<$  # )(R<=
M203)% DQ N)KBV1LJ9(U18QC& 0 1C &0> 0.H.:FP<^ERG$V&5C>W,>"1&8
M[-B <\G:%.20>XXZ<$\QP6:332EM1>*)5PS2+'#Y9)(P. P)ZY)XR ,=*T8[
M<13*MNU]-Y9)#6X3 [ @%0I)!.>W'':H;JQDE$;GST>,DQN\4>Y>><N 3G)P
M>1R3P1187-KN9\=E;6[ETG6:6506\N!':,G "_* 02,\MDC)Y.:>S?O)B+LR
M>8 DC-;2YX.0"F %/N1CC'4BM3[+:R6[K)<32AD ,"D.')!!4@*2<'GVSS4;
M6ML%C2YDEB\M,P1SA,$ 8 3:/P R203QR:+#Y]2F[2VJF-)_W1(*^?9.H&>X
M(7Y3D=&X(Z&F[GF5O-N&(E8.(!:/)$V3R02N<'KM!!/3J>;K33'F26<QLP#>
M7"(2V    YSD#!P"!QD#G!EDCD962.6XFL=X.\(&=6'4(1[GT.".#U%/E#F,
MFZDN^%>[:WAC&%18T0 C@,3(F >^#D#)Z]GV,<]Q,EM]L\NW7+!XUB*C )(/
M')(R#GL<Y!QC2>&[ERB&X!W$J\A4.&P,Y"G!( ].,D\G.(Y-/:>W07*7<VX;
MMWEK(N1R"HP6SG!(XQR1@XH#GT,Z.!806CU5A,JL=UO'!O!!X4Y3'S \9&<#
MJ>34L<DB+'Y5Y)> 8RLD+%%((.U65,$9&,G/4@') K1,=DPC/VFX9MN6A6<L
MR/QA0HZ$G/&,$#., U%-%)$VR<Z@\Y7C][&2!W)&0=N>1@$\<^E*PN<J,SE9
MC&IM!(.8T@F<L.I^=D7:3D\$9Z8P#FHF"[V\O47>)P%;RK4%7.><,J<$?7!Q
MT)S6H755S%=W5P755E"F-B.3E6.WJ,GH0<GDXY#88E\F:3[7MD4@B-V60N<]
M3GG<.1@$ #(Y&*=@4B@+>-;>*4:M.=SD1HMNF5((RP 3)(SD @CYL8Z 1_98
M_.6235+JV\T$?:GM8E..,$EHL#=W[# '&2#H+;PR3.\33374HP[LD.<$D;6'
M#9(.<#@ C&,DTL:Q+M2(W:."=_EP*A4DG=L!!8\DGC(YX.<4K!S&6UC:QM+Y
M=P;DD;7"6J,N!P&+!><Y!Y) &, #K+_9MG,S3F[B2,+E@MKM56!  "-D@D'@
MCDC&,UH/;(VUX[N]\P@B4*K/(H!X&-I."3R!@9)//.&M9P3S!D2\DEC!X:$_
M*>< $J!C&<XSZ9!R*>H^<H-$\ZH712R@*\XLV+;1R3@H%!&<9&<]1[*MK! _
MFHGV^->6-Q8O$>^,%8N, C'!)[9))K362;#I9RW;QL.?M%N&[8/4J5XP 2,8
M'0\979J*1R(L;B,DF4M A4@]<$2 @XQU!^AI6%SF3':P!O-=_*NPV0D5FS;0
M2,$,06'K@D$D8QGBEDM;>:0+<Z@?,8D2-<6L:'!!P=S(,@< @# )&16J[76W
MY[5@BS>:0JMDL>,$;2>O0@G@C@XS0\<\BF=Q?)*6^:2 @)Z#:@))(Z=,\$9Z
M468<_4S=J,J^9>3S1*Q"LUCD!><8*H,YX& <CJ>>:7?--'% ':".,D+-%;N7
M()'9DP"..A)SP<$X-](1(\8#ZH91@<2!<'GA58CITR1@C/)S@N$<WEA+?[1)
M)$"55HU54.<@'"C.<9XS@\<\T6#G*4+26>_;,6F=0)))M-E)<CCG:%YY'.,'
MCN#FG#96ENNX7L\$XR1"EN"22 0<E"P /<$ XYR#SM&:\FP1+<%]A,FZ./ 4
MX!V8((&1C<0?IU(;'&=S+!)?@, JP!HSU!ZCG@ #D'(&*+,.<HS2#F-M3$L$
MVUI)&MP01C!SQA<#&00/PP:(8P9/+M-4F(##;Y<(:-@2!NW;2!CD  @$=NE6
MOLMY:R/-]GC1T;<QDC0 $G ) EQSG.2!G&>,8+_[/N)I"TT=S)+NPSH$7G@X
M(!'/<8R.A)!YHL/F\S-DA:=/,^VWCLS9V&T^4C/W@1&2#C@ '([#(JRVH7,C
M0^8?)2$8$GV::0LP!!) "G&#TZ ]^U2*D\,8WR7$4:EO+CM5C3)'4Y+'+#W/
M('W1WEV3-#ND^U^4 61HGCA."022V_D9QD@CL ".I9"YB@TT\L<40(E"C:JB
MWEC8 X(;=AMQ& <@8ZY(!)%&'2X_W[R6^W<P)E:WEF9L$$M\P &,9P0 >@!X
MK?AMV65#%%=^<R9+MY;9!& 1ELX'N,X]Z%DN;7Y(WN8H2@9OW$;MC  ( /"]
M!PI/K@\DL'/8YL:+9MYKO>?O&8^1]FBCRXQP3MC&T D')[C!)Z5<N-/DTI_(
MAUR\AD0 %_M#)DD<DG(48X.  .<^PV=EXB.(ED^SR$))YL<9.<  ## \Y Y!
MXQT.34/V6&WD,0%[9QJV3%&H (ZGB,?>'..N>""3T=NPKJ6Y2MM0UE),1^)=
M24[0%5'CN-QSRQ!1CC&3D$ ] ,UI6/B+Q$LD@;Q*'"*6_P!+L%CX&#R.#@CG
M/&.1@D&F^5<>8)+:2\(# )]HC.[..X9E))YX/4 'C%-ELA>M&DJWT\X;S,,L
M> 0<Y4,,9!P,X &,<'BCYF;C3E]E%F/XC>(UD$8;39LX"R30R0A_S?/<9XXY
MXXK1?XCZS9S^5/IMG<.H^?R991@X! _U9R.>HSCOCMCM9RE$5X[]HW! CW1[
M>F3@9Y4]P1D]<=:9#:V6GV\:6[W<:;<%;: (<YR1R@4#WR,XY)SR]3)T*+^R
M=''\4YE@,LNASE0VPK;S+(V3S]T@'UYQV)Z5)'\7M/!Q<:=J%JW/RNB%N/10
MY8COD"N8^PQLZ/<>?;LL>U9&5,%<'"AE 8 ] ">1D'.0 LL;8R9+Z.0 *K"(
M$#C@':N5 YP6&,'.<]"[,WA:#Z6.UM_BIX=N,8NYE)&<&VE/'KD*1^O8^E7(
M?B-X:N, :S:J>F)'V']<5YY-IX:WB6:.\N,L#F8J5!!X(\P'YL@#!Q@]>E2B
M*X5U$$=P+A6(&Z&(J#R<$@@D\$$*0!R,@8-/F9F\%2Z-GJ%OXBTJ[_U&I6DW
M^Y,K?R-75FCD^ZZM]#7BTWAV.\F=KK35GE8[BT=M#NW#J?G9L@9'&"1T&>M0
M?\(OI<4B;+"Z@=@&+PD*>G!4(>1G.>AY]1BCF9F\#'I+\#W(,/6G9KQ:#3Y+
M6W+6]UK89%!*B_D5 3U/7[HQQP<_3FK'G:U:2#RM<UJ$@;MLL<<ZD<YRVTA1
MZ$GIVR*?,S+ZC+I(]@R*7->2GQ%XJM6 &HAP#AI)K0-SZ$(!CMU/.> :M6_C
M+Q.'4D6=PC?WK22-CC&0 7^IY XZ ] <Q#P53H>H4M>=I\0-<4;?[!CNF[^5
M<F,]>OS+C]>*2X^+$FFKOU+0Y;2/<%+"ZB8 GL<L,?7I[T<T2/J==NRB>B45
MY-=_M.> =+;;J&KPV+YP1)/$W/\ P%S5*;]K[X30Y#>+8G([0VTTO_H"&LW6
MIK>2-HY;C9?#1D_DSV7<:6O"+K]M+X90QEH+W5+T#_GCI%R!^;(H_6N=U#]O
M#PA;*3:>'O$%X>Q\F&,?^/2Y_2L7C,.MYH[:>09K4^'#R^YGTQ^E%?),G[>W
MGY^P>!I7';[5J:1G\E1_YU@:A^W1XLO&9+'PII6G\?>N+J6X_0*E<\LSPD=Y
MGJ4^#\ZJ?\N+>K7^9]K9HW5^?EW^VG\3;J8HEUX?M$S_ ,L=,D8_FTQ'Z5SV
MK?M8?$ZZ4JOBV:#L?LME;Q_EF,G]:YWG&&3LKL]2GP%F\_BY8^K_ ,D?I%N7
MN:0R+W8#\:_+R3XS_$#7(7:7QSKYE_NQWAA'_D,+C\*Y76O$_B*]4KJ>OZQJ
M ;((NM3GE'Y,Y%8//*-[1B[GIT_#K&O6I6BEY7?^1^L5WK6GV*EKB^MX%'>2
M55_F:YC5/C1X"T;/VWQEH5L1U63480?RW5^3SZ3:S.9'MX=^.6D4,?S.33XH
M4B_U6V,#^XN!^@K)YT_LP_$].GX<QTY\1]T?^"?IM??M8?">P;8_C2QF;/2U
M62?_ -%J:PM4_;6^&.GQEH+[4M1QVM]+G7]751^M?GFLCW$BN1D+@%LXJY<:
MA%Y.Q</VVUQRSJOM&*/8I>'67+6=63^[_(^TKO\ X*">$EW?8_"WB*[V_P 3
M);1C]9L_I7.7?_!1%'RMEX'<'H#>:FJ?3.V-OYU\>227,>2D0"'L!VJE)Y32
M \KSDK6?]K8F76QZ4.!LFIVO!R]6_P!#ZDU;_@H1XT$S+:>%-#M5ZAIKB:?^
M02L:Z_;D^)6I1GRY]"T__KWL')'XO*P_2OG22,3/D2C';--FL'ACWD[AVVUA
M+,,3)6Y['I4N$\FINZPZ?K=_J>QZM^U1\5;H_O/'MU;*W\-K96B#\"8B1^=<
MY??'/QUJK;;GQWX@F+?\\[UH1^4>VO-?+DD<+@GTJY<6J6\R;GV#'05S2Q%9
MZ.H[^IZ]+)\MI_!AH+_MU&MK'BK5+Z0B]U;5M0)'_+SJ$\H/X,YK!DL(KMS-
M)$L9'.6 )_6KT-F682"4NG7!JO<6XDF(-Q@YX6N;VDGNW<]2.&I07NP2^2([
M>.VBSEUQC&-H%-;3Q(_[O;Y9[YYIQTUS(#(X*BD:&XBD'E$&+TI<W9FJBMG$
M9_9\5HP<N<]0*;]LDD<@*-G3<#S1J$,\N<XV 9K+5'9MJYS[&G%<VK82?*[)
M$TD*SDGS#QUR*KO(BQE$!S_>IT<<BR %6QGD8J2XD1_D\HK[@5>SL9[^0NG!
MR26/'N:6\O%A)&.<56W>3'D.RG. "*@,B,Q:0DGVI<MW?H7S:6ZC4B>:3(XY
MSS3IHY=^"<)WJ?[<BJ @]JAN+P2,5(R.]%Y-[ E%+<I30;.0<CN:A8^F<]ZL
M-('^3&!FF30JBC#<^]6GT9FU?5%9F*]\TWS&SQ_*G,I3FHR3C/:JL3JB.3YF
M.336POW>M!]Z0D<\4"OH1'FF-4A8 \5&U&H65B,\4VGM4;<T[O8FR&U&>O2I
M*8>M42-8#K32-W0\4_A>M1LV",4$A3<_-0Q.>!3#GO31DXB2,5QBAOK3FQWI
MC;?I5F#CH1L3[8IC1=P2*EVKBDXQ5IG/*!$%<'[V13SC\:9YO[S;C\:5LYZX
MK1,Y)0&LVW.>E1F3(R%H8.6P0"*D/;' JTSDE3*Y;S&W8Q^%2 YI],+ 5=SF
ME3-KP.P_X3;P^,\_VA;_ /HQ:_=K)K\(/!!_XKOP\<<?VC;\^_F+7[O9%>U@
M'[LC\WXIC:=+T?Z'GFGZ;)<:AJTN)'C_ +2G4Q^>P1LOC!7. 3GJ!GO]+JV%
MM')Y31W=LC954A9AC'(&$)SCDG'7(S[,TF",W.K,[0E&U*Y#QR2E<@.<;ATQ
M[D'&>.M:D5K'(PBBLK65%!W!,$..P!P!@9.!ST[5["V/CU.RL98@AMY,SK(8
M=N"\EPT6W R, =R>"20?<BB"W@FSB*3@?/\ 9[J0D<<< @J.1R,Y!SCK6K;V
M9N-T<2P<<^6[D$#.>BG'!QTX^IILUCM1#,+9PPRJW#9'U&1P?J2,D],T] YT
M4F6* ?NVN.%VD995#'L2QP1R<  \]/9LVGNF[S(I &&3FX:7KD\ANG0X(P1R
M!D'%:$5JMNT4CP0,F#GRP,X)P3SWR02!Z4RX6S$@^S0)$">&"+&0><\$ACDX
MZ ]/S>H<^I2;2#DN8!''&VTHD[.03@^V#@C!'//TIQTT, T=G*\;-L4M<R(V
M.@R.H/&<GGL>*MRI'))YDYM[F1N N]"5]2 <8!  ZG(YX&32QP(A/G6^R G#
M(C,H'&,8R >.IP"<'L<4M0Y]"I#9R0R1/%&0[DB-_M+$GMM!8$8 !Y(^8@'M
MRQK.-MB>1<EP"7+W<B)QGE2#QTR2  >F2<XO+9V\9,ILHY8I"00A5B2 <!QT
MXX'7C'UP[[#Y,8=H[>W63D%79"?8XQG@X [X /I1ZASF<]CMC5W@G9&4E6CN
MW(/3!8;A\H],$<YQR:(K,3QM/#;[HDZE+MMC8Y)P.,'&"!QS]:O/;P>86061
M8\%XYLG.?O$]2<= 3V//6FW-BBNOF20RL"-C!P2OT#$CD8R1SW'H!#Y[E-K>
M*.3S(XIK=/NL)+C'KD%<D$G'!)R#WJ1;&S:-_*2\D!($3!Y=N. =ISA2>>>"
M>#D]:N?949LI]F50!Q'*6'ID8 !([C!QGCK4?V6W6Y$LRVDX&5:-=FY@?7<
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M9;O?BQ\19LG_ (2+R1S_ ,>]E ,#GH61B!^/%8[>//%=UO:]\8:T"1C;!>&
M9QC@1A0./2J5Q)=^>5&-F?TJW!HJRQF78N>^:Y_KF(GHYL]2&58"G\-&/W(R
M5N-2OK@M<ZUJ]U&>USJD[@Y.3P7(Y^E9L^AP75]NDLHW7.2TJAC^9S5V_LFC
ME9Q*$]!G%1PPW?F#<Y([$'BL'5G+5R.^&'HPTC!+Y&G_ &+9K9Y2&&,X^ZJ
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M(,F*>WW]EP2%'';.!GGH!U_&KV.S3R@AN5(4G/J!C)/Z4JJ5P1-.O7H@]?\
M=[_YQ1<+L@VR>297O(0 =H+(,=!QR>O;^E1Q,+>-HP( L@ZL"G/H 1@GZ'D\
M]ZFVK'('#DY&" J@Y/N0#QUX-+)*=N7?:J@#*KZ?[W?WP*!ZE=;=)" [K&,Y
M7<F[GIR6 /Y8[\FGC%O+QLFV\#:2JY]QD@8/;.?;BJNI>*M*L(S]OUBPM!CD
MSR(AX^K$#\JYRX^-G@?3QY;^+-)(&"5BN5D(QZ!>3TZ=JESBMV;1HUJGPP;^
M1UX\UU\TRPQJ6S_J\J"!G).1QC''K4:KM;*R*AP0)!&WS#/!(QC('?/&>G:N
M#?X[>!RVZ+4[N\;_ *=]+G?)[<B+'7WQ_.J-U^T=I"*$AT/7=0VYPR6BQ$Y!
M'_+1EP>?05FZ]/\ F.N.6XV?PTG]QZ8MT\>T&-"8Q@,S%0V1@9)&/R)Y%,9!
M<$@SV\B*!CY YR!T!SD'KS7E$G[1%Q*H%MX2U*/:,*US<VZ?GM9\=AT_^MAZ
ME^T1XF@8+;^'M/@SP#-J+/QZ$"$9'XY]ZPGC:%/64CNIY%F-1VC2_%'N_F2+
M#Y0"%>09-C X/)&"/UR?IW,4J"3<6FADXZF' ^A)/&.X/6O YOCIXX:W.&T&
MU+#(!MII3SQU\Q?Y5F+\3OB'JLC._B6&R0_\^.G1#IT_UF_I6#S+#J2BMSLA
MPSF$E>227FSZ0AC9(P/-2,*<[5A(4>^00,>HSS2;!NRTW.?O+"WYCKU^AQWS
MD5\KZIXX\72L8G\9ZP^""WE^1#T_ZYQ*1^=85Q-JFHY^TZ]K=R!U#ZM< ?D'
M _2N2IG5&+<5%MGI4N#\7+651)/U/L9MFT>=-%$B#"ELLQYY)/!_3COFL?4O
M&>@Z2JC4?$>E6F1@K)-''@9]W]CSZ9[D5\@_\([:7"L\T/VK'4W,C3'_ ,>)
MIL6CV-NV8K&UC/JD*@_F!7)+/%T@>C3X,O\ '7_#_@GU/>?&;P+;$^9XUT:<
M@8VV\JRG'3 "L3DYZBLJZ_: \&VBR.NIWUV,_P#+#2KF56(Z$'9@9SC@\UX-
M+&MQ''Y3*N!C;TJ5K26.SV;P23DJ#VJ7G%5M\L58Z8<(X6*7M*C;^7^1[,G[
M26C74?E66BZY<?,6+_8DC!]!^\D7]1R,>]9NJ_M"7T<+^1X0GGC/47-U#%VQ
MG"F3'TYYYKRS2[:>.4N00F/SJ*ZUF5I"HP%SCFH>;5O9\T]'Z'9#A; QG97D
MEW?^1WUQ^TYXA=52V\(:79A>09=2DD[$<A85]?6L6^^/GCR^"J%T"T0= MC+
M*1QZF89_(5Q<DS,Y(QDG)J_I-HMSO,J9 _G7G+,<75DHJ6YZL>'\KHKF]E>W
MF_\ ,Z-?B9XTU&W:6Z\1QVZ@_=M-.A49]MX?%95QXUUV\<B?Q9KC \'RYHX>
M/^V:+C\#6;JTA1O*B&(U&0%JC:VYN)0-N"3ZTIX_$745*[1V4LHP,8\WLE]Q
MT3VDMY"QN-7UJ[1QRLVJW#*<^HWX/Y5QNH:#IEQ.?-T^&?G ,R[SCZMDUW<<
M8A@"#H!BN6OXH_M#8?C-&,J5'&-V=&$H4HR?+%?<9T&E:?I>'MK"W@/8QQ*/
MY"K,VK2S*%R2/2FS95, _)[TV%4A7>S;O2O*4G:UWJ>KRQO>Q ZS/\W0'WIT
M4)W N_/IFM,1KJ2[(E"D=L]:KR:8+5P)& /H3FJ<7:_0I25[=2\-%BFMU?>.
MF2:K26ELB&-9?F^G%7]\9TTI%)EE%<U)#.9,AN,^M;5.2*5D9T^:3=WL78TM
MX"5<EA[4MU%$8P8&Z\<UEWL960$MS[4D;%=I,N!V%87TM8Z>76]R"2UD63!R
M0>I%6+I3!  B93&3FMW36M;A,. 6'<]ZBUJ:-&"I&" .HK1P]Q3N)3][EL8]
MBP\HG 0]*CDCGC8N9,H#G'M5M-.^WMN0%<=1G%:B:?#!;[)V&?K41IRG=K8N
M511TZE?2]8#?(QR@_B(J;4@E_"!%(,CT-8VHJZ96V&1G@@54A6\3!)&.^36B
MK/EY):H/9*ZDM!+O19%^\[#TW'-4IL:>NV,YD)Y..U=!<64U]:*023C'!JK9
M:!*LN9,D=RU1RR;T6ALI)+5F9'J%S&OSQD@]Q5>[LY;AQ)&N,C)YKI=4TM$@
M^0X&,'GFL>WC2W8@2%F/8FIDG!VL:1:FK]#*N)FMY%\U,OZ@\5J0WLDUEA.
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M (NLW@:LMY'5#BG 4_@H-?)'R[:^&=)L2#;Z79P'J#';J/U K2CC6, *H [
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M/DC36CL<F7A^PJOJ2K>2EDD//:OKUOV</APW)\+VY/J99/\ XJD_X9O^&_\
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M'X7_  E\8:MX:U.YUG5-2T6%+C63H>D3WT.E1L-P>YDC4K&-O)&20.H%:/Q
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPSQQ("3G^+WK[E^ /Q"O?BU\$_ _C34;>"TU#7M(MM1GM[4,(HWDC#%4W$G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI^D02G=)%86L<"N?4A0,GFK.DZ+I^@V8M--L;;3[4$L(+6%8DR>IVJ ,GUH
MYOP]\'_!/A2^T:\T?PKI.F76BV3Z;ILUK:(C6EN[;GCC('RAFY..2222<FNR
MI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O/=<^ 'PU\376LW.K> /#>I7&M2QS:E+=:7#(UX\?\
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MET?0]-TF6XYFDL;2.%I><_,5 SSZT^Y\(Z'>:Y#K-QHVGSZQ"-L6H26L;7"
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C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>oncolyticslogoblue.jpg
<TEXT>
begin 644 oncolyticslogoblue.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  $! 0(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!
M 0$! @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" O_  !$(!H\/  ,!(@ "$0$#$0'_Q  ?  $
M 00# 0$!            ! $" P4)"@L(!P;_Q !W$  ! @,#" <$ PD(# H%
M A<  0(#! 4&$2$'$C%!46%Q\ @3@9&AL=$)"L'A%"+Q%1HR-U=V=[6V%B,X
M0E)REM49,S0V5F)T=967LK,7)"4G<X*2TM/6-4-3M]08)BA$1564HN)&1U1G
MA<)C96:3M&2&IL7&_\0 ' $!  (" P$               <( 08"! 4#_\0
M6!$!  (! @(%!0@+#0<#! (#  $" P01!2$&!Q(Q01,B46%Q(S(U0G)S@;,4
M%S-24V)TD9.AL14D-$-4@I2RP<+1TM1C@Y*BM-/P%J/A1%7#\25DA*1%_]H
M# ,!  (1 Q$ /P#O\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    "EXO!NJ"GAW"[?Y>@8W]2H*"Y#&XJ"EZ;A>)M#*H
M!2]#$6W\)"_FY1?S<HO07H9W]7[&.?\ Y'_R7\W*+^;E%Z"]!OZOV'/_ ,C_
M .2\J4O0K>8FWJED *7H(M J"F&X7&=Q4%+M_D+N/@98W]2H*7[A>&=U0
M
M
M
M
M
M
M
M
M
M                                                    *7@W5!07
M+M&[&ZMY2\7)L**Y-IC<YK@8UB)J\KRQ7KJ^*> W_P#/_(99;N;U*\[3!G+M
M[N? 8[5&T^G]1LRJ].5*=8GV8\_88KA>-ADZS<OD.LW>)CO*9Z&1?G+RJ_84
MO7[$N\2Q7IW&/KDY2[S,;1Z!GQVJ4[5YX&#K>/A\!UBZD\53T,FS/<+DV&#.
M?J3GB,Y^SP#.W_F\,]R;!<FPP9S]G@,Y^SP!M_YO#/<FP7)L,&<_9X#.?L\
M;?\ F\,]R;!=SH\C!G/V> SG[/ &W_F\,]W-ZE<=JD;/=L\5*];Q\/B@8V2+
MUV]^(SEW>*>"&!(O."^5Q>V(BI?\#&WJ9V9NL79XE>LW+X&+/3:5OYN,[,,O
M6(51Z;N_[##>@N,;"0BE+N;U,";E4K>NWOQ,;3Z?U&R04,.>O*KY:_B7)$37
MY7&9&2_<+RB/3:5N39X#=CFJ"EW. ,[FZH*7E0SN
M
M
M
M
M
M
M
M
M
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M HB"\1(J!>#(
M
M
M
M
M
M
M
M
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M 1TPT<\[4,C8FA%OO\!#&S(BE2V\8\J(G<7 I>5,L@
M
M
M
M
M
M
M
M
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M@ 99
M
M
M
M
M
M
M
M
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M^1E:^_48[O6,@+;BZ\S$@ #(
M
M
M
M
M
M
M
M
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MNN^XS7HN\P(H3#1MUX_8<9CZ!(0J8FOON37@7W;+NXSNPN!1%*F60
M
M
M
M
M
M
M
M
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M6];C,8F-QFTE;R.WZO#GGR,S7(O?P,3.WL%X+;^=A5%.1NJ
M
M
M
M
M
M
M
M
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MCD;=FW)>BJO5! GJVX-_(_\ W]1_9FABO6CQV/\ Z[\^GTL__@=O&E>\_P!
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M7JW1BG.'$D-?>FKE PSL?M+T0CW%[7ZEY2XXSR&5'(I4L71@OCP+D4S$[BH
M,@
M
M
M
M
M
M
M
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MM9=I[ML5-]I]62^.4:\:ZW.%Z;>N"<FMR1X88[.+?GRG-DVCZ<=,D.^5E_\
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MS'/>&&="I1<?D#,2PJ #+(
M
M
M
M
M
M
M
M                                                !:JE548)ZF)E
MC?\ ^5+N>>>XQ.B7X)WE'NOX7<-//P!B(\9941+C%$B=^S7SSHQ*NB78:]G.
M)A3#C\%U]B=YR941+L5Q79\>_N*JMUU_//.P*J(BWZ=/.S5@1U7.W(G.C7P[
M5#"KGWZ-'.G=\M1:JIK1;L.V[;\"BNP[KD]>;M1BOV\\[0*N=?PYYN,+GWZ.
M_2G/.HM<^_7A?WHG/:1W/V+<G=S\ +G/V:=:\\W;".Y]U_Q^/.[C8K^[QYWZ
MR,]Z<XZ_/?JN NB/N\MF],>;]!'<[E-:;><5+'1-7A\//@1G/VK]O/9W 7N?
MAL3[.[MQ([XMR;.=GKJ,3XNC'?PYV^1%?$TKWKKT=V.B[8!E=$[<=":>WAH(
MCW>?=QV<W%CHG9V\^I%?%P6[YKZ=O:!F=$QQQ7LP]+N\BOB^?/'T,#XG#AH1
M/52(^+OWXW=OAKW 2'QN/@J\_;J(CHFKO1/&]><3$Y^U;N.E>/.@BOC8=OAS
MM D.?M[DYO741WQ^;^?7L(CXJZL-OQN[/D8%>G%;^[G3Q S/B+=AHQN5>?2X
MP*[MYUZN=9_/6EM33J/(S54J]0DJ73)&$^-.U"HS<"2D)2"QJN=%F9N9B0H$
M%B-3.<L2(W"_4AU[NF)[P_D[LBZ:H^2ZGNRCUN$D2$M9BQ(U+L;*1D16HZ'-
M+"2HUM&.Q_XA EY-^;^]SD:%$2(GK\)X#J]=?L:7!?+,;=JT1M2F_P!_DMM2
MOJWM$SX1,\GC<9Z0:+A^/RFKU&/#$^]K,[Y+_(QUWO?^;68CQF(=B*H5*#*P
M(TS,QX4M+2\-T:8F)B+#EY>6@LQ?%F9F,YD&!"9_&C1GPX;-+G(APN]+'V[V
M1+)NLU3J%/S&4FT<NL2$M.LG$A?<>7F8:JU84_:>98ZG0\UZ*R*E-A56/#<E
MZ0'-<UR].KI5>T0ROY9H[_W;VNG8])6(L6!9BDWT>S$JMSD;F4B4B(R9<U'*
MQ)BIQJA-JQ5:Z85MS6_%B-2Y$U(B(B)@B(FA$1,$3<B7;B9>!=4&.NU^(9IR
M3W^0P;UI[+99B+V]<4KCVGNM*#^D'73DMVL?#<'DHYQ]D:B(MD]M,,3..OIB
M;VR;QWTCN<Q_2D]NKETRBI-2-*JTODZL_,HZ']S+'=9!J46"[#,G+23*Q*K%
M5R7=8DDZ0AY][H+(35S3AXGY^8G9F/.3DQ'FYN8B.BS$W-1HLS-3$5ZWNB1Y
MF.^)'CQ7+BZ)%B/>Y<7*JD?-0(A+/#>#Z71T[&FP8\-?&*5B)MMXVMSM>?7:
M9GUH;XGQG5ZV_E-7J,NHMX>4M,UK\BGO*1ZJ5K$>A;F(7(5!Z;S
M         MSD!NN!3.07[O(QNQNJ"E^[R*9R<!N;PN!;GIM+KS+(
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MRSL=FZ=W/.@SD<JUUW"_PY[DP.,QXQWL,R+\BXI@I1%,UG=CN_L7  RR
M
M
M
M
M
M
M
M
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MK6E8]E:Q$>WT]\H2U>LRY\ELN?+DS9+SO;)DO-[S[;6F9Y>'HCEW  .RZX
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M9JJWRNYT(8IJ72/_ &]&S'^4,;'W?^M1^I+KMR7'J8.N;41]UT.&WS>6^/\
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M_4::W9U&#-@M][FQ7QSR]$7K&_T,(,:O5-2IMOP+VK@=N)=/=4 &0
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M><#,8"K77:=&/CHP\O'$XS'C'?\ M89T4J6Z>=?.DK>9B6%0 99
M
M
M
M
M
M
M
M
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M*9&NU*<)C;G##*"W!,>TJBG/<5
M
M
M
M
M
M
M
M                                        "BJ#=1<?L**MR?9JYYP*
MWW:N[@8'+>N[#GLV'#??V,0HBWXKV<\W![KD52JK<15=G+NT]FKM74AS94TW
MJNA-15=%ZZM&[=\]? KLU8<^'S,#WWX)X[.>=(9F5'N5;]B:T^&W<6.==Y(G
MCWA51+MR>>CM4PWW7JOV!A1[KKU7G5SMTZC ]5TKCSLY[BKW)??JYU>1$>[6
MO._U I$B:U[O7XD5RZ-=]Z;KM*X[$\2KHB8W[/+5OWJ0XC[]/.S#9L36!5[M
M//#LW:U(KW;?G?MXKHV=RE'OU\\;MO@0WQ+]?.SU 1(FGF[60GQ/LV[U*OB7
M[=W9BGR]2(^)=QY\-FT"L2)<B[>/.@A1(MZ[?BF'<EY9$B<[KM*_#>0WQ$WX
M^/9J3 "Z(_3MVZN'=H(;G[>>/IWEKW]_ESM^!"B1M-R_+G4!?%C:-NS1C?SP
MU$)S[M*X\Z.? M?$NWK\=_CPU'Q)TV.GOD_R$6=6MVQJ"Q*A-PXOW LQ3W0X
ME>M!,PT5,R2EW+=+R4.(F;-U:;S)&4^LF=&CYDM$[&DTF7/DIAPX[9,MY[-*
M4C>UI]4>J.<S/*(B9F8B'6UFLQ:?%?-GR4Q8L<=J^2\Q6M8]<SZ>Z(CG,S$1
M$S,0^G<I>4Z@6/HE0M):BL4^@T*E0'3%0JE3F&2TI+0DT9T1RYSXL1;F0)>"
MV),3$16PI>%$B.:U>F3[2GV\%HK??="QF2.)/V3L7$ZV4G[2WOE+56G@._>W
MLEG,=UEG*/'9>U8$%WW6G83U;-3$K!<Z4=QE].SVBF4++[7$GK3S?W/L[)1G
MQ*!8RFQHJ42CL6]K(\1KE1]4JSX:W3-6G$6,YRN9*PY277J3X):U;^=I87H=
MU9XM+V=1KHKFU/*U<7*V'!/?'JRY(],^96?>Q:8BZM73;K5S:SMZ7A\WP:6=
MZWS<Z9\\=T[>.''/WL;9+5]]-8FV-<V]555O55O557%555O555;[U5557*MZ
MN<JN555;S(@!+41LAV  &0    Q]8@W&0IG(?K^1+H_6URE5J%9RPEFJK:>K
MQ;E=*TR6=$9*PK\9FH33\R4ITJQ/K/F9V/ A-8BO1RHU53L[]#7W<.4E_HM:
MRWU_Z;%_>XO[B;)S3H<HQ<%6!6K3*Q(LS=>C8LO18,*#>US4J4U#B(]NM\=Z
M5Z'AU=]1FK%]MZX:>?FMZ-J1/*)\+7FE/QFS='^B'$.)VB-+@M./?:V>_F8*
M>G?),;6F/&F.+W_%=7O([D)MEE$K#*#8>S59M35GXK*4>3B3*P&*MW6S<Q]2
M4D("+@L>>F):!G7-ZS/5&KV.NB?[MO6)WZ/5,LEJH=%E_J1'63L=$A3]3>E]
M[H-1M#,PG4Z2O;<CF4Z4J$5JK$A+%@/1D8[5V27(M96P='@6>L;9RD68HLO=
MF4^C24*3@O<B(WKIA[46/.S#D:G63<['F9J(B)UD9^:EWZBV'NOP^5V[Q(1X
M]UKZS4=JFBI&CQ<_/GLY,]O#?>8[&/>/"M;6K/=DE//1[J=T.FVR:ZTZW+&T
M]CGCTU9]58GMY-I\;VBMH[\7@^4.C9T(LEF2.59 L!8NDT*81K6Q:SU*SUHI
MQ6WIGS5?GEF*G$=BMR,F(4-B.6&QC8=S4^K60DPXKV[]_;VDE(?V)SZ8&5L*
M[4B8\5YXX:R+]1J<F:\Y,N2^7);WU\EK7M/MM:9F?SI:TVFQX:5QX<=,6.O*
MN/'6*4K'HBM8B(^B$=L/==V<X_:AE2&FQ5V<^)(:Q-27W=IDS%T+AN\]_"[B
M?%]V!K-MVKS[N;R]&)Q71W\?302VP=B=_=SH,R2^B]>SG3Q\@(75+V%Z0<-:
MW\J;%D&[0FO7JX<Z3*V&NJ[L]= $!L!=EVC9SSWY$@[^[7MY^)/ZG;XJ96PE
M^Q/4#7M@HFI5YW]QD2%N3X]WP-@D';=VZN?F7-@[$3N7G?N @=7P[E\_B7)"
MXJ;%(*_+!.?D7)!X=MZ^7.K4!KNIW7=J)S\;MP2#S>J^7/<;1("ZD\/F7) 7
MAV)\0-7U/#N4=2FQ.Y3;=3N7L7X#J>/:X#4]2FQ.Y1U*;$[E-OU"[/\ [8I]
M'YP7Q U'4\WW?84ZGG.-NL!4^Q"WJ5V)W :E87%.=B<H6+"[>*<\Z<#;=2FQ
M.Y?/F\LZGG!>>=@&I6#NPW+\"Q8*;%3G=SP-MU*[$[E,?4[/!;O/E0-0L!$T
M+AL7GS+'0%NT(O/.PW#H2[.]#$L+AV:>[F\#3]3=AC?X<JFO3P,/5[/AJYTZ
M,#=.AK]J7]UQB=!OU8;@-,]FG#'=\MV!8L/9Y>G.HVRP-BW;ETW]I'= NU:]
M+>< -:L/L\O+O,*L[>'./-YLE8N-V[#7AX]R&%6;NWQ]>'@!KEAI\ODI^,9:
M^CU8C*+3%HUNK*T2U5.5+F0:S(0IJ)+*EZ-?)3BM2=D7PU<KH;I28A9C[GHB
MO1%/W5S%X[\/LN,/5_8O/<?3%EM2T7I:U+UG>MJ6FMJSZ8M$Q,3ZXE\\N&F2
MLTR5K>EHVM2]8M6T>B:S$Q,>J8=6?I8>[<T"?29J>1RU,Q9^:7.B,LK:Z)&J
M=(<N*]3)6@A-?59)-#83:G!J3$7ZT:=8W1UGNDMT,,IV2"?^@Y0+(U2A,?$Z
MN6JJP_I=!J"K>K?H%<E>MITPKVIGM@NBPIM&7.B2T-%N/3S?#VISQ]?F?S=I
M[)TZLR$S2ZQ3I"KTR<8L.;IM4DY:H2$U#72R8DIN%&EHS5_DQ(3DO1%2ZZ\D
MG@76EK]--:ZG;68HY3VY[.>(]66(GM>F?*5O:?OH19TAZHN':OM7TN^AS3O,
M>3CM8)GUX9F.S'S=J1'?V9>4LCDN["MYW6^F5[O+D_M=]*K&2J?_ .#NO1.L
MC?<282/4;&3L9UZYD."KHE4H*O=AGR46<E(><YWW/>U&0DZJ?2EZ#F4_(O44
MD+?V7FZ9+QHCF2%=EKJA9NJ(U43.I]:ED=*N>M[565F5E9YF>UD65AQ+X;9N
MZ/\ 370<1VKARQ3+MSP9=L>6/3V8F9KDCUX[6VC:;;=R!ND?07B/#)FV?#V\
M$=VIP[Y,/J[4[1;'OX1DK7>?>[][Y1!9GISI+D6\VW=I^ZH     8W)=HV\Z
M#( .5+V=_M:\H&06:@4G/BVKR=Q9A'3UCI^:<WZ V(Y.OF[+3L3/2CSJI]9T
MJJ/I4XYJ-CR\)ZI-0N])T4^E_8++-9J%:BP=;A5*63JX=2I\5&R]:H4X]N<L
MA6Z:YSHTG'1;^JB_7E)QB=;)S$:'?F>8,Y%/W#H[=(^VN2FT\G:ZPE<F:'6)
M549$="7K)*HRF<CHM.J\@]?H]2IT>ZZ+*S#5S5NBP'P9AD.*R-NF'5YI^(1;
M-@[.GUFV_;B/<\T^C-6O=:?PM8FW/SHO$1$2=T*ZR]3PR:X-1V]3H>4=F9WR
MX(].&T]]8C^*M/9GXDTF;3/J5M?MTI?==W^.SL)L.-CBN.U-?V>9PV>S4]KM
M8W+O*0*#4TE[*Y3)>!?.69C1_P#B5:ZMJ]=4+*3,9<Z<@JB=9&I,5?NG3T5<
M)N58DV[F$9%VX^2^FY=Z%;^)<,SZ/-;!J<=L66G?6W=,>%JS'*U9\+5F8GTK
M0\*XMI];@IJ-+EKFQ7[K5GG$^-;UG:U+U^-2T1:/&&[:^_9?W)L[MY+AOYV?
M+8IHX<6[7AY;/@;!L2_X+W<^!T'HMQ#B:._Y[EVDYD2_G'??SCJ-%#?HY3BB
M[B=#B^??QW@;MC\?/8I+AQ.=E^I=R^&!IX<2_G'G>2V.YV_- -TQ]_&[0NQ?
M-.;B3#?WW^6KT76F"FHAQ-'-R_%-WFA,:_#?KV77W:=:8 ;:$[L^S3\%)3']
MBZ?GSH-6QV._?AP[M2DIC\.><0-HQ]_/-Z>1(:Z_<N/A=SM-:U]_'3SQ3N3L
M)3':+M-_*=FK@!L&+??MY\-RZ"],+E[TV+?SY$9'7Z-/SYW&9JW\4P79MN[@
M)2+>G//-Q5?Y2:4NP].;B.CKN'BEW/IH)-^A4YO!$LT-UZ%Z[4TD55UIVIZ[
M[TPNUZ22UR*!F8Z]/#P#4N[>>?$PKACWDA%13A/+V?L)7 I>5.9$@
M
M
M
M
M
M
M
M
M   %$WE+\2US[M5^A._G$QNPL<^];D[>>'AO+0U+C%$?=@B<W<W;3,,K8CK\
M$QV\/M[2V_5J33JO^7.HHB78)KTKLPU<Z,2Q[[DNNO\ DN/=K^)@4>_4B]WC
MSJ,6V[5XKOW)?\2NY%QTJNQ%\;]M^@P.7N3F[G&\R"K>N/9]A&>Z_P ;MZZN
MS[2Z(Z]=W.'/S(KWX;K^>S7\@*.>F*]VKGFXBO=MYW(FTK$?C?W?/?PQU$1[
M_2[;M3MU@4B/QT\IJYT\-$-S]?<G.O8FHJ]Z8[$T=FCNT)=O(<6)SLWKOV;
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M+=]=XYJY\;X!J^'99PZO#;%;XMN_'DC[['DCS;QZ=IWKW6B+<EP /8>.
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MV'4'=;/45J-ZSZ1(->LMW+Z559><EY>;DX\":E)J!"F9::EHT./+S$O'8V)
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M"QUV'CQ7F\S*<8Y<A4! <@
M
M
M
M
M
M
M
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M*!*4S0W7\\\]I@8MZ(7(MRW[</F<;1N,^":RXMTW+P+CE
M
M
M
M
M
M
M
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MR A]7Q[D^'V;2G5KS>2\U-W/:,QN[GM A]7N[OE<6K#3^2I.ZM-OC>46'O\
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MV<W&9CKSC/*=Q>"U.WM+CD1(
M
M
M
M
M
M
M
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M;N=5_=@O#09W)>@$G@5,;'7\ZTY[2Y$N.-8VY?F]@N !R
M
M
M
M
M
M
M
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MYU#TO3GGM/IOH==+"TV16WM'MW9A^='D(BRU4I<2(Z')UZAS3F)4J+.HV_\
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MM*&%2^&[3?XG&WI]'[&&5"I2\J<@
M
M
M
M
M
M
M
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MBQ33AO33Z+=K BJV_CY=W/ Q.9=IYX\W<-*3G-1;_!?CN\$,*I=IV:?7G1I
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M .3(
M
M
M
M
M
M
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M4%J+Y;"XR
M
M
M
M
M
M
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M1<G;HOOU<;](!C-2:.?#?KX$R'#U)L[MB^EV"%6,7?J\T^Q$V$EC-7?SY[-
M%6,U:MO;HW;]V@E,;?N3G1Z]Q1K+TPV^7/ DHFI$ M:EV"78<\Z3.C+K[L=^
MCGAK#6HB+NTKZ=F@O1BKP3SVKMV@43'!-&%Z[?ENV&9$N[>/*\ZB[!,$YWWE
M%79BNO=CAX@5<NV[ANW_ "+FLSL5PV)SMYN+F0[KE7G S7@$2X7A&JNI43G1
MSP,J-NY3GG>8F?SBB0]N/9A\RY%1,.=!787&-O3^;T"A4 Y
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M= D2&K@G!/(JBW+Q\[KKNTP0EQNV8=O.OL,Z@2%"*4:Y%T%;S$2*@ R
M
M
M
M
M
M
M
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MF(SUB1IB/&>^+&CQHCL7QHT5SHL5ZXN>YSEQ4QEJ-N+BVU8VC93;?T]X #(
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M,#COOW"FA, F\JB%3,1L  ,@
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MK@412IEF)
M
M
M
M
M
M
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M^DX=_L<9E33SX(7@',B/S@ #(
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MN.-HW@9DUEQ;\RXS$L0  RR
M
M
M
M
M
M
M
M    !1%"EJZ/#88EC=B?^$NZY?F8XBW(7)K7:O/.@QQEP1.=WCX8F8984T;W
M+X=FCXED==%V].>VZ\R:.Q+M^U>.XP.5%6_^2BZ-O9J2_2!C<MR*N"JGP^?B
M18F"7)NXWK?CQ\,<=1F=J3YZ/1?':87+>J;DOX?;Y(!%B+J3G4E_;CCA<08C
MM?=MNU?._2EQ*B+@J[51/A<0XB;D3?X<IJ AQ78;UONW;KOBG'408JHG!$\;
MD3OW=I)BNQNYW=V*[MY C/U]N.[1Q3&] (D5_A==JQUZ-5^L@Q5NPV)CMO\
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MXHA4Y00
M!;HX%P#$K'(BIRG/P,&A;E[.=IG1+MEV):YE^///.HX]WL_8RP/:BZC FG-6
M^^_!>>>TDHICB,PYVWG(8E1%P\".J7+=LT=N-RZM7P)"+KUW8\-'?N,3VWI>
MFGY\]VH".],45-F.'.KM(\1B:4W)V?+[2:BZ]5]R[UV_!2,J:MMZ^./CV*!
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M4B\J8X:WIW>GPO[2^\XUC85 !R
M
M
M
M
M
M
M
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M-7%9X*7K?CL3[=_ VC&ZMF'%=7K?Z$6"RZY=F''"]5NVZN)L(3?#'M7TU;\
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M.&TD,:B:$3F\"],"Z&E^E.'/EN+;KUNX7\%PY[C/H.-I\#=7@4:EQ5"IF(
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M#)"75L\M7=H7:9==_.DPM6Y>Q? D''Q8F  ')D
M
M
M
M
M
M
M
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M2XNAXK?Q\_LXB9&2&VY,>?D7IP**I<<:_M8  <F0
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MBWMK.UH]<1+T>$<1MI-7IM53OP9L>7;NWBMHF:SZKUWK/IB7K$PEXINUHO\
M&1=ER87;2? ?=CAA=?HX8>!^!=&W+'+90; V-MQ*/1\*U=G*16U7!%29G92&
M^>AN:W^UN9._26K#N18:(C51%0_>8?X5VW5HQ12EF;%;'>U+QM:EII:/1:L[
M6CZ)B87KPY:Y*5R4G>MZUO6?36T1-9^F)W;>&N_6BWZ$NT8<5U=ILH*ZNS1M
MQ2[<AJ(:X(O>NS5\.\V4);^-WBF_9OUWGS?1N8:Z%VI<NCOV$Z$[TX*FS:N&
MLUD.(MR>G;HW8FPAKINW+RG"_#:!MH;DP7<N/;RJDV&[5HPO1-6&/.W0:R&N
M";EV=J>%_#0MY/A+Z\]B^N" ;%B^';]N%_ FL79P3LQ1.*Z/(@0O@N'#Y8<"
M:S1O14W[L>SG ":Q,=R^G.\RM71PNO[,>U-2&-N"M[O R7K=P6_O39N E)=?
MCH5%3GGR*PL%NV+\M/<6WX7[%3R35VZ"Y'?6XW>=_/<!G=J78O@9TT<]YA70
MIF8N"+N&XN12I1-?'X(5#$2  ,@
M
M
M
M
M
M
M
M  !2XJ4&Y*V(MR+P7X&%,$X(9(JZ$VW]QB=H.-?VC"MRN5=-R>*>'.XQ.6Y,
M<-*\]Z=I?>J9R[<.W=Z=IBBX)ARF%_VG(E@S<$VK>OA=WW^IB5=*[_+[%P)#
MD1+\=7P(K\$3'8FKM AO7#C=XJNOAW$2*Z]?#@ORU\=EY)B;-GV8_P#5]=Q!
MB:-Z]FE;D[+D[-.L"+$<FU-?'PW7?$@Q-2=J]GQO[]R$J+O^&OT0@QW7Z]B=
M_/8! B.[D3S6]+M_D0(N&GBO9\;U[29$73O5$[-G @3#KEXX>ODG #715TIV
M=NOO6[CJN-=&=IWX)X:.%W.)-C+AWKI[..]#6Q5NPYO1$V 07KBO9RNK0G:?
M ?M-\N[LG&0C*7:>!&ZBH)9V9H]'>BW1$J]HGLH<A$A)>U7Q)5\\Z>5EZ?O<
MI$OP13[WB+@N_3?YZ,<-!UA/>9<M2R%B<GN3^!%S8EH[0SUIZA"T*^GV:EOH
M4@_!<6_=.JQVO14S5N8K;W-PV'HGP[[+XEH\$QO6V:MKQX3CQ;Y<D3[:4F/I
M:STRXG]A\+UVHB=K5T]ZXY\8R9=L6.8]E[UGZ'3<@-S6HU-#6M:G!J7)X(AF
M,4/GGG<92XT*2P  R!B5_8FU;KKM=^Q/AB93]:Z/.2*9M_;VQUB)1KGQ[5VD
MI%"1&WHK8,_.0X4V^]/P>KDUF'YUZ9MR*JHB8?'/FKCI:]I[-:5FUI]%:Q,S
M/T1#Z8<-LEZ8Z1O?)>M*1'C:TQ6(^F9V=\#V)/1[2P'1[L@Z8@=55;:K,VZJ
MBJW-B75WJVTB#$1WUVK+T*5IZ.A+<D.8B3*M:U8CK^72&NGA=?OY7'Q-)0J)
M*TZ2DZ?)-2')4^5E:?),1J-1LI)0(<K+)FHF:B]3!AWHF&=?K6\W\--&&_M7
MX?'@4LXKK[:K4Y]3?WV?+?),>CMVF8K'JK&U8]40O7PGA]=)I=/I:;=G!AQX
MHF/'L5B)M[;3$VGUS,^*5";H39=W)\[[C90FZ5VX)HPUW_$A0VW>6G?J[;[_
M !-G#;=V)>G'XW'0>BEPF]RX]B>6.)LH+=.W3HVZ.U.<") :EZ;-";MOHO<;
M*&F&]5VZE\L.X"5#;=F]Z]FGS3=@;"&W2NS'OT=R8\"+!;>N[X-^"J;"$F&]
M5XX<.=0$F&EWKL3Y)AVDYB+=HTX;^43OTF"&S1XXZE^6PF,3P^.S@B8;\ )4
M-N/#SNN[[O7<2X:(B7X;>S5W$=B:M:Z?CW)H^1+1-"<HG-UX&1B>/E@O@FO>
M9H>*WZM"<$]/-2Q5NO[$Y7P)")<GRW_#7V@77Z5_DZ./.K29(2:^WOP3G68G
MIH:FJ[Y\.W$E(B(@!RZN;M9(1,.XQPT1;S*<9YSZC<0J <@
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M(U=#D7@J%YD                           !2\J     I>!4
M                       "\I>!4%+Q>!4%%<FU#"D6_0M_#'ROX@9P8<]=
MB]R^=UWP+U?AH6_@H%X,*O78MW#[0V*E]RJB+=HO0#,"EZ"\"H   I>5
M                              I>+T J"EY8^*B(N*)Q4#(#"UZK\DO^
M'-Y5'KK1>Y>= &4&)7+J\E]#&Z+=I5$XX;-NW'E )(+&O14TH77@5!2\J
M
M     "\7@       7@                               I>!4
M  I>!4                                     !2\J
M7@                                         "EX%04O%X%08'Q41?
MPD[TT]Y7/7>J;D7T[P,P+$?N7N7T*.?L1>Y?0#(# L14TX<4N3RP+V1$70J+
MVH!D O*7@5 O*7@5                            I>!4"\I>!4&)T5$N
MQ2^_1>@:]=?DO.@#*"W.3?W+Z%BN7?=P7GG:!E!'6-=IN39JO,R.1=:=Z 7
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M9
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MK%5L2&]KFKB;HKE,;<IC:8Y3'H6=B8F(F.<3SB8[ICU  ,,@
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MB8Y;3$]T^I(U;Q:(FLQ,3$3$Q.\3$]TQ,<IB?"85 !AR
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M_P 4??8.3C\E-N?]+6=_\4Z. 'VKN#?@,G](S?YS[;'&_P"4X_Z/@_R.\?\
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MC\E-N?\ 2UG?_%.CAMXKY@M%]J[@WX#)_2,W^=4O[;'&_P"4X_Z/@_R.\?\
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MJZ?4UKEGNP9O<LN_HK6T[7GYNUW(@"U')M[]/:,Y-IJS;EP
M      QO<EWAM^TXD>GQ[9W(UD"^D4FK5=]JK;PV(K+$66B2\Y5)=RH[,^[D
MZYZTZS\-;FWMGXJS[F1(<6%3XL)R1$[F@X?GU62,6GQ7S9)[JTB9F(],^%:Q
MXVM,5CQET>(\3T^DQ3FU.;'@Q5[[Y+16-_"M8[[6GPK6)M/A$N6V(^[TV[M'
M@A\@=(SI\9'LDS'+E"RB6:LW,(Q[V4R8J#)FMQLQB/5L"B2*355C/<BHC&)*
M(YZK<U%N4Z&G3+]X%R^Y5(DW3J+6&Y,+*QE>QE'L9$B0:M'EW)F9E4M7%:E6
MF'N8KTBPZ8E'DXK7N9%EHR-:\X19N?F)J/&FIJ/&FIJ.Y71YJ9C1)B:CN5;U
M='F8SGQXKE6_&)$==J)<X+U/Y;Q%]=J(Q1/.<.#:^2/5;):.Q6?56N2/6A?C
MG77AI-J</TTYICE&;4;TQSZZXJSY2U?1-K8Y_%=[/+O[U'DEHSHLO8"Q%L;;
MQX:JQD[4W2=CZ/%O3ZL6"Z9;4ZR]B+BL.8H\@]R?51S;\Y.)7*I[T;EUJZQ(
M=F;-6 LC!SU6#$=(U*T<ZUE^"17U&>@2CGW8+U<K#:EUZ-OO.M=<@N)&T/5Q
MPC!$?O:,UOOL]K9)GVUWC'^:D(SU_6;QK43/[[G#6>ZFGI3%$>R^TY?SY)<L
MUM_;I]*FNO>Z+E:JE+;$TPK/TBSU(AM3-5+F.92X\>'?IOAQVO1;E1R8'S[7
M?:9](:I.SYS+5E*>[K7QOWFU-0DDZR)^&J-D'RK4:NJ'F]4S_P!6QI\-W(5-
MCP<!T./WFCTM?DZ?%'[*M9S=(=?DW\IK=7??[[499_;=]A_V0O+S^6?*A_3B
MT/\ \<;&F^TBZ0,D]T27RTY36/<W,<L2V%7F$5MZ+<C9J8CL:M_\9K6OU9UV
M!\5@[$\+TL\ITV"8]$X<?^5UXXMJHYQJ=1'^^R?YG)50/;*]**FJSZ/EMMG$
M2'F(C)Y]&J<-R0TN:UZ3](F7JVZ_.5(B/>J7O>Y6I=]-V-]XPZ4U)2$R8M99
MRO0H:HKF5JQ]*B1(B(B(J.F9!TA%;?=>KFII551,<.#FY!<FPZ&;HOP[)OV]
M#I)__P ?%$_GBN_ZW?P]*^*8YWIQ#65VC;;[(RS&WR9MMOZ]G:PR9>]<Y19.
M)#;:_);9"N0&HQ'OL_6*O9^;B(BKGN_X^VMR;'*U6HQ6RZ-:J*KFNON3E!R+
M^]&Y"*XL.!:^@6YL+,.S4B3,6FRMIZ1#OP6^9H<=U6?FNOSKJ$B9JHY%55<U
MG0.S4%QKVLZL^$9M]M/;#:?C8<EZ[>RMIOC_ .1LFAZT^-8)C?4USUCXN?#C
MM$^VU8IE_P#<]CUB<@'M ,C&5)K/W!Y2K)VAF(BPVI39>K2\K6&1(J+F0HE&
MGUE:FR*JI=U2RRQ,6JB7.:J_8K7HOI<M_=I3M/&PAQXD.*R/#>^'&@N1T&/#
M<Z''@N3%'08\-6Q83F_Q5A/:N]#E+Z+/MHND5DF=+0*/;Z>M%0I9L.$EFK<)
M$M12/H\-?JR\M%FXS*Q38:(JW)3*I)IG+?$;%:F:NA<5ZGKQO;1:J+^C'J*]
MF?9&7'$Q,SX;XZQZ;0D+@_7=CM,5UVCM3GM.736[5?1OY+),3$1X[9+3Z(EZ
M@UY4ZP?0T]YNR7VP?)T?*O2)K)C68RLA?=F$^-7+%QHKL_Z\2=@P65:C,>[J
MF)]/D8\M#<]5B3K(4-T8[*-C;:4>T%.E*Q0:K3JU2)^$V/(52DSTM4:=.0'I
MG,BRL[*18TO'AN3%'0XCD5-"W$5<6X#K-#?L:K!?%,SYMIC?'?;O[&2N]+>N
M(M,QRWB$P\&Z1:+B%.WI-1CS1'OJQ.V2GR\=MKT]'G5B)\)E_5@I>A4\A[0
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M"ID
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M]/M^QPO6WY\JZ/->>_GRTUYGQ[O(S,_[+\'#M4 QM??X;/0R$'+
M             #J>>]?_ (N<DWZ0JK^R%0.CD=XWWK_\7.2;](55_9"H'1R+
M2=5OP/A^<S_6W5+ZV_AK-\SI_JX  2(C,.R[[K%^/JV/Z+*A^TMGSK1'9=]U
MB_'U;']%E0_:6SYJ/3SX(UWS/]ZK<>K_ .&>'_/Q_5L[^8 *BKG@
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MZ;Z/BU/<;>3U%8WR:;),>4IZ;5VY9,>_+MU]7;K29B'[X"B*5-5;B
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M3LK?^16<_;"@'N=&/A+A_P"6Z7Z^CP.E?P7Q'\AU?U&1YF:Z5*%5TJ4+F*/
M                                  [X/NJGXG<H'Z2HO[,T8[1YU</=
M5/Q.Y0/TE1?V9HQVCRHW3WX8U_SL?5T7,ZN_@7A_S,_67  :@W0        /
MS7+)_>E:;\WJY^J9P_2C\URR?WI6F_-ZN?JF</K@]_3Y5?VP^.H^YW^1;^K+
MQ^=O%?,#;Q7S!>-04  $2H?W-,_Y-,_[B(>O-T8/Q;V!_,JR7[.TT\AFH?W-
M,_Y-,_[B(>O-T8/Q;V!_,JR7[.TTA/KG^Y:#YS4?U<2>>H_[IK_DX?VY'[J
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M)$>Y5<^(]ZJY[XCG*KGO>Y5<][U5SG*KG*KE52\ D6(V1F  R
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MXIOGKCM>NIQUB*VK2(W\O6-JTMSB(O6(I:TQ7LUG:;<^B*5+6:$+B)4R@
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M4E-T)P -2]5[//GL)%_/88H6OLNX<H7II^SGGB8VYL2O !ED
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M:/57_?V&OFVG_P"IQ5^/Z\M(^Z1\:/=(W\_L<B0+6+@7$8I9
M      !U//>O_P 7.2;](55_9"H'1R.\;[U_^+G)-^D*J_LA4#HY%I.JWX'P
M_.9_K;JE];?PUF^9T_U<  )$1F'9=]UB_'U;']%E0_:6SYUHCLN^ZQ?CZMC^
MBRH?M+9\U'IY\$:[YG^]5N/5_P##/#_GX_JV=_, %15SP
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MMI_!9LW^=EN?V@F3GL*<]+?A3B'Y7J/K++M]#/@CAOY%I_JJ@ ->;,
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MK8U.6N^ET=JWMO'++GY3CQ<^4Q&W;R1Z(K68VR0^OVLNN6^_NQYW&0 K$MB
M       '#O[>Q_\ ]";E;71=)6<T_GA0.?(YB#^-M[D[L_:JDS=!M/0Z1:.A
MU!(;9^C5VFR=7I4ZV#&AS$%LW3I^#'E)AL*/"A1X:1H+T9%APXC41[&JG?X5
MK(T^JTVHFLVC!GPYIK&T3:,>2MYB)GE$SMM&_)YW&-%.ITFJTU;16VHT^;#%
MIYQ6<N.U(M,1SF(FV\Q'@\=U8J?RF]Y3K$_E-[SUC?['9T?_ ,AN1[_5I8S^
MIA_8[.C_ /D,R/?ZL[&?U,3E]N33?R//^DQ_X*__ &C]7_+\'Z/(\G+K$_E-
M[QUB?RF]YZQO]CLZ/_Y#,CW^K.QG]3#^QV='_P#(9D>_U9V,_J8?;DTW\CS_
M *3'_@?:/U?\OP?H\CR<NL3^4WO'6)_*;WGK&_V.SH__ )#,CW^K.QG]3#^Q
MV='_ /(9D>_U9V,_J8?;DTW\CS_I,?\ @?:/U?\ +\'Z/(\G+K$_E-[QUB?R
MF]YZQO\ 8[.C_P#D,R/?ZL[&?U,/['9T?_R&9'O]6=C/ZF'VY--_(\_Z3'_@
M?:/U?\OP?H\CR<NL3^4WO'6)_*;WGK&_V.SH_P#Y#,CW^K.QG]3#^QV='_\
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M,'XM[ _F59+]G::0GUS_ '+0?.:C^KB3SU'_ '37_)P_MR/W4 $!K#@
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M/:/^KCUI.K3_ !O^T[U*YB;_ /M.]3H3URZC^18?TM_\KT/M':;^7Y_T./\
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M[N>&HDK@AA@ZUY[C,J7W)O#,LS$P\.XO*(5.-?'VRP  Y
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M;3,S,[S,SO,S/?,S/.92]2L5B*UB(B(VB(B(B(CNB(CE$1Z(6YI< <7(
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M\[+<_M!,G/84YZ6_"G$/RO4?667;Z&?!'#?R+3_55  :\V8
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MS0G!/(K=UP?"6'\CQ_79UH.I7X+S_EV3ZC3K@ 10F
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M M)H,<8M)I\>&NW/LU\^^WC?).][SZ[VF5,WG[2F;S@7 \QZRB)<5
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MS,_N4+0FGG6JZU72J[5[LP!$2:@
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M.JE2BH5,1W  #(
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MG6B.R[[K%^/JV/Z+*A^TMGS4>GGP1KOF?[U6X]7_ ,,\/^?C^K9W\P 5%7/
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M7BT1,3$Q,1,3$Q,3$]TQ,<IB8\855FLQ,Q:)K,3,3$QM,3'*8F)YQ,>,3$3
M #DPPQ;M:7HJ7*BZ%1;[T7<O=J72=_SW<GVB\3*3D_BY*+43ZS%LLFDC+PZ5
M'F(N=,UJPV<R5ID97/<KH\S9Z+F4:;=B_P"B.I4:+>^(Z(_H#N;>?4O0DZ5E
M9R)94;)92:(KXD2S]03[IR+7N:VKT"<:LK7*3&1J*CFSE/B1>IO:_J9V'*34
M-O72\%S=2Z9]'8XEHLF&(CRU-\FGMRWC+6.5=_"N2-Z6\(WBVV]8;?T'Z2VX
M7Q#'GWGR&28Q:FL>.*TQO;;QMCG:]?'E-=]K2]:MKKRX_@\F&46D6NL]1;44
M&;9/46T%+D:Q2IN&J*R8D*C+LFI6+]57(URPHC4B,O7,B(]BJJM4_O"HUJS6
M9K:)BT3,3$\IB8Y3$QZ8GDN?2\6B+5F)K:(F)CG$Q,;Q,3XQ,<X  <7(
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M/L32QH,%MM1JZSY28GGCTV^UO9.:8G''XD9.[S9?F3.=O;O,A:UMQ<61A6"
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M1YGWL"?X5N3+A:;]G*@>F"S0G!/(K=UP?"6'\CQ_79UH.I7X+S_EV3ZC3K@
M10F                         /S7+)_>E:;\WJY^J9P_2C\URR?WI6F_-
MZN?JF</K@]_3Y5?VP^.H^YW^1;^K+Q^=O%?,#;Q7S!>-04  $2H?W-,_Y-,_
M[B(>O-T8/Q;V!_,JR7[.TT\AFH?W-,_Y-,_[B(>O-T8/Q;V!_,JR7[.TTA/K
MG^Y:#YS4?U<2>>H_[IK_ ).']N1^Z@ @-8<              #$K[EU=^CL
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M%#:F#60X4-K&-30UJ(;TP0]*\7>?J9RDDSOSGOE?.(B(B(Y1'*(]0 ##(
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MOOV<&>WWN');T]U+3W/+\E?P6)_B-X?@IHYT$LC2Z8-_FHG<B8DDN[50BO=
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MV)YF-B?#R0R,3%>*>0&9=14
M                                          Q1/*[Q,3N?(RQ/3S4Q
MKZ>8&#^*NY;_ !,,;0F[Y&1/XW#XJ61OP0,3TO1=Y$BZ$XDU_P /@0XFCM0"
M#$;B[O($1-'#X*;&)I7AZFOB)@G!$[[T U\34O.A%\S7Q4Q5-B+SXFPB>O\
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MB8G:5QN'<1PZO!CU&GO&3#EKVJ6CT=TQ,=\6K.];5GG6T3$QO"\ '4=T
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M2*5CQG;OM;TWO:9M>=N=IF0 '1>B
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MB%L^JGCTZSA=<5[;Y=';['MOWSCV[6"9]E)\G'S>_BR  CM)H
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MF5S<.*N.E,=*Q2E*UI2M8VK6E8B*UK'A$1$1$>$  /F^@
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M;V!_,JR7[.TTA/KG^Y:#YS4?U<2>>H_[IK_DX?VY'[J " UAP
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MCMUC^+RQ&V3'/CO6^\1OWUVM'*890412IX[W
M                                 CKI[$)!'73V(<?'_P ]0PQM"]GQ
M,;=#>"^9DC:%[/B8VZ&\%\SDY>'T_P!C&[\+L7R0CO\ XO.HD._"[%\D([_X
MO.H.*+$TKP]2"_\ B\ZB=$TKP]2"_P#B\Z@(+_3XFOB_QNWX&P?Z?$U\7^-V
M_ #71]"_SC6O5<;_ .4G??Z7&RC:%XD"+K_G)\ -5%_!7BOP-9,:^PV<;\%>
MWX&LF-?8!K'Z7<$/DCIX?B1RR_HKRA?LC6#ZVB+BN]$0^2NG<BKD2RRHB*JK
MDLRA(B(BJJJMD:PB(B)BJKH2X[O#?X3I_G\7UE7G\6_@NI_)\WU=GF'04^JW
M^:WR,Q@@.^JW^:G@AG+M1_C^U0Z  &60(J7MO_E-_P!I 89B+U;'Q%2_JH<2
M+=MZIJONOQNOS;K]7 XV[F8>J_DY_O>H'YOT']32)_?-U<%\C\WR6S*1K,6:
MC(F:D>S-FXR-7%6I&H,A$1JKM:CKE5,%NO32?I#=7!?(H[EC:UH_&G]J_>&?
M,I\FO[(3H6GN-E"TK_U?@:R$N/=S\C9PM*_]7X'S?1M87_>-DS3V+Y(:R&OF
MY.\V;-/8OD@&P@_Q>"FR;H7M\S6P?XO!39-UIS^$!/9I3L)T+0WG:0(:Z.SS
M4GPM#>=H$R%Z?[)*9H[?B187I_LDIFCM^(&>#_&XF5?P%XF"%I7G69U_ 7B!
MG;Z>2&2'I7C\#&WT\D,D/2O'X 9@
M                                               8HGIYJ8U]/,R1
M/3S4QKZ>8$9-#N'Q4LC?@EZ:'</BI9&_! L?\/@0XFCM0F/^'P(<31VH!#B:
M5X>I!?H3_JDZ)I7AZD!ZX)_U0(,?5S_%-?%T]J^1/C+\4_\ M2!%T]J^0&LB
M:OYQK8VA>"^9L8FE.-_C<:Z-H7@OF!K(NGM]#51?B;6+I[?0U47X@0XVG_K>
MAK8NC?GFRC:?^M\$(-U]R;8C4PWN1 /-*]I.Q&]('+&UJ(U$R@U[ZK41$2^+
M"5;D2Y,;U5<-*JNE3XH/K[V@]0?-9=<KLQ%S>LB90+29V:ES?J3JPFW)>MR9
ML-NE=/$^02ZO!8VT>ECT:?#'_MU44X[:)UNLF.Z=5J-OTMP 'IO*"Q^@O+'Z
M#%NZ6+=TO0!]@;_!EL=_GBV?[33YS/M7GLYQ.%_V!B__ $,ECE__ &S;-/\
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M^BRH?M+9\U'IY\$:[YG^]5N/5_\ #/#_ )^/ZMG?S !45<\
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MX4XA^5ZCZRR[?0SX(X;^1:?ZJH #7FS
M 6JTN 'G_>\;>SH_X.+?,RO68I_4V,RCS\7[N0I:$Y):B6[B,BS4YG(UN9!E
MK4061JK ^LB?=.#56,:C8C&MZUR/0];_ *6G1DL]E?R>6HR=VH@I$I5I*;%E
M>O:QKIBFS\-4C4RL2;G(O5SM*GX<O.R[TP5T'JW(^'$>QWE4=)'H_6AR5VZM
M-D_M5+_1JY9>IQJ=-W-<V!.0FW1)*J2:O1%B4^JR42!4)&+BCI>89CG-4LQU
M9=*/LS2_8N6V^HTL17>9YY,'=CO[:<L=_P"9,SO957K6Z)_8.L^R\-=M+K+3
M:8B.6+4=^2GHB,D>Z4_GUB(BN[\9 !*"*0L>U+EO3#0O#CI3BFC2A>470!Z+
M'N__ +1%<LN2MME+1U!(]O\ )I DJ/4W1XC?I5:LXL-8-G[0W8.C1>J@+2:K
M%3.5)^39'C*GT^"L3GWSD/*"]GMTRZQD$RJV;RATSKH\G)QEI]IJ5"B.:E;L
MO/OAPZO3G-3ZL2,R&UE0I^>US65.2DWX*F<GJAY-,H-(M90*-:>S\]!J=#M!
M3)*L4FH2[VOA3=/J$"',2L9JIH5T*(W/8MSH;\Z&]&N8K4JWUC]&/L#63FQU
MVTVJFV2FT<L>3OR8N7*(WGMT[H[-NS$>9*V?5?TK_=#0QARVWU6CBN.^\^=D
MQ;;8LOIF=H[%YY^=7M3/GP_O #$L3&XCM)K5UZNR=-DINH3\U DI&1EIB<G9
MR9B-@R\I*2L%\>9F8\5ZHR%!@0(<2+%B/5&L8QSG+<BGEV^U=Z>TWT@\K]:M
M5!B1V61I+HEG[!R$7/8DO9R4C.5*C$A._M<]:"9SZM.(OUH38TM)JJI*(YW9
M]]Y<]H>VR=DY3(;9>?1EH[;RK*A;.+*Q4ZVE6,2*YL"F1'0WY\&9M/.0%8]B
MW1$H\G-*Y&LGI9T3HL-9V;DP1-UVB[=H35L+ =5'1CR>.>(YJ^Z98[&GB8YU
MQ;^?DY^.28VKRB>Q69B=LBM_7#TL\KEKPO!;W/!,9-5,3[[-MYF/V8HG>T??
MVC>(MC9+BH!-"#PL?H+E4_I;$V,JMI:S2;/4&1CU.MURHRE)I-.EFY\Q/5&?
MC-EI25A(E]SHL5Z(KE^K#9G18ET.&]4X7O%8F;3$1$3,S,[1$1WS,^$1Z6:U
MFTQ6(F;6G:(CG,S/*(B(\9F=H<M_L1/9T.R]Y6)68KDB^-DZL)%DZ[;![F/2
M7JD=(BQ*+99(EV:YU8F8#HM0AM>V(RC2TWFJR),0'M]+.5EV0FMAPX;8<-C&
ML8QC48QC&(C6L8UJ(UK6M1&M:U$:UJ(U$1$1$^ _9G=!FD]'[)19^PLFD"9K
M2L^Z]L*S"9FNK-J)YD-:A,(Y55RRDFC8=,IC%7ZDA)P7.3KHD=\3D&*F].>D
MT\3UMK4F?L;!OBT\<]IKOYV7;TY9B)],4BE9YU7%ZONBD<*T-:7K$:K/V<NI
MMRWBVWFXM_O<59[/+E-YO:/?  -,;T                             !
MU7_>LOQ2Y.?TC/\ V:J1VH#JO^]9?BER<_I&?^S52-OZ!?"^A^<M]5D:5UB_
M G$/FJ_6XW1.U]_P*E-??\"I;B.Z%,J=P #+DYC?8$_PK<F7"TW[.5 ],%FA
M.">1YGWL"?X5N3+A:;]G*@>F"S0G!/(K=UP?"6'\CQ_79UH.I7X+S_EV3ZC3
MK@ 10F                         /S7+)_>E:;\WJY^J9P_2C\URR?WI6
MF_-ZN?JF</K@]_3Y5?VP^.H^YW^1;^K+Q^=O%?,#;Q7S!>-04  $2H?W-,_Y
M-,_[B(>O-T8/Q;V!_,JR7[.TT\AFH?W-,_Y-,_[B(>O-T8/Q;V!_,JR7[.TT
MA/KG^Y:#YS4?U<2>>H_[IK_DX?VY'[J " UAP            !'B[$TKH^'9
M>>8#[:GI"+E(Z2>4FIP8_7TR@51EB:-FO5T)LE9-GW,F70T5SFM6+66U.)$5
MGU7W->J*IZ3_ $B<J<"PU@[:6TF<U8-E+*V@M"]KM$3[D4J:GF04Q:JOC1(#
M8+&HJ*Y\1K45%5%3R'ZA5YFH34S4)V*^/.3\Q'GIN/$6]\>:G(KYF9C/7^7%
MC1'Q'?XSE)JZG.&Q;-K-5,?<Z4P4GUY)F]]O7$8Z1[+;()Z[^*=G!HM'$_=<
ME]1DC\7%$4IOZK3DO]-/3MM$;H+@"?H5U "Q7XW&)D<Y'N^/1%9E/Z0='K%2
MEDF+.9,95+;5-L1$6%&J\&,LI9.3<EZ(Y7U?.J>8YKX<6#18\&(W-BHB^D0Q
M,.>WCB=;GW9#HWI9?(5.6YF9=K*AE+M'.U&#&5$SWT"S[GT.E0\ZY'M8Z=@5
M:8ZM+F9[^L3.5ZJG9':A57K(XO.JXIFK$[X]+^]L<1/*)I,SEG;NWG+-HW]%
M:QX+>=5_!8T?"<%IKMDU?[YR3X[7B(Q1OZ(Q168CPFUI\97  T)(@
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M7L5'L>U',>U45CVN2]KF/2]KVN145KFK<J*BHJHIG:Z\TIO:X
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M+5]"X,  #(
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MSTM^%.(?E>H^LLNWT,^".&_D6G^JJ  UYLP
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M?]ZR_%+DY_2,_P#9JI&W] OA?0_.6^JR-*ZQ?@3B'S5?K<;HG:^_X%2FOO\
M@5+<1W0IE3N  9<G,;[ G^%;DRX6F_9RH'I@LT)P3R/,^]@3_"MR9<+3?LY4
M#TP6:$X)Y%;NN#X2P_D>/Z[.M!U*_!>?\NR?4:=< "*$P
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M4NF['"YOMSS:C+??QVK%,<?KI957KCU7;XO%/##I<5-O#>TWRS/T^4B/HAE
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MK:/3%JS,3'LEE !\WU
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M01++"Y\.?(S)^$G:G:8(&OL\C,JW7<3$C.OIYEQ;<B\["J"O<PJ #+(
M
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MM$=EWW6+\?5L?T65#]I;/FH]//@C7?,_WJMQZO\ X9X?\_']6SOY@ J*N>
M           -?5)N'+R\>/%>V'#@P8T:)$>N:R'#A0W/>][EP:UC6JYSET(B
MJ>.95ZO$GYZ=GHW]MGIR:G(OUG/_ 'R:F(DQ$^O$57ON?$=]9ZJ]WX3E5553
MU_,K]29)64M/.1&O?#E+.UN9>UEV>YD"F345S6WX9RHU4;>MV<J7X'CW0%O1
M%W(O//# G7J7IRXC;UZ6-_9&HF8_7'YE?.O/)YW#*>K66_/.FB/V3M]*0 "<
MT!!B?I3GCS\S*8GKBG'U.-NYB9Y/2-]W6LJVG=%6P<RUF:M:J-KJN]<QS<]8
MEI)^01][G.1Z*VG-:CV(UJYJMS;VN<[G(.)/V%5+;)]$_(U"8YSD=0:M,JKD
M2]'3EJ[03CVX:F/CN8V_%6M178WG+84UZ3Y.UQ+7S/CK-3^:,UXC]4+P]$L<
M4X7PZL>&ATOYYP4F?US( #PVP
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M?\5L=?[D+$=1N./(\1OXSET]?HK3+/[;RO !"R>
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M?P6;-_G9;G]H)DY["G/2WX4XA^5ZCZRR[?0SX(X;^1:?ZJH #7FS
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MTN'28(VQX:12N_?:>^U[;=]KVF;VGQM,@ //>D
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MLQ M;D[M%*5VF.5D.<@MOEZI1YQS<Y:?6Z7&NFZ9/,5'(D*.SJX[6K&E(LQ
M5L5WU"CK^?D0SGP7Q7MCR4MCR4F:VI>LUM68[XFL[3$^U.6GU&/+2N3%>N3'
M>(M2]+1:EHGQK:-XF/8N !\GV
M  %#%%30N]/@AE+(FCM0;L,9%1<%XH2B&G\;=ZAR6Q/CYI<8(R:>U?(SQ?GW
M+\S!$1<=Z>:7_#SW!A%B?%/._P ='$AO7'L\D6_N)STO:O A1$2].WSN\O4#
M7Q454PW>1#?I)K[[L.<;L=F'J0(E^'#3V+]F(&MC)\4^/D0WKBG GQDT[EN[
MTN^SQ-<[5VIW?'#@!J8Z:>4TZO)=JFNC+CVKY&TC:%[<>TUL>Z_M;SSV@:>,
MEW9=?<G:O8:^/>W.5--RJFC2F*&TC-P77ITW;371<<=6CR7OW?$#S??:VV12
MB=)/+!*,8K(,>U<2IRZ9MU\"J4^0G6OP:U%SXD2,N<F#MJK>IQUG-W[P?8K[
ME](ZHS[69D*T5D+)U1BW*F?&EI*+2IQ]ZHB.SYB2555JK<J9JW*BHG"(7)Z*
MY_*<-T%]]]])@B?;7'6MOUQ*D/2[3^2XIQ#'][K-1MRV\VV2UJ_\LP  ]]KH
M8XAD*.2\Q([IWNTEM/I622V]#<_.?1,H3YW-54SH<"NT&F]4VY-#%C4B:>V]
M,7.B7*ZZYO9"9BJ\/4Z??NQUN^IM#E:LNZ(B).T.S-HX<+.NSWTNHS5)>K&J
MY,YS(=757(C55K+W*J-13N!05Q[_ (E3>L33>2XQK(\+VQY(_P!YAQVG_FFR
MXG5GJ?*\$T,^-*9,4_[K-DI7_DBL_2G,=H71CKX)Z&R@KAVWW]NW1H4UC-"X
MZ+KNQ;OMN-G 6]%X&E-\;2%JXJG9LX<WFV@X\%0TL%="IN7'#=HV?$VT!UUZ
M<=7;RG8!LH:^6'8MYLX6AV_T-5!Q1.U/%,-Z+M-E!=A=M1,=>F[P3Y@;!FK%
M<+\-V"^6*&PA.YX+?Y&MA.ONWIW:EN\%QUD^&M]U^[1O1;[]E]P&PA.T;KOB
MB]UZ$Q%NNX*GP-?#5;N>/PN^9.1V';Z+X: )"^2]U^/CYDI,+EWW]_VD5VO@
MGFO.'$D-55:FWT R,5$<J7;?#M,ZD=5O5JIK1>>S42$Q3B@9G_S]C.U2XQ0E
MP[K^/KH,IQB.]@ !R
M                             "\H[0%+7K<G Q:/_/4,.M5VJ8(KM7'T
MT<?#$SH1U5<Y.=-Z_9MUF11VO<B>2D76[L3Y)S@2472NV_@1FHG>J^&.&[E
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M57_&^"\\=P$A5P7L\CJ]^]2X9&+!?I'@_J"I>IV@7:%V*OEL^/@=7[WJ=/\
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MUM-J4_3XN>C4=UDC-QI5^<C'/8CLZ"N<C'N8BX-<YJ(JSIU+Y/A&OKTMH_\
M]B)G]GYU?>O/%SX9?U:RO_33']OYFG !.B 0Q/3%.>;]1E,,3T^)B6)>F][!
MZJNF^B=D<B/S,Z'1JY+*D-<$;)VPM'*PT5+U7/6%"AN>BW+G+G7(BH<O!P*>
M[<VR95.BY9F4:Z]UG[26QHCTN:F:]E6^Z>;]5J*[ZE4:[.<KG?6NSKD1K>>L
MIMTHQ]CB6OK_ /W-3,>RV6]H_5,+O]$<T7X5PZT?R+2Q/MKAI6?UQ( #P6Q
M                                     =?SWER4B1>B_5(D-N<R6MO8
MN/'6]$ZN$ZH199KKE6];XT>"RYMZIGYRIFM<J=@,X3/>%;,K4^BAE'5K%?$I
MLW8ZK,7]\7,9)6QHBS,2Z'@J?0WS#56(BPF9W6/S<Q'-V'HED[/%.'S_ /W-
M/'_%EK7^UK73+'V^$\2K_P#TM3/_  XK6_L>;"W05*(EV''S*EQU)   ?3_0
M:JD*4RUY(9J,KD@RV4NQ$:*K6J]R,9:*GJY6M;BY;DT)BNA#UKF+AVN_VE/'
MFR86@?2+3V;JS'9KZ9:&A5!KKU;<LG592/?G-5'-1$8JWHJ7;4/8)IM0AS$"
M%'@N;$@QV-CPGM6]'PHS4BPG)JN<Q[5P6['3K("ZYL4QET%_"<>>OJWK;%;^
M^L/U&9/<>(T\8RZ>_P#QTRQ^:.Q^MLP$!"B>0
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MG\%FS?YV6Y_:"9.>PISTM^%.(?E>H^LLNWT,^".&_D6G^JJ  UYLP
M                           !^-9?LB%GLI-C;26%M7)I/V?M/2IFE5*7
MN;GMA1T184U+/5'=5.2,PV#.R4=&JL";@08S4567'[*8G,QOQ\-ASQY+4M6]
M)FMJVBU;1.TUM6=XF)CNF)C>)\)?/+BK>MJ7K%J7K-;5M&];5M$Q:LQ/*8F)
MF)CQB7DE],;HKVAR*91[3Y-[2L5T]0)Y6RD^V&Z' K5%F46/1JW*HM_[S4I%
M8<5S$<_Z---FI-SG1)9ZK\SHMYZ"GO$7LX_^%/)RW*99:06-;O)I)S,U,P9:
M$KIJT%BDOF:O3FM8BNC35%=UE;IK,5=#;4Y-B.B3<%8?GRMB7XHJ*BHBHJ+>
MBHJ7HJ;E145%UWEM^AG26O$]%3-,Q&:FV/44CEV<D1'G1'WN2-KUVY1O-=YF
MLJ9=..C%N%:_)@VG['R>ZZ6\\]\5IGS)GQOBGS+;[3.T6VVM#. @-N:@   6
MN=<7&.(FCGGS,3)+]5R$Y$[192K8V=L+9.26>M!:>J2]*IL"Y>J9$C*JQIN:
MB-:[J9&GRS(\]/S#FJV!)R\:(MZM:UWJG]"SHF6>R)Y-K,Y.;-M1\I0Y)J3M
M05B0X]9K4S=&K%;FFHKKH]2G5B1\Q7OZB!U$LUZL@M4Z]ONTOLX_W,V:CY>;
M62&97K82CY"PDO,PF=93+(O>GTJN,1Z*Z%,VFC0VLE7MS'MHLLR(BNAU-6L[
M7[67<IP*V=9_2G[+U/V'BMO@TMI[<QW9-1SBWMC%&]*_C3DGG'96BZINB7V'
MI?L_-7;4ZNL>3B8YXM-OO7V6S3MDM^)&..4]J%6)<A< 16EX
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M;IIGV>6IO^IZA4);T1=W/.XR&& OU&WZ;DO3>B8F8IHO
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MM#.[+#7%>ST,FOM^'/V&!<%O[%^"]BDE-!QWYL2J #D
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M?TE+K?=5FOC/P731OO;!;+@OZII>;5COG^+O3Z/#;9D !H:0P
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MGL*<]+?A3B'Y7J/K++M]#/@CAOY%I_JJ@ ->;,
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MZ*9QSMJ-1VL6"8^+.WGY?1[G6?-_'FG*8W;]U==%8XIKXC)&^FTT5S:B/O\
MG[GB]F2T3VOQ*WVF)V<J= HLK39.4I\C+PI22D9:7DY.5EV)"@2LK*PF0)>6
M@0FW)#@P(,-D*$Q$N:QC4U*;LHC40J51F>^9[YG>97!B-N41M$<HB/   9
M                                 .J_[UE^*7)S^D9_[-5([4!U7_>L
MOQ2Y.?TC/_9JI&W] OA?0_.6^JR-*ZQ?@3B'S5?K<;HG:^_X%2FOO^!4MQ'=
M"F5.X !ER<QOL"?X5N3+A:;]G*@>F"S0G!/(\S[V!/\ "MR9<+3?LY4#TP6:
M$X)Y%;NN#X2P_D>/Z[.M!U*_!>?\NR?4:=< "*$P
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M=H]%J6FL_KA?/1ZJN?#BS4YTS8Z9:3^+DK%Z_JF  'P=D
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M^!@:MY=#P6[FZ[UU&+?_ ",Z<]I4M73W<\]A<98C_P _L  &0
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M[+ONL7X^K8_HLJ'[2V?-1Z>?!&N^9_O5;CU?_#/#_GX_JV=_, %15SP
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M3H+SM&>(SX8F?XS''9R5CTS;'M;V8I<\@+6Z$+B %C@
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MPYJY*4R4F+4O6MZ6CNM6T1-;1ZIB8F/4  ^;Z
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M21I7^UP_YK/]A"27BC_']J@5.X !ER8H_P" _P#F.\E/7NZ./XO;"?F99?\
M4<@>0C'_  '_ ,UWDIZ]W1Q_%[83\S;+_J.0(2ZY_N7#_EZC^KA3QU&_=>(_
M-Z;^MF?LX ($6(                                      ZK_O67XI
M<G/Z1G_LU4CM0'5?]ZR_%+DY_2,_]FJD;?T"^%]#\Y;ZK(TKK%^!.(?-5^MQ
MNB=K[_@5*:^_X%2W$=T*94[@ &7)S&^P)_A6Y,N%IOV<J!Z8+-"<$\CS/O8$
M_P *W)EPM-^SE0/3!9H3@GD5NZX/A+#^1X_KLZT'4K\%Y_R[)]1IUP (H3
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M?)[$SCCUX[>AG !'23@
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M///>7&&$NF_G9X:C(B<[SC$^ N !R
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M8VOFBVHO_OI[5-_7Y*,<?0IWUE\5^RN,ZN8G>F":Z:G/>(C#&V3;_?3EGDJ
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MYT,/=4?QTY1/T9)^U%-.^>5;ZTOA?+\SI_JX6SZH_@7%\]J/K  $=I-
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MF%VN \:P\0TF'5X)WIEKO-=]YQWCE?';\:EMX]$QM:/-F)7  \I[
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M6Y,N%IOV<J!Z8+-"<$\BMW7!\)8?R/']=G6@ZE?@O/\ EV3ZC3K@ 10F
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M4Q,<XF.^%0 8<@
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MR1&W=M%YB-E]N'WFV#!:=][8<<SOW[S2LSOZP '5=L
M              *%2U0Q*R*F'CW+\S&9UQ13 FCP.-?1Z&4=4N<J)LU<WF&(
MF"</%-'#7Y&:)>CK^>?B6JW2FQ>?BAR9E&OUWWHJ7=R;-MQ&5,+EU7IX>.KM
M)*I<BIL7AAQ,%V/&Y>[3W:+@PA1$POX8X=I B-^S5CI[OCB;)Z7(Y.>=)"C)
M?==KU^/PQ UL5,,+K_5-!!BM1;L-+>4^2FQB:UXX:L?MNPU$!Z(E^Y4[D^V[
M8!J8B;$QP7NTIW^)!C)?VI?H75==VZ39Q4[T6Y=^Y37Q6W7ZKM'#1?IX)P0#
M3Q4\%T[ET+XK=P-9&;A=LN3LT87=_%3<1&Z>%W;?@G&Y>TU\1+[\-*8:ME_:
MBHEX&FB-TIJ5?EX:^Y#A9]O1D16U_1VM'4($'K9^P]2I-L)96L18GT24F%IM
M88U?XD-:=47SD=?_ &=/W7+S51$U]N[Y+>?GN4NP4G:FSU>LO4838M/M'1JI
M0IV$^Y&/E:O)1Y",UU^<B-5DPN<JHN"+J0]+@W$)TNKTVIC?W'-CR3$>-:VB
M;5_G5WK]+R^-\.C6:/4Z6>7E\&3%$SX6M68K;^;;:WMAY3T/7SVF0_KLH=A)
MVRM?KEF:FU65&SU7J-$G45JMOF:5.1I*+$1JXHR,Z#UT-<;X<1BWK?>O\@BE
MT\=XM6+5F)K,1,3'=,3&\3],**WI-)FEHVM69K:)[XF.4Q/KB>2H .;B&%KG
M-<BL>Z&]+E9$8JM?#>F+8C')<K7PW7/8Y%1R.:BHMZ(9BBF)C<>F#[/W+ZW*
M9D:R=VS<]KYRIV;DY:K9KD=F5NCYU&J[%UX3\A&<BO1'N:Y'JGUD/L^&MW9]
M;Y=F*(G:=6'W:;I$)-4"WN2R<CIU]&J$O;.A0GN2]U/JK85,KD&$CESE2#/R
MM/F6PF)=#;,3,9R)UBN7M-,?BB\$[+M/?AO*==+.%?87$=5I]MJURVMC]'DL
MGNF/;V5M%9]<3'@NUT.XQ]G<,T>IF=[VPUIE^=Q;X\DS\J])M$?>S$^+9L7%
M%77AI[K_  Q-E"7#A<B\+O2[L1-9IH:X:-&%R:=J</L-E+/\4N38NPUULS;P
MG:.U+^.A=UZ&T@K@NW#L5,-/BO>:6$[1JPN7CI3AM-G"?]B[-#NS7O V\-VB
M[7M30NA/L-A!?>B\W7K<O<N*[C4P]-W:F_;V^2*3X3_7LOU[/B!MH:WW;L/E
MV+=WDZ&["_?=IP]<%Q0UL-URZ<%1/FO=ZDZ$["Y>4UW<,.;@-G#NO5.U-W*I
M>2V+AOQW8IZ^IK(:^&GAH7L5+N[438:W77Z-*KSM^>D":UU^G0N&_E%,['+H
M7F]<.>TBM5->A45?7AO^!E3"Y=F#N=^'<!(NTILQ3N\$^)(ANO1.'J8,[7LT
M\.<> AX.NVZ.[Q#*2N&/9SP)&HP+B7PW:ETW;/'A\3$L,J+L*EJJB:BXR
M
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M/=4?QTY1/T9)^U%-.^>5;ZTOA?+\SI_JX6SZH_@7%\]J/K  $=I-
M   **U"H XS/:A^S=LUTD+ 1K/5!8-,M91VS$_8BU"PU?$HU6?"1KY:;S%2)
M,4*JHR'+U:4177-;!GX#/IDE+N/,HRSY';2Y/;55RQ=KJ7'HUH[.ST6GU2GQ
M\5A1F7*R+!BI]29DIN"Z',R,W!5T&;E(L*8@JK(B7>P4<"?MN/9(RF7VRKK6
MV0E):5RM64D8GW*BYK(+;74B!GQWV5J,;!%F&N=%C6>G(UZ2D]$B2<5T.2GH
ML2#*/5WTVG0Y(T>IM^],MO,O,_P?):>_U8KS[^.ZEO=(V\_M1'UF= HU^.=;
MI*?OW#7SZ5CGJ<58][M'?FI$>9/?>L>3G?W/L^<TBX%236*--TV<FJ?4)68D
M9^1FIB3G9*;@Q)>;DYR5BO@34I-2\5&Q($S+QV/A1X,1J/AQ&N:K<"*A96EM
MXWCN5;VF-XF-IB=IB>^)]"I;FH7 Y#;)7Y]*>M(2=FDI3I]E5=3>NB?05J<.
M5B2+*@LM?U7TQLE&BRB3&;UOT:(Z"KE9<B:D Q%8CNB(W[]H[V9M,[;S,[1M
M&_A'HCU  ,L!V7?=8OQ]6Q_194/VEL^=:([+ONL7X^K8_HLJ'[2V?-1Z>?!&
MN^9_O5;CU?\ PSP_Y^/ZMG?S !45<\               !\P=,7HS4;+%DUM
MCDWKJI#D[44>/(PIM&(^)3:E#5LS2*K";>F=$IM3@2DVC,YJ16PGP'NZN*]%
M\HO*]DJKMA;4V@L;:25?)5ZS-8G:+5994<UK)N0C.@NB0E>C7/E9EB,FY.+<
MB1Y2/ C)]6(A["2\]ITXO>9_9S.F($GTA;)R-\22A2E$RE2\O#3.?(M<DO0K
M5O1N*_0WO;1JO%7.NEGTN9>C84K-1"5^JSI)&FU-M%EMMBU5HG%O.T5U$1M$
M>KRM8BF_W]<<>F4.=;W16=5I:Z_#3?/HXF,D5CG?33,S/Z&TS>/16V2>>T0Z
M9C=!4L143!<-2[EV*7ED=U8@  ?I&1++5:3)W:R@VVLA4HM)M'9RH0:C3)Z%
MBC8L)5;$@3,)51LS(SDNZ+*3TG$_>IJ4CQ8,1,U^'IR>S-]HY9;I'6!EK24E
M\O3;3TUL"3MI9/Z0D2:H%75GX<)'JD6/1:EF/F://JU4C05=*QE;.RLS"9Y:
M+D/I[H==,.W&0RW%.MY86H)*U*43Z-/T^9SXE)M!2(D1CYNB5J68YJS$A-*Q
MKF/8YDS)3+84[)184S!1SM#Z<=#:<4P=JFU-7BB9PY)Y1:.^<.2?O+3SK/?C
MMYT<IO%M]Z!=-LG"-1,7[631Y[1Y?''.:3W1FQ^$7K'*T<HR5\V>=:VKZV=Y
M4XW?9Q>TPL#TC;*LJ]G)AM-M-38$!MJ[&3D9BU:@3;VHUT2'^"M2HL>+?] J
M\NU8,5MT&9;+3K8DLSD@ST*NZW19=/EOASX[8LN.=KTM&TQ/[)B8YUM&\6B8
MF)F)A;C0:_#JL-,^GR5RX<E>U2])WB8_LF)Y6K.TUF)B8B8F%P .J[8
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MZS'6/+X-]I]$Y<43SMBM.WC,TF8K?OK:W[0"W/0N-,;R
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MIQ#\KU'UEEV^AGP1PW\BT_U50 &O-F
M        _/<K?]ZMI?S?K7ZMFC]"/SW*W_>K:7\WZU^K9H^N#W]/E5_;#Y9_
M>7^3;]DO'HE?[7#_ )K/]A"21I7^UP_YK/\ 80DEXH_Q_:H%3N  9<F*/^ _
M^:[R4]>[HX_B]L)^9ME_U'('D(Q_P'_S7>2GKW=''\7MA/S-LO\ J.0(2ZY_
MN7#_ )>H_JX4\=1OW7B/S>F_K9G[. "!%B
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M,'XM[ _F59+]G::0GUS_ '+0?.:C^KB3SU'_ '37_)P_MR/W4 $!K#@
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M.QL2#'@1H3G0XT"+#<V)"BPW.9$8Y',<YJHILD5%T$!+&Q*H
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M/*8GN,66MZUO2U;TM$6K:LQ:MJS&\6K,;Q,3'.)CE,+@ <',
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M #D
M    "BJ47;SCS\2J<Z##$=?@GV'&9WY,0MSK^!:]<%+E4C/Q73A>JKV;^&K7
MI.3*B+KUNT;,,>SB6Q,$WZN*_;\2Z_&_5JX?#G0A'OQOV:./..Y 2I==IU)M
MW\X]Q&5=?9V;M]W>IE?L[_/QV;"-$??X+Z=^H#"]VO6N&K7H[$32F\AQ'^'*
M?/82(CD6_=?Y77_#P(41UR;UO\M?9?AP P/7'NY]+C7Q':]F"<4\L<5X)M)$
M5VS#TT=R(0HS^Q4P[5W;DT@1(CM78G#7V^%Y!>_<F&":MEW?CW&>*[3HP2[;
MI\[U\2#&=HW7>-_.U (<9VG;>NK5I7G6IKHCKUU7+CJOPT<]BDF*[#LN[DOY
MNTFNBNU[=&A.WNOOX[@(45]_;A?SWW_$AO[D1+_!._U,T1=.Q,/'9N1=!"BK
MWK>O9NW^0$=[\%OUZ;_ES=VG1:]X4Z2J6ORSP;%R4QUM)R:4B'2HC6.OANM)
M6.JJ=<>JI@Y\K!6FTU<Y,^#&EYZ$BYCDO[G_ $A\M5-R=6(M7;JKJQ*?96B5
M"LQ6/5+IF-*P7.DY-&HJ*]T[.++RJ0VJKW)%7,177(OF"6]MI4;3UVLVCJ\=
MTQ5J_5:A6JG'>Y7NBSU3FHLY,N5ZXNNBQ5:BKCFM1=*DP=47!O*:G-K;1YNG
MIY+'Z\N6/.F/D8MXGU980GUU<<\EI,&@I/GZF_E<L1/\3AF.S$QZ+Y9B8^:E
M_+,T%Y:U+BXL0K6  "BGUQT \@+LI^67)Y8I6N=*56T<G,59S$15AT2CYU8K
M,7%')>V0D8Z(CD1KU<D-53/O/D=3M%^[1=')9RT-N\JDY!18%%D8-C*%$>V]
M%J-76'4JU'A7I@Z7I\K(RK8L-55OTR:@.N1ZWZWTNXK]A<.U6HWVO7%-,4^/
ME<GN>.8]EK1:8]$2V;H;P;[/XGH]/-=Z3EK?+Z/(XO=,F_H[5:S2/7:/'9W!
MH$-C41K(;(3&HF9"AHB0X;$P9"AMPS8<)MS&-3!K&HB8(AL828JNC4G#LY5"
M)"3!5WW\]N*78&S@-OQ^/8GAB4[7:2V)X8=_RQ3>MQLH+<?L3!-*\Z2% 3#M
MOXZKD^%YLX+?+'CI7PP6X"<Q$N;@F//8EZ(3H6K9>J]G.C:18:>B?+A@AL(3
M=79NN33V)KX@3&)@E_'C\M"D^%Y;M?I?\"+!3'X=Z_+#RP)T)-R8?;V[P),/
MQT)V:?%>[$FMU)JQ7NV]OPN,$)ERMQU<-'VXDV&W3V>'S0#.S2FNY.>TR)JX
MJN'ANNNVZ#%#X:5[]2>%]VZ\SM3&[3=AIYTI@H$A=*=_/IK*LTKHTW>-_EK[
M"W.NOPU)\>?(RP4P3M^ &1RX'5Z]ZH_$S83])$#PH%30[0MUZIN15]/LUG5[
M]ZJ2[(S8/](\#]050VWH'/\ _,:#Y[^Y=I?6)\"<1^8_OT=#T %NU,PHNA2I
M1="@=H+W5'\=.43]&2?M133OGG0P]U1_'3E$_1DG[44T[YY5OK2^%\OS.G^K
MA;/JC^!<7SVH^L  1VDT             "QR)<N'SW%Y10.IE[P+['M+62E0
MRZ9,:6JVJITLZ8R@6=D("N?::F2D+&TE.EX,-71;0TR S_E. U%=5Z;#2.W-
MG9)WTWH\M>BW8Z;KKM"HJ7HJ;EU+A>>R=F7>O/.K6=$#V_7L?ER?U*?RVY-*
M5FV%K$VZ/;6@T^#=!L?6)R*F=6I27AI^\V;K$T]5FF,:D"BU.+<B0I";@M@3
MIU:=./><-U=_Q=)EM/AX:>T^GPPS,]WN?A2%?>M/H#MV^*:*G+WVLPTC\^II
M$?\ O1$?[7\)+JZ L:Z_5=NV;B\G1 (     '9=]UB_'U;']%E0_:6SYUHCL
MN^ZQ?CZMC^BRH?M+9\U'IY\$:[YG^]5N/5_\,\/^?C^K9W\P 5%7/
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M!DOBRXY[5,E)VM6?V3$QRFL[UM$S%HF)F'J0^SY]J=DMZ1-)2+96I-I5JI6
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M!/W;3^"S9O\ .RW/[03)SV%.>EOPIQ#\KU'UEEV^AGP1PW\BT_U50 &O-F
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M0/3!9H3@GD5NZX/A+#^1X_KLZT'4K\%Y_P NR?4:=< "*$P
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M-ZK@NF[88(;[TYYYXF3'4)C<9T*EC%O0JBH8K/YV%P .3(
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M .I!]\']$[\IZ_T3M?\ U(>:KCM48[5'VG^&_AM9^DP_Z<^W5Q7\!H/T>?\
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MZ]W1Q_%[83\S;+_J.0(2ZY_N7#_EZC^KA3QU&_=>(_-Z;^MF?LX ($6(
M                                  ZK_O67XI<G/Z1G_LU4CM0'5?\
M>LOQ2Y.?TC/_ &:J1M_0+X7T/SEOJLC2NL7X$XA\U7ZW&Z)VOO\ @5*:^_X%
M2W$=T*94[@ &7)S&^P)_A6Y,N%IOV<J!Z8+-"<$\CS/O8$_PK<F7"TW[.5 ]
M,%FA.">16[K@^$L/Y'C^NSK0=2OP7G_+LGU&G7  BA,
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M.:HG2#H[JN&9YT^JQS6><TR1SQY:;[=O';EO'IB8BU9Y6K6>2X%+RI[;PP
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M1'N>'>.7F1,S?;OR6M&\Q6LJHEQ4 T1(8
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MWIY=U_AB!N83O#%,=*:OGM)D)V'#OP\]G U,)^K<MWQ3@3V.T+J6Y5O[O+U
MVK'+RNK6G9J4F,=W*OV]Z=QK(;KKTT\X7]UUY,AKH3NYW78=P&RAJF*+V)NY
M4D,<NCNYW*06+WIAW_!?,DM=>B;KN53G:!*ONQ[TYU[#.BWIAIN2_>1FNO[%
M\^<%,D-;ENU:M6GGL S?XR)I\%1<>>PDHY%T$9=>M%P5/CSYAKLU=J+KW>FX
M,I.*:-!G147GTW\XF%%O0([-YV\XF)CT=["0A4M1<"J*(EA4 &60
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M42O32(F+$J$5TI1H;OXS)B9:B*Q7JWG>JE4@2<O'FIJ/#E924@1IF:F8[T9
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MYUG:8[IA!&OX=GTN2<6IPY,&2O?3)6:3MZ8W[XGPM&\3'.)9@6M=>7'==,
M              !8Y]WV7EKHJ)?>J(B:UP\=7.S'&[&Z_.3:6N<ERXI=M5<,
M5N1.U;D1-:JB)>JH<D_0J]DMEMRZQI:8LI9:-2[,1G,6);:U#(]&LTR ]S46
M-(QHD%TY7+D=G(RBRLZQUSF]<U4<B=T+V?7L ,DF1I9&T%I&-RF6]E\V,RLU
MZ3A,H-&FM.=9^S3G3$M#BPEPAU*JQ*C4%<BQ9=TBU_T:'I72+IYH>'Q:MLD9
ML\<HT^&8M;?_ &EO>XH],6GM[3O6ENYO/1GJ^XCQ.:VIBG!II[]3GB:TF/\
M9U]_E\=IK'8WC:UZO@7W9/HW9<;&R]J;06CI;[/Y)[82$K.4RF5[Z1*5NI6@
ME5A0Y.T%&I+H:192EQZ8^+*3L[/I+)4V0J<^1A1X4LL<[<IA8VY?FJKXXKQ[
M-1F*S=(.-6XAJ\NJOCQXK9-O,QQ.T16(K7>9YVMM$=JT[=J8WVB.46KZ-\"I
MPW1XM'3+DRUQ;^?DF-YFTS:W9B.5*=J9FM(W[._?,[S( 'C/=
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M\7MA/S-LO^HY A+KG^Y</^7J/ZN%/'4;]UXC\WIOZV9^S@ @18@
M                            #JO^]9?BER<_I&?^S52.U =5_P!ZR_%+
MDY_2,_\ 9JI&W] OA?0_.6^JR-*ZQ?@3B'S5?K<;HG:^_P"!4IK[_@5+<1W0
MIE3N  9<G,;[ G^%;DRX6F_9RH'I@LT)P3R/,^]@3_"MR9<+3?LY4#TP6:$X
M)Y%;NN#X2P_D>/Z[.M!U*_!>?\NR?4:=< "*$P
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MTBN^O%CL60JC_K(VIPU>]731T8ZUYKV<7$JS:(Y1JL=8[7H]UQQW^N^.-_\
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M_P!C,BZBXM1;TT]Q5!$L*@ RR
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M,4TKDSX^Q2<DS%(GM5GSIK6TQRCPK//\[R8[UV>(O79XGI+?>[/1,_)W5/\
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M+T?S<,X?CTF>V.V2N3):9Q6M:FU[;QM-J4G?T^;  #5&X
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M&0X3&0X<-B,APX;&L9#8U$1K(;&(C6,1J(B-8B(ER7)<2VI<7 TUO
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M8G'.29[7;Q8]HGM1MMOX]S?@ C)*P
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M-_ ZS]%A_P!0?:4XM_*-#^DS_P"F>:]4%7Z/,X?_ $M,:_\ ]1$/7GZ+Z_\
M-O8#\R;)?L[33BVB>[K=$MS7,=DZJBM>US')_P (64+%KVJUR?WRZT54P.9Z
MR5EY*ATNG4:FPG0*?2I"2ILC!=%BQW0I.0E84G*PG1H[XD:*L.!!AL6)%>^)
M$5N?$>Y[G*L=]8'3/2\5IIJZ>F>LX;99MY:E*Q,7BD1V>QDR;SYL[[[>'>DW
MJXZ#ZOA%]5;4Y-/>,U<<4\C;);;L3;?M=O%CV]]&VV[^A !&25@
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M1O/C,RF3@O1W1</IY/2:>F&)V[5HC?)?;[_);>]O5$SM'A$*(5 /'>T
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MSP)"K<@%6)>M^JY43X\ZS-V["R$G/'%?ARIE.,3O/L  '(
M                  "BH5 %K6HA<  +5:FXN %$*@
M               45+RF:7 "S,3G[1F)N+P!2Y-A4 "W,38G*7%,SGE2\ 6Y
MB8C,3GE2X                                         6YJ;$*9B;N
M>TO %B,3=SVE4:FDN %JM12F8FQ.XO %N:F&X9I<
M
M
M
M                    M5MXS>>5+@!:C434A1&(7@ 45+RH LS$W<]HS$V)
MW%X MS4+@                               6JWGLN+@!;F)N&:FPN %
M%0(EQ4 45"F:A< *7)L*(TN
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M;+E7R3Q*IH3@7PD33OYY[3$SL,JE0!6.0  R
M
M
M
M
M
M
M
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M <@
M
M
M
M
M
M
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M#7Z+ZB6&9J8)PW%Q14O*F(  &0
M
M
M
M
M
M
M
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MB15[=6[>N\I$BJJX+NX;N<4TD1[_ )]WCY 7.=COUW]Z=VI.\AO=ANU\^:[
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M3(:</LV</%0+X;-J:5^?AIXDYFV[@G.W5PQ,3&;.U;NWO7636:;]2?9Z7:U
MO:F%VU?AW[K]NXEHW&Y.W<G.CF_$QNM=U^Q.!)8FG"]5P3X)W8KL N:MR7;/
M7#G3MN,T%-?.*\]^!C1MZW;+K]^CXWIP).G#M7GFX"E^O6N";DV]IE@MN3NY
MYVF-F*[K^W#5YX_&XD@%U)M,S$N0QPVXW\W:N>S0950Q_P"?_!*J*5 ,@
M
M
M
M
M
M
M
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M!$>FW5MVZK_AW&!7]G.S?O\ 0P.BIQ\N=:@9WQ%5-.&_9SX=Q'=$3;VKS\C
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MQR8  99    *7@5         +;P+@4O*@                 "BJ!4%$4J
M!15"*!4                   "W.YP N!;G<X#.YP N O**H%04O%X%0
M           HJ@5!2_G J                    %%47@5
M            **H%0412H                 %%47@5!;G<X%;P*@I>4S@+
M@6W\\^6G<510*@             **I4  450*@HBE0         !2\"H*(O.
M!4  6YR<W 7                              **MP10*@%%4"H%X
M        "BJ$4"H**MW*!% J           !2\"H   %%4"H*(I4
M       %+P*@MSN;T]2X "EXO J"W.YYYV%44"H
M
M
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M17JKGQ8K(36M<KHK42]>3;(WTN,EV4)B.L/E"L;:I^;GOEJ):.ES\[!1<?\
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M\2RQYL":5["<>K7HKH-=H<F75:>N7)759*1:;9(F*1BP6BNU;UCE-K3W;\T
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M%8M[8LO,07,C08C5Q;$A/8]JXHY#6.)=4.@R1,Z;+GT]O")F,V/_ (;=F_\
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M\5
M
M                                                     M52XHJ
MECB-[[[^?+@8T\=9(1#!$2Y;^%_.[7Q.,#!%;L0QZ<=::=Z<.;R61HC51;\=
M_"[E-IR&&(R^Z[F_YX\3"N/FOK\.S!%)2:MGIJ[OM,+V78\;^?"[M C*VY=V
MK=NYX*1WMNOPPPNU\WZ.\FJV_ABG/#4NPPJFI>>?#N UKF:EOW>.'9X]Y$>W
MGX^OR0VCV8W;4P\._<NDBO2_LYOVW;0-7%;MW>/QV$.(W5W+W_'2;1[>S5=J
M3TOU*18C//'==\=J)I U$1F*X:L=R[MR[2"YFCQ]4V\H;I[+[]2W>'SVZB"]
MFCF[<NWSO T\1F[Y?;W7X&OB0^=GJAO(C=/CVKIX)<0XL+G9NX:K]X&BB0]/
M*<>"ZR'&A(OP79SM-U$AZ=VS5\M7<07MNY\4W?:!HW0]**F/GO3XIZ'S_P!)
M/HUV1RL62J=B[:TQE2HU28BHJ*D.=IT[#1WT2K4F;S7/DJG)/=GRTS#P5%?
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M8B7=O/.%Y*0 7PVZUOQN^SX[M18U+UW<Z]W.!(4XSZ/SBE_-VPN*(A4Y0Q
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M&+_L*>M7T%/Q*Y(_T:6'_9NGD+]<OW#1?.Y?ZD)TZC_X1K_F</\ 7L^K0 0
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MS]'F*E!DYF-"2/"EYB) :J0HL2"J16,=^%#5')@I^R_V-/I"_D6RE?T5GO\
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MM'143U\SO5^]=_BGR8_I)C?LI6CHJ)Z^9:/JM^",/SF?ZVRI76W\-Y_FM/\
M555+':4+RQVE"1)[I1G/^'[7I'^[I_P3K ?YYRA?M]:$YQ#@[]W3_@G6 _SS
ME"_;ZT)SB%-NE/PGQ#\MU7UUUX.B7P7P[\BTOU-  '@MA      XDO;K?P4,
MLG^8J9^T='.6TXDO;K?P4,LG^8J9^T='/8Z/?"&A_+--]=1XG27X-XA^1:OZ
MC(\QQ=+OYR^8"Z7?SE\P7/CNA1I1?3S.Z?[I=_Z!RW_G!87]36A.E@OIYG=/
M]TN_] Y;_P X+"_J:T)H'6=\#:GY6#_J,21.JKX<T?R=3_TN9W @ 576\
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M"?#B2\S*2Z)!D'PWL<^HS,G!O1L1[F_&2O7===CL1+L;UU;U7!$0] 7W<'H
M?\'.3&)E2M%))"M?E0@2\U3V1X>;,TFPT!RQ:-+W.1%A1:[&5U=F67WK*OI4
M*(C8L&,PU'IMTBKP[0Y,L3'EK^Y8*SM.^2\3':F/&N.N]YWC:=HK/OHWW'H)
MT;MQ3B&+#,3Y#%[MJ+1RVQTGWL3'=;);:E9CG&\V^++L<T.DLDI.4E&19F,R
M4EH$JR-.3$6;FXK)>$R"V+-34=7QYF9B-8CX\Q%>Z+&BJ^+$<Y[U4W!1"I4:
M97.B-N4  #(
M
M
M *7 J6JO<8F-V)1\W-PU:O3T*JB+J0S.;>84V;.>PQ6?SLHF;FZ="Z]?/K>5
M78O9L5+^?L,\1MY'3^2NG5NX<-7Q.3+ YEU]^A?#>6.9I39]OCK^PE77Z>'/
M.PCZ+D5=%]R^'-^@,(RMOPYQUI\/2\C/;?JQT_#[=Y/<W&_0J8<\_&[ YMZ7
M[^[;\P-=$AWKHQ1-"\]RD5[4TIBN&'9YFS5M]ZZTU</7RN(CV87\$5.=GCW
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MZ?[I=_Z!RW_G!87]36A- ZSO@;4_*P?]1B2)U5?#FC^3J?\ I<SN!  JNMX
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M)_'5'MMA:.5CHZJ0;U1SK,T5%@S=:15:^&V?<^4I+8C7(DY'>QT!>X%T4/8
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MV'+CI><V3-EF]\TUBMK4KRQ4VB9Y4KO,\^=[6GNVB+@ :DW0
M
M
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M=.OQ?Y7_ ,^*#^S, [9I4CI_\,:[Y>/ZG&N3U<? G#_F[_790 &G-W
M       '\3E)_O>KG^9ZI^KYD\=N0_N>6_R:7_W,,]B3*3_>]7/\SU3]7S)X
M[<A_<\M_DTO_ +F&3OU+^]XA[=-^S.K[UY=_#?9JOVX$H $XH!=B3W8;^$I.
M_HRM3^M;-GH6'GG^[#Q$3I*3JJJ)_P V5J=.ZJ6;X<]QZ%38[53\)O>A6+K7
M^%I_)L/[<BU74Y\#_P#^7G_9C9@8^N9_*;_VD'7,_E-_[2$:)69 8^N9_*;_
M -I!US/Y3?\ M(!D!CZYG\IO_:0=<S^4W_M(!D!8D1JX(YJKL14+P
M !:[0O;Y%Q8], .AC[T-THWVARI68R6R4RKJ;8"BI6*K"8]%AOM+:AK7L9%1
MBXQ)"ARTHC6Q$582S[W,5O7/OZP!]1=.++A$RD98\I=N'QNOA6BMI79N0?J^
MY$O.OI]$AIN@4:2D(5Z7(JL541+SY=+D]%^&1H^'Z73Q&TTQ5F_SMX[>6?\
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M?TWM9=CHAT=Q\+T&'35B/*=GMY[1WWSWB)O,SXQ'*E?Q*U\=YFH -=;.
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MU-:Y]1;;SNU>-Z8Y]6*DQ7;N[?;M'OAJ%0#2V^        *7%0
M
M
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MKEOU)HY\R4A1$1"NE435K] 3(B7Z-%_*<\"1=J+6HB;"ZXX]_L841-9< <@
M            #JY>]5_B:L)^D>!^H*H=HTZN7O5?XFK"?I'@?J"J&W= _AC0
M?/?W+M+ZQ/@3B/S']^CH>  MTIF(IS>]%?V^N67)#D_LSDXLS1["S%#LK)QY
M&GQZK2ZC,5&+"CS\W47NFHT"I0(3WI&G8C6YD)K4AM9AG9RKPA%+CSN)<)TV
MLI7'J<-,U*VB\5R1O$6B+5BT>O:TQ[)EZ7#.,:K17MDTF>^#):O8M;'.TS3>
M+=F>4\MZUGZ'8_\ OH?I!_\ UAR:_P"A:O\ UN/OH?I!_P#UAR:_Z%J_];G7
M NW^7H+M_EZ'B_\ HCA/_P!OT_\ PR]K_P!><:_^XZG_ (X_RNQZ[WHCI":J
M#DU_T+5OZW/X&V?O+O28J;%93YBPMGLYF8L6G642<CM56JBNAQ*K/3+(;L4<
MCNI>C51+KL53K_JU->(S$.5>A7"HG>-!IM_7C[4?FMO'ZG&W3KC,QM/$M5]&
M28_77:8?472*Z;&5G*Y$1^4:W]I+5061.M@TV>GNIHLO$;?F/EZ'(,DZ3"B0
MT<K61OH;IE&JJ+'=>JK\N9F-_/.WY%R)<5-BT^FQXJQ3%CICI7NICK6E8W[]
MJUB(C\S7-1J<F:\Y,V2^7);WU\EIO>?;:TS,_G6.6Y.?D?VV3/)G:*V==IMF
M+*46H6AM!5YALK3:12I9\U.S<9RXHR&Q%1D.&WZ\Q,170Y>6A(L68BPV)G&H
MLPM*^Z4BM=;4W49)F$M391EDVU5\FCD6,R0?4/\ B4.9>V]L.),HZ%#5<]S'
MYN8O?0]BMTDNA93Y.!9K)/#;8NWU6APH%0@Y15@LMU:&.UK5^C0+2Q7+2ZG!
M6(KD@TJAQY&7?$1\2!1VJY[EUSI7TAR</T]LN+29M5;LS,>3KOBQ[?'S6C>U
M:QW\JSOW3-(GM-CZ(]&L?$M37%EUN#24WB-LEHC+E_%P4G:MKSW>=:-N^*WV
MFKZ.]B][(.2Z.] C6DM5]"JF5>TTDR#6)R65LQ)V8I3W,CI9BCS-UT=5C0X4
M:MU*$C65";A08$NJR,G B1N=5J7)<86+CP[-7S0SE4>*<4SZW/DU.HOV\N2=
MYGNB(CE6M8^+6L;16(\/7O*XG".$X-#I\>FTU(IBQQM$=\VF>=KWGXU[3SM:
M>^>[:(B(  \]Z0        =$+WK3\;N3']&]3_:R;.]Z=$+WK3\;N3']&]3_
M &LFR0>K#X7P_-Y_JK(TZVO@7/\ +P_60ZM3?3R0N+6^GDA<6FCNA4F.Z$>:
M_M47_H8O^PIZU?04_$KDC_1I8?\ 9NGGDJ37]JB_]#%_V%/6KZ"GXE<D?Z-+
M#_LW3R%^N7[AHOG<O]2$Z=1_\(U_S.'^O9]6@ @!8T     "U^A2XH[0H'0H
M]ZCRA1)[++8*SC8BNEJ!D]6>6&N=<R=KM=GW17)_%^M)4^115;>JJQ45<$1.
ML.<[/O(%3BQ^E-:&$_-S)*QUA8$'-O1<R-2HLR_.O<J*O6Q779J,3-NO17(K
MEX)BWW0C#&/A.@K'CIZ7^G)[I/Z[*6=/,TY.,<1M/?&IO3Z,>V.O_+6 8:UN
M36NQ-:]B BSRW2\PJ:4EYA4XI!>J>*&U-3B-YB/3R>G)[#3(S"L3T8,ETJD%
MT*<M!2H]LZGG0\R*^<M3.QJHQ(MZ(JK+R,23DV*J(J09>$RY<V]>75#YWZ)]
M)@2&3#)U)2[$9+REA;(P(+&HC41C+/4Y46YJ(W.55555$1+U/HA"E'&-3.;5
MZG+;OR:C->?YV2T[?1W?0O9P72UP:/2X:QM&+3X:1_-QUKO].V_KGGXJ@ \Y
MZ8       "BG\1E%L)(VFL_7+-5-BQ:;:&CU2AU"'?C$D:O(QZ?-L2]+OKP)
MA[>T_N"UR>:>:'*MIB8F)VF)B8F.^)CG$Q['&](M$UM&\6B8F)[IB8VF)]L/
M'0MG8^9L]6ZQ0)UN;.4*K5*BS;516JV9I,]'D)AN:Y5<W-C2[TS78IH7&\T!
M]J>TFL]#I?2$RU24'-ZMF4VU\=,U%:U%GZO,5%Z9JWJET2<>BXW*Z]R(C51$
M^*R[>@S^5P8LOX3'CR?\=*V_M4*UNG\CGS8H_BLV3'S_ !+S7^SP#D:]C_;]
MUFND]D3J+8BP_I-N9"@O5%P<RU,O-69=#<E]RI$6KHB(O\?,<B*K6G'*?0G0
M\K3J;E=R5U!B/5\CE'L1-M1C^K>KI>TM-B(C'IBQU[4S7Z6KJO0^/%\/E-+J
M<<QO&33YJ3'I[6.T?V_^=S[\(SSBU>ER1.TX]3@O$^B:Y*V_L>N4W07%K5\U
M\U+BE"^              XD?;L?P3LLG^9:)^UM /,=V\5\STXO;L?P3LLG^
M9:)^UM /,=V\5\RQG4]\'ZC\MM]1A5BZ[/A/3?D-/^HU(47T\RI1?3S)<0X[
MPGNG7XO\K_Y\4']F8!VS3J9>Z=?B_P K_P"?%!_9F =LTJ1T_P#AC7?+Q_4X
MUR>KCX$X?\W?Z[*  TYNX             _B<I/][U<_S/5/U?,GCMR']SRW
M^32_^YAGL292?[WJY_F>J?J^9/';D/[GEO\ )I?_ ',,G?J7][Q#VZ;]F=7W
MKR[^&^S5?MP)0 )Q0"_;.C]TD+=9*J\^T^3RTU0LG7HE/F*5$JE-9(Q)A].F
MHLO&F)1S:C)3TOU46+*2T1R]1UF=!9FO;]:_[83VU/2I_+;:W_[$LHO_ /S1
MQ=@\[4\(TF>W;S:73Y;[1';R8<=[;1W1VK5F=H\(W>GI.-:S3T\G@U6HPTWF
MW8QY;TKO/?/9K:(WG:-Y<HO]FJZ5/Y;;6?\ V'93_P M#^S5=*G\MMK/_L.R
MG_EHXN@=?_TYP_\ D.D_HV'_ ".U_P"I^)?R_5_TC+_F<HO]FJZ5/Y;;6?\
MV'93_P M#^S5=*G\MMK/_L.RG_EHXN@/_3G#_P"0Z3^C8?\ (?\ J?B7\OU?
M](R_YG*+_9JNE3^6VUG_ -AV4_\ +0_LU72I_+;:S_[#LI_Y:.+H#_TYP_\
MD.D_HV'_ "'_ *GXE_+]7_2,O^9VQ?88^TKR[Y3.D)1K)V\RFU^T]G9BREL9
MZ/2:A+T"'+1)NGR<G$DH[G2%%DIE'R[XKW,1LPC%5?KM>F!WBSSD/=O/X4M
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M[:>A6GKEXOPZEHWK]E8K3'I\G/E.?JWKSCQ[GH",3 O*-2[G<5*>+L
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M_P"M.+__ '+6?TC)_F<YGWQGTK?\,K-_T%H7H/OC/I6_X96;_H+0O0X,P/\
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MUH2/^L[X&U/RL'_48DB=57PYH_DZG_I<SN!  JNMX
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MW<B$XQ0?P4X)Y&4I/NOA
M
M
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MS$XXGNR2XPD4J86Q4NPQTIVII3BFMNE%P6XR(Z\WB):'NN !D
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M_P#5AI_VVN%^C5?H:_\ >;I]IOC'IT?Z>_\ V7G@YW-Z>HSD/0^^]E>C)_\
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MRC'@S7F?DXK3_8['!]/.76:3%$;SDU.#''\_+6O]KU(V_%?-2XM;H+BE*]X
M            XD?;L?P3LLG^9:)^UM /,=V\5\STXO;L?P3LLG^9:)^UM /,
M=V\5\RQG4]\'ZC\MM]1A5BZ[/A/3?D-/^HU(47T\RI1?3S)<0X[PGNG7XO\
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M3M6-5BBT\MHB]NQ,SOW1':WWY/3U9H[O)"XM9HWZ%+BG2[8
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M_P X+"_J:T)H'6=\#:GY6#_J,21.JKX<T?R=3_TN9W @ 576\
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MB8YQ/.)CQ@ !AD
M
M
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MN7ZDY0RHR['7RGEAN*M:B<WJ5\$.,QOZO[7&5$QV%X!R9@
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M]%J\Y3)Z3J=/COEI^G3<K4)&8AKF1)>=DH\.:E8S'IBUT*/"AO1R8HK45,2
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MZFM":!UG? VI^5@_ZC$D3JJ^'-'\G4_]+F=P( %5UO
M         <47MQ?X*.6K\V);]>4H\PY_X3OYRGIX^W%_@HY:OS8EOUY2CS#G
M_A._G*6+ZG?X!J?RNWU.!6;KM^$-)^1Q]?F6EC^>]"\L?SWH2Y/=*%Y[I=V[
MW33^\[+'^=5EOU+4CMRG4:]TT_O.RQ_G59;]2U([<I4OK"^&-;\K%]1B7%ZL
M?@+A_P C-_U.8 !IC?        '"9[P__!*RE?Y?D_\ _>)98\V!-*]AZ3_O
M#_\ !*RE?Y?D_P#_ 'B66/-@32O861ZG_@W-^69?J=.JWUU_"V#\@Q?7ZE<
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M2>O$.'8\=K1.ITE:X<U9GSK5K&V++Z9B](B+3^$K?U;_ -&"B*5-"2*
M  O  I>5
M
M
M                6W7%P#&RVZ\PN;=VX?/MU^AF5-8TX''N]GB,!AB0]FGN
MYY0SN:J*JIHW%#.[*-?CL71CKX[RBI?@O//-QE?#O\/#G Q+L7L7G5\S++ Y
MJMOUMV<\IVEJHG'#7\?@2ET8IZ*8G0\;T#"*YJIPYX?(QK#UHO/.PE)]J>GH
M8W,QO3NYT;_4#7N9LTZ>4X8IKX&![+[[\%Y[TYU&R<B+AH,#F:E3#AS=S<!K
M'0[KM7==V;".Z'SSYH;5S.U.;N/J1G0]V&[X;MH&K?#NQ1=FKX?'O,#F=B\]
M_-YM',W=V_=\=!'?#YUW=F"@:ET*[9\+_@170T^6I?EX&X5FS%-_ECY+V&!T
M/9W<\ZE T[F*FI=6&'/ CNA7X>'.S5=>;=T+=W[]BZT(SH6[OTI\OL T[X/-
M_DO*)VD=T+G0O9QYN4W+F:4\\%([H=_HOPYW@:586ST7NYU&!S.WG9Y;C<OA
M;;NWL73SJ(SH6[X?:GB!IW0471W:O5,2*^#=NPQPP[=/EN-V^%I2Z_S[%Y\#
M Z&J8>?KH TKH>"87[]O.W#7<8>K35SLTZN!N7PD6^]+EW;L.[G$P.E\=%^%
MVQ?G=]@&ECRS7L?#>UKX<1KH<6&Y$=#BPW(J.AQ8;D5D6&Y,'LB-<QR8*BHM
MQQM](KV2.0/*8^-,UNP<A2*O&1U]=LBYUF*EGNONBQF4U&4Z<5MZJUDY(1H2
MJJJYCM7)JZ%=MTZ]"X&-6[4XKI7$[>BU^?3W\II\V7#?[[%>U)GU3-9C>/5.
M\.GKN':?4T\GJ,.+/3[S+CKDK'KB+1.T^N-I];I]Y?\ W9JLRW7S>3#*+*52
M&F<Z%1+;22TZ<NQS8,.NTEL:0F(CL+XLW3:7!;CIP.%/+O[,3+SDX6,^TF3>
MT+Y&"J_\L4&72TU'>UOX41L[1%FWLA(GX468EX#&JN+L44]*SJTX8Z.?LOP4
MQJQ4ON_C)<Y$PO36B[=Z+>F!(7#.M;B6#:,WDM76/PE?)Y-O5?'V:_3;'>9]
M<HUXMU/\*U&]L'EM'>>?N5YR8^??[GE[5MO57)2(\(AY,R*J.<QV#VJYKF+@
M]KFK<YKFK]9JM5%:K51%:J*U4O0R'IZY:^A=DFRBH];;9.[*6@CQ$N=/3=)@
M0*HB*B-PK%/23JK41$2Y&SJ(BHGU;T.)'+'[N-D5KBQX]E*M:^PTR_.=#@2T
M]+VAI+'W?58V3J\+Z5"@7W7M9/1(J7+FQ/K82#P[K>T&2(C48<^GMXS&V;''
M\ZO9R3]&)''$NI;B&+>=-GT^IK'=$]K!DG^;;MXX^G*Z/ .QKE=]VHRK4OK(
MUC;96-M;!;>YL"H)4++5)S?XK(;(T.JT^+%OP<Y\[)PKKWI=^ <9>5'V4G2)
ML=UL2KY*+41Y: BNBSU @RUII%D-/_6/F:#,S[(;%NO^OFN3!'-:[ZINVAZ7
M\,U.WDM;IYF>ZM\D8K_\&7L7_4T+B'0SBNEW\MP_4Q$=]Z8YS8X_WF+MT_7[
M-W'\#<VAL[4:1%6!5J?/TJ,CE8L*J24U3HF>F"M1D["@*KDN7!M]]V%YI46]
M+TQ3:F*=Z7HO8;%6\3&\3$QX3$[Q]#6[5F)VF)B?1,;3^:506YR#/0SNX[K@
M6J]-I5%,BH           HJW%N>FT"\%N>G-PSDYN,;L;K@$QT(J]AGI\K%G
M(O42<*+.1]4"3AOFX]V"7]3+-BQ;KU1/P-*HFE4':CTPY1$SRB-_8P ^RLEO
MLZ<NMMDAQ+-Y*K:3DM$1JLGYJCQJ33;GI]7.J%761E6*Y%SD1T5%S45<$15.
M2S)+[N3ESK:P8EIJE8VQ,N_-6-#FZI%M#4X%]]Z?0J%"?(15:EU^96T156YJ
MKI/!UW2GAVFW\MK-/28[Z^5K:_+_ &=)M?\ Y6P:#HGQ/53'D-!J;Q.VUYQ6
MICY_[2\5Q_\ -^IP$F.(]&IBJ-XJB>9W1<CONT>36F]3&MO;>UEJX[+NODZ/
M"DK+4R(J8_O<9&U*JM8JWHK(D=5S;D1Z.O<<M>1#V:N0O)YU,2S&3&R\&=@X
MMJM4D4M!5D?_ .V9/UQT_%EHSM"NDDE&W7M1K6N<BZ5Q#K;X=BWC!3-J;>$Q
M7R6.?;;)M>/HQ2WOAO4UQ/+M.HOI]+6=MXF\YLD1ZJXXFDS'H\K'M>?CD,Z$
MN5S*5$AML3D^M378$6Y6U"%2XTI2$;A>]:Q44E*:K6HN<_JIF*]&W+U>*9W-
M+D#]VPRD5A8,SE#MA9ZQ<J[-=$IU&;$M56T;I5BQ(;Y"BP55OU57Z?&?#>J_
MO,3-N7NFPX"(UL-K4;#;^##2YD--29L-+FI=<B8-U)L)'5[5[L.?6\C[B?6U
MQ#+O73TQ:6L^,1Y;+'\[)$8__:W]:1N$]37#<.TZG)GUEHVWB;>0Q3_,QSY3
M\^:8]3AOZ/?L+>C[8-8$S-V<F[>56"K7I4+<3GW2EVQ$Q1T*B2<.0HL/-?\
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MW)JU_ SHER<H$1$U=R%;D4X=_L_P%-/ N .;&P  R
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M]OK*0).CY)<NU5;*_1(4"F62RD5"*]T&+!9="DZ-;.9BN<L"+"9U<M(6B?=
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MRG%]']D16,>6E[8\V&)F?)VWWI,3,1,UO28F+3$1VHM$>]ED !JK<
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M        <)GO#_\ !*RE?Y?D_P#_ 'B66/-@32O8>D_[P_\ P2LI7^7Y/_\
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MCOB>4[3"H /@[
M
M
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M%V=RZ^'B=S2\0U&#GASYL/S62^/^I,.EJ^':?41,9\&'-$\MLN*F2-O9>LN
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MY7_SXH/[,P#MFE2.G_PQKOEX_J<:Y/5Q\"</^;O]=E  :<W<
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M?9$1^QROEO;WUK6^5:9_;+"B+?CCVW\W_,S 'TB'S1U1>=7QY[N]%[LOT_\
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M[SX4B/!9GJ4U>2^@U.*TS./#J?<M^Z/*4BUZQX;1:.UM'C>9GOWFX $1IG
M
M
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M8NCO0CAW#/.T^")S;;3J,LQDS3$]^UIB(QQ/C&.M(GQW6(Q$+P#5VV@
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M=$N$9-!P[2Z3--+9,-+5M..9FDS.2]_-FU:S,;6COK', !X#8@
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M+EV'I9_>_P!T4_R8P_Z16D_K,?>_W13_ "8P_P"D5I/ZS'VX.&_@=9^CP_\
M?/M*\4_#Z'])G_T[S3+EV"Y=AZ6?WO\ =%/\F,/^D5I/ZS'WO]T4_P F,/\
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MQ+!K,^72VQXHS1:N*^6;SY3#DQQM%L-(Y3:)GSHY>E]E@ A9.H
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MD]]#^#9>'\-TNCS6I;)@KDBUL<S-)[67)DCLS:M9[K1$[UCGN  U]LH
M  #A,]X?_@E92O\ +\G_ /[Q++GFPHBWK@NH]=_I&]':R.56R-2L-;JE)6K,
M5>)3XE0IJS,S*)'?2ZC*U:27Z1)Q8,PSJ9Z2EH]S(C4?U>8^]BN:O&BWW?\
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M@ \%L0
M
M
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MQ4         "EQ4 4N0J                  *7%0    I<5
M         "EQ4 4N%Q4 "EQ4 4N07%0                         *7%0
M   %$0J                                    %+BH
M     I<FPJ *7(5  I<+BH I<5               *7(5  %+BH HA4
M       *7%0 !2Y-A4                              %%0J    %+BH
M            447%0   %+BH            "EQ4 "EQ4
M  "ER%0!2X(A4 4N%Q4 4NW%0         !2Y"H IFIS<+D*@
M
M
M                                                           %
M+BH MQOW=@<B;OL+BEQB8&#-5-_?YZREY(+',3G28WV[_P XPJU# L)47#GG
MM)*HJ<\^!1%.6XBW[45%VISRA7QX<]O-YG5B+SS]IA6&J8HO?SCSO L<Q%^T
MQJU4WIV<]J&17;=>Z[OVEU_!>&GN\OB!&W<,%]=.O7O+58G#GNYN)6:B\\]G
M-V)8=VA?+QV]NL"-F+QYV>BW:2Q6HNKX$E=..'#S**B*N@"&L->/.WG#M,:L
M36EW.WG:3NKUHO9SH^!8J+K3NY\+OF$#J^WOQV8Z.;]AC=#W7;]'//9/1B;D
MX<^!8K%37?X :Y86R[G>AB>Q;M'>G-W'YFR6'NNW\]_CHP+.KV+V?,#5K#YO
MOT\_ M6%LO\ AX^ILE9N[M':GKCVF/JTV]^SMNYP UZP]NC=ROJEZ&)8>ZZY
M?AM3N-BL+AV+=Q+5A[E[K_'2!KNKQP5?CXW=Q8L-4U(O.!L,WMN\^W06K#W+
MQ3Y>@&OZO_%^/Q+%8F_S\+KO$V*PMGCAYIKVE.JP^5WE>!K5AIN[O0MZG<GB
MAL5A\+NQ+^]+RWJDV=J;-V(&O6#N7L4MZI=_GYW&PZO&['CB'0[M?/=Y :Y8
M*[^Y"SJN'<OV&SZM=O=<4ZKF^[X\H!KNKX?]E1U?#N4V74K_ (WAZCJ5W]OR
M#&[6]7P[E'5\.Y39=2N_LO\ B.I7_&Y[0;M9U7#N4N2#Q[D^//;>;'JN/?\
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M7:RH!D
M
M
M
M
M
M
M
M
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MD*(J\Z2X=GTL;K4\"X Y&P  R
M
M
M
M
M
M
M
M
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M[E,3.PQHM^C$NS%7=Y^AE1$*F)]7_P "QK+OLYYW%]X*F=O2PH"H,L@
M
M
M
M
M
M
M
M
M
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M$S7(45=G@.?_ )_Y!NLZK:O9J]>!>C;BH&W_ .A4I<5 B!1$*@&2(
M
M
M
M
M
M
M
M
M
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M(
M
M
M
M
M
M
M
M
M
M   *7<WJ+N;U*@,;1Z  !D             4NYO%W-ZE0&-O4  ,@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>oncolyticslogotaglineblue.jpg
<TEXT>
begin 644 oncolyticslogotaglineblue.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  $! 0(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!
M 0$! @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" O_  !$(!H\/  ,!(@ "$0$#$0'_Q  ?  $
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M947_V@ , P$  A$#$0 _ -_@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                         $,Q
MF!J1!#V>0R[?=\@8U]!$$!DAC4$00S3L&8<D9(@$,T,*6O<P,^,E&?&2C-!F
MAG7T?48Y_P#:_P#<9\9*,^,E&:#-!KZ/J'/_ +7_ +C,B0S0CF8<O0S( (9H
M%) B"&KL&1G4$00R[?<,N_V&3&OH(@AGV#,&=2(
M
M
M
M
M
M
M
M
M
M
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M@4>>O"K[M_Q)DD3?[LC+!4S[!F01Z=9').KV#4QS(@AEQJ!G4:D00S(@SJ
M
M
M
M
M
M
M
M
M
M
M                                            !F  0S(AL:@@0S0E
M5Z)L]B&&_ P5""E%7*N?5[?+82Y=?O",E59$XXR]NHEZ1=R>?V$A#G)QD- 3
M:^$R(9%-94[?(D63/8FKCKX4R"X)>=QJ+=V>]?;QXD.:G:OAY?< 5ND3KX\R
M'2]7'D2:MS43CL&?AV)J^\ BKG+L3V9^\AKRVHGL]WN(*J<+D2\]H&I,J)O<
MJ]Q#FIU+YH0Z1.WR).D5=B+QM[=0,ZE9$3J\USXXZB.:]2(6_.7L3O\ M7C9
MN)><O7EW?+X P76:]GD-?6I;+_?9^?&H:NMWD 7&7>,N,U+;5UKY$$5.WS1/
M8 7&:<+]HS3A?M+?ZO4OF@^KU>U "XS3A?M&:<+]I056]7M0A]7J]J %UEQF
M,N,U+;-.I?\ I(1^K_= %SKZU&:_>F9;>*^0\<N]-?&\ N45>Q?#(AJZD+=5
M7^VS]@YR[=2]W&8!6YJ=2^?SX]Q').MWD4N>O4OA]N9/TJ=OD#.K*B9K^^3C
MC<$5R;O)$]Z%/GIO)D5.%!C4GZ5=_'F3=*G'WE/G=OG]OW#)-[45./  K\[C
M5\R8M51.I4[$1%0-1=R^WY^\ N<@FK9[=9;\Y4VHO?\ =QNZRHV5%Z_( KH]
M>SW$4E3N[_L*2.3C(BBF- 7"<:R);9$45?O7Y;0"X!221-_M0G14[ F_ $P(
M(@S"8(@9@R
M
M
M
M
M
M
M
M
M
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MOM(*_JS\\O> 7VOK4:^M2Q1_7GYY^XCST[?: 7NOK49KU^99<].WVCGIV^T
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M$7//V!&-"HBD27,:^%">H)@0S(F3(
M
M
M
M
M
M
M
M
M
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M]1'C86^75J)TDRVIX[OL..FGI&A5S0B01<R"HNXRF8;)@ 9,@
M
M
M
M
M
M
M
M
M
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M9E,  &0
M
M
M
M
M
M
M
M
M
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MO[CBU\P+A")2:_/)-^HGRZLO(SJ8)@012)DR
M
M
M
M
M
M
M
M
M
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MU<;^.$*K7Y]BY<=_> 72*GLXXR"Z]N[?Y<=766^7GQL^77U%5LFM475MXX\
M"HCE3+>FS/L*Z/1=Y0R^[=KXUY$,M>:>7'7V %TJ$S7Y;2@R7-<BL8:U!6VD
M<RW;]7NXX]Q6:Y%\^XPWIZ@3@ESXZB**<AJ1
M
M
M
M
M
M
M
M
M
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M*[']9.B%OD3M?N7A,CB^0*J.12)(NS4OM[B9%,IZ@B #(
M
M
M
M
M
M
M
M
M
M                     !!1F,S#8(9<=13>_<FWC+[/,/?KR3C[?OV$F7RS
M,):]OT =N\E<]$(/?EQQQ[+?-5UNS5-R=?=UZM?Q.1G0BJJJY[N-A'+P3OWK
MMS(+[MB%)TF>I/9X P3/?N3;N*.7G[$RZ_EXJ1S^_P"7?U[BES]>K4G'N]H!
M,Y_5MXVE)51-:\<<=DCG(FSKXU\:]10>[7K7->Y.$ )GOZ]2>WQW^7B47/\
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MSUTLLG**^#%OACZHI(I)'DF2:F]2;/+8&QY9*50>EPH\M(  Y
M                 D<W,E1BIL4J@QPH%>UUM10U$5715$]%50/22&II)I:6
MHBD38^*>!T<L;TW/8]%3<IZ)Z$O2V<H7 *0Q6G25>;G00(B-M6+$BQ70.1-C
M7_A=)J_)J?5:C;@UK6Y(UJ(C43SE(*F9TLW9F/DQX;Z*KH^%M<;$O5QIZ>M'
M>P-IY.++BQK[J):ZZU63KU]?"UJO0^1M0:#/6:KI L%-I)T;4E=']5LUWP7<
MI*&I1N?UYGV6\_2*2:14SYL%/<;=$FI.<F:J>UG)^],OR>](;H*:CQS3X;NM
M0K6,L^-:=^&ZMTKD16Q15=0Z6SU4B[/]R7*9B*UR<_--?.QZ-""QHJ*U=;5V
MM<B*U>]JZE\4-#VGNLV9?JZHV8LWWTSUAKZ:[%):>B#@2%LG>YM;'T5TJLR"
MY:704;$O195P-OTS4SK%6V[4]93PU=)4055'4(CJ>KI9XJJDJ&]<%53ND@F3
M^ZBE>FU,T4R+9,]VSJU^78<O'03RN=)VC*H;48#QUB/#2-<U7T5#<)7VF=&K
MFV.IL]5](M=1"B_^9FI'QKO:I[K\F[UE+&UIZ"BTHX.M>+:5JM9+>\-2-P[?
M4C1$19);=+T]CK)E=FYSHEM<?-R9' CM9&NU]TN?3K+&G5EP7O4U3=_0FW6_
MFMU?<B4MC;Y-G7\,<JNW#F]$Y-==3K\.M*Q?/2DOPC<\1_4OAQ[=JE5LN79W
M=?'9L/,GDR^ELT%:5%IZ6RXUH[/?)T8U,.8N1N'+NLS\LH:5:R3\&W%RN1S8
MVT%PFJ)49TBTT;7(>E#95^KK_&3G-7<Y/[9CMCF]J*J=I&V;L^_&GU>1393/
M\&R$H-KQ7$EJO!K5$I8.T<?*@K,>ZJ^M^_JG&:7H;BWH_&+T:[T9B.?9GDO=
M\BX;)U:NSM[OD85'^''7L^_(K-E5.[7WIE\^PZAW#-I+PNM/FA<-E\/:G&>K
M(PL=1K1,\_?V=W<7+94Z\O=\N/$ S+)=GWIOU)\%[RY9+LV_/QXW(85LF6_Y
M>7'85V2IQL7R^S( SK)/),M7'QU%9C_NX^'S,.V7A?GPA=,DU;?GQEU>X RS
M)-WAK7RR7O\ ',NV2IW]F6O[>]/D89DGBG5QV:N$+ADFS7]F7'W@&88_J^[5
MN^WN+AK^[C=GN]QB6R=N>K;U=_W:BZ9*BY:_;QW9 &3:_+V:MR??Y%U&_+5E
M[>..PQ+7[,^OPUKQJ747+7[-?;L\/#W:@#*-D\4ZO#9\?LS+AK^KLU<<;3%-
MD[^_5X9_--1=M?X+[_F 9!KD5$Z_=Q]V961W7]GCVE@Q^S<O?MRV?-/N*R2;
MEXX\EW %XB=OCQ[]GF5&/RU+V<<>]2V1V7=[D^)4S3V^7'E[@"[[N,]I+LS5
M-WGJ7J]WQ*37JG=LS^7&K<5L]Z+KX]G"=0!7:]%]G&XG4M%3JU*GM3L]W<56
MR\+QQ[ 9T+AK\MNS5DOS*NW7QU*40U^62;N.,SBUSU1@KH1(+K^P&4S!$ &3
M(
M
M
M
M
M
M
M
M
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M@S[/<8U,:D00S[/<0YR=PU&J)@2\].LFS,F0                  2JQ"8
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M]G'DFHXM=Z[3!61?L)B&I2"*9B]3'9_<3  R9
M
M
M
M
M
M
M
M
M
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MS5[O;K.+7>NWZS!712)+MXW\;2.9E,P1 !DR
M
M
M
M
M
M
M
M
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MLO:-KNR[I6RU?#%O2NM:Z\-=:TC"/H2U?;)R>K)$83@'L'D       #,@JH
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M.PJJA04J-=N4X-:<T8*H)=2:_$BBG/4$0
M
M
M
M
M
M
M
M
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M]#W>2CH4ZD\E,MT/8O@OP'0]_BX Q/0IU)Y*.A3J3R4R_0+U?_?$/H_&I?:
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M:F7CQQ[2BNK7YEPBHIP?+U?4&3 AF1.83
M
M
M
M
M
M
M
M
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M[VR#\J#\-4E+MCJN97/;>P,O9UKIRZ952][+MKL7X5=B\F:\='K'LDE+D3
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M?/-"+2BQV6KV]Z\9E93BN7($0$!R
M
M
M
M
M
M
M
M
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M)B7;DO<3')
M
M
M
M
M
M
M
M
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M3L^..L KQN78O;X\;.TJJI07<O5QD5F.S.+Y/4$X)4\?$F.03
M
M
M
M
M
M
M
M
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M^,E\Z:<9)232N7L+;F/M'%KRL:6L)K1Q>G%78O=US7=*#^9K24=8RBWG6/\
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M(XQ6G+Z/4"8 '(
M
M
M
M
M
M
M
M
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M+&F)\3MCYS((UYKUL%@Z1J24UEII,NFER947>H8E34\V%L%/%_-^BL]%[9M
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M;G[3C+Q\/J,%5")#,B<@
M
M
M
M
M
M
M
M
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M'13P3PO1'Q30RL?'+&]$<R1JL5,\R@663UYKL*MM=WAR  ,F 4W-SZN.%*@
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MU.RZ]GV%T 5D743%")=W9EQ\]Y5WG&/>C!, #D9
M
M
M
M
M
M
M
M
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M]_R)M2&&_ :E-(^OY?>543(B0R,:>/T 9@B#*6AC0$$0B#)D
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MCO9Z$]3*6U<6'M5DE[+KBN5=DGHKTEV0L;2L6G*QJ7\8^'R)!(Q5R)R:2#0
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MQD
M
M
M
M
M
M
M
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M-G'<54;EPG'':8;^D$$CZ]?AJ^TF1435QL(]1,8T\?H\ 0(@'(
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M"A%(-<B[".9A,$0 9
M
M
M
M
M
M
M
M
M  !!4*<NQ./'P)TV>90<N:]V?G]B*8[_ %&$-B%J[6OO[-Z^*>XN7+DA:[N]
M=W5W^Y3)D9[5ZU]FK[^KNUENB[5U9_BIQOU%65R99=R9?#YE%51/#W[U\\DU
M %%5\F^_+9X)\T*#G:]>[WY*JIX%5RY)KVKPF?=O+.3JWKM\]?CLRZ@"B_\
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M1%C,B*KP@,$54F:S/;X$S8\N_CCC(J9=6HXZZ]@(;$U!.TBB$3*6@  ,@
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MM3XIU%>)4R *T29*J=GO*JK\"@JY:^]/,K[>.HP__8PR8$$4B9,I@
M
M
M
M
M
M
M
M
M                                    @-0%V+O+9O7UZ\^.PJ2.W=R?
M/R362;$\D,(%"95V;OLU>WA-I+JS1-R)[1FBN5>KW_'62*N2)YKQU9ZNS,R"
MDYWUM^K7X\:D*+TV)U[>[/=W[R;/5KVK[L];?%=125VO/;EDFKV^[P *$KMW
M'4FS9KUY]1:/DWY\)V=J[NK87#G9(J[<]2>&KSXW%E,NQ-F2:_#9JVZE7- "
MWDRRR^676OR+";P55VY>?M74I=/=\<LO9XY["Q<_;OW>.S/Q7W %K*_MU)[D
MW^.Q3'2/V]NI.[N[MG67,B^W-$7VY]ON3(LY':W+KSRR\LNS5M +.5^[<G=J
MZ_DGD8R1V2=^WY=FKR+J9WR^?FNWN,=([-5[=O8F>I/'W %M*[)/[[;E[?9[
M#&2.VKMVIX)]OFFLNJB1?@G>F_S^9CYGY9[LM:KU9>_7OZMFL \^?2=<KEFA
M;0]BC%D$L;,05</['L)1.<B/EQ'>&204M2QBJBN;:8$J+M+S4<C?HD7/:L;G
M'-LDG?+(Z621TLDCW222R*JODD>Y7R2/<JJJOD<JO>JZU<Y5SS-@GUASE:KC
M'2I1:.;94\^QZ,Z=\5P;'(JQ5&,+M%%+=%>U%YKGV>A^BVIN:<Z*=]R1KG,F
M;EK\H6AW9; ]A[/C=..EV9PW3U7-5Z>T1_HMV>*=C3]%3-ZW2'V;M.5,):TX
M/%1'3L=VJ=\OZ:5>JY-5)KM(@ D<C( $%7( IR+D>QWH3.0^FEW2O!=[U1K4
MX)T>K28@OJ3-5::Y75)G.P[87+L>E55P/N%9&G_UA;YFN_JL;)?'FFI):F:&
MGIXI)YYY8H(((6JZ6>>9Z1PPQM1%5TDLCFQL1$UN<B;SH[^C"Y&T6A+1)8,+
M5%/$S$]P:F(,:5#$:KY<17**-TU(Z5OX\-EI6T]I@1%<UOT:1S5<C^<Z/=XW
M2/V!@RA7+3(RM::M'SC'3VZQ:=\8M1B^Z<XM=C)'W8=&/W1VC&RR.N-A\-UN
MJUC.>OM-3[M)2BYR3Y.$)+O1Z&,3>NU=:IDB>"(FI,]2(B9(B:DRU%W&S_\
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MB>*[ONZNX BU,UU;-W6J[<^.[>7&66SN[$XZB"-RR3P3CCPS"IN1,U^6KCL
M&W4GC\_D7#&(A%B9(39]F8,ZD,]B)W%5C.O7QQW=^88S+CP^[J3V3[3AV^HX
MMD-O'L0G .82^D  &0
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MJ?=L\ "_9M[TS]F7N7P*J9IK\-O5L[M6OOR+='9Y+U:^HKMZNS5WIK1>_+P
M+K/8OWY*1;J7)%U9>W[_ #)&.S3+LRWKLVD>I=^>7ELS[>.H NU0JL7ZO;K\
MRF&+DN7<OFN7W>1QDM4"LF\F)?M)C*9A  &3(
M
M
M
M
M
M
M
M
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M]?R]QIIO!<1M3-O4GOW=_6OV&0BCXZUS]R;4W=9;0MRR[/:JY<+D9*%GQ_\
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M5&,R[0UF_CCCL)]IQ[1J$7CQ)B"$3D@@
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M<8K0$0 <@
M
M
M
M
M
M
M
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MJ)L1.,P"=-1-&F>U.[CW=A+EFN7=GW+JX\BOL.,GW#4CW$&ID10B92  !D
M
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M=F75K\_D7,>Q-X!4B7=U>[=Y;%ZRKOSXVE%JY+X+["X./>8:  .1D
M
M
M
M
M
M
M
M
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MIW$%4F.,?K,  '(R
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M%[!J"9%(D$W]_P $(@PF  #(
M
M
M
M
M
M
M
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MO\?/4G&\I/38U-V7V]WCK+I$1$ #EW<9;RX1-7D4XT1<RJ<7S?H&H0B <@
M
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M;_TD^9'IF?VS?^D@3Y J D21J['(O<J$YD
M     $,R(     (9@$0                                    ,R&8!
M$$,QF 1!!7)UH44ESV+GW:_=GW@%<%'GKU+Y+[\LO@3J_5L7/N4 G!15Z]2Y
M=WWALJ9Y*J(N6S- "L"&:#, B   "&9$
M          AF,T (@AF2/E1$76B=Z@%0%%KU7[$S^'&9%'KO1?)>-@!5!25R
M[O<OR*;I<MJHG?JZNOKU\( 7()&O14VH39@$00S(@
M                                                         #,9
M@        9@                                   AF 1
M(9@$0                                          0S(@
M     9@                                               AF 1!#
M,9@$04'RHB_C)YIM\R//7M5.Q%^7F 5@2(_L7R7Y$'/ZD7R7Y %0%!9%3;J[
MTR3W:B=DB+L5%\4 *@&9#, B!F0S (@
M $,P"(&9#, B"DZ5$RUIGGLS0->N_P!R\; "J"7G)V^2_(D5R]N7<O''6 50
M6ZS9;<DZMV961R+O3S0 F!#,B  0S(@
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M%EHU:J(Y'&^Q43QQHKYI&10QMY\LCUYK8HFISII7NUY-CC1\CEW-:J[CEO\
M*>TJ28XTDX]QA*YRKB3%^(+M&COWE/57.I=2Q)U,AIDABC:BJB1M:B+DA+FY
M_ X\[(R&M51C\"]$[I:)_P!"NQ?.0SOKVCU>!C8R>CR<CBEZ:Z(-R7Z2RI_-
MW]WX<B9$0"QA64   'N[ZO#H1_9)IUGQ//#SZ/1_A>Y75KG)SF-N]Z_WCM2*
MBHJ<]L,]TJX'JJ*R6C8]N:IJ\(<T-U/U;70RVTZ*L6XVFA:E3C/%S[=3399/
M=:L*4K*7HEWJQ;I7ULS'9HU5>Y&HN3G+H^\7:/L;9.4T])7*./'_ (SX9_\
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M3).-VKCM)V:W=WR^'GX&&P56-R^SLX5?$BB$50B$S  !DR
M
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M;'T1WC[6R]I8>-??"5-UJA.*HIBW'AD].*,$UV+FF;^:;"(!7HLJ
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MG]AFAH$HN+::::>C36C37+1I]C]!(T9J23BTTTFFGJFGV--<FGW-$0 8.0
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M-UHJIDI_0YH:$UIR:T:Y:/DT_#3Q)&C)-)III\TUS37H(@ P9
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MP[_WI*[UL'1Q_!3CK_&V'O\ O%X\31R)')[E^!A[K]C?B+/ZQ=_K,/>SMO\
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M13U$4<\$\+VR0SP3,;)%-#(U5;)%+&YKXWM56N8YJHJHJ*7Q78LRF
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M$V.C8.#7[C#Q8_!QZE]436;ND.?9KUF;ESU_"R+7]<S[#_VPO3S_  SZ4/\
M+C$/_P \9&V^DBY0-$]TE/IITFL>YO,<LF,+O4(K<T7)&U51.QJY_OFM:_=S
MLM1\5@[#V7BOD\:AKP=-?^DZZVME+FLG(7_&L_U'I58/3*\J*VJSZ/IMQG(D
M?,1&5S[-<XW)&F36O2OM%2]6Y9\Y4D1[U3-[W*U,OIO!OK&'*FM*1,J,68<O
MT4:HKF7K!]JDDD1$1%1U30.H)6YY9JYJ;55437J\.<D&2=1T+NB^SK->/!Q'
M_P#3U)_2HZ_K._3TKVI6]8;0S(Z+33V1:UI\%RTU].AM8:,O6N=(M')&W%^B
MW"%\@:C$>_#]XN^'ZN1$5>>[_=[;W1L<K5:C%;3HUJHJN:[/)/4'0OZT;H(O
MBQP8OL&.<"U#N:DE3+;:7$]HCSU+G4V.=UV?S79\[*Q(G-5'(JJKFLT#N:@R
M->S-V>R+M=,>5,G[ZFR<=/5&3G7_ ,ALF#O3VU0UKDQOBO>WTUR3]<HJ%O\
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MPZY:3AX>5%)]S9_5@AFA$\@]H
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M\NTFC1=J[_A\UUIV:@"X)HF[]6Y?'6GN\BFNY.M=?<7";$[D,-@F!!")D
M
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M=48PKA&$(K2,(148Q7A&,4DEZD0G??.V<K+9SLLD]93LDYSD_%REJV_2WJ
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MK0]IEU>1%:V8UC760\91TY65Z\N./HXXP;2/WP$$4B:J;B
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MNONCIEY:C.>JTE53VUU>*?/CL7;Q-1:]K1. ".B3@      >/GI[?S3M+?\
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MCW*KGR/>JN>^1SE5SWO<JN>]ZJYSE5SE5RJI. 2*EH1F  9
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M7%*,HP2UZ^*TC"7-)3BE"4FH\,7HY>^B*1)6;$)B)290
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M1/JHOCWK\RZ;L3N #4S5?#W\>!<9\>!2BW^&7=PA.FW[N..\QIS,,G !DR
M
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MX/2</Y\41EM;869@3X,O&MH>NB<X^1+X%BUA-+OX9,PP)&+JW^)/F>LF>2
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MX;_E9CG]8*D]["G/2WSIM#Y7D?:2+M]#/-&S?D6/]E$  UXV8
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M&?T,/NR8WY'?^DK_ ,A]P_+_ "^C]'8<G+I$_MF^8Z1/[9OF=8W_ &NSD_\
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MHEHDDJB;9VSD[0OEDY5KMLEV=T81UY0KCV0A'7E%=O-O63;9$(@'JGF  AF
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M+HK[*RGM"Z/M&)+2I-<K,G1./S4Q?&^_C=?A)'ZLV/(J %<2SX
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MW:U1=6K=K]IJ9N1DHDRU]ON3(RE.F2>'V[?$Q<2;.W-=77\NPRL::E\O-$0
MO8]W8B\>SY&3B34O<G5U<?>8^///9_:IX[>%,DQ-2]J_'6 7C$V=_P ,O'A"
M^8FOSR\-G&\LXT3/++9K]NY2_B;M7JR^?"?$ N8TU<=>I/!$RU?,O4W)NS7R
M3X=Q;QHOU=75[,_FA=-38F6Q/+/4F0!6=O3N3V\;/>7";$3C4O5QVEO_ &J=
M:JO"[?%?$N6_O?/CSV $<LW+V(J;>SCNW%RNI"C#O7CR*RIGDG:#+*S$U>SR
M)R"$3C'O];,  '(
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MJVOC<3X89=*4<FI/O[%;!=O5V:-I<^"6L&WHI2_L@ ::;P
M    :GGK7_Y.=$WZ0KK^J%P-'(WC?6O_ ,G.B;](5U_5"X&CD6DW6^9Z?C+_
M +694O>WYZN^)Q_LT  2(1F#9=]5B_+UC']%EP_67#YK1&R[ZK%^7K&/Z++A
M^LN'S4>GGFC.^)_Q1-QW?^>=G_'K]F1OY@ J*7/                  !*X
MF/R[31IAP_@'"M^QEBFX16O#^&[;57:ZULSFHD5+2QJ]S8VN<WI:F=W-@I*=
MJ\^HJ98H8_KO0Y0@Y2C&*<I2:C&*6KDV]$DES;;:22[SA99&$92DU&,4Y2DW
MHHQ2U;;?))+FV?!_I4/216'DX:.ZB_U"0W/&%Z^D6W ^&WRY.N5V2-%?75K6
M_ND=DLS7MJKG,G-65>@M\+TJ*R-S>9;I7TL8BQWB:\XOQ;=:J]XCQ!737&[7
M2K=SI:FIF74C6I]2"FIXT9345) UE/14<4-+3LCBB:T^G_2%\N3$O*"TEW?'
M=]6:EH'*ZW85L+I5D@PYAJ"5SJ*WQIJ8M7-FM;=JAK46JN,TSOZE%3QQ_$9:
MOH)T0CLS&4K$GEW).^7;P=ZI@_P8>^:]W/66K2@HU!W@=,Y[6RG&MRCA42<<
M>'9QOL=\U^%/WJ?N*](Z*3GK!$(@&]F@  @JY $54R%CL-?=:ZDMEJHJRY7*
MOG92T%NM]+/75];4RJC8Z:CHZ6.6HJ:A[ER9#!&^1ZZFM4^P>0]R!-(O*"Q6
MS#& [7SX*=T,E_Q)7I)#A_#5%*Y$2JNE8UJJZ9[><ZDM=*DMQKE8[H(4B;)/
M'T)?1R^B-T8<G:VQ3V:A;B+'4T"Q7;'UXIX77:;I&HDU)9X/W2'#]JVM2DH5
M^D3LR6X5E6_F\W1^EG3K%V9%P?M^2UK&B$EJM>R5LM&JXOM2T<Y+LCIK);WT
M/W?Y>UWQKVC$3TEDSCJI:/G&F.JZV7<^:A'FI2UTB]9[D">K,XRQ:VCQ%ION
M=3@*Q2<V9F#[2M-48TK(\VN1MSJY&U-KPXR5BY]$C+I<FY.CDIZ1SFRLV^>2
MWR$=$^ABW-M^CG!5HP^O-1M3=&0NK+_<'<U&.DN%^K5GNM6YZ)]9'U219+S4
MC1J(T^OF-RX^14*[[>Z89^T6^ON<:M>6/5K"E>N*>LVOPK'*7@TN19GH[T)V
M=LR*]CT*5NGE9%ND[I/O:DUI6G^#6H1?>F^9*C40<TF!JYMA!$(@
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M*C+5R4%=,-T$6IY&R?)DN<L.<M8R\>HLDVXOPKFVGSX9QY1?.>1<R)^M:>M
M&+]&&*KI@O'5CK,/XCL\O1U=!5L:K7QOS6GK:*I9G3W"VU;/W6CKZ1\E-41K
MFQZ.1S6_D:/3CCA"=JKHSC&<)1E"24HRBU*,HM:J46M4TT]4TVFBOUM4JY2A
M9&4)PDXRA).,HRB]'%IZ--/DTUJN\F !]#@4WIDA]B\A'ENXOT Z0K9CS"<R
MRMB5M'B"Q32O9;\36"61KJRT5R-S1KERZ>W5BL=+;KA'#51HK4EBE^/B5R:M
M1ULO%KOKG5;!3KLBX3A):J47VK_+O3T:T:/OBY5E%L+J9RKMJDIUSCRE&2>J
M:_O3Y/L?+4ZY')7Y3>%-+^!K%I P96I6V._4J2L:_FMJ[?61+T=?:;E"CG+3
MW*V5224M7 JY(]B21J^&2-[OHE%.;QZ#3TGD^@;2"W#6)J]S-%N/*VEI+^R9
MSG4^&[W)T=);L6PIKZ&%B='07_F(B36SHJJ7GNM<"LZ/M).R1C)(W,?&]J/9
M(QS7L>QR(YKVN;J<UR*BM<FIR*BIJ*F],NB\]EY;JYRHLUGCV/WT-><)/LXZ
MWI&6G:G&>B4DE<;H/TMAM?#5O*.15I#)K7O9Z<IQ7;U=J3E'P:E#5N#9=@ U
M(W,                  E?L7N7W'+H],U^='II_E:O\UVXZB[]B]R^XY='I
MFOSH]-/\K5_FNW$N[G/X?D_)']M40QOM\WXGRQ?87'F0 "Q968$KO@OP)B5W
MP7X&'V,P^QG1F]6T_-9PW_*S'/ZP5)[V'@GZMI^:SAO^5F.?U@J3WL*<]+?.
MFT/E>1]I(NWT,\T;-^18_P!E$  UXV8                           $C
MR< '@OZ>ST<BZ;-%DF)<-T"3Z0]'$%;>;*R"-'5=\L71]/?L-(K4Y\\TT4#+
MA:(E5V5RI4IXF(M<Y3G(1.1<E38J(J=RIFB\=QV4I4S3RUIN[? YU?K 7HZ5
MT.:3UQOARAZ'1_I,JZVY4C((\J:Q8LS6IOMD^JJMAIZU9'7JU,5&-Z&:OIH&
MN;0/YLX[I^D^C>S+I<GQ68K;[^<K*5K\]D5X]9XI$ ;XNB6O#M:B/9PUYB2[
MN4:KWZN54WZ:WW29X$ E1R*3$[E?@4I.//CS*H /8KT(OI"I- NEZC2\52QZ
M/\>+1X;QBQZKT-O<^=6V/$R(JHC'V2MJ',K'HB\^T5E>U6NDBIG0]+NDJ8Y(
MVR1O:^.1J/8]CFO8]CDYS',>BJUS'-5',<U51S51R+DJ*<;61F>[-%U*BY*B
MHJ9*BHNI45,T5%U*FK?JZ#GJ[?I$_P#92T:NT:XGN#JC'6C*FI:.&:JFZ2JO
MN"E5*>RW!9)%62>HLZHVQW"1><]6QVVIE>^2KE5L';V.C&L8[2ICSAPUY22[
M8]E=OIX>5<GV\+AW19/.YSI6XRELJ^7*?%;B-]TM-;:5Z)+6R"Y+B5G?)(V.
M$4B2,\"<@@L.         "&9$_E,:XOMF'[5<;[>JV"VVBST-7<[G<*IZ,IJ
M*@HH9*BKJIWK^+%!!&^1RZU7)&HBN5#,4VTDFVWHDN;;?8DO$Q*22;;226K;
MY))=K;[DN]GC/Z=GTB'^P;HEJ;98*Q(-(.D..MP_AA8I$2IM-#T367[$R(GU
MF?@NEJ&4U!(BM5MWK:.1CEZ%6KS;VIJWKVKK79O5<U5=ZJN?;K/OCTF'+?NG
M*!TMXAQU4.GBL3)%LV"[7*JHEJPK02RI;F.B5SFLJ[BY\EVN2M7ZU;6/9JBA
MACB^"6ELN@G1I;-PHPG%+(NTMR'WJ37DUZ^%4?)\.)SDN4BG&\#I2]J9\YP;
M]C4:TXR[G%/RK=/&Z7E>/ H1?N2( -U-'!!5(*]#TA]%1R!ZWE"Z6[1A-T<T
M>$[5T=^QW<8T>Q*7#E),Q)*"*9J?4K[_ %',M-%S51\:35%8W)*17)T\_.KQ
MJ;+[9<-=4'.;\(Q6O+Q;Y**[6VDN;1W-GX-N5?5CTQX[;IQKA'TR>FK\$EJY
M/L44V^2-E'U9[T<Z6.RSZ?\ %5"B7?$E-4VG1]!41ITE!AQSUBNF(6-<WG15
M-^FC=044F:/2ST\[F?N5S>LFV\C3 8;PW16BW4%JM=)3T%MME'2V^WT-,QL5
M-1T-%!'34E)3Q-1&QP4U/%'#$QJ9-C8UJ)DF1_0E/>D.V[-H9=N59JN-Z0AK
MJJZH\H07J7;V:R<I:+5EUNC6P:MFX5.)5H^".MD]-';;+G98U^<^Q/5QBHQU
M>@ !XI[P                           -5_UK+\DNCG](S_U:N1M0&J_Z
MUE^271S^D9_ZM7(V_H%YWP?C)?96&E;Q?,FT/BH_:UFB=O\ /X$2&_S^!$MP
MNQ%,H=@ !DY'L;Z G\ZW1EW8F_5RX'3!9L3N3W',^] 3^=;HR[L3?JY<#I@L
MV)W)[BMV^#SE3\CK^VO+0;E?-=_RZS[#')@ 103
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M7@XM>9=!2S,F"GK)<Z*9I.%<-?<RE'25CY/5\'9'F:GL^TG (T)4
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M:X6:+@G7%OCXEPN3BH2AHVW^Y1;$V\;U7>J[57K7RK $1$U
M                             $,R@]=:>*_#CYE=-_&Y"B[;Y^\XZ\_F
M,(IO7)%[E^!0W)WE:38O<OP**;$[U]QR.7=]']Y1D;FYI1=L3OS]O'85W+]9
M.PHNV(#!9R9Y^?RX\MI9/74O;G\"_=M\_>6,FS_WOB 64GS]Z&/>NONS^*\?
M(OGJO"KW_ L7[?!/<H!C95__ %2PE=K\/@OS+Z?9_P!$QTJ;>Q,O++RS]FX
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MBYW941&ISEO%^N=P5^355,WK.KU<N3W*JJ]K7:CU+C;[7:_AY'Q-Z.6PK:]
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M<O9D B:'CP1"LFU/,IQ)[N/<56_C=V7M4,%=5(D%0B878  #(
M
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M77]4+@:.1O&^M?\ Y.=$WZ0KK^J%P-'(M)NM\ST_&7_:S*E[V_/5WQ./]F@
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M:<2%=\/2ET8\-G4RTMREQWM/G''3:4?0[IQ:?YD)1?*9_/MV$2"$2Q16D
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MY2G)N4I2?-MM\VWXLM=11"J$*ZX1KKA%1A""48QBEHHQ2T2278D  ?(^H
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M4(^+T]U*7C*<M92??)ME(]J[4NS<F[*OEQ6W3<Y>$5V1A%=T812C%=T4EJP
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MZEW>YCI%%PNAG0W'V1CJ$$K,FQ)Y&1ISG+\&/?&J+]S'O?E2\IDP -3-R
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M8>"?JVGYK.&_Y68Y_6"I/>PISTM\Z;0^5Y'VDB[?0SS1LWY%C_91  ->-F
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M[$WZN7 Z8+-B=R>XK=O@\Y4_(Z_MKRT&Y7S7?\NL^PQR8 $4$P
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M-*YL<44;5DDD<UC&N<Y$-\'T)WH,:'1Q36O2MI@M4-;I&F;'78:PO6,9446
MXI8UZ*KKX%Y]/68N>Q_.57I+!A[-(J977-):B'Y\]7@]$9'24]KY06D>UM?7
M53?I6C&PU\*.2AI'M5K,:UM-,Q<JZK:KOV,L>F=)2*MX:U)ZFBDAW"TCX7S(
M#WC=/)3E/9^'/2$=89-T'SG+LE3"2[(1]S;)<YO6'*"EQV(W8;O(PC7M/.KU
MLEI/$HFN4(]L;[(OMG+W546M(1TF]9N/ 8S+C7XKMXUZRJ 0H3P
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MVLOFDDDER2Y)>@  P9
M                     ()OXW%%VU/'WE<MLM?@AQ7;_P!^@(DDV+W+\"DO
M[U.]?APGB33)J7P^)(W8WN7WG(SW?.4G)];P]R?:47ZN;QN*[OQO!?<A;O\
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MN(@
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M?O6\YSG9)DWG.5=JJJ^T$?R]R%-NE,=-I[07_P"MROMYLO!T1>NRMF_(,/\
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MY>L8_HLN'ZRX?-1Z>>:,[XG_ !1-QW?^>=G_ !Z_9D;^8 *BESP
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MRC%=T812C%=T4D7:V3LNG"QZL6B/#53!0BN]Z=LI>,YR;E-Z<Y-L  Z)Z(
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MXQ(MGNIV\\S9<:IRUMPY>QY:]KKTXJ&_5!]6OB]>\J  CLDT
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MN4I/5MOO;;U;+FTU1KA"N$5"$(QA",5I&,(I*,8KN2222[D  ?,^@
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MMJG^+5/^@D.O-R8/R;X!_D5A+]7;:0GOG^]8'QF1^S43SN/^^9_P:?KL/W4
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M..*&&&-L4,,4349%%%$Q$9''&QK61QL1&L8UK6HB(B%Z038A$JP6[0
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MB>.>X
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M5(]J]_P *P
M                                       *4GR]ZE-?E[RI)\O>I37Y
M>\ MDV.[OBI)-^*3IL=W?%22;\4 D?\ #X%G)L\4+Q_P^!9R;/% "SDVKW?,
ML7[$_P#=+Z3:O=\RP>NI/_= +&?=Q^],?+M\5]Q?S+\4_P#O2PEV^*^X QDF
M[^^,;-L7N7WF1DVIWY^W(QTVQ>Y?> 8R7;X_(Q4OQ,K+M\?D8J7X@%G-M_\
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M7#]9</FM$;+OJL7Y>L8_HLN'ZRX?-1Z>>:,[XG_%$W'=_P">=G_'K]F1OY@
MJ*7/               !X2^L4\H5<#<FK$5LIJCH+GI#NEKP-2(Q?W1:&M?)
M<L0+DFM(I+';*VCD?J:U]9 U5SD:UWNNYV6XT?/6M=-CJ[&6BW1]#*BPV2PW
MC%E;&QR*GTR^UD-KHFSM15^O'16F26#-J<QE5)DJ](Y$W#H%L[V5M7$@UK&$
MW?+U41=B3]#G&,?G-)WB;3>)L?-G%Z3LK6/#N>M\E5+3LYQA*<E\$U,8USS7
MK7,J$K4R)BVZ*:H  R"W>J)FJYY(BN7FISER;K5$:GXSERU-VJJHB:]1T\_0
ML<D1FA[D_P"#;/4TR0XAQ)3IC7%3E1J2K>,10P5$-+([-5_WJM++9:V)JU4B
MN<U)'R*O/X]&;R=$TKZ>M&&")H%J+=<,3TMPOD:*Y$7#^'VR7Z]-5Z(O1K+0
MVZ6FB>Y%;T\T3%S1V2]6:"-&-1K41K41,D3)$1-S6HB(B-1,D1$U(FI$3(@W
M?#M=I8V#%^ZUR;5XI:UU)^AOK&UV:QB^XGO<EL5.67M"4?<:8M+T[&TK+FO2
MHNJ*?A*2[^=5-B$0""2PH
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M7 Z8+-B=R>XK=O@\Y4_(Z_MKRT&Y7S7?\NL^PQR8 $4$P
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M+7P52BTNYRD^]DP -")$
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MQ4>Q[4<Q[516/:Y,VN8],VO:Y%16N:N2HJ*BJBE=KLS2C>R8
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M-7ZW?\%S]H!7(DJ_(F!@  &0
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M7RN>JJ<*8^CJX14E^D<RX6['"5&Q<3EI*U67R]+LLEPOM?\ %J!, #1S?@
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MHZ$YG4;7V=9KIKE55M_FW2ZF7S<,WJ=-%NPB2L7-$4F*?%V
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M[1BRTH37*S([>+3OC2M))_C'!I^3)+^W;'EEM3CV%8 KJ6;
M                       !JO\ K67Y)='/Z1G_ *M7(VH#5?\ 6LOR2Z.?
MTC/_ %:N1M_0+SO@_&2^RL-*WB^9-H?%1^UK-$[?Y_ B0W^?P(EN%V(IE#L
M ,G(]C?0$_G6Z,N[$WZN7 Z8+-B=R>XYGWH"?SK=&7=B;]7+@=,%FQ.Y/<5N
MWP><J?D=?VUY:#<KYKO^76?88Y, "*"8
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MONE9.=DGK*<I3D_&4FY-_.V7SQZ(U5PJ@M(5PC"*\(PBHQ7S)(  ^1]@
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M7BI1;37J95 !\SZ@
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MB\=1%!'L,$0 9,@
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MZ%=-+]2+P]$JU#9>SHKNP<7Z71!O];8 !X9L
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MP(=T:[Y?TI5Q_P "+$;C:UU.T9][MQX_-&%K^N;)P 0L3P
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M:?FLX;_E9CG]8*D]["G/2WSIM#Y7D?:2+M]#/-&S?D6/]E$  UXV8
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M[X.B775+:E$?;*$H92BN<Z?>VO3M=3>DGV]6TWRK-5-%(E.,J%A$5O!#)"(
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M^KEP.F"S8G<GN*W;X/.5/R.O[:\M!N5\UW_+K/L,<F !%!,
M               /S73)_8EB;^3U\_FFL/TH_-=,G]B6)OY/7S^::P^M'NX?
M"C]:/CD?>Y_ E^RSC\]?>OO Z^]?>"\904   M+A_6U3_%JG_02'7FY,'Y-\
M _R*PE^KMM.0S</ZVJ?XM4_Z"0Z\W)@_)O@'^16$OU=MI">^?[U@?&9'[-1/
M.X_[YG_!I^NP_=0 0&6'             !!5 --;UM#$BI'H2M'/3FOFQQ=%
MCZ5V:K!%8:%']#GS51$K%;TJISFJ[HT7)ZH::D9MT>MEU<3L6:$8$<BS1X;Q
M]*]FO-L4]VPDV%ZZLE;(ZFG1N2JO[F[-$^KGJ.%K]V]:6QL-^*N?TY-W]VA3
M[>A+7;F;WZ=0O5ICTK3]0 !O)H /63T&>$TN_*JT1QJQSTM]TN]YR:Q7Y+;,
M/71[7NYJIS6M67-7NS:S4JHIY-GM]ZNQ2=)RK<%/5V7T;#N.ZG++/G\S#LK.
M8JYIDB]+SN=KRYJ(B+GJ\#I39P;-SY>&'D:?HI&P]$JN/:FSHOL>;C:^I6P;
M_4NSO[#I&P)DQO8U$*I)'L0G*;%WP
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M9]_SV%4XI=I@  Y
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M_-A-3E_RQ9K?3#*ZG96T+-=-,.^*?A*RMUP_YI(T<FM5%*@!<<I&@   ?U6
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MVM<=UP_?Z5:>IB7)E32SM_=*2Y6ZH1%?1W2W5#655!5QY.AJ(VJJ/C=)&_\
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MY&.>Q'<Z%><C'N8BZFN<U$59TW+V><8^G%DO_P"0F_J^DK[OSJY[,GZ,R/\
M9FO[_H,. "=" 04GIK3CC/<52C)\OB89AG3>] ]=75?).T.2/YG.CLU\IE2-
M=2-H\88CI8T5,U7GK%%&YZ+DO.7G9(BH>O!X*>K<XR9=.2YAFD:[-V'\28QL
MCTR:G->R[?A/F_5:BN^I=&NYSE<[ZV7.R1&M]ZRFW2BO@VEGQ_\ UF2UZI6S
MDOU-%W^B-RGLK9TE^18J?KC3"+_6F  >";$
M                 #7\]9<I))>2_=)(V\YE-C?!<\ZYHG1Q.N$M,UV2KFN<
MT\+,FYJG/YRIS6N5-@,\3/6%<,K<^2AI'5K%?);:O!UV8O[HO,918QLBU,F4
M>I4^AOJ&JLB+$SG=(_F\Q'-V'HE9P[4V>_\ ]9CK^E;&/]YK73*OCV3M*/\
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M5R9W]E5\>7BQ[Y9%,?IM@CJQ1[/%W^<I.4XE^JG6J9KWKK7VE0I07Q
M         )7[%[E]QRZ/3-?G1Z:?Y6K_ #7;CJ+OV+W+[CET>F:_.CTT_P K
M5_FNW$N[G/X?D_)']M40QOM\WXGRQ?87'F0 "Q968$KO@OP)B5WP7X&'V,P^
MQG1F]6T_-9PW_*S'/ZP5)[V'@GZMI^:SAO\ E9CG]8*D]["G/2WSIM#Y7D?:
M2+M]#/-&S?D6/]E$  UXV8
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MKA+1;INB7L/%]GW1TR<N*ZM-<ZL;76/JE<]+)?F*M<GQ(BQ,D)@"*R7@
M                                   :K_K67Y)='/Z1G_JU<C:@-5_U
MK+\DNCG](S_U:N1M_0+SO@_&2^RL-*WB^9-H?%1^UK-$[?Y_ B0W^?P(EN%V
M(IE#L  ,G(]C?0$_G6Z,N[$WZN7 Z8+-B=R>XYGWH"?SK=&7=B;]7+@=,%FQ
M.Y/<5NWP><J?D=?VUY:#<KYKO^76?88Y, "*"8
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M/G^#FXS?JZZ&OZCJ%1+FB+V<<=A4*,"_4;GMR3-.U$UE8IH7@
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MJV*G":[&GXKM33U4HO1QDG%I--$P .J=P
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MW%!=2Y^"_!?!2Y38<=>9AD0 <@
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MC/166KE&8*^E6B*CH-*.%J6HEPA>9>9!'<8ESFFPK>JA6JK[7<'HKJ*:1?\
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ME%=K_BYP^;NTT*@ -#)#
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MVAD8[>GLC'<H^F=,E)+T^1.Q]O<_FV'4(D$(E<BS@
M           (+L(DCW9(N]<MG;N3Q -*7UL;2JV:]Z',$1R(CZ&VXIQ95Q(Y
M<W-N=5;[+;WO9^*B1K:KDD3D^LO2RHJ(B-SU"V[#V8]/YIQ;C7E.XWC@F6:@
MP9!:,$T?UT>QLMIHF5-U6-4U9.NE?4-?_:R1/:NMJY^,S=B%O.@V"\?96%6U
MHW2K9+OUOE*[GZN-+YBEO3W/63MC/M3UBKNJB_11&-*:]#ZO7Y]>\F !MAJ)
M!3V7]7WP%^'>5=HX<Z/GT]CI\5X@J-6?,2@PS<X:-^:(J)S;E64*+SLM2Y(O
M/5N?C0IM+>JI:*OI^E72-C*2-5CPW@>DLD$BM56I58IO,50]&*OU>D92X=7G
M+^.V*HR3ZLKC5^FN4J=E9\^S7'G6G^=<NIC^NQ:&U=!L/K]L;.K\,JNUKQC0
M^NE^JOGZ#>Y8FI"8@W81*?EU@              "5^Q>Y?<<NCTS7YT>FG^5
MJ_S7;CJ+OV+W+[CET>F:_.CTT_RM7^:[<2[N<_A^3\D?VU1#&^WS?B?+%]A<
M>9  +%E9@2N^"_ F)7?!?@8?8S#[&=&;U;3\UG#?\K,<_K!4GO8>"?JVGYK.
M&_Y68Y_6"I/>PISTM\Z;0^5Y'VDB[?0SS1LWY%C_ &40 #7C9@
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M&"&-D43$3)K&-3<IFR"-1")5%OM;[6]6RX*6G)+1+DDNX  &0
M                            :K_K67Y)='/Z1G_JU<C:@-5_UK+\DNCG
M](S_ -6KD;?T"\[X/QDOLK#2MXOF3:'Q4?M:S1.W^?P(D-_G\");A=B*90[
M #)R/8WT!/YUNC+NQ-^KEP.F"S8G<GN.9]Z G\ZW1EW8F_5RX'3!9L3N3W%;
MM\'G*GY'7]M>6@W*^:[_ )=9]ACDP (H)@
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M\/*C?35=#G"ZN%L'^;9%3C^IH  ^!V0
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MP2-5DL,T;)(WIS7-12=-@](\3:-768MG%IIQUR\FVMONG#M7HDM82T?#)Z$
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M8G6].<V;+P)6KJ0F( +'@
ME=L\O>3$J[%[@P6[?BI1>NMO?\$["OO7O*4VSQ 1(JZW:NWCR+5%R54[4]I<
MJN?BB=G7Y%LN]-ZI[=_=E[/$ INVKQM,?)LR[_?]FTOEVY]?WIY)\BU?Y;/B
MB^2[0#'O77X9^W5GW)Y%C)O3Q[]>>KCK+Z1-7C]GPS1/,M9$V:MO'AK ,<]/
MJ^/Q7A#&/UJB:MB_+[S)R)J=GW^S+C(QTR9+XHOGW;M_O ,;(S5XK[=7L^!B
MYD7R3_-^9EI,\EZT7[>$,9*FM>K7VZ]ON ,3,W5W.W>9C)$UKWHO4NO[#+2)
MM14VIGXIJ5>-IC)$UIEJVIQQV 'F+Z8/1DN*^3?I2H61]+46ZQ0XEI(T;F]U
M5AJXTEUC:Q434[F0R+U9(Y'+S5U\Y1N6>K6BZVKUHNM/8=6S'V#H,0V2]8?J
M48M/?;3<[+-TC><Q(;O05%O>]R*BIE&E3TJ:E5',1S=;4.5CB?#519;K<[-5
MQ20U5GN%=:JB*75)'+;JF6C>V1->3T6'7VKYS]N;S=:,S'_%VUW)?&P<']'4
MK7X2\2N._#!TR,')2^^4V4-^FF:G'7UJZ6GJ?@88 $U$&@  %!\CF+SV*J/9
MD]JHJM5'L^LQ45%145'(BHY%147)4V'4;Y,.E1F-]'6!<7MD21V),)6"[S.S
M1?\ =M5;:=;@S-J9*L5P2JA54R15C541-B<N=6KGFG@IOH^K_P"E_P#9+R>K
M79Y)>DJ\"X@O>&)&\[-8Z":9+[:FY9YMS@N4ZY:FZT5NK41!O@P./#Q\A+[Q
M>X/EV0OAHW_3JK7S^HF?<GM#@SLK&;T61CQG'TSHGR7S0LL?+P/<1GXJ=_CU
M?'>7T:KK39FB>'9JW:C&LW^"_9]V[M+YCMGAY+\,RNQ9DR\6QO:F7CM1?!=>
M1DXE5=?8B]OGVZ^S68>%V7@OLZ]6S+(R42Y=V:^2_>F79K ,U&[4W5L79XHG
MQ^!?1KK7O\T5<E\,_D8N+/4G7[]^ONV=O:7\2ZNU=2]6?N\?$ R\:[/%,\MV
M]<N,O$OXUW]R+O[%U=?&PQD67FF:=NK=[^\OHWZD]NO5GV]V\ R4:;NOWJFO
MNZ]OD7K-B+VY9>2*G?VEA$J(J=7S^2Y\*7K':LNW[?AL\ #((N2]Z>[CO)^I
M>I5\,]B^.Y-A;HJKKWHJ+[..[P*[=G8J>66SQW*H!>+U]7NWAJISE\/?GU;B
ME$N>WN\N/D5%7\5>S7JU^.P NE3,K,=FB;]2<>PH-7,FCU+EQEE\]QB7_N"N
MG'B1)5V^7''@3&3"_P"_[@  9
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M7#]9</FM$;+OJL7Y>L8_HLN'ZRX?-1Z>>:,[XG_%$W'=_P">=G_'K]F1OY@
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MI7TIO^,K7#9%>+E7I+U5,]Y 2MV(3$ %C@
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MI\J7_.ZOUDQ;EMFNW:-^2UY&+0XI_P K>^&*_1QM_5V=_P!5(1((1*Y%G@
M            "5^Q>Y?<<NCTS7YT>FG^5J_S7;CJ+OV+W+[CET>F:_.CTT_R
MM7^:[<2[N<_A^3\D?VU1#&^WS?B?+%]A<>9  +%E9@2N^"_ F)7?!?@8?8S#
M[&=&;U;3\UG#?\K,<_K!4GO8>"?JVGYK.&_Y68Y_6"I/>PISTM\Z;0^5Y'VD
MB[?0SS1LWY%C_91  ->-F
M   !^>Z6_P"Q7$O\G[U_-M4?H1^>Z6_[%<2_R?O7\VU1]:/=P^%'ZT?*_P!Q
M/X,OJ9QZ*7^IQ_WC/\Q"Y+:E_J<?]ZS_ #$+DO$O\_K*!0[  #)R*4_XC_[Q
MWN4Z]W)Q_)[@3^1F%_YCH#D(S_B/_O7>Y3KW<G'\GN!/Y&X7_F.@(2WS_>MG
M_#R/V:2>-QOWW:/Q>-^U<?LX ($+$
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M\W)@_)O@'^16$OU=MI">^?[U@?&9'[-1/.X_[YG_  :?KL/W4 $!EAP
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MB2[^K]U3+X/ W6O37+P*X (Z).
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M:(O6FSJ[/ G+6BJ&RQ1RL7-DK&RL74OU9&H]-:9HNIQ=%+"]28
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MZ76G> 5]O'''F3%&)=N?'5[-Q41..TXI]P)@ <@
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MO4R=$R(@$ND-@ I*NO+5OVZNO7GLR[]6W,PV#V$]!5R5ETI\HO"#*JF^D6+
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MLQS^L%2>]AX)^K:?FLX;_E9CG]8*D]["G/2WSIM#Y7D?:2+M]#/-&S?D6/\
M91  ->-F                                          !^>Z6_[%<2
M_P G[U_-M4?H1^>Z6_[%<2_R?O7\VU1]:/=P^%'ZT?*_W$_@R^IG'HI?ZG'_
M 'K/\Q"Y+:E_J<?]ZS_,0N2\2_S^LH%#L  ,G(I3_B/_ +UWN4Z]W)Q_)[@3
M^1N%_P"8Z Y",_XC_P"]=[E.O=R<?R>X$_D;A?\ F.@(2WS_ 'K9_P /(_9I
M)XW&_?=H_%XW[5Q^S@ @0L0
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M:T::Y--/FFGR:?8RXD)J24HM2C))Q:>J::U337)IKFFNU$0 8.0
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M9+E=6OPX[BXW%!=9/&[<NW+J]O=\3#,%5%ZB)*JHFXF,@
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M]J[?%2SA3ZJ=JF1B3?KWKX;E[O?OR-<-G,A U$RR3?LZLDX\2_8F?BN7AO\
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MM-GT7TQM%-+2)4<WI?HTCH5<K,D3$@&%%+L26O;HNTRY-Z:MO1:+7N7@O0
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M:::331, #JG;                   !*KDV $P)>>G639@
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M.H<C8UQ%AQ9G)%3W>&-J-JZ5SHZ6\T[&P5#HJJ.GJXNC?H!Y0&$-)V%+5C3
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MY%<^:IJ)Y))II7JKI)'N<NTL43(B"R48I<EW<OF\/F*N]^KYM\VWS;U\7V@
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M.?U@J3WL*<]+?.FT/E>1]I(NWT,\T;-^18_V40 #7C9@
M                          ?GNEO^Q7$O\G[U_-M4?H1^>Z6_[%<2_P G
M[U_-M4?6CW</A1^M'RO]Q/X,OJ9QZ*7^IQ_WK/\ ,0N2VI?ZG'_>L_S$+DO$
MO\_K*!0[  #)R*4_XC_[UWN4Z]W)Q_)[@3^1N%_YCH#D(S_B/_O7>Y3KW<G'
M\GN!/Y&X7_F.@(2WS_>MG_#R/V:2>-QOWW:/Q>-^U<?LX ($+$
M                                 U7_ %K+\DNCG](S_P!6KD;4!JO^
MM9?DET<_I&?^K5R-OZ!>=\'XR7V5AI6\7S)M#XJ/VM9HG;_/X$2&_P _@1+<
M+L13*'8  9.1[&^@)_.MT9=V)OU<N!TP6;$[D]QS/O0$_G6Z,N[$WZN7 Z8+
M-B=R>XK=O@\Y4_(Z_MKRT&Y7S7?\NL^PQR8 $4$P
M        _-=,G]B6)OY/7S^::P_2C\UTR?V)8F_D]?/YIK#ZT>[A\*/UH^.1
M][G\"7[+./SU]Z^\#K[U]X+QE!0  "TN'];5/\6J?]!(=>;DP?DWP#_(K"7Z
MNVTY#-P_K:I_BU3_ *"0Z\W)@_)O@'^16$OU=MI">^?[U@?&9'[-1/.X_P"^
M9_P:?KL/W4 $!EAP               2*Q.HG !I ^L_\A1;5B*RZ>;#2/\
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M"HIYV-DAG@FB<Z.:"6-S9(I8W.9(QR.8YS513)(J+L("+&ID0
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M?W+$1J>Q"X*0VV.<I2?;*3D_6WK_ 'E^*:U"$8+LA&,5ZHI)?4  ?,^@
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M +]09$ '(
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MJ/Y:=(GZ,D_6BVF^>5;WI>=[?B<?[-%L]T?F6KX[(^T  ([)-
M    !(Y$R75]O83D% -3+U@7T/:8LI+AITT8VM5Q5;J9U1I P[00*Y^)K921
M:\26ZGAC5TN(;9 S_?.!J*Z[VV-)V\VMHG?3='EKT7+7MRRRV*BIFBIV+N75
MF=D[F9?/CC=O-$#T_7H?ET?W*OTVZ-+5S<"WBK=/C6PV^'*'!]XK)4YUZI*>
M-/W'#=XJGJM4QC4@LMSER1(J"KA;!.F[3IQ[C9N7/\W$MD^[NQY/Q[J6WV>U
M]T$5]WI] =./:F%#E[K,I@OIR8)?^LDOY7\8S5T!(UV>[+LZNPG)T(!
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M.+C*/KC))KYT33CY-=T(V560MKDM8SKE&<)+Q4HMI_,RJ""*1/B?8
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M0^5Y'VDB[?0SS1LWY%C_ &40 #7C9@
M            ?GNEO^Q7$O\ )^]?S;5'Z$?GNEO^Q7$O\G[U_-M4?6CW</A1
M^M'RO]Q/X,OJ9QZ*7^IQ_P!ZS_,0N2VI?ZG'_>L_S$+DO$O\_K*!0[  #)R*
M4_XC_P"]=[E.O=R<?R>X$_D;A?\ F.@.0C/^(_\ O7>Y3KW<G'\GN!/Y&X7_
M )CH"$M\_P!ZV?\ #R/V:2>-QOWW:/Q>-^U<?LX ($+$
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MI_BU3_H)#KS<F#\F^ ?Y%82_5VVD)[Y_O6!\9D?LU$\[C_OF?\&GZ[#]U !
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M!\5K@M/P>)]S-BF)N36IU(B>14)6;$)BJ!<(
M                  @4Y=GBA.X.RR[-1Q:[#&I078I:HGUE3K35\,_EN+IJ
M^]?>6\B<U47C5\DV>"'(R2*F;5[O<6^W)?#CCLWERNK/S^/AQM+;++--Z+SD
MZ_LS3:@!;N34Y.WW_;Y%F_<O5E\E[^%0OG[>_5[,_CPA;N9K[]?LR ,6]/)<
ME7XY>S5NW%G(FW/;GX9?$R+VZO'X99^6OV%B_7EGNSS34FK9\@#&O:F6?;EX
M9]W&TQST7X=N>Q.-YE94VHN]<_A]J=ACY&^&_L7+:O9F 8J1J9)JZT^6?OS,
M7*W;W9]ZIQX[3,R)M_NO?L^WJ1#&S-SW=N77N=]@!AY4VIN76B<=6SQ3M,9(
MFO9M3VI[NTS,F[LR\MW=V)YF.G9K7L7//?\ 8O5U@'XYIKT4V['6$<3X,N[&
M/MN*+'<K%5](SI&QQW&F?#'4]'^^=15"PUL3=JRTS.XY=&D; =RPGB&^86O,
M3J>ZX<N]RL=RA?K='66JLEH9\U34Y'/A<Y')]5R.1S55JM4ZM3T3S^.:\;T-
M&#UA[DPKA'2_1X]H:;H[/I+MC*NH>QN44>*;''#;[M&N348Q]90);:]K$S<N
M<\TCE=(N4O;H]L]5E784GY.3!65K^5J3;27Y];DW\6D0MOHV'UN'1G07E8L^
MKM:_$W-)-_ M44E_*R/ =%U$2"$2Q16@   @[8;&/JY?*H_8YI$ONBZY521V
MO']$EQLK)'JC&8LL,#GK%&BJC&R7>R_2(-[YJBW4$#$57N-<\_M-&FD.Z80Q
M%8L4V.=::\8=NU!>K;,URLYE9;JB.HB1SFJB]'+S%@F3/7#+(W>>)TCV1'/P
MLC%EHNMK? W[VR.DJI>J,XQ;\5JN\]WHSMJ6S\_&S(ZZ4V+K(KW]4DX6Q^>N
M4DM>2EH^XZJ<;]2:\TVZM?=QJ\R_C<FOJ5,^_5NXUGX)R<=.=JTE8&PICRR.
M:MNQ39J6Z,C:J9TE1*U8[A02(GXLUNN$550S,_>2T[V:\LS]T9ORV[4XW9\(
M4VNJE7.5<XN,X2E"<7VQE%M23]*::?J+OTW1LA"R#4H61C.$ES4HR7%&2]#3
MU7HT,M [++-=:>.KCXF18[;QJW^:;M_L,-&N_5MX[^K5O,E$[5VIEY:_MUGS
M/H9B)>W+Y;?8NPR;':L^Y%3Q^>_P,(Q_7U+V:EVHG=[3)Q2:O8N>S9J\T\E
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M:]P:U!70B2,7-"**AB+^DP3  Y&0
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MY[RLNI.X&63LUKQQXFKOZU7^1K ?Z1X?Y@N9M%1-RXWKKS\=7D:NGK5B_P#
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ML7"RN<H3B^V,HO1KYFO4^U<BZ^+E5WU5W524Z[81LKDNR4)I2B_G3[.U=C
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MH'3LBKCGPVYML?;;M.4$]'U5.JU4$UY4M$[&M6DE&,9D;D3 &C$@@
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M_;!W).7)$TGKFJHB?^2>+]JZM]DR.:KKZU)X\^<W6OXR>\?<?V;^.S/TE/\
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M]RG7NY./Y/<"?R-PO_,= 0EOG^];/^'D?LTD\;C?ONT?B\;]JX_9P 0(6(
M                                        !JO^M9?DET<_I&?^K5R-
MJ U7_6LOR2Z.?TC/_5JY&W] O.^#\9+[*PTK>+YDVA\5'[6LT3M_G\")#?Y_
M B6X78BF4.P  R<CV-] 3^=;HR[L3?JY<#I@LV)W)[CF?>@)_.MT9=V)OU<N
M!TP6;$[D]Q6[?!YRI^1U_;7EH-ROFN_Y=9]ACDP (H)@
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M-R1;O=QT0_<K"UMC^^\GALO[&ZTE[73JN7D)MST[;)26K48LBB9$0#1"0P
M                                        2Y:LNPF(9F&"W5,E7S*<
MVSQ]F\JR;<^Y%^'Q[DUDKDSXX^\)@M4W+WHO'S*4J9*B]^>2[MO'D5&IM3QZ
M\LM^?=YD)=:>&:=^WRRSS\C(9:O34O9E[-G;WE"7<OGW?9O+I=G8J+YIQK[=
M1;N;GJZM6O>F7S^8!8/3;V^_[M>7463T\TX5$[TUIU&2D;J15\?++QX4LI6(
MB]>_X*OC\@#%S)OZLM^S<O<N183,UKJ[>_KU<9*961./8OL]NHL'M7R5?EXY
M)EWKF 8J1.KL^W+KRV=ACYVYKX9IV[E^SM,K(WPRU>>[MS+&2/;V9Y:]WW+X
M9( 8.9OLU*O9N7PZ]YCY6ZE5=VWC=U]RF7E;M3_W?+9\O:6$B;>W;W[_  RX
MU@&$>S=[>K/9V;=1Y+^F@Y*SM*6@K$L5#2I4XBP9EC7#R,:KIY);/#(MWM\/
M-:Y[G7*ROJV1PMR2>MIZ%'JC(\T];IVY+[%^?NU[C'SQM<BM>ULC7-5KV/3-
MDC'(K7QO3>R1JJQ[<_K,<Y,]9WMF9\\7(IR*^4Z;(61]/"^<7Z)+6+]#:.AM
M79U>7C7XMJ]KOJG5+Q7&FE)?G0>DHONDEZSDUM>BHBHJ9*B*B[E1=:*G8J9*
MG85#[Y])_P E-^AW31BW"L$#XK#657[),*/5$YDF';Y)+54D+'(B-7\&U/TN
MU2M:G-BDHEBV,S7X%0N=@9L,FFJ^MZUW5PL@_P V<5):^#6NC7<^11K:&#9C
M7W8]JTLHMG5-?G0DXMKT/36+[&FFN3(@ [ATP2/XXV^1. #:^]6_Y8;>;B+0
ME>:I4<JU&+L%)-(N664<>)K- CEU*B?1KS3PM77E<'1QJKIY$VRV.V=?5V;T
M[MZ'+-T$::;UHYQIAG'.'I.CO&&+O276D157F5"0.5M30S(BISZ:X4;ZB@J8
M\T22"ID8JHBKETV=!>F2SZ0,(X;QMAZ9)K-BBT4=XH55R.?"RJCSFHYU3+_=
M-!4MFHJE%:W]VIWN1J-<S.MN]7H][&S(YE:]JR_=Z=D<B"7%^DCI->,E8^XM
M#N@Z2>R<%X-DM;L+10U[9XTV^#U]5+6M]T8=4NUG[-$[=NW<)VZ_87M._+5U
M:E3K3K3V;3%1NV)U:TXWHG7\B^8[8O'BGL[=69%)+YFHW*G5KV?'[/(R,3_;
MGXHJZU[,N-QAH7>:<>?7]FO(0NV>:<>.67B 9N-^S?NW<:]J=RE[$_9L77J7
MK3?Y;C$PR;%[$V]7&[JUE]&[5EU+FGN\L_9K ,S$[V:TU[4W?;UEY$[5W>>K
MW]7<8F)^[L7+XIW%^QVQ=RY*N?E[OF 95CEX7=O3PW*7C'>2K]_FGD8R-V6:
M;>-6?EEF7D:[$\N.S+5Y &2C5-:+X)V<*7#'+L\N.Q2Q8OFFKS^"^\N6NS1.
MS+A4XZP"ZSRU^:<;^HKHN::MN29]I;-=GX+[^-2E2-<ERW;MVWCP *W]TB;?
M8J+KX\"Y1R+L+9=^]%U*GQX]X:[FKUHN_L^78#)<ZTV;"NBHO'R[>-911<T"
M.YO'7QK,->':8+A")*BZB**$S!$ &3(
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MT67#]9</FH]//-&=\3_BB;CN_P#/.S_CU^S(W\P 5%+G@
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ML*&S<.K#A;9;&K7R[&M6Y-REPI<H0XFW&"UX=>UO5L #QCW0
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M])22ZVZ>DKK6OPYZ+DNZ$5&$>Z.K;<,DZB(!X!L@
M   !*_8O<ON.71Z9K\Z/33_*U?YKMQU%W[%[E]QRZ/3-?G1Z:?Y6K_-=N)=W
M.?P_)^2/[:HAC?;YOQ/EB^PN/,@ %BRLP
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MD?LTD\;C?ONT?B\;]JX_9P 0(6(
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M _R*PE^KMM(3WS_>L#XS(_9J)YW'_?,_X-/UV'[J " RPX
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M&FN3378UVD2V0E"3C-.,HO249)QE%KM33YI^AE0$K5S)CZ'$
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M?%ZK-$M(E;M\_1QUY%6TJX^1D:4Y&B6BNA'VN3^,J7#_ ,+5O61\M@ F8A
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M'4I012*+EXY<)\C#7A__ )!61=Q,2HN:;?(B@3,$0 9,@
M                                    @H4(8;!+VKD4G.S7)-FK[OG[
M"#G<[5NU]_V$3"7B"&PH2/UY)OR39W\=F\2/U9)O]G''42Y9:DV[U[^K[3D"
M"=2>*]W'"E.1^29)QDO':NXF>_)-6107>N_;\<N_( +O3MU]6S8G=OZ]I15<
MUSW;OGQN(N7/5N1>-F[[2WD?M3=ORXV_< 0>]%5%SU9;_?QUEF]V_CCK[.HJ
M/=GW)W;?DGD6;W;>M,\T[^-6_( IO?MS[^.S7D6<C]7'&77N7N*CW:^-B;?D
MG;K+.1=6>_8G&WM7Y %*1^U,^_O7=XK\BPDDV^?EN[?#5L*DK^KMR7MV>S;G
MN4L7O]F>?9K^W/L74 4WOU+UKW9)]WO,=*_MU?#=Y]FTKS2;?=U]2?,QDK]G
M?Y_=M[ "E([\;JW_ "^?4G:8^:3JUY_B\>\KRR;NO6O<G&7=KWF->[?ELS^7
MGKR3L *4B[O-?'X[>XM'O]VKCKUZT)Y';M6O;[LOMWY'\#I(TAV?"EAO.)\0
M5C+?8\/VRLN]UK9%^K3T-#$LTST;FBOD=S4B@B;]>>HDB@C1TDC$7E"#DU&*
M;E)I)):MMO1)+O;?))<V^1QG-13E)J,8IRE)M)**6K;;Y))=K[ES[#PM]/\
M<MO]@FCF'1I8ZOHL4Z28YH;@Z%Z)-;<%4[T9<Y'*B\^)]]J>;::=V6NE;=')
MS'] ]='U&[/=Y<(FQ$\CZAY9G*FN^F;23B3']W1\*7>K6*T6YS^>RSX?H^=!
M9K5'N1::CR?4N8C6S5LU5/S6](C&_,1;CH5T>6S<&NF277S]MR)+GK;)+6.O
M>JUI!=SX7+363*8].>DSVKM"V^+?45^TXT7JM*HM^4UW2LDW8]>:4E'72*
M-N-/   )'.R-H;U;ODC+<<08DTS76FSI,/QS85PDZ1NJ2]7"!K[]<855N2_@
M^UR16UKVJBLDN53&Y%1Z*W6@P5@FZ8EO5IP]9*5]=>+[<:*TVNDCUOJ:^X5#
M*:FBV+S6K)(U9)%3FQ1-DE?DQCE3IM<C_DWVW1)HWPCH^M?1O9AZU0T]=61L
M1GX1O,_^Z;U<WHF:JZNN<M1*SG*]S($@@YSHX6$6[U-O^QL+V+!Z6YC<&D^:
MHCH[7_/UC7Z4YZ=A+.Z+HZ\K:#R[(ZTX*4HZKE+(GRJ7\Q*5NJUX91KU]T?3
M$2:L^[[O@9*!FS5VKW;N//(LXVHO=M[MR9_'J,G%&N66S/;W?=[=96DM.7$;
M?O79DBYY_;O4R<4>OM77\N-^TM(D]J^Q/?\ ':92!NS/O]_NW>(!<1IL3JU\
M?9K+Z).OO\]GEY:RWB:BY>:[=2<;%ZC(PLS7VKFF_+A0"ZC3\5-N6WCO]Q>,
M;L\-NK/[UUIGU%M$WJWY?++-.K:OF7S$V;=FKLSU)XIM7V %Q&G?U<>/FFK8
M7K$W;MJIUY;4\5V=91C38G5\\M7&I"]C3/->WW?;K0 JM36B=2:^KO*V[L54
MW;OMW>TI,3OS5?LU>&97:F:[LFZDR]_?[-P!7W(FS/5W#+6B=2)JZNSQ]Y'/
M+PU>:;._V$T3-^>OA>/D#)<9E2+9GUYJ47=7&6\N&[/,P_08'W>9JX^M5O\
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MB]5&<UZO*)SZ"]'[MF;/KQ+Y5RLC99)NJ4I0TG+5:.4(/7Q\E  &J&X
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M))/FSV>A/1+:=&U<&Z[ R:JJ[DYSG4XQBN&7-M]BYFU6""*1*R%K@
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MB,CCC8UC(V-1$:R-C$1K&(U$1&L1$3),DR+MJ9$P---X
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MR=,IRCPRKJ@D^.%;XM8/7EIIIS\)@ :2;Z
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MBDEK9/3\.R6LY>A-Z+N2((1 /'/:
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MEQW%PJY( 18F:Y[LE1/CQO*WCU$D2<=^M?API5.*>K]0  .0
M                        !!4(@ E:U$)@  2JU.PF !!"(
M                          !!4S(<TF !)S$X^\<Q.PG !#).HB  2\Q.
MI.$R(<SCA2< $O,36.8G'"DP
M          )>:G4A#F)V<>). "1&)V<>)%&IM)@ 2JU%(<Q.I/(G !+S4U=@
MYI,
M
M
M
M          "56YCF\<*3  E1J)N0@C$)P ""IF1 !)S$[./$<Q.I/(G !+S4
M)@                                   2JWCPR)@ 2\Q.P<U.HF !!4
M")D1 !!4(<U"8 $,DZB"-)@
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M  9
M
M
M
M
M
M
M
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MKM0IIUPC0<^X6BF@HM(='2Q_NM79H.;#;L4\QFN2>T(K*"[.1'2.MKJ2I?\
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MM35QU(A1CUK[/%-J_ JKU<9(<=>>AALF3/>1 .0
M
M
M
M
M
M
M
M
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MJJ6IB=#4TU1$Y%;+!40O?#+&Y%1T;W-5%150YX7I8O1\5>@72'-#;8)WZ/\
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M80  ,@
M
M
M
M
M
M
M
M
M@J9EOEDN7CK[=I<9%-[>$[,_N]QC7F"B]J*A;(JY=K=GN[U[N[>7:;"WE3)<
MTU=>S89!2D;FGCQ\O?U%%-GL7C>J;%+G5X+K3JX^W:49-2Y\<=2@%KEN\=?M
M3PXU%N]N2JGBGR["]>FI$[=7;U>>\H.;GQO0 QDC=B;TRW[=6WQW*6;V[<NK
MPR^&6_YF4?N7+8NOCVEI(W:NY<OO\?8 8J1.KNRXVY)L["RD9U=>KR\MFHRL
MK?=QGQK+1[=J9:EU=W9\O: 81[?+;W9+O[E^19R,14SZMW=U>W+/<9>5ONUK
M\?GU*64C?/J\<\TZ]0!A98]OCFON7W&/D;[]?S\M2F<E;U=2JGR\?N,=(SWZ
MN[/)>_6 8::+YI\O+9UH8Z1OFFWK[NKN,X]B?+O3Y;NPQTT>_LU_-%XU@'A=
MZ:#T9C--&$_V783HXTTF8/HIW4#(FM9)BRQQ\Z>HPY4/U(^N@7I*O#\SUS;4
M.FMRNZ.M;T>A;)3R12OBECDBEB>^.6.5CHY8Y8W.CDCDC>C7QR1O:YDC'(US
M)&JQ[4<BG65D;OW;=6I<]RIO1477GM;N-1GT[_HM%II;CITT>VU/HTKEJ=(]
MAH85_P!SRJO-=C.BIXDR;!*O-;B.&)G-BE5MW1K8I*U631NQZ:=5*.S<J>E<
MW^];)/E"<G]YDW[V<GK6_>S?!V2CPP9O6Z"]=&6U,2'ML(_ORN*^^5Q7W^*7
M;.M:*S\*M*7)PEQ:J()&.S\MO&KN7>F]2<L 5R   !2>S;YE4&&@T>GWHPO2
M7W_D_P"*7-J/I=YT>7V>-N*,-,ES=$]>:QN(+)'(Y(H;U1L3*2+..&[4J.HZ
MAR2I35$'0"T2Z6<.XWP[:L5X4NM+>\/WNF;66ZXT;^=%-&[-',>Q<I*>JIWH
MZ"KHYFLJ*2H9)#.QDD:H<KES-_5QU<;<LSU.]&'Z3S$/)_Q$M+5)5WO1U>ZM
MC\2X:;)SI:65W-C=B##Z2.2.GN]/&B?2*=5937BG8E-4*R=M-50Q7T^Z!+.4
MLO%BHYD5Y4%HEDQCV+N2N2Y1D^4DN";]S*,M[N=XKV?*.%F2<L*<O:['JY8L
MI/FUVMTMO6<%JX/6</?1ET1&/\4XX5-VXNF.V)UK]WC[T3(_*M$VEK#N.,/6
MK%F%+K27O#][I6UENN-&_G131+J>U[5RDIZJGD1T%723M9/25$<D$\;)&JA^
MF-=Y=7RX[BM]D)0DXRBXRBW&49)J49)Z--/1II\FGS3+15V1E&,HM2C)*491
M:<91:U4HM<FFN::Y-<T92.1?+V]?DOB9!C\]?=GV\;E\S",>FSR^WJ^)<LER
MRU[-B^&>7&PX',ST<OL7R[^PO8I=G=JR^'Q0PD<N??\ #Y;LMI>,DUIMV;/E
M[P#.LDSRZ_9QV%VQ^[)->WM^TP;)4XXU*7T<J:\^-2<:MV0!F&R^SS3J^XNV
MRY[=74O=N7C:85K_ +]6?CQ[2Z9+QNV;^\ S#9/LR]G=[BZ;)E\^-FWC=AV2
M;/=N[<BZ:_J^7&OPW &523SU<=I7Z3KU=O5\E,4V3[MW':GB7"2=_9QOR3C8
M 95'^7G]_&\K1NZMG'B8MK_#CJVH5VR)]J<9<99@&21Z+Q\=F?&XJ(Y4X^/'
MD6#7]>ON3CV:BHUZ;O+PZO/5O +]KD[EX\%3[R;C5X:_N+5'IOX4F1>K[/+/
MCJ +MKE3MX\\NHF23K^S[/'X%LC^OV<>[O4G1Z=?@O;V %RBHOW_ '>TFXX4
MM4\>-FI>/+5'-4^W9[?  N,DZE\%^8R3<N2[L^OP]O@4>>OW<+QXDZ2)QD 5
M/K)L<BIEU\>!.KW=7R*//:1S3M\_DH!/TR]0Z5>I?#[4)47M5..TBBKU_$&=
M?1]9-TR=WE\"/2IU^S[27->SR(\Y>I./ &"/2IPGVCID(<Y>I./ E7N3R!G_
M +_[Y$4FSV(OL'3+U$,U[$\$'._NO:GR U]!-TCEV-(.YR[\O'P^TDU=OM3W
MD%<WL!@CDFW-5[OM"(FW+S7;Y<;"'2(4U>NY-7''V@:EQFN[5W<=7S)5U?;Y
M%NJKO]GV>_,AJ[?%4X^8!5Z7C9[_ ($CGN[MN7'Q[R57HG9[_GYE-7ZM2:^U
M./F 5.W;W\<;R"O\>Q,O<GMS**KQNXX["17IN]G'&T J\Y5[.[CW:BDKD3[.
M/?X%%S^O5V9\=GL*;G]2>:<?/> 5G/7NXZRCTG4G5QUE!STX3+?[/N*#I,^W
MNU)\0"L^3;O7CCMV%%S^OCM3+CM*#I/NW;T]FS-?D6[Y-GWYY>_W %=\B]N6
M_?U[^$W%LYZ[MO&K5YY(4GOZ_#KX[,LBW?+]F67"=_4 3O?EQL^7&\M7R[5S
MV[^OPW<:BD^3C<FOMVK\"V?)[MN[PS *CG[-2=WEM\-A:/DU\:NLD=)EU_/C
M;[M1922;=O'7V_8 5))./AW;NW<6,DFWW]78A*^3C?U>'S+.21$^"?+Y@$SY
M-ZZD3J^/'M,?)*OCN[.U>TA)*JKJ7L[NSC6FTM'O^WR]ON )G.U]N_/S3RW)
MYEF]VKLW\>]>H/=W_/[_ #V9&'N]VI:*FJ*VMJ(*.BHX)JJKJZJ:.GIJ6EIX
MUDGJ:F>9S8H*>")KI999'-CC8U7O5$0)&&_F%VNU-14U365E1!1T5)!-55=7
M5S1T]+2TM/&Z:HJ:FHE5D4%/#$QTLTTCFQQ,:KW*B(IH\^F']+G-I;JY]'FC
MVKGIM&=MJE2XW.-9:>?'E=3O3F32Q_5?'AFDE;TELHY41]RE1MQKF(Q*2"&Z
M],!Z7^ITK5-;HYT<UM11Z,Z2=8KK=8NDIZG'E53R9H]Z?5E@PM!*Q'T-$]&2
M75Z-KZ]C8DIJ6+7_ $9GQQQJ[K!;O]W_ +'X,[-A[>UQ4427WA:<K+$_XYZ^
M3%_>NU^V:=76W>3O(]D]9L_9]G[W3<,C(@_O^G*5537\3W3FOOON8^UZNRLW
MC,B01,B),Q"0    )7+QX $LGV^7RV]AMO>@/]&(ZDBH=.V/+<B5,\:R:-;1
M61?6IZ>1%8_&=1%(W)LU2Q9(,/-<WG1P++=4YKIJ-QYP>AJ]%_/IIQ*W&6+Z
M*5FB_"]<Q*EDC5C;B^]TZLF9AZG5<G/ME/G'+B"HC16I$K+;&Y)ZF58-]"AH
M8H(HH((HX888XX8888V11111,;'%#%$Q$9%#%&QL<<3$:R*-J,8B-1$2$]YW
M310C+9N+/VR2TRK(OW$&OO":]_-/VW\&#X.V4N&=MU'07K)0VKEP]KB]<.N2
M]W-/^$-/WD7]Z_"FNLY*,'*ZC:B:]R>WM]JZR^BCX[$Z^S?Y$D;$77EJU>?9
MV*9&-GFO=JR3+[>H@,L43M8FM-R>]=J>/&1?Q,V=?QW)]FLI1,\LM^[K7LSX
MR,C%'LXR3W9KL[@"K$S:O4N?>ONRZNLO8V?-=VKVY=A38W[$V9KMU>Y.KWW\
M;=B?+6O5X;P"I&SVIXIEK\UW>1?,3?LU:OG\BFQFU//VIJ\=F9>1IW?=U=WM
M4 GC9UIM7[?9M[R^9UY=R<=>[NUE)C.KQ7+Q\UWEZS;GN3[OEEO4 G:FK+K7
MX>?9GU]A=HW7DGCV)QLXSI,;O7LSZD[BY8FW5FJZD^">6M>H F:N29=7SU<;
M>O(K0IOXUKQYZBFC<URZLL^W9\<T[BYVZO%>.,@"&>_>NI.Q.OQ*L+<D\N..
MLILUKV9^.K=[]?QR+D +N3K*S$R0IQMUY\9;N/#8550Q_P!_^P9%%(@&0
M
M
M
M
M
M
M
M
M                                                      ""$254
M,,%NNI>S9X\;.K9M"MS*\B9H4$7V"+!:HFO)>S)>[8OV;R.6:+GMXW>XGECU
M9]O'S),]_5M^:;_ R9+5$V]>U.U.KX]13D3R5-?S^!=2-V+U>>O7W%'=LV^_
M[>L&"SD9EXKK^?N3J+1[=VY?GL\4V;O)#(JW+4J=WQXWH6SF[NW5X &+<S[,
MLO/RU*A9O;EJU[_9L\=_<95[57=K1$\N/M+*1O&OLU9=:>X Q<C?%>WJW^>S
ML7P,>]FK5X?)>I3-2,UZLL_AMR[E+&1FI>I5]O=LRX0 Q#V)LW*GEQU;4,?*
MQ/CQX:EW9[3,R,VYIW]_7\2RD;FF75Y*G?EY@&#E9K7/J^Y>[K+)[=G9]WW?
M,S4L>M?=N[N[A#'O9L[]79UHOP]@!A)(\E7J7V<;S$U]!%/%)3U$44\$\4D,
MT$T;989H96.CFAFB>BLEAFB>Z*6)Z*R2)SVO:K5<B_TTD>WOU_/C:8R2/+4O
M:J9[\_<-0:%GID_17SZ&;])CG!5%+)HNQ%79-@B:Z7]A=ZJW.?\ @2I<O.<E
MGJW(Y]AK'JO1HC[94JDT,$E1X9M7K.K%I&T=67%=CNN&L1VVEO%BOE#/;;I;
M:UG/IZVBJ6JV6%^2H^-V>4D,\2LGIYV1U$#V31,>G/B]*/Z-2^<G[%F=,E7=
M-'>(*F9V$\0R-17Q/^M/)AR\O9]5EXM\2_N4ZI&R[4<?TZ%J2,J88K';N^G7
MLN$<++G^^JXZ562?\(A%=C;[;H)>5WSCY?-J;*P[S=W[PIRVAAP_>EDM;JH]
MF-9)]J7=1-OR=.5<GP<HN"/+T$C7$Y+1#H   4I.:B(J\>/'7UE4&&@>E_HV
MO2<XLY/V(%;&E1?\ W:=KL1X0?4JQBO=S6+>;&^3G16^^P1HF;LFTUSC:VEK
MM?15$._AH"Y0.$])N%K;C+!-YI[W8;HQ>BJ(<XYZ:IC1OTJW7&E?E-07*B>O
M1U5',U'L=S9(UDIY(9I.6X]NS+CR/N'D)<O['&@/$Z7O#,_TZS5[X8\284K9
M94M%^I(URS>C<UHKG3M55H+K3-2>%R)%,D]*^2!8QZ<= *]H)Y&,HUYJ7/L4
M,A)<HS[%&Q):0L[^49ZQX90E7H!O'LV:XXN6Y6X#>D7SE9BMOG*'-N53[9U<
MVGK*OGK"?2N8_;EXZ^[V^\NF/SR3;GQPNU#XWY&_+5P-IPPK%BC!5>KUB2.&
M^6*L6-E[PY<)&YK0W6E8Y41'*BK27"#G4-PC3I*:57))%']?,<F[R^'L^16W
M)Q;*;)U6PE797)QG"::E%KN:?ZNYK1IM,M'B95=]<+J9QMJLBI0L@U*,HOL:
M:^CQ3U3YIF39)Y>[O^?GUE^R;/+/?X<>XPK)/MXX3=V%RQWVI\.S[LMI\#L&
M<9*O7J]BY[<^WJV%[')V+FGFGB8&*;+5EJZE]W'?U%]&_J[M6[CJ ,Y'-\.[
M["Z9)[MGQ,$V7[^_KX\B];+X;=_RXRV &89)L3V?)?=XERR7X:MB]O>8EDJ+
MEQEU]WAJ+EK^O7U+O ,PV39K3OV+QPI<(_QX]OL4P[9/O3;Y=?O+ADOOVILR
M[4X[ #+-D[>-Z9[4W%=LG?MU\?(Q;7IJU>.>KQX^!7;(J=O=[NK: 95LF6Q=
MFWJ]N7?W:]1523Y:MGW? QB2)N[=7:N[LXS*B2>_;W<;]H!EDD7L7CC;XDS7
M^"\>:&/1Z>/E[O;U%1)=GW+\@#)=(O9QQO)T>G=QQE]ACTD3N]W'85$D7O3C
MPXW &01V6Q?B1YZ]_<GQ++GIW<>\G1_=QVIK +OGIV^7Q343H_/>GEK^\M4>
MO5[?F3=(G" %UQQM(:NK+NR^_J4M>>G"JGP)\^U?;\@"Y35L5WD11R_VWFG&
MO["VS7A"*.7L]WNX\P"YYZ_VR*1YSNSS3Y%MSEZO:I'G_P!S[@"XYSNSS3Y$
M.>O6B>TH<_\ N?<0YR]7M7X %=7+_;)X$,]6UWD4><O9YJ0S7L\@"JF7:OBG
MN(^7G\"W5>U>/(E5R?>OW_/P +A7(F]$[N%ZR57IW\=:\;BATB=7L(+)U)Q[
M_D 5E?U)EWZ_=]_@0YW;\N/N+97Y;_9D2=(G?QU\:P"XYZ)L]FOCA217KW<>
M7'44'2=F7'&WW9E%7IVK[OEW> !<O?UKGQU>[L]M/I%[$[^,O(MW2=2<=W'L
M+=9.W7X+U]6S5[E +IS]?6OA]R%%[^W5V+QF6RR)N7/MZN_<A3?(G"ZEZM>W
MC( KJ_/5N[4\O9U[2A(].O=U]>[/X>105_AQU=O;\B@Z5._W<;U *[Y%5-NK
MMZN/9Y%NZ1.OQ7C["@^7C=QW[2U=+U=6U?#[?M *[Y/;\>KJSZ^XMGR=^O=O
M4HND\NU>%[M9;NEZO/?QU;$]@!6>_K\$XU\;RTDDX[-RK[=77DA2=+W>:Y\9
MEB^7;W=>KPW^Y?: 5I)=GSU^'5QN+-\GQ[O'K7J^1(Y^K7J3KWKW]7=N+*2;
MRXS\,_'W@%5\J(NW7UY:M7&SS+!\BKGU9KKWKX=1+(_P3;EG[/CUEM))J7JR
MV?9\/, G63JR3+K[O=VEJYVK;J37Q\//L(.?EK7V>'GWGXUIST[X3T;X:N&+
ML:WJEL5AMC.=/65+E5\LJM<Z&BH*9F<]?<:MR+'24%,Q\\TGXK6L:^1GTJJE
M.480C*<Y-1C&*<I2DWHHI+5MM]B7-GSMMC7"4YRC"$$Y2G)J,8Q2U;<GR22Y
MMMI)']UC+&5JL%KN-[OEQH[39[3235]SN=?,RGHJ&CIVJ^6IJ9GKDR-B:D3Z
MTDCU;%$Q\KV,=HX^EE],-=-,=35X&P%/5V?1?25$D=5.CI*6X8[DA?\ N=7<
MH_J24M@:YO24%E>O.J5Z.MN:+(D%-3?B/I-?2MXIT^W1]GH&U6'-&=NJ^EM.
M&4E1M3=IH5<D%YQ0^)[HZFOYJJZDMT;GV^UM5.B2>L62K7R95J<9%A^@N[I8
MG!EYJC/*Y2JI>DH8_A)]T[O!^YK][K+22K1O!WF2S./"V?)PQ.<;;UK&>3XQ
MCV.-#[_?6=CTAK&5)K476N?CQYE5$R"(1)<2(:  ,@ $%4 @Y=1Z$^C?]'UB
M'E XWBLU+])MN$K0^"KQEB5D6;+9;WOS904+WM6&:_71K7PVVE=SDB;TMPG8
MM/2O:_\ '>1MR/,7Z;\;T&"\)4^3I>;4WJ]3QR/M>&[,V1&U-VN<C$U1MS6*
MDI47I[A6.CI(&JYSW,Z*W)*Y*6$]#6"K9@?"%)T-#1)TU;7S-C_"5\NLK6I6
M7FZSL3.:KJWM^HQ7NCHZ9L-%3\V"!B$;]/NFT=G5=11)/-MB^%<FJ(/5=;-?
MA/\ BX/M:XFN%:2DW=UT#EM2[V1D1E' IEY7<\B:T?50?;PK^-DGJEY$?*EK
M#]2T1:)L/X&PW9L)85MD%GL%AH8K?;*"G1$9#!%FKGO>OUIZJIE<^IK*J573
M5=5++/,]SWJ?I[(UV)LSU^/SWK\"5C-R;5R]VWLR35]YD(HD1.S/Q5>.-Y6&
M=DI2E*3<I2;E*4FVY2;U;;?-MOFV^;?,MA77&$8PA%1C%*,8Q248QBM$HI:)
M))))):)<B>-B)Y:N.OW%[&SX9_).[:08Q57JW]W;\.\O(X]F[;JZDW^/4<3F
M58H]>OV;,^K/JV9^2F18Q-2=>W=NR]VI.PIQLRW;=2>2<9^9=Q,V?+;Q[ "I
M&S/6GAW=:^!?QL[-^KW>U=?AK)88_8N[9OU<>1>QLSR\-OO^&0!-&WSS]W&K
M/:7T;,MVM?'CM7Y(4F-ZLMO=LSV]B=6\O(TV+V?9QU( 3M;JRZ]:]V_V[.O:
M7C6HJY;OEK0I,;M3>J\>6[V;=5VUN2(B)KRRZN$ (HW=N^/&M2OW;]7E\5V)
MEXDJ)DGCFO'7GN*D3<U\\O/A.W+4 58VHB)PG&HBJZLMZ[4^'&6Y2*=>Y,T[
MU^6KQ)XVYZUWI[]6KVH 56-1$3C;M(KKU=^?'6152I$F2=^WCL3[3#8)TR1"
M*(,T4B(KD8  ,F0    0S (@         $N8!,"&9$
M  $%4 B""*1  (*H10"(                     !+SN-0!,"7G<:ASN-0!
M,!F050"((9C, B                050"((9\:B(
M   !!5&8!$                            @J@$0012(
M      !!5&8!$$O.XU$<P"((9D.< 3 ESXX]VWL(HH!$               $
M%4B  ""J 1!!%(@           AF 1!!%XU$0  2\Y.,@"8
M                    $%7((H!$ @J@$0,P              050B@$005<
MN$"* 1             (9@$0   ""J 1!!%(@                 AF 1!+
MSN,T^9,  0S&8!$$O.XXXZB** 1
M
M
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MG>)L[:;5<+'1D/\ ^7OTC*3_ )*:;A9S[$FIZ<W!(]4@2(_,G-*-[
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M]KY&;AT63H==V5CU32HBFX670A))KL?"WH^XZ:D>S9D5"";$(E<BS@
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M$;Q]IY^U,7$R)TNFUV\:C3&,GP46V+22>J\J"^;D;G[28 @8L,
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MRVXI;S[Q32(S/HUKW72!'\U98)6-Z-=S?T?GIC=$'*"C@MUFN+\,8X6%9*G
MN(YH(+L]6(BS26.J:YM'B*D9K<DE"K:UD;5?56^EUL;$_2'H!M#9R=DJU?0N
MVZC62BOY2&G'7Z9-."[.-DQ=&MXNSMI.-<+'CY#[*+](RD_"N:;A9Z(IJ;[>
M!(]: 4^D)T-)-\(@
M
M
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MCUHFT Q$C-:ZMVOL7L[%ZRQ<S9[?FG7PAFGLSSW+E[/MZ]Q8O9LXR[%Z_?F
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M*=:OD*?D5T1_HTP/^K=O(7WR_>,+XVW]A$Z;C_X1G_$T_MR/JT $ %C0
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MDY4=I;/E+%R(QCG8DI-TV))*^MMMN.B27-M\DCH8IL0B4XES3CJ0J%0BZ0
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M9LGX5']HJ)$W5>?,/X.3_9;C<" !5<MX
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M#_5+?Z]TY?\ -8!_S\3FC;R?,N;_ ,#^TTF_;K_/N!Z\C^R7FZ" "J!<(
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MLM553J^>IJ9&L1\]1*]TLTJOED<Y[U4S!!")49LN<EIR0  ,@
M
M
M
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M^_CX%)TN?WZOFO" %\Z;7M\]OEQ["@Z7O\=19ODRVKEQU[>,B@LR;DSX[?@
M7KI>$V??[2BLG6OEQK["Q=4+U[4U(G'LV[5+=9%XX\^WK +U\V6Q/%?CQW%J
MZ;/9K[]GAQWENK_%>/#S["DZ3K7R[>-6KR *SG]O@FQ=6PI.?X=^_MU;/O*+
MG_?OX[]Y;NE1%^W5JZ@"NKU[NWCCP*+I$3MZUS\\U\S\"Y07*?P#HMLZWS'^
M*;3AJ@5KEITKID6ON#F)KAM5KA22X7*955&<VDIY(V.<SII84<CC5@Y:GK%N
M(KS],L6A2TNPS;E<^']FE^A@J<1U,>;F++:K,]):"R)(WZT=17+7W"-KD5D5
M#4,1Z[)L'HGG;1DO8]+ZO725]FL*8Z=OEZ/B:[XUJ<_S=.9J_2+ICL_9<6\J
MY=9IK''K\N^?AI6GY*?=.QPA^<;,'*RY<FC/0K:OPEC_ !)3VZHFB=);K!2(
ME=B2\.;EDRVV:)Z3N8KG,1:NJ6EH(4<U\]7&Q4<NGGR\O3HZ1]*:5N'\%_2=
M'&")^?#)!;ZM78JO5,N;52[WVG2):*"5N:26VS_1XGQJL=355+7/8[Q=QGC2
M\XCN=7>K_=+C>[O7RK+6W2ZUD]?7U3U7;-55#Y)7(W->8SG-CC3-L;&)J/YU
MC=6LGKHSNUP\%QMN_?>0N:G..E5<OY.IZK5=JG-RDFM8J#Y%=>E6]/.VAQTT
M:X>*]4XUM]=9'OZRY:-)_@5J*T;C)V+F39)MWKFJYZU55UJJY[7*NMRKK5=:
MJJCFIU$0241B      ""J05V11>[:NY-^[MS75J3K74F_88&I753T]]'!Z+;
M&G* O#:J-)L.Z/K?5-BON,9Z=7-D>S-9;5AV&7FQ76\N:G-D5'.HK6CVS5S^
M<L5/-]O>B[]!S>=(WX-QWI7IZ[#V 7HRKMF'5Z6BQ#B^%,G12RHK6SV7#\^^
MI>UERN,6:44=/$Y*Q-T[ V!;1ANTV^PV"V45FLUII8J*VVNW4\=+0T5+$B-C
M@IX(T1K$VN<JYR2R*LLSWRN<]8BZ:[R:\93Q<"4;,GW,[EI*JA]C4?>V6KPY
MP@UY7$TX$S= ]UMF7P9>T8RIQ>4J\?5QMR%W.?8ZJ7\UDUSCPQ<9O\PY-_)I
MP=HHPK08.P-9X;19Z%.>Y&KTM;<*QZ?N]SN]:Y$FN%QJ'*JRU$RY,;S:>G9#
M3110L^@6LRU9:^KL^7O(L9U)GUKV]I?Q1*GQ7/LX[MI7JZ^=DY662E.<VY3G
M)N4I2;U;DWS;;[V65HHA5"-=<(UUPBHPA!*,8Q2T48Q6B22[$B2*%$[]ZY;.
M[N^)>M8FO+C/J^9&-FS+6F[M[.[MZ]I>1Q\;LTV(G'L/D?41L]GBB;_/+/X%
M]%%JV?8G;V^X11;$X35U[U["]:S5V;_BG>N_Q (M:GEM7MU;^WVEU&SSSV=2
M9^]?L(L9L\TZD+R./5V9\>W8 3QQY:U3N3C?V>)=,9U\=2?-?:&,W[-R?+[=
MQ=,BWZO/5J[>I/:O8 08SW)KW?=N1.LO&,V*O9EQUKL#&Y[=GEW%RQNI'>2<
M;U7?U[ "=B9;4UKJ\>HN&-RU]Z^>O408S:J\<;%]A6:W8J[MF[CP )F,VZLU
MW>_Y9E1&YKDGG[_;L(9[MZIK[.PKM:C43+C/C4@!,B9)D0R_>IWKKV\>[4-G
M>ODB;4XZRNR-$]X,DT;<D(KKU(15?/<58VY<=>O[#&I@BW)$[B+4"$P2,?\
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MO^8IUJ^0I^171'^C3 _ZMV\A??+]XPOC;?V$3IN/_A&?\33^W(^K0 0 6-
M       !\A<N;E?X<T&:-,2:1<2.Z2"T4W16NV,>UE3?;]6(Z*SV6D_?=)75
M2)T\J-<E+0QU5:]JQ4SSZZ>N2'/A]9 Y=4ND+2U_L8V:L63"FBN26BK&1._<
M+ACFH8B7NH>B+^Z)8X%BL<"/3]RK&7;FMULD=M?0WHZ]I9M=+3ZF'MM[7XN+
M7DI]TK)-03[5JY<^$T[ISTF6RMGV7QT=\_:L:+YZVR3TDUWQKBG-KL>BBVN)
M'ACR@M/N)]*6,\08]QE7NN6(<25SZZNF57]! W\2DM]!&]5^C6RVTR1T5NI6
MY-AI86)DKUD<[\>1"G&G'W<>14+<44QKA&$(J$8148Q2248Q6D4DN226B278
MN132VZ5DY63DY3G*4YRD]92E)ZN3?:VWS;!3D75PA%^P],?1?^C'Q9RD\9NM
M5O=+9L&6.2FFQGBYT/216NEG<KHK;;&/1(JW$-QCC>E#2*JQTL2.N%=S:9D;
M:CK[0SZL6F=]\U757'BG.78EV+3O<F]%&*\J4FHI-M'8P,"[*NKQ\>N5MULN
M&$(]K?>V^R,4N<I/2,8IRDTD?/')$Y$NDK3GB-N&-'&'9[Q51(R2Z7&9_P!"
ML%BI7N1/I=[N\K7044>2\Z*!B3W"JYJMH:*JDR8NZ#R+/5GM%&#(J.ZZ5ZN?
M2=B-K6RS6[GU-HP51SYJO,@M]/+'<[LD2\Q4FN=:R&96OY]OZ)_0M]XN3)R7
M,$:(<)V_!> ;#2V*QV]J*K(6H^KN%6YJ)/<[M7.3Z1<;G5.;SZBLJ'*]5RBB
M2*!D<3/H7+C,KATGWEYF7*5>)*6)C<TN!Z7V+LXIV+G#5>\K:TU:E*?+2SW1
M/=3A84(V9D89F4TF^-:X]3[=*ZFM)Z/W]JEKR:C#O_.]&VB7"V#[;#:,)X;L
M>&+53MYD%NL%IH;/1Q)DB+S*>@@@CS7).<[F\YRIFYRKK/T%8FKM1%RZ]?OS
M*@(UE-R;E)N4F]6VVVWXMOFWZ62G"N,4HQBHQ2T48I))>"2Y)%+H69Y\UN?7
MDF:=R[BQN=LIZN)]/500U5/*U62P5,;)X9&N16JU\4S7QN:Y%5'(K51454WF
M3!Q3.36O:>+O+!]!%R?M+$=560X5BT?XFGYSV8CP)%!9E=.K5^O7V%C/P#<6
M.D_=)E=14]5,_-SZW-5STM/2*^AMTL<GA\EVN=/'BS +YDBIL<6""?Z'2J_+
MHX<1VU_2U6'JAZJD;)9Y*BUU$F3:>X+*KJ>/IV9&#O\ 8**Z4E3;KC1TMPM]
M;!)2UE%70155)5TTS%9-3U--.U\,\,K%5LD4K',>U>:Y%U&]]'-X.?@2C&5D
MLG'U2E3;)MJ/\E8]95M+L7E0_,\(]Z4;M=G;1C*4*XXF3S<;Z(J*<OY6M:1L
M3[WY-GY^G)\<I.I=O43&RQZ</T)W^Q#+6Z5]%M%+)HQK*IKK_AZ%)9IL UE7
M)S634RKSWRX1JIW-BA?(Y9+%421TDSGT,M-)!K2-=NWEEMB;<Q]H8\,G'GQ0
MER:?*<)I+BA./O91U[.::TE%N,DW5K;NP\C9V3/%R8<-D.<9+G"R#;4;*Y:+
MBA+3P33UC)*2:4RIF4E7FJBIFBHJ*BM56N14R5'(Y-;7)DBM<U4<U41R*BY*
M5AD>LUJ>-H=$;T _I,I=->CZ7!F+;BM3I)T=TE'35]14R-6KQ-AER_1K3B%<
M\GSUM,YC;7?I,G.6L;25LSU?=&9[!#=AR;>01RN;IH/TKX3TBVYTSJ>T5S(,
M04,*JGX6PO7JV"^VU[-:2.DHU=4TK51>;74M*]O-<UKDZMF#<76^_6BUWNU5
M4=;:[Q;Z.Z6VLB<CHJN@N%/'54=3&Y,VN9-3RQO147+ZVK45=WD]&8X&;UM,
M>''RN*<(KLKM3765KN4=9*<%RT4N%>X+9[KNE<MHX+INEQ9.'PUSDWK*RIKV
MJQ^,M$X3?-N45)O69_4  CHDX      @J)]VKW$.:G;YK\R8 $O-3M\U^8YJ
M=OFOS)@ 2\U.WS7YCFIV^:_,F !Y(>G8;_\ 4G:9-O\ Q+9-Z_\ *VP=IS'<
MMO>OO.G'Z=C\T[3)_@6R?K;8#F.]?>OO+&;GO-^1\MG]A25BWV><\;Y##^T9
M((+\O>1(+\O>2X0X;P?JG2?\'^E[;_9Q8=ZI_P#8S!U*;9G-3M\U^9J:>J=?
MD_TO_P N+#^K,!MFE2.G_GC.^'7]C67)W;^9-G_%3^VM)>:G;YK\QS4[?-?F
M3 TXW<EYJ=OFOS'-3M\U^9, "5&]_FJD4:G41          !_$Z2?['KY_@>
MZ?S?4G';H/ZWIOXM3_Z&,[$FDG^QZ^?X'NG\WU)QVZ#^MZ;^+4_^AC)WW+^Y
MVAZ\;ZKRON_+MV;ZLKZZ"Z !.) )L1^K"I_]4I6[O^#+%.Q53_\ &N&NKN0Z
M%?-3M\U^9SU?5AOSE*W]&6*?YUPV="PK%O7\[/Y/3]=A:K<WYG_^KO\ JK)>
M:G;YK\QS4[?-?F3 C0E8EYJ=OFOS'-3M\U^9, "7FIV^:_,<U.WS7YDP )>:
MG;YK\QS4[?-?F3  @B9;"(         (* 4Y'(B9]7'";]AH@>L?>DQDQGBI
M^@K!]P7]BF#:Z.3&]53/_<[[B^GR>RSN>QR]);L+*Y$GB7ZLU^=*KD5ML@?+
MM->E@Y:#= ^A+%>-*:2-N)*F*/#F#(9<EZ7%%Z9+!03JU53I(K3 RKO<\>KI
M(+:^)%1[V'+?N%?45E3/65<\U5554\U355-0]9*BIJ:B5TU143R.^M)-/,]\
MLKUUND>YV]$29-U'1E763VA='6%,NKQTUR=VFL[/^'%I0[N.3?*4$0=OBZ5N
MFJ&S*)<,[X]9DN/:J-6H5:]W6RBW-<GP12YQL9:,V^>OR*H!8-%;TM 01CGJ
MUC&N>][FL8QB*YSWO<C6,8UN;G/>Y4:QC45SW*C6HKE1"[MMMJ*ZIIZ*BIYJ
MNLK*B"DI*2FC?-4U-54RLAIZ>GAC1SY9YYI&10Q,1722/:UNM3?J]#/Z#.RZ
M**"U:2=*5OI;UI1JZ>*LMUEK(H:JV:/DF9SVPPQN66"NQ0V-6MK+H]KH[9+T
ME):T1S):V?6>E'2G'V71UEWESGJJ:8M<=LEV_!A'5<<WRCR23DXQ>T]%.B>3
MM?(ZFA<-<-'??)/@I@^SPXYRT?!!-.33>L8J4H^''H__ %<O2?I/@H<2Z2*J
M71?A"K;'44]%54B5.-[M2N17-D@L\ZLI[##,F71U-Z5U6K'=(RU(QT4[]LOD
MO^A?Y.NBJ.GDM&CRUX@O,"H_]D>-HX\5WATK57F3Q)<HGVV@E9FJ,=;;?1O;
MJ17O5J./5*-N7&WM[>W?GM*N16_;O3K:.?*7%=*FE]E%$G7#3PDTU.ST\;:U
MYJ,5HE:'H_N^V9L^,>"B-]RTUR,B,;)N7C!-<%?HX(IZ=LI/F[&@M\%/&V&G
MAC@A8F3(H(VP1M:FIJ-9&C6HB(F2(B99)LU%XL;5VHB]^OWYDX-.-W2)$C:F
MQ,N[5[C$WJQT=?3R4M=24U=33-='+3UD$-5!*QZ9/9)%.R2-['IFCFN:K51<
ME3(S(,IZ=AAK7DUJO \@N5!Z#KDX:3XZF:IP%180O4_.<E^P'S<,5C)7(N<D
MM#1Q_@.L5\BM?,M3:WRS*B_[H9SWJNJCR\O5R-*^C*GK,1:/*AVE7"M,CYIZ
M6@HTH\:VRF;SG+)/8XWR0WJ*)N723625U4BJKUM20LDG9T*LBBYNSPW)Q\=F
M76;CL/IYM+!<5&^5U2TUIO;LAIX1DWQU^C@DEXQ?8:/M_=WLO:$9<6/''N>N
ME^,HU34O&48K@L]/'%O3LE%\UH&^K?>C\?CK275:5\2V]RX:T6UC8K3!5P/:
MROQ^YG/I6NCE:BYX5IU_"4S53I*>[2VQ'L8^),]_9K41-A_/V3#-OMGTK\'6
M^CH/IU;/<:WZ%2P4WTRX57,^E5U2D#(TGK*GHX^GJI>=--S&K*]ZM13^C.CT
MJZ26;4RGD3CU<5"-=57%Q*N"YM:Z1U<I.4F]%VZ::)'H]$.B]6R<-8T)=9-S
ME9;=P\+MG)Z)Z:O11@HP4=6EIKVM@ &MFT         &JSZUW^2?1C^DF;]5
M+T:*B?/WF]7ZUW^2?1C^DF;]5+T:*B?/WEH]UOFBGXR_[614K>WY[O\ BL?[
M*)$D=M0G)';4)$?8R,W_ )?6=(_U=/\ -.P!_AG2%^OV(3W$/#OU=/\ -.P!
M_AG2%^OV(3W$*;=*?.>T/EN5]M,O!T2\U[.^18OV,  #P380      >27IUO
MS4-,G^ K9^L=G/6T\DO3K?FH:9/\!6S]8[.>QT>\X8/RS&^V@>)TE\V[0^19
M?V%AS'%VN_OE]X"[7?WR^\%SUV(HT07Y>\W3_5+O^(=-_P#*# O\S8A-+!?E
M[S=/]4N_XATW_P H,"_S-B$T#>=YFR?A4?VBHD3=5Y\P_@Y/]EN-P( %5RW@
M                             !Y1>G%_-1TU?R8IOY\M1S#G_C._OE.G
MCZ<7\U'35_)BF_GRU',.?^,[^^4L7N=_@&3\KE]C05FWV^<,3Y&OM[B4D?QY
MH3DC^/-"7'V,A=]C-V[U33^P[3'_ "JPM_,MR-N4U&O5-/[#M,?\JL+?S+<C
M;E*E[PO/&;\*K["HN+NQ\Q;/^!=_:;@ #3#?         #Q,]8?_ #2M)7\?
MT?\ _P 1,+'-@3:O@=)_UA_\TK25_']'_P#\1,+'-@3:O@61W/\ FV[Y9;]C
MCE6]]?G:CY!5]ODDP )7(C(*A2>U-F6I4R5-RHNI45-^>Q>O/7O*P,,&ZKZ
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M)OE".K?/G.4GV:)3  U(W0
M
M
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M]9RT_.JT5B>G-\,9Q7X;[2;MA;S]E9ND96O$M?\ %Y7#!:_FW:NIKPUE"3_
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MJ\7;&.M=(97%C36O;UBUK]&JMC#3T:I=IT! 01=1$JJ6]
M/)'T['YIVF3_  +9/UML!S'>OO7WG3B].Q^:=ID_P+9/UML!S'>OO7WEC-SW
MF_(^6R^PI*Q;[/.>-\AA_:,D$%^7O(D%^7O)<(<-X3U3K\G^E_\ EQ8?U9@-
MLTU,O5.OR?Z7_P"7%A_5F VS2I'3_P \9WPZ_L:RY.[CS)L_XN?VUH !IQNX
M              !_$Z2?['KY_@>Z?S?4G';H/ZWIOXM3_P"AC.Q)I)_L>OG^
M![I_-]2<=N@_K>F_BU/_ *&,G?<O[G:'KQOJO*^[\NW9OJROKH+H $XD FQ)
MZL-^<I6_HRQ3_.N&SH6'//\ 5AY$3E*5JJJ)_P &6*=O9=,-]W'D="IL[53\
M9OFA6+>OYV?R:GZ["U6YSS/_ /5W_565@4^F9_;-_P"D@Z9G]LW_ *2$:$K%
M0%/IF?VS?^D@Z9G]LW_I( 5 4^F9_;-_Z2#IF?VS?^D@!4!(DC5U(YJKU(J$
MX          )7;%\?<3$CTU &ACZT-RHWXATI88T6T52KK;@"RI>+K$QZ+&_
M$N*&M>QDJ,77)06.FI$:V1%6):][F*WIGYZP!]1<N+3A)I(TQZ2\</FZ>+$6
M-+[5T#]WX(IZU]OLD:=D%FHJ"+-,D56*J(F9\NER>B^S%A[/Q<=+1PJBY_&S
M7':_Z<I%'^E6UGG;1S,G5N-E\U7SU]JAY%2^:N,>SOU!(Y^U-Y.?TV L#W+$
M]_LF&K/"ZIN^(;Q;+%:Z=F?/EN%WK8*"BC:FO6Z>HC1-7AD>Y9-13;:22;;?
M8DNUOP2[SP(Q;:C%:RDTDES;;Y))=[?8D;7?JT/HWZ:]UU5R@<743)Z.QUU3
M:-'-%4QH^*2]4Z)'=\5\UZ*UWX*5ZVJT/R=S*]UQJT1DE)1RKNT-CRRRU(FK
M++J/P[DT:!+1HQP#A+ -BC9';,*6*WV:%T<:1_29*6!J5E=*W-<I[A6K45U1
M_P#MJA^62(B)^[HF2%/.E6WI[1S;<B3?!JX41?O*8MJ"T[G+W<_&<I%V.B'1
MVO9>!3C12ZSAX[Y+MG?-)S;?>ERA'\R,>_5N( -=-G      !#(B "&1$
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MYNG^J7?\0Z;_ .4&!?YFQ":!O.\S9/PJ/[142)NJ\^8?P<G^RW&X$ "JY;P
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M)C&_(EIY7%-:PK?HJ@U'3LX^.2]T&H1 -+-\         (9$0
M
M
M
M            05"( (%!S<E5<M6_Q7;Y;? KY$-1QTY@HEJZ-4UH73D1JZMF
M7@05,SD-2U1=Z>*;_#C62/CW\;>->[<5'IDN>[?GO[!XYI[ES\/L!EEJFWY[
M<BDJ9:]VI/MR]Y>/9GK3V%OV;]_'6GM!@MGLSS5/OR+56[T3O3CJXZUOW-ZM
MG&>7R\BB]O5MR]N[/CJ ,<]FU?-../$M7LWHG&6[M[-^TR;F?=N^S66KV9[N
MQ4V<=B[/, QCXM6S9E[/?VEJYF:IUI[OD9-[.-FOJ7M]Y;/9KV>.S7\%V]@!
MB)(]2\9=O&PM9(]?;N7KX^XS#V:OCQO[^\M'Q=B<;,NI?B 8=\>>S;J]G&WX
MEE)%DJ[=G'>AF7,^_?\ 9M+5[/O38 8-\7'R^1:N9J7/6G7\S-R1=BZN,DZN
MKL+-\6W4O'6B\>0!AI8?#M]V?'>63XUV*GC\>-JF:='V<;45"VDBU+[M_AU:
MMGB 8*:G1R*UR(YCFJUR*B.16N16O:YJYHYKFJK7-5%16KDJ*AKO^D-] AA+
M2"M?BK12ZWX%QE+TM34V-T2PX-Q!4+]9?W&!JKAJNF=MJJ&*6VR.UU%OBS6>
M/8P?$J;/+C8GO+9T:;NOA,OB>KLC;>5@6J[%ME7+LDNV$X_@V0?DSCZUJNV+
M4M&O'VUL'$VC2Z,NF-L.V+?*=<OPJYK24)>IZ-<I)QU3Y86G+0!C31I?ZC"^
M.</7##EZIE5WT6OBYL=5 BHB5ENJV*^DN5#(BM='64,T\+FN;FYJN1%_(T.H
MGRC.2W@32Q89,-8^PY0W^VN1[J99VK'7VRH<BHE99[E#S:RV5;%<KTDI96MD
M75/%-&KXW:>_+Q] +CS *UF(-%DE;I#PG'TD\EH;$Q,:VB!%5RL6A@:D.(Z>
M)O\ ]<VMD=<K4S?;%<N26#Z+[SL7,X:LKAQ<EZ+63THL?YDY?>V_P+&NY1G-
ME;NEFZG,P>*[#XLS%6KT2UR*EV^76E[9%+MG6M>3<JXI&OJ!/!+#+)#-')%-
M#(Z*:&9CHY8I6.5KXY8GHU\4C'(K71R-:]JHO.1%U#,D]/4B@  R      ""
MH2=&G'AQ\"H #]5T0:>L;:/:]+G@?%=^PK7<YKGRV2Y5%$R?FY<U*NE:Y:*M
M8U4:J1UM-41ZD7F9M3+W$Y/7K'6E7#R4]'C_  _8=(5%&C&/KX<\,8C<QB)S
MG/JJ*&HM-5._6Z26IM6;EU-:Q,S7E5N9#F)U'A[5Z-X.;_"<6JUZ:*;CPV+T
M*R'#8EZ%+^X]W9'2?:& _P!Z9=M,==>K3XJF_%U34JV_2X,WX= /I[.3_C-(
M*>[WFY:/;G*C4?3XPH5CMJ2*J(YL=_MKJVV="CE3F25BT$LC55RT[.:Y&^NV
M!-(]AQ11LN.&[W:,0T#V-E;5V2XTET@Z-WXKGNHI9NA1=R3)$[K:B9'*I:U$
MV:NX_K<%:0+]ABK9<,-WN[X?KHWH]E79+C5VN=K]S^?12P\YVSZST<NI.I"-
M]I[G<:>LL3)MH?="V*NAZE).$TO3)V,E'9.^S*AI',Q:KUV.=,G1/UN+5D)/
MT15:]1U7FRHNM%[<\_D5$?X\=:<9'/IT,^G4Y1V$$AAJ,74>,Z*)&I]&QK::
M>[3N1-3N?=Z5UNO<LCD_\Y47"HR=D_F+FYKO5_0_ZS9;W]%#C[1=5TSD1&RW
M'!]\BJH^=JSF?;KU!3RM;K=^X05<KD^JK9%3,C_:&Z_:M.KA75DQ\:;4GIZ8
M6]5+7T1XN_M)%V9O;V/D:*RRW%EX9%3TU[])U.V&GIDX]W)&UTCNSLVDZ2]N
M7?KX[#Q]T4^G+Y-V*.C9)CBHPM5/YN5+C"R7*TJKUVL;5TL=SM_U=JR35=/&
MK=;5S^J>C>CK3_@;%\:2X5QGA3$C%8V15L>(K3<W-8[8KXZ2KEDC7<K)&LD:
M_-CVM>BHFFYFQ\O&^_XU]/ILJG!?-)Q47\S9O.#MO#ROX/E8]_HJNKG)>N*E
MJGZ&DS]J;)W+W:O9L^TF1_9M7CN+)4<C>>YKD:NQRM7FKEU/V+YZE[B#94U9
M.3P7[SS3U"_YZ=2^&?P)N>FYWM+-'[-?N'2+V>X OD=U.S3M)N>O7Y)F8_G]
MC2/2=GDO'&8!D$DXUCI%X3[#'])V+Y_;K(](G;Y+\P#()(O"*061>,RPYZ=O
MDOS'2=BKXY>S, O>>O7YI\R"N7^V3X%DLG9YJA#I.QH!>+(G]M[?L)>>G&>7
M&1:](O6GD.D[4 +I7]GN\M_R)%D[DU\;=_N[BR65-[M7:OW$69O158UST1-:
MM:KD1$VJJIFB(F]5ZMP!<K*G7GW:D\?<2*_J3CWGYKCG2WA;"\'TK$N)\.X=
MILU3Z1?;Y:[3"F6M462OJJ=B9)K5%5,MJGG?I6]--R;\)I+'-I'I;_51(O.H
ML(6ZX8AG=EGET=1##3VF3-4R3F7-=RKDU44[^'LK*R/O&-?=W>U53FEZW&+2
M^=GG9NV,3&_A&3CT?&W5UM^I2DF_4EJ>JZO7KX]_CWE%TB=?'C]YJ[:7_69L
M+4R2Q8$T9WN\3(KDCKL5W:ELM$Y%U->E#;(KC<$5OXRQR2-1ZY,Y[=;D\I--
M7I]^4-BI)8+3=['@2BDYS4BPK9H5KNB=L:^[WIUSJV2MVI/0-MTFI,D1,T7<
M=G[L=K7Z<5,,:+]]?9%/^A6K9I^B44:/M+>OL;'U4;[,J2Y<.-4Y<_AV]56U
MZI/T)F^/B3%5NLU(ZX7>OH+301M<Y]==:RFMU$UK$5SO]U5LL$"JUJ9\UKW/
M78UJKDAY2Z?O3@<GK B5$$6+9<;72!'I^#<#T;KPU96+S5ADN\SZ*QP/1Z<U
MR/K^>U$5S6ORR70STD:9,78TJI*[&&*,08IK)%1SZC$%WKKJ]RHN:+S:R:6)
M%:N664:*BHF662'YRK47+LV=F74FQ/<;_LS<Y1'267E66]C<*8JJ/J<I<<I+
MTQ5;]1'>UM]N1/6.%AUTIZI67R=LEZ5"'5Q3]#E8O6;*/*']9/QW=NGI-&N#
M;+A"E=SF1W;$,BXFOG-5O-Z2.D:RBLU*Y?QV(Z"LDA?S?W>5&YN\*].W*NTD
MZ4*Q:S'V-<08G=TG2QTUQKY/P93OUHCJ2T4_06JE5K5YB/@HV2.9DU\C\LS\
M!YB=1%&HFPDC9/1; P='C8M5<E_&:<=OZ6SBL^;BT(NVQTLVCGZK*R[;(/\
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MSSXU%9&^6_/> 1:W/N3Y_ J[DZMW;U;-W4-G8F[CJ3[B>-F>2KQU9IX[-WB
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MIO\ G62>GS=GS%[-BXL:,/%IBM%5CTP7\VN,=?GTU]+Y]Y$ 'G'I@
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ML/OLB]U9>+8GHZ\FB:?@XV1E_<=<INPF)6K[U]ZDQ2@O@
M>2/IV/S3M,G^!;)^MM@.8[U]Z^\Z<7IV/S3M,G^!;)^MM@.8[U]Z^\L9N>\W
MY'RV7V%)6+?9YSQOD,/[1D@@OR]Y$@OR]Y+A#AO">J=?D_TO_P N+#^K,!MF
MFIEZIU^3_2__ "XL/ZLP&V:5(Z?^>,[X=?V-9<G=QYDV?\7/[:T  TXW<
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M(=-_\H,"_P S8A(_WG>9LGX5']HJ)$W5>?,/X.3_ &6XW @ 57+>
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MU2W^O=.7_-8!_P _$YHV\GS+F_\  _M-)OVZ_P ^X'KR/[)>;H( *H%P@
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M-K6M[$0OBE#^*G<GN*I2?4O@@
M
M
M
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M62IJYI*JIE7KDJ*ATDTB]KWN7JR0I-3),AD1/9C%):(\/O;?-OM;[6  <@
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MSO3\7?\ 92(TWM>9;_AT_:(U:F_+W(3$K?E[D)BTR[$5)78BWJOZE+_S,O\
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M(MAZ^&<DG\Z2:]!>O8>7&_"Q+HM-6X]-G+\ZN+:]:>J:[GR(@ \T]0
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MT73;^#5)_P!QV-CX[MS,2I+5V9-%:_GVQC_>=2-OQ7WJ3$K=A,4I+W@
M         'DCZ=C\T[3)_@6R?K;8#F.]?>OO.G%Z=C\T[3)_@6R?K;8#F.]?
M>OO+&;GO-^1\ME]A25BWV><\;Y##^T9((+\O>1(+\O>2X0X;PGJG7Y/]+_\
M+BP_JS ;9IJ9>J=?D_TO_P N+#^K,!MFE2.G_GC.^'7]C67)W<>9-G_%S^VM
M  -.-W               /XG23_8]?/\#W3^;ZDX[=!_6]-_%J?_ $,9V)-)
M/]CU\_P/=/YOJ3CMT'];TW\6I_\ 0QD[[E_<[0]>-]5Y7W?EV[-]65]=!=
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M\D<0_P!+#[HFQ_RV'Z.__IC[F>W/R)_I*O\ J&I]SN,T^8YW&:?,VP?VI_I
M_A@P9_DCB'^EA^U/]('\,&#/\D<0_P!+#[HFQ_RV'Z.__IC[F>W/R)_I*O\
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M-/[#M,?\JL+?S+<C;E*E[PO/&;\*K["HN+NQ\Q;/^!=_:;@ #3#?
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MM3)\$K'9IJUZM1_0%)VM'H^37)HO@FFDUS3YIKO0 !@R
M
M
M
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M2KDOYLDG_P!\BX S&9VCK
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M^WN!G49[DX0JHS+7OX3W:NPBUJ)QFI'V(<6M?1_><6037U$X!R,H
M             &KEZU7^1K GZ1X/Y@NAM&FKEZU7^1K GZ1X/Y@NAMW0/SQ@
M?'?X)FE[Q/,FT?B/\<#0\ !;HIF3,VIWI[SIO>@F_-/T,?R=N/ZU8A.9"S:G
M>GO.F]Z";\T_0Q_)VX_K5B$B/?%YOQ_ED/L<@F7<EYRROD4OMZ#UP !7,LV
M  04_,]+>A_#>.L.W7">+K/0W_#U[I)*.Y6JX0MFIZF%Z+DJ9_6AGA=S9:6J
MA='4TE0R.HIY8I6-<GZ:2NX\E.4)RBU*+<91:<91;3BUS336C33YIKFCA97&
M<7&45*,DXRC))QE%K1II\FFN33Y-'*F])ER(:OD_Z7\18 =--661O07K"-SJ
M.:LUQPO=%E?;W5#FM:QU;02Q5-JN#FL8DE50OJ&QQPU,*+\%&W%ZV'AJD9B;
M0W>&JGTZILF++7,B(SG.HZ:X6VL@5RY\]49//*UF:<UO/>C5S<J&HZ7!Z'[3
MGF;-Q,BSG9.MJ;_"E7*5;EZY\'$].2UY:+D4JZ:;)KP=J9F-5RJKM3KCV\,+
M(1MC!/MT@IJ*UY\N>KY@^E>1ER@JO17I7P!I!I)'L_8QBBUUU:UBN1:BSR3I
M1WVD5&JG.2JL]370\U4<U'OC>K7JQ$/FHLJI51DBIM1CU1=FM&JJ;^M/CM/>
MRJ8VUSKFM861E7->,9Q<9+YTV:YCY$ZK*[:WPSKG"R$E[V4&I1?S-([*E'4Q
MS11RQ/;)%*QDD4C%YS'Q2-1\;V.34YKF.16JFI45%+D^6N1)BB2\Z'-%%UEE
MZ::XZ.,#U<\OUTY]1-AFUNJ7?7^NO^Z.E3-V:KEGFN>:_4B+J*29%75V3K?-
MPG*']&37]Q?3%O5E==B[+(0FOYT5+^\B #XGW      !HA>M:?E=T8_HWN?Z
MV59O>FB%ZUI^5W1C^C>Y_K95D@[L/.]/Q=_V4B--[7F6_P"'3]HC5J;\O<A,
M2M^7N0F+3+L14E=B+>J_J4O_ #,O^8IUJ^0I^171'^C3 _ZMV\Y*E5_4I?\
MF9?\Q3K5\A3\BNB/]&F!_P!6[>0OOE^\87QMO[")TW'_ ,(S_B:?VY'U: "
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MNO@E5DP[XVQ6CEI^#8O+B^S1N/NHR2N  :J;>       !F  0S(@
M    &JSZUW^2?1C^DF;]5+T:*B?/WF]7ZUW^2?1C^DF;]5+T:*B?/WEH]UOF
MBGXR_P"UD5*WM^>[_BL?[*)$D=M0G)';4)$?8R,W_E]9TC_5T_S3L ?X9TA?
MK]B$]Q#P[]73_-.P!_AG2%^OV(3W$*;=*?.>T/EN5]M,O!T2\U[.^18OV,
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M5-/[#M,?\JL+?S+<C;E*E[PO/&;\*K["HN+NQ\Q;/^!=_:;@ #3#?
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M*E&*TJM\6IP24G^,C/T:_P!&""*1-")%        S  (9D0
M
M
M
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M5&-RU(G'>56MRV\<>T @V/8J^153/=QQ[/8D4;GDN[5QEQF55U;4[<M_V>\
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MV%4+:I5SE7.+A.$G&<))QE&47HXRB^:::T:?8R( /H?,&X?ZI;_7NG+_ )K
M/^?B<T\#</\ 5+?Z]TY?\U@'_/Q.:-O)\RYO_ _M-)OVZ_S[@>O(_LEYN@@
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MXKFN1+F)EUWUPNIG&RJR*E"<'K&47V-/ZUVI\GHT1 !\#L
M
M
M
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M,#_JW;R%]\OWC"^-M_81.FX_^$9_Q-/[<CZM ! !8T         %-[=7&14
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M%UT=)8^*]'U3[K;N;76+MA7[QZ2EY:4808S+V]785 "&"=
M    #R1].Q^:=ID_P+9/UML!S'>OO7WG3B].Q^:=ID_P+9/UML!S'>OO7WEC
M-SWF_(^6R^PI*Q;[/.>-\AA_:,D$%^7O(D%^7O)<(<-X3U3K\G^E_P#EQ8?U
M9@-LTU,O5.OR?Z7_ .7%A_5F VS2I'3_ ,\9WPZ_L:RY.[CS)L_XN?VUH !I
MQNX              !_$Z2?['KY_@>Z?S?4G';H/ZWIOXM3_ .AC.Q)I)_L>
MOG^![I_-]2<=N@_K>F_BU/\ Z&,G?<O[G:'KQOJO*^[\NW9OJROKH+H $XD
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MHG*R6&:&1K9(9HGHK9(I6MDC<BM>UKDR)44F5-/L(2(E)R+GFFWO\-VXJ@-
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MOAU?=!+N+,[E,NR>!DU2;==.3[5KV+K(*4XKNT4EQ:+OFV^W5S  B,F<
M
M
M
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M-A5:S++>O'EQX 4FLZO;O^?7[$*R,35EK7KXU>.[<5DCSV^SCV>95;V<?+X
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M+GKH21NYZ"Y>R+<F>391-75UPCU,K)-.,FWQ<==>G;W:G]@ ","6
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MVS/*QZ$[M-'D6M67-/MTDTE6GWJN,$^_4D1B(3@&KFV@
M    'DCZ=C\T[3)_@6R?K;8#F/9+KU+M7WG7NT]:#,,:2L)7G!&,K:EWPSB"
M&"GNMM6HJ*5*J*FJZ>NA8L]+)#41\RJI8)<XY&JO,1JYM547S";ZO_R4E_\
MR8Q_Y18C_I,E?H%TZQ-EXMM&17D3E/(=J=4:Y1X757#1\5D'KK!]VFFG,AW>
M)N^S-K9E.1CV8\(5XT:6KI61EQ*VV>JX*IKATFNUIZI\CFG9+U$%1>I=WO.E
MI^U_N2G_  8Q_P"46)/Z3(+ZO]R4LE_X,8_\HL2?TF;U]V#9OXG,_1T_]<T'
M[BNU/Q^#^DO_ -N>9_JG2?\ !_I>_EQ8?U9@-LT^0N23R'M&6@^@O%KT9X=;
MAVAOU=!<KI"VX7"O^DUE+2MHX9>?7U%0^/F4[$9S(U:QV7.<G.UGUZ0;THVI
M7FY^3E5*<:[I1<5-)36E<(O51<EVQ?8WR)^Z);(LP-G8N)<X2LIA*,G6VX-N
MR<_)<HQ;6DEVQ7,  \ V(               _B=)/]CU\_P/=/YOJ3CN4"+]
M'IM2_P!;4_\ H6'9+N=NAK*>>EJ&=)!4PRT\S,U;SXIXW12-S;DJ<YCW-S14
M5,\T7,\;H_5^^2DUK6)HQCR8UK&I^R+$BY-8U&M3/\)Z\D1->\DK=]TQQME+
M*61"Z?7NEPZF,):=7UG%Q<=D-/=K337O["+MX_0G*VP\3V-91#J%=Q]=*<=>
MLZK3AX*[-=.!ZZZ=QS3\EZADO4=+/]K_ ')3_@QC_P HL2?TF/VO]R4_X,8_
M\HL2?TF2/]V#9OXG,_1T_P#7(P^XKM3\?@_I+_\ ;G-,R7J&2]1TL_VO]R4_
MX,8_\HL2?TF/VO\ <E/^#&/_ "BQ)_28^[!LW\3F?HZ?^N/N*[4_'X/Z2_\
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M"MV.?LW:5&9?;BRKJ5RE&J=KF^LILK6BE3!<G)-^4N7B?98 (6)U
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M=[M7!VKB963CQA34[N.2OIFUQX]M<?)A-R>LI17)>GL/80$C'9IX$Y )8T
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M3T6LI-I16D59+HMT<IV5AUXE3<]&YVV-:.VV6G%-I=BT2C&.KX81BFVTVX@
M\$V(
M
M
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M&7@11J)QXD47L.*; 1>H<WK(HA$Y&-   9
M       !#(B           0R(@ ADA$                    $,B(    !
M#(B                       0R(@ AD,B( !#(B "&2#(B
M                 0R(@    @B$0
M         "&1$                    $,DZB( (9(1  (9#(B "&1$
M             ADA$  $,B( ((1              (9$0  0R3J(@
M                           @J$0    "&1$              @HR(@
M  AD1              !#(B  0R(@                   $,D(@ AD$0B
M"&0R(@ AEV$0           0R0B "'-3C(9(1
M
M
M
M            (9$0 2Z\^SP#D3L^XF(9&&@4.:J=OG[]Y#,N"1S$XVF-=.WZ
M045:A06)475QQXERJ*G''L((IRU!:Y]:*B]:<<(1]O=QX\9E=6(O''WE%8U3
M6B^?&OCM )',1?O*:M5.U/#CQ0J*[KW]F7GUDV?<O=M\O=\0"V[.[4OSV[]_
M:2JQ.[CRXR+KFHO''AQE26/+8ON]O7X[P"VYB]_'5\ERVDBM1=WP+E=NO5W>
M\@J(J[ "S6->_CKXU>)35B;TRXZ^.LONCWHOAQL^!(J+O3RX]F7V@6'1^/GK
MZM>SC/J*;H^S+MV<<>%^C$[$[N/82*Q4WY^P QRQ=67':A2>Q<MGFG&7?]ID
MEC[,NWCS]NS42='U+X?: 8M8^,\]O'P)5BZL_A[?F9)6=GEL\4^>OQ*?1IU^
M?5XY<:@#'K'U[.SA?FF:%)8^S+)?AUIY&16+N\%R[R58^Q?+/V[0#'='KU*O
MQ]N7D2+&J;D7C49#F^.7O\=A*L?8O>GV?( Q_1_W/Q^)(K$[??[,LO:9%8NK
MVZO>F_K(=%J^S+W9@&-6-.SR^1+T/8GM0R*Q]V7@F?FF9+T2=7BG5V:P#'K#
MV+X*2]$O;[_?D9#H]>6OOUAT>6_CR]P!CEA7M\D).B[O)?N,GT:]?ED0Z+C/
M+X\( 8[H^[_HJ.C[O)3)="O]U[/F.A7M\?L!C4QO1]WDHZ/N\E,ET*]OAG\1
MT*_W7'B!J8SHN[R4F2'O\D^/'CF9'HN_S^WA D2]:^SCO\09+#HE[?)"/0]B
M^:_(O4;V]N[Y$RQ[-N?C\ "RZ'L3SXXUD>B[N._CP+[HDZE7OW>TCT?8GLU>
M&2^0!9HQ.WCN3CR)^C_N>//V[B\YG&OPZ@D6S[/AF 6J1]2)QQ\B/,[?+[<R
M\2).K/OX0GYG<GP\D^* %FD?&2_8A52/J3)?-/872,\?#/MW\=>LGZ+N\5S]
MVP M6Q>7A]N9.D?9U\;U+M(TZ_!,DX\/#43I'U)YZO?Y^?< 6C8^$3JVZRMT
M77EO[>.[RUETD?;E[O;PA,C$[^.O8B>T MVL3OXZMFWVE1&>'7J^6SVERV->
M[CRXU[R=(TWK\/8 6[6)U9KY\? J)&O5EQ\?=X%9J=2?+CC7EJJ(Q5WY<=O&
M\ HHQ.]>-WGV%3F+U9>SV%5J=7R]NW=U?:S^&_A5\0"5&)W^7SR3CL)MGR3C
M5E]Y4:Q5VZN.-N?45$C1/GQL *36KU99;-7'?U%1L:)QV]1/GW>*DJ.ZM:[E
MW>0!-W;..-7F05<NWW;=WQ)N8JKKU(FQ/NW<(56QH@!1YBNVZN..%*[6(GD3
MD$U[/G[ON &9%&JO6B<<>XG2/QV[BH<6_#__  "5K$3<17/=\!EQN)C*0(9;
MR(!D
M
M
M
M
M
M
M
M
M
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MJ2I["8 Y#0  &0
M
M
M
M
M
M
M
M
M
M                                   0(@ @JDKF(I.04PEH"ET:[O+X
M)]I(NK:A<$,D4PM>\%$E<W,K+&A3YJ]_@O'893!;NAZMO'=Q[89+LR1?+[RN
MB^?'@1,@M.<G:GM1..-A.G8J+[/>5E8A(L2;N..-8!37+>GGQD2.8B_>3\UR
M;/+X9+Q\(+GM5N76NS5W)JU SH4^C7KX]Q#FKU(N_A$*V?;Y_81R7L7Q^ ,%
MKFG:G?K[N$(ZM^7S*^77G[?M^9#F-X4 MUC[.S4J9DJQ]Z<=J9<:MI<K&F[X
M?82\Q>O5VI\M0!;\Q=R^?V:AS%ZBLK5ZD]GV?;M()W+YK\=7'6 4>:J;O(E5
M$ZO87"Y=OCDO&KC60U=:^7R +96IV>7W$.8WLX\2[1N?5QWY\;-XYG=YI\@"
MTZ-/N7)!T??YEUT6?[W/R^SW#HD_M?=\P"SZ/M7V$>C[^/$NN9V*.:G;Y?8#
M&A:]'W\>(Z/O]GS+KF)NS(]'V+[ -"T2/O\ /+W$>C[_ #7Y%TD:=6??E\QT
M2?VON^8,EKS&]G'B$:G9QXEUS>[S3Y$>;EU>:?! "W1.I,_ FR7J*NK>N?=K
M]_P&2=J^2<<+U %)&+U)[";HUZT*GA[U^SC7O)LE_M43P1/BO&H H<SM7CNS
M)TCRW+XKJ]ON^XJ\U>O+N3CCM(I'UY^P I9(G5JZOAQWYC5]W&?85^8W[R.2
M?=]@!11JK^]X^S83=&J[5\_LR*V79EWZ@O:J)W:^,O: 4TCZ^/!.-Y,B)[_:
M/_=5?'A"+4?W>2>[:#.A'R1.O["3G)VKL[N/B56Q)OX^)41B P4$SRU)EVY_
M/K(I"NO,N$0*H!*UB(3A&KW<=G'F3MCZ]OL\E,-Z IHN>S63<Q5[/?\ (JHB
M$3#]'_L"1K,ONXX["?,$3.GB8( B#)D
M
M
M
M
M
M
M
M
M
M
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M(2
M
M
M
M
M
M
M
M
M
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M[/(F"0(9C,9$0E_VS',AQP@R(@:#0  R9
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M4.)RK?E2UT6D9R?/1]QXNR>F&S<ZWJ,7*A=;PN? H61?"M$WK.$5RU7>?>P
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MM57M&DZZV^USMU4.6C7#!SDGR:7:MO!%(DD:9(3FHFY@
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MJQW_ (VP[_VQ^VO-'/\ !5CO_&V'?^V/N?;9_(;/Z=/_ %!]TC8GY?7^CO\
M^D;8'.3CCCN(YFNKR-?6'\#Z9=)F%=&=KT>XNL]?BJJK::GN5QN-DFHJ5U%:
MZZYO?/%2N6=Z/CH7Q-2-,T>]JK]5%/LCTG'I6L.<F-F#7X@PI?<2_LQ?>HZ5
M++5VZF6C_ C;<^5:CZ>J<_IDN+.BZ+/+HW\[6K3S+>B^?#)KPY8TEDW0=E=7
M%7K*"XVVFI\*T5<^V2?D]G8>I1TOV;9BVYT,J$L6B:KMN4;.&$WP)1:<%)MN
MR'9%KREZ3UB50BFN/R3/6/M&VE/2+A71Y^PS%.%I\6W!;3;[S>*^S3VZ.YRP
M2OMU'.RD?TZ.N54R.@IW-S1M341<_P"HKE38TB7-,SJ;5V-E8,XUY5,J9RCQ
MQ4G%ZQU<=4XN4>U--:ZKO7-'>V/MW$SZY6X=\;X0GP2<5)<,M%+1J<8R[&FG
MIH^Y\F50 >6>L0S&9*_+CL/!OT@7I[-'V@/2%-HYKL+8AQ9=Z"U6ZXW>>QUM
MJIZ:UU%T;)44MLJ$KG)(ZM^@)35\J,3F1T]=2:U>]S6>CLO9.3FV]3BU2NL4
M7-QCHM(II.3<FDDFTN;[6EWGF;6VSBX-779=T::N)04Y*3UG+5J*45*3;2;Y
M+L3;Y(]YLPBGB_Z-+TR^%N4OB;$>&K#@W$6&ZC#EB@OD]3>:VUU,-1#/<(K>
MD,+:%5>V5))DD5TGU.8BHGUE0]GV)DB'#:6S+\2UT9-;JMBHMP;BVE):Q]RV
MN:>O:<]E[5Q\VF.1BV*ZF3DHSBI)-Q;C):247R::["8 '1/0
M
M
M
M
M
M                                 (9<9J,N,U(@&-%X   R
M       0RXS&7&:D0#&GH  !D
M                                              &KEZU7^1K GZ1X
M/Y@NAM&FKEZU7^1K GZ1X/Y@NAMW0/SQ@?'?X)FE[Q/,FT?B/\<#0Z?L.A3Z
ML-^;4_\ 2/C;W64YZS]AT*?5AOS:G_I'QM[K*35O:\UKY33]5A ^YWSP_DMO
M[4#8I !6<M8
M  #5?]:R8G^Q%H[U(JII%5454UM7]CUPV:M2[L]2FU :L?K6/Y(M'GZ15_5Z
MX&W] ?/&!\:_LYFE;Q?,FT?B5]I T26IDAT./5DOS9H/T@XZ_P!;H#GDG0V]
M62_-F@_2#CK_ %N@)IWM^:X_*JOV;""]SGG9_)K?VJS8: !6<M2
M         #6]]:-;GR<;5LU:5,'JB]7^]>*MG4NO+5N5>LV0C6_]:+_-QM?Z
M4\'_ ,UXJ-HZ%>=L#Y37]9J?3KS/M#Y-/^XY];6JBF_'ZK#^0S%OZ2KI_,UI
M-" WW_58?R&8M_25=/YFM)/&]7S1/X^C]IE>MT/GFOXC(_91LX@ J^6Q
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M(MCTW\T;0^(E]<2G'0'SSL_Y5#ZF= 8 %1"Z8
M          *;VYJB]2I[RH07Y>\ Y'?+,C_X8=+.62)_LF8]U(FK/]E5US75
MUYZ]29[SZ3]#Y^<]H/\ Y>4/^H7,^<^69^6'2S^DW'OZU74^C?0^_G/Z#_Y>
M4/\ J-S+B;17_P *N^06?V:12/9GG>C_ /<:_P"THZE[-A,2LV$Q3LNX   2
M2;/%%\$5%7V'(_Y9V$[Y8M+VD^TXD;*E]H\?8J9<W3H_I)ZF6\U=1])YST19
M(JR*:.KAG3-M1!-'/&YS)&N7KA*F9XQ^D>]"7HNY1%RCQ175=TP;CEE/#1U&
M*</LI9_PK14S>CI8+Y::UJTEP?2,RBIJV-]-7Q4^5.Z>:&.!D,A;O.E5&S,B
M[V0I*G(A&+LC'B=<H2;BW%<W!J4E+AU>JB]'S(UWF=$+]K8U'L64>OQK)25<
MY<,;(V)*24GR4TXQ<>+1:<2U6J.:(]Z;5V)K5>I$UKV9(B+V9'43]"]A*]V/
MDO:&;?B&.>&Y)A/Z:D52CTFCMUUN]SNME:]LB(^-$LM;;T9&Y$6-G-9DB-R/
M,ODM>K!Z*\'8@HK_ ([Q5>M)++?,RJIL/U-NH['AV:HAE;) Z[04TM36W.G:
MK45] ^KAHYU1&5+)H5?"_9QIZ9D3&1QL;''&UK(XV(C6,8QJ-:QC&HC6,:U$
M:UK41K41$1$1,CV-X_37%VA73C8G%9"NWKIW2A*"U4)0C"$9)2?*<G)N,5RC
MIKJ]/#W7]!,S9EM^5F<-<[*51"F,XS?"YQLE.;AK%/6$5%*3?.6NG+6X !$I
M,P                             !0J458WHB9JK'HB)UJU<O;J.8!B;T
M.?*BFN5RFBT(XU?%-<*Z6-Z?@#)T<E5,]CTSOJ+DYKFJG8OEU!5*'T9G]HW_
M *+?$VWHMTOOV2[W1559U_5\76J;TZKCTX>&4>WK'KKKV+0TWI=T*QML=1[(
MLMK]C]9P=4XK7K>KUXN*,NSJUIIIVO4Y='^TU\J3^ _&WEA_^GCX7TO:'<4X
M Q%<,)8SL==AS$EK^C_A"SW)($K*1*NGCJJ99?HT]3!E-3RQS1JR9Z*QZ*N2
MZCK^RT[.:OU&[%W(F[N.9OZ>AJ)RK=*2(B(B2X<RRU?_ &-VXF3H+T]R=J9=
ME%U5%<842M3J4U+53KBD^*<EII-]W<N9".\'=[B[)PZLBBV^<YY,:6K'!QX7
M7;/5<,(O76"[^S4^ >3UR5=(VEBX7&UZ-\'7?&-PM-''<+E26CZ#TM'133K3
M0U,WTZLHF=').U8F\Q[W\Y%S8B)F?6/^TU\J3^ _&W_]O_T\>N?JH\:+I2TK
M9HB_\'UHVHB__9,O6FTWIDIV?VC?^BATNF&\;+V=GV8M5&/.$(UM2L5G$W."
MD]>&R*[7RY+EXGH="MV6'M+9]67==D0G.5L7&#@HI0FXK36$GV+Q- 7T0_HQ
M.4!@7E':,,68OT3XJP_ANSW*[RW2\5Z6;Z'11SX;O5)"^;Z-=ZF?FR5-1!"W
MHX7KSY&YHC<W)]N^MH?U'09_S^/?]!ADW&VT[45%1J(J?W+4]WP-.7UM'^HZ
M#?XQCW_0X9-7Z.=);MJ=(=GWW5UURA7=4E5Q<+BJ<F>KXI2>NLWWZ:)<C:.D
MW16C9'1O:6/1.R<++L>YNUQ;4GD8L-%PQBM-()]G;KS--^SWNKMM=1W&WU#Z
M2OM]53UU#5Q+E)2UE'-'4TM2Q=63X)XXY$W+S4:NI50ZLWH[N5C1Z:]#N"=(
M=.Z+Z9>+6R"_TL;D7Z!B:VJM!?J-S4UL1MP@FGA1R(KZ6>"5N<<K'+RB'-SX
M0VM_5>>6;^ L88ET)W>L5EMQC%)BC"<<K\HX\36JF9%>:&%%<B))=K)%#5(U
M,UD?9LF-U/-^WI;"]E8'LB$=;<-NSEVRIEHKE_-2C9Z%"7B1WNDZ0^Q-H^QI
MO2G.2J]"OCJZ9?SM95>N<? WFFJ15<D)(UU>1,_8I64M8?CNG_359]'>"L48
MYO\ *D-GPI9+A?*]RNYBOAH('3-IXUR=^[5<J1TD"<U56:=B(U5U')DTZZ9K
MSI$QKBG'6(9737K%E\N%]KU7\6*6NG=)'21-V1T]#3K#14\3?J0T\$<4:(QC
M43<?]:-Y9_X)POA70A9JM6UV*YV8LQ>D3LE9ARTU#H[';ILLTYMUO<<E=(S-
MKTALD37M?3URFD6C"QNZ;8748D\V<=)Y;X8:KFJ*VTM.]=99Q-]SC&ME8M\?
M2#V1FUX-<M:\-:V:=CR+8IOU]77PQ_-E*:[F;47JI/Y5M*/Z/;?^LU$;V1HF
M^JD_E6TH_H]M_P"LU$;V1&N]'SQ?\71]E$E+=)YDH^-R?MI@ $>$E@
M
M
M
M
M
M
M
M                           U<O6J_P C6!/TCP?S!=#:--7+UJO\C6!/
MTCP?S!=#;N@?GC ^._P3-+WB>9-H_$?XX&AT_8="GU8;\VI_Z1\;>ZRG/6?L
M.A3ZL-^;4_\ 2/C;W64FK>UYK7RFGZK"!]SOGA_);?VH&Q2 "LY:P$,PNPTV
M/3,^F2T\:&-.EUP+@*_6*@P[288PG<X::OPM;;K4I5W:DJI:U[JRI>DKF/DA
M9S(U3FQIJ;MU^WL#8%^TKWCX[K5BKE9[9)QCPQ<4^<8R>NLEHM/$\'I%TBQ]
MEX_LG)5CKZR->E45*7%-2:Y2E!:>2]7K\QN3YH1.<(GK'G*K5S47%>%M;FHO
M_D+9EU*Y$7_SB&V=R^?3,X(Y/V#\/_A5JXLTF8CPY;;K;,&VR:.E5J5=%#(Z
M[W^L1)66.SOJ72MIV]%-77!S71V^F?#%45=+[>T]W^T<6S'I<*[K<ES5<*)2
MDUU:BYRFYP@H12FFY-Z):MM'@;*WD;,RZLFY3LHJQ(UNV>1&,/OKFH1@H3LE
M.3<&E%+B;T44]3VG5RY_9GJ]Y'-W4<R#E-^G'Y1^DRLJW/Q[7X)LT[W]!A_
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MT92T3?@M?H/Z'-#5C]:Q7_@BT>?I%7]7KB>#-)ZR#RK'11.7%>%E5\,3U_\
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M-R?MI@ $>$E@
M
M
M
M
M
M
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MR4?&Y/VTP "/"2P
M
M
M
M
M
M
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MS,_H]7B.\Q(^:-_[V1]#::RG5/WT<SU_>F^,W8:4_JF#?]_=.'^"L";_ /\
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M$OOE9.=DWQ3LG*<Y/M<IMRD_G;;+I8^/"JN%5<5&%<(UPBNR,()1BEZ$DD
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M_J?:"5=T'G.WY';]M01!OJ\U4?+JOL,D\4JO^I2_\U+_ *-YV.\+_P#%MO\
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MEZ6V2=D]7&F2;4I::IODDM=$C;]!J!?MM+#_ / ?>_\ +JW_ /AP?MM+#_\
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M'-3RK#*Q\4K62+S)&.8[)S50\+=)="O:5SG*,$\.Q:RDHK7KL?DM=.?+L_\
M<V+?+3.>RZ5"$IM9U3TA%R>G49'/1)O3T]A]!^JD_E6TH_H]M_ZS41O9&E/Z
ML;H!QWA#2=I)K,5X+Q7AFDJ\"4%-2U-_P_=;/3U-0W$5)*Z"":X4L#)IFQ-=
M(L4;G/2-%>J<U,S=6:N:'G;S;8SVO=*$E*+KHYQ::^]1[TV>GNHJE#8M$9QE
M"2MR.4DXOG=)KDTF3  T D<
M
M
M
M
M
M
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MP_H0C^VR,2?P+V7_ "RN']"&I5^QRX?^SKA_]P5?_<C]CEP_]G5__P!P5?\
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M:B%LC[134-)3U&(KC1]+&O1U=QDKZ6VI60N1[*.GJJ9KD2:H:[<5C3:G'O\
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MJ_<S6CE&7'R3CJM.<I)\O<[U:7\YZB_D+B__ $5 =%0YU?JTOYSU%_(7%_\
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M6JZGT;Z'W\Y_0?\ R\H?]1N9\Y<LS\L.EG])N/?UJNI]&^A]_.?T'_R\H?\
M4;F7%VCYIN^06?V:12/9GG?'_P#W&O\ M*.I>S83$K-A,4Z+N   $%V*<U7U
MA+\[+2/_ !/!?ZGV@Z52[%.:KZPE^=EI'_B>"_U/M!*NZ#SG;\CM^VH(@WU>
M:J/EU7V&2>*57_4I?^:E_P!&\['>%_\ BVW_ ,2I/]7C..)5_P!2E_YJ7_1O
M.QWA?_BVW_Q*D_U>,V#?1V;._P#J_P#^N:YN,[=J>K#^O*,Z ""BP1!5-2WU
MIWDIK=,&8)TP6^G1U5A&YNPGB*1C<W_@'$4G2VFHE=DB-@H;_']$37FLU\B1
M$1K54VTSYEY9/)YHM*VB['.CRO:U8L5X=N%K@D=S?]S7%\*S6FM8YS7)')1W
M.*DJ(Y$1%C=&CVJBM13WNC&UW@Y^-D^]KL2L]-4_(M7KX)-KPDD^XUWI7L9;
M0V=E8NGE65-U>BZ'EU/T>7&*?YK:[SDA29=6:+J5-RM5,E1>]-2]^6\Z2'J_
M'*B=I(Y.F':&LJG5%\T>5,^ [JLK^=,^GMD<538*A^IOU9K%5T43<M2+3NCY
MROC<<XG$.':ZT7*X6FYP.I;G:ZZJMUQIGM5CH*^AJ)*6KB5CD:YO,J(I$:BM
M1>;DJHAL<^K'<J5<(Z:+UH[KJCH[3I.L2MHXWOYK&XHPQT]PMJMYR\U'U=JJ
M+S2<QJ(^HF^A-5RI"UJV'WD[)]F;+LL@M9XS63#3GK"*TM2?AU4I3Y=KBBM&
MZ[;+PMKU5S?##*XL6:?+AG)ZU:^GK8QASYKC?I3W;.5_I_HM%FB_'>D*O<SH
ML)X9NEV@C>Y&I57&.!T5HH4<NI)+A=9:.BBSVR5##DM8BQ!67>OK[M<IEJ;C
M=*ZLN5PJ')]:HK[A4RUM;.Y-:HLU5/-+EFN2ORV(;P?K3/*>_ ^CS!NBJAFY
MM7CB\OQ#>&LD<UZ8?PLK/H\4K$5&OAK;W64SN:],E6@:YBJL;D31A5Z-:JJN
MI$55[D3-5]F9Y.Z39'4X-F5)>7E6>2_Y&G6$=/78[-?%<)[.^7;77;0KPXR\
MC$J3DM?XZ[24OHK527@W)=YM)^JX<E=,0:3<4Z5J^GY]%@"SI9+)(]&JW]DV
M*(I&54T>:Y]+;\/1U,6:9MYEY<BHCF,4WPT:B'D=Z$/DI+HFY.^!K=64RT]_
MQ53.QUB)KVHV9E?B9D5724DK53GQR6^S-MM%+"]SDBJHZKF\U'Y'KF0]TYVO
M[-VGDV)ZUURZBKPX*M8ZKT3GQS7PB;-WVQ/8&R<6IQX;+(>R+O'K+DI:/TPA
MP5OX  !J)NAIZ>MIT$KK)H-J48G10WS'T+W9MS;)46O##XF\W/G*CFTTJJY$
M5&\WZV2N;GI<)L-]OUIS1N^XZ#<(8DAC61V&=(U#'4.1N?0T%_LUVHY)G/VM
M9]/IK9!E^*YT[,\U:B+H0NV>?'9W>!:3==<I;&H2Y]79?!^MVSLT_HS3^<J/
MO9I<-MY,GV658TX^I4QK_:K9E*:S5DS$D@HJV:-55J204=5-&JMU.1)(HGL5
M6KJ<B.S:NIR(I<?L>N/_ +-N7^+J[_Y<WO/5;M(]%>M"&*<*RQP/K,(X_KYG
M->V.23Z#B>@HKG3S(CVN5L;ZN*OITUZWTTBY:T-FA+-1K_\ 6U/_ /:(?^[/
M#V[O3>%EWXLMGJ;IL<5/V3P\<=%*,N'J):<46GIQ/37M-AV!NCCGX>/F1VCP
M*^M3X/8O%P2U<91XO9$=>&2:UX5V=B..W^QZX_\ LVY?XNKO_EQ^QZX_^S;E
M_BZN_P#ESL2_@2D_]6I__M$/_=C\"4G_ *M3_P#VB'_NSR?NS_\ ^M7]:_\
MQCV/N&+_ ,S_ /X?_P"2<=E<.W'_ -FW+_%M=_\ +D$PY</_ &;<O\6UW_RY
MV)_P)2?^K4__ -HA_P"['X$I/_5J?_[1#_W8^[1__K5_6O\ \<?<+7_F?_\
M#_\ R3CISX=N.3E_!MR_%=_^+JWJ_B_'8=4KT7%DGM_)VT+TM2U63-T<87D>
MQ6O8YB5-NCJF-<R1K'M>V.=B/:YJ*CD5-:)FOV^ZS4G_ *K3_P#W/#_V#(PL
M1J(B(B(B9(B(B(B)J1$1-2(B(B(B:D35N-.Z8].WM:JJKV+U'56.S7KNMXM8
MN.FG55Z=NO:S=>A&[Q;&OON]E^R'=4JM.IZKA2DI:Z];9KV)::(K  CXDH@J
M$JL3M_Z2I[E)P 2HQ.WQ55]ZD40B ""H2\Q.WP54]RDX ).8G;_TG?,FR(@
ME5J$C(6-1&M:C6HF2(U$1$3J1$R1$[D*H (9$O,3M\'*GN4G !)S$[5[U5?>
MI.
M
M
M
M
M
M
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MS'."KC49-5>;3LJJ^D555/Q,I*V).<[ZJ9HFU4.=Y)N.K9Z2;DX2Z6M!FDS
M5*WI+G><,U<EE8BHU9+[:'Q7JR0=(O\ 4VU-SM]-22R?O89Y=2HJHO*6GBEC
M>^*:-\,T3W1RPRL='+#+&Y62121N1'1R12-='(QR(YCVN8Y$<BHEC=T.9&>!
M?1KY=60Y-=_!;7#@?SRA8OYI6+?5A2AM''OT?5W8JC%]W653FIKYHSK?\XZ
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M&V5#-JP5D1G.UN+NK:ECU3]["=NO#K)\M8<48/3C<>[=CR(E-C\\^PJ&F&]
M
M
M
M
M
M
M
M
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MNYR4)<4?+OLLCI+EKY,EKRY/D1 !JQMY_(:0?^(;U_@FY?ZE.<=S/\;^^?\
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M=53Y;3]%DE&OUS-LB%,D1,D3+<FQ,M2(B)DF2;$[-1<$$3(B5$+H@
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MFW)J,4HQ7%)N3T27-MM][;  /D?4
M
M
M
M
M
M
M
M                                              AD1
M      (9$0           0R(@             AD1        !#(B
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M:<]RFQ.KQLC/FO*R)=32].?55/6<EZ)V/A]=16 !#A.
M                 (9$0       0R(@        AD1 !#(B        ##8A
M_K&L_BM3_J\AF3#8A_K&L_BM3_J\ARAVKUKZSC/L?J?U''9O/]>UO\;J_P#6
M9CUT] 1^=SHB_P"=QK_\.<7GD7>?Z]K?XW5_ZS,>NGH"/SN=$7_.XU_^'.+R
MXW23S7G_ "'*^PL*0=%_.NS?_P!PP_[34=,I-B#()L0B4W+P@
M             AD1       !#(B              "&1$     AD1
M
M
M
M
M
M
M
M
M
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M2P #S3U0
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M6M5H^*/;,Q=1.01,B)$)-0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
L                                                      !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798876784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ONCOLYTICS BIOTECH INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001129928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">141,805,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799342864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,836,119<span></span>
</td>
<td class="nump">$ 12,034,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,088,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromContractsWithCustomers', window );">Contract receivable</a></td>
<td class="nump">4,767,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">37,726<span></span>
</td>
<td class="nump">54,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">1,176,063<span></span>
</td>
<td class="nump">260,841<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">17,817,008<span></span>
</td>
<td class="nump">14,438,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">333,441<span></span>
</td>
<td class="nump">319,955<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">333,441<span></span>
</td>
<td class="nump">319,955<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">18,150,449<span></span>
</td>
<td class="nump">14,758,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">3,684,023<span></span>
</td>
<td class="nump">4,068,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liability</a></td>
<td class="nump">1,545,645<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">5,229,668<span></span>
</td>
<td class="nump">4,068,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liability</a></td>
<td class="nump">4,636,935<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">4,636,935<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,866,603<span></span>
</td>
<td class="nump">4,068,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsAndContingencies1', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital Authorized: unlimited Issued: December 31, 2017 &#8211; 141,805,722 December 31, 2016 &#8211; 121,258,222</a></td>
<td class="nump">271,710,138<span></span>
</td>
<td class="nump">262,321,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsandRightsOutstanding', window );">Warrants</a></td>
<td class="nump">3,617,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalPaidinCapital', window );">Contributed surplus</a></td>
<td class="nump">27,028,238<span></span>
</td>
<td class="nump">26,643,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="nump">373,730<span></span>
</td>
<td class="nump">554,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(294,446,160)<span></span>
</td>
<td class="num">(278,829,309)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">8,283,846<span></span>
</td>
<td class="nump">10,689,620<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 18,150,449<span></span>
</td>
<td class="nump">$ 14,758,284<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of resources: (a) controlled by the entity as a result of past events; and (b) from which future economic benefits are expected to flow to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from contracts with customers. [Refer: Receivables from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of present obligations of the entity arising from past events, the settlement of which is expected to result in an outflow from the entity of resources embodying economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2017-03-01&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAndContingencies1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAndContingencies1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsandRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsandRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783733424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfFinancialPositionAbstract', window );"><strong>Statement of financial position [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued (shares)</a></td>
<td class="nump">141,805,722<span></span>
</td>
<td class="nump">121,258,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799120016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 9,392,623<span></span>
</td>
<td class="nump">$ 9,770,007<span></span>
</td>
<td class="nump">$ 8,601,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating</a></td>
<td class="nump">6,212,831<span></span>
</td>
<td class="nump">5,524,500<span></span>
</td>
<td class="nump">5,315,837<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss before the following</a></td>
<td class="num">(15,605,454)<span></span>
</td>
<td class="num">(15,294,507)<span></span>
</td>
<td class="num">(13,917,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents', window );">Interest</a></td>
<td class="nump">130,101<span></span>
</td>
<td class="nump">163,902<span></span>
</td>
<td class="nump">197,859<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income taxes</a></td>
<td class="num">(15,475,353)<span></span>
</td>
<td class="num">(15,130,605)<span></span>
</td>
<td class="num">(13,719,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="num">(141,498)<span></span>
</td>
<td class="num">(9,374)<span></span>
</td>
<td class="num">(3,153)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">(15,616,851)<span></span>
</td>
<td class="num">(15,139,979)<span></span>
</td>
<td class="num">(13,722,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive (loss) income items that may be reclassified to net loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Translation adjustment</a></td>
<td class="num">(180,330)<span></span>
</td>
<td class="num">(206,918)<span></span>
</td>
<td class="nump">480,935<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net comprehensive loss</a></td>
<td class="num">$ (15,797,181)<span></span>
</td>
<td class="num">$ (15,346,897)<span></span>
</td>
<td class="num">$ (13,242,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Basic and diluted loss per common share (cad per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares (basic)</a></td>
<td class="nump">132,395,752<span></span>
</td>
<td class="nump">119,880,200<span></span>
</td>
<td class="nump">112,613,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares (diluted)</a></td>
<td class="nump">132,395,752<span></span>
</td>
<td class="nump">119,880,200<span></span>
</td>
<td class="nump">112,613,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2017-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=33&amp;date=2017-03-01&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax that relate to continuing operations. [Refer: Continuing operations [member]; Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2017-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=26&amp;date=2017-03-01&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2017-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=4&amp;date=2017-03-01&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2017-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=32&amp;date=2017-03-01&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2017-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2017-03-01&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2017-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=33&amp;date=2017-03-01&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800230608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - CAD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share Purchase Agreement</div></th>
<th class="th"><div>At-the-market agreement</div></th>
<th class="th"><div>Public Offering</div></th>
<th class="th"><div>Share Capital $</div></th>
<th class="th">
<div>Share Capital $ </div>
<div>Share Purchase Agreement</div>
</th>
<th class="th">
<div>Share Capital $ </div>
<div>At-the-market agreement</div>
</th>
<th class="th">
<div>Share Capital $ </div>
<div>Public Offering</div>
</th>
<th class="th"><div>Warrants $</div></th>
<th class="th">
<div>Warrants $ </div>
<div>Public Offering</div>
</th>
<th class="th"><div>Contributed Surplus $</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income $</div></th>
<th class="th"><div>Accumulated Deficit $</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2014</a></td>
<td class="nump">$ 13,819,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,657,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,848,429<span></span>
</td>
<td class="nump">$ 280,043<span></span>
</td>
<td class="num">$ (249,966,335)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income</a></td>
<td class="num">(13,242,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,935<span></span>
</td>
<td class="num">(13,722,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue pursuant to At the Market Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,371,687<span></span>
</td>
<td class="nump">$ 20,049,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,371,687<span></span>
</td>
<td class="nump">$ 20,049,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based compensation</a></td>
<td class="nump">429,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">(753,744)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(753,744)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2015</a></td>
<td class="nump">24,674,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,324,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,277,966<span></span>
</td>
<td class="nump">760,978<span></span>
</td>
<td class="num">(263,689,330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income</a></td>
<td class="num">(15,346,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(206,918)<span></span>
</td>
<td class="num">(15,139,979)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue pursuant to At the Market Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,456,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,456,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based compensation</a></td>
<td class="nump">406,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">(500,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2016</a></td>
<td class="nump">10,689,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,321,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,643,044<span></span>
</td>
<td class="nump">554,060<span></span>
</td>
<td class="num">(278,829,309)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income</a></td>
<td class="num">(15,797,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,330)<span></span>
</td>
<td class="num">(15,616,851)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue pursuant to At the Market Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,348,821<span></span>
</td>
<td class="nump">$ 11,511,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,348,821<span></span>
</td>
<td class="nump">$ 7,893,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 536,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(193,509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based compensation</a></td>
<td class="nump">578,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">(1,391,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (245,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,391,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2017</a></td>
<td class="nump">$ 8,283,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,710,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,028,238<span></span>
</td>
<td class="nump">$ 373,730<span></span>
</td>
<td class="num">$ (294,446,160)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799332720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (15,616,851)<span></span>
</td>
<td class="num">$ (15,139,979)<span></span>
</td>
<td class="num">$ (13,722,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Amortization - property and equipment</a></td>
<td class="nump">90,768<span></span>
</td>
<td class="nump">162,233<span></span>
</td>
<td class="nump">180,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share based compensation</a></td>
<td class="nump">578,703<span></span>
</td>
<td class="nump">406,078<span></span>
</td>
<td class="nump">429,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized foreign exchange gain</a></td>
<td class="num">(124,793)<span></span>
</td>
<td class="num">(139,810)<span></span>
</td>
<td class="num">(816,319)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Net change in non-cash working capital</a></td>
<td class="nump">180,855<span></span>
</td>
<td class="nump">2,233,865<span></span>
</td>
<td class="num">(1,105,464)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash used in operating activities</a></td>
<td class="num">(14,891,318)<span></span>
</td>
<td class="num">(12,477,613)<span></span>
</td>
<td class="num">(15,034,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property and equipment</a></td>
<td class="num">(105,765)<span></span>
</td>
<td class="num">(23,527)<span></span>
</td>
<td class="num">(108,268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments', window );">Redemption (purchase) of short-term investments</a></td>
<td class="nump">2,088,800<span></span>
</td>
<td class="num">(27,823)<span></span>
</td>
<td class="num">(29,292)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash provided by (used in) investing activities</a></td>
<td class="nump">1,983,035<span></span>
</td>
<td class="num">(51,350)<span></span>
</td>
<td class="num">(137,560)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from Share Purchase Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,305,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">343,440<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">12,812,704<span></span>
</td>
<td class="nump">956,133<span></span>
</td>
<td class="nump">23,667,636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">(Decrease) increase in cash</a></td>
<td class="num">(95,579)<span></span>
</td>
<td class="num">(11,572,830)<span></span>
</td>
<td class="nump">8,495,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">12,034,282<span></span>
</td>
<td class="nump">24,016,275<span></span>
</td>
<td class="nump">14,152,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Impact of foreign exchange on cash and cash equivalents</a></td>
<td class="num">(102,584)<span></span>
</td>
<td class="num">(409,163)<span></span>
</td>
<td class="nump">1,368,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">11,836,119<span></span>
</td>
<td class="nump">12,034,282<span></span>
</td>
<td class="nump">24,016,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">2,103,166<span></span>
</td>
<td class="nump">956,133<span></span>
</td>
<td class="nump">19,362,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">$ 10,366,098<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=sect_AStatementofcashflowsforanentityotherthanafinancialinstitution&amp;doctype=Illustrative%20Examples<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2017-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=4&amp;date=2017-03-01&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799263328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Incorporation and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract', window );"><strong>Disclosure Of Notes And Other Explanatory Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Incorporation and Nature of Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Incorporation and Nature of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;8, 2018</font><font style="font-family:inherit;font-size:10pt;">.  We are a limited company incorporated and domiciled in Canada.  Our shares are publicly traded and our registered office is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics.  Our lead product, REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to existing cytotoxic or cytostatic therapies. Our clinical development program for REOLYSIN emphasizes three programs: chemotherapy combinations to trigger selective tumor lysis;  immune modulator (IMiD) combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 51<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Notes And Other Explanatory Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799050112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Financial Statement Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate Information And Statement Of IFRS Compliance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Financial Statement Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Basis of Financial Statement Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries Oncolytics Biotech (Barbados) Inc., Oncolytics Biotech (US) Inc., and Oncolytics Biotech (UK) Inc. and are presented in Canadian dollars, our functional currency.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our accounts include the accounts of Oncolytics Biotech Inc. and our subsidiaries.  Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and has the ability to affect those returns through our power to govern.  Accounting policies of subsidiaries are consistent with our accounting policies and all intra-group transactions, balances, income and expenses are eliminated on consolidation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A change in ownership interest of a subsidiary, without a change in control, is accounted for as an equity transaction.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Information And Statement Of IFRS Compliance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768089840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Deferred income taxes</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We follow the liability method of accounting for income taxes.  Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Financial instruments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial assets</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets are comprised of cash and cash equivalents, contract receivable, other receivables and short-term investments.  Financial assets are initially recorded at fair market value and are classified as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents consist of cash on hand and interest bearing deposits with our bank and have been designated as held for trading.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contract receivable and other receivables</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable and other receivables have been classified as loans and receivables.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term investments </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determine the appropriate classification of our short-term investments at the time of purchase and re-evaluate such classification as of each reporting date.  We classify our short-term investments as held-to-maturity as we have the positive intent and ability to hold the securities to maturity.  Held-to-maturity securities are stated at original cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest rate method.  Such amortization and interest on securities classified as held-to-maturity are included in interest income. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of financial assets</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We assess at each reporting date whether there is any objective evidence that a financial asset or a group of financial assets is impaired. A financial asset or a group of financial assets is deemed to be impaired if, and only if, there is objective evidence of impairment as a result of one or more events that has occurred after the initial recognition of the asset (an incurred loss event) and that loss event has an impact on the estimated future cash flows of the financial asset or the group of financial assets that can be reliably estimated.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial liabilities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Trade accounts payable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable are non interest-bearing and recorded at fair market value.  They are classified as other financial liabilities and are subsequently measured at amortized cost using the effective interest rate method.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Transaction Costs</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction costs are expensed as incurred for financial instruments designated as held for trading.  Transaction costs for other financial instruments are recognized as part of the financial instrument's carrying value.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Foreign currency translation</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements for each of our subsidiaries are prepared using their functional currency.  Our presentation currency is the Canadian dollar which is also Oncolytics Biotech Inc.'s functional currency.  Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions.  Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency.  These exchange differences are initially recognized in equity.  The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period.  Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used.  Exchange differences on translation into Canadian dollars are recognized as a separate component of equity.  On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Investment tax credits</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment tax credits ("ITCs") relating to qualifying scientific research and experimental development expenditures that are refundable are accounted for as a reduction in research and development expenditures.  ITCs that are non-refundable, but are recoverable against future taxes payable, are accrued only when there is reasonable assurance that the credits will be realized.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ITCs are subject to technical and financial review by the Canadian tax authorities on a project-by-project basis.  Therefore,  amounts ultimately received may vary significantly from the amounts recorded. Any such differences are recorded as an adjustment to the recognized amount in the year the review by the Canadian tax authority is completed and the results are made known to us.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loss per common share</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the treasury stock method to calculate diluted loss per common share.  Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive.  The number of additional common shares is calculated by assuming that any outstanding &#8220;in the money&#8221; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Property and equipment </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives.  Depreciation is recorded using the declining balance method at the following annual rates:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:51%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line over the term of the lease</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Research and development costs</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research costs are expensed as incurred, net of recoveries.  We record accruals for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the treatment phase of clinical trials based on the total estimated cost of the treatment phase on a per patient basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized.  To date, all development costs have been expensed. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract receivable</font><font style="font-family:inherit;font-size:10pt;"> - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&#8217;s credit risk and payment histories, including payments made subsequent to year-end.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract liability</font><font style="font-family:inherit;font-size:10pt;"> - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Share based payments</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock option plan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> stock option plan (the &#8220;Option Plan&#8221;) available to officers, directors, employees, consultants and suppliers with grants under the Option Plan approved from time to time by our Board of Directors (the &#8220;Board&#8221;).  Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines.  Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;"> from the date of grant.  Exercised stock options are settled with common shares issued from treasury. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the fair value based method of accounting for stock option awards granted under the Option Plan.  We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black Scholes Option Pricing Model. The fair value of stock options with a graded vesting schedule is determined based on different expected lives for the options that vest each year, as it would be if the award were viewed as several separate awards, each with a different vesting date, and it is accounted for over the respective vesting period taking into consideration forfeiture estimates.      Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments to non-employees are measured at the date we obtain the goods or the date the counterparty renders the service. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Incentive share award plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board.  Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria.  Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 15 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue from Contracts with Customers</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the IASB issued IFRS 15 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">. The new standard will replace IAS 18 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue</font><font style="font-family:inherit;font-size:10pt;"> and IAS 11 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Construction Contracts</font><font style="font-family:inherit;font-size:10pt;">. IFRS 15 establishes a comprehensive framework for determining whether, how much and when revenue is recognised, and also contains new requirements related to presentation. The core principle in that framework is that revenue should be recognised dependent on the transfer of promised goods or services to the customer for an amount that reflects the consideration which should be received in exchange for those goods or services. The objective of the standard is to provide a five-step approach to revenue recognition that includes identifying contracts with customers, identifying performance obligations, determining transaction prices, allocating transaction prices to performance obligations, and recognising revenue when or as performance obligations are satisfied. Judgment will need to be applied, including making estimates and assumptions, for multiple-element contracts in identifying performance obligations, in constraining estimates of variable consideration and in allocating the transaction price to each performance obligation. This new standard is effective for annual periods beginning on or after January 1, 2018, with early adoption permitted. We early adopted this standard effective for our year ended December 31, 2017 using the full retrospective method. There were no adjustments to our consolidated financial statements resulting from this early adoption. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Accounting Standards and Interpretations Issued but Not Yet Effective</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 9 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014, on completion of the impairment phase of the project to reform accounting for financial instruments and replace IAS 39 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments: Recognition and Measurement</font><font style="font-family:inherit;font-size:10pt;">, the IASB issued the final version of IFRS 9 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments. </font><font style="font-family:inherit;font-size:10pt;">IFRS 9 includes guidance on the classification and measurement of financial assets and financial liabilities and impairment of financial assets (i.e. recognition of credit losses).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the classification and measurement requirements for financial assets, financial assets must be classified and measured at either amortized cost or at fair value through profit or loss or through other comprehensive income, depending on the basis of the entity&#8217;s business model for managing the financial asset and the contractual cash flow characteristics of the financial asset. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The classification requirements for financial liabilities are unchanged from IAS 39. IFRS 9 requirements address the problem of volatility in net earnings arising from an issuer choosing to measure certain liabilities at fair value and require that the portion of the change in fair value due to changes in the entity&#8217;s own credit risk be presented in other comprehensive income, rather than within net earnings. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new requirements for impairment of financial assets introduce an expected loss impairment model that requires more timely recognition of expected credit losses. IAS 39 impairment requirements are based on an incurred loss model where credit losses are not recognized until there is evidence of a trigger event. IFRS 9 is effective for annual periods beginning on or after January 1, 2018 with early adoption permitted. We are assessing the impact of adopting this standard on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 16 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the IASB issued IFRS 16 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;IFRS 16&#8221;), which replaces IAS 17 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;IAS 17&#8221;) and related interpretations. IFRS 16 provides a single lessee accounting model, requiring the recognition of assets and liabilities for all leases, unless the lease term is 12-months or less or the underlying asset has a low value. IFRS 16 substantially carries forward the lessor accounting in IAS 17 with the distinction between operating leases and finance leases being retained. IFRS 16 will be applied retrospectively for annual periods beginning on or after January 1, 2019. Early adoption is permitted under certain circumstances.  We are assessing the potential impact of adopting this standard on our consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768079696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Judgments, Estimates and Assumptions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract', window );"><strong>Significant Judgments, Estimates And Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant Judgments, Estimates and Assumptions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Significant Judgments, Estimates and Assumptions</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Judgments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amount of expenses, assets, liabilities, and the disclosure of contingent liabilities, at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Estimates and assumptions</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods.  Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting our consolidated financial statements include:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue recognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into an Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share based payments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Part of our share based payment expense is measured by reference to the fair value of our stock options at the date at which they are granted.  Estimating fair value for granted stock options requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant.  This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the option, volatility, dividend yield, and rate of forfeitures and making assumptions about them.  The value of the share based payment expense for the year along with the assumptions and model used for estimating fair value for share based compensation transactions are disclosed in Note 8.    </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income.  Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset.  Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date we have determined that none of our deferred tax assets should be recognized.  Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits.  These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries.  As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Judgments, Estimates And Assumptions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768017568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Short Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash Equivalents And Short Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash Equivalents and Short Term Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Cash Equivalents and Short Term Investments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of interest bearing deposits with our bank totaling $</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">9,204,919</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> &#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10,679,992</font><font style="font-family:inherit;font-size:10pt;">).&#160;&#160;The current annual interest rate earned on these deposits is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.38%</font><font style="font-family:inherit;font-size:10pt;">  (</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> &#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.96%</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term Investments </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments consisted of guaranteed investment certificates which are liquid investments that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.&#160;&#160;The objectives for holding short-term investments were to invest our excess cash resources in investment vehicles that provided a better rate of return compared to our interest bearing bank account with limited risk to the principal invested.&#160;&#160;We intended to match the maturities of these short-term investments with the cash requirements of the Company&#8217;s activities and treat these as held-to-maturity short-term investments.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Face</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Original Cost</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Accrued Interest</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Carrying</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Fair</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Effective</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Interest Rate</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.41%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is determined by using published market prices provided by our investment advisor.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Short Term Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Short Term Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768079696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:164px;" rowspan="1" colspan="1"></td><td style="width:80px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:87px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Computer Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Furniture</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leasehold Improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">685,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,651,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,098</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,502</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">770</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,370</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,673,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,811</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,665</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,254</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">197,870</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">681,985</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">225,896</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">89,466</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">534,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,729,517</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">505,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,191,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization for the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,929</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,241</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,233</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">452,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,353,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization for the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,365</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,558</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,710</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,515</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,768</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">154,334</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">549,564</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">147,334</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">68,787</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">476,057</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,396,076</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net book value</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">43,536</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">132,421</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">78,562</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20,679</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">58,243</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">333,441</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,901</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,201</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,461</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,299</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,093</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319,955</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2017-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768057040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Share Capital</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Share Capital</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Authorized:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unlimited number of no par value common shares</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:595px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:222px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued:</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br clear="none"/></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,512,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,657,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Share Purchase<br clear="none"/>   Agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,778,674</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,371,687</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" sales agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,860,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,049,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(753,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,151,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,324,692</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,006,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500,163</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,258,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,321,825</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">801,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">536,949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,301,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,348,821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,893,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,391,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">141,805,722</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">271,710,138</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,900</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2014, we entered into a share purchase agreement (the "Share Purchase Agreement") with Lincoln Park Capital Fund, LLC ("LPC") to sell up to </font><font style="font-family:inherit;font-size:10pt;">US$26,000,000</font><font style="font-family:inherit;font-size:10pt;"> of common stock.  Subject to the terms and conditions of the Share Purchase Agreement and at our sole discretion, we may sell up to </font><font style="font-family:inherit;font-size:10pt;">US$26.0 million</font><font style="font-family:inherit;font-size:10pt;"> worth of common shares to LPC over the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-month term. The purchase price of the common shares was based on prevailing market prices of our  common shares immediately preceding the notice of a sale without any fixed discount. Subject to the Share Purchase Agreement, we controlled the timing and amount of each investment and LPC was obligated to make such purchases, if and when elected.  The Share Purchase Agreement did not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities, but required that we maintained our NASDAQ listing. Under the Share Purchase Agreement, we issued an initial  commitment fee of </font><font style="font-family:inherit;font-size:10pt;">292,793</font><font style="font-family:inherit;font-size:10pt;"> common shares to LPC valued at fair value of </font><font style="font-family:inherit;font-size:10pt;">US$455,000</font><font style="font-family:inherit;font-size:10pt;">.  An additional </font><font style="font-family:inherit;font-size:10pt;">292,793</font><font style="font-family:inherit;font-size:10pt;"> common shares was to be issued on a pro rata basis under the terms of the Share Purchase Agreement as an additional commitment fee.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 20, 2014, we reached an agreement to amend the Share Purchase Agreement.  The specific amendments included allowing the Company to sell shares to LPC at the Company's sole option independent of the closing price of the Common Stock, increasing the number of shares that may have been sold to LPC at certain price levels and changed the way the number of Commitment Shares issuable was to be calculated. In consideration of the amendments to the Agreement, the Company issued </font><font style="font-family:inherit;font-size:10pt;">146,397</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock to LPC. </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2015, under the terms of the amended Share Purchase Agreement, we issued </font><font style="font-family:inherit;font-size:10pt;">5,778,674</font><font style="font-family:inherit;font-size:10pt;"> common shares for net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">US$3.5 million</font><font style="font-family:inherit;font-size:10pt;">. As part of the shares issued, we issued </font><font style="font-family:inherit;font-size:10pt;">78,674</font><font style="font-family:inherit;font-size:10pt;"> commitment shares. The commitment shares have been valued at fair value of </font><font style="font-family:inherit;font-size:10pt;">US$50,024</font><font style="font-family:inherit;font-size:10pt;"> and have been recorded as additional share issue costs.  On November 5, 2015, we were delisted from the NASDAQ Capital Market and as a result we were unable to sell common shares under the Share Purchase Agreement.</font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 24, 2014, we entered into an "at-the-market" ("ATM") equity distribution agreement with Canaccord Genuity Inc. acting as sole agent. Under the terms of the distribution agreement, we were able to, from time to time, sell shares of our common stock having an aggregate offering value of up to </font><font style="font-family:inherit;font-size:10pt;">US$20 million</font><font style="font-family:inherit;font-size:10pt;"> through Canaccord Genuity Inc. directly to investors in the US through our NASDAQ listing.  We were able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility.  During 2015, we issued </font><font style="font-family:inherit;font-size:10pt;">18,860,454</font><font style="font-family:inherit;font-size:10pt;"> common shares for net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">US$15.5 million</font><font style="font-family:inherit;font-size:10pt;">. On November 5, 2015, we were delisted from the NASDAQ Capital Market and as a result we were unable to sell common shares under our existing ATM.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;"> which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During 2017, we sold </font><font style="font-family:inherit;font-size:10pt;">3,301,500</font><font style="font-family:inherit;font-size:10pt;"> (2016 - </font><font style="font-family:inherit;font-size:10pt;">3,006,600</font><font style="font-family:inherit;font-size:10pt;">) common shares for gross proceeds of $</font><font style="font-family:inherit;font-size:10pt;">2,348,821</font><font style="font-family:inherit;font-size:10pt;"> (2016 - $</font><font style="font-family:inherit;font-size:10pt;">1,456,296</font><font style="font-family:inherit;font-size:10pt;">). We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">245,655</font><font style="font-family:inherit;font-size:10pt;"> (2016 - </font><font style="font-family:inherit;font-size:10pt;">$500,163</font><font style="font-family:inherit;font-size:10pt;">).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2017, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">16,445,000</font><font style="font-family:inherit;font-size:10pt;"> units were sold at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.70</font><font style="font-family:inherit;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$11,511,500</font><font style="font-family:inherit;font-size:10pt;">. Each unit included </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share (ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$0.48</font><font style="font-family:inherit;font-size:10pt;">) and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share purchase warrant (ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$0.22</font><font style="font-family:inherit;font-size:10pt;">). The ascribed value was determined using the relative fair value method. The ascribed value of the common share purchase warrants was determined using the Black Scholes option pricing model. Each common share purchase warrant entitles the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share in the capital of the Company until June 1, 2022, at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.95</font><font style="font-family:inherit;font-size:10pt;">. The common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds </font><font style="font-family:inherit;font-size:10pt;">$2.50</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading dates. We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$1,145,402</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the assumptions used in the Black Scholes Option Pricing Model with respect to the valuation of warrants issued:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:394px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:261px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.70%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility in the price of the Company's shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">89.30%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the warrants. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the warrants represents the estimated length of time the warrants are expected to remain outstanding.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our outstanding warrants at December 31, 2017:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:531px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:77px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:102px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:134px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, Beginning of the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Granted During the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, End of the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.95</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.42</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768047200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract', window );"><strong>Disclosure Of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share Based Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Share Based Payments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Stock Option Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:650px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:158px;" rowspan="1" colspan="1"></td><td style="width:75px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:80px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,674,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,561,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,446,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">405,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.48</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,572,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,280,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,012,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(737,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(116,900</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(721,667</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.61</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(801,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.43</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,148,667</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,674,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.83</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,561,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,453,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.51</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,729,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,476,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the stock options outstanding and exercisable at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:182px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.26 - $0.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,437,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.46</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,921,834</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.51 - $0.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">538,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">358,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.70</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.45 - $2.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,002,667</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.62</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.77</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,002,667</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.77</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$2.13 - $3.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">545,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">545,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$4.01 - $6.72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.94</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.34</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.34</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,148,667</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,453,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.51</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-exercisable options vest either annually over periods ranging from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;"> or upon satisfaction of certain performance criteria.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of stock options issued during the year was determined using the Black Scholes Option Pricing Model using the following weighted average assumptions and fair value of options: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:464px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:245px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:72px;" rowspan="1" colspan="1"></td><td style="width:72px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.18%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.82%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.63%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility in the price of the Company's shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90.73%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94.84%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rate of forfeiture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$0.28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.24</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incentive Share Award Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Share Units</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued restricted share units ("RSUs") to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> year period. The following RSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:515px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:269px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,322,829</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,831</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">486,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,053,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Vested during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,809,067</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,322,829</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:36px;"><font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:24px;">(1)</font><font style="font-family:inherit;font-size:8pt;">The weighted average fair value of the RSUs granted was </font><font style="font-family:inherit;font-size:8pt;">$0.63</font><font style="font-family:inherit;font-size:8pt;"> in 2017 (2016 - </font><font style="font-family:inherit;font-size:8pt;">$0.31</font><font style="font-family:inherit;font-size:8pt;">).</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Performance Share Units</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also issued performance share units ("PSUs") to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after </font><font style="font-family:inherit;font-size:10pt;">3 years</font><font style="font-family:inherit;font-size:10pt;"> or vest over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> year period, depending on the grant. PSU grants to certain officers will vest immediately upon a change of control of the Company. If certain officers cease employment with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. The following PSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:521px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:274px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:75px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">840,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">60,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(660,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Outstanding, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">900,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">840,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:36px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) &#160;&#160;&#160;&#160;The weighted average fair value of the PSUs granted was $</font><font style="font-family:inherit;font-size:8pt;">0.35</font><font style="font-family:inherit;font-size:8pt;"> in 2017 (2016 - </font><font style="font-family:inherit;font-size:8pt;">$0.36</font><font style="font-family:inherit;font-size:8pt;">).</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have reserved </font><font style="font-family:inherit;font-size:10pt;">14,180,572</font><font style="font-family:inherit;font-size:10pt;"> common shares for issuance relating to our outstanding equity compensation plans.  Compensation expense related to stock options, RSUs and PSUs for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$578,703</font><font style="font-family:inherit;font-size:10pt;">  (</font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">$406,078</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">$429,537</font><font style="font-family:inherit;font-size:10pt;">).</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768005360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Loss Per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Loss Per Common Share</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">132,395,752</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">119,880,200</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">112,613,845</font><font style="font-family:inherit;font-size:10pt;">).  The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2017-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=33&amp;date=2017-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6597385264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability and Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Contract liability and receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Contract liability and receivable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Regional licensing agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into a regional licensing agreement (the "Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrant purchase agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also entered into a warrant purchase agreement with Adlai. Under the terms of the warrant purchase agreement, we are entitled to receive two milestone payments totaling US</font><font style="font-family:inherit;font-size:10pt;">$8 million</font><font style="font-family:inherit;font-size:10pt;"> made of of two common share purchase warrants:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One common share purchase warrant of US</font><font style="font-family:inherit;font-size:10pt;">$2 million</font><font style="font-family:inherit;font-size:10pt;"> whereby, upon exercise, Adlai may purchase our common shares priced at a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> premium to the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant when the first patient is enrolled in the phase 3 metastatic breast cancer study or </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months after execution of the Agreement, whichever is later.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One common share purchase warrant of US</font><font style="font-family:inherit;font-size:10pt;">$6 million</font><font style="font-family:inherit;font-size:10pt;"> whereby, upon exercise, Adlai may purchase our common shares priced at a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> premium to the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant upon the enrollment of the </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;">th patient in the phase 3 metastatic breast cancer study.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contract liability</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Our contract liability balance at December 31, which w</font><font style="font-family:inherit;font-size:10pt;">e expect to record in revenue over the next </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:443px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:236px;" rowspan="1" colspan="1"></td><td style="width:102px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regional licensing agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,182,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized in the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,182,580</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,545,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - non-current</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,636,935</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,182,580</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contract receivable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our contract receivable due from Adlai at December 31, 2017 is </font><font style="font-family:inherit;font-size:10pt;">$4,767,100</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=sect_Presentation&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768048496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">Commitments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Commitments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to payments totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5,980,454</font><font style="font-family:inherit;font-size:10pt;"> during </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;"> for activities related to our clinical trial, manufacturing and collaboration programs. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to rental payments (excluding our portion of operating costs and rental taxes) under the terms of our office leases.  Annual payments under the terms of these leases are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:33.984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,987</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">740,850</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;"> plus an overhead repayment of </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">, upon sales of a specified product.&#160;&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> of gross sales of a specified product; or (b) </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;"> per annum once sales of a specified product commence.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6629789312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContingenciesAbstract', window );"><strong>Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory', window );">Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assumption Agreement</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 1999, we entered into an agreement that assumed certain obligations (the &#8220;Assumption Agreement&#8221;) in connection with a Share Purchase Agreement (the &#8220;Agreement&#8221;) between SYNSORB and our former shareholders to make milestone payments and royalty payments.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, a milestone payment was still outstanding for </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">, due within </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> to the public or the approval of a new drug application for REOLYSIN.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the milestone payment, payments may become due and payable in accordance with the Agreement upon realization of sales of REOLYSIN.&#160;&#160;If we receive royalty payments or other payments as a result of entering into partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders </font><font style="font-family:inherit;font-size:10pt;">10.75%</font><font style="font-family:inherit;font-size:10pt;"> (2016 - </font><font style="font-family:inherit;font-size:10pt;">11.75%</font><font style="font-family:inherit;font-size:10pt;">) of the royalty payments and other payments received.&#160;&#160;Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of </font><font style="font-family:inherit;font-size:10pt;">2.15%</font><font style="font-family:inherit;font-size:10pt;"> (2016 -  </font><font style="font-family:inherit;font-size:10pt;">2.35%</font><font style="font-family:inherit;font-size:10pt;">) of Net Sales received for such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">BRI &#8220;Work in Kind&#8221; Contribution</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into an engineering and process development agreement with the Biotechnology Research Institute of the National Research Council of Canada (&#8220;BRI&#8221;).&#160;&#160;The terms of this Agreement include a &#8220;work in kind&#8221; contribution from BRI.&#160;&#160;In exchange for this &#8220;work in kind&#8221; contribution, we agreed to provide a royalty, contingent upon receiving Sales Revenue, at the lesser of </font><font style="font-family:inherit;font-size:10pt;">0.5%</font><font style="font-family:inherit;font-size:10pt;"> of Sales Revenue or </font><font style="font-family:inherit;font-size:10pt;">$20,000</font><font style="font-family:inherit;font-size:10pt;"> per year.&#160;&#160;The total royalty under this Agreement is equal to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> times the &#8220;work in kind&#8221; contribution.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we estimate that the accumulated work in kind totals approximately </font><font style="font-family:inherit;font-size:10pt;">$301,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2017-01-01<br> -Paragraph 86<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=37&amp;date=2017-03-01&amp;anchor=para_86&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingencies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768089552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:583px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:316px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:13px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,475,353</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,130,605</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,719,842</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statutory Canadian corporate tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anticipated tax recovery</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,178,345</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,085,263</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,567,159</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign jurisdiction tax rate difference</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,899,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,184,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,659,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee stock based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">156,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,641</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,336,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to opening tax pools</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">162,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,569</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,339,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other permanent differences</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">53,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in deferred tax benefits deemed not probable to <br clear="none"/>  be recovered</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,051,725</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,739,557</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,455,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">144,021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment in respect to prior periods</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,523</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(313</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,347</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">141,498</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,374</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,153</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we have the following non-capital losses for income tax purposes in Canada:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,809,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,170,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,009,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,774,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,343,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,873,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,457,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,472,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,125,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,430,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2037</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,846,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">57,308,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:190px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:97px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">471,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">596,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2028</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">622,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2030</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2032</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">487,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2037</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">600</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,463,600</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As well, we have unclaimed scientific research and experimental development expenditures available to reduce future years&#8217; taxable income of approximately </font><font style="font-family:inherit;font-size:10pt;">$27,400,000</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We have not recorded the potential benefits of these tax pools in these consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized.  The components of our unrecognized deferred tax asset are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:612px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:345px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses carried forward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19,160,218</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,821,631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,950,044</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific research and experimental development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,406,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,394,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,278,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,988,325</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,990,664</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,987,214</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,927,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,908,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,839,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">493,343</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">432,659</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">619,066</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net capital losses carried forward</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized deferred tax asset</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">32,983,223</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,555,913</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,681,313</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6634437408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory', window );">Capital Disclosures</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Capital Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our objective when managing capital is to maintain a strong statement of financial position.  We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection.&#160;&#160;We include shareholders&#8217; equity, cash and cash equivalents and short-term investments in the definition of capital.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,836,119</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,034,282</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,283,846</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,689,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of REOLYSIN.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 16, 2016, we renewed our short form base shelf prospectus (the &#8220;Base Shelf&#8221;) that qualifies for distribution of up to </font><font style="font-family:inherit;font-size:10pt;">$150,000,000</font><font style="font-family:inherit;font-size:10pt;"> of common shares, subscription receipts, warrants, or units (the &#8220;Securities&#8221;) in Canada. Under our Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received from a Prospectus Supplement will be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf expires on March 16, 2018 and allowed us to enter into our Canadian ATM equity distribution agreement (see Note 7). We use this equity arrangement to assist us in achieving our capital objective.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2017.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 134<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_134&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6632406064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents, short-term investments,&#160;contract receivable, other receivables and accounts payable.&#160;&#160;As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there are no significant differences between the carrying values of these amounts and their estimated market values.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;&#160;We are exposed to credit risk on our cash and cash equivalents, short-term investments and contract receivable in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents, short-term investments and contract receivable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also mitigate our exposure to credit risk by restricting our portfolio to investment grade securities with short-term maturities and by monitoring the credit risk and credit standing of counterparties.&#160;As at December 31, 2016, </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of our short-term investments were in guaranteed investment certificates.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk connected to our contract receivable by performing a review of our customer's credit risk and payment histories, including payments made subsequent to year-end. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments.&#160;&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Currency risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.&#160;In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from operating and financing activities.  As well, we are exposed to currency risk related to our regional licensing agreement. The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> increase in the value of the U.S. dollar against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;"> by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5,056</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.10</font><font style="font-family:inherit;font-size:10pt;"> increase in the value of the British pound against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;"> by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$21,492</font><font style="font-family:inherit;font-size:10pt;">.  The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.10</font><font style="font-family:inherit;font-size:10pt;"> increase in the value of the Euro against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;"> by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$11,736</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:596px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:197px;" rowspan="1" colspan="1"></td><td style="width:128px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:128px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:128px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">US dollars </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">British pounds</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">&#163;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro<br clear="none"/>&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,948,573</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,755</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,372</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,800,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(777,271</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,949</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,971,302</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,806</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 14. Accounts payable are all due within the current operating period.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=sect_Scope&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787283200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory', window );">Additional Cash Flow Disclosures</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Additional Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change In Non-Cash Working Capital</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:629px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:392px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,767,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,653</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148,308</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(915,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(215,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(384,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,359,172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(664,505</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,182,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash impact of foreign exchange</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">48,558</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,212</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77,535</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in non-cash working capital related to operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">180,855</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,233,865</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,105,464</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:342px;" rowspan="1" colspan="1"></td><td style="width:58px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:51px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:51px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash interest received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">130,101</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,902</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,859</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash taxes paid</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">136,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,468</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,421</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Section Presentation of a statement of cash flows<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=sect_Presentationofastatementofcashflows&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashFlowStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6702803888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indemnification of Officers and Directors<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract', window );"><strong>Disclosure Of Indemnification Of Officers and Directors [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock', window );">Indemnification of Officers and Directors</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Indemnification of Officers and Directors</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal or administrative action or proceeding as it relates to their services to the Company.&#160;&#160;The by-laws provide no limit to the amount of the indemnification.&#160;&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Indemnification Of Officers and Directors [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Indemnification Of Officers and Directors [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784305904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Economic Dependence<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfEconomicDependenceAbstract', window );"><strong>Disclosure Of Economic Dependence [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfEconomicDependenceTextBlock', window );">Economic Dependence</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Economic Dependence</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are economically dependent on our toll manufacturers. We primarily use </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> toll manufacturer in the US to produce the clinical grade REOLYSIN required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturer has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade REOLYSIN at a smaller scale.&#160;We have attempted to mitigate this risk by producing sufficient REOLYSIN in advance of patient enrollment in a particular clinical trial.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfEconomicDependenceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Economic Dependence [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfEconomicDependenceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfEconomicDependenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Economic Dependence [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfEconomicDependenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6609691968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses and Adjustments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory', window );">Other Expenses and Adjustments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Other Expenses and Adjustments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We present our expenses based on the function of each expense and therefore include realized foreign exchange gains and losses, unrealized non-cash foreign exchange gains and losses and non-cash stock based compensation associated with research and development activity as a component of research and development expenses and amortization of property and equipment and stock based compensation associated with operating activities as a component of operating expenses.  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:420px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br clear="none"/></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in research and development expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Realized foreign exchange (gain) loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(120,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized non-cash foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">55,538</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(816,319</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">230,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90,768</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,233</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">348,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">231,509</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,600</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196,601</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6702153456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation of Key Management Personnel</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole.  We have determined that key management personnel consists of the members of the Board of Directors along with certain officers of the Company.   </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:520px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:301px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term employee compensation and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,596,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,753,553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,941,342</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">779,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,330,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">459,298</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">372,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353,419</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,835,046</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,456,389</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,294,761</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assumption Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2017, with the signing of a regional licensing agreement with upfront license fees (see Note 10), the Company triggered a liability of US</font><font style="font-family:inherit;font-size:10pt;">$178,125</font><font style="font-family:inherit;font-size:10pt;"> to an officer as detailed in the Assumption Agreement (see Note 12). As at December 31, 2017, US$</font><font style="font-family:inherit;font-size:10pt;">178,125</font><font style="font-family:inherit;font-size:10pt;"> was included in accounts payable and accrued liabilities. US</font><font style="font-family:inherit;font-size:10pt;">$35,625</font><font style="font-family:inherit;font-size:10pt;"> was paid in January 2018 and the balance will be paid after receipt of the contract receivable from Adlai.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2017-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2017-03-01&amp;anchor=sect_Disclosures&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799668688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPolicieAbstract', window );"><strong>Summary Of Significant Accounting Policie [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory', window );">Deferred income taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We follow the liability method of accounting for income taxes.  Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Financial assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets are comprised of cash and cash equivalents, contract receivable, other receivables and short-term investments.  Financial assets are initially recorded at fair market value and are classified as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents consist of cash on hand and interest bearing deposits with our bank and have been designated as held for trading.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contract receivable and other receivables</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable and other receivables have been classified as loans and receivables.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term investments </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determine the appropriate classification of our short-term investments at the time of purchase and re-evaluate such classification as of each reporting date.  We classify our short-term investments as held-to-maturity as we have the positive intent and ability to hold the securities to maturity.  Held-to-maturity securities are stated at original cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest rate method.  Such amortization and interest on securities classified as held-to-maturity are included in interest income. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of financial assets</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We assess at each reporting date whether there is any objective evidence that a financial asset or a group of financial assets is impaired. A financial asset or a group of financial assets is deemed to be impaired if, and only if, there is objective evidence of impairment as a result of one or more events that has occurred after the initial recognition of the asset (an incurred loss event) and that loss event has an impact on the estimated future cash flows of the financial asset or the group of financial assets that can be reliably estimated.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory', window );">Financial liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Trade accounts payable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable are non interest-bearing and recorded at fair market value.  They are classified as other financial liabilities and are subsequently measured at amortized cost using the effective interest rate method.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory', window );">Transaction costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction costs are expensed as incurred for financial instruments designated as held for trading.  Transaction costs for other financial instruments are recognized as part of the financial instrument's carrying value.  </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements for each of our subsidiaries are prepared using their functional currency.  Our presentation currency is the Canadian dollar which is also Oncolytics Biotech Inc.'s functional currency.  Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions.  Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency.  These exchange differences are initially recognized in equity.  The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period.  Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used.  Exchange differences on translation into Canadian dollars are recognized as a separate component of equity.  On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory', window );">Investment tax credits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment tax credits ("ITCs") relating to qualifying scientific research and experimental development expenditures that are refundable are accounted for as a reduction in research and development expenditures.  ITCs that are non-refundable, but are recoverable against future taxes payable, are accrued only when there is reasonable assurance that the credits will be realized.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ITCs are subject to technical and financial review by the Canadian tax authorities on a project-by-project basis.  Therefore,  amounts ultimately received may vary significantly from the amounts recorded. Any such differences are recorded as an adjustment to the recognized amount in the year the review by the Canadian tax authority is completed and the results are made known to us.  </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per common share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the treasury stock method to calculate diluted loss per common share.  Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive.  The number of additional common shares is calculated by assuming that any outstanding &#8220;in the money&#8221; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives.  Depreciation is recorded using the declining balance method at the following annual rates:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:51%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line over the term of the lease</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research costs are expensed as incurred, net of recoveries.  We record accruals for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the treatment phase of clinical trials based on the total estimated cost of the treatment phase on a per patient basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized.  To date, all development costs have been expensed. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract receivable</font><font style="font-family:inherit;font-size:10pt;"> - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&#8217;s credit risk and payment histories, including payments made subsequent to year-end.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract liability</font><font style="font-family:inherit;font-size:10pt;"> - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share based payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock option plan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> stock option plan (the &#8220;Option Plan&#8221;) available to officers, directors, employees, consultants and suppliers with grants under the Option Plan approved from time to time by our Board of Directors (the &#8220;Board&#8221;).  Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines.  Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;"> from the date of grant.  Exercised stock options are settled with common shares issued from treasury. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the fair value based method of accounting for stock option awards granted under the Option Plan.  We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black Scholes Option Pricing Model. The fair value of stock options with a graded vesting schedule is determined based on different expected lives for the options that vest each year, as it would be if the award were viewed as several separate awards, each with a different vesting date, and it is accounted for over the respective vesting period taking into consideration forfeiture estimates.      Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments to non-employees are measured at the date we obtain the goods or the date the counterparty renders the service. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Incentive share award plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board.  Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria.  Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations', window );">Adoption of new accounting standards</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 15 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue from Contracts with Customers</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the IASB issued IFRS 15 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">. The new standard will replace IAS 18 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue</font><font style="font-family:inherit;font-size:10pt;"> and IAS 11 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Construction Contracts</font><font style="font-family:inherit;font-size:10pt;">. IFRS 15 establishes a comprehensive framework for determining whether, how much and when revenue is recognised, and also contains new requirements related to presentation. The core principle in that framework is that revenue should be recognised dependent on the transfer of promised goods or services to the customer for an amount that reflects the consideration which should be received in exchange for those goods or services. The objective of the standard is to provide a five-step approach to revenue recognition that includes identifying contracts with customers, identifying performance obligations, determining transaction prices, allocating transaction prices to performance obligations, and recognising revenue when or as performance obligations are satisfied. Judgment will need to be applied, including making estimates and assumptions, for multiple-element contracts in identifying performance obligations, in constraining estimates of variable consideration and in allocating the transaction price to each performance obligation. This new standard is effective for annual periods beginning on or after January 1, 2018, with early adoption permitted. We early adopted this standard effective for our year ended December 31, 2017 using the full retrospective method. There were no adjustments to our consolidated financial statements resulting from this early adoption. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">Accounting standards and interpretations issued but not yet effective</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 9 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014, on completion of the impairment phase of the project to reform accounting for financial instruments and replace IAS 39 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments: Recognition and Measurement</font><font style="font-family:inherit;font-size:10pt;">, the IASB issued the final version of IFRS 9 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments. </font><font style="font-family:inherit;font-size:10pt;">IFRS 9 includes guidance on the classification and measurement of financial assets and financial liabilities and impairment of financial assets (i.e. recognition of credit losses).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the classification and measurement requirements for financial assets, financial assets must be classified and measured at either amortized cost or at fair value through profit or loss or through other comprehensive income, depending on the basis of the entity&#8217;s business model for managing the financial asset and the contractual cash flow characteristics of the financial asset. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The classification requirements for financial liabilities are unchanged from IAS 39. IFRS 9 requirements address the problem of volatility in net earnings arising from an issuer choosing to measure certain liabilities at fair value and require that the portion of the change in fair value due to changes in the entity&#8217;s own credit risk be presented in other comprehensive income, rather than within net earnings. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new requirements for impairment of financial assets introduce an expected loss impairment model that requires more timely recognition of expected credit losses. IAS 39 impairment requirements are based on an incurred loss model where credit losses are not recognized until there is evidence of a trigger event. IFRS 9 is effective for annual periods beginning on or after January 1, 2018 with early adoption permitted. We are assessing the impact of adopting this standard on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 16 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the IASB issued IFRS 16 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;IFRS 16&#8221;), which replaces IAS 17 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;IAS 17&#8221;) and related interpretations. IFRS 16 provides a single lessee accounting model, requiring the recognition of assets and liabilities for all leases, unless the lease term is 12-months or less or the underlying asset has a low value. IFRS 16 substantially carries forward the lessor accounting in IAS 17 with the distinction between operating leases and finance leases being retained. IFRS 16 will be applied retrospectively for annual periods beginning on or after January 1, 2019. Early adoption is permitted under certain circumstances.  We are assessing the potential impact of adopting this standard on our consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for deferred income tax. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for finance costs. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2018-01-01<br> -Name IAS<br> -Number 18<br> -IssueDate 2017-01-01<br> -Paragraph 35<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=18&amp;date=2017-03-02&amp;anchor=para_35_a&amp;doctype=Standard&amp;book=B<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for taxes other than income tax. [Refer: Tax expense other than income tax expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPolicieAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policie [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPolicieAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787170544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of depreciation rates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation is recorded using the declining balance method at the following annual rates:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:51%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line over the term of the lease</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:164px;" rowspan="1" colspan="1"></td><td style="width:80px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:87px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Computer Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Furniture</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leasehold Improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">685,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,651,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,098</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,502</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">770</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,370</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,673,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,811</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,665</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,254</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">197,870</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">681,985</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">225,896</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">89,466</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">534,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,729,517</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">505,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,191,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization for the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,929</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,241</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,233</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">452,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,353,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization for the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,365</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,558</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,710</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,515</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,768</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">154,334</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">549,564</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">147,334</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">68,787</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">476,057</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,396,076</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net book value</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">43,536</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">132,421</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">78,562</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20,679</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">58,243</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">333,441</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,901</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,201</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,461</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,299</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,093</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319,955</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Paragraph 73<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2017-03-01&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768052528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Short Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash Equivalents And Short Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ScheduleOfShortTermInvestmentsTableTextBlock', window );">Schedule of short-term investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Face</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Original Cost</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Accrued Interest</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Carrying</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Fair</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Value</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Effective</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Interest Rate</font></div><div style="text-align:center;vertical-align:middle;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.41%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Short Term Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleOfShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Short-Term Investments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleOfShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787222224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation is recorded using the declining balance method at the following annual rates:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:51%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line over the term of the lease</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:164px;" rowspan="1" colspan="1"></td><td style="width:80px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:87px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Computer Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Furniture</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leasehold Improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">685,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,651,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,098</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,502</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">770</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,370</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,673,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,811</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,665</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,254</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">197,870</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">681,985</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">225,896</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">89,466</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">534,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,729,517</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">505,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,191,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization for the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,929</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,241</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,233</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">452,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,353,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization for the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,365</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,558</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,710</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,515</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,768</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">154,334</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">549,564</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">147,334</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">68,787</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">476,057</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,396,076</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net book value</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">43,536</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">132,421</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">78,562</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20,679</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">58,243</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">333,441</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,901</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,201</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,461</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,299</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,093</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319,955</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Paragraph 73<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2017-03-01&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787234880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of share capital</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Authorized:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unlimited number of no par value common shares</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:595px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:222px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued:</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br clear="none"/></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,512,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,657,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Share Purchase<br clear="none"/>   Agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,778,674</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,371,687</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" sales agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,860,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,049,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(753,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,151,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,324,692</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,006,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500,163</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,258,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,321,825</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">801,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">536,949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,301,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,348,821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,893,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,391,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">141,805,722</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">271,710,138</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,900</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2014, we entered into a share purchase agreement (the "Share Purchase Agreement") with Lincoln Park Capital Fund, LLC ("LPC") to sell up to </font><font style="font-family:inherit;font-size:10pt;">US$26,000,000</font><font style="font-family:inherit;font-size:10pt;"> of common stock.  Subject to the terms and conditions of the Share Purchase Agreement and at our sole discretion, we may sell up to </font><font style="font-family:inherit;font-size:10pt;">US$26.0 million</font><font style="font-family:inherit;font-size:10pt;"> worth of common shares to LPC over the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-month term. The purchase price of the common shares was based on prevailing market prices of our  common shares immediately preceding the notice of a sale without any fixed discount. Subject to the Share Purchase Agreement, we controlled the timing and amount of each investment and LPC was obligated to make such purchases, if and when elected.  The Share Purchase Agreement did not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities, but required that we maintained our NASDAQ listing. Under the Share Purchase Agreement, we issued an initial  commitment fee of </font><font style="font-family:inherit;font-size:10pt;">292,793</font><font style="font-family:inherit;font-size:10pt;"> common shares to LPC valued at fair value of </font><font style="font-family:inherit;font-size:10pt;">US$455,000</font><font style="font-family:inherit;font-size:10pt;">.  An additional </font><font style="font-family:inherit;font-size:10pt;">292,793</font><font style="font-family:inherit;font-size:10pt;"> common shares was to be issued on a pro rata basis under the terms of the Share Purchase Agreement as an additional commitment fee.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 20, 2014, we reached an agreement to amend the Share Purchase Agreement.  The specific amendments included allowing the Company to sell shares to LPC at the Company's sole option independent of the closing price of the Common Stock, increasing the number of shares that may have been sold to LPC at certain price levels and changed the way the number of Commitment Shares issuable was to be calculated. In consideration of the amendments to the Agreement, the Company issued </font><font style="font-family:inherit;font-size:10pt;">146,397</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock to LPC. </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2015, under the terms of the amended Share Purchase Agreement, we issued </font><font style="font-family:inherit;font-size:10pt;">5,778,674</font><font style="font-family:inherit;font-size:10pt;"> common shares for net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">US$3.5 million</font><font style="font-family:inherit;font-size:10pt;">. As part of the shares issued, we issued </font><font style="font-family:inherit;font-size:10pt;">78,674</font><font style="font-family:inherit;font-size:10pt;"> commitment shares. The commitment shares have been valued at fair value of </font><font style="font-family:inherit;font-size:10pt;">US$50,024</font><font style="font-family:inherit;font-size:10pt;"> and have been recorded as additional share issue costs.  On November 5, 2015, we were delisted from the NASDAQ Capital Market and as a result we were unable to sell common shares under the Share Purchase Agreement.</font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 24, 2014, we entered into an "at-the-market" ("ATM") equity distribution agreement with Canaccord Genuity Inc. acting as sole agent. Under the terms of the distribution agreement, we were able to, from time to time, sell shares of our common stock having an aggregate offering value of up to </font><font style="font-family:inherit;font-size:10pt;">US$20 million</font><font style="font-family:inherit;font-size:10pt;"> through Canaccord Genuity Inc. directly to investors in the US through our NASDAQ listing.  We were able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility.  During 2015, we issued </font><font style="font-family:inherit;font-size:10pt;">18,860,454</font><font style="font-family:inherit;font-size:10pt;"> common shares for net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">US$15.5 million</font><font style="font-family:inherit;font-size:10pt;">. On November 5, 2015, we were delisted from the NASDAQ Capital Market and as a result we were unable to sell common shares under our existing ATM.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;"> which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During 2017, we sold </font><font style="font-family:inherit;font-size:10pt;">3,301,500</font><font style="font-family:inherit;font-size:10pt;"> (2016 - </font><font style="font-family:inherit;font-size:10pt;">3,006,600</font><font style="font-family:inherit;font-size:10pt;">) common shares for gross proceeds of $</font><font style="font-family:inherit;font-size:10pt;">2,348,821</font><font style="font-family:inherit;font-size:10pt;"> (2016 - $</font><font style="font-family:inherit;font-size:10pt;">1,456,296</font><font style="font-family:inherit;font-size:10pt;">). We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">245,655</font><font style="font-family:inherit;font-size:10pt;"> (2016 - </font><font style="font-family:inherit;font-size:10pt;">$500,163</font><font style="font-family:inherit;font-size:10pt;">).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2017, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">16,445,000</font><font style="font-family:inherit;font-size:10pt;"> units were sold at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.70</font><font style="font-family:inherit;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$11,511,500</font><font style="font-family:inherit;font-size:10pt;">. Each unit included </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share (ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$0.48</font><font style="font-family:inherit;font-size:10pt;">) and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share purchase warrant (ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$0.22</font><font style="font-family:inherit;font-size:10pt;">). The ascribed value was determined using the relative fair value method. The ascribed value of the common share purchase warrants was determined using the Black Scholes option pricing model. Each common share purchase warrant entitles the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share in the capital of the Company until June 1, 2022, at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.95</font><font style="font-family:inherit;font-size:10pt;">. The common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds </font><font style="font-family:inherit;font-size:10pt;">$2.50</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading dates. We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$1,145,402</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory', window );">Summary of assumptions used in the Black Scholes Option Pricing Model for Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the assumptions used in the Black Scholes Option Pricing Model with respect to the valuation of warrants issued:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:394px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:261px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.70%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility in the price of the Company's shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">89.30%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Summary of Outstanding Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our outstanding warrants at December 31, 2017:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:531px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:77px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:102px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:134px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, Beginning of the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Granted During the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, End of the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.95</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.42</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the stock options outstanding and exercisable at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:182px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.26 - $0.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,437,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.46</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,921,834</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.51 - $0.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">538,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">358,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.70</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.45 - $2.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,002,667</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.62</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.77</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,002,667</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.77</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$2.13 - $3.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">545,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">545,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$4.01 - $6.72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.94</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.34</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.34</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,148,667</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,453,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.51</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799057536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofsharebasedpaymentarrangementAbstract', window );"><strong>Disclosure of share-based payment arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of stock options and weighted average exercise prices of share options</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:650px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:158px;" rowspan="1" colspan="1"></td><td style="width:75px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:80px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,674,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,561,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,446,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">405,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.48</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,572,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,280,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,012,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(737,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(116,900</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(721,667</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.61</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(801,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.43</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,148,667</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,674,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.83</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,561,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,453,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.51</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,729,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,476,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Schedule of stock options outstanding and exercisable by range of exercise price</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the stock options outstanding and exercisable at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:182px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.26 - $0.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,437,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.46</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,921,834</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.51 - $0.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">538,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">358,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.70</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.45 - $2.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,002,667</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.62</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.77</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,002,667</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.77</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$2.13 - $3.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">545,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">545,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$4.01 - $6.72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.94</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.34</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.34</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,148,667</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,453,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.51</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Schedule of weighted average remaining contractual life and outstanding stock options by exercise price</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our outstanding warrants at December 31, 2017:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:531px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:77px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:102px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:134px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, Beginning of the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Granted During the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, End of the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.95</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.42</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the stock options outstanding and exercisable at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:182px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.26 - $0.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,437,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.46</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,921,834</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.51 - $0.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">538,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">358,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.70</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.45 - $2.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,002,667</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.62</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.77</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,002,667</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.77</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$2.13 - $3.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">545,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">545,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$4.01 - $6.72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.94</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.34</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.34</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,148,667</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,453,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.51</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Disclosure weighted average assumptions and fair value of options</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of stock options issued during the year was determined using the Black Scholes Option Pricing Model using the following weighted average assumptions and fair value of options: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:464px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:245px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:72px;" rowspan="1" colspan="1"></td><td style="width:72px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.18%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.82%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.63%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility in the price of the Company's shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90.73%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94.84%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rate of forfeiture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$0.28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.24</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of number of other equity instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following RSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:515px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:269px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,322,829</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,831</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">486,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,053,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Vested during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,809,067</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,322,829</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:36px;"><font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:24px;">(1)</font><font style="font-family:inherit;font-size:8pt;">The weighted average fair value of the RSUs granted was </font><font style="font-family:inherit;font-size:8pt;">$0.63</font><font style="font-family:inherit;font-size:8pt;"> in 2017 (2016 - </font><font style="font-family:inherit;font-size:8pt;">$0.31</font><font style="font-family:inherit;font-size:8pt;">).</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The following PSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:521px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:274px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:75px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">840,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">60,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(660,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Outstanding, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">900,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">840,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:36px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) &#160;&#160;&#160;&#160;The weighted average fair value of the PSUs granted was $</font><font style="font-family:inherit;font-size:8pt;">0.35</font><font style="font-family:inherit;font-size:8pt;"> in 2017 (2016 - </font><font style="font-family:inherit;font-size:8pt;">$0.36</font><font style="font-family:inherit;font-size:8pt;">).</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the range of exercise prices for outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofsharebasedpaymentarrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share-based payment arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofsharebasedpaymentarrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787158464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability and Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Explanation of significant changes in contract assets and contract liabilities [text block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Our contract liability balance at December 31, which w</font><font style="font-family:inherit;font-size:10pt;">e expect to record in revenue over the next </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:443px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:236px;" rowspan="1" colspan="1"></td><td style="width:102px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regional licensing agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,182,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized in the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,182,580</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,545,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - non-current</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,636,935</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,182,580</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Paragraph 118<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767952752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory', window );">Disclosure of rental payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to rental payments (excluding our portion of operating costs and rental taxes) under the terms of our office leases.  Annual payments under the terms of these leases are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:33.984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,987</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">740,850</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2019-01-01<br> -Name IFRS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Paragraph 97<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=16&amp;date=2017-03-01&amp;anchor=para_97&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783409264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock', window );">Provision for income taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:583px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:316px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:13px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(15,475,353</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,130,605</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,719,842</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statutory Canadian corporate tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anticipated tax recovery</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,178,345</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,085,263</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,567,159</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign jurisdiction tax rate difference</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,899,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,184,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,659,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee stock based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">156,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,641</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,336,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to opening tax pools</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">162,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,569</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,339,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other permanent differences</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">53,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in deferred tax benefits deemed not probable to <br clear="none"/>  be recovered</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,051,725</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,739,557</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,455,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">144,021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment in respect to prior periods</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,523</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(313</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,347</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">141,498</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,374</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,153</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we have the following non-capital losses for income tax purposes in Canada:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,809,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,170,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,009,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,774,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,343,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,873,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,457,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,472,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,125,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,430,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2037</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,846,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">57,308,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:190px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:97px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">471,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">596,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2028</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">622,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2030</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2032</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">487,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2037</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">600</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,463,600</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized.  The components of our unrecognized deferred tax asset are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:612px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:345px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses carried forward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19,160,218</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,821,631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,950,044</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific research and experimental development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,406,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,394,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,278,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,988,325</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,990,664</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,987,214</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,927,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,908,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,839,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">493,343</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">432,659</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">619,066</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net capital losses carried forward</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized deferred tax asset</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">32,983,223</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,555,913</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,681,313</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6638224656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfCapitalComponentsTableTextBlock', window );">Schedule of capital components</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,836,119</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,034,282</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,283,846</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,689,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfCapitalComponentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Capital Components [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfCapitalComponentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799282704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock', window );">Schedule of balances in foreign currencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:596px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:197px;" rowspan="1" colspan="1"></td><td style="width:128px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:128px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:128px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">US dollars </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">British pounds</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">&#163;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro<br clear="none"/>&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,948,573</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,755</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,372</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,800,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(777,271</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,949</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,971,302</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,806</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Foreign Currency Held [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6702102896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashFlowOperatingCapital1TableTextBlock', window );">Net change in non-cash working capital</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change In Non-Cash Working Capital</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:629px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:392px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,767,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,653</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148,308</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(915,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(215,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(384,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,359,172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(664,505</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,182,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash impact of foreign exchange</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">48,558</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,212</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77,535</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in non-cash working capital related to operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">180,855</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,233,865</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,105,464</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock', window );">Other cash flow disclosures</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:342px;" rowspan="1" colspan="1"></td><td style="width:58px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:51px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:51px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash interest received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">130,101</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,902</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,859</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash taxes paid</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">136,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,468</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,421</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashFlowOperatingCapital1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Operating Capital1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashFlowOperatingCapital1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6638569584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses and Adjustments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsTableTextBlock', window );">Other expenses and adjustments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:420px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br clear="none"/></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in research and development expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Realized foreign exchange (gain) loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(120,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized non-cash foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">55,538</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(816,319</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">230,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90,768</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,233</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">348,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">231,509</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,600</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196,601</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherExpensesAndAdjustmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Expenses And Adjustments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherExpensesAndAdjustmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779865952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of related party transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:520px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:301px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term employee compensation and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,596,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,753,553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,941,342</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">779,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,330,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">459,298</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">372,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353,419</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,835,046</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,456,389</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,294,761</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2017-01-01<br> -Paragraph 18<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2017-03-01&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784151680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment, Annual Depreciation Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PropertyPlantandEquipmentAnnualDepreciationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783429312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>plan</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPolicieAbstract', window );"><strong>Summary Of Significant Accounting Policie [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_NumberOfStockOptionPlans', window );">Number of plans</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement', window );">Maximum option expiration term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Term Of Options Granted For Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfStockOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Stock Option Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfStockOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPolicieAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policie [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPolicieAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799371456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Short Term Investments - Narrative (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash Equivalents And Short Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">$ 9,204,919<span></span>
</td>
<td class="nump">$ 10,679,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashEquivalentsInterestRate', window );">Current annual interest rate</a></td>
<td class="nump">1.38%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Short Term Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashEquivalentsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashEquivalentsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800042880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Short Term Investments - Schedule Of Short-term Investments (Details) - Held-to-maturity short-term investments - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShortTermInvestmentEffectiveInterestRate', window );">Effective Interest Rate %</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.41%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,088,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtCostMember', window );">Original Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,088,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair Value | Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,088,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair Value | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,088,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 35I<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 35M<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 35N<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShortTermInvestmentEffectiveInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term Investment, Effective Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShortTermInvestmentEffectiveInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_HeldtomaturityInvestmentsCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_HeldtomaturityInvestmentsCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=oncyf_FinancialAssetsAtFaceValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=oncyf_FinancialAssetsAtFaceValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802088736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">$ 319,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">333,441<span></span>
</td>
<td class="nump">$ 319,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1,673,431<span></span>
</td>
<td class="nump">1,651,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">104,254<span></span>
</td>
<td class="nump">22,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(48,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1,729,517<span></span>
</td>
<td class="nump">1,673,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1,353,476<span></span>
</td>
<td class="nump">1,191,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">90,768<span></span>
</td>
<td class="nump">162,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1,396,076<span></span>
</td>
<td class="nump">1,353,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">52,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">43,536<span></span>
</td>
<td class="nump">52,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">197,870<span></span>
</td>
<td class="nump">197,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">197,870<span></span>
</td>
<td class="nump">197,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">144,969<span></span>
</td>
<td class="nump">133,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">9,365<span></span>
</td>
<td class="nump">11,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">154,334<span></span>
</td>
<td class="nump">144,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">151,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">132,421<span></span>
</td>
<td class="nump">151,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">705,375<span></span>
</td>
<td class="nump">685,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">24,778<span></span>
</td>
<td class="nump">20,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(48,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">681,985<span></span>
</td>
<td class="nump">705,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">554,174<span></span>
</td>
<td class="nump">505,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">43,558<span></span>
</td>
<td class="nump">48,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">549,564<span></span>
</td>
<td class="nump">554,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Office Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">76,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">78,562<span></span>
</td>
<td class="nump">76,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Office Furniture | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">214,085<span></span>
</td>
<td class="nump">214,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">11,811<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">225,896<span></span>
</td>
<td class="nump">214,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Office Furniture | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">137,624<span></span>
</td>
<td class="nump">127,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">9,710<span></span>
</td>
<td class="nump">10,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">147,334<span></span>
</td>
<td class="nump">137,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">25,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">20,679<span></span>
</td>
<td class="nump">25,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office Equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">89,466<span></span>
</td>
<td class="nump">87,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">89,466<span></span>
</td>
<td class="nump">89,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office Equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">64,167<span></span>
</td>
<td class="nump">58,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">4,620<span></span>
</td>
<td class="nump">5,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">68,787<span></span>
</td>
<td class="nump">64,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">14,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">58,243<span></span>
</td>
<td class="nump">14,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">466,635<span></span>
</td>
<td class="nump">465,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">67,665<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">534,300<span></span>
</td>
<td class="nump">466,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">452,542<span></span>
</td>
<td class="nump">366,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">23,515<span></span>
</td>
<td class="nump">86,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">$ 476,057<span></span>
</td>
<td class="nump">$ 452,542<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2017-03-01&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2017-03-01&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2017-03-01&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800859968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2017</div></th>
<th class="th"><div>Oct. 20, 2014</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,689,620<span></span>
</td>
<td class="nump">$ 24,674,306<span></span>
</td>
<td class="nump">$ 13,819,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,258,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,391,057)<span></span>
</td>
<td class="num">(500,163)<span></span>
</td>
<td class="num">(753,744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,283,846<span></span>
</td>
<td class="nump">$ 10,689,620<span></span>
</td>
<td class="nump">24,674,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,805,722<span></span>
</td>
<td class="nump">121,258,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderSharePurchaseAgreementMember', window );">Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,371,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,348,821<span></span>
</td>
<td class="nump">$ 1,456,296<span></span>
</td>
<td class="nump">$ 20,049,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301,500<span></span>
</td>
<td class="nump">3,006,600<span></span>
</td>
<td class="nump">18,860,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,348,821<span></span>
</td>
<td class="nump">$ 1,456,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(245,655)<span></span>
</td>
<td class="num">(500,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,511,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="nump">$ 11,511,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">$ (1,145,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,321,825<span></span>
</td>
<td class="nump">$ 261,324,692<span></span>
</td>
<td class="nump">$ 237,657,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,258,222<span></span>
</td>
<td class="nump">118,151,622<span></span>
</td>
<td class="nump">93,512,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 536,949<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,397<span></span>
</td>
<td class="nump">801,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,391,057)<span></span>
</td>
<td class="num">$ (500,163)<span></span>
</td>
<td class="num">$ (753,744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,710,138<span></span>
</td>
<td class="nump">$ 262,321,825<span></span>
</td>
<td class="nump">$ 261,324,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,805,722<span></span>
</td>
<td class="nump">121,258,222<span></span>
</td>
<td class="nump">118,151,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,371,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,778,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,348,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,049,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,860,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,893,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember', window );">Warrants | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderSharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderSharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803991520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital Footnotes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 01, 2017 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 20, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 01, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 25, 2016 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 24, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,283,846<span></span>
</td>
<td class="nump">$ 10,689,620<span></span>
</td>
<td class="nump">$ 24,674,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,819,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,391,057<span></span>
</td>
<td class="nump">$ 500,163<span></span>
</td>
<td class="nump">$ 753,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderSharePurchaseAgreementMember', window );">Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Share Purchase Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301,500<span></span>
</td>
<td class="nump">3,006,600<span></span>
</td>
<td class="nump">18,860,454<span></span>
</td>
<td class="nump">18,860,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_InitialCommitmentFeeSharesIssuedFairValue', window );">Proceeds from shares issued under Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,348,821<span></span>
</td>
<td class="nump">$ 1,456,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,655<span></span>
</td>
<td class="nump">$ 500,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="nump">$ 11,511,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="nump">$ 1,145,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="nump">$ 0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,397<span></span>
</td>
<td class="nump">801,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares', window );">Future issuance pursuant to Share Purchase Agreement (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,710,138<span></span>
</td>
<td class="nump">$ 262,321,825<span></span>
</td>
<td class="nump">$ 261,324,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,657,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,391,057<span></span>
</td>
<td class="nump">500,163<span></span>
</td>
<td class="nump">$ 753,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,778,674<span></span>
</td>
<td class="nump">5,778,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Initial commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_InitialCommitmentFeeSharesIssuedFairValue', window );">Proceeds from shares issued under Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Amended Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,778,674<span></span>
</td>
<td class="nump">5,778,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_InitialCommitmentFeeSharesIssuedFairValue', window );">Proceeds from shares issued under Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Amended initial commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,674<span></span>
</td>
<td class="nump">78,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_InitialCommitmentFeeSharesIssuedFairValue', window );">Proceeds from shares issued under Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,860,454<span></span>
</td>
<td class="nump">18,860,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember', window );">Warrants | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="nump">0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharePurchaseWarrantPerUnit', window );">Common share purchase warrant per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedWarrantPricePerShare', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="nump">0.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantPricePerShareAccelerationThreshold', window );">Acceleration threshold weighted average price (cad per share) | $ / shares</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays', window );">Acceleration threshold weighted average price, trading days</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharePurchaseWarrantPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Share Purchase Warrant Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharePurchaseWarrantPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_InitialCommitmentFeeSharesIssuedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Commitment Fee, Shares Issued, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_InitialCommitmentFeeSharesIssuedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Share Purchase Agreement, Future Issues, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquitySharePurchaseAgreementFutureIssuesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Price Per Share1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedWarrantPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Warrant Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedWarrantPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantPricePerShareAccelerationThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Price Per Share, Acceleration Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantPricePerShareAccelerationThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Price Per Share, Acceleration Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantPricePerShareAccelerationThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderSharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderSharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_InitialCommitmentFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_InitialCommitmentFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAmendedSharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAmendedSharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_AmendedInitialCommitmentFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_AmendedInitialCommitmentFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800934688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details) - year<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">1.18%<span></span>
</td>
<td class="nump">0.82%<span></span>
</td>
<td class="nump">0.63%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected hold period to exercise</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility in the price of the Company's shares</a></td>
<td class="nump">90.73%<span></span>
</td>
<td class="nump">94.84%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected hold period to exercise</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility in the price of the Company's shares</a></td>
<td class="nump">89.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DividendYieldPercent', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DividendYieldPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend Yield, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DividendYieldPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802452352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Summary of Outstanding Warrants (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($) </div>
<div>year </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="nump">121,258,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="nump">141,805,722<span></span>
</td>
<td class="nump">121,258,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted average remaining contractual life of outstanding share options | year</a></td>
<td class="nump">7.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ExercisePriceofOutstandingWarrants', window );">Exercise Price | $</a></td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="nump">16,445,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted average remaining contractual life of outstanding share options</a></td>
<td class="nump">4.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExercisePriceofOutstandingWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise Price of Outstanding Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExercisePriceofOutstandingWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785284944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract', window );"><strong>Disclosure Of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, beginning of the year (shares) | shares</a></td>
<td class="nump">8,674,227<span></span>
</td>
<td class="nump">8,561,394<span></span>
</td>
<td class="nump">5,446,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted during the year (shares) | shares</a></td>
<td class="nump">405,000<span></span>
</td>
<td class="nump">1,572,000<span></span>
</td>
<td class="nump">3,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (shares) | shares</a></td>
<td class="num">(2,012,660)<span></span>
</td>
<td class="num">(737,500)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired during the year (shares) | shares</a></td>
<td class="num">(116,900)<span></span>
</td>
<td class="num">(721,667)<span></span>
</td>
<td class="num">(65,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the year (shares) | shares</a></td>
<td class="num">(801,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, end of the year (shares) | shares</a></td>
<td class="nump">6,148,667<span></span>
</td>
<td class="nump">8,674,227<span></span>
</td>
<td class="nump">8,561,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options exercisable, end of the year (shares)</a></td>
<td class="nump">5,453,501<span></span>
</td>
<td class="nump">6,729,643<span></span>
</td>
<td class="nump">6,476,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,453,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of the year (cad per share)</a></td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted during the year (cad per share)</a></td>
<td class="nump">0.48<span></span>
</td>
<td class="nump">0.28<span></span>
</td>
<td class="nump">0.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (cad per share)</a></td>
<td class="nump">3.45<span></span>
</td>
<td class="nump">0.65<span></span>
</td>
<td class="nump">1.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired during the year (cad per share)</a></td>
<td class="nump">2.22<span></span>
</td>
<td class="nump">3.61<span></span>
</td>
<td class="nump">1.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the year (cad per share)</a></td>
<td class="nump">0.43<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of the year (cad per share)</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="nump">1.83<span></span>
</td>
<td class="nump">2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options exercisable, end of the year (cad per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
<td class="nump">$ 2.73<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802419616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Non-cash share based compensation | $</a></td>
<td class="nump">$ 578,703<span></span>
</td>
<td class="nump">$ 406,078<span></span>
</td>
<td class="nump">$ 429,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember', window );">Restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember', window );">Performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember', window );">Reserve of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Common shares reserved for issuance | shares</a></td>
<td class="nump">14,180,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issue under options and contracts for the sale of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_79_a_vii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6801279232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (options) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,148,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,674,227<span></span>
</td>
<td class="nump">8,561,394<span></span>
</td>
<td class="nump">5,446,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted Average Remaining Contractual Life (years) | year</a></td>
<td class="nump">7.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="nump">$ 3.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (options)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,453,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,453,501<span></span>
</td>
<td class="nump">6,729,643<span></span>
</td>
<td class="nump">6,476,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
<td class="nump">$ 2.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.26 - $0.42</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (options) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,437,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted Average Remaining Contractual Life (years) | year</a></td>
<td class="nump">8.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (options)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,921,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.26 - $0.42 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.26 - $0.42 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$0.51 - $0.80</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (options) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted Average Remaining Contractual Life (years) | year</a></td>
<td class="nump">8.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (options)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$0.51 - $0.80 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$0.51 - $0.80 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$1.45 - $2.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (options) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,002,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted Average Remaining Contractual Life (years) | year</a></td>
<td class="nump">5.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (options)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,002,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$1.45 - $2.00 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$1.45 - $2.00 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$2.13 - $3.89</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (options) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted Average Remaining Contractual Life (years) | year</a></td>
<td class="nump">3.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (options)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$2.13 - $3.89 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$2.13 - $3.89 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$4.01 - $6.72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (options) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted Average Remaining Contractual Life (years) | year</a></td>
<td class="nump">3.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (options)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$4.01 - $6.72 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$4.01 - $6.72 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783607728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract', window );"><strong>Disclosure Of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">1.18%<span></span>
</td>
<td class="nump">0.82%<span></span>
</td>
<td class="nump">0.63%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Option life, share options granted | year</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility in the price of the Company's shares</a></td>
<td class="nump">90.73%<span></span>
</td>
<td class="nump">94.84%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ExpectedForfeitureShareOptionsGranted', window );">Rate of forfeiture</a></td>
<td class="nump">3.67%<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value of options (cad per share) | $</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExpectedForfeitureShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected Forfeiture, Share Options Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExpectedForfeitureShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785528000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Schedule of Number of Other Equity Instruments (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember', window );">Restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of the year (shares)</a></td>
<td class="nump">1,322,829<span></span>
</td>
<td class="nump">368,831<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year (shares)</a></td>
<td class="nump">486,238<span></span>
</td>
<td class="nump">1,053,998<span></span>
</td>
<td class="nump">368,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the year (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of the year (shares)</a></td>
<td class="nump">1,809,067<span></span>
</td>
<td class="nump">1,322,829<span></span>
</td>
<td class="nump">368,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Weighted average fair value at measurement date, other equity instruments granted | $</a></td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember', window );">Performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of the year (shares)</a></td>
<td class="nump">840,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year (shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(660,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of the year (shares)</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">840,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Weighted average fair value at measurement date, other equity instruments granted | $</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799517728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">132,395,752<span></span>
</td>
<td class="nump">119,880,200<span></span>
</td>
<td class="nump">112,613,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2017-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=33&amp;date=2017-03-01&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785169824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability and Receivable - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($) </div>
<div>patient</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRight1LineItems', window );"><strong>Class of Warrant or Right1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantPurchaseAgreement', window );">Warrant purchase agreement</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContractLiabilityRecognitionPeriod', window );">Expected recognition period</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromContractsWithCustomers', window );">Contract receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,767,100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_MilestoneAxis=oncyf_MilestoneOneMember', window );">Milestone 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRight1LineItems', window );"><strong>Class of Warrant or Right1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantPurchaseAgreement', window );">Warrant purchase agreement</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePricePremiumPercent', window );">Common share premium</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WeightedAverageClosingPriceDuration', window );">Weighted average closing price term</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_NumberofPatients', window );">Patients | patient</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_RighttoCallWarrantMilestoneOneTerm', window );">Right to call warrant from time of agreement, term</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_MilestoneAxis=oncyf_MilestoneTwoMember', window );">Milestone 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRight1LineItems', window );"><strong>Class of Warrant or Right1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantPurchaseAgreement', window );">Warrant purchase agreement</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePricePremiumPercent', window );">Common share premium</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WeightedAverageClosingPriceDuration', window );">Weighted average closing price term</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_NumberofPatients', window );">Patients | patient</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from contracts with customers. [Refer: Receivables from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRight1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Class of Warrant or Right1 [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRight1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContractLiabilityRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Liability, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContractLiabilityRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberofPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberofPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_RighttoCallWarrantMilestoneOneTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to Call Warrant, Milestone One, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_RighttoCallWarrantMilestoneOneTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePricePremiumPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Price Premium, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePricePremiumPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WeightedAverageClosingPriceDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Closing Price Duration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WeightedAverageClosingPriceDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_MilestoneAxis=oncyf_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_MilestoneAxis=oncyf_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_MilestoneAxis=oncyf_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_MilestoneAxis=oncyf_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783634960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Balance, beginning of the year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Regional licensing agreement</a></td>
<td class="nump">6,182,580<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Revenue recognized in the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Balance, end of the year</a></td>
<td class="nump">6,182,580<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liability - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,545,645<span></span>
</td>
<td class="nump">$ 1,545,645<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liability - non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,636,935<span></span>
</td>
<td class="nump">4,636,935<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,182,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785168816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PurchaseObligation1', window );">Commitment for payment</a></td>
<td class="nump">$ 5,980,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease', window );">Rental payments</a></td>
<td class="nump">740,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_FundedandRoyaltyRepayment', window );">Repayment, maximum</a></td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OverheadRepayment', window );">Overhead repayment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AnnualContingentPaymentGrossSalesPercent', window );">Annual installment of gross sales of product, percent</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AnnualContingentPayment', window );">Annual installment of annual product sales</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">2018</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease', window );">Rental payments</a></td>
<td class="nump">285,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease', window );">Rental payments</a></td>
<td class="nump">251,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease', window );">Rental payments</a></td>
<td class="nump">159,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease', window );">Rental payments</a></td>
<td class="nump">$ 43,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of future minimum lease payments payable under non-cancellable operating leases. Minimum lease payments are payments over the lease term that the lessee is or can be required to make, excluding contingent rent, costs for services and taxes to be paid by, and reimbursed to, the lessor, together with: (a) for a lessee, any amounts guaranteed by the lessee or by a party related to the lessee; or (b) for a lessor, any residual value guaranteed to the lessor by: (i) the lessee; (ii) a party related to the lessee; or (iii) a third party unrelated to the lessor that is financially capable of discharging the obligations under the guarantee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2019-01-01<br> -Name IAS<br> -Number 17<br> -IssueDate 2017-01-01<br> -Paragraph 35<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=17&amp;date=2017-03-02&amp;anchor=para_35_a&amp;doctype=Standard&amp;book=B<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AnnualContingentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Contingent Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AnnualContingentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AnnualContingentPaymentGrossSalesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Contingent Payment, Gross Sales, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AnnualContingentPaymentGrossSalesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_FundedandRoyaltyRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funded and Royalty Repayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_FundedandRoyaltyRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OverheadRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Overhead Repayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OverheadRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PurchaseObligation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PurchaseObligation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785382000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue', window );">Royalty payment on sales revenue, percent</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContingentRoyaltyPaymentAnnualMaximum', window );">Royalty payment maximum</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContingentRoyaltyPaymentContributionRate', window );">Contingent Royalty Payment, Contribution Rate</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AccruedRoyalties1', window );">Estimated accumulated work in kind total</a></td>
<td class="nump">$ 301,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=oncyf_SYNSORBMember', window );">SYNSORB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions', window );">Milestone payment in connection with Share Purchase Agreement</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue', window );">Payment due period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage', window );">Royalty payment due to founding shareholders, percent</a></td>
<td class="nump">10.75%<span></span>
</td>
<td class="nump">11.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage', window );">Royalty payment on net sales due to founding shareholders, percent</a></td>
<td class="nump">2.15%<span></span>
</td>
<td class="nump">2.35%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2017-01-01<br> -Paragraph 21<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2017-03-01&amp;anchor=para_21_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AccruedRoyalties1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Royalties1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AccruedRoyalties1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments Made By Entity, Related Party Transactions, Period Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments Made By Entity, Related Party Transactions, Royalty Payment Received, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingentRoyaltyPaymentAnnualMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Payment, Annual Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingentRoyaltyPaymentAnnualMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingentRoyaltyPaymentContributionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Payment, Contribution Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingentRoyaltyPaymentContributionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Payment, Percent Of Sales Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=oncyf_SYNSORBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=oncyf_SYNSORBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783575344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Loss before income taxes</a></td>
<td class="num">$ (15,475,353)<span></span>
</td>
<td class="num">$ (15,130,605)<span></span>
</td>
<td class="num">$ (13,719,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory Canadian corporate tax rate</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Anticipated tax recovery</a></td>
<td class="num">$ (4,178,345)<span></span>
</td>
<td class="num">$ (4,085,263)<span></span>
</td>
<td class="num">$ (3,567,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Foreign jurisdiction tax rate difference</a></td>
<td class="nump">2,899,190<span></span>
</td>
<td class="nump">2,184,796<span></span>
</td>
<td class="nump">2,659,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_TaxEffectOfStockBasedCompensation', window );">Employee stock based compensation</a></td>
<td class="nump">156,250<span></span>
</td>
<td class="nump">109,641<span></span>
</td>
<td class="nump">111,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectFromChangeInTaxRate', window );">Change in tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,336,941)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_TaxEffectOfTaxPools', window );">Adjustment to opening tax pools</a></td>
<td class="nump">162,162<span></span>
</td>
<td class="num">(39,569)<span></span>
</td>
<td class="num">(1,339,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Other permanent differences</a></td>
<td class="nump">53,039<span></span>
</td>
<td class="nump">100,525<span></span>
</td>
<td class="nump">23,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1', window );">Change in deferred tax benefits deemed not probable to be recovered</a></td>
<td class="nump">1,051,725<span></span>
</td>
<td class="nump">1,739,557<span></span>
</td>
<td class="nump">3,455,622<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current income taxes</a></td>
<td class="nump">144,021<span></span>
</td>
<td class="nump">9,687<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod', window );">Adjustment in respect to prior periods</a></td>
<td class="num">(2,523)<span></span>
</td>
<td class="num">(313)<span></span>
</td>
<td class="num">(3,347)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods', window );">Net current tax expense</a></td>
<td class="nump">$ 141,498<span></span>
</td>
<td class="nump">$ 9,374<span></span>
</td>
<td class="nump">$ 3,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments of tax expense (income) recognised in the period for current tax of prior periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 80<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_80_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 80<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_80&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Stock Based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfTaxPools">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Tax Pools</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfTaxPools</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785873952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Non-capital Losses (Details) - Non-capital losses<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">$ 57,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">9,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">12,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember', window );">2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember', window );">2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember', window );">2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember', window );">2032</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">2,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember', window );">2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">2,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember', window );">2034</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">2,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember', window );">2035</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">3,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember', window );">2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">6,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember', window );">2037</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">$ 4,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784918256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember', window );">Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">$ 5,463,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember', window );">Unclaimed scientific research and experimental development expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">27,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyMember', window );">2020 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">189,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyOneMember', window );">2021 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">471,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember', window );">2022 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">465,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember', window );">2023 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">361,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember', window );">2024 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">228,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember', window );">2025 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">271,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember', window );">2026 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">520,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember', window );">2027 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">596,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember', window );">2028 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">622,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember', window );">2029 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">173,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember', window );">2030 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember', window );">2031 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">114,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember', window );">2032 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">381,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember', window );">2033 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">487,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember', window );">2034 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">270,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember', window );">2035 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">183,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember', window );">2036 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">41,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember', window );">2037 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">$ 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786108112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 32,983,223<span></span>
</td>
<td class="nump">$ 31,555,913<span></span>
</td>
<td class="nump">$ 29,681,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember', window );">Net operating losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">19,160,218<span></span>
</td>
<td class="nump">17,821,631<span></span>
</td>
<td class="nump">15,950,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember', window );">Scientific research and experimental development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">7,406,099<span></span>
</td>
<td class="nump">7,394,707<span></span>
</td>
<td class="nump">7,278,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember', window );">Investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">3,988,325<span></span>
</td>
<td class="nump">3,990,664<span></span>
</td>
<td class="nump">3,987,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember', window );">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">1,927,640<span></span>
</td>
<td class="nump">1,908,654<span></span>
</td>
<td class="nump">1,839,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">493,343<span></span>
</td>
<td class="nump">432,659<span></span>
</td>
<td class="nump">619,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember', window );">Net capital losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 7,598<span></span>
</td>
<td class="nump">$ 7,598<span></span>
</td>
<td class="nump">$ 7,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786052560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Disclosures (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Feb. 16, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,836,119<span></span>
</td>
<td class="nump">$ 12,034,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,016,275<span></span>
</td>
<td class="nump">$ 14,152,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,088,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders&#8217; equity</a></td>
<td class="nump">$ 8,283,846<span></span>
</td>
<td class="nump">$ 10,689,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,674,306<span></span>
</td>
<td class="nump">$ 13,819,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_EquityAuthorized', window );">Base Shelf securities authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_EquityAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_EquityAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786245184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent', window );">Short-Term Investment Held In Guaranteed Investment Certificates, Percent</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | US dollars $</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">(Increase) decrease in net loss due to change in currency value</a></td>
<td class="num">(5,056)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | British pounds &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">(Increase) decrease in net loss due to change in currency value</a></td>
<td class="nump">21,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | Euro &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">(Increase) decrease in net loss due to change in currency value</a></td>
<td class="nump">$ 11,736<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term Investment Held In Guaranteed Investment Certificates, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShortTermInvestmentHeldInGuaranteedInvestmentCertificatesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1Axis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1Axis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1Axis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1Axis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1Axis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1Axis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784884032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Balances in Foreign Currencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,836,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,034,282<span></span>
</td>
<td class="nump">$ 24,016,275<span></span>
</td>
<td class="nump">$ 14,152,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromContractsWithCustomers', window );">Contract receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,767,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1Axis=currency_USD', window );">US dollars $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,948,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromContractsWithCustomers', window );">Contract receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(777,271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,971,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1Axis=currency_GBP', window );">British pounds &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 21,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromContractsWithCustomers', window );">Contract receivable | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Accounts payable | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 7,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1Axis=currency_EUR', window );">Euro &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents | &#8364;</a></td>
<td class="nump">&#8364; 19,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromContractsWithCustomers', window );">Contract receivable | &#8364;</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Accounts payable | &#8364;</a></td>
<td class="num">(1,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies | &#8364;</a></td>
<td class="nump">&#8364; 18,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from contracts with customers. [Refer: Receivables from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 15<br> -IssueDate 2017-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2017-03-01&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_BalanceHeldInForeignCurrencyNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance Held In Foreign Currency, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_BalanceHeldInForeignCurrencyNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Currency1 [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1Axis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1Axis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1Axis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1Axis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1Axis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1Axis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786331856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Contract receivable</a></td>
<td class="num">$ (4,767,100)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Other receivables</a></td>
<td class="nump">16,680<span></span>
</td>
<td class="nump">285,653<span></span>
</td>
<td class="num">(148,308)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncreaseDecreaseinPrepaidExpense1', window );">Prepaid expenses</a></td>
<td class="num">(915,222)<span></span>
</td>
<td class="nump">245,828<span></span>
</td>
<td class="num">(215,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(384,641)<span></span>
</td>
<td class="nump">1,359,172<span></span>
</td>
<td class="num">(664,505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables', window );">Contract liability</a></td>
<td class="nump">6,182,580<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets', window );">Non-cash impact of foreign exchange</a></td>
<td class="nump">48,558<span></span>
</td>
<td class="nump">343,212<span></span>
</td>
<td class="num">(77,535)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital', window );">Change in non-cash working capital related to operating activities</a></td>
<td class="nump">$ 180,855<span></span>
</td>
<td class="nump">$ 2,233,865<span></span>
</td>
<td class="num">$ (1,105,464)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph IG20B<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseinPrepaidExpense1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Expense1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseinPrepaidExpense1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784594416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ProceedsfromInterestReceived', window );">Cash interest received</a></td>
<td class="nump">$ 130,101<span></span>
</td>
<td class="nump">$ 163,902<span></span>
</td>
<td class="nump">$ 197,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Cash taxes paid</a></td>
<td class="nump">$ 136,163<span></span>
</td>
<td class="nump">$ 4,468<span></span>
</td>
<td class="nump">$ 3,421<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Interest Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6705258112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Economic Dependence (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>manufacturer</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member', window );">Toll manufacturer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ConcentrationRiskType1LineItems', window );"><strong>Concentration Risk Type1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ConcentrationRiskNumber', window );">Concentration, number</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskType1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Concentration Risk Type1 [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskType1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785345120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses and Adjustments (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized non-cash foreign exchange loss (gain)</a></td>
<td class="num">$ (124,793)<span></span>
</td>
<td class="num">$ (139,810)<span></span>
</td>
<td class="num">$ (816,319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Non-cash share based compensation</a></td>
<td class="nump">578,703<span></span>
</td>
<td class="nump">406,078<span></span>
</td>
<td class="nump">429,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentMember', window );">Included in research and development expenses:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Realized foreign exchange (gain) loss</a></td>
<td class="num">(120,794)<span></span>
</td>
<td class="nump">104,851<span></span>
</td>
<td class="nump">238,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized non-cash foreign exchange loss (gain)</a></td>
<td class="nump">55,538<span></span>
</td>
<td class="nump">67,109<span></span>
</td>
<td class="num">(816,319)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Non-cash share based compensation</a></td>
<td class="nump">230,141<span></span>
</td>
<td class="nump">233,919<span></span>
</td>
<td class="nump">257,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember', window );">Included in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Non-cash share based compensation</a></td>
<td class="nump">348,562<span></span>
</td>
<td class="nump">172,159<span></span>
</td>
<td class="nump">172,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Amortization of property and equipment</a></td>
<td class="nump">90,768<span></span>
</td>
<td class="nump">162,233<span></span>
</td>
<td class="nump">180,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense', window );">Office minimum lease payments</a></td>
<td class="nump">$ 231,509<span></span>
</td>
<td class="nump">$ 148,600<span></span>
</td>
<td class="nump">$ 196,601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=sect_AStatementofcashflowsforanentityotherthanafinancialinstitution&amp;doctype=Illustrative%20Examples<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2017-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=21&amp;date=2017-03-01&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payments on leases and subleases recognised as an expense by the lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2019-01-01<br> -Name IAS<br> -Number 17<br> -IssueDate 2017-01-01<br> -Paragraph 35<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=17&amp;date=2017-03-02&amp;anchor=para_35_c&amp;doctype=Standard&amp;book=B<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseAndSubleasePaymentsRecognisedAsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherExpensesAndAdjustmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Other Expenses And Adjustments [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherExpensesAndAdjustmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784807904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,596,082<span></span>
</td>
<td class="nump">$ 2,753,553<span></span>
</td>
<td class="nump">$ 2,941,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">779,666<span></span>
</td>
<td class="nump">1,330,828<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459,298<span></span>
</td>
<td class="nump">372,008<span></span>
</td>
<td class="nump">353,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Compensation of key management personnel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,835,046<span></span>
</td>
<td class="nump">$ 4,456,389<span></span>
</td>
<td class="nump">$ 3,294,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties', window );">Liability to officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,125<span></span>
</td>
<td class="nump">$ 178,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1', window );">Officer liability paid</a></td>
<td class="nump">$ 35,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2017-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2017-03-01&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2017-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2017-03-01&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2017-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2017-03-01&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2017-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2017-03-01&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Expenses from Transactions with Related Party1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_RelatedPartyTransactionExpensesfromTransactionswithRelatedParty1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>97
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M=-A1 EYR8'*<&$Y#V\ 5,,((HTO?!30S<:K^B9TZP,[)(=DYU?=]V==3+N_
MX>WI\65:M[!=(M5IS+^2%70*N&:7R:_UPV:W97)1\;NBJ@M^O^-+4:_$[>I]
M=/WA=Q5VWMB]_<?&%T'9P*^[D%]02P,$%     @ TH1S3)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M4#*CX\J8I"J4\$DE7*N/@^70TJO4VU3M^30AIX-DPSS]@^43I/P'4$L#!!0
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MYKX$  !]%0  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;(V866_B2!"
M_PKB/>.^CX@@+<F28P**9K6[ST[H!#0&L[839O_]M$USN+H,*%*PS5?55=5U
M-!YL\N)G.7>NZOU:9JORIC^OJO5UDI1O<[=,RV_YVJW\-^]YL4PK?UM\).6Z
M<.FL$5IF"2-$)<MTL>H/!\VSEV(XR#^K;+%R+T6O_%PNT^+_D<ORS4V?]G</
M?BP^YE7](!D.UNF'^\M5?Z]?"G^7[+7,%DNW*A?YJE>X]YO^'_1Z2FTMT!#_
M+-RF/+KNU:Z\YOG/^N9Q=M,GM44N<V]5K2+U'U_NUF59K<G;\5]0VM^O60L>
M7^^TCQOGO3.O:>EN\^S?Q:R:W_1-OS=S[^EG5OW(-P\N."3[O>#]L_MRF<=K
M2_P:;WE6-O][;Y]EE2^#%F_*,OVU_5RLFL_-]ALI@Q@NP(( VPM0?E* !P&^
M%V"G5Q!!0!P$Q$D!&03DP21U4D % 76I@ X">B\@R$D!$P3,7H#;DP(V"-B#
M #TI0,ENY\C!"W9:9+_9A]UFIQVGN^VFA_UF9U;9;3@][+@XX\MNRZD JR3;
M]&WJX2ZMTN&@R#>]8EO2Z[3N'/3:2WGE]=.FPIHO?4V4_NG74)M!\E4K"LAH
MB[!CQ+:1VQ@QI(W<(0AM(W\B"&LC8P3A;>0>040;>4 0V48>$42UD2<$T6WD
M.X* Z#XC"(CN)$8LB.X400[137P*[/. X7G &@7B6 &(_6B+J 99-0CEAEIJ
MP0Z,8Y!QK:0F$H8P)H%CSX@N:801# 8) 0TA M@VC;$K)JQ5BG.)!XSC >-Q
MP,!:HRTBC]>BG E&%/!R$I/"$,M!4DY1A9HQ:SML%[CM(K8=E,BMB.(DN*8*
M9OA=S/F#AK *!N/^0H4/%RALN2AQ%V7L(HCF2,9!9U9R8-#S6:QECL+-4;$Y
MH!9&*MY<[9<18&?&Y[F601HW2,<& <='.EJ(":4%)\#R,0*J.M$5;"%/,0GK
M'=/%M/8%"DHF!K4B%@ZO:8Q=,<65L9P3/& &#Y@Y7^\&*4_)A5\,A':"D+XK
M6 JM1S52;NW1!&X9;W'C[=F"O[/14E1(Q6":/ISG6@;5ARWTW$%BDX#WMX$Y
MD2[W""(H(3"K$.RJS;6-[CHLT?-=)3 MBWS#AXGY?)YKF]0QMRDRN&%G"4S+
M>TD(52"![RX%QQ> ;>L[ABA%IJB%UL=3CQ)?4XH1:%5,^N;!&34,[-(3@D8Y
M@VE3OOW!CCQ!2"E%-.6G"'?%M#',<M)1S[1C@E-DA,-V%!C0/;35%)Z\)RAJ
MR'&/#"Z@.I6?X[+CO$D[!C1%)C3L232>O8P+'[#HEX.,SZ:^45().\$#0J(J
M'Q%0^ZFAH,;O",@5U;:SN70<$2AR1H@ZHHK7$ER(J"W&G.3*"@MS'#E,^/.\
M[$S'CM,$18X346.,1['41A,.;3K+M4WJF-<4&=A18\3F*[>42'C,#23XW2"5
ME+ '7:"R;7_'R*;QS*8P]T8!.C;+,,.-@$<T!&2::DK\3SC8&F,4YG/8*$PG
M889!E1-,I?9_47>)N2MFA1"^P<!J2HY><=0O)B=I\;%8E;W7O*KR9?-*XSW/
M*^?UDF]^.^8NG>UO,O=>U9?:7Q?;%X+;FRI?AY>=R?Z-Z_ W4$L#!!0    (
M -*$<TQ SIM;4 0  .$2   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
ME5AM;^,V#/XK0;[W+%+O11J@27#8@ TH;MCVV4W4)C@[SFRWN?W[R2^72RBZ
MPZ% 8\L/J8<4S<?2XES57YM]".WL6UD<FX?YOFU/]UG6;/>AS)M/U2D<XY.7
MJB[S-M[6KUESJD.^ZXW*(D,A3%;FA^-\N>C'GNKEHGIKB\,Q/-6SYJTL\_K?
M52BJ\\,<YM\'OAQ>]VTWD"T7I_PU_!':/T]/=;S++EYVAS(<FT-UG-7AY6'^
M"/<;M)U!C_CK$,[-U?6L"^6YJKYV-[_N'N:B8Q2*L&T[%WG\>0_K4!2=I\CC
MG]'I_#)G9WA]_=W[YS[X&,QSWH1U5?Q]V+7[A[F;SW;A)7\KVB_5^9<P!J3G
MLS'ZW\)[*"*\8Q+GV%9%T_^?;=^:MBI'+Y%*F7\;?@_'_O<\/-%F-.,-<#3
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MBO#2=I<V7M?#H<MPTU:G\4 INYQJ+?\#4$L#!!0    ( -*$<TQVE20-M0$
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M"94/VT^XM^.<C8$WW?2$V/R.\U]02P,$%     @ TH1S3*UA-#^U 0  TP,
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M@]^;<<[&P&$W/2$VO^/\-U!+ P04    " #2A'-,"#(IR[4!  #3 P  &
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;'U3[6Z<,!!\%<L/$-]Q7',] 5(N
M5=5*K71*U?2W#Q:PX@]JFR-]^ZX-H;0A_8.]R\SLK+W.!F.?7 O@R;.2VN6T
M];X[,N;*%A1W-Z8#C7]J8Q7W&-J&N<X"KR))299L-N^8XD+3(HNYLRTRTWLI
M-)PM<;U2W/XZ@31#3K?T)?$@FM:'!"NRCC?P#?SW[FPQ8K-*)11H)XPF%NJ<
MWFV/IS3@(^!1P. 6>Q(ZN1CS%(+/54XWP1!(*'U0X+A<X1ZD#$)HX^>D2>>2
M@;C<OZA_C+UC+Q?NX-[('Z+R;4X/E%10\U[Z!S-\@JF?/253\U_@"A+AP0G6
M*(UT\4O*WGFC)A6THOCSN H=UV'\LT\GVCHAF0C)3#C$.FPL%)U_X)X7F34#
ML>/9=SQ<\?:8X-F4(1F/(OY#\PZSUV*;W&;L&H0FS&G$)$O,C&"H/I=(UDJ<
MDE?T_6&=OUNUN(O\W5\6WQ!(5P72*)#^M\<US/M_BK#%H2JP31PG1TK3ZSC*
MB^P\L7=)O)0_\''<OW+;".W(Q7B\VG@!M3$>T,KF!F>HQ1<V!Q)J'[:WN+?C
MG(V!-]WTA-C\CHO?4$L#!!0    ( -*$<TP[U^2LM $  -,#   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;'U386^;,!#]*Y9_0$U(VD41(#6=IE5:
MI:C3ML\.'&#5]E';A/;?SS:$L8WM"_8=[[U[9Y^S <V+;0$<>5-2VYRVSG4'
MQFS9@N+V!CO0_D^-1G'G0],PVQG@520IR=(DN6.*"TV++.9.ILBP=U)H.!EB
M>Z6X>3^"Q"&G&WI-/(NF=2'!BJSC#7P%]ZT[&1^Q6:42"K05J(F!.J?WF\-Q
M%_ 1\%W 8!=[$CHY([Z$X+'*:1(,@832!07NEPL\@)1!R-MXG33I7#(0E_NK
M^J?8N^_ES"T\H/PA*M?F=$])!37OI7O&X3-,_=Q2,C7_!2X@/3PX\35*E#9^
M2=E;AVI2\584?QM7H>,ZC'_NKK1U0CH1TIFPCP0V%HK./W+'B\S@0,QX]AT/
M5[PYI/YLRI",1Q'_>?/69R_%9IMD[!*$)LQQQ*1+S(Q@7GTND:Z5.*9_T6_W
MZ_SMJL5MY&]_L_@/ [M5@5T4V/VWQS5,^D<1MCA4!::)XV1)B;V.H[S(SA-[
MG\9+^04?Q_V)FT9H2\[H_-7&"Z@1'7@KR8V?H=:_L#F04+NP_>#W9IRS,7#8
M34^(S>^X^ E02P,$%     @ TH1S3*^ 97NU 0  TP,  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL?5/;;MP@$/T5Q >$75_2U<JVE$U4)5(KK5*U
M?6;M\44!Q@&\3O^^@!W7;:V\&&9\SIDS,&0CZA?3 ECR)H4R.6VM[8^,F;(%
MR<T-]J#<GQJUY-:%NF&FU\"K0)*"1;O=+9.\4[3(0NZLBPP'*SH%9TW,("77
MOTX@<,SIGKXGGKNFM3[!BJSG#7P#^[T_:Q>Q1:7J)"C3H2(:ZIS>[8^GQ.,#
MX$<'HUGMB>_D@OCB@Z<JISMO" 24UBMPMUSA'H3P0L[&ZZQ)EY*>N-Z_JW\.
MO;M>+MS /8J?767;G!XHJ:#F@[#/.#["W$]*R=S\%[B"<'#OQ-4H49CP)>5@
M+,I9Q5F1_&U:.Q76<?J3IC-MFQ#-A&@A'$(=-A4*SA^XY46F<21Z.ON>^RO>
M'R-W-J5/AJ,(_YQYX[+78A_'&;MZH1ESFC#1&K,@F%-?2D1;)4[1?_3TL,V/
M-RW&@1__93'9%D@V!9(@D'S8XQ8F_:<(6QVJ!-V$<3*DQ$&%45YEEXF]B\*E
M_(%/X_Z5ZZ93AES0NJL-%U C6G!6=C=NAEKWPI9 0&W]]I/;ZVG.IL!B/S\A
MMKSCXC=02P,$%     @ TH1S3$/2OS2Q 0  TP,  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL?5/MCILP$'P5RP]P3DCN0Q$@7:ZJ6JF5HJO:_G9@
M >MLEMHF7-^^:T,X>D7]@[W+S.RLO4X'M"^N ?#LU>C69;SQOCL(X8H&C'0W
MV$%+?RJT1GH*;2U<9T&6D62T2#:;.V&D:GF>QMS)YBGV7JL63I:YWAAI?Q]!
MXY#Q+;\FGE7=^) 0>=K)&KZ!_]Z=+$5B5BF5@=8I;)F%*N./V\-Q'_ 1\$/!
MX!9[%CHY([Z$X'.9\4TP!!H*'Q0D+1=X JV#$-GX-6GRN60@+O=7]8^Q=^KE
M+!T\H?ZI2M]D_(&S$BK9:_^,PR>8^KGE;&K^"UQ $SPXH1H%:A>_K.B=1S.I
MD!4C7\=5M7$=)OTK;9V03(3D'4&,A:+S#]++/+4X,#N>?2?#%6\/"9U-$9+Q
M*.(_,N\H>\FWN[M47(+0A#F.F&2)F1&"U.<2R5J)8_(/_?9AG;];M;B+_-U?
M%N_7!?:K OLHL/]OCVN8]R[%XE -V#J.DV,%]FT<Y45VGMC')%[*&WP<]Z_2
MUJIU[(R>KC9>0(7H@:QL;FB&&GIA<Z"A\F%[3WL[SMD8>.RF)R3F=YS_ 5!+
M P04    " #2A'-,]FP]1;8!  #3 P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q,RYX;6Q]4]N.FS 0_17+'[ FA+1I!$B;K:I6:J5HJ[;/#@Q@K2_4-F'[
M]QT;EJ(NVA?;,S[GS,7C?#3VR74 GCPKJ5U!.^_[$V.NZD!Q=V=ZT'C3&*NX
M1].VS/46>!U)2K(T2=XQQ86F91Y]%UOF9O!2:+A8X@:EN/US!FG&@N[HB^-1
MM)T/#E;F/6_A._@?_<6BQ1:56BC03AA-+#0%O=^=SEG 1\!/ :-;G4FHY&K,
M4S"^U 5-0D(@H?)!@>-V@P>0,@AA&K]G3;J$#,3U^47]4ZP=:[ER!P]&_A*U
M[PIZI*2&A@_2/YKQ,\SU'"B9B_\*-Y (#YE@C,I(%U=2#<X;-:M@*HH_3[O0
M<1^GF_>'F;9-2&="NA".,0Z; L7,/W+/R]R:D=BI]ST/3[P[I=B;*CAC*^(=
M)N_0>RMW^P\YNP6A&7.>,.D:LR 8JB\ATJT0Y_05_7#<YN\W4]Q'_GX=/DNV
M!;)-@2P*9&_6N(')_J^2K9JJP+9QG!RIS*#C**^\R\3>I_%1_L&G<?_&;2NT
M(U?C\6GC S3&>,!4DCN<H0Y_V&)(:'PXXD00.\W99'C3SU^(+?^X_ M02P,$
M%     @ TH1S3$+D:NBU 0  TP,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL?5/M;IPP$'P5RP\0WW%<<SH!4BY1U4JI=$J5]+</%K#B#VJ;(WW[
MK@VAM$7Y@[W+S.RLO<X&8U]="^#)FY+:Y;3UOCLRYLH6%'<WI@.-?VIC%?<8
MVH:YS@*O(DE)EFPVGYCB0M,BB[FS+3+3>RDTG"UQO5+<_CJ!-$-.M_0]\22:
MUH<$*[*.-_ =_'-WMABQ6:42"K031A,+=4[OML=3&O 1\")@<(L]"9U<C'D-
MP=<JIYM@""24/BAP7*YP#U(&(;3Q<]*D<\E 7.[?U3_'WK&7"W=P;^0/4?DV
MIP=**JAY+_V3&;[ U,^>DJGY1[B"1'AP@C5*(UW\DK)WWJA)!:TH_C:N0L=U
M&/_L#Q-MG9!,A&0F'&(=-A:*SA^XYT5FS4#L>/8=#U>\/29X-F5(QJ.(_]"\
MP^RUV*9)QJY!:,*<1DRRQ,P(ANISB62MQ"GYC[X_K/-WJQ9WD;_[R^)N72!=
M%4BC0/IACVN8])\B;'&H"FP3Q\F1TO0ZCO(B.T_L71(OY0]\'/=OW#9".W(Q
M'J\V7D!MC >TLKG!&6KQA<V!A-J'[2WN[3AG8^!--STA-K_CXC=02P,$%
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M!=3&>$ KFSN<H19?V!Q(J'W8/N#>CG,V!MYTTQ-B\SLN?@%02P,$%     @
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MF/2?(FQUJ!I,$\?)DA*'+H[R*KM,[#V/E_('/HW[%V$:V5ER1>>O-EY C>C
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MM@0*:A>V'_S>3',V!0[[^0FQY1T7OP%02P,$%     @ TH1S3.XK/0VV 0
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MI,TB0&HZ3:O42E&G;7\[<(!5_V"V">VWW]E0QEJV?[#O>._=._N<]L8^NP;
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M\F%[@WL[S-D0>-..3XA-[SC_#5!+ P04    " #2A'-,NFGFVK4!  #3 P
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M'O=VG+,Q\*:;GA";WW'^!U!+ P04    " #2A'-,A.S3=+4!  #3 P  &0
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M/T.]_V&K(:!UX?C>G\T\9[/A]+!\(;+^X^H/4$L#!!0    ( -*$<TR"1J>
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M[OV$6VZ4LN"L;&Z<E\Z-\1)P:*S?WKF]GA[S%%C5SW-*EC^+\B]02P,$%
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MC<>GC0]0&^,!4TGN<(9:_&&+H:#VX?@.SW::L\GPII^_$%O^<?$'4$L#!!0
M   ( -*$<TQZJ?'IN $  -,#   9    >&PO=V]R:W-H965T<R]S:&5E=#,W
M+GAM;&U3VV[<(!#]%<0'A%W6FZQ6MJ5LHJB56FF5JLTS:X\O"A<7\#K]^P[8
M<=S4+\ ,YYRY,*2#L:^N ?#D34GM,MIXWQT9<T4#2K@;TX'&F\I8)3R:MF:N
MLR#*2%*2\<WFEBG1:IJGT7>V>6IZ+UL-9TM<KY2P?TX@S9#1+7UW/+=UXX.#
MY6DG:O@!_F=WMFBQ6:5L%6C7&DTL5!F]WQY/2<!'P*\6!K<XDU#)Q9C78'PM
M,[H)"8&$P@<%@=L5'D#*((1I_)XTZ1PR$)?G=_6G6#O6<A$.'HQ\:4O?9/1
M20F5Z*5_-L,7F.K94S(5_PVN(!$>,L$8A9$NKJ3HG3=J4L%4E'@;]U;'?1AO
M[I*)MD[@$X'/A$.,P\9 ,?-'X46>6C,0._:^$^&)MT>.O2F",[8BWF'R#KW7
MG.^W*;L&H0ES&C%\@?E ,%2?0_"U$"?^'WU_6.?O5E/<1?YN&?YVORZ0K HD
M42#YIT;^J<8US.Y3$+9HJ@);QW%RI#"]CJ.\\,X3>\_CHWS QW'_+FS=:D<N
MQN/3Q@>HC/& J6QN<(8:_&&S(:'RX7B'9SO.V6AXTTU?B,W_./\+4$L#!!0
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M8_Y@I@@.%>X93@LC?1;;9C$M)*<%:TAR6.C6L^$  -DY>S!2)$>*]#92!2:
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MX_I]T?W"WCU4^<'^]4!T^A.&Z?]02P,$%     @ TH1S3 %VN^9A @  3 @
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M-TFD,=L. P<8T",<P=Y+0)/$%D["O3!ZE-B9,/$C9F_"+,U&/&.NGB+PA@3
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MJ.O_3 C'PJ2[$$7(Q2=$/RGQF<MA),:TZZ/=A)-&?R,X_8=*^A=02P,$%
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M8A-$+-A[MHD30E$1.\G;N1RZ;E.$ ^MV(9P2?/,FKO28P-V;(&M?<DDHT(Z
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MW+-N).@.@C;]N&,-,U?Z%U!+ P04    " #2A'-,ELIG#%,%  #['@  &0
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M63:VS=B>1*>3E2V6IXN-?6VZKZ;]7AU?QQXOFG+O7C6GI_?=B_\!4$L#!!0
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MXO#N\1Z).D7H(939WZA)G6S]FTQ/*V?/JS#P%]Y9&?6:=:?!(PT:%)YT'Y;
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M;\]@,#AKNUV8O?03Z TMVOYQ0<,+5_P'4$L#!!0    ( -*$<TPQBV'#G@(
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M+W-H965T-C$N>&ULE9?;CILP$(9?!?$ BT^<HB12=ZNJE5HIVJKMM3=Q$K2
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M96*"4T<:C.#?-X)8'4\+.SR"_6DQ; %,/'B'H&FM#+G>+(:M@BG 2UW%PC[
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M*<S.=8=)>UP/^X##B;.'<8\S.FVTKO\#4$L#!!0    ( -*$<TQI@L@,Y@(
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M0R2[02*7Y"U3BF9*?3SK?X(0G("A!,P3\#>EBD&I+49Z3.DQC*J$4<H&!2-
M$$(H&  W8R!5,@$&$\5S-'>.Y"YQ H$2B/GJ291 SE"OQ8A>K:! $@K#[8(
MXX2"9#!0#P$*Y3+G',\]1G./D=QCG"!!"9+YZBF40,U03XUJC3F11 T.TAK!
M,<5C$@^T0W#4J9Q,2 <$-P@R2AW4Q-:#"8^!^?(!?OB!SA"P _4K9BIQIU<,
MW0H#*B(E'WH6RAA3F-(0=Q[ K">9H, - /@[-,0M ,0<#05RAFDL.1EJB %)
M(L5(0P28, 5DX@0"[C\P-J#);8B[ ,3OD!#W 4CF2)B,"N:*,3Z\0C <HW)\
M<8YQ$IK=.I$Z[D" 69#"*2AN!93,%Y#B5D!AAH =J']GQD(-[Y!9J,W_4&W2
M4:]=:AK>;VEUR,HZ>#+6=5Z^/]H;8[5C)!_<'W%T/?9MDNN];8:Q&U=MH]E.
MK#EU371TZ^17?P%02P,$%     @ TH1S3.0*%81. @   @<  !D   !X;"]W
M;W)K<VAE971S+W-H965T-C0N>&ULC57;CILP%/P5Q <LOH>L2*0FV:B56BG:
MJNVSDS@!+6!J.\GV[VL;%A%PJ_" ;S-SSAP;G-VD>M.Y$"9ZK\I:+^+<F.8Y
M2?0A%Q773[(1M5TY255Q8X?JG.A&"7[TI*I,$  LJ7A1Q\O,S^W4,I,74Q:U
MV*E(7ZJ*JS\K4<K;(H;QQ\1K<<Z-FTB66<//XKLP/YJ=LJ.D5SD6E:AU(>M(
MB=,B_@2?M\SA/>!G(6YZT(^<D[V4;V[PY;B(@4M(E.)@G *WS56L15DZ(9O&
M[TXS[D,ZXK#_H;[UWJV7/==B+<M?Q='DBSB-HZ,X\4MI7N7ML^C\T#CJS'\5
M5U%:N,O$QCC(4OMW=+AH(ZM.Q:92\?>V+6K?WMH5@CI:F( Z NH)D/R7@#L"
M?I1 .@)YE$ [ GV4P#H"&Q&2MEB^^AMN^#)3\A:I]OPTW!U3^,SL_A[<I-].
MOV8W0-O9ZY)BD"57)]1A5BT&#3'I/60=@,SO(9L !,-[S,L4P_ ]9!N203TF
ML69[QRCH&'D!/!" [!\"."B O0 9"$PJUD*8A]1M#)AB!N&H*.L $ %,4(I&
ME9D"$0$V\1D=U2>@2""U@C3LD00]DJG'T5ZM6@@=!!I583U%()"F*0#A3&@P
M$SK)A(R*N*(3RRE*<4K8*)\I#@*6SAD:)?XR!2+"9@2#D>(VH(A3.(=S'+;(
M@A;9Q"+%HV._8=-(%+3/*%0R^/3=[?"-JW-1ZV@OC?V+^&_])*415A4\60.Y
MO9#Z02E.QG5GMJ_:WW([,++I;IRDO_:6?P%02P,$%     @ TH1S3*6-&V%/
M @  T0<  !D   !X;"]W;W)K<VAE971S+W-H965T-C4N>&ULE55=CYLP$/PK
MB/<&;+Z2B" E5U6MU$K15=<^.\DFH -,;2=<_WUM0RB7+%+N)=AF=F9WR'K3
MEHM7F0,HYZTJ:[ER<Z6:I>?)?0X5DS/>0*W?'+FHF-);<?)D(X =;%!5>M3W
M8Z]B1>UFJ3W;BBSE9U46-6R%(\]5Q<3?#92\7;G$O1X\%Z=<F0,O2QMV@I^@
M7IJMT#MO8#D4%=2RX+4CX+ARUV2Y(;$)L(A?!;1RM'9,*3O.7\WFVV'E^B8C
M*&&O# 73CPL\05D:)IW'GY[4'31-X'A]9?]BB]?%[)B$)U[^+@XJ7[ESUSG
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MA:Z4W1>6!C1(I(1#%)(1K9&."(C6F+MX9X /M ; >P.XS8$Q8C?='@1P6<W
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M.\U>2B6TT?1!E_>H3ROCI!1[98:9'K=]R^XG2C;#<209ST2K_U!+ P04
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M-]D[Q,.@]_Z'/,K2P*T2<\9*E:V[!JM#JU75LQ@I5?[6W8O:W4_=&PZ]&6Y
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M<],-9-U"JWT_;$;#Q#O[#U!+ P04    " #2A'-,W#'1P[ "   B"0  &0
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M-.S6ON5<,6TRO='K::\O+$.G9EMEFD2W17=L=QW%#_V-)!FN1?._4$L#!!0
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M@E.QE/=P';=D+H;YX?! A,#C"SQDP8WOHD'2AQU()M/HSR@(%'<[&.H%M+I
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M<BF:_3(DGC?9[@$7KV75043;;A]Q*$3I/0=%\4*D']\;LQ::0SLG.8%6482
M8^'[KTY;UZJKC8 /H99V1Y<)B#..!K8^*^ XADVAT"(MI0_$K#)Z!.G19K-Z
M5*:%NA22:B&9K:-5HNE:8/\ $BND!B@7[G:@T#!GSIC< 9%HV9VN*1*%\+3
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MK%NFRZ, PAK)4[A8P1Q[[8R$R#-)L3 V.9H"RXOA]^_*7?0S\/Y7;MI$J^?
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M-"X S=<!XK6BDUY5I9!FM?"@-=4UQ]W79^!;D@61%Q[KQ57,#C:6C"Z9R6O
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MGZ:!@0'J./&PF?(7HH+FBUVZT^B FN^95N,F6U$PE#)DUCPU_*DY[Q_1"8
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MWP2%"?+R%H$+CF:M29BV3/C'$F]!&?&6N0"9NWV.IM0"B?=?,P%H,8ZN6Z[
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MY2B55)R8'RG>GM0$K*X9&L#%W'*XS'PS@0P7*YAC"S-J83X>> "HWL[E"[%
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MMDQI"/2T5WA/2&4_,X:"TY;K<[<E+$ES@9X;55G;>&Z,#*>:5L\^^0;?D39
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MOHI^?Q!/)M-HW,/2V+WIU'Q''^'!! L'@2(^FT=CV%)DQ\,>:-=#'*#_!CZ
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MELKKO<OK0MD;'C(^SFQ\7%\1E^-G.=;LGD,':[BW P=#T97F0T682?VAAKN
M_04&H>K-AY8<U/4'A'$5XS2TP])\Z#-8*>.$E.,(%]E0CG-1ELTX$W5?CO/0
M].XLV-E%X&1?CS/0E./PHQ,$[-Q+Y;O_E(NN1U2<F]-#A_%0[%"W;B07S0^Q
M^F[8JG&@+<C:T"OF-@;N:">_4K%WJ8SU5SP2OMU/([P:S@Z$A!T9Y#BM5T7Y
M[LPRIG6^ULM&\[W?H0G@/\;%VM+(6_5ELO[Y@F;ZB7=,XB[D0-)-U0AXO[*
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M(2$%T_?VB%4PQ)W]P8('PW;7I)4(<6??04P+[F;>[IUJ_ M02P,$%     @
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MPM=;@-["UUN WL+76X#>PM=;@=[*UUN!WLK76X'>NL!9"3HLX>NM0&_EZZU
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M   3    6T-O;G1E;G1?5'EP97-=+GAM;,W:RT[C,!0&X%>ILD6-ZVL91-D
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MWYL7_P!02P$"% ,4    " #2A'-,'R// \     3 @  "P
M@ $     7W)E;',O+G)E;'-02P$"% ,4    " #2A'-,9O,+8((   "Q
M$               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M -*$<TRL-W+G[P   "L"   1              "  9D!  !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( -*$<TR97)PC$ 8  )PG   3
M  "  ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ TH1S3,'$
MT$QF @  C@@  !@              ( !^ @  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( -*$<TPIU,V*V0,  %T1   8
M  "  90+  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #2
MA'-,@AZ#U[@!  #: P  &               @ &C#P  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ TH1S3$8.39QM P  0PT  !@
M         ( !D1$  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( -*$<TSN@ESFO@0  'T5   8              "  305  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #2A'-,0,Z;6U $  #A$@
M&               @ $H&@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ TH1S3':5) VU 0  TP,  !@              ( !KAX  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( -*$<TRM830_M0$
M -,#   8              "  9D@  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " #2A'-,"#(IR[4!  #3 P  &               @ &$
M(@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ TH1S3#O7
MY*RT 0  TP,  !D              ( !;R0  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " #2A'-,KX!E>[4!  #3 P  &0
M    @ %:)@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M -*$<TQ#TK\TL0$  -,#   9              "  48H  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ TH1S3/9L/46V 0  TP,  !D
M             ( !+BH  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " #2A'-,0N1JZ+4!  #3 P  &0              @ $;+   >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -*$<TSZIF>SM0$
M -,#   9              "  0<N  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ TH1S3/F!<E6W 0  TP,  !D              ( !
M\R\  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #2A'-,
M'TG[I+0!  #3 P  &0              @ 'A,0  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( -*$<TQK C>*M0$  -,#   9
M      "  <PS  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ TH1S3/0NN2.W 0  TP,  !D              ( !N#4  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #2A'-,NWUR.+4!  #3 P
M&0              @ &F-P  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( -*$<TSN*ST-M@$  -,#   9              "  9(Y  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ TH1S3.4<%CZV
M 0  TP,  !D              ( !?SL  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " #2A'-,NFGFVK4!  #3 P  &0
M@ %L/0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( -*$
M<TR$[--TM0$  -,#   9              "  5@_  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ TH1S3,] E'>T 0  TP,  !D
M         ( !1$$  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " #2A'-,WQ^@U;8!  #3 P  &0              @ $O0P  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( -*$<TPJ [U<;0(   P)
M   9              "  1Q%  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ TH1S3%S%4"JW 0  TP,  !D              ( !P$<
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #2A'-,6RXV
MF+@!  #3 P  &0              @ &N20  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( -*$<TRT0V6+M $  -,#   9
M  "  9U+  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
MTH1S3'W+>TS/ 0  G00  !D              ( !B$T  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " #2A'-,.8"Z-^P!  !G!0  &0
M            @ &.3P  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( -*$<TP-8Z4CM $  -,#   9              "  ;%1  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ TH1S3/5B'XFV 0
MTP,  !D              ( !G%,  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " #2A'-,@D:G@,,!   X!   &0              @ &)
M50  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( -*$<TQ\
MJ)UIN0$  -,#   9              "  8-7  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ TH1S3'JI\>FX 0  TP,  !D
M     ( !<UD  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -*$<TP(F7-GR@$  #<$   9              "
M 6]C  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ TH1S
M3.X'L??W 0  ]00  !D              ( !<&4  'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " #2A'-,D_=0YV$"  "H"   &0
M        @ &>9P  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( -*$<TS*RML7M 8  %\I   9              "  39J  !X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ TH1S3%O E[]3!0  Y1P
M !D              ( !(7$  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " #2A'-,G="9X-,%  #.(   &0              @ &K=@
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( -*$<TP!=KOF
M80(  $P(   9              "  ;5\  !X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ TH1S3$YA\UF) @  M @  !D
M ( !37\  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #2
MA'-,(5_C\* #   /#P  &0              @ $-@@  >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( -*$<TP "ZPUB@(  '\)   9
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M970U-2YX;6Q02P$"% ,4    " #2A'-,,8MAPYX"   ("@  &0
M    @ $VE@  >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M -*$<TS[17N*J0(  /X)   9              "  0N9  !X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ TH1S3"UH.VE^ @  :PD  !D
M             ( !ZYL  'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    " #2A'-,2YDOIU@"  #B!P  &0              @ &@G@  >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( -*$<TQ\QYU*40,
M ,P,   9              "  2^A  !X;"]W;W)K<VAE971S+W-H965T-C N
M>&UL4$L! A0#%     @ TH1S3*G5^D/M @  GPT  !D              ( !
MMZ0  'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " #2A'-,
MZ;VA@,,#  !T%0  &0              @ ';IP  >&PO=V]R:W-H965T<R]S
M:&5E=#8R+GAM;%!+ 0(4 Q0    ( -*$<TQI@L@,Y@(  -4+   9
M      "  =6K  !X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%
M  @ TH1S3.0*%81. @   @<  !D              ( !\JX  'AL+W=O<FMS
M:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #2A'-,I8T;84\"  #1!P
M&0              @ %WL0  >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+
M 0(4 Q0    ( -*$<TPLPMEK)P,  -\,   9              "  ?VS  !X
M;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ TH1S3!EI<YZZ
M @  'PD  !D              ( !6[<  'AL+W=O<FMS:&5E=',O<VAE970V
M-RYX;6Q02P$"% ,4    " #2A'-,%,K5DQ8"  "6!0  &0
M@ %,N@  >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( -*$
M<TQ/\"59QP$  !,$   9              "  9F\  !X;"]W;W)K<VAE971S
M+W-H965T-CDN>&UL4$L! A0#%     @ TH1S3+4U<F#X @  _0H  !D
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M='EL97,N>&UL4$L! A0#%     @ TH1S3.&LT(8E!0  6"X   \
M     ( !3TL! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( -*$<TR<E%[_
M40(  *HJ   :              "  :%0 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( -*$<TQMVM,@" (  ,4I   3
M  "  2I3 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !0 %  XA4  &-5
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>277</ContextCount>
  <ElementCount>235</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>76</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001001 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Incorporation and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations</Role>
      <ShortName>Incorporation and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Basis of Financial Statement Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation</Role>
      <ShortName>Basis of Financial Statement Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Significant Judgments, Estimates and Assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions</Role>
      <ShortName>Significant Judgments, Estimates and Assumptions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Cash Equivalents and Short Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestments</Role>
      <ShortName>Cash Equivalents and Short Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Share Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPayments</Role>
      <ShortName>Share Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Contract Liability and Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable</Role>
      <ShortName>Contract Liability and Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2134100 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2137100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2140100 - Disclosure - Capital Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosures</Role>
      <ShortName>Capital Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2143100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2146100 - Disclosure - Additional Cash Flow Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures</Role>
      <ShortName>Additional Cash Flow Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2149100 - Disclosure - Indemnification of Officers and Directors</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors</Role>
      <ShortName>Indemnification of Officers and Directors</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2152100 - Disclosure - Economic Dependence</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/EconomicDependence</Role>
      <ShortName>Economic Dependence</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2155100 - Disclosure - Other Expenses and Adjustments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments</Role>
      <ShortName>Other Expenses and Adjustments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2156100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2207201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Cash Equivalents and Short Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsTables</Role>
      <ShortName>Cash Equivalents and Short Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/PropertyAndEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ShareCapital</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Share Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ShareBasedPayments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2328301 - Disclosure - Contract Liability and Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables</Role>
      <ShortName>Contract Liability and Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2331301 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/Commitments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2337301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2340301 - Disclosure - Capital Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables</Role>
      <ShortName>Capital Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CapitalDisclosures</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2343301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/FinancialInstruments</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2346301 - Disclosure - Additional Cash Flow Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables</Role>
      <ShortName>Additional Cash Flow Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2355301 - Disclosure - Other Expenses and Adjustments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables</Role>
      <ShortName>Other Expenses and Adjustments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2356301 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Cash Equivalents and Short Term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsNarrativeDetails</Role>
      <ShortName>Cash Equivalents and Short Term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Cash Equivalents and Short Term Investments - Schedule Of Short-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CashEquivalentsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails</Role>
      <ShortName>Cash Equivalents and Short Term Investments - Schedule Of Short-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Share Capital - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2419404 - Disclosure - Share Capital - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails</Role>
      <ShortName>Share Capital - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2419405 - Disclosure - Share Capital - Summary of Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails</Role>
      <ShortName>Share Capital - Summary of Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails</Role>
      <ShortName>Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Share Based Payments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails</Role>
      <ShortName>Share Based Payments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2422404 - Disclosure - Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails</Role>
      <ShortName>Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2422405 - Disclosure - Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails</Role>
      <ShortName>Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2422406 - Disclosure - Share Based Payments - Schedule of Number of Other Equity Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails</Role>
      <ShortName>Share Based Payments - Schedule of Number of Other Equity Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2425401 - Disclosure - Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails</Role>
      <ShortName>Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/LossPerCommonShare</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Contract Liability and Receivable - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails</Role>
      <ShortName>Contract Liability and Receivable - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2428403 - Disclosure - Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails</Role>
      <ShortName>Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2431402 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CommitmentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2434401 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/Contingencies</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2437402 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2437403 - Disclosure - Income Taxes - Summary of Non-capital Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails</Role>
      <ShortName>Income Taxes - Summary of Non-capital Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2437404 - Disclosure - Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails</Role>
      <ShortName>Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2437405 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2440402 - Disclosure - Capital Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails</Role>
      <ShortName>Capital Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2443402 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2443403 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails</Role>
      <ShortName>Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2446402 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails</Role>
      <ShortName>Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2446403 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails</Role>
      <ShortName>Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2452401 - Disclosure - Economic Dependence (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails</Role>
      <ShortName>Economic Dependence (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/EconomicDependence</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2455402 - Disclosure - Other Expenses and Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails</Role>
      <ShortName>Other Expenses and Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="oncyf-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2456402 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>oncyf-20171231.xml</File>
    <File>oncyf-20171231.xsd</File>
    <File>oncyf-20171231_cal.xml</File>
    <File>oncyf-20171231_def.xml</File>
    <File>oncyf-20171231_lab.xml</File>
    <File>oncyf-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2016-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2017-03-09/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>103
<FILENAME>0001129928-18-000028-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001129928-18-000028-xbrl.zip
M4$L#!!0    ( -*$<TPN%XX(&F<! +@8%0 2    ;VYC>68M,C Q-S$R,S$N
M>&UL[+U9FQM'<BCZ?,ZOT-7SI93[,I]'Y\MUS&-)I$G*XWG2!Z&K25QU S2
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M@G3N$_W+L,A=/'OQ-OS%Q+-'23FU9(MV\>Q%;\^7'L^>)!L\'G\;##]"R/(
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MKEBE3J*-X?N?_I44_Z8O+4,3!W?%V(%4?1R-M^&F")((2[D'H0F&4LV,+X$
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MBFU"]>!65K-H3>H/Q]-A>BKI25,SHU/:*5#E?(TXR/5Z;C\:#2:?1Q. ;NU
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M?,0'%(RT_.G2A)%UH]L0X>K W)SUPMIIY(;35!DJ*<=4.N05"[Z*9&.LF;A
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M6O-<*!+41NF!WBSPTA4WSLBL+$,QG<YL5J#?"K1#(;1)N5!),.Q$1FUJ"L;
M8:E&I8>0-]?$$'\0M7S_Z=0H-0N8H^ I2,48%L%$1<$=>TI?DWSF[*O4Z$T?
M Y]_CL9_@GIZO'2PJZP%"+.1L@:G&;IIH%6()1Y&"I$?"&/$F5A5_8T@/1>!
M9ME*S8L"3@UU-<<12Q)1E:1EWM:T_B&4*L%/B4&S*(&T&-CDRKMT+"^9]+QJ
MF.-C?M$Z-:-3_( (?/@T'CU\_%16'94]V==[X@MAXQY7"[>]<C6_^_8 ?B?
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M#<_3P',!:.\ #U*#<N\Q2U"M E5#UT^YLB*C<M[6>C34]*_+*3EPRT<WB.-
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M7<\AP":YB(CDH<"ID9:CQ([L2;EG@O8O;4^ C[W\!^:^D-"/F9<$L11![)"
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MTTL\ISLCBSM.RT6Y"D,#NF:8HFP&!BSFCA?4;Z7Y -;!^,<<$)E(5>Q*0-K
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MTB&/'9'2T(M!+*=IX/B.36?AB4<[?8[?$B*9.,HV]&/J!6_+AB8EL>>&/G%
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M7)F2 ^ ,/?NS;HV(PL%(Y?DHT*HE 'KAZ]FU?A/H]^/"0*$?.@3(1OG= A8
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M'A:,'C;TM=S:GCT#,Z$8ZYC+^VQ2!6_G&5SQ5H/8O?H1.5PKS(@XQZ>1WZJ
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M5-UP@&Z;'=C1F+SOZY&O+=:6H7QSD)[\=>__IJE?L<A7W0O^NV@%:^MS3_7
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ME&HS^"='_?/393;Z'76FZ1AILYR]^Z?1*,^OKGYJG4*DEN81:WXVCVY^I<_
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M)$H()2^<AKHFMTPZ#:W4?KR\F=CRT\Y&,V$%1PQMX;96K[MA<==5=AI)2]Z
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MDB4>=^T^@81 LH-JIN-PTR64$$IV%P73^SHH)K3E5&L_UKY%DE(S<LE5C=7
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M@#/@6UR>Q7*Q.S_Z<[$I/@;9F'T;C,4P!P!_E+^F".1K4!6'_A+B/L2)? "
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MY>Z!/">!R20PT00MEOEI9DTM[ZUC$0YI:2MU@>0).JZ>:BV^5R9Y!LD]LY-
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M=T@"WSG!I^O<W5"YYCBA6%,%M=:FP$:/WKJ*N^'D(\U'8.$%\L1P39_C<__
M?KI?H?.5<8\;5<E-"AY'=4V>-:S.>SW^H*:$KS\TWONA'PU6+9^EI6E/!(<T
M#WR,X)4.JW<J%N2%.I-+HZPD8&@S'WX0#6$$^7GY,85EN>KWQVOF \MP?C8
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M.!81FY109(.2T$'*LI@A6V3P'_/A&4D,OP,W9&("4@&K8HR"R(\& 5P^C=,
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M_J7^RYMBI4$RAL%HMHL-,1HHN,MG:E$^Q=5>H]8QK_:3;FM8,G!CV<!C!I0
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MVG:4-*3O1Y4D_'V?0T54 TJ5H.N6_^;=R[:Y;7ID^'<# _(^Q^6Z.E%+2]Z
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M[F9SG.4*E%>J/'B4A?V;&,J64OOM_D1R!22_CB?3'!M5$,W/1O/2-_<A3Z(
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M(S"B#--Z5'"FMA%$1B(CD9'(2&0D,C9""VJ-LK-9I?XD,G87QW^R!S_,116
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M;^XHOMW(K@]^*-\%YNT'2?%1V?1!_%CV9OOPF.$ ;%<1PTT?80!DKSN-D:V
MSG=SR&"N$4 _9HF?^2A<@I3E<] 5N\J+VPAN/,M46,4>$.ED-;_Y&G>MWN!S
MQ#X/LAA=\H;&%QI8@N*X$"0+=0N5,?ACN!,$I=A-IV(0C()!<0?^D&+[I3 ?
MXJAA&#_.=IWK>#)%X3O3OU:%@)\M7_1?::&?E#4& L#G%(87Q18B]\DP3G'D
ME<WSNH#^-]28.$X#7B^=[WJY/)& 2V=/1HF,*L_8!U%_)V!+@8<.EV8T -4:
M1/5LIQ /(BQ5KK$?W9>[W".,L#K^]8(;OI5[,?">-, 6[ @:^R /?;F!@4X,
M6V<: !?Z\H7+]UFB:;G]+NT"RS0M>5N) -$MAYO]]1.;HX112>J2*+.U*4G<
MVRTF:L5 S1<!A>%E\VW27H(-0+2/WJ$$'#9W78\[KE7%OC<"A2V2*G(\$&(H
MW]*?PJ<?P:30B56I%V;/5FK<]-A5RJ9^,A=UZ4*&B*'R55"]!*7@*R9=6#IK
M7R])W*J5/QML<D/1ZZ'D7\P<3"ITQ ZE-K10A=+G(96P4<+N^PDL";D_V+QD
M0UC'1P&7#@4J_S#.*(DG<L%+FV#FPBC2Q@LS"AZ%=D@>9O/[\TCN++-M=94-
M\A?-B5YS)!@Y/EOK^+QKO^-S606W^#8G:,1>^=E;8-BWD[):Q.M75]]_>_5F
M=]6(P@-Z[4?^ *42^X>(Y-4?HT%/^B30-5$JU?Z]5-]_WZP&;!Y_(:Y*8<-+
M<05,(G53^)>OZ/6E4VK9B8G"LW (P< P,KIZYOF%"]&OV/FHV/68C9,XO]]*
MZV$ ^T(6/A5M:-'+%2=H$4G:_OYM?OLFWP_[8Y7&L#7@T@!.^5:O[3,_V[J1
M(XT-:=?,]@(P^ %1L-\.@A#F#<^]R>4*S/<EI>:$QSU'XY;=<#5/MY7K>9=6
M"Q!0XD>!/H0$^6U(86B*PC#HA,+P0=PEN9\\,:.0#\Y&C0&EN0KM8+[!2 VA
MN.E\>_5/5L]1?$HX#@;CP@D)(B^=R\)EO63F"BQV912SY;X8B+E*]#U.8B1U
MX;NZ_5%X__!(*(:?$_:J4-6FH3\0LSA\0_^%O0::#L5(GO6 !O#)+TW$CQ$L
M4BX7QM#?ZII>RG(Y /L\+;V ;_ F7+2ASU[CG%_)#T&QXJ_>K)W-S?4XO'CY
M6HD:__R*Q4*O<.44Y-5J#F6W%M0Z"BFOD;?86U5SV]9A]9C1WFS0>.Z3.$U7
M=)Z?U)Q#;2T_=1)5U4QN>T/2H\C:0VT[B 9Y@J)TS6NCD*B6S1U[O2O"Y8'Z
MT[9>8L<1E'1'TAT;H3L..Z$[_G]Y)%B9?L57*CN!4B"W[$>X.Q/1\TI/7)'A
MOSTR_RC1ET<!B&5IVTH] A07?T,0E1K)J/5<1=/&2".<^I:-6\UT=="%='7Z
M4(_=8I26G/;\,%_)R"!&U;N!4-$>@-4#DU1[?@0PL-8SFX[3XE")KC$)YXST
MZ"<)RHD*:;HA8?%(%0Y/%Y_-\U$:7:5Y [;)//XC$6$1U+=TT#@1V3@>;AQG
M0SSF&I'2[4][#[;<G^S;8 QV53KOE0%"2H9OQD,1EDRV>Q7 1@RR4%JH@L%8
MTM"*%]?5&%&ESWM0NBL7(3HR8B6'%PN7]BC#D*8H;$WBAT@&014BO:]&"5\<
M:N\"1A"&TD!>F.C^ !3!681/4)#C(0[S"7IL43/ LV30,_Q[L1;65 9%K9J"
MXM^Y'\K05/&CV%#44,KHV8HV/]SSU"@3BNPG#+,2@US*@2SQ94CTT,\P4N%%
M<U#15LUUT(HL38T,?"&$J@*KZ^(VUF7F6WS$R]^A. L&Q3=KV8!_E *@AJ_0
M-)++^U#4CN)Y'*FTK]-\,O$3N*[8%GU@T\FT",O/T\+7NKX%?RZVX"_E%OP;
M;L&%BQM$Z73)BXK;_SP*<R[/BR/1=RK(-)#^^ZU46AIES>Z5HP0R$%9^7GY,
M%"<3/UQ)M-57;&5ESHEG,X>UN ^B8I)^GL6S+XIJ)O*;PD-A]JU%FB_8RZ$_
M3<6[V1^_/$]'W>SSF-O9QHK]?;C+HO2:./KA;I.5$733/'"$)G:G/L39@?E7
M(^#8=^-@"%!5*[_D^8KN:+LE5EV;4"HK!?F"$#EF=ULO[W% X9Z&U$RO>+?Z
M&J1_OATE E5)/*--,TRS6;>NSEB@ME&(0[?;SY5"KI[<K+S\PNV/J4R.E#X#
M]$$&L4QLF1O7RJ1G+>EY%NG8T]@3:-%[U\QMGHA4#LO_C=$'A\$!,R5]BZ.C
M\'"0W-P3BUZ_9U8M.!NI)E6QR=\$#\$0TR.? A$.20VM&MR?@O!D)U<3J@8U
MQ<VC?%?X0Z#?AHT##)9'SD"7K"_5%: ,QG'+W4',=)KA"@/*D[7Y;P^+':8,
MA"M2#V"[F9W3S(YH5A/.BE3>PMM3>/B3S<H\"Y9J<N!=_T![-YJ4R<EEP-Z=
MB 9CC MD=_%\IGB[3 8 OD6/4YGT+),HX-9[>>3CEXG7\U<*@]':#%DBIC"C
M(C48+RX)!5>+Z+ZHC5+D9BS?A$[M^;! WD1@-0J@4I9F\%A,0J@E0!J%YA<\
ME@C))8(O+4ZV7C:7_(VG^!MM4U?H;]1U)0Y'YT1WH^N>., 186*K_DY-N_@,
M]M)8*IQ!_^(D,$\=X=#[MX%[?I?YJCD*[H%*;?^X/:&_5:6]G;EA\#CJ$/?@
M\ND'47M/:G]>;+><O1>P5T@=L%2I_@E*!:U M2OP#U1Q0.<L$T*([!< _BW8
M%03YL]'^CUE(UU49TO55&EL(_VNX(?$'60Z6[J]HW+V6?N2]H](K\=_5I6+W
M,WOLA'4IXJW.Y9^K28'S4^FU,4JR*I=F%PJ9MX4OF]&RBA!'B#LJ)8D 1X C
MP!'@&@XXJV=5U VNHU#;ZT1YT]]__4LP2M*WHSP,W]T$*=8KSA/Q>23K,)8U
MG+Z*5"0/(KV*AI^QDLBM+.+RL3QMO/TQ#?W(S^+DZ>__^1]_W3&</([\XC_A
M&>05'B?=R[(OZ=((LC8_T/FK&/WMU8<;/%SZ'^N?WV]>L6 (7X U^E9SW/Z-
MK1GZ[8>K*^O&,XR^<>UIYJUC7=_:VH=7?W^V;@><V6Q:]K4SJY6CI-GIT]8S
M<N=(:#A;3?:B1.9[>;9;4O/X/(Z5ES%??!OCR+<QMK^-//>>I3T #L[U*BKB
M 629U;(,77& 'Y<9'C*13O946*TMN%Q8;_D.ABP@4SED-:!LY706UWOY,-;/
M]L_R>@'QI8.K%(>28D.L&"M32]ZA("JCB<HSWT5@NZFF_ J='9]R=NS86OW.
MCG7;._7TV+[PP:5WZ@#NN0\^U][@U,-G[]*'Q^ZI,0BJSHX;<YC0M(2G_0_E
M51+QE/.7"Z<O$<WF-%NOK[8'S:PZG0S6CZ9['ZG4YFAO72 J,_?K*RU//=\^
M-Z$OC^UE(U-9ND[=R%RO=(BUP(+U8+)-#J]##L*)(8@AB"&((2[)$$3RVC)$
M'1/O*SN,6IF>\\RO^1:_4*F_KD1LWCT/57XZ+&[S?.M1^\/1S8PB6]]QPSC$
M37 <43MQ5MI"$7 .<:WWO/42['4@<>VYNF1BV]&YV5_O+T5,3$RLGHD+GU[O
M(-\R\>SJ?3:W9)=IXMGF\6PS$&;V]#Z!2P6XJ&S5/'UQN$A?5&F*G7S&52NC
MRM*4!CS7!0-5R^C6EW':V$NC8QQ3V'O<=@UBD4ZS2,D1!G&$5-:XX6G$$1U;
M==@0E/F]VK+@=3Q:J0MM/\3)2 05ZN'5!:'52D%_#<J';G#'49>4^!+A%F"J
MCG(J\;:9<*>WC:PUPY[#"#![EKKR$FUCUX([7=/=V,B1>'/I/F+%P[4MASAO
M-^?IFE(CA#BO@R#2>T[UYPYUP<)%K)UV&36W/Z9!0D<+>UHNNN[POCH)W51!
M7+%YTB+59S.EC$TMJ#O&8:6Q8>C<<92%LC25H8A_=L=2..LE*3K)+H[2HVWB
MEL8C0N]9RM3]NJSL1;3Z!E5[J-8<*#)UJCOCN%@B?KTL"4_3SUJ6L6V^(#HA
MJ2Y,ZI!3\2[4YE=5%D)MJ>D.(+0RVG5M$ZH=(6NP@YPE0(J0=FE"M@5I"JP:
M\^*U"5Z@OTIZKV2RBWGOH9WDKF@J2T6AYG]59U.I6>7:9UEMUEX=KEN>2H_R
M2[3M1 I6AQS.FV&E]TQUI^I=Y%9YG_IR%\2<G6+.DA<5EJOH,"^JKEI!O$AX
M.U/!"H):1?;@^8JKK#^[0472RE8@HC@LPU81RR9FA>=E%:]8%>MS!J//YI9M
M<EM3%B1R--$K WB=) ^=3&PW$^W+8["5C%\Z=URCSQUU6;O$Y\3G>^FN9W19
M=)&M+5=M,39B:T*H6@'@TIY3GW:G9YO8$M%V-Z6<FYP%6:MH2OE]I7%DT9\P
MS2<3/X'K4A9$(^QI*#M.^G=QGDE+=+5UY4JG23!7E^S7NG2>Y&QCUZQC"$;]
M)T_J/^F94W7])STU[2=/;GW8/W?GP;57T$YMOGCZ" TD0G=#^OO'[1O]K3Z*
MK]B=&SV5JTTY+M(:I<8QO\KI_BG'O8XMA255HU$V!>?54WRM#<U7,?$#V<_D
M&FY(_$&6^R'[-1@)]AI]]JFZ](%V+$D%+M(F-<OJH'BZ79@$Q M-YX4+EC<Y
MPQ'\"2P@;_M)ZQD.>\O@7^NBU1C.$<!Q*K%,;IEN!0F+[8[1:"ZOJ=QPBGBS
MGG5(8V\BVRP;TU16-:^MLLG@?4/GGJGZ_(AD$S&9(D]4+55<]?J4K1?ZE'>^
M&I87R(\\E5"VZ9VES&=7)%4]N:L"#4I=T;B.D$SK.=5W^&NP)#)MDD0DB8Y@
M*W=OS#2^Q.[):I'>LVQ4BXR>^LI]#90Y6/;*4)FAW17ATBX98O><BSI=ZTL9
MO><JKX=+<H+D1/NY@7PS6Y40HZ>;J(28/:_Z]A -ECJV99^E^5%7A%$]N4NY
ME#)[;CT=#74FF;I3=Y)$)(F(K0YFJX;X9A2J059/DT=43L]M0P.64^GA&$IE
M3%=$2=LDAKK,VW91QNZIBRDA*4%2HBN\T/#25*<%*L7P>J,P?GPW#H9#L9:
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MQ8^*Q-#B[]R:1G FW!G-DT*YDU,D7AXO\>L8"O:G"(N&\=#QNG]^\%5IVDU
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M/\-MW\\R:H_ET_08<O@L<;W,2)C'@D?RPRI"D%(BMN&DU2MU[P?FR!F9EL)
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MH=40MHG^;DW8>]<8<<:\+0H]8_+6HQNJ]#_O0\[3:!%HF1,,,8^49?:<14_
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MCF0^*$_:.O#Z R_OG_7C[;-^_&"WZW>S?H$YM"I)\2V%H3KK5C:,/1W"UK^
M(O+6WWP7HF_-66UT[?1K-9-UR\N .K$]-',:K_%/-\S;^AY;EKU+"<+))&UW
MP]NG^>%9\L//0/L@<D/C.DZW-PS5#*4EN-<,13.4]C*4*\]+<N8;GW!93/.4
MTX"^YBF:I[27IUR[2;*$/>C JVC#[62.KN:)FB>VEY'<N4'2@=?0_/!DCJWF
MA\U'3-IV/&^G4^9EP6-;C^@N[R(M4N,7-VOK^VQ9_E]>>S+V&IS8F3CA&B+H
M1K*5H;&Q@^&N; :CLITA6D.IPUI&:?!H\&CP:/"TACX:/!H\&CP:/!H\;T&<
M_6;:OS":H)V>C"9Z+% MP048X7,C**L)FG'%G0J=C]$4M(FN*:=#[!/AKZ='
M6(UBC>+3)ZQ&L4;QZ1-6HUBC^/0)JU&L47SZA'T[%.L8\^LA^CRD?'B[%>TA
MT^Y5#1X-'@V>5A%'@T>#1X-'@T>#IVWTT>#1(64=4FZYTX&NZYN]\1BG^9PA
M94^$F9X>835D-61/C+ -SZ/6\0@-VE,#K>:S&K(:LB=#60W9DX2L=3FP]HGN
M'MHS_N7V[^M-X^/IM9O.[@!D7_+%(F1XD1O>!*D7QFF>L-3:N8&\,[Z^M8?V
MK3.\&DTFMGUW=7LC&LA?3?IW5V_60%Y)!/]S!E\VD&@&4LVHD&KKEF];\.OA
M6+G+RJEI;0_\N9L\!!%?I)MGL?R GUOZA/?U'EJC13%3X^ ^^2,E;?+MP:L8
MRY9NY</Q@3<8'+H Z]P6T,@(U7;*KM8-0*D>P?Z[TR'Y,56$>K$B^V3447^7
M!DB:_/N2W]'D?TOR#P\F_UZ,OUO\F]320/9>2IC'@D?FJS+P]J%5&^:@U6/.
MLGNFU5,V#KLM$% @PCL) K[GCFU.U(T2U7M^"GL^&9GCH;(AY5W9<VTF'2AF
M,_<;2XV%&RB3KT>E;AO.YR;![)C J-^<JFU!6]/<_>Q@1]<-S($S?G,2:HQU
M&6.V.>@K,S#.'F/*(F6[QKQJHV;Q? %O$&5I//T4>?&<?76_W7Y;L"AE'UG$
MID&V>^3LX\=;Z_IFW+_MC\=.K^>,!U9/1L[N[GJCQB-G#2< ?YTQ8Y'$CT$:
MQ)$QC1,C(-()72IA'F+<AT^-#+X*!".(NQE\-@TB-_("-X2'P@<4W#3\8#IE
M26I,DWA.E[AS. "9\30+O)GQ%.>A;]PS([[/7'A5^'EIN+#C.-^$OHZWRK,X
M65868B1P>R.+Z0L B!3N $MEJVMUX:%Q"!!*/VS%[QM2>Z_SIL.4+X0IQW;[
MPI26<V",;73H#2S[T!4<&BBU#HTS'G\%V@0_@+GMD[ZDHS,'Q28UE8\1@M14
M/D:D40<47\5F?]J@_ZHR:O>AE@ T*8=K:&Z#[5^/O/?6T!R,AJ8]5.;:7,?-
M&Y&O^:$RWVG$O716$6 8U'9ZK^9P9PDPC:?7XLDV1];$' ^4!<PUGK31=P"1
MOQ3NNFLW<OW C6 QR2+F'COANGMS?_NIABPV*,RCRZ9JK_:@Z4Z,HP6PK:?I
MJXN#-$;KKM.0/)B$&H&'(=#1"#P6 K47YH>K"%XQ6% <E-0<YF%I\/(M;9@V
MG,4-CI:!:8W&ICUX6S.X!>!IH2NE#;"1*.F-AV9?7:+AJ:)$@Z($A6T.G9%I
MJ4L7/P]0[.?4. ^GQ5V<  >.C'_G29#Z@9=A[E.19\0SF%CDJ?-;=$WCWN"7
M,,>3B6E-U*GA7<^?/#O@")Q8XX$YFAP^,D+CI-LX<8; 3]09#9W'B3;,?[B=
M+\)XR3"1&#.\[]V486;.'-/ 713TYZY5U\MN:^B8_:$RR=T6-#3->$\5!'S/
M>Q/3&>AR^[/:<\LRG;$^Y]I:?GUI]<R-'AA5 *F.YW=-;:V7K4WTI>ZZ)GMV
MT-%(T4C9*1/0M&W'G*A3W[H9TV[67]XM07_E8\TKEO%BK6T,%G. 1;D@]!<Q
M+.K<]><-AK/3-^'_6J$^#Q"(F.3$'#HZ(+D3@^TV(E <3\R!LTM5I@:%MKNW
M$)&WM5^P9.YB5Y-*7%K=@+ZNZ<;U,GIHFSU;&;O6%E774".\X3USV->Q1HV2
MK3%IVW3Z.L&E6?G^0O;]VXOYE158>+=J"Z4+^J09%[S/0 =(1-+Y/>]JEL*G
M; Z?17&&S;SNJ2,3F/";=L_ #EPB8UU=+_(FMJT-YWZ#W6_VAI8Y4B@P7B!?
M5UC"N<)(H&:$OH.A,C-1H^8,4&.;@^$0] YE7L9S08UV+VS1*7+0(^"R)GH(
M=4[WWZ ## 9F3V$[X:Y; V<'&[IN8CIC=?)>8Z2+&'',H<+J]:YC1,?JJ['Z
M( );/ETPC\+VBR2(*6H0Q+X.V=>*[?=]<]@_^QKC>MKH<"XAQ+;.'A\:#M4:
M='N@(_L[ 4*!Y[]_[*9Z)]'6\.\L,SQANV,0@/$))\VXAAK>@M9WW=QD]UOF
M8-+0J*H=2'X2>#VNY_?< 2L\#O9H\.;TU>C4Z*R/9ECJ^JUK=+Y2"3MX/MO.
MT]5P1EL81+]_F,9Q%L49^PE^,;[11TF,9)AEV>+#]]\_/3U=?KM/PLLX>?B^
MW^O9W^.?O\<OOA/?SY8+^#[<F44^\]_AK;]?N_>/?_KK]WB?X /^^\?_#U!+
M P04    " #2A'-,BJ-S?OL6   M#P$ $@   &]N8WEF+3(P,3<Q,C,Q+GAS
M9.T]VW+;N)+O\Q5</\U6K6++EV222N:4?)O1*4?26L[DS-,41((2-A2A Y"V
MM5^_ '@#21"\2![#2[TD,M%H=*.![D:C 7S^Q_/:LQXAH0C[7XZ&[TZ.+.C;
MV$'^\LO1M_E@-+\:CX_^\>M/G_]C,/C7Y?V==8WM< W]P+HB$ 30L9Y0L+*^
M.Y#^L%R"U]9W3'Z@1S 81)4L\>.9.I^HO8)K8($@(&@1!O 6D_4U=$'H!5^.
M0O_?(?"0BZ##2/ @;R('(!4'@"QA, %K2#? AE^.5D&P^71\_/3T] XSZKUM
M@&RZ0#B ]NJ=C=?'IR?##\/3L^&1Q?CUZ2</^3]RU9X7Q'N'R9)!GIP=\^(%
MH# !]['OAVMU!2<@Q\%V X\9T(!!08+LM%Y]I7P%1OW6[< /1^P$:469FXOC
MJ% &11K>D4\#X-LI[\^EOGHZ$]##CQ\_'HO2%)0Z*D"&=GC\KZ]W<R'_HU]_
MLBPQ'M!Z@TE@^24YNH N1,V0#I8 ; 2[@Y/A@#,<C:([;(- C%F9967%8^@%
M-/DRR%"]8S0<6<?UY.CZJ(*:<A7^UR"I-^"?!L/3W:C(1FD[*I)Z^Z#BXS$@
M-L$>9$*S@P%\WGC !P$FVUOV=S/*/$)R6&XR))S$CYS$X?L=2!28?;CDZJHY
M27*MO=+1HEN2&CNWK]923<B0:TZBBGNDIALEW<D0R)!+J, 8@&?LX_4V5C!G
M R8D7CAP0\_3JQHM#E[]+PZ1_1K8F/R5@;0CN*3*&T[XI +OJ8MV35)HOUOB
MQV,;AWY MHU5L*I>\D<7Y9M'&A+"W!.!]7TK:N2*Z5^##$TW>AR(.,;S-J0D
M=?B/05:Y&P'PV5ZU%DU:2?S:62C(?X0TX C/VE A58M_#S(4W2CQ 7.36G='
M5BOZN7.'4&1S=,,V1"1U^(]!5KDC <&&M*<@J21^:6@ OH\#@8A_2CYN-LAW
M<?2%?>,^QJ?$T;B'KB4<Q4^QF=>[D\<;@C>0! A2V1,7"%8$,O]8N,F#Q G^
MRP;>.^:!)C"E%O(^D+"IK(H=>H*+NXS*! .W,E^.*.MM#\:L__U<.=!MRQ6K
M@GQD,E,>6+1EBE6!GJG\; ALRP^K0MGBMM/8XP@>&("%V$IKY#A"UL"[ G1U
MZ^&G:T1M#].0M7!D<=AO]^,&JTE!EAY;0D9"2#;2?CT=GK\?GIQ8 RNKP/[(
M\%D<H<4Q2A#T\W$14:&)D$)GZO\J?A?[+*X<@V@J%N9YXWKYF:2L%G],1-)5
M4!,87*V OX1C?X)]#B "*/[R"FQ0 +QK& #D[5F>31O5B?W\_/WYR6E;L3,0
MUK@5M6Z-?8NU/Q"0,0563(+U<TS$?QY&2M1UTV %B>+[BXR0NL9J1\99AY$A
M&JTH/0R'@B0>P,+;MYZ/<>J$>W;^_NQDV%JX/T>H^R2]2T 1G;JWR >^C8 W
M9XR(N/9,8JNU_)IAU=KKDW.%O19X+>Q:*68K16W)N'LDP<0:[N!6*5#H?:D3
MA6P2D]A/]ZG<A5TM7C4FO3D[43@Z"IGTTD:5^[2C8:I$I+=&)PIKI)1-_PP0
MM\0W_P[1(_ 8$W3D._,5)L$#).NQB+AQW=Y%4(W0:M7<\$RIYICG(&&V@.]8
M K?%D5L2]H,4"]T] 80P0A]A=]W8J1FMXAR>*15G8RGSQ6+28$^5:Q.A\(UU
M)_3@U%65ONR :-9V[2@IK1;;C9*$"FOJ1D"#H AT&#Y5(NQLKUL@U]KPX9G2
MAC<? 'VT[7B]1ET-N%17:Z7/ABHKG=7N9W]W5JAE%%J]>#946<\,23]56L9_
M5[U5PJ!53DP[*923+(4^*A^?8@\Y/#4J#1+1J9M$%+L(I0ZC1DA,29V?"$65
M1:R8C*:3^?1N?#UZN+FVY@_LOZ\WDX>Y-;VUKD;SWZW;N^GW^4%H;K050\<^
M-[;!=G^B*^#5"_"LG0!_'TU^NYE;XXEU\]_?Q@]_'N28181GF*).H>7FF/6R
M'+:2Y>UX,II<C4=WUFPZ'S^,IY.#,,M=/@.$E:P@$QSP7DZR^69JQ3S<1<S6
MS[G6#@9TZMYARA=2S+U@_*V@3]$CY-_V)O#*!O2B/FTUH^^F\[DUFEPSF*^S
M^YO?;R;S\1\WXG._9!P@9@'9_.KDI<JU]:LTU79>KGY?>[W[2DV!1+]6.S]7
MK1(D-#U=K?D! 79PA\ "><P+9+KG'MH0/?(U4R>Y:-!I9\GI+Q6SA".T4HPB
MS)3A/,@J[HC=]Q?:H=?.MM-?E)&1&ED>=A.T(L@B^0G</7R$?@BYPY!4V5&I
M[J_UVO%1WE%H,#[2?03L9O )(0)<(N4PADI2[!R2:X!4&Z4[_449I:N3> ]C
M=\GY;=;%-\P]";9CW\5D+:A*REH+L!%2C0!/TJ!!>KQ<^LF%%J&U)+QI>8^$
M=V/SLX;(OH8;Z#M0'$%N*2H%"JW?='&J\)L2)%:&I==2Z&H3JS%I[=O%J6*U
MH9!)+RU4&M,:^S0@8;<M4B42[3PY5V4T9;FT$IZ>RV+GE40CI-KY<Z[*2U+*
MJO=K!E5G9[[Z)?#X?19T[-]B M'2OXJ.5N^P3-BYP5K)EU8&59*75P-)PQ;R
MK;AI*VO[,#3B7NNX -"@TKK]YZK,(;4X>^CJCUF'K]GRZ;F#1.2Z^NCS!X7=
MBVI;HGH_.WQ&\"/BMVHQ92%][JH5FV/6AZD_* R?+"SV9XK?8DNM?&$?M9S4
MQ9D9^N83:..EC_X7.M?0A<P.. QD1"GLGA_6O:5:F5_4R%RV='*+5M(DA[2B
M1GL_"L+U&I#MU!4GI\5!$[Z#NI>Y78N[5M(EYZ8HZ:@%+FA^\MJ.3\I$K1Q$
MFW7_/71#W^$^PRUT(.&N29)PS&"OV)Q ^YGJ7=NL'0KG[88"21NWXM:E'&LQ
M_V,"^CY*.OJX90Q:U_;L@\*US5OC?GJT9(.)(&/D.Q,0L(Z9NM,-C+YU$TL-
M2JW_>Z+*D<\A%?'K""V?:QGB7@G.@6L?N2BZ@HIUK\M^0\)W]ZX1<S@"3+K(
MK@E6?=CNHU)\.;Q":C%F(<P4=X\DR#V$&20\\QW[\Q4@[;<>%"CT*1L7"MEP
M)-:,7Q,BT%@"3Z_ET-4)J<:DWUR_4&P^**722T=!W&%S\[R!/A6Y"R/G?\*N
M)ZUUN/2;=JJ9$]VNDZ 3BDQ">!#1+F>[&J#4[^A=* (S>H$=9E>^GSNZY?48
MM6[ZQ87"3:\37/\<]UETKR)/[.''@3:=LDR42+1Z<*BZF3!!$^65)(AZ+HRN
MBD^'2ZOQAJK; ]6BZ:6F4W5L1Q6G0:75;4/536]5(NJ?3KN''C]>,P.L-QX(
M\"FPNX4@*A'I?3R5;HM160*7)2,["*:S<U>'3^_9J?1<M9AZJ>NJ.KBCOJM!
MI_?G5#I/)Z[^Z3VQMK\$E/?PMMO"5H%"'PE2):%&,0:!Q4K0]%H,6>]\AVBY
M8B-V] @)6,(1I>%Z(P8L\P%N 2)_ "\40>Z=%.,+D* //9TJMK)5PR /DY!B
MQ;18$C'"C>'D6(*>*$#?7TU<ENC.Z9H-4-8*O;2K72'T?N=JEGLZRR.9A.L%
M)&RZB7"'N)%#RH[;GVS;ME@K^O<-12^GL$1-B[D<16)$Z_ETP,/XR-_>%V#[
MQS15T 7M??,,B8THG!%D=T]TV7?[M6.GY'<W&#N"D-0&<.M0,A\)-59$SF$L
M:60Y#0/^YB%_4)2''Z*>XR[SY?:>WP\T=7.R?>FAU9&<VI%6RK5I/=(DRJ+0
M2D:;M=A:@CI>*S_X#F-OE]A_)2+M$O'T5+%$5,J[KXO#.'6QFSR2ROK OBIM
M(Y)!7+^G?2[?QYM]W4FM-L*LC_5_K+3%R57M!=68*^NMCM/V_"W&@<_DM9L[
MUJZ)6BE7+-2:2#EM["#O)"58BE-\8WC'_J4'[!^L"UE-&CD.W M@+L-7[$ F
M+O*=+X!W7=#MGXS:<5/A/TGC)DM6EJ,WG!Y^)(\M\RQ!E163%?M55DR8)2@3
M)UH2V@[#+)&OY'J^R/C1X*\=&!7A/N7 D%WH@Y3C+MK%-<ZCT.\5?ZQTBE,S
MWD-O&"VC-&(_^&?H+,6JX(8&: V"*-DH4V7M)=0"M]Z75CTY)6&W4O3_9:4-
M1$E-61-]$FJBUZ0^&MGBC7.F>6;80YUN?&R(5BO*$]5A7$E#RE+-<%L)\H,0
M"[V]^^9'MV:T9O%$=;:KN9 /VR2-9/+"\[C1?#X]^7"JL*K-1?US\NL@WZ(
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M>N]R:<?<L\*[9&@YZNKQVXV0LPFEX;ORL2CJ'&IMMF9L17*GG5OXM99VWM\
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M"8Z\8Q)AQAFH=1+?(YUSKG2'5/H#YP_<S1K1059[L2I<^'NA?"KJ4V=GILY
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M^T]I'F#<GI);Q^8SZT7]N=7\0I]3_[#.IG]>[67JA<"YKVD^G:_2ZSSHYZT
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MUU)0'Y9AV;X//RK%^Q>M$P6H V&:4CJA-+<(8UO,E(7?U!8 ='D"T R;(:7
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MEWC%# N'LB>&(^'"S7!_%:2,U+_:5A>5$5U?6@5M1/O,;F(/U3>9;WLF &)
M@!+6(H QT5X%!6J'@'8>C/Y&TQ:'S^T[K>#V(TK06"\[(Q6<\0C,_TP7LW7
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M0 BLJ790$+_'3PI7/U"R)Z=?GT;,'H'NT5]T^M'=KKPTE9[/+>6T.>Y++3X
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MD-TK>5J)^C>?UH-JN^%<=0R:^!;CN;">?]F&ITT6#ZOYRF?Y3H__;?NX3%0
MWZ>35;8,6M[#=;9:S8.V]U@W]LW6M?+/23Z/&J"ZC[5_CKLCV_]6HJG@0;=$
M/KZ%)</Q9)W8 >64Q;T>LG6R]WNV!H^%$6.1V#?WGR?3]=7R.D\_3KX6;TKV
M(\&'OYT$X"1%**8Q <THMH&K!9#4CO,YZ.]+HEMAS+">XZ=P:#U9A-_& M\!
MD'1^NWQV4'40"%M<(-Z>CWU]U30Q7FL,F-08*\S#AN(00I1#114P07]I-]RU
M^/Z9*-=OFB7.(RN@% 9)JS65A-H=B=(3]/(M^<&"6QM@>]@X4V?VO8>QUC#:
M <68!AX[B30*2SE<<EPQ(Q\F-S:'73.VG#"\50/B4FPPQF.M?)@;5=AZ8H4Q
MN)!ZR""X',-;:?Z4,<;4@^5[8?KH#6^]\GJ<AC= K-<^'%3>,&*PXTKP@FI!
MV(B"&-L!_Y#AK1H&8S&\(2,P9)9AAVE0E$VX^ZF":@<:U"SNU_!6FW/5,1B+
MX0T# 8C"QDOE*- 2:^P*J@$5]3W._1K>:G.N.@:#1AA,5G?QX9WP1WRZZ<MD
M<23=_5R7A!+$($1"8&&=\>&#'NSG;!KPO:N \>:WFY8Q&3[29/V46;R*1I8B
M^7CUQWQ]9S:K=7:?YF>DH\) B>(F;'!2*R>D49S!\(,"'^YLJ9CF7BN<M"HS
MW2$U:-!:/IE%P]W5^B[-KR</VYE]S+8_+M)DSL3#EADA458@[["6D".IN%,>
MDOWI2.7XJJ:T*3M=0-3 FKXS#_[/=#%[:2%\>)<>]^6<Z9< +X*DB_@_*H@4
MV)D]0/&UX]H\[JJ82EL6LW:!&=:*W%^-BL?'SC].OO;^N>L\^S*/-_3 JV<_
M[K%.R+.O/IGM?U_FZ32[7<[_;SJSZ4T:!&@6FJC5*EV/_N7!C^G]YRR?Y ]V
M?A-(CT4W?E]N5ML9Q+<AMT59]C\Q86KS.FE9S3Z3$(X\ILH3+6E8WA1YO8N.
MB*^P@U*FWPO"MUI:5OU/) @9207&ED.C@64J*#D[7(U1MD_S6X6TK+Z$Z61:
M5F^H7UY:5AUDSN=OU1TU08Y&ZTZ,01>6,RJA( 7<4/D^[9,-@KW[D+?7&G!/
MH ]ZE:HSQS*)0O7'3:A#5@,NE??6>LR@=GN.:>/'GV/6O=RT(ZN-\/Z7U%9#
M<53.O.]76%LS.#Q^/]R$K\*I-8DO%T72S"3/'\(-[*])/CLN415'2)CW4!+L
M")2"A,-*(U= :7GX^W@,VSTS,>L#ST9",EU,PFJ;?9C&(K3SF_GT?;I*PXAW
MV\#"0&A<B^O)PJ9?TD7V.?XC_G@9T B:S7D1:F7\Q!E)",4">T*I =)#90M
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M0> 1\B <YX53T0HB&Y0XN3SC3D-P!D\X9-PA!VC8.@ACQF,"%=K'+1#=X)F
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MW#ONL50&2R.<PK# !;)>LQ N2%/L"-XAQ>[D7$KL/B7Z)X H;8"C6!#OK =
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M]=!@[XG60F/&"M*M:E!1NL,G H=F?%WT1N'6/0Q1.4?MX;Y)C,X Q$!L(9?
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M'MT?CG=)N.64AZU-<8PY)@ SLY=K04G](T!>))=;QJL!FZ,JFRUW)J@T_ST
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M^SLF9[S/P+E:AN4.KM%] -FC';F4,>ZLA7E'9OS/I\DJ_<]_^W]02P,$%
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M3Y_GMNI[6@_J.$V.VBFWK\3WUTHYCM^BC?*1"3\ME-[JJ$QDG,28M-U 2H5
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MP,U&OKSP7+J>_;2GSS]MF^K6:7),"MU+Y<6FYIWN? [^?>=TEY5REZ/Q%L
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M:A#!4:2:JF% U+T5L4DAJ (/$07)LDCR7.9(XCR-"_6C+.#+5,$6_%/59#\
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MRICSK+U3N#>8,PI8WF]EQC>PXQ_#;E D_9%8CEQ#M#,$MA_97 "[72SN"-@
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MDYP;RJI?>>4]J/(KII63:%G/O1]%5K!1*FE68U2G&B\(CEP,G,!WB$U'"OS
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M[O1909<1U!T^R>"OE7F^T'XITD4#]UB$\D*31R5FG0A;M%8/]X+4BT7;2[E
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M=Z;HIXE7TG,-_GPO:J[#5&$MU\:O 27_5&0_BDW;&>!9A$D!24@0^A@D*(6
MA- 9<*$D3 W)N22:R31]L\=G3-AE/:)=W2=PAE&)/W#6>]7YXR[0(_:*[GUW
MBJ]JK[SL:V%:H_9G1?VO;+/+/^=9LZOSOIW>B,M/$X0B'SHPC#QH$PR&2\H4
MEP-MS=JOB,:T]E-XUB/#9]WO 6H7?U67:!/_";UA0OR/>NN]J?]Y'ZBIOR;_
MOAOUUV6ON/IK95IWYI_#JGF^$@G<- F(XV <NR&VHR#VW &/BZ&1#1QQ%(;5
MOKU_P%KGL<92#)N9+%^"?;W9O5GBC67U>>>4]Z;GQRG7D,7+N_'=Z+>JG9)9
MNRJS&O7Z^7GOP0VI0W013CUDIR"*  20V$[JCVL)#WB"EU.GP60Z<W]> ?3$
M=<_QLD[2)O*3^\>$Y)_QWWN+ #S^4(L'6CW^;J*#7JO%8X4!UO5%CF^LL*2]
MAOOM+BN/'B1#F 1V2E+7\WR7.(1Z*1F@.1AQE8Q."LAPS+C2\@3X%([1%2HF
M]HF!.-'63UE5VP1A2VUXOP4[;_M"*49H=/5["1 Z31:.#MKYUA<:ACN1PWW(
M9PN=*,5!D *("7M8)R2Q'8\+'4 $W^@RB<1P,/AT[!JW[EB@Y E=06 J)QA0
M__'F]WCE^YV)_AGNE=1>AT_?B\QKL558W_4QK$_8;VK6=7?[=$.1;$&Y8LWN
M'UX>/808N;$?NZ&7^,1W4>BA\>@!AK'@4V:30#(L]0/&MJE$/@#4K?5ZG*-+
M]"?WBP'U?^AM^&@QR-OG[GMG@8#''TH10:O#WTMHT&NT<(PPP+F^8''V9<UG
MT8Q &T:)0Y ?HB!-;&]_]F$#"/0&#&VP# >-DT_3&CDYUN<L70'D(GXR$$3J
M-YX8?F=QA-<M2K%$N^_?2SS1;[AP3#'$O<ZXLJQNRZ+[\R\48KG+%TD*G=@#
MCN] &".?I'B_U96ZH?88(@'!>+QH8;#^\@,V_4%"AGE] <$PZ4;$?\3,_E+=
M^^B]2?YKXA7E7<&3[T?*58R4D&UE3O5)=+MA]2-K\M5-]L3"QT'EX[.RI\@/
M@P"EH9\@XOMN%!)ON&J<0NTGQ-I@&9;R%J?5 K4>.J3:$WY]+M*E[Q?QC@'-
M;X\)?G_FO:ZXJ#?EG:D_KUN4(H)VW[^7**'?<.'(88A[R6ARQ6)8M@$/#Q1>
MUOW>5]8",:M7S77=OKS[4.?;_GTW]HZ+[R8P2%%D.[X=P)1B K:=QG'J1Y%"
M -&,Q'#, *MJU*4R_WFH3<T 6BF&Z':,5-BXH$\$(T71+#<5NYG#'%)TL*UL
MC[MMJ#H@ITI$_\XS['..$F)>X \,AKP[RUA@RM;S\F^484G%9UM+RVV^NKI_
MH$'G.,8_\Y]G8 +6"C5".$Q0XA." (C)$)A"-Q9\='!B<*;CPI$XT&Y%O]2;
MHFEV-&/]L=M:9;6UGO*ME:_7U/CB4:TL:0+_2L62>;E6);SDO256T9IR)N*P
MS."]1AUE?_$'HND^C5G&I@G-/Q^NIO:#Z'L![<Y,VTYO6>=T!755#O^D:ZA5
MWFOOEWR9%X^LB^H"@C1.,?V_)$BQG]J.0_\/8&B[(8(4D,Q# MI!&(Y([)UN
M]A8GVQSO(<F])*"??=XX,@/BQ>+% >"^_6@'U?I0]*#9B\5LFVJ5#TO'AL=!
M$S\^($KY6<DW[,6Y2+MI,T^\8V"85WU2W=ZAN'[(ZXQER7M -'C ,'*([Y$@
MA7[@1B1,_ &1Z\>"7:7-X3 LV-T+L'LQ$-Y',N@!78H]#?E&1+N[FU8-V+D<
M-1O9/LF[DG*K>_.]B+<&2X7U6Q>[?&_4#.,..(KRILX?LF+5ER0Y"T3S>S_V
M0!K%*(VQAZ$3#Z.&,.3:_M$UEO&;!"V<H790Z-49#42>5]M+<"BFJ ,VZ\.
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M4?'FYFC&6LUO X\T"S*R5^)#EWZB__8__\OP._0_?F1-_C__R_\'4$L#!!0
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M]:^'ICM-#=J><+A-(6[>Q0D'W]"\->ZA[:$'QR58I6J!'"/&]XU6I[L:G6*
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MLIA.&J7<'-9-/T(<[B8G==N/D"UK;!B:>YJ*;'Y?YN-)%;'^.#ID9FOY1?T
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MDT!8^F_"MHM^GXQ]*=+GV[)XN+E='9!SW\;58G9]"&UY=F@G88_J,=/.6^^
MMAXA%5?Y[DE%C-E&J\4M?&4_$%]/ ?Y #.SG(CB_P>.93//+LKB>+.*1C>I[
M_!R$7-=5^3[\TM34'M5Y!JTB2C./(=16,0*4UNN)*OR:0&)^,(E?1?;?#(E/
MK(<!10\/JC%YEE%#K $3V@/HF9  0Q[>OPK\8D6A.B9JN'4A&R@USO.K>>3V
MNUDP^_E\%0O*KS:(L+]19I%S!EMBK?06&4481_7PC3'DAPK>-=9ET1&^/3M6
MZ\/F8>V]/,6[SW%ZW2)#C 0#)CTP'%#&L=' U!(+Y1OMRIU-6.U01K4+[H F
MBDT9/V<Y'U@FJ0(&:1V\4LNY)\JN-"0$$XTV7AO/!_7KUPNZE4,!*[@_!X!U
MZ.O/K5-#P_89YT(CP;#E$#"B/-!>KX22RCKZ0\T2C35<= ]U0E"\3C@LGC:V
M'^[OIY78W]4N;DJF8SO,),40<>>Y<,8K+# GI!;96IRR"GE[,\9Q[#H1]J>=
M4(XHHMYH2MEN3E=5-?)GQ=!B&>$G?;WS'S_%TI/322S,M&.V2.LPDY(S8@&!
MF#.'(&+:<@>E#HIR@"HYK%R$YUDR*Z55.SCEJKS':PW.CTEX.KSKS(4/B5@O
M-8&.<X3#IV1K'"4#*7N\!T]<7_/R2]&1<3D5W78F2'6NG].:GWUW(@S(??V^
M)O/!3NSFYAD7F&'#N!6" L(TLPP:$5CBN18$-]K:[L<(77SY5SZ.!V/6ITC"
M9U"MTV/I+5^4OP4"WCPY8<=8HX1W9%YK@HW%@D* '95 NS6R6+*S]J=3R;;3
M!)U.*7W;HJ%'6#LR29 H:H2WRG+C,)#6@4I'CF,M?:-PY>GPB+YXK%7^_<44
M.S'8W"03PE%&'/0.<@TQ!8JS6FX6%HD_HL%H2H57!J,5C/L,U2[+P"XV7,JS
MF5.O'@\.G[&4,P$M$]X'_PM9N9*54,Y3TH,.7G)WZ1>?BE&I"/?)IN\O\MC(
MH.4CF=*J.D)AJ;!5)AZ!HI;)*IVRFAI\KF/KG#D*TX1XWVK@#XO;HHP%=K<&
M+5X^F FHM34$ <DY(1I*@7T]1*ULRH[.X',)6U)[*\CV[7(.? ^G&X\3.  \
MPUYX H32QEJ*'026 \<LE(UFRL;?Z/?'S2K\8[2FF*W+)>T/PQ_01X8L#%.1
MT!X'_BK E13008F1]HIX(<XE/-:-QHO3P'[JS_[P2R 3H^Z-WK@_UGY0-YDD
MF$J. ?%.(J44"G9[&7EDAE/6_CYM@ZL)&^W7'M!/AAW#!OG +NIA<"<(=KX6
M,OS3F1S-ZU;_KW9QNU/ $+_TW36&WN*7#PA%EEAII6"*<0M5O><05FN2-)KT
M3AM#.B1X]%U$ TIJ-,+*0.JETMJ)FN."(W32W:^!??Z-2; Q>G0\R D+N!<O
M7J<:!H>FZ:?QO$V&"#?*F>#9!"/(B->$NWK@1-I&F:O#3[LX"3O:!GN($\$1
M%T6_Q=G!:LP8$]8Q3:&2BFONEJGXWMG@)0QK=GB^ZGAQ2.;SWGH/^QIGF&%"
M'%&8"P8%]IP#46-!#/F1W<?&--FY7=D"ZGU&CG_+1U&.ZA[);Y/=OLF+9S/,
M-3! &T>HT( Y3 &KI>3>\//@5A=J?\6H-&A[/1UW<U,NZ[H]D^&W/);*WTFF
M'>TR;CC7BDAC@U_F$8UBU](KKU,*,@R26$=K__4QMM90[953"U/,&Y'HV8.9
MTXA2I[VG4#B+*8%,U_)19QLE7+XEUK2BZ]<,.A[2?BFSODJE$6]>/)TI0!T(
M8DKIA-+<(HQM+2D+_W(>*ZGNR9.&:Z\9&=-13#![-;7O=8MV-<PXDA!:+K7$
MVBK'"2>TEE\X#\^-5QWZ2"WBW"?/7HR^@;7:V"*34&@79!,.$&@0=<ZNORQN
MV=D=^VU'_:]8U0:X"1'!E\($ SK.=T]CS1IFDC'GA>4F+'*E"")H#-:00'#2
MC>%3\"-1D46'X [(W*B%NBO*Q62>7S7TL9MTD"'&%8)00@"@%T@C3]96'5EP
M)H'HMLG6*<B#(MTASOF^QL&G),YY9R$10!%(I(1K',(4D&+9!IG#V#G9T@#N
MU6D/*YB;HIP<Y;?O;AL6OXH9%AP)3PQ'PH55T7H91!E)61(.DF9=NNZM0CT@
MR[82[/%PL_9]RPQ # A0PEH$,";:J^ JKA#0[OQ.A[3&B'W6+0GG/IGVO_+I
MU:*X&RT>RNJFV?4&U@&<:]A'!C$,[JL.KBMS"".(-,-KM&V2J1LD^UKBR"ON
M=8-WGRS<,2F\G\SR=XO\;O<LVZ2#S#GFE648&X:\#7ZMYFJ%AU<$G%VIXPZG
MV@[P'M!\>\@,FW$$-,+,(TZA5;$J@C>UE%2X'VE_^@C5[YM8#X0WI<S1ZRP.
M=WV]/"3>*(6N:0<9E8IPR(/CX1SPQ JF:\OOL8 I&\^##&-TPIA.,1]B6MW1
MAZH&EC?GI0$8(@F(9MIHPQU7JP1'19!M5+^]^4>],Q?QP'IE33K)O/":,Z"%
MIP!(H(!CN!;/FW.I@->MYC=6+.L _1-_YL7=W:2#4U%/W38H,_;JV0PX"9EU
M$!+"O/8,>,"7U4R ,](<]3V>Z'+$)VF.NA9Q8_-,.6Q<G"ID0$)"2K@G-1Z
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M'$T7CQ_S^^58M^[H;6V1&1+F.*Z]UXJ#,%0G76T1%$@K SR@]5+;^WIMX9E
M@HNO>7F;CZ[V*__5DQG#R!$I!2*8">NQ(ZP66L& P7FL0MI6>BJ."<I6L]E#
M+"H]B]8FO'EEF_Y1%O/YI]$TGU_FY7@7!YIVD%E&")#< TV4#RX!0&AM.ZE6
M9[($:)L:'<';/F,.)4AF+014.4J]MT89!@+(3W.I3DE^9#\<'PY$L[=DJ0X2
MDQ-SI7A8"2,(7%BW&,ND-IPOK]0)\RS4NI$#/.R%\C'YCD?TG<E@>ISW@E)G
MM)8:&X9K))EJ=K/C\)<2+3"IE27P\<B?^N.?S8OIY"K&PIZN:WUV2?41QN T
M5[^\O$5[Y\>S\_IM12&FV ,9+#$R7D)I./9$(^\!=;#=ZU[6(X';,N8V/I=)
M9CQ"@324*@0#G:QF]2 !E&>W\]^.QHKV($TYCS:JSCPLBO&?6Y+4-CZ7L6BS
M*!=>&TL4AT9(60]0$'XFYQ$3E5.TAV [*K;%W6@R:Z+DY9,9 X0S:0601%.M
M-0TK@GJ0A)HS*>60J*!M:CX*PZ2SI4'*>1445(O%;7XW*O_,%^JFS'<7,CZ@
M=:8]5])#:IF3U!#BM 1K\Q9$/%-"'*K*HFMDDVER^?!E.AE?7 >\@X/8B!N;
MFF1QV:B%U9@"P^*PC81K2)P_Z=6M;XL0+<"9PH+UI/9^QW;HUF<S1!5W4A(@
MM!'*0L -K0?*%3^3(L.M.@#)*/9;G6SEZ?H SN_S_.K=;+V\5/$D_&01K[=O
MLN(YK*M,,>R4MU1!@U4LNJRD6AM&=B[+BQ8XLO%NJ,Z [I.,EV5Q/5F\+^:[
M4SB>'LNPXDI3@HTP+MYWA"1?RP8I/K\*PQVI_A7'CL:XUV,T5_]Z6!WM]T5I
M\Z"_\62IU]G5JEQI]5?W[3Z?[<FB.+2SS E@<567TKCP_2)%V=K3(T:<71WU
MDW&Q8TT,A[&5 _EE%*"L@[H',/1UXXQ(9X&AT",O&*!. N_77RXD*=EJ \JX
MZ)V1R<@/AX&_S\I\-(U%G<-?\LE-^*3&U076<2;(Y_\(BZ-#.-FDNYC2SPDS
MUC'OPQ03ELH.K[]6D71+P(!21'IG:0>ZZ).W[V;C,FY_V7SY^[O9'T7Y9X!P
M=2WZ3I;N:YPAA8F"T  "'-%:4B5MC0,3+F4N;YZ;(I><G*WRQL^)FBTK8)@K
MZ&*/K=S9,K.:"QKKNG)N2*RD_X0 U&'Q>-)TF"+HY%RXUR;L R/>LK99*Z&;
M'5UE,>'8>(P%@D8CBX1$]68HI#(I=#.@E<Z)0C?M =UKZ*8N/W1]61;A:UH\
M7DY'LT58H,4:?_<1P.IVI,GU)+]2\PU"[P[Y)'>?$8P!@\QBSK"0G$O*ZN@N
M9)B=YK*A04SIK3#N=<3HU"H:F.U]<F7JWZN2D\$^W=G\OIA/JAJ7SZI/'FJ1
M#WY!1@@!%GHOE;):2:>=J>=(2.BY5+'J@>L]:&=@;#_4@#?K(C.&*^HA%$XY
M1XTW@I(:$RA$HT*%K46L^G%Z3\;8=/P'QLE5>? VO-\=7670&:.)15K9\/ER
M!@65ZUF*)Z5&#"BJ>B+OMSV@>]ZX'.?Y5277N_G\(3A!%^55$*U\7":%[-O/
MW-TZ0RQ\[L91+:$!EK  ^OJS),J<25GA[HFR:9NS5>B'1,* U1'D6[?*O! 6
M&D,DL5!H[;PT:U0YABES\5OQ'D]#NF,A'PK9W+>\'$_BRN_B?G_4<V?+S$CG
MXRDX3B"U1AN+/%B'WZA(V0P:T.3:,^E281^^W]>"OY<YCY5BW@H@'*+<2K].
M!X3&JY0 _.'[DOVL1;JA8B?X#VLO,HH8EOLO[C@Y<$]R<R<9M-@AQ^)E:]Q@
MC@1YPD6&9=IY\+*+]4='$/=M#@\DVA:9-<:,.,0YTU8R*I  ZRE 8992SO+@
M<@SW>3DIXNG0<O%FR-4*K'U2:7GWV<5UG1<2KSXSU9_F%\<8M"/ZRP+*F !@
MC+<:6TX#:G6 "S&&3[OI_:9B*]VC?1YF#@D&N%? QK(H"!+DXN6E2YF#EY&R
MP.#'F3DWNWHS+&L%U('4&UA^'.]F49#%X_=#'%#5@>^'>7#M@<W-LWB%GJ!"
M$L> HC)6H*>>(^(YQ"A,4$T^@R'@L?\2H#UM,\^H)G'/62$-$>*2"%TC 1@^
MDSL7NR''*_O0+MB]SCC%W7TQ6YJ*%3S[;OO9W"0#V C+K$,0(APL+0)$K-$D
M]DS*X'3 @=>S3QL ]^IB5X-N4$_[^8.9L\@[ [Q$V -F6/AK_3D2P,695&MH
M3\VO?>/CT>PUK!0WI*Y6&=$-2+/A^4QS2SG4 FCFC8Y1#;R6-CB 9S>[':?J
MUY&B9"@3SO#_,2K+46#_GNH-WS^6Q;K:V&+@@E4E!L6$.;L6%LL430]RNRY)
MTRT@V*=EJ+8++\O\;O)PU\ PO'X\,U(+:8(%!1CQ>#Z2 U3+:F#23>.#W&=K
MR2XD(]GK4;_Q^.'N81H7PA>+V[R,\VR9W^:S^>1KS%LL[O(FMPXV[24#A'J!
MG)?$,(*<X +C&AD-8<KQTT$>[&N)8UT!W"?U/L8[L6?YE1N5L\GLILF5,IN;
M9)@SA0T$QC =8.56.[;^W*1/B1 /J&ITZZ1J!<UVJM4=5)#0<N*4419ZX+WB
M7$BZ'J!R\NPN7&E[\=P&JNVH_> BA0IZ3VD8IN.,6NV9A?!I8DVZP&Q 2Y=$
M!>TI4G@8ALG5YZIB>$L?:74:Z(@RA;O:9Q)*IS053GO!,#( R9K_A#IR)@5_
MDM6YK5!AB]BV0Y;.*EIRH8SQTDLKK,026RC)6AC)S7E,')T1I35DDVG25D5+
M3#FD'JK@(R/M--$"BK6SC/V9%,/I@A MP-EKL&2K2_6^T8V!#=IG4786,,4,
MA\48 ,:A=>@(J?.["[B[/9[VT>Y_PZ?!5D_&#1".6R<PQ-0X@@E;6]5@<$]:
M#K/K]+N.M+UEW^= :/O>='X1ZMF[X_SB^2Q,R%8PIYD 83YUV#N]#@IY>B[%
M.4Y%H72$$QR@U8FTI3357+SVQ;9Z0#O:9 8)83$$$A)GI;=: EX//'IQ/\XL
M=3PUVD:Y]PWF6HK]6\OUDQF,=0N$\I+%9:+$P:OT:V>2G/ADS!OE43O8#NG4
MR^?;LGBXN3WL-&#33C*@D+ ."$T=<I)B*:U:X4+#OZ3<3#/(N'_'G.L&]@'2
M\55QUL_E:#8?C8^FYLX.,Q-/4E*!N:<,>L2UA'7@EAKB4G*U!G2 H6>:MJF"
MWM,X*O/_,:_V>TTQWY/9O:E%)D@0&&#D(75,>ZB@?Y+8BA3;V/Q,P^E+FW7+
MO3:@?ANA!QD&KA$51F!GE#?0PMIAI<HE%;L5PSH2<^+ PV' #N-8S.HD]FAZ
M&6N6A?Z_'^1P#L:\&NBA1V.V=I !2ZUEBE%*)4,J'I*34#D<"$&X0(TR]D^8
MUC6?YSOO.M[V:!9(#07B'.)XRD-Y1Y%=R<F].&W,\<3.2@O*?YVXE8)NKV''
MAS("> "1-K;(M*0,Q1ON9+23PE)-^4IB)8P\D]M#TQ7^.LK8 ISG<3R76*NY
M)T8#J+2!$%H!5S)KH_29Y'>TIOFF!W0/@W4 MJAQG=Q7CV? J>!P,2JEYH9"
MJ85WM:P6)Z6V#W(#I'4*I4(Z /I\S,=Y(/^7:5X5&0K.;H7*_(_)XM8\S!?%
M75!,$V(UZBC3P%INE<%AH6 1L!HH7.%C@'10G-UIBHXHUP78?9)QF;[_2K:=
MO-O2)N-:.P&%XDIB;J&CE#U]@F&1>FY[+FU3K!U<!V#:+LO\?C2Y6MUUU\B(
MO6B246Z4!9PH@KQP&F)F526S!(#*I"*+@]Q+Z<A<I<$Z "HM 6F^T,OB]=70
M&N\I$<YY8 6%M812@I2 P3#O).J&.$>AV2=?/A2S\<$Q@FV-,BV8)I@:(B$S
MGGD*F*GE!@RGA D&Z:"W%B9H"=$^F;3U;IB=5-K:*@.4$16/+5@9]V6X1@34
MDF,-SJXR>CH%-E4&;@7<(1FH@PQ3%CY#@AG$#B%I*8G17[&2$P(.4TZ:'6Z0
M3C"M=4"B1$Q[/1:_GS$KF3A@ EE%N1#>>B ,0ZR6"2,ISXTG)]DO.1#5_K?4
M@XE\/QE]F4R;WS"SJV&F+4" A"4H@I8(SIWQ]4<7%Z$I%],-,GC4,:M:Q'H
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M^]!0OP?#T^=W"1E#W&HI.510!\@1K>J'84,)2EH3'!ST6L[O;G9U1IQ,QWP
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M]XY[+)7!TH2U+(8U+I"=W\4G??I%'2FE3[+NE*6!O6O0/@-$:0,<Q8)X9ST
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M5*E:4"HH0Q1LNR8D9SD;ESHSA@R,=09%DN&_NMLYSNOUO^)Q8"\W7OEMY93
MAJ90)<X$"^#B+MM\J# XQ[^3ZBR?(2OR41Z&#HU]OHL:[4&.UY^LO 82J">@
MA;-:.6MU.PF+\NJ+GZ?#>&C,!]IJFF]XKM(Z;3BO/5CAE"MAM8RJ,#FZK6"J
M@0:0S+H(Q6?L0AX.\AQUDZ:WNMY]Q&K]*?4[>\S_75U_KB\?ULO[9;VQBYN;
M^NJW[WYQ^?N/O]UOR.0/74E0$+RP/C@E X"V@6-#O)1.<VMS[D7Q>?JI)Q?*
MK"ZAY^WZ]C:-?=MEU&F(BC%L5300E:7 P?B $6[6:X"L4CSXW-SB(X.?GSCU
M@ZK6EY?U3;W>2NU+?'[S^^H)N7TY5>^/4!G+9%Q=P6[#/)T"9=H=(%H.67?[
MY^D 'PO[*0CU9;U(M'>+[_L=FH<,5@6'K&= L(N'&)$J$U/3GFL0RLKOZ>T,
M/R^:'2Z&&8NK/-S>+M;?+ZYUM%UO'_7OOS8I2-C<+"[_^'P9)Q8!W?Z/A$ *
M_UM=U3=AM6YR'\^G (O0UJ%H(G'&4X4<4(P&$BP(ZCF!3HZ9@H(>!RO PC!V
MR@"*5J2*.[6-?T2!(A>D,\J;DPK4GXI"AQ9@Z2>+XFIC9!1@$9A3RJG45%@J
M&5AMY6[FE@@XD68YXQ&B1P&6?E 71[+, BS$.&R]0)AZ2YVE2%#8S=YAFA7;
M7231!N!!KP(L_?"=O&P&"5Y1S@QE,IXBC*<!A_AYGFG$-7&3QFC/7S:CL[#>
M*IO1#]+SRB0)7#@204 *,:.9$(Z*%F!M3B2+;<)M;33L9^5EO;E<+[>GM(OK
M3\O-'V%=UXWU^6EQ7S_WK_V2UMX[]5D/&;#B1!GM'81HU(*RU'K+DG4;5[7"
MPI[(06!<*KWDZ_B2*(:YC[/X=7F=Q]<WAZD VXB-582#Y)H2 \Q&; +CQ I)
M)]6HQ46+#L33(250##O]7]_JR_C]_[VZB8*_::*N#V5II^$J[["+AJNC)M@H
M!(HE3UA9RY6F3DV:M'RJ;!U#$AGG$K?\<WE5WUW]S[*^N?I8KR_K-_))7_MQ
M)86U 4N,O4C=+.(W!YT^U1,?EYS+.:+VOKP\>M(,AG,!7OYG-ZYGY[Z7CG-+
MB58!*P0>844,04P8K5045J=P[().FH.Y[RW2X%F0.E71I0PSXVB#2S#L1!RG
MTU+H4/=]/UD4YUG-<-\[P[S6CDK-F>%LJT.;F7,)YU?ZH"<A>KCO^T%=',DR
MW?><8J6LBJO8.F2UT$'R%E&FV*D1;0 >]'+?]\-W<O>]D5@0Q@Q(R:3STG/<
M3II9G)-R<X3N^\[">LM]WP_2\W+?*P+$!2$59=XI%E'BXLEBR*JL>\SN^\.W
MM=&PS]!$/X2UKEX[9.W53N\_6GGFL?(1J4 8]E%+,P\$6>P=2IV3Q:EM6&-(
M>#4JYG.JM&$Z[P44X4.> 7=@@E<L'G1:(('GG %/HQMZ7Z8-BO>,=:5,- N%
M9B ]LXP)#Q#/O(\?JE/9ZBG=SR>A?/)!/GYM(P4-B#@'F@@5M:J%()OYIMZX
M4[JG"^SS.;"NZ8?VG.SZ=YT2TNHK'0]&BZ_UISH5KHW;LEW=;?UO#PFEZP,3
MOW('KQB@5/1/8^R8\UYS\K1*XY]S\O*//7_G<,9.+)7YKF"VYYXSN&51'"FM
M+3 6+1J#F7#![;H*"VNZ'7@+<@CXO[[=+.[2-[Y=B:S/0!6FTHMHYE' +E"-
ML./08&1T5KVR@DYTT]*IOZ/@<(F4XL+Z$-7ANKZ\_T>]2'^1*OY=7+?E)2^N
M?UFMKC87Z\\1Z'C2W7RJ+^OEG_6/>$><']*#39B#>T@EWC\^6D4'D'_";ZJT
MB>0 K!F/-.$Z-4&7C=0\LO(TG&L%K:-RA5O*DGRTP*,P<@V;0];>&"^O2#2K
M".4*!S!(,R7BZ:&10R#=VLX?0P!:0<NL #E.;"@OO]XMKY>742'\U\/5UZUZ
M\)O[Y>WB?@OYL^3D(2WH'J]]UVP^8*S**8,\ HF-=\)(F5+#/5;&!_!1,IWL
MP'G4G+Z\3"T4(MW29+<;09ID.^%#M%>/,2O#,"+*:6\92$LP9\0UR&F;%<-=
MG 4]*K/>U$/C261B]=*$/SZ#\FEN'U<WR\OEL&?S;F]\7ZGT&J:2U(,)1 5P
MV&+*K6+$"X-8U/F(RDZU/^;1)]TF>HA6Z3URY3#QE'G$%$4\<&8!AQ9%(*?5
M#'<D@KVI5L8628G*Y9_I9OD^'H9&"+?N] 7#Z)HG0U<!I<Q8SBGRQB@DHWD9
M)4*U4,ZS3AMPYPFVUQJIG=VN%DWDQOZ;S'T/5!1)8CB2UDJO$8G'2^6;SQ:.
MGU;W\W$$NAH!Z(P+[G\L_EK>/MRF;DU-VEGC60BKQV)-ORTV]=7'Q?=MZZ\4
MX/%HRNQES^%#5DA8$ Y1< BE&E/2/BK(1Q2SB@,4YY&:@E^3B:+$/6,VPW3@
MO0)AY (&@;U(.<E6$/UX16>(YKI;'X294CY_FM3W2#JW6X,?HGAOZR^+OSI;
MI1D#5PH3A1GRD@=/E9(<P#88"G"G=> =AUUOYX".*Y!B<IA?F698WBWN+I>+
M&[W9U/?=#UD'#UL9;3Q!Q@H5?,!6,F%1@YT1@I_O+CD>F0<3QU%0^=?EXK>4
MR-W':9 W=J72/7'@P+Q6SE@=P.(&1:>R$M@*BI0LE-2#R*1H9C>7K,^N7@=C
M]MMC5\PHYP1+D8."6A2\9J)%$=N<0W-!I= +8_:@,BF:V=LU7*<V7@/KZA=C
M5IP8Q0/&WDL"'@DN*6E0(][F&!X%A7 6QN1!9%$T@U?K.F)L'Z+L(_1?UHN[
MS<V6'X/QN<L;*N$-=<AH(;35-B!L6+O;49W58;>@RN^%L7L$R93,]7@*KC?;
M")@OOR_N!O>!O#]\9:WBR 1#*&4DX!"9T\H2>Y>3JE90_]:R6#ZX6$JFN%^L
M4XS5INGU,!2WWQBWXL)XSHVV/C#/! 2)9+L9ZI!3Y:V@5K%ED7HX>93,YH_K
MU;=Z??\]7<O=I^"=_WU8?AOR]-CE!15X1R2+AAY5+##B@+KVN&)!YE2&+:C1
M;5G\'D$P)1,]1>C&[_L]SM35?]8WJV:N]=UF,!W>]245#Q99H7!P#!PW"M&G
MTPV*1F#.?4U!37S+8OQ(TBF;]9>KB/FN.G2<]-W#.T4!#QBP4L9B235FV%KI
M6##^R;@S!++8_/?UXWB2*)FY+X(WMF?G"&FO[)>!7E()!IP[ TRYP!B)%A]M
MKG.-S3M5EM02N2R&CR2=8EC_(:W>Q8W^]BU.>/'X=Y]3FLYBG=+DMME#D1F/
MC'FGY-CAXU;>!V!$I>:7 F&&N#41/8V0D2GY)ZN U-]7DZ,+I!@Z-V72/]Q^
MB]B]/NM_UO\W!,.S7U5IAC 1SH-R\603G-8R-"H#B,RIUE%2 ^<923^UC$H,
MT?Q\^7M]]7!37UR[.K[T<KE]9>K*,D9=]7FRBN*>F]IZ24:!!$^<T4&F0%JD
M:2!<=[HTG2>K:*\'I%_M]+>'J2@7J3(@9RJU   55U.+CT RYU+Y.,]&!U#G
MS7RA0?$OHISUWAEU+Z#^YA 5=C8PBZG0RJ:V.A$8U6#B%>3<)Q3$R7'ILK_J
M]9#8S\G'O?/H4&+]G6<K4!+Y>%J+4Z<T(!X$W<',D-4AR_XJD8%#D^,%^X8%
M?$[:75S'C:/N0[97GZA(P!BPPQY1(9RVT9P-S8PU\2>2$S$" UYP:PA\<W+X
MZJMH2=R\SXBW?EYI:I0'C 58A8!HI()H/I=PE>.D+LB#-QX=!@1W5B-K=?OM
MX?ZQ0D]7_;+GF0I%E0Q>,>FL3B4T*->FA1#CG%XA!3G.IM PPR!<2I6OO3C]
MVKM_Q/M#58X$XY UC%G#"3%!6MY@I((\Z1X2HQGSH\H@8R_\X5L6S\W'N[N'
MQ<W/;J:]FV3/<2J(>&%.0M3ET@HAK89V@@+$B72!&U_^J^F$4*)#=/@RQ_,X
M/:FG@O#@M9$&K%<VE2U(U0-<H,K3@IV>CW[GE+5\O5K?/J[%WU8/]_F!@ .]
MI%(44^<P(UY%8A-!P<@&6Q0$G(:J&9=V;^YG$TJG@P[:_8_TKW37_Y__\?]0
M2P$"% ,4    " #2A'-,+A>."!IG 0"X&!4 $@              @ $
M;VYC>68M,C Q-S$R,S$N>&UL4$L! A0#%     @ TH1S3(JC<W[[%@  +0\!
M !(              ( !2F<! &]N8WEF+3(P,3<Q,C,Q+GAS9%!+ 0(4 Q0
M   ( -*$<TSUL>#*.!<  (7V   6              "  75^ 0!O;F-Y9BTR
M,#$W,3(S,5]C86PN>&UL4$L! A0#%     @ TH1S3 O6@-7K0@  &TT# !8
M             ( !X94! &]N8WEF+3(P,3<Q,C,Q7V1E9BYX;6Q02P$"% ,4
M    " #2A'-,[D26D>RR  #\@@D %@              @ $ V0$ ;VYC>68M
M,C Q-S$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( -*$<TR&:/>V0V\  !2@!0 6
M              "  2", @!O;F-Y9BTR,#$W,3(S,5]P<F4N>&UL4$L%!@
0   &  8 D $  )?[ @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
